{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "wNhBviOWN-YW"
   },
   "source": [
    "<center><font size=\"6\"><b>Комп'ютерний практикум 7.\n",
    "\n",
    "<center><b> Кластеризація текстової інформації </font>\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "VxvYo3tdI3uM"
   },
   "source": [
    "\n",
    "<center><img src=\"https://miro.medium.com/v2/resize:fit:1100/format:webp/1*7j6tM_xSGCAwuB-fx6-N3w.jpeg\" width=\"600\"></center>\n",
    "\n",
    ">__Навчання без вчителя (Unsupervised learning)__ - це напрямок машинного навчання, що об'єднує алгоритми і методи побудови моделей на основі опису множини об'єктів (навчальної вибірки) та необхідності знайти внутрішні взаємозв'язки, залежності, закономірності, що існують між об'єктами.\n",
    "\n",
    "> В алгоритмах навчання без вчителя помилка моделі на множині для навчання не обраховується. Замість помилки використовується інформація про поточний стан параметрів моделі та прикладів навчальної множини.\n",
    "_Типи вхідних даних__\n",
    "\n",
    "* _<u>Опис об'єктів за ознаками.</u>_ Кожен об'єкт описується набором своїх характеристик - ознаками, які можуть бути числовими або категоріальними.\n",
    "\n",
    "* _<u>Матриця відстаней між об'єктами.</u>_ Кожен об'єкт описується відстанню до інших об'єктів навчальної вибірки.\n",
    "\n",
    "__Типи задач__\n",
    "* Кластеризація\n",
    "* Пошук асоціативних правил\n",
    "* Поповнення пропущених значень\n",
    "* Скорочення розмірності\n",
    "* Візуалізація даних\n",
    "\n",
    ">___Задачі кластеризації___\n",
    "\n",
    "<center><img src=\"https://metana.io/wp-content/uploads/2023/08/uL-1024x512.png\" width=\"400\"></center>\n",
    "\n",
    "Вибірка об'єктів розбивається на неперетинні підмножини - кластери за схожістю об'єктів в одному кластрі. Вихідна інформація подається у вигляді матриці відстаней.\n",
    "\n",
    "__Методи кластеризації__\n",
    "* Графові алгоритми\n",
    "* Статистичні алгоритми\n",
    "* Ієрархічні алгоритми\n",
    "* Нейронна мережа Кохонена\n",
    "\n",
    "\n",
    ">___Задачі пошуку правил асоціації___\n",
    "\n",
    "<center><img src=\"https://eastgate-software.com/wp-content/uploads/2023/10/Unsupervised-Learning-Association.png\" width=\"400\"></center>\n",
    "\n",
    "Вихідна інформація подається у вигляді опису характеристик об'єктів. Необхідно знайти такі набори ознак і такі значення цих ознак, які досить часто (невипадково) зустрічаються в описі характеристик об'єктів.\n",
    "\n",
    "__Методи__\n",
    "* Аналіз ринкових кошиків\n",
    "* Apriori\n",
    "\n",
    ">___Задача поповнення пропущених даних___\n",
    "\n",
    "<center><img src=\"https://thepracticaldev.s3.amazonaws.com/i/egr5hnuazl4rz5mi4llw.jpg\" width=\"400\"></center>\n",
    "\n",
    "\n",
    "Вихідна інформація подається у вигляді опису характеристик об'єктів. Значення деяких характеристик можуть бути відсутніми. Для поповнення таких значень вважають даний об'єкт цільовим, будують алгоритм, який прогнозує його значення в залежності від інших ознак. Пропущені значення заповнюють прогнозами.\n",
    "\n",
    "__Методи__\n",
    "\n",
    "Якщо ознака кількісна, застосовується регресійний аналіз, якщо категоріальна - методи класифікації.\n",
    "\n",
    ">___Задачі скорочення розмірності___\n",
    "\n",
    "<center><img src=\"https://miro.medium.com/max/1192/1*vXQ5sgMF0XmiY4Jc6gJVwA.png\" width=\"600\"></center>\n",
    "\n",
    "Вихідна інформація подається у вигляді опису характеристик об'єктів, причому число ознак (факторів) може бути достатньо великим. Задача полягая у відображенні цих даних в простір меншої розмірності з мінімальною втратою інформації.\n",
    "\n",
    "__Методы__\n",
    "* Метод головних компонент (PCA)\n",
    "* Метод незалежних компонент\n",
    "* Лінійний дискримінантний аналіз (LDA)\n",
    "\n",
    ">___Задачі візуалізації даних___\n",
    "\n",
    "<center><img src=\"https://thumbs.dreamstime.com/z/abstract-d-big-data-visualization-concept-clustering-infographics-design-cluster-analysis-vector-illustration-188989840.jpg\" width=\"300\"></center>\n",
    "\n",
    "\n",
    "Деякі методи кластеризації та пониження розмірності будують представлення вибірки в просторі розмірності два, що дозволяє відображати багатовимірні дані у вигляді плоских графіків та аналізувати їх візуально, що покращує розуміння суті задачі.\n",
    "\n",
    "__Методи__\n",
    "\n",
    "* Дендрограма\n",
    "* Карта Кохонена\n",
    "* Карта схожості\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "id": "ZbxcPHZ8H1yp"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: pyspark in ./venv/lib/python3.10/site-packages (3.5.3)\n",
      "Requirement already satisfied: py4j==0.10.9.7 in ./venv/lib/python3.10/site-packages (from pyspark) (0.10.9.7)\n",
      "Requirement already satisfied: findspark in ./venv/lib/python3.10/site-packages (2.0.1)\n",
      "Requirement already satisfied: pyarrow in ./venv/lib/python3.10/site-packages (18.1.0)\n"
     ]
    }
   ],
   "source": [
    "# Встановлюємо необхідні пакети\n",
    "! pip install pyspark\n",
    "! pip install findspark\n",
    "! pip install pyarrow"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "id": "7MBSLFPWH3RY"
   },
   "outputs": [],
   "source": [
    "# імпорт допоміжної бібліотеки для організації правильного шляху до Spark\n",
    "import findspark\n",
    "findspark.init()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "id": "sBROoBcCH7Qu"
   },
   "outputs": [],
   "source": [
    "#імпорт бібліотек та модулів\n",
    "\n",
    "import pandas as pd\n",
    "from pyspark import SparkContext, SparkConf\n",
    "from pyspark.sql import SparkSession"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "id": "1uoCsTc_H-Jx"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting default log level to \"WARN\".\n",
      "To adjust logging level use sc.setLogLevel(newLevel). For SparkR, use setLogLevel(newLevel).\n",
      "24/12/07 09:26:50 WARN NativeCodeLoader: Unable to load native-hadoop library for your platform... using builtin-java classes where applicable\n"
     ]
    }
   ],
   "source": [
    "# Створення spark session\n",
    "\n",
    "spark = SparkSession \\\n",
    "    .builder \\\n",
    "    .appName(\"My_Spark_Text_Сlassification_2\") \\\n",
    "    .config(\"spark.executor.memory\", \"4g\") \\\n",
    "    .config(\"spark.driver.memory\", \"4g\")\\\n",
    "    .config(\"spark.executor.cores\", \"4\") \\\n",
    "    .config(\"spark.sql.shuffle.partitions\", \"200\") \\\n",
    "    .config(\"spark.serializer\", \"org.apache.spark.serializer.KryoSerializer\") \\\n",
    "    .config(\"spark.sql.autoBroadcastJoinThreshold\", \"-1\")\\\n",
    "    .config(\"spark.driver.maxResultSize\", \"4g\") \\\n",
    "    .getOrCreate()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "id": "AtCW7m2KII2A"
   },
   "outputs": [],
   "source": [
    "# Використаємо `read_csv` з pandas для завантаження датасету\n",
    "df = pd.read_csv('data/Covid_text.csv', encoding='latin-1')\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "Qm_QlyxEJrfP"
   },
   "source": [
    "Датасет охоплює множину повідомлень Tweeter, що стосуються Covid-19 з різними настроями:\n",
    "- Extremely Negative\n",
    "- Negative\n",
    "- Neutral\n",
    "- Positive\n",
    "- Extremely Positive"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "id": "ZOZtns0-I-T1"
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>UserName</th>\n",
       "      <th>ScreenName</th>\n",
       "      <th>Location</th>\n",
       "      <th>TweetAt</th>\n",
       "      <th>OriginalTweet</th>\n",
       "      <th>Sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>44953</td>\n",
       "      <td>NYC</td>\n",
       "      <td>02-03-2020</td>\n",
       "      <td>TRENDING: New Yorkers encounter empty supermar...</td>\n",
       "      <td>Extremely Negative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>44954</td>\n",
       "      <td>Seattle, WA</td>\n",
       "      <td>02-03-2020</td>\n",
       "      <td>When I couldn't find hand sanitizer at Fred Me...</td>\n",
       "      <td>Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>44955</td>\n",
       "      <td>NaN</td>\n",
       "      <td>02-03-2020</td>\n",
       "      <td>Find out how you can protect yourself and love...</td>\n",
       "      <td>Extremely Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>44956</td>\n",
       "      <td>Chicagoland</td>\n",
       "      <td>02-03-2020</td>\n",
       "      <td>#Panic buying hits #NewYork City as anxious sh...</td>\n",
       "      <td>Negative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>44957</td>\n",
       "      <td>Melbourne, Victoria</td>\n",
       "      <td>03-03-2020</td>\n",
       "      <td>#toiletpaper #dunnypaper #coronavirus #coronav...</td>\n",
       "      <td>Neutral</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>44958</td>\n",
       "      <td>Los Angeles</td>\n",
       "      <td>03-03-2020</td>\n",
       "      <td>Do you remember the last time you paid $2.99 a...</td>\n",
       "      <td>Neutral</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>44959</td>\n",
       "      <td>NaN</td>\n",
       "      <td>03-03-2020</td>\n",
       "      <td>Voting in the age of #coronavirus = hand sanit...</td>\n",
       "      <td>Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>44960</td>\n",
       "      <td>Geneva, Switzerland</td>\n",
       "      <td>03-03-2020</td>\n",
       "      <td>@DrTedros \"We canÂt stop #COVID19 without pro...</td>\n",
       "      <td>Neutral</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>44961</td>\n",
       "      <td>NaN</td>\n",
       "      <td>04-03-2020</td>\n",
       "      <td>HI TWITTER! I am a pharmacist. I sell hand san...</td>\n",
       "      <td>Extremely Negative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>44962</td>\n",
       "      <td>Dublin, Ireland</td>\n",
       "      <td>04-03-2020</td>\n",
       "      <td>Anyone been in a supermarket over the last few...</td>\n",
       "      <td>Extremely Positive</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   UserName  ScreenName             Location     TweetAt  \\\n",
       "0         1       44953                  NYC  02-03-2020   \n",
       "1         2       44954          Seattle, WA  02-03-2020   \n",
       "2         3       44955                  NaN  02-03-2020   \n",
       "3         4       44956          Chicagoland  02-03-2020   \n",
       "4         5       44957  Melbourne, Victoria  03-03-2020   \n",
       "5         6       44958          Los Angeles  03-03-2020   \n",
       "6         7       44959                  NaN  03-03-2020   \n",
       "7         8       44960  Geneva, Switzerland  03-03-2020   \n",
       "8         9       44961                  NaN  04-03-2020   \n",
       "9        10       44962      Dublin, Ireland  04-03-2020   \n",
       "\n",
       "                                       OriginalTweet           Sentiment  \n",
       "0  TRENDING: New Yorkers encounter empty supermar...  Extremely Negative  \n",
       "1  When I couldn't find hand sanitizer at Fred Me...            Positive  \n",
       "2  Find out how you can protect yourself and love...  Extremely Positive  \n",
       "3  #Panic buying hits #NewYork City as anxious sh...            Negative  \n",
       "4  #toiletpaper #dunnypaper #coronavirus #coronav...             Neutral  \n",
       "5  Do you remember the last time you paid $2.99 a...             Neutral  \n",
       "6  Voting in the age of #coronavirus = hand sanit...            Positive  \n",
       "7  @DrTedros \"We canÂt stop #COVID19 without pro...             Neutral  \n",
       "8  HI TWITTER! I am a pharmacist. I sell hand san...  Extremely Negative  \n",
       "9  Anyone been in a supermarket over the last few...  Extremely Positive  "
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Перегляд датасету\n",
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "id": "nbh7G0j6BYcQ"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Унікальні значення: ['Extremely Negative' 'Positive' 'Extremely Positive' 'Negative' 'Neutral']\n"
     ]
    }
   ],
   "source": [
    "unique_values = df['Sentiment'].unique()\n",
    "print(\"Унікальні значення:\", unique_values)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "id": "28DkcYgyMcgV"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['UserName', 'ScreenName', 'Location', 'TweetAt', 'OriginalTweet',\n",
       "       'Sentiment'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "id": "_7fuJ2eVmtmi"
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>OriginalTweet</th>\n",
       "      <th>Sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>TRENDING: New Yorkers encounter empty supermar...</td>\n",
       "      <td>Extremely Negative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>When I couldn't find hand sanitizer at Fred Me...</td>\n",
       "      <td>Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Find out how you can protect yourself and love...</td>\n",
       "      <td>Extremely Positive</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>#Panic buying hits #NewYork City as anxious sh...</td>\n",
       "      <td>Negative</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>#toiletpaper #dunnypaper #coronavirus #coronav...</td>\n",
       "      <td>Neutral</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                       OriginalTweet           Sentiment\n",
       "0  TRENDING: New Yorkers encounter empty supermar...  Extremely Negative\n",
       "1  When I couldn't find hand sanitizer at Fred Me...            Positive\n",
       "2  Find out how you can protect yourself and love...  Extremely Positive\n",
       "3  #Panic buying hits #NewYork City as anxious sh...            Negative\n",
       "4  #toiletpaper #dunnypaper #coronavirus #coronav...             Neutral"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Оберемо два стовпчика з техстом та настороями (класами)\n",
    "df= df[['OriginalTweet', 'Sentiment']]\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "id": "NaZOpbY_ri0Z"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 44955 entries, 0 to 44954\n",
      "Data columns (total 2 columns):\n",
      " #   Column         Non-Null Count  Dtype \n",
      "---  ------         --------------  ----- \n",
      " 0   OriginalTweet  44955 non-null  object\n",
      " 1   Sentiment      44955 non-null  object\n",
      "dtypes: object(2)\n",
      "memory usage: 702.5+ KB\n"
     ]
    }
   ],
   "source": [
    "df.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "id": "k0HeI9NGJBRl"
   },
   "outputs": [],
   "source": [
    "#завантажимо дані в spark dataframe\n",
    "tdf = spark.createDataFrame(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "id": "-k-rUe1PJDJj"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:29:42 WARN TaskSetManager: Stage 0 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "                                                                                \r"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+--------------------+------------------+\n",
      "|       OriginalTweet|         Sentiment|\n",
      "+--------------------+------------------+\n",
      "|TRENDING: New Yor...|Extremely Negative|\n",
      "|When I couldn't f...|          Positive|\n",
      "|Find out how you ...|Extremely Positive|\n",
      "|#Panic buying hit...|          Negative|\n",
      "|#toiletpaper #dun...|           Neutral|\n",
      "|Do you remember t...|           Neutral|\n",
      "|Voting in the age...|          Positive|\n",
      "|@DrTedros \"We can...|           Neutral|\n",
      "|HI TWITTER! I am ...|Extremely Negative|\n",
      "|Anyone been in a ...|Extremely Positive|\n",
      "|Best quality couc...|          Positive|\n",
      "|Beware of counter...|Extremely Negative|\n",
      "|Panic food buying...|Extremely Negative|\n",
      "|#Covid_19 Went to...|Extremely Positive|\n",
      "|While we were bus...|          Positive|\n",
      "|#AirSewa  @flyspi...|Extremely Negative|\n",
      "|What Precautionar...|Extremely Positive|\n",
      "|When youÂre stoc...|           Neutral|\n",
      "|That's about a we...|          Positive|\n",
      "|Studies show the ...|Extremely Positive|\n",
      "+--------------------+------------------+\n",
      "only showing top 20 rows\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#виведемо dataframe на екран\n",
    "tdf.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "yVKe9KcOEVe4"
   },
   "source": [
    "## **Підготовка даних**\n",
    "Підготовка даних до моделювання виконується  у декілька кроків (__Model Pipeline__)\n",
    "\n",
    "У PySpark `Pipeline` — це об’єкт, що поєднує кілька етапів обробки.\n",
    "\n",
    "- regexTokenizer: Токенізація\n",
    "- stopwordsRemover: Видалення стоп-слів\n",
    "- countVectors: Векторизація\n",
    "\n",
    "### Переваги Model Pipeline:\n",
    "- **Автоматизація та відтворюваність**: спрощує запуск задач, особливо при великих обсягах даних.\n",
    "- **Масштабованість**: легкість інтеграції нових даних або оновлення існуючих етапів.\n",
    "- **Управління ресурсами**: дозволяє ефективно розподіляти обчислювальні ресурси для різних етапів.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "i4QM8B9-k3Ex"
   },
   "source": [
    "Функція `StopWordsRemover` у PySpark зазвичай використовується для видалення стандартних слів-стопів (наприклад, \"the\", \"is\", \"and\"). Однак вона не підходить для видалення URL-адрес та інших службових символів, оскільки URL-адреси не є стандартними словами.\n",
    "\n",
    "---\n",
    "\n",
    "Для видалення URL-адрес найкраще попередньо обробити текст за допомогою регулярних виразів. У PySpark це можна зробити за допомогою функції `regexp_replace` з модуля `pyspark.sql.functions`.\n",
    "\n",
    "---\n",
    "\n",
    "#### Код для видалення URL-адрес:\n",
    "\n",
    "```python\n",
    "from pyspark.sql import functions as F\n",
    "\n",
    "# Видалення URL-адрес із тексту\n",
    "tdf = tdf.withColumn(\n",
    "    'Text',\n",
    "    F.regexp_replace(F.col('Text'), r'http\\S+', '')  # Видалити всі рядки, що починаються з \"http\"\n",
    ")\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "1. **`regexp_replace`**:\n",
    "   - Це функція для заміни тексту, яка працює з регулярними виразами.\n",
    "2. **`r'http\\S+'`**:\n",
    "   - Це регулярний вираз, який шукає всі слова, що починаються з `http` і включають інші символи, доки не зустрінеться пробіл.\n",
    "   - `\\S+` — це набір символів, що означає \"будь-який непорожній текст\".\n",
    "3. **`''`**:\n",
    "   - URL-адреса буде замінена на порожній рядок.\n",
    "\n",
    "---\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "id": "EXBaVWDVlhNY"
   },
   "outputs": [],
   "source": [
    "from pyspark.sql import functions as F"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "id": "hi2T8-gelb0r"
   },
   "outputs": [],
   "source": [
    "# Видалення URL-адрес із тексту\n",
    "tdf = tdf.withColumn(\n",
    "    'OriginalTweet',\n",
    "    F.regexp_replace(F.col('OriginalTweet'), r'http\\S+', '')  # Видалити всі рядки, що починаються з \"http\"\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "0aCjh-GCllzZ"
   },
   "source": [
    "Для видалення HTML-тегів із тексту в PySpark можна використовувати регулярні вирази (`regexp_replace`). HTML-теги мають формат `<tag>...</tag>` або `<tag ... />`, що легко розпізнається за допомогою регулярок.\n",
    "\n",
    "---\n",
    "\n",
    "### Код для видалення HTML-тегів:\n",
    "```python\n",
    "from pyspark.sql import functions as F\n",
    "\n",
    "# Видалення HTML-тегів із тексту\n",
    "tdf = tdf.withColumn(\n",
    "    'Text',\n",
    "    F.regexp_replace(F.col('Text'), r'<[^>]+>', '')  # Видалення всіх HTML-тегів\n",
    ")\n",
    "```\n",
    "\n",
    "---\n",
    "1. **`F.regexp_replace`**:\n",
    "   - Використовується для заміни тексту за допомогою регулярних виразів.\n",
    "2. **`<[^>]+>`**:\n",
    "   - `<` і `>` шукають відкриття і закриття тегу.\n",
    "   - `[^>]` означає \"всі символи, крім `>`\".\n",
    "   - `+` означає \"один або більше символів\".\n",
    "   - Цей вираз знаходить весь текст між `<` і `>`, тобто HTML-теги.\n",
    "3. **`''`**:\n",
    "   - HTML-тег замінюється на порожній рядок.\n",
    "\n",
    "---\n",
    "\n",
    "### Приклад:\n",
    "Вхідні дані:\n",
    "```plaintext\n",
    "\"<p>This is a <b>test</b> string with <a href='link'>HTML tags</a>.</p>\"\n",
    "```\n",
    "\n",
    "Результат:\n",
    "```plaintext\n",
    "\"This is a test string with HTML tags.\"\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "### Додаткова обробка:\n",
    "Якщо в тексті багато зайвих пробілів після видалення HTML-тегів, можна їх очистити:\n",
    "\n",
    "```python\n",
    "# Видалення зайвих пробілів\n",
    "tdf = tdf.withColumn(\n",
    "    'Text',\n",
    "    F.trim(F.regexp_replace(F.col('Text'), r'\\s+', ' '))  # Замінити кілька пробілів на один\n",
    ")\n",
    "```\n",
    "\n",
    "---\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "id": "c1ihItE7lyYp"
   },
   "outputs": [],
   "source": [
    "# Видалення HTML-тегів із тексту\n",
    "tdf = tdf.withColumn(\n",
    "    'OriginalTweet',\n",
    "    F.regexp_replace(F.col('OriginalTweet'), r'<[^>]+>', '')  # Видалення всіх HTML-тегів\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "id": "ak3nRqhul5bQ"
   },
   "outputs": [],
   "source": [
    "# Видалення зайвих пробілів\n",
    "tdf = tdf.withColumn(\n",
    "    'OriginalTweet',\n",
    "    F.trim(F.regexp_replace(F.col('OriginalTweet'), r'\\s+', ' '))  # Замінити кілька пробілів на один\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "Mugj1s_RmDOT"
   },
   "source": [
    "Щоб видалити хештеги (`#example`) або витягнути їх із тексту, можна використовувати регулярні вирази в PySpark.\n",
    "\n",
    "---\n",
    "\n",
    "### Видалення хештегів\n",
    "Якщо потрібно видалити всі хештеги з тексту:\n",
    "\n",
    "```python\n",
    "from pyspark.sql import functions as F\n",
    "\n",
    "# Видалення хештегів\n",
    "tdf = tdf.withColumn(\n",
    "    'Text',\n",
    "    F.regexp_replace(F.col('Text'), r'#\\w+', '')  # Видалення слів, які починаються з \"#\"\n",
    ")\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "1. **`r'#\\w+'`**:\n",
    "   - `#` шукає символ хештегу.\n",
    "   - `\\w+` означає \"один або більше буквено-цифрових символів\" (слово).\n",
    "2. **`F.regexp_replace`**:\n",
    "   - Змінює всі знайдені хештеги на порожній рядок (`''`).\n",
    "\n",
    "---\n",
    "\n",
    "### Витягування хештегів\n",
    "Якщо потрібно витягнути всі хештеги в окрему колонку:\n",
    "\n",
    "```python\n",
    "# Витягнення хештегів\n",
    "tdf = tdf.withColumn(\n",
    "    'Hashtags',\n",
    "    F.regexp_extract(F.col('Text'), r'(#\\w+)', 1)  # Витягнути перший знайдений хештег\n",
    ")\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "### Витягнення всіх хештегів (списком)\n",
    "Якщо потрібно витягти всі хештеги як список:\n",
    "\n",
    "```python\n",
    "from pyspark.sql.functions import udf\n",
    "from pyspark.sql.types import ArrayType, StringType\n",
    "import re\n",
    "\n",
    "# Створення UDF для витягнення всіх хештегів\n",
    "def extract_hashtags(text):\n",
    "    return re.findall(r'#\\w+', text) if text else []\n",
    "\n",
    "extract_hashtags_udf = udf(extract_hashtags, ArrayType(StringType()))\n",
    "\n",
    "# Додати колонку з усіма хештегами\n",
    "tdf = tdf.withColumn('Hashtags', extract_hashtags_udf(F.col('Text')))\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "### Приклад\n",
    "Вхідні дані:\n",
    "```plaintext\n",
    "\"Here is a #test tweet with multiple #hashtags.\"\n",
    "```\n",
    "\n",
    "#### Після видалення:\n",
    "```plaintext\n",
    "\"Here is a tweet with multiple.\"\n",
    "```\n",
    "\n",
    "#### Після витягнення:\n",
    "Колонка `Hashtags`:\n",
    "```plaintext\n",
    "[\"#test\", \"#hashtags\"]\n",
    "```\n",
    "\n",
    "---\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "id": "tedOr_mTmXp6"
   },
   "outputs": [],
   "source": [
    "# Видалення хештегів\n",
    "tdf = tdf.withColumn(\n",
    "    'OriginalTweet',\n",
    "    F.regexp_replace(F.col('OriginalTweet'), r'#\\w+', '')  # Видалення слів, які починаються з \"#\"\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "q0RJX0Kvmf4L"
   },
   "source": [
    "Щоб обробляти числа (цифри) в тексті у PySpark, можна використовувати регулярні вирази з функцією `regexp_replace` для видалення, або `regexp_extract` для витягування чисел.\n",
    "\n",
    "---\n",
    "\n",
    "### Видалення чисел\n",
    "Щоб видалити всі числа з тексту:\n",
    "\n",
    "```python\n",
    "from pyspark.sql import functions as F\n",
    "\n",
    "# Видалення всіх чисел\n",
    "tdf = tdf.withColumn(\n",
    "    'Text',\n",
    "    F.regexp_replace(F.col('Text'), r'\\d+', '')  # Видалити всі числа\n",
    ")\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "1. **`r'\\d+'`**:\n",
    "   - `\\d` шукає цифру (0-9).\n",
    "   - `+` означає \"одна або більше цифр\".\n",
    "2. **`F.regexp_replace`**:\n",
    "   - Замість чисел вставляє порожній рядок (`''`).\n",
    "\n",
    "---\n",
    "\n",
    "### Витягування чисел\n",
    "Щоб витягнути перше знайдене число:\n",
    "\n",
    "```python\n",
    "# Витягнення першого числа\n",
    "tdf = tdf.withColumn(\n",
    "    'FirstNumber',\n",
    "    F.regexp_extract(F.col('Text'), r'(\\d+)', 1)  # Витягти перше число\n",
    ")\n",
    "```\n",
    "\n",
    "Щоб витягти всі числа як список:\n",
    "\n",
    "```python\n",
    "from pyspark.sql.functions import udf\n",
    "from pyspark.sql.types import ArrayType, StringType\n",
    "import re\n",
    "\n",
    "# UDF для витягнення всіх чисел\n",
    "def extract_digits(text):\n",
    "    return re.findall(r'\\d+', text) if text else []\n",
    "\n",
    "extract_digits_udf = udf(extract_digits, ArrayType(StringType()))\n",
    "\n",
    "# Додати колонку з усіма числами\n",
    "tdf = tdf.withColumn('Numbers', extract_digits_udf(F.col('Text')))\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "### Заміна чисел на певне значення\n",
    "Якщо потрібно замінити всі числа на, наприклад, `[NUM]`:\n",
    "\n",
    "```python\n",
    "# Заміна чисел на [NUM]\n",
    "tdf = tdf.withColumn(\n",
    "    'Text',\n",
    "    F.regexp_replace(F.col('Text'), r'\\d+', '[NUM]')\n",
    ")\n",
    "```\n",
    "\n",
    "---\n",
    "\n",
    "### Приклад\n",
    "Вхідний текст:\n",
    "```plaintext\n",
    "\"Order 1234 was placed on 2024-11-15.\"\n",
    "```\n",
    "\n",
    "#### Після видалення:\n",
    "```plaintext\n",
    "\"Order  was placed on -.\"\n",
    "```\n",
    "\n",
    "#### Після витягнення:\n",
    "Колонка `Numbers`:\n",
    "```plaintext\n",
    "[\"1234\", \"2024\", \"11\", \"15\"]\n",
    "```\n",
    "\n",
    "#### Після заміни:\n",
    "```plaintext\n",
    "\"Order [NUM] was placed on [NUM]-[NUM]-[NUM].\"\n",
    "```\n",
    "\n",
    "---"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "id": "7bt1gwRMmuH-"
   },
   "outputs": [],
   "source": [
    "# Видалення всіх чисел\n",
    "tdf = tdf.withColumn(\n",
    "    'OriginalTweet',\n",
    "    F.regexp_replace(F.col('OriginalTweet'), r'\\d+', '')  # Видалити всі числа\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "id": "4OhhiEm8EM4I"
   },
   "outputs": [],
   "source": [
    "from pyspark.ml import Pipeline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "id": "F-DWuezdGZHn"
   },
   "outputs": [],
   "source": [
    "from pyspark.ml.feature import Tokenizer, StopWordsRemover, CountVectorizer, VectorAssembler, HashingTF, IDF, StringIndexer\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "id": "m6ZWLczDsw0j"
   },
   "outputs": [],
   "source": [
    "tokenizer_tdf = Tokenizer(inputCol='OriginalTweet',outputCol='tokenized_Tweet')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "id": "JPEaNbmjvo4J"
   },
   "outputs": [],
   "source": [
    "add_stopwords = ['a','the','or', 'i', 'and', 'is', 'to','in', 'on']\n",
    "stopwordsRemover_tdf = StopWordsRemover(inputCol='tokenized_Tweet', outputCol='stopwordsremoved_Tweet').setStopWords(add_stopwords)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "id": "rfQWxAln2SIG"
   },
   "outputs": [],
   "source": [
    "countVectors_tdf = CountVectorizer(inputCol='stopwordsremoved_Tweet', outputCol='countvectorizer_Tweet')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "id": "XcG8eYNo53TO"
   },
   "outputs": [],
   "source": [
    "label_stringIdx_tdf = StringIndexer(inputCol = \"Sentiment\", outputCol = \"Sentiment_label\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "id": "pGaAD8OZIYkr"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:39:07 WARN TaskSetManager: Stage 1 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:39:11 WARN TaskSetManager: Stage 5 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+--------------------+------------------+--------------------+----------------------+---------------------+---------------+\n",
      "|       OriginalTweet|         Sentiment|     tokenized_Tweet|stopwordsremoved_Tweet|countvectorizer_Tweet|Sentiment_label|\n",
      "+--------------------+------------------+--------------------+----------------------+---------------------+---------------+\n",
      "|TRENDING: New Yor...|Extremely Negative|[trending:, new, ...|  [trending:, new, ...| (80942,[14,17,30,...|            4.0|\n",
      "|When I couldn't f...|          Positive|[when, i, couldn'...|  [when, couldn't, ...| (80942,[0,1,2,3,5...|            0.0|\n",
      "|Find out how you ...|Extremely Positive|[find, out, how, ...|  [find, out, how, ...| (80942,[4,20,33,3...|            3.0|\n",
      "| buying hits  Cit...|          Negative|[, buying, hits, ...|  [, buying, hits, ...| (80942,[0,14,30,6...|            1.0|\n",
      "|           One we...|           Neutral|[, , , , , , , , ...|  [, , , , , , , , ...| (80942,[0,30,77,8...|            2.0|\n",
      "+--------------------+------------------+--------------------+----------------------+---------------------+---------------+\n",
      "only showing top 5 rows\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:39:12 WARN TaskSetManager: Stage 8 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    }
   ],
   "source": [
    "pipeline = Pipeline(stages=[tokenizer_tdf, stopwordsRemover_tdf, countVectors_tdf,label_stringIdx_tdf])\n",
    "\n",
    "pipelineFit = pipeline.fit(tdf)\n",
    "dataset = pipelineFit.transform(tdf)\n",
    "dataset.show(5)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "xSMMk6oCnozZ"
   },
   "source": [
    "##__Задачі кластеризації__\n",
    "\n",
    "<center><img src=\"https://www.tutorialandexample.com/wp-content/uploads/2019/11/An-example-of-a-cluster-system.png\" width=\"600\"></center>\n",
    "\n",
    "Задача кластеризації в машинному навчанні — це задача розбиття множини об'єктів на групи за схожими характеристиками. На відміну від класифікації перелік груп не вказаний і визначається в процесі роботи алгоритму.\n",
    "\n",
    ">__Етапи кластеризації__\n",
    "\n",
    "* Відбір даних\n",
    "* Визначення множини змінних, по яким будуть оцінюватися об'єкти у виборці\n",
    "* Обчислення міри схожості між об'єктами\n",
    "* Застосування методів кластерного аналізу для створення групп схожих об'єктів\n",
    "\n",
    "Після отримання та аналізу результатів можливе коригування обраної метрики та методу кластеризації до отримання оптимального результату.\n",
    "\n",
    "\n",
    ">__Метрика (відстань)__\n",
    "\n",
    "* __Евклідова метрика__\n",
    "$$\\rho(x, y)=\\sqrt{\\sum_{i=1}^n{(x_i-y_i)^2}} $$\n",
    "\n",
    "* __Манхеттенська метрика ($L_1$)__\n",
    "$$\\rho(x, y)=\\sum_{i=1}^n{|x_i-y_i|} $$\n",
    "Міра впливу викидів менша в порівнянні з Евклідовою метрикою\n",
    "* __Метрика Мінковського__\n",
    "$$\\rho(x, y)=\\left(\\sum_{i=1}^n{|x_i-y_i|^q} \\right)^{1/q}$$\n",
    "Застосовується у випадку, коли необхідно збільшити або зменшити вагу, яка відноситься до розмірності, для якої відповідні об'єкти сильно відрізняються\n",
    "\n",
    "$q=1$ - Манхетенська метрика\n",
    "\n",
    "$q=2$ - Евклідова метрика\n",
    "\n",
    "* __Метрика Чебишева__\n",
    "$$\\rho(x, y)=\\max\\left(|x_i-y_i|\\right)$$\n",
    "Корисна, коли необхідно визначити два об'єкти як \"різні\", якщо вони відрізняються координатою\n",
    "\n",
    ">__Класифікація алгоритмів__\n",
    "\n",
    "* _<u>Ієрархічні алгоритми (алгоритми таксономії)</u>_ будують систему вкладених розбиттів. На виході отримується дерево кластерів, де корінь - вся вибірка, а листя - найменші кластери\n",
    "* _<u>Плоскі алгоритми</u>_ будують одне розбиття об'єктів на кластери.\n",
    "* _<u>Чіткі (неперетинні) алгоритми_</u> кожному об'єкту вибірки ставлять у відповідність номер кластеру, тобто кожен об'єкт належить лише одному кластеру.\n",
    "* _<u>Нечіеткі (перетинні) алгоритми_</u> кожному об'єкту ставлять у відповідність набір дійсних чисел, які показують степінь (ймовірність) відношення об'єкту до кластерів.\n",
    "\n",
    "### __Застосування кластеризації__\n",
    ">___Медицина___\n",
    "\n",
    "__Візуалізація__. На скануванні кластерний аналіз можна використовувати для розрізнення різних типів тканин на тривимірному зображенні для багатьох різних цілей.\n",
    "\n",
    "__Аналіз антимікробної активності.__ Кластерний аналіз можна використовувати для аналізу закономірностей резистентності до антибіотиків, для класифікації антимікробних сполук за механізмом їх дії, для класифікації антибіотиків за їх антибактеріальною активністю.\n",
    "\n",
    "__Сегментація IMRT.__ Кластеризація може бути використана для поділу зображення на окремі зони для аналізу в радіаційній терапії.\n",
    "\n",
    ">___Бізнес і маркетинг___\n",
    "\n",
    "__Маркетингове дослідження.__ Кластерний аналіз широко використовується в маркетингових дослідженнях при роботі з багатоваріантними даними опитувань і тестових панелей. Дослідники ринку використовують кластерний аналіз для поділу загальної сукупності споживачів на сегменти ринку та для кращого розуміння відносин між різними групами споживачів/потенційних клієнтів, а також для сегментації ринку, позиціонування продукту, розробки нових продуктів та вибору тестових ринків.\n",
    "\n",
    "__Групування товарів для покупок.__ Кластеризація може бути використана для групування всіх товарів, доступних в Інтернеті, в набір унікальних продуктів. Наприклад, усі товари на eBay можна згрупувати в унікальні продукти.\n",
    "\n",
    ">___Суспільні науки___\n",
    "\n",
    "__Аналіз злочинності.__ Кластерний аналіз може бути використаний для виявлення областей, де є більші випадки окремих видів злочинів. Визначивши ці окремі зони або «гарячі точки», де подібний злочин стався протягом певного періоду часу, можна ефективніше керувати ресурсами правоохоронних органів.\n",
    "\n",
    "__Навчальний аналіз даних.__ Кластерний аналіз використовується, наприклад, для визначення груп шкіл або учнів зі схожими характеристиками.\n",
    "\n",
    "__Типології.__ На основі даних опитувань такі проекти, як ті, що здійснюються дослідницьким центром Pew Research Center, використовують кластерний аналіз для визначення типологій думок, звичок і демографії, які можуть бути корисними в політиці та маркетингу.\n",
    "\n",
    "\n",
    "<center><img src=\"https://miro.medium.com/v2/resize:fit:1100/format:webp/0*c7ZmpQdReYtT_e1b.png\" width=\"600\"></center>\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "CXrfRXeWoXJ0"
   },
   "source": [
    "##__Метод $k$-середніх ($k$-means)__\n",
    "\n",
    "Метод $k$-средних (k-means) — найбільш вживаний метод кластеризации. Полягає в мінімізації сумарного квадрату відхилення точок кластеру від центроїдів цього кластеру (**inertia**).\n",
    "$$g$$\n",
    "$$V=\\sum_{i=1}^{k}\\sum_{x \\in S_{i}} (x-\\mu_{i})^{2}$$\n",
    "\n",
    "де $k$ — число кластерів, $S_{i}$ — отримані кластери, $i=1,2,\\dots ,k$, а $\\mu _{i}$ — центри мас усіх векторів $x$ з кластеру $S_{i}$.\n",
    "\n",
    "Інерцію можна розпізнати як міру внутрішньої когерентності кластерів. Вона має недоліки:\n",
    "\n",
    "* є припущення, що кластери є опуклими та ізотропними, що не завжди так.Погано реагує на подовжені скупчення або різноманіття неправильної форми.\n",
    "\n",
    "* не є нормалізованим показником: ми просто знаємо, що нижчі значення краще, а нуль оптимальний. Але в багатовимірних просторах евклідові відстані мають тенденцію до збільшення (це приклад так званого «прокляття розмірності»). Виконання алгоритму зменшення розмірності, такого як аналіз головних компонентів (PCA) перед кластеризацією k-середніх, може полегшити цю проблему та прискорити обчислення.\n",
    "\n",
    "<center><img src=\"https://miro.medium.com/max/720/1*KrcZK0xYgTa4qFrVr0fO2w.gif\" width=\"400\"></center>\n",
    "\n",
    "###__Етапи алгоритму:__\n",
    "1. Початкова ініціалізація центроїдів кластерів будь-яким способом (наприклад, можна задати початкові значення випадково обраними точками з простору даних; можна обрати випадкові точки з вхідного масиву даних і т.д.).\n",
    "2. Відбувається ассоціація між елементами даних та кластерами, представлених своїми центроїдами.\n",
    "3. Відбувається перерозподіл центроїдів, як среднє значення від даних, які були включені у відповідний кластер (відбувається модифікація параметрів моделі таким чином, щоб максимізувати ймовірність потрапляння елементу в обраний кластер). У випадку, якщо кластер після кроку 2 виявився порожнім, то відбувається переініціалізація іншим способом.\n",
    "\n",
    "Кроки 2-3 повторються до збіжності, або доки не буде досягнуто іншого критерію зупинки алгоритму.\n",
    "\n",
    "\n",
    "### __Переваги методу__\n",
    "\n",
    "1. Простий у реалізації\n",
    "2. Достатньо швидкий\n",
    "3. Має лінійну складність $O(n)$\n",
    "4. Добре працює, коли кластери приблизно однакового розміру та регулярної опуклої форми\n",
    "\n",
    "\n",
    "### __Недоліки методу__\n",
    "\n",
    "1 Не гарантується досягнення глобального мінімуму сумарного квадрату відхилення $V$, а лише одного з локальних мінімумів.\n",
    "2. Результат залежить від вибору вихідних центроїдів та метрики, не існує методу оптимального вибору центроїдів.\n",
    "3. Кількість кластерів необхідно знати наперед.\n",
    "4. Не справляється з випадком, коли об'єкт належить різним кластерам в рівній мірі обо не належить жодному кластеру.\n",
    "5. Погано кластеризує дані з різною щільністю або кластери неопуклої форми\n",
    "\n",
    "<center><img src=\"https://miro.medium.com/max/536/1*Xvl-pXxsLAZ7gbTUuvgMtA.png\" width=\"400\"></center>\n",
    "\n",
    "<img src=\"https://arogozhnikov.github.io/images/opera/post/clustering-kmeans-smiley.gif\" width=\"600\" >\n",
    "</center>\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "TO9r_fjosiiF"
   },
   "source": [
    "`ClusteringEvaluator` в PySpark є інструментом для оцінки якості кластеризації, який можна використовувати разом з такими алгоритмами, як KMeans або BisectingKMeans. Він допомагає визначити, наскільки добре обрані кластери розділяють дані.\n",
    "\n",
    "### Основні параметри:\n",
    "- **`predictionCol`**: Назва стовпця, що містить результати класифікації (кластерні мітки).\n",
    "- **`featuresCol`**: Назва стовпця, що містить ознаки для кластеризації.\n",
    "- **`metricName`**: Тип метрики, яку ви хочете використовувати. Наприклад, `silhouette` (Silhouette Score) є найпоширенішою метрикою.\n",
    "- **`distanceMeasure`**: Вимірювання відстані. Для Silhouette Score зазвичай використовують `\"squaredEuclidean\"`, але можна вибрати й інші метрики, такі як \"cosine\".\n",
    "\n",
    "### Silhouette Score:\n",
    "Silhouette Score є метрикою, яка вимірює, наскільки добре кожен об'єкт вписується в свій кластер у порівнянні з іншими кластерами. Він має значення від -1 до 1:\n",
    "- Значення близьке до **1** вказує на те, що об'єкт добре класифікований у правильний кластер.\n",
    "- Значення близьке до **0** вказує на те, що об'єкт знаходиться на межі між двома кластерами.\n",
    "- Значення **менше 0** свідчить про те, що кластеризація була проведена погано, і дані, ймовірно, були віднесені до невідповідних кластерів.\n",
    "\n",
    "### Як це працює:\n",
    "1. Створюється модель кластеризації (наприклад, KMeans).\n",
    "2. Модель застосовується до даних, і для кожного об'єкта класифікації визначається його приналежність до кластера.\n",
    "3. `ClusteringEvaluator` оцінює якість кластеризації на основі заданої метрики (наприклад, Silhouette Score).\n",
    "\n",
    "### Приклад використання:\n",
    "\n",
    "```python\n",
    "from pyspark.ml.clustering import KMeans\n",
    "from pyspark.ml.evaluation import ClusteringEvaluator\n",
    "\n",
    "# Створення моделі KMeans\n",
    "kmeans = KMeans(k=3, featuresCol=\"features\", predictionCol=\"prediction\")\n",
    "model = kmeans.fit(dataset)\n",
    "predictions = model.transform(dataset)\n",
    "\n",
    "# Оцінка результатів кластеризації\n",
    "evaluator = ClusteringEvaluator(metricName=\"silhouette\", featuresCol=\"features\", predictionCol=\"prediction\")\n",
    "silhouette_score = evaluator.evaluate(predictions)\n",
    "print(\"Silhouette Score = \" + str(silhouette_score))\n",
    "```\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "hwSvcGYMtWZV"
   },
   "source": [
    "**Сума квадратів внутрішньокластерних відхилень (WSS або SSE)**\n",
    "**Within Set Sum of Squared Errors**\n",
    "— це метрика, яка використовується в алгоритмах кластеризації для оцінки компактності кластерів. Вона обчислює суму квадратів відстаней між кожною точкою даних у кластері та його центроїдом. Ця метрика допомагає визначити якість кластеризації.\n",
    "\n",
    "---\n",
    "\n",
    "$$\n",
    "WSS = \\sum_{k=1}^{K} \\sum_{i \\in C_k} ||x_i - \\mu_k||^2\n",
    "$$\n",
    "де:\n",
    "- $ K $: Кількість кластерів.\n",
    "- $ C_k $: Набір точок у кластері $ k $.\n",
    "- $ x_i $: Точка даних у кластері $ C_k $.\n",
    "- $ \\mu_k $: Центроїд кластера $ C_k $.\n",
    "- $ ||x_i - \\mu_k||^2 $: Квадрат евклідової відстані між точкою даних і центроїдом.\n",
    "\n",
    "---\n",
    "\n",
    "### Інтерпретація:\n",
    "- **Менші значення WSS** означають, що точки ближчі до центроїда, тобто кластери компактніші.\n",
    "- **Вищі значення WSS** вказують на більшу розпорошеність кластерів, що може свідчити про неякісну кластеризацію.\n",
    "\n",
    "---\n",
    "\n",
    "### Використання:\n",
    "1. **Метод \"лікоть\" (Elbow Method)**: WSS часто використовується для визначення оптимальної кількості кластерів у $ K $-середніх чи інших алгоритмах кластеризації. Побудова графіка залежності WSS від кількості кластерів $ K $ зазвичай показує \"лікоть\" — оптимальну кількість кластерів.\n",
    "2. **Оцінка кластеризації**: Допомагає зрозуміти, чи покращується кластеризація в процесі навчання.\n",
    "\n",
    "---\n",
    "\n",
    "### Переваги:\n",
    "- Простота обчислення й інтерпретації.\n",
    "- Добре підходить для оцінки компактності кластерів.\n",
    "\n",
    "---\n",
    "\n",
    "### Недоліки:\n",
    "- Не враховує відокремленість кластерів.\n",
    "- Чутлива до масштабу даних і до викидів.\n",
    "\n",
    "Для кращої оцінки якості кластеризації WSS часто використовується разом із іншими метриками, такими як **силуетний коефіцієнт** або **індекс Девіса-Болдіна**."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "id": "V9j1WldLpMQr"
   },
   "outputs": [],
   "source": [
    "from pyspark.ml.evaluation import ClusteringEvaluator\n",
    "from pyspark.ml.clustering import KMeans"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "! pip install matplotlib --quiet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "id": "NGOKautgpQdb"
   },
   "outputs": [],
   "source": [
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "id": "WrKhJMJNpGB2"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:39:57 WARN TaskSetManager: Stage 90 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:39:58 WARN TaskSetManager: Stage 93 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:39:59 WARN TaskSetManager: Stage 94 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:39:59 WARN TaskSetManager: Stage 95 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:00 WARN TaskSetManager: Stage 96 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:00 WARN TaskSetManager: Stage 97 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:00 WARN TaskSetManager: Stage 98 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:00 WARN TaskSetManager: Stage 99 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:01 WARN TaskSetManager: Stage 101 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:02 WARN TaskSetManager: Stage 103 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:02 WARN TaskSetManager: Stage 105 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:02 WARN TaskSetManager: Stage 107 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:03 WARN DAGScheduler: Broadcasting large task binary with size 2.2 MiB\n",
      "24/12/07 09:40:03 WARN TaskSetManager: Stage 109 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:04 WARN DAGScheduler: Broadcasting large task binary with size 2.2 MiB\n",
      "24/12/07 09:40:04 WARN DAGScheduler: Broadcasting large task binary with size 2.2 MiB\n",
      "24/12/07 09:40:04 WARN TaskSetManager: Stage 112 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:05 WARN DAGScheduler: Broadcasting large task binary with size 2.2 MiB\n",
      "24/12/07 09:40:05 WARN TaskSetManager: Stage 114 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:06 WARN TaskSetManager: Stage 117 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Кількість кластерів: 2, Silhouette Score: 0.20249849365977313\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:40:07 WARN TaskSetManager: Stage 120 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:08 WARN TaskSetManager: Stage 121 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:08 WARN TaskSetManager: Stage 122 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:08 WARN TaskSetManager: Stage 123 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:08 WARN TaskSetManager: Stage 124 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:09 WARN TaskSetManager: Stage 125 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:09 WARN TaskSetManager: Stage 126 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:09 WARN TaskSetManager: Stage 128 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:10 WARN TaskSetManager: Stage 130 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:10 WARN TaskSetManager: Stage 132 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:10 WARN TaskSetManager: Stage 134 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:10 WARN TaskSetManager: Stage 136 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:10 WARN TaskSetManager: Stage 138 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:11 WARN TaskSetManager: Stage 140 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:11 WARN TaskSetManager: Stage 142 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:11 WARN TaskSetManager: Stage 144 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:11 WARN TaskSetManager: Stage 146 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:11 WARN TaskSetManager: Stage 148 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:11 WARN TaskSetManager: Stage 150 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:12 WARN TaskSetManager: Stage 152 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:12 WARN TaskSetManager: Stage 154 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:12 WARN TaskSetManager: Stage 156 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:12 WARN TaskSetManager: Stage 158 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:12 WARN TaskSetManager: Stage 160 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:12 WARN TaskSetManager: Stage 162 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:13 WARN TaskSetManager: Stage 164 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:13 WARN TaskSetManager: Stage 166 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:13 WARN DAGScheduler: Broadcasting large task binary with size 2.8 MiB\n",
      "24/12/07 09:40:13 WARN TaskSetManager: Stage 168 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:14 WARN DAGScheduler: Broadcasting large task binary with size 2.8 MiB\n",
      "24/12/07 09:40:14 WARN DAGScheduler: Broadcasting large task binary with size 2.8 MiB\n",
      "24/12/07 09:40:14 WARN TaskSetManager: Stage 171 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:15 WARN DAGScheduler: Broadcasting large task binary with size 2.8 MiB\n",
      "24/12/07 09:40:15 WARN TaskSetManager: Stage 173 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:16 WARN TaskSetManager: Stage 176 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Кількість кластерів: 3, Silhouette Score: 0.06758581461677055\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:40:17 WARN TaskSetManager: Stage 179 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:17 WARN TaskSetManager: Stage 180 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:17 WARN TaskSetManager: Stage 181 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:17 WARN TaskSetManager: Stage 182 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:17 WARN TaskSetManager: Stage 183 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:17 WARN TaskSetManager: Stage 184 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:18 WARN TaskSetManager: Stage 185 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:18 WARN TaskSetManager: Stage 187 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:18 WARN TaskSetManager: Stage 189 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:18 WARN TaskSetManager: Stage 191 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:18 WARN TaskSetManager: Stage 193 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 195 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 197 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 199 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 201 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 203 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 205 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 207 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 209 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:19 WARN TaskSetManager: Stage 211 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:20 WARN TaskSetManager: Stage 213 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:20 WARN TaskSetManager: Stage 215 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:20 WARN TaskSetManager: Stage 217 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:20 WARN TaskSetManager: Stage 219 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:20 WARN TaskSetManager: Stage 221 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:20 WARN TaskSetManager: Stage 223 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:20 WARN TaskSetManager: Stage 225 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:20 WARN DAGScheduler: Broadcasting large task binary with size 3.4 MiB\n",
      "24/12/07 09:40:20 WARN TaskSetManager: Stage 227 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:21 WARN DAGScheduler: Broadcasting large task binary with size 3.4 MiB\n",
      "24/12/07 09:40:21 WARN DAGScheduler: Broadcasting large task binary with size 3.4 MiB\n",
      "24/12/07 09:40:21 WARN TaskSetManager: Stage 230 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:22 WARN DAGScheduler: Broadcasting large task binary with size 3.4 MiB\n",
      "24/12/07 09:40:22 WARN TaskSetManager: Stage 232 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:22 WARN TaskSetManager: Stage 235 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Кількість кластерів: 4, Silhouette Score: 0.0849724272376007\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:40:23 WARN TaskSetManager: Stage 238 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:24 WARN TaskSetManager: Stage 239 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:24 WARN TaskSetManager: Stage 240 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:24 WARN TaskSetManager: Stage 241 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:24 WARN TaskSetManager: Stage 242 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:24 WARN TaskSetManager: Stage 243 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:24 WARN TaskSetManager: Stage 244 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:24 WARN TaskSetManager: Stage 246 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:25 WARN TaskSetManager: Stage 248 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:25 WARN TaskSetManager: Stage 250 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:25 WARN TaskSetManager: Stage 252 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:25 WARN TaskSetManager: Stage 254 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:25 WARN TaskSetManager: Stage 256 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:25 WARN TaskSetManager: Stage 258 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:25 WARN TaskSetManager: Stage 260 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 262 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 264 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 266 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 268 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 270 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 272 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 274 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 276 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:26 WARN TaskSetManager: Stage 278 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:27 WARN TaskSetManager: Stage 280 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:27 WARN TaskSetManager: Stage 282 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:27 WARN TaskSetManager: Stage 284 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:27 WARN DAGScheduler: Broadcasting large task binary with size 4.1 MiB\n",
      "24/12/07 09:40:27 WARN TaskSetManager: Stage 286 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:28 WARN DAGScheduler: Broadcasting large task binary with size 4.0 MiB\n",
      "24/12/07 09:40:28 WARN DAGScheduler: Broadcasting large task binary with size 4.1 MiB\n",
      "24/12/07 09:40:28 WARN TaskSetManager: Stage 289 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:28 WARN DAGScheduler: Broadcasting large task binary with size 4.1 MiB\n",
      "24/12/07 09:40:28 WARN TaskSetManager: Stage 291 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:29 WARN TaskSetManager: Stage 294 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Кількість кластерів: 5, Silhouette Score: 0.0439385589359011\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:40:30 WARN TaskSetManager: Stage 297 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:30 WARN TaskSetManager: Stage 298 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:30 WARN TaskSetManager: Stage 299 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:30 WARN TaskSetManager: Stage 300 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:30 WARN TaskSetManager: Stage 301 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:31 WARN TaskSetManager: Stage 302 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:31 WARN TaskSetManager: Stage 303 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:31 WARN TaskSetManager: Stage 305 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:31 WARN TaskSetManager: Stage 307 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 309 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 311 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 313 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 315 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 317 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 319 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 321 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 323 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:32 WARN TaskSetManager: Stage 325 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 327 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 329 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 331 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 333 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 335 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 337 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 339 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 341 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:33 WARN TaskSetManager: Stage 343 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:34 WARN DAGScheduler: Broadcasting large task binary with size 4.7 MiB\n",
      "24/12/07 09:40:34 WARN TaskSetManager: Stage 345 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:34 WARN DAGScheduler: Broadcasting large task binary with size 4.7 MiB\n",
      "24/12/07 09:40:34 WARN DAGScheduler: Broadcasting large task binary with size 4.7 MiB\n",
      "24/12/07 09:40:34 WARN TaskSetManager: Stage 348 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:35 WARN DAGScheduler: Broadcasting large task binary with size 4.7 MiB\n",
      "24/12/07 09:40:35 WARN TaskSetManager: Stage 350 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Кількість кластерів: 6, Silhouette Score: 0.023572708163353596\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:40:36 WARN TaskSetManager: Stage 353 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:36 WARN TaskSetManager: Stage 356 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:37 WARN TaskSetManager: Stage 357 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:37 WARN TaskSetManager: Stage 358 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:37 WARN TaskSetManager: Stage 359 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:37 WARN TaskSetManager: Stage 360 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:37 WARN TaskSetManager: Stage 361 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:37 WARN TaskSetManager: Stage 362 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:37 WARN TaskSetManager: Stage 364 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:38 WARN TaskSetManager: Stage 366 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:38 WARN TaskSetManager: Stage 368 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:38 WARN TaskSetManager: Stage 370 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:38 WARN TaskSetManager: Stage 372 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:38 WARN TaskSetManager: Stage 374 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:39 WARN TaskSetManager: Stage 376 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:39 WARN TaskSetManager: Stage 378 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:39 WARN TaskSetManager: Stage 380 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:39 WARN TaskSetManager: Stage 382 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:39 WARN TaskSetManager: Stage 384 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:39 WARN TaskSetManager: Stage 386 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:39 WARN TaskSetManager: Stage 388 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:39 WARN TaskSetManager: Stage 390 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:40 WARN TaskSetManager: Stage 392 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:40 WARN TaskSetManager: Stage 394 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:40 WARN TaskSetManager: Stage 396 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:40 WARN TaskSetManager: Stage 398 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:40 WARN TaskSetManager: Stage 400 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:40 WARN TaskSetManager: Stage 402 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:40 WARN DAGScheduler: Broadcasting large task binary with size 5.3 MiB\n",
      "24/12/07 09:40:40 WARN TaskSetManager: Stage 404 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:41 WARN DAGScheduler: Broadcasting large task binary with size 5.3 MiB\n",
      "24/12/07 09:40:41 WARN DAGScheduler: Broadcasting large task binary with size 5.3 MiB\n",
      "24/12/07 09:40:41 WARN TaskSetManager: Stage 407 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:40:42 WARN DAGScheduler: Broadcasting large task binary with size 5.3 MiB\n",
      "24/12/07 09:40:42 WARN TaskSetManager: Stage 409 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Кількість кластерів: 7, Silhouette Score: -0.007406893693465897\n",
      "Кількість кластерів: 2, Silhouette Score: 0.20249849365977313\n",
      "Кількість кластерів: 3, Silhouette Score: 0.06758581461677055\n",
      "Кількість кластерів: 4, Silhouette Score: 0.0849724272376007\n",
      "Кількість кластерів: 5, Silhouette Score: 0.0439385589359011\n",
      "Кількість кластерів: 6, Silhouette Score: 0.023572708163353596\n",
      "Кількість кластерів: 7, Silhouette Score: -0.007406893693465897\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Порожній список для зберігання значень Silhouette Score\n",
    "wssse_values = []\n",
    "\n",
    "# Ініціалізація ClusteringEvaluator\n",
    "evaluator = ClusteringEvaluator(\n",
    "    predictionCol='prediction',\n",
    "    featuresCol='countvectorizer_Tweet',\n",
    "    metricName='silhouette',\n",
    "    distanceMeasure='squaredEuclidean'\n",
    ")\n",
    "\n",
    "# Цикл для різних значень k\n",
    "for i in range(2, 8):  # k від 2 до 7\n",
    "    KMeans_mod = KMeans(featuresCol='countvectorizer_Tweet', k=i)\n",
    "    KMeans_fit = KMeans_mod.fit(dataset)\n",
    "    output = KMeans_fit.transform(dataset)\n",
    "\n",
    "    # Обчислення Silhouette Score\n",
    "    score = evaluator.evaluate(output)\n",
    "    wssse_values.append((i, score))  # Зберігаємо (k, score)\n",
    "\n",
    "    print(f\"Кількість кластерів: {i}, Silhouette Score: {score}\")\n",
    "\n",
    "# Виведення результатів\n",
    "for k, score in wssse_values:\n",
    "    print(f\"Кількість кластерів: {k}, Silhouette Score: {score}\")\n",
    "\n",
    "# Побудова графіка\n",
    "ks, scores = zip(*wssse_values)\n",
    "plt.plot(ks, scores, marker='o', linestyle='-', color='b')\n",
    "plt.xlabel('Кількість кластерів (k)')\n",
    "plt.ylabel('Silhouette Score')\n",
    "plt.title('Залежність Silhouette Score від кількості кластерів')\n",
    "plt.grid(True)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "! pip install scikit-learn --quiet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {
    "id": "27Kw4zMW6h6k"
   },
   "outputs": [],
   "source": [
    "from pyspark.sql.functions import col\n",
    "from sklearn.metrics import confusion_matrix, classification_report"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {
    "id": "fB4gyEFz4ex_"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:41:36 WARN TaskSetManager: Stage 412 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:37 WARN TaskSetManager: Stage 415 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:37 WARN TaskSetManager: Stage 416 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:37 WARN TaskSetManager: Stage 417 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:38 WARN TaskSetManager: Stage 418 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:38 WARN TaskSetManager: Stage 419 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:38 WARN TaskSetManager: Stage 420 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:38 WARN TaskSetManager: Stage 421 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:38 WARN TaskSetManager: Stage 423 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 425 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 427 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 429 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 431 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 433 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 435 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 437 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 439 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:39 WARN TaskSetManager: Stage 441 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:40 WARN TaskSetManager: Stage 443 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:40 WARN TaskSetManager: Stage 445 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:40 WARN TaskSetManager: Stage 447 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:40 WARN TaskSetManager: Stage 449 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:40 WARN TaskSetManager: Stage 451 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:40 WARN TaskSetManager: Stage 453 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:40 WARN TaskSetManager: Stage 455 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:40 WARN TaskSetManager: Stage 457 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:41 WARN TaskSetManager: Stage 459 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:41 WARN TaskSetManager: Stage 461 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:41 WARN DAGScheduler: Broadcasting large task binary with size 4.1 MiB\n",
      "24/12/07 09:41:41 WARN TaskSetManager: Stage 463 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:41 WARN DAGScheduler: Broadcasting large task binary with size 4.0 MiB\n"
     ]
    }
   ],
   "source": [
    "# Створення моделі KMeans\n",
    "K=5\n",
    "kmeans = KMeans(k=K, featuresCol=\"countvectorizer_Tweet\", predictionCol=\"prediction\")\n",
    "model = kmeans.fit(dataset)\n",
    "predictions = model.transform(dataset)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {
    "id": "8UP8_i8R_b4y"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:41:55 WARN DAGScheduler: Broadcasting large task binary with size 4.1 MiB\n",
      "24/12/07 09:41:55 WARN TaskSetManager: Stage 466 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 09:41:56 WARN DAGScheduler: Broadcasting large task binary with size 4.1 MiB\n",
      "24/12/07 09:41:56 WARN TaskSetManager: Stage 468 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Кількість кластерів: 5, Silhouette Score: 0.0439385589359011\n"
     ]
    }
   ],
   "source": [
    "score = evaluator.evaluate(predictions)\n",
    "# Зберігаємо (k, score)\n",
    "\n",
    "print(f\"Кількість кластерів: {K}, Silhouette Score: {score}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {
    "id": "nnaIT5HsAMje"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+--------------------+------------------+--------------------+----------------------+---------------------+---------------+----------+\n",
      "|       OriginalTweet|         Sentiment|     tokenized_Tweet|stopwordsremoved_Tweet|countvectorizer_Tweet|Sentiment_label|prediction|\n",
      "+--------------------+------------------+--------------------+----------------------+---------------------+---------------+----------+\n",
      "|TRENDING: New Yor...|Extremely Negative|[trending:, new, ...|  [trending:, new, ...| (80942,[14,17,30,...|            4.0|         0|\n",
      "|When I couldn't f...|          Positive|[when, i, couldn'...|  [when, couldn't, ...| (80942,[0,1,2,3,5...|            0.0|         1|\n",
      "|Find out how you ...|Extremely Positive|[find, out, how, ...|  [find, out, how, ...| (80942,[4,20,33,3...|            3.0|         0|\n",
      "| buying hits  Cit...|          Negative|[, buying, hits, ...|  [, buying, hits, ...| (80942,[0,14,30,6...|            1.0|         1|\n",
      "|           One we...|           Neutral|[, , , , , , , , ...|  [, , , , , , , , ...| (80942,[0,30,77,8...|            2.0|         3|\n",
      "|Do you remember t...|           Neutral|[do, you, remembe...|  [do, you, remembe...| (80942,[0,2,3,4,5...|            2.0|         4|\n",
      "|Voting in the age...|          Positive|[voting, in, the,...|  [voting, age, of,...| (80942,[0,1,33,68...|            0.0|         2|\n",
      "|@DrTedros \"We can...|           Neutral|[@drtedros, \"we, ...|  [@drtedros, \"we, ...| (80942,[0,1,8,11,...|            2.0|         2|\n",
      "|HI TWITTER! I am ...|Extremely Negative|[hi, twitter!, i,...|  [hi, twitter!, am...| (80942,[1,2,3,4,1...|            4.0|         4|\n",
      "|Anyone been in a ...|Extremely Positive|[anyone, been, in...|  [anyone, been, su...| (80942,[12,17,26,...|            3.0|         0|\n",
      "|Best quality couc...|          Positive|[best, quality, c...|  [best, quality, c...| (80942,[2,3,5,8,1...|            0.0|         0|\n",
      "|Beware of counter...|Extremely Negative|[beware, of, coun...|  [beware, of, coun...| (80942,[0,1,5,79,...|            4.0|         2|\n",
      "|Panic food buying...|Extremely Negative|[panic, food, buy...|  [panic, food, buy...| (80942,[0,7,9,20,...|            4.0|         1|\n",
      "| Went to the Groc...|Extremely Positive|[, went, to, the,...|  [, went, grocery,...| (80942,[0,1,2,10,...|            3.0|         2|\n",
      "|While we were bus...|          Positive|[while, we, were,...|  [while, we, were,...| (80942,[2,13,18,2...|            0.0|         0|\n",
      "| @flyspicejet is ...|Extremely Negative|[, @flyspicejet, ...|  [, @flyspicejet, ...| (80942,[0,3,5,6,1...|            4.0|         1|\n",
      "|What Precautionar...|Extremely Positive|[what, precaution...|  [what, precaution...| (80942,[0,4,11,22...|            3.0|         4|\n",
      "|When youÂre stoc...|           Neutral|[when, youâre, s...|  [when, youâre, s...| (80942,[2,9,11,23...|            2.0|         0|\n",
      "|That's about a we...|          Positive|[that's, about, a...|  [that's, about, w...| (80942,[2,15,20,2...|            0.0|         0|\n",
      "|Studies show the ...|Extremely Positive|[studies, show, t...|  [studies, show, ,...| (80942,[0,1,4,5,2...|            3.0|         1|\n",
      "+--------------------+------------------+--------------------+----------------------+---------------------+---------------+----------+\n",
      "only showing top 20 rows\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:41:59 WARN DAGScheduler: Broadcasting large task binary with size 4.0 MiB\n",
      "24/12/07 09:41:59 WARN TaskSetManager: Stage 471 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n"
     ]
    }
   ],
   "source": [
    "predictions.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "! pip install seaborn --quiet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {
    "id": "rVAOV-BV-tkT"
   },
   "outputs": [],
   "source": [
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {
    "id": "XsAD5Jjo81Ba"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 09:42:16 WARN DAGScheduler: Broadcasting large task binary with size 4.0 MiB\n",
      "24/12/07 09:42:16 WARN TaskSetManager: Stage 472 contains a task of very large size (1119 KiB). The maximum recommended task size is 1000 KiB.\n",
      "                                                                                \r"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[5317 1877 3524  175 1476]\n",
      " [4599 1742 3480  165  972]\n",
      " [4437 1334 1880  227  454]\n",
      " [2616 1161 2104   83 1259]\n",
      " [2241 1034 2118   51  629]]\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x600 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "              precision    recall  f1-score   support\n",
      "\n",
      "         0.0       0.28      0.43      0.34     12369\n",
      "         1.0       0.24      0.16      0.19     10958\n",
      "         2.0       0.14      0.23      0.18      8332\n",
      "         3.0       0.12      0.01      0.02      7223\n",
      "         4.0       0.13      0.10      0.12      6073\n",
      "\n",
      "    accuracy                           0.21     44955\n",
      "   macro avg       0.18      0.19      0.17     44955\n",
      "weighted avg       0.20      0.21      0.19     44955\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Порівняння з відомими мітками (наприклад, 'true_labels')\n",
    "true_labels = predictions.select(\"Sentiment_label\", \"prediction\").toPandas()\n",
    "\n",
    "# Обчислення Confusion Matrics\n",
    "cm = confusion_matrix(true_labels['Sentiment_label'], true_labels['prediction'])\n",
    "print(cm)\n",
    "\n",
    "# Візуалізація за допомогою теплової карти\n",
    "plt.figure(figsize=(8, 6))\n",
    "sns.heatmap(cm, annot=True, fmt=\"d\", cmap=\"Blues\",yticklabels=[\"Positive\", \"Negative\",\"Neutral\",\"Extremely Positive\",\"Extremely Negative\"])\n",
    "plt.title(\"Confusion Matrix\")\n",
    "plt.xlabel(\"Predicted Labels\")\n",
    "plt.ylabel(\"True Labels\")\n",
    "plt.show()\n",
    "\n",
    "# Додатково можна обчислити інші метрики\n",
    "print(classification_report(true_labels['Sentiment_label'], true_labels['prediction']))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "uEoeTCVzgj0O"
   },
   "source": [
    "##__Самостійні завдання__\n",
    "\n",
    "> Скопіювати блок самостійних завдань в окремий файл ***LastName_CP7.ipynb***\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "0BDe0NyTgmSY"
   },
   "source": [
    "### Завдання №1\n",
    "\n",
    "1. Інсталювати та імпортувати необхідні бібліотеки та модулі\n",
    "2. Створити Spark Session\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "id": "s0XIjMe_gpOr"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Setting default log level to \"WARN\".\n",
      "To adjust logging level use sc.setLogLevel(newLevel). For SparkR, use setLogLevel(newLevel).\n",
      "24/12/07 13:50:04 WARN NativeCodeLoader: Unable to load native-hadoop library for your platform... using builtin-java classes where applicable\n"
     ]
    }
   ],
   "source": [
    "# МІСЦЕ ДЛЯ КОДУ\n",
    "# імпорт допоміжної бібліотеки для організації правильного шляху до Spark\n",
    "import findspark\n",
    "findspark.init()\n",
    "#імпорт бібліотек та модулів\n",
    "\n",
    "import pandas as pd\n",
    "from pyspark import SparkContext, SparkConf\n",
    "from pyspark.sql import SparkSession\n",
    "\n",
    "# Створення spark session\n",
    "\n",
    "spark = SparkSession \\\n",
    "    .builder \\\n",
    "    .appName(\"My_Spark_Text_Сlassification_2\") \\\n",
    "    .config(\"spark.executor.memory\", \"4g\") \\\n",
    "    .config(\"spark.driver.memory\", \"4g\")\\\n",
    "    .config(\"spark.executor.cores\", \"4\") \\\n",
    "    .config(\"spark.sql.shuffle.partitions\", \"200\") \\\n",
    "    .config(\"spark.serializer\", \"org.apache.spark.serializer.KryoSerializer\") \\\n",
    "    .config(\"spark.sql.autoBroadcastJoinThreshold\", \"-1\")\\\n",
    "    .config(\"spark.driver.maxResultSize\", \"4g\") \\\n",
    "    .getOrCreate()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "T2xu6a8QfN35"
   },
   "source": [
    "### Завдання №2\n",
    "\n",
    "* Завантажте фійл `text_data_med.csv` в локальне сховище\n",
    "та застосуйте команду для зчитування файлу\n",
    "`df = pd.read_csv('text_data_med.csv')`\n",
    "\n",
    "Набір даних включає документи про рак, які класифікуються за 3 категоріями: «Рак щитовидної залози», «Рак товстої кишки», «Рак легенів».\n",
    "Загальна кількість публікацій = 7569. у наборі даних є 3 мітки класів.\n",
    "\n",
    "* перетворіть датасет у DataFrame PySpark\n",
    "* перевірте на пропущені дані, при необхідності вилучіть порожні записи\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>0</th>\n",
       "      <th>a</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>Thyroid_Cancer</td>\n",
       "      <td>Thyroid surgery in  children in a single insti...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Thyroid_Cancer</td>\n",
       "      <td>\" The adopted strategy was the same as that us...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Thyroid_Cancer</td>\n",
       "      <td>coronary arterybypass grafting thrombosis ï¬b...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>Thyroid_Cancer</td>\n",
       "      <td>Solitary plasmacytoma SP of the skull is an u...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>Thyroid_Cancer</td>\n",
       "      <td>This study aimed to investigate serum matrix ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0               0  \\\n",
       "0           0  Thyroid_Cancer   \n",
       "1           1  Thyroid_Cancer   \n",
       "2           2  Thyroid_Cancer   \n",
       "3           3  Thyroid_Cancer   \n",
       "4           4  Thyroid_Cancer   \n",
       "\n",
       "                                                   a  \n",
       "0  Thyroid surgery in  children in a single insti...  \n",
       "1  \" The adopted strategy was the same as that us...  \n",
       "2  coronary arterybypass grafting thrombosis ï¬b...  \n",
       "3   Solitary plasmacytoma SP of the skull is an u...  \n",
       "4   This study aimed to investigate serum matrix ...  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Використаємо `read_csv` з pandas для завантаження датасету\n",
    "df = pd.read_csv('data/text_data_med.csv', encoding='latin-1')\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 13:50:13 WARN TaskSetManager: Stage 0 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "                                                                                \r"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+----------+--------------+--------------------+\n",
      "|Unnamed: 0|             0|                   a|\n",
      "+----------+--------------+--------------------+\n",
      "|         0|Thyroid_Cancer|Thyroid surgery i...|\n",
      "|         1|Thyroid_Cancer|\" The adopted str...|\n",
      "|         2|Thyroid_Cancer|coronary arteryby...|\n",
      "|         3|Thyroid_Cancer| Solitary plasmac...|\n",
      "|         4|Thyroid_Cancer| This study aimed...|\n",
      "|         5|Thyroid_Cancer| This study was p...|\n",
      "|         6|Thyroid_Cancer| This study was p...|\n",
      "|         7|Thyroid_Cancer|Journal of Intern...|\n",
      "|         8|Thyroid_Cancer| Gastric cancer G...|\n",
      "|         9|Thyroid_Cancer| Scars Burns  Hea...|\n",
      "|        10|Thyroid_Cancer| In  a novel coro...|\n",
      "|        11|Thyroid_Cancer| Cabozantinib is ...|\n",
      "|        12|Thyroid_Cancer|\" Despite several...|\n",
      "|        13|Thyroid_Cancer| Purpose of Revie...|\n",
      "|        14|Thyroid_Cancer|Neurologic Manife...|\n",
      "|        15|Thyroid_Cancer|EndocrinesyPostop...|\n",
      "|        16|Thyroid_Cancer|Neck Tissues A a0...|\n",
      "|        17|Thyroid_Cancer|Molecular Medicin...|\n",
      "|        18|Thyroid_Cancer|increasing releva...|\n",
      "|        19|Thyroid_Cancer|generate a map of...|\n",
      "+----------+--------------+--------------------+\n",
      "only showing top 20 rows\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#завантажимо дані в spark dataframe\n",
    "df_cleaned = df.dropna()\n",
    "tdf = spark.createDataFrame(df_cleaned)\n",
    "tdf.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "r5xD3xxVpvNI"
   },
   "source": [
    "### Завдання №3\n",
    "Виконайте:\n",
    "* токенізацію\n",
    "* вилучення стоп слів по замовчуванню та задопомогою створення власного списку стоп слів, щоб було видно видалення слів при виводі на екран\n",
    "* перетворення у векторну форму\n",
    "* використайте об'єднання цих команд `pipeline`\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "id": "3_V_77Igpzgi"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 13:51:01 WARN TaskSetManager: Stage 1 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:51:12 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:51:12 WARN TaskSetManager: Stage 5 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "                                                                                \r"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n",
      "|tokens                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |filtered_tokens_default                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |filtered_tokens_custom                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |features                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
      "+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n",
      "|[thyroid, surgery, in, , children, in, a, single, institution, from, osama, ibrahim, almosallama, ali, aseerib, ahmed, alhumaida, ali, s, alzahranic, saif, alsobhib, saud, alshanafeybfrom, the, , adepartment, of, surgery, college, of, medicine, qassim, university, buraidah, al, qassim, saudi, arabia, , bdepartment, of, surgery, king, faisal, specialist, hospital, and, research, center, riyadh, saudi, arabia, cdepartment, of, medicine, king, faisal, specialist, hospital, and, research, center, riyadh, saudi, arabia, correspondence, , , dr, , osama, ibrahim, , almosallam, , department, of, , surgery, , college, , of, , medicine, qassim, , university, , po, , box, , , buraidah, , al, , qassim, , , saudi, , arabia, , osama_iaahotmailcom, orcid, orcid0000000290367564, , , , , , , , citation, , almosallam, oi, aseeri, a, alhumaid, a, alzahrani, as, alsobhi, s, alshanafey, s, thyroid, surgery, in, , children, , in, , a, , single, , institution, , from, , , ann, , saudi, , med, , , , , , , , , received, january, , accepted, may, , published, august, , copyright, copyright, , , annals, of, saudi, medicine, saudi, arabia, this, is, an, , , access, , under, the, creative, commons, attributionnoncommercialnoderivatives, , international, license, cc, byncnd, the, details, of, which, can, be, accessed, at, httpcreativecommons, licensesbyncnd40funding, nonebackground, data, on, thyroid, surgery, in, children, are, scarceobjective, analyze, outcome, data, on, thyroid, surgery, in, a, pediatric, populationdesign, medical, record, reviewsetting, tertiary, health, care, institutionpatients, and, methods, we, collected, demographic, and, clinical, data, on, patients, , years, or, younger, who, had, thyroid, surgery, in, the, period, , to, , descriptive, data, are, presentedmain, outcome, measures, indications, for, thyroidectomy, thyroid, pathology, complications, length, of, stay, and, radioactive, iodine, treatment, and, recurrencessample, size, results, of, , patients, who, underwent, , thyroidectomy, procedures, , , were, females, and, the, mean, age, at, operation, was, , years, and, , , were, associated, with, multiple, endocrine, neoplasia, type, , there, was, no, history, of, radiation, exposure, eightyone, patients, , had, fine, needle, aspiration, fna, which, correlated, with, the, final, histopathology, in, , of, cases, sixtysix, patients, , had, malignant, cancer, , papillary, , , of, , patients, who, had, neck, dissection, had, lymph, node, metastasis, and, , , had, distant, metastases, to, the, lung, procedures, included, total, thyroidectomy, , hemithyroidectomy, , completion, , and, subtotal, thyroidectomy, , twentythree, , patients, , , , developed, , hypocalcemia, , , , permanent, and, , , had, unilateral, recurrent, laryngeal, nerve, injury, , permanent, patients, were, followed, up, for, a, mean, duration, of, , months, median, , months, of, , patients, with, thyroid, cancer, , , received, radioactive, iodine, and, , , had, recurrence, , malignancy, , is, , the, , commonest, , indication, , for, , thyroid, surgery, , in, , children, , and, , fna, , is, , highly, , diagnostic, , hypocalcemia, , and, recurrent, laryngeal, nerve, injury, are, significant, complications, the, recurrence, rate, in, thyroid, cancer, is, , limitations, retrospectiveconflict, of, interest, noneoriginal, ann, saudi, med, , julyaugust, wwwannsaudimednet, 0cthyroid, , diseases, , requiring, , surgery, , are, , relatively, uncommon, in, children, compared, to, adults, the, prevalence, , of, , palpable, , thyroid, , nodules, , in, , children, , ranges, , from, , , , to, , , , sporadic, , welldifferentiated, thyroid, cancer, is, the, most, common, endocrine, malignancy, in, children, accounting, for, , of, pediatric, cancers, , in, , the, , prepubertal, , age, , group, , and, , up, , to, , , of, cancers, in, adolescents, aged, , year2, the, most, common, indication, for, thyroid, surgery, in, children, varies, among, published, studies, but, thyroidectomy, for, malignant, conditions, is, rising38, data, in, children, throughout, the, , world, , are, , relatively, , scarce, , the, , objective, , of, , this, study, was, to, analyze, the, clinical, data, and, outcome, of, thyroid, , surgery, , in, , a, , large, , series, , of, , children, , treated, , at, a, , single, , center, , at, , king, , faisal, , specialist, , hospital, , and, research, center, kfshrc, in, riyadhpatient, and, methods, with, the, approval, of, the, institutional, review, board, irb, at, kfshrc, the, medical, records, of, all, patients, , years, old, and, younger, who, underwent, a, thyroid, surgery, between, , , , and, , , , were, , retrospectively, , reviewed, we, elected, to, include, patients, up, to, the, year, , to, ensure, a, reasonable, followup, period, patients, for, the, study, were, identified, by, a, search, of, the, operating, room, log, for, all, procedures, involving, the, thyroid, gland, for, the, specified, age, groupdemographic, , data, , clinical, , features, , and, , surgical, outcomes, , were, , collected, , specific, , data, , that, , were, , obtained, included, age, at, operation, gender, family, history, presenting, , symptoms, , history, , of, , radiation, , exposure, presence, of, multiple, endocrine, neoplasia, type, , men, , , thyroid, , function, , test, , presence, , and, , size, , of, , thyroid, nodules, by, ultrasound, presence, of, lymph, nodes, metastasis, or, distant, metastasis, fine, needle, aspiration, fna, cytology, , surgical, , procedure, , final, , histopathology, , and, length, of, followup, outcomes, analyzed, were, postoperative, complications, including, transient, or, permanent, hypocalcemia, , transient, , or, , permanent, , recurrent, , laryngeal, nerve, paralysis, wound, infection, and, hematoma, length, of, stay, and, radioactive, iodine, treatment, and, recurrences, thyroid, procedures, in, this, series, included, hemithyroidectomy, , subtotal, , total, , and, , completion, , thyroidectomy, surgeries, were, performed, by, either, an, endocrine, adult, surgeon, or, a, pediatric, surgeon, no, intraoperative, nerve, monitoring, was, used, early, in, the, series, procedures, were, performed, by, adult, endocrine, surgeons, but, lately, a, combined, approach, was, adopted, where, pediatric, surgeons, and, adult, endocrine, surgeons, collaborated, in, such, cases, , proceduresthe, normal, range, in, our, laboratory, regardless, of, symptoms, transient, hypocalcemia, was, identified, if, it, lasted, for, less, than, , months, while, permanent, hypocalcemia, was, , considered, , if, , the, , serum, , calcium, , level, , remained, below, normal, range, and, the, patient, continued, on, calcium, , supplementation, , after, , , , months, , of, , the, , surgery, all, patients, with, a, family, history, of, men, , underwent, genetic, testing, of, the, ret, protooncogene, to, confirm, the, diagnosis, all, patients, who, underwent, completion, thyroidectomy, , had, , a, , preoperative, , and, , postoperative, vocal, , cords, , assessment, , at, , the, , otolaryngology, , clinic, descriptive, data, were, generated, and, comparisons, were, conducted, using, the, t, test, for, continuous, data, and, the, chisquare, or, fisher, exact, tests, for, proportionsresultsbetween, , , , and, , , , , , patients, , underwent, , , surgical, , procedures, , , , patients, , underwent, , two, , procedures, , for, , thyroid, , disease, , at, , our, , institution, , eighty, , patients, , were, females, the, mean, age, at, operation, was, , years, median, , years, range, , years, the, most, common, indication, for, thyroidectomy, was, thyroid, nodule, which, was, present, in, , , of, cases, table, , the, mean, sd, size, of, thyroid, nodules, was, , , mm, there, were, , cases, , associated, with, men, , syndromes, the, final, pathology, in, two, patients, with, men, syndrome, showed, medullary, thyroid, cancer, mtc, while, the, remaining, , patients, had, prophylactic, procedures, before, development, of, mtc, none, of, the, patients, had, a, history, of, radiation, exposure, eightyone, patients, , fna, , which, , correlated, , with, , the, , final, , histopathology, , in, , of, cases, there, were, three, cases, of, toxic, adenoma, and, one, case, of, graves, disease, which, did, not, require, fna, , the, , remaining, , cases, , underwent, , fna, , at, , another, institution, and, fna, was, not, repeated, at, our, institution, or, they, came, for, completion, thyroidectomy, with, documented, , pathology, , for, , malignancy, , after, , they, , had, , their, first, surgery, in, another, hospitalthe, , most, , common, , diagnoses, , included, , papillary, thyroid, cancer, , and, multinodular, goiter, or, colloid, table, , indications, for, thyroidectomy, in, , patients, indicationnodulen, , men, , prophylaxishyperthyroidismmultinodular, goitercompletion, thyroidectomy, , , , hypocalcemia, was, defined, by, calcium, levels, below, data, are, number, , original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0cnodule, , table, , surgical, procedures, included, total, thyroidectomy, , hemithyroidectomy, , completion, , thyroidectomy, , , , and, , subtotal, , thyroidectomy, , neck, dissection, was, performed, in, , , patients, , operative, , complications, , were, , observed, in, , , , patients, , , , the, , most, , common, , complication, was, hypocalcemia, , transient, , permanent, and, table, , thyroid, pathology, in, the, , patientspathologyn, , benignnormal, thyroid, tissuecolloid, nodulecystadenomathyroiditisgraves, diseasethyroid, cancerpapillaryfollicularmedullaryhurthleanaplastictotaldata, are, number, , , , , , , , , , , , , , table, , benign, and, malignant, lesions, in, , patientsbenignn37malignantn66, p, value, , age, meanyearsgender, malefemalepresence, of, nodulehypocalcemiarecurrent, laryngeal, nerve, palsybleedinghematomawound, infectiontracheal, injuryoverall, complicationsmean, length, of, stay, daysmen, recurrent, laryngeal, nerve, palsy, , transient, , permanent, all, were, unilateral, table, , of, , patients, with, malignant, lesions, , , had, lymph, node, metastasis, and, , patients, , had, distant, metastases, to, the, lung, , none, , of, , the, , patients, , developed, , postoperative, bleeding, wound, infection, or, tracheal, injury, patients, were, followed, up, for, a, mean, of, , months, median, , , range, , , , months, , radioactive, , iodine, , treatment, , was, , delivered, , to, , , , patients, , , , with, , malignant, , lesions, , , , patients, , , , had, , recurrences, , , were, , local, , recurrences, , and, , , , were, , local, , and, , distant, recurrences, to, the, lung, three, cases, received, radioactive, iodine, rai, before, and, after, recurrence, one, case, was, low, risk, before, recurrence, so, did, not, receive, rai, until, after, recurrence, one, case, had, medullary, thyroid, cancer, , so, , did, , not, , receive, , rai, , in, , the, , remaining, , five, cases, , there, was, no, clear, data, whether, those, patients, received, rai, before, or, only, after, a, recurrence, all, local, recurrences, , underwent, , resection, , except, , for, , one, , patient, who, was, lost, follow, up, there, was, no, mortality, in, this, study, discussionthe, most, common, indication, for, thyroidectomy, in, this, series, was, thyroid, nodule, which, correlates, with, previously, published, reports, in, the, pediatric, population35, children, with, thyroid, nodules, have, an, estimated, fourfold, , higher, , risk, , of, , developing, , thyroid, , cancer, , compared, to, adults910, the, high, incidence, of, malignancy, in, this, series, suggests, children, with, a, thyroid, nodule, should, be, carefully, evaluatedfna, is, a, valuablemethod, for, preoperative, evaluation, of, thyroid, nodules, however, there, are, limitations, on, , the, , routine, , use, , of, , fna, , in, , children, , including, , the, need, , for, , sedation, , sampling, , errors, , and, , the, , limited, availability, , of, , experienced, , cytopathologists11, , many, previous, studies, reported, high, sensitivity, and, specificity, of, fna, in, evaluating, thyroid, nodule, in, children1114, which, correlate, with, our, findingsour, data, showed, lymph, node, metastasis, in, , of, , thyroid, , cancer, , cases, , which, , supports, , the, , notion, that, , children, , with, , thyroid, , cancer, , frequently, , present, with, more, extensive, disease, than, adults, lymphnode, involvement, , at, , diagnosis, , is, , seen, , in, , , , to, , , , of, children, , compared, , with, , , , to, , , , of, , adults, , with, differentiated, thyroid, cancer1523, because, our, hospital, is, the, largest, referral, center, in, saudi, arabia, especially, for, oncology, cases, this, may, explain, the, large, number, of, lymph, node, and, distant, metastasis, in, this, cohortthe, , most, , common, , complication, , reported, , after, thyroidectomy, in, children, is, hypoparathyroidism, with, an, incidence, ranging, between, , to, , which, original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0ccorresponds, with, our, results, of, , which, are, reported, as, hypocalcemia, in, table, , , , one, study, found, that, total, thyroidectomy, central, and, bilateral, neck, dissection, graves, disease, and, malignancy, were, , risk, , factors, , for, , hypocalcemia, , after, , thyroid, , surgery3, in, this, cohort, postoperative, hypocalcemia, was, noted, more, in, malignant, cases, but, it, failed, to, reach, statistical, significance, moreover, there, was, no, significant, difference, between, benign, and, malignant, cases, in, , terms, , of, , mean, , age, , gender, , distribution, , recurrent, laryngeal, nerve, injury, or, overall, complications, a, finding, that, was, reported, previously26, multiple, studies, in, recent, years, have, found, an, inverse, relationship, between, surgeon, volume, and, complication, , rates2728, , but, , similar, , data, , in, , the, , pediatric, population, is, lacking, one, study, found, that, highvolume, , endocrine, , surgeons, , have, , better, , outcomes, , and, shorter, lengths, of, stay, and, lower, costs, after, thyroidectomy, and, parathyroidectomy, in, children, compared, to, pediatric, surgeons, general, surgeons, or, otolaryngologists29, , scheumann, , and, , colleagues, , also, , concluded, that, a, collaborative, approach, between, pediatric, and, endocrine, surgeons, would, have, better, outcomes, this, has, led, other, authors, to, suggest, that, a, combined, approach, with, endocrine, and, pediatric, surgeons, in, addition, to, pediatric, endocrinologists, may, optimize, the, care, of, children, with, surgical, thyroid, disease, given, the, low, number, of, pediatric, patients4, our, data, do, not, allow, for, comparisons, of, different, approaches, given, the, late, adoption, of, the, combined, approach, the, , recurrence, , rate, , for, , thyroid, , cancer, , in, , children, after, , thyroidectomy, , has, , varied, , widely, , in, , reported, studies, , ranging, , from, , , , to, , , , while, , it, , was, , , in, , this, , cohort, , only, , a, , few, , studies, , explored, , the, predictors, , of, , recurrence, , lymph, , node, , involvement, multiple, nodules, male, gender, younger, age, histologic, subtype, and, advanced, tumor, stage, were, risk, factors, associated, with, recurrence17233033, in, , this, , study, , , , of, , patients, , with, , malignant, , lesions, received, rai, although, there, are, conflicting, data, regarding, , the, , indications, , of, , postoperative, , rai, , treatment, in, lowrisk, patients, the, current, recommendation, is, that, lowrisk, patients, can, be, treated, without, rai3436there, are, some, limitations, to, this, study, the, retrospective, nature, may, affect, the, validity, and, quality, of, the, data, the, small, number, of, cases, in, some, categories, did, not, enable, us, to, compare, groups, and, explore, predictors, relative, to, these, factors, on, the, other, hand, this, study, adds, to, the, scarce, data, on, thyroid, surgery, in, pediatric, age, group, malignancy, is, the, commonest, indication, , for, , thyroid, , surgery, , in, , children, , and, , fna, , is, highly, , diagnostic, , hypocalcemia, , and, , recurrent, , laryngeal, nerve, injury, are, significant, complications, cancerrelated, , death, , is, , extremely, , rare, , but, , recurrence, , is, , not, uncommon, and, a, significant, number, of, patients, with, malignant, cases, received, rai, treatmentoriginal, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0creferences, , trowbridge, , fl, , matovinovic, , j, , mclaren, gd, nichaman, mz, iodine, and, goiter, in, children, pediatrics, , ries, lag, melbert, d, krapcho, m, stinchcomb, , dg, , howlader, , n, , horner, , mj, , et, , al, seer, , cancer, , statistics, , review, , , bethesda, , national, , cancer, , institute, , , based, , on, , november, , , , seer, , data, , submission, chen, y[h], masiakos, pt, gaz, rd, hodin, ra, parangi, s, randolph, gw, et, al, pediatric, thyroidectomy, in, a, high, volume, thyroid, surgery, center, risk, factors, for, postoperative, hypocalcemia, j, pediatr, surg, , aug5081316, , , wood, , jh, , partrick, , da, , barham, , hp, , bensard, dd, travers, hs, bruny, jl, et, al, pediatric, thyroidectomy, , a, , collaborative, , surgical, , approach, j, pediatr, surg, , may4658238, , scholz, s, smith, jr, chaignaud, b, shamberger, , rc, , huang, , sa, , thyroid, , surgery, , at, childrens, hospital, boston, a, 35year, singleinstitution, , experience, , j, , pediatr, , surg, , , mar46343742, , , josefson, , j, , zimmerman, , d, , thyroid, , nodules, and, cancers, in, children, pediatr, endocrinol, rev, , sep611423, hameed, r, zacharin, mr, , changing, face, of, paediatric, and, adolescent, thyroid, cancer, j, paediatr, child, health, , , lugovicente, , h, , ortiz, , vn, , irizarry, , h, camps, , ji, , pagã¡n, , v, , pediatric, , thyroid, , nodules, management, in, the, era, of, fine, needle, aspirationj, pediatr, surg, , mussa, a, de, andrea, m, motta, m, mormile, a, , palestini, , n, , corrias, , a, , predictors, , of, , malignancy, in, children, with, thyroid, nodules, j, pediatr, , oct167488692, amirazodi, e, propst, ej, chung, ct, parra, da, , wasserman, , jd, , pediatric, , thyroid, , fna, biopsy, , outcomes, , and, , impact, , on, , management, over, , years, at, a, tertiary, care, center, cancer, cytopathol, , , , partyka, , kl, , huang, , ec2, , cramer, , hm, chen, , s, , wu, , hh, , histologic, , and, , clinical, followup, , of, , thyroid, , fineneedle, , aspirates, in, , pediatric, , patients, , cancer, , cytopathol, , sinha, ck, decoppi, p, pierro, a, brain, c, hindmarsh, p, butler, g, et, al, thyroid, surgery, in, children, clinical, outcomes, eur, j, pediatr, surg, , oct2554259, kundel, a, thompson, gb, richards, ml, qiu, lx, cai, y, schwenk, fw, et, al, pediatric, endocrine, surgery, a, 20year, experience, at, the, , mayo, , clinic, , j, , clin, , endocrinol, , metab, february, , , jiang, w, newbury, ro, newfield, rs, pediatric, , thyroid, , surgery, , and, , management, , of, thyroid, , nodulesan, , institutional, , experience, features, , and, over, a, 10year, period, int, j, pediatr, endocrinol, , burke, jf, sippel, rs, chen, h, evolution, of, pediatric, thyroid, surgery, at, a, tertiary, medical, center, surg, res, , , , , alqahtani, , kh, , tunio, , ma, , al, , asiri, , m, aljohani, nj, bayoumi, y, riaz, k, et, al, clinicopathological, treatment, outcomes, , of, , differentiated, , thyroid, , cancer, in, , saudi, , children, , and, , adults, , j, , otolaryngol, head, neck, surg, , nov, , kluijfhout, wp, van, beek, dj, verrijn, stuart, , aa, , lodewijk, , l, , valk, , gd, , van, , der, , zee, dc, , et, , al, , postoperative, , complications, after, , prophylactic, , thyroidectomy, , for, , very, young, , patients, , with, , multiple, , endocrine, neoplasia, , type, , , , medicine, , baltimore, 20159429e1108, , raval, mv, browne, m, chin, ac, zimmerman, d, angelos, p, reynolds, m, total, thyroidectomy, , for, , benign, , disease, , in, , the, , pediatric, patientfeasible, , and, , safe, , j, , pediatr, , surg, , stavrakis, ai, ituarte, ph, ko, cy, yeh, mw, surgeon, volume, as, a, predictor, of, outcomes, in, , inpatient, , and, , outpatient, , endocrine, , surgery, surgery, , , sosa, ja, bowman, hm, tielsch, jm, powe, nr, , gordon, , ta, , udelsman, , r, , the, , importance, of, surgeon, experience, for, clinical, and, economic, , outcomes, , from, , thyroidectomy, ann, surg, , , tuggle, ct, , roman, sa, wang, ts, boudourakis, , l, , thomas, , d, , udelsman, , r, , et, , al, pediatric, , endocrine, , surgery, , who, , is, , operating, , on, , our, , children, , surgery, , , dec144686977, , park, , s, , jeong, , js, , ryu, , hr, , lee, , c, , park, jh, kang, s, et, al, differentiated, thyroid, carcinoma, of, children, and, adolescents27year, experience, , in, , the, , yonsei, , university, , health, system, j, korean, med, sci, , , palmer, ba, zarroug, ae, poley, rn, kollars, , jp, , moir, , cr, , papillary, , thyroid, , carcinoma, in, children, risk, factors, and, complications, , of, , disease, , recurrence, , j, , pediatr, , surg, , wada, n, sugino, k, mimura, t, nagahama, m, , kitagawa, , w, , shibuya, , h, , et, , al, , pediatric, differentiated, , thyroid, , carcinoma, , in, , stage, , i, risk, , factor, , analysis, , for, , disease, , free, , survival, bmc, cancer, , , , d, danese, gardini, a, farsetti, a, sciacchitano, , s, , andreoli, , m, , pontecorvi, , a, , thyroid, carcinoma, in, children, and, adolescents, eur, j, pediatr, , , astl, , j, , chovanec, , m, , lukes, , p, , katra, , r, dvorakova, m, vlcek, p, et, al, thyroid, carcinoma, surgery, in, children, and, adolescents, , , years, experience, surgery, of, pediatric, thyroid, lymph, , node, , metastases, carcinoma, , int, , j, , pediatr, , otorhinolaryngol, , , chaukar, , da, , rangarajan, , v, , nair, , n, nadkarni, , ms, , pai, , ps, , dcruz, , ak, , et, , al, , pediatric, , thyroid, , cancer, , j, , surg, , oncol, , , , , dzodic, , r, , buta, , m, , markovic, , i, , gavrilo, d, matovic, m, milovanovic, z, et, al, surgical, management, , of, , welldifferentiated, , thyroid, carcinoma, , in, , children, , and, , adolescents, , , years, of, experience, of, a, single, institution, in, serbia, endocr, j, , , scheumann, , gf, , gimm, , o, , wegener, g, , hundeshagen, , h, , dralle, , h, , prognostic, significance, , and, , surgical, , management, , of, locoregional, in, papillary, thyroid, cancer, world, j, surg, , , shi, rl, qu, n, yang, sw, tumor, size, interpretation, for, predicting, cervical, lymph, node, metastasis, using, a, differentiated, thyroid, cancer, risk, model, onco, targets, ther, , , , zimmerman, d, hay, id, gough, ir, goellner, jr, ryan, jj, grant, cs, et, al, papillary, thyroid, carcinoma, in, children, and, adults, longterm, , followup, , of, , , , patients, , conservatively, treated, at, one, institution, during, three, decades, surgery, , , collini, , p, , mattavelli, , f, , pellegrinelli, , a, barisella, m, ferrari, a, massimino, m, papillary, carcinoma, of, the, thyroid, gland, of, childhood, and, adolescence, morphologic, subtypes, biologic, behavior, and, prognosis, a, clinicopathologic, study, of, , sporadic, cases, treated, at, a, single, institution, during, a, 30year, period, am, j, surg, pathol, , , borsonchazot, , causeret, , s, , lifante, , jc, augros, m, berger, n, peix, jl, predictive, factors, for, recurrence, from, a, series, of, , children, and, , adolescents, , with, , differentiated, , thyroid, cancer, world, j, surg, , , baumgarten, hd, bauer, aj, isaza, a, mostoufimoab, s, kazahaya, k, adzick, ns, surgical, management, of, pediatric, thyroid, disease, complication, , rates, , after, , thyroidectomy, , at, the, childrens, hospital, of, philadelphia, highvolume, pediatric, thyroid, center, journal, of, pediatric, , surgery, , , , oct, , , kurzawinski, tr, de, coppi, p, thyroidectomy, in, children, inpediatric, surgery, , pp, , springer, berlin, heidelberg, , francis, , g, , waguespack, , sg, , bauer, , aj, angelog, p, benvenga, s, et, al, management, guidelines, , for, , children, , with, , thyroid, , nodules, , and, , differentiated, , thyroid, , cancer, , the, american, , thyroid, , association, , guidelines, task, force, on, pediatric, thyroid, cancer, thyroid, volume, , number, , original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |[thyroid, surgery, , children, single, institution, osama, ibrahim, almosallama, ali, aseerib, ahmed, alhumaida, ali, alzahranic, saif, alsobhib, saud, alshanafeybfrom, , adepartment, surgery, college, medicine, qassim, university, buraidah, al, qassim, saudi, arabia, , bdepartment, surgery, king, faisal, specialist, hospital, research, center, riyadh, saudi, arabia, cdepartment, medicine, king, faisal, specialist, hospital, research, center, riyadh, saudi, arabia, correspondence, , , dr, , osama, ibrahim, , almosallam, , department, , surgery, , college, , , medicine, qassim, , university, , po, , box, , , buraidah, , al, , qassim, , , saudi, , arabia, , osama_iaahotmailcom, orcid, orcid0000000290367564, , , , , , , , citation, , almosallam, oi, aseeri, alhumaid, alzahrani, alsobhi, alshanafey, thyroid, surgery, , children, , , , single, , institution, , , , ann, , saudi, , med, , , , , , , , , received, january, , accepted, may, , published, august, , copyright, copyright, , , annals, saudi, medicine, saudi, arabia, , , access, , creative, commons, attributionnoncommercialnoderivatives, , international, license, cc, byncnd, details, accessed, httpcreativecommons, licensesbyncnd40funding, nonebackground, data, thyroid, surgery, children, scarceobjective, analyze, outcome, data, thyroid, surgery, pediatric, populationdesign, medical, record, reviewsetting, tertiary, health, care, institutionpatients, methods, collected, demographic, clinical, data, patients, , years, younger, thyroid, surgery, period, , , descriptive, data, presentedmain, outcome, measures, indications, thyroidectomy, thyroid, pathology, complications, length, stay, radioactive, iodine, treatment, recurrencessample, size, results, , patients, underwent, , thyroidectomy, procedures, , , females, mean, age, operation, , years, , , associated, multiple, endocrine, neoplasia, type, , history, radiation, exposure, eightyone, patients, , fine, needle, aspiration, fna, correlated, final, histopathology, , cases, sixtysix, patients, , malignant, cancer, , papillary, , , , patients, neck, dissection, lymph, node, metastasis, , , distant, metastases, lung, procedures, included, total, thyroidectomy, , hemithyroidectomy, , completion, , subtotal, thyroidectomy, , twentythree, , patients, , , , developed, , hypocalcemia, , , , permanent, , , unilateral, recurrent, laryngeal, nerve, injury, , permanent, patients, followed, mean, duration, , months, median, , months, , patients, thyroid, cancer, , , received, radioactive, iodine, , , recurrence, , malignancy, , , , commonest, , indication, , , thyroid, surgery, , , children, , , fna, , , highly, , diagnostic, , hypocalcemia, , recurrent, laryngeal, nerve, injury, significant, complications, recurrence, rate, thyroid, cancer, , limitations, retrospectiveconflict, interest, noneoriginal, ann, saudi, med, , julyaugust, wwwannsaudimednet, 0cthyroid, , diseases, , requiring, , surgery, , , relatively, uncommon, children, compared, adults, prevalence, , , palpable, , thyroid, , nodules, , , children, , ranges, , , , , , , , sporadic, , welldifferentiated, thyroid, cancer, common, endocrine, malignancy, children, accounting, , pediatric, cancers, , , , prepubertal, , age, , group, , , , , , cancers, adolescents, aged, , year2, common, indication, thyroid, surgery, children, varies, among, published, studies, thyroidectomy, malignant, conditions, rising38, data, children, throughout, , world, , , relatively, , scarce, , , objective, , , study, analyze, clinical, data, outcome, thyroid, , surgery, , , , large, , series, , , children, , treated, , , single, , center, , , king, , faisal, , specialist, , hospital, , research, center, kfshrc, riyadhpatient, methods, approval, institutional, review, board, irb, kfshrc, medical, records, patients, , years, old, younger, underwent, thyroid, surgery, , , , , , , , retrospectively, , reviewed, elected, include, patients, year, , ensure, reasonable, followup, period, patients, study, identified, search, operating, room, log, procedures, involving, thyroid, gland, specified, age, groupdemographic, , data, , clinical, , features, , , surgical, outcomes, , , collected, , specific, , data, , , , obtained, included, age, operation, gender, family, history, presenting, , symptoms, , history, , , radiation, , exposure, presence, multiple, endocrine, neoplasia, type, , men, , , thyroid, , function, , test, , presence, , , size, , , thyroid, nodules, ultrasound, presence, lymph, nodes, metastasis, distant, metastasis, fine, needle, aspiration, fna, cytology, , surgical, , procedure, , final, , histopathology, , length, followup, outcomes, analyzed, postoperative, complications, including, transient, permanent, hypocalcemia, , transient, , , permanent, , recurrent, , laryngeal, nerve, paralysis, wound, infection, hematoma, length, stay, radioactive, iodine, treatment, recurrences, thyroid, procedures, series, included, hemithyroidectomy, , subtotal, , total, , , completion, , thyroidectomy, surgeries, performed, either, endocrine, adult, surgeon, pediatric, surgeon, intraoperative, nerve, monitoring, used, early, series, procedures, performed, adult, endocrine, surgeons, lately, combined, approach, adopted, pediatric, surgeons, adult, endocrine, surgeons, collaborated, cases, , proceduresthe, normal, range, laboratory, regardless, symptoms, transient, hypocalcemia, identified, lasted, less, , months, permanent, hypocalcemia, , considered, , , , serum, , calcium, , level, , remained, normal, range, patient, continued, calcium, , supplementation, , , , , months, , , , surgery, patients, family, history, men, , underwent, genetic, testing, ret, protooncogene, confirm, diagnosis, patients, underwent, completion, thyroidectomy, , , , preoperative, , , postoperative, vocal, , cords, , assessment, , , , otolaryngology, , clinic, descriptive, data, generated, comparisons, conducted, using, test, continuous, data, chisquare, fisher, exact, tests, proportionsresultsbetween, , , , , , , , , patients, , underwent, , , surgical, , procedures, , , , patients, , underwent, , two, , procedures, , , thyroid, , disease, , , , institution, , eighty, , patients, , females, mean, age, operation, , years, median, , years, range, , years, common, indication, thyroidectomy, thyroid, nodule, present, , , cases, table, , mean, sd, size, thyroid, nodules, , , mm, , cases, , associated, men, , syndromes, final, pathology, two, patients, men, syndrome, showed, medullary, thyroid, cancer, mtc, remaining, , patients, prophylactic, procedures, development, mtc, none, patients, history, radiation, exposure, eightyone, patients, , fna, , , correlated, , , , final, , histopathology, , , cases, three, cases, toxic, adenoma, one, case, graves, disease, require, fna, , , remaining, , cases, , underwent, , fna, , , another, institution, fna, repeated, institution, came, completion, thyroidectomy, documented, , pathology, , , malignancy, , , , , first, surgery, another, hospitalthe, , , common, , diagnoses, , included, , papillary, thyroid, cancer, , multinodular, goiter, colloid, table, , indications, thyroidectomy, , patients, indicationnodulen, , men, , prophylaxishyperthyroidismmultinodular, goitercompletion, thyroidectomy, , , , hypocalcemia, defined, calcium, levels, data, number, , original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0cnodule, , table, , surgical, procedures, included, total, thyroidectomy, , hemithyroidectomy, , completion, , thyroidectomy, , , , , subtotal, , thyroidectomy, , neck, dissection, performed, , , patients, , operative, , complications, , , observed, , , , patients, , , , , , common, , complication, hypocalcemia, , transient, , permanent, table, , thyroid, pathology, , patientspathologyn, , benignnormal, thyroid, tissuecolloid, nodulecystadenomathyroiditisgraves, diseasethyroid, cancerpapillaryfollicularmedullaryhurthleanaplastictotaldata, number, , , , , , , , , , , , , , table, , benign, malignant, lesions, , patientsbenignn37malignantn66, p, value, , age, meanyearsgender, malefemalepresence, nodulehypocalcemiarecurrent, laryngeal, nerve, palsybleedinghematomawound, infectiontracheal, injuryoverall, complicationsmean, length, stay, daysmen, recurrent, laryngeal, nerve, palsy, , transient, , permanent, unilateral, table, , , patients, malignant, lesions, , , lymph, node, metastasis, , patients, , distant, metastases, lung, , none, , , , patients, , developed, , postoperative, bleeding, wound, infection, tracheal, injury, patients, followed, mean, , months, median, , , range, , , , months, , radioactive, , iodine, , treatment, , , delivered, , , , , patients, , , , , malignant, , lesions, , , , patients, , , , , recurrences, , , , local, , recurrences, , , , , , local, , , distant, recurrences, lung, three, cases, received, radioactive, iodine, rai, recurrence, one, case, low, risk, recurrence, receive, rai, recurrence, one, case, medullary, thyroid, cancer, , , , , receive, , rai, , , , remaining, , five, cases, , clear, data, whether, patients, received, rai, recurrence, local, recurrences, , underwent, , resection, , except, , , one, , patient, lost, follow, mortality, study, discussionthe, common, indication, thyroidectomy, series, thyroid, nodule, correlates, previously, published, reports, pediatric, population35, children, thyroid, nodules, estimated, fourfold, , higher, , risk, , , developing, , thyroid, , cancer, , compared, adults910, high, incidence, malignancy, series, suggests, children, thyroid, nodule, carefully, evaluatedfna, valuablemethod, preoperative, evaluation, thyroid, nodules, however, limitations, , , routine, , use, , , fna, , , children, , including, , need, , , sedation, , sampling, , errors, , , , limited, availability, , , experienced, , cytopathologists11, , many, previous, studies, reported, high, sensitivity, specificity, fna, evaluating, thyroid, nodule, children1114, correlate, findingsour, data, showed, lymph, node, metastasis, , , thyroid, , cancer, , cases, , , supports, , , notion, , children, , , thyroid, , cancer, , frequently, , present, extensive, disease, adults, lymphnode, involvement, , , diagnosis, , , seen, , , , , , , , children, , compared, , , , , , , , , adults, , differentiated, thyroid, cancer1523, hospital, largest, referral, center, saudi, arabia, especially, oncology, cases, may, explain, large, number, lymph, node, distant, metastasis, cohortthe, , , common, , complication, , reported, , thyroidectomy, children, hypoparathyroidism, incidence, ranging, , , original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0ccorresponds, results, , reported, hypocalcemia, table, , , , one, study, found, total, thyroidectomy, central, bilateral, neck, dissection, graves, disease, malignancy, , risk, , factors, , , hypocalcemia, , , thyroid, , surgery3, cohort, postoperative, hypocalcemia, noted, malignant, cases, failed, reach, statistical, significance, moreover, significant, difference, benign, malignant, cases, , terms, , , mean, , age, , gender, , distribution, , recurrent, laryngeal, nerve, injury, overall, complications, finding, reported, previously26, multiple, studies, recent, years, found, inverse, relationship, surgeon, volume, complication, , rates2728, , , similar, , data, , , , pediatric, population, lacking, one, study, found, highvolume, , endocrine, , surgeons, , , better, , outcomes, , shorter, lengths, stay, lower, costs, thyroidectomy, parathyroidectomy, children, compared, pediatric, surgeons, general, surgeons, otolaryngologists29, , scheumann, , , colleagues, , also, , concluded, collaborative, approach, pediatric, endocrine, surgeons, better, outcomes, led, authors, suggest, combined, approach, endocrine, pediatric, surgeons, addition, pediatric, endocrinologists, may, optimize, care, children, surgical, thyroid, disease, given, low, number, pediatric, patients4, data, allow, comparisons, different, approaches, given, late, adoption, combined, approach, , recurrence, , rate, , , thyroid, , cancer, , , children, , thyroidectomy, , , varied, , widely, , , reported, studies, , ranging, , , , , , , , , , , , , , cohort, , , , , studies, , explored, , predictors, , , recurrence, , lymph, , node, , involvement, multiple, nodules, male, gender, younger, age, histologic, subtype, advanced, tumor, stage, risk, factors, associated, recurrence17233033, , , study, , , , , patients, , , malignant, , lesions, received, rai, although, conflicting, data, regarding, , , indications, , , postoperative, , rai, , treatment, lowrisk, patients, current, recommendation, lowrisk, patients, treated, without, rai3436there, limitations, study, retrospective, nature, may, affect, validity, quality, data, small, number, cases, categories, enable, us, compare, groups, explore, predictors, relative, factors, hand, study, adds, scarce, data, thyroid, surgery, pediatric, age, group, malignancy, commonest, indication, , , thyroid, , surgery, , , children, , , fna, , highly, , diagnostic, , hypocalcemia, , , recurrent, , laryngeal, nerve, injury, significant, complications, cancerrelated, , death, , , extremely, , rare, , , recurrence, , , uncommon, significant, number, patients, malignant, cases, received, rai, treatmentoriginal, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0creferences, , trowbridge, , fl, , matovinovic, , j, , mclaren, gd, nichaman, mz, iodine, goiter, children, pediatrics, , ries, lag, melbert, d, krapcho, m, stinchcomb, , dg, , howlader, , n, , horner, , mj, , et, , al, seer, , cancer, , statistics, , review, , , bethesda, , national, , cancer, , institute, , , based, , , november, , , , seer, , data, , submission, chen, y[h], masiakos, pt, gaz, rd, hodin, ra, parangi, randolph, gw, et, al, pediatric, thyroidectomy, high, volume, thyroid, surgery, center, risk, factors, postoperative, hypocalcemia, j, pediatr, surg, , aug5081316, , , wood, , jh, , partrick, , da, , barham, , hp, , bensard, dd, travers, hs, bruny, jl, et, al, pediatric, thyroidectomy, , , collaborative, , surgical, , approach, j, pediatr, surg, , may4658238, , scholz, smith, jr, chaignaud, b, shamberger, , rc, , huang, , sa, , thyroid, , surgery, , childrens, hospital, boston, 35year, singleinstitution, , experience, , j, , pediatr, , surg, , , mar46343742, , , josefson, , j, , zimmerman, , d, , thyroid, , nodules, cancers, children, pediatr, endocrinol, rev, , sep611423, hameed, r, zacharin, mr, , changing, face, paediatric, adolescent, thyroid, cancer, j, paediatr, child, health, , , lugovicente, , h, , ortiz, , vn, , irizarry, , h, camps, , ji, , pagã¡n, , v, , pediatric, , thyroid, , nodules, management, era, fine, needle, aspirationj, pediatr, surg, , mussa, de, andrea, m, motta, m, mormile, , palestini, , n, , corrias, , , predictors, , , malignancy, children, thyroid, nodules, j, pediatr, , oct167488692, amirazodi, e, propst, ej, chung, ct, parra, da, , wasserman, , jd, , pediatric, , thyroid, , fna, biopsy, , outcomes, , , impact, , , management, , years, tertiary, care, center, cancer, cytopathol, , , , partyka, , kl, , huang, , ec2, , cramer, , hm, chen, , , wu, , hh, , histologic, , , clinical, followup, , , thyroid, , fineneedle, , aspirates, , pediatric, , patients, , cancer, , cytopathol, , sinha, ck, decoppi, p, pierro, brain, c, hindmarsh, p, butler, g, et, al, thyroid, surgery, children, clinical, outcomes, eur, j, pediatr, surg, , oct2554259, kundel, thompson, gb, richards, ml, qiu, lx, cai, y, schwenk, fw, et, al, pediatric, endocrine, surgery, 20year, experience, , mayo, , clinic, , j, , clin, , endocrinol, , metab, february, , , jiang, w, newbury, ro, newfield, rs, pediatric, , thyroid, , surgery, , , management, , thyroid, , nodulesan, , institutional, , experience, features, , 10year, period, int, j, pediatr, endocrinol, , burke, jf, sippel, rs, chen, h, evolution, pediatric, thyroid, surgery, tertiary, medical, center, surg, res, , , , , alqahtani, , kh, , tunio, , ma, , al, , asiri, , m, aljohani, nj, bayoumi, y, riaz, k, et, al, clinicopathological, treatment, outcomes, , , differentiated, , thyroid, , cancer, , saudi, , children, , , adults, , j, , otolaryngol, head, neck, surg, , nov, , kluijfhout, wp, van, beek, dj, verrijn, stuart, , aa, , lodewijk, , l, , valk, , gd, , van, , der, , zee, dc, , et, , al, , postoperative, , complications, , prophylactic, , thyroidectomy, , , young, , patients, , , multiple, , endocrine, neoplasia, , type, , , , medicine, , baltimore, 20159429e1108, , raval, mv, browne, m, chin, ac, zimmerman, d, angelos, p, reynolds, m, total, thyroidectomy, , , benign, , disease, , , , pediatric, patientfeasible, , , safe, , j, , pediatr, , surg, , stavrakis, ai, ituarte, ph, ko, cy, yeh, mw, surgeon, volume, predictor, outcomes, , inpatient, , , outpatient, , endocrine, , surgery, surgery, , , sosa, ja, bowman, hm, tielsch, jm, powe, nr, , gordon, , ta, , udelsman, , r, , , importance, surgeon, experience, clinical, economic, , outcomes, , , thyroidectomy, ann, surg, , , tuggle, ct, , roman, sa, wang, ts, boudourakis, , l, , thomas, , d, , udelsman, , r, , et, , al, pediatric, , endocrine, , surgery, , , , operating, , , , children, , surgery, , , dec144686977, , park, , , jeong, , js, , ryu, , hr, , lee, , c, , park, jh, kang, et, al, differentiated, thyroid, carcinoma, children, adolescents27year, experience, , , , yonsei, , university, , health, system, j, korean, med, sci, , , palmer, ba, zarroug, ae, poley, rn, kollars, , jp, , moir, , cr, , papillary, , thyroid, , carcinoma, children, risk, factors, complications, , , disease, , recurrence, , j, , pediatr, , surg, , wada, n, sugino, k, mimura, nagahama, m, , kitagawa, , w, , shibuya, , h, , et, , al, , pediatric, differentiated, , thyroid, , carcinoma, , , stage, , risk, , factor, , analysis, , , disease, , free, , survival, bmc, cancer, , , , d, danese, gardini, farsetti, sciacchitano, , , andreoli, , m, , pontecorvi, , , thyroid, carcinoma, children, adolescents, eur, j, pediatr, , , astl, , j, , chovanec, , m, , lukes, , p, , katra, , r, dvorakova, m, vlcek, p, et, al, thyroid, carcinoma, surgery, children, adolescents, , , years, experience, surgery, pediatric, thyroid, lymph, , node, , metastases, carcinoma, , int, , j, , pediatr, , otorhinolaryngol, , , chaukar, , da, , rangarajan, , v, , nair, , n, nadkarni, , ms, , pai, , ps, , dcruz, , ak, , et, , al, , pediatric, , thyroid, , cancer, , j, , surg, , oncol, , , , , dzodic, , r, , buta, , m, , markovic, , , gavrilo, d, matovic, m, milovanovic, z, et, al, surgical, management, , , welldifferentiated, , thyroid, carcinoma, , , children, , , adolescents, , , years, experience, single, institution, serbia, endocr, j, , , scheumann, , gf, , gimm, , o, , wegener, g, , hundeshagen, , h, , dralle, , h, , prognostic, significance, , , surgical, , management, , locoregional, papillary, thyroid, cancer, world, j, surg, , , shi, rl, qu, n, yang, sw, tumor, size, interpretation, predicting, cervical, lymph, node, metastasis, using, differentiated, thyroid, cancer, risk, model, onco, targets, ther, , , , zimmerman, d, hay, id, gough, ir, goellner, jr, ryan, jj, grant, cs, et, al, papillary, thyroid, carcinoma, children, adults, longterm, , followup, , , , , patients, , conservatively, treated, one, institution, three, decades, surgery, , , collini, , p, , mattavelli, , f, , pellegrinelli, , barisella, m, ferrari, massimino, m, papillary, carcinoma, thyroid, gland, childhood, adolescence, morphologic, subtypes, biologic, behavior, prognosis, clinicopathologic, study, , sporadic, cases, treated, single, institution, 30year, period, j, surg, pathol, , , borsonchazot, , causeret, , , lifante, , jc, augros, m, berger, n, peix, jl, predictive, factors, recurrence, series, , children, , adolescents, , , differentiated, , thyroid, cancer, world, j, surg, , , baumgarten, hd, bauer, aj, isaza, mostoufimoab, kazahaya, k, adzick, ns, surgical, management, pediatric, thyroid, disease, complication, , rates, , , thyroidectomy, , childrens, hospital, philadelphia, highvolume, pediatric, thyroid, center, journal, pediatric, , surgery, , , , oct, , , kurzawinski, tr, de, coppi, p, thyroidectomy, children, inpediatric, surgery, , pp, , springer, berlin, heidelberg, , francis, , g, , waguespack, , sg, , bauer, , aj, angelog, p, benvenga, et, al, management, guidelines, , , children, , , thyroid, , nodules, , , differentiated, , thyroid, , cancer, , american, , thyroid, , association, , guidelines, task, force, pediatric, thyroid, cancer, thyroid, volume, , number, , original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |[thyroid, surgery, , children, single, institution, from, osama, ibrahim, almosallama, ali, aseerib, ahmed, alhumaida, ali, s, alzahranic, saif, alsobhib, saud, alshanafeybfrom, , adepartment, surgery, college, medicine, qassim, university, buraidah, al, qassim, saudi, arabia, , bdepartment, surgery, king, faisal, specialist, hospital, research, center, riyadh, saudi, arabia, cdepartment, medicine, king, faisal, specialist, hospital, research, center, riyadh, saudi, arabia, correspondence, , , dr, , osama, ibrahim, , almosallam, , department, , surgery, , college, , , medicine, qassim, , university, , po, , box, , , buraidah, , al, , qassim, , , saudi, , arabia, , osama_iaahotmailcom, orcid, orcid0000000290367564, , , , , , , , citation, , almosallam, oi, aseeri, alhumaid, alzahrani, as, alsobhi, s, alshanafey, s, thyroid, surgery, , children, , , , single, , institution, , from, , , ann, , saudi, , med, , , , , , , , , received, january, , accepted, may, , published, august, , copyright, copyright, , , annals, saudi, medicine, saudi, arabia, an, , , access, , under, creative, commons, attributionnoncommercialnoderivatives, , international, license, cc, byncnd, details, which, can, be, accessed, at, httpcreativecommons, licensesbyncnd40funding, nonebackground, data, on, thyroid, surgery, children, are, scarceobjective, analyze, outcome, data, on, thyroid, surgery, pediatric, populationdesign, medical, record, reviewsetting, tertiary, health, care, institutionpatients, methods, we, collected, demographic, clinical, data, on, patients, , years, or, younger, who, had, thyroid, surgery, period, , , descriptive, data, are, presentedmain, outcome, measures, indications, thyroidectomy, thyroid, pathology, complications, length, stay, radioactive, iodine, treatment, recurrencessample, size, results, , patients, who, underwent, , thyroidectomy, procedures, , , were, females, mean, age, at, operation, , years, , , were, associated, with, multiple, endocrine, neoplasia, type, , there, no, history, radiation, exposure, eightyone, patients, , had, fine, needle, aspiration, fna, which, correlated, with, final, histopathology, , cases, sixtysix, patients, , had, malignant, cancer, , papillary, , , , patients, who, had, neck, dissection, had, lymph, node, metastasis, , , had, distant, metastases, lung, procedures, included, total, thyroidectomy, , hemithyroidectomy, , completion, , subtotal, thyroidectomy, , twentythree, , patients, , , , developed, , hypocalcemia, , , , permanent, , , had, unilateral, recurrent, laryngeal, nerve, injury, , permanent, patients, were, followed, up, mean, duration, , months, median, , months, , patients, with, thyroid, cancer, , , received, radioactive, iodine, , , had, recurrence, , malignancy, , , , commonest, , indication, , , thyroid, surgery, , , children, , , fna, , , highly, , diagnostic, , hypocalcemia, , recurrent, laryngeal, nerve, injury, are, significant, complications, recurrence, rate, thyroid, cancer, , limitations, retrospectiveconflict, interest, noneoriginal, ann, saudi, med, , julyaugust, wwwannsaudimednet, 0cthyroid, , diseases, , requiring, , surgery, , are, , relatively, uncommon, children, compared, adults, prevalence, , , palpable, , thyroid, , nodules, , , children, , ranges, , from, , , , , , , sporadic, , welldifferentiated, thyroid, cancer, most, common, endocrine, malignancy, children, accounting, , pediatric, cancers, , , , prepubertal, , age, , group, , , up, , , , cancers, adolescents, aged, , year2, most, common, indication, thyroid, surgery, children, varies, among, published, studies, but, thyroidectomy, malignant, conditions, rising38, data, children, throughout, , world, , are, , relatively, , scarce, , , objective, , , study, analyze, clinical, data, outcome, thyroid, , surgery, , , , large, , series, , , children, , treated, , at, , single, , center, , at, , king, , faisal, , specialist, , hospital, , research, center, kfshrc, riyadhpatient, methods, with, approval, institutional, review, board, irb, at, kfshrc, medical, records, all, patients, , years, old, younger, who, underwent, thyroid, surgery, between, , , , , , , were, , retrospectively, , reviewed, we, elected, include, patients, up, year, , ensure, reasonable, followup, period, patients, study, were, identified, by, search, operating, room, log, all, procedures, involving, thyroid, gland, specified, age, groupdemographic, , data, , clinical, , features, , , surgical, outcomes, , were, , collected, , specific, , data, , that, , were, , obtained, included, age, at, operation, gender, family, history, presenting, , symptoms, , history, , , radiation, , exposure, presence, multiple, endocrine, neoplasia, type, , men, , , thyroid, , function, , test, , presence, , , size, , , thyroid, nodules, by, ultrasound, presence, lymph, nodes, metastasis, or, distant, metastasis, fine, needle, aspiration, fna, cytology, , surgical, , procedure, , final, , histopathology, , length, followup, outcomes, analyzed, were, postoperative, complications, including, transient, or, permanent, hypocalcemia, , transient, , or, , permanent, , recurrent, , laryngeal, nerve, paralysis, wound, infection, hematoma, length, stay, radioactive, iodine, treatment, recurrences, thyroid, procedures, series, included, hemithyroidectomy, , subtotal, , total, , , completion, , thyroidectomy, surgeries, were, performed, by, either, an, endocrine, adult, surgeon, or, pediatric, surgeon, no, intraoperative, nerve, monitoring, used, early, series, procedures, were, performed, by, adult, endocrine, surgeons, but, lately, combined, approach, adopted, where, pediatric, surgeons, adult, endocrine, surgeons, collaborated, such, cases, , proceduresthe, normal, range, our, laboratory, regardless, symptoms, transient, hypocalcemia, identified, if, it, lasted, less, than, , months, while, permanent, hypocalcemia, , considered, , if, , , serum, , calcium, , level, , remained, below, normal, range, patient, continued, on, calcium, , supplementation, , after, , , , months, , , , surgery, all, patients, with, family, history, men, , underwent, genetic, testing, ret, protooncogene, confirm, diagnosis, all, patients, who, underwent, completion, thyroidectomy, , had, , , preoperative, , , postoperative, vocal, , cords, , assessment, , at, , , otolaryngology, , clinic, descriptive, data, were, generated, comparisons, were, conducted, using, t, test, continuous, data, chisquare, or, fisher, exact, tests, proportionsresultsbetween, , , , , , , , , patients, , underwent, , , surgical, , procedures, , , , patients, , underwent, , two, , procedures, , , thyroid, , disease, , at, , our, , institution, , eighty, , patients, , were, females, mean, age, at, operation, , years, median, , years, range, , years, most, common, indication, thyroidectomy, thyroid, nodule, which, present, , , cases, table, , mean, sd, size, thyroid, nodules, , , mm, there, were, , cases, , associated, with, men, , syndromes, final, pathology, two, patients, with, men, syndrome, showed, medullary, thyroid, cancer, mtc, while, remaining, , patients, had, prophylactic, procedures, before, development, mtc, none, patients, had, history, radiation, exposure, eightyone, patients, , fna, , which, , correlated, , with, , , final, , histopathology, , , cases, there, were, three, cases, toxic, adenoma, one, case, graves, disease, which, did, not, require, fna, , , remaining, , cases, , underwent, , fna, , at, , another, institution, fna, not, repeated, at, our, institution, or, they, came, completion, thyroidectomy, with, documented, , pathology, , , malignancy, , after, , they, , had, , their, first, surgery, another, hospitalthe, , most, , common, , diagnoses, , included, , papillary, thyroid, cancer, , multinodular, goiter, or, colloid, table, , indications, thyroidectomy, , patients, indicationnodulen, , men, , prophylaxishyperthyroidismmultinodular, goitercompletion, thyroidectomy, , , , hypocalcemia, defined, by, calcium, levels, below, data, are, number, , original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0cnodule, , table, , surgical, procedures, included, total, thyroidectomy, , hemithyroidectomy, , completion, , thyroidectomy, , , , , subtotal, , thyroidectomy, , neck, dissection, performed, , , patients, , operative, , complications, , were, , observed, , , , patients, , , , , most, , common, , complication, hypocalcemia, , transient, , permanent, table, , thyroid, pathology, , patientspathologyn, , benignnormal, thyroid, tissuecolloid, nodulecystadenomathyroiditisgraves, diseasethyroid, cancerpapillaryfollicularmedullaryhurthleanaplastictotaldata, are, number, , , , , , , , , , , , , , table, , benign, malignant, lesions, , patientsbenignn37malignantn66, p, value, , age, meanyearsgender, malefemalepresence, nodulehypocalcemiarecurrent, laryngeal, nerve, palsybleedinghematomawound, infectiontracheal, injuryoverall, complicationsmean, length, stay, daysmen, recurrent, laryngeal, nerve, palsy, , transient, , permanent, all, were, unilateral, table, , , patients, with, malignant, lesions, , , had, lymph, node, metastasis, , patients, , had, distant, metastases, lung, , none, , , , patients, , developed, , postoperative, bleeding, wound, infection, or, tracheal, injury, patients, were, followed, up, mean, , months, median, , , range, , , , months, , radioactive, , iodine, , treatment, , , delivered, , , , , patients, , , , with, , malignant, , lesions, , , , patients, , , , had, , recurrences, , , were, , local, , recurrences, , , , , were, , local, , , distant, recurrences, lung, three, cases, received, radioactive, iodine, rai, before, after, recurrence, one, case, low, risk, before, recurrence, so, did, not, receive, rai, until, after, recurrence, one, case, had, medullary, thyroid, cancer, , so, , did, , not, , receive, , rai, , , , remaining, , five, cases, , there, no, clear, data, whether, those, patients, received, rai, before, or, only, after, recurrence, all, local, recurrences, , underwent, , resection, , except, , , one, , patient, who, lost, follow, up, there, no, mortality, study, discussionthe, most, common, indication, thyroidectomy, series, thyroid, nodule, which, correlates, with, previously, published, reports, pediatric, population35, children, with, thyroid, nodules, have, an, estimated, fourfold, , higher, , risk, , , developing, , thyroid, , cancer, , compared, adults910, high, incidence, malignancy, series, suggests, children, with, thyroid, nodule, should, be, carefully, evaluatedfna, valuablemethod, preoperative, evaluation, thyroid, nodules, however, there, are, limitations, on, , , routine, , use, , , fna, , , children, , including, , need, , , sedation, , sampling, , errors, , , , limited, availability, , , experienced, , cytopathologists11, , many, previous, studies, reported, high, sensitivity, specificity, fna, evaluating, thyroid, nodule, children1114, which, correlate, with, our, findingsour, data, showed, lymph, node, metastasis, , , thyroid, , cancer, , cases, , which, , supports, , , notion, that, , children, , with, , thyroid, , cancer, , frequently, , present, with, more, extensive, disease, than, adults, lymphnode, involvement, , at, , diagnosis, , , seen, , , , , , , , children, , compared, , with, , , , , , , , adults, , with, differentiated, thyroid, cancer1523, because, our, hospital, largest, referral, center, saudi, arabia, especially, oncology, cases, may, explain, large, number, lymph, node, distant, metastasis, cohortthe, , most, , common, , complication, , reported, , after, thyroidectomy, children, hypoparathyroidism, with, an, incidence, ranging, between, , , which, original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0ccorresponds, with, our, results, , which, are, reported, as, hypocalcemia, table, , , , one, study, found, that, total, thyroidectomy, central, bilateral, neck, dissection, graves, disease, malignancy, were, , risk, , factors, , , hypocalcemia, , after, , thyroid, , surgery3, cohort, postoperative, hypocalcemia, noted, more, malignant, cases, but, it, failed, reach, statistical, significance, moreover, there, no, significant, difference, between, benign, malignant, cases, , terms, , , mean, , age, , gender, , distribution, , recurrent, laryngeal, nerve, injury, or, overall, complications, finding, that, reported, previously26, multiple, studies, recent, years, have, found, an, inverse, relationship, between, surgeon, volume, complication, , rates2728, , but, , similar, , data, , , , pediatric, population, lacking, one, study, found, that, highvolume, , endocrine, , surgeons, , have, , better, , outcomes, , shorter, lengths, stay, lower, costs, after, thyroidectomy, parathyroidectomy, children, compared, pediatric, surgeons, general, surgeons, or, otolaryngologists29, , scheumann, , , colleagues, , also, , concluded, that, collaborative, approach, between, pediatric, endocrine, surgeons, would, have, better, outcomes, has, led, other, authors, suggest, that, combined, approach, with, endocrine, pediatric, surgeons, addition, pediatric, endocrinologists, may, optimize, care, children, with, surgical, thyroid, disease, given, low, number, pediatric, patients4, our, data, do, not, allow, comparisons, different, approaches, given, late, adoption, combined, approach, , recurrence, , rate, , , thyroid, , cancer, , , children, after, , thyroidectomy, , has, , varied, , widely, , , reported, studies, , ranging, , from, , , , , , , while, , it, , , , , , cohort, , only, , , few, , studies, , explored, , predictors, , , recurrence, , lymph, , node, , involvement, multiple, nodules, male, gender, younger, age, histologic, subtype, advanced, tumor, stage, were, risk, factors, associated, with, recurrence17233033, , , study, , , , , patients, , with, , malignant, , lesions, received, rai, although, there, are, conflicting, data, regarding, , , indications, , , postoperative, , rai, , treatment, lowrisk, patients, current, recommendation, that, lowrisk, patients, can, be, treated, without, rai3436there, are, some, limitations, study, retrospective, nature, may, affect, validity, quality, data, small, number, cases, some, categories, did, not, enable, us, compare, groups, explore, predictors, relative, these, factors, on, other, hand, study, adds, scarce, data, on, thyroid, surgery, pediatric, age, group, malignancy, commonest, indication, , , thyroid, , surgery, , , children, , , fna, , highly, , diagnostic, , hypocalcemia, , , recurrent, , laryngeal, nerve, injury, are, significant, complications, cancerrelated, , death, , , extremely, , rare, , but, , recurrence, , , not, uncommon, significant, number, patients, with, malignant, cases, received, rai, treatmentoriginal, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0creferences, , trowbridge, , fl, , matovinovic, , j, , mclaren, gd, nichaman, mz, iodine, goiter, children, pediatrics, , ries, lag, melbert, d, krapcho, m, stinchcomb, , dg, , howlader, , n, , horner, , mj, , et, , al, seer, , cancer, , statistics, , review, , , bethesda, , national, , cancer, , institute, , , based, , on, , november, , , , seer, , data, , submission, chen, y[h], masiakos, pt, gaz, rd, hodin, ra, parangi, s, randolph, gw, et, al, pediatric, thyroidectomy, high, volume, thyroid, surgery, center, risk, factors, postoperative, hypocalcemia, j, pediatr, surg, , aug5081316, , , wood, , jh, , partrick, , da, , barham, , hp, , bensard, dd, travers, hs, bruny, jl, et, al, pediatric, thyroidectomy, , , collaborative, , surgical, , approach, j, pediatr, surg, , may4658238, , scholz, s, smith, jr, chaignaud, b, shamberger, , rc, , huang, , sa, , thyroid, , surgery, , at, childrens, hospital, boston, 35year, singleinstitution, , experience, , j, , pediatr, , surg, , , mar46343742, , , josefson, , j, , zimmerman, , d, , thyroid, , nodules, cancers, children, pediatr, endocrinol, rev, , sep611423, hameed, r, zacharin, mr, , changing, face, paediatric, adolescent, thyroid, cancer, j, paediatr, child, health, , , lugovicente, , h, , ortiz, , vn, , irizarry, , h, camps, , ji, , pagã¡n, , v, , pediatric, , thyroid, , nodules, management, era, fine, needle, aspirationj, pediatr, surg, , mussa, de, andrea, m, motta, m, mormile, , palestini, , n, , corrias, , , predictors, , , malignancy, children, with, thyroid, nodules, j, pediatr, , oct167488692, amirazodi, e, propst, ej, chung, ct, parra, da, , wasserman, , jd, , pediatric, , thyroid, , fna, biopsy, , outcomes, , , impact, , on, , management, over, , years, at, tertiary, care, center, cancer, cytopathol, , , , partyka, , kl, , huang, , ec2, , cramer, , hm, chen, , s, , wu, , hh, , histologic, , , clinical, followup, , , thyroid, , fineneedle, , aspirates, , pediatric, , patients, , cancer, , cytopathol, , sinha, ck, decoppi, p, pierro, brain, c, hindmarsh, p, butler, g, et, al, thyroid, surgery, children, clinical, outcomes, eur, j, pediatr, surg, , oct2554259, kundel, thompson, gb, richards, ml, qiu, lx, cai, y, schwenk, fw, et, al, pediatric, endocrine, surgery, 20year, experience, at, , mayo, , clinic, , j, , clin, , endocrinol, , metab, february, , , jiang, w, newbury, ro, newfield, rs, pediatric, , thyroid, , surgery, , , management, , thyroid, , nodulesan, , institutional, , experience, features, , over, 10year, period, int, j, pediatr, endocrinol, , burke, jf, sippel, rs, chen, h, evolution, pediatric, thyroid, surgery, at, tertiary, medical, center, surg, res, , , , , alqahtani, , kh, , tunio, , ma, , al, , asiri, , m, aljohani, nj, bayoumi, y, riaz, k, et, al, clinicopathological, treatment, outcomes, , , differentiated, , thyroid, , cancer, , saudi, , children, , , adults, , j, , otolaryngol, head, neck, surg, , nov, , kluijfhout, wp, van, beek, dj, verrijn, stuart, , aa, , lodewijk, , l, , valk, , gd, , van, , der, , zee, dc, , et, , al, , postoperative, , complications, after, , prophylactic, , thyroidectomy, , , very, young, , patients, , with, , multiple, , endocrine, neoplasia, , type, , , , medicine, , baltimore, 20159429e1108, , raval, mv, browne, m, chin, ac, zimmerman, d, angelos, p, reynolds, m, total, thyroidectomy, , , benign, , disease, , , , pediatric, patientfeasible, , , safe, , j, , pediatr, , surg, , stavrakis, ai, ituarte, ph, ko, cy, yeh, mw, surgeon, volume, as, predictor, outcomes, , inpatient, , , outpatient, , endocrine, , surgery, surgery, , , sosa, ja, bowman, hm, tielsch, jm, powe, nr, , gordon, , ta, , udelsman, , r, , , importance, surgeon, experience, clinical, economic, , outcomes, , from, , thyroidectomy, ann, surg, , , tuggle, ct, , roman, sa, wang, ts, boudourakis, , l, , thomas, , d, , udelsman, , r, , et, , al, pediatric, , endocrine, , surgery, , who, , , operating, , on, , our, , children, , surgery, , , dec144686977, , park, , s, , jeong, , js, , ryu, , hr, , lee, , c, , park, jh, kang, s, et, al, differentiated, thyroid, carcinoma, children, adolescents27year, experience, , , , yonsei, , university, , health, system, j, korean, med, sci, , , palmer, ba, zarroug, ae, poley, rn, kollars, , jp, , moir, , cr, , papillary, , thyroid, , carcinoma, children, risk, factors, complications, , , disease, , recurrence, , j, , pediatr, , surg, , wada, n, sugino, k, mimura, t, nagahama, m, , kitagawa, , w, , shibuya, , h, , et, , al, , pediatric, differentiated, , thyroid, , carcinoma, , , stage, , i, risk, , factor, , analysis, , , disease, , free, , survival, bmc, cancer, , , , d, danese, gardini, farsetti, sciacchitano, , s, , andreoli, , m, , pontecorvi, , , thyroid, carcinoma, children, adolescents, eur, j, pediatr, , , astl, , j, , chovanec, , m, , lukes, , p, , katra, , r, dvorakova, m, vlcek, p, et, al, thyroid, carcinoma, surgery, children, adolescents, , , years, experience, surgery, pediatric, thyroid, lymph, , node, , metastases, carcinoma, , int, , j, , pediatr, , otorhinolaryngol, , , chaukar, , da, , rangarajan, , v, , nair, , n, nadkarni, , ms, , pai, , ps, , dcruz, , ak, , et, , al, , pediatric, , thyroid, , cancer, , j, , surg, , oncol, , , , , dzodic, , r, , buta, , m, , markovic, , i, , gavrilo, d, matovic, m, milovanovic, z, et, al, surgical, management, , , welldifferentiated, , thyroid, carcinoma, , , children, , , adolescents, , , years, experience, single, institution, serbia, endocr, j, , , scheumann, , gf, , gimm, , o, , wegener, g, , hundeshagen, , h, , dralle, , h, , prognostic, significance, , , surgical, , management, , locoregional, papillary, thyroid, cancer, world, j, surg, , , shi, rl, qu, n, yang, sw, tumor, size, interpretation, predicting, cervical, lymph, node, metastasis, using, differentiated, thyroid, cancer, risk, model, onco, targets, ther, , , , zimmerman, d, hay, id, gough, ir, goellner, jr, ryan, jj, grant, cs, et, al, papillary, thyroid, carcinoma, children, adults, longterm, , followup, , , , , patients, , conservatively, treated, at, one, institution, during, three, decades, surgery, , , collini, , p, , mattavelli, , f, , pellegrinelli, , barisella, m, ferrari, massimino, m, papillary, carcinoma, thyroid, gland, childhood, adolescence, morphologic, subtypes, biologic, behavior, prognosis, clinicopathologic, study, , sporadic, cases, treated, at, single, institution, during, 30year, period, am, j, surg, pathol, , , borsonchazot, , causeret, , s, , lifante, , jc, augros, m, berger, n, peix, jl, predictive, factors, recurrence, from, series, , children, , adolescents, , with, , differentiated, , thyroid, cancer, world, j, surg, , , baumgarten, hd, bauer, aj, isaza, mostoufimoab, s, kazahaya, k, adzick, ns, surgical, management, pediatric, thyroid, disease, complication, , rates, , after, , thyroidectomy, , at, childrens, hospital, philadelphia, highvolume, pediatric, thyroid, center, journal, pediatric, , surgery, , , , oct, , , kurzawinski, tr, de, coppi, p, thyroidectomy, children, inpediatric, surgery, , pp, , springer, berlin, heidelberg, , francis, , g, , waguespack, , sg, , bauer, , aj, angelog, p, benvenga, s, et, al, management, guidelines, , , children, , with, , thyroid, , nodules, , , differentiated, , thyroid, , cancer, , american, , thyroid, , association, , guidelines, task, force, on, pediatric, thyroid, cancer, thyroid, volume, , number, , original, pediatric, thyroid, surgeryann, saudi, med, , julyaugust, wwwannsaudimednet, 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,15,16,17,18,19,20,21,22,23,24,25,26,28,29,30,31,33,34,35,36,37,38,39,40,43,44,45,47,48,49,50,51,52,54,55,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,77,78,80,81,82,86,87,88,93,94,95,97,98,99,101,105,108,111,112,113,114,115,119,120,122,125,126,128,133,134,136,137,139,140,142,143,144,146,148,149,151,153,154,155,156,157,158,161,163,164,165,166,167,168,170,172,173,174,175,178,179,180,184,185,186,187,188,189,193,194,195,196,198,199,201,205,210,212,217,218,223,224,228,229,232,236,238,240,242,245,248,249,253,255,256,260,264,268,269,270,273,279,280,281,282,286,287,288,289,293,299,301,305,307,310,312,313,316,318,320,321,326,328,333,341,343,349,350,351,355,357,359,360,365,369,370,374,376,377,378,380,384,385,389,391,392,396,397,398,399,401,408,412,414,425,434,440,444,447,448,449,451,452,453,455,460,464,470,471,473,475,476,477,480,481,482,483,489,495,496,497,498,499,503,504,518,519,521,524,527,532,535,546,551,559,560,561,564,568,572,576,577,578,586,589,596,601,602,608,609,617,625,631,632,633,638,639,658,661,663,665,674,680,684,692,693,711,718,730,746,747,752,754,759,761,770,771,783,784,785,788,795,797,798,801,805,808,814,815,827,832,834,838,872,875,879,882,884,889,894,912,915,924,932,935,955,965,978,984,993,1008,1041,1060,1069,1084,1103,1108,1114,1126,1133,1136,1140,1160,1163,1166,1168,1171,1174,1176,1183,1184,1188,1197,1198,1217,1222,1232,1242,1248,1253,1256,1262,1283,1285,1297,1299,1300,1308,1309,1312,1315,1321,1332,1345,1363,1384,1393,1395,1400,1406,1408,1423,1439,1448,1451,1453,1454,1473,1492,1501,1505,1519,1530,1536,1539,1560,1568,1569,1585,1595,1596,1605,1608,1618,1624,1645,1647,1655,1657,1660,1666,1671,1674,1687,1693,1697,1700,1706,1709,1721,1736,1737,1754,1767,1781,1792,1793,1803,1809,1827,1830,1832,1846,1849,1860,1903,1906,1921,1940,1962,2016,2017,2021,2068,2078,2085,2089,2101,2102,2123,2142,2152,2156,2185,2198,2219,2240,2252,2284,2300,2304,2332,2351,2370,2371,2401,2415,2430,2448,2453,2456,2457,2483,2488,2492,2526,2541,2544,2569,2575,2627,2628,2634,2646,2675,2699,2728,2749,2771,2801,2812,2821,2843,2934,2945,2956,2966,2984,3000,3028,3035,3036,3066,3082,3098,3101,3108,3110,3121,3125,3129,3154,3163,3172,3205,3220,3224,3233,3236,3247,3256,3261,3268,3269,3270,3284,3297,3298,3299,3303,3308,3340,3377,3384,3430,3446,3448,3472,3513,3537,3609,3615,3625,3695,3720,3721,3757,3765,3781,3792,3795,3814,3826,3839,3846,3864,3869,3888,3889,3893,3920,3942,3962,4010,4020,4045,4069,4073,4094,4110,4173,4184,4413,4420,4576,4577,4589,4610,4627,4663,4664,4665,4670,4693,4708,4716,4742,4747,4801,4831,4868,4920,4936,4947,5018,5070,5071,5100,5113,5119,5193,5207,5233,5276,5284,5296,5300,5372,5418,5419,5621,5644,5671,5696,5774,5875,5926,6030,6040,6046,6094,6101,6114,6168,6175,6196,6231,6264,6274,6289,6299,6308,6340,6490,6529,6588,6604,6615,6720,6779,6802,6877,6901,7032,7137,7161,7338,7371,7448,7511,7588,7592,7608,7638,7670,7709,7735,7783,7900,7991,8078,8221,8373,8464,8693,8822,8839,8895,9115,9206,9338,9459,9473,9493,9624,9625,9663,9815,9922,10203,10219,10224,10292,10345,10419,10627,10635,10653,10674,10690,11049,11166,11173,11309,11330,11385,11745,11816,11887,12120,12328,12348,12645,13081,13093,13097,13182,13710,13860,13877,14064,14255,14319,14442,14855,14885,15299,15644,15785,15788,15871,16151,17047,17199,17546,17906,17971,18027,19187,19257,20027,20311,20467,20608,20790,20981,21198,21522,22668,23478,23724,24375,25202,25557,25572,26108,27036,27321,27503,27563,27706,28164,28458,28763,29145,30085,30927,31781,31831,32008,32228,32237,32492,32995,33302,33497,33610,34761,34892,35002,36593,37217,37945,38654,39013,39160,39211,40136,40646,40686,41662,41774,42263,43994,44638,46000,48009,49007,50764,51276,51639,52695,52732,52829,53462,53903,54817,55042,55108,55696,56393,58476,60750,62861,63309,63980,64173,64635,65251,65612,66199,67815,70610,71640,73760,74298,74929,78258,78777,80707,80796,81922,84317,84344,85616,85624,85892,86151,86693,88209,89132,90453,91905,91977,92080,93965,94582,96278,97515,99168,99794,100033,102394,102608,103368,104517,105565,106501,106903,107875,108087,109249,111252,111874,111958,112655,112709,113093,114941,115996,116021,116238,116324,120205,120263,121479,121522,121572,121899,121955,124579,125808,125859,126271,126394,127498,127953,128765,128865,129238,129460,130440,131215,131626,132318,135314,135546,135781,137100,137548,140160,143099,143440,143825,144043,144111,144730,145906,147284,147480,148045,148858,149783,151134,153021,153328,153611,154094,154339,157141,157482,157722,157885,158337,158452,158529,159578,159864,160101,160594,160753,160869,161003,161352,162316,162323,162324,162623,162727,162781,163008,164353,165045,168728,170042,170796,171005,171285,171993,172017,173173,173299,174040,174086,174861,175096,175223,176107,176231,176611,176639,178670,178721,179220,180168,180702,180848,180852,181346,182664,182803,182960,183089,184367,184429,185191,185852,186995,190131,192191,193480,193745,193933,194413,194868,195141,196261,196350,197890,199995,200708,200891,201562,202199,202859,203762,204457,204938,205385,206006,206659,207164,207741,209584,210570,210663],[1052.0,30.0,22.0,5.0,8.0,3.0,24.0,37.0,12.0,11.0,6.0,12.0,3.0,8.0,19.0,5.0,2.0,9.0,19.0,4.0,10.0,7.0,2.0,2.0,5.0,9.0,1.0,3.0,1.0,22.0,1.0,1.0,5.0,6.0,2.0,11.0,3.0,5.0,2.0,5.0,9.0,2.0,6.0,2.0,15.0,4.0,2.0,2.0,2.0,1.0,1.0,7.0,4.0,8.0,15.0,12.0,6.0,6.0,3.0,2.0,8.0,1.0,2.0,16.0,1.0,7.0,3.0,7.0,2.0,1.0,2.0,1.0,3.0,5.0,3.0,7.0,1.0,4.0,5.0,1.0,7.0,2.0,3.0,16.0,1.0,1.0,2.0,8.0,2.0,1.0,5.0,1.0,3.0,2.0,1.0,2.0,18.0,1.0,9.0,9.0,5.0,2.0,3.0,5.0,1.0,6.0,1.0,3.0,1.0,3.0,3.0,2.0,1.0,10.0,2.0,7.0,32.0,1.0,3.0,1.0,1.0,4.0,2.0,2.0,1.0,7.0,1.0,2.0,2.0,1.0,6.0,2.0,77.0,3.0,2.0,1.0,6.0,1.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,3.0,3.0,5.0,1.0,1.0,1.0,1.0,3.0,1.0,5.0,1.0,1.0,1.0,4.0,7.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,6.0,2.0,2.0,4.0,1.0,4.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,4.0,2.0,1.0,1.0,8.0,2.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,9.0,3.0,2.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,7.0,5.0,5.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,5.0,2.0,1.0,1.0,2.0,2.0,1.0,6.0,2.0,9.0,1.0,1.0,1.0,2.0,2.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,3.0,11.0,4.0,7.0,1.0,2.0,1.0,1.0,3.0,2.0,2.0,2.0,5.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,5.0,4.0,2.0,7.0,1.0,1.0,1.0,4.0,4.0,1.0,3.0,1.0,1.0,3.0,2.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,10.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,14.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,6.0,7.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,4.0,1.0,1.0,2.0,8.0,1.0,1.0,2.0,2.0,1.0,1.0,3.0,1.0,1.0,3.0,9.0,1.0,2.0,1.0,1.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,3.0,1.0,1.0,1.0,6.0,2.0,1.0,2.0,2.0,1.0,35.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,6.0,6.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,3.0,7.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,33.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,3.0,2.0,2.0,1.0,3.0,1.0,1.0,1.0,13.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,2.0,3.0,1.0,8.0,1.0,4.0,3.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,14.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,26.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,12.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,7.0,1.0,1.0,5.0,8.0,2.0,1.0,1.0,1.0,7.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,3.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,5.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,11.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,12.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,5.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,3.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
      "|[\", the, adopted, strategy, was, the, same, as, that, used, in, prior, years, [], and, is, based, on, four, exclusive, queries, that, return, , four, , disjoint, , citation, , subsets, the, first, query, qpub_plain, is, based, on, a, plaintext, search, in, pubmed, titles, and, s, using, keywords, the, , second, , query, , qpub_indexed, relies, on, the, pubmed, indexing, scheme, using, mesh, terms, and, results, are, made, exclusive, of, the, previous, set, the, third, one, qwos_restricted, is, based, on, a, plaintext, search, in, wos, restricted, to, the, two, research, areas, medical, informatics, and, health, care, sciences, , services, the, fourth, query, qwos_filtered, is, based, on, the, same, plaintext, search, used, in, wos, but, filtered, by, nonrelevant, research, areas, eg, archeology, dance, zoology, etc, and, the, two, research, areas, of, the, previous, query, it, is, of, note, that, the, two, wos, queries, select, , only, , nonpubmedindexed, , papers, that, are, supposed, to, be, caught, by, the, two, pubmed, queriesa, , first, , review, , of, , the, , four, , subsets, , of, retrieved, , citations, , was, , performed, , by, , the, two, section, editors, to, select, , candidate, best, papers, following, the, imia, yearbook, protocol, these, candidate, best, papers, were, then, individually, reviewed, and, rated, by, both, section, editors, the, chief, editor, of, the, decision, support, section, and, external, reviewers, from, the, international, medical, informatics, community, based, on, the, reviewers, ratings, and, comments, the, yearbook, editorial, committee, then, selected, the, best, papers, of, the, year, in, the, decision, support, domainimia, yearbook, of, medical, informatics, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , imia, and, ge, thieme, verlag, kg, 0creview, results, the, , , , literature, , search, , has, , been, , performed, on, january, , , a, total, of, , unique, references, were, obtained, distributed, as, follows, , for, qpub_plain, , for, qpub_indexed, , for, qwos_restricted, and, , for, qwos_filtered, yielding, subtotals, of, , references, from, pubmed, and, , from, wos, compared, to, the, previous, year, the, global, query, retrieved, , , more, , papers, after, , a, , first, , individual, screening, independently, performed, by, both, section, editors, based, on, the, title, and, , of, papers, , not, rejected, by, both, section, editors, were, discussed, by, the, two, editors, to, achieve, a, final, selection, of, , candidate, best, , papers, after, , the, , external, , review, , of, these, , , , s, , the, , editorial, , committee, finally, selected, three, of, them, as, best, papers, for, , [], table, , they, are, discussed, in, the, next, section, and, summaries, of, their, contents, are, available, in, the, appendixdiscussion, and, outlookin, the, first, paper, hendriks, , [], propose, an, approach, to, the, modeling, of, clinical, practice, guidelines, which, certainly, builds, on, already, existing, approaches, but, which, is, systematically, conducted, in, order, to, be, scalable, and, used, to, represent, complex, guidelines, they, promote, the, formalism, of, clinical, decision, trees, cdts, as, they, are, both, clinically, interpretable, , by, , healthcare, , professionals, and, , computerinterpretable, , thus, , suitable, for, implementation, in, datadriven, cdsss, the, disambiguation, of, textual, guidelines, is, supported, first, by, the, formal, unequivocal, specification, of, data, items, used, as, decision, criteria, using, international, coding, systems, to, enforce, interoperability, and, second, by, the, representation, of, guideline, knowledge, as, cdts, the, method, is, applied, to, the, dutch, breast, cancer, guidelines, sixty, cdts, were, built, , involving, , a, , total, , of, , , , data, , items, among, , which, , , , could, , not, , be, , linked, , to, standard, terminologies, the, authors, report, the, ambiguity, of, certain, criteria, which, could, be, subjective, or, had, multiple, definitions, the, resulting, knowledge, base, was, implemented, in, a, decision, support, application, where, it, can, be, interactively, browsed, or, automatically, executed, by, modeling, guidelines, in, such, a, way, this, work, is, a, step, forward, in, the, sharing, of, encoded, knowledgein, the, second, paper, kamiå¡aliä, , [], tackled, the, issues, linked, to, the, formalization, of, the, medical, processes, used, for, managing, chronic, diseases, and, their, execution, in, cdsss, they, analyzed, the, decisionmaking, dimensions, of, the, therapeutic, management, of, chronic, diseases, like, those, known, to, increase, the, cardiovascular, risk, and, identified, three, basic, levels, therapy, strategy, dosage, adaptation, and, intolerance, management, to, handle, these, , different, , aspects, , consistently, , they, propose, a, formalism, called, extended, timed, transition, diagram, ettd, with, ettds, they, illustrate, the, multilevel, and, finegrained, modeling, required, to, capture, the, contents, of, arterial, hypertension, management, guidelines, this, detailed, demonstration, on, how, procedural, knowledge, for, hypertension, management, can, be, formalized, to, develop, a, cdss, could, certainly, be, used, in, other, medical, domainsthe, third, paper, by, khalifa, , [], presents, a, conceptual, and, practical, framework, to, help, assess, confidence, in, predictive, tools, grasp, , for, , grade, , and, assess, , predictive, tools, is, both, a, method, to, look, for, evidence, from, the, published, literature, and, an, analysis, grid, it, standardizes, the, assessment, of, the, available, literature, associated, to, a, predictive, tool, and, the, grading, of, its, level, of, proof, three, phases, of, evaluation, are, considered, i, before, the, implementation, of, the, tool, to, assess, both, its, internal, and, external, validity, ii, during, the, implementation, to, assess, its, potential, effect, and, usability, and, iii, after, the, implementation, to, assess, its, effectiveness, and, safety, in, each, phase, the, level, of, evidence, , can, , be, , assessed, , from, , the, , study, design, a, qualitative, , summarizes, the, direction, of, evidence, positive, negative, mixed, this, grid, can, be, considered, as, similar, to, existing, grids, for, instance, the, consort, statement, for, clinical, trials, however, it, gives, a, rigorous, methodology, for, a, critical, appraisal, of, predictive, tools, and, could, be, extended, to, all, kind, of, cdsss, it, might, be, a, useful, tool, to, extend, the, evidencebased, culture, in, the, field, of, medical, informaticsbesides, the, three, best, papers, selected, for, the, , decision, , support, section, , of, , the, , , edition, of, the, imia, yearbook, several, other, works, retrieved, from, the, literature, review, deserve, to, be, cited, some, of, them, deal, with, the, personalization, of, decisions, laleci, , , [], , propose, , a, , scientific, , and, , technical, approach, to, develop, personalized, care, plans, that, comply, with, clinical, practice, guidelines, for, the, management, of, complex, polypathology, situations, jafarpour, , [], propose, a, solution, to, dynamically, manage, the, conflicts, that, can, rise, in, this, type, of, complex, contexts, ben, souissi, , [], introduce, the, use, of, health, , information, , technology, , involving, multiple, criteria, decision, to, support, the, choice, between, antibiotics, alternatives, interestingly, other, works, promote, the, creation, and, sharing, of, operational, knowledge, bases, as, exemplified, by, hendriks, , [], thus, huibers, , [], transform, the, textual, stoppstart, criteria, into, unambiguous, definitions, mapped, to, , medical, , terminologies, , canovas, et, , al, [], formalize, eucast, expert, rules, as, an, ontology, and, production, rules, to, detect, antimicrobial, therapies, at, risk, of, failure, m¼ller, , [], propose, an, , , diagnostic, knowledge, base, that, can, compete, with, commercial, ones, replacing, humans, is, another, topic, of, research, and, spnig, , [], work, on, two, aspects, to, virtualize, a, doctor, the, automatic, acquisition, of, data, through, sensors, and, speech, recognition, and, the, automation, of, diagnostic, reasoning, rozenblum, et, al[], propose, a, machine, learning, method, to, generate, clinically, valid, alerts, to, detect, errors, in, prescriptions, acceptability, , of, , cdss, , is, , another, , key, point, kannan, , [], propose, a, method, for, a, cdss, design, to, best, meet, a, precisely, specified, and, assessable, user, purpose, design, alerts, , may, , also, , avoid, , rejection, , of, , cdsss, by, caregivers, fernandes, , [], created, algorithms, able, to, aggregate, filter, and, reduce, the, notifications, delivered, to, healthcare, professionals, amrose, et, , al, [], tried, to, understand, in, real, life, the, impact, of, alerts, on, users, and, to, find, the, actions, they, triggered, finally, it, is, always, interesting, to, obtain, varied, evaluation, results, of, controversial, cdsss, in, this, respect, kim, , [], evaluated, watson, for, oncology, in, thyroid, carcinoma, and, reported, a, concordance, rate, with, local, practices, considered, as, too, low, to, adopt, the, tool, as, , evidenced, , by, , the, , number, , and, , the, variety, of, works, around, decision, support, research, in, the, field, is, very, active, this, years, selection, highlighted, pragmatic, works, that, promote, the, transparency, and, sharing, of, the, imia, yearbook, of, medical, informatics, 2020duclos, , 0ctable, , , , , best, paper, selection, of, s, for, the, imia, yearbook, of, medical, informatics, , in, the, section, 'decision, support', the, s, are, listed, in, alphabetical, order, of, the, first, authors, surname, section, decision, support\\uf0a7, , hendriks, mp, verbeek, xaam, van, vegchel, t, van, der, sangen, mjc, strobbe, lja, merkus, jws, zonderland, hm, smorenburg, ch, jager, a, siesling, s, transformation, of, the, national, breast, cancer, guideline, into, datadriven, clinical, decision, trees, jco, clin, cancer, inform, \\uf0a7\\t, kamiå¡aliä\\ta\\tria±o\\td\\tkert\\ts\\twelzer\\tt\\tnemec\\tzlatolas\\tl\\tmultilevel\\tmedical\\tknowledge\\tformalization\\tto\\tsupport\\tmedical\\tpractice, for, chronic, diseases, data, , knowledge, engineering, \\uf0a7, , khalifa, m, magrabi, f, gallego, b, developing, a, framework, for, evidencebased, grading, and, assessment, of, predictive, tools, for, clinical, decision, support, bmc, med, inform, decis, mak, , knowledge, bases, used, by, decision, support, tools, as, well, as, the, grading, of, their, utility, the, ultimate, goal, is, that, users, could, trust, such, tools, to, then, use, themacknowledgementwe, would, like, to, thank, all, the, present, and, past, editorial, boards, of, the, imia, yearbook, especially, martina, hutter, and, adrien, ugon, for, their, support, as, well, as, the, reviewers, for, , their, , participation, , to, , the, , selection, , of, the, , best, , papers, , for, , the, , decision, , support, section, we, cannot, end, this, synopsis, without, a, meaningful, thought, for, our, colleague, and, friend, vassilis, , koutkias, , who, , started, , this, year, again, to, tackle, the, tasks, of, a, decision, support, section, coeditor, but, passed, away, in, last, december, and, unfortunately, could, not, finishreferences, , jankovic, i, chen, jh, clinical, decision, support, and, implications, for, the, clinician, burnout, crisis, , yearb, med, inform, , , koutkias, v, bouaud, j, contributions, on, clinical, decision, support, from, the, , literature, yearb, med, inform, , aug2811357, , hendriks, mp, verbeek, xaam, van, vegchel, t, van, der, sangen, mjc, strobbe, lja, merkus, jws, , transformation, of, the, national, breast, cancer, guideline, , into, , datadriven, , clinical, , decision, trees, jco, clin, cancer, inform, , , kamiå¡aliä, a, ria±o, d, kert, s, welzer, t, nemec, zlatolas, , l, , multilevel, , medical, , knowledge, formalization, , to, , support, , medical, , practice, , for, chronic, diseases, data, , knowledge, engineering, , , khalifa, , m, , magrabi, , f, , gallego, , b, , developing, a, , framework, , for, , evidencebased, , grading, , and, assessment, , of, , predictive, , tools, , for, , clinical, , decision, , support, , bmc, , med, , inform, , decis, , mak, , , , laleci, , gb, yuksel, , m, , sarigul, , b, arvanitis, tn, lindman, p, chen, r, , a, collaborative, platform, for, management, of, chronic, diseases, via, guidelinedriven, , individualized, , care, , plans, , comput, struct, biotechnol, j, , , , jafarpour, , b, , raza, abidi, , s, van, , woensel, , w, raza, abidi, , ss, , executiontime, , integration, , of, clinical, , practice, , guidelines, , to, , provide, , decision, support, for, comorbid, conditions, artif, intell, med, , , ben, souissi, s, abed, m, el, hiki, l, fortemps, p, pirlot, , m, , pars, , a, , system, , combining, , semantic, technologies, with, multiple, criteria, decision, aiding, for, supporting, antibiotic, prescriptions, j, biomed, inform, , , huibers, , cja, , sallevelt, , btgm, , de, , groot, , da, boer, mj, van, campen, jpcm, davids, cj, , conversion, , of, , stoppstart, , version, , , , into, coded, algorithms, for, software, implementation, a, multidisciplinary, consensus, procedure, int, j, med, inform, , c¡novassegura, b, morales, a, juarez, jm, campos, m, palacios, f, impact, of, expert, knowledge, on, the, detection, of, patients, at, risk, of, antimicrobial, therapy, failure, by, clinical, decision, support, systems, j, biomed, inform, , m¼ller, l, gangadharaiah, r, klein, sc, perry, j, bernstein, g, nurkse, d, , an, , , access, medical, knowledge, base, for, community, driven, diagnostic, decision, support, system, development, bmc, med, inform, decis, mak, , spnig, , s, , embergerklein, a, , sowa, , jp, , canbay, a, menrad, k, heider, d, the, virtual, doctor, an, interactive, clinicaldecisionsupport, system, based, on, deep, learning, for, noninvasive, prediction, of, diabetes, artif, intell, med, , rozenblum, r, rodriguezmonguio, r, volk, la, forsythe, kj, myers, s, mcgurrin, m, , using, a, machine, learning, system, to, identify, and, prevent, medication, prescribing, errors, a, clinical, and, cost, analysis, evaluation, jt, comm, j, qual, patient, saf, , , kannan, v, , basit, , ma, , bajaj, , p, , carrington, ar, donahue, ib, flahaven, el, , user, stories, as, lightweight, requirements, for, agile, clinical, decision, support, development, j, am, med, inform, assoc, , fernandes, co, miles, s, lucena, cjp, cowan, d, artificial, , intelligence, technologies, , for, , coping, with, alarm, , fatigue, , in, , hospital, , environments, because, , of, , sensory, , overload, algorithm, , development, , and, validation, , j, , med, , internet, , res, 20192111e15406, amroze, a, , field, ts, , fouayzi, , h, , sundaresan, d, , burns, , l, , garber, , l, , et, , al, , use, , of, , electronic, health, record, access, and, audit, logs, to, identify, physician, actions, following, noninterruptive, alert, , ing, descriptive, study, jmir, med, inform, 201971e12650, kim, m, kim, bh, kim, jm, kim, eh, kim, k, pak, k, , concordance, in, postsurgical, radioactive, iodine, therapy, recommendations, between, watson, for, , oncology, , and, , clinical, , practice, , in, , patients, with, , differentiated, , thyroid, , carcinoma, cancer, correspondence, topr, catherine, ducloslimics, inserm, facult©, l©onard, de, vinci, rue, marcel, cachin, , bobigny, franceemail, catherineduclosaphpfr, imia, yearbook, of, medical, informatics, 2020pragmatic, considerations, on, clinical, decision, support, from, the, , literature, 0cappendix, content, summaries, of, best, papers, for, the, decision, support, section, of, the, , imia, yearbookhendriks, mp, verbeek, xaam, van, vegchel, t, van, der, sangen, mjc, strobbe, lja, merkus, jws, zonderland, hm, smorenburg, ch, jager, a, siesling, stransformation, of, the, national, breast, cancer, guideline, into, datadriven, clinical, decision, treesjco, clin, cancer, inform, , may3114since, , clinical, , practice, , guidelines, , are, , still, narrative, and, described, in, large, textual, documents, the, aim, of, this, work, was, to, model, complex, guidelines, as, datadriven, clinical, decision, trees, cdts, that, could, be, still, humaninterpretable, while, computerinterpretable, for, implementation, in, decision, support, systems, the, dutch, national, breast, cancer, guidelines, were, translated, into, cdts, data, items, , which, , characterize, , the, , patient, , and, the, tumor, and, represent, decisional, criteria, were, encoded, unambiguously, using, existing, classifications, and, coding, systems, related, to, breast, cancer, when, feasible, in, total, , cdts, , were, , necessary, , to, , cover, , the, , whole, guidelines, driven, by, , data, items, of, all, data, items, , , could, be, coded, using, existing, classification, and, coding, systems, all, , cdts, represented, , unique, patient, subpopulations, complex, guidelines, could, be, transformed, as, systematically, constructed, modular, datadriven, cdts, that, are, clinically, interpretable, and, executable, in, a, decision, support, applicationkamiå¡aliä, a, ria±o, d, kert, s, welzer, t, nemec, zlatolas, lmultilevel, medical, knowledge, formalization, to, support, medical, practice, for, chronic, diseasesdata, , knowledge, engineering, , this, research, is, focused, on, knowledge, representation, to, support, the, medical, processes, involved, in, chronic, diseases, management, which, can, be, viewed, as, a, procedural, and, sequential, , application, , of, , knowledge, an, intuitive, easy, and, effective, mechanism, for, medical, , knowledge, , formalization, , is, , proposed, through, a, formalism, called, extended, timed, transition, , diagram, , ettd, this, formalism, allows, for, the, consistent, representation, of, three, basic, levels, of, decision, making, that, should, be, taken, into, account, in, the, prescription, and, adaptation, of, longterm, treatment, therapy, strategy, dosage, and, intolerances, the, methodology, can, be, manually, applied, to, build, ettds, from, clinical, practice, guidelines, ettds, implementation, is, demonstrated, by, modeling, clinical, practice, guidelines, for, the, therapeutic, management, of, arterial, hypertension, the, obtained, models, can, be, used, as, a, baseline, framework, for, the, development, of, decision, support, systems, involving, medical, procedureskhalifa, m, magrabi, f, gallego, bdeveloping, a, framework, for, evidencebased, grading, and, assessment, of, predictive, tools, for, clinical, decision, supportbmc, med, inform, decis, mak, , oct, deciding, to, choose, a, clinical, predictive, tool, in, clinical, practice, should, be, guided, by, its, correctly, assessed, effectiveness, the, objective, of, this, work, is, to, developp, a, conceptual, and, practical, framework, to, grade, and, assess, predictive, tools, grasp, and, provide, clinicians, with, a, standardised, evidencebased, system, to, support, their, search, for, and, selection, of, efficient, predictive, tools, the, grasp, framework, grades, predictive, tools, based, on, published, evidence, across, three, dimensions, phase, of, evaluation, level, of, evidence, and, direction, of, evidence, the, final, grade, of, the, tool, is, based, on, the, phase, of, evaluation, that, gets, , the, , hightest, , grade, , supported, , by, , the, highest, level, of, positive, or, mixed, evidence, that, , supports, , a, , positive, , , this, framework, was, successfully, applied, to, five, predictive, , tools, , grasp, , report, , updates, could, be, a, way, to, maintain, a, data, base, that, documents, the, evidence, of, predictive, tools, imia, yearbook, of, medical, informatics, 2020duclos, , 0c\"]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |[\", adopted, strategy, used, prior, years, [], based, four, exclusive, queries, return, , four, , disjoint, , citation, , subsets, first, query, qpub_plain, based, plaintext, search, pubmed, titles, using, keywords, , second, , query, , qpub_indexed, relies, pubmed, indexing, scheme, using, mesh, terms, results, made, exclusive, previous, set, third, one, qwos_restricted, based, plaintext, search, wos, restricted, two, research, areas, medical, informatics, health, care, sciences, , services, fourth, query, qwos_filtered, based, plaintext, search, used, wos, filtered, nonrelevant, research, areas, eg, archeology, dance, zoology, etc, two, research, areas, previous, query, note, two, wos, queries, select, , , nonpubmedindexed, , papers, supposed, caught, two, pubmed, queriesa, , first, , review, , , , four, , subsets, , retrieved, , citations, , , performed, , , two, section, editors, select, , candidate, best, papers, following, imia, yearbook, protocol, candidate, best, papers, individually, reviewed, rated, section, editors, chief, editor, decision, support, section, external, reviewers, international, medical, informatics, community, based, reviewers, ratings, comments, yearbook, editorial, committee, selected, best, papers, year, decision, support, domainimia, yearbook, medical, informatics, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , imia, ge, thieme, verlag, kg, 0creview, results, , , , literature, , search, , , , performed, january, , , total, , unique, references, obtained, distributed, follows, , qpub_plain, , qpub_indexed, , qwos_restricted, , qwos_filtered, yielding, subtotals, , references, pubmed, , wos, compared, previous, year, global, query, retrieved, , , , papers, , , first, , individual, screening, independently, performed, section, editors, based, title, , papers, , rejected, section, editors, discussed, two, editors, achieve, final, selection, , candidate, best, , papers, , , external, , review, , , , , , , editorial, , committee, finally, selected, three, best, papers, , [], table, , discussed, next, section, summaries, contents, available, appendixdiscussion, outlookin, first, paper, hendriks, , [], propose, approach, modeling, clinical, practice, guidelines, certainly, builds, already, existing, approaches, systematically, conducted, order, scalable, used, represent, complex, guidelines, promote, formalism, clinical, decision, trees, cdts, clinically, interpretable, , , healthcare, , professionals, , computerinterpretable, , thus, , suitable, implementation, datadriven, cdsss, disambiguation, textual, guidelines, supported, first, formal, unequivocal, specification, data, items, used, decision, criteria, using, international, coding, systems, enforce, interoperability, second, representation, guideline, knowledge, cdts, method, applied, dutch, breast, cancer, guidelines, sixty, cdts, built, , involving, , , total, , , , , data, , items, among, , , , , , , , linked, , standard, terminologies, authors, report, ambiguity, certain, criteria, subjective, multiple, definitions, resulting, knowledge, base, implemented, decision, support, application, interactively, browsed, automatically, executed, modeling, guidelines, way, work, step, forward, sharing, encoded, knowledgein, second, paper, kamiå¡aliä, , [], tackled, issues, linked, formalization, medical, processes, used, managing, chronic, diseases, execution, cdsss, analyzed, decisionmaking, dimensions, therapeutic, management, chronic, diseases, like, known, increase, cardiovascular, risk, identified, three, basic, levels, therapy, strategy, dosage, adaptation, intolerance, management, handle, , different, , aspects, , consistently, , propose, formalism, called, extended, timed, transition, diagram, ettd, ettds, illustrate, multilevel, finegrained, modeling, required, capture, contents, arterial, hypertension, management, guidelines, detailed, demonstration, procedural, knowledge, hypertension, management, formalized, develop, cdss, certainly, used, medical, domainsthe, third, paper, khalifa, , [], presents, conceptual, practical, framework, help, assess, confidence, predictive, tools, grasp, , , grade, , assess, , predictive, tools, method, look, evidence, published, literature, analysis, grid, standardizes, assessment, available, literature, associated, predictive, tool, grading, level, proof, three, phases, evaluation, considered, implementation, tool, assess, internal, external, validity, ii, implementation, assess, potential, effect, usability, iii, implementation, assess, effectiveness, safety, phase, level, evidence, , , , assessed, , , , study, design, qualitative, , summarizes, direction, evidence, positive, negative, mixed, grid, considered, similar, existing, grids, instance, consort, statement, clinical, trials, however, gives, rigorous, methodology, critical, appraisal, predictive, tools, extended, kind, cdsss, might, useful, tool, extend, evidencebased, culture, field, medical, informaticsbesides, three, best, papers, selected, , decision, , support, section, , , , , edition, imia, yearbook, several, works, retrieved, literature, review, deserve, cited, deal, personalization, decisions, laleci, , , [], , propose, , , scientific, , , technical, approach, develop, personalized, care, plans, comply, clinical, practice, guidelines, management, complex, polypathology, situations, jafarpour, , [], propose, solution, dynamically, manage, conflicts, rise, type, complex, contexts, ben, souissi, , [], introduce, use, health, , information, , technology, , involving, multiple, criteria, decision, support, choice, antibiotics, alternatives, interestingly, works, promote, creation, sharing, operational, knowledge, bases, exemplified, hendriks, , [], thus, huibers, , [], transform, textual, stoppstart, criteria, unambiguous, definitions, mapped, , medical, , terminologies, , canovas, et, , al, [], formalize, eucast, expert, rules, ontology, production, rules, detect, antimicrobial, therapies, risk, failure, m¼ller, , [], propose, , , diagnostic, knowledge, base, compete, commercial, ones, replacing, humans, another, topic, research, spnig, , [], work, two, aspects, virtualize, doctor, automatic, acquisition, data, sensors, speech, recognition, automation, diagnostic, reasoning, rozenblum, et, al[], propose, machine, learning, method, generate, clinically, valid, alerts, detect, errors, prescriptions, acceptability, , , cdss, , , another, , key, point, kannan, , [], propose, method, cdss, design, best, meet, precisely, specified, assessable, user, purpose, design, alerts, , may, , also, , avoid, , rejection, , , cdsss, caregivers, fernandes, , [], created, algorithms, able, aggregate, filter, reduce, notifications, delivered, healthcare, professionals, amrose, et, , al, [], tried, understand, real, life, impact, alerts, users, find, actions, triggered, finally, always, interesting, obtain, varied, evaluation, results, controversial, cdsss, respect, kim, , [], evaluated, watson, oncology, thyroid, carcinoma, reported, concordance, rate, local, practices, considered, low, adopt, tool, , evidenced, , , , number, , , variety, works, around, decision, support, research, field, active, years, selection, highlighted, pragmatic, works, promote, transparency, sharing, imia, yearbook, medical, informatics, 2020duclos, , 0ctable, , , , , best, paper, selection, imia, yearbook, medical, informatics, , section, 'decision, support', listed, alphabetical, order, first, authors, surname, section, decision, support\\uf0a7, , hendriks, mp, verbeek, xaam, van, vegchel, van, der, sangen, mjc, strobbe, lja, merkus, jws, zonderland, hm, smorenburg, ch, jager, siesling, transformation, national, breast, cancer, guideline, datadriven, clinical, decision, trees, jco, clin, cancer, inform, \\uf0a7\\t, kamiå¡aliä\\ta\\tria±o\\td\\tkert\\ts\\twelzer\\tt\\tnemec\\tzlatolas\\tl\\tmultilevel\\tmedical\\tknowledge\\tformalization\\tto\\tsupport\\tmedical\\tpractice, chronic, diseases, data, , knowledge, engineering, \\uf0a7, , khalifa, m, magrabi, f, gallego, b, developing, framework, evidencebased, grading, assessment, predictive, tools, clinical, decision, support, bmc, med, inform, decis, mak, , knowledge, bases, used, decision, support, tools, well, grading, utility, ultimate, goal, users, trust, tools, use, themacknowledgementwe, like, thank, present, past, editorial, boards, imia, yearbook, especially, martina, hutter, adrien, ugon, support, well, reviewers, , , participation, , , , selection, , , best, , papers, , , , decision, , support, section, end, synopsis, without, meaningful, thought, colleague, friend, vassilis, , koutkias, , , started, , year, tackle, tasks, decision, support, section, coeditor, passed, away, last, december, unfortunately, finishreferences, , jankovic, chen, jh, clinical, decision, support, implications, clinician, burnout, crisis, , yearb, med, inform, , , koutkias, v, bouaud, j, contributions, clinical, decision, support, , literature, yearb, med, inform, , aug2811357, , hendriks, mp, verbeek, xaam, van, vegchel, van, der, sangen, mjc, strobbe, lja, merkus, jws, , transformation, national, breast, cancer, guideline, , , datadriven, , clinical, , decision, trees, jco, clin, cancer, inform, , , kamiå¡aliä, ria±o, d, kert, welzer, nemec, zlatolas, , l, , multilevel, , medical, , knowledge, formalization, , , support, , medical, , practice, , chronic, diseases, data, , knowledge, engineering, , , khalifa, , m, , magrabi, , f, , gallego, , b, , developing, , framework, , , evidencebased, , grading, , assessment, , , predictive, , tools, , , clinical, , decision, , support, , bmc, , med, , inform, , decis, , mak, , , , laleci, , gb, yuksel, , m, , sarigul, , b, arvanitis, tn, lindman, p, chen, r, , collaborative, platform, management, chronic, diseases, via, guidelinedriven, , individualized, , care, , plans, , comput, struct, biotechnol, j, , , , jafarpour, , b, , raza, abidi, , van, , woensel, , w, raza, abidi, , ss, , executiontime, , integration, , clinical, , practice, , guidelines, , , provide, , decision, support, comorbid, conditions, artif, intell, med, , , ben, souissi, abed, m, el, hiki, l, fortemps, p, pirlot, , m, , pars, , , system, , combining, , semantic, technologies, multiple, criteria, decision, aiding, supporting, antibiotic, prescriptions, j, biomed, inform, , , huibers, , cja, , sallevelt, , btgm, , de, , groot, , da, boer, mj, van, campen, jpcm, davids, cj, , conversion, , , stoppstart, , version, , , , coded, algorithms, software, implementation, multidisciplinary, consensus, procedure, int, j, med, inform, , c¡novassegura, b, morales, juarez, jm, campos, m, palacios, f, impact, expert, knowledge, detection, patients, risk, antimicrobial, therapy, failure, clinical, decision, support, systems, j, biomed, inform, , m¼ller, l, gangadharaiah, r, klein, sc, perry, j, bernstein, g, nurkse, d, , , , access, medical, knowledge, base, community, driven, diagnostic, decision, support, system, development, bmc, med, inform, decis, mak, , spnig, , , embergerklein, , sowa, , jp, , canbay, menrad, k, heider, d, virtual, doctor, interactive, clinicaldecisionsupport, system, based, deep, learning, noninvasive, prediction, diabetes, artif, intell, med, , rozenblum, r, rodriguezmonguio, r, volk, la, forsythe, kj, myers, mcgurrin, m, , using, machine, learning, system, identify, prevent, medication, prescribing, errors, clinical, cost, analysis, evaluation, jt, comm, j, qual, patient, saf, , , kannan, v, , basit, , ma, , bajaj, , p, , carrington, ar, donahue, ib, flahaven, el, , user, stories, lightweight, requirements, agile, clinical, decision, support, development, j, med, inform, assoc, , fernandes, co, miles, lucena, cjp, cowan, d, artificial, , intelligence, technologies, , , coping, alarm, , fatigue, , , hospital, , environments, , , sensory, , overload, algorithm, , development, , validation, , j, , med, , internet, , res, 20192111e15406, amroze, , field, ts, , fouayzi, , h, , sundaresan, d, , burns, , l, , garber, , l, , et, , al, , use, , , electronic, health, record, access, audit, logs, identify, physician, actions, following, noninterruptive, alert, , ing, descriptive, study, jmir, med, inform, 201971e12650, kim, m, kim, bh, kim, jm, kim, eh, kim, k, pak, k, , concordance, postsurgical, radioactive, iodine, therapy, recommendations, watson, , oncology, , , clinical, , practice, , , patients, , differentiated, , thyroid, , carcinoma, cancer, correspondence, topr, catherine, ducloslimics, inserm, facult©, l©onard, de, vinci, rue, marcel, cachin, , bobigny, franceemail, catherineduclosaphpfr, imia, yearbook, medical, informatics, 2020pragmatic, considerations, clinical, decision, support, , literature, 0cappendix, content, summaries, best, papers, decision, support, section, , imia, yearbookhendriks, mp, verbeek, xaam, van, vegchel, van, der, sangen, mjc, strobbe, lja, merkus, jws, zonderland, hm, smorenburg, ch, jager, siesling, stransformation, national, breast, cancer, guideline, datadriven, clinical, decision, treesjco, clin, cancer, inform, , may3114since, , clinical, , practice, , guidelines, , , still, narrative, described, large, textual, documents, aim, work, model, complex, guidelines, datadriven, clinical, decision, trees, cdts, still, humaninterpretable, computerinterpretable, implementation, decision, support, systems, dutch, national, breast, cancer, guidelines, translated, cdts, data, items, , , characterize, , , patient, , tumor, represent, decisional, criteria, encoded, unambiguously, using, existing, classifications, coding, systems, related, breast, cancer, feasible, total, , cdts, , , necessary, , , cover, , , whole, guidelines, driven, , data, items, data, items, , , coded, using, existing, classification, coding, systems, , cdts, represented, , unique, patient, subpopulations, complex, guidelines, transformed, systematically, constructed, modular, datadriven, cdts, clinically, interpretable, executable, decision, support, applicationkamiå¡aliä, ria±o, d, kert, welzer, nemec, zlatolas, lmultilevel, medical, knowledge, formalization, support, medical, practice, chronic, diseasesdata, , knowledge, engineering, , this, research, focused, knowledge, representation, support, medical, processes, involved, chronic, diseases, management, viewed, procedural, sequential, , application, , , knowledge, intuitive, easy, effective, mechanism, medical, , knowledge, , formalization, , , proposed, formalism, called, extended, timed, transition, , diagram, , ettd, formalism, allows, consistent, representation, three, basic, levels, decision, making, taken, account, prescription, adaptation, longterm, treatment, therapy, strategy, dosage, intolerances, methodology, manually, applied, build, ettds, clinical, practice, guidelines, ettds, implementation, demonstrated, modeling, clinical, practice, guidelines, therapeutic, management, arterial, hypertension, obtained, models, used, baseline, framework, development, decision, support, systems, involving, medical, procedureskhalifa, m, magrabi, f, gallego, bdeveloping, framework, evidencebased, grading, assessment, predictive, tools, clinical, decision, supportbmc, med, inform, decis, mak, , oct, deciding, choose, clinical, predictive, tool, clinical, practice, guided, correctly, assessed, effectiveness, objective, work, developp, conceptual, practical, framework, grade, assess, predictive, tools, grasp, provide, clinicians, standardised, evidencebased, system, support, search, selection, efficient, predictive, tools, grasp, framework, grades, predictive, tools, based, published, evidence, across, three, dimensions, phase, evaluation, level, evidence, direction, evidence, final, grade, tool, based, phase, evaluation, gets, , , hightest, , grade, , supported, , , highest, level, positive, mixed, evidence, , supports, , , positive, , , framework, successfully, applied, five, predictive, , tools, , grasp, , report, , updates, way, maintain, data, base, documents, evidence, predictive, tools, imia, yearbook, medical, informatics, 2020duclos, , 0c\"]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |[\", adopted, strategy, same, as, that, used, prior, years, [], based, on, four, exclusive, queries, that, return, , four, , disjoint, , citation, , subsets, first, query, qpub_plain, based, on, plaintext, search, pubmed, titles, s, using, keywords, , second, , query, , qpub_indexed, relies, on, pubmed, indexing, scheme, using, mesh, terms, results, are, made, exclusive, previous, set, third, one, qwos_restricted, based, on, plaintext, search, wos, restricted, two, research, areas, medical, informatics, health, care, sciences, , services, fourth, query, qwos_filtered, based, on, same, plaintext, search, used, wos, but, filtered, by, nonrelevant, research, areas, eg, archeology, dance, zoology, etc, two, research, areas, previous, query, it, note, that, two, wos, queries, select, , only, , nonpubmedindexed, , papers, that, are, supposed, be, caught, by, two, pubmed, queriesa, , first, , review, , , , four, , subsets, , retrieved, , citations, , , performed, , by, , two, section, editors, select, , candidate, best, papers, following, imia, yearbook, protocol, these, candidate, best, papers, were, then, individually, reviewed, rated, by, both, section, editors, chief, editor, decision, support, section, external, reviewers, from, international, medical, informatics, community, based, on, reviewers, ratings, comments, yearbook, editorial, committee, then, selected, best, papers, year, decision, support, domainimia, yearbook, medical, informatics, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , imia, ge, thieme, verlag, kg, 0creview, results, , , , literature, , search, , has, , been, , performed, on, january, , , total, , unique, references, were, obtained, distributed, as, follows, , qpub_plain, , qpub_indexed, , qwos_restricted, , qwos_filtered, yielding, subtotals, , references, from, pubmed, , from, wos, compared, previous, year, global, query, retrieved, , , more, , papers, after, , , first, , individual, screening, independently, performed, by, both, section, editors, based, on, title, , papers, , not, rejected, by, both, section, editors, were, discussed, by, two, editors, achieve, final, selection, , candidate, best, , papers, after, , , external, , review, , these, , , , s, , , editorial, , committee, finally, selected, three, them, as, best, papers, , [], table, , they, are, discussed, next, section, summaries, their, contents, are, available, appendixdiscussion, outlookin, first, paper, hendriks, , [], propose, an, approach, modeling, clinical, practice, guidelines, which, certainly, builds, on, already, existing, approaches, but, which, systematically, conducted, order, be, scalable, used, represent, complex, guidelines, they, promote, formalism, clinical, decision, trees, cdts, as, they, are, both, clinically, interpretable, , by, , healthcare, , professionals, , computerinterpretable, , thus, , suitable, implementation, datadriven, cdsss, disambiguation, textual, guidelines, supported, first, by, formal, unequivocal, specification, data, items, used, as, decision, criteria, using, international, coding, systems, enforce, interoperability, second, by, representation, guideline, knowledge, as, cdts, method, applied, dutch, breast, cancer, guidelines, sixty, cdts, were, built, , involving, , , total, , , , , data, , items, among, , which, , , , could, , not, , be, , linked, , standard, terminologies, authors, report, ambiguity, certain, criteria, which, could, be, subjective, or, had, multiple, definitions, resulting, knowledge, base, implemented, decision, support, application, where, it, can, be, interactively, browsed, or, automatically, executed, by, modeling, guidelines, such, way, work, step, forward, sharing, encoded, knowledgein, second, paper, kamiå¡aliä, , [], tackled, issues, linked, formalization, medical, processes, used, managing, chronic, diseases, their, execution, cdsss, they, analyzed, decisionmaking, dimensions, therapeutic, management, chronic, diseases, like, those, known, increase, cardiovascular, risk, identified, three, basic, levels, therapy, strategy, dosage, adaptation, intolerance, management, handle, these, , different, , aspects, , consistently, , they, propose, formalism, called, extended, timed, transition, diagram, ettd, with, ettds, they, illustrate, multilevel, finegrained, modeling, required, capture, contents, arterial, hypertension, management, guidelines, detailed, demonstration, on, how, procedural, knowledge, hypertension, management, can, be, formalized, develop, cdss, could, certainly, be, used, other, medical, domainsthe, third, paper, by, khalifa, , [], presents, conceptual, practical, framework, help, assess, confidence, predictive, tools, grasp, , , grade, , assess, , predictive, tools, both, method, look, evidence, from, published, literature, an, analysis, grid, it, standardizes, assessment, available, literature, associated, predictive, tool, grading, its, level, proof, three, phases, evaluation, are, considered, i, before, implementation, tool, assess, both, its, internal, external, validity, ii, during, implementation, assess, its, potential, effect, usability, iii, after, implementation, assess, its, effectiveness, safety, each, phase, level, evidence, , can, , be, , assessed, , from, , , study, design, qualitative, , summarizes, direction, evidence, positive, negative, mixed, grid, can, be, considered, as, similar, existing, grids, instance, consort, statement, clinical, trials, however, it, gives, rigorous, methodology, critical, appraisal, predictive, tools, could, be, extended, all, kind, cdsss, it, might, be, useful, tool, extend, evidencebased, culture, field, medical, informaticsbesides, three, best, papers, selected, , decision, , support, section, , , , , edition, imia, yearbook, several, other, works, retrieved, from, literature, review, deserve, be, cited, some, them, deal, with, personalization, decisions, laleci, , , [], , propose, , , scientific, , , technical, approach, develop, personalized, care, plans, that, comply, with, clinical, practice, guidelines, management, complex, polypathology, situations, jafarpour, , [], propose, solution, dynamically, manage, conflicts, that, can, rise, type, complex, contexts, ben, souissi, , [], introduce, use, health, , information, , technology, , involving, multiple, criteria, decision, support, choice, between, antibiotics, alternatives, interestingly, other, works, promote, creation, sharing, operational, knowledge, bases, as, exemplified, by, hendriks, , [], thus, huibers, , [], transform, textual, stoppstart, criteria, into, unambiguous, definitions, mapped, , medical, , terminologies, , canovas, et, , al, [], formalize, eucast, expert, rules, as, an, ontology, production, rules, detect, antimicrobial, therapies, at, risk, failure, m¼ller, , [], propose, an, , , diagnostic, knowledge, base, that, can, compete, with, commercial, ones, replacing, humans, another, topic, research, spnig, , [], work, on, two, aspects, virtualize, doctor, automatic, acquisition, data, through, sensors, speech, recognition, automation, diagnostic, reasoning, rozenblum, et, al[], propose, machine, learning, method, generate, clinically, valid, alerts, detect, errors, prescriptions, acceptability, , , cdss, , , another, , key, point, kannan, , [], propose, method, cdss, design, best, meet, precisely, specified, assessable, user, purpose, design, alerts, , may, , also, , avoid, , rejection, , , cdsss, by, caregivers, fernandes, , [], created, algorithms, able, aggregate, filter, reduce, notifications, delivered, healthcare, professionals, amrose, et, , al, [], tried, understand, real, life, impact, alerts, on, users, find, actions, they, triggered, finally, it, always, interesting, obtain, varied, evaluation, results, controversial, cdsss, respect, kim, , [], evaluated, watson, oncology, thyroid, carcinoma, reported, concordance, rate, with, local, practices, considered, as, too, low, adopt, tool, as, , evidenced, , by, , , number, , , variety, works, around, decision, support, research, field, very, active, years, selection, highlighted, pragmatic, works, that, promote, transparency, sharing, imia, yearbook, medical, informatics, 2020duclos, , 0ctable, , , , , best, paper, selection, s, imia, yearbook, medical, informatics, , section, 'decision, support', s, are, listed, alphabetical, order, first, authors, surname, section, decision, support\\uf0a7, , hendriks, mp, verbeek, xaam, van, vegchel, t, van, der, sangen, mjc, strobbe, lja, merkus, jws, zonderland, hm, smorenburg, ch, jager, siesling, s, transformation, national, breast, cancer, guideline, into, datadriven, clinical, decision, trees, jco, clin, cancer, inform, \\uf0a7\\t, kamiå¡aliä\\ta\\tria±o\\td\\tkert\\ts\\twelzer\\tt\\tnemec\\tzlatolas\\tl\\tmultilevel\\tmedical\\tknowledge\\tformalization\\tto\\tsupport\\tmedical\\tpractice, chronic, diseases, data, , knowledge, engineering, \\uf0a7, , khalifa, m, magrabi, f, gallego, b, developing, framework, evidencebased, grading, assessment, predictive, tools, clinical, decision, support, bmc, med, inform, decis, mak, , knowledge, bases, used, by, decision, support, tools, as, well, as, grading, their, utility, ultimate, goal, that, users, could, trust, such, tools, then, use, themacknowledgementwe, would, like, thank, all, present, past, editorial, boards, imia, yearbook, especially, martina, hutter, adrien, ugon, their, support, as, well, as, reviewers, , their, , participation, , , , selection, , , best, , papers, , , , decision, , support, section, we, cannot, end, synopsis, without, meaningful, thought, our, colleague, friend, vassilis, , koutkias, , who, , started, , year, again, tackle, tasks, decision, support, section, coeditor, but, passed, away, last, december, unfortunately, could, not, finishreferences, , jankovic, i, chen, jh, clinical, decision, support, implications, clinician, burnout, crisis, , yearb, med, inform, , , koutkias, v, bouaud, j, contributions, on, clinical, decision, support, from, , literature, yearb, med, inform, , aug2811357, , hendriks, mp, verbeek, xaam, van, vegchel, t, van, der, sangen, mjc, strobbe, lja, merkus, jws, , transformation, national, breast, cancer, guideline, , into, , datadriven, , clinical, , decision, trees, jco, clin, cancer, inform, , , kamiå¡aliä, ria±o, d, kert, s, welzer, t, nemec, zlatolas, , l, , multilevel, , medical, , knowledge, formalization, , , support, , medical, , practice, , chronic, diseases, data, , knowledge, engineering, , , khalifa, , m, , magrabi, , f, , gallego, , b, , developing, , framework, , , evidencebased, , grading, , assessment, , , predictive, , tools, , , clinical, , decision, , support, , bmc, , med, , inform, , decis, , mak, , , , laleci, , gb, yuksel, , m, , sarigul, , b, arvanitis, tn, lindman, p, chen, r, , collaborative, platform, management, chronic, diseases, via, guidelinedriven, , individualized, , care, , plans, , comput, struct, biotechnol, j, , , , jafarpour, , b, , raza, abidi, , s, van, , woensel, , w, raza, abidi, , ss, , executiontime, , integration, , clinical, , practice, , guidelines, , , provide, , decision, support, comorbid, conditions, artif, intell, med, , , ben, souissi, s, abed, m, el, hiki, l, fortemps, p, pirlot, , m, , pars, , , system, , combining, , semantic, technologies, with, multiple, criteria, decision, aiding, supporting, antibiotic, prescriptions, j, biomed, inform, , , huibers, , cja, , sallevelt, , btgm, , de, , groot, , da, boer, mj, van, campen, jpcm, davids, cj, , conversion, , , stoppstart, , version, , , , into, coded, algorithms, software, implementation, multidisciplinary, consensus, procedure, int, j, med, inform, , c¡novassegura, b, morales, juarez, jm, campos, m, palacios, f, impact, expert, knowledge, on, detection, patients, at, risk, antimicrobial, therapy, failure, by, clinical, decision, support, systems, j, biomed, inform, , m¼ller, l, gangadharaiah, r, klein, sc, perry, j, bernstein, g, nurkse, d, , an, , , access, medical, knowledge, base, community, driven, diagnostic, decision, support, system, development, bmc, med, inform, decis, mak, , spnig, , s, , embergerklein, , sowa, , jp, , canbay, menrad, k, heider, d, virtual, doctor, an, interactive, clinicaldecisionsupport, system, based, on, deep, learning, noninvasive, prediction, diabetes, artif, intell, med, , rozenblum, r, rodriguezmonguio, r, volk, la, forsythe, kj, myers, s, mcgurrin, m, , using, machine, learning, system, identify, prevent, medication, prescribing, errors, clinical, cost, analysis, evaluation, jt, comm, j, qual, patient, saf, , , kannan, v, , basit, , ma, , bajaj, , p, , carrington, ar, donahue, ib, flahaven, el, , user, stories, as, lightweight, requirements, agile, clinical, decision, support, development, j, am, med, inform, assoc, , fernandes, co, miles, s, lucena, cjp, cowan, d, artificial, , intelligence, technologies, , , coping, with, alarm, , fatigue, , , hospital, , environments, because, , , sensory, , overload, algorithm, , development, , validation, , j, , med, , internet, , res, 20192111e15406, amroze, , field, ts, , fouayzi, , h, , sundaresan, d, , burns, , l, , garber, , l, , et, , al, , use, , , electronic, health, record, access, audit, logs, identify, physician, actions, following, noninterruptive, alert, , ing, descriptive, study, jmir, med, inform, 201971e12650, kim, m, kim, bh, kim, jm, kim, eh, kim, k, pak, k, , concordance, postsurgical, radioactive, iodine, therapy, recommendations, between, watson, , oncology, , , clinical, , practice, , , patients, with, , differentiated, , thyroid, , carcinoma, cancer, correspondence, topr, catherine, ducloslimics, inserm, facult©, l©onard, de, vinci, rue, marcel, cachin, , bobigny, franceemail, catherineduclosaphpfr, imia, yearbook, medical, informatics, 2020pragmatic, considerations, on, clinical, decision, support, from, , literature, 0cappendix, content, summaries, best, papers, decision, support, section, , imia, yearbookhendriks, mp, verbeek, xaam, van, vegchel, t, van, der, sangen, mjc, strobbe, lja, merkus, jws, zonderland, hm, smorenburg, ch, jager, siesling, stransformation, national, breast, cancer, guideline, into, datadriven, clinical, decision, treesjco, clin, cancer, inform, , may3114since, , clinical, , practice, , guidelines, , are, , still, narrative, described, large, textual, documents, aim, work, model, complex, guidelines, as, datadriven, clinical, decision, trees, cdts, that, could, be, still, humaninterpretable, while, computerinterpretable, implementation, decision, support, systems, dutch, national, breast, cancer, guidelines, were, translated, into, cdts, data, items, , which, , characterize, , , patient, , tumor, represent, decisional, criteria, were, encoded, unambiguously, using, existing, classifications, coding, systems, related, breast, cancer, when, feasible, total, , cdts, , were, , necessary, , , cover, , , whole, guidelines, driven, by, , data, items, all, data, items, , , could, be, coded, using, existing, classification, coding, systems, all, , cdts, represented, , unique, patient, subpopulations, complex, guidelines, could, be, transformed, as, systematically, constructed, modular, datadriven, cdts, that, are, clinically, interpretable, executable, decision, support, applicationkamiå¡aliä, ria±o, d, kert, s, welzer, t, nemec, zlatolas, lmultilevel, medical, knowledge, formalization, support, medical, practice, chronic, diseasesdata, , knowledge, engineering, , this, research, focused, on, knowledge, representation, support, medical, processes, involved, chronic, diseases, management, which, can, be, viewed, as, procedural, sequential, , application, , , knowledge, an, intuitive, easy, effective, mechanism, medical, , knowledge, , formalization, , , proposed, through, formalism, called, extended, timed, transition, , diagram, , ettd, formalism, allows, consistent, representation, three, basic, levels, decision, making, that, should, be, taken, into, account, prescription, adaptation, longterm, treatment, therapy, strategy, dosage, intolerances, methodology, can, be, manually, applied, build, ettds, from, clinical, practice, guidelines, ettds, implementation, demonstrated, by, modeling, clinical, practice, guidelines, therapeutic, management, arterial, hypertension, obtained, models, can, be, used, as, baseline, framework, development, decision, support, systems, involving, medical, procedureskhalifa, m, magrabi, f, gallego, bdeveloping, framework, evidencebased, grading, assessment, predictive, tools, clinical, decision, supportbmc, med, inform, decis, mak, , oct, deciding, choose, clinical, predictive, tool, clinical, practice, should, be, guided, by, its, correctly, assessed, effectiveness, objective, work, developp, conceptual, practical, framework, grade, assess, predictive, tools, grasp, provide, clinicians, with, standardised, evidencebased, system, support, their, search, selection, efficient, predictive, tools, grasp, framework, grades, predictive, tools, based, on, published, evidence, across, three, dimensions, phase, evaluation, level, evidence, direction, evidence, final, grade, tool, based, on, phase, evaluation, that, gets, , , hightest, , grade, , supported, , by, , highest, level, positive, or, mixed, evidence, that, , supports, , , positive, , , framework, successfully, applied, five, predictive, , tools, , grasp, , report, , updates, could, be, way, maintain, data, base, that, documents, evidence, predictive, tools, imia, yearbook, medical, informatics, 2020duclos, , 0c\"]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,15,16,17,18,19,20,21,23,24,25,26,28,29,30,32,33,34,35,36,37,38,39,40,42,43,45,49,50,52,54,57,59,60,61,62,63,64,65,66,68,69,70,72,73,74,75,78,81,82,83,85,86,88,92,93,95,96,98,99,101,105,108,109,112,113,114,118,122,125,126,131,134,136,139,143,145,146,147,148,151,153,155,156,158,159,160,161,164,166,167,169,171,173,174,179,180,184,186,187,188,189,190,192,198,199,201,217,219,220,221,223,224,226,229,231,235,244,248,249,253,255,262,265,270,275,281,282,292,294,299,301,310,311,312,322,325,330,335,345,351,352,356,361,366,367,369,373,376,380,386,388,389,391,398,411,415,422,428,429,435,439,446,449,452,453,465,468,473,475,477,480,482,494,496,497,498,504,506,517,519,520,523,528,539,546,548,551,552,557,560,567,569,572,576,590,598,601,602,618,623,627,637,639,642,646,647,648,654,668,674,679,681,704,707,708,713,714,718,724,733,735,747,749,751,753,754,763,764,767,768,769,770,773,779,784,788,796,802,811,818,835,843,846,848,849,853,854,864,875,879,887,901,908,909,911,972,975,982,992,1002,1007,1014,1027,1031,1035,1045,1048,1066,1076,1079,1084,1093,1129,1133,1134,1139,1150,1153,1154,1158,1161,1166,1188,1190,1191,1195,1201,1241,1245,1248,1252,1254,1265,1278,1293,1296,1321,1359,1362,1380,1387,1390,1399,1411,1415,1419,1423,1435,1459,1477,1485,1490,1499,1505,1535,1578,1579,1586,1591,1594,1595,1610,1624,1643,1647,1659,1666,1668,1670,1672,1686,1695,1700,1728,1736,1738,1752,1760,1787,1804,1810,1834,1865,1868,1907,1956,1984,2034,2036,2053,2076,2079,2082,2143,2154,2173,2182,2210,2213,2263,2278,2290,2291,2302,2304,2311,2312,2316,2324,2332,2337,2368,2371,2383,2390,2395,2439,2471,2491,2499,2537,2543,2544,2552,2606,2624,2660,2678,2689,2690,2705,2717,2727,2743,2746,2774,2781,2806,2817,2825,2873,2883,2907,2926,2936,2940,2958,2963,2969,2972,2984,3005,3028,3063,3087,3088,3103,3132,3159,3160,3165,3167,3199,3220,3230,3237,3247,3248,3250,3261,3275,3297,3300,3329,3334,3347,3355,3358,3365,3383,3430,3438,3529,3532,3544,3551,3607,3641,3655,3658,3745,3752,3777,3786,3846,3857,3862,3869,3907,3981,4006,4020,4032,4061,4121,4131,4145,4180,4243,4248,4279,4303,4320,4348,4355,4389,4455,4480,4529,4547,4588,4602,4608,4616,4633,4669,4680,4690,4736,4793,4824,4827,4835,4837,4839,4842,4938,4952,4960,4995,5110,5118,5124,5140,5210,5268,5276,5295,5296,5368,5392,5483,5495,5534,5536,5571,5634,5682,5708,5774,5817,5821,5828,5836,5895,5917,5933,5942,5954,6012,6041,6080,6122,6125,6182,6236,6262,6308,6419,6453,6474,6515,6544,6556,6632,6678,6744,6750,6771,6933,7064,7094,7243,7258,7288,7294,7298,7299,7333,7391,7393,7535,7620,7633,7717,7778,7836,7871,7915,8013,8056,8076,8083,8162,8182,8450,8463,8571,8586,8756,8839,8845,8884,8937,8976,9039,9126,9192,9278,9308,9326,9454,9512,9523,9531,9585,9609,9625,9668,9805,9831,9838,9877,9983,10046,10240,10274,10372,10453,10467,10528,10587,10601,10684,10718,10855,10912,11087,11115,11127,11180,11443,11547,11622,12118,12206,12348,12417,12479,12575,13004,13074,13169,13193,13611,13696,13708,14047,14203,14611,14649,14659,14801,15186,15269,15480,15792,15839,15922,16201,16394,16814,16930,16996,17058,17077,17089,17231,17274,17462,17681,17718,17839,18202,18316,18465,18490,18498,18529,18578,18904,18998,19846,20014,20329,20539,20599,20688,22358,22409,22735,23052,23066,23132,23143,23419,23436,23457,23531,23657,24199,24411,24577,25949,26202,26297,26349,27442,27496,27756,28072,28192,28279,28503,28951,29352,29484,29583,29713,30430,30441,31127,31272,31400,31401,31738,31797,32596,32710,32850,33575,33837,34662,34752,35636,36256,36342,36758,36941,37152,37499,37582,38083,38162,38851,39349,39504,40246,40752,40828,41036,41081,42052,42323,42566,42922,45779,47656,48408,49675,50170,50735,51266,51872,52175,52582,53739,54729,55343,55485,55899,55991,57696,58075,58203,59299,61439,61621,62065,62969,62995,63270,64328,64473,64661,64680,64727,65077,67105,67509,69042,69091,69099,69462,70618,70848,71139,71699,73227,73419,80461,80966,81956,82192,84968,85082,87510,88933,89369,89393,90561,91190,92072,93442,93681,95651,96459,97429,98729,100805,100817,102924,103032,103850,104369,104988,105127,107302,108112,109433,112861,116117,116434,117383,118079,123837,126242,128148,129452,131165,133279,135064,136251,137325,137571,137806,138797,140812,141853,146091,146201,146613,146931,147051,148038,149414,150482,150704,151031,151337,152857,154523,154756,156166,156167,156389,159385,161321,162055,162588,163119,167915,174300,175189,176035,176426,178387,179676,180975,181534,185764,186682,187099,187454,188445,188996,190168,191267,192103,192166,192644,193081,194527,195193,195610,200947,202285,202779,203564,203645,205508,205692,205906,206796,206913,207483,207658,207850,208710,209382,209781],[427.0,9.0,7.0,21.0,15.0,20.0,10.0,2.0,3.0,19.0,9.0,9.0,21.0,2.0,2.0,7.0,1.0,2.0,9.0,6.0,3.0,1.0,6.0,2.0,3.0,2.0,16.0,1.0,9.0,8.0,3.0,1.0,4.0,1.0,3.0,1.0,6.0,9.0,3.0,24.0,4.0,1.0,3.0,5.0,2.0,1.0,1.0,1.0,9.0,12.0,1.0,1.0,5.0,3.0,1.0,1.0,2.0,6.0,1.0,6.0,7.0,6.0,1.0,1.0,1.0,6.0,3.0,1.0,7.0,3.0,3.0,1.0,3.0,6.0,5.0,4.0,9.0,1.0,10.0,4.0,1.0,2.0,2.0,1.0,3.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,18.0,6.0,4.0,1.0,4.0,1.0,1.0,6.0,1.0,3.0,2.0,7.0,1.0,4.0,5.0,2.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,5.0,2.0,3.0,1.0,1.0,1.0,2.0,3.0,1.0,3.0,1.0,2.0,3.0,4.0,3.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,6.0,2.0,2.0,3.0,1.0,3.0,1.0,8.0,1.0,1.0,2.0,5.0,12.0,1.0,2.0,2.0,1.0,1.0,2.0,4.0,1.0,1.0,4.0,4.0,1.0,7.0,3.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,3.0,1.0,2.0,2.0,1.0,1.0,2.0,3.0,1.0,4.0,6.0,1.0,1.0,1.0,5.0,1.0,2.0,3.0,1.0,2.0,2.0,2.0,8.0,1.0,2.0,1.0,2.0,1.0,27.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,6.0,1.0,1.0,1.0,2.0,1.0,10.0,1.0,10.0,1.0,2.0,1.0,1.0,1.0,1.0,15.0,1.0,2.0,2.0,6.0,2.0,1.0,5.0,1.0,1.0,16.0,1.0,2.0,3.0,13.0,1.0,6.0,1.0,1.0,2.0,12.0,1.0,2.0,1.0,3.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,6.0,6.0,3.0,2.0,4.0,2.0,8.0,1.0,1.0,32.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,2.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,13.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,2.0,8.0,2.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,2.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,6.0,1.0,7.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,2.0,2.0,1.0,1.0,3.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,3.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,14.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,11.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,9.0,9.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,6.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,4.0,1.0,4.0,2.0,4.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,3.0,3.0,3.0,3.0,3.0,2.0,2.0,1.0,3.0,3.0,3.0,3.0,3.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,2.0,2.0,2.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n",
      "|[coronary, arterybypass, grafting, thrombosis, ï¬brin, ï¬brinogen, mutationintroduction, intraoperative, thrombosis, of, saphenous, veins, sv, during, , , harvesting, is, very, rarecase, report, we, present, a, case, of, a, 60yearold, male, patient, with, multivesselcoronary, artery, disease, and, a, history, of, a, nonst, elevation, acute, coronary, syndromeand, type2, diabetes, mellitus, admitted, for, coronary, artery, bypass, grafting, in, whombilateralintraoperative, sv, thrombosis, occurred, during, graft, harvesting, routinethrombophilia, screening, showed, no, abnormalities, and, cancer, was, excluded, compared, with, healthy, controls, we, observed, prolonged, ï¬brin, clot, lysis, time, and, increasedthrombin, generation, reï¬ected, by, endogenous, thrombin, potential, scanning, electronmicroscopy, of, the, thrombosed, material, revealed, compact, and, thick, ï¬brin, layer, on, theclot, surface, with, a, solid, mass, of, unusually, compressed, platelets, and, erythrocytesunderneath, the, patient, was, tested, for, ï¬brinogen, and, factor, f, xiii, polymorphismsand, was, found, to, be, heterozygous, for, ï¬brinogen, haeiii, 455g, , a, and, fxiiival34leu, 100g, , tconclusion, ï¬brinogen, haeiii, and, fxiii, val34leu, polymorphisms, are, reï¬ected, inreduced, clot, permeability, and, susceptibility, to, lysis, and, might, contribute, to, intraoperative, sv, thrombosis, during, vascular, grafting, procedures, carriers, of, those, are, atrisk, of, primary, venous, graft, failure, after, bypass, proceduresintroductioncoronary, artery, bypass, grafting, cabg, is, a, method, of, choicefor, revascularization, in, patients, with, multivessel, disease, anddiabetes, mellitus, dm, although, arterial, grafts, are, preferredin, selected, scenarios, the, common, practice, is, to, use, leftinternal, thoracic, artery, lita, to, bypass, the, left, anteriordescending, artery, lad, and, to, place, venous, conduits, toother, target, vessels, an, often, chosen, vascular, graft, the, greatsaphenous, vein, sv, offers, decent, durability, and, is, easy, toharvest, sv, graft, occlusion, may, occur, in, up, to, , of, caseswithin, the, ï¬rst, , months, and, as, many, as, , may, occludewithin, ï¬rst, , to, , weeks1, sv, harvesting, dramaticallychanges, the, veins, environment, with, disruption, of, bloodï¬ow, in, vasa, vasorum, damage, to, the, adventitia, hypoxia, andhyponutrition, of, the, vessel, wall, along, with, focal, endothelialdisruption2, acute, sv, graft, failure, is, usually, a, result, of, graftthrombosis, which, among, other, factors, like, technical, failuregrafttarget, vessel, disproportion, etc, may, be, caused, byhypercoagulabilityreceivedmarch, , acceptedjuly, , , 101055s00401715657issn, , , ge, thieme, verlag, kgstuttgart, ·, new, york, 0ce198bilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, alcase, reporta, 60yearold, male, patient, with, multivessel, coronary, arterydisease, who, suffered, from, a, nonst, elevation, acute, coronarysyndrome, nsteacs, , month, prior, to, admission, a, nonsmoker, with, type2, dm, on, metformin, peptic, ulcer, diseaseand, a, history, of, alcohol, abuse, was, admitted, to, our, institutionfor, cabg, just, after, the, nsteacs, a, left, ventricle, lv, thrombus, was, seen, on, one, echocardiographic, examination, but, itwas, absent, during, followup, there, was, no, deep, venousthrombosis, or, bleeding, diathesis, history, on, admission, thepatient, was, on, aspirin, , mg, once, daily, and, enoxaparin, mg, once, daily, routine, laboratory, tests, were, withinnormal, ranges, ºtable, , there, were, no, abnormalities, onphysical, examination, apart, from, obesity, body, mass, index, kgm2, when, the, patient, was, admitted, the, lower, extremities, appeared, normal, there, were, no, varicose, veins, nosigns, or, symptoms, of, venous, insufï¬ciency, and, the, pastmedical, history, was, negative, for, both, personal, and, familyhistory, of, chronic, venous, insufï¬ciency, or, varicose, veins, thepatient, was, operated, on, following, the, standard, proceduresduring, lita, harvest, a, cardiac, surgery, resident, harvested, theright, sv, using, the, , , technique, the, wall, of, the, sv, lookedgrossly, normal, upon, dissection, the, side, branches, were, tiedoff, and, clipped, and, a, needle, was, placed, at, the, distal, end, whilethe, proximal, end, was, still, not, separated, an, attempt, was, madetable, , results, of, initial, and, followup, laboratory, testingvariablecoagulation, testsred, blood, count, 103µlhemoglobin, gdlwhite, blood, count, 103µlplatelet, count, 103µlaptt, spt, spt, inrplatelet, aggregation, mmoll, arachidonic, acid, , µmoll, adp, thrombophilia, screeningfibrinogen, glantithrombin, iii, ddimer, µglantixa, iumlhomocysteine, µmollprotein, c, protein, s, factor, viii, leiden, c1601g, , a, 0397g, , aprothrombin, cï¬brinogen, 455g, , afactor, xiii, 100g, , tlupus, anticoagulant, ratiolupus, anticoagulant, ratio, apttanticardiolipin, igganticardiolipin, igmanti2glycoprotein, i, igg, antibodyanti2glycoprotein, i, igm, antibodynormal, rangespreoperativepostoperative, day, postoperative, day, , gg, no, mutationgg, no, mutation, gpl, mpl, sgu, smugg, no, mutationgg, no, mutationga, heterozygotegt, heterozygote, gpl, mpl, sgu, smuabbreviations, aptt, activated, partial, thromboplastin, time, gpl, igg, phospholipid, unit, ig, immunoglobulin, inr, international, normalized, ratiompl, igm, phospholipid, unit, pt, prothrombin, time, sgu, standard, igg, 2, glycoprotein, unit, smu, standard, igm, 2, glycoprotein, unitth, , vol, , no, 0cbilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, ale199to, ï¬ush, the, vein, with, a, solution, containing, blood, , mlheparin, , iu, and, normal, saline, , ml, while, the, distalend, was, closed, with, an, atraumatic, vascular, clamp, and, veinthrombosis, was, noted, upon, the, separation, of, the, distal, end, aluminal, thrombus, was, visible, the, left, sv, was, then, taken, downusing, the, same, protocol, by, an, experienced, staff, cardiacsurgeon, with, the, same, result, presence, of, a, luminal, thrombuswas, conï¬rmed, upon, separation, of, the, proximal, end, systemicheparin, was, administered, and, normal, lita, outï¬ow, wasconï¬rmed, concerns, regarding, safety, of, cardiopulmonarybypass, use, were, raised, due, to, suspected, thrombotic, issueand, the, approach, was, modiï¬ed, the, litalad, anastomosiswas, completed, offpump, on, a, beating, heartthe, postoperative, course, was, uneventful, on, postoperative, day, , the, patient, received, dual, antiplatelet, therapy, withaspirin, and, clopidogrel, and, was, discharged, on, day, , with, nosigns, of, thrombosis, or, myocardial, ischemia, elective, angioplasty, of, nongrafted, vessels, was, scheduled, and, a, completethrombophilia, screening, was, done, ºtable, , on, the, , and12month, followup, the, patient, did, welldiagnostic, approachbecause, a, thrombophilia, was, suspected, screening, wasinitiated, showing, no, abnormalities, ºtable, cancer, was, excluded, as, a, cause, of, thrombosis, positiveantibodies, against, neutrophil, cytoplasm, antigens, pancaand, canca, were, excluded, as, a, cause, of, vasculitis, we, thenproceeded, to, analyze, ï¬brin, phenotype, using, the, previouslydescribed, methodology34, brieï¬y, plasma, ï¬brin, clot, permeability, was, determined, in, a, hydrostatic, pressure, systemtubes, containing, ï¬brin, clots, formed, from, adding, , mmollcalcium, chloride, and, , uml, human, thrombin, sigma, tocitrated, plasma, were, connected, through, plastic, tubing, to, abuffer, reservoir, , m, trishcl, , m, nacl, ph, , thevolume, ï¬owing, through, the, gel, was, measured, within, minutes, a, permeation, coefï¬cient, ks, reï¬ecting, poresize, was, calculated, from, equation, ks, ¼, q, 02, l, î·t, 02, a, 02, îpwhere, q, is, the, ï¬ow, rate, in, time, t, l, is, the, length, of, a, ï¬brin, gelî·, is, the, viscosity, of, liquid, a, is, the, cross, section, area, and, îp, isa, differential, pressure, in, dynecm2, lower, ks, values, indicated, reduced, permeability, fibrinogen, was, determined, usingthe, clauss, method, even, though, the, followup, ï¬brinogenlevel, was, normal, we, identiï¬ed, strongly, decreased, ï¬brin, clotpermeability, ks, ¼, , 06, , 02, 9cm2, compared, withhealthy, controls, from, our, previous, report, n, ¼, , ks, ¼, , 9cm23, samples, collected, during, late, follow[], up, appointment, on, postoperative, day, , compared, withhealthy, controls, n, ¼, , we, observed, prolonged, clot, lysistime, clt, , 06, , vs, , 06, , minutes, and, increasedthrombin, generation, reï¬ected, by, endogenous, thrombinpotential, etp, in, the, studied, subject, etp, ¼, , 06, vs, , 06, , nm, 02, min, respectively, measurement, ofthe, thrombin, generation, was, done, with, calibrated, automated, thrombography, thrombinoscope, bv, maastricht, thenetherlands, according, to, the, manufacturers, instructionsin, the, 96well, plate, ï¬uorometer, ascent, reader, thermolabsystems, oy, helsinki, finland, equipped, with, the, ï¬lter, set, at, a, temperature, of, °c, brieï¬y, microliters, of, plateletpoor, plasma, were, diluted, with, µl, of, the, reagent, containing, , pmoll, recombinant, tissuefactor, , micromolar, phosphatidylserinephosphatidylcholinephosphatidylethanolamine, vesicle, and, , µl, of, flucasolution, hepes, ph, , , nmoll, cacl2, , mgml, bovinealbumin, and, , mmoll, zglyglyarg7amino4methylcoumarin, each, plasma, sample, was, analyzed, in, duplicatefor, analysis, the, maximum, concentration, of, thrombin, generated, was, used3cryosectioned, tissue, sections, were, ï¬xed, in, icecold, methanolacetone, , mixture, peroxidase, activity, was, quenchedwith, , h2o2, and, unspeciï¬c, background, was, blocked, with, bovine, albumin, bsa, sigma, co, st, louis, missouri, unitedstates, primary, adequate, antibodies, against, ï¬brin, or, tissuefactor, tf, were, applied, both, abcam, cambridge, unitedkingdom, primary, antibodies, were, followed, by, thecorresponding, secondary, antibodies, conjugated, with, ï¬uorochrome, abcam, as, previously, described5, images, were, analyzed, using, olympus, bx, , microscope, svs, immunostainingrevealed, thick, layer, of, ï¬brin, directly, on, the, vessel, endotheliumºfig, 1a, and, high, tf, ºfig, 1b, activity, within, the, thrombuswe, found, abundant, blood, nuclear, cells, nuclei, stained, usingdapi, suggesting, the, presence, of, proinï¬ammatory, monocyteswhich, are, known, source, of, tf, unfortunately, we, were, not, ableto, immunostain, cd68, due, to, high, unspeciï¬c, backgroundresulting, from, large, amounts, of, ï¬brin, the, microscopic, analysisshowed, abundant, adventitial, vessels, ºfig, 1c, d, withinalmost, every, single, vessel, we, found, thrombi, rich, in, bothprothrombin, ºfig, 1c, and, tf, ºfig, 1dprothrombotic, ï¬brin, clot, phenotype, reï¬ected, by, reducedks, and, prolonged, clt, along, with, enhanced, thrombin, generation, and, unusualimages, obtained, from, the, immunostaining, of, the, svs, prompted, us, to, perform, analysis, ofwhole, blood, clot, morphology, using, scanning, electron, microscopy, sem, as, previously, described6, after, washing, thethrombus, was, ï¬xed, with, , glutaraldehyde, phosphatebuffered, saline, solution, specimens, were, dehydrated, goldcoated, and, photographed, digitally, with, a, jeol, jsm, jeol, tokyo, japan, the, analysis, revealed, compact, and, thickï¬brin, layer, on, the, clot, surface, with, a, solid, massof, unusually, compressed, platelets, and, erythrocytes, underneath, this, observation, suggested, veryhigh, contractileforces, during, clot, formation, in, a, plateletdriven, ï¬brinmediated, mechanism, of, clot, contraction, and, prompted, usto, study, common, ï¬brinogen, and, factor, f, xiii, polymorphisms, the, patient, was, heterozygous, for, ï¬brinogen, haeiii455g, , a, and, fxiii, val34leu, 100g, , tdiscussiona, dramatic, intraoperative, sv, thrombosis, provoked, by, graftharvesting, for, cabg, lead, to, change, in, revascularizationstrategy, but, its, cause, remained, unknown, following, thestandard, thrombophilia, screening, the, cases, of, acute, svgraft, thrombosis, in, the, perioperative, period, are, very, rareand, as, few, as, , of, grafts, occlude, within, ï¬rst, , to, weeks17th, , vol, , no, 0ce200bilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, alfig, , representative, images, of, sv, graft, immunostaining, after, massive, thrombosis, ad, prothrombin, stained, red, tf, stained, green, nucleistained, blue, using, dapi, and, scanning, electron, microscopic, images, e, f, of, the, surface, of, whole, blood, clot, formed, in, vitro, from, citrated, bloodobtained, from, the, patient, undergoing, cabg, box, and, arrow, represent, magniï¬cation, of, the, fragment, in, the, box, arrows, show, pertinent, stainedfragments, see, text, cabg, coronary, artery, bypass, grafting, sv, saphenous, veins, tf, tissue, factora, normal, sv, is, composed, of, the, intima, the, media, and, theadventitia8, the, intima, is, built, of, the, layer, of, endothelial, cellson, the, luminal, side, the, media, consists, of, smooth, musclecells, and, the, adventitia, forms, the, outer, part8, in, a, normalsetting, the, endothelium, is, crucial, for, vein, integrity, andprevention, of, thrombosis9, and, its, focal, disruption, maypredispose, to, vessel, thrombosis2, sv, manipulation, andimplantation, leads, to, loss, of, endothelial, integrity, and, elicitsan, inï¬ammatory, response, with, platelet, adhesion, and, leukocyte, recruitment, notwithstanding, an, overt, thrombosis, isextremely, rare, in, the, operating, room, sv, dissection, results, inblood, ï¬ow, disruption, in, vasa, vasorum, and, causes, adventitial, damage, hypoxia, and, vessel, wall, hyponutrition10, acuteperioperative, saphenous, vein, graft, failure, is, almost, always, aresult, of, graft, thrombosis, but, this, very, uncommonly, occursprior, to, graft, placement, surgical, factorslike, technicalanastomotic, failure, or, severe, disproportion, between, thetarget, vessel, and, the, graft, may, lead, to, thrombosis, butvessel, injury, and, hypercoagulability, are, among, potentialcauses, as, well11there, was, no, evident, inï¬ammatory, process, in, microscopy, inour, patient, but, even, if, an, inï¬ammatory, process, was, presentth, , vol, , no, 0cbilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, ale201preoperatively, in, our, patients, svs, the, inï¬ammatory, background, alone, could, not, explain, the, dramatic, intraoperativethrombosis, we, hypothesized, that, increased, thrombin, generation, and, prothrombotic, ï¬brin, clot, phenotype, were, responsiblefor, the, clinical, presentation, conversion, of, ï¬brinogen, to, ï¬brinfacilitated, by, thrombin, is, a, concluding, step, of, coagulation, ithas, been, shown, that, ï¬brin, clots, with, small, pores, betweentightly, packed, thin, ï¬brin, ï¬bers, are, relatively, lysis, resistant12such, clot, phenotype, has, been, evidenced, in, multiple, thromboticpathologies, such, as, myocardial, infarction6, ischemic, stroke13and, venous, thromboembolism4, the, prothrombotic, clotphenotype, reï¬ected, by, a, tendency, to, form, dense, ï¬brin, clotsresistant, to, lysis, has, been, previously, reported, in, patients, withinstent, thrombosis14, while, routine, thrombophilia, screeningresults, in, a, high, almost, , detection, rate, of, commonhypercoagulable, states15, there, are, prothrombotic, conditionsthat, escape, routine, diagnostic, approach, the, overall, microscopic, clot, appearance, and, prothrombotic, ï¬brin, properties, lead, tothe, discovery, of, two, mutations, in, our, patient, that, are, notroutinely, tested, during, thrombophilia, screening, namely, ï¬brinogen, 455g, , a, and, fxiii100g, , televated, ï¬brinogen, was, postulated, as, one, of, the, riskfactors, for, early, graft, failure, after, cabg1116, epidemiologicalstudies, have, established, that, elevated, ï¬brinogen, is, stronglyassociated, with, cardiovascular, diseases17, a, , metaanalysis, of, individual, records, of, , participants, from, prospective, studies, revealed, that, age, and, sexadjustedhazard, ratio, per, , gl, increase, in, usual, ï¬brinogen, level, forcoronary, heart, disease, was, , , conï¬dence, interval, [ci], while, for, stroke, the, hazard, ratio, was, as, high, as, 95ci, , risk, of, coronary, disease, progression, wasalso, linked, to, genetic, polymorphisms, of, the, ï¬brinogen, genede, maat, et, al, found, that, a, allele, of, ï¬brinogen, 455g, , awas, associated, with, more, severe, progression, of, coronarydisease, as, documented, angiographically18, gu, and, colleagues, in, a, metaanalysis, of, , studies, with, , patientsfound, that, a, allele, of, the, ï¬brinogen, 455g, , a, is, associated, with, susceptibility, to, coronary, disease, and, also, withischemic, stroke, odds, ratio, for, stroke, ¼, , [, ci, ]for, aa, ã¾, ga, vs, gg19, in, a, recent, study, of, patients, with, atrialï¬brillation, hu, and, colleagues, found, that, the, a, allele, of, ï¬brinogen, 455g, , a, was, a, risk, factor, for, cardioembolicstroke, probably, by, elevating, the, level, of, plasma, ï¬brinogen20, on, the, other, hand, in, a, , metaanalysis, of, studies, involving, , cases, and, , controls, fxiiival34leu, polymorphism, was, shown, to, be, associated, withrisk, myocardial, infarction21, fxiii, is, crucial, to, thrombusstabilization, and, changes, of, its, plasma, concentration, reï¬ectnonspeciï¬cally, the, extent, of, thrombosis, as, shown, by, li, et, alin, a, study, on, patients, with, cerebral, venous, thrombosis22interesting, associations, of, fxiii, val34leu, polymorphism, andthrombotic, disorders, have, been, reported, jung, et, al, reportedin, a, metaanalysis, of, , studies, that, fxiii, val34leu, polymorphism, is, associated, with, recurrent, pregnancy, loss23although, no, association, with, the, incidence, of, ischemicstroke, was, found, for, this, polymorphism24, apparentlywhen, the, stroke, occurs, val34leu, polymorphism, of, fxiiiaffects, the, severity, of, its, outcome25, furthermore, kreutzand, colleagues, suggested, in, , that, fxiii, val34leu, polymorphism, may, increase, risk, of, recurrent, mi, and, death, inpatients, with, angiographically, established, coronary, arterydisease26, in, , our, group, has, shown, in, a, study, of, patients, that, in, patients, undergoing, cabg, fxiii, leu34, alleleis, associated, with, decreased, ï¬brin, clot, permeability, andefï¬ciency, of, ï¬brinolysis27conclusionour, extensive, workup, showed, that, ï¬brinogen, haeiii, andfxiii, val34leu, polymorphisms, are, reï¬ected, in, reduced, clotpermeability, and, susceptibility, to, lysis, these, mutationslikely, contributed, to, intraoperative, saphenous, graft, thrombosis, further, studies, are, needed, to, elucidate, the, role, ofthese, polymorphisms, in, early, graft, failure, after, bypassgrafting, procedures, however, their, contributory, role, seemsevidentfundingthis, study, was, funded, by, a, grant, from, the, jagiellonianuniversity, medical, college, no, kzds007961, to, pmconï¬ict, of, interestnone, declaredreferences, bourassa, mg, fate, of, venous, grafts, the, past, the, present, and, thefuture, j, am, coll, cardiol, , roubos, n, rosenfeldt, fl, richards, sm, conyers, ra, davis, bbimproved, preservation, of, saphenous, vein, grafts, by, the, use, ofglyceryl, trinitrateverapamil, solution, during, harvesting, circulation, 19959209ii31ii36, mazur, p, sokoåowski, g, hubalewskadydejczyk, a, påaczkiewiczjankowska, e, undas, a, prothrombotic, alterations, in, plasma, ï¬brinclot, properties, in, thyroid, disorders, and, their, posttreatmentmodiï¬cations, thromb, res, , undas, a, zawilska, k, ciesladul, m, et, al, altered, ï¬brin, clotstructurefunction, in, patients, with, idiopathic, venous, thromboembolism, and, in, theirrelatives, blood, , natorska, j, marek, g, hlawaty, m, sadowski, j, tracz, w, undas, afibrin, presence, within, aortic, valves, in, patients, with, aorticstenosis, association, with, in, vivo, thrombin, generation, and, ï¬brinclot, properties, thromb, haemost, , undas, a, szuådrzynski, k, stepien, e, et, al, reduced, clot, permeability, and, susceptibility, to, lysis, in, patients, with, acute, coronarysyndrome, effects, of, inï¬ammation, and, oxidative, stress, atherosclerosis, , fitzgibbon, gm, kafka, hp, leach, aj, keon, wj, hooper, gd, burtonjr, coronary, bypass, graft, fate, and, patient, outcome, angiographicfollowup, of, , grafts, related, to, survival, and, reoperation, in, patients, during, , years, j, am, coll, cardiol, , kim, fy, marhefka, g, ruggiero, nj, adams, s, whellan, dj, saphenous, vein, graft, disease, review, of, pathophysiology, preventionand, treatment, cardiol, rev, , allaire, e, clowes, aw, endothelial, cell, injury, in, cardiovascularsurgery, the, intimal, hyperplastic, response, ann, thorac, surg, mcgeachie, jk, meagher, s, prendergast, fj, veintoartery, graftsthe, longterm, development, of, neointimal, hyperplasia, and, itsth, , vol, , no, 0ce202bilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, alrelationship, to, vasa, vasorum, and, sympathetic, innervation, aust, nz, j, surg, , harskamp, re, lopes, rd, baisden, ce, de, winter, rj, alexander, jhsaphenous, vein, graft, failure, after, coronary, artery, bypass, surgerypathophysiology, management, and, future, directions, ann, surg, undas, a, fibrin, clot, properties, and, their, modulation, in, thrombotic, disorders, thromb, haemost, , undas, a, podolec, p, zawilska, k, et, al, altered, ï¬brin, clotstructurefunction, in, patients, with, cryptogenic, ischemic, strokestroke, , undas, a, zalewski, j, krochin, m, et, al, altered, plasma, ï¬brin, clotproperties, are, associated, with, instent, thrombosis, arteriosclerthromb, vasc, biol, , goldmanmazur, s, wypasek, e, karpiåski, m, stanisz, a, undas, ahigh, detection, rates, of, antithrombin, deï¬ciency, and, antiphospholipid, syndrome, in, outpatients, aged, over, , years, using, thestandardized, protocol, for, thrombophilia, screening, thromb, res, moor, e, hamsten, a, blombã¤ck, m, herzfeld, i, wiman, b, rydã©n, lhaemostatic, factors, and, inhibitors, and, coronary, artery, bypassgrafting, preoperative, alterations, and, relations, to, graft, occlusionthromb, haemost, , danesh, j, collins, r, appleby, p, peto, r, association, of, ï¬brinogen, creactive, protein, albumin, or, leukocyte, count, with, coronary, heartdisease, metaanalyses, of, prospective, studies, jama, , de, maat, mp, kastelein, jj, jukema, jw, et, al, 455ga, polymorphismof, the, betaï¬brinogen, gene, is, associated, with, the, progression, ofcoronary, atherosclerosis, in, symptomatic, men, proposed, role, foran, acutephase, reaction, pattern, of, ï¬brinogen, regress, grouparterioscler, thromb, vasc, biol, , gu, l, liu, w, yan, y, et, al, inï¬uence, of, the, ï¬brinogen455gapolymorphism, on, development, of, ischemic, stroke, and, coronaryheart, disease, thromb, res, , hu, x, wang, j, li, y, et, al, the, ï¬brinogen, gene, 455ga, polymorphism, associated, with, cardioembolic, stroke, in, atrial, ï¬brillationwith, low, cha2ds2vasc, score, sci, rep, , jung, jh, song, gg, kim, jh, seo, yh, choi, sj, association, of, factor, xiiival34leu, polymorphism, and, coronary, artery, disease, a, metaanalysis, cardiol, j, , li, b, heldner, mr, arnold, m, et, al, coagulation, factor, xiiiin, cerebral, venous, thrombosis, th, , , e227e229, jung, jh, kim, jh, song, gg, choi, sj, association, of, the, f13a1val34leu, polymorphism, and, recurrent, pregnancy, loss, a, metaanalysis, eur, j, obstet, gynecol, reprod, biol, , shemirani, ah, pongrã¡cz, e, antalï¬, b, adã¡ny, r, muszbek, l, factorxiii, a, subunit, val34leu, polymorphism, in, patients, sufferingatherothrombotic, ischemic, stroke, thromb, res, , shemirani, ah, antalï¬, b, pongrã¡cz, e, mezei, za, bereczky, z, csiki, zfactor, xiiia, subunit, val34leu, polymorphism, in, fatal, atherothrombotic, ischemic, stroke, blood, coagul, fibrinolysis, , kreutz, rp, bitar, a, owens, j, et, al, factor, xiii, val34leu, polymorphism, and, recurrent, myocardialinfarction, in, patients, withcoronary, artery, disease, j, thromb, thrombolysis, , stepieå, e, plicner, d, kapelak, b, wypasek, e, sadowski, j, undasa, factor, xiii, val34leu, polymorphism, as, a, modulator, of, ï¬brinclot, permeability, and, resistance, to, lysis, in, patients, withsevere, coronary, artery, disease, kardiol, pol, 2009678ath, , vol, , no, 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |[coronary, arterybypass, grafting, thrombosis, ï¬brin, ï¬brinogen, mutationintroduction, intraoperative, thrombosis, saphenous, veins, sv, , , harvesting, rarecase, report, present, case, 60yearold, male, patient, multivesselcoronary, artery, disease, history, nonst, elevation, acute, coronary, syndromeand, type2, diabetes, mellitus, admitted, coronary, artery, bypass, grafting, whombilateralintraoperative, sv, thrombosis, occurred, graft, harvesting, routinethrombophilia, screening, showed, abnormalities, cancer, excluded, compared, healthy, controls, observed, prolonged, ï¬brin, clot, lysis, time, increasedthrombin, generation, reï¬ected, endogenous, thrombin, potential, scanning, electronmicroscopy, thrombosed, material, revealed, compact, thick, ï¬brin, layer, theclot, surface, solid, mass, unusually, compressed, platelets, erythrocytesunderneath, patient, tested, ï¬brinogen, factor, f, xiii, polymorphismsand, found, heterozygous, ï¬brinogen, haeiii, 455g, , fxiiival34leu, 100g, , tconclusion, ï¬brinogen, haeiii, fxiii, val34leu, polymorphisms, reï¬ected, inreduced, clot, permeability, susceptibility, lysis, might, contribute, intraoperative, sv, thrombosis, vascular, grafting, procedures, carriers, atrisk, primary, venous, graft, failure, bypass, proceduresintroductioncoronary, artery, bypass, grafting, cabg, method, choicefor, revascularization, patients, multivessel, disease, anddiabetes, mellitus, dm, although, arterial, grafts, preferredin, selected, scenarios, common, practice, use, leftinternal, thoracic, artery, lita, bypass, left, anteriordescending, artery, lad, place, venous, conduits, toother, target, vessels, often, chosen, vascular, graft, greatsaphenous, vein, sv, offers, decent, durability, easy, toharvest, sv, graft, occlusion, may, occur, , caseswithin, ï¬rst, , months, many, , may, occludewithin, ï¬rst, , , weeks1, sv, harvesting, dramaticallychanges, veins, environment, disruption, bloodï¬ow, vasa, vasorum, damage, adventitia, hypoxia, andhyponutrition, vessel, wall, along, focal, endothelialdisruption2, acute, sv, graft, failure, usually, result, graftthrombosis, among, factors, like, technical, failuregrafttarget, vessel, disproportion, etc, may, caused, byhypercoagulabilityreceivedmarch, , acceptedjuly, , , 101055s00401715657issn, , , ge, thieme, verlag, kgstuttgart, ·, new, york, 0ce198bilateral, saphenous, vein, thrombosis, cabg, mazur, et, alcase, reporta, 60yearold, male, patient, multivessel, coronary, arterydisease, suffered, nonst, elevation, acute, coronarysyndrome, nsteacs, , month, prior, admission, nonsmoker, type2, dm, metformin, peptic, ulcer, diseaseand, history, alcohol, abuse, admitted, institutionfor, cabg, nsteacs, left, ventricle, lv, thrombus, seen, one, echocardiographic, examination, itwas, absent, followup, deep, venousthrombosis, bleeding, diathesis, history, admission, thepatient, aspirin, , mg, daily, enoxaparin, mg, daily, routine, laboratory, tests, withinnormal, ranges, ºtable, , abnormalities, onphysical, examination, apart, obesity, body, mass, index, kgm2, patient, admitted, lower, extremities, appeared, normal, varicose, veins, nosigns, symptoms, venous, insufï¬ciency, pastmedical, history, negative, personal, familyhistory, chronic, venous, insufï¬ciency, varicose, veins, thepatient, operated, following, standard, proceduresduring, lita, harvest, cardiac, surgery, resident, harvested, theright, sv, using, , , technique, wall, sv, lookedgrossly, normal, upon, dissection, side, branches, tiedoff, clipped, needle, placed, distal, end, whilethe, proximal, end, still, separated, attempt, madetable, , results, initial, followup, laboratory, testingvariablecoagulation, testsred, blood, count, 103µlhemoglobin, gdlwhite, blood, count, 103µlplatelet, count, 103µlaptt, spt, spt, inrplatelet, aggregation, mmoll, arachidonic, acid, , µmoll, adp, thrombophilia, screeningfibrinogen, glantithrombin, iii, ddimer, µglantixa, iumlhomocysteine, µmollprotein, c, protein, factor, viii, leiden, c1601g, , 0397g, , aprothrombin, cï¬brinogen, 455g, , afactor, xiii, 100g, , tlupus, anticoagulant, ratiolupus, anticoagulant, ratio, apttanticardiolipin, igganticardiolipin, igmanti2glycoprotein, igg, antibodyanti2glycoprotein, igm, antibodynormal, rangespreoperativepostoperative, day, postoperative, day, , gg, mutationgg, mutation, gpl, mpl, sgu, smugg, mutationgg, mutationga, heterozygotegt, heterozygote, gpl, mpl, sgu, smuabbreviations, aptt, activated, partial, thromboplastin, time, gpl, igg, phospholipid, unit, ig, immunoglobulin, inr, international, normalized, ratiompl, igm, phospholipid, unit, pt, prothrombin, time, sgu, standard, igg, 2, glycoprotein, unit, smu, standard, igm, 2, glycoprotein, unitth, , vol, , 0cbilateral, saphenous, vein, thrombosis, cabg, mazur, et, ale199to, ï¬ush, vein, solution, containing, blood, , mlheparin, , iu, normal, saline, , ml, distalend, closed, atraumatic, vascular, clamp, veinthrombosis, noted, upon, separation, distal, end, aluminal, thrombus, visible, left, sv, taken, downusing, protocol, experienced, staff, cardiacsurgeon, result, presence, luminal, thrombuswas, conï¬rmed, upon, separation, proximal, end, systemicheparin, administered, normal, lita, outï¬ow, wasconï¬rmed, concerns, regarding, safety, cardiopulmonarybypass, use, raised, due, suspected, thrombotic, issueand, approach, modiï¬ed, litalad, anastomosiswas, completed, offpump, beating, heartthe, postoperative, course, uneventful, postoperative, day, , patient, received, dual, antiplatelet, therapy, withaspirin, clopidogrel, discharged, day, , nosigns, thrombosis, myocardial, ischemia, elective, angioplasty, nongrafted, vessels, scheduled, completethrombophilia, screening, done, ºtable, , , and12month, followup, patient, welldiagnostic, approachbecause, thrombophilia, suspected, screening, wasinitiated, showing, abnormalities, ºtable, cancer, excluded, cause, thrombosis, positiveantibodies, neutrophil, cytoplasm, antigens, pancaand, canca, excluded, cause, vasculitis, thenproceeded, analyze, ï¬brin, phenotype, using, previouslydescribed, methodology34, brieï¬y, plasma, ï¬brin, clot, permeability, determined, hydrostatic, pressure, systemtubes, containing, ï¬brin, clots, formed, adding, , mmollcalcium, chloride, , uml, human, thrombin, sigma, tocitrated, plasma, connected, plastic, tubing, abuffer, reservoir, , m, trishcl, , m, nacl, ph, , thevolume, ï¬owing, gel, measured, within, minutes, permeation, coefï¬cient, ks, reï¬ecting, poresize, calculated, equation, ks, ¼, q, 02, l, î·t, 02, 02, îpwhere, q, ï¬ow, rate, time, l, length, ï¬brin, gelî·, viscosity, liquid, cross, section, area, îp, isa, differential, pressure, dynecm2, lower, ks, values, indicated, reduced, permeability, fibrinogen, determined, usingthe, clauss, method, even, though, followup, ï¬brinogenlevel, normal, identiï¬ed, strongly, decreased, ï¬brin, clotpermeability, ks, ¼, , 06, , 02, 9cm2, compared, withhealthy, controls, previous, report, n, ¼, , ks, ¼, , 9cm23, samples, collected, late, follow[], appointment, postoperative, day, , compared, withhealthy, controls, n, ¼, , observed, prolonged, clot, lysistime, clt, , 06, , vs, , 06, , minutes, increasedthrombin, generation, reï¬ected, endogenous, thrombinpotential, etp, studied, subject, etp, ¼, , 06, vs, , 06, , nm, 02, min, respectively, measurement, ofthe, thrombin, generation, done, calibrated, automated, thrombography, thrombinoscope, bv, maastricht, thenetherlands, according, manufacturers, instructionsin, 96well, plate, ï¬uorometer, ascent, reader, thermolabsystems, oy, helsinki, finland, equipped, ï¬lter, set, temperature, °c, brieï¬y, microliters, plateletpoor, plasma, diluted, µl, reagent, containing, , pmoll, recombinant, tissuefactor, , micromolar, phosphatidylserinephosphatidylcholinephosphatidylethanolamine, vesicle, , µl, flucasolution, hepes, ph, , , nmoll, cacl2, , mgml, bovinealbumin, , mmoll, zglyglyarg7amino4methylcoumarin, plasma, sample, analyzed, duplicatefor, analysis, maximum, concentration, thrombin, generated, used3cryosectioned, tissue, sections, ï¬xed, icecold, methanolacetone, , mixture, peroxidase, activity, quenchedwith, , h2o2, unspeciï¬c, background, blocked, bovine, albumin, bsa, sigma, co, st, louis, missouri, unitedstates, primary, adequate, antibodies, ï¬brin, tissuefactor, tf, applied, abcam, cambridge, unitedkingdom, primary, antibodies, followed, thecorresponding, secondary, antibodies, conjugated, ï¬uorochrome, abcam, previously, described5, images, analyzed, using, olympus, bx, , microscope, svs, immunostainingrevealed, thick, layer, ï¬brin, directly, vessel, endotheliumºfig, 1a, high, tf, ºfig, 1b, activity, within, thrombuswe, found, abundant, blood, nuclear, cells, nuclei, stained, usingdapi, suggesting, presence, proinï¬ammatory, monocyteswhich, known, source, tf, unfortunately, ableto, immunostain, cd68, due, high, unspeciï¬c, backgroundresulting, large, amounts, ï¬brin, microscopic, analysisshowed, abundant, adventitial, vessels, ºfig, 1c, d, withinalmost, every, single, vessel, found, thrombi, rich, bothprothrombin, ºfig, 1c, tf, ºfig, 1dprothrombotic, ï¬brin, clot, phenotype, reï¬ected, reducedks, prolonged, clt, along, enhanced, thrombin, generation, unusualimages, obtained, immunostaining, svs, prompted, us, perform, analysis, ofwhole, blood, clot, morphology, using, scanning, electron, microscopy, sem, previously, described6, washing, thethrombus, ï¬xed, , glutaraldehyde, phosphatebuffered, saline, solution, specimens, dehydrated, goldcoated, photographed, digitally, jeol, jsm, jeol, tokyo, japan, analysis, revealed, compact, thickï¬brin, layer, clot, surface, solid, massof, unusually, compressed, platelets, erythrocytes, underneath, observation, suggested, veryhigh, contractileforces, clot, formation, plateletdriven, ï¬brinmediated, mechanism, clot, contraction, prompted, usto, study, common, ï¬brinogen, factor, f, xiii, polymorphisms, patient, heterozygous, ï¬brinogen, haeiii455g, , fxiii, val34leu, 100g, , tdiscussiona, dramatic, intraoperative, sv, thrombosis, provoked, graftharvesting, cabg, lead, change, revascularizationstrategy, cause, remained, unknown, following, thestandard, thrombophilia, screening, cases, acute, svgraft, thrombosis, perioperative, period, rareand, , grafts, occlude, within, ï¬rst, , weeks17th, , vol, , 0ce200bilateral, saphenous, vein, thrombosis, cabg, mazur, et, alfig, , representative, images, sv, graft, immunostaining, massive, thrombosis, ad, prothrombin, stained, red, tf, stained, green, nucleistained, blue, using, dapi, scanning, electron, microscopic, images, e, f, surface, whole, blood, clot, formed, vitro, citrated, bloodobtained, patient, undergoing, cabg, box, arrow, represent, magniï¬cation, fragment, box, arrows, show, pertinent, stainedfragments, see, text, cabg, coronary, artery, bypass, grafting, sv, saphenous, veins, tf, tissue, factora, normal, sv, composed, intima, media, theadventitia8, intima, built, layer, endothelial, cellson, luminal, side, media, consists, smooth, musclecells, adventitia, forms, outer, part8, normalsetting, endothelium, crucial, vein, integrity, andprevention, thrombosis9, focal, disruption, maypredispose, vessel, thrombosis2, sv, manipulation, andimplantation, leads, loss, endothelial, integrity, elicitsan, inï¬ammatory, response, platelet, adhesion, leukocyte, recruitment, notwithstanding, overt, thrombosis, isextremely, rare, operating, room, sv, dissection, results, inblood, ï¬ow, disruption, vasa, vasorum, causes, adventitial, damage, hypoxia, vessel, wall, hyponutrition10, acuteperioperative, saphenous, vein, graft, failure, almost, always, aresult, graft, thrombosis, uncommonly, occursprior, graft, placement, surgical, factorslike, technicalanastomotic, failure, severe, disproportion, thetarget, vessel, graft, may, lead, thrombosis, butvessel, injury, hypercoagulability, among, potentialcauses, well11there, evident, inï¬ammatory, process, microscopy, inour, patient, even, inï¬ammatory, process, presentth, , vol, , 0cbilateral, saphenous, vein, thrombosis, cabg, mazur, et, ale201preoperatively, patients, svs, inï¬ammatory, background, alone, explain, dramatic, intraoperativethrombosis, hypothesized, increased, thrombin, generation, prothrombotic, ï¬brin, clot, phenotype, responsiblefor, clinical, presentation, conversion, ï¬brinogen, ï¬brinfacilitated, thrombin, concluding, step, coagulation, ithas, shown, ï¬brin, clots, small, pores, betweentightly, packed, thin, ï¬brin, ï¬bers, relatively, lysis, resistant12such, clot, phenotype, evidenced, multiple, thromboticpathologies, myocardial, infarction6, ischemic, stroke13and, venous, thromboembolism4, prothrombotic, clotphenotype, reï¬ected, tendency, form, dense, ï¬brin, clotsresistant, lysis, previously, reported, patients, withinstent, thrombosis14, routine, thrombophilia, screeningresults, high, almost, , detection, rate, commonhypercoagulable, states15, prothrombotic, conditionsthat, escape, routine, diagnostic, approach, overall, microscopic, clot, appearance, prothrombotic, ï¬brin, properties, lead, tothe, discovery, two, mutations, patient, notroutinely, tested, thrombophilia, screening, namely, ï¬brinogen, 455g, , fxiii100g, , televated, ï¬brinogen, postulated, one, riskfactors, early, graft, failure, cabg1116, epidemiologicalstudies, established, elevated, ï¬brinogen, stronglyassociated, cardiovascular, diseases17, , metaanalysis, individual, records, , participants, prospective, studies, revealed, age, sexadjustedhazard, ratio, per, , gl, increase, usual, ï¬brinogen, level, forcoronary, heart, disease, , , conï¬dence, interval, [ci], stroke, hazard, ratio, high, 95ci, , risk, coronary, disease, progression, wasalso, linked, genetic, polymorphisms, ï¬brinogen, genede, maat, et, al, found, allele, ï¬brinogen, 455g, , awas, associated, severe, progression, coronarydisease, documented, angiographically18, gu, colleagues, metaanalysis, , studies, , patientsfound, allele, ï¬brinogen, 455g, , associated, susceptibility, coronary, disease, also, withischemic, stroke, odds, ratio, stroke, ¼, , [, ci, ]for, aa, ã¾, ga, vs, gg19, recent, study, patients, atrialï¬brillation, hu, colleagues, found, allele, ï¬brinogen, 455g, , risk, factor, cardioembolicstroke, probably, elevating, level, plasma, ï¬brinogen20, hand, , metaanalysis, studies, involving, , cases, , controls, fxiiival34leu, polymorphism, shown, associated, withrisk, myocardial, infarction21, fxiii, crucial, thrombusstabilization, changes, plasma, concentration, reï¬ectnonspeciï¬cally, extent, thrombosis, shown, li, et, alin, study, patients, cerebral, venous, thrombosis22interesting, associations, fxiii, val34leu, polymorphism, andthrombotic, disorders, reported, jung, et, al, reportedin, metaanalysis, , studies, fxiii, val34leu, polymorphism, associated, recurrent, pregnancy, loss23although, association, incidence, ischemicstroke, found, polymorphism24, apparentlywhen, stroke, occurs, val34leu, polymorphism, fxiiiaffects, severity, outcome25, furthermore, kreutzand, colleagues, suggested, , fxiii, val34leu, polymorphism, may, increase, risk, recurrent, mi, death, inpatients, angiographically, established, coronary, arterydisease26, , group, shown, study, patients, patients, undergoing, cabg, fxiii, leu34, alleleis, associated, decreased, ï¬brin, clot, permeability, andefï¬ciency, ï¬brinolysis27conclusionour, extensive, workup, showed, ï¬brinogen, haeiii, andfxiii, val34leu, polymorphisms, reï¬ected, reduced, clotpermeability, susceptibility, lysis, mutationslikely, contributed, intraoperative, saphenous, graft, thrombosis, studies, needed, elucidate, role, ofthese, polymorphisms, early, graft, failure, bypassgrafting, procedures, however, contributory, role, seemsevidentfundingthis, study, funded, grant, jagiellonianuniversity, medical, college, kzds007961, pmconï¬ict, interestnone, declaredreferences, bourassa, mg, fate, venous, grafts, past, present, thefuture, j, coll, cardiol, , roubos, n, rosenfeldt, fl, richards, sm, conyers, ra, davis, bbimproved, preservation, saphenous, vein, grafts, use, ofglyceryl, trinitrateverapamil, solution, harvesting, circulation, 19959209ii31ii36, mazur, p, sokoåowski, g, hubalewskadydejczyk, påaczkiewiczjankowska, e, undas, prothrombotic, alterations, plasma, ï¬brinclot, properties, thyroid, disorders, posttreatmentmodiï¬cations, thromb, res, , undas, zawilska, k, ciesladul, m, et, al, altered, ï¬brin, clotstructurefunction, patients, idiopathic, venous, thromboembolism, theirrelatives, blood, , natorska, j, marek, g, hlawaty, m, sadowski, j, tracz, w, undas, afibrin, presence, within, aortic, valves, patients, aorticstenosis, association, vivo, thrombin, generation, ï¬brinclot, properties, thromb, haemost, , undas, szuådrzynski, k, stepien, e, et, al, reduced, clot, permeability, susceptibility, lysis, patients, acute, coronarysyndrome, effects, inï¬ammation, oxidative, stress, atherosclerosis, , fitzgibbon, gm, kafka, hp, leach, aj, keon, wj, hooper, gd, burtonjr, coronary, bypass, graft, fate, patient, outcome, angiographicfollowup, , grafts, related, survival, reoperation, patients, , years, j, coll, cardiol, , kim, fy, marhefka, g, ruggiero, nj, adams, whellan, dj, saphenous, vein, graft, disease, review, pathophysiology, preventionand, treatment, cardiol, rev, , allaire, e, clowes, aw, endothelial, cell, injury, cardiovascularsurgery, intimal, hyperplastic, response, ann, thorac, surg, mcgeachie, jk, meagher, prendergast, fj, veintoartery, graftsthe, longterm, development, neointimal, hyperplasia, itsth, , vol, , 0ce202bilateral, saphenous, vein, thrombosis, cabg, mazur, et, alrelationship, vasa, vasorum, sympathetic, innervation, aust, nz, j, surg, , harskamp, re, lopes, rd, baisden, ce, de, winter, rj, alexander, jhsaphenous, vein, graft, failure, coronary, artery, bypass, surgerypathophysiology, management, future, directions, ann, surg, undas, fibrin, clot, properties, modulation, thrombotic, disorders, thromb, haemost, , undas, podolec, p, zawilska, k, et, al, altered, ï¬brin, clotstructurefunction, patients, cryptogenic, ischemic, strokestroke, , undas, zalewski, j, krochin, m, et, al, altered, plasma, ï¬brin, clotproperties, associated, instent, thrombosis, arteriosclerthromb, vasc, biol, , goldmanmazur, wypasek, e, karpiåski, m, stanisz, undas, ahigh, detection, rates, antithrombin, deï¬ciency, antiphospholipid, syndrome, outpatients, aged, , years, using, thestandardized, protocol, thrombophilia, screening, thromb, res, moor, e, hamsten, blombã¤ck, m, herzfeld, wiman, b, rydã©n, lhaemostatic, factors, inhibitors, coronary, artery, bypassgrafting, preoperative, alterations, relations, graft, occlusionthromb, haemost, , danesh, j, collins, r, appleby, p, peto, r, association, ï¬brinogen, creactive, protein, albumin, leukocyte, count, coronary, heartdisease, metaanalyses, prospective, studies, jama, , de, maat, mp, kastelein, jj, jukema, jw, et, al, 455ga, polymorphismof, betaï¬brinogen, gene, associated, progression, ofcoronary, atherosclerosis, symptomatic, men, proposed, role, foran, acutephase, reaction, pattern, ï¬brinogen, regress, grouparterioscler, thromb, vasc, biol, , gu, l, liu, w, yan, y, et, al, inï¬uence, ï¬brinogen455gapolymorphism, development, ischemic, stroke, coronaryheart, disease, thromb, res, , hu, x, wang, j, li, y, et, al, ï¬brinogen, gene, 455ga, polymorphism, associated, cardioembolic, stroke, atrial, ï¬brillationwith, low, cha2ds2vasc, score, sci, rep, , jung, jh, song, gg, kim, jh, seo, yh, choi, sj, association, factor, xiiival34leu, polymorphism, coronary, artery, disease, metaanalysis, cardiol, j, , li, b, heldner, mr, arnold, m, et, al, coagulation, factor, xiiiin, cerebral, venous, thrombosis, th, , , e227e229, jung, jh, kim, jh, song, gg, choi, sj, association, f13a1val34leu, polymorphism, recurrent, pregnancy, loss, metaanalysis, eur, j, obstet, gynecol, reprod, biol, , shemirani, ah, pongrã¡cz, e, antalï¬, b, adã¡ny, r, muszbek, l, factorxiii, subunit, val34leu, polymorphism, patients, sufferingatherothrombotic, ischemic, stroke, thromb, res, , shemirani, ah, antalï¬, b, pongrã¡cz, e, mezei, za, bereczky, z, csiki, zfactor, xiiia, subunit, val34leu, polymorphism, fatal, atherothrombotic, ischemic, stroke, blood, coagul, fibrinolysis, , kreutz, rp, bitar, owens, j, et, al, factor, xiii, val34leu, polymorphism, recurrent, myocardialinfarction, patients, withcoronary, artery, disease, j, thromb, thrombolysis, , stepieå, e, plicner, d, kapelak, b, wypasek, e, sadowski, j, undasa, factor, xiii, val34leu, polymorphism, modulator, ï¬brinclot, permeability, resistance, lysis, patients, withsevere, coronary, artery, disease, kardiol, pol, 2009678ath, , vol, , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |[coronary, arterybypass, grafting, thrombosis, ï¬brin, ï¬brinogen, mutationintroduction, intraoperative, thrombosis, saphenous, veins, sv, during, , , harvesting, very, rarecase, report, we, present, case, 60yearold, male, patient, with, multivesselcoronary, artery, disease, history, nonst, elevation, acute, coronary, syndromeand, type2, diabetes, mellitus, admitted, coronary, artery, bypass, grafting, whombilateralintraoperative, sv, thrombosis, occurred, during, graft, harvesting, routinethrombophilia, screening, showed, no, abnormalities, cancer, excluded, compared, with, healthy, controls, we, observed, prolonged, ï¬brin, clot, lysis, time, increasedthrombin, generation, reï¬ected, by, endogenous, thrombin, potential, scanning, electronmicroscopy, thrombosed, material, revealed, compact, thick, ï¬brin, layer, on, theclot, surface, with, solid, mass, unusually, compressed, platelets, erythrocytesunderneath, patient, tested, ï¬brinogen, factor, f, xiii, polymorphismsand, found, be, heterozygous, ï¬brinogen, haeiii, 455g, , fxiiival34leu, 100g, , tconclusion, ï¬brinogen, haeiii, fxiii, val34leu, polymorphisms, are, reï¬ected, inreduced, clot, permeability, susceptibility, lysis, might, contribute, intraoperative, sv, thrombosis, during, vascular, grafting, procedures, carriers, those, are, atrisk, primary, venous, graft, failure, after, bypass, proceduresintroductioncoronary, artery, bypass, grafting, cabg, method, choicefor, revascularization, patients, with, multivessel, disease, anddiabetes, mellitus, dm, although, arterial, grafts, are, preferredin, selected, scenarios, common, practice, use, leftinternal, thoracic, artery, lita, bypass, left, anteriordescending, artery, lad, place, venous, conduits, toother, target, vessels, an, often, chosen, vascular, graft, greatsaphenous, vein, sv, offers, decent, durability, easy, toharvest, sv, graft, occlusion, may, occur, up, , caseswithin, ï¬rst, , months, as, many, as, , may, occludewithin, ï¬rst, , , weeks1, sv, harvesting, dramaticallychanges, veins, environment, with, disruption, bloodï¬ow, vasa, vasorum, damage, adventitia, hypoxia, andhyponutrition, vessel, wall, along, with, focal, endothelialdisruption2, acute, sv, graft, failure, usually, result, graftthrombosis, which, among, other, factors, like, technical, failuregrafttarget, vessel, disproportion, etc, may, be, caused, byhypercoagulabilityreceivedmarch, , acceptedjuly, , , 101055s00401715657issn, , , ge, thieme, verlag, kgstuttgart, ·, new, york, 0ce198bilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, alcase, reporta, 60yearold, male, patient, with, multivessel, coronary, arterydisease, who, suffered, from, nonst, elevation, acute, coronarysyndrome, nsteacs, , month, prior, admission, nonsmoker, with, type2, dm, on, metformin, peptic, ulcer, diseaseand, history, alcohol, abuse, admitted, our, institutionfor, cabg, just, after, nsteacs, left, ventricle, lv, thrombus, seen, on, one, echocardiographic, examination, but, itwas, absent, during, followup, there, no, deep, venousthrombosis, or, bleeding, diathesis, history, on, admission, thepatient, on, aspirin, , mg, once, daily, enoxaparin, mg, once, daily, routine, laboratory, tests, were, withinnormal, ranges, ºtable, , there, were, no, abnormalities, onphysical, examination, apart, from, obesity, body, mass, index, kgm2, when, patient, admitted, lower, extremities, appeared, normal, there, were, no, varicose, veins, nosigns, or, symptoms, venous, insufï¬ciency, pastmedical, history, negative, both, personal, familyhistory, chronic, venous, insufï¬ciency, or, varicose, veins, thepatient, operated, on, following, standard, proceduresduring, lita, harvest, cardiac, surgery, resident, harvested, theright, sv, using, , , technique, wall, sv, lookedgrossly, normal, upon, dissection, side, branches, were, tiedoff, clipped, needle, placed, at, distal, end, whilethe, proximal, end, still, not, separated, an, attempt, madetable, , results, initial, followup, laboratory, testingvariablecoagulation, testsred, blood, count, 103µlhemoglobin, gdlwhite, blood, count, 103µlplatelet, count, 103µlaptt, spt, spt, inrplatelet, aggregation, mmoll, arachidonic, acid, , µmoll, adp, thrombophilia, screeningfibrinogen, glantithrombin, iii, ddimer, µglantixa, iumlhomocysteine, µmollprotein, c, protein, s, factor, viii, leiden, c1601g, , 0397g, , aprothrombin, cï¬brinogen, 455g, , afactor, xiii, 100g, , tlupus, anticoagulant, ratiolupus, anticoagulant, ratio, apttanticardiolipin, igganticardiolipin, igmanti2glycoprotein, i, igg, antibodyanti2glycoprotein, i, igm, antibodynormal, rangespreoperativepostoperative, day, postoperative, day, , gg, no, mutationgg, no, mutation, gpl, mpl, sgu, smugg, no, mutationgg, no, mutationga, heterozygotegt, heterozygote, gpl, mpl, sgu, smuabbreviations, aptt, activated, partial, thromboplastin, time, gpl, igg, phospholipid, unit, ig, immunoglobulin, inr, international, normalized, ratiompl, igm, phospholipid, unit, pt, prothrombin, time, sgu, standard, igg, 2, glycoprotein, unit, smu, standard, igm, 2, glycoprotein, unitth, , vol, , no, 0cbilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, ale199to, ï¬ush, vein, with, solution, containing, blood, , mlheparin, , iu, normal, saline, , ml, while, distalend, closed, with, an, atraumatic, vascular, clamp, veinthrombosis, noted, upon, separation, distal, end, aluminal, thrombus, visible, left, sv, then, taken, downusing, same, protocol, by, an, experienced, staff, cardiacsurgeon, with, same, result, presence, luminal, thrombuswas, conï¬rmed, upon, separation, proximal, end, systemicheparin, administered, normal, lita, outï¬ow, wasconï¬rmed, concerns, regarding, safety, cardiopulmonarybypass, use, were, raised, due, suspected, thrombotic, issueand, approach, modiï¬ed, litalad, anastomosiswas, completed, offpump, on, beating, heartthe, postoperative, course, uneventful, on, postoperative, day, , patient, received, dual, antiplatelet, therapy, withaspirin, clopidogrel, discharged, on, day, , with, nosigns, thrombosis, or, myocardial, ischemia, elective, angioplasty, nongrafted, vessels, scheduled, completethrombophilia, screening, done, ºtable, , on, , and12month, followup, patient, did, welldiagnostic, approachbecause, thrombophilia, suspected, screening, wasinitiated, showing, no, abnormalities, ºtable, cancer, excluded, as, cause, thrombosis, positiveantibodies, against, neutrophil, cytoplasm, antigens, pancaand, canca, were, excluded, as, cause, vasculitis, we, thenproceeded, analyze, ï¬brin, phenotype, using, previouslydescribed, methodology34, brieï¬y, plasma, ï¬brin, clot, permeability, determined, hydrostatic, pressure, systemtubes, containing, ï¬brin, clots, formed, from, adding, , mmollcalcium, chloride, , uml, human, thrombin, sigma, tocitrated, plasma, were, connected, through, plastic, tubing, abuffer, reservoir, , m, trishcl, , m, nacl, ph, , thevolume, ï¬owing, through, gel, measured, within, minutes, permeation, coefï¬cient, ks, reï¬ecting, poresize, calculated, from, equation, ks, ¼, q, 02, l, î·t, 02, 02, îpwhere, q, ï¬ow, rate, time, t, l, length, ï¬brin, gelî·, viscosity, liquid, cross, section, area, îp, isa, differential, pressure, dynecm2, lower, ks, values, indicated, reduced, permeability, fibrinogen, determined, usingthe, clauss, method, even, though, followup, ï¬brinogenlevel, normal, we, identiï¬ed, strongly, decreased, ï¬brin, clotpermeability, ks, ¼, , 06, , 02, 9cm2, compared, withhealthy, controls, from, our, previous, report, n, ¼, , ks, ¼, , 9cm23, samples, collected, during, late, follow[], up, appointment, on, postoperative, day, , compared, withhealthy, controls, n, ¼, , we, observed, prolonged, clot, lysistime, clt, , 06, , vs, , 06, , minutes, increasedthrombin, generation, reï¬ected, by, endogenous, thrombinpotential, etp, studied, subject, etp, ¼, , 06, vs, , 06, , nm, 02, min, respectively, measurement, ofthe, thrombin, generation, done, with, calibrated, automated, thrombography, thrombinoscope, bv, maastricht, thenetherlands, according, manufacturers, instructionsin, 96well, plate, ï¬uorometer, ascent, reader, thermolabsystems, oy, helsinki, finland, equipped, with, ï¬lter, set, at, temperature, °c, brieï¬y, microliters, plateletpoor, plasma, were, diluted, with, µl, reagent, containing, , pmoll, recombinant, tissuefactor, , micromolar, phosphatidylserinephosphatidylcholinephosphatidylethanolamine, vesicle, , µl, flucasolution, hepes, ph, , , nmoll, cacl2, , mgml, bovinealbumin, , mmoll, zglyglyarg7amino4methylcoumarin, each, plasma, sample, analyzed, duplicatefor, analysis, maximum, concentration, thrombin, generated, used3cryosectioned, tissue, sections, were, ï¬xed, icecold, methanolacetone, , mixture, peroxidase, activity, quenchedwith, , h2o2, unspeciï¬c, background, blocked, with, bovine, albumin, bsa, sigma, co, st, louis, missouri, unitedstates, primary, adequate, antibodies, against, ï¬brin, or, tissuefactor, tf, were, applied, both, abcam, cambridge, unitedkingdom, primary, antibodies, were, followed, by, thecorresponding, secondary, antibodies, conjugated, with, ï¬uorochrome, abcam, as, previously, described5, images, were, analyzed, using, olympus, bx, , microscope, svs, immunostainingrevealed, thick, layer, ï¬brin, directly, on, vessel, endotheliumºfig, 1a, high, tf, ºfig, 1b, activity, within, thrombuswe, found, abundant, blood, nuclear, cells, nuclei, stained, usingdapi, suggesting, presence, proinï¬ammatory, monocyteswhich, are, known, source, tf, unfortunately, we, were, not, ableto, immunostain, cd68, due, high, unspeciï¬c, backgroundresulting, from, large, amounts, ï¬brin, microscopic, analysisshowed, abundant, adventitial, vessels, ºfig, 1c, d, withinalmost, every, single, vessel, we, found, thrombi, rich, bothprothrombin, ºfig, 1c, tf, ºfig, 1dprothrombotic, ï¬brin, clot, phenotype, reï¬ected, by, reducedks, prolonged, clt, along, with, enhanced, thrombin, generation, unusualimages, obtained, from, immunostaining, svs, prompted, us, perform, analysis, ofwhole, blood, clot, morphology, using, scanning, electron, microscopy, sem, as, previously, described6, after, washing, thethrombus, ï¬xed, with, , glutaraldehyde, phosphatebuffered, saline, solution, specimens, were, dehydrated, goldcoated, photographed, digitally, with, jeol, jsm, jeol, tokyo, japan, analysis, revealed, compact, thickï¬brin, layer, on, clot, surface, with, solid, massof, unusually, compressed, platelets, erythrocytes, underneath, observation, suggested, veryhigh, contractileforces, during, clot, formation, plateletdriven, ï¬brinmediated, mechanism, clot, contraction, prompted, usto, study, common, ï¬brinogen, factor, f, xiii, polymorphisms, patient, heterozygous, ï¬brinogen, haeiii455g, , fxiii, val34leu, 100g, , tdiscussiona, dramatic, intraoperative, sv, thrombosis, provoked, by, graftharvesting, cabg, lead, change, revascularizationstrategy, but, its, cause, remained, unknown, following, thestandard, thrombophilia, screening, cases, acute, svgraft, thrombosis, perioperative, period, are, very, rareand, as, few, as, , grafts, occlude, within, ï¬rst, , weeks17th, , vol, , no, 0ce200bilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, alfig, , representative, images, sv, graft, immunostaining, after, massive, thrombosis, ad, prothrombin, stained, red, tf, stained, green, nucleistained, blue, using, dapi, scanning, electron, microscopic, images, e, f, surface, whole, blood, clot, formed, vitro, from, citrated, bloodobtained, from, patient, undergoing, cabg, box, arrow, represent, magniï¬cation, fragment, box, arrows, show, pertinent, stainedfragments, see, text, cabg, coronary, artery, bypass, grafting, sv, saphenous, veins, tf, tissue, factora, normal, sv, composed, intima, media, theadventitia8, intima, built, layer, endothelial, cellson, luminal, side, media, consists, smooth, musclecells, adventitia, forms, outer, part8, normalsetting, endothelium, crucial, vein, integrity, andprevention, thrombosis9, its, focal, disruption, maypredispose, vessel, thrombosis2, sv, manipulation, andimplantation, leads, loss, endothelial, integrity, elicitsan, inï¬ammatory, response, with, platelet, adhesion, leukocyte, recruitment, notwithstanding, an, overt, thrombosis, isextremely, rare, operating, room, sv, dissection, results, inblood, ï¬ow, disruption, vasa, vasorum, causes, adventitial, damage, hypoxia, vessel, wall, hyponutrition10, acuteperioperative, saphenous, vein, graft, failure, almost, always, aresult, graft, thrombosis, but, very, uncommonly, occursprior, graft, placement, surgical, factorslike, technicalanastomotic, failure, or, severe, disproportion, between, thetarget, vessel, graft, may, lead, thrombosis, butvessel, injury, hypercoagulability, are, among, potentialcauses, as, well11there, no, evident, inï¬ammatory, process, microscopy, inour, patient, but, even, if, an, inï¬ammatory, process, presentth, , vol, , no, 0cbilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, ale201preoperatively, our, patients, svs, inï¬ammatory, background, alone, could, not, explain, dramatic, intraoperativethrombosis, we, hypothesized, that, increased, thrombin, generation, prothrombotic, ï¬brin, clot, phenotype, were, responsiblefor, clinical, presentation, conversion, ï¬brinogen, ï¬brinfacilitated, by, thrombin, concluding, step, coagulation, ithas, been, shown, that, ï¬brin, clots, with, small, pores, betweentightly, packed, thin, ï¬brin, ï¬bers, are, relatively, lysis, resistant12such, clot, phenotype, has, been, evidenced, multiple, thromboticpathologies, such, as, myocardial, infarction6, ischemic, stroke13and, venous, thromboembolism4, prothrombotic, clotphenotype, reï¬ected, by, tendency, form, dense, ï¬brin, clotsresistant, lysis, has, been, previously, reported, patients, withinstent, thrombosis14, while, routine, thrombophilia, screeningresults, high, almost, , detection, rate, commonhypercoagulable, states15, there, are, prothrombotic, conditionsthat, escape, routine, diagnostic, approach, overall, microscopic, clot, appearance, prothrombotic, ï¬brin, properties, lead, tothe, discovery, two, mutations, our, patient, that, are, notroutinely, tested, during, thrombophilia, screening, namely, ï¬brinogen, 455g, , fxiii100g, , televated, ï¬brinogen, postulated, as, one, riskfactors, early, graft, failure, after, cabg1116, epidemiologicalstudies, have, established, that, elevated, ï¬brinogen, stronglyassociated, with, cardiovascular, diseases17, , metaanalysis, individual, records, , participants, from, prospective, studies, revealed, that, age, sexadjustedhazard, ratio, per, , gl, increase, usual, ï¬brinogen, level, forcoronary, heart, disease, , , conï¬dence, interval, [ci], while, stroke, hazard, ratio, as, high, as, 95ci, , risk, coronary, disease, progression, wasalso, linked, genetic, polymorphisms, ï¬brinogen, genede, maat, et, al, found, that, allele, ï¬brinogen, 455g, , awas, associated, with, more, severe, progression, coronarydisease, as, documented, angiographically18, gu, colleagues, metaanalysis, , studies, with, , patientsfound, that, allele, ï¬brinogen, 455g, , associated, with, susceptibility, coronary, disease, also, withischemic, stroke, odds, ratio, stroke, ¼, , [, ci, ]for, aa, ã¾, ga, vs, gg19, recent, study, patients, with, atrialï¬brillation, hu, colleagues, found, that, allele, ï¬brinogen, 455g, , risk, factor, cardioembolicstroke, probably, by, elevating, level, plasma, ï¬brinogen20, on, other, hand, , metaanalysis, studies, involving, , cases, , controls, fxiiival34leu, polymorphism, shown, be, associated, withrisk, myocardial, infarction21, fxiii, crucial, thrombusstabilization, changes, its, plasma, concentration, reï¬ectnonspeciï¬cally, extent, thrombosis, as, shown, by, li, et, alin, study, on, patients, with, cerebral, venous, thrombosis22interesting, associations, fxiii, val34leu, polymorphism, andthrombotic, disorders, have, been, reported, jung, et, al, reportedin, metaanalysis, , studies, that, fxiii, val34leu, polymorphism, associated, with, recurrent, pregnancy, loss23although, no, association, with, incidence, ischemicstroke, found, polymorphism24, apparentlywhen, stroke, occurs, val34leu, polymorphism, fxiiiaffects, severity, its, outcome25, furthermore, kreutzand, colleagues, suggested, , that, fxiii, val34leu, polymorphism, may, increase, risk, recurrent, mi, death, inpatients, with, angiographically, established, coronary, arterydisease26, , our, group, has, shown, study, patients, that, patients, undergoing, cabg, fxiii, leu34, alleleis, associated, with, decreased, ï¬brin, clot, permeability, andefï¬ciency, ï¬brinolysis27conclusionour, extensive, workup, showed, that, ï¬brinogen, haeiii, andfxiii, val34leu, polymorphisms, are, reï¬ected, reduced, clotpermeability, susceptibility, lysis, these, mutationslikely, contributed, intraoperative, saphenous, graft, thrombosis, further, studies, are, needed, elucidate, role, ofthese, polymorphisms, early, graft, failure, after, bypassgrafting, procedures, however, their, contributory, role, seemsevidentfundingthis, study, funded, by, grant, from, jagiellonianuniversity, medical, college, no, kzds007961, pmconï¬ict, interestnone, declaredreferences, bourassa, mg, fate, venous, grafts, past, present, thefuture, j, am, coll, cardiol, , roubos, n, rosenfeldt, fl, richards, sm, conyers, ra, davis, bbimproved, preservation, saphenous, vein, grafts, by, use, ofglyceryl, trinitrateverapamil, solution, during, harvesting, circulation, 19959209ii31ii36, mazur, p, sokoåowski, g, hubalewskadydejczyk, påaczkiewiczjankowska, e, undas, prothrombotic, alterations, plasma, ï¬brinclot, properties, thyroid, disorders, their, posttreatmentmodiï¬cations, thromb, res, , undas, zawilska, k, ciesladul, m, et, al, altered, ï¬brin, clotstructurefunction, patients, with, idiopathic, venous, thromboembolism, theirrelatives, blood, , natorska, j, marek, g, hlawaty, m, sadowski, j, tracz, w, undas, afibrin, presence, within, aortic, valves, patients, with, aorticstenosis, association, with, vivo, thrombin, generation, ï¬brinclot, properties, thromb, haemost, , undas, szuådrzynski, k, stepien, e, et, al, reduced, clot, permeability, susceptibility, lysis, patients, with, acute, coronarysyndrome, effects, inï¬ammation, oxidative, stress, atherosclerosis, , fitzgibbon, gm, kafka, hp, leach, aj, keon, wj, hooper, gd, burtonjr, coronary, bypass, graft, fate, patient, outcome, angiographicfollowup, , grafts, related, survival, reoperation, patients, during, , years, j, am, coll, cardiol, , kim, fy, marhefka, g, ruggiero, nj, adams, s, whellan, dj, saphenous, vein, graft, disease, review, pathophysiology, preventionand, treatment, cardiol, rev, , allaire, e, clowes, aw, endothelial, cell, injury, cardiovascularsurgery, intimal, hyperplastic, response, ann, thorac, surg, mcgeachie, jk, meagher, s, prendergast, fj, veintoartery, graftsthe, longterm, development, neointimal, hyperplasia, itsth, , vol, , no, 0ce202bilateral, saphenous, vein, thrombosis, during, cabg, mazur, et, alrelationship, vasa, vasorum, sympathetic, innervation, aust, nz, j, surg, , harskamp, re, lopes, rd, baisden, ce, de, winter, rj, alexander, jhsaphenous, vein, graft, failure, after, coronary, artery, bypass, surgerypathophysiology, management, future, directions, ann, surg, undas, fibrin, clot, properties, their, modulation, thrombotic, disorders, thromb, haemost, , undas, podolec, p, zawilska, k, et, al, altered, ï¬brin, clotstructurefunction, patients, with, cryptogenic, ischemic, strokestroke, , undas, zalewski, j, krochin, m, et, al, altered, plasma, ï¬brin, clotproperties, are, associated, with, instent, thrombosis, arteriosclerthromb, vasc, biol, , goldmanmazur, s, wypasek, e, karpiåski, m, stanisz, undas, ahigh, detection, rates, antithrombin, deï¬ciency, antiphospholipid, syndrome, outpatients, aged, over, , years, using, thestandardized, protocol, thrombophilia, screening, thromb, res, moor, e, hamsten, blombã¤ck, m, herzfeld, i, wiman, b, rydã©n, lhaemostatic, factors, inhibitors, coronary, artery, bypassgrafting, preoperative, alterations, relations, graft, occlusionthromb, haemost, , danesh, j, collins, r, appleby, p, peto, r, association, ï¬brinogen, creactive, protein, albumin, or, leukocyte, count, with, coronary, heartdisease, metaanalyses, prospective, studies, jama, , de, maat, mp, kastelein, jj, jukema, jw, et, al, 455ga, polymorphismof, betaï¬brinogen, gene, associated, with, progression, ofcoronary, atherosclerosis, symptomatic, men, proposed, role, foran, acutephase, reaction, pattern, ï¬brinogen, regress, grouparterioscler, thromb, vasc, biol, , gu, l, liu, w, yan, y, et, al, inï¬uence, ï¬brinogen455gapolymorphism, on, development, ischemic, stroke, coronaryheart, disease, thromb, res, , hu, x, wang, j, li, y, et, al, ï¬brinogen, gene, 455ga, polymorphism, associated, with, cardioembolic, stroke, atrial, ï¬brillationwith, low, cha2ds2vasc, score, sci, rep, , jung, jh, song, gg, kim, jh, seo, yh, choi, sj, association, factor, xiiival34leu, polymorphism, coronary, artery, disease, metaanalysis, cardiol, j, , li, b, heldner, mr, arnold, m, et, al, coagulation, factor, xiiiin, cerebral, venous, thrombosis, th, , , e227e229, jung, jh, kim, jh, song, gg, choi, sj, association, f13a1val34leu, polymorphism, recurrent, pregnancy, loss, metaanalysis, eur, j, obstet, gynecol, reprod, biol, , shemirani, ah, pongrã¡cz, e, antalï¬, b, adã¡ny, r, muszbek, l, factorxiii, subunit, val34leu, polymorphism, patients, sufferingatherothrombotic, ischemic, stroke, thromb, res, , shemirani, ah, antalï¬, b, pongrã¡cz, e, mezei, za, bereczky, z, csiki, zfactor, xiiia, subunit, val34leu, polymorphism, fatal, atherothrombotic, ischemic, stroke, blood, coagul, fibrinolysis, , kreutz, rp, bitar, owens, j, et, al, factor, xiii, val34leu, polymorphism, recurrent, myocardialinfarction, patients, withcoronary, artery, disease, j, thromb, thrombolysis, , stepieå, e, plicner, d, kapelak, b, wypasek, e, sadowski, j, undasa, factor, xiii, val34leu, polymorphism, as, modulator, ï¬brinclot, permeability, resistance, lysis, patients, withsevere, coronary, artery, disease, kardiol, pol, 2009678ath, , vol, , no, 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |(224581,[0,1,2,3,4,5,6,7,8,9,10,11,12,13,15,16,17,18,19,20,22,23,24,26,28,29,30,33,34,36,37,39,40,42,44,46,47,48,49,50,51,52,53,54,57,58,59,61,62,63,64,65,67,68,69,70,71,72,74,75,76,77,79,80,81,82,85,87,88,90,92,95,98,99,100,103,104,105,107,109,111,112,115,118,122,123,124,128,129,130,131,132,133,134,136,137,140,143,147,149,151,153,155,158,159,160,161,163,164,165,167,168,169,174,176,179,180,181,184,185,188,190,191,198,199,200,202,203,205,207,209,213,217,218,223,226,227,235,236,237,241,242,243,245,247,248,249,254,255,261,263,264,266,267,270,275,277,279,283,284,286,289,290,292,303,305,313,322,323,328,335,337,343,344,346,349,350,356,358,370,373,374,378,382,383,387,388,390,394,397,398,402,406,409,410,411,412,413,416,418,427,428,429,430,432,433,435,436,440,441,447,448,452,453,462,470,473,475,480,481,483,486,492,503,506,525,530,534,541,542,549,556,557,565,566,567,568,569,570,572,573,578,579,589,595,597,600,601,606,608,613,622,625,627,633,638,639,641,642,650,652,658,662,679,686,688,698,700,704,708,711,716,739,743,746,748,749,762,767,769,772,778,784,787,792,801,803,805,811,814,816,831,839,849,857,862,881,882,885,887,889,890,893,894,898,903,916,924,927,932,933,935,942,943,944,947,956,961,964,972,976,978,981,988,989,1017,1026,1027,1039,1044,1046,1048,1049,1057,1061,1066,1076,1081,1086,1087,1089,1091,1093,1095,1099,1101,1117,1130,1131,1133,1142,1149,1151,1154,1159,1163,1177,1184,1190,1197,1198,1220,1231,1239,1253,1254,1274,1299,1302,1306,1333,1344,1347,1363,1364,1366,1371,1384,1385,1386,1406,1417,1425,1437,1444,1451,1454,1493,1510,1512,1519,1530,1536,1554,1560,1562,1563,1567,1573,1582,1585,1588,1596,1598,1610,1615,1620,1625,1628,1645,1646,1649,1654,1657,1660,1666,1670,1676,1679,1682,1711,1718,1731,1743,1771,1777,1789,1792,1794,1806,1809,1822,1825,1828,1829,1830,1848,1852,1869,1919,1933,1937,1973,1975,1979,1984,1990,2018,2019,2021,2039,2040,2065,2071,2074,2111,2114,2119,2142,2156,2168,2178,2185,2203,2207,2211,2221,2231,2252,2255,2272,2277,2300,2313,2330,2331,2340,2341,2349,2365,2369,2370,2387,2403,2438,2445,2475,2496,2508,2539,2544,2564,2570,2593,2595,2609,2624,2653,2658,2669,2676,2677,2691,2695,2697,2734,2738,2760,2774,2779,2786,2790,2809,2821,2840,2842,2869,2871,2883,2884,2910,2913,2955,2957,2959,2964,2995,3061,3065,3066,3092,3146,3148,3173,3174,3182,3186,3188,3245,3256,3269,3270,3274,3280,3290,3294,3308,3325,3330,3334,3344,3377,3385,3393,3418,3438,3454,3473,3487,3492,3494,3529,3545,3549,3555,3567,3586,3600,3641,3678,3686,3695,3731,3754,3799,3814,3863,3865,3916,3935,3941,3942,3948,3949,4004,4010,4045,4052,4055,4057,4078,4107,4110,4124,4158,4162,4181,4183,4219,4233,4251,4259,4285,4337,4356,4402,4453,4459,4497,4500,4544,4553,4556,4590,4608,4609,4655,4663,4667,4693,4738,4837,4916,4948,4963,4967,4976,4978,5068,5104,5111,5131,5199,5255,5282,5287,5302,5318,5339,5341,5344,5368,5457,5483,5487,5553,5647,5652,5692,5701,5767,5792,5840,5848,5862,5880,5881,5944,5950,6026,6038,6039,6086,6090,6123,6173,6294,6357,6454,6472,6473,6605,6654,6753,6790,6801,6812,6873,6921,6990,7057,7134,7138,7210,7250,7257,7261,7342,7367,7388,7413,7490,7516,7520,7532,7548,7655,7702,7733,7741,7872,7885,7984,8298,8313,8346,8349,8489,8559,8560,8670,8701,8747,8828,8889,8918,8964,9057,9058,9073,9178,9186,9196,9238,9372,9565,9581,9794,9980,9990,10001,10100,10116,10151,10203,10244,10448,10503,10504,10715,10869,10895,10916,10934,10939,11036,11224,11279,11284,11351,11410,11565,11779,11788,12142,12221,12402,12409,12418,12432,12447,12558,12670,12739,12748,12777,12778,12900,12988,13048,13134,13245,13249,13355,13404,13593,13710,13751,13842,13977,14299,14397,14408,14479,14598,14936,14952,15114,15200,15233,15234,15293,15342,15359,15638,15848,16036,16284,16564,16616,16640,16797,16895,16913,16980,17021,17194,17320,17473,17515,17636,17812,17840,17851,17996,18031,18150,19299,19428,19462,19472,19473,19707,20105,20142,20415,20434,20446,21264,21272,21319,21344,21554,21582,21648,21711,21868,21978,22171,22187,22528,22767,22961,23735,24091,24501,24733,24747,25056,25145,25175,25186,25327,25940,25977,26232,26632,26777,27570,27646,27717,27848,27849,28104,28192,28409,28466,28618,28797,28903,28912,29802,30075,30137,30257,31053,31080,31237,31440,32154,32176,32549,34011,34603,34635,34680,34779,34861,34900,34932,35051,35122,35663,35752,35979,36359,37561,37626,37678,38125,38407,38538,39403,39613,39747,39814,40372,40828,41093,41378,41791,41886,41907,42350,42615,42856,44989,45638,46225,46267,46910,47274,47433,48088,48281,48776,49186,50093,51929,52206,52479,52838,52920,53047,53302,53660,53974,54731,55170,56250,56896,57368,58279,58532,58958,58962,59196,59586,59781,60234,61208,61993,62095,62284,62305,62360,63569,63973,64429,64964,65054,65825,65963,66181,66546,66553,66698,68036,68522,68951,69138,69313,70305,70830,71118,71160,71400,71536,71593,71971,73553,73634,74052,74239,74792,79685,80794,80954,81806,81862,82593,82936,83199,83855,83892,84145,84341,84669,84711,84972,85714,85850,86702,86846,86880,86920,87225,87672,87947,88608,88920,89569,89877,90688,90771,91517,91622,91656,92244,92316,92641,93332,93535,94035,94058,94347,94380,95227,96407,97276,97314,97984,98888,99241,100603,101327,101381,102536,102985,103057,103506,104082,104693,106085,106117,106574,107705,108059,108280,109388,109398,110307,110472,110574,110828,110888,111151,111235,111449,111624,111767,111882,112278,112679,112857,112989,113703,113869,113958,114006,114923,115228,115309,115619,115710,116085,116847,117753,118655,118945,118987,119233,119632,119769,120360,120441,122403,122585,122748,123426,123531,123685,124000,124849,124964,124993,125032,125060,125504,126226,126408,126468,126614,127061,128000,128090,128779,129094,129689,129692,130512,131054,132237,132987,133658,134401,134718,135189,135244,135873,136319,136538,136552,136591,136649,136883,137934,138629,138979,139440,139459,139667,139923,141089,141752,142540,142604,142819,143141,143509,143538,143878,144613,145939,146537,147021,147134,147477,147996,148772,148860,149104,149378,150010,151012,151047,151080,151413,151425,151605,151606,152041,152248,152657,152716,152795,153030,153081,153110,153258,153416,153899,154364,154880,155607,155715,156130,156139,156281,157098,158091,158680,160019,160298,160470,160691,161248,161290,161345,162135,162155,162220,162388,162695,163302,163497,163699,163791,164406,164715,165043,165202,165613,165714,166650,167105,167384,167445,167756,168228,168940,169287,169288,169954,170379,170393,171299,172601,174117,174340,174657,174884,175211,175315,175741,175746,176379,176402,176509,176763,176886,177455,177509,177545,178577,178591,178768,179117,179160,179612,180148,180486,181035,181523,181986,182033,182894,183066,183099,183407,183420,183747,183927,184388,184422,184641,185028,185268,186046,186185,186574,186776,186984,187042,187077,188451,188937,189379,189724,189943,190188,190343,190755,191181,191717,191961,192149,192177,192408,192803,193053,193227,193499,193836,194002,194152,194293,194636,194807,194880,195938,196113,196133,196246,197095,197445,198775,199701,199742,200084,200506,201379,201732,202900,202991,203234,203818,204197,204398,204519,205760,205962,206358,206634,207120,207132,207254,207544,208024,208461,208993,209203,209643,209757,210146,210767],[102.0,42.0,15.0,12.0,12.0,16.0,2.0,1.0,14.0,7.0,16.0,11.0,12.0,1.0,3.0,21.0,2.0,6.0,8.0,5.0,2.0,1.0,3.0,6.0,1.0,3.0,3.0,1.0,13.0,1.0,1.0,3.0,7.0,4.0,17.0,2.0,6.0,10.0,2.0,1.0,1.0,17.0,2.0,5.0,2.0,1.0,5.0,2.0,3.0,5.0,8.0,4.0,3.0,8.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,6.0,1.0,2.0,3.0,1.0,1.0,4.0,2.0,1.0,2.0,1.0,4.0,3.0,3.0,2.0,4.0,11.0,1.0,4.0,2.0,2.0,4.0,1.0,3.0,4.0,2.0,6.0,1.0,2.0,2.0,1.0,10.0,14.0,11.0,2.0,1.0,2.0,1.0,2.0,2.0,3.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,3.0,8.0,1.0,1.0,3.0,3.0,4.0,3.0,3.0,5.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,8.0,1.0,1.0,1.0,3.0,2.0,1.0,2.0,2.0,4.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,5.0,3.0,3.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,3.0,3.0,1.0,4.0,1.0,5.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,4.0,1.0,5.0,2.0,4.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,2.0,1.0,6.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,3.0,2.0,3.0,1.0,1.0,3.0,1.0,2.0,1.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,7.0,3.0,1.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,4.0,2.0,2.0,1.0,1.0,3.0,4.0,1.0,3.0,1.0,6.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,2.0,4.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,6.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,12.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,3.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,7.0,4.0,1.0,1.0,1.0,5.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,3.0,2.0,2.0,2.0,8.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,11.0,2.0,1.0,1.0,1.0,3.0,4.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,2.0,6.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,14.0,1.0,1.0,1.0,1.0,1.0,1.0,12.0,9.0,1.0,7.0,2.0,1.0,2.0,1.0,1.0,2.0,3.0,1.0,3.0,1.0,1.0,21.0,2.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,16.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,2.0,1.0,1.0,2.0,2.0,5.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,17.0,1.0,2.0,2.0,5.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,21.0,1.0,1.0,1.0,1.0,16.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,8.0,1.0,2.0,4.0,1.0,1.0,19.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,2.0,11.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,11.0,11.0,1.0,5.0,1.0,2.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,5.0,6.0,1.0,1.0,1.0,1.0,1.0,6.0,6.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,3.0,2.0,1.0,3.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,2.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n",
      "|[, solitary, plasmacytoma, sp, of, the, skull, is, an, uncommon, clinical, entity, that, is, characterized, by, alocalized, proliferation, of, neoplastic, monoclonal, plasma, cells, this, case, report, describes, a50yearold, male, that, presented, with, a, headache, and, an, exophytic, soft, mass, on, the, occiputthe, diagnosis, of, sp, was, based, on, the, pathological, results, and, imaging, examinations, the, patientunderwent, occipital, craniotomy, skull, reconstruction, and, lower, trapezius, myocutaneous, flapltmf, transplantation, under, general, anaesthesia, the, tumour, was, capsulized, and, extended, tothe, subcutaneous, and, the, subdural, space, through, the, dura, mater, with, skull, defects, the, neoplasm, of, the, occipital, bone, involved, large, areas, of, scalp, and, subcutaneous, tissue, which, resultedin, a, large, postoperative, scalp, defect, that, was, repaired, using, ltmf, transplantation, all, of, thetumour, was, removed, and, the, transplanted, flap, grew, well, followup, at, , months, identified, anaggressive, mass, lesion, on, the, right, frontallobe, the, patient, received, six, cycles, of, the, padchemotherapy, regimen, bortezomib, doxorubicin, and, dexamethasone, and, the, lesion, was, significantly, reduced, this, case, demonstrates, that, ltmf, is, an, alternative, approach, for, the, repair, ofscalp, and, subcutaneous, soft, tissue, defects, caused, by, the, excision, of, a, large, malignant, tumourof, the, occipital, region, chemotherapy, is, the, choice, of, treatment, for, neoplastic, recurrencekeywordssolitary, plasmacytoma, lower, trapezius, myocutaneous, flap, scalp, reconstruction, plasma, cellsdate, received, , july, , accepted, , march, 1department, of, neurosurgery, hunan, cancer, hospitaland, the, affiliated, cancer, hospital, of, xiangya, school, ofmedicine, central, south, university, changsha, hunanprovince, china2department, of, head, and, neck, surgery, hunan, cancerhospital, and, the, affiliated, cancer, hospital, of, xiangyaschool, of, medicine, central, south, university, changshahunan, province, chinacorresponding, authorslei, wang, and, zhengwen, he, department, ofneurosurgery, hunan, cancer, hospital, and, the, affiliatedcancer, hospital, of, xiangya, school, of, medicine, centralsouth, university, , tongzipo, road, yuelu, districtchangsha, , hunan, province, chinaemails, wangsengyi163com, hezhw2001163comcreative, commons, non, commercial, cc, bync, this, , is, distributed, under, the, terms, of, the, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, and, distribution, of, the, work, without, further, permission, provided, the, original, work, is, attributedas, specified, on, the, sage, and, , , access, pages, ussagepubcomenusnam, accessatsage, 0cintroductionsolitary, plasmacytoma, sp, is, the, pathological, manifestation, of, the, proliferationof, monoclonal, plasma, cells, and, an, spthat, originates, in, bone, tissue, is, called, a, solitary, plasmacytoma, of, bone, spb1, bonedestruction, may, occur, in, any, osseous, location, but, the, most, common, sites, are, thepelvis, spine, femur, humerus, and, ribs2an, spb, of, the, skull, is, rare, and, a, hugegrowth, in, the, occipital, bone, is, rarely, mentioned, in, the, literature34, complete, tumourremoval, is, the, ï¬rst, and, best, approach, forpatients, with, no, lesions, in, other, parts, of, thebody3, this, current, case, report, describes, arare, case, of, spb, of, the, occipital, bone, withscalp, involvement, in, which, the, patient, underwent, radical, resection, and, reconstruction, ofjournal, of, international, medical, researchthe, large, scalp, defects, through, lower, trapeziusmyocutaneous, ï¬ap, ltmf, transplantationcase, reporta, 50yearold, male, patient, presented, inoctober, , to, the, department, ofneurosurgery, hunan, cancer, hospitaland, the, afï¬liated, cancer, hospital, ofxiangya, school, of, medicine, centralsouth, university, changsha, hunanprovince, china, with, a, headache, and, an, exophytic, mass, on, the, occiputatheexaminationphysicalshowed, no, ï¬ndings, computed, tomographyct, showed, a, large, mass, with, homogeneousenhancement, on, the, occiput, compressing, thebilateral, occipital, lobe, b, and, theneurologicalfigure, , preoperative, imaging, examinations, a, preoperative, appearance, of, the, tumour, b, preoperativeenhanced, computed, tomography, scan, c, preoperative, enhanced, magnetic, resonance, imaging, mrid, preoperative, enhanced, mri, scan, , axial, view, e, preoperative, digital, subtraction, angiographythe, colour, version, of, this, figure, is, available, at, httpimrsagepubcom, 0cwang, et, alresonanceandbone, window, revealed, a, solitary, osteolyticlesion, involving, the, whole, entire, of, the, occipital, bone, magneticimagingmri, showed, an, intra, and, extracerebralexpansile, osseous, lesion, 02, , mm, themass, was, mostly, isointense, with, the, brainparenchyma, on, both, t1, and, t2weightedimagesenhancedfigures, 1c, and, 1d, digital, subtraction, angiography, dsa, demonstrated, that, all, of, thetumour, had, hypervascularity, that, was, supplied, from, the, occipital, artery, in, order, todecrease, bleeding, volume, and, shorten, thesurgery, time, the, feeding, blood, vessel, wasembolized, during, dsa, ehomogeneouslythe, patient, underwent, occipital, craniotomy, skull, reconstruction, and, ltmf, transplantation, under, general, anaesthesia, thetumour, was, capsulized, and, extended, tothe, subcutaneous, and, the, subdural, spacethrough, the, dura, mater, with, skull, defectsgrossly, the, tumour, had, a, ï¬shmeat, likeappearance, mixed, with, hard, cartilage, andbroken, bone, a, the, tumour, had, arich, blood, supply, and, despite, embolizationof, the, main, blood, supply, artery, duringdsa, before, surgery, there, was, a, lot, ofblood, loss, during, the, operation, thetumour, mass, underwent, extended, resectionincluding, the, marginal, bone, and, involvedscalp, forming, an, 02, , cm, bone, windowand, a, 02, , cm, scalp, defect, the, skulldefect, was, reconstructed, using, titaniummesh, and, the, scalp, defect, was, transplantedusing, ltmf, the, trapezius, and, the, skinisland, 02, , cm, and, the, supplying, vesselsof, the, transverse, cervical, artery, and, thedorsal, scapular, artery, were, marked, on, theskin, b, the, island, ï¬ap, was, excisedand, its, muscle, pedicle, dissected, up, to, thefigure, , perioperative, procedures, and, imaging, examinations, a, the, tumour, was, fishmeat, soft, tan, inappearance, b, the, trapezius, and, the, skin, island, and, the, supplying, vessels, of, the, transverse, cervicalartery, and, the, dorsal, scapular, artery, marked, out, on, the, skin, c, the, island, flap, and, its, muscle, pedicle, wereexcised, d, the, flap, was, set, into, the, defect, with, a, wellperfused, distal, end, e, the, stiches, were, removedafter, surgery, f, postoperative, enhanced, magnetic, resonance, imaging, mri, scan, , sagittal, viewg, postoperative, enhanced, mri, scan, , axial, view, the, colour, version, of, this, figure, is, available, at, httpimrsagepubcom, 0crotation, point, at, the, medialsuperior, edgeof, the, scapula, c, the, ltmf, wasrotated, vertically, into, the, occipital, scalpdefect, through, the, neck, posterior, subcutaneous, tunnel, d, two, weeks, afterthe, operation, the, transplanted, skin, islandwas, vital, and, wound, healing, undisturbedfigurethattheremovedtumour, wasfigures, 2f, and, 2g2e, mricompletelyindicatedhaematoxylin, and, eosin, staining, of, thetumour, showed, the, presence, of, atypicalplasma, cells, with, typical, eccentric, roundnucleistainingshowed, the, following, staining, patterncytokeratinp, , epithelial, membrane, antigen, , melana, , cd38, ¾, cd138immunohistochemicaljournal, of, international, medical, research¾, cd20, , kappa, ¾, lambda, ¾glial, ï¬brillary, acidic, protein, , s100cd68, ¾, thyroid, transcription, factor1, vim, , cd3, , and, ki67, figure, the, patient, refused, further, radiotherapyfor, ï¬nancial, reasons, after, a, followupperiod, of, around, , months, he, was, symptom, free, and, had, no, clinical, evidence, ofdisease, at, the, 5month, followup, visitmri, revealed, no, eld, recurrence, butan, aggressive, mass, lesion, with, enhancementwaslobefigures, 4a, and, 4b, chemotherapy, padregimen, bortezomib, pegylated, liposomaldoxorubicindexamethasone, wasadministered, from, , april, , in, thefound, on, thefrontalrightandfigure, , representative, photomicrographs, of, the, tumour, a, haematoxylin, and, eosin, stained, sectionshowing, diffuse, sheets, of, plasma, cells, b, immunohistochemical, staining, for, cd138, showing, strong, positivity, in, the, tumour, cells, c, immunohistochemical, staining, for, cd38, showing, strong, positivity, in, thetumour, cells, d, the, positive, expression, of, ki67, was, , the, colour, version, of, this, figure, is, available, athttpimrsagepubcom, scale, bar, , mm, 0cwang, et, alfigure, , magnetic, resonance, imaging, scans, of, the, patient, during, followup, a, , b, at, the, 5month, followup, visit, showing, no, recurrence, in, situ, but, an, aggressive, mass, lesion, with, enhancement, on, the, right, frontallobe, c, , d, after, six, consecutive, cycles, of, chemotherapy, showing, no, recurrence, in, situ, and, the, lesion, onthe, right, frontal, lobe, was, significantly, reduceddepartmentof, haematology, hunancancer, hospital, and, the, afï¬liated, cancerhospital, of, xiangya, school, of, medicinecentralsouth, university, changshahunan, province, china, after, six, consecutive, cycles, of, chemotherapy, the, lesion, on, hisright, frontal, lobe, was, signiï¬cantly, reducedfigures, 4c, and, 4d, postoperative, reviewafter, , months, showed, no, tumour, recurrence, in, situ, of, the, original, spbas, this, was, a, case, report, the, institutionalreview, board, of, hunan, cancer, hospitalwaived, the, need, for, ethical, approval, thepatient, provided, written, informed, consentfor, publication, that, was, approved, by, theinstitutional, review, board, and, the, detailsof, the, patient, have, been, anonymizeddiscussionhuge, intra, and, extracranial, sps, of, theoccipital, bone, are, very, rare, and, few, caseshave, been, reported34, spb, is, characterizedby, the, presence, of, a, solitary, lytic, lesion, dueto, monoclonal, plasma, cell, ltration, withsofttissue, extension5, spbsor, withoutaccount, for, , of, all, sp, cases, and, theyoccur, primarily, in, red, marrowcontainingbones6, plasma, cells, are, highly, sensitive, toradiation78, radiation, therapy, remains, the, 0cjournal, of, international, medical, researchtreatment, of, choice, for, patients, after, surgery, according, to, recommendations, froma, european, expert, panel, a, total, fractionated, dose, of, , gy, should, be, given, anda, margin, of, atleast, , cm, should, beemployed6, in, this, current, caseit, wasunfortunate, that, the, patient, refused, radiationreasonsa, review, was, performed, , months, afterthe, operation, and, a, new, mass, was, foundon, the, right, frontal, lobe, after, six, cyclesof, chemotherapy, the, tumour, had, reducedin, size, signiï¬cantly, which, suggests, that, chemotherapy, has, a, positive, impact, on, thegrowth, of, recurrent, tumourseconomictherapyforthe, imaging, characteristics, of, spb, in, theskull, are, complex, and, can, easily, lead, tomisdiagnosis, enhanced, ct, scanning, combined, with, observation, of, the, bone, windoware, credible, means, by, which, to, diagnosespb, and, they, could, provide, more, information, about, osteolytic, lesions, in, the, currentcase, the, mri, examination, allowed, for, theidentiï¬cation, of, the, location, size, and, shapeof, the, tumour, as, well, as, its, relationship, tothe, surrounding, structures, in, our, opinionpreoperative, dsa, is, necessary, for, the, identiï¬cation, of, the, blood, supply, vessels, and, tofacilitate, vessel, embolizationduringthetumourrecurrencecurrent, operationthetumour, was, found, to, involve, the, scalpand, subcutaneous, tissue, to, reduce, theprobability, oftheinvolved, scalp, underwent, an, extendedresection, ltmf, was, used, to, facilitateoccipital, scalp, reconstruction, ltmf, provides, available, muscle, compartments, transferred, on, a, reliable, vascular, pedicle, to, thedorsal, suprascapular, and, neck, regions9the, beneï¬ts, of, ltmf, include, well, vascularized, tissue, ease, of, harvest, and, the, provision, of, a, large, ï¬ap, located, far, enoughaway, from, the, damaged, area10, the, mainblood, supply, to, the, ltmf, originates, fromthe, transverse, cervical, artery, and, the, dorsalscapular, artery1112, this, method, couldsolve, the, problem, ofinsufï¬cient, bloodsupply, caused, by, titanium, plate, implantation, in, additionthe, musculocutaneouspedicle, could, ï¬ll, the, subcutaneous, cavitycreated, by, the, huge, tumourresectionpreventing, occipitalia, scalp, hydrops, andsecondary, infection, ltmf, is, an, alternative, approach, for, the, repair, of, scalp, andsubcutaneous, soft, tissue, defects, caused, byexcision, of, a, malignanttheoccipital, regiontumour, ofauthors, contributionslw, studied, the, case, collected, the, referencesand, wrote, the, paper, zh, designed, the, reportand, wrote, the, paper, hc, and, hz, wrote, thepaper, xp, analysed, the, data, nr, served, as, theï¬rst, chief, during, surgery, and, wrote, the, paperall, authorsread, and, approved, the, ï¬nalmanuscriptdeclaration, of, conflicting, interestthe, authors, declare, that, there, are, no, conï¬icts, ofinterestfundingthis, project, was, supported, by, grants, from, thescientiï¬c, research, project, of, hunan, provincialhealth, commission, no20200709, the, hunanprovincial, natural, science, foundation, of, chinano2019jj40182, and, the, sailing, programme, ofhunan, provincial, cancer, hospitalorcid000000021069orcid, idlei, wangreferences, sabattini, e, bacci, f, sagramoso, c, et, alwho, classiï¬cation, of, tumours, of, haematopoietic, and, lymphoid, tissues, in, , anoverview, pathologica, , , , gee, ed, and, sadovsky, r, multiple, myeloma, recognition, and, management, amfam, physician, , , , rizea, re, popescu, m, ghehit¸, 15a, klet, al, neurosurgical, rare, disease, solitary, 0cwang, et, alplasmacytoma, of, the, skull, , case, report, andliterature, review, rom, j, morphol, embryol, , , chang, my, shih, ly, dunn, p, et, al, solitaryplasmacytoma, of, bone, j, formos, med, assoc, , , weber, dm, solitary, bone, and, extramedullary, plasmacytoma, hematology, am, sochematol, educ, program, , , , caers, j, paiva, b, zamagni, e, et, aldiagnosis, treatment, and, response, assessment, in, solitary, plasmacytoma, updated, recommendations, from, a, european, expertpanel, j, hematol, oncol, , , , knobel, d, zouhair, a, tsang, rw, et, alprognostic, factors, in, solitary, plasmacytomaof, the, bone, a, multicenter, rare, cancernetwork, study, bmc, cancer, , , , liebross, rh, ha, cs, cox, jd, et, alsolitary, bone, plasmacytoma, outcome, andprognostic, factors, following, radiotherapyint, j, radiat, oncol, biol, phys, , , mohos, g, vass, g, kemeny, l, et, alextended, lowertrapezius, myocutaneousï¬ap, to, cover, a, deep, lateral, neck, defect, onirradiated, skin, a, new, application, j, plastsurg, hand, surg, , , , u, 15gurlu, k, ozc¸, elik, d, hu¨, thu¨, t, i, et, alextended, vertical, trapezius, myocutaneousï¬ap, in, head, and, neck, reconstruction, as, asalvage, procedure, plast, reconstr, surg, , , baek, sm, biller, hf, krespi, yp, et, al, thelower, trapezius, island, myocutaneous, ï¬apann, plast, surg, , , , netterville, jl, and, wood, de, the, lower, trapezius, ï¬ap, vascular, anatomy, and, surgicaltechnique, arch, otolaryngol, head, necksurg, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |[, solitary, plasmacytoma, sp, skull, uncommon, clinical, entity, characterized, alocalized, proliferation, neoplastic, monoclonal, plasma, cells, case, report, describes, a50yearold, male, presented, headache, exophytic, soft, mass, occiputthe, diagnosis, sp, based, pathological, results, imaging, examinations, patientunderwent, occipital, craniotomy, skull, reconstruction, lower, trapezius, myocutaneous, flapltmf, transplantation, general, anaesthesia, tumour, capsulized, extended, tothe, subcutaneous, subdural, space, dura, mater, skull, defects, neoplasm, occipital, bone, involved, large, areas, scalp, subcutaneous, tissue, resultedin, large, postoperative, scalp, defect, repaired, using, ltmf, transplantation, thetumour, removed, transplanted, flap, grew, well, followup, , months, identified, anaggressive, mass, lesion, right, frontallobe, patient, received, six, cycles, padchemotherapy, regimen, bortezomib, doxorubicin, dexamethasone, lesion, significantly, reduced, case, demonstrates, ltmf, alternative, approach, repair, ofscalp, subcutaneous, soft, tissue, defects, caused, excision, large, malignant, tumourof, occipital, region, chemotherapy, choice, treatment, neoplastic, recurrencekeywordssolitary, plasmacytoma, lower, trapezius, myocutaneous, flap, scalp, reconstruction, plasma, cellsdate, received, , july, , accepted, , march, 1department, neurosurgery, hunan, cancer, hospitaland, affiliated, cancer, hospital, xiangya, school, ofmedicine, central, south, university, changsha, hunanprovince, china2department, head, neck, surgery, hunan, cancerhospital, affiliated, cancer, hospital, xiangyaschool, medicine, central, south, university, changshahunan, province, chinacorresponding, authorslei, wang, zhengwen, department, ofneurosurgery, hunan, cancer, hospital, affiliatedcancer, hospital, xiangya, school, medicine, centralsouth, university, , tongzipo, road, yuelu, districtchangsha, , hunan, province, chinaemails, wangsengyi163com, hezhw2001163comcreative, commons, non, commercial, cc, bync, , distributed, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, permitsnoncommercial, use, reproduction, distribution, work, without, permission, provided, original, work, attributedas, specified, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cintroductionsolitary, plasmacytoma, sp, pathological, manifestation, proliferationof, monoclonal, plasma, cells, spthat, originates, bone, tissue, called, solitary, plasmacytoma, bone, spb1, bonedestruction, may, occur, osseous, location, common, sites, thepelvis, spine, femur, humerus, ribs2an, spb, skull, rare, hugegrowth, occipital, bone, rarely, mentioned, literature34, complete, tumourremoval, ï¬rst, best, approach, forpatients, lesions, parts, thebody3, current, case, report, describes, arare, case, spb, occipital, bone, withscalp, involvement, patient, underwent, radical, resection, reconstruction, ofjournal, international, medical, researchthe, large, scalp, defects, lower, trapeziusmyocutaneous, ï¬ap, ltmf, transplantationcase, reporta, 50yearold, male, patient, presented, inoctober, , department, ofneurosurgery, hunan, cancer, hospitaland, afï¬liated, cancer, hospital, ofxiangya, school, medicine, centralsouth, university, changsha, hunanprovince, china, headache, exophytic, mass, occiputatheexaminationphysicalshowed, ï¬ndings, computed, tomographyct, showed, large, mass, homogeneousenhancement, occiput, compressing, thebilateral, occipital, lobe, b, theneurologicalfigure, , preoperative, imaging, examinations, preoperative, appearance, tumour, b, preoperativeenhanced, computed, tomography, scan, c, preoperative, enhanced, magnetic, resonance, imaging, mrid, preoperative, enhanced, mri, scan, , axial, view, e, preoperative, digital, subtraction, angiographythe, colour, version, figure, available, httpimrsagepubcom, 0cwang, et, alresonanceandbone, window, revealed, solitary, osteolyticlesion, involving, whole, entire, occipital, bone, magneticimagingmri, showed, intra, extracerebralexpansile, osseous, lesion, 02, , mm, themass, mostly, isointense, brainparenchyma, t1, t2weightedimagesenhancedfigures, 1c, 1d, digital, subtraction, angiography, dsa, demonstrated, thetumour, hypervascularity, supplied, occipital, artery, order, todecrease, bleeding, volume, shorten, thesurgery, time, feeding, blood, vessel, wasembolized, dsa, ehomogeneouslythe, patient, underwent, occipital, craniotomy, skull, reconstruction, ltmf, transplantation, general, anaesthesia, thetumour, capsulized, extended, tothe, subcutaneous, subdural, spacethrough, dura, mater, skull, defectsgrossly, tumour, ï¬shmeat, likeappearance, mixed, hard, cartilage, andbroken, bone, tumour, arich, blood, supply, despite, embolizationof, main, blood, supply, artery, duringdsa, surgery, lot, ofblood, loss, operation, thetumour, mass, underwent, extended, resectionincluding, marginal, bone, involvedscalp, forming, 02, , cm, bone, windowand, 02, , cm, scalp, defect, skulldefect, reconstructed, using, titaniummesh, scalp, defect, transplantedusing, ltmf, trapezius, skinisland, 02, , cm, supplying, vesselsof, transverse, cervical, artery, thedorsal, scapular, artery, marked, theskin, b, island, ï¬ap, excisedand, muscle, pedicle, dissected, thefigure, , perioperative, procedures, imaging, examinations, tumour, fishmeat, soft, tan, inappearance, b, trapezius, skin, island, supplying, vessels, transverse, cervicalartery, dorsal, scapular, artery, marked, skin, c, island, flap, muscle, pedicle, wereexcised, d, flap, set, defect, wellperfused, distal, end, e, stiches, removedafter, surgery, f, postoperative, enhanced, magnetic, resonance, imaging, mri, scan, , sagittal, viewg, postoperative, enhanced, mri, scan, , axial, view, colour, version, figure, available, httpimrsagepubcom, 0crotation, point, medialsuperior, edgeof, scapula, c, ltmf, wasrotated, vertically, occipital, scalpdefect, neck, posterior, subcutaneous, tunnel, d, two, weeks, afterthe, operation, transplanted, skin, islandwas, vital, wound, healing, undisturbedfigurethattheremovedtumour, wasfigures, 2f, 2g2e, mricompletelyindicatedhaematoxylin, eosin, staining, thetumour, showed, presence, atypicalplasma, cells, typical, eccentric, roundnucleistainingshowed, following, staining, patterncytokeratinp, , epithelial, membrane, antigen, , melana, , cd38, ¾, cd138immunohistochemicaljournal, international, medical, research¾, cd20, , kappa, ¾, lambda, ¾glial, ï¬brillary, acidic, protein, , s100cd68, ¾, thyroid, transcription, factor1, vim, , cd3, , ki67, figure, patient, refused, radiotherapyfor, ï¬nancial, reasons, followupperiod, around, , months, symptom, free, clinical, evidence, ofdisease, 5month, followup, visitmri, revealed, eld, recurrence, butan, aggressive, mass, lesion, enhancementwaslobefigures, 4a, 4b, chemotherapy, padregimen, bortezomib, pegylated, liposomaldoxorubicindexamethasone, wasadministered, , april, , thefound, thefrontalrightandfigure, , representative, photomicrographs, tumour, haematoxylin, eosin, stained, sectionshowing, diffuse, sheets, plasma, cells, b, immunohistochemical, staining, cd138, showing, strong, positivity, tumour, cells, c, immunohistochemical, staining, cd38, showing, strong, positivity, thetumour, cells, d, positive, expression, ki67, , colour, version, figure, available, athttpimrsagepubcom, scale, bar, , mm, 0cwang, et, alfigure, , magnetic, resonance, imaging, scans, patient, followup, , b, 5month, followup, visit, showing, recurrence, situ, aggressive, mass, lesion, enhancement, right, frontallobe, c, , d, six, consecutive, cycles, chemotherapy, showing, recurrence, situ, lesion, onthe, right, frontal, lobe, significantly, reduceddepartmentof, haematology, hunancancer, hospital, afï¬liated, cancerhospital, xiangya, school, medicinecentralsouth, university, changshahunan, province, china, six, consecutive, cycles, chemotherapy, lesion, hisright, frontal, lobe, signiï¬cantly, reducedfigures, 4c, 4d, postoperative, reviewafter, , months, showed, tumour, recurrence, situ, original, spbas, case, report, institutionalreview, board, hunan, cancer, hospitalwaived, need, ethical, approval, thepatient, provided, written, informed, consentfor, publication, approved, theinstitutional, review, board, detailsof, patient, anonymizeddiscussionhuge, intra, extracranial, sps, theoccipital, bone, rare, caseshave, reported34, spb, characterizedby, presence, solitary, lytic, lesion, dueto, monoclonal, plasma, cell, ltration, withsofttissue, extension5, spbsor, withoutaccount, , sp, cases, theyoccur, primarily, red, marrowcontainingbones6, plasma, cells, highly, sensitive, toradiation78, radiation, therapy, remains, 0cjournal, international, medical, researchtreatment, choice, patients, surgery, according, recommendations, froma, european, expert, panel, total, fractionated, dose, , gy, given, anda, margin, atleast, , cm, beemployed6, current, caseit, wasunfortunate, patient, refused, radiationreasonsa, review, performed, , months, afterthe, operation, new, mass, foundon, right, frontal, lobe, six, cyclesof, chemotherapy, tumour, reducedin, size, signiï¬cantly, suggests, chemotherapy, positive, impact, thegrowth, recurrent, tumourseconomictherapyforthe, imaging, characteristics, spb, theskull, complex, easily, lead, tomisdiagnosis, enhanced, ct, scanning, combined, observation, bone, windoware, credible, means, diagnosespb, provide, information, osteolytic, lesions, currentcase, mri, examination, allowed, theidentiï¬cation, location, size, shapeof, tumour, well, relationship, tothe, surrounding, structures, opinionpreoperative, dsa, necessary, identiï¬cation, blood, supply, vessels, tofacilitate, vessel, embolizationduringthetumourrecurrencecurrent, operationthetumour, found, involve, scalpand, subcutaneous, tissue, reduce, theprobability, oftheinvolved, scalp, underwent, extendedresection, ltmf, used, facilitateoccipital, scalp, reconstruction, ltmf, provides, available, muscle, compartments, transferred, reliable, vascular, pedicle, thedorsal, suprascapular, neck, regions9the, beneï¬ts, ltmf, include, well, vascularized, tissue, ease, harvest, provision, large, ï¬ap, located, far, enoughaway, damaged, area10, mainblood, supply, ltmf, originates, fromthe, transverse, cervical, artery, dorsalscapular, artery1112, method, couldsolve, problem, ofinsufï¬cient, bloodsupply, caused, titanium, plate, implantation, additionthe, musculocutaneouspedicle, ï¬ll, subcutaneous, cavitycreated, huge, tumourresectionpreventing, occipitalia, scalp, hydrops, andsecondary, infection, ltmf, alternative, approach, repair, scalp, andsubcutaneous, soft, tissue, defects, caused, byexcision, malignanttheoccipital, regiontumour, ofauthors, contributionslw, studied, case, collected, referencesand, wrote, paper, zh, designed, reportand, wrote, paper, hc, hz, wrote, thepaper, xp, analysed, data, nr, served, theï¬rst, chief, surgery, wrote, paperall, authorsread, approved, ï¬nalmanuscriptdeclaration, conflicting, interestthe, authors, declare, conï¬icts, ofinterestfundingthis, project, supported, grants, thescientiï¬c, research, project, hunan, provincialhealth, commission, no20200709, hunanprovincial, natural, science, foundation, chinano2019jj40182, sailing, programme, ofhunan, provincial, cancer, hospitalorcid000000021069orcid, idlei, wangreferences, sabattini, e, bacci, f, sagramoso, c, et, alwho, classiï¬cation, tumours, haematopoietic, lymphoid, tissues, , anoverview, pathologica, , , , gee, ed, sadovsky, r, multiple, myeloma, recognition, management, amfam, physician, , , , rizea, re, popescu, m, ghehit¸, 15a, klet, al, neurosurgical, rare, disease, solitary, 0cwang, et, alplasmacytoma, skull, , case, report, andliterature, review, rom, j, morphol, embryol, , , chang, shih, ly, dunn, p, et, al, solitaryplasmacytoma, bone, j, formos, med, assoc, , , weber, dm, solitary, bone, extramedullary, plasmacytoma, hematology, sochematol, educ, program, , , , caers, j, paiva, b, zamagni, e, et, aldiagnosis, treatment, response, assessment, solitary, plasmacytoma, updated, recommendations, european, expertpanel, j, hematol, oncol, , , , knobel, d, zouhair, tsang, rw, et, alprognostic, factors, solitary, plasmacytomaof, bone, multicenter, rare, cancernetwork, study, bmc, cancer, , , , liebross, rh, ha, cs, cox, jd, et, alsolitary, bone, plasmacytoma, outcome, andprognostic, factors, following, radiotherapyint, j, radiat, oncol, biol, phys, , , mohos, g, vass, g, kemeny, l, et, alextended, lowertrapezius, myocutaneousï¬ap, cover, deep, lateral, neck, defect, onirradiated, skin, new, application, j, plastsurg, hand, surg, , , , u, 15gurlu, k, ozc¸, elik, d, hu¨, thu¨, et, alextended, vertical, trapezius, myocutaneousï¬ap, head, neck, reconstruction, asalvage, procedure, plast, reconstr, surg, , , baek, sm, biller, hf, krespi, yp, et, al, thelower, trapezius, island, myocutaneous, ï¬apann, plast, surg, , , , netterville, jl, wood, de, lower, trapezius, ï¬ap, vascular, anatomy, surgicaltechnique, arch, otolaryngol, head, necksurg, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |[, solitary, plasmacytoma, sp, skull, an, uncommon, clinical, entity, that, characterized, by, alocalized, proliferation, neoplastic, monoclonal, plasma, cells, case, report, describes, a50yearold, male, that, presented, with, headache, an, exophytic, soft, mass, on, occiputthe, diagnosis, sp, based, on, pathological, results, imaging, examinations, patientunderwent, occipital, craniotomy, skull, reconstruction, lower, trapezius, myocutaneous, flapltmf, transplantation, under, general, anaesthesia, tumour, capsulized, extended, tothe, subcutaneous, subdural, space, through, dura, mater, with, skull, defects, neoplasm, occipital, bone, involved, large, areas, scalp, subcutaneous, tissue, which, resultedin, large, postoperative, scalp, defect, that, repaired, using, ltmf, transplantation, all, thetumour, removed, transplanted, flap, grew, well, followup, at, , months, identified, anaggressive, mass, lesion, on, right, frontallobe, patient, received, six, cycles, padchemotherapy, regimen, bortezomib, doxorubicin, dexamethasone, lesion, significantly, reduced, case, demonstrates, that, ltmf, an, alternative, approach, repair, ofscalp, subcutaneous, soft, tissue, defects, caused, by, excision, large, malignant, tumourof, occipital, region, chemotherapy, choice, treatment, neoplastic, recurrencekeywordssolitary, plasmacytoma, lower, trapezius, myocutaneous, flap, scalp, reconstruction, plasma, cellsdate, received, , july, , accepted, , march, 1department, neurosurgery, hunan, cancer, hospitaland, affiliated, cancer, hospital, xiangya, school, ofmedicine, central, south, university, changsha, hunanprovince, china2department, head, neck, surgery, hunan, cancerhospital, affiliated, cancer, hospital, xiangyaschool, medicine, central, south, university, changshahunan, province, chinacorresponding, authorslei, wang, zhengwen, he, department, ofneurosurgery, hunan, cancer, hospital, affiliatedcancer, hospital, xiangya, school, medicine, centralsouth, university, , tongzipo, road, yuelu, districtchangsha, , hunan, province, chinaemails, wangsengyi163com, hezhw2001163comcreative, commons, non, commercial, cc, bync, , distributed, under, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, distribution, work, without, further, permission, provided, original, work, attributedas, specified, on, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cintroductionsolitary, plasmacytoma, sp, pathological, manifestation, proliferationof, monoclonal, plasma, cells, an, spthat, originates, bone, tissue, called, solitary, plasmacytoma, bone, spb1, bonedestruction, may, occur, any, osseous, location, but, most, common, sites, are, thepelvis, spine, femur, humerus, ribs2an, spb, skull, rare, hugegrowth, occipital, bone, rarely, mentioned, literature34, complete, tumourremoval, ï¬rst, best, approach, forpatients, with, no, lesions, other, parts, thebody3, current, case, report, describes, arare, case, spb, occipital, bone, withscalp, involvement, which, patient, underwent, radical, resection, reconstruction, ofjournal, international, medical, researchthe, large, scalp, defects, through, lower, trapeziusmyocutaneous, ï¬ap, ltmf, transplantationcase, reporta, 50yearold, male, patient, presented, inoctober, , department, ofneurosurgery, hunan, cancer, hospitaland, afï¬liated, cancer, hospital, ofxiangya, school, medicine, centralsouth, university, changsha, hunanprovince, china, with, headache, an, exophytic, mass, on, occiputatheexaminationphysicalshowed, no, ï¬ndings, computed, tomographyct, showed, large, mass, with, homogeneousenhancement, on, occiput, compressing, thebilateral, occipital, lobe, b, theneurologicalfigure, , preoperative, imaging, examinations, preoperative, appearance, tumour, b, preoperativeenhanced, computed, tomography, scan, c, preoperative, enhanced, magnetic, resonance, imaging, mrid, preoperative, enhanced, mri, scan, , axial, view, e, preoperative, digital, subtraction, angiographythe, colour, version, figure, available, at, httpimrsagepubcom, 0cwang, et, alresonanceandbone, window, revealed, solitary, osteolyticlesion, involving, whole, entire, occipital, bone, magneticimagingmri, showed, an, intra, extracerebralexpansile, osseous, lesion, 02, , mm, themass, mostly, isointense, with, brainparenchyma, on, both, t1, t2weightedimagesenhancedfigures, 1c, 1d, digital, subtraction, angiography, dsa, demonstrated, that, all, thetumour, had, hypervascularity, that, supplied, from, occipital, artery, order, todecrease, bleeding, volume, shorten, thesurgery, time, feeding, blood, vessel, wasembolized, during, dsa, ehomogeneouslythe, patient, underwent, occipital, craniotomy, skull, reconstruction, ltmf, transplantation, under, general, anaesthesia, thetumour, capsulized, extended, tothe, subcutaneous, subdural, spacethrough, dura, mater, with, skull, defectsgrossly, tumour, had, ï¬shmeat, likeappearance, mixed, with, hard, cartilage, andbroken, bone, tumour, had, arich, blood, supply, despite, embolizationof, main, blood, supply, artery, duringdsa, before, surgery, there, lot, ofblood, loss, during, operation, thetumour, mass, underwent, extended, resectionincluding, marginal, bone, involvedscalp, forming, an, 02, , cm, bone, windowand, 02, , cm, scalp, defect, skulldefect, reconstructed, using, titaniummesh, scalp, defect, transplantedusing, ltmf, trapezius, skinisland, 02, , cm, supplying, vesselsof, transverse, cervical, artery, thedorsal, scapular, artery, were, marked, on, theskin, b, island, ï¬ap, excisedand, its, muscle, pedicle, dissected, up, thefigure, , perioperative, procedures, imaging, examinations, tumour, fishmeat, soft, tan, inappearance, b, trapezius, skin, island, supplying, vessels, transverse, cervicalartery, dorsal, scapular, artery, marked, out, on, skin, c, island, flap, its, muscle, pedicle, wereexcised, d, flap, set, into, defect, with, wellperfused, distal, end, e, stiches, were, removedafter, surgery, f, postoperative, enhanced, magnetic, resonance, imaging, mri, scan, , sagittal, viewg, postoperative, enhanced, mri, scan, , axial, view, colour, version, figure, available, at, httpimrsagepubcom, 0crotation, point, at, medialsuperior, edgeof, scapula, c, ltmf, wasrotated, vertically, into, occipital, scalpdefect, through, neck, posterior, subcutaneous, tunnel, d, two, weeks, afterthe, operation, transplanted, skin, islandwas, vital, wound, healing, undisturbedfigurethattheremovedtumour, wasfigures, 2f, 2g2e, mricompletelyindicatedhaematoxylin, eosin, staining, thetumour, showed, presence, atypicalplasma, cells, with, typical, eccentric, roundnucleistainingshowed, following, staining, patterncytokeratinp, , epithelial, membrane, antigen, , melana, , cd38, ¾, cd138immunohistochemicaljournal, international, medical, research¾, cd20, , kappa, ¾, lambda, ¾glial, ï¬brillary, acidic, protein, , s100cd68, ¾, thyroid, transcription, factor1, vim, , cd3, , ki67, figure, patient, refused, further, radiotherapyfor, ï¬nancial, reasons, after, followupperiod, around, , months, he, symptom, free, had, no, clinical, evidence, ofdisease, at, 5month, followup, visitmri, revealed, no, eld, recurrence, butan, aggressive, mass, lesion, with, enhancementwaslobefigures, 4a, 4b, chemotherapy, padregimen, bortezomib, pegylated, liposomaldoxorubicindexamethasone, wasadministered, from, , april, , thefound, on, thefrontalrightandfigure, , representative, photomicrographs, tumour, haematoxylin, eosin, stained, sectionshowing, diffuse, sheets, plasma, cells, b, immunohistochemical, staining, cd138, showing, strong, positivity, tumour, cells, c, immunohistochemical, staining, cd38, showing, strong, positivity, thetumour, cells, d, positive, expression, ki67, , colour, version, figure, available, athttpimrsagepubcom, scale, bar, , mm, 0cwang, et, alfigure, , magnetic, resonance, imaging, scans, patient, during, followup, , b, at, 5month, followup, visit, showing, no, recurrence, situ, but, an, aggressive, mass, lesion, with, enhancement, on, right, frontallobe, c, , d, after, six, consecutive, cycles, chemotherapy, showing, no, recurrence, situ, lesion, onthe, right, frontal, lobe, significantly, reduceddepartmentof, haematology, hunancancer, hospital, afï¬liated, cancerhospital, xiangya, school, medicinecentralsouth, university, changshahunan, province, china, after, six, consecutive, cycles, chemotherapy, lesion, on, hisright, frontal, lobe, signiï¬cantly, reducedfigures, 4c, 4d, postoperative, reviewafter, , months, showed, no, tumour, recurrence, situ, original, spbas, case, report, institutionalreview, board, hunan, cancer, hospitalwaived, need, ethical, approval, thepatient, provided, written, informed, consentfor, publication, that, approved, by, theinstitutional, review, board, detailsof, patient, have, been, anonymizeddiscussionhuge, intra, extracranial, sps, theoccipital, bone, are, very, rare, few, caseshave, been, reported34, spb, characterizedby, presence, solitary, lytic, lesion, dueto, monoclonal, plasma, cell, ltration, withsofttissue, extension5, spbsor, withoutaccount, , all, sp, cases, theyoccur, primarily, red, marrowcontainingbones6, plasma, cells, are, highly, sensitive, toradiation78, radiation, therapy, remains, 0cjournal, international, medical, researchtreatment, choice, patients, after, surgery, according, recommendations, froma, european, expert, panel, total, fractionated, dose, , gy, should, be, given, anda, margin, atleast, , cm, should, beemployed6, current, caseit, wasunfortunate, that, patient, refused, radiationreasonsa, review, performed, , months, afterthe, operation, new, mass, foundon, right, frontal, lobe, after, six, cyclesof, chemotherapy, tumour, had, reducedin, size, signiï¬cantly, which, suggests, that, chemotherapy, has, positive, impact, on, thegrowth, recurrent, tumourseconomictherapyforthe, imaging, characteristics, spb, theskull, are, complex, can, easily, lead, tomisdiagnosis, enhanced, ct, scanning, combined, with, observation, bone, windoware, credible, means, by, which, diagnosespb, they, could, provide, more, information, about, osteolytic, lesions, currentcase, mri, examination, allowed, theidentiï¬cation, location, size, shapeof, tumour, as, well, as, its, relationship, tothe, surrounding, structures, our, opinionpreoperative, dsa, necessary, identiï¬cation, blood, supply, vessels, tofacilitate, vessel, embolizationduringthetumourrecurrencecurrent, operationthetumour, found, involve, scalpand, subcutaneous, tissue, reduce, theprobability, oftheinvolved, scalp, underwent, an, extendedresection, ltmf, used, facilitateoccipital, scalp, reconstruction, ltmf, provides, available, muscle, compartments, transferred, on, reliable, vascular, pedicle, thedorsal, suprascapular, neck, regions9the, beneï¬ts, ltmf, include, well, vascularized, tissue, ease, harvest, provision, large, ï¬ap, located, far, enoughaway, from, damaged, area10, mainblood, supply, ltmf, originates, fromthe, transverse, cervical, artery, dorsalscapular, artery1112, method, couldsolve, problem, ofinsufï¬cient, bloodsupply, caused, by, titanium, plate, implantation, additionthe, musculocutaneouspedicle, could, ï¬ll, subcutaneous, cavitycreated, by, huge, tumourresectionpreventing, occipitalia, scalp, hydrops, andsecondary, infection, ltmf, an, alternative, approach, repair, scalp, andsubcutaneous, soft, tissue, defects, caused, byexcision, malignanttheoccipital, regiontumour, ofauthors, contributionslw, studied, case, collected, referencesand, wrote, paper, zh, designed, reportand, wrote, paper, hc, hz, wrote, thepaper, xp, analysed, data, nr, served, as, theï¬rst, chief, during, surgery, wrote, paperall, authorsread, approved, ï¬nalmanuscriptdeclaration, conflicting, interestthe, authors, declare, that, there, are, no, conï¬icts, ofinterestfundingthis, project, supported, by, grants, from, thescientiï¬c, research, project, hunan, provincialhealth, commission, no20200709, hunanprovincial, natural, science, foundation, chinano2019jj40182, sailing, programme, ofhunan, provincial, cancer, hospitalorcid000000021069orcid, idlei, wangreferences, sabattini, e, bacci, f, sagramoso, c, et, alwho, classiï¬cation, tumours, haematopoietic, lymphoid, tissues, , anoverview, pathologica, , , , gee, ed, sadovsky, r, multiple, myeloma, recognition, management, amfam, physician, , , , rizea, re, popescu, m, ghehit¸, 15a, klet, al, neurosurgical, rare, disease, solitary, 0cwang, et, alplasmacytoma, skull, , case, report, andliterature, review, rom, j, morphol, embryol, , , chang, my, shih, ly, dunn, p, et, al, solitaryplasmacytoma, bone, j, formos, med, assoc, , , weber, dm, solitary, bone, extramedullary, plasmacytoma, hematology, am, sochematol, educ, program, , , , caers, j, paiva, b, zamagni, e, et, aldiagnosis, treatment, response, assessment, solitary, plasmacytoma, updated, recommendations, from, european, expertpanel, j, hematol, oncol, , , , knobel, d, zouhair, tsang, rw, et, alprognostic, factors, solitary, plasmacytomaof, bone, multicenter, rare, cancernetwork, study, bmc, cancer, , , , liebross, rh, ha, cs, cox, jd, et, alsolitary, bone, plasmacytoma, outcome, andprognostic, factors, following, radiotherapyint, j, radiat, oncol, biol, phys, , , mohos, g, vass, g, kemeny, l, et, alextended, lowertrapezius, myocutaneousï¬ap, cover, deep, lateral, neck, defect, onirradiated, skin, new, application, j, plastsurg, hand, surg, , , , u, 15gurlu, k, ozc¸, elik, d, hu¨, thu¨, t, i, et, alextended, vertical, trapezius, myocutaneousï¬ap, head, neck, reconstruction, as, asalvage, procedure, plast, reconstr, surg, , , baek, sm, biller, hf, krespi, yp, et, al, thelower, trapezius, island, myocutaneous, ï¬apann, plast, surg, , , , netterville, jl, wood, de, lower, trapezius, ï¬ap, vascular, anatomy, surgicaltechnique, arch, otolaryngol, head, necksurg, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |(224581,[0,1,2,3,4,5,6,7,8,10,11,12,13,14,15,16,17,18,20,21,22,23,26,29,34,35,37,38,39,40,42,44,45,46,48,49,50,52,54,57,58,59,63,64,69,72,73,75,77,80,82,84,89,92,93,94,96,98,99,105,108,109,111,113,115,118,122,123,124,127,130,131,132,133,134,136,144,146,148,149,153,155,160,162,165,170,171,173,179,180,184,186,187,188,192,193,199,203,209,216,220,221,226,231,232,236,240,241,245,249,253,257,260,262,264,269,270,274,275,277,280,282,283,285,286,299,314,321,333,336,350,352,359,362,366,367,368,369,373,375,380,389,397,398,400,404,407,415,426,437,447,451,453,455,459,460,464,471,473,481,483,490,495,496,499,513,516,518,519,521,527,535,540,559,561,564,567,572,576,577,578,586,589,594,595,601,606,609,611,613,617,627,639,644,649,660,683,696,700,714,716,724,733,746,761,762,763,768,775,784,787,792,795,799,815,832,834,838,840,841,847,864,869,880,882,886,890,891,894,896,903,914,924,942,958,975,982,983,989,1011,1013,1029,1047,1073,1093,1095,1126,1144,1149,1153,1157,1168,1181,1182,1187,1188,1194,1195,1203,1214,1217,1222,1241,1254,1264,1278,1288,1299,1306,1308,1365,1374,1375,1376,1384,1388,1406,1438,1440,1445,1458,1459,1480,1512,1530,1540,1545,1552,1559,1570,1613,1620,1633,1636,1645,1648,1666,1676,1681,1691,1727,1728,1778,1838,1851,1853,1866,1891,1918,1933,1951,1971,1977,1992,2004,2031,2034,2036,2082,2091,2116,2119,2125,2130,2225,2228,2294,2306,2328,2369,2374,2379,2407,2413,2422,2424,2431,2434,2438,2461,2492,2497,2498,2526,2537,2575,2589,2598,2617,2641,2658,2723,2741,2750,2756,2766,2784,2786,2811,2821,2832,2862,2886,2926,2964,2997,3040,3056,3071,3076,3080,3087,3093,3098,3133,3197,3218,3234,3244,3256,3268,3297,3298,3302,3309,3391,3417,3427,3441,3445,3470,3482,3549,3550,3565,3577,3586,3588,3635,3676,3731,4022,4149,4170,4192,4236,4246,4267,4282,4394,4417,4436,4459,4536,4575,4596,4616,4709,4775,5074,5078,5119,5166,5192,5238,5491,5499,5539,5639,5643,5680,5691,5733,5772,5880,5912,5991,6093,6164,6189,6227,6236,6275,6381,6445,6464,6589,6659,6668,6728,6799,6818,6897,6974,7008,7038,7043,7071,7099,7108,7263,7317,7346,7402,7413,7469,7511,7532,7551,7561,7563,7620,7665,7676,7962,8116,8246,8276,8332,8523,8532,8591,8638,8662,8798,8830,8865,9007,9029,9038,9473,9503,9868,9967,9970,10093,10321,10422,10564,10568,10680,10765,10823,11350,11442,11611,11622,11887,11947,12100,12548,12777,12890,12920,13055,13066,13259,13714,13813,13901,13921,14012,14106,14121,14362,14367,14536,14580,14747,14858,15089,15172,15255,15964,16602,16967,17068,17236,17618,17657,18106,18213,18338,18761,19286,19291,19343,19356,19446,19472,19567,19714,20001,20039,20102,20141,20652,20944,21228,21780,21944,22291,23245,23359,23552,23765,23866,24241,24651,24719,25028,25157,25394,25523,25620,25755,26171,26503,26583,26590,26669,27506,27564,27684,27852,27858,27989,28531,29206,29239,29658,31566,34536,35424,36436,38131,38292,38820,39061,39485,39862,40022,40041,40155,40335,40659,40704,41605,41859,42207,45237,45540,46541,48041,48317,48356,49531,49890,50168,50477,51228,53315,54061,55340,55392,55409,56436,56566,57191,57954,59129,59221,61303,61327,61356,61410,62260,62562,67842,67920,68606,70358,71063,71273,72558,72649,80765,81528,81648,82212,83037,84123,84321,85037,85136,85188,85909,85970,86875,87920,88578,89390,89771,89828,90807,92170,92331,92450,92953,93713,94799,97444,99065,100877,101217,101293,102344,102489,103966,104864,105815,106078,106759,107993,108281,110321,111052,111814,112920,113058,113123,113173,113185,115393,116597,118524,118846,118910,119471,119482,120729,121603,121948,122257,123326,123960,124437,125034,125626,126043,126355,126454,126698,127280,127494,127637,127841,128312,128473,128743,129306,129545,130322,130952,131283,131764,132205,132548,132797,132891,134161,134212,135263,135461,136003,136270,136662,137706,138142,138322,138617,138793,138864,139945,140117,141253,141637,141811,142431,143777,144401,145411,146073,146187,146488,146958,147103,147371,147895,149896,150291,150659,151232,151432,151696,151949,152344,153654,154096,155577,155940,156140,156314,156462,157213,157928,158086,158600,158815,158970,159221,161954,164507,164691,164720,164834,167151,168076,169946,170385,170418,171190,171548,172103,172429,172584,173297,173309,173925,174563,174607,175007,175145,175495,175738,176685,177967,178141,178144,178440,178739,179209,179681,180888,180900,181151,181664,181963,182316,182416,182951,183291,183625,185617,186469,186892,186944,187069,187255,187533,190479,190512,190653,190906,191111,191510,192231,192605,193263,194143,194375,194963,195009,195717,196351,198136,198409,198909,199558,199780,200763,201708,202092,202255,202677,202717,203365,203445,203964,205576,205769,208328,208915,209014,209023,209547,210545],[54.0,13.0,2.0,7.0,10.0,4.0,9.0,7.0,1.0,14.0,5.0,5.0,1.0,1.0,1.0,22.0,6.0,10.0,1.0,1.0,1.0,5.0,2.0,1.0,6.0,1.0,2.0,3.0,1.0,5.0,2.0,8.0,1.0,1.0,1.0,1.0,2.0,11.0,1.0,1.0,6.0,7.0,1.0,1.0,1.0,1.0,5.0,6.0,1.0,4.0,1.0,4.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,8.0,1.0,3.0,1.0,1.0,2.0,2.0,1.0,1.0,6.0,1.0,1.0,3.0,2.0,4.0,4.0,3.0,5.0,1.0,1.0,2.0,2.0,3.0,1.0,1.0,5.0,3.0,3.0,1.0,2.0,1.0,1.0,6.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,4.0,2.0,1.0,3.0,4.0,1.0,2.0,7.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,6.0,4.0,1.0,4.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,2.0,1.0,2.0,6.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,3.0,2.0,15.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,10.0,2.0,1.0,4.0,4.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,5.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,4.0,4.0,1.0,3.0,3.0,1.0,4.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,4.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,4.0,3.0,2.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,3.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,6.0,1.0,1.0,3.0,2.0,2.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,4.0,7.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,3.0,1.0,3.0,1.0,1.0,2.0,4.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,8.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,3.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,2.0,1.0,1.0,10.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,10.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,11.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,3.0,3.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n",
      "|[, this, study, aimed, to, investigate, serum, matrix, metalloproteinase, mmp2, and, mmp9levels, in, patients, with, papillary, thyroid, carcinoma, ptcmethods, fortyone, patients, with, ptc, undergoing, ultrasoundguided, radiofrequency, ablationrfa, and, , controls, were, included, serum, mmp2, and, mmp9, levels, were, determined, byenzymelinked, immunosorbent, assay, before, and, after, surgery, potential, affecting, factors, wereevaluated, by, logistic, regression, analysisresults, serum, mmp2, and, mmp9, levels, were, significantly, higher, in, ptc, patients, comparedwith, controls, and, decreased, significantly, after, surgery, according, to, receiver, operating, characteristic, curve, analysis, diagnostic, values, for, preoperative, serum, mmp2, and, mmp9, levels, were, and, , there, was, no, contrastagent, perfusion, in, the, ablation, zone, in, , of, lesionsand, enhancement, within, or, at, the, lesion, edge, in, , the, volume, reduction, at, , monthsfollowup, was, , age, microcalcification, irregular, shape, and, lesion, diameter, and, numberwere, influencing, factors, for, ptc, age, and, lesion, diameter, and, number, were, independent, riskfactors, while, calcification, and, morphology, were, protective, factorsconclusion, serum, mmp2, and, mmp9, levels, have, important, clinical, values, for, the, diagnosis, andtreatment, of, ptc, by, rfa, preoperative, serum, mmp2, and, mmp9, levels, combined, with, otheraffecting, factors, contribute, to, disease, prognosisdepartment, of, ultrasound, beilun, peoples, hospital, ofningbo, beilun, branch, of, the, first, affiliated, hospital, ofzhejiang, university, ningbo, zhejiang, chinathese, authors, contributed, equally, to, this, studycorresponding, authorqian, ding, department, of, ultrasound, beilun, peopleshospital, of, ningbo, beilun, branch, of, the, first, affiliatedhospital, of, zhejiang, university, no, , east, lushanroad, ningbo, , zhejiang, chinaemail, qianding02sohucomcreative, commons, non, commercial, cc, bync, this, , is, distributed, under, the, terms, of, the, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, and, distribution, of, the, work, without, further, permission, provided, the, original, work, is, attributedas, specified, on, the, sage, and, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, of, international, medical, researchkeywordspapillary, thyroid, carcinoma, radiofrequency, ablation, matrix, metalloproteinase2, matrix, metalloproteinase9, disease, prognosis, serum, leveldate, received, , june, , accepted, , march, introductionpapillary, thyroid, carcinoma, ptcis, acommon, thyroid, malignancy, accountingfor, about, , of, systemic, malignancies1ptc, is, currently, characterized, by, a, highincidence, and, low, mortality2clinicalrecentimprovementsin, highfrequencyultrasonic, diagnostic, technologies, and, theapplication, of, ultrasoundguided, puncturetechniques, have, led, to, an, apparent, increasein, the, incidence, of, ptc, year, by, year3regardingthyroidtumors, the, palpation, detection, rate, forthyroid, microtumors, in, the, general, population, is, about, , compared, with, as, highas, , to, , for, highfrequency, ultrasound6, which, has, thus, greatly, improveddisease, diagnosisdiagnosistheofsurgical, resection, is, a, routine, treatmentfor, thyroid, tumors, but, the, recurrence, rateis, usually, high, and, the, consequent, reduction, in, thyroid, function, can, seriously, affectthe, patients, quality, of, life7, associatedwith, the, increasing, detection, rate, of, thyroidtumors, and, the, pursuit, of, minimally, invasive, treatments, radiofrequency, ablationrfa, has, been, gradually, applied, in, theclinic, rfa, uses, local, hyperthermia, tocause, tissue, necrosis, the, thermal, effectsdo, not, depend, on, the, tissue, type, andmost, lesions, can, be, completely, eliminatedby, rfa89, rfa, has, thus, become, a, novellocal, treatment, for, tumorsthe, clinical, diagnosis, of, benign, andmalignant, thyroid, tumors, currently, dependson, the, clinical, manifestations, and, pathological, examinations, howeverthe, clinicalmanifestations, are, mostly, derived, frominvolvessubjective, empirical, analysis, while, a, ï¬nalpathological, diagnosisinvasiveprocedures, with, lesssatisfactory, speciï¬city, it, is, therefore, necessary, to, identifyappropriatepredictivetumor, markersdiagnosticandforimplicationsthe, collagenases, matrix, metalloproteinase, mmp2, and, mmp9, can, degradetype, iv, collagen, in, the, basement, membranewith, importanttumorangiogenesis, and, tumor, cell, invasion, andmetastasis10, mmp2, and, mmp9, expression, levels, were, found, to, be, upregulatedin, thyroid, cancer, tissue11, however, thesestudies, mostly, examined, pathological, tissuesafterinvasive, surgery, and, lessinvasivemeasures, such, as, serum, levels, of, mmp2and, mmp9, have, been, lesswell, consideredin, this, study, we, detected, serum, levels, ofmmp2, and, mmp9, in, patients, with, ptcbefore, and, after, ultrasoundguided, rfawe, also, determined, the, therapeutic, effectsof, rfa, during, the, followup, period, andinvestigated, the, relevant, prognostic, factorsmaterials, and, methodsstudy, subjectspatients, who, underwent, ultrasoundguidedrfa, in, our, hospital, from, may, , tooctober, , were, included, in, this, studythe, inclusion, criteria, were, as, follows, patients, diagnosed, by, preoperative, ï¬neneedle, aspiration, cytology, , no, historyof, neck, surgery, and, , patients, requiringminimally, invasive, treatment, for, aestheticreasons, and, because, of, neck, oppression, 0cpan, et, alwith, anxiety, the, exclusion, criteria, were, asfollows, , benign, lesions, conï¬rmed, by, ï¬neneedle, aspiration, cytology, , history, ofneck, surgery, and, , severe, coagulopathyperipheral, venous, blood, samples, wereobtained, from, the, included, patients, beforeand, at, , , , and, , months, after, the, operation, and, serum, levels, of, mmp2, andmmp9, were, determined, additional, subjects, with, conï¬rmed, benign, thyroid, noduleswithout, rfa, were, included, as, a, controlgroup, prior, written, informed, consent, wasobtained, from, all, patients, and, the, studywas, approved, by, the, ethics, review, boardof, our, hospitalpreoperative, preparationcalciï¬cationthe, number, size, nature, echo, boundarymorphologysurroundinghalo, and, nodular, blood, ï¬ow, distributionof, the, tumors, were, assessed, before, the, operation, after, skin, disinfection, local, anesthesia, was, performed, with, , lidocainesolution, a, total, of, , ml, sonovue, bracco, milan, italy, was, injected, via, the, elbowvein, and, the, bloodsupply, characteristicswere, then, evaluated, by, contrastenhancedultrasound, ceus, of, the, ablationtargetedlesions, using, a, mylab90, ultrasonic, devicewith, 10mhz, probe, esaote, shenzhenguangdong, chinaaccording, to, the, location, of, the, thyroidnodules, the, thyroid, and, carotid, space, thyroid, and, tracheal, space, thyroid, and, esophageal, space, and, posterior, thyroid, spacerecurrent, laryngeal, nerve, were, separatedusing, a, saline, and, lidocaine, mixture, basedon, the, intraoperative, conditions, to, form, aliquid, separation, zone, to, protectthesestructures, from, thermal, damageablation, treatmentunder, ultrasound, guidancethe, tip, ofthe, rfa, needle, rated, power, , woutput, frequency, , khz, was, accuratelypenetrated, into, the, nodule, and, rfa, wasperformed, using, an, olympuscelon, powerrfa, system, germany, in, mobile, mode12following, the, fromdeeptoshallow, principle, the, lesions, were, subjected, to, multipointed, and, multifaceted, ablation, untilthe, thyroid, tissue, layer, with, the, noduleswas, completely, covered, by, the, strong, echogenerated, by, heat, accumulation, the, wholeprocess, was, carried, out, under, continuousultrasound, monitoring, a, highecho, areawas, produced, in, the, ablation, zone, duringthe, ablation, treatment, the, position, of, theelectrode, needle, was, gradually, adjustedaccording, to, the, lesion, size, after, ensuringthat, there, was, no, residual, enhancement, inthe, ablation, zone, the, ablation, needle, wasremoved, and, the, ablation, was, completedafter, the, operation, an, ice, compress, wasapplied, for, , h, to, avoid, skin, burnsserum, mmp, determinationfor, all, subjects, , ml, venous, blood, wascollected, from, the, elbow, vein, under, fastingconditions, before, and, after, the, operationrespectively, blood, samples, in, the, controlgroup, were, collected, after, ultrasound, contrast, examination, the, blood, samples, wereplaced, at, room, temperature, for, , minutesand, then, subjected, to, centrifugation, at, 02, g, for, , minutes, the, serum, washarvested, and, serum, levels, of, mmp3, andmmp9, were, determined, using, enzymelinked, immunosorbentelisakitsboster, bioengineering, wuhanhubei, chinaassayfollowup, and, efficacy, evaluationimmediately, after, the, operation, the, ablation, range, was, evaluated, by, ceus, if, residualtissues, were, detected, ablation, wasrepeated, immediately, ultrasound, detectionwas, performed, at, , , , and, , monthsafter, surgery, to, determine, the, nodule, sizesand, volumes, the, volumereduction, rate, 0cwas, calculated, according, to, the, followingformula, volume, reduction, rate¼, preoperative, volume, , followup, volumepreoperative, volume, 02, , echo, and, bloodï¬owchanges, in, the, ablation, zone, were, alsoobserved, and, analyzed, the, efï¬cacy, wasdetermined, based, on, the, criteria, for, rfafor, treating, tumors13, disappearance, ofnodules, indicated, by, complete, disappearance, of, blood, ï¬ow, conï¬rmed, by, ultrasonography, indicated, complete, cure, noduleby, , 15, indicatedvolumemarked, effect, and, nodule, volume, reducedby, , to, , indicated, improvementreducedclinicopathological, featuresinformation, on, ultrasoundbased, clinicopathologicalincluding, numbersize, and, calciï¬cation, of, the, lesion, wereobtainedfeaturesversion, statistical, analysisdata, were, expressed, as, mean, 06, standarddeviation, statistical, analysis, was, performed, using, ibm, spss, statisticsforwindowsibm, corparmonk, ny, usa, comparisons, betweengroups, were, performed, using, v2testspotentially, related, factors, were, analyzedby, univariate, or, multivariate, logistic, regression, the, prognostic, predictive, effects, ofserum, mmp2, and, mmp9, levels, wereevaluated, by, receiver, operating, characteristic, roc, curve, analysis, p, , , was, considered, statistically, signiï¬cantresultspatientsjournal, of, international, medical, research, men, mean, age, , 06, , years, range, yearsserum, mmp2, and, mmp9, levels, beforeand, after, treatmentthe, characteristics, of, the, ultrasound, images, inthe, included, subjects, are, shown, in, table, serum, levels, of, mmp2, and, mmp9, weremeasured, before, and, after, treatment, serumlevels, of, mmp2, and, mmp9, were, signiï¬cantly, higher, in, patients, with, ptc, comparedwith, the, control, subjects, p, , , serumlevels, of, mmp2, and, mmp9, had, declinedat, , month, after, the, operation, comparedwith, before, surgery, but, the, difference, wasnot, signiï¬cant, however, serum, levels, ofmmp2, and, mmp9, had, declined, signiï¬cantly, in, the, ptc, patients, at, , , and, , monthsall, p, , , table, , these, results, suggestthat, changes, in, serum, mmp2, and, mmp9levels, between, before, and, after, surgery, mayhave, signiï¬cant, implications, for, the, therapyof, ptcroc, curve, analysis, of, preoperative, serummmp2, and, mmp9, levelspreoperative, serum, mmp2, and, mmp9levels, were, used, as, potential, diagnostic, indicators, in, the, , patients, with, ptc, the, predictive, probability, from, theregressionmodel, was, used, as, the, diagnostic, resultsand, the, gold, standard, classiï¬cation, criteriawere, used, as, the, pathological, results, roccurves, were, obtained, accordingly, the, areaundercurve, auc, values, for, serum, mmp, and, mmp9, levels, were, , and, respectively, figure, , these, results, suggestthat, serum, levels, of, mmp2, and, mmp9could, contribute, to, the, disease, diagnosisfortyone, patients, with, ptc, , lesionswere, enrolledincluding, , women, and, men, mean, age, , 06, , years, range, to, ã¾65, years, the, control, group, included, , patients, with, conï¬rmed, benignthyroid, nodules, including, , women, andevaluation, of, rfa, efficacywe, also, evaluated, the, efï¬cacy, of, rfa, ceusof, the, , lesions, before, ablation, showed, hypoenhancement, in, , nodules, isoenhancementin, , nodules, and, slight, hyperenhancement, 0cpan, et, altable, , characteristics, of, thyroid, ultrasound, imagesptc, patientsnormal, controllesion, numberonetwomultiplelesion, size, 14, cm, cmcalcificationmicrocalcificationcoarse, calcificationmorphologyregularirregularage, years, 15, yearsnp, , , compared, with, the, control, groupntable, , serum, matrix, metalloproteinase2, and, , levels, in, controls, and, inpatients, with, papillary, thyroid, carcinoma, before, and, after, treatmentcontrolsptc, patientsbefore, surgery, month, after, surgery, months, after, surgery, months, after, surgery, months, after, surgerymmp2, 06, , 06, , 06, , 06, , 06, , 06, pmmp9p, 06, , 06, , , 06, , 06, , 06, , 06, , mmp, matrix, metalloproteinase, ptc, papillary, thyroid, carcinomain, , nodules, ultrasound, examination, afterablation, showed, no, contrastagent, perfusionin, the, ablation, zone, in, , lesions, and, enhancement, of, different, degrees, at, theedge, or, inside, the, lesion, in, the, other, lesions, , and, the, ablation, area, wasgradually, reduced, with, prolonged, ablationfigure, , there, was, no, signiï¬cant, changein, ablation, volume, in, any, patients, at, month, after, surgery, compared, with, beforesurgery, however, the, volume, was, reducedby, , at, , months, offollowupcompared, with, before, surgery, p, , table, , these, results, showed, that, rfatreatmentthetumor, volume, in, patients, with, ptccould, effectively, reduceinfluence, of, relevant, factors, on, diseaseprognosistheclinical, data, of, patients, beforerfa, were, retrospectively, analyzed, by, 0cjournal, of, international, medical, researchirregularlogistic, regression, to, identify, factors, thatmay, affectthe, disease, prognosis, agemicrocalciï¬cationshape, anddiameter, and, number, of, lesions, were, significant, inï¬uencing, factors, for, ptc, p, , the, hazard, ratios, hrsfor, age, andlesion, diameter, and, number, were, , indicating, that, these, represented, independentrisk, factors, in, contrast, the, hrs, for, microcalciï¬cation, and, irregular, shape, were, negativeindicating, that, a, greater, degree, ofcalciï¬cation, and, regular, shape, were, associated, with, lower, risks, of, developing, the, disease, and, were, thus, protective, factorstable, figure, , roc, analyses, of, serum, mmp2, andmmp9, levels, mmp, matrix, metalloproteinasefigure, , efficacy, evaluation, of, radiofrequency, ablation, a, twodimensional, 2d, ultrasound, showingobvious, bloodflow, signals, around, the, tumor, and, fewer, signals, within, the, tumor, b, preoperative, contrastenhanced, ultrasound, showing, no, obvious, enhancement, in, the, lesion, with, lowperfusion, performance, c, inthe, 2d, imaging, localization, the, ablation, needle, was, inserted, into, the, tumor, for, ablation, d, the, tumor, wascompletely, ablated, with, no, bloodflow, signal, at, , year, after, ablation, 0cpan, et, aldiscussionitis, difï¬cultptc, is, a, type, of, thyroid, tumor, with, a, highincidence14, which, has, been, increasingrapidly, worldwide1516, mostthyroidtumor, cases, are, currently, diagnosed, by, hiscytological, detectiontopathological, orhoweverto, distinguishbetween, benign, and, malignant, papillaryhyperplastic, nodules, and, it, is, therefore, difï¬cult, to, diagnose, ptc, there, is, also, a, lackof, effective, and, speciï¬c, prognostic, molecular, markers, for, ptc17, the, relationshipbetween, mmps, and, tumors, is, a, currenthotspot, of, modern, cancer, research, mmpsplay, important, roles, in, pathophysiologicalprocesses, such, as, the, dynamic, extracellularmatrix, balance, as, well, as, in, tissue, remodeling, and, repair10, tumor, cells, may, inducethe, matrix, to, secrete, mmps, via, a, series, ofsignalingprovidingpathwaysthustable, , volume, reductions, after, radiofrequencyablation, of, papillary, thyroid, carcinomasreductionrate, lesionvolumecm3, 06, , 06, , 06, , , 06, , , months, after, surgery, , 06, , p, , , p, , , compared, with, before, surgerybefore, surgery, month, after, surgery, months, after, surgery, months, after, surgeryfavorable, conditions, for, tumor, cell, invasionand, metastasisalternatingthe, extensive, surgicalsurgical, resection, is, a, traditional, methodthyroid, nodules18for, the, treatment, ofhowevertraumaunsightly, neck, scars, and, risks, of, laryngealnerve, injuries, postoperative, recurrenceand, multiple, operations, mean, that, increasing, numbers, of, patients, are, opting, for, minimally, invasive, ablation, methods, rfa, is, athermal, ablation, therapy, that, uses, highfrequencyelectromagneticwaves, generated, by, the, radiofrequencyinstrument, inserted, into, the, tumor, tissueto, accumulate, heat, by, rapid, friction, of, positive, and, negative, ions, within, the, cells, causing, local, coagulation, in, the, tumor, tissuewhich, isthen, removed, by, the, bodyssystem19, reduction, ratesimmuneforbenign, thyroid, nodules, of, , to, after, , month, of, ablation, and, , to, after, , months, of, ablation, have, beenreported20, in, this, study, ultrasound, performed, immediately, after, ablation, of, lesions, showed, no, perfusion, of, contrastagents, in, , lesions, and, enhancementto, varying, degrees, at, the, edge, or, inside, thelesion, in, , of, lesions, although, therewere, no, signiï¬cant, changes, in, lesion, volumeat, , month, after, the, operation, the, lesionvolumes, were, reduced, by, , to, , at, months, after, surgery, considering, thatthe, ablation, effects, might, be, associatedwith, the, heat, and, the, ablation, needle, atable, , logistic, regression, analysis, of, relevant, risk, factors, for, disease, prognosisagemicrocalcificationirregular, morphologylesion, diameterlesion, numberb, , hrhr, hazard, ratio, ci, confidence, interval95cilower, limitupper, limitp, 0cjournal, of, international, medical, researchï¬ne, needle, is, good, for, mobile, conformalablationthe, highfrequency, alternatingelectromagnetic, wave, only, circulates, in, theeffective, region, between, the, two, needle, tipsthus, allowing, accurate, control, of, the, ablation, zone, the, ablation, safety, zone, aroundthe, ptc, was, relatively, small, in, the, currentstudy, and, the, nodulereduction, rate, afterablation, was, thus, relatively, greaterwe, analyzed, the, serum, levels, of, mmp2and, mmp9, in, ptc, patients, by, elisapreoperative, serum, levels, of, both, enzymeswere, signiï¬cantly, higher, in, patients, withptc, compared, with, patients, with, benigninthyroid, nodules, regarding, changesserum, mmp2, and, mmp9, levelstheauc, values, based, on, the, roc, curveswere, , and, , for, mmp2, andmmp9, respectively, suggesting, satisfactory, clinical, diagnostic, and, prognostic, valuesin, the, present, study, serum, levels, mmp2and, mmp9, were, lower, in, the, ï¬rst, monthafter, surgery, compared, with, before, surgerybut, the, difference, was, not, signiï¬cant, thismight, be, because, before, ablationthetumor, parenchyma, induced, the, tumorstroma, to, produce, larger, amounts, ofmmp2, and, mmp9, which, were, releasedinto, the, blood, these, results, suggest, thatfailure, to, completely, ablate, the, tumor, ortumor, recurrence, may, result, in, the, secretionof, high, levels, of, mmp2, and, mmp9, intothe, blood, however, serum, levels, of, mmp, and, mmp9, were, signiï¬cantly, decreasedat, , , and, , months, after, surgery, compared, with, before, surgery, suggesting, thatserum, mmp2, and, mmp9, were, secretedby, the, tumor, the, lesions, disappearedafter, ptc, ablation, thus, reducing, the, secretion, of, mmp2, and, mmp9, and, therebyreducing, the, degradation, and, destructionof, type, iv, collagen, protecting, the, basement, membrane, of, normaltissues, andinhibiting, the, growth, and, metastasis, oftumorresults, alsoshowed, that, age, microcalciï¬cation, irregular, shape, and, lesion, diameter, and, numbercells, thecurrentwere, risk, factors, for, ptc, logistic, regression, analysis, showed, that, age, , 14, yearswas, an, important, risk, factor, for, ptc, inline, with, the, ï¬ndings, of, yu, et, al21microcalciï¬cation, is, caused, by, the, deposition, of, calcium, salts, at, the, tip, of, the, nippleor, the, secretion, of, calcium, salts, by, thetumor, itself, and, has, been, considered, tobe, the, most, speciï¬c, sign, of, ptc, in, thisstudy, the, incidence, of, microcalciï¬cationwas, higher, in, ptc, patients, compared, withthe, control, group, and, logistic, regressionidentiï¬ed, it, as, an, independent, risk, sign, forthyroid, ptc, our, results, also, identiï¬edirregular, morphology, two, nodules, and, anodule, diameter, , 14, cm, as, danger, signs, forptclargely, consistent, with, previousï¬ndings22this, study, had, some, limitations, it, was, asinglecenter, study, with, a, relatively, smallnumber, of, cases, moreover, the, relevantthyroid, hormone, analysis, and, other, serumindicators, could, not, be, followed, up, for, alonger, periodtreating, ptc, furthermorein, summary, the, results, of, this, studyshowed, that, rfa, could, shrink, or, eliminatethyroid, lesions, thus, representing, a, minimally, invasive, safe, and, effective, methodforserumlevels, of, mmp2, and, mmp9, before, rfacould, provide, a, valuable, reference, for, thediagnosis, of, ptc, these, serological, indexes, combined, with, relevant, risk, factors, mayalso, help, to, predict, the, prognosis, of, ptcafter, ablationacknowledgementsthis, work, wasprovincial, healthcommission, , project, wj2017f102supported, by, the, hubeiplanningand, familydeclaration, of, conflicting, interestthe, authors, declare, that, there, is, no, conï¬ict, ofinterest, 0cpan, et, alfundingthis, research, received, no, speciï¬c, grant, from, anyfunding, agency, in, the, public, commercial, ornotforproï¬t, sectorsorcid000000026050orcid, idqian, dingreferences, zhang, yb, zhang, b, yan, dg, et, al[central, compartment, reoperation, for, recurrentpersistent, differentiated, thyroid, cancer]zhonghua, er, bi, yan, hou, tou, jing, wai, keza, zhi, , , , [in, chinese], pellegriti, g, frasca, f, regalbuto, c, et, alworldwide, increasing, incidence, of, thyroidcancer, update, on, epidemiology, and, risk, factors, j, cancer, epidemiol, , , doi, , brito, jp, gionfriddo, mr, al, nofal, a, et, althe, accuracy, of, thyroid, nodule, ultrasoundto, predict, thyroid, cancer, systematic, reviewand, metaanalysis, j, clin, endocrinol, metab, , , doi, 101210jc2013, zhao, p, zheng, d, dong, x, et, al, clinicaldiagnosis, and, treatment, of, thyroid, microcarcinoma, a, report, of, , cases, chinese, jgene, surg, , , , anil, g, hegde, a, and, chong, fh, thyroidnodules, risk, stratiï¬cation, for, malignancywith, ultrasound, and, guided, biopsy, cancerimaging, , , , doi, , levine, ra, current, guidelines, for, the, management, of, thyroid, nodules, endocr, pract, , , doi, 104158ep12071co, zhang, y, zhang, mb, luo, yk, et, al, effectof, chronic, lymphocytic, thyroiditis, on, theefï¬cacy, and, safety, of, ultrasoundguidedradiofrequency, ablation, for, papillary, thyroid, microcarcinoma, cancer, med, , , liu, y, wang, w, wang, y, et, al, ultrasoundguided, percutaneous, microwave, ablation, inthe, treatment, of, recurrent, thyroid, nodulesj, clin, otolaryngol, head, neck, surg, , , weslley, rosario, p, franco, mourao, gregina, calsolari, m, et, al, role, of, adjuvanttherapy, with, radioactive, iodine, in, patientswith, elevated, serum, thyroglobulin, afterneck, reoperation, due, to, recurrent, papillarythyroid, cancer, a, monoinstitutional, comparative, study, endocrine, , , , zhang, wj, song, b, and, yang, t, mmp2mmp9, timp1, and, timp2, in, theperipheral, blood, of, patients, with, differentiated, thyroid, carcinoma, cancer, manag, res, , wu, r, luo, y, tang, j, et, al, ultrasoundguidedradiofrequency, ablation, for, papillary, thyroidmicrocarcinomaa, retrospective, analysis, of, patients, int, j, hyperthermia, , , zhao, ck, hu, hx, lu, f, et, al, factors, associated, with, initial, incomplete, ablation, forbenign, thyroid, nodules, after, radiofrequencyablation, first, results, of, ceus, evaluationclin, hemorheol, microcirc, , , , faggiano, a, ramundo, v, assanti, ap, et, althyroid, nodules, treated, with, percutaneousradiofrequency, thermal, ablation, a, comparative, study, j, clin, endocrinol, metab, , , doi, 101210jc20122251, tomayko, ej, cachia, aj, chung, hr, et, alresveratrol, supplementation, reduces, aorticatherosclerosis, and, calciï¬cation, and, attenuates, loss, of, aerobic, capacity, in, a, mousemodel, of, uremia, j, med, food, , , doi, 101089jmf20120219, xhaard, c, rubino, c, clero, e, et, almenstrual, and, reproductive, factors, in, therisk, of, differentiated, thyroid, carcinoma, inyoung, women, in, france, a, populationbased, casecontrol, study, am, j, epidemiol, , , doi, 101093ajekwu220, tafani, m, de, santis, e, coppola, l, et, albridging, hypoxia, inï¬ammation, and, estrogen, receptors, in, thyroid, cancer, progressionbiomed, pharmacother, , , , doi101016jbiopha201310013, bumber, b, marjanovic, kavanagh, mjacovcevic, a, et, al, role, of, matrix, metalloproteinases, and, their, inhibitors, in, the, development, of, cervical, metastases, in, papillary, 0cjournal, of, international, medical, researchthyroid, cancer, clin, otolaryngol, , ofassociation, gharib, h, papini, e, paschke, r, et, alamericanclinicalendocrinologists, associazione, mediciendocrinologiand, european, thyroidassociation, medical, guidelines, for, clinicalpractice, for, the, diagnosis, and, managementof, thyroid, nodules, executive, summary, ofrecommendations, j, endocrinol, invest, , , baek, jh, leejh, valcavi, ret, althermal, ablation, for, benign, thyroid, nodules, radiofrequency, and, laser, korean, jradiol, , , , doi, kjr2011125525, vuong, nl, dinh, lq, radiofrequency, ablation, for, benign, thyroid, nodules, 1yearfollowup, in, , patients, world, j, surg, , , lang, bhh, woo, yc, and, chiu, kwidentifying, predictive, factors, for, efï¬cacy, inhigh, intensity, focused, ultrasound, hifuablation, of, benign, thyroid, nodules, , a, retrospective, analysis, int, j, hyperthermia, , , buryk, ma, simons, jp, picarsic, j, et, al, canmalignant, thyroid, nodules, be, distinguishedfrom, benign, thyroid, nodules, in, children, andadolescents, by, clinical, characteristics, areview, of, , pediatric, patients, with, thyroidnodules, thyroid, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |[, study, aimed, investigate, serum, matrix, metalloproteinase, mmp2, mmp9levels, patients, papillary, thyroid, carcinoma, ptcmethods, fortyone, patients, ptc, undergoing, ultrasoundguided, radiofrequency, ablationrfa, , controls, included, serum, mmp2, mmp9, levels, determined, byenzymelinked, immunosorbent, assay, surgery, potential, affecting, factors, wereevaluated, logistic, regression, analysisresults, serum, mmp2, mmp9, levels, significantly, higher, ptc, patients, comparedwith, controls, decreased, significantly, surgery, according, receiver, operating, characteristic, curve, analysis, diagnostic, values, preoperative, serum, mmp2, mmp9, levels, , contrastagent, perfusion, ablation, zone, , lesionsand, enhancement, within, lesion, edge, , volume, reduction, , monthsfollowup, , age, microcalcification, irregular, shape, lesion, diameter, numberwere, influencing, factors, ptc, age, lesion, diameter, number, independent, riskfactors, calcification, morphology, protective, factorsconclusion, serum, mmp2, mmp9, levels, important, clinical, values, diagnosis, andtreatment, ptc, rfa, preoperative, serum, mmp2, mmp9, levels, combined, otheraffecting, factors, contribute, disease, prognosisdepartment, ultrasound, beilun, peoples, hospital, ofningbo, beilun, branch, first, affiliated, hospital, ofzhejiang, university, ningbo, zhejiang, chinathese, authors, contributed, equally, studycorresponding, authorqian, ding, department, ultrasound, beilun, peopleshospital, ningbo, beilun, branch, first, affiliatedhospital, zhejiang, university, , east, lushanroad, ningbo, , zhejiang, chinaemail, qianding02sohucomcreative, commons, non, commercial, cc, bync, , distributed, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, permitsnoncommercial, use, reproduction, distribution, work, without, permission, provided, original, work, attributedas, specified, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, international, medical, researchkeywordspapillary, thyroid, carcinoma, radiofrequency, ablation, matrix, metalloproteinase2, matrix, metalloproteinase9, disease, prognosis, serum, leveldate, received, , june, , accepted, , march, introductionpapillary, thyroid, carcinoma, ptcis, acommon, thyroid, malignancy, accountingfor, , systemic, malignancies1ptc, currently, characterized, highincidence, low, mortality2clinicalrecentimprovementsin, highfrequencyultrasonic, diagnostic, technologies, theapplication, ultrasoundguided, puncturetechniques, led, apparent, increasein, incidence, ptc, year, year3regardingthyroidtumors, palpation, detection, rate, forthyroid, microtumors, general, population, , compared, highas, , , highfrequency, ultrasound6, thus, greatly, improveddisease, diagnosisdiagnosistheofsurgical, resection, routine, treatmentfor, thyroid, tumors, recurrence, rateis, usually, high, consequent, reduction, thyroid, function, seriously, affectthe, patients, quality, life7, associatedwith, increasing, detection, rate, thyroidtumors, pursuit, minimally, invasive, treatments, radiofrequency, ablationrfa, gradually, applied, theclinic, rfa, uses, local, hyperthermia, tocause, tissue, necrosis, thermal, effectsdo, depend, tissue, type, andmost, lesions, completely, eliminatedby, rfa89, rfa, thus, become, novellocal, treatment, tumorsthe, clinical, diagnosis, benign, andmalignant, thyroid, tumors, currently, dependson, clinical, manifestations, pathological, examinations, howeverthe, clinicalmanifestations, mostly, derived, frominvolvessubjective, empirical, analysis, ï¬nalpathological, diagnosisinvasiveprocedures, lesssatisfactory, speciï¬city, therefore, necessary, identifyappropriatepredictivetumor, markersdiagnosticandforimplicationsthe, collagenases, matrix, metalloproteinase, mmp2, mmp9, degradetype, iv, collagen, basement, membranewith, importanttumorangiogenesis, tumor, cell, invasion, andmetastasis10, mmp2, mmp9, expression, levels, found, upregulatedin, thyroid, cancer, tissue11, however, thesestudies, mostly, examined, pathological, tissuesafterinvasive, surgery, lessinvasivemeasures, serum, levels, mmp2and, mmp9, lesswell, consideredin, study, detected, serum, levels, ofmmp2, mmp9, patients, ptcbefore, ultrasoundguided, rfawe, also, determined, therapeutic, effectsof, rfa, followup, period, andinvestigated, relevant, prognostic, factorsmaterials, methodsstudy, subjectspatients, underwent, ultrasoundguidedrfa, hospital, may, , tooctober, , included, studythe, inclusion, criteria, follows, patients, diagnosed, preoperative, ï¬neneedle, aspiration, cytology, , historyof, neck, surgery, , patients, requiringminimally, invasive, treatment, aestheticreasons, neck, oppression, 0cpan, et, alwith, anxiety, exclusion, criteria, asfollows, , benign, lesions, conï¬rmed, ï¬neneedle, aspiration, cytology, , history, ofneck, surgery, , severe, coagulopathyperipheral, venous, blood, samples, wereobtained, included, patients, beforeand, , , , , months, operation, serum, levels, mmp2, andmmp9, determined, additional, subjects, conï¬rmed, benign, thyroid, noduleswithout, rfa, included, controlgroup, prior, written, informed, consent, wasobtained, patients, studywas, approved, ethics, review, boardof, hospitalpreoperative, preparationcalciï¬cationthe, number, size, nature, echo, boundarymorphologysurroundinghalo, nodular, blood, ï¬ow, distributionof, tumors, assessed, operation, skin, disinfection, local, anesthesia, performed, , lidocainesolution, total, , ml, sonovue, bracco, milan, italy, injected, via, elbowvein, bloodsupply, characteristicswere, evaluated, contrastenhancedultrasound, ceus, ablationtargetedlesions, using, mylab90, ultrasonic, devicewith, 10mhz, probe, esaote, shenzhenguangdong, chinaaccording, location, thyroidnodules, thyroid, carotid, space, thyroid, tracheal, space, thyroid, esophageal, space, posterior, thyroid, spacerecurrent, laryngeal, nerve, separatedusing, saline, lidocaine, mixture, basedon, intraoperative, conditions, form, aliquid, separation, zone, protectthesestructures, thermal, damageablation, treatmentunder, ultrasound, guidancethe, tip, ofthe, rfa, needle, rated, power, , woutput, frequency, , khz, accuratelypenetrated, nodule, rfa, wasperformed, using, olympuscelon, powerrfa, system, germany, mobile, mode12following, fromdeeptoshallow, principle, lesions, subjected, multipointed, multifaceted, ablation, untilthe, thyroid, tissue, layer, noduleswas, completely, covered, strong, echogenerated, heat, accumulation, wholeprocess, carried, continuousultrasound, monitoring, highecho, areawas, produced, ablation, zone, duringthe, ablation, treatment, position, theelectrode, needle, gradually, adjustedaccording, lesion, size, ensuringthat, residual, enhancement, inthe, ablation, zone, ablation, needle, wasremoved, ablation, completedafter, operation, ice, compress, wasapplied, , h, avoid, skin, burnsserum, mmp, determinationfor, subjects, , ml, venous, blood, wascollected, elbow, vein, fastingconditions, operationrespectively, blood, samples, controlgroup, collected, ultrasound, contrast, examination, blood, samples, wereplaced, room, temperature, , minutesand, subjected, centrifugation, 02, g, , minutes, serum, washarvested, serum, levels, mmp3, andmmp9, determined, using, enzymelinked, immunosorbentelisakitsboster, bioengineering, wuhanhubei, chinaassayfollowup, efficacy, evaluationimmediately, operation, ablation, range, evaluated, ceus, residualtissues, detected, ablation, wasrepeated, immediately, ultrasound, detectionwas, performed, , , , , monthsafter, surgery, determine, nodule, sizesand, volumes, volumereduction, rate, 0cwas, calculated, according, followingformula, volume, reduction, rate¼, preoperative, volume, , followup, volumepreoperative, volume, 02, , echo, bloodï¬owchanges, ablation, zone, alsoobserved, analyzed, efï¬cacy, wasdetermined, based, criteria, rfafor, treating, tumors13, disappearance, ofnodules, indicated, complete, disappearance, blood, ï¬ow, conï¬rmed, ultrasonography, indicated, complete, cure, noduleby, , 15, indicatedvolumemarked, effect, nodule, volume, reducedby, , , indicated, improvementreducedclinicopathological, featuresinformation, ultrasoundbased, clinicopathologicalincluding, numbersize, calciï¬cation, lesion, wereobtainedfeaturesversion, statistical, analysisdata, expressed, mean, 06, standarddeviation, statistical, analysis, performed, using, ibm, spss, statisticsforwindowsibm, corparmonk, ny, usa, comparisons, betweengroups, performed, using, v2testspotentially, related, factors, analyzedby, univariate, multivariate, logistic, regression, prognostic, predictive, effects, ofserum, mmp2, mmp9, levels, wereevaluated, receiver, operating, characteristic, roc, curve, analysis, p, , , considered, statistically, signiï¬cantresultspatientsjournal, international, medical, research, men, mean, age, , 06, , years, range, yearsserum, mmp2, mmp9, levels, beforeand, treatmentthe, characteristics, ultrasound, images, inthe, included, subjects, shown, table, serum, levels, mmp2, mmp9, weremeasured, treatment, serumlevels, mmp2, mmp9, signiï¬cantly, higher, patients, ptc, comparedwith, control, subjects, p, , , serumlevels, mmp2, mmp9, declinedat, , month, operation, comparedwith, surgery, difference, wasnot, signiï¬cant, however, serum, levels, ofmmp2, mmp9, declined, signiï¬cantly, ptc, patients, , , , monthsall, p, , , table, , results, suggestthat, changes, serum, mmp2, mmp9levels, surgery, mayhave, signiï¬cant, implications, therapyof, ptcroc, curve, analysis, preoperative, serummmp2, mmp9, levelspreoperative, serum, mmp2, mmp9levels, used, potential, diagnostic, indicators, , patients, ptc, predictive, probability, theregressionmodel, used, diagnostic, resultsand, gold, standard, classiï¬cation, criteriawere, used, pathological, results, roccurves, obtained, accordingly, areaundercurve, auc, values, serum, mmp, mmp9, levels, , respectively, figure, , results, suggestthat, serum, levels, mmp2, mmp9could, contribute, disease, diagnosisfortyone, patients, ptc, , lesionswere, enrolledincluding, , women, men, mean, age, , 06, , years, range, ã¾65, years, control, group, included, , patients, conï¬rmed, benignthyroid, nodules, including, , women, andevaluation, rfa, efficacywe, also, evaluated, efï¬cacy, rfa, ceusof, , lesions, ablation, showed, hypoenhancement, , nodules, isoenhancementin, , nodules, slight, hyperenhancement, 0cpan, et, altable, , characteristics, thyroid, ultrasound, imagesptc, patientsnormal, controllesion, numberonetwomultiplelesion, size, 14, cm, cmcalcificationmicrocalcificationcoarse, calcificationmorphologyregularirregularage, years, 15, yearsnp, , , compared, control, groupntable, , serum, matrix, metalloproteinase2, , levels, controls, inpatients, papillary, thyroid, carcinoma, treatmentcontrolsptc, patientsbefore, surgery, month, surgery, months, surgery, months, surgery, months, surgerymmp2, 06, , 06, , 06, , 06, , 06, , 06, pmmp9p, 06, , 06, , , 06, , 06, , 06, , 06, , mmp, matrix, metalloproteinase, ptc, papillary, thyroid, carcinomain, , nodules, ultrasound, examination, afterablation, showed, contrastagent, perfusionin, ablation, zone, , lesions, enhancement, different, degrees, theedge, inside, lesion, lesions, , ablation, area, wasgradually, reduced, prolonged, ablationfigure, , signiï¬cant, changein, ablation, volume, patients, month, surgery, compared, beforesurgery, however, volume, reducedby, , , months, offollowupcompared, surgery, p, , table, , results, showed, rfatreatmentthetumor, volume, patients, ptccould, effectively, reduceinfluence, relevant, factors, diseaseprognosistheclinical, data, patients, beforerfa, retrospectively, analyzed, 0cjournal, international, medical, researchirregularlogistic, regression, identify, factors, thatmay, affectthe, disease, prognosis, agemicrocalciï¬cationshape, anddiameter, number, lesions, significant, inï¬uencing, factors, ptc, p, , hazard, ratios, hrsfor, age, andlesion, diameter, number, , indicating, represented, independentrisk, factors, contrast, hrs, microcalciï¬cation, irregular, shape, negativeindicating, greater, degree, ofcalciï¬cation, regular, shape, associated, lower, risks, developing, disease, thus, protective, factorstable, figure, , roc, analyses, serum, mmp2, andmmp9, levels, mmp, matrix, metalloproteinasefigure, , efficacy, evaluation, radiofrequency, ablation, twodimensional, 2d, ultrasound, showingobvious, bloodflow, signals, around, tumor, fewer, signals, within, tumor, b, preoperative, contrastenhanced, ultrasound, showing, obvious, enhancement, lesion, lowperfusion, performance, c, inthe, 2d, imaging, localization, ablation, needle, inserted, tumor, ablation, d, tumor, wascompletely, ablated, bloodflow, signal, , year, ablation, 0cpan, et, aldiscussionitis, difï¬cultptc, type, thyroid, tumor, highincidence14, increasingrapidly, worldwide1516, mostthyroidtumor, cases, currently, diagnosed, hiscytological, detectiontopathological, orhoweverto, distinguishbetween, benign, malignant, papillaryhyperplastic, nodules, therefore, difï¬cult, diagnose, ptc, also, lackof, effective, speciï¬c, prognostic, molecular, markers, ptc17, relationshipbetween, mmps, tumors, currenthotspot, modern, cancer, research, mmpsplay, important, roles, pathophysiologicalprocesses, dynamic, extracellularmatrix, balance, well, tissue, remodeling, repair10, tumor, cells, may, inducethe, matrix, secrete, mmps, via, series, ofsignalingprovidingpathwaysthustable, , volume, reductions, radiofrequencyablation, papillary, thyroid, carcinomasreductionrate, lesionvolumecm3, 06, , 06, , 06, , , 06, , , months, surgery, , 06, , p, , , p, , , compared, surgerybefore, surgery, month, surgery, months, surgery, months, surgeryfavorable, conditions, tumor, cell, invasionand, metastasisalternatingthe, extensive, surgicalsurgical, resection, traditional, methodthyroid, nodules18for, treatment, ofhowevertraumaunsightly, neck, scars, risks, laryngealnerve, injuries, postoperative, recurrenceand, multiple, operations, mean, increasing, numbers, patients, opting, minimally, invasive, ablation, methods, rfa, athermal, ablation, therapy, uses, highfrequencyelectromagneticwaves, generated, radiofrequencyinstrument, inserted, tumor, tissueto, accumulate, heat, rapid, friction, positive, negative, ions, within, cells, causing, local, coagulation, tumor, tissuewhich, isthen, removed, bodyssystem19, reduction, ratesimmuneforbenign, thyroid, nodules, , , month, ablation, , , months, ablation, beenreported20, study, ultrasound, performed, immediately, ablation, lesions, showed, perfusion, contrastagents, , lesions, enhancementto, varying, degrees, edge, inside, thelesion, , lesions, although, therewere, signiï¬cant, changes, lesion, volumeat, , month, operation, lesionvolumes, reduced, , , months, surgery, considering, thatthe, ablation, effects, might, associatedwith, heat, ablation, needle, atable, , logistic, regression, analysis, relevant, risk, factors, disease, prognosisagemicrocalcificationirregular, morphologylesion, diameterlesion, numberb, , hrhr, hazard, ratio, ci, confidence, interval95cilower, limitupper, limitp, 0cjournal, international, medical, researchï¬ne, needle, good, mobile, conformalablationthe, highfrequency, alternatingelectromagnetic, wave, circulates, theeffective, region, two, needle, tipsthus, allowing, accurate, control, ablation, zone, ablation, safety, zone, aroundthe, ptc, relatively, small, currentstudy, nodulereduction, rate, afterablation, thus, relatively, greaterwe, analyzed, serum, levels, mmp2and, mmp9, ptc, patients, elisapreoperative, serum, levels, enzymeswere, signiï¬cantly, higher, patients, withptc, compared, patients, benigninthyroid, nodules, regarding, changesserum, mmp2, mmp9, levelstheauc, values, based, roc, curveswere, , , mmp2, andmmp9, respectively, suggesting, satisfactory, clinical, diagnostic, prognostic, valuesin, present, study, serum, levels, mmp2and, mmp9, lower, ï¬rst, monthafter, surgery, compared, surgerybut, difference, signiï¬cant, thismight, ablationthetumor, parenchyma, induced, tumorstroma, produce, larger, amounts, ofmmp2, mmp9, releasedinto, blood, results, suggest, thatfailure, completely, ablate, tumor, ortumor, recurrence, may, result, secretionof, high, levels, mmp2, mmp9, intothe, blood, however, serum, levels, mmp, mmp9, signiï¬cantly, decreasedat, , , , months, surgery, compared, surgery, suggesting, thatserum, mmp2, mmp9, secretedby, tumor, lesions, disappearedafter, ptc, ablation, thus, reducing, secretion, mmp2, mmp9, therebyreducing, degradation, destructionof, type, iv, collagen, protecting, basement, membrane, normaltissues, andinhibiting, growth, metastasis, oftumorresults, alsoshowed, age, microcalciï¬cation, irregular, shape, lesion, diameter, numbercells, thecurrentwere, risk, factors, ptc, logistic, regression, analysis, showed, age, , 14, yearswas, important, risk, factor, ptc, inline, ï¬ndings, yu, et, al21microcalciï¬cation, caused, deposition, calcium, salts, tip, nippleor, secretion, calcium, salts, thetumor, considered, tobe, speciï¬c, sign, ptc, thisstudy, incidence, microcalciï¬cationwas, higher, ptc, patients, compared, withthe, control, group, logistic, regressionidentiï¬ed, independent, risk, sign, forthyroid, ptc, results, also, identiï¬edirregular, morphology, two, nodules, anodule, diameter, , 14, cm, danger, signs, forptclargely, consistent, previousï¬ndings22this, study, limitations, asinglecenter, study, relatively, smallnumber, cases, moreover, relevantthyroid, hormone, analysis, serumindicators, followed, alonger, periodtreating, ptc, furthermorein, summary, results, studyshowed, rfa, shrink, eliminatethyroid, lesions, thus, representing, minimally, invasive, safe, effective, methodforserumlevels, mmp2, mmp9, rfacould, provide, valuable, reference, thediagnosis, ptc, serological, indexes, combined, relevant, risk, factors, mayalso, help, predict, prognosis, ptcafter, ablationacknowledgementsthis, work, wasprovincial, healthcommission, , project, wj2017f102supported, hubeiplanningand, familydeclaration, conflicting, interestthe, authors, declare, conï¬ict, ofinterest, 0cpan, et, alfundingthis, research, received, speciï¬c, grant, anyfunding, agency, public, commercial, ornotforproï¬t, sectorsorcid000000026050orcid, idqian, dingreferences, zhang, yb, zhang, b, yan, dg, et, al[central, compartment, reoperation, recurrentpersistent, differentiated, thyroid, cancer]zhonghua, er, bi, yan, hou, tou, jing, wai, keza, zhi, , , , [in, chinese], pellegriti, g, frasca, f, regalbuto, c, et, alworldwide, increasing, incidence, thyroidcancer, update, epidemiology, risk, factors, j, cancer, epidemiol, , , doi, , brito, jp, gionfriddo, mr, al, nofal, et, althe, accuracy, thyroid, nodule, ultrasoundto, predict, thyroid, cancer, systematic, reviewand, metaanalysis, j, clin, endocrinol, metab, , , doi, 101210jc2013, zhao, p, zheng, d, dong, x, et, al, clinicaldiagnosis, treatment, thyroid, microcarcinoma, report, , cases, chinese, jgene, surg, , , , anil, g, hegde, chong, fh, thyroidnodules, risk, stratiï¬cation, malignancywith, ultrasound, guided, biopsy, cancerimaging, , , , doi, , levine, ra, current, guidelines, management, thyroid, nodules, endocr, pract, , , doi, 104158ep12071co, zhang, y, zhang, mb, luo, yk, et, al, effectof, chronic, lymphocytic, thyroiditis, theefï¬cacy, safety, ultrasoundguidedradiofrequency, ablation, papillary, thyroid, microcarcinoma, cancer, med, , , liu, y, wang, w, wang, y, et, al, ultrasoundguided, percutaneous, microwave, ablation, inthe, treatment, recurrent, thyroid, nodulesj, clin, otolaryngol, head, neck, surg, , , weslley, rosario, p, franco, mourao, gregina, calsolari, m, et, al, role, adjuvanttherapy, radioactive, iodine, patientswith, elevated, serum, thyroglobulin, afterneck, reoperation, due, recurrent, papillarythyroid, cancer, monoinstitutional, comparative, study, endocrine, , , , zhang, wj, song, b, yang, mmp2mmp9, timp1, timp2, theperipheral, blood, patients, differentiated, thyroid, carcinoma, cancer, manag, res, , wu, r, luo, y, tang, j, et, al, ultrasoundguidedradiofrequency, ablation, papillary, thyroidmicrocarcinomaa, retrospective, analysis, patients, int, j, hyperthermia, , , zhao, ck, hu, hx, lu, f, et, al, factors, associated, initial, incomplete, ablation, forbenign, thyroid, nodules, radiofrequencyablation, first, results, ceus, evaluationclin, hemorheol, microcirc, , , , faggiano, ramundo, v, assanti, ap, et, althyroid, nodules, treated, percutaneousradiofrequency, thermal, ablation, comparative, study, j, clin, endocrinol, metab, , , doi, 101210jc20122251, tomayko, ej, cachia, aj, chung, hr, et, alresveratrol, supplementation, reduces, aorticatherosclerosis, calciï¬cation, attenuates, loss, aerobic, capacity, mousemodel, uremia, j, med, food, , , doi, 101089jmf20120219, xhaard, c, rubino, c, clero, e, et, almenstrual, reproductive, factors, therisk, differentiated, thyroid, carcinoma, inyoung, women, france, populationbased, casecontrol, study, j, epidemiol, , , doi, 101093ajekwu220, tafani, m, de, santis, e, coppola, l, et, albridging, hypoxia, inï¬ammation, estrogen, receptors, thyroid, cancer, progressionbiomed, pharmacother, , , , doi101016jbiopha201310013, bumber, b, marjanovic, kavanagh, mjacovcevic, et, al, role, matrix, metalloproteinases, inhibitors, development, cervical, metastases, papillary, 0cjournal, international, medical, researchthyroid, cancer, clin, otolaryngol, , ofassociation, gharib, h, papini, e, paschke, r, et, alamericanclinicalendocrinologists, associazione, mediciendocrinologiand, european, thyroidassociation, medical, guidelines, clinicalpractice, diagnosis, managementof, thyroid, nodules, executive, summary, ofrecommendations, j, endocrinol, invest, , , baek, jh, leejh, valcavi, ret, althermal, ablation, benign, thyroid, nodules, radiofrequency, laser, korean, jradiol, , , , doi, kjr2011125525, vuong, nl, dinh, lq, radiofrequency, ablation, benign, thyroid, nodules, 1yearfollowup, , patients, world, j, surg, , , lang, bhh, woo, yc, chiu, kwidentifying, predictive, factors, efï¬cacy, inhigh, intensity, focused, ultrasound, hifuablation, benign, thyroid, nodules, , retrospective, analysis, int, j, hyperthermia, , , buryk, ma, simons, jp, picarsic, j, et, al, canmalignant, thyroid, nodules, distinguishedfrom, benign, thyroid, nodules, children, andadolescents, clinical, characteristics, areview, , pediatric, patients, thyroidnodules, thyroid, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |[, study, aimed, investigate, serum, matrix, metalloproteinase, mmp2, mmp9levels, patients, with, papillary, thyroid, carcinoma, ptcmethods, fortyone, patients, with, ptc, undergoing, ultrasoundguided, radiofrequency, ablationrfa, , controls, were, included, serum, mmp2, mmp9, levels, were, determined, byenzymelinked, immunosorbent, assay, before, after, surgery, potential, affecting, factors, wereevaluated, by, logistic, regression, analysisresults, serum, mmp2, mmp9, levels, were, significantly, higher, ptc, patients, comparedwith, controls, decreased, significantly, after, surgery, according, receiver, operating, characteristic, curve, analysis, diagnostic, values, preoperative, serum, mmp2, mmp9, levels, were, , there, no, contrastagent, perfusion, ablation, zone, , lesionsand, enhancement, within, or, at, lesion, edge, , volume, reduction, at, , monthsfollowup, , age, microcalcification, irregular, shape, lesion, diameter, numberwere, influencing, factors, ptc, age, lesion, diameter, number, were, independent, riskfactors, while, calcification, morphology, were, protective, factorsconclusion, serum, mmp2, mmp9, levels, have, important, clinical, values, diagnosis, andtreatment, ptc, by, rfa, preoperative, serum, mmp2, mmp9, levels, combined, with, otheraffecting, factors, contribute, disease, prognosisdepartment, ultrasound, beilun, peoples, hospital, ofningbo, beilun, branch, first, affiliated, hospital, ofzhejiang, university, ningbo, zhejiang, chinathese, authors, contributed, equally, studycorresponding, authorqian, ding, department, ultrasound, beilun, peopleshospital, ningbo, beilun, branch, first, affiliatedhospital, zhejiang, university, no, , east, lushanroad, ningbo, , zhejiang, chinaemail, qianding02sohucomcreative, commons, non, commercial, cc, bync, , distributed, under, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, distribution, work, without, further, permission, provided, original, work, attributedas, specified, on, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, international, medical, researchkeywordspapillary, thyroid, carcinoma, radiofrequency, ablation, matrix, metalloproteinase2, matrix, metalloproteinase9, disease, prognosis, serum, leveldate, received, , june, , accepted, , march, introductionpapillary, thyroid, carcinoma, ptcis, acommon, thyroid, malignancy, accountingfor, about, , systemic, malignancies1ptc, currently, characterized, by, highincidence, low, mortality2clinicalrecentimprovementsin, highfrequencyultrasonic, diagnostic, technologies, theapplication, ultrasoundguided, puncturetechniques, have, led, an, apparent, increasein, incidence, ptc, year, by, year3regardingthyroidtumors, palpation, detection, rate, forthyroid, microtumors, general, population, about, , compared, with, as, highas, , , highfrequency, ultrasound6, which, has, thus, greatly, improveddisease, diagnosisdiagnosistheofsurgical, resection, routine, treatmentfor, thyroid, tumors, but, recurrence, rateis, usually, high, consequent, reduction, thyroid, function, can, seriously, affectthe, patients, quality, life7, associatedwith, increasing, detection, rate, thyroidtumors, pursuit, minimally, invasive, treatments, radiofrequency, ablationrfa, has, been, gradually, applied, theclinic, rfa, uses, local, hyperthermia, tocause, tissue, necrosis, thermal, effectsdo, not, depend, on, tissue, type, andmost, lesions, can, be, completely, eliminatedby, rfa89, rfa, has, thus, become, novellocal, treatment, tumorsthe, clinical, diagnosis, benign, andmalignant, thyroid, tumors, currently, dependson, clinical, manifestations, pathological, examinations, howeverthe, clinicalmanifestations, are, mostly, derived, frominvolvessubjective, empirical, analysis, while, ï¬nalpathological, diagnosisinvasiveprocedures, with, lesssatisfactory, speciï¬city, it, therefore, necessary, identifyappropriatepredictivetumor, markersdiagnosticandforimplicationsthe, collagenases, matrix, metalloproteinase, mmp2, mmp9, can, degradetype, iv, collagen, basement, membranewith, importanttumorangiogenesis, tumor, cell, invasion, andmetastasis10, mmp2, mmp9, expression, levels, were, found, be, upregulatedin, thyroid, cancer, tissue11, however, thesestudies, mostly, examined, pathological, tissuesafterinvasive, surgery, lessinvasivemeasures, such, as, serum, levels, mmp2and, mmp9, have, been, lesswell, consideredin, study, we, detected, serum, levels, ofmmp2, mmp9, patients, with, ptcbefore, after, ultrasoundguided, rfawe, also, determined, therapeutic, effectsof, rfa, during, followup, period, andinvestigated, relevant, prognostic, factorsmaterials, methodsstudy, subjectspatients, who, underwent, ultrasoundguidedrfa, our, hospital, from, may, , tooctober, , were, included, studythe, inclusion, criteria, were, as, follows, patients, diagnosed, by, preoperative, ï¬neneedle, aspiration, cytology, , no, historyof, neck, surgery, , patients, requiringminimally, invasive, treatment, aestheticreasons, because, neck, oppression, 0cpan, et, alwith, anxiety, exclusion, criteria, were, asfollows, , benign, lesions, conï¬rmed, by, ï¬neneedle, aspiration, cytology, , history, ofneck, surgery, , severe, coagulopathyperipheral, venous, blood, samples, wereobtained, from, included, patients, beforeand, at, , , , , months, after, operation, serum, levels, mmp2, andmmp9, were, determined, additional, subjects, with, conï¬rmed, benign, thyroid, noduleswithout, rfa, were, included, as, controlgroup, prior, written, informed, consent, wasobtained, from, all, patients, studywas, approved, by, ethics, review, boardof, our, hospitalpreoperative, preparationcalciï¬cationthe, number, size, nature, echo, boundarymorphologysurroundinghalo, nodular, blood, ï¬ow, distributionof, tumors, were, assessed, before, operation, after, skin, disinfection, local, anesthesia, performed, with, , lidocainesolution, total, , ml, sonovue, bracco, milan, italy, injected, via, elbowvein, bloodsupply, characteristicswere, then, evaluated, by, contrastenhancedultrasound, ceus, ablationtargetedlesions, using, mylab90, ultrasonic, devicewith, 10mhz, probe, esaote, shenzhenguangdong, chinaaccording, location, thyroidnodules, thyroid, carotid, space, thyroid, tracheal, space, thyroid, esophageal, space, posterior, thyroid, spacerecurrent, laryngeal, nerve, were, separatedusing, saline, lidocaine, mixture, basedon, intraoperative, conditions, form, aliquid, separation, zone, protectthesestructures, from, thermal, damageablation, treatmentunder, ultrasound, guidancethe, tip, ofthe, rfa, needle, rated, power, , woutput, frequency, , khz, accuratelypenetrated, into, nodule, rfa, wasperformed, using, an, olympuscelon, powerrfa, system, germany, mobile, mode12following, fromdeeptoshallow, principle, lesions, were, subjected, multipointed, multifaceted, ablation, untilthe, thyroid, tissue, layer, with, noduleswas, completely, covered, by, strong, echogenerated, by, heat, accumulation, wholeprocess, carried, out, under, continuousultrasound, monitoring, highecho, areawas, produced, ablation, zone, duringthe, ablation, treatment, position, theelectrode, needle, gradually, adjustedaccording, lesion, size, after, ensuringthat, there, no, residual, enhancement, inthe, ablation, zone, ablation, needle, wasremoved, ablation, completedafter, operation, an, ice, compress, wasapplied, , h, avoid, skin, burnsserum, mmp, determinationfor, all, subjects, , ml, venous, blood, wascollected, from, elbow, vein, under, fastingconditions, before, after, operationrespectively, blood, samples, controlgroup, were, collected, after, ultrasound, contrast, examination, blood, samples, wereplaced, at, room, temperature, , minutesand, then, subjected, centrifugation, at, 02, g, , minutes, serum, washarvested, serum, levels, mmp3, andmmp9, were, determined, using, enzymelinked, immunosorbentelisakitsboster, bioengineering, wuhanhubei, chinaassayfollowup, efficacy, evaluationimmediately, after, operation, ablation, range, evaluated, by, ceus, if, residualtissues, were, detected, ablation, wasrepeated, immediately, ultrasound, detectionwas, performed, at, , , , , monthsafter, surgery, determine, nodule, sizesand, volumes, volumereduction, rate, 0cwas, calculated, according, followingformula, volume, reduction, rate¼, preoperative, volume, , followup, volumepreoperative, volume, 02, , echo, bloodï¬owchanges, ablation, zone, were, alsoobserved, analyzed, efï¬cacy, wasdetermined, based, on, criteria, rfafor, treating, tumors13, disappearance, ofnodules, indicated, by, complete, disappearance, blood, ï¬ow, conï¬rmed, by, ultrasonography, indicated, complete, cure, noduleby, , 15, indicatedvolumemarked, effect, nodule, volume, reducedby, , , indicated, improvementreducedclinicopathological, featuresinformation, on, ultrasoundbased, clinicopathologicalincluding, numbersize, calciï¬cation, lesion, wereobtainedfeaturesversion, statistical, analysisdata, were, expressed, as, mean, 06, standarddeviation, statistical, analysis, performed, using, ibm, spss, statisticsforwindowsibm, corparmonk, ny, usa, comparisons, betweengroups, were, performed, using, v2testspotentially, related, factors, were, analyzedby, univariate, or, multivariate, logistic, regression, prognostic, predictive, effects, ofserum, mmp2, mmp9, levels, wereevaluated, by, receiver, operating, characteristic, roc, curve, analysis, p, , , considered, statistically, signiï¬cantresultspatientsjournal, international, medical, research, men, mean, age, , 06, , years, range, yearsserum, mmp2, mmp9, levels, beforeand, after, treatmentthe, characteristics, ultrasound, images, inthe, included, subjects, are, shown, table, serum, levels, mmp2, mmp9, weremeasured, before, after, treatment, serumlevels, mmp2, mmp9, were, signiï¬cantly, higher, patients, with, ptc, comparedwith, control, subjects, p, , , serumlevels, mmp2, mmp9, had, declinedat, , month, after, operation, comparedwith, before, surgery, but, difference, wasnot, signiï¬cant, however, serum, levels, ofmmp2, mmp9, had, declined, signiï¬cantly, ptc, patients, at, , , , monthsall, p, , , table, , these, results, suggestthat, changes, serum, mmp2, mmp9levels, between, before, after, surgery, mayhave, signiï¬cant, implications, therapyof, ptcroc, curve, analysis, preoperative, serummmp2, mmp9, levelspreoperative, serum, mmp2, mmp9levels, were, used, as, potential, diagnostic, indicators, , patients, with, ptc, predictive, probability, from, theregressionmodel, used, as, diagnostic, resultsand, gold, standard, classiï¬cation, criteriawere, used, as, pathological, results, roccurves, were, obtained, accordingly, areaundercurve, auc, values, serum, mmp, mmp9, levels, were, , respectively, figure, , these, results, suggestthat, serum, levels, mmp2, mmp9could, contribute, disease, diagnosisfortyone, patients, with, ptc, , lesionswere, enrolledincluding, , women, men, mean, age, , 06, , years, range, ã¾65, years, control, group, included, , patients, with, conï¬rmed, benignthyroid, nodules, including, , women, andevaluation, rfa, efficacywe, also, evaluated, efï¬cacy, rfa, ceusof, , lesions, before, ablation, showed, hypoenhancement, , nodules, isoenhancementin, , nodules, slight, hyperenhancement, 0cpan, et, altable, , characteristics, thyroid, ultrasound, imagesptc, patientsnormal, controllesion, numberonetwomultiplelesion, size, 14, cm, cmcalcificationmicrocalcificationcoarse, calcificationmorphologyregularirregularage, years, 15, yearsnp, , , compared, with, control, groupntable, , serum, matrix, metalloproteinase2, , levels, controls, inpatients, with, papillary, thyroid, carcinoma, before, after, treatmentcontrolsptc, patientsbefore, surgery, month, after, surgery, months, after, surgery, months, after, surgery, months, after, surgerymmp2, 06, , 06, , 06, , 06, , 06, , 06, pmmp9p, 06, , 06, , , 06, , 06, , 06, , 06, , mmp, matrix, metalloproteinase, ptc, papillary, thyroid, carcinomain, , nodules, ultrasound, examination, afterablation, showed, no, contrastagent, perfusionin, ablation, zone, , lesions, enhancement, different, degrees, at, theedge, or, inside, lesion, other, lesions, , ablation, area, wasgradually, reduced, with, prolonged, ablationfigure, , there, no, signiï¬cant, changein, ablation, volume, any, patients, at, month, after, surgery, compared, with, beforesurgery, however, volume, reducedby, , at, , months, offollowupcompared, with, before, surgery, p, , table, , these, results, showed, that, rfatreatmentthetumor, volume, patients, with, ptccould, effectively, reduceinfluence, relevant, factors, on, diseaseprognosistheclinical, data, patients, beforerfa, were, retrospectively, analyzed, by, 0cjournal, international, medical, researchirregularlogistic, regression, identify, factors, thatmay, affectthe, disease, prognosis, agemicrocalciï¬cationshape, anddiameter, number, lesions, were, significant, inï¬uencing, factors, ptc, p, , hazard, ratios, hrsfor, age, andlesion, diameter, number, were, , indicating, that, these, represented, independentrisk, factors, contrast, hrs, microcalciï¬cation, irregular, shape, were, negativeindicating, that, greater, degree, ofcalciï¬cation, regular, shape, were, associated, with, lower, risks, developing, disease, were, thus, protective, factorstable, figure, , roc, analyses, serum, mmp2, andmmp9, levels, mmp, matrix, metalloproteinasefigure, , efficacy, evaluation, radiofrequency, ablation, twodimensional, 2d, ultrasound, showingobvious, bloodflow, signals, around, tumor, fewer, signals, within, tumor, b, preoperative, contrastenhanced, ultrasound, showing, no, obvious, enhancement, lesion, with, lowperfusion, performance, c, inthe, 2d, imaging, localization, ablation, needle, inserted, into, tumor, ablation, d, tumor, wascompletely, ablated, with, no, bloodflow, signal, at, , year, after, ablation, 0cpan, et, aldiscussionitis, difï¬cultptc, type, thyroid, tumor, with, highincidence14, which, has, been, increasingrapidly, worldwide1516, mostthyroidtumor, cases, are, currently, diagnosed, by, hiscytological, detectiontopathological, orhoweverto, distinguishbetween, benign, malignant, papillaryhyperplastic, nodules, it, therefore, difï¬cult, diagnose, ptc, there, also, lackof, effective, speciï¬c, prognostic, molecular, markers, ptc17, relationshipbetween, mmps, tumors, currenthotspot, modern, cancer, research, mmpsplay, important, roles, pathophysiologicalprocesses, such, as, dynamic, extracellularmatrix, balance, as, well, as, tissue, remodeling, repair10, tumor, cells, may, inducethe, matrix, secrete, mmps, via, series, ofsignalingprovidingpathwaysthustable, , volume, reductions, after, radiofrequencyablation, papillary, thyroid, carcinomasreductionrate, lesionvolumecm3, 06, , 06, , 06, , , 06, , , months, after, surgery, , 06, , p, , , p, , , compared, with, before, surgerybefore, surgery, month, after, surgery, months, after, surgery, months, after, surgeryfavorable, conditions, tumor, cell, invasionand, metastasisalternatingthe, extensive, surgicalsurgical, resection, traditional, methodthyroid, nodules18for, treatment, ofhowevertraumaunsightly, neck, scars, risks, laryngealnerve, injuries, postoperative, recurrenceand, multiple, operations, mean, that, increasing, numbers, patients, are, opting, minimally, invasive, ablation, methods, rfa, athermal, ablation, therapy, that, uses, highfrequencyelectromagneticwaves, generated, by, radiofrequencyinstrument, inserted, into, tumor, tissueto, accumulate, heat, by, rapid, friction, positive, negative, ions, within, cells, causing, local, coagulation, tumor, tissuewhich, isthen, removed, by, bodyssystem19, reduction, ratesimmuneforbenign, thyroid, nodules, , after, , month, ablation, , after, , months, ablation, have, beenreported20, study, ultrasound, performed, immediately, after, ablation, lesions, showed, no, perfusion, contrastagents, , lesions, enhancementto, varying, degrees, at, edge, or, inside, thelesion, , lesions, although, therewere, no, signiï¬cant, changes, lesion, volumeat, , month, after, operation, lesionvolumes, were, reduced, by, , , at, months, after, surgery, considering, thatthe, ablation, effects, might, be, associatedwith, heat, ablation, needle, atable, , logistic, regression, analysis, relevant, risk, factors, disease, prognosisagemicrocalcificationirregular, morphologylesion, diameterlesion, numberb, , hrhr, hazard, ratio, ci, confidence, interval95cilower, limitupper, limitp, 0cjournal, international, medical, researchï¬ne, needle, good, mobile, conformalablationthe, highfrequency, alternatingelectromagnetic, wave, only, circulates, theeffective, region, between, two, needle, tipsthus, allowing, accurate, control, ablation, zone, ablation, safety, zone, aroundthe, ptc, relatively, small, currentstudy, nodulereduction, rate, afterablation, thus, relatively, greaterwe, analyzed, serum, levels, mmp2and, mmp9, ptc, patients, by, elisapreoperative, serum, levels, both, enzymeswere, signiï¬cantly, higher, patients, withptc, compared, with, patients, with, benigninthyroid, nodules, regarding, changesserum, mmp2, mmp9, levelstheauc, values, based, on, roc, curveswere, , , mmp2, andmmp9, respectively, suggesting, satisfactory, clinical, diagnostic, prognostic, valuesin, present, study, serum, levels, mmp2and, mmp9, were, lower, ï¬rst, monthafter, surgery, compared, with, before, surgerybut, difference, not, signiï¬cant, thismight, be, because, before, ablationthetumor, parenchyma, induced, tumorstroma, produce, larger, amounts, ofmmp2, mmp9, which, were, releasedinto, blood, these, results, suggest, thatfailure, completely, ablate, tumor, ortumor, recurrence, may, result, secretionof, high, levels, mmp2, mmp9, intothe, blood, however, serum, levels, mmp, mmp9, were, signiï¬cantly, decreasedat, , , , months, after, surgery, compared, with, before, surgery, suggesting, thatserum, mmp2, mmp9, were, secretedby, tumor, lesions, disappearedafter, ptc, ablation, thus, reducing, secretion, mmp2, mmp9, therebyreducing, degradation, destructionof, type, iv, collagen, protecting, basement, membrane, normaltissues, andinhibiting, growth, metastasis, oftumorresults, alsoshowed, that, age, microcalciï¬cation, irregular, shape, lesion, diameter, numbercells, thecurrentwere, risk, factors, ptc, logistic, regression, analysis, showed, that, age, , 14, yearswas, an, important, risk, factor, ptc, inline, with, ï¬ndings, yu, et, al21microcalciï¬cation, caused, by, deposition, calcium, salts, at, tip, nippleor, secretion, calcium, salts, by, thetumor, itself, has, been, considered, tobe, most, speciï¬c, sign, ptc, thisstudy, incidence, microcalciï¬cationwas, higher, ptc, patients, compared, withthe, control, group, logistic, regressionidentiï¬ed, it, as, an, independent, risk, sign, forthyroid, ptc, our, results, also, identiï¬edirregular, morphology, two, nodules, anodule, diameter, , 14, cm, as, danger, signs, forptclargely, consistent, with, previousï¬ndings22this, study, had, some, limitations, it, asinglecenter, study, with, relatively, smallnumber, cases, moreover, relevantthyroid, hormone, analysis, other, serumindicators, could, not, be, followed, up, alonger, periodtreating, ptc, furthermorein, summary, results, studyshowed, that, rfa, could, shrink, or, eliminatethyroid, lesions, thus, representing, minimally, invasive, safe, effective, methodforserumlevels, mmp2, mmp9, before, rfacould, provide, valuable, reference, thediagnosis, ptc, these, serological, indexes, combined, with, relevant, risk, factors, mayalso, help, predict, prognosis, ptcafter, ablationacknowledgementsthis, work, wasprovincial, healthcommission, , project, wj2017f102supported, by, hubeiplanningand, familydeclaration, conflicting, interestthe, authors, declare, that, there, no, conï¬ict, ofinterest, 0cpan, et, alfundingthis, research, received, no, speciï¬c, grant, from, anyfunding, agency, public, commercial, ornotforproï¬t, sectorsorcid000000026050orcid, idqian, dingreferences, zhang, yb, zhang, b, yan, dg, et, al[central, compartment, reoperation, recurrentpersistent, differentiated, thyroid, cancer]zhonghua, er, bi, yan, hou, tou, jing, wai, keza, zhi, , , , [in, chinese], pellegriti, g, frasca, f, regalbuto, c, et, alworldwide, increasing, incidence, thyroidcancer, update, on, epidemiology, risk, factors, j, cancer, epidemiol, , , doi, , brito, jp, gionfriddo, mr, al, nofal, et, althe, accuracy, thyroid, nodule, ultrasoundto, predict, thyroid, cancer, systematic, reviewand, metaanalysis, j, clin, endocrinol, metab, , , doi, 101210jc2013, zhao, p, zheng, d, dong, x, et, al, clinicaldiagnosis, treatment, thyroid, microcarcinoma, report, , cases, chinese, jgene, surg, , , , anil, g, hegde, chong, fh, thyroidnodules, risk, stratiï¬cation, malignancywith, ultrasound, guided, biopsy, cancerimaging, , , , doi, , levine, ra, current, guidelines, management, thyroid, nodules, endocr, pract, , , doi, 104158ep12071co, zhang, y, zhang, mb, luo, yk, et, al, effectof, chronic, lymphocytic, thyroiditis, on, theefï¬cacy, safety, ultrasoundguidedradiofrequency, ablation, papillary, thyroid, microcarcinoma, cancer, med, , , liu, y, wang, w, wang, y, et, al, ultrasoundguided, percutaneous, microwave, ablation, inthe, treatment, recurrent, thyroid, nodulesj, clin, otolaryngol, head, neck, surg, , , weslley, rosario, p, franco, mourao, gregina, calsolari, m, et, al, role, adjuvanttherapy, with, radioactive, iodine, patientswith, elevated, serum, thyroglobulin, afterneck, reoperation, due, recurrent, papillarythyroid, cancer, monoinstitutional, comparative, study, endocrine, , , , zhang, wj, song, b, yang, t, mmp2mmp9, timp1, timp2, theperipheral, blood, patients, with, differentiated, thyroid, carcinoma, cancer, manag, res, , wu, r, luo, y, tang, j, et, al, ultrasoundguidedradiofrequency, ablation, papillary, thyroidmicrocarcinomaa, retrospective, analysis, patients, int, j, hyperthermia, , , zhao, ck, hu, hx, lu, f, et, al, factors, associated, with, initial, incomplete, ablation, forbenign, thyroid, nodules, after, radiofrequencyablation, first, results, ceus, evaluationclin, hemorheol, microcirc, , , , faggiano, ramundo, v, assanti, ap, et, althyroid, nodules, treated, with, percutaneousradiofrequency, thermal, ablation, comparative, study, j, clin, endocrinol, metab, , , doi, 101210jc20122251, tomayko, ej, cachia, aj, chung, hr, et, alresveratrol, supplementation, reduces, aorticatherosclerosis, calciï¬cation, attenuates, loss, aerobic, capacity, mousemodel, uremia, j, med, food, , , doi, 101089jmf20120219, xhaard, c, rubino, c, clero, e, et, almenstrual, reproductive, factors, therisk, differentiated, thyroid, carcinoma, inyoung, women, france, populationbased, casecontrol, study, am, j, epidemiol, , , doi, 101093ajekwu220, tafani, m, de, santis, e, coppola, l, et, albridging, hypoxia, inï¬ammation, estrogen, receptors, thyroid, cancer, progressionbiomed, pharmacother, , , , doi101016jbiopha201310013, bumber, b, marjanovic, kavanagh, mjacovcevic, et, al, role, matrix, metalloproteinases, their, inhibitors, development, cervical, metastases, papillary, 0cjournal, international, medical, researchthyroid, cancer, clin, otolaryngol, , ofassociation, gharib, h, papini, e, paschke, r, et, alamericanclinicalendocrinologists, associazione, mediciendocrinologiand, european, thyroidassociation, medical, guidelines, clinicalpractice, diagnosis, managementof, thyroid, nodules, executive, summary, ofrecommendations, j, endocrinol, invest, , , baek, jh, leejh, valcavi, ret, althermal, ablation, benign, thyroid, nodules, radiofrequency, laser, korean, jradiol, , , , doi, kjr2011125525, vuong, nl, dinh, lq, radiofrequency, ablation, benign, thyroid, nodules, 1yearfollowup, , patients, world, j, surg, , , lang, bhh, woo, yc, chiu, kwidentifying, predictive, factors, efï¬cacy, inhigh, intensity, focused, ultrasound, hifuablation, benign, thyroid, nodules, , retrospective, analysis, int, j, hyperthermia, , , buryk, ma, simons, jp, picarsic, j, et, al, canmalignant, thyroid, nodules, be, distinguishedfrom, benign, thyroid, nodules, children, andadolescents, by, clinical, characteristics, areview, , pediatric, patients, with, thyroidnodules, thyroid, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |(224581,[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,28,29,30,33,34,35,36,37,38,39,40,42,43,44,45,48,49,50,51,52,54,57,58,59,60,62,63,64,66,68,69,70,73,74,75,77,78,80,81,82,84,86,87,89,91,92,93,94,95,96,97,98,99,100,101,104,107,108,111,113,114,115,117,118,119,120,122,124,129,132,133,134,136,139,140,142,143,144,145,146,148,149,150,153,155,158,159,160,161,163,164,165,166,167,168,169,170,171,172,174,178,179,180,183,186,188,189,190,191,192,193,194,195,197,200,201,202,203,209,214,215,216,217,218,219,223,224,225,227,236,237,238,239,240,247,248,249,253,254,256,260,265,267,269,270,274,276,279,281,283,284,286,288,292,293,296,297,299,305,307,318,320,321,325,331,334,335,336,346,350,351,355,356,359,366,368,369,371,372,375,377,382,389,402,410,411,415,419,426,427,429,434,436,437,440,447,449,452,453,455,460,465,468,471,475,477,480,481,483,487,492,494,495,503,506,510,512,515,516,518,520,521,531,535,543,546,549,559,560,564,567,568,570,572,573,574,576,579,581,582,583,588,594,595,597,601,602,608,611,612,615,617,620,623,632,644,650,657,661,673,674,681,695,700,701,702,708,711,716,733,743,746,747,755,761,765,771,775,777,784,785,788,795,797,799,800,801,805,823,826,832,841,849,860,872,873,875,879,884,886,894,898,899,906,918,924,934,943,944,948,949,954,965,968,971,978,990,992,1012,1023,1029,1036,1060,1064,1070,1081,1083,1084,1092,1095,1104,1116,1122,1140,1144,1153,1157,1163,1177,1197,1198,1215,1217,1222,1228,1252,1262,1263,1264,1285,1288,1292,1301,1304,1306,1307,1325,1331,1335,1350,1359,1368,1371,1382,1392,1423,1434,1436,1440,1442,1450,1455,1458,1459,1465,1473,1491,1492,1497,1498,1503,1530,1539,1545,1550,1559,1563,1565,1568,1572,1575,1578,1582,1592,1594,1607,1613,1622,1624,1640,1645,1652,1657,1671,1675,1678,1679,1691,1693,1697,1705,1711,1718,1720,1728,1740,1782,1784,1832,1845,1852,1868,1872,1880,1891,1923,1937,1955,1971,1973,1975,1977,2004,2016,2025,2030,2043,2060,2065,2087,2098,2116,2142,2145,2149,2157,2185,2198,2207,2213,2216,2228,2231,2234,2300,2326,2337,2370,2389,2422,2425,2445,2452,2453,2467,2477,2503,2508,2527,2533,2544,2555,2557,2566,2575,2578,2587,2599,2603,2622,2628,2671,2681,2708,2716,2728,2738,2754,2771,2801,2831,2837,2867,2874,2922,2947,2998,3061,3065,3067,3109,3118,3146,3186,3208,3220,3256,3269,3290,3294,3297,3299,3323,3344,3377,3402,3410,3427,3441,3460,3471,3516,3520,3525,3553,3580,3616,3694,3801,3825,3831,3875,3920,3965,4023,4045,4048,4076,4083,4092,4099,4103,4118,4233,4263,4288,4324,4398,4432,4441,4451,4486,4506,4515,4518,4524,4588,4603,4610,4614,4625,4632,4684,4749,4800,4801,4823,4882,4996,5019,5029,5030,5037,5092,5096,5172,5239,5276,5307,5334,5397,5419,5517,5525,5537,5600,5621,5680,5740,5772,5804,5846,5856,5967,5982,6030,6058,6090,6157,6168,6220,6233,6264,6279,6301,6302,6366,6387,6416,6526,6623,6640,6692,6726,6788,6872,6929,7033,7176,7252,7285,7313,7381,7413,7469,7500,7511,7567,7607,7638,7693,7699,7720,7729,7820,7948,8073,8078,8123,8131,8195,8276,8299,8305,8362,8418,8532,8802,8987,9004,9032,9049,9259,9268,9288,9317,9418,9547,9706,9812,9838,9876,9916,10001,10017,10029,10042,10058,10074,10142,10144,10150,10191,10406,10555,10577,10584,10627,10679,10752,10804,10869,11014,11320,11350,11379,11397,11399,11400,11525,11887,12132,12409,12484,12598,12645,12755,13008,13284,13347,13452,13523,13537,13600,13979,13984,13994,14012,14051,14070,14106,14113,14126,14292,14322,14480,14753,14830,15122,15139,15172,15572,15845,15858,15990,16044,16272,16365,16381,16382,16395,16424,16478,16777,16839,17001,17292,17604,17628,17657,17895,18026,18114,18408,18566,18717,18856,18971,18985,19343,19366,19423,19442,19468,19714,20022,20055,20087,20160,20796,20931,21019,21170,21266,21828,21914,21956,22023,22167,22764,22823,23015,23788,23937,24092,24150,24561,24719,24902,24967,25157,25567,26159,26246,26277,26451,26494,27704,28144,28711,28861,28981,29340,29424,29606,29853,30317,30340,30402,30471,30493,30531,30646,30696,31244,31870,31918,31926,32340,32911,33486,34054,34060,34473,34489,34812,34952,35220,35396,35538,35744,35835,35963,36910,36938,36975,37490,37646,37761,37867,37982,38457,39056,39528,39588,39973,40396,40709,41020,41046,41056,41232,41273,41275,41605,41717,41865,42187,43349,44780,47441,47855,47911,48449,48458,49326,49367,50019,50094,50216,50421,50892,50927,51975,52022,52937,53056,53551,53558,53776,55720,56311,56412,56593,57291,57375,57607,57925,58044,58517,58687,60065,60098,60310,60558,61101,61158,61487,61960,62810,62887,63035,63120,63121,63294,63863,65023,65227,65504,65797,65867,66355,66607,66755,67961,68211,70076,71169,71667,71931,71984,72714,73103,73586,74690,80688,80955,82337,82374,82940,83590,84023,84868,85930,86309,86489,86797,87727,87870,89123,89278,89294,89906,90360,90450,90494,90498,90847,90976,91025,91045,91604,92445,92463,92748,93588,93838,93907,93996,94022,94276,94431,94439,95821,96758,97029,97563,97627,97676,97935,98056,98137,98205,99631,100144,100498,100558,100772,101984,102011,102217,102316,102371,102640,102864,103187,104610,104765,105250,105447,105664,105736,106809,107310,108152,108164,108798,108850,109835,109954,111823,111873,111929,111992,112265,113009,113377,113384,113385,113674,113749,113998,114075,114536,115607,115764,115871,115893,115974,117143,117207,117381,118202,118543,119111,119509,120790,120907,121038,121907,122303,122306,122460,122752,123499,123705,123712,125855,126077,126504,126512,127037,128369,128900,128923,129641,131922,132487,133569,134009,134193,134788,134874,134891,136791,137320,138602,138820,139242,139682,140229,141196,141553,141653,142053,142521,142846,142997,143704,144463,144513,144936,145353,145636,145809,146049,146632,147033,148162,148471,148970,149469,149506,150883,151469,151695,151865,152548,153405,153684,154104,154375,154559,155413,155517,155572,155771,157170,157303,157529,157755,157821,158376,158745,158918,158972,159049,159563,160068,160121,160275,161138,161405,162178,162233,162278,162621,162823,162918,162926,163286,163508,164079,164082,164119,164453,164722,164901,165154,165482,165964,166002,166061,166067,166162,166515,166822,167317,168536,168725,168769,169652,169758,170055,170129,170828,170850,171025,171074,171504,172018,172631,172664,173563,174213,174773,174792,175711,176585,176597,177394,178028,178959,180054,180142,180220,180292,180745,180890,181132,181340,181585,181964,182036,182103,182734,183940,184173,186008,186428,186480,186613,186932,187284,188293,188458,188697,189181,191697,191780,192051,192194,192523,193307,193601,193948,194274,194575,195134,195416,196040,196438,196770,196923,196975,197012,197060,197282,197871,198104,198300,198398,198419,199336,199338,199773,199782,200123,200230,200271,200559,200742,201456,201487,202162,202280,202951,203158,203828,204726,205112,205155,205736,206063,206345,206355,206390,206613,207198,207305,207325,207947,208816,209474,210311],[172.0,37.0,37.0,25.0,9.0,13.0,9.0,2.0,25.0,5.0,8.0,7.0,4.0,2.0,1.0,6.0,19.0,14.0,5.0,1.0,9.0,1.0,4.0,4.0,3.0,12.0,5.0,2.0,9.0,10.0,4.0,11.0,3.0,6.0,7.0,2.0,5.0,32.0,4.0,4.0,12.0,3.0,6.0,8.0,5.0,2.0,21.0,3.0,2.0,4.0,4.0,23.0,8.0,3.0,2.0,2.0,2.0,1.0,7.0,3.0,2.0,2.0,1.0,3.0,5.0,1.0,2.0,2.0,1.0,2.0,2.0,5.0,1.0,5.0,1.0,4.0,3.0,1.0,2.0,1.0,2.0,4.0,1.0,3.0,3.0,3.0,2.0,1.0,5.0,1.0,2.0,1.0,4.0,2.0,4.0,2.0,1.0,3.0,1.0,9.0,6.0,7.0,6.0,4.0,2.0,1.0,1.0,2.0,15.0,4.0,3.0,6.0,1.0,2.0,1.0,4.0,4.0,1.0,22.0,3.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,38.0,3.0,1.0,1.0,1.0,3.0,1.0,4.0,1.0,3.0,1.0,2.0,9.0,2.0,3.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,2.0,3.0,2.0,4.0,25.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,6.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,2.0,2.0,11.0,1.0,1.0,4.0,3.0,1.0,14.0,1.0,1.0,2.0,1.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,2.0,3.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,5.0,12.0,1.0,3.0,1.0,1.0,1.0,2.0,5.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,2.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,2.0,1.0,4.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,2.0,1.0,1.0,1.0,4.0,3.0,1.0,3.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,17.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,3.0,1.0,1.0,1.0,1.0,36.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,13.0,9.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,2.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,22.0,1.0,1.0,7.0,1.0,3.0,1.0,6.0,1.0,1.0,1.0,1.0,6.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,8.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,20.0,1.0,2.0,1.0,4.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,4.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,26.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,4.0,3.0,1.0,2.0,1.0,1.0,5.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,7.0,2.0,1.0,1.0,1.0,8.0,1.0,4.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,24.0,1.0,1.0,1.0,8.0,2.0,1.0,1.0,2.0,3.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,11.0,1.0,1.0,1.0,1.0,1.0,6.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,3.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n",
      "|[, this, study, was, performed, to, explore, the, effective, management, of, bleeding, associated, with, radiofrequency, ablation, rfa, of, benign, thyroid, nodulesmethods, thirtyfive, patients, with, benign, thyroid, nodules, who, were, treated, with, ultrasoundguided, rfa, from, july, , to, december, , at, the, third, affiliated, hospital, of, sun, yatsenuniversity, were, retrospectively, reviewed, the, technique, efficacy, bleeding, and, other, complications, were, assessed, during, the, followup, periodresults, the, mean, technique, efficacy, was, 06, at, , month, and, 06, at, months, after, the, procedure, one, case, of, an, intranodular, haematoma, and, two, cases, of, voicechange, , month, were, observed, all, patients, recovered, with, corresponding, treatmentconclusion, although, the, incidence, of, haemorrhage, is, low, serious, haematomas, are, lifethreatening, therefore, having, a, comprehensive, understanding, of, the, potential, complicationsan, accurate, clinical, strategy, and, adequate, technical, skills, may, prevent, or, help, to, properly, managethese, complicationskeywordsradiofrequency, ablation, benign, thyroid, nodules, haemorrhage, management, haematomaultrasounddate, received, , january, , accepted, , june, 1department, of, medical, ultrasound, the, third, affiliatedhospital, of, sun, yatsen, university, guangzhou, china2general, surgery, department, the, third, affiliatedhospital, of, sun, yatsen, university, guangzhou, chinathese, authors, contributed, equally, to, this, workcorresponding, authorsbo, liu, general, surgery, department, the, third, affiliatedhospital, of, sun, yatsen, university, , tianhe, roadguangzhou, city, guangdong, province, china, jie, rendepartment, of, medical, ultrasound, the, third, affiliatedhospital, of, sun, yatsen, university, , tianhe, roadguangzhou, city, guangdong, province, chinaemails, renjieguangzhou126com, liubojake126comcreative, commons, non, commercial, cc, bync, this, , is, distributed, under, the, terms, of, the, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, and, distribution, of, the, work, without, further, permission, provided, the, original, work, is, attributedas, specified, on, the, sage, and, , , access, pages, ussagepubcomenusnam, accessatsage, 0cintroductionassociationfor, adultthyroid, nodules, are, extremely, commonand, the, associated, morbidity, rate, rangesfrom, , to, , according, to, highresolution, ultrasound, us, ï¬ndings12mostthyroid, nodules, are, benign, andrequire, no, intervention, other, than, clinicalfollowup, according, to, the, , americanthyroidmanagementguidelinespatients, withthyroid, nodulesand, differentiatedthyroid, cancer, thyroidstimulating, hormone, suppression, therapy, for, benign, thyroid, nodules, btns, is, not, recommendedbecause, the, potential, harm, outweighs, thebeneï¬t3, radioiodine, therapy, was, historically, an, effective, treatment, for, thyroid, hotnodules, and, a, possible, alternative, to, surgery, howeverthis, technique, has, beenproven, to, have, uncertain, efï¬cacy, andsome, adverse, effects, such, as, hypothyroidrecurrence4, surgery, may, beism, orconsideredgrowing, btns, withpressurerelated, symptoms, neck, discomfort, cosmetic, concerns, or, decreased, quality, of, life3, at, present, partialtotal, thyroidsurgery, is, considered, the, gold, standardtreatment, surgeryassociated, withnumerous, complications, such, as, nerveinjury, anaesthesiarelated, problemslonghospital, stays, conspicuous, scars, haemorrhage, and, lesions, ofthe, parathyroidglands78, in, addition, hypothyroidism, isinevitable, after, totalthyroidectomy, andrequires, lifelong, hormone, supplementationhenceincreasingly, minimally, invasivetherapeutic, strategies, are, currently, used, totreat, btns, in, most, cases, several, thermalablation, techniques, such, as, laser, ablationmicrowave, ablation, radiofrequency, ablation, rfa, and, highintensity, focused, ushave, been, shown, to, be, effective, in, btnsamong, these, thermal, ablation, techniquesrfa, is, the, most, widely, applied910forisrfa, of, thyroid, diseases, ï¬rst, reported, in, is, considered, efï¬cacious, and, safejournal, of, international, medical, researchfor, treatment, of, btns1415, to, date, no, lifethreatening, complications, related, to, rfahave, been, reported, howeverseveralcases, of, haemorrhagerelated, to, ï¬neneedle, aspiration, fna, or, core, needlebiopsy, cnb, have, been, reported16although, a, microinvasive, procedure, suchas, fna, can, result, in, massive, uncontrolledbleeding, resulting, in, upper, airway, respiratoryuncontrolledbleeding, is, a, rare, but, lifethreatening, complication, of, rfa, thus, management, ofbleeding, associated, with, rfa, of, btns, isof, vitalimportance, this, study, was, performed, to, explore, the, effective, managementof, bleeding, associated, with, rfa, of, btnsobstructionsuchmaterials, and, methodsofthis, study, was, approved, by, the, ethicscommitteethe, third, afï¬liatedhospital, of, sun, yatsen, university, andwritten, informed, consent, was, obtainedfrom, all, patients, prior, to, the, performanceof, usguided, fna, or, cnb, and, rfa, therequirement, to, obtain, informed, consent, forpublication, was, waived, because, of, the, retrospective, nature, of, the, studypatientsall, consecutive, patients, who, underwentrfa, of, btns, at, our, institution, from, july, to, december, , were, analysed, thefollowing, inclusion, criteria, were, appliedconï¬rmation, of, benignancybethesdaclass, ii, by, fna, cytology, or, cnb, complaints, of, pressure, symptoms, compressivesymptoms, neck, discomfort, orforeignbody, sensation, or, cosmetic, problems, a2cm, maximum, diameter, of, the, indexnodule, anxiety, about, a, malignancy, unsuitability, for, surgery, or, unwillingness, toundergo, surgery, and, a, normal, serum, thyrotropin, concentration, normal, completeblood, counts, and, normal, blood, coagulation, test, results, the, exclusion, criteria, 0chu, et, alwere, nodules, showing, malignant, featuresie, taller, than, wide, spiculated, marginmarked, hypoechoic, appearance, or, microcalciï¬cations, on, us, imaging19, abnormalthyroid, function, performance, of, othertreatments, for, the, thyroid, nodules, within, months, before, the, procedure, pregnancyand, age, of, , years, for, the, presentstudy, only, patients, with, 15, months, offollowup, after, the, procedure, were, included, thirtyï¬ve, patients, met, the, inclusioncriteriapretreatment, assessmentbefore, the, procedure, conventional, usï¬ndings, usguidedfna, ï¬ndingscontrastenhanced, us, ceus, ï¬ndingsand, laboratory, and, clinical, results, wereevaluated, two, radiologists, tw, and, jr, with, , and, , years, of, thyroid, us, experiencerespectively, performed, the, ususguided, fna, and, ceus, examinationsusing, a, logiq, e9, us, device, ge, medicalsystems, milwaukee, wi, usa, equippedwithtransducerwith, a, mhzfrequency, range, , mhz, the, usexamination, included, characterisation, ofthe, location, shape, size, margins, solidcystic, proportions, echogenicity, calciï¬cation, status, and, internal, vascularity, ofeach, nodulefrequency, ofan, ml615centrelinearlaboratory, tests, included, the, levels, ofthyroidstimulating, hormone, free, triiodothyronine, free, thyroxin, and, thyrotropina, complete, blood, cell, count, and, a, coagulation, test, prothrombin, time, and, activatedpartial, thromboplastin, time, the, nodulevolume, was, calculated, using, the, followingvolume¼, length, 02, width, 02equationdepth, 02, in, addition, all, patientsunderwent, vocal, cord, function, assessmentsby, an, experienced, laryngologist, before, theablation, procedure, atenrolment, allpatients, were, asked, to, rate, their, pressuresymptoms, on, a, 10cm, visual, analoguescale, grade, , cm, and, the, cosmeticgrading, score, was, assessed, by, the, physicianas, described, in, the, consensus, statement20procedures, and, equipmentpreventsignificantall, rfa, procedures, were, performed, by, oneradiologist, jr, with, , years, of, experienceperforming, rfa, in, an, outpatient, clinic, weused, an, rf, generator, viva, rf, systemvr, starmed, gyeonggisi, south, korea, andan, internally, cooled, 18gauge, 70mmlength, , or, 10mm, activetip, electrodestar, rf, electrodevr, , starmed, localanaesthesia, with, , lidocaine, was, appliedto, the, puncture, site, the, hydrodissectiontechnique, was, used, under, us, guidance, glucose, and, norepinephrine, weremixed, and, injected, into, the, surroundingthyroid, capsule, which, provided, a, safe, distance, between, the, needle, tip, and, adjacentcritical, structures, during, the, procedurewe, paid, special, attention, to, the, preservation, of, surrounding, important, structurestocomplicationstherefore, two, essential, techniques, werethe, transisthmic, approach, andappliedtechnique2122, ablationthe, movingshotwas, suspended, when, the, index, nodule, wascovered, by, hyperechoic, zones, the, technique, efï¬cacy, te, was, then, evaluated, byceus, at, , to, , minutes, after, rfa, untilthedisappearedtechnicalthechange, of, an, entire, nodule, to, a, noenhancement, zone, on, realtime, ceusfor, nodules, with, an, enhancement, zonean, additional, ablation, was, performed, todestroy, the, nodule, as, much, as, possiblecomplications, were, monitored, immediatelyafter, the, procedure, and, during, the, followup, period, major, and, minor, complicationsand, adverse, effects, were, deï¬ned, accordingto, the, criteria, established, by, the, society, ofinterventional, radiology2324success, was, deï¬ned, ashyperechoiczones, 0cjournal, of, international, medical, researchfollowup, evaluationatandperformedserum, thyroidany, speciï¬c, complaints, or, concerns, wererecorded, for, , month, postproceduralfollowup, wasand, months, after, treatment, at, each, followup, visit, a, us, examination, ceus, examinationhormonemeasurements, were, performed, pressuresymptoms, and, the, cosmetic, grading, scorewere, evaluated, and, the, volume, ofthetreated, nodule, was, calculated, the, te, wascalculated, using, the, following, equationte¼, ï¬nal, nodule, volumeinitial, nodule, volume, 02, statistical, analysisstatistical, analyses, were, performedallusing, spss, software, version, , ibmcorp, armonk, ny, usa, continuousvariables, are, expressed, as, mean, 06, standarddeviation, quantitative, data, for, volumeand, te, were, analysed, using, a, pairedttest, a, p, value, of, 14, was, consideredstatistically, significantresultsthe, patients, characteristics, are, summarised, in, table, , thirtyï¬ve, patients, underwent, rfa, including, , male, and, , femalepatients, mean, age, , years, the, meanlargest, btn, dimension, was, 06, , mmrange, , mm, and, the, mean, btnvolume, was, 06, , ml, twentytwototal, complications, , minor, and, , majorcomplications, were, observed, among, thetreated, patients, none, of, these, complications, was, lifethreatening, and, all, occurredwithout, sequelaenodule, volumeafter, treatment, the, overall, volume, of, thesignificantly, decreased, 06nodules, 06, , ml, at, ml, at, month, and, 06, , ml, at, , monthsbaselinetable, , patients, baseline, characteristics, n¼, characteristics, 06, 06, 06, 06, 06, 06, 06, 06, age, at, treatment, yearsmalefemale, ratiobody, weight, kgbody, height, cmbody, mass, index, kgm2symptom, score, cosmetic, score, cosmetic, score, of, cosmetic, score, of, cosmetic, score, of, preablation, serum, ft4, level, pmollpreablation, serum, tsh, level, miulindex, nodule, on, ultrasoundright, sideleft, sidelargest, dimension, mm, to, , to, 15data, are, presented, as, mean, 06, standard, deviation, ornumber, of, patientsft4, free, thyroxin, tsh, thyroidstimulating, hormonep, , , and, the, te, was, 06, at, , month, and, 06, , at, months, p, , , table, , figure, shows, the, shrinkage, of, the, nodules, at, and, , months, after, the, procedure, comparedwith, baseline, no, hypoechoic, blood, supplywas, observed, within, the, area, ofthenodulesbleeding, complicationstwelve, patients, developed, bleeding, complicationsincluding, a, perithyroidal, haematoma, minor, complication, in, , patientsand, an, intranodular, haematoma, majorcomplication, in, , patient, as, shown, intable, , the, haematomas, were, detectedby, us, scans, which, revealed, gradualenlargement, of, a, hyperechoic, mass, in, oraround, the, nodules, figure, , for, thepatient, with, intranodular, haemorrhage, 0chu, et, altable, , changes, in, volume, before, rfa, and, at, each, followup, visitparameterinitial, month, laterlargest, diameter, mm, 06, , , 06, , volume, mltechnique, efficacy, , data, are, presented, as, mean, 06, standard, deviation, range, 06, , , 06, , , 06, , , months, laterp, value, 06, , , 06, , , 06, , , figure, , a, c, e, ultrasound, examination, and, b, d, f, contrastenhanced, ultrasound, examination, of, a39yearold, woman, treated, with, radiofrequency, ablation, a, b, ultrasound, and, contrastenhanced, ultrasound, revealed, a, cysticsolid, nodule, before, ablation, c, d, one, month, after, ablation, ultrasound, showed, ahypoechoic, nodule, with, a, decreased, volume, d, e, six, months, after, ablation, the, volume, of, the, nodule, haddecreased, further, and, no, blood, supply, was, observed, within, the, area, of, the, nodule, 0cjournal, of, international, medical, researchtable, , complications, and, adverse, effects, in, patients, who, underwent, rfa, of, thyroid, nodulescomplication, or, adverse, effectadverse, effectsfeverpaindizzinesssensation, of, heatminorperithyroidal, haematomavomitingnauseaoedemaswellingvoice, change, for, , monthmajorvoice, change, for, , monthintranodular, haemorrhagedata, are, presented, as, n, , , , , , , , , , , , , , the, haematoma, was, controlled, throughtimely, use, of, the, ablation, needle, to, coagulate, the, injured, blood, vessel, and, by, injecting, lyophilising, thrombin, powder, into, thehaematoma, figure, , most, of, the, perithyroidalseriesrequired, only, observation, with, or, withoutcompression, and, disappeared, within, , to, weeks, after, the, procedure, none, of, the, patientssubscapularhaematomahaematomasdevelopedthisinaother, complications, and, adverse, effectsthe, adverse, effects, of, rfa, included, fevern¼, , , pain, n¼, , , dizziness, n¼, , , and, a, sensation, of, heatn¼, , , minor, complications, includedoedemaswelling, n¼, , , and, a, voicechange, for, , month, n¼, , vomitingnausean¼, discussionimageguided, thermal, ablation, techniquessuch, as, laser, ablation, ethanol, ablationmicrowave, ablation, highintensity, focusedus, and, particularly, rfa, have, recentlybecome, more, widely, used, to, treat, thyroidthe, creation, ofnodules, brieï¬y, the, basic, mechanism, ofrfa, involvesthermaldamage, by, friction, and, heat, conductionwhich, is, generated, from, an, oscillatinghighfrequency, alternating, electric, currentproduced, by, the, rfa, generator, and, thentransferred, through, the, electrode, tip, theenergy, of, rfa, is, powerful, and, accurate2526, rfa, is, considered, an, effectiveand, safe, treatment, for, control, of, btnsin, most, cases, the, incidence, of, haemorrhage, and, other, complications, is, low20however, haemorrhage, is, sometimes, lifethreatening, because, serious, haematomasmay, compress, the, upper, airways, manyreports, have, described, active, bleedingduring, fna, of, thyroid, nodules, and, rfaof, hepatocellular, carcinomas14, andsome, reports, have, described, fatalities14thusimportantcomplicationhaemorrhageanisthree, types, of, haemorrhage, may, occurperithyroidal, subcapsular, and, intranodular121427, the, mechanism, of, haemorrhage, is, thoughtto, be, related, to, themechanical, or, thermal, injuries, induced, bythe, rfa, electrode, tip3031, thyroid, nodulesreportedly, have, abundant, capsular, vesselsthat, are, usually, anastomosed, with, vesselspenetrating, into, the, core32, these, numerousvessels, are, abnormal, thinwalled, and, susceptible, to, rupture, large, thyroid, nodulesare, another, cause, of, haemorrhage, becausemultiple, insertions, are, often, required, totreat, such, nodules, in, additionthepatient, cannot, coordinate, with, the, physician, during, the, rfa, procedure, the, perithyroidal, orintrathyroidal, vessels, mayeasily, be, damaged, by, movement, of, theneedle, tip, or, production, of, heat, energyifit, is, important, to, manage, bleeding, associated, with, rfa, of, btns, based, on, ourexperience, we, suggest, several, steps, to, preventshouldobtain, a, thorough, medical, history, of, eachpatient, before, the, procedure, all, risk, factorsdrugssuch, bleeding, physiciansincludingbleedingfor, 0chu, et, alfigure, , ultrasound, examination, and, contrastenhanced, ultrasound, examination, of, patients, with, intranodular, haemorrhage, and, perithyroidal, haemorrhage, a, ultrasound, and, contrastenhanced, ultrasoundrevealed, a, hyperechoic, mass, lesion, in, the, nodule, b, ultrasound, and, contrastenhanced, ultrasound, revealedperithyroidal, haemorrhagedrugsnonsteroidalantiplateletantiinï¬ammatory, drugs, and, anticoagulantsand, diseases, affecting, coagulation, shouldbe, recorded33, in, addition, the, patientscoagulation, function, should, be, thoroughlyevaluated, all, patients, with, clinical, coagulation, disorders, should, be, excluded, evenwhen, coagulation, indices, are, normalinpatients, with, high, risk, factors, for, bleedingsuch, as, liver, cirrhosis, endstage, renal, disease, anticoagulant, use, or, hypertension34sufï¬cient, preoperative, preparation, shouldbe, emphasised, a, patient, with, active, bleedingthesein, the, presentstudy, metconditions, although, his, coagulation, indices, were, normal, he, had, a, subclinical, coagulation, disorder, due, to, endstage, liverdisease, fresh, frozen, plasma, or, human, prothrombin, complex, should, be, used, inpatients, with, liver, cirrhosis, and, anticoagulants, should, be, withdrawn, in, these, patientswhich, will, help, to, improve, coagulation, function, before, the, procedure, if, a, possibility, ofbleeding, exists, reptilase, haemocoagulaseatrox, forinjection, pentapharm, baselswitzerland, can, be, used, preoperativelyduring, the, rfa, procedure, an, effectiveclinical, strategy, and, adequate, technical, 0cjournal, of, international, medical, researchfigure, , ultrasound, examination, and, contrastenhanced, ultrasound, examination, of, patients, with, intranodular, haemorrhage, or, perithyroidal, haemorrhage, during, ablation, a, ultrasound, revealed, a, hyperechoicmass, lesion, in, the, nodule, b, ultrasound, showed, an, ablation, needle, inserted, into, the, nodule, to, coagulatebleeding, vessels, c, after, lyophilising, thrombin, powder, was, injected, into, the, hematoma, ultrasound, andcontrastenhanced, ultrasound, showed, disappearance, of, the, hyperechoic, mass, lesion, and, microbubbleextravasation, d, ultrasound, showed, a, hyperechoic, mass, lesion, around, the, thyroid, and, contrastenhancedultrasound, showed, no, microbubble, extravasation, around, the, thyroid, e, after, lyophilising, thrombinpowder, was, injected, into, the, haematoma, no, microbubble, extravasation, was, observedskills, are, both, essential, patient, cooperationis, the, ï¬rst, requirement, when, the, needle, tipis, in, the, patients, body, any, uncooperativemotion, of, the, patient, may, lead, to, injury, ofvessels, or, other, structures, most, patientscan, endure, the, procedure, under, local, anaesthesia, however, anxious, patients, mayrequire, general, anaesthesia, to, achieve, cooperation, if, possible, smallbore, electrodesshould, be, chosen, to, decrease, the, risk, ofbleeding35, it, is, necessary, to, cauterise, thesupplying, vasculature, of, nodules, to, avoidrecurrence, and, residue, howeverthepuncture, route, should, be, carefully, designedto, avoid, pericapsular, vessels, and, the, electrode, tip, should, be, closely, monitoredactive, bleeding, during, needle, puncture, isvisible, as, a, rapidly, expanding, hypoechoicor, anechoic, signal, locating, the, haemorrhagic, focus, is, not, difï¬cult, with, ceusguidance, the, bleeding, pointcan, beblocked, by, rf, electrode, tip, insertion, anddirect, ablation, when, the, bleeding, is, toorapid, to, control, with, the, rf, electrode, tipby, increasing, the, power, drug, injection, is, asuitable, alternative, lyophilised, thrombin, 0chu, et, alpowder, can, be, dissolved, in, normal, salineand, then, injected, at, the, bleeding, pointthrough, a, syringe, with, us, guidance, onereport, also, described, haemorrhage, treatedby, local, injection, of, hypertonic, saline, andepinephrine, solution, in, a, patient, with, hepatocarcinoma36, mildbleeding, whichappears, as, a, hypoechoic, layer, can, mostlybe, controlled, using, ice, and, compression, ofthe, neck, for, several, minutes, after, the, procedure30, all, bleeding, can, be, controlled, byconservative, methodsthus, no, surgicalintervention, is, needed, ecchymosis, can, befound, after, the, procedure, and, usually, disappears, in, approximately, , to, , weekspostprocedure, ceus, is, indispensablefor, all, patients, regardless, of, whether, bleeding, occurs, ceus, is, an, objective, evaluationtool, for, active, bleeding37, close, clinicalobservation, for, , hours, postoperatively, isrecommended, in, our, department, becausemost, bleeding, occurs, during, the, ï¬rstlobectomy38observation, of, the, neck, can, help, to, detecta, haematoma, early, and, may, aid, in, preventing, serious, adverse, effectsthyroidhoursafterconclusionacute, thyroid, bleeding, is, one, possible, complication, of, rfa, although, rare, it, is, potentially, lifethreatening, proper, selection, ofpatients, and, sufï¬cient, preparation, areessential, during, the, rfa, procedureboth, an, effective, clinical, strategy, and, adequate, technical, skills, are, indispensable, thephysician, should, trace, the, electrode, tipusing, realtime, us, and, sufï¬ciently, managebleeding, mild, bleeding, has, limited, morbidity, and, can, be, easily, controlled, by, compression, active, bleeding, tends, to, be, rarehowever, it, may, be, disastrous, if, the, operator, is, unaware, or, careless, direct, ablationwith, the, rf, electrode, tip, and, drug, injectioninto, the, bleeding, focus, are, effective, modalities, for, active, bleeding, ceus, and, closeobservation, are, also, recommended, afterthe, procedureto, detect, abnormalitiesearly, rfa, is, an, effective, and, relativelysafe, alternative, for, selected, patients, withbtns, if, performed, by, skilled, physiciansauthor, contributionsi, conception, and, design, jie, ren, and, bo, liuii, administrative, support, jie, reniiistudy, materials, or, patientsprovision, ofkunpeng, hu, and, yufan, lian, iv, collectionand, assembly, of, datajinfen, wang, andwenchao, li, v, data, analysis, and, interpretation, wenchao, li, and, zhicheng, yaovimanuscript, writing, all, authors, vii, finalapproval, of, manuscript, all, authorsdata, availabilitydata, regarding, the, patients, characteristics, usedto, support, the, funding, are, shown, in, table, declaration, of, conflicting, interestthe, authors, declare, that, there, is, no, conï¬ict, ofinterestfundingthe, naturalthis, work, was, supported, by, the, nationalnatural, science, foundation, of, china, cnnosciencefoundation, of, guangdong, provinceno2016a030313200, the, science, and, technologyproject, of, guangzhou, city, no, the, hengrui, foundation, of, hepatobiliary, andpancreaticnocxpjjh1180000120183331naturalscience, foundation, of, guangdong, provincenothe, fundamentalresearch, funds, for, the, central, universitiessun, yatsen, university, no, 17ykpy67, andthe, , clinical, research, project, of, sun, yatsen, university, no, 2017a030313580thecancerresearchorcid, idkunpeng, huorcid00000001, 0creferences, guth, s, theune, u, aberle, j, et, al, very, highprevalence, of, thyroid, nodules, detected, byhigh, frequency, , mhz, ultrasound, examination, eur, j, clin, invest, , , , tan, gh, and, gharib, h, thyroid, incidentalomas, management, approaches, to, nonpalpable, nodules, discovered, incidentally, onthyroid, imaging, ann, intern, med, , , haugen, br, alexander, ek, bible, kc, et, al, americanthyroid, associationmanagement, guidelines, for, adult, patientswith, thyroid, nodules, and, differentiatedthyroid, cancer, the, american, thyroidassociation, guidelines, task, force, onthyroid, nodulesand, differentiatedthyroid, cancer, thyroid, , , , ceccarelli, c, bencivelli, w, vitti, p, et, aloutcome, ofradioiodine131, therapy, inhyperfunctioning, thyroid, nodules, a, years, retrospective, study, clin, endocrinoloxf, , , , reiners, c, and, schneider, p, radioiodinetherapy, of, thyroid, autonomy, eur, j, nuclmed, mol, imaging, , , s471s478, nieuwlaat, wa, hermus, ar, sivroprndeljf, et, al, pretreatment, with, recombinanthuman, tsh, changes, the, regional, distribution, of, radioiodine, on, thyroid, scintigramsof, nodular, goiters, j, clin, endocrinol, metab, , , linosdeconomopouloskpkiriakopoulos, a, et, al, scar, perceptionsafter, thyroid, and, parathyroid, surgery, comparison, of, minimaland, conventionalapproaches, surgery, , , , jeannon, jp, orabi, aa, bruch, ga, et, allaryngeal, nervethyroidectomy, a, systematicdiagnosis, ofpalsy, afterreview, int, j, clin, pract, , , recurrent, lang, b, woo, yc, and, chiu, kw, identifyingpredictive, factors, for, efï¬cacy, in, high, intensity, focused, ultrasound, hifu, ablationof, benign, thyroid, nodules, , a, retrospectiveint, j, hyperthermia, , analysis, mauri, g, pacella, cm, papini, e, et, alimageguided, thyroid, ablation, proposalforterminology, andstandardization, ofjournal, of, international, medical, researchreportingcriteria, thyroid, sato, m, tateishi, r, yasunaga, h, et, almortality, and, hemorrhagic, complicationsassociated, with, radiofrequency, ablation, fortreatment, of, hepatocellular, carcinoma, inendstagepatients, on, hemodialysissurveyrenaljgastroenterol, hepatolnationwidediseasefora, krokidis, m, spiliopoulos, s, jarzabek, met, al, percutaneous, radiofrequency, ablationof, small, renal, tumours, in, patients, with, asingle, functioning, kidney, longterm, resultseur, radiol, , , , lim, hk, lee, dupuy, de, monchik, jm, decrea, c, et, alradiofrequency, ablation, of, regional, recurrence, from, welldifferentiated, thyroid, malignancy, surgery, , , jh, ha, ejalradiofrequency, ablation, of, benign, nonfunctioning, thyroid, nodules, 4year, followup, results, for, , patients, eur, radiol, , et, braga, m, cavalcanti, tc, collaco, lm, et, alefï¬cacy, of, ultrasoundguided, ï¬neneedleaspiration, biopsy, in, the, diagnosis, of, complex, thyroid, nodules, j, clin, endocrinolmetab, , , , kakiuchi, y, idota, n, nakamura, m, et, ala, fatal, case, of, cervical, hemorrhage, after, ï¬neneedle, aspiration, and, core, needle, biopsy, ofthe, thyroid, gland, am, j, forensic, med, pathol, , , donatini, g, masoni, t, ricci, v, et, al, acuterespiratory, distress, following, ï¬ne, needleaspiration, of, thyroid, nodule, case, reportand, review, of, the, literature, g, chir, , , roh, jl, intrathyroid, hemorrhage, and, acuteupper, airway, obstruction, after, ï¬ne, needleaspirationthyroidglandlaryngoscope, , , theofofassociation, gharib, h, papini, e, garber, jr, et, alamericanclinicalendocrinologists, american, college, ofendocrinology, and, associazione, mediciendocrinologi, medical, guidelines, for, clinicalpractice, for, the, diagnosis, and, managementthyroid, nodules, update, endocrofpract, , , , 0chu, et, al, na, dg, leeetjhjung, slalradiofrequency, ablation, of, benign, thyroidnodules, and, recurrent, thyroid, cancers, consensusstatement, and, recommendationskorean, j, radiol, , , , ha, ej, baek, jh, and, lee, jh, movingshotversus, ï¬xed, electrode, techniques, for, radiofrequency, ablation, comparison, in, an, exvivo, bovine, liver, tissue, model, korean, jradiol, , , , jeong, wk, baek, jh, rhim, h, et, alradiofrequency, ablation, of, benign, thyroidnodules, safety, and, imaging, followup, inpatients, eur, radiol, cardella, jf, kundu, s, miller, dl, et, alsociety, of, interventional, radiology, clinicalpractice, guidelines, j, vasc, interv, radiol, , s189s191, sacks, d, mcclenny, te, cardella, jf, et, alsociety, of, interventional, radiology, clinicalpractice, guidelines, j, vasc, interv, radiol, , s199s202, goldberg, sn, radiofrequency, tumor, ablation, principles, and, techniques, eur, jultrasound, , , , rhim, h, goldberg, sn, dodd, gr, et, alessential, techniques, for, successful, radiofrequency, thermal, ablation, of, malignanthepatic, tumors, radiographics, , spec, no, s17s35, s36s39, korkusuz, y, erbelding, c, kohlhase, ket, al, bipolar, radiofrequency, ablation, ofbenign, symptomatic, thyroid, nodules, initial, experience, rofo, , , , garberoglio, r, aliberti, c, appetecchia, met, al, radiofrequency, ablation, for, thyroidnodules, which, indications, the, ï¬rst, italianopinion, statement, j, ultrasound, , , baek, jh, leejh, sung, jyet, alcomplications, encountered, in, the, treatmentof, benign, thyroid, nodules, with, usguidedradiofrequencya, multicenterstudy, radiology, , , ablation, chen, mh, dai, y, yan, kalintraperitoneal, hemorrhage, duringandafter, percutaneous, radiofrequency, ablationof, hepatic, tumors, reasons, and, managementchin, med, j, engl, , , et, rhim, h, dodd, gr, chintapalli, kn, et, alradiofrequency, thermal, ablation, of, abdominal, tumors, lessons, learned, from, complications, radiographics, , , , terry, wi, radium, emanations, in, exophthalmic, goiterblood, vessels, of, adenomas, ofthyroid, j, am, med, assoc, , , , hor, t, and, lahiri, sw, bilateral, thyroidhematomas, after, ï¬neneedle, aspiration, causing, acute, airway, obstruction, thyroid, , , minami, y, hayaishi, s, and, kudo, mradiofrequency, ablation, for, hepatic, malignancies, is, needle, tract, cauterization, necessary, for, preventing, iatrogenic, bleeding, digdis, , , , baek, jh, kim, ys, lee, d, et, al, benign, predominantly, solid, thyroid, nodules, prospective, study, of, efï¬cacy, of, sonographicallyguided, radiofrequency, ablation, versus, control, condition, ajr, am, j, roentgenol, , , koda, m, murawaki, y, hirooka, y, et, alcomplications, of, radiofrequency, ablationfor, hepatocellular, carcinoma, in, a, multicenter, study, an, analysis, of, , , treated, nodules, in, , , patients, hepatol, res, , , wiggermann, p, wohlgemuth, wa, heibl, met, al, dynamic, evaluation, and, quantiï¬cationof, microvascularization, during, degradablestarch, microspheres, transarterial, chemoembolisation, dsmtace, of, hcc, lesionsusingultrasoundceus, a, feasibility, study, clin, hemorheolmicrocirc, , , enhancedcontrast, rosenbaum, ma, haridas, m, and, mchenrycr, lifethreatening, neck, hematoma, complicating, thyroid, and, parathyroid, surgeryam, j, surg, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |[, study, performed, explore, effective, management, bleeding, associated, radiofrequency, ablation, rfa, benign, thyroid, nodulesmethods, thirtyfive, patients, benign, thyroid, nodules, treated, ultrasoundguided, rfa, july, , december, , third, affiliated, hospital, sun, yatsenuniversity, retrospectively, reviewed, technique, efficacy, bleeding, complications, assessed, followup, periodresults, mean, technique, efficacy, 06, , month, 06, months, procedure, one, case, intranodular, haematoma, two, cases, voicechange, , month, observed, patients, recovered, corresponding, treatmentconclusion, although, incidence, haemorrhage, low, serious, haematomas, lifethreatening, therefore, comprehensive, understanding, potential, complicationsan, accurate, clinical, strategy, adequate, technical, skills, may, prevent, help, properly, managethese, complicationskeywordsradiofrequency, ablation, benign, thyroid, nodules, haemorrhage, management, haematomaultrasounddate, received, , january, , accepted, , june, 1department, medical, ultrasound, third, affiliatedhospital, sun, yatsen, university, guangzhou, china2general, surgery, department, third, affiliatedhospital, sun, yatsen, university, guangzhou, chinathese, authors, contributed, equally, workcorresponding, authorsbo, liu, general, surgery, department, third, affiliatedhospital, sun, yatsen, university, , tianhe, roadguangzhou, city, guangdong, province, china, jie, rendepartment, medical, ultrasound, third, affiliatedhospital, sun, yatsen, university, , tianhe, roadguangzhou, city, guangdong, province, chinaemails, renjieguangzhou126com, liubojake126comcreative, commons, non, commercial, cc, bync, , distributed, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, permitsnoncommercial, use, reproduction, distribution, work, without, permission, provided, original, work, attributedas, specified, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cintroductionassociationfor, adultthyroid, nodules, extremely, commonand, associated, morbidity, rate, rangesfrom, , , according, highresolution, ultrasound, us, ï¬ndings12mostthyroid, nodules, benign, andrequire, intervention, clinicalfollowup, according, , americanthyroidmanagementguidelinespatients, withthyroid, nodulesand, differentiatedthyroid, cancer, thyroidstimulating, hormone, suppression, therapy, benign, thyroid, nodules, btns, recommendedbecause, potential, harm, outweighs, thebeneï¬t3, radioiodine, therapy, historically, effective, treatment, thyroid, hotnodules, possible, alternative, surgery, howeverthis, technique, beenproven, uncertain, efï¬cacy, andsome, adverse, effects, hypothyroidrecurrence4, surgery, may, beism, orconsideredgrowing, btns, withpressurerelated, symptoms, neck, discomfort, cosmetic, concerns, decreased, quality, life3, present, partialtotal, thyroidsurgery, considered, gold, standardtreatment, surgeryassociated, withnumerous, complications, nerveinjury, anaesthesiarelated, problemslonghospital, stays, conspicuous, scars, haemorrhage, lesions, ofthe, parathyroidglands78, addition, hypothyroidism, isinevitable, totalthyroidectomy, andrequires, lifelong, hormone, supplementationhenceincreasingly, minimally, invasivetherapeutic, strategies, currently, used, totreat, btns, cases, several, thermalablation, techniques, laser, ablationmicrowave, ablation, radiofrequency, ablation, rfa, highintensity, focused, ushave, shown, effective, btnsamong, thermal, ablation, techniquesrfa, widely, applied910forisrfa, thyroid, diseases, ï¬rst, reported, in, considered, efï¬cacious, safejournal, international, medical, researchfor, treatment, btns1415, date, lifethreatening, complications, related, rfahave, reported, howeverseveralcases, haemorrhagerelated, ï¬neneedle, aspiration, fna, core, needlebiopsy, cnb, reported16although, microinvasive, procedure, suchas, fna, result, massive, uncontrolledbleeding, resulting, upper, airway, respiratoryuncontrolledbleeding, rare, lifethreatening, complication, rfa, thus, management, ofbleeding, associated, rfa, btns, isof, vitalimportance, study, performed, explore, effective, managementof, bleeding, associated, rfa, btnsobstructionsuchmaterials, methodsofthis, study, approved, ethicscommitteethe, third, afï¬liatedhospital, sun, yatsen, university, andwritten, informed, consent, obtainedfrom, patients, prior, performanceof, usguided, fna, cnb, rfa, therequirement, obtain, informed, consent, forpublication, waived, retrospective, nature, studypatientsall, consecutive, patients, underwentrfa, btns, institution, july, december, , analysed, thefollowing, inclusion, criteria, appliedconï¬rmation, benignancybethesdaclass, ii, fna, cytology, cnb, complaints, pressure, symptoms, compressivesymptoms, neck, discomfort, orforeignbody, sensation, cosmetic, problems, a2cm, maximum, diameter, indexnodule, anxiety, malignancy, unsuitability, surgery, unwillingness, toundergo, surgery, normal, serum, thyrotropin, concentration, normal, completeblood, counts, normal, blood, coagulation, test, results, exclusion, criteria, 0chu, et, alwere, nodules, showing, malignant, featuresie, taller, wide, spiculated, marginmarked, hypoechoic, appearance, microcalciï¬cations, us, imaging19, abnormalthyroid, function, performance, othertreatments, thyroid, nodules, within, months, procedure, pregnancyand, age, , years, presentstudy, patients, 15, months, offollowup, procedure, included, thirtyï¬ve, patients, met, inclusioncriteriapretreatment, assessmentbefore, procedure, conventional, usï¬ndings, usguidedfna, ï¬ndingscontrastenhanced, us, ceus, ï¬ndingsand, laboratory, clinical, results, wereevaluated, two, radiologists, tw, jr, , , years, thyroid, us, experiencerespectively, performed, ususguided, fna, ceus, examinationsusing, logiq, e9, us, device, ge, medicalsystems, milwaukee, wi, usa, equippedwithtransducerwith, mhzfrequency, range, , mhz, usexamination, included, characterisation, ofthe, location, shape, size, margins, solidcystic, proportions, echogenicity, calciï¬cation, status, internal, vascularity, ofeach, nodulefrequency, ofan, ml615centrelinearlaboratory, tests, included, levels, ofthyroidstimulating, hormone, free, triiodothyronine, free, thyroxin, thyrotropina, complete, blood, cell, count, coagulation, test, prothrombin, time, activatedpartial, thromboplastin, time, nodulevolume, calculated, using, followingvolume¼, length, 02, width, 02equationdepth, 02, addition, patientsunderwent, vocal, cord, function, assessmentsby, experienced, laryngologist, theablation, procedure, atenrolment, allpatients, asked, rate, pressuresymptoms, 10cm, visual, analoguescale, grade, , cm, cosmeticgrading, score, assessed, physicianas, described, consensus, statement20procedures, equipmentpreventsignificantall, rfa, procedures, performed, oneradiologist, jr, , years, experienceperforming, rfa, outpatient, clinic, weused, rf, generator, viva, rf, systemvr, starmed, gyeonggisi, south, korea, andan, internally, cooled, 18gauge, 70mmlength, , 10mm, activetip, electrodestar, rf, electrodevr, , starmed, localanaesthesia, , lidocaine, appliedto, puncture, site, hydrodissectiontechnique, used, us, guidance, glucose, norepinephrine, weremixed, injected, surroundingthyroid, capsule, provided, safe, distance, needle, tip, adjacentcritical, structures, procedurewe, paid, special, attention, preservation, surrounding, important, structurestocomplicationstherefore, two, essential, techniques, werethe, transisthmic, approach, andappliedtechnique2122, ablationthe, movingshotwas, suspended, index, nodule, wascovered, hyperechoic, zones, technique, efï¬cacy, te, evaluated, byceus, , , minutes, rfa, untilthedisappearedtechnicalthechange, entire, nodule, noenhancement, zone, realtime, ceusfor, nodules, enhancement, zonean, additional, ablation, performed, todestroy, nodule, much, possiblecomplications, monitored, immediatelyafter, procedure, followup, period, major, minor, complicationsand, adverse, effects, deï¬ned, accordingto, criteria, established, society, ofinterventional, radiology2324success, deï¬ned, ashyperechoiczones, 0cjournal, international, medical, researchfollowup, evaluationatandperformedserum, thyroidany, speciï¬c, complaints, concerns, wererecorded, , month, postproceduralfollowup, wasand, months, treatment, followup, visit, us, examination, ceus, examinationhormonemeasurements, performed, pressuresymptoms, cosmetic, grading, scorewere, evaluated, volume, ofthetreated, nodule, calculated, te, wascalculated, using, following, equationte¼, ï¬nal, nodule, volumeinitial, nodule, volume, 02, statistical, analysisstatistical, analyses, performedallusing, spss, software, version, , ibmcorp, armonk, ny, usa, continuousvariables, expressed, mean, 06, standarddeviation, quantitative, data, volumeand, te, analysed, using, pairedttest, p, value, 14, consideredstatistically, significantresultsthe, patients, characteristics, summarised, table, , thirtyï¬ve, patients, underwent, rfa, including, , male, , femalepatients, mean, age, , years, meanlargest, btn, dimension, 06, , mmrange, , mm, mean, btnvolume, 06, , ml, twentytwototal, complications, , minor, , majorcomplications, observed, among, thetreated, patients, none, complications, lifethreatening, occurredwithout, sequelaenodule, volumeafter, treatment, overall, volume, thesignificantly, decreased, 06nodules, 06, , ml, ml, month, 06, , ml, , monthsbaselinetable, , patients, baseline, characteristics, n¼, characteristics, 06, 06, 06, 06, 06, 06, 06, 06, age, treatment, yearsmalefemale, ratiobody, weight, kgbody, height, cmbody, mass, index, kgm2symptom, score, cosmetic, score, cosmetic, score, cosmetic, score, cosmetic, score, preablation, serum, ft4, level, pmollpreablation, serum, tsh, level, miulindex, nodule, ultrasoundright, sideleft, sidelargest, dimension, mm, , 15data, presented, mean, 06, standard, deviation, ornumber, patientsft4, free, thyroxin, tsh, thyroidstimulating, hormonep, , , te, 06, , month, 06, , months, p, , , table, , figure, shows, shrinkage, nodules, , months, procedure, comparedwith, baseline, hypoechoic, blood, supplywas, observed, within, area, ofthenodulesbleeding, complicationstwelve, patients, developed, bleeding, complicationsincluding, perithyroidal, haematoma, minor, complication, , patientsand, intranodular, haematoma, majorcomplication, , patient, shown, intable, , haematomas, detectedby, us, scans, revealed, gradualenlargement, hyperechoic, mass, oraround, nodules, figure, , thepatient, intranodular, haemorrhage, 0chu, et, altable, , changes, volume, rfa, followup, visitparameterinitial, month, laterlargest, diameter, mm, 06, , , 06, , volume, mltechnique, efficacy, , data, presented, mean, 06, standard, deviation, range, 06, , , 06, , , 06, , , months, laterp, value, 06, , , 06, , , 06, , , figure, , c, e, ultrasound, examination, b, d, f, contrastenhanced, ultrasound, examination, a39yearold, woman, treated, radiofrequency, ablation, b, ultrasound, contrastenhanced, ultrasound, revealed, cysticsolid, nodule, ablation, c, d, one, month, ablation, ultrasound, showed, ahypoechoic, nodule, decreased, volume, d, e, six, months, ablation, volume, nodule, haddecreased, blood, supply, observed, within, area, nodule, 0cjournal, international, medical, researchtable, , complications, adverse, effects, patients, underwent, rfa, thyroid, nodulescomplication, adverse, effectadverse, effectsfeverpaindizzinesssensation, heatminorperithyroidal, haematomavomitingnauseaoedemaswellingvoice, change, , monthmajorvoice, change, , monthintranodular, haemorrhagedata, presented, n, , , , , , , , , , , , , , haematoma, controlled, throughtimely, use, ablation, needle, coagulate, injured, blood, vessel, injecting, lyophilising, thrombin, powder, thehaematoma, figure, , perithyroidalseriesrequired, observation, withoutcompression, disappeared, within, , weeks, procedure, none, patientssubscapularhaematomahaematomasdevelopedthisinaother, complications, adverse, effectsthe, adverse, effects, rfa, included, fevern¼, , , pain, n¼, , , dizziness, n¼, , , sensation, heatn¼, , , minor, complications, includedoedemaswelling, n¼, , , voicechange, , month, n¼, , vomitingnausean¼, discussionimageguided, thermal, ablation, techniquessuch, laser, ablation, ethanol, ablationmicrowave, ablation, highintensity, focusedus, particularly, rfa, recentlybecome, widely, used, treat, thyroidthe, creation, ofnodules, brieï¬y, basic, mechanism, ofrfa, involvesthermaldamage, friction, heat, conductionwhich, generated, oscillatinghighfrequency, alternating, electric, currentproduced, rfa, generator, thentransferred, electrode, tip, theenergy, rfa, powerful, accurate2526, rfa, considered, effectiveand, safe, treatment, control, btnsin, cases, incidence, haemorrhage, complications, low20however, haemorrhage, sometimes, lifethreatening, serious, haematomasmay, compress, upper, airways, manyreports, described, active, bleedingduring, fna, thyroid, nodules, rfaof, hepatocellular, carcinomas14, andsome, reports, described, fatalities14thusimportantcomplicationhaemorrhageanisthree, types, haemorrhage, may, occurperithyroidal, subcapsular, intranodular121427, mechanism, haemorrhage, thoughtto, related, themechanical, thermal, injuries, induced, bythe, rfa, electrode, tip3031, thyroid, nodulesreportedly, abundant, capsular, vesselsthat, usually, anastomosed, vesselspenetrating, core32, numerousvessels, abnormal, thinwalled, susceptible, rupture, large, thyroid, nodulesare, another, cause, haemorrhage, becausemultiple, insertions, often, required, totreat, nodules, additionthepatient, coordinate, physician, rfa, procedure, perithyroidal, orintrathyroidal, vessels, mayeasily, damaged, movement, theneedle, tip, production, heat, energyifit, important, manage, bleeding, associated, rfa, btns, based, ourexperience, suggest, several, steps, preventshouldobtain, thorough, medical, history, eachpatient, procedure, risk, factorsdrugssuch, bleeding, physiciansincludingbleedingfor, 0chu, et, alfigure, , ultrasound, examination, contrastenhanced, ultrasound, examination, patients, intranodular, haemorrhage, perithyroidal, haemorrhage, ultrasound, contrastenhanced, ultrasoundrevealed, hyperechoic, mass, lesion, nodule, b, ultrasound, contrastenhanced, ultrasound, revealedperithyroidal, haemorrhagedrugsnonsteroidalantiplateletantiinï¬ammatory, drugs, anticoagulantsand, diseases, affecting, coagulation, shouldbe, recorded33, addition, patientscoagulation, function, thoroughlyevaluated, patients, clinical, coagulation, disorders, excluded, evenwhen, coagulation, indices, normalinpatients, high, risk, factors, bleedingsuch, liver, cirrhosis, endstage, renal, disease, anticoagulant, use, hypertension34sufï¬cient, preoperative, preparation, shouldbe, emphasised, patient, active, bleedingthesein, presentstudy, metconditions, although, coagulation, indices, normal, subclinical, coagulation, disorder, due, endstage, liverdisease, fresh, frozen, plasma, human, prothrombin, complex, used, inpatients, liver, cirrhosis, anticoagulants, withdrawn, patientswhich, help, improve, coagulation, function, procedure, possibility, ofbleeding, exists, reptilase, haemocoagulaseatrox, forinjection, pentapharm, baselswitzerland, used, preoperativelyduring, rfa, procedure, effectiveclinical, strategy, adequate, technical, 0cjournal, international, medical, researchfigure, , ultrasound, examination, contrastenhanced, ultrasound, examination, patients, intranodular, haemorrhage, perithyroidal, haemorrhage, ablation, ultrasound, revealed, hyperechoicmass, lesion, nodule, b, ultrasound, showed, ablation, needle, inserted, nodule, coagulatebleeding, vessels, c, lyophilising, thrombin, powder, injected, hematoma, ultrasound, andcontrastenhanced, ultrasound, showed, disappearance, hyperechoic, mass, lesion, microbubbleextravasation, d, ultrasound, showed, hyperechoic, mass, lesion, around, thyroid, contrastenhancedultrasound, showed, microbubble, extravasation, around, thyroid, e, lyophilising, thrombinpowder, injected, haematoma, microbubble, extravasation, observedskills, essential, patient, cooperationis, ï¬rst, requirement, needle, tipis, patients, body, uncooperativemotion, patient, may, lead, injury, ofvessels, structures, patientscan, endure, procedure, local, anaesthesia, however, anxious, patients, mayrequire, general, anaesthesia, achieve, cooperation, possible, smallbore, electrodesshould, chosen, decrease, risk, ofbleeding35, necessary, cauterise, thesupplying, vasculature, nodules, avoidrecurrence, residue, howeverthepuncture, route, carefully, designedto, avoid, pericapsular, vessels, electrode, tip, closely, monitoredactive, bleeding, needle, puncture, isvisible, rapidly, expanding, hypoechoicor, anechoic, signal, locating, haemorrhagic, focus, difï¬cult, ceusguidance, bleeding, pointcan, beblocked, rf, electrode, tip, insertion, anddirect, ablation, bleeding, toorapid, control, rf, electrode, tipby, increasing, power, drug, injection, asuitable, alternative, lyophilised, thrombin, 0chu, et, alpowder, dissolved, normal, salineand, injected, bleeding, pointthrough, syringe, us, guidance, onereport, also, described, haemorrhage, treatedby, local, injection, hypertonic, saline, andepinephrine, solution, patient, hepatocarcinoma36, mildbleeding, whichappears, hypoechoic, layer, mostlybe, controlled, using, ice, compression, ofthe, neck, several, minutes, procedure30, bleeding, controlled, byconservative, methodsthus, surgicalintervention, needed, ecchymosis, befound, procedure, usually, disappears, approximately, , , weekspostprocedure, ceus, indispensablefor, patients, regardless, whether, bleeding, occurs, ceus, objective, evaluationtool, active, bleeding37, close, clinicalobservation, , hours, postoperatively, isrecommended, department, becausemost, bleeding, occurs, ï¬rstlobectomy38observation, neck, help, detecta, haematoma, early, may, aid, preventing, serious, adverse, effectsthyroidhoursafterconclusionacute, thyroid, bleeding, one, possible, complication, rfa, although, rare, potentially, lifethreatening, proper, selection, ofpatients, sufï¬cient, preparation, areessential, rfa, procedureboth, effective, clinical, strategy, adequate, technical, skills, indispensable, thephysician, trace, electrode, tipusing, realtime, us, sufï¬ciently, managebleeding, mild, bleeding, limited, morbidity, easily, controlled, compression, active, bleeding, tends, rarehowever, may, disastrous, operator, unaware, careless, direct, ablationwith, rf, electrode, tip, drug, injectioninto, bleeding, focus, effective, modalities, active, bleeding, ceus, closeobservation, also, recommended, afterthe, procedureto, detect, abnormalitiesearly, rfa, effective, relativelysafe, alternative, selected, patients, withbtns, performed, skilled, physiciansauthor, contributionsi, conception, design, jie, ren, bo, liuii, administrative, support, jie, reniiistudy, materials, patientsprovision, ofkunpeng, hu, yufan, lian, iv, collectionand, assembly, datajinfen, wang, andwenchao, li, v, data, analysis, interpretation, wenchao, li, zhicheng, yaovimanuscript, writing, authors, vii, finalapproval, manuscript, authorsdata, availabilitydata, regarding, patients, characteristics, usedto, support, funding, shown, table, declaration, conflicting, interestthe, authors, declare, conï¬ict, ofinterestfundingthe, naturalthis, work, supported, nationalnatural, science, foundation, china, cnnosciencefoundation, guangdong, provinceno2016a030313200, science, technologyproject, guangzhou, city, hengrui, foundation, hepatobiliary, andpancreaticnocxpjjh1180000120183331naturalscience, foundation, guangdong, provincenothe, fundamentalresearch, funds, central, universitiessun, yatsen, university, 17ykpy67, andthe, , clinical, research, project, sun, yatsen, university, 2017a030313580thecancerresearchorcid, idkunpeng, huorcid00000001, 0creferences, guth, theune, u, aberle, j, et, al, highprevalence, thyroid, nodules, detected, byhigh, frequency, , mhz, ultrasound, examination, eur, j, clin, invest, , , , tan, gh, gharib, h, thyroid, incidentalomas, management, approaches, nonpalpable, nodules, discovered, incidentally, onthyroid, imaging, ann, intern, med, , , haugen, br, alexander, ek, bible, kc, et, al, americanthyroid, associationmanagement, guidelines, adult, patientswith, thyroid, nodules, differentiatedthyroid, cancer, american, thyroidassociation, guidelines, task, force, onthyroid, nodulesand, differentiatedthyroid, cancer, thyroid, , , , ceccarelli, c, bencivelli, w, vitti, p, et, aloutcome, ofradioiodine131, therapy, inhyperfunctioning, thyroid, nodules, years, retrospective, study, clin, endocrinoloxf, , , , reiners, c, schneider, p, radioiodinetherapy, thyroid, autonomy, eur, j, nuclmed, mol, imaging, , , s471s478, nieuwlaat, wa, hermus, ar, sivroprndeljf, et, al, pretreatment, recombinanthuman, tsh, changes, regional, distribution, radioiodine, thyroid, scintigramsof, nodular, goiters, j, clin, endocrinol, metab, , , linosdeconomopouloskpkiriakopoulos, et, al, scar, perceptionsafter, thyroid, parathyroid, surgery, comparison, minimaland, conventionalapproaches, surgery, , , , jeannon, jp, orabi, aa, bruch, ga, et, allaryngeal, nervethyroidectomy, systematicdiagnosis, ofpalsy, afterreview, int, j, clin, pract, , , recurrent, lang, b, woo, yc, chiu, kw, identifyingpredictive, factors, efï¬cacy, high, intensity, focused, ultrasound, hifu, ablationof, benign, thyroid, nodules, , retrospectiveint, j, hyperthermia, , analysis, mauri, g, pacella, cm, papini, e, et, alimageguided, thyroid, ablation, proposalforterminology, andstandardization, ofjournal, international, medical, researchreportingcriteria, thyroid, sato, m, tateishi, r, yasunaga, h, et, almortality, hemorrhagic, complicationsassociated, radiofrequency, ablation, fortreatment, hepatocellular, carcinoma, inendstagepatients, hemodialysissurveyrenaljgastroenterol, hepatolnationwidediseasefora, krokidis, m, spiliopoulos, jarzabek, met, al, percutaneous, radiofrequency, ablationof, small, renal, tumours, patients, asingle, functioning, kidney, longterm, resultseur, radiol, , , , lim, hk, lee, dupuy, de, monchik, jm, decrea, c, et, alradiofrequency, ablation, regional, recurrence, welldifferentiated, thyroid, malignancy, surgery, , , jh, ha, ejalradiofrequency, ablation, benign, nonfunctioning, thyroid, nodules, 4year, followup, results, , patients, eur, radiol, , et, braga, m, cavalcanti, tc, collaco, lm, et, alefï¬cacy, ultrasoundguided, ï¬neneedleaspiration, biopsy, diagnosis, complex, thyroid, nodules, j, clin, endocrinolmetab, , , , kakiuchi, y, idota, n, nakamura, m, et, ala, fatal, case, cervical, hemorrhage, ï¬neneedle, aspiration, core, needle, biopsy, ofthe, thyroid, gland, j, forensic, med, pathol, , , donatini, g, masoni, ricci, v, et, al, acuterespiratory, distress, following, ï¬ne, needleaspiration, thyroid, nodule, case, reportand, review, literature, g, chir, , , roh, jl, intrathyroid, hemorrhage, acuteupper, airway, obstruction, ï¬ne, needleaspirationthyroidglandlaryngoscope, , , theofofassociation, gharib, h, papini, e, garber, jr, et, alamericanclinicalendocrinologists, american, college, ofendocrinology, associazione, mediciendocrinologi, medical, guidelines, clinicalpractice, diagnosis, managementthyroid, nodules, update, endocrofpract, , , , 0chu, et, al, na, dg, leeetjhjung, slalradiofrequency, ablation, benign, thyroidnodules, recurrent, thyroid, cancers, consensusstatement, recommendationskorean, j, radiol, , , , ha, ej, baek, jh, lee, jh, movingshotversus, ï¬xed, electrode, techniques, radiofrequency, ablation, comparison, exvivo, bovine, liver, tissue, model, korean, jradiol, , , , jeong, wk, baek, jh, rhim, h, et, alradiofrequency, ablation, benign, thyroidnodules, safety, imaging, followup, inpatients, eur, radiol, cardella, jf, kundu, miller, dl, et, alsociety, interventional, radiology, clinicalpractice, guidelines, j, vasc, interv, radiol, , s189s191, sacks, d, mcclenny, te, cardella, jf, et, alsociety, interventional, radiology, clinicalpractice, guidelines, j, vasc, interv, radiol, , s199s202, goldberg, sn, radiofrequency, tumor, ablation, principles, techniques, eur, jultrasound, , , , rhim, h, goldberg, sn, dodd, gr, et, alessential, techniques, successful, radiofrequency, thermal, ablation, malignanthepatic, tumors, radiographics, , spec, s17s35, s36s39, korkusuz, y, erbelding, c, kohlhase, ket, al, bipolar, radiofrequency, ablation, ofbenign, symptomatic, thyroid, nodules, initial, experience, rofo, , , , garberoglio, r, aliberti, c, appetecchia, met, al, radiofrequency, ablation, thyroidnodules, indications, ï¬rst, italianopinion, statement, j, ultrasound, , , baek, jh, leejh, sung, jyet, alcomplications, encountered, treatmentof, benign, thyroid, nodules, usguidedradiofrequencya, multicenterstudy, radiology, , , ablation, chen, mh, dai, y, yan, kalintraperitoneal, hemorrhage, duringandafter, percutaneous, radiofrequency, ablationof, hepatic, tumors, reasons, managementchin, med, j, engl, , , et, rhim, h, dodd, gr, chintapalli, kn, et, alradiofrequency, thermal, ablation, abdominal, tumors, lessons, learned, complications, radiographics, , , , terry, wi, radium, emanations, exophthalmic, goiterblood, vessels, adenomas, ofthyroid, j, med, assoc, , , , hor, lahiri, sw, bilateral, thyroidhematomas, ï¬neneedle, aspiration, causing, acute, airway, obstruction, thyroid, , , minami, y, hayaishi, kudo, mradiofrequency, ablation, hepatic, malignancies, needle, tract, cauterization, necessary, preventing, iatrogenic, bleeding, digdis, , , , baek, jh, kim, ys, lee, d, et, al, benign, predominantly, solid, thyroid, nodules, prospective, study, efï¬cacy, sonographicallyguided, radiofrequency, ablation, versus, control, condition, ajr, j, roentgenol, , , koda, m, murawaki, y, hirooka, y, et, alcomplications, radiofrequency, ablationfor, hepatocellular, carcinoma, multicenter, study, analysis, , , treated, nodules, , , patients, hepatol, res, , , wiggermann, p, wohlgemuth, wa, heibl, met, al, dynamic, evaluation, quantiï¬cationof, microvascularization, degradablestarch, microspheres, transarterial, chemoembolisation, dsmtace, hcc, lesionsusingultrasoundceus, feasibility, study, clin, hemorheolmicrocirc, , , enhancedcontrast, rosenbaum, ma, haridas, m, mchenrycr, lifethreatening, neck, hematoma, complicating, thyroid, parathyroid, surgeryam, j, surg, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |[, study, performed, explore, effective, management, bleeding, associated, with, radiofrequency, ablation, rfa, benign, thyroid, nodulesmethods, thirtyfive, patients, with, benign, thyroid, nodules, who, were, treated, with, ultrasoundguided, rfa, from, july, , december, , at, third, affiliated, hospital, sun, yatsenuniversity, were, retrospectively, reviewed, technique, efficacy, bleeding, other, complications, were, assessed, during, followup, periodresults, mean, technique, efficacy, 06, at, , month, 06, at, months, after, procedure, one, case, an, intranodular, haematoma, two, cases, voicechange, , month, were, observed, all, patients, recovered, with, corresponding, treatmentconclusion, although, incidence, haemorrhage, low, serious, haematomas, are, lifethreatening, therefore, having, comprehensive, understanding, potential, complicationsan, accurate, clinical, strategy, adequate, technical, skills, may, prevent, or, help, properly, managethese, complicationskeywordsradiofrequency, ablation, benign, thyroid, nodules, haemorrhage, management, haematomaultrasounddate, received, , january, , accepted, , june, 1department, medical, ultrasound, third, affiliatedhospital, sun, yatsen, university, guangzhou, china2general, surgery, department, third, affiliatedhospital, sun, yatsen, university, guangzhou, chinathese, authors, contributed, equally, workcorresponding, authorsbo, liu, general, surgery, department, third, affiliatedhospital, sun, yatsen, university, , tianhe, roadguangzhou, city, guangdong, province, china, jie, rendepartment, medical, ultrasound, third, affiliatedhospital, sun, yatsen, university, , tianhe, roadguangzhou, city, guangdong, province, chinaemails, renjieguangzhou126com, liubojake126comcreative, commons, non, commercial, cc, bync, , distributed, under, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, distribution, work, without, further, permission, provided, original, work, attributedas, specified, on, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cintroductionassociationfor, adultthyroid, nodules, are, extremely, commonand, associated, morbidity, rate, rangesfrom, , , according, highresolution, ultrasound, us, ï¬ndings12mostthyroid, nodules, are, benign, andrequire, no, intervention, other, than, clinicalfollowup, according, , americanthyroidmanagementguidelinespatients, withthyroid, nodulesand, differentiatedthyroid, cancer, thyroidstimulating, hormone, suppression, therapy, benign, thyroid, nodules, btns, not, recommendedbecause, potential, harm, outweighs, thebeneï¬t3, radioiodine, therapy, historically, an, effective, treatment, thyroid, hotnodules, possible, alternative, surgery, howeverthis, technique, has, beenproven, have, uncertain, efï¬cacy, andsome, adverse, effects, such, as, hypothyroidrecurrence4, surgery, may, beism, orconsideredgrowing, btns, withpressurerelated, symptoms, neck, discomfort, cosmetic, concerns, or, decreased, quality, life3, at, present, partialtotal, thyroidsurgery, considered, gold, standardtreatment, surgeryassociated, withnumerous, complications, such, as, nerveinjury, anaesthesiarelated, problemslonghospital, stays, conspicuous, scars, haemorrhage, lesions, ofthe, parathyroidglands78, addition, hypothyroidism, isinevitable, after, totalthyroidectomy, andrequires, lifelong, hormone, supplementationhenceincreasingly, minimally, invasivetherapeutic, strategies, are, currently, used, totreat, btns, most, cases, several, thermalablation, techniques, such, as, laser, ablationmicrowave, ablation, radiofrequency, ablation, rfa, highintensity, focused, ushave, been, shown, be, effective, btnsamong, these, thermal, ablation, techniquesrfa, most, widely, applied910forisrfa, thyroid, diseases, ï¬rst, reported, in, considered, efï¬cacious, safejournal, international, medical, researchfor, treatment, btns1415, date, no, lifethreatening, complications, related, rfahave, been, reported, howeverseveralcases, haemorrhagerelated, ï¬neneedle, aspiration, fna, or, core, needlebiopsy, cnb, have, been, reported16although, microinvasive, procedure, suchas, fna, can, result, massive, uncontrolledbleeding, resulting, upper, airway, respiratoryuncontrolledbleeding, rare, but, lifethreatening, complication, rfa, thus, management, ofbleeding, associated, with, rfa, btns, isof, vitalimportance, study, performed, explore, effective, managementof, bleeding, associated, with, rfa, btnsobstructionsuchmaterials, methodsofthis, study, approved, by, ethicscommitteethe, third, afï¬liatedhospital, sun, yatsen, university, andwritten, informed, consent, obtainedfrom, all, patients, prior, performanceof, usguided, fna, or, cnb, rfa, therequirement, obtain, informed, consent, forpublication, waived, because, retrospective, nature, studypatientsall, consecutive, patients, who, underwentrfa, btns, at, our, institution, from, july, december, , were, analysed, thefollowing, inclusion, criteria, were, appliedconï¬rmation, benignancybethesdaclass, ii, by, fna, cytology, or, cnb, complaints, pressure, symptoms, compressivesymptoms, neck, discomfort, orforeignbody, sensation, or, cosmetic, problems, a2cm, maximum, diameter, indexnodule, anxiety, about, malignancy, unsuitability, surgery, or, unwillingness, toundergo, surgery, normal, serum, thyrotropin, concentration, normal, completeblood, counts, normal, blood, coagulation, test, results, exclusion, criteria, 0chu, et, alwere, nodules, showing, malignant, featuresie, taller, than, wide, spiculated, marginmarked, hypoechoic, appearance, or, microcalciï¬cations, on, us, imaging19, abnormalthyroid, function, performance, othertreatments, thyroid, nodules, within, months, before, procedure, pregnancyand, age, , years, presentstudy, only, patients, with, 15, months, offollowup, after, procedure, were, included, thirtyï¬ve, patients, met, inclusioncriteriapretreatment, assessmentbefore, procedure, conventional, usï¬ndings, usguidedfna, ï¬ndingscontrastenhanced, us, ceus, ï¬ndingsand, laboratory, clinical, results, wereevaluated, two, radiologists, tw, jr, with, , , years, thyroid, us, experiencerespectively, performed, ususguided, fna, ceus, examinationsusing, logiq, e9, us, device, ge, medicalsystems, milwaukee, wi, usa, equippedwithtransducerwith, mhzfrequency, range, , mhz, usexamination, included, characterisation, ofthe, location, shape, size, margins, solidcystic, proportions, echogenicity, calciï¬cation, status, internal, vascularity, ofeach, nodulefrequency, ofan, ml615centrelinearlaboratory, tests, included, levels, ofthyroidstimulating, hormone, free, triiodothyronine, free, thyroxin, thyrotropina, complete, blood, cell, count, coagulation, test, prothrombin, time, activatedpartial, thromboplastin, time, nodulevolume, calculated, using, followingvolume¼, length, 02, width, 02equationdepth, 02, addition, all, patientsunderwent, vocal, cord, function, assessmentsby, an, experienced, laryngologist, before, theablation, procedure, atenrolment, allpatients, were, asked, rate, their, pressuresymptoms, on, 10cm, visual, analoguescale, grade, , cm, cosmeticgrading, score, assessed, by, physicianas, described, consensus, statement20procedures, equipmentpreventsignificantall, rfa, procedures, were, performed, by, oneradiologist, jr, with, , years, experienceperforming, rfa, an, outpatient, clinic, weused, an, rf, generator, viva, rf, systemvr, starmed, gyeonggisi, south, korea, andan, internally, cooled, 18gauge, 70mmlength, , or, 10mm, activetip, electrodestar, rf, electrodevr, , starmed, localanaesthesia, with, , lidocaine, appliedto, puncture, site, hydrodissectiontechnique, used, under, us, guidance, glucose, norepinephrine, weremixed, injected, into, surroundingthyroid, capsule, which, provided, safe, distance, between, needle, tip, adjacentcritical, structures, during, procedurewe, paid, special, attention, preservation, surrounding, important, structurestocomplicationstherefore, two, essential, techniques, werethe, transisthmic, approach, andappliedtechnique2122, ablationthe, movingshotwas, suspended, when, index, nodule, wascovered, by, hyperechoic, zones, technique, efï¬cacy, te, then, evaluated, byceus, at, , , minutes, after, rfa, untilthedisappearedtechnicalthechange, an, entire, nodule, noenhancement, zone, on, realtime, ceusfor, nodules, with, an, enhancement, zonean, additional, ablation, performed, todestroy, nodule, as, much, as, possiblecomplications, were, monitored, immediatelyafter, procedure, during, followup, period, major, minor, complicationsand, adverse, effects, were, deï¬ned, accordingto, criteria, established, by, society, ofinterventional, radiology2324success, deï¬ned, ashyperechoiczones, 0cjournal, international, medical, researchfollowup, evaluationatandperformedserum, thyroidany, speciï¬c, complaints, or, concerns, wererecorded, , month, postproceduralfollowup, wasand, months, after, treatment, at, each, followup, visit, us, examination, ceus, examinationhormonemeasurements, were, performed, pressuresymptoms, cosmetic, grading, scorewere, evaluated, volume, ofthetreated, nodule, calculated, te, wascalculated, using, following, equationte¼, ï¬nal, nodule, volumeinitial, nodule, volume, 02, statistical, analysisstatistical, analyses, were, performedallusing, spss, software, version, , ibmcorp, armonk, ny, usa, continuousvariables, are, expressed, as, mean, 06, standarddeviation, quantitative, data, volumeand, te, were, analysed, using, pairedttest, p, value, 14, consideredstatistically, significantresultsthe, patients, characteristics, are, summarised, table, , thirtyï¬ve, patients, underwent, rfa, including, , male, , femalepatients, mean, age, , years, meanlargest, btn, dimension, 06, , mmrange, , mm, mean, btnvolume, 06, , ml, twentytwototal, complications, , minor, , majorcomplications, were, observed, among, thetreated, patients, none, these, complications, lifethreatening, all, occurredwithout, sequelaenodule, volumeafter, treatment, overall, volume, thesignificantly, decreased, 06nodules, 06, , ml, at, ml, at, month, 06, , ml, at, , monthsbaselinetable, , patients, baseline, characteristics, n¼, characteristics, 06, 06, 06, 06, 06, 06, 06, 06, age, at, treatment, yearsmalefemale, ratiobody, weight, kgbody, height, cmbody, mass, index, kgm2symptom, score, cosmetic, score, cosmetic, score, cosmetic, score, cosmetic, score, preablation, serum, ft4, level, pmollpreablation, serum, tsh, level, miulindex, nodule, on, ultrasoundright, sideleft, sidelargest, dimension, mm, , 15data, are, presented, as, mean, 06, standard, deviation, ornumber, patientsft4, free, thyroxin, tsh, thyroidstimulating, hormonep, , , te, 06, at, , month, 06, , at, months, p, , , table, , figure, shows, shrinkage, nodules, at, , months, after, procedure, comparedwith, baseline, no, hypoechoic, blood, supplywas, observed, within, area, ofthenodulesbleeding, complicationstwelve, patients, developed, bleeding, complicationsincluding, perithyroidal, haematoma, minor, complication, , patientsand, an, intranodular, haematoma, majorcomplication, , patient, as, shown, intable, , haematomas, were, detectedby, us, scans, which, revealed, gradualenlargement, hyperechoic, mass, oraround, nodules, figure, , thepatient, with, intranodular, haemorrhage, 0chu, et, altable, , changes, volume, before, rfa, at, each, followup, visitparameterinitial, month, laterlargest, diameter, mm, 06, , , 06, , volume, mltechnique, efficacy, , data, are, presented, as, mean, 06, standard, deviation, range, 06, , , 06, , , 06, , , months, laterp, value, 06, , , 06, , , 06, , , figure, , c, e, ultrasound, examination, b, d, f, contrastenhanced, ultrasound, examination, a39yearold, woman, treated, with, radiofrequency, ablation, b, ultrasound, contrastenhanced, ultrasound, revealed, cysticsolid, nodule, before, ablation, c, d, one, month, after, ablation, ultrasound, showed, ahypoechoic, nodule, with, decreased, volume, d, e, six, months, after, ablation, volume, nodule, haddecreased, further, no, blood, supply, observed, within, area, nodule, 0cjournal, international, medical, researchtable, , complications, adverse, effects, patients, who, underwent, rfa, thyroid, nodulescomplication, or, adverse, effectadverse, effectsfeverpaindizzinesssensation, heatminorperithyroidal, haematomavomitingnauseaoedemaswellingvoice, change, , monthmajorvoice, change, , monthintranodular, haemorrhagedata, are, presented, as, n, , , , , , , , , , , , , , haematoma, controlled, throughtimely, use, ablation, needle, coagulate, injured, blood, vessel, by, injecting, lyophilising, thrombin, powder, into, thehaematoma, figure, , most, perithyroidalseriesrequired, only, observation, with, or, withoutcompression, disappeared, within, , weeks, after, procedure, none, patientssubscapularhaematomahaematomasdevelopedthisinaother, complications, adverse, effectsthe, adverse, effects, rfa, included, fevern¼, , , pain, n¼, , , dizziness, n¼, , , sensation, heatn¼, , , minor, complications, includedoedemaswelling, n¼, , , voicechange, , month, n¼, , vomitingnausean¼, discussionimageguided, thermal, ablation, techniquessuch, as, laser, ablation, ethanol, ablationmicrowave, ablation, highintensity, focusedus, particularly, rfa, have, recentlybecome, more, widely, used, treat, thyroidthe, creation, ofnodules, brieï¬y, basic, mechanism, ofrfa, involvesthermaldamage, by, friction, heat, conductionwhich, generated, from, an, oscillatinghighfrequency, alternating, electric, currentproduced, by, rfa, generator, thentransferred, through, electrode, tip, theenergy, rfa, powerful, accurate2526, rfa, considered, an, effectiveand, safe, treatment, control, btnsin, most, cases, incidence, haemorrhage, other, complications, low20however, haemorrhage, sometimes, lifethreatening, because, serious, haematomasmay, compress, upper, airways, manyreports, have, described, active, bleedingduring, fna, thyroid, nodules, rfaof, hepatocellular, carcinomas14, andsome, reports, have, described, fatalities14thusimportantcomplicationhaemorrhageanisthree, types, haemorrhage, may, occurperithyroidal, subcapsular, intranodular121427, mechanism, haemorrhage, thoughtto, be, related, themechanical, or, thermal, injuries, induced, bythe, rfa, electrode, tip3031, thyroid, nodulesreportedly, have, abundant, capsular, vesselsthat, are, usually, anastomosed, with, vesselspenetrating, into, core32, these, numerousvessels, are, abnormal, thinwalled, susceptible, rupture, large, thyroid, nodulesare, another, cause, haemorrhage, becausemultiple, insertions, are, often, required, totreat, such, nodules, additionthepatient, cannot, coordinate, with, physician, during, rfa, procedure, perithyroidal, orintrathyroidal, vessels, mayeasily, be, damaged, by, movement, theneedle, tip, or, production, heat, energyifit, important, manage, bleeding, associated, with, rfa, btns, based, on, ourexperience, we, suggest, several, steps, preventshouldobtain, thorough, medical, history, eachpatient, before, procedure, all, risk, factorsdrugssuch, bleeding, physiciansincludingbleedingfor, 0chu, et, alfigure, , ultrasound, examination, contrastenhanced, ultrasound, examination, patients, with, intranodular, haemorrhage, perithyroidal, haemorrhage, ultrasound, contrastenhanced, ultrasoundrevealed, hyperechoic, mass, lesion, nodule, b, ultrasound, contrastenhanced, ultrasound, revealedperithyroidal, haemorrhagedrugsnonsteroidalantiplateletantiinï¬ammatory, drugs, anticoagulantsand, diseases, affecting, coagulation, shouldbe, recorded33, addition, patientscoagulation, function, should, be, thoroughlyevaluated, all, patients, with, clinical, coagulation, disorders, should, be, excluded, evenwhen, coagulation, indices, are, normalinpatients, with, high, risk, factors, bleedingsuch, as, liver, cirrhosis, endstage, renal, disease, anticoagulant, use, or, hypertension34sufï¬cient, preoperative, preparation, shouldbe, emphasised, patient, with, active, bleedingthesein, presentstudy, metconditions, although, his, coagulation, indices, were, normal, he, had, subclinical, coagulation, disorder, due, endstage, liverdisease, fresh, frozen, plasma, or, human, prothrombin, complex, should, be, used, inpatients, with, liver, cirrhosis, anticoagulants, should, be, withdrawn, these, patientswhich, will, help, improve, coagulation, function, before, procedure, if, possibility, ofbleeding, exists, reptilase, haemocoagulaseatrox, forinjection, pentapharm, baselswitzerland, can, be, used, preoperativelyduring, rfa, procedure, an, effectiveclinical, strategy, adequate, technical, 0cjournal, international, medical, researchfigure, , ultrasound, examination, contrastenhanced, ultrasound, examination, patients, with, intranodular, haemorrhage, or, perithyroidal, haemorrhage, during, ablation, ultrasound, revealed, hyperechoicmass, lesion, nodule, b, ultrasound, showed, an, ablation, needle, inserted, into, nodule, coagulatebleeding, vessels, c, after, lyophilising, thrombin, powder, injected, into, hematoma, ultrasound, andcontrastenhanced, ultrasound, showed, disappearance, hyperechoic, mass, lesion, microbubbleextravasation, d, ultrasound, showed, hyperechoic, mass, lesion, around, thyroid, contrastenhancedultrasound, showed, no, microbubble, extravasation, around, thyroid, e, after, lyophilising, thrombinpowder, injected, into, haematoma, no, microbubble, extravasation, observedskills, are, both, essential, patient, cooperationis, ï¬rst, requirement, when, needle, tipis, patients, body, any, uncooperativemotion, patient, may, lead, injury, ofvessels, or, other, structures, most, patientscan, endure, procedure, under, local, anaesthesia, however, anxious, patients, mayrequire, general, anaesthesia, achieve, cooperation, if, possible, smallbore, electrodesshould, be, chosen, decrease, risk, ofbleeding35, it, necessary, cauterise, thesupplying, vasculature, nodules, avoidrecurrence, residue, howeverthepuncture, route, should, be, carefully, designedto, avoid, pericapsular, vessels, electrode, tip, should, be, closely, monitoredactive, bleeding, during, needle, puncture, isvisible, as, rapidly, expanding, hypoechoicor, anechoic, signal, locating, haemorrhagic, focus, not, difï¬cult, with, ceusguidance, bleeding, pointcan, beblocked, by, rf, electrode, tip, insertion, anddirect, ablation, when, bleeding, toorapid, control, with, rf, electrode, tipby, increasing, power, drug, injection, asuitable, alternative, lyophilised, thrombin, 0chu, et, alpowder, can, be, dissolved, normal, salineand, then, injected, at, bleeding, pointthrough, syringe, with, us, guidance, onereport, also, described, haemorrhage, treatedby, local, injection, hypertonic, saline, andepinephrine, solution, patient, with, hepatocarcinoma36, mildbleeding, whichappears, as, hypoechoic, layer, can, mostlybe, controlled, using, ice, compression, ofthe, neck, several, minutes, after, procedure30, all, bleeding, can, be, controlled, byconservative, methodsthus, no, surgicalintervention, needed, ecchymosis, can, befound, after, procedure, usually, disappears, approximately, , , weekspostprocedure, ceus, indispensablefor, all, patients, regardless, whether, bleeding, occurs, ceus, an, objective, evaluationtool, active, bleeding37, close, clinicalobservation, , hours, postoperatively, isrecommended, our, department, becausemost, bleeding, occurs, during, ï¬rstlobectomy38observation, neck, can, help, detecta, haematoma, early, may, aid, preventing, serious, adverse, effectsthyroidhoursafterconclusionacute, thyroid, bleeding, one, possible, complication, rfa, although, rare, it, potentially, lifethreatening, proper, selection, ofpatients, sufï¬cient, preparation, areessential, during, rfa, procedureboth, an, effective, clinical, strategy, adequate, technical, skills, are, indispensable, thephysician, should, trace, electrode, tipusing, realtime, us, sufï¬ciently, managebleeding, mild, bleeding, has, limited, morbidity, can, be, easily, controlled, by, compression, active, bleeding, tends, be, rarehowever, it, may, be, disastrous, if, operator, unaware, or, careless, direct, ablationwith, rf, electrode, tip, drug, injectioninto, bleeding, focus, are, effective, modalities, active, bleeding, ceus, closeobservation, are, also, recommended, afterthe, procedureto, detect, abnormalitiesearly, rfa, an, effective, relativelysafe, alternative, selected, patients, withbtns, if, performed, by, skilled, physiciansauthor, contributionsi, conception, design, jie, ren, bo, liuii, administrative, support, jie, reniiistudy, materials, or, patientsprovision, ofkunpeng, hu, yufan, lian, iv, collectionand, assembly, datajinfen, wang, andwenchao, li, v, data, analysis, interpretation, wenchao, li, zhicheng, yaovimanuscript, writing, all, authors, vii, finalapproval, manuscript, all, authorsdata, availabilitydata, regarding, patients, characteristics, usedto, support, funding, are, shown, table, declaration, conflicting, interestthe, authors, declare, that, there, no, conï¬ict, ofinterestfundingthe, naturalthis, work, supported, by, nationalnatural, science, foundation, china, cnnosciencefoundation, guangdong, provinceno2016a030313200, science, technologyproject, guangzhou, city, no, hengrui, foundation, hepatobiliary, andpancreaticnocxpjjh1180000120183331naturalscience, foundation, guangdong, provincenothe, fundamentalresearch, funds, central, universitiessun, yatsen, university, no, 17ykpy67, andthe, , clinical, research, project, sun, yatsen, university, no, 2017a030313580thecancerresearchorcid, idkunpeng, huorcid00000001, 0creferences, guth, s, theune, u, aberle, j, et, al, very, highprevalence, thyroid, nodules, detected, byhigh, frequency, , mhz, ultrasound, examination, eur, j, clin, invest, , , , tan, gh, gharib, h, thyroid, incidentalomas, management, approaches, nonpalpable, nodules, discovered, incidentally, onthyroid, imaging, ann, intern, med, , , haugen, br, alexander, ek, bible, kc, et, al, americanthyroid, associationmanagement, guidelines, adult, patientswith, thyroid, nodules, differentiatedthyroid, cancer, american, thyroidassociation, guidelines, task, force, onthyroid, nodulesand, differentiatedthyroid, cancer, thyroid, , , , ceccarelli, c, bencivelli, w, vitti, p, et, aloutcome, ofradioiodine131, therapy, inhyperfunctioning, thyroid, nodules, years, retrospective, study, clin, endocrinoloxf, , , , reiners, c, schneider, p, radioiodinetherapy, thyroid, autonomy, eur, j, nuclmed, mol, imaging, , , s471s478, nieuwlaat, wa, hermus, ar, sivroprndeljf, et, al, pretreatment, with, recombinanthuman, tsh, changes, regional, distribution, radioiodine, on, thyroid, scintigramsof, nodular, goiters, j, clin, endocrinol, metab, , , linosdeconomopouloskpkiriakopoulos, et, al, scar, perceptionsafter, thyroid, parathyroid, surgery, comparison, minimaland, conventionalapproaches, surgery, , , , jeannon, jp, orabi, aa, bruch, ga, et, allaryngeal, nervethyroidectomy, systematicdiagnosis, ofpalsy, afterreview, int, j, clin, pract, , , recurrent, lang, b, woo, yc, chiu, kw, identifyingpredictive, factors, efï¬cacy, high, intensity, focused, ultrasound, hifu, ablationof, benign, thyroid, nodules, , retrospectiveint, j, hyperthermia, , analysis, mauri, g, pacella, cm, papini, e, et, alimageguided, thyroid, ablation, proposalforterminology, andstandardization, ofjournal, international, medical, researchreportingcriteria, thyroid, sato, m, tateishi, r, yasunaga, h, et, almortality, hemorrhagic, complicationsassociated, with, radiofrequency, ablation, fortreatment, hepatocellular, carcinoma, inendstagepatients, on, hemodialysissurveyrenaljgastroenterol, hepatolnationwidediseasefora, krokidis, m, spiliopoulos, s, jarzabek, met, al, percutaneous, radiofrequency, ablationof, small, renal, tumours, patients, with, asingle, functioning, kidney, longterm, resultseur, radiol, , , , lim, hk, lee, dupuy, de, monchik, jm, decrea, c, et, alradiofrequency, ablation, regional, recurrence, from, welldifferentiated, thyroid, malignancy, surgery, , , jh, ha, ejalradiofrequency, ablation, benign, nonfunctioning, thyroid, nodules, 4year, followup, results, , patients, eur, radiol, , et, braga, m, cavalcanti, tc, collaco, lm, et, alefï¬cacy, ultrasoundguided, ï¬neneedleaspiration, biopsy, diagnosis, complex, thyroid, nodules, j, clin, endocrinolmetab, , , , kakiuchi, y, idota, n, nakamura, m, et, ala, fatal, case, cervical, hemorrhage, after, ï¬neneedle, aspiration, core, needle, biopsy, ofthe, thyroid, gland, am, j, forensic, med, pathol, , , donatini, g, masoni, t, ricci, v, et, al, acuterespiratory, distress, following, ï¬ne, needleaspiration, thyroid, nodule, case, reportand, review, literature, g, chir, , , roh, jl, intrathyroid, hemorrhage, acuteupper, airway, obstruction, after, ï¬ne, needleaspirationthyroidglandlaryngoscope, , , theofofassociation, gharib, h, papini, e, garber, jr, et, alamericanclinicalendocrinologists, american, college, ofendocrinology, associazione, mediciendocrinologi, medical, guidelines, clinicalpractice, diagnosis, managementthyroid, nodules, update, endocrofpract, , , , 0chu, et, al, na, dg, leeetjhjung, slalradiofrequency, ablation, benign, thyroidnodules, recurrent, thyroid, cancers, consensusstatement, recommendationskorean, j, radiol, , , , ha, ej, baek, jh, lee, jh, movingshotversus, ï¬xed, electrode, techniques, radiofrequency, ablation, comparison, an, exvivo, bovine, liver, tissue, model, korean, jradiol, , , , jeong, wk, baek, jh, rhim, h, et, alradiofrequency, ablation, benign, thyroidnodules, safety, imaging, followup, inpatients, eur, radiol, cardella, jf, kundu, s, miller, dl, et, alsociety, interventional, radiology, clinicalpractice, guidelines, j, vasc, interv, radiol, , s189s191, sacks, d, mcclenny, te, cardella, jf, et, alsociety, interventional, radiology, clinicalpractice, guidelines, j, vasc, interv, radiol, , s199s202, goldberg, sn, radiofrequency, tumor, ablation, principles, techniques, eur, jultrasound, , , , rhim, h, goldberg, sn, dodd, gr, et, alessential, techniques, successful, radiofrequency, thermal, ablation, malignanthepatic, tumors, radiographics, , spec, no, s17s35, s36s39, korkusuz, y, erbelding, c, kohlhase, ket, al, bipolar, radiofrequency, ablation, ofbenign, symptomatic, thyroid, nodules, initial, experience, rofo, , , , garberoglio, r, aliberti, c, appetecchia, met, al, radiofrequency, ablation, thyroidnodules, which, indications, ï¬rst, italianopinion, statement, j, ultrasound, , , baek, jh, leejh, sung, jyet, alcomplications, encountered, treatmentof, benign, thyroid, nodules, with, usguidedradiofrequencya, multicenterstudy, radiology, , , ablation, chen, mh, dai, y, yan, kalintraperitoneal, hemorrhage, duringandafter, percutaneous, radiofrequency, ablationof, hepatic, tumors, reasons, managementchin, med, j, engl, , , et, rhim, h, dodd, gr, chintapalli, kn, et, alradiofrequency, thermal, ablation, abdominal, tumors, lessons, learned, from, complications, radiographics, , , , terry, wi, radium, emanations, exophthalmic, goiterblood, vessels, adenomas, ofthyroid, j, am, med, assoc, , , , hor, t, lahiri, sw, bilateral, thyroidhematomas, after, ï¬neneedle, aspiration, causing, acute, airway, obstruction, thyroid, , , minami, y, hayaishi, s, kudo, mradiofrequency, ablation, hepatic, malignancies, needle, tract, cauterization, necessary, preventing, iatrogenic, bleeding, digdis, , , , baek, jh, kim, ys, lee, d, et, al, benign, predominantly, solid, thyroid, nodules, prospective, study, efï¬cacy, sonographicallyguided, radiofrequency, ablation, versus, control, condition, ajr, am, j, roentgenol, , , koda, m, murawaki, y, hirooka, y, et, alcomplications, radiofrequency, ablationfor, hepatocellular, carcinoma, multicenter, study, an, analysis, , , treated, nodules, , , patients, hepatol, res, , , wiggermann, p, wohlgemuth, wa, heibl, met, al, dynamic, evaluation, quantiï¬cationof, microvascularization, during, degradablestarch, microspheres, transarterial, chemoembolisation, dsmtace, hcc, lesionsusingultrasoundceus, feasibility, study, clin, hemorheolmicrocirc, , , enhancedcontrast, rosenbaum, ma, haridas, m, mchenrycr, lifethreatening, neck, hematoma, complicating, thyroid, parathyroid, surgeryam, j, surg, , , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,13,15,16,17,18,19,20,21,22,23,24,25,26,28,29,30,33,34,35,36,37,38,39,40,42,43,44,45,48,49,50,52,54,55,57,58,59,60,61,63,64,65,66,67,68,69,70,72,73,74,75,76,78,80,81,82,84,85,87,88,91,92,93,94,95,96,98,99,104,105,108,110,111,112,113,114,115,119,122,123,124,125,128,129,131,132,133,134,136,137,139,140,142,143,144,147,148,149,150,151,153,155,157,159,160,161,163,164,165,169,170,172,174,179,186,188,190,191,193,194,195,196,203,204,205,209,210,214,215,216,218,223,225,226,227,228,238,239,240,244,245,253,254,257,260,261,265,269,270,274,276,277,278,279,281,284,286,295,299,305,307,309,312,318,321,331,333,334,335,350,351,365,367,368,369,370,372,375,377,380,385,386,389,394,398,407,409,410,413,414,415,422,426,427,428,431,435,437,446,449,452,453,455,460,462,465,470,471,473,475,483,486,492,494,495,503,504,508,509,513,516,517,518,520,523,529,538,539,541,543,546,547,548,551,555,556,559,560,562,564,568,571,572,575,576,578,579,581,582,585,590,596,601,602,606,608,615,617,618,623,625,635,636,637,639,643,646,653,658,660,661,670,674,700,701,708,712,724,727,733,736,739,743,747,750,761,762,775,784,786,788,792,795,797,798,801,802,805,815,818,822,825,832,834,846,848,849,864,869,872,878,886,889,891,892,893,894,924,932,943,944,949,958,960,967,971,978,984,988,990,992,998,1021,1022,1029,1039,1057,1059,1060,1061,1076,1086,1092,1095,1110,1111,1113,1114,1120,1131,1133,1144,1153,1160,1161,1166,1180,1184,1188,1190,1196,1203,1205,1208,1212,1214,1217,1219,1232,1233,1253,1256,1263,1266,1267,1276,1285,1288,1292,1297,1299,1302,1306,1310,1317,1325,1348,1359,1363,1371,1375,1376,1392,1396,1400,1404,1406,1411,1419,1424,1425,1434,1436,1440,1451,1457,1458,1459,1473,1485,1490,1495,1501,1505,1514,1530,1542,1554,1563,1565,1572,1585,1589,1600,1613,1629,1633,1639,1640,1645,1647,1659,1660,1671,1676,1679,1691,1694,1695,1697,1700,1705,1708,1711,1728,1736,1753,1758,1778,1782,1803,1804,1816,1838,1845,1847,1852,1872,1917,1921,1932,1937,1955,1957,2002,2030,2049,2064,2091,2098,2111,2118,2119,2121,2123,2145,2152,2198,2211,2213,2223,2225,2228,2231,2247,2340,2344,2372,2405,2422,2434,2445,2457,2467,2477,2492,2538,2544,2548,2578,2587,2609,2613,2617,2637,2675,2689,2697,2702,2725,2735,2756,2757,2771,2774,2795,2801,2821,2835,2853,2864,2867,2868,2874,2884,2897,2915,2941,2967,2971,2994,2997,3013,3056,3060,3061,3065,3067,3093,3100,3113,3121,3165,3202,3210,3220,3221,3226,3244,3256,3273,3297,3299,3344,3363,3377,3419,3471,3473,3483,3516,3529,3549,3603,3607,3609,3624,3633,3694,3717,3731,3732,3757,3765,3771,3795,3826,3829,3838,3915,3920,3952,3965,4019,4022,4026,4099,4183,4187,4192,4231,4234,4242,4259,4268,4297,4324,4404,4412,4439,4451,4486,4489,4531,4581,4596,4616,4617,4622,4775,4801,4803,4807,4824,4834,4871,4893,4908,4947,4982,5064,5068,5096,5106,5115,5122,5150,5172,5217,5239,5284,5293,5300,5350,5383,5405,5470,5506,5509,5517,5567,5586,5622,5649,5665,5740,5772,5828,5887,5967,5988,5999,6030,6049,6057,6143,6157,6160,6168,6264,6285,6299,6301,6328,6387,6533,6561,6573,6640,6659,6692,6769,6788,6806,6820,6885,6908,6922,7103,7134,7263,7267,7307,7315,7321,7328,7346,7371,7391,7413,7419,7469,7487,7507,7511,7525,7532,7620,7638,7684,7715,7733,7810,7819,7845,7970,7971,8097,8216,8276,8305,8314,8392,8465,8532,8551,8559,8712,8850,8853,8895,9026,9183,9289,9313,9399,9459,9513,9687,9706,9708,9709,9747,9815,9866,9947,9961,10017,10020,10042,10090,10110,10306,10319,10404,10474,10495,10510,10555,10567,10721,10748,10752,10895,10918,10991,11259,11279,11306,11350,11397,11407,11425,11525,11701,11852,11926,11933,12036,12100,12112,12130,12262,12280,12290,12432,12574,12579,12606,12739,12755,12906,12997,13008,13051,13153,13518,13675,13928,14012,14043,14051,14087,14106,14168,14375,14800,15122,15172,15308,15382,15786,15850,15900,15932,16120,16140,16149,16224,16279,16319,16381,16395,16416,16466,16615,16683,16844,16912,17017,17146,17300,17461,17473,17657,17808,18026,18124,18566,18591,18771,18884,18948,19195,19282,19343,19396,19535,19539,19555,19649,19714,20009,20019,20020,20085,20160,20173,20202,20305,20467,21141,21154,21286,22009,22150,22625,22702,23015,23640,23720,23937,24498,24661,24696,24699,24719,24745,24897,25157,25174,25344,25394,25612,25685,25882,26282,26362,26521,26632,27461,27704,27964,28246,28306,28590,28683,28921,29019,29090,29340,29636,29978,30414,30473,30531,30724,30735,31059,31390,31400,31495,31507,31554,31555,31749,31885,31937,32687,33249,33486,33854,34023,34244,34333,35382,35458,35940,36427,36629,36679,36685,36691,37240,37451,37668,37698,37761,37828,37982,38211,38244,38447,38654,38832,39033,39254,39344,39714,39817,39926,41845,41976,42031,44024,44780,45659,45886,45967,47169,47224,47323,47742,48021,48487,49299,49520,49680,49748,50114,50168,50313,50452,50841,50927,52354,53066,53457,53769,54572,55677,55824,56515,56907,57190,57409,57411,57736,57908,57954,58694,59023,59164,59393,59733,60031,60065,60391,60558,62031,62699,63985,64782,64995,65000,65193,65561,65584,66274,66952,67146,67149,67222,67932,68647,68828,68834,69226,69333,69425,69446,69501,69758,70279,70958,71356,71399,71495,72001,72141,72901,73586,74014,74139,74223,74371,75904,76099,78009,78564,79724,80746,81276,82056,82170,82221,82684,82995,83032,83510,83679,83797,84594,84708,85743,86097,86689,87851,88064,88478,88693,88840,89141,89276,89814,90031,90032,90088,90169,90816,91118,91122,91393,91562,91657,91783,92007,92168,92333,92531,92619,92721,92873,93008,93095,93318,93420,93554,93682,94021,94942,95349,95464,96345,96425,96804,96903,97378,97484,97607,97852,98770,98950,99460,99482,100039,100724,101034,101354,101665,101909,101989,102032,102134,102442,103121,103330,103796,104084,104379,104670,104948,105107,105365,105650,105786,105924,106105,106121,106456,106687,106865,106993,107535,107621,107886,108019,108278,108293,108405,109052,109475,109487,109607,109650,109917,110200,110409,110455,110558,110576,110579,110962,111255,111457,111836,111983,112088,112377,112388,112646,112927,113298,113369,113709,113737,113814,113899,114069,114211,114612,114895,114940,115132,115169,115181,115512,115698,115805,116066,116653,117353,117366,117377,117683,117972,118301,118425,118487,119144,120370,120781,121027,121314,121351,121706,121981,122073,122208,122322,122329,122471,122616,122653,122885,123059,123233,123509,123737,123853,123879,124050,124454,124554,125021,125131,125258,125372,125546,125737,125740,126628,127241,127370,127403,127665,127837,128327,128542,129053,129813,129981,130054,130590,130873,131066,131209,131447,131919,132291,133156,133933,134001,134520,135554,135652,136277,136369,136404,136430,136439,136664,136747,136763,137188,137506,138259,138513,138556,138733,139531,139835,139983,140097,140169,140197,140283,140449,140450,140606,140689,141429,141747,142075,142169,142262,142332,142483,142523,142556,142737,143002,143170,143271,143829,144155,144169,144267,144756,144929,145587,146242,146386,146429,146493,146694,147082,147136,147227,147476,147490,148408,148451,148534,148736,149047,149957,150339,150362,150510,150916,150942,151248,151330,151515,151786,151867,152184,152331,153108,153122,153324,153453,153900,154410,154510,154781,155327,155508,155522,155529,155632,155760,156011,156534,156697,156957,156985,157253,157493,157841,157932,157979,158580,158947,159339,159410,159568,159686,159794,160065,160330,160538,160762,161069,161346,161566,162262,162783,162789,163727,164319,164708,164955,165192,165197,165393,165623,165898,165916,165985,166133,166165,166718,166733,167110,167160,167381,168003,169007,169369,170148,170166,170246,170996,171177,171417,171953,172097,172101,172201,172310,172785,172952,173241,174417,174422,174442,175300,175415,175540,175972,176065,176654,177241,179208,179321,179774,179846,179903,179984,180139,180324,180507,180984,181153,181282,181464,182422,182667,182723,183029,183137,183438,183689,183870,184261,184300,184692,185088,185270,185407,185770,185919,186514,186653,186667,186753,186971,187346,187349,187395,187516,187593,188796,189663,189997,190157,191216,191285,191355,191933,191948,192085,192347,192898,193458,193554,194329,194464,194540,194566,194853,194964,195593,196356,196494,196877,197196,197535,197688,197739,197879,198861,200343,200471,200621,201085,201245,201272,201406,201714,202292,202822,202959,203133,203204,203636,203997,204529,205189,205358,205617,206220,206322,206369,206963,207359,207646,207779,208446,208519,208631,209008,209105,210171,210172,210437,210479,210583,210639,210789],[164.0,32.0,17.0,14.0,1.0,14.0,3.0,19.0,20.0,8.0,5.0,18.0,1.0,16.0,34.0,16.0,17.0,1.0,7.0,2.0,6.0,4.0,2.0,1.0,4.0,1.0,5.0,2.0,2.0,16.0,5.0,4.0,6.0,10.0,2.0,16.0,3.0,3.0,12.0,8.0,1.0,3.0,5.0,25.0,6.0,2.0,4.0,8.0,5.0,1.0,3.0,2.0,6.0,4.0,6.0,2.0,5.0,2.0,3.0,1.0,1.0,4.0,6.0,1.0,3.0,5.0,1.0,3.0,4.0,2.0,2.0,2.0,3.0,1.0,7.0,5.0,1.0,6.0,1.0,3.0,3.0,5.0,1.0,1.0,3.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,5.0,4.0,1.0,2.0,5.0,9.0,11.0,4.0,2.0,3.0,4.0,2.0,7.0,3.0,3.0,2.0,3.0,1.0,3.0,9.0,2.0,2.0,3.0,4.0,6.0,3.0,9.0,2.0,3.0,3.0,1.0,1.0,1.0,37.0,2.0,1.0,2.0,4.0,6.0,3.0,5.0,3.0,1.0,2.0,2.0,2.0,1.0,1.0,4.0,1.0,1.0,2.0,4.0,1.0,3.0,1.0,1.0,3.0,3.0,1.0,3.0,2.0,1.0,6.0,1.0,2.0,1.0,4.0,1.0,3.0,1.0,1.0,3.0,2.0,8.0,2.0,6.0,3.0,1.0,1.0,2.0,1.0,6.0,1.0,3.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,4.0,1.0,1.0,3.0,2.0,7.0,1.0,4.0,1.0,2.0,1.0,3.0,1.0,2.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,6.0,1.0,5.0,1.0,1.0,2.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,6.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,2.0,7.0,1.0,1.0,7.0,1.0,1.0,1.0,5.0,7.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,5.0,1.0,1.0,3.0,1.0,5.0,1.0,1.0,1.0,10.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,24.0,1.0,1.0,1.0,1.0,2.0,1.0,6.0,1.0,10.0,1.0,1.0,31.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,15.0,1.0,1.0,3.0,1.0,4.0,2.0,2.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,23.0,4.0,2.0,1.0,1.0,1.0,3.0,1.0,4.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,8.0,2.0,1.0,5.0,2.0,1.0,1.0,2.0,3.0,1.0,4.0,1.0,1.0,1.0,1.0,11.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,27.0,1.0,2.0,1.0,5.0,1.0,1.0,2.0,1.0,1.0,2.0,4.0,3.0,2.0,1.0,3.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,3.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,5.0,1.0,2.0,1.0,3.0,3.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,15.0,3.0,1.0,1.0,19.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,8.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,6.0,2.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,25.0,1.0,4.0,2.0,1.0,1.0,13.0,3.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,7.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,5.0,1.0,1.0,1.0,14.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,6.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,7.0,4.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,5.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,2.0,2.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n",
      "|[, this, study, was, performed, assess, the, clinical, outcomes, of, elderly, patients, withosteoporotic, femoral, neck, fractures, fnfs, aoota, 31bc, treated, by, initial, uncementedtotal, hip, arthroplasty, uta, or, cemented, total, hip, arthroplasty, ctamethods, this, study, involved, consecutive, elderly, patients, with, osteoporotic, fnfs, aoota31bc, treated, by, initial, uta, or, cta, in, our, medical, centre, from, , to, , the, primaryoutcomes, were, the, harris, hip, score, hhs, and, the, rates, of, revision, loosening, periprostheticfracture, and, dislocationresults, in, total, , patients, were, included, in, the, final, analysis, uta, n¼, , cta, n¼, the, mean, followup, duration, was, , months, range, , months, the, mean, hhs, was1department, of, microsurgery, trauma, and, hand, surgerythe, first, affiliated, hospital, sun, yatsen, universityguangzhou, china2department, of, pediatrics, the, first, affiliated, hospitalsun, yatsen, university, guangzhou, china3department, of, orthopaedics, the, first, affiliatedhospital, sun, yatsen, university, guangzhou, china4department, of, orthopaedics, the, third, peopleshospital, of, wuxi, jiangsu, province, the, affiliated, hospitalof, jiangnan, university, wuxi, china5department, of, urology, the, first, affiliated, hospital, sunyatsen, university, guangzhou, chinathese, authors, contributed, equally, to, this, workcorresponding, authorsjunxing, ye, department, of, orthopeadics, the, thirdpeoples, hospital, of, wuxi, jiangsu, province, the, affiliatedhospital, of, jiangnan, university, no, , xingyuan, northroad, liangxi, district, wuxi, jiangsu, , chinaemail, yejunxing0514163comjintao, zhuang, department, of, urology, the, first, affiliatedhospital, sun, yatsen, university, no, , zhongshan, 2ndroad, yuexiu, district, guangzhou, , chinaemail, brianzg86163comcreative, commons, non, commercial, cc, bync, this, , is, distributed, under, the, terms, of, the, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, and, distribution, of, the, work, without, further, permission, provided, the, original, work, is, attributedas, specified, on, the, sage, and, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, of, international, medical, research, 06, , for, uta, and, 06, , for, cta, significant, dissimilarities, were, detected, in, therates, of, revision, loosening, and, periprosthetic, fracture, between, uta, and, cta, , vs, , vs, , and, , vs, , respectively, a, significant, difference, was, also, detected, inthe, probability, of, revision, between, the, two, groupsconclusion, elderly, patients, with, osteoporotic, fnfs, aoota, 31bc, treated, with, cta, showgreater, improvements, in, functional, outcomes, and, key, orthopaedic, complications, than, thosetreated, with, utakeywordsfemoral, neck, fracture, arthroplasty, outcome, complication, retrospective, osteoporosisdate, received, , december, , accepted, , july, introduction31bcaootafemoral, neck, fracturesmanagement, ofin, elderlyfnfspatients, is, still, undergoing, considerableresearch12, uncemented, total, hip, arthroplasty, uta, or, cemented, total, hip, arthroplasty, cta, for, displaced, fnfs, tendsto, be, a, recognised, surgical, strategy3comparisons, between, uta, and, cta, forelderly, individuals, with, an, fnf, generallyfavour, cta, this, is, primarily, attributed, tothe, exceptional, clinical, outcomes, of, cta, interms, of, relieving, pain, and, improving, dailyactivities, as, well, as, the, higher, rate, of, majororthopaedic, complications, ie, revisionloosening, periprosthetic, fracture, and, dislocation, associated, with, uta4, howeverrecent, studies, of, uta, in, elderly, individualshave, demonstrated, encouraging, shorttermclinical, outcomes67, moreover, cementedprosthesis, syndrome, tends, to, occur, morefrequently, in, cta, than, uta8, cementedprosthesis, syndrome, theoretically, poses, asignificantlifealthough, the, speciï¬c, probability, of, thisthreat, has, not, been, calculated89, hencewhether, to, utilise, cta, for, elderly, individuals, may, present, the, clinician, with, a, dilemma9, the, lack, of, consensus, regarding, whichtechnique, uta, or, cta, is, preferable, fortreating, fnfs, aoota, 31bc, in, elderlyindividuals, is, related, to, the, remarkableto, the, patientsthreatdistinction, in, clinical, outcomes, betweenthe, two, types, of, implants610most, previousconcentrated, medicalstudies, have, involvedhighlycentresand, several, brands, of, prostheses356additionally, shortterm, followup, is, commonplace, in, these, studies, to, overcomethese, drawbacks, of, previous, studies, and, tocompare, the, midterm, results, of, the, twoprostheses, we, assessed, the, clinical, outcomesof, elderly, patients, with, osteoporotic, fnfsaoota, 31bc, treated, with, initial, utaor, cta, with, a, mean, followup, of, , yearsmaterials, and, methodsstudy, populationtheandrequirementethical, approval, was, obtained, from, thefirst, afï¬liated, hospital, of, sun, yatsenuniversityforinformed, consent, was, waived, by, theinvestigational, review, board, consecutiveelderly, individuals, with, the, principle, diagnosis, of, an, fnf, aoota, 31bc, whounderwentinitial, uta, or, cta, from, march, , to, , march, , and, forwhom, detailed, information, was, availablethroughoutidentiï¬edfrom, the, orthopaedics, department, of, thefirst, afï¬liated, hospital, sun, yatsenuniversity, the, manufacturer, details, offollowup, were, 0cmao, et, altable, , manufacturer, details, of, stems, and, cupsemployed, in, the, arthroplasty, proceduresprocedurestemcupcorail1exeter3exeter3reflectionuncemented2uta, n¼, cta, n¼, 1depuy, synthes, warsaw, in, usa2smith, , nephew, london, uk3stryker, corporation, kalamazoo, mi, usauta, uncemented, total, hip, arthroplasty, cta, cementedtotal, hip, arthroplastyclosed, fnfsthe, stems, and, cups, employed, in, the, arthroplasty, are, shown, in, table, , the, surgicalprocedure, and, postoperative, rehabilitationprotocol, were, described, in, our, previouslypublished, study11, the, inclusion, criteriawereaoota, 31bcactive, and, cognitively, intact, patients, ageof, 15, years, independently, mobile, priorto, the, injury, and, a, bone, mineral, densitytscore, of, , , at, the, femoral, neck, themajor, exclusion, criteria, were, multiple, fractures, or, contralateral, limb, fractures, pathological, fnfs, lower, limb, dyskinesia, priorto, surgery, cancer, planned, surgery, polytrauma, severe, comorbidities, eg, thyroiddisorder, with, calcium, and, phosphorusmetabolism, disorderwithcomplications, drug, abuse, affecting, bonehealing, or, bone, metabolism, early, interruption, of, followup, , months, and, cognitive, impairment, clinical, and, radiographicassessments, were, performed, at, , , and, months, after, surgery, and, every, , monthsthereafter, the, primary, outcomes, were, theharris, hip, score, hhs, and, the, rates, ofrevision, loosening, periprosthetic, fractureand, dislocationdiabetesstatistical, analysisrevision, was, deï¬ned, as, partial, or, completereplacement, of, the, prosthesis12, looseningof, the, acetabulum, andor, stem, componentstomographycompared, usingas, well, as, dislocation, were, deï¬ned, based, ona, previous, description13, periprostheticconï¬rmed, by, xray, orfracture, wascomputedexaminationcontinuous, data, ie, age, bone, mineraldensity, body, mass, index, followup, timeand, hhs, wereanindependentsamples, t, test, and, categoricalvariables, ie, sex, side, [leftright], fracturetype, comorbidities, mechanism, of, injuryamerican, society, of, anesthesiologists, classiï¬cation, and, major, orthopaedic, complications, were, compared, using, the, chisquaretest, or, the, mannwhitney, test, a, kaplanmeier, survival, curve, was, used, to, assess, theprobability, of, revision, hazard, ratios, werecalculated, using, a, cox, proportional, hazards, model, the, signiï¬cance, threshold, wasset, at, p, , , the, statistical, analysis, wasperformed, using, spss, , ibm, corparmonk, ny, usaresultsin, total, , consecutive, patientsarthroplasties, with, an, fnf, aoota31bc, who, underwentinitial, uta, orcta, met, our, inclusion, criteria, and, wereincluded, for, analysis, figure, , the, meanfollowup, duration, was, , months, range, months, the, patients, mean, age, was, 06, , years, for, uta, and, 06, for, cta, the, mean, body, mass, indexfor, uta, andwas, 06, , kgm2, for, cta, the, patientsbaselinesimilarbetween, the, two, groups, table, 06, , kgm2characteristics, wereprimary, outcomesimproved, functional, outcomes, were, notedin, both, groups, as, indicated, by, the, hhsuta, , 06, , prior, to, surgery, vs, 06, , at, ï¬nal, analysis, p, , cta, 06, , prior, to, surgery, vs, 06, , at, ï¬nal, analysis, p, , at, the, end, of, followup, the, hhs, was, 0cjournal, of, international, medical, researchfigure, , flow, diagram, exhibiting, methods, for, identifying, patients, with, fnfs, aoota, 31bc, whounderwent, an, initial, uta, or, ctafnfs, femoral, neck, fractures, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hiparthroplastysignificantly, different, between, the, twouta, , 06, , vs, ctagroups, 06, , p¼, , and, patients, whounderwent, cta, had, higherfunctionalscores, than, those, who, underwent, utano, distinct, betweengroup, differenceswere, observed, at, any, time, point, before, months, postoperatively, table, no, early, , year, postoperative, complications, were, detectedincluding, revisionloosening, periprosthetic, fracture, or, dislocation, the, rate, of, key, orthopaedic, complications, wasfor, utaand, , , for, cta, p, , table, , in, the, uta, group, , patients, underwent, revision, uta, developed, prosthesis, loosening, , developed, periprosthetic, fracturesand, , , developed, prosthesis, dislocation, in, the, cta, group, , , patientsunderwent, revision, uta, , , developed, prosthesis, loosening, , , developed, periprosthetic, fractures, and, , developed, prosthesis, dislocation, the, average, time, interval, from, the, initial, surgery, torevision, uta, was, , months, range, months, for, uta, and, , months, rangefor, cta, p¼, , monthssigniï¬cant, differences, in, revision, looseningand, periprosthetic, fracture, were, observedbetween, the, uta, and, cta, groups, revision, , vs, , p¼, , loosening, 0cmao, et, altable, , patient, demographics, and, outcomesvariablesex, femalemaleage, yearsbmi, kgm2bmdside, leftrightfnfs, aoota, type31b31ccomorbiditiesdiabetes, mellitushypertensioncerebrovascular, diseasemechanism, of, fnfstraffic, accidentfallingtamping, accidentasa, classificationuta, n¼, 06, 06, , 06, , , , , , , , , , , , 06, hhs, prior, to, surgerydata, are, presented, as, n, n, , or, mean, 06, standard, deviationpvaluecta, n¼, 06, 06, , 06, , , , , , , , , , , , 06, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplasty, hhs, harris, hip, score, asa, americansociety, of, anesthesiologists, bmi, body, mass, index, bmd, bone, mineral, density, fnfs, femoral, neck, fracturestable, , comparison, of, hip, functional, scoresmonths, postoperativelyfinal, followupdata, are, presented, as, mean, 06, standard, deviationuta, n¼, 06, 06, 06, 06, 06, 06, 06, 06, cta, n¼, 06, 06, 06, 06, 06, 06, 06, 06, pvaluestatistically, significantuta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplasty, vs, , p¼, , and, periprosthetic, fracture, , vs, , p¼, respectively, a, significant, difference, in, theprobability, of, revision, was, also, detectedbetween, the, groups, hazard, ratio, interval, conï¬dencep¼, , figure, , no, significant, difference, was, found, in, the, rate, of, prosthesis, dislocation, between, the, uta, and, cta, groups, vs, , respectively, 0cjournal, of, international, medical, researchtable, , rates, of, key, orthopaedic, complicationscomplicationsprosthesis, revisionprosthesis, looseningperiprosthetic, fracturedislocationuta, n¼, cta, n¼, , , , , , , , , pvaluedata, are, presented, as, n, statistically, significantuta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplastyfigure, , kaplanmeier, curves, showing, probability, of, revision, after, primary, surgery, hr, was, calculatedper, the, cox, proportional, hazards, model, with, age, sex, american, society, of, anesthesiologists, classificationbody, mass, index, bone, mineral, density, and, femoral, neck, fracture, type, as, covariates, and, surgery, as, the, timedependent, factorhr, hazard, ratio, ci, confidence, interval, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hiparthroplastysurgeryprobablediscussionthis, review, characterised, the, outcomes, of, asolitary, brand, of, a, total, hip, arthroplastyimplant, during, a, mean, followup, of, years, in, elderly, patients, with, osteoporoticfnfs, aoota, 31bc, the, data, demonstrated, that, patients, treated, with, ctashowed, better, improvements, in, functionaloutcomes, and, key, orthopaedic, complications, than, those, treated, with, utathe, current, ï¬ndings, are, consistent, withprevious, studies361415, although, the, betterfunctional, outcomes, and, lower, rates, ofrevision, loosening, periprosthetic, fractureand, dislocation, are, apt, to, favour, cta, nosignificant, betweengroup, differences, in, thehhs, were, detected, during, the, initial, , yearsafterexplanationsinclude, the, timedependent, clinical, efï¬cacyof, the, implants, and, the, properties, of, theprostheses34616, whether, uta, or, cta, ispreferable, in, elderly, patients, with, a, discontroversial6917placed, fnf, remainsa, recent, retrospective, study, involving, patients, with, an, fnf, aoota, 31b, whounderwent, primary, unilateral, uta, or, ctashowed, that, the, mean, hhs, was, , 06, for, cta, and, 06, , for, utap¼, , a, singleblinded, randomisedcontrolled, trial, chancetrial, involving, individuals, treated, with, an, uncementedor, cemented, tapered, hydroxyapatitecoatedfemoral, stem, and, a, cemented, cup, demonstratedtaperedhydroxyapatitecoated, femoral, stem, andcementedthatthe, 0cmao, et, alcemented, cup, provided, better, functionalresultsthan, the, uncemented, taperedhydroxyapatitecoated, femoral, stem, andcemented, cup16ratesrevisionthe, bone, microstructurein, the, present, study, the, kaplanmeiersurvival, curve, demonstrated, that, at, the2year, analysis, neither, group, showed, evidence, of, a, target, event, and, no, significantbetweengroup, differences, were, found, inofthelooseningfracture, or, dislocationperiprostheticneverthelessit, would, be, interesting, toexplore, whether, the, prosthesis, materialinï¬uencesthepeak, effect, and, the, duration, of, the, effectand, if, so, what, mechanisms, affect, the, bonemicrostructure, and, whether, there, is, a, wayto, change, the, outcome, by, blocking, thiseffect, during, a, 2year, followup, we, currently, have, one, option, for, prevention, oravoidance, of, adverse, events, and, thesechanges, in, treatment, strategies, may, play, akey, role, in, improving, the, clinical, resultsif, the, effects, of, the, prosthesis, materialitself, cannot, be, blocked18, there, is, still, alack, of, consensus, on, standards, for, prosthesis, revision, in, this, context19when, assessing, the, impact, of, cta, onthe, target, events, we, did, not, observe, anincreased, incidence, of, severe, orthopaediccomplications, other, than, the, complicationsmentioned, in, this, study, in, one, systematicreview, the, authors, presumed, that, cta, wassuperior, to, uta, with, respect, to, functionalscores, and, tolerable, orthopaedic, complications20, we, obtained, analogous, results, interms, of, hiprelated, complications, andfunctional, scores, multicentre, hip, arthroplasty, data, indicate, that, uta, remains, ahighrisk, factor, for, late, revision, looseningand, periprosthetic, fractures810, the, notabledissimilarities, in, the, results, of, these, variousstudies, on, hiprelated, complications, may, belargely, attributed, to, the, design, of, the, prosthesis, prosthesis, size, and, material, selection, and, the, surgeons, experience46affected, thethis, study, has, several, limitations, it, hada, small, sample, and, its, retrospective, designis, association, with, some, inherent, disadvantages, we, did, not, stratify, the, patientsaccording, to, fracture, type, or, sex, in, addition, the, potential, comorbidities, betweengroups, were, not, well, exposed, and, compared, the, statistical, power, used, to, addressdifferences, between, the, groups, was, insufï¬cient, differences, in, the, patients, baselinedata, may, haveresultsfurthermore, our, analysis, did, not, determine, whether, the, deaths, were, instigatedby, bone, cement, the, risk, of, hiprelatedcomplications, was, not, analysed, the, survivalcurve, of, other, prosthesisrelatedcomplications, was, estimated, using, thekaplanmeier, method, and, competitiverisks, ie, death, could, have, affected, thesurvival, of, the, prosthesis, patients, whodied, lostrevisionhence, the, revision, rate, might, have, beenunderestimated, during, this, long, followupwith, a, fairly, high, mortality, ratethe, opportunity, forevidencein, conclusion, the, ï¬ndings, described, inthe, current, review, uphold, an, increasingbody, ofthat, cta, provideshigher, functional, scores, and, lower, rates, ofhiprelated, complications, than, does, utain, elderly, patients, with, osteoporotic, displaced, fnfs, aoota, 31bc, in, thiscontext, we, recommend, cta, for, the, treatment, of, such, fnfs, our, ï¬ndings, may, beconducive, to, alleviating, continuing, debateregarding, which, prosthesis, uta, or, ctais, more, suitable, for, the, elderly, populationa, future, prospective, study, may, be, essentialto, conï¬rm, whether, our, conclusion, continues, to, be, acceptable, as, the, followup, timeincreasesdeclaration, of, conflicting, interestthe, authors, declare, that, there, is, no, conï¬ict, ofinterest, 0cfundingthis, research, received, no, speciï¬c, grant, from, anyfunding, agency, in, the, public, commercial, ornotforproï¬t, sectorsorcid, idsweiguang, yuguowei, hanreferencesorcid00000001orcid00000003, chammout, g, muren, o, laurencikas, eet, al, more, complications, with, uncementedthan, cemented, femoral, stems, in, total, hipreplacement, for, displaced, femoral, neck, fractures, in, the, elderly, a, singleblinded, randomized, controlled, trial, with, , patientsacta, orthop, , , , gjertsen, je, lie, sa, fevang, jm, et, al, totalhip, replacement, after, femoral, neck, fracturesin, elderly, patients, results, of, , fracturesreported, to, the, norwegian, arthroplastyregister, acta, orthop, , , , hailer, np, garellick, g, and, karrholm, juncemented, and, cemented, primary, totalhip, arthroplastyin, the, swedish, hiparthroplasty, registerof, operations, acta, orthop, , evaluation, makela, kt, eskelinen, a, paavolainen, pet, al, cementless, total, hip, arthroplasty, forprimary, osteoarthritis, in, patients, aged, years, and, older, results, ofthe, , mostcommon, cementless, designs, compared, tocemented, reference, implants, in, the, finnisharthroplasty, register, acta, orthop, , , ylikyyny, t, sund, r, heinanen, m, et, alcemented, or, uncemented, hemiarthroplastyfor, the, treatment, of, femoral, neck, fracturesacta, orthop, , , , yang, c, han, xl, wang, j, et, al, cementedversus, uncemented, femoral, component, totalhip, arthroplasty, in, elderly, patients, with, primary, osteoporosisretrospective, analysiswith, 5year, followup, j, int, med, res, , journal, of, international, medical, research, solarino, g, zagra, l, piazzolla, a, et, alceramiconresults, of, , consecutiveceramic, cementless, hip, arthroplastiesinpatients, up, to, , years, of, age, a, , yearsof, followup, study, j, arthroplasty, , s232s237, hanly, rj, whitehouse, sl, lorimer, mfet, al, the, outcome, of, cemented, acetabularcomponents, in, total, hip, arthroplasty, forosteoarthritis, deï¬nes, a, proï¬ciency, thresholdresults, of, , cases, from, the, australianorthopaedic, association, nationaljointreplacement, registry, j, arthroplasty, , , imam, ma, shehata, msa, elsehili, a, et, alcontemporary, cemented, versus, uncementedhemiarthroplasty, for, the, treatment, of, displaced, intracapsular, hip, fractures, a, metaanalysis, offortytwo, thousand, fortysixhips, int, orthop, , , , jameson, ss, baker, pn, mason, j, et, al, thedesign, of, the, acetabular, component, and, sizeof, the, femoral, head, inï¬uence, the, risk, of, revision, following, , , singlebrand, cementedhip, replacements, a, retrospective, cohortstudy, of, mediumterm, data, from, a, nationaljoint, registry, j, bone, joint, surg, br, 94b, , zeng, xs, zhan, k, zhang, ll, et, alconversion, to, total, hip, arthroplasty, afterfailed, proximal, femoral, nail, antirotationsor, dynamic, hip, screw, ï¬xations, for, stableintertrochanteric, femur, fractures, a, retrospective, study, with, a, minimum, followupof, , years, bmc, musculoskelet, disord, , , johnson, rl, abdel, mp, frank, rd, et, alimpact, of, frailty, on, outcomes, after, primaryandarthroplastyj, arthroplasty, , , 64e5revisiontotalhip, chen, kh, tsai, sw, wu, pk, et, al, partialcomponentretained, twostage, reconstruction, for, chronic, infection, after, uncementedtotal, hip, arthroplasty, results, of, sixteen, casesafter, ï¬ve, years, of, followup, int, orthop, , , deangelis, jp, ademi, a, staff, i, et, alcemented, versus, uncemented, hemiarthroplasty, for, displaced, femoral, neck, fracturesa, prospective, randomized, trial, with, early, 0cmao, et, alfollowup, j, orthop, trauma, , , rolfson, o, donahue, gs, hallsten, m, et, alpatientreported, outcomes, in, cemented, anduncemented, total, hip, replacements, hip, int, , , chammout, g, muren, o, boden, h, et, alcemented, compared, to, uncemented, femoralstems, in, total, hip, replacement, for, displacedfemoral, neck, fractures, in, the, elderly, studyprotocol, for, a, singleblinded, randomizedchancetrial, bmccontrolled, trialmusculoskelet, disord, , , , liu, t, hua, x, yu, w, et, al, longtermfollowup, outcomes, for, patients, undergoingprimary, total, hip, arthroplasty, with, uncemented, versus, cemented, femoral, components, a, retrospective, observational, studywith5year, minimum, followupj, orthop, surg, res, , , a, engesaeter, lb, espehaug, b, lie, sa, et, aldoes, cement, increase, the, risk, of, infection, inprimary, total, hip, arthroplasty, revisionrates, in, , cemented, and, uncementedprimary, thas, followed, for, , years, inthe, norwegian, arthroplasty, register, actaorthop, , , , schmale, ga, lachiewicz, pf, and, kelley, ssearly, failure, of, revision, total, hip, arthroplasty, with, cemented, precoated, femoralcomponents, , comparison, with, uncementedcomponents, at, , to, , years, j, arthroplasty, , , azegami, s, gurusamy, ks, and, parker, mjcemented, versus, uncemented, hemiarthroplasty, for, hip, fractures, a, systematic, reviewof, randomised, controlled, trials, hip, int, , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |[, study, performed, assess, clinical, outcomes, elderly, patients, withosteoporotic, femoral, neck, fractures, fnfs, aoota, 31bc, treated, initial, uncementedtotal, hip, arthroplasty, uta, cemented, total, hip, arthroplasty, ctamethods, study, involved, consecutive, elderly, patients, osteoporotic, fnfs, aoota31bc, treated, initial, uta, cta, medical, centre, , , primaryoutcomes, harris, hip, score, hhs, rates, revision, loosening, periprostheticfracture, dislocationresults, total, , patients, included, final, analysis, uta, n¼, , cta, n¼, mean, followup, duration, , months, range, , months, mean, hhs, was1department, microsurgery, trauma, hand, surgerythe, first, affiliated, hospital, sun, yatsen, universityguangzhou, china2department, pediatrics, first, affiliated, hospitalsun, yatsen, university, guangzhou, china3department, orthopaedics, first, affiliatedhospital, sun, yatsen, university, guangzhou, china4department, orthopaedics, third, peopleshospital, wuxi, jiangsu, province, affiliated, hospitalof, jiangnan, university, wuxi, china5department, urology, first, affiliated, hospital, sunyatsen, university, guangzhou, chinathese, authors, contributed, equally, workcorresponding, authorsjunxing, ye, department, orthopeadics, thirdpeoples, hospital, wuxi, jiangsu, province, affiliatedhospital, jiangnan, university, , xingyuan, northroad, liangxi, district, wuxi, jiangsu, , chinaemail, yejunxing0514163comjintao, zhuang, department, urology, first, affiliatedhospital, sun, yatsen, university, , zhongshan, 2ndroad, yuexiu, district, guangzhou, , chinaemail, brianzg86163comcreative, commons, non, commercial, cc, bync, , distributed, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, permitsnoncommercial, use, reproduction, distribution, work, without, permission, provided, original, work, attributedas, specified, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, international, medical, research, 06, , uta, 06, , cta, significant, dissimilarities, detected, therates, revision, loosening, periprosthetic, fracture, uta, cta, , vs, , vs, , , vs, , respectively, significant, difference, also, detected, inthe, probability, revision, two, groupsconclusion, elderly, patients, osteoporotic, fnfs, aoota, 31bc, treated, cta, showgreater, improvements, functional, outcomes, key, orthopaedic, complications, thosetreated, utakeywordsfemoral, neck, fracture, arthroplasty, outcome, complication, retrospective, osteoporosisdate, received, , december, , accepted, , july, introduction31bcaootafemoral, neck, fracturesmanagement, ofin, elderlyfnfspatients, still, undergoing, considerableresearch12, uncemented, total, hip, arthroplasty, uta, cemented, total, hip, arthroplasty, cta, displaced, fnfs, tendsto, recognised, surgical, strategy3comparisons, uta, cta, forelderly, individuals, fnf, generallyfavour, cta, primarily, attributed, tothe, exceptional, clinical, outcomes, cta, interms, relieving, pain, improving, dailyactivities, well, higher, rate, majororthopaedic, complications, ie, revisionloosening, periprosthetic, fracture, dislocation, associated, uta4, howeverrecent, studies, uta, elderly, individualshave, demonstrated, encouraging, shorttermclinical, outcomes67, moreover, cementedprosthesis, syndrome, tends, occur, morefrequently, cta, uta8, cementedprosthesis, syndrome, theoretically, poses, asignificantlifealthough, speciï¬c, probability, thisthreat, calculated89, hencewhether, utilise, cta, elderly, individuals, may, present, clinician, dilemma9, lack, consensus, regarding, whichtechnique, uta, cta, preferable, fortreating, fnfs, aoota, 31bc, elderlyindividuals, related, remarkableto, patientsthreatdistinction, clinical, outcomes, betweenthe, two, types, implants610most, previousconcentrated, medicalstudies, involvedhighlycentresand, several, brands, prostheses356additionally, shortterm, followup, commonplace, studies, overcomethese, drawbacks, previous, studies, tocompare, midterm, results, twoprostheses, assessed, clinical, outcomesof, elderly, patients, osteoporotic, fnfsaoota, 31bc, treated, initial, utaor, cta, mean, followup, , yearsmaterials, methodsstudy, populationtheandrequirementethical, approval, obtained, thefirst, afï¬liated, hospital, sun, yatsenuniversityforinformed, consent, waived, theinvestigational, review, board, consecutiveelderly, individuals, principle, diagnosis, fnf, aoota, 31bc, whounderwentinitial, uta, cta, march, , , march, , forwhom, detailed, information, availablethroughoutidentiï¬edfrom, orthopaedics, department, thefirst, afï¬liated, hospital, sun, yatsenuniversity, manufacturer, details, offollowup, 0cmao, et, altable, , manufacturer, details, stems, cupsemployed, arthroplasty, proceduresprocedurestemcupcorail1exeter3exeter3reflectionuncemented2uta, n¼, cta, n¼, 1depuy, synthes, warsaw, usa2smith, , nephew, london, uk3stryker, corporation, kalamazoo, mi, usauta, uncemented, total, hip, arthroplasty, cta, cementedtotal, hip, arthroplastyclosed, fnfsthe, stems, cups, employed, arthroplasty, shown, table, , surgicalprocedure, postoperative, rehabilitationprotocol, described, previouslypublished, study11, inclusion, criteriawereaoota, 31bcactive, cognitively, intact, patients, ageof, 15, years, independently, mobile, priorto, injury, bone, mineral, densitytscore, , , femoral, neck, themajor, exclusion, criteria, multiple, fractures, contralateral, limb, fractures, pathological, fnfs, lower, limb, dyskinesia, priorto, surgery, cancer, planned, surgery, polytrauma, severe, comorbidities, eg, thyroiddisorder, calcium, phosphorusmetabolism, disorderwithcomplications, drug, abuse, affecting, bonehealing, bone, metabolism, early, interruption, followup, , months, cognitive, impairment, clinical, radiographicassessments, performed, , , months, surgery, every, , monthsthereafter, primary, outcomes, theharris, hip, score, hhs, rates, ofrevision, loosening, periprosthetic, fractureand, dislocationdiabetesstatistical, analysisrevision, deï¬ned, partial, completereplacement, prosthesis12, looseningof, acetabulum, andor, stem, componentstomographycompared, usingas, well, dislocation, deï¬ned, based, ona, previous, description13, periprostheticconï¬rmed, xray, orfracture, wascomputedexaminationcontinuous, data, ie, age, bone, mineraldensity, body, mass, index, followup, timeand, hhs, wereanindependentsamples, test, categoricalvariables, ie, sex, side, [leftright], fracturetype, comorbidities, mechanism, injuryamerican, society, anesthesiologists, classiï¬cation, major, orthopaedic, complications, compared, using, chisquaretest, mannwhitney, test, kaplanmeier, survival, curve, used, assess, theprobability, revision, hazard, ratios, werecalculated, using, cox, proportional, hazards, model, signiï¬cance, threshold, wasset, p, , , statistical, analysis, wasperformed, using, spss, , ibm, corparmonk, ny, usaresultsin, total, , consecutive, patientsarthroplasties, fnf, aoota31bc, underwentinitial, uta, orcta, met, inclusion, criteria, wereincluded, analysis, figure, , meanfollowup, duration, , months, range, months, patients, mean, age, 06, , years, uta, 06, cta, mean, body, mass, indexfor, uta, andwas, 06, , kgm2, cta, patientsbaselinesimilarbetween, two, groups, table, 06, , kgm2characteristics, wereprimary, outcomesimproved, functional, outcomes, notedin, groups, indicated, hhsuta, , 06, , prior, surgery, vs, 06, , ï¬nal, analysis, p, , cta, 06, , prior, surgery, vs, 06, , ï¬nal, analysis, p, , end, followup, hhs, 0cjournal, international, medical, researchfigure, , flow, diagram, exhibiting, methods, identifying, patients, fnfs, aoota, 31bc, whounderwent, initial, uta, ctafnfs, femoral, neck, fractures, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hiparthroplastysignificantly, different, twouta, , 06, , vs, ctagroups, 06, , p¼, , patients, whounderwent, cta, higherfunctionalscores, underwent, utano, distinct, betweengroup, differenceswere, observed, time, point, months, postoperatively, table, early, , year, postoperative, complications, detectedincluding, revisionloosening, periprosthetic, fracture, dislocation, rate, key, orthopaedic, complications, wasfor, utaand, , , cta, p, , table, , uta, group, , patients, underwent, revision, uta, developed, prosthesis, loosening, , developed, periprosthetic, fracturesand, , , developed, prosthesis, dislocation, cta, group, , , patientsunderwent, revision, uta, , , developed, prosthesis, loosening, , , developed, periprosthetic, fractures, , developed, prosthesis, dislocation, average, time, interval, initial, surgery, torevision, uta, , months, range, months, uta, , months, rangefor, cta, p¼, , monthssigniï¬cant, differences, revision, looseningand, periprosthetic, fracture, observedbetween, uta, cta, groups, revision, , vs, , p¼, , loosening, 0cmao, et, altable, , patient, demographics, outcomesvariablesex, femalemaleage, yearsbmi, kgm2bmdside, leftrightfnfs, aoota, type31b31ccomorbiditiesdiabetes, mellitushypertensioncerebrovascular, diseasemechanism, fnfstraffic, accidentfallingtamping, accidentasa, classificationuta, n¼, 06, 06, , 06, , , , , , , , , , , , 06, hhs, prior, surgerydata, presented, n, n, , mean, 06, standard, deviationpvaluecta, n¼, 06, 06, , 06, , , , , , , , , , , , 06, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplasty, hhs, harris, hip, score, asa, americansociety, anesthesiologists, bmi, body, mass, index, bmd, bone, mineral, density, fnfs, femoral, neck, fracturestable, , comparison, hip, functional, scoresmonths, postoperativelyfinal, followupdata, presented, mean, 06, standard, deviationuta, n¼, 06, 06, 06, 06, 06, 06, 06, 06, cta, n¼, 06, 06, 06, 06, 06, 06, 06, 06, pvaluestatistically, significantuta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplasty, vs, , p¼, , periprosthetic, fracture, , vs, , p¼, respectively, significant, difference, theprobability, revision, also, detectedbetween, groups, hazard, ratio, interval, conï¬dencep¼, , figure, , significant, difference, found, rate, prosthesis, dislocation, uta, cta, groups, vs, , respectively, 0cjournal, international, medical, researchtable, , rates, key, orthopaedic, complicationscomplicationsprosthesis, revisionprosthesis, looseningperiprosthetic, fracturedislocationuta, n¼, cta, n¼, , , , , , , , , pvaluedata, presented, n, statistically, significantuta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplastyfigure, , kaplanmeier, curves, showing, probability, revision, primary, surgery, hr, calculatedper, cox, proportional, hazards, model, age, sex, american, society, anesthesiologists, classificationbody, mass, index, bone, mineral, density, femoral, neck, fracture, type, covariates, surgery, timedependent, factorhr, hazard, ratio, ci, confidence, interval, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hiparthroplastysurgeryprobablediscussionthis, review, characterised, outcomes, asolitary, brand, total, hip, arthroplastyimplant, mean, followup, years, elderly, patients, osteoporoticfnfs, aoota, 31bc, data, demonstrated, patients, treated, ctashowed, better, improvements, functionaloutcomes, key, orthopaedic, complications, treated, utathe, current, ï¬ndings, consistent, withprevious, studies361415, although, betterfunctional, outcomes, lower, rates, ofrevision, loosening, periprosthetic, fractureand, dislocation, apt, favour, cta, nosignificant, betweengroup, differences, thehhs, detected, initial, , yearsafterexplanationsinclude, timedependent, clinical, efï¬cacyof, implants, properties, theprostheses34616, whether, uta, cta, ispreferable, elderly, patients, discontroversial6917placed, fnf, remainsa, recent, retrospective, study, involving, patients, fnf, aoota, 31b, whounderwent, primary, unilateral, uta, ctashowed, mean, hhs, , 06, cta, 06, , utap¼, , singleblinded, randomisedcontrolled, trial, chancetrial, involving, individuals, treated, uncementedor, cemented, tapered, hydroxyapatitecoatedfemoral, stem, cemented, cup, demonstratedtaperedhydroxyapatitecoated, femoral, stem, andcementedthatthe, 0cmao, et, alcemented, cup, provided, better, functionalresultsthan, uncemented, taperedhydroxyapatitecoated, femoral, stem, andcemented, cup16ratesrevisionthe, bone, microstructurein, present, study, kaplanmeiersurvival, curve, demonstrated, the2year, analysis, neither, group, showed, evidence, target, event, significantbetweengroup, differences, found, inofthelooseningfracture, dislocationperiprostheticneverthelessit, interesting, toexplore, whether, prosthesis, materialinï¬uencesthepeak, effect, duration, effectand, mechanisms, affect, bonemicrostructure, whether, wayto, change, outcome, blocking, thiseffect, 2year, followup, currently, one, option, prevention, oravoidance, adverse, events, thesechanges, treatment, strategies, may, play, akey, role, improving, clinical, resultsif, effects, prosthesis, materialitself, blocked18, still, alack, consensus, standards, prosthesis, revision, context19when, assessing, impact, cta, onthe, target, events, observe, anincreased, incidence, severe, orthopaediccomplications, complicationsmentioned, study, one, systematicreview, authors, presumed, cta, wassuperior, uta, respect, functionalscores, tolerable, orthopaedic, complications20, obtained, analogous, results, interms, hiprelated, complications, andfunctional, scores, multicentre, hip, arthroplasty, data, indicate, uta, remains, ahighrisk, factor, late, revision, looseningand, periprosthetic, fractures810, notabledissimilarities, results, variousstudies, hiprelated, complications, may, belargely, attributed, design, prosthesis, prosthesis, size, material, selection, surgeons, experience46affected, thethis, study, several, limitations, hada, small, sample, retrospective, designis, association, inherent, disadvantages, stratify, patientsaccording, fracture, type, sex, addition, potential, comorbidities, betweengroups, well, exposed, compared, statistical, power, used, addressdifferences, groups, insufï¬cient, differences, patients, baselinedata, may, haveresultsfurthermore, analysis, determine, whether, deaths, instigatedby, bone, cement, risk, hiprelatedcomplications, analysed, survivalcurve, prosthesisrelatedcomplications, estimated, using, thekaplanmeier, method, competitiverisks, ie, death, affected, thesurvival, prosthesis, patients, whodied, lostrevisionhence, revision, rate, might, beenunderestimated, long, followupwith, fairly, high, mortality, ratethe, opportunity, forevidencein, conclusion, ï¬ndings, described, inthe, current, review, uphold, increasingbody, ofthat, cta, provideshigher, functional, scores, lower, rates, ofhiprelated, complications, utain, elderly, patients, osteoporotic, displaced, fnfs, aoota, 31bc, thiscontext, recommend, cta, treatment, fnfs, ï¬ndings, may, beconducive, alleviating, continuing, debateregarding, prosthesis, uta, ctais, suitable, elderly, populationa, future, prospective, study, may, essentialto, conï¬rm, whether, conclusion, continues, acceptable, followup, timeincreasesdeclaration, conflicting, interestthe, authors, declare, conï¬ict, ofinterest, 0cfundingthis, research, received, speciï¬c, grant, anyfunding, agency, public, commercial, ornotforproï¬t, sectorsorcid, idsweiguang, yuguowei, hanreferencesorcid00000001orcid00000003, chammout, g, muren, o, laurencikas, eet, al, complications, uncementedthan, cemented, femoral, stems, total, hipreplacement, displaced, femoral, neck, fractures, elderly, singleblinded, randomized, controlled, trial, , patientsacta, orthop, , , , gjertsen, je, lie, sa, fevang, jm, et, al, totalhip, replacement, femoral, neck, fracturesin, elderly, patients, results, , fracturesreported, norwegian, arthroplastyregister, acta, orthop, , , , hailer, np, garellick, g, karrholm, juncemented, cemented, primary, totalhip, arthroplastyin, swedish, hiparthroplasty, registerof, operations, acta, orthop, , evaluation, makela, kt, eskelinen, paavolainen, pet, al, cementless, total, hip, arthroplasty, forprimary, osteoarthritis, patients, aged, years, older, results, ofthe, , mostcommon, cementless, designs, compared, tocemented, reference, implants, finnisharthroplasty, register, acta, orthop, , , ylikyyny, sund, r, heinanen, m, et, alcemented, uncemented, hemiarthroplastyfor, treatment, femoral, neck, fracturesacta, orthop, , , , yang, c, han, xl, wang, j, et, al, cementedversus, uncemented, femoral, component, totalhip, arthroplasty, elderly, patients, primary, osteoporosisretrospective, analysiswith, 5year, followup, j, int, med, res, , journal, international, medical, research, solarino, g, zagra, l, piazzolla, et, alceramiconresults, , consecutiveceramic, cementless, hip, arthroplastiesinpatients, , years, age, , yearsof, followup, study, j, arthroplasty, , s232s237, hanly, rj, whitehouse, sl, lorimer, mfet, al, outcome, cemented, acetabularcomponents, total, hip, arthroplasty, forosteoarthritis, deï¬nes, proï¬ciency, thresholdresults, , cases, australianorthopaedic, association, nationaljointreplacement, registry, j, arthroplasty, , , imam, ma, shehata, msa, elsehili, et, alcontemporary, cemented, versus, uncementedhemiarthroplasty, treatment, displaced, intracapsular, hip, fractures, metaanalysis, offortytwo, thousand, fortysixhips, int, orthop, , , , jameson, ss, baker, pn, mason, j, et, al, thedesign, acetabular, component, sizeof, femoral, head, inï¬uence, risk, revision, following, , , singlebrand, cementedhip, replacements, retrospective, cohortstudy, mediumterm, data, nationaljoint, registry, j, bone, joint, surg, br, 94b, , zeng, xs, zhan, k, zhang, ll, et, alconversion, total, hip, arthroplasty, afterfailed, proximal, femoral, nail, antirotationsor, dynamic, hip, screw, ï¬xations, stableintertrochanteric, femur, fractures, retrospective, study, minimum, followupof, , years, bmc, musculoskelet, disord, , , johnson, rl, abdel, mp, frank, rd, et, alimpact, frailty, outcomes, primaryandarthroplastyj, arthroplasty, , , 64e5revisiontotalhip, chen, kh, tsai, sw, wu, pk, et, al, partialcomponentretained, twostage, reconstruction, chronic, infection, uncementedtotal, hip, arthroplasty, results, sixteen, casesafter, ï¬ve, years, followup, int, orthop, , , deangelis, jp, ademi, staff, et, alcemented, versus, uncemented, hemiarthroplasty, displaced, femoral, neck, fracturesa, prospective, randomized, trial, early, 0cmao, et, alfollowup, j, orthop, trauma, , , rolfson, o, donahue, gs, hallsten, m, et, alpatientreported, outcomes, cemented, anduncemented, total, hip, replacements, hip, int, , , chammout, g, muren, o, boden, h, et, alcemented, compared, uncemented, femoralstems, total, hip, replacement, displacedfemoral, neck, fractures, elderly, studyprotocol, singleblinded, randomizedchancetrial, bmccontrolled, trialmusculoskelet, disord, , , , liu, hua, x, yu, w, et, al, longtermfollowup, outcomes, patients, undergoingprimary, total, hip, arthroplasty, uncemented, versus, cemented, femoral, components, retrospective, observational, studywith5year, minimum, followupj, orthop, surg, res, , , engesaeter, lb, espehaug, b, lie, sa, et, aldoes, cement, increase, risk, infection, inprimary, total, hip, arthroplasty, revisionrates, , cemented, uncementedprimary, thas, followed, , years, inthe, norwegian, arthroplasty, register, actaorthop, , , , schmale, ga, lachiewicz, pf, kelley, ssearly, failure, revision, total, hip, arthroplasty, cemented, precoated, femoralcomponents, , comparison, uncementedcomponents, , , years, j, arthroplasty, , , azegami, gurusamy, ks, parker, mjcemented, versus, uncemented, hemiarthroplasty, hip, fractures, systematic, reviewof, randomised, controlled, trials, hip, int, , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |[, study, performed, assess, clinical, outcomes, elderly, patients, withosteoporotic, femoral, neck, fractures, fnfs, aoota, 31bc, treated, by, initial, uncementedtotal, hip, arthroplasty, uta, or, cemented, total, hip, arthroplasty, ctamethods, study, involved, consecutive, elderly, patients, with, osteoporotic, fnfs, aoota31bc, treated, by, initial, uta, or, cta, our, medical, centre, from, , , primaryoutcomes, were, harris, hip, score, hhs, rates, revision, loosening, periprostheticfracture, dislocationresults, total, , patients, were, included, final, analysis, uta, n¼, , cta, n¼, mean, followup, duration, , months, range, , months, mean, hhs, was1department, microsurgery, trauma, hand, surgerythe, first, affiliated, hospital, sun, yatsen, universityguangzhou, china2department, pediatrics, first, affiliated, hospitalsun, yatsen, university, guangzhou, china3department, orthopaedics, first, affiliatedhospital, sun, yatsen, university, guangzhou, china4department, orthopaedics, third, peopleshospital, wuxi, jiangsu, province, affiliated, hospitalof, jiangnan, university, wuxi, china5department, urology, first, affiliated, hospital, sunyatsen, university, guangzhou, chinathese, authors, contributed, equally, workcorresponding, authorsjunxing, ye, department, orthopeadics, thirdpeoples, hospital, wuxi, jiangsu, province, affiliatedhospital, jiangnan, university, no, , xingyuan, northroad, liangxi, district, wuxi, jiangsu, , chinaemail, yejunxing0514163comjintao, zhuang, department, urology, first, affiliatedhospital, sun, yatsen, university, no, , zhongshan, 2ndroad, yuexiu, district, guangzhou, , chinaemail, brianzg86163comcreative, commons, non, commercial, cc, bync, , distributed, under, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, distribution, work, without, further, permission, provided, original, work, attributedas, specified, on, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, international, medical, research, 06, , uta, 06, , cta, significant, dissimilarities, were, detected, therates, revision, loosening, periprosthetic, fracture, between, uta, cta, , vs, , vs, , , vs, , respectively, significant, difference, also, detected, inthe, probability, revision, between, two, groupsconclusion, elderly, patients, with, osteoporotic, fnfs, aoota, 31bc, treated, with, cta, showgreater, improvements, functional, outcomes, key, orthopaedic, complications, than, thosetreated, with, utakeywordsfemoral, neck, fracture, arthroplasty, outcome, complication, retrospective, osteoporosisdate, received, , december, , accepted, , july, introduction31bcaootafemoral, neck, fracturesmanagement, ofin, elderlyfnfspatients, still, undergoing, considerableresearch12, uncemented, total, hip, arthroplasty, uta, or, cemented, total, hip, arthroplasty, cta, displaced, fnfs, tendsto, be, recognised, surgical, strategy3comparisons, between, uta, cta, forelderly, individuals, with, an, fnf, generallyfavour, cta, primarily, attributed, tothe, exceptional, clinical, outcomes, cta, interms, relieving, pain, improving, dailyactivities, as, well, as, higher, rate, majororthopaedic, complications, ie, revisionloosening, periprosthetic, fracture, dislocation, associated, with, uta4, howeverrecent, studies, uta, elderly, individualshave, demonstrated, encouraging, shorttermclinical, outcomes67, moreover, cementedprosthesis, syndrome, tends, occur, morefrequently, cta, than, uta8, cementedprosthesis, syndrome, theoretically, poses, asignificantlifealthough, speciï¬c, probability, thisthreat, has, not, been, calculated89, hencewhether, utilise, cta, elderly, individuals, may, present, clinician, with, dilemma9, lack, consensus, regarding, whichtechnique, uta, or, cta, preferable, fortreating, fnfs, aoota, 31bc, elderlyindividuals, related, remarkableto, patientsthreatdistinction, clinical, outcomes, betweenthe, two, types, implants610most, previousconcentrated, medicalstudies, have, involvedhighlycentresand, several, brands, prostheses356additionally, shortterm, followup, commonplace, these, studies, overcomethese, drawbacks, previous, studies, tocompare, midterm, results, twoprostheses, we, assessed, clinical, outcomesof, elderly, patients, with, osteoporotic, fnfsaoota, 31bc, treated, with, initial, utaor, cta, with, mean, followup, , yearsmaterials, methodsstudy, populationtheandrequirementethical, approval, obtained, from, thefirst, afï¬liated, hospital, sun, yatsenuniversityforinformed, consent, waived, by, theinvestigational, review, board, consecutiveelderly, individuals, with, principle, diagnosis, an, fnf, aoota, 31bc, whounderwentinitial, uta, or, cta, from, march, , , march, , forwhom, detailed, information, availablethroughoutidentiï¬edfrom, orthopaedics, department, thefirst, afï¬liated, hospital, sun, yatsenuniversity, manufacturer, details, offollowup, were, 0cmao, et, altable, , manufacturer, details, stems, cupsemployed, arthroplasty, proceduresprocedurestemcupcorail1exeter3exeter3reflectionuncemented2uta, n¼, cta, n¼, 1depuy, synthes, warsaw, usa2smith, , nephew, london, uk3stryker, corporation, kalamazoo, mi, usauta, uncemented, total, hip, arthroplasty, cta, cementedtotal, hip, arthroplastyclosed, fnfsthe, stems, cups, employed, arthroplasty, are, shown, table, , surgicalprocedure, postoperative, rehabilitationprotocol, were, described, our, previouslypublished, study11, inclusion, criteriawereaoota, 31bcactive, cognitively, intact, patients, ageof, 15, years, independently, mobile, priorto, injury, bone, mineral, densitytscore, , , at, femoral, neck, themajor, exclusion, criteria, were, multiple, fractures, or, contralateral, limb, fractures, pathological, fnfs, lower, limb, dyskinesia, priorto, surgery, cancer, planned, surgery, polytrauma, severe, comorbidities, eg, thyroiddisorder, with, calcium, phosphorusmetabolism, disorderwithcomplications, drug, abuse, affecting, bonehealing, or, bone, metabolism, early, interruption, followup, , months, cognitive, impairment, clinical, radiographicassessments, were, performed, at, , , months, after, surgery, every, , monthsthereafter, primary, outcomes, were, theharris, hip, score, hhs, rates, ofrevision, loosening, periprosthetic, fractureand, dislocationdiabetesstatistical, analysisrevision, deï¬ned, as, partial, or, completereplacement, prosthesis12, looseningof, acetabulum, andor, stem, componentstomographycompared, usingas, well, as, dislocation, were, deï¬ned, based, ona, previous, description13, periprostheticconï¬rmed, by, xray, orfracture, wascomputedexaminationcontinuous, data, ie, age, bone, mineraldensity, body, mass, index, followup, timeand, hhs, wereanindependentsamples, t, test, categoricalvariables, ie, sex, side, [leftright], fracturetype, comorbidities, mechanism, injuryamerican, society, anesthesiologists, classiï¬cation, major, orthopaedic, complications, were, compared, using, chisquaretest, or, mannwhitney, test, kaplanmeier, survival, curve, used, assess, theprobability, revision, hazard, ratios, werecalculated, using, cox, proportional, hazards, model, signiï¬cance, threshold, wasset, at, p, , , statistical, analysis, wasperformed, using, spss, , ibm, corparmonk, ny, usaresultsin, total, , consecutive, patientsarthroplasties, with, an, fnf, aoota31bc, who, underwentinitial, uta, orcta, met, our, inclusion, criteria, wereincluded, analysis, figure, , meanfollowup, duration, , months, range, months, patients, mean, age, 06, , years, uta, 06, cta, mean, body, mass, indexfor, uta, andwas, 06, , kgm2, cta, patientsbaselinesimilarbetween, two, groups, table, 06, , kgm2characteristics, wereprimary, outcomesimproved, functional, outcomes, were, notedin, both, groups, as, indicated, by, hhsuta, , 06, , prior, surgery, vs, 06, , at, ï¬nal, analysis, p, , cta, 06, , prior, surgery, vs, 06, , at, ï¬nal, analysis, p, , at, end, followup, hhs, 0cjournal, international, medical, researchfigure, , flow, diagram, exhibiting, methods, identifying, patients, with, fnfs, aoota, 31bc, whounderwent, an, initial, uta, or, ctafnfs, femoral, neck, fractures, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hiparthroplastysignificantly, different, between, twouta, , 06, , vs, ctagroups, 06, , p¼, , patients, whounderwent, cta, had, higherfunctionalscores, than, those, who, underwent, utano, distinct, betweengroup, differenceswere, observed, at, any, time, point, before, months, postoperatively, table, no, early, , year, postoperative, complications, were, detectedincluding, revisionloosening, periprosthetic, fracture, or, dislocation, rate, key, orthopaedic, complications, wasfor, utaand, , , cta, p, , table, , uta, group, , patients, underwent, revision, uta, developed, prosthesis, loosening, , developed, periprosthetic, fracturesand, , , developed, prosthesis, dislocation, cta, group, , , patientsunderwent, revision, uta, , , developed, prosthesis, loosening, , , developed, periprosthetic, fractures, , developed, prosthesis, dislocation, average, time, interval, from, initial, surgery, torevision, uta, , months, range, months, uta, , months, rangefor, cta, p¼, , monthssigniï¬cant, differences, revision, looseningand, periprosthetic, fracture, were, observedbetween, uta, cta, groups, revision, , vs, , p¼, , loosening, 0cmao, et, altable, , patient, demographics, outcomesvariablesex, femalemaleage, yearsbmi, kgm2bmdside, leftrightfnfs, aoota, type31b31ccomorbiditiesdiabetes, mellitushypertensioncerebrovascular, diseasemechanism, fnfstraffic, accidentfallingtamping, accidentasa, classificationuta, n¼, 06, 06, , 06, , , , , , , , , , , , 06, hhs, prior, surgerydata, are, presented, as, n, n, , or, mean, 06, standard, deviationpvaluecta, n¼, 06, 06, , 06, , , , , , , , , , , , 06, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplasty, hhs, harris, hip, score, asa, americansociety, anesthesiologists, bmi, body, mass, index, bmd, bone, mineral, density, fnfs, femoral, neck, fracturestable, , comparison, hip, functional, scoresmonths, postoperativelyfinal, followupdata, are, presented, as, mean, 06, standard, deviationuta, n¼, 06, 06, 06, 06, 06, 06, 06, 06, cta, n¼, 06, 06, 06, 06, 06, 06, 06, 06, pvaluestatistically, significantuta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplasty, vs, , p¼, , periprosthetic, fracture, , vs, , p¼, respectively, significant, difference, theprobability, revision, also, detectedbetween, groups, hazard, ratio, interval, conï¬dencep¼, , figure, , no, significant, difference, found, rate, prosthesis, dislocation, between, uta, cta, groups, vs, , respectively, 0cjournal, international, medical, researchtable, , rates, key, orthopaedic, complicationscomplicationsprosthesis, revisionprosthesis, looseningperiprosthetic, fracturedislocationuta, n¼, cta, n¼, , , , , , , , , pvaluedata, are, presented, as, n, statistically, significantuta, uncemented, total, hip, arthroplasty, cta, cemented, total, hip, arthroplastyfigure, , kaplanmeier, curves, showing, probability, revision, after, primary, surgery, hr, calculatedper, cox, proportional, hazards, model, with, age, sex, american, society, anesthesiologists, classificationbody, mass, index, bone, mineral, density, femoral, neck, fracture, type, as, covariates, surgery, as, timedependent, factorhr, hazard, ratio, ci, confidence, interval, uta, uncemented, total, hip, arthroplasty, cta, cemented, total, hiparthroplastysurgeryprobablediscussionthis, review, characterised, outcomes, asolitary, brand, total, hip, arthroplastyimplant, during, mean, followup, years, elderly, patients, with, osteoporoticfnfs, aoota, 31bc, data, demonstrated, that, patients, treated, with, ctashowed, better, improvements, functionaloutcomes, key, orthopaedic, complications, than, those, treated, with, utathe, current, ï¬ndings, are, consistent, withprevious, studies361415, although, betterfunctional, outcomes, lower, rates, ofrevision, loosening, periprosthetic, fractureand, dislocation, are, apt, favour, cta, nosignificant, betweengroup, differences, thehhs, were, detected, during, initial, , yearsafterexplanationsinclude, timedependent, clinical, efï¬cacyof, implants, properties, theprostheses34616, whether, uta, or, cta, ispreferable, elderly, patients, with, discontroversial6917placed, fnf, remainsa, recent, retrospective, study, involving, patients, with, an, fnf, aoota, 31b, whounderwent, primary, unilateral, uta, or, ctashowed, that, mean, hhs, , 06, cta, 06, , utap¼, , singleblinded, randomisedcontrolled, trial, chancetrial, involving, individuals, treated, with, an, uncementedor, cemented, tapered, hydroxyapatitecoatedfemoral, stem, cemented, cup, demonstratedtaperedhydroxyapatitecoated, femoral, stem, andcementedthatthe, 0cmao, et, alcemented, cup, provided, better, functionalresultsthan, uncemented, taperedhydroxyapatitecoated, femoral, stem, andcemented, cup16ratesrevisionthe, bone, microstructurein, present, study, kaplanmeiersurvival, curve, demonstrated, that, at, the2year, analysis, neither, group, showed, evidence, target, event, no, significantbetweengroup, differences, were, found, inofthelooseningfracture, or, dislocationperiprostheticneverthelessit, would, be, interesting, toexplore, whether, prosthesis, materialinï¬uencesthepeak, effect, duration, effectand, if, so, what, mechanisms, affect, bonemicrostructure, whether, there, wayto, change, outcome, by, blocking, thiseffect, during, 2year, followup, we, currently, have, one, option, prevention, oravoidance, adverse, events, thesechanges, treatment, strategies, may, play, akey, role, improving, clinical, resultsif, effects, prosthesis, materialitself, cannot, be, blocked18, there, still, alack, consensus, on, standards, prosthesis, revision, context19when, assessing, impact, cta, onthe, target, events, we, did, not, observe, anincreased, incidence, severe, orthopaediccomplications, other, than, complicationsmentioned, study, one, systematicreview, authors, presumed, that, cta, wassuperior, uta, with, respect, functionalscores, tolerable, orthopaedic, complications20, we, obtained, analogous, results, interms, hiprelated, complications, andfunctional, scores, multicentre, hip, arthroplasty, data, indicate, that, uta, remains, ahighrisk, factor, late, revision, looseningand, periprosthetic, fractures810, notabledissimilarities, results, these, variousstudies, on, hiprelated, complications, may, belargely, attributed, design, prosthesis, prosthesis, size, material, selection, surgeons, experience46affected, thethis, study, has, several, limitations, it, hada, small, sample, its, retrospective, designis, association, with, some, inherent, disadvantages, we, did, not, stratify, patientsaccording, fracture, type, or, sex, addition, potential, comorbidities, betweengroups, were, not, well, exposed, compared, statistical, power, used, addressdifferences, between, groups, insufï¬cient, differences, patients, baselinedata, may, haveresultsfurthermore, our, analysis, did, not, determine, whether, deaths, were, instigatedby, bone, cement, risk, hiprelatedcomplications, not, analysed, survivalcurve, other, prosthesisrelatedcomplications, estimated, using, thekaplanmeier, method, competitiverisks, ie, death, could, have, affected, thesurvival, prosthesis, patients, whodied, lostrevisionhence, revision, rate, might, have, beenunderestimated, during, long, followupwith, fairly, high, mortality, ratethe, opportunity, forevidencein, conclusion, ï¬ndings, described, inthe, current, review, uphold, an, increasingbody, ofthat, cta, provideshigher, functional, scores, lower, rates, ofhiprelated, complications, than, does, utain, elderly, patients, with, osteoporotic, displaced, fnfs, aoota, 31bc, thiscontext, we, recommend, cta, treatment, such, fnfs, our, ï¬ndings, may, beconducive, alleviating, continuing, debateregarding, which, prosthesis, uta, or, ctais, more, suitable, elderly, populationa, future, prospective, study, may, be, essentialto, conï¬rm, whether, our, conclusion, continues, be, acceptable, as, followup, timeincreasesdeclaration, conflicting, interestthe, authors, declare, that, there, no, conï¬ict, ofinterest, 0cfundingthis, research, received, no, speciï¬c, grant, from, anyfunding, agency, public, commercial, ornotforproï¬t, sectorsorcid, idsweiguang, yuguowei, hanreferencesorcid00000001orcid00000003, chammout, g, muren, o, laurencikas, eet, al, more, complications, with, uncementedthan, cemented, femoral, stems, total, hipreplacement, displaced, femoral, neck, fractures, elderly, singleblinded, randomized, controlled, trial, with, , patientsacta, orthop, , , , gjertsen, je, lie, sa, fevang, jm, et, al, totalhip, replacement, after, femoral, neck, fracturesin, elderly, patients, results, , fracturesreported, norwegian, arthroplastyregister, acta, orthop, , , , hailer, np, garellick, g, karrholm, juncemented, cemented, primary, totalhip, arthroplastyin, swedish, hiparthroplasty, registerof, operations, acta, orthop, , evaluation, makela, kt, eskelinen, paavolainen, pet, al, cementless, total, hip, arthroplasty, forprimary, osteoarthritis, patients, aged, years, older, results, ofthe, , mostcommon, cementless, designs, compared, tocemented, reference, implants, finnisharthroplasty, register, acta, orthop, , , ylikyyny, t, sund, r, heinanen, m, et, alcemented, or, uncemented, hemiarthroplastyfor, treatment, femoral, neck, fracturesacta, orthop, , , , yang, c, han, xl, wang, j, et, al, cementedversus, uncemented, femoral, component, totalhip, arthroplasty, elderly, patients, with, primary, osteoporosisretrospective, analysiswith, 5year, followup, j, int, med, res, , journal, international, medical, research, solarino, g, zagra, l, piazzolla, et, alceramiconresults, , consecutiveceramic, cementless, hip, arthroplastiesinpatients, up, , years, age, , yearsof, followup, study, j, arthroplasty, , s232s237, hanly, rj, whitehouse, sl, lorimer, mfet, al, outcome, cemented, acetabularcomponents, total, hip, arthroplasty, forosteoarthritis, deï¬nes, proï¬ciency, thresholdresults, , cases, from, australianorthopaedic, association, nationaljointreplacement, registry, j, arthroplasty, , , imam, ma, shehata, msa, elsehili, et, alcontemporary, cemented, versus, uncementedhemiarthroplasty, treatment, displaced, intracapsular, hip, fractures, metaanalysis, offortytwo, thousand, fortysixhips, int, orthop, , , , jameson, ss, baker, pn, mason, j, et, al, thedesign, acetabular, component, sizeof, femoral, head, inï¬uence, risk, revision, following, , , singlebrand, cementedhip, replacements, retrospective, cohortstudy, mediumterm, data, from, nationaljoint, registry, j, bone, joint, surg, br, 94b, , zeng, xs, zhan, k, zhang, ll, et, alconversion, total, hip, arthroplasty, afterfailed, proximal, femoral, nail, antirotationsor, dynamic, hip, screw, ï¬xations, stableintertrochanteric, femur, fractures, retrospective, study, with, minimum, followupof, , years, bmc, musculoskelet, disord, , , johnson, rl, abdel, mp, frank, rd, et, alimpact, frailty, on, outcomes, after, primaryandarthroplastyj, arthroplasty, , , 64e5revisiontotalhip, chen, kh, tsai, sw, wu, pk, et, al, partialcomponentretained, twostage, reconstruction, chronic, infection, after, uncementedtotal, hip, arthroplasty, results, sixteen, casesafter, ï¬ve, years, followup, int, orthop, , , deangelis, jp, ademi, staff, i, et, alcemented, versus, uncemented, hemiarthroplasty, displaced, femoral, neck, fracturesa, prospective, randomized, trial, with, early, 0cmao, et, alfollowup, j, orthop, trauma, , , rolfson, o, donahue, gs, hallsten, m, et, alpatientreported, outcomes, cemented, anduncemented, total, hip, replacements, hip, int, , , chammout, g, muren, o, boden, h, et, alcemented, compared, uncemented, femoralstems, total, hip, replacement, displacedfemoral, neck, fractures, elderly, studyprotocol, singleblinded, randomizedchancetrial, bmccontrolled, trialmusculoskelet, disord, , , , liu, t, hua, x, yu, w, et, al, longtermfollowup, outcomes, patients, undergoingprimary, total, hip, arthroplasty, with, uncemented, versus, cemented, femoral, components, retrospective, observational, studywith5year, minimum, followupj, orthop, surg, res, , , engesaeter, lb, espehaug, b, lie, sa, et, aldoes, cement, increase, risk, infection, inprimary, total, hip, arthroplasty, revisionrates, , cemented, uncementedprimary, thas, followed, , years, inthe, norwegian, arthroplasty, register, actaorthop, , , , schmale, ga, lachiewicz, pf, kelley, ssearly, failure, revision, total, hip, arthroplasty, with, cemented, precoated, femoralcomponents, , comparison, with, uncementedcomponents, at, , , years, j, arthroplasty, , , azegami, s, gurusamy, ks, parker, mjcemented, versus, uncemented, hemiarthroplasty, hip, fractures, systematic, reviewof, randomised, controlled, trials, hip, int, , , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,15,16,17,18,19,20,21,22,23,24,26,28,29,30,33,34,35,36,37,39,40,42,43,44,47,49,50,51,52,54,55,57,58,59,61,62,63,64,65,66,67,68,69,70,71,72,73,74,77,78,80,82,84,86,87,92,93,97,99,100,104,105,108,109,111,113,115,118,120,122,123,125,129,132,134,136,137,140,142,143,144,145,146,148,153,154,155,157,159,161,164,165,166,168,170,171,172,176,180,181,184,185,186,189,190,193,195,196,198,199,200,201,202,207,216,218,220,223,226,231,235,236,239,240,242,244,247,248,249,253,255,260,261,262,266,267,269,270,275,279,280,282,286,288,289,295,299,303,305,309,318,327,329,335,349,350,352,355,356,359,365,369,370,374,377,386,389,396,401,402,407,412,413,415,419,421,423,426,428,429,431,434,436,439,440,447,450,452,453,457,459,460,462,469,471,475,483,487,492,494,496,497,502,503,504,509,510,512,520,547,553,556,559,569,576,579,580,582,589,590,596,599,602,604,606,625,627,631,632,636,637,638,647,653,657,670,672,673,677,681,683,685,692,695,700,708,710,718,722,727,733,735,746,747,752,761,773,795,798,799,812,831,832,838,846,875,881,883,884,886,894,915,919,924,937,943,944,956,969,970,975,978,984,986,1023,1026,1030,1034,1060,1066,1092,1107,1108,1111,1131,1136,1177,1182,1208,1214,1217,1222,1229,1231,1252,1262,1309,1317,1366,1367,1381,1384,1392,1411,1426,1434,1436,1440,1458,1477,1500,1512,1532,1559,1596,1620,1657,1659,1666,1691,1693,1700,1708,1718,1728,1740,1778,1792,1847,1872,1880,1891,1898,1923,1929,1931,1937,1955,1961,1988,1989,2001,2012,2017,2035,2088,2090,2091,2104,2145,2166,2173,2195,2207,2324,2328,2340,2364,2392,2398,2422,2457,2467,2491,2495,2499,2512,2526,2625,2677,2689,2710,2756,2803,2867,2878,2886,2921,3002,3003,3026,3067,3140,3218,3220,3224,3256,3280,3297,3317,3357,3381,3496,3523,3546,3625,3637,3641,3650,3661,3672,3694,3695,3697,3717,3745,3787,3799,3829,3876,3878,3907,3927,3963,4026,4075,4087,4104,4136,4174,4202,4219,4280,4467,4539,4559,4566,4579,4584,4631,4754,4815,4836,4901,4948,5019,5029,5030,5092,5303,5306,5402,5477,5553,5573,5600,5641,5680,5772,5875,5886,5905,6034,6231,6299,6422,6454,6492,6629,6640,6714,6743,7097,7106,7136,7165,7219,7247,7307,7328,7362,7402,7406,7469,7495,7511,7720,7753,7803,7845,7886,7889,8276,8417,8477,8478,8493,8532,8625,8781,8861,8951,8976,8990,9066,9431,9581,9671,9696,9706,9837,9961,10008,10015,10269,10292,10451,10474,10508,10552,10574,10598,10648,10758,10798,10817,11078,11100,11161,11178,11239,11350,11525,11806,11813,12103,12132,13171,13321,13349,13360,13367,13499,14009,14012,14106,14301,14747,14874,14902,14933,14978,15065,15139,15172,15373,15444,15455,15480,15483,15526,15584,15690,15817,15901,16047,16319,16325,16473,16553,16738,16777,17064,17399,17753,17793,17885,17893,17907,17937,17942,18130,18170,18328,18568,18744,18917,19343,19423,19555,19571,19687,19714,19717,20022,20338,20681,20971,21478,21731,22002,22553,22699,22896,23042,23359,23804,23904,23937,23938,24288,24498,24554,24719,24965,25065,25139,25157,25315,25341,25456,26030,26446,27217,27498,27633,27906,28133,28531,28727,29010,29498,29990,30047,30786,30852,30919,31081,31145,31459,31476,31867,32088,32397,32658,34162,34473,34671,35884,35936,36413,36544,36676,36938,38563,38697,39254,39429,39718,40247,40558,40605,40616,40889,40942,42020,46444,46598,46950,47417,47903,49380,50019,50267,51606,52065,52609,52802,54035,54683,54992,55395,55451,55549,56212,56456,57208,57424,59229,60714,61449,62045,62812,63294,64351,64439,64839,66375,66511,66581,66702,66723,68721,68828,69121,69425,69546,69746,70004,70152,71027,71306,72992,73882,74326,74328,74423,74509,74660,80546,80937,81149,81600,81647,82422,83130,83143,83786,84070,84121,84155,84598,84684,85076,85183,85593,86581,86638,86793,87396,87541,88217,88253,88844,89112,89317,90604,91037,91241,92198,92211,92474,92870,93199,93292,93510,94419,94862,94889,94896,94924,95037,95379,95826,95842,95939,96511,96556,96585,97297,98195,98225,98484,99299,99844,100087,101280,101709,102003,102063,102893,102902,102936,103078,103981,104038,104604,105186,106118,106247,106345,106521,106713,107042,107172,107189,108469,108572,108579,108939,109705,109716,110479,110661,110667,111324,111425,111563,112777,114334,114456,115012,115830,115927,116252,116285,117417,117967,119597,119904,120113,120932,122089,122695,124163,124207,124455,124647,124675,124706,124715,124802,125087,125551,126540,127101,127355,127506,127821,127897,128092,128287,129565,130480,130665,130938,131232,131253,131638,131743,132095,132258,132384,132485,133561,133866,134295,134364,134776,135227,135541,135747,136021,136122,136130,136269,136704,137391,137430,137964,138217,138360,138374,139785,140367,141402,142705,143071,144066,144397,145377,145717,146268,146587,146629,146809,146928,147560,147896,147989,149035,149768,150226,151356,151551,151590,152671,152933,153270,153532,153811,153975,154642,155213,155412,155419,155756,155966,156241,156304,156448,156553,156782,158188,158713,158723,159043,159093,159750,160602,161087,161677,161820,162546,162702,162743,163045,164280,164539,164822,165003,165221,166008,166217,166364,166479,166749,166930,166965,167724,168143,168216,168462,168934,169741,170016,170949,171143,171264,172075,172353,172802,175061,175317,175599,176049,176161,177532,177723,178060,178635,178711,178804,179164,179229,179705,180015,180319,180511,180615,180866,181087,181721,181774,181783,181945,182244,182492,183101,183309,183334,183816,184398,184601,185061,185288,186413,187115,187598,187697,187814,188154,189908,190971,191140,191168,191502,191543,192109,192769,193486,193516,194341,195191,195259,195818,196250,196312,196453,196458,196842,196916,197137,197188,197622,197717,198072,198214,198280,198864,199097,199278,199785,200085,200137,200431,201615,202777,203146,203220,203244,203450,203990,204908,205172,205343,206457,206490,206605,207354,208228,208375,209368,209480,210499,210607],[171.0,32.0,17.0,6.0,6.0,11.0,1.0,19.0,18.0,4.0,7.0,6.0,5.0,15.0,9.0,7.0,6.0,9.0,4.0,4.0,2.0,6.0,4.0,6.0,4.0,7.0,2.0,8.0,2.0,2.0,4.0,2.0,5.0,1.0,1.0,7.0,3.0,6.0,7.0,3.0,18.0,6.0,6.0,2.0,1.0,1.0,2.0,4.0,6.0,2.0,1.0,1.0,3.0,1.0,3.0,3.0,1.0,2.0,1.0,1.0,2.0,4.0,1.0,3.0,2.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,4.0,8.0,1.0,4.0,1.0,4.0,6.0,1.0,26.0,3.0,4.0,6.0,5.0,2.0,1.0,9.0,2.0,8.0,5.0,1.0,1.0,3.0,7.0,5.0,1.0,10.0,1.0,2.0,5.0,2.0,1.0,1.0,9.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,9.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,3.0,1.0,2.0,2.0,1.0,11.0,1.0,2.0,3.0,5.0,3.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,3.0,2.0,4.0,1.0,1.0,4.0,2.0,4.0,1.0,8.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,3.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,6.0,1.0,5.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,5.0,1.0,1.0,4.0,3.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,12.0,1.0,1.0,10.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,12.0,1.0,2.0,2.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,2.0,2.0,4.0,1.0,1.0,2.0,3.0,2.0,3.0,1.0,1.0,1.0,2.0,1.0,2.0,14.0,1.0,1.0,1.0,40.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,15.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,35.0,1.0,1.0,1.0,1.0,1.0,10.0,1.0,1.0,39.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,29.0,2.0,1.0,29.0,1.0,4.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,16.0,2.0,1.0,1.0,1.0,2.0,6.0,2.0,1.0,1.0,7.0,2.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,10.0,3.0,1.0,17.0,2.0,2.0,1.0,1.0,1.0,9.0,1.0,1.0,2.0,1.0,1.0,3.0,14.0,1.0,3.0,1.0,1.0,1.0,12.0,2.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,10.0,1.0,2.0,1.0,1.0,10.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,9.0,1.0,1.0,1.0,1.0,1.0,8.0,7.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,5.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n",
      "|[journal, of, international, medical, research, , the, authors, , reuse, guidelinessagepubcomjournalspermissions, journalssagepubcomhomeimrcase, reportnivolumab, plus, gemcitabinedexamethasone, and, cisplatinchemotherapy, induce, durablecomplete, remission, inrelapsedrefractory, primarymediastinal, bcell, lymphomaa, case, report, andliterature, reviewgang, huang1, ju, huang2, zhili, zhang2chongchong, xue1, and, yuan, liu2abstractprimary, mediastinal, large, bcell, lymphoma, pmbcl, is, an, uncommon, but, aggressive, type, ofbcell, lymphoma, patients, with, relapsed, refractory, pmbcl, rrpmbcl, have, limited, therapeuticoptions, and, usually, have, a, relatively, poor, outcome, immune, checkpoint, blockade, has, become, apotential, treatment, for, this, disease, we, report, here, a, case, of, a, female, patient, with, rrpmbclwho, was, treated, with, nivolumab, plus, gemcitabine, dexamethasone, and, cisplatin, gdp, chemotherapy, complete, remission, was, achieved, after, four, cycles, of, combined, therapy, with, continuednivolumab, maintenance, monotherapy, she, has, remained, in, complete, remission, for, longer, than, months, this, is, the, first, report, of, nivolumab, plus, gdp, chemotherapy, inducing, completeremission, in, patient, with, rrpmbcl, this, case, supplements, the, limited, literature, and, providesimplications, for, clinical, trial, designs, regarding, the, potential, use, of, nivolumab, in, the, treatment, ofrrpmbcl1department, of, hematology, yuebei, peoples, hospitalshantou, university, medical, college, shaoguanguangdong, province, china2guangdong, women, and, children, hospital, guangzhouguangdong, chinacorresponding, authoryuan, liu, medical, genetic, centre, guangdong, womenand, children, hospital, no, , xingnan, rd, panyudistrict, guangzhou, guangdong, , chinaemail, yuanliu005163comcreative, commons, non, commercial, cc, bync, this, , is, distributed, under, the, terms, of, the, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, and, distribution, of, the, work, without, further, permission, provided, the, original, work, is, attributedas, specified, on, the, sage, and, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, of, international, medical, researchkeywordsrelapsed, refractory, primary, mediastinal, bcelllymphoma, nivolumab, checkpoint, blockadegemcitabine, dexamethasone, cisplatin, chemotherapy, programmed, cell, death, , completeremissiondate, received, , february, , accepted, , july, introductionprimary, mediastinal, large, bcell, lymphomapmbcl, is, an, uncommon, but, aggressivetumor, that, accounts, for, , to, , of, nonhodgkin, lymphoma1, pmbcl, is, distinguished, from, diffuse, large, bcell, lymphomaby, virtue, of, distinct, clinical, pathologicaland, genetic, features2, recently, pmbclwas, listed, as, a, separate, entity, in, the, latestworld, health, anization, , classiï¬cation, of, hematopoieticand, lymphoidtumors5, pmbcl, has, a, similar, clinical, presentation, as, classical, hodgkin, lymphomachl, and, pmbcl, also, shares, certain, features, at, the, molecular, level, particularly9p241, alterations, and, programmed, celldeath, protein, ligand, 1ligand, , pdl1pdl2, expression6, at, present, management, and, outcome, of, pmbcl, are, still, critical, and, a, more, serious, situation, is, faced, bypeople, who, are, diagnosed, with, relapsedand, refractory, pmbcl, rrpmbcl19the, optimal, salvage, chemotherapy, andautologousforrrpmbcl, are, of, limited, efï¬cacy19stem, celltransplantrecently, agents, targeting, programmedcell, death, , pd1, and, pdl1, have, beenimmunotherapy10developed, in, tumorantipd1, therapy, with, monoclonal, antibodies, has, been, approved, for, the, treatmentof, several, types, of, solid, tumor, and, chlthe, therapeutic, potential, of, antipd1, therapy, in, other, malignancies, is, likely, to, beapproved, soonin, , a, humanizedimmunoglobulin, g1, recombinant, monoclonal, antibody, for, the, pd1, receptor, pidilizumab, was, approved, by, the, us, food, anddrug, administration, fda, for, treatingandpediatricpatientsthatwithadultrrpmbcl11, another, agenttargetsthe, pd1, receptor, called, nivolumab, isa, fully, humanized, immunoglobulin, g4monoclonal, antibody, that, has, been, grantedapproval, by, the, us, fda, for, treating, several, solid, malignancies, and, chl, the, therapeutic, efï¬cacy, of, nivolumab, in, patientswith, rrpmbcl, remains, unclearwe, report, here, a, patient, with, rrpmbclwho, received, combined, treatment, with, offlabel, nivolumab, and, gdp, chemotherapycomplete, remission, cr, was, achievedafter, four, cycles, of, such, combined, treatment, at, the, time, of, this, submission, thepatient, has, remained, in, cr, for, longerthan, , months, with, continued, nivolumabmaintenance, monotherapycase, reporta, 32yearold, woman, presented, to, yuebeipeoples, hospital, with, intermittent, dyspneaand, chest, pain, a, positron, emission, tomography, pet, scan, showed, a, 10cm, mass, inthe, anterior, superior, mediastinum, with, astandardized, uptake, value, of, , themass, showed, unclear, margins, and, compressed, the, ascending, aorta, and, pulmonarytrunk, small, pericardial, and, left, pleuraleffusions, were, also, observedthe, mass, was, diagnosed, as, pmbcl, by, asubsequent, biopsy, immunohistochemicalstaining, showed, thatlarge, lymphocyteswere, positive, for, cd20, cd79a, pax5bcl6, cd23, cd30and, multiplemyeloma1, and, negative, for, cd10, cd3cd5chromogranin, asynaptophysin, 0chuang, et, alterminalencodingandincludingtwocycles, positiveregion, inendomysialdeoxynucleotidyltransferase, cytokeratin, ck, ck19, andands100, ki67, wassituepsteinbarrhybridization, was, negative, she, was, initially, treated, with, six, cycles, of, frontline, chemotherapyofrituximab, cyclophosphamide, doxorubicinvincristine, and, prednisolone, rchopand, four, cycles, of, doseadjusted, etoposidecyclophosphaprednisolonemiderituximabdaepochr, were, administered, thetimeline, of, treatment, is, shown, in, ashe, received, tumor, resection, by, thoracoscopic, surgery, after, she, continued, twodoxorubicinvincristinecycles, ofgemcitabine, dexamethasonecisplatinumetoposide, and, rituximabtherapy, her, ï¬rst, cr, was, achieved, indecember, however, , monthslater, a, petcomputed, tomography, ct, scan, showedhypermetabolic, lesions, located, at, the, leftlung, and, right, adrenal, gland, but, not, inthe, primary, mediastinal, site, bthe, patient, reported, no, physical, symptomsand, received, a, repeat, tissue, biopsy, whichconï¬rmed, a, relapse, with, pmbcl, she, wastreated, with, each, cycle, of, a, dexamethasoneifosfamide, cisplatin, and, etoposide, regimenand, ibrutinib, bendamustine, and, cytarabine, therapy, a, chest, ct, scan, showedfigure, , summary, of, treatment, and, monitoring, the, tumor, response, a, patients, timeline, chart, with, thedates, of, treatment, and, monitoring, the, tumor, response, b, positron, emission, tomography, images, upperpanel, a, scan, of, the, relapsed, hypermetabolic, lesions, located, at, the, left, lung, and, right, adrenal, gland, beforecombined, treatment, lower, panel, complete, remission, was, achieved, after, four, cycles, of, nivolumab, plusgdp, chemotherapyrchop, rituximab, cyclophosphamide, doxorubicin, vincristine, and, prednisolone, daepochr, doseadjusted, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and, rituximab, gdpergemcitabine, dexamethasone, cisplatinum, etoposide, and, rituximab, cr, complete, remission, pmbclprimary, mediastinal, large, bcell, lymphoma, dice, dexamethasone, ifosfamide, cisplatin, and, etoposideibc, ibrutinib, bendamustine, and, cytarabine, gdp, gemcitabine, dexamethasone, and, cisplatin, 0cjournal, of, international, medical, researchthat, the, right, adrenal, gland, lesion, had, partially, responded, while, the, lesions, in, the, leftlung, had, progressed, after, those, cycles, ofchemotherapy, the, patient, showed, gradeiv, myelosuppression, and, had, to, receiveblood, transfusion, treatment, moreover, acerebrospinal, ï¬uid, examination, showedthe, presence, of, atypical, lymphocytes, andno, symptoms, of, infection, of, the, central, nervous, system, were, observed, intrathecal, chemotherapy, cytarabine, , mg, methotrexate, mg, and, dexamethasone, , mg, was, thenadministered, and, no, atypical, lymphocyteswere, detected, by, repeated, cerebrospinalï¬uid, analysis, these, ï¬ndings, highly, suggested, a, potential, risk, of, metastasis, of, thecentral, nervous, systemtreatmentbecause, the, disease, had, progressed, withsevere, myelosuppression, and, there, were, nostandard, chemotherapy, guidelines, or, alternative, treatment, options, for, the, patientother, salvage, treatments, of, her, refractorydisease, needed, to, be, considered, aftermuch, discussion, with, the, patient, and, herfamily, she, declined, autologous, hematopoietic, stem, cell, transplantation, and, receivedcombinedgemcitabine, mg, dexamethasone, , mg, and, cisplatinum, , mg, gdpchemotherapyand, the, offlabel, antipd1, antibody, nivolumab, , mg, after, four, cycles, of, combined, treatment, a, repeated, petct, scanshowed, thatshe, had, secondary, crb, she, received, two, more, cyclesof, combined, treatment, with, nivolumab, andgdp, chemotherapy, and, then, continuedsingle, nivolumab, maintenance, treatment, mg, since, her, ï¬rst, dose, in, may, she, received, , doses, of, nivolumab, shereported, moderate, fatigue, and, pyrexia, in, to, , days, after, each, administration, ofnivolumab, blood, tests, indicated, normalfunction, of, the, liver, kidney, and, thyroidfigure, , she, also, had, normal, bloodlevels, of, creatinine, albumin, globulin, lactate, dehydrogenase, aspartate, transaminasetotalaminotransferaseofalaninethey2b, neutrophilbilirubin, and, urea, nitrogen, during, thewhole, process, of, nivolumab, therapyfigureand, plateletcounts, were, decreased, in, the, ï¬rst, four, combined, therapies, because, of, toxicity, of, gdpchemotherapy, butrecovered, tonormal, levels, during, continued, nivolumabmaintenance, monotherapy, figure, 2cfurthermore, no, adverse, signs, and, symptoms, were, observed, in, the, lungs, brainand, skin, at, the, time, of, this, submissionshe, has, remained, in, cr, for, longer, than, months, with, continued, nivolumab, maintenance, therapyethics, approval, was, obtained, from, theethicalcommittee, of, yuebei, peopleshospital, written, informed, consent, wasobtained, from, the, patient, for, analysis, ofthe, samples, and, publicationdiscussiontreatment, and, outcome, are, critical, in, managing, pmbcl, because, there, is, no, established, standard, approachthe, ï¬rstlinetreatment, of, pmbcl, is, generally, thesame, as, that, for, diffuse, large, bcell, lymphoma, including, rchop, and, daepochr, relapse, of, pmbcl, usually, occurs, in, theï¬rst, , to, , months, after, completion, offrontline, therapy, with, a, lower, incidenceapproximately, than, diffuselarge, bcell, lymphoma19, there, are, varioussecondlineregimens, for, patients, with, rrpmbcl, includingthe, rituximab, ifosfamide, carboplatin, andetoposide, regimenthe, rituximab, dexamethasone, cytarabine, and, cisplatin, regimen, and, rituximabgdp12, because, of, alack, of, standard, guidelines, or, treatmentoptions, for, pmbcl, the, outcome, greatlydepends, on, the, patients, response, to, theregimen, thisremains, poordespite, these, secondline, salvage, chemotherapies, and, subsequent, autologous, hematopoietic, stem, cell, transplantation912immunochemotherapyresponse, 0chuang, et, alfigure, , blood, test, values, during, the, whole, treatment, process, since, the, first, dose, of, nivolumab, the, firstfour, cycles, were, nivolumab, plus, gdp, chemotherapy, and, nivolumab, maintenance, monotherapy, wasadministered, since, the, fifth, cycle, a, thyroxine, thyrotropin, ft3, and, ft4, levels, b, levels, of, creatininealbumin, globulin, lactate, dehydrogenase, aspartate, transaminase, alanine, aminotransferase, total, bilirubinand, urea, nitrogen, c, neutrophil, and, platelet, countsft4, free, thyroxine, ft3, free, triiodothyronine, gdp, gemcitabine, dexamethasone, and, cisplatin, 0cjournal, of, international, medical, researchin, recent, years, strategies, focusing, on, thecheckpoint, blockade, have, been, developedin, tumor, immunotherapy10, therapeuticantibodies, targeting, the, pd1pdl1, axispossess, clinical, activity, and, an, acceptablesafety, proï¬le, in, treating, a, growing, list, oflymphomas13solid, tumors, and, bcellbased, on, a, clinical, study, of, , patientswith, rrpmbcl, pidilizumab, was, approvedby, the, us, fda, for, treatment, of, adult, andpediatric, patients, with, rrpmbcl, in, another, antibody, nivolumab, has, beengranted, approval, for, treating, several, solidmalignancies, and, chl, however, studiesregarding, application, of, nivolumab, forpmbcl, are, limited, only, ï¬ve, reportshave, described, using, nivolumab, for, treatment, of, pmbclrrpmbcl, table, , asfollows, in, a, phase, i, study, published, intwo, patients, with, pmbcl, wererecruited, and, treated, with, nivolumab, atdoses, of, , or, , mgkg, every, , weeks, afterprevious, systemic, treatments14, no, objective, responses, were, observed, in, this, previous, study, in, another, phase, i, study, onewithrefractorypatient, with, pmbcl, received, combinedtherapy, of, nivolumab, and, ipilimumaband, died, during, the, therapeutic, process15recently, two, reports, showed, the, potentialtherapeutic, efï¬ciency, of, nivolumab, forpatientspmbclrrpmbcl, who, showed, failure, with, conventional, immunochemotherapy1617, both, ofthese, two, cases, had, immunerelated, adverseeffects, during, the, antibody, treatment, process, one, patient, with, highgrade, neutr, ia, had, nivolumab, stopped, temporarilyand, was, treated, with, intravenous, immunoglobulin16, the, other, patient, with, zosterreactivation, was, controlled, by, administration, of, valacyclovir17, recently, zinzaniand, colleagues, showed, that, combined, treatment, of, nivolumab, and, brentuximab, vedotin, had, promising, antitumor, activity, and, amanageable, safety, proï¬le, in, patients, withrrpmbcl18, in, this, phase, ii, study, patients, were, recruited, and, treated, withnivolumab, , mgkg, and, brentuximab, vedotin, , mgkg, every, , weeks, the, objectiveresponse, rate, was, , and, , achievedtable, , reports, regarding, application, of, nivolumab, in, primary, mediastinal, large, bcell, lymphomarelapsedand, refractory, primary, mediastinal, large, bcell, lymphomanumberof, cases, dosecombinedtreatmentadverse, events, or, , mgkg, mgkgipilimumabresponseyesnonono, ofpatientsreportslesokhin, amet, al, ansell, s, et, alwright, zet, al, yassin, r, et, alzinzani, mgkgnonohighgrade, neutr, iayeszoster, reactivationyes, mgbrentuximabneutr, iapl, et, al, vedotinthrombocyt, iaand, peripheralneuropathy, of, patientspresent, case, mgkggdpmild, fatigue, and, pyrexiayeschemotherapynote, , means, not, indicated, in, the, report, 0chuang, et, alofcyclescombinedcr, and, , achieved, partial, remission, of, patients, , of, them, had, drugrelatedadverse, events, and, the, most, common, wereneutr, ia, thrombocyt, ia, and, peripheral, neuropathy18, in, the, present, case, weattempted, several, available, approaches, intreating, the, patients, relapsed, disease, butfailed, to, control, the, progress, of, the, massafter, much, discussion, with, the, patient, andher, family, we, considered, an, offlabel, nivolumab, and, gdp, chemotherapy, as, salvagetreatmentfor, the, patient, in, september, her, second, cr, was, achieved, afterfourtreatmentcurrently, with, continued, nivolumab, maintenance, monotherapythe, patient, hasremained, in, cr, for, longer, than, , monthsimmunerelated, adverse, events, that, areassociated, with, checkpoint, blockade, oftenstart, within, the, ï¬rst, few, weeks, to, monthsafter, treatment, but, can, occur, any, time, andin, any, an, the, most, common, immunerelated, adverse, events, are, hypothyroidismnausea, diarrhea, pyrexia, and, fatigue1920in, the, present, case, we, were, concernedabout, immunerelated, an, damage, sincethe, ï¬rst, dose, of, nivolumab, the, patientreported, moderate, fatigue, and, pyrexiaafter, each, administration, of, nivolumaband, soon, recovered, within, , to, , daysblood, testing, was, performed, during, thewhole, therapeutic, process, and, the, datawere, reviewed, and, analyzed, blood, levelsof, thyroxine, thyrotropin, free, triiodothyronine, and, free, thyroxine, indicated, no, thyroiditisfigure, 2a, our, patient, alsoshowed, normal, metabolic, data, during, thewhole, process, of, nivolumab, therapyfigureand, plateletcounts, were, decreased, in, the, ï¬rst, four, combined, therapies, because, of, toxicity, of, gdpchemotherapy, but, they, then, recovered, tonormal, levels, during, continued, nivolumabmaintenance, monotherapy, figure, 2c2b, neutrophilunlike, otherarelymphomas, prognosticbiomarkersinpmbcl12, some, serum, molecules, such, aslackinglargelyccl17, and, cd163, are, considered, aspotential, biomarkers, for, predicting, andmonitoring, responses, and, detection, ofrelapses, in, patients, with, hodgkin, lymphoma1221, the, role, of, serum, biomarkers, inpmbcl, remainsinvestigatedradiological, imaging, should, only, be, usedin, patients, who, have, new, clinical, symptomsor, signs, suggestive, of, relapse, but, not, inasymptomatic, patients922betoto, the, best, of, our, knowledge, this, is, theï¬rst, reported, case, of, nivolumab, plus, gdpchemotherapy, that, induced, cr, with, nosevere, immunerelated, an, damage, in, apatient, with, rrpmbcl, we, also, reportthe, longest, followup, observation, of, successful, application, of, nivolumab, in, apatient, with, rrpmbclthis, report, supplements, the, limited, literature, of, nivolumab, fortreatment, ofpmbclrrpmbcl, and, provides, implications, for, clinical, trial, design, regarding, thepotential, use, of, nivolumab, in, treatment, ofrrpmbcl, further, investigation, needs, to, beperformed, for, potential, application, of, singleor, combined, use, of, nivolumab, for, patientswith, rrpmbcl, who, experience, failure, withconventional, therapeutic, approachesdeclaration, of, conflicting, interestthe, authors, declare, that, there, is, no, conï¬ict, ofinterestfundingthis, research, received, no, speciï¬c, grant, from, anyfunding, agency, in, the, public, commercial, ornotforproï¬t, sectorsorcid000000034880orcid, idyuan, liureferences, martelli, m, ferreri, a, di, rocco, a, et, alprimary, mediastinal, large, bcell, lymphomacrit, rev, oncol, hematol, , , , 0cjournal, of, international, medical, research, savage, kj, monti, s, kutok, jl, et, al, themolecular, signature, of, mediastinallargebcell, lymphoma, differs, from, that, of, otherdiffuse, large, bcell, lymphomas, and, sharesfeatures, with, classical, hodgkin, lymphomablood, , , , rosenwald, a, wright, g, leroy, k, et, almolecular, diagnosis, of, primary, mediastinalb, cell, lymphoma, identiï¬es, a, clinically, favorable, subgroup, of, diffuse, large, b, cell, lymphoma, related, to, hodgkin, lymphoma, j, expmed, , , , mottok, a, wright, g, rosenwald, a, et, almolecular, classiï¬cation, of, primary, mediastinal, large, bcell, lymphoma, using, routinelyavailable, tissue, specimens, blood, , , swerdlow, sh, campo, e, pileri, sa, et, althe, , revision, ofthe, world, healthanization, classiï¬cation, of, lymphoid, neoplasms, blood, , , , xumonette, zy, zhou, j, and, young, khpd1, expression, and, clinical, pd1, blockadelymphomas, blood, , in, bcell, van, roosbroeck, k, ferreiro, jf, tousseynt, et, al, genomic, alterations, of, the, jak2and, pdl, loci, occur, in, a, broad, spectrum, oflymphoid, malignancies, genes, chromosomescancer, , , rearrangements, twa, dd, chan, fc, benneriah, s, et, algenomicinvolving, programmed, death, ligands, are, recurrent, in, primary, mediastinallymphomablood, , , large, bcell, cwynarski, k, marzolini, mav, barringtonsf, et, al, the, management, of, primary, mediastinal, bcell, lymphoma, a, british, societyfor, haematology, good, practice, paper, brj, haematol, , , , ribas, a, and, wolchok, jd, cancer, immunotherapy, using, checkpoint, blockade, science, , , hematologyoncology, cancer, approvals, safety, notiï¬cations, available, online, url, wwwfdagovdrugsinformationondrugsapproveddrugsucm610670htmdrugsapproveddrugsucm610670htmwwwfdagovdrugsinformationon, lees, c, keane, c, gandhi, mk, et, al, biologyand, therapy, of, primary, mediastinal, bcelllymphoma, current, status, and, future, directions, br, j, haematol, , , , goodman, a, patel, sp, and, kurzrock, rpd1pdl1, immunecheckpoint, blockadein, bcell, lymphomas, nat, rev, clin, oncol, , , lesokhin, am, ansell, sm, armand, p, et, alnivolumab, in, patients, with, relapsed, orrefractory, hematologic, malignancy, preliminary, results, of, a, phase, ib, study, j, clin, oncol, , , ansell, s, gutierrez, me, shipp, ma, et, ala, phase, , study, of, nivolumab, in, combination, with, ipilimumab, for, relapsed, or, refractory, hematologic, malignancies, checkmate, blood, , , , wright, z, and, brown, a, highgrade, neutr, ia, in, a, patient, successfully, treated, withnivolumab, for, refractory, primary, mediastilymphoma, blood, adv, , nal, bcell, yassin, r, hajeer, a, alshieban, s, et, al, hlagenotype, and, response, to, nivolumab, therapy, in, relapsed, refractory, primary, mediastinal, bcell, lymphoma, curr, res, transl, med, , , zinzani, pl, santoro, a, gritti, g, et, alnivolumab, combined, with, brentuximabvedotin, forrelapsedrefractory, primarymediastinal, large, bcell, lymphoma, efï¬cacyand, safety, from, the, phase, ii, checkmate, study, j, clin, oncol, , , , postow, ma, sidlow, r, and, hellmann, mdimmunerelated, adverse, events, associatedwith, immune, checkpoint, blockade, n, englj, med, , , , zinzani, pl, ribrag, v, moskowitz, ch, et, alsafety, and, tolerability, of, pembrolizumab, inpatients, with, relapsedrefractory, primarylymphoma, bloodmediastinal, , large, bcell, jones, k, vari, f, keane, c, et, al, serumcd163, and, tarc, as, disease, response, biomarkers, in, classical, hodgkin, lymphomaclin, cancer, res, , , for, cheson, bd, fisher, ri, barrington, sf, et, alinitial, evaluationrecommendationsstagingofhodgkin, and, nonhodgkin, lymphoma, thelugano, classiï¬cation, j, clin, oncol, , assessmentandresponse, 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |[journal, international, medical, research, , authors, , reuse, guidelinessagepubcomjournalspermissions, journalssagepubcomhomeimrcase, reportnivolumab, plus, gemcitabinedexamethasone, cisplatinchemotherapy, induce, durablecomplete, remission, inrelapsedrefractory, primarymediastinal, bcell, lymphomaa, case, report, andliterature, reviewgang, huang1, ju, huang2, zhili, zhang2chongchong, xue1, yuan, liu2abstractprimary, mediastinal, large, bcell, lymphoma, pmbcl, uncommon, aggressive, type, ofbcell, lymphoma, patients, relapsed, refractory, pmbcl, rrpmbcl, limited, therapeuticoptions, usually, relatively, poor, outcome, immune, checkpoint, blockade, become, apotential, treatment, disease, report, case, female, patient, rrpmbclwho, treated, nivolumab, plus, gemcitabine, dexamethasone, cisplatin, gdp, chemotherapy, complete, remission, achieved, four, cycles, combined, therapy, continuednivolumab, maintenance, monotherapy, remained, complete, remission, longer, months, first, report, nivolumab, plus, gdp, chemotherapy, inducing, completeremission, patient, rrpmbcl, case, supplements, limited, literature, providesimplications, clinical, trial, designs, regarding, potential, use, nivolumab, treatment, ofrrpmbcl1department, hematology, yuebei, peoples, hospitalshantou, university, medical, college, shaoguanguangdong, province, china2guangdong, women, children, hospital, guangzhouguangdong, chinacorresponding, authoryuan, liu, medical, genetic, centre, guangdong, womenand, children, hospital, , xingnan, rd, panyudistrict, guangzhou, guangdong, , chinaemail, yuanliu005163comcreative, commons, non, commercial, cc, bync, , distributed, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, permitsnoncommercial, use, reproduction, distribution, work, without, permission, provided, original, work, attributedas, specified, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, international, medical, researchkeywordsrelapsed, refractory, primary, mediastinal, bcelllymphoma, nivolumab, checkpoint, blockadegemcitabine, dexamethasone, cisplatin, chemotherapy, programmed, cell, death, , completeremissiondate, received, , february, , accepted, , july, introductionprimary, mediastinal, large, bcell, lymphomapmbcl, uncommon, aggressivetumor, accounts, , , nonhodgkin, lymphoma1, pmbcl, distinguished, diffuse, large, bcell, lymphomaby, virtue, distinct, clinical, pathologicaland, genetic, features2, recently, pmbclwas, listed, separate, entity, latestworld, health, anization, , classiï¬cation, hematopoieticand, lymphoidtumors5, pmbcl, similar, clinical, presentation, classical, hodgkin, lymphomachl, pmbcl, also, shares, certain, features, molecular, level, particularly9p241, alterations, programmed, celldeath, protein, ligand, 1ligand, , pdl1pdl2, expression6, present, management, outcome, pmbcl, still, critical, serious, situation, faced, bypeople, diagnosed, relapsedand, refractory, pmbcl, rrpmbcl19the, optimal, salvage, chemotherapy, andautologousforrrpmbcl, limited, efï¬cacy19stem, celltransplantrecently, agents, targeting, programmedcell, death, , pd1, pdl1, beenimmunotherapy10developed, tumorantipd1, therapy, monoclonal, antibodies, approved, treatmentof, several, types, solid, tumor, chlthe, therapeutic, potential, antipd1, therapy, malignancies, likely, beapproved, soonin, , humanizedimmunoglobulin, g1, recombinant, monoclonal, antibody, pd1, receptor, pidilizumab, approved, us, food, anddrug, administration, fda, treatingandpediatricpatientsthatwithadultrrpmbcl11, another, agenttargetsthe, pd1, receptor, called, nivolumab, isa, fully, humanized, immunoglobulin, g4monoclonal, antibody, grantedapproval, us, fda, treating, several, solid, malignancies, chl, therapeutic, efï¬cacy, nivolumab, patientswith, rrpmbcl, remains, unclearwe, report, patient, rrpmbclwho, received, combined, treatment, offlabel, nivolumab, gdp, chemotherapycomplete, remission, cr, achievedafter, four, cycles, combined, treatment, time, submission, thepatient, remained, cr, longerthan, , months, continued, nivolumabmaintenance, monotherapycase, reporta, 32yearold, woman, presented, yuebeipeoples, hospital, intermittent, dyspneaand, chest, pain, positron, emission, tomography, pet, scan, showed, 10cm, mass, inthe, anterior, superior, mediastinum, astandardized, uptake, value, , themass, showed, unclear, margins, compressed, ascending, aorta, pulmonarytrunk, small, pericardial, left, pleuraleffusions, also, observedthe, mass, diagnosed, pmbcl, asubsequent, biopsy, immunohistochemicalstaining, showed, thatlarge, lymphocyteswere, positive, cd20, cd79a, pax5bcl6, cd23, cd30and, multiplemyeloma1, negative, cd10, cd3cd5chromogranin, asynaptophysin, 0chuang, et, alterminalencodingandincludingtwocycles, positiveregion, inendomysialdeoxynucleotidyltransferase, cytokeratin, ck, ck19, andands100, ki67, wassituepsteinbarrhybridization, negative, initially, treated, six, cycles, frontline, chemotherapyofrituximab, cyclophosphamide, doxorubicinvincristine, prednisolone, rchopand, four, cycles, doseadjusted, etoposidecyclophosphaprednisolonemiderituximabdaepochr, administered, thetimeline, treatment, shown, ashe, received, tumor, resection, thoracoscopic, surgery, continued, twodoxorubicinvincristinecycles, ofgemcitabine, dexamethasonecisplatinumetoposide, rituximabtherapy, ï¬rst, cr, achieved, indecember, however, , monthslater, petcomputed, tomography, ct, scan, showedhypermetabolic, lesions, located, leftlung, right, adrenal, gland, inthe, primary, mediastinal, site, bthe, patient, reported, physical, symptomsand, received, repeat, tissue, biopsy, whichconï¬rmed, relapse, pmbcl, wastreated, cycle, dexamethasoneifosfamide, cisplatin, etoposide, regimenand, ibrutinib, bendamustine, cytarabine, therapy, chest, ct, scan, showedfigure, , summary, treatment, monitoring, tumor, response, patients, timeline, chart, thedates, treatment, monitoring, tumor, response, b, positron, emission, tomography, images, upperpanel, scan, relapsed, hypermetabolic, lesions, located, left, lung, right, adrenal, gland, beforecombined, treatment, lower, panel, complete, remission, achieved, four, cycles, nivolumab, plusgdp, chemotherapyrchop, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, daepochr, doseadjusted, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab, gdpergemcitabine, dexamethasone, cisplatinum, etoposide, rituximab, cr, complete, remission, pmbclprimary, mediastinal, large, bcell, lymphoma, dice, dexamethasone, ifosfamide, cisplatin, etoposideibc, ibrutinib, bendamustine, cytarabine, gdp, gemcitabine, dexamethasone, cisplatin, 0cjournal, international, medical, researchthat, right, adrenal, gland, lesion, partially, responded, lesions, leftlung, progressed, cycles, ofchemotherapy, patient, showed, gradeiv, myelosuppression, receiveblood, transfusion, treatment, moreover, acerebrospinal, ï¬uid, examination, showedthe, presence, atypical, lymphocytes, andno, symptoms, infection, central, nervous, system, observed, intrathecal, chemotherapy, cytarabine, , mg, methotrexate, mg, dexamethasone, , mg, thenadministered, atypical, lymphocyteswere, detected, repeated, cerebrospinalï¬uid, analysis, ï¬ndings, highly, suggested, potential, risk, metastasis, thecentral, nervous, systemtreatmentbecause, disease, progressed, withsevere, myelosuppression, nostandard, chemotherapy, guidelines, alternative, treatment, options, patientother, salvage, treatments, refractorydisease, needed, considered, aftermuch, discussion, patient, herfamily, declined, autologous, hematopoietic, stem, cell, transplantation, receivedcombinedgemcitabine, mg, dexamethasone, , mg, cisplatinum, , mg, gdpchemotherapyand, offlabel, antipd1, antibody, nivolumab, , mg, four, cycles, combined, treatment, repeated, petct, scanshowed, thatshe, secondary, crb, received, two, cyclesof, combined, treatment, nivolumab, andgdp, chemotherapy, continuedsingle, nivolumab, maintenance, treatment, mg, since, ï¬rst, dose, may, received, , doses, nivolumab, shereported, moderate, fatigue, pyrexia, , days, administration, ofnivolumab, blood, tests, indicated, normalfunction, liver, kidney, thyroidfigure, , also, normal, bloodlevels, creatinine, albumin, globulin, lactate, dehydrogenase, aspartate, transaminasetotalaminotransferaseofalaninethey2b, neutrophilbilirubin, urea, nitrogen, thewhole, process, nivolumab, therapyfigureand, plateletcounts, decreased, ï¬rst, four, combined, therapies, toxicity, gdpchemotherapy, butrecovered, tonormal, levels, continued, nivolumabmaintenance, monotherapy, figure, 2cfurthermore, adverse, signs, symptoms, observed, lungs, brainand, skin, time, submissionshe, remained, cr, longer, months, continued, nivolumab, maintenance, therapyethics, approval, obtained, theethicalcommittee, yuebei, peopleshospital, written, informed, consent, wasobtained, patient, analysis, ofthe, samples, publicationdiscussiontreatment, outcome, critical, managing, pmbcl, established, standard, approachthe, ï¬rstlinetreatment, pmbcl, generally, thesame, diffuse, large, bcell, lymphoma, including, rchop, daepochr, relapse, pmbcl, usually, occurs, theï¬rst, , , months, completion, offrontline, therapy, lower, incidenceapproximately, than, diffuselarge, bcell, lymphoma19, varioussecondlineregimens, patients, rrpmbcl, includingthe, rituximab, ifosfamide, carboplatin, andetoposide, regimenthe, rituximab, dexamethasone, cytarabine, cisplatin, regimen, rituximabgdp12, alack, standard, guidelines, treatmentoptions, pmbcl, outcome, greatlydepends, patients, response, theregimen, thisremains, poordespite, secondline, salvage, chemotherapies, subsequent, autologous, hematopoietic, stem, cell, transplantation912immunochemotherapyresponse, 0chuang, et, alfigure, , blood, test, values, whole, treatment, process, since, first, dose, nivolumab, firstfour, cycles, nivolumab, plus, gdp, chemotherapy, nivolumab, maintenance, monotherapy, wasadministered, since, fifth, cycle, thyroxine, thyrotropin, ft3, ft4, levels, b, levels, creatininealbumin, globulin, lactate, dehydrogenase, aspartate, transaminase, alanine, aminotransferase, total, bilirubinand, urea, nitrogen, c, neutrophil, platelet, countsft4, free, thyroxine, ft3, free, triiodothyronine, gdp, gemcitabine, dexamethasone, cisplatin, 0cjournal, international, medical, researchin, recent, years, strategies, focusing, thecheckpoint, blockade, developedin, tumor, immunotherapy10, therapeuticantibodies, targeting, pd1pdl1, axispossess, clinical, activity, acceptablesafety, proï¬le, treating, growing, list, oflymphomas13solid, tumors, bcellbased, clinical, study, , patientswith, rrpmbcl, pidilizumab, approvedby, us, fda, treatment, adult, andpediatric, patients, rrpmbcl, another, antibody, nivolumab, beengranted, approval, treating, several, solidmalignancies, chl, however, studiesregarding, application, nivolumab, forpmbcl, limited, ï¬ve, reportshave, described, using, nivolumab, treatment, pmbclrrpmbcl, table, , asfollows, phase, study, published, intwo, patients, pmbcl, wererecruited, treated, nivolumab, atdoses, , , mgkg, every, , weeks, afterprevious, systemic, treatments14, objective, responses, observed, previous, study, another, phase, study, onewithrefractorypatient, pmbcl, received, combinedtherapy, nivolumab, ipilimumaband, died, therapeutic, process15recently, two, reports, showed, potentialtherapeutic, efï¬ciency, nivolumab, forpatientspmbclrrpmbcl, showed, failure, conventional, immunochemotherapy1617, ofthese, two, cases, immunerelated, adverseeffects, antibody, treatment, process, one, patient, highgrade, neutr, ia, nivolumab, stopped, temporarilyand, treated, intravenous, immunoglobulin16, patient, zosterreactivation, controlled, administration, valacyclovir17, recently, zinzaniand, colleagues, showed, combined, treatment, nivolumab, brentuximab, vedotin, promising, antitumor, activity, amanageable, safety, proï¬le, patients, withrrpmbcl18, phase, ii, study, patients, recruited, treated, withnivolumab, , mgkg, brentuximab, vedotin, , mgkg, every, , weeks, objectiveresponse, rate, , , achievedtable, , reports, regarding, application, nivolumab, primary, mediastinal, large, bcell, lymphomarelapsedand, refractory, primary, mediastinal, large, bcell, lymphomanumberof, cases, dosecombinedtreatmentadverse, events, , mgkg, mgkgipilimumabresponseyesnonono, ofpatientsreportslesokhin, amet, al, ansell, et, alwright, zet, al, yassin, r, et, alzinzani, mgkgnonohighgrade, neutr, iayeszoster, reactivationyes, mgbrentuximabneutr, iapl, et, al, vedotinthrombocyt, iaand, peripheralneuropathy, patientspresent, case, mgkggdpmild, fatigue, pyrexiayeschemotherapynote, , means, indicated, report, 0chuang, et, alofcyclescombinedcr, , achieved, partial, remission, patients, , drugrelatedadverse, events, common, wereneutr, ia, thrombocyt, ia, peripheral, neuropathy18, present, case, weattempted, several, available, approaches, intreating, patients, relapsed, disease, butfailed, control, progress, massafter, much, discussion, patient, andher, family, considered, offlabel, nivolumab, gdp, chemotherapy, salvagetreatmentfor, patient, september, second, cr, achieved, afterfourtreatmentcurrently, continued, nivolumab, maintenance, monotherapythe, patient, hasremained, cr, longer, , monthsimmunerelated, adverse, events, areassociated, checkpoint, blockade, oftenstart, within, ï¬rst, weeks, monthsafter, treatment, occur, time, andin, common, immunerelated, adverse, events, hypothyroidismnausea, diarrhea, pyrexia, fatigue1920in, present, case, concernedabout, immunerelated, damage, sincethe, ï¬rst, dose, nivolumab, patientreported, moderate, fatigue, pyrexiaafter, administration, nivolumaband, soon, recovered, within, , , daysblood, testing, performed, thewhole, therapeutic, process, datawere, reviewed, analyzed, blood, levelsof, thyroxine, thyrotropin, free, triiodothyronine, free, thyroxine, indicated, thyroiditisfigure, 2a, patient, alsoshowed, normal, metabolic, data, thewhole, process, nivolumab, therapyfigureand, plateletcounts, decreased, ï¬rst, four, combined, therapies, toxicity, gdpchemotherapy, recovered, tonormal, levels, continued, nivolumabmaintenance, monotherapy, figure, 2c2b, neutrophilunlike, otherarelymphomas, prognosticbiomarkersinpmbcl12, serum, molecules, aslackinglargelyccl17, cd163, considered, aspotential, biomarkers, predicting, andmonitoring, responses, detection, ofrelapses, patients, hodgkin, lymphoma1221, role, serum, biomarkers, inpmbcl, remainsinvestigatedradiological, imaging, usedin, patients, new, clinical, symptomsor, signs, suggestive, relapse, inasymptomatic, patients922betoto, best, knowledge, theï¬rst, reported, case, nivolumab, plus, gdpchemotherapy, induced, cr, nosevere, immunerelated, damage, apatient, rrpmbcl, also, reportthe, longest, followup, observation, successful, application, nivolumab, apatient, rrpmbclthis, report, supplements, limited, literature, nivolumab, fortreatment, ofpmbclrrpmbcl, provides, implications, clinical, trial, design, regarding, thepotential, use, nivolumab, treatment, ofrrpmbcl, investigation, needs, beperformed, potential, application, singleor, combined, use, nivolumab, patientswith, rrpmbcl, experience, failure, withconventional, therapeutic, approachesdeclaration, conflicting, interestthe, authors, declare, conï¬ict, ofinterestfundingthis, research, received, speciï¬c, grant, anyfunding, agency, public, commercial, ornotforproï¬t, sectorsorcid000000034880orcid, idyuan, liureferences, martelli, m, ferreri, di, rocco, et, alprimary, mediastinal, large, bcell, lymphomacrit, rev, oncol, hematol, , , , 0cjournal, international, medical, research, savage, kj, monti, kutok, jl, et, al, themolecular, signature, mediastinallargebcell, lymphoma, differs, otherdiffuse, large, bcell, lymphomas, sharesfeatures, classical, hodgkin, lymphomablood, , , , rosenwald, wright, g, leroy, k, et, almolecular, diagnosis, primary, mediastinalb, cell, lymphoma, identiï¬es, clinically, favorable, subgroup, diffuse, large, b, cell, lymphoma, related, hodgkin, lymphoma, j, expmed, , , , mottok, wright, g, rosenwald, et, almolecular, classiï¬cation, primary, mediastinal, large, bcell, lymphoma, using, routinelyavailable, tissue, specimens, blood, , , swerdlow, sh, campo, e, pileri, sa, et, althe, , revision, ofthe, world, healthanization, classiï¬cation, lymphoid, neoplasms, blood, , , , xumonette, zy, zhou, j, young, khpd1, expression, clinical, pd1, blockadelymphomas, blood, , bcell, van, roosbroeck, k, ferreiro, jf, tousseynt, et, al, genomic, alterations, jak2and, pdl, loci, occur, broad, spectrum, oflymphoid, malignancies, genes, chromosomescancer, , , rearrangements, twa, dd, chan, fc, benneriah, et, algenomicinvolving, programmed, death, ligands, recurrent, primary, mediastinallymphomablood, , , large, bcell, cwynarski, k, marzolini, mav, barringtonsf, et, al, management, primary, mediastinal, bcell, lymphoma, british, societyfor, haematology, good, practice, paper, brj, haematol, , , , ribas, wolchok, jd, cancer, immunotherapy, using, checkpoint, blockade, science, , , hematologyoncology, cancer, approvals, safety, notiï¬cations, available, online, url, wwwfdagovdrugsinformationondrugsapproveddrugsucm610670htmdrugsapproveddrugsucm610670htmwwwfdagovdrugsinformationon, lees, c, keane, c, gandhi, mk, et, al, biologyand, therapy, primary, mediastinal, bcelllymphoma, current, status, future, directions, br, j, haematol, , , , goodman, patel, sp, kurzrock, rpd1pdl1, immunecheckpoint, blockadein, bcell, lymphomas, nat, rev, clin, oncol, , , lesokhin, ansell, sm, armand, p, et, alnivolumab, patients, relapsed, orrefractory, hematologic, malignancy, preliminary, results, phase, ib, study, j, clin, oncol, , , ansell, gutierrez, shipp, ma, et, ala, phase, , study, nivolumab, combination, ipilimumab, relapsed, refractory, hematologic, malignancies, checkmate, blood, , , , wright, z, brown, highgrade, neutr, ia, patient, successfully, treated, withnivolumab, refractory, primary, mediastilymphoma, blood, adv, , nal, bcell, yassin, r, hajeer, alshieban, et, al, hlagenotype, response, nivolumab, therapy, relapsed, refractory, primary, mediastinal, bcell, lymphoma, curr, res, transl, med, , , zinzani, pl, santoro, gritti, g, et, alnivolumab, combined, brentuximabvedotin, forrelapsedrefractory, primarymediastinal, large, bcell, lymphoma, efï¬cacyand, safety, phase, ii, checkmate, study, j, clin, oncol, , , , postow, ma, sidlow, r, hellmann, mdimmunerelated, adverse, events, associatedwith, immune, checkpoint, blockade, n, englj, med, , , , zinzani, pl, ribrag, v, moskowitz, ch, et, alsafety, tolerability, pembrolizumab, inpatients, relapsedrefractory, primarylymphoma, bloodmediastinal, , large, bcell, jones, k, vari, f, keane, c, et, al, serumcd163, tarc, disease, response, biomarkers, classical, hodgkin, lymphomaclin, cancer, res, , , for, cheson, bd, fisher, ri, barrington, sf, et, alinitial, evaluationrecommendationsstagingofhodgkin, nonhodgkin, lymphoma, thelugano, classiï¬cation, j, clin, oncol, , assessmentandresponse, 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |[journal, international, medical, research, , authors, , reuse, guidelinessagepubcomjournalspermissions, journalssagepubcomhomeimrcase, reportnivolumab, plus, gemcitabinedexamethasone, cisplatinchemotherapy, induce, durablecomplete, remission, inrelapsedrefractory, primarymediastinal, bcell, lymphomaa, case, report, andliterature, reviewgang, huang1, ju, huang2, zhili, zhang2chongchong, xue1, yuan, liu2abstractprimary, mediastinal, large, bcell, lymphoma, pmbcl, an, uncommon, but, aggressive, type, ofbcell, lymphoma, patients, with, relapsed, refractory, pmbcl, rrpmbcl, have, limited, therapeuticoptions, usually, have, relatively, poor, outcome, immune, checkpoint, blockade, has, become, apotential, treatment, disease, we, report, here, case, female, patient, with, rrpmbclwho, treated, with, nivolumab, plus, gemcitabine, dexamethasone, cisplatin, gdp, chemotherapy, complete, remission, achieved, after, four, cycles, combined, therapy, with, continuednivolumab, maintenance, monotherapy, she, has, remained, complete, remission, longer, than, months, first, report, nivolumab, plus, gdp, chemotherapy, inducing, completeremission, patient, with, rrpmbcl, case, supplements, limited, literature, providesimplications, clinical, trial, designs, regarding, potential, use, nivolumab, treatment, ofrrpmbcl1department, hematology, yuebei, peoples, hospitalshantou, university, medical, college, shaoguanguangdong, province, china2guangdong, women, children, hospital, guangzhouguangdong, chinacorresponding, authoryuan, liu, medical, genetic, centre, guangdong, womenand, children, hospital, no, , xingnan, rd, panyudistrict, guangzhou, guangdong, , chinaemail, yuanliu005163comcreative, commons, non, commercial, cc, bync, , distributed, under, terms, creativecommons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permitsnoncommercial, use, reproduction, distribution, work, without, further, permission, provided, original, work, attributedas, specified, on, sage, , , access, pages, ussagepubcomenusnam, accessatsage, 0cjournal, international, medical, researchkeywordsrelapsed, refractory, primary, mediastinal, bcelllymphoma, nivolumab, checkpoint, blockadegemcitabine, dexamethasone, cisplatin, chemotherapy, programmed, cell, death, , completeremissiondate, received, , february, , accepted, , july, introductionprimary, mediastinal, large, bcell, lymphomapmbcl, an, uncommon, but, aggressivetumor, that, accounts, , , nonhodgkin, lymphoma1, pmbcl, distinguished, from, diffuse, large, bcell, lymphomaby, virtue, distinct, clinical, pathologicaland, genetic, features2, recently, pmbclwas, listed, as, separate, entity, latestworld, health, anization, , classiï¬cation, hematopoieticand, lymphoidtumors5, pmbcl, has, similar, clinical, presentation, as, classical, hodgkin, lymphomachl, pmbcl, also, shares, certain, features, at, molecular, level, particularly9p241, alterations, programmed, celldeath, protein, ligand, 1ligand, , pdl1pdl2, expression6, at, present, management, outcome, pmbcl, are, still, critical, more, serious, situation, faced, bypeople, who, are, diagnosed, with, relapsedand, refractory, pmbcl, rrpmbcl19the, optimal, salvage, chemotherapy, andautologousforrrpmbcl, are, limited, efï¬cacy19stem, celltransplantrecently, agents, targeting, programmedcell, death, , pd1, pdl1, have, beenimmunotherapy10developed, tumorantipd1, therapy, with, monoclonal, antibodies, has, been, approved, treatmentof, several, types, solid, tumor, chlthe, therapeutic, potential, antipd1, therapy, other, malignancies, likely, beapproved, soonin, , humanizedimmunoglobulin, g1, recombinant, monoclonal, antibody, pd1, receptor, pidilizumab, approved, by, us, food, anddrug, administration, fda, treatingandpediatricpatientsthatwithadultrrpmbcl11, another, agenttargetsthe, pd1, receptor, called, nivolumab, isa, fully, humanized, immunoglobulin, g4monoclonal, antibody, that, has, been, grantedapproval, by, us, fda, treating, several, solid, malignancies, chl, therapeutic, efï¬cacy, nivolumab, patientswith, rrpmbcl, remains, unclearwe, report, here, patient, with, rrpmbclwho, received, combined, treatment, with, offlabel, nivolumab, gdp, chemotherapycomplete, remission, cr, achievedafter, four, cycles, such, combined, treatment, at, time, submission, thepatient, has, remained, cr, longerthan, , months, with, continued, nivolumabmaintenance, monotherapycase, reporta, 32yearold, woman, presented, yuebeipeoples, hospital, with, intermittent, dyspneaand, chest, pain, positron, emission, tomography, pet, scan, showed, 10cm, mass, inthe, anterior, superior, mediastinum, with, astandardized, uptake, value, , themass, showed, unclear, margins, compressed, ascending, aorta, pulmonarytrunk, small, pericardial, left, pleuraleffusions, were, also, observedthe, mass, diagnosed, as, pmbcl, by, asubsequent, biopsy, immunohistochemicalstaining, showed, thatlarge, lymphocyteswere, positive, cd20, cd79a, pax5bcl6, cd23, cd30and, multiplemyeloma1, negative, cd10, cd3cd5chromogranin, asynaptophysin, 0chuang, et, alterminalencodingandincludingtwocycles, positiveregion, inendomysialdeoxynucleotidyltransferase, cytokeratin, ck, ck19, andands100, ki67, wassituepsteinbarrhybridization, negative, she, initially, treated, with, six, cycles, frontline, chemotherapyofrituximab, cyclophosphamide, doxorubicinvincristine, prednisolone, rchopand, four, cycles, doseadjusted, etoposidecyclophosphaprednisolonemiderituximabdaepochr, were, administered, thetimeline, treatment, shown, ashe, received, tumor, resection, by, thoracoscopic, surgery, after, she, continued, twodoxorubicinvincristinecycles, ofgemcitabine, dexamethasonecisplatinumetoposide, rituximabtherapy, her, ï¬rst, cr, achieved, indecember, however, , monthslater, petcomputed, tomography, ct, scan, showedhypermetabolic, lesions, located, at, leftlung, right, adrenal, gland, but, not, inthe, primary, mediastinal, site, bthe, patient, reported, no, physical, symptomsand, received, repeat, tissue, biopsy, whichconï¬rmed, relapse, with, pmbcl, she, wastreated, with, each, cycle, dexamethasoneifosfamide, cisplatin, etoposide, regimenand, ibrutinib, bendamustine, cytarabine, therapy, chest, ct, scan, showedfigure, , summary, treatment, monitoring, tumor, response, patients, timeline, chart, with, thedates, treatment, monitoring, tumor, response, b, positron, emission, tomography, images, upperpanel, scan, relapsed, hypermetabolic, lesions, located, at, left, lung, right, adrenal, gland, beforecombined, treatment, lower, panel, complete, remission, achieved, after, four, cycles, nivolumab, plusgdp, chemotherapyrchop, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, daepochr, doseadjusted, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab, gdpergemcitabine, dexamethasone, cisplatinum, etoposide, rituximab, cr, complete, remission, pmbclprimary, mediastinal, large, bcell, lymphoma, dice, dexamethasone, ifosfamide, cisplatin, etoposideibc, ibrutinib, bendamustine, cytarabine, gdp, gemcitabine, dexamethasone, cisplatin, 0cjournal, international, medical, researchthat, right, adrenal, gland, lesion, had, partially, responded, while, lesions, leftlung, had, progressed, after, those, cycles, ofchemotherapy, patient, showed, gradeiv, myelosuppression, had, receiveblood, transfusion, treatment, moreover, acerebrospinal, ï¬uid, examination, showedthe, presence, atypical, lymphocytes, andno, symptoms, infection, central, nervous, system, were, observed, intrathecal, chemotherapy, cytarabine, , mg, methotrexate, mg, dexamethasone, , mg, thenadministered, no, atypical, lymphocyteswere, detected, by, repeated, cerebrospinalï¬uid, analysis, these, ï¬ndings, highly, suggested, potential, risk, metastasis, thecentral, nervous, systemtreatmentbecause, disease, had, progressed, withsevere, myelosuppression, there, were, nostandard, chemotherapy, guidelines, or, alternative, treatment, options, patientother, salvage, treatments, her, refractorydisease, needed, be, considered, aftermuch, discussion, with, patient, herfamily, she, declined, autologous, hematopoietic, stem, cell, transplantation, receivedcombinedgemcitabine, mg, dexamethasone, , mg, cisplatinum, , mg, gdpchemotherapyand, offlabel, antipd1, antibody, nivolumab, , mg, after, four, cycles, combined, treatment, repeated, petct, scanshowed, thatshe, had, secondary, crb, she, received, two, more, cyclesof, combined, treatment, with, nivolumab, andgdp, chemotherapy, then, continuedsingle, nivolumab, maintenance, treatment, mg, since, her, ï¬rst, dose, may, she, received, , doses, nivolumab, shereported, moderate, fatigue, pyrexia, , days, after, each, administration, ofnivolumab, blood, tests, indicated, normalfunction, liver, kidney, thyroidfigure, , she, also, had, normal, bloodlevels, creatinine, albumin, globulin, lactate, dehydrogenase, aspartate, transaminasetotalaminotransferaseofalaninethey2b, neutrophilbilirubin, urea, nitrogen, during, thewhole, process, nivolumab, therapyfigureand, plateletcounts, were, decreased, ï¬rst, four, combined, therapies, because, toxicity, gdpchemotherapy, butrecovered, tonormal, levels, during, continued, nivolumabmaintenance, monotherapy, figure, 2cfurthermore, no, adverse, signs, symptoms, were, observed, lungs, brainand, skin, at, time, submissionshe, has, remained, cr, longer, than, months, with, continued, nivolumab, maintenance, therapyethics, approval, obtained, from, theethicalcommittee, yuebei, peopleshospital, written, informed, consent, wasobtained, from, patient, analysis, ofthe, samples, publicationdiscussiontreatment, outcome, are, critical, managing, pmbcl, because, there, no, established, standard, approachthe, ï¬rstlinetreatment, pmbcl, generally, thesame, as, that, diffuse, large, bcell, lymphoma, including, rchop, daepochr, relapse, pmbcl, usually, occurs, theï¬rst, , , months, after, completion, offrontline, therapy, with, lower, incidenceapproximately, than, diffuselarge, bcell, lymphoma19, there, are, varioussecondlineregimens, patients, with, rrpmbcl, includingthe, rituximab, ifosfamide, carboplatin, andetoposide, regimenthe, rituximab, dexamethasone, cytarabine, cisplatin, regimen, rituximabgdp12, because, alack, standard, guidelines, or, treatmentoptions, pmbcl, outcome, greatlydepends, on, patients, response, theregimen, thisremains, poordespite, these, secondline, salvage, chemotherapies, subsequent, autologous, hematopoietic, stem, cell, transplantation912immunochemotherapyresponse, 0chuang, et, alfigure, , blood, test, values, during, whole, treatment, process, since, first, dose, nivolumab, firstfour, cycles, were, nivolumab, plus, gdp, chemotherapy, nivolumab, maintenance, monotherapy, wasadministered, since, fifth, cycle, thyroxine, thyrotropin, ft3, ft4, levels, b, levels, creatininealbumin, globulin, lactate, dehydrogenase, aspartate, transaminase, alanine, aminotransferase, total, bilirubinand, urea, nitrogen, c, neutrophil, platelet, countsft4, free, thyroxine, ft3, free, triiodothyronine, gdp, gemcitabine, dexamethasone, cisplatin, 0cjournal, international, medical, researchin, recent, years, strategies, focusing, on, thecheckpoint, blockade, have, been, developedin, tumor, immunotherapy10, therapeuticantibodies, targeting, pd1pdl1, axispossess, clinical, activity, an, acceptablesafety, proï¬le, treating, growing, list, oflymphomas13solid, tumors, bcellbased, on, clinical, study, , patientswith, rrpmbcl, pidilizumab, approvedby, us, fda, treatment, adult, andpediatric, patients, with, rrpmbcl, another, antibody, nivolumab, has, beengranted, approval, treating, several, solidmalignancies, chl, however, studiesregarding, application, nivolumab, forpmbcl, are, limited, only, ï¬ve, reportshave, described, using, nivolumab, treatment, pmbclrrpmbcl, table, , asfollows, phase, i, study, published, intwo, patients, with, pmbcl, wererecruited, treated, with, nivolumab, atdoses, , or, , mgkg, every, , weeks, afterprevious, systemic, treatments14, no, objective, responses, were, observed, previous, study, another, phase, i, study, onewithrefractorypatient, with, pmbcl, received, combinedtherapy, nivolumab, ipilimumaband, died, during, therapeutic, process15recently, two, reports, showed, potentialtherapeutic, efï¬ciency, nivolumab, forpatientspmbclrrpmbcl, who, showed, failure, with, conventional, immunochemotherapy1617, both, ofthese, two, cases, had, immunerelated, adverseeffects, during, antibody, treatment, process, one, patient, with, highgrade, neutr, ia, had, nivolumab, stopped, temporarilyand, treated, with, intravenous, immunoglobulin16, other, patient, with, zosterreactivation, controlled, by, administration, valacyclovir17, recently, zinzaniand, colleagues, showed, that, combined, treatment, nivolumab, brentuximab, vedotin, had, promising, antitumor, activity, amanageable, safety, proï¬le, patients, withrrpmbcl18, phase, ii, study, patients, were, recruited, treated, withnivolumab, , mgkg, brentuximab, vedotin, , mgkg, every, , weeks, objectiveresponse, rate, , , achievedtable, , reports, regarding, application, nivolumab, primary, mediastinal, large, bcell, lymphomarelapsedand, refractory, primary, mediastinal, large, bcell, lymphomanumberof, cases, dosecombinedtreatmentadverse, events, or, , mgkg, mgkgipilimumabresponseyesnonono, ofpatientsreportslesokhin, amet, al, ansell, s, et, alwright, zet, al, yassin, r, et, alzinzani, mgkgnonohighgrade, neutr, iayeszoster, reactivationyes, mgbrentuximabneutr, iapl, et, al, vedotinthrombocyt, iaand, peripheralneuropathy, patientspresent, case, mgkggdpmild, fatigue, pyrexiayeschemotherapynote, , means, not, indicated, report, 0chuang, et, alofcyclescombinedcr, , achieved, partial, remission, patients, , them, had, drugrelatedadverse, events, most, common, wereneutr, ia, thrombocyt, ia, peripheral, neuropathy18, present, case, weattempted, several, available, approaches, intreating, patients, relapsed, disease, butfailed, control, progress, massafter, much, discussion, with, patient, andher, family, we, considered, an, offlabel, nivolumab, gdp, chemotherapy, as, salvagetreatmentfor, patient, september, her, second, cr, achieved, afterfourtreatmentcurrently, with, continued, nivolumab, maintenance, monotherapythe, patient, hasremained, cr, longer, than, , monthsimmunerelated, adverse, events, that, areassociated, with, checkpoint, blockade, oftenstart, within, ï¬rst, few, weeks, monthsafter, treatment, but, can, occur, any, time, andin, any, an, most, common, immunerelated, adverse, events, are, hypothyroidismnausea, diarrhea, pyrexia, fatigue1920in, present, case, we, were, concernedabout, immunerelated, an, damage, sincethe, ï¬rst, dose, nivolumab, patientreported, moderate, fatigue, pyrexiaafter, each, administration, nivolumaband, soon, recovered, within, , , daysblood, testing, performed, during, thewhole, therapeutic, process, datawere, reviewed, analyzed, blood, levelsof, thyroxine, thyrotropin, free, triiodothyronine, free, thyroxine, indicated, no, thyroiditisfigure, 2a, our, patient, alsoshowed, normal, metabolic, data, during, thewhole, process, nivolumab, therapyfigureand, plateletcounts, were, decreased, ï¬rst, four, combined, therapies, because, toxicity, gdpchemotherapy, but, they, then, recovered, tonormal, levels, during, continued, nivolumabmaintenance, monotherapy, figure, 2c2b, neutrophilunlike, otherarelymphomas, prognosticbiomarkersinpmbcl12, some, serum, molecules, such, aslackinglargelyccl17, cd163, are, considered, aspotential, biomarkers, predicting, andmonitoring, responses, detection, ofrelapses, patients, with, hodgkin, lymphoma1221, role, serum, biomarkers, inpmbcl, remainsinvestigatedradiological, imaging, should, only, be, usedin, patients, who, have, new, clinical, symptomsor, signs, suggestive, relapse, but, not, inasymptomatic, patients922betoto, best, our, knowledge, theï¬rst, reported, case, nivolumab, plus, gdpchemotherapy, that, induced, cr, with, nosevere, immunerelated, an, damage, apatient, with, rrpmbcl, we, also, reportthe, longest, followup, observation, successful, application, nivolumab, apatient, with, rrpmbclthis, report, supplements, limited, literature, nivolumab, fortreatment, ofpmbclrrpmbcl, provides, implications, clinical, trial, design, regarding, thepotential, use, nivolumab, treatment, ofrrpmbcl, further, investigation, needs, beperformed, potential, application, singleor, combined, use, nivolumab, patientswith, rrpmbcl, who, experience, failure, withconventional, therapeutic, approachesdeclaration, conflicting, interestthe, authors, declare, that, there, no, conï¬ict, ofinterestfundingthis, research, received, no, speciï¬c, grant, from, anyfunding, agency, public, commercial, ornotforproï¬t, sectorsorcid000000034880orcid, idyuan, liureferences, martelli, m, ferreri, di, rocco, et, alprimary, mediastinal, large, bcell, lymphomacrit, rev, oncol, hematol, , , , 0cjournal, international, medical, research, savage, kj, monti, s, kutok, jl, et, al, themolecular, signature, mediastinallargebcell, lymphoma, differs, from, that, otherdiffuse, large, bcell, lymphomas, sharesfeatures, with, classical, hodgkin, lymphomablood, , , , rosenwald, wright, g, leroy, k, et, almolecular, diagnosis, primary, mediastinalb, cell, lymphoma, identiï¬es, clinically, favorable, subgroup, diffuse, large, b, cell, lymphoma, related, hodgkin, lymphoma, j, expmed, , , , mottok, wright, g, rosenwald, et, almolecular, classiï¬cation, primary, mediastinal, large, bcell, lymphoma, using, routinelyavailable, tissue, specimens, blood, , , swerdlow, sh, campo, e, pileri, sa, et, althe, , revision, ofthe, world, healthanization, classiï¬cation, lymphoid, neoplasms, blood, , , , xumonette, zy, zhou, j, young, khpd1, expression, clinical, pd1, blockadelymphomas, blood, , bcell, van, roosbroeck, k, ferreiro, jf, tousseynt, et, al, genomic, alterations, jak2and, pdl, loci, occur, broad, spectrum, oflymphoid, malignancies, genes, chromosomescancer, , , rearrangements, twa, dd, chan, fc, benneriah, s, et, algenomicinvolving, programmed, death, ligands, are, recurrent, primary, mediastinallymphomablood, , , large, bcell, cwynarski, k, marzolini, mav, barringtonsf, et, al, management, primary, mediastinal, bcell, lymphoma, british, societyfor, haematology, good, practice, paper, brj, haematol, , , , ribas, wolchok, jd, cancer, immunotherapy, using, checkpoint, blockade, science, , , hematologyoncology, cancer, approvals, safety, notiï¬cations, available, online, url, wwwfdagovdrugsinformationondrugsapproveddrugsucm610670htmdrugsapproveddrugsucm610670htmwwwfdagovdrugsinformationon, lees, c, keane, c, gandhi, mk, et, al, biologyand, therapy, primary, mediastinal, bcelllymphoma, current, status, future, directions, br, j, haematol, , , , goodman, patel, sp, kurzrock, rpd1pdl1, immunecheckpoint, blockadein, bcell, lymphomas, nat, rev, clin, oncol, , , lesokhin, am, ansell, sm, armand, p, et, alnivolumab, patients, with, relapsed, orrefractory, hematologic, malignancy, preliminary, results, phase, ib, study, j, clin, oncol, , , ansell, s, gutierrez, me, shipp, ma, et, ala, phase, , study, nivolumab, combination, with, ipilimumab, relapsed, or, refractory, hematologic, malignancies, checkmate, blood, , , , wright, z, brown, highgrade, neutr, ia, patient, successfully, treated, withnivolumab, refractory, primary, mediastilymphoma, blood, adv, , nal, bcell, yassin, r, hajeer, alshieban, s, et, al, hlagenotype, response, nivolumab, therapy, relapsed, refractory, primary, mediastinal, bcell, lymphoma, curr, res, transl, med, , , zinzani, pl, santoro, gritti, g, et, alnivolumab, combined, with, brentuximabvedotin, forrelapsedrefractory, primarymediastinal, large, bcell, lymphoma, efï¬cacyand, safety, from, phase, ii, checkmate, study, j, clin, oncol, , , , postow, ma, sidlow, r, hellmann, mdimmunerelated, adverse, events, associatedwith, immune, checkpoint, blockade, n, englj, med, , , , zinzani, pl, ribrag, v, moskowitz, ch, et, alsafety, tolerability, pembrolizumab, inpatients, with, relapsedrefractory, primarylymphoma, bloodmediastinal, , large, bcell, jones, k, vari, f, keane, c, et, al, serumcd163, tarc, as, disease, response, biomarkers, classical, hodgkin, lymphomaclin, cancer, res, , , for, cheson, bd, fisher, ri, barrington, sf, et, alinitial, evaluationrecommendationsstagingofhodgkin, nonhodgkin, lymphoma, thelugano, classiï¬cation, j, clin, oncol, , assessmentandresponse, 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,29,30,31,33,34,36,37,39,40,41,42,44,45,46,48,49,50,52,54,55,57,58,59,60,61,63,64,65,67,70,72,73,74,78,80,82,84,85,88,91,92,93,94,95,98,99,100,103,104,105,107,108,111,112,114,115,119,122,123,124,126,128,130,132,133,134,136,137,138,143,144,146,148,150,153,155,157,159,160,161,164,165,166,167,169,170,172,173,176,178,179,184,186,189,190,192,193,197,198,199,200,201,203,204,210,216,217,221,223,224,227,230,234,236,237,238,239,240,241,242,244,245,248,253,254,255,264,269,278,279,280,281,285,286,292,296,301,309,310,325,326,327,330,335,338,345,346,351,355,358,359,369,372,374,375,378,379,380,384,385,386,389,393,397,398,400,407,411,414,415,426,432,437,446,449,451,452,453,455,458,460,461,469,470,476,483,492,499,507,512,513,521,529,535,542,551,552,559,560,567,569,572,576,579,582,586,588,589,593,606,629,633,636,637,644,660,669,670,672,673,683,688,691,696,699,703,707,713,719,729,732,733,747,748,750,755,763,766,767,775,778,783,784,785,788,795,809,815,818,828,832,834,836,838,849,850,853,863,873,880,881,882,886,889,891,893,894,899,923,926,932,956,959,968,978,979,981,982,994,997,1029,1035,1036,1057,1061,1066,1072,1073,1077,1087,1089,1093,1095,1105,1111,1132,1160,1164,1166,1194,1198,1203,1214,1219,1226,1239,1241,1248,1266,1288,1297,1306,1317,1362,1363,1365,1366,1371,1372,1374,1388,1408,1409,1414,1426,1435,1436,1440,1445,1448,1456,1458,1460,1462,1473,1474,1491,1495,1505,1510,1511,1512,1536,1539,1545,1547,1559,1561,1568,1584,1605,1645,1647,1649,1656,1657,1676,1679,1681,1689,1697,1708,1728,1782,1790,1793,1803,1810,1821,1830,1839,1840,1843,1847,1850,1853,1858,1873,1883,1918,1928,1940,1958,1964,1965,1968,1970,1976,2025,2036,2060,2091,2096,2124,2135,2141,2146,2153,2154,2158,2164,2166,2211,2234,2306,2334,2337,2343,2348,2379,2422,2492,2495,2527,2531,2536,2545,2571,2604,2613,2634,2688,2694,2743,2775,2784,2788,2819,2846,2891,2941,2942,2964,2995,3002,3050,3061,3091,3114,3142,3154,3174,3190,3217,3224,3256,3268,3297,3298,3330,3369,3445,3450,3451,3455,3506,3517,3544,3547,3548,3587,3588,3603,3606,3609,3633,3695,3740,3742,3779,3787,3804,3828,3894,3919,3979,3982,3991,3993,4010,4026,4029,4046,4076,4078,4084,4316,4339,4377,4526,4560,4627,4916,4937,4956,5030,5047,5078,5082,5096,5209,5326,5412,5430,5562,5586,5611,5613,5620,5632,5658,5668,5680,5753,5772,5800,5838,5887,5921,6082,6146,6161,6189,6275,6355,6589,6640,6711,6745,6771,6852,6981,7098,7099,7210,7393,7448,7469,7511,7532,7548,7626,7704,7796,7825,7884,7937,7971,7974,8078,8271,8276,8351,8432,8532,8584,8633,8668,8691,8886,8951,8965,8977,9039,9268,9289,9322,9468,9504,9624,9774,9825,9949,10033,10090,10349,10387,10510,10559,10742,10876,11023,11051,11163,11164,11215,11219,11350,11778,12072,12079,12100,12131,12166,12544,12600,12816,13060,13194,13404,13777,13868,13984,14012,14075,14106,14163,14244,14278,14394,14858,14951,15124,15139,15172,15572,15931,16061,16424,17323,17693,17847,17895,17979,18043,18246,18542,18555,19343,19423,19472,19522,19663,19714,19841,19892,20020,20039,20091,20156,20446,20478,20756,21302,21335,21599,21680,21999,22006,22163,22186,22412,22449,22625,22673,23103,23107,23994,24104,24241,24301,24391,24404,24605,24719,24780,25040,25157,25219,25343,26201,26909,27564,28795,28913,29148,29416,29873,30096,30119,30129,30352,30444,30786,31271,31979,32036,33249,34473,34536,34704,34918,35346,35658,36585,36938,37297,37440,37530,38195,38529,38615,38921,39399,39582,40046,40097,40367,40376,41041,41261,41289,41290,41369,41958,42214,42275,42732,45142,45323,45540,45914,46930,47094,49278,50491,50589,50918,51040,52485,53406,53423,53450,54223,55409,55500,56186,56828,57150,57802,57852,57942,58051,58274,58665,59221,59936,61494,62366,62606,63327,63881,63912,64292,65239,65594,65843,66030,66358,66392,66687,66777,67272,67920,67978,68432,68922,69674,69853,70920,74338,74418,74917,79517,79951,83435,83451,84020,84061,84585,84601,84748,85121,85167,85566,85591,85752,86592,86677,86861,87169,87342,87433,87593,88023,89645,89882,89984,90153,90262,90475,91370,91936,93063,93197,93230,94396,94984,95133,95471,95803,95812,96541,97512,97718,97900,98749,98938,99010,100005,100251,100706,102235,102359,102361,103142,103769,103944,103980,104590,104639,104813,105297,106044,106128,106279,107016,108024,108093,108388,108642,108758,109536,110071,110130,110161,110205,110669,110796,111241,111715,112504,112795,113131,113138,113366,113889,114166,114551,114722,114948,115483,115884,115902,116106,116276,117144,117715,117933,118898,119540,119792,120155,120231,121128,121206,121525,121552,121680,121745,122921,123081,123832,125625,127277,127315,128061,128418,128744,128861,130927,131482,131487,132204,132764,133082,133370,133856,134052,134315,134318,134536,134783,134927,135308,135952,136337,137080,137163,137582,137819,137839,139605,140928,141661,141681,141984,142589,142624,142848,143586,143908,143923,144026,144235,144452,144574,144736,144883,145498,145611,146297,147055,147171,147857,148067,148540,149756,150106,150998,151601,152066,152077,152171,152617,153437,153601,154261,154718,155028,155089,156009,156048,156588,157968,158099,158575,158734,158784,159186,159515,159675,159834,159850,160142,160726,160972,161983,162121,162343,162462,163722,164029,164209,164281,166330,167170,167235,167992,168198,168271,168496,168724,168990,169667,169995,170860,170881,170931,171084,171213,171293,171361,171600,172037,172069,172176,172969,173981,174039,175029,175111,175306,175533,175556,175790,176705,176909,178649,178770,178818,179654,180571,181053,182003,182106,182297,182907,183009,183320,184206,184358,184515,184533,184879,185875,186262,186326,187112,189569,190056,190957,191454,191742,192142,192417,193212,193525,194741,195914,196500,196958,197142,197912,198395,198543,198604,198745,199381,199522,199803,200644,201892,201971,202099,203239,203633,203798,204501,204583,204668,204891,205225,205349,205557,206499,206513,206695,207366,207435,207739,207871,209096,209535,209718,210039],[84.0,41.0,11.0,6.0,8.0,6.0,3.0,10.0,5.0,4.0,6.0,9.0,5.0,1.0,2.0,16.0,6.0,7.0,4.0,8.0,1.0,5.0,1.0,3.0,5.0,3.0,1.0,2.0,1.0,4.0,6.0,2.0,20.0,8.0,7.0,1.0,3.0,9.0,1.0,1.0,4.0,1.0,8.0,22.0,1.0,3.0,2.0,4.0,3.0,4.0,1.0,2.0,1.0,5.0,1.0,1.0,2.0,10.0,2.0,1.0,7.0,3.0,2.0,3.0,2.0,1.0,1.0,1.0,2.0,2.0,6.0,4.0,1.0,2.0,1.0,14.0,1.0,3.0,2.0,1.0,2.0,4.0,1.0,3.0,3.0,2.0,1.0,2.0,5.0,2.0,1.0,8.0,9.0,3.0,2.0,1.0,1.0,1.0,2.0,1.0,3.0,7.0,1.0,4.0,7.0,1.0,4.0,1.0,2.0,1.0,2.0,1.0,6.0,1.0,11.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,3.0,1.0,8.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,3.0,4.0,6.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,9.0,4.0,2.0,1.0,1.0,1.0,1.0,5.0,1.0,2.0,7.0,2.0,1.0,6.0,1.0,4.0,1.0,5.0,1.0,2.0,1.0,1.0,1.0,2.0,5.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,12.0,3.0,1.0,1.0,5.0,2.0,1.0,1.0,2.0,2.0,4.0,2.0,2.0,5.0,3.0,1.0,1.0,2.0,5.0,2.0,1.0,8.0,2.0,1.0,2.0,1.0,3.0,10.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,6.0,1.0,2.0,1.0,1.0,1.0,5.0,2.0,4.0,1.0,2.0,3.0,1.0,4.0,1.0,1.0,1.0,4.0,1.0,2.0,2.0,1.0,2.0,1.0,3.0,1.0,2.0,1.0,2.0,3.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,2.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,3.0,2.0,7.0,1.0,3.0,1.0,1.0,4.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,8.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,3.0,1.0,2.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,3.0,3.0,2.0,1.0,1.0,4.0,1.0,1.0,8.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,2.0,3.0,1.0,6.0,3.0,1.0,4.0,3.0,13.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,5.0,1.0,1.0,4.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,37.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,4.0,1.0,8.0,1.0,1.0,3.0,7.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,7.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,18.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,12.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,3.0,2.0,2.0,1.0,15.0,1.0,1.0,1.0,1.0,4.0,2.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,7.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,5.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,8.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n",
      "|[, gastric, cancer, gc, persists, as, a, worldwide, public, health, crisis, according, to, the, american, cancer, society, the, 5yearsurvival, rate, of, gc, remains, at, , worldwide, and, , withinthe, united, states1, these, survival, statistics, have, increasedoverall, since, the, 1980s, when, the, 5year, survival, rate, for, stageii, disease, was, below, , and, near, , for, stage, iiib, andhigher1, with, the, development, of, chemotherapies, such, as, platinums, and, taxanes, survival, beyond, stage, ii, increased, steadilyto, , although, chemotherapies, improved, overall, survivalthis, is, not, as, dramatic, as, that, in, other, solid, malignancies, suchas, prostate, or, breast, furthermore, even, with, the, identificationof, molecular, targets, such, as, brca, mutations, and, her2amplifications, clinical, success, with, available, therapies, hasbeen, minimal23, a, recent, clinical, trial, with, olaparib, a, polyadp, ribose, polymerase, inhibitor, showed, little, efficacy, compared, to, standard, of, care4, although, a, subset, of, gastric, diseasehas, her2, amplification, monoclonal, antibodies, against, her2have, demonstrated, very, limited, success, in, gc, unlike, theresponse, seen, in, her2, positive, breast, cancer5, it, is, clear, that, department, of, oncology, wayne, state, university, school, of, medicinedetroit, mi, usacorresponding, authorasfar, s, azmi, phd, department, of, oncology, wayne, state, university, schoolof, medicine, karmanos, cancer, institute, , john, r, hwcrc, , detroitmi, , usaemail, azmiakarmanoscreative, commons, cc, by, this, , is, distributed, under, the, terms, of, the, creative, commons, attribution, , license, creativecommonslicensesby40which, permits, any, use, reproduction, and, distribution, of, the, work, without, further, permission, provided, the, original, work, is, attributed, as, specified, on, the, sage, and, , access, pages, ussagepubcomenusnam, accessatsage, 0ctechnology, in, cancer, research, , treatmentmore, work, is, needed, to, elucidate, the, underlying, moleculardrivers, and, resistance, mechanisms, in, gcgastric, cancer, is, classified, mainly, using, either, the, laurenclassification, or, the, world, health, anization, who, criteria, the, lauren, classification, compares, tumors, based, ongrowth, invasion, pattern, with, , subtypes, intestinal, well, differentiated, diffuse, poorly, differentiated, and, intermediatemixed67, the, majority, of, patients, outside, us, with, gc, areyounger, 60years, old, and, have, the, poorly, differentiated, diffuse, subtype, which, is, located, within, the, distal, portion, of, thestomach, characterized, by, poor, cellular, differentiation, and, highintratumor, heterogeneity, this, subtype, has, poorer, outcomesdue, to, its, widespread, infiltration, and, invasive, nature, of, thedisease78, conversely, within, the, united, states, the, pathologyof, gc, is, similar, to, that, of, malignancies, found, within, the, gastroesophageal, junction8, older, patients, are, primarily, impactedand, the, disease, is, commonly, well, differentiated, intestinalthe, welldifferentiated, subtype, is, found, in, the, cardia, or, lowerregion, of, the, stomach, with, welldefined, glandular, structuresand, growth, pattern, the, who, designation, for, gc, was, createdin, , and, expands, vastly, on, the, lauren, classification67there, are, , subtypes, tubular, adenocarcinoma, papillary, adenocarcinoma, mucinous, adenocarcinoma, poorly, cohesivesignet, ring, cell, carcinoma, and, mixed, carcinoma67, similarities, exist, between, the, lauren, and, who, classificationssignetring, cell, carcinoma, comparable, to, poorly, differentiatedgc, is, steadily, increasing, in, incidence, within, the, united, statesand, around, the, world9, this, increase, is, attributed, to, , eradication, efforts, of, helicobacter, pylori, a, pathogen, known, toinduce, intestinal, type, gc, , increases, in, genetic, predisposition, to, genes, such, as, ecadherin, cdh1, hypermethylationand, , less, screening, and, detection, due, to, the, low, riskpopulation, within, the, united, states, compared, to, other, regionssuch, as, japan10here, we, aim, to, analyze, the, molecular, signatures, as, well, asdifferences, between, lauren, classified, gcs, we, also, aim, tounderstand, the, molecular, differences, between, male, and, femalepatients, with, gc, we, chose, to, look, solely, at, lauren, classifiedcancers, within, this, , due, to, its, established, use, within, themedical, community, as, well, as, its, availability, and, relevancewithin, publicly, available, data, sets, our, overarching, goal, is, toidentify, and, dissect, some, of, the, heterogeneous, aspects, of, gcthat, are, commonly, overlooked, within, the, literaturemethodsoncomine, database, searchoncomine, compendia, bioscience, was, used, for, analysis, andvisualization, three, separate, data, sets, were, used, to, explore, theup, and, downregulation, of, lauren, subtypes, of, gc, chen, gastric, mol, biol, cell, , mrna, derrico, gastric, europeanjournal, dataset2, , mrna, and, cho, gastric, clinicalcancer, research, , mrna, for, the, nonsubtyped, gc, analysis, we, have, used, , separate, data, sets, cui, gastric, nucleicacids, research, , mrna, wang, gastric, medicaloncology, , mrna, and, cho, gastric, clinical, cancerresearch, , mrna, to, find, highly, ranked, genes, weselected, our, subtype, of, interest, or, gc, compared, to, normaland, assessed, upregulated, or, downregulated, genes, we, averaged, the, fold, changes, for, genes, in, the, individual, analyses, andhave, used, the, computed, p, values, provided, by, the, oncominesoftwarekyoto, encyclopedia, of, genes, and, genomes, pathwayanalysisto, identify, pathways, involved, in, the, genes, found, to, be, upregulated, or, downregulated, from, our, oncomine, analysis, weutilized, the, kyoto, encyclopedia, of, genes, and, genomesmirwalk, database, analysismirwalk, database, university, of, heidelberg, was, used, foranalysis, of, genemicrornas, mirna, interactions11druggene, interaction, analysisdgidb, database, was, used, to, identify, druggable, targets, withinour, genes, found, to, be, differentially, expressed12protein, databasethe, human, protein, atlas, available, from, httpwwwproteinatlas, was, used, to, identify, survival, curves, in, stomach, cancerwith, the, following, proteins, cwd43, stage, iiv, survivalcurves, wwwproteinatlasensg00000109182cwh43pathologystomach¾cancer, metll7a, stage, iivwwwproteinatlasensg00000185432mettl7apathologystomach¾cancer, slc2a12, stage, iiv, wwwproteinatlasensg00000146411slc2a12pathologystomach¾cancer, mal, stage, iiv, wwwproteinatlasensg00000172005malpathologystomach¾cancer, dmrt1, stage, iiv, wwwproteinatlasensg00000137090dmrt1pathologystomach¾cancerall, are, available, from, v19proteinatlasproteinprotein, interaction, networksstring, , database, was, used, to, identify, proteinproteininteractions, for, the, following, genes, cwh43, metll7aslc2a12, mal, btd, capn9, adam17, epb41, tom1l1and, dmrt113geo, database, analysisthe, data, discussed, within, this, publication, have, been, previously, deposited, in, ncbis, gene, expression, omnibus, andare, accessible, through, geo, series, accession, numbergse118916, wwwncbinlmnihgovgeoqueryacccgiacc¼gse118916, 0csexton, et, altable, , top, upregulated, genes, found, in, gastric, cancer, cohort, viaoncomine, databaseagene, namefold, change, diffusevs, normal, averagepublicationsp, valuefoundinhbacol1a2cldn1cdh11col3a1col5a2col1a1timp1sulf1spon2549e7949e12664e6117e10241e6289e6299e6383e6465e6644e10ap, values, were, calculated, using, oncomine, softwarestatisticsoncomine, software, and, human, protein, atlas, providedstatisticsethical, approvalthe, data, are, not, obtained, from, patients, and, does, not, requireinstitutional, review, board, approvalresultsgenetic, analysis, of, upregulated, gc, geneswithin, the, literature, various, genetic, aberrations, have, beenproposed, that, can, serve, as, prognostic, or, therapeutic, markersincluding, sox17, hypermethylation, bcl2, transforminggrowth, factor, beta, tgfb, vascular, endothelial, growth, factorvegfr, and, her21418, many, of, these, proposed, markersare, studied, extensively, and, do, not, serve, as, ideal, targets, dueto, their, limited, clinical, utility, as, either, drug, targets, or, predictors, of, therapeutic, response, some, examples, of, this, include, lesssuccessful, attempts, to, target, her2, with, monoclonal, antibodiesand, the, use, of, tgfb, inhibitors, which, although, promisinghave, proven, to, be, highly, toxic1920, additionally, these, targetshave, demonstrated, limited, clinical, utility, due, to, the, crosstalkbetween, tgfb, and, other, signaling, pathways, such, as, ras, aknown, nontargetable, protein2122, while, vegf, inhibitors, areused, as, a, therapeutic, modality, in, gc, they, do, not, improveoverall, survival23, an, indepth, investigation, of, the, molecularmechanisms, are, urgently, and, investigations, need, to, be, distinctfrom, the, commonly, studied, and, clinically, intractable, targetsalthough, this, is, the, case, discrepancies, exist, within, the, literature, as, some, groups, look, at, the, molecular, composition, of, gc, asa, whole, while, others, focus, on, differences, within, the, laurenclassification, systemusing, the, oncomine, database, we, have, found, significantupregulation, in, several, understudied, genes, in, all, gcs, including, col3a1, col5a2, spon2, and, cdh11, table, , wealso, have, confirmed, the, upregulated, status, of, many, of, thegenes, found, within, the, literature, that, are, somewhat, well, knownsuch, as, inhba, a, gene, associated, with, poor, overall, outcomes24, but, are, still, understudied, claudin, , cldn1, hasbeen, found, to, be, highly, expressed, in, gc, and, is, a, poor, predictive, disease, marker, by, mediating, tumor, necrosis, factorainduced, cell, migration, enhancement, of, proliferation, andmetastasis, while, sulf1, has, been, found, to, be, significantlyhypomethylated, causing, significant, downregulated, proteinexpression2528, this, sulf1, downregulation, may, be, indicativeof, a, posttranslational, modification, feedback, loop, or, degradation, event, via, proteinprotein, interactions, but, is, still, unclearnot, surprisingly, a, significant, underrepresentation, was, notedwhen, comparing, publications, related, to, these, genes, over, publications, to, the, commonly, studied, genes, such, as, mapkpi3k, and, tp53, over, , total, publicationsgenetic, analysis, of, upregulated, gc, genes, using, laurentype, classified, gcswe, stratified, the, data, sets, based, on, the, respective, lauren, distinguished, subtype, and, have, highlighted, the, vast, heterogeneticmolecular, landscape, within, the, poorly, differentiated, diffusewell, differentiated, intestinal, and, mixed, gc, subtypestable, , poorly, differentiated, gc, shares, many, similaritieswith, gc, overall, including, perturbations, in, various, collagentranscribing, genes, stimulation, of, pi3kakt, signaling, andperturbations, in, cellular, structural, components, this, is, a, dominant, subtype, throughout, the, world, for, reasons, we, have, previously, mentioned, due, to, the, overabundance, of, collagentranscribing, genes, we, wanted, to, explore, whether, a, potentialgenetic, link, exists, literature, search, identified, a, study, correlating, ehlersdanlos, syndrome, eds, a, disease, caused, bycollagen, gene, perturbations, to, the, development, of, gc29ehlersdanlos, syndrome, also, presents, with, gastrointestinalinvolvement, such, as, increased, rates, of, heartburn, which, is, arisk, factor, for, developing, esophageal, cancer3031, based, on, thelocation, of, these, gastric, tumors, within, the, stomach, that, is, inthe, proximal, stomach, near, the, esophagus, and, the, connectionbetween, gastric, and, esophageal, cancers, it, is, quite, possiblethere, may, be, a, much, stronger, correlation, between, eds, anddiffuse, gc, than, previously, thoughtwe, have, found, gc, overall, does, not, share, many, molecularsimilarities, with, the, welldifferentiated, subtype, of, gc, withinthe, scope, of, our, analysis, we, have, found, only, a, similaritycldn1, expression, claudin, , is, a, gene, involved, in, coding, forthe, protein, involved, in, epithelial, barrier, functions, and, is, part, ofthe, claudin, family, within, gc, cldn1, has, found, to, be, differentially, expressed, in, gc, and, has, been, found, to, be, upregulatedin, a, small, patient, population, being, linked, to, poor, survival, outcomes, indicative, of, an, oncogenic, function32, other, groupshave, found, claudin1, has, tumor, suppressive, activities, and, canreverse, the, epithelialtomesenchymal, transition, in, gc, cellsand, was, found, to, be, downregulated, in, intestinal, type, gc, in, aof, , patients, cohort3334, it, is, clear, that, work, needs, to, be, donein, order, to, elucidate, the, role, cldn1, plays, within, intestinaltype, gastric, tumors, as, it, has, differing, functions, based, on, the, 0ctechnology, in, cancer, research, , treatmenttable, , top, significantly, upregulated, genes, based, on, molecular, subtype, of, gastric, cancer, well, differentiated, poorly, differentiatedmixed, subtype, based, on, oncomine, databaseafold, change, diffusevs, normal, averagep, valuekegg, pathway, analysisgastric, cancersubtypegene, namethy1timp1bgncol1a2sulf1col6a3olfml2brab31thbs2col1a1ttyh3thy1cadube2ccldn1prc1dazap1atp11adcaf13mthfd1lcol6a3fbn1rcc2ahcytgif1fn1myo9bvcanlummcm4pi3kakt, focal, adhesion, ecm, receptor, proteoglycanspi3kakt, focal, adhesion, ecm, receptorimmune, component161e12124e11, hif, signaling238e11223e10139e9, metabolism585e9404e8361e9, membrane, trafficking118e8165e7232e23, transporter346e21202e8phagosome, pi3kakt, focal, adhesion, ecmreceptor, interactionpi3kakt, focal, adhesion, ecm, receptor, proteoglycansimmune, componentphenylpropanoid, biosynthesis, metabolic, pathways, biosynthesis, ofsecondary, metabolitesmrna, surveillance262e20, ubiquitinmediated, proteolysis650e15, cell, adhesion, tight, junction134e14, tubulin, binding, protein680e8768e19, metabolism, translocase971e8893e9109e7191e7161e9213e6733e9943e9ribosome, biogenesisone, carbon, metabolismpi3kakt, signaling, focal, adhesion, ecmreceptor, interactiontgfb, signalingcysteine, and, methionine, metabolismtgfb, signalingpi3kakt, signaling, focal, adhesion, ecmreceptor, interactionregulation, of, actin, cytoskeleton, proteoglycans, and, pathways, in, cancer224e6, membrane, trafficking260e6380e6833e6cell, adhesion, molecules, camsproteoglycans, in, cancerdna, replication, cell, cyclediffusediffusediffusediffusediffusediffusediffusediffusediffusediffuseintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalmixedmixedmixedmixedmixedmixedmixedmixedmixedmixedabbreviations, ecm, extracellular, matrix, kegg, kyoto, encyclopedia, of, genes, and, genomes, tgfb, transforming, growth, factor, betaap, values, were, calculated, via, oncomine, software, and, kegg, pathway, analysis, was, used, to, analyze, gene, functionliterature, many, of, the, processes, underlying, intestinal, gcinvolve, alterations, in, metabolism, and, cellular, crosstalktable, , it, is, not, surprising, that, the, intestinal, and, diffuse, gcsare, distinctly, different, but, we, did, find, similarity, with, thy1expression, both, having, similar, fold, changes, although, thisgene, has, not, been, investigated, in, gc, it, is, overexpressed, inthe, pancreatic, cancer, microenvironment35, further, investigation, may, be, needed, as, this, gene, may, have, importance, in, gcdevelopmentwe, finally, investigated, the, mixed, subtype, of, gc, a, subtypethat, is, commonly, overlooked, within, the, literature, table, interestingly, mixed, gc, has, some, similarities, to, the, diffusesubtype, including, pi3kakt, signaling, a, collagen, transcribinggene, and, upregulation, of, cellular, anizational, componentsinterestingly, we, have, found, the, genes, perturbed, within, thissubtype, are, involved, in, driving, a, number, of, genetic, diseasessuch, as, marfan, syndrome, fbn1, and, hypermethioninemiaahcy, research, has, shown, marfan, syndrome, due, to, aberrant, tgfb, signaling, can, induce, gc, development, in, a, murinemodel36, hypermethioninemia, which, can, go, undetected, foryears, was, found, to, induce, aggressive, cancers, by, protectingtumors, from, 5flurouracil, 5fuinduced, death, a, chemotherapy, commonly, used, to, treat, gc3738, it, is, likely, the, diffusesubtype, is, not, the, only, subtype, with, a, strong, genetic, link, butthe, mixed, subtype, may, have, a, stronger, genetic, component, thanpreviously, thought, we, hypothesize, some, of, the, genetic, diversity, within, gc, is, masked, when, analyzed, as, a, whole, whichfurther, supports, the, notion, of, this, disease, being, highlyheterogeneousgenetic, analysis, of, downregulated, gc, genesthere, are, about, twice, as, many, published, studies, looking, atupregulated, gc, genes, compared, to, downregulated, , vs, the, most, common, downregulated, gc, genes, are, influenced, in, part, by, aberrant, dna, methylation3940, other, thanthis, much, less, is, studied, pertaining, to, highly, significant, downregulated, genes, in, gc, using, the, oncomine, database, we, have, 0csexton, et, altable, , top, significantly, downregulated, genes, according, to, oncomine, database, in, gastric, canceragene, namelifrcwh43rdh12mfsd4mettl7aatp4bslc2a12ghrlmaladh7fold, change, diffusevs, normal, averagep, valuekegg, pathway, analysis, , , , , , , , , , 251e6cytokinecytokine, receptor, interaction, signaling, for, pluripotency, in, stem, cells279e9136e8220e5227e5165e10365e10617e8119e9947e8jakstat, signalingretinol, metabolism, metabolic, pathwaysoxidative, phosphorylation, metabolic, pathways, gastric, acid, secretiontransportercamp, signaling, neuroactive, ligandreceptor, interaction, growth, hormonesynthesis, secretion, and, actionglycolysisgluconeogenesis, fatty, acid, degradation, tyrosine, metabolism, retinolmetabolism, chemical, carcinogenesisabbreviation, kegg, kyoto, encyclopedia, of, genes, and, genomesap, values, were, calculated, via, oncomine, software, and, kegg, pathway, analysis, was, used, to, analyze, gene, functionfound, the, most, significant, downregulated, genes, were, lifrrdh12, msfd4, atp4b, ghrl, and, adh7, all, of, these, arepoorly, represented, within, the, literature, table, , we, haveinvestigated, the, survival, outcomes, of, select, genes, from, table, that, have, not, been, investigated, in, gastric, cancer, to, the, best, ofour, knowledge, these, genes, include, mettl7a, malslc2a12, and, cwh43, figure, 1a, we, found, a, trend, towardimproved, survival, with, upregulated, cwh43, and, downregulated, metll7awe, have, included, protein, interaction, networks, for, the, genes, we, have, obtained, using, the, string, databasefigure, 1be, slc2a12, interacts, with, akt1, a, commonly, studied, gene, of, interest, within, gc, known, to, contribute, to, chemoresistance41, although, many, of, the, interacting, proteins, are, not, aswell, studied, as, akt1, various, genes, such, as, mtus1, pgap3aldoa, and, pmp22, have, been, shown, within, the, literature, toonly, influence, gc, but, pancreatic, cancer, as, well4246, it, is, clearthat, further, investigation, into, these, understudied, specific, geneticinteraction, networks, are, needed, we, then, wanted, to, look, intowhether, any, of, these, genetic, aberrations, or, their, interactor, proteins, were, targetable, to, do, this, we, utilized, the, dgidb, mettl7a, is, a, methyltransferase, that, is, located, primarily, in, lipiddroplets, and, is, silenced, via, dna, methylation, in, thyroid, cancer47, there, is, a, variety, of, drug, interactions, within, the, networkof, mettl7a, including, cda, gemcitabine, cytaribine, deoxycytidine, lta4, h, kelatophan, ubenimex, and, a, variety, of, preliminary, drug, compounds, b2, m, pembrolizumab, qpctpramipexole, aldoa, a, variety, of, preliminary, compoundsand, hp, estradiol, pyridoxine, pembrolizumab, has, been, fdaapproved, for, the, treatment, of, advanced, staged, gc, with, positivepdl1, expression, b2m, acquired, mutations, were, found, to, conferresistance, to, pembrolizumab, in, other, malignancies48, but, little, isknown, in, gc, downregulation, of, these, genes, may, partiallyexplain, why, there, is, some, efficacy, issues, with, pembrolizumabor, other, chemotherapies, mal, encodes, a, membrane, proteinwithin, the, endoplasmic, reticulum, er, of, tcells, and, is, involvedin, myelin, biogenesis49, drug, interactions, within, the, networkinclude, acta1, kabiramide, c, latrunculin, ab, aplyronine, a, anda, variety, of, preclinical, compounds, limk1, dabrafenibpmp22, progesterone, and, mag, gsk249320, cwh43, isinvolved, in, cell, wall, biogenesis, and, involved, in, lipid, remodeling50, drugs, that, interact, with, the, protein, network, include, upp2fluorouracil, brivudine, understanding, the, genetic, landscape, ofgc, gene, interaction, networks, and, how, those, genes, respond, totherapies, may, explain, partially, why, this, disease, is, highly, resistant, to, conventional, chemotherapies, however, more, work, isneeded, to, understand, the, possible, underlying, resistance, mechanisms, within, subsets, of, gc, that, would, bring, forward, the, idealpopulations, that, benefit, from, conventional, and, commonly, usedtherapiesincreasing, interest, has, been, placed, around, small, rnasincluding, mirnas, involvement, within, gc, development5152we, wanted, to, investigate, the, interaction, networks, betweenthese, uncharacterized, genes, of, interest, bold, and, mirnasusing, the, mirwalk, database, we, found, mirna, to, interactwith, our, genes, of, interest, figure, 1fi, many, of, the, mirnasare, uncharacterized, in, gc, but, we, did, find, that, mirna612mir612, a, mettl7a, interacting, mirna, induces, pax8, atumorsuppressor, and, represses, foxm1, to, inhibit, angiogenesis, and, metastasis, of, gc53, our, labs, work, in, part, involves, studying, the, role, of, nuclear, export, and, mirna, expression, and, uncovering, ways, in, which, tumor, suppressive, mirnas, canbe, upregulated, within, the, nucleus, by, manipulating, nuclearexport, nuclear, export, via, xpo1, has, a, limited, role, in, exportingmirna, from, the, nucleus, to, the, cytosol, rather, than, its, nuclearexport, family, member, xpo5, which, exports, the, majority, ofcellular, mirnas54, xpo1, overexpression, was, found, to, be, atherapeutic, target, in, gc, and, we, have, found, blocking, the, protein, with, the, small, fda, approved, molecule, selinexor, xpovio, influences, the, expression, of, a, subset, of, tumorassociatedmirnas55, furthermore, we, have, found, via, small, rnasequencing, that, after, xpo1, inhibition, with, selinexor, as, well, 0ctechnology, in, cancer, research, , treatmentfigure, , gastric, cancer, is, a, highly, heterogeneous, disease, a, survival, curves, taken, from, the, human, protein, atlas, for, cwh43, mettl7aslc2a12, and, mal, bd, protein, interaction, networks, for, cwh43, mettl7a, slc2a12, and, mal, taken, from, the, string, database, ehmirna, interaction, networks, found, from, top, interactions, with, cwh43, mettl7a, slc2a12, and, mal, in, the, mirdb, as, the, second, generation, inhibitor, kpt8602, mir7977cwh43, interacting, mirna, is, significantly, upregulated, foldchange, , p, ¼, 392e23, and, fold, change, , p, ¼, 546e, in, the, early, stage, diffuse, gastric, cell, line, snu1, suggestiveof, the, tumor, suppressive, role, of, this, mirna, the, connectionbetween, nuclear, export, and, cancerspecific, mirnas, in, gc, has, 0csexton, et, altable, , top, significantly, downregulated, genes, based, on, molecular, subtype, of, gastric, cancer, well, differentiated, poorly, differentiatedmixed, subtype, based, on, oncomine, databaseagenenamemt1gmt1fgcnt2slc9a1ppfibp2dbtmt1mpxmp2mt1hgsta2malpga3sidt2adrb2brp44, lsstgcnt2ckmt2rab27astk32bfgapxmp2nrxn1gsta2pkibpou2af1slc22a23aqp4mlxcxcl14fold, change, diffuse, vsnormal, averagep, value, kegg, pathway, analysisgastric, cancersubtype, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 143e4, mineral, absorption213e10, mineral, absorption597e7, glycosphingolipid, biosynthesis, metabolism762e7, transporter150e9654e4, valine, leucine, isoleucine, degradation, propionate, metabolism, metabolicpathwayperoxisome903e7172e9113e6, mineral, absorption231e9, glutathione, metabolism, drug, metabolism, platinum, drug, resistancepathways, in, cancer, chemical, carcinogenesis881e11, ribosome, biogenesis454e12, protein, digestion, and, absorption199e10, 103e12, camp, signaling, neuroactive, ligandreceptor, interaction188e12, mitochondrial, biogenesis422e8camp, signaling, neuroactive, ligandreceptor, interaction, gastric, acidsecretion, growth, hormone, synthesis, secretion, and, action206e12, glycosphingolipid, biosynthesis, metabolic, pathways537e8, arginine, and, proline, metabolism, metabolic, pathways258e12, membrane, trafficking156e9, metabolism318e10, membrane, trafficking175e8190e7, cell, adhesion, molecules, cams155e6, glutathione, metabolism, drug, metabolism, platinum, drug, resistanceperoxisomepathways, in, cancer, chemical, carcinogenesis184e6890e7111e5, anic, acid, transporters384e6, bile, secretion, vasopressinregulated, water, absorption139e5139e5, cytokinecytokine, receptor, interaction, viral, protein, interaction, chemokineinsulin, resistance, nonalcoholic, fatty, liver, disease, naflddiffusediffusediffusediffusediffusediffusediffusediffusediffusediffuseintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalmixedmixedmixedmixedmixedmixedmixedmixedmixedmixedabbreviation, kegg, kyoto, encyclopedia, of, genes, and, genomesap, values, were, calculated, via, oncomine, software, and, kegg, pathway, analysis, was, used, to, analyze, gene, functionsignaling, pathwaynot, been, investigated, in, depth, we, are, working, toward, not, onlycharacterizing, this, novel, interaction, but, also, using, this, information, to, uncover, novel, genes, pertinent, to, gc, growth, anddevelopmentgenetic, analysis, of, downregulated, gc, genes, usinglauren, type, classified, gcswe, stratified, the, data, sets, based, on, the, respective, lauren, distinguished, subtype, as, we, did, previously, and, have, highlightedthe, vast, heterogenetic, molecular, landscape, within, the, diffuseintestinal, and, mixed, table, , gc, subtypes, all, subtypes, areexpectedly, distinct, from, one, another, within, our, molecular, analysis, the, diffuse, and, intestinal, type, gcs, seem, to, have, moreprominent, downregulation, of, metabolism, related, genes, suchas, gsta2, and, dbt, gsta2, is, involved, with, chemoresistancedue, to, the, action, of, glutathione, metabolism, an, antioxidant, andthis, observation, suggests, that, this, subtype, may, be, more, sensitiveto, platinum, drugs56, this, overall, downregulation, of, metabolicpathways, may, also, point, to, an, increase, in, the, warburg, effectthis, alternative, metabolic, pathway, has, been, suggested, to, contribute, phenotypically, to, high, rates, of, invasion, and, aggressivegcs57, we, also, observed, downregulation, of, adrb2, in, theintestinal, type, gc, table, , zhang, et, al, described, adrb2signaling, as, essential, in, gc, and, is, likely, related, to, stressinduced, tumor, induction58, they, suggest, treating, with, antagonists, of, ardb2, likely, will, provide, survival, benefit, this, may, beimportant, to, note, and, be, beneficial, for, nonintestinal, like, gcsbecause, there, is, a, clear, trend, of, significant, downregulation, ofthis, gene, , , fold, differencewe, next, assessed, the, molecular, aberrations, in, the, downregulated, genes, of, mixed, subtype, gc, table, , interestingly, 0ctechnology, in, cancer, research, , treatmentwe, found, various, genes, that, are, significantly, downregulatedwith, no, pathway, analysis, and, no, real, evidence, of, a, mechanismat, the, protein, level, table, , pkib, function, has, not, beenexplored, within, the, literature, in, regard, to, gc, but, has, beenshown, to, promote, proliferation, through, pi3kakt, pathwayin, breast, cancer59, pou2af1, is, another, gene, that, has, not, beencharacterized, within, the, gc, literature, but, has, been, found, to, bea, highrisk, gene, in, gastrointestinal, stromal, tumors, a, type, ofsoft, tissue, sarcoma, and, rheumatoid, arthritis6061, again, themixed, subtype, is, molecularly, different, from, the, intestinal, anddiffuse, gastric, subtypes, based, on, this, genetic, pathway, analysiswith, notably, less, involvement, of, metabolism, related, genesalthough, this, is, expected, due, to, its, difference, in, subtypingthe, mixed, gastric, subtype, has, a, much, smaller, representationwithin, the, literature, than, the, intestinal, and, diffuse, types, and, itis, clear, that, further, investigation, is, needed, a, better, understanding, of, the, diverse, nature, of, downregulated, genes, in, allaspects, of, gc, is, needed, as, a, first, step, to, identify, new, therapeutic, options, that, will, benefit, patients, with, gcgastric, cancer, exhibits, high, molecular, differencesbetween, genderswithin, the, united, states, men, and, women, older, than, , are, athigher, risk, for, developing, gc, while, the, male, population, ishigher, in, risk, for, welldifferentiated, gc, development, than, thefemale, population, mainly, due, to, the, protective, effect, of, estrogen, against, developing, h, pylori, induced, gastric, carcinogenesis62, females, have, higher, incidence, of, poorly, differentiatedgcs, compared, to, their, male, counterparts, for, reasons, largelyunknown, various, environmental, factors, play, a, role, in, diseasedevelopment, as, a, whole, including, obesity, smoking, drinkingand, a, poor, diet6366, a, retrospective, study, by, kim, et, al, hasshown, that, women, not, only, have, a, higher, incidence, of, diffusetype, gc, but, have, a, worse, overall, prognosis, as, well, as, geneticdifferences, compared, to, men, including, erb, expression67, suggesting, a, hormonal, component, may, also, be, a, contributing, factor, to, this, subset, of, disease, due, to, the, evident, genderdisparities, in, gc, we, investigated, the, underlying, moleculardifferences, between, male, and, female, patients, by, preforminggeo2r, analysis, on, the, gse118916, data, set, our, results, showstriking, differences, in, differentially, expressed, genes, betweenmales, and, femalesoverall, both, male, and, female, patients, with, gc, showed, anabundance, of, upregulated, genes, figure, 2a, after, stratifyingbased, on, gender, the, female, patients, with, gc, have, a, higherabundance, of, upregulated, genes, oncogenic, like, genes, genes, greater, than, 5fold, upregulation, compared, to, downregulated, genes, figure, 2b, while, male, patients, with, gc, have, agreater, abundance, of, downregulated, genes, tumor, suppressorlike, genes, figure, 2b, this, trend, can, also, be, seen, from, just, thetop, differentially, expressed, genes, in, the, provided, tables, current, treatment, options, for, gc, are, somewhat, limited, in, achieving, a, longterm, survival, benefit, and, we, wanted, to, use, ourcohorts, to, identify, whether, there, are, differences, in, actionabletargets, between, gendersfemale, patients, with, gc, are, vastly, underrepresentedwithin, clinical, studieswe, found, no, direct, druggable, targets, according, to, the, dgidbdatabase, with, the, top, differentially, expressed, genes, therefore, we, looked, further, into, the, individual, proteinproteininteraction, networks, using, string, database, figure, 2cfbroadening, the, scope, of, our, search, allowed, us, to, find, manypotential, druggable, targets, table, , we, narrowed, the, scopeof, our, search, to, inhibitorsantagonist, type, compounds, due, tothe, substantial, genes, found, to, be, upregulated, many, of, thedruggable, targets, such, as, estimated, glomerular, filtration, rateegfr, tyrosine, kinase, inhibitors, tkis, are, currently, beingexplored, in, a, variety, of, malignancies, including, gc, erlotinibwas, investigated, in, a, phase, ii, clinical, trial, in, combination, withoxaliplatinleucovorin5fu, in, metastatic, gc68, lapatinib, atki, responsible, for, inhibiting, her2neu, and, egfr, wastested, in, a, phase, iii, clinical, trial, tytan, trial, in, asianpatients, with, gc69, there, was, no, statistically, significant, difference, in, overall, survival, for, paclitaxel, plus, lapatinib, overpaclitaxel, alone70, we, looked, further, into, the, patient, demographics, of, the, tytan, trial, and, noticed, a, large, underrepresentation, of, female, patients, within, all, arms, of, the, study, total, female, patients, another, example, of, this, is, a, trial, withbortezomib, which, interacts, with, the, adam17, pathway, andhas, been, tried, unsuccessfully, in, phase, ii, clinical, trials, in, combination, with, paclitaxel, and, carboplatin, in, metastatic, patientswith, gc71, as, with, the, lapatinib, trial, this, one, had, an, overrepresentation, of, male, patients, , compared, to, femalepatients, , a, common, occurrence, within, many, of, thegc, clinical, trials, is, combination, of, new, therapies, with, paclitaxel, or, some, type, of, taxol, we, have, found, the, female, cohortto, have, an, abundance, of, druggable, targets, interact, with, paclitaxel, including, epb41l4b, and, capn9, table, , but, largelythis, demographic, is, underrepresented, within, clinical, trial, studies, it, is, clear, that, based, on, the, molecular, profile, of, femalepatients, with, gc, this, issue, demands, further, investigationmale, patients, with, gc, may, benefit, from, hormoneinhibiting, therapiesas, we, have, previously, mentioned, the, male, cohort, has, anopposite, molecular, profile, compared, to, the, female, cohort, withwhen, screening, for, actionable, drug, targets, we, limited, thescope, of, our, analysis, to, agonists, due, to, the, substantial, geneticdownregulation, already, occurring, naturally, and, notion, thatmale, patients, with, gc, have, an, abundance, of, tumor, suppressorlike, genes, in, doing, so, we, have, found, direct, druggable, targetssuch, as, sstr1, and, gpt, table, , gpt, is, a, gene, that, encodesthe, alanine, aminotransaminase, , protein, and, catalyzes, thereversible, transamination, between, alanine, and, 2oxoglutaratewithin, the, tricarboxylic, acid, tca, cycle, to, generate, pyruvatea, tca, intermediate, and, glutamate72, glucagon, and, tacrolimus, interact, with, gpt, but, the, stimulation, of, this, gene, wouldlikely, enhance, glucose, metabolism, through, the, tca, cyclelikely, being, nonbeneficial, as, a, treatment, option, furthermore, 0csexton, et, alfigure, , male, and, female, patients, with, gastric, cancer, have, different, molecular, signatures, a, density, plots, of, , differentially, expressedgenes, in, the, gse118916, data, set, for, all, gastric, cancer, cases, within, the, cohort, b, male, and, female, cohort, density, plots, of, the, , differentiallyexpressed, genes, in, the, gse118916, data, set, cg, string, database, interaction, networks, for, protein, networks, from, genes, found, to, bedifferentially, expressed, in, female, gastric, cancer, cases, within, the, cohort, btd, capns9, epb41l4b, adam17, tomil1tacrolimus, can, influence, the, development, of, lymphomas73although, targeting, gpt, would, not, be, beneficial, targetingsstr1, may, have, more, benefit, hypermethylation, of, sstr1was, found, to, contribute, to, the, pathogenesis, of, gc, by, actingin, a, tumor, suppressive, manner, this, hypermethylation, wasfound, to, be, caused, by, epsteinbarr, virus, infection74, a, positive, 0ctechnology, in, cancer, research, , treatmenttable, , genes, found, to, be, significantly, differentially, expressed, within, the, female, cohort, from, the, geo, database, gse118916afold, change, diffuse, vsgene, namenormal, averagep, value, drugfbx13dmrta1btdpfdn2gramd1ccapn9pbldepb41l4badam17, , 109e9, 201e8, testosterone, tretinoin, ly294002201e8, biotin, hydrocortisone, aspartic, acid, celiponase, alfa319e9, 533e8, 620e8, emricasan, paclitaxel, rizatriptan, celecoxib, idronoxil956e8, 961e8, paclitaxel, vindesine, colchicine, docetaxel, cabzitaxel, erbulin, mesylate, ixabepilonelexibulin, tamoxifen, ornithine144e7, cetuximab, nimotuzumab, tesevatinib, infliximab, etanercept, adalimumab, golimumabhydrocortisone, everolimus, methotrexate, mercaptopurine, bortezomib, prednisolonedexamethasone, ribociclib, nitrogacestat, dacomitinib, lapatinib, erlotinib, poziotinibibrutinib, pelitinibtom1l1155e7, erlotinib, afatinib, gefitinib, cetuximab, lapatinib, panitumumab, rociletinib, icotiniblacomi]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |[, gastric, cancer, gc, persists, worldwide, public, health, crisis, according, american, cancer, society, 5yearsurvival, rate, gc, remains, , worldwide, , withinthe, united, states1, survival, statistics, increasedoverall, since, 1980s, 5year, survival, rate, stageii, disease, , near, , stage, iiib, andhigher1, development, chemotherapies, platinums, taxanes, survival, beyond, stage, ii, increased, steadilyto, , although, chemotherapies, improved, overall, survivalthis, dramatic, solid, malignancies, suchas, prostate, breast, furthermore, even, identificationof, molecular, targets, brca, mutations, her2amplifications, clinical, success, available, therapies, hasbeen, minimal23, recent, clinical, trial, olaparib, polyadp, ribose, polymerase, inhibitor, showed, little, efficacy, compared, standard, care4, although, subset, gastric, diseasehas, her2, amplification, monoclonal, antibodies, her2have, demonstrated, limited, success, gc, unlike, theresponse, seen, her2, positive, breast, cancer5, clear, department, oncology, wayne, state, university, school, medicinedetroit, mi, usacorresponding, authorasfar, azmi, phd, department, oncology, wayne, state, university, schoolof, medicine, karmanos, cancer, institute, , john, r, hwcrc, , detroitmi, , usaemail, azmiakarmanoscreative, commons, cc, , distributed, terms, creative, commons, attribution, , license, creativecommonslicensesby40which, permits, use, reproduction, distribution, work, without, permission, provided, original, work, attributed, specified, sage, , access, pages, ussagepubcomenusnam, accessatsage, 0ctechnology, cancer, research, , treatmentmore, work, needed, elucidate, underlying, moleculardrivers, resistance, mechanisms, gcgastric, cancer, classified, mainly, using, either, laurenclassification, world, health, anization, criteria, lauren, classification, compares, tumors, based, ongrowth, invasion, pattern, , subtypes, intestinal, well, differentiated, diffuse, poorly, differentiated, intermediatemixed67, majority, patients, outside, us, gc, areyounger, 60years, old, poorly, differentiated, diffuse, subtype, located, within, distal, portion, thestomach, characterized, poor, cellular, differentiation, highintratumor, heterogeneity, subtype, poorer, outcomesdue, widespread, infiltration, invasive, nature, thedisease78, conversely, within, united, states, pathologyof, gc, similar, malignancies, found, within, gastroesophageal, junction8, older, patients, primarily, impactedand, disease, commonly, well, differentiated, intestinalthe, welldifferentiated, subtype, found, cardia, lowerregion, stomach, welldefined, glandular, structuresand, growth, pattern, designation, gc, createdin, , expands, vastly, lauren, classification67there, , subtypes, tubular, adenocarcinoma, papillary, adenocarcinoma, mucinous, adenocarcinoma, poorly, cohesivesignet, ring, cell, carcinoma, mixed, carcinoma67, similarities, exist, lauren, classificationssignetring, cell, carcinoma, comparable, poorly, differentiatedgc, steadily, increasing, incidence, within, united, statesand, around, world9, increase, attributed, , eradication, efforts, helicobacter, pylori, pathogen, known, toinduce, intestinal, type, gc, , increases, genetic, predisposition, genes, ecadherin, cdh1, hypermethylationand, , less, screening, detection, due, low, riskpopulation, within, united, states, compared, regionssuch, japan10here, aim, analyze, molecular, signatures, well, asdifferences, lauren, classified, gcs, also, aim, tounderstand, molecular, differences, male, femalepatients, gc, chose, look, solely, lauren, classifiedcancers, within, , due, established, use, within, themedical, community, well, availability, relevancewithin, publicly, available, data, sets, overarching, goal, toidentify, dissect, heterogeneous, aspects, gcthat, commonly, overlooked, within, literaturemethodsoncomine, database, searchoncomine, compendia, bioscience, used, analysis, andvisualization, three, separate, data, sets, used, explore, theup, downregulation, lauren, subtypes, gc, chen, gastric, mol, biol, cell, , mrna, derrico, gastric, europeanjournal, dataset2, , mrna, cho, gastric, clinicalcancer, research, , mrna, nonsubtyped, gc, analysis, used, , separate, data, sets, cui, gastric, nucleicacids, research, , mrna, wang, gastric, medicaloncology, , mrna, cho, gastric, clinical, cancerresearch, , mrna, find, highly, ranked, genes, weselected, subtype, interest, gc, compared, normaland, assessed, upregulated, downregulated, genes, averaged, fold, changes, genes, individual, analyses, andhave, used, computed, p, values, provided, oncominesoftwarekyoto, encyclopedia, genes, genomes, pathwayanalysisto, identify, pathways, involved, genes, found, upregulated, downregulated, oncomine, analysis, weutilized, kyoto, encyclopedia, genes, genomesmirwalk, database, analysismirwalk, database, university, heidelberg, used, foranalysis, genemicrornas, mirna, interactions11druggene, interaction, analysisdgidb, database, used, identify, druggable, targets, withinour, genes, found, differentially, expressed12protein, databasethe, human, protein, atlas, available, httpwwwproteinatlas, used, identify, survival, curves, stomach, cancerwith, following, proteins, cwd43, stage, iiv, survivalcurves, wwwproteinatlasensg00000109182cwh43pathologystomach¾cancer, metll7a, stage, iivwwwproteinatlasensg00000185432mettl7apathologystomach¾cancer, slc2a12, stage, iiv, wwwproteinatlasensg00000146411slc2a12pathologystomach¾cancer, mal, stage, iiv, wwwproteinatlasensg00000172005malpathologystomach¾cancer, dmrt1, stage, iiv, wwwproteinatlasensg00000137090dmrt1pathologystomach¾cancerall, available, v19proteinatlasproteinprotein, interaction, networksstring, , database, used, identify, proteinproteininteractions, following, genes, cwh43, metll7aslc2a12, mal, btd, capn9, adam17, epb41, tom1l1and, dmrt113geo, database, analysisthe, data, discussed, within, publication, previously, deposited, ncbis, gene, expression, omnibus, andare, accessible, geo, series, accession, numbergse118916, wwwncbinlmnihgovgeoqueryacccgiacc¼gse118916, 0csexton, et, altable, , top, upregulated, genes, found, gastric, cancer, cohort, viaoncomine, databaseagene, namefold, change, diffusevs, normal, averagepublicationsp, valuefoundinhbacol1a2cldn1cdh11col3a1col5a2col1a1timp1sulf1spon2549e7949e12664e6117e10241e6289e6299e6383e6465e6644e10ap, values, calculated, using, oncomine, softwarestatisticsoncomine, software, human, protein, atlas, providedstatisticsethical, approvalthe, data, obtained, patients, requireinstitutional, review, board, approvalresultsgenetic, analysis, upregulated, gc, geneswithin, literature, various, genetic, aberrations, beenproposed, serve, prognostic, therapeutic, markersincluding, sox17, hypermethylation, bcl2, transforminggrowth, factor, beta, tgfb, vascular, endothelial, growth, factorvegfr, her21418, many, proposed, markersare, studied, extensively, serve, ideal, targets, dueto, limited, clinical, utility, either, drug, targets, predictors, therapeutic, response, examples, include, lesssuccessful, attempts, target, her2, monoclonal, antibodiesand, use, tgfb, inhibitors, although, promisinghave, proven, highly, toxic1920, additionally, targetshave, demonstrated, limited, clinical, utility, due, crosstalkbetween, tgfb, signaling, pathways, ras, aknown, nontargetable, protein2122, vegf, inhibitors, areused, therapeutic, modality, gc, improveoverall, survival23, indepth, investigation, molecularmechanisms, urgently, investigations, need, distinctfrom, commonly, studied, clinically, intractable, targetsalthough, case, discrepancies, exist, within, literature, groups, look, molecular, composition, gc, asa, whole, others, focus, differences, within, laurenclassification, systemusing, oncomine, database, found, significantupregulation, several, understudied, genes, gcs, including, col3a1, col5a2, spon2, cdh11, table, , wealso, confirmed, upregulated, status, many, thegenes, found, within, literature, somewhat, well, knownsuch, inhba, gene, associated, poor, overall, outcomes24, still, understudied, claudin, , cldn1, hasbeen, found, highly, expressed, gc, poor, predictive, disease, marker, mediating, tumor, necrosis, factorainduced, cell, migration, enhancement, proliferation, andmetastasis, sulf1, found, significantlyhypomethylated, causing, significant, downregulated, proteinexpression2528, sulf1, downregulation, may, indicativeof, posttranslational, modification, feedback, loop, degradation, event, via, proteinprotein, interactions, still, unclearnot, surprisingly, significant, underrepresentation, notedwhen, comparing, publications, related, genes, publications, commonly, studied, genes, mapkpi3k, tp53, , total, publicationsgenetic, analysis, upregulated, gc, genes, using, laurentype, classified, gcswe, stratified, data, sets, based, respective, lauren, distinguished, subtype, highlighted, vast, heterogeneticmolecular, landscape, within, poorly, differentiated, diffusewell, differentiated, intestinal, mixed, gc, subtypestable, , poorly, differentiated, gc, shares, many, similaritieswith, gc, overall, including, perturbations, various, collagentranscribing, genes, stimulation, pi3kakt, signaling, andperturbations, cellular, structural, components, dominant, subtype, throughout, world, reasons, previously, mentioned, due, overabundance, collagentranscribing, genes, wanted, explore, whether, potentialgenetic, link, exists, literature, search, identified, study, correlating, ehlersdanlos, syndrome, eds, disease, caused, bycollagen, gene, perturbations, development, gc29ehlersdanlos, syndrome, also, presents, gastrointestinalinvolvement, increased, rates, heartburn, arisk, factor, developing, esophageal, cancer3031, based, thelocation, gastric, tumors, within, stomach, inthe, proximal, stomach, near, esophagus, connectionbetween, gastric, esophageal, cancers, quite, possiblethere, may, much, stronger, correlation, eds, anddiffuse, gc, previously, thoughtwe, found, gc, overall, share, many, molecularsimilarities, welldifferentiated, subtype, gc, withinthe, scope, analysis, found, similaritycldn1, expression, claudin, , gene, involved, coding, forthe, protein, involved, epithelial, barrier, functions, part, ofthe, claudin, family, within, gc, cldn1, found, differentially, expressed, gc, found, upregulatedin, small, patient, population, linked, poor, survival, outcomes, indicative, oncogenic, function32, groupshave, found, claudin1, tumor, suppressive, activities, canreverse, epithelialtomesenchymal, transition, gc, cellsand, found, downregulated, intestinal, type, gc, aof, , patients, cohort3334, clear, work, needs, donein, order, elucidate, role, cldn1, plays, within, intestinaltype, gastric, tumors, differing, functions, based, 0ctechnology, cancer, research, , treatmenttable, , top, significantly, upregulated, genes, based, molecular, subtype, gastric, cancer, well, differentiated, poorly, differentiatedmixed, subtype, based, oncomine, databaseafold, change, diffusevs, normal, averagep, valuekegg, pathway, analysisgastric, cancersubtypegene, namethy1timp1bgncol1a2sulf1col6a3olfml2brab31thbs2col1a1ttyh3thy1cadube2ccldn1prc1dazap1atp11adcaf13mthfd1lcol6a3fbn1rcc2ahcytgif1fn1myo9bvcanlummcm4pi3kakt, focal, adhesion, ecm, receptor, proteoglycanspi3kakt, focal, adhesion, ecm, receptorimmune, component161e12124e11, hif, signaling238e11223e10139e9, metabolism585e9404e8361e9, membrane, trafficking118e8165e7232e23, transporter346e21202e8phagosome, pi3kakt, focal, adhesion, ecmreceptor, interactionpi3kakt, focal, adhesion, ecm, receptor, proteoglycansimmune, componentphenylpropanoid, biosynthesis, metabolic, pathways, biosynthesis, ofsecondary, metabolitesmrna, surveillance262e20, ubiquitinmediated, proteolysis650e15, cell, adhesion, tight, junction134e14, tubulin, binding, protein680e8768e19, metabolism, translocase971e8893e9109e7191e7161e9213e6733e9943e9ribosome, biogenesisone, carbon, metabolismpi3kakt, signaling, focal, adhesion, ecmreceptor, interactiontgfb, signalingcysteine, methionine, metabolismtgfb, signalingpi3kakt, signaling, focal, adhesion, ecmreceptor, interactionregulation, actin, cytoskeleton, proteoglycans, pathways, cancer224e6, membrane, trafficking260e6380e6833e6cell, adhesion, molecules, camsproteoglycans, cancerdna, replication, cell, cyclediffusediffusediffusediffusediffusediffusediffusediffusediffusediffuseintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalmixedmixedmixedmixedmixedmixedmixedmixedmixedmixedabbreviations, ecm, extracellular, matrix, kegg, kyoto, encyclopedia, genes, genomes, tgfb, transforming, growth, factor, betaap, values, calculated, via, oncomine, software, kegg, pathway, analysis, used, analyze, gene, functionliterature, many, processes, underlying, intestinal, gcinvolve, alterations, metabolism, cellular, crosstalktable, , surprising, intestinal, diffuse, gcsare, distinctly, different, find, similarity, thy1expression, similar, fold, changes, although, thisgene, investigated, gc, overexpressed, inthe, pancreatic, cancer, microenvironment35, investigation, may, needed, gene, may, importance, gcdevelopmentwe, finally, investigated, mixed, subtype, gc, subtypethat, commonly, overlooked, within, literature, table, interestingly, mixed, gc, similarities, diffusesubtype, including, pi3kakt, signaling, collagen, transcribinggene, upregulation, cellular, anizational, componentsinterestingly, found, genes, perturbed, within, thissubtype, involved, driving, number, genetic, diseasessuch, marfan, syndrome, fbn1, hypermethioninemiaahcy, research, shown, marfan, syndrome, due, aberrant, tgfb, signaling, induce, gc, development, murinemodel36, hypermethioninemia, go, undetected, foryears, found, induce, aggressive, cancers, protectingtumors, 5flurouracil, 5fuinduced, death, chemotherapy, commonly, used, treat, gc3738, likely, diffusesubtype, subtype, strong, genetic, link, butthe, mixed, subtype, may, stronger, genetic, component, thanpreviously, thought, hypothesize, genetic, diversity, within, gc, masked, analyzed, whole, whichfurther, supports, notion, disease, highlyheterogeneousgenetic, analysis, downregulated, gc, genesthere, twice, many, published, studies, looking, atupregulated, gc, genes, compared, downregulated, , vs, common, downregulated, gc, genes, influenced, part, aberrant, dna, methylation3940, thanthis, much, less, studied, pertaining, highly, significant, downregulated, genes, gc, using, oncomine, database, 0csexton, et, altable, , top, significantly, downregulated, genes, according, oncomine, database, gastric, canceragene, namelifrcwh43rdh12mfsd4mettl7aatp4bslc2a12ghrlmaladh7fold, change, diffusevs, normal, averagep, valuekegg, pathway, analysis, , , , , , , , , , 251e6cytokinecytokine, receptor, interaction, signaling, pluripotency, stem, cells279e9136e8220e5227e5165e10365e10617e8119e9947e8jakstat, signalingretinol, metabolism, metabolic, pathwaysoxidative, phosphorylation, metabolic, pathways, gastric, acid, secretiontransportercamp, signaling, neuroactive, ligandreceptor, interaction, growth, hormonesynthesis, secretion, actionglycolysisgluconeogenesis, fatty, acid, degradation, tyrosine, metabolism, retinolmetabolism, chemical, carcinogenesisabbreviation, kegg, kyoto, encyclopedia, genes, genomesap, values, calculated, via, oncomine, software, kegg, pathway, analysis, used, analyze, gene, functionfound, significant, downregulated, genes, lifrrdh12, msfd4, atp4b, ghrl, adh7, arepoorly, represented, within, literature, table, , haveinvestigated, survival, outcomes, select, genes, table, investigated, gastric, cancer, best, ofour, knowledge, genes, include, mettl7a, malslc2a12, cwh43, figure, 1a, found, trend, towardimproved, survival, upregulated, cwh43, downregulated, metll7awe, included, protein, interaction, networks, genes, obtained, using, string, databasefigure, 1be, slc2a12, interacts, akt1, commonly, studied, gene, interest, within, gc, known, contribute, chemoresistance41, although, many, interacting, proteins, aswell, studied, akt1, various, genes, mtus1, pgap3aldoa, pmp22, shown, within, literature, toonly, influence, gc, pancreatic, cancer, well4246, clearthat, investigation, understudied, specific, geneticinteraction, networks, needed, wanted, look, intowhether, genetic, aberrations, interactor, proteins, targetable, utilized, dgidb, mettl7a, methyltransferase, located, primarily, lipiddroplets, silenced, via, dna, methylation, thyroid, cancer47, variety, drug, interactions, within, networkof, mettl7a, including, cda, gemcitabine, cytaribine, deoxycytidine, lta4, h, kelatophan, ubenimex, variety, preliminary, drug, compounds, b2, m, pembrolizumab, qpctpramipexole, aldoa, variety, preliminary, compoundsand, hp, estradiol, pyridoxine, pembrolizumab, fdaapproved, treatment, advanced, staged, gc, positivepdl1, expression, b2m, acquired, mutations, found, conferresistance, pembrolizumab, malignancies48, little, isknown, gc, downregulation, genes, may, partiallyexplain, efficacy, issues, pembrolizumabor, chemotherapies, mal, encodes, membrane, proteinwithin, endoplasmic, reticulum, er, tcells, involvedin, myelin, biogenesis49, drug, interactions, within, networkinclude, acta1, kabiramide, c, latrunculin, ab, aplyronine, anda, variety, preclinical, compounds, limk1, dabrafenibpmp22, progesterone, mag, gsk249320, cwh43, isinvolved, cell, wall, biogenesis, involved, lipid, remodeling50, drugs, interact, protein, network, include, upp2fluorouracil, brivudine, understanding, genetic, landscape, ofgc, gene, interaction, networks, genes, respond, totherapies, may, explain, partially, disease, highly, resistant, conventional, chemotherapies, however, work, isneeded, understand, possible, underlying, resistance, mechanisms, within, subsets, gc, bring, forward, idealpopulations, benefit, conventional, commonly, usedtherapiesincreasing, interest, placed, around, small, rnasincluding, mirnas, involvement, within, gc, development5152we, wanted, investigate, interaction, networks, betweenthese, uncharacterized, genes, interest, bold, mirnasusing, mirwalk, database, found, mirna, interactwith, genes, interest, figure, 1fi, many, mirnasare, uncharacterized, gc, find, mirna612mir612, mettl7a, interacting, mirna, induces, pax8, atumorsuppressor, represses, foxm1, inhibit, angiogenesis, metastasis, gc53, labs, work, part, involves, studying, role, nuclear, export, mirna, expression, uncovering, ways, tumor, suppressive, mirnas, canbe, upregulated, within, nucleus, manipulating, nuclearexport, nuclear, export, via, xpo1, limited, role, exportingmirna, nucleus, cytosol, rather, nuclearexport, family, member, xpo5, exports, majority, ofcellular, mirnas54, xpo1, overexpression, found, atherapeutic, target, gc, found, blocking, protein, small, fda, approved, molecule, selinexor, xpovio, influences, expression, subset, tumorassociatedmirnas55, furthermore, found, via, small, rnasequencing, xpo1, inhibition, selinexor, well, 0ctechnology, cancer, research, , treatmentfigure, , gastric, cancer, highly, heterogeneous, disease, survival, curves, taken, human, protein, atlas, cwh43, mettl7aslc2a12, mal, bd, protein, interaction, networks, cwh43, mettl7a, slc2a12, mal, taken, string, database, ehmirna, interaction, networks, found, top, interactions, cwh43, mettl7a, slc2a12, mal, mirdb, second, generation, inhibitor, kpt8602, mir7977cwh43, interacting, mirna, significantly, upregulated, foldchange, , p, ¼, 392e23, fold, change, , p, ¼, 546e, early, stage, diffuse, gastric, cell, line, snu1, suggestiveof, tumor, suppressive, role, mirna, connectionbetween, nuclear, export, cancerspecific, mirnas, gc, 0csexton, et, altable, , top, significantly, downregulated, genes, based, molecular, subtype, gastric, cancer, well, differentiated, poorly, differentiatedmixed, subtype, based, oncomine, databaseagenenamemt1gmt1fgcnt2slc9a1ppfibp2dbtmt1mpxmp2mt1hgsta2malpga3sidt2adrb2brp44, lsstgcnt2ckmt2rab27astk32bfgapxmp2nrxn1gsta2pkibpou2af1slc22a23aqp4mlxcxcl14fold, change, diffuse, vsnormal, averagep, value, kegg, pathway, analysisgastric, cancersubtype, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 143e4, mineral, absorption213e10, mineral, absorption597e7, glycosphingolipid, biosynthesis, metabolism762e7, transporter150e9654e4, valine, leucine, isoleucine, degradation, propionate, metabolism, metabolicpathwayperoxisome903e7172e9113e6, mineral, absorption231e9, glutathione, metabolism, drug, metabolism, platinum, drug, resistancepathways, cancer, chemical, carcinogenesis881e11, ribosome, biogenesis454e12, protein, digestion, absorption199e10, 103e12, camp, signaling, neuroactive, ligandreceptor, interaction188e12, mitochondrial, biogenesis422e8camp, signaling, neuroactive, ligandreceptor, interaction, gastric, acidsecretion, growth, hormone, synthesis, secretion, action206e12, glycosphingolipid, biosynthesis, metabolic, pathways537e8, arginine, proline, metabolism, metabolic, pathways258e12, membrane, trafficking156e9, metabolism318e10, membrane, trafficking175e8190e7, cell, adhesion, molecules, cams155e6, glutathione, metabolism, drug, metabolism, platinum, drug, resistanceperoxisomepathways, cancer, chemical, carcinogenesis184e6890e7111e5, anic, acid, transporters384e6, bile, secretion, vasopressinregulated, water, absorption139e5139e5, cytokinecytokine, receptor, interaction, viral, protein, interaction, chemokineinsulin, resistance, nonalcoholic, fatty, liver, disease, naflddiffusediffusediffusediffusediffusediffusediffusediffusediffusediffuseintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalmixedmixedmixedmixedmixedmixedmixedmixedmixedmixedabbreviation, kegg, kyoto, encyclopedia, genes, genomesap, values, calculated, via, oncomine, software, kegg, pathway, analysis, used, analyze, gene, functionsignaling, pathwaynot, investigated, depth, working, toward, onlycharacterizing, novel, interaction, also, using, information, uncover, novel, genes, pertinent, gc, growth, anddevelopmentgenetic, analysis, downregulated, gc, genes, usinglauren, type, classified, gcswe, stratified, data, sets, based, respective, lauren, distinguished, subtype, previously, highlightedthe, vast, heterogenetic, molecular, landscape, within, diffuseintestinal, mixed, table, , gc, subtypes, subtypes, areexpectedly, distinct, one, another, within, molecular, analysis, diffuse, intestinal, type, gcs, seem, moreprominent, downregulation, metabolism, related, genes, suchas, gsta2, dbt, gsta2, involved, chemoresistancedue, action, glutathione, metabolism, antioxidant, andthis, observation, suggests, subtype, may, sensitiveto, platinum, drugs56, overall, downregulation, metabolicpathways, may, also, point, increase, warburg, effectthis, alternative, metabolic, pathway, suggested, contribute, phenotypically, high, rates, invasion, aggressivegcs57, also, observed, downregulation, adrb2, theintestinal, type, gc, table, , zhang, et, al, described, adrb2signaling, essential, gc, likely, related, stressinduced, tumor, induction58, suggest, treating, antagonists, ardb2, likely, provide, survival, benefit, may, beimportant, note, beneficial, nonintestinal, like, gcsbecause, clear, trend, significant, downregulation, ofthis, gene, , , fold, differencewe, next, assessed, molecular, aberrations, downregulated, genes, mixed, subtype, gc, table, , interestingly, 0ctechnology, cancer, research, , treatmentwe, found, various, genes, significantly, downregulatedwith, pathway, analysis, real, evidence, mechanismat, protein, level, table, , pkib, function, beenexplored, within, literature, regard, gc, beenshown, promote, proliferation, pi3kakt, pathwayin, breast, cancer59, pou2af1, another, gene, beencharacterized, within, gc, literature, found, bea, highrisk, gene, gastrointestinal, stromal, tumors, type, ofsoft, tissue, sarcoma, rheumatoid, arthritis6061, themixed, subtype, molecularly, different, intestinal, anddiffuse, gastric, subtypes, based, genetic, pathway, analysiswith, notably, less, involvement, metabolism, related, genesalthough, expected, due, difference, subtypingthe, mixed, gastric, subtype, much, smaller, representationwithin, literature, intestinal, diffuse, types, itis, clear, investigation, needed, better, understanding, diverse, nature, downregulated, genes, allaspects, gc, needed, first, step, identify, new, therapeutic, options, benefit, patients, gcgastric, cancer, exhibits, high, molecular, differencesbetween, genderswithin, united, states, men, women, older, , athigher, risk, developing, gc, male, population, ishigher, risk, welldifferentiated, gc, development, thefemale, population, mainly, due, protective, effect, estrogen, developing, h, pylori, induced, gastric, carcinogenesis62, females, higher, incidence, poorly, differentiatedgcs, compared, male, counterparts, reasons, largelyunknown, various, environmental, factors, play, role, diseasedevelopment, whole, including, obesity, smoking, drinkingand, poor, diet6366, retrospective, study, kim, et, al, hasshown, women, higher, incidence, diffusetype, gc, worse, overall, prognosis, well, geneticdifferences, compared, men, including, erb, expression67, suggesting, hormonal, component, may, also, contributing, factor, subset, disease, due, evident, genderdisparities, gc, investigated, underlying, moleculardifferences, male, female, patients, preforminggeo2r, analysis, gse118916, data, set, results, showstriking, differences, differentially, expressed, genes, betweenmales, femalesoverall, male, female, patients, gc, showed, anabundance, upregulated, genes, figure, 2a, stratifyingbased, gender, female, patients, gc, higherabundance, upregulated, genes, oncogenic, like, genes, genes, greater, 5fold, upregulation, compared, downregulated, genes, figure, 2b, male, patients, gc, agreater, abundance, downregulated, genes, tumor, suppressorlike, genes, figure, 2b, trend, also, seen, thetop, differentially, expressed, genes, provided, tables, current, treatment, options, gc, somewhat, limited, achieving, longterm, survival, benefit, wanted, use, ourcohorts, identify, whether, differences, actionabletargets, gendersfemale, patients, gc, vastly, underrepresentedwithin, clinical, studieswe, found, direct, druggable, targets, according, dgidbdatabase, top, differentially, expressed, genes, therefore, looked, individual, proteinproteininteraction, networks, using, string, database, figure, 2cfbroadening, scope, search, allowed, us, find, manypotential, druggable, targets, table, , narrowed, scopeof, search, inhibitorsantagonist, type, compounds, due, tothe, substantial, genes, found, upregulated, many, thedruggable, targets, estimated, glomerular, filtration, rateegfr, tyrosine, kinase, inhibitors, tkis, currently, beingexplored, variety, malignancies, including, gc, erlotinibwas, investigated, phase, ii, clinical, trial, combination, withoxaliplatinleucovorin5fu, metastatic, gc68, lapatinib, atki, responsible, inhibiting, her2neu, egfr, wastested, phase, iii, clinical, trial, tytan, trial, asianpatients, gc69, statistically, significant, difference, overall, survival, paclitaxel, plus, lapatinib, overpaclitaxel, alone70, looked, patient, demographics, tytan, trial, noticed, large, underrepresentation, female, patients, within, arms, study, total, female, patients, another, example, trial, withbortezomib, interacts, adam17, pathway, andhas, tried, unsuccessfully, phase, ii, clinical, trials, combination, paclitaxel, carboplatin, metastatic, patientswith, gc71, lapatinib, trial, one, overrepresentation, male, patients, , compared, femalepatients, , common, occurrence, within, many, thegc, clinical, trials, combination, new, therapies, paclitaxel, type, taxol, found, female, cohortto, abundance, druggable, targets, interact, paclitaxel, including, epb41l4b, capn9, table, , largelythis, demographic, underrepresented, within, clinical, trial, studies, clear, based, molecular, profile, femalepatients, gc, issue, demands, investigationmale, patients, gc, may, benefit, hormoneinhibiting, therapiesas, previously, mentioned, male, cohort, anopposite, molecular, profile, compared, female, cohort, withwhen, screening, actionable, drug, targets, limited, thescope, analysis, agonists, due, substantial, geneticdownregulation, already, occurring, naturally, notion, thatmale, patients, gc, abundance, tumor, suppressorlike, genes, found, direct, druggable, targetssuch, sstr1, gpt, table, , gpt, gene, encodesthe, alanine, aminotransaminase, , protein, catalyzes, thereversible, transamination, alanine, 2oxoglutaratewithin, tricarboxylic, acid, tca, cycle, generate, pyruvatea, tca, intermediate, glutamate72, glucagon, tacrolimus, interact, gpt, stimulation, gene, wouldlikely, enhance, glucose, metabolism, tca, cyclelikely, nonbeneficial, treatment, option, furthermore, 0csexton, et, alfigure, , male, female, patients, gastric, cancer, different, molecular, signatures, density, plots, , differentially, expressedgenes, gse118916, data, set, gastric, cancer, cases, within, cohort, b, male, female, cohort, density, plots, , differentiallyexpressed, genes, gse118916, data, set, cg, string, database, interaction, networks, protein, networks, genes, found, bedifferentially, expressed, female, gastric, cancer, cases, within, cohort, btd, capns9, epb41l4b, adam17, tomil1tacrolimus, influence, development, lymphomas73although, targeting, gpt, beneficial, targetingsstr1, may, benefit, hypermethylation, sstr1was, found, contribute, pathogenesis, gc, actingin, tumor, suppressive, manner, hypermethylation, wasfound, caused, epsteinbarr, virus, infection74, positive, 0ctechnology, cancer, research, , treatmenttable, , genes, found, significantly, differentially, expressed, within, female, cohort, geo, database, gse118916afold, change, diffuse, vsgene, namenormal, averagep, value, drugfbx13dmrta1btdpfdn2gramd1ccapn9pbldepb41l4badam17, , 109e9, 201e8, testosterone, tretinoin, ly294002201e8, biotin, hydrocortisone, aspartic, acid, celiponase, alfa319e9, 533e8, 620e8, emricasan, paclitaxel, rizatriptan, celecoxib, idronoxil956e8, 961e8, paclitaxel, vindesine, colchicine, docetaxel, cabzitaxel, erbulin, mesylate, ixabepilonelexibulin, tamoxifen, ornithine144e7, cetuximab, nimotuzumab, tesevatinib, infliximab, etanercept, adalimumab, golimumabhydrocortisone, everolimus, methotrexate, mercaptopurine, bortezomib, prednisolonedexamethasone, ribociclib, nitrogacestat, dacomitinib, lapatinib, erlotinib, poziotinibibrutinib, pelitinibtom1l1155e7, erlotinib, afatinib, gefitinib, cetuximab, lapatinib, panitumumab, rociletinib, icotiniblacomi]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |[, gastric, cancer, gc, persists, as, worldwide, public, health, crisis, according, american, cancer, society, 5yearsurvival, rate, gc, remains, at, , worldwide, , withinthe, united, states1, these, survival, statistics, have, increasedoverall, since, 1980s, when, 5year, survival, rate, stageii, disease, below, , near, , stage, iiib, andhigher1, with, development, chemotherapies, such, as, platinums, taxanes, survival, beyond, stage, ii, increased, steadilyto, , although, chemotherapies, improved, overall, survivalthis, not, as, dramatic, as, that, other, solid, malignancies, suchas, prostate, or, breast, furthermore, even, with, identificationof, molecular, targets, such, as, brca, mutations, her2amplifications, clinical, success, with, available, therapies, hasbeen, minimal23, recent, clinical, trial, with, olaparib, polyadp, ribose, polymerase, inhibitor, showed, little, efficacy, compared, standard, care4, although, subset, gastric, diseasehas, her2, amplification, monoclonal, antibodies, against, her2have, demonstrated, very, limited, success, gc, unlike, theresponse, seen, her2, positive, breast, cancer5, it, clear, that, department, oncology, wayne, state, university, school, medicinedetroit, mi, usacorresponding, authorasfar, s, azmi, phd, department, oncology, wayne, state, university, schoolof, medicine, karmanos, cancer, institute, , john, r, hwcrc, , detroitmi, , usaemail, azmiakarmanoscreative, commons, cc, by, , distributed, under, terms, creative, commons, attribution, , license, creativecommonslicensesby40which, permits, any, use, reproduction, distribution, work, without, further, permission, provided, original, work, attributed, as, specified, on, sage, , access, pages, ussagepubcomenusnam, accessatsage, 0ctechnology, cancer, research, , treatmentmore, work, needed, elucidate, underlying, moleculardrivers, resistance, mechanisms, gcgastric, cancer, classified, mainly, using, either, laurenclassification, or, world, health, anization, who, criteria, lauren, classification, compares, tumors, based, ongrowth, invasion, pattern, with, , subtypes, intestinal, well, differentiated, diffuse, poorly, differentiated, intermediatemixed67, majority, patients, outside, us, with, gc, areyounger, 60years, old, have, poorly, differentiated, diffuse, subtype, which, located, within, distal, portion, thestomach, characterized, by, poor, cellular, differentiation, highintratumor, heterogeneity, subtype, has, poorer, outcomesdue, its, widespread, infiltration, invasive, nature, thedisease78, conversely, within, united, states, pathologyof, gc, similar, that, malignancies, found, within, gastroesophageal, junction8, older, patients, are, primarily, impactedand, disease, commonly, well, differentiated, intestinalthe, welldifferentiated, subtype, found, cardia, or, lowerregion, stomach, with, welldefined, glandular, structuresand, growth, pattern, who, designation, gc, createdin, , expands, vastly, on, lauren, classification67there, are, , subtypes, tubular, adenocarcinoma, papillary, adenocarcinoma, mucinous, adenocarcinoma, poorly, cohesivesignet, ring, cell, carcinoma, mixed, carcinoma67, similarities, exist, between, lauren, who, classificationssignetring, cell, carcinoma, comparable, poorly, differentiatedgc, steadily, increasing, incidence, within, united, statesand, around, world9, increase, attributed, , eradication, efforts, helicobacter, pylori, pathogen, known, toinduce, intestinal, type, gc, , increases, genetic, predisposition, genes, such, as, ecadherin, cdh1, hypermethylationand, , less, screening, detection, due, low, riskpopulation, within, united, states, compared, other, regionssuch, as, japan10here, we, aim, analyze, molecular, signatures, as, well, asdifferences, between, lauren, classified, gcs, we, also, aim, tounderstand, molecular, differences, between, male, femalepatients, with, gc, we, chose, look, solely, at, lauren, classifiedcancers, within, , due, its, established, use, within, themedical, community, as, well, as, its, availability, relevancewithin, publicly, available, data, sets, our, overarching, goal, toidentify, dissect, some, heterogeneous, aspects, gcthat, are, commonly, overlooked, within, literaturemethodsoncomine, database, searchoncomine, compendia, bioscience, used, analysis, andvisualization, three, separate, data, sets, were, used, explore, theup, downregulation, lauren, subtypes, gc, chen, gastric, mol, biol, cell, , mrna, derrico, gastric, europeanjournal, dataset2, , mrna, cho, gastric, clinicalcancer, research, , mrna, nonsubtyped, gc, analysis, we, have, used, , separate, data, sets, cui, gastric, nucleicacids, research, , mrna, wang, gastric, medicaloncology, , mrna, cho, gastric, clinical, cancerresearch, , mrna, find, highly, ranked, genes, weselected, our, subtype, interest, or, gc, compared, normaland, assessed, upregulated, or, downregulated, genes, we, averaged, fold, changes, genes, individual, analyses, andhave, used, computed, p, values, provided, by, oncominesoftwarekyoto, encyclopedia, genes, genomes, pathwayanalysisto, identify, pathways, involved, genes, found, be, upregulated, or, downregulated, from, our, oncomine, analysis, weutilized, kyoto, encyclopedia, genes, genomesmirwalk, database, analysismirwalk, database, university, heidelberg, used, foranalysis, genemicrornas, mirna, interactions11druggene, interaction, analysisdgidb, database, used, identify, druggable, targets, withinour, genes, found, be, differentially, expressed12protein, databasethe, human, protein, atlas, available, from, httpwwwproteinatlas, used, identify, survival, curves, stomach, cancerwith, following, proteins, cwd43, stage, iiv, survivalcurves, wwwproteinatlasensg00000109182cwh43pathologystomach¾cancer, metll7a, stage, iivwwwproteinatlasensg00000185432mettl7apathologystomach¾cancer, slc2a12, stage, iiv, wwwproteinatlasensg00000146411slc2a12pathologystomach¾cancer, mal, stage, iiv, wwwproteinatlasensg00000172005malpathologystomach¾cancer, dmrt1, stage, iiv, wwwproteinatlasensg00000137090dmrt1pathologystomach¾cancerall, are, available, from, v19proteinatlasproteinprotein, interaction, networksstring, , database, used, identify, proteinproteininteractions, following, genes, cwh43, metll7aslc2a12, mal, btd, capn9, adam17, epb41, tom1l1and, dmrt113geo, database, analysisthe, data, discussed, within, publication, have, been, previously, deposited, ncbis, gene, expression, omnibus, andare, accessible, through, geo, series, accession, numbergse118916, wwwncbinlmnihgovgeoqueryacccgiacc¼gse118916, 0csexton, et, altable, , top, upregulated, genes, found, gastric, cancer, cohort, viaoncomine, databaseagene, namefold, change, diffusevs, normal, averagepublicationsp, valuefoundinhbacol1a2cldn1cdh11col3a1col5a2col1a1timp1sulf1spon2549e7949e12664e6117e10241e6289e6299e6383e6465e6644e10ap, values, were, calculated, using, oncomine, softwarestatisticsoncomine, software, human, protein, atlas, providedstatisticsethical, approvalthe, data, are, not, obtained, from, patients, does, not, requireinstitutional, review, board, approvalresultsgenetic, analysis, upregulated, gc, geneswithin, literature, various, genetic, aberrations, have, beenproposed, that, can, serve, as, prognostic, or, therapeutic, markersincluding, sox17, hypermethylation, bcl2, transforminggrowth, factor, beta, tgfb, vascular, endothelial, growth, factorvegfr, her21418, many, these, proposed, markersare, studied, extensively, do, not, serve, as, ideal, targets, dueto, their, limited, clinical, utility, as, either, drug, targets, or, predictors, therapeutic, response, some, examples, include, lesssuccessful, attempts, target, her2, with, monoclonal, antibodiesand, use, tgfb, inhibitors, which, although, promisinghave, proven, be, highly, toxic1920, additionally, these, targetshave, demonstrated, limited, clinical, utility, due, crosstalkbetween, tgfb, other, signaling, pathways, such, as, ras, aknown, nontargetable, protein2122, while, vegf, inhibitors, areused, as, therapeutic, modality, gc, they, do, not, improveoverall, survival23, an, indepth, investigation, molecularmechanisms, are, urgently, investigations, need, be, distinctfrom, commonly, studied, clinically, intractable, targetsalthough, case, discrepancies, exist, within, literature, as, some, groups, look, at, molecular, composition, gc, asa, whole, while, others, focus, on, differences, within, laurenclassification, systemusing, oncomine, database, we, have, found, significantupregulation, several, understudied, genes, all, gcs, including, col3a1, col5a2, spon2, cdh11, table, , wealso, have, confirmed, upregulated, status, many, thegenes, found, within, literature, that, are, somewhat, well, knownsuch, as, inhba, gene, associated, with, poor, overall, outcomes24, but, are, still, understudied, claudin, , cldn1, hasbeen, found, be, highly, expressed, gc, poor, predictive, disease, marker, by, mediating, tumor, necrosis, factorainduced, cell, migration, enhancement, proliferation, andmetastasis, while, sulf1, has, been, found, be, significantlyhypomethylated, causing, significant, downregulated, proteinexpression2528, sulf1, downregulation, may, be, indicativeof, posttranslational, modification, feedback, loop, or, degradation, event, via, proteinprotein, interactions, but, still, unclearnot, surprisingly, significant, underrepresentation, notedwhen, comparing, publications, related, these, genes, over, publications, commonly, studied, genes, such, as, mapkpi3k, tp53, over, , total, publicationsgenetic, analysis, upregulated, gc, genes, using, laurentype, classified, gcswe, stratified, data, sets, based, on, respective, lauren, distinguished, subtype, have, highlighted, vast, heterogeneticmolecular, landscape, within, poorly, differentiated, diffusewell, differentiated, intestinal, mixed, gc, subtypestable, , poorly, differentiated, gc, shares, many, similaritieswith, gc, overall, including, perturbations, various, collagentranscribing, genes, stimulation, pi3kakt, signaling, andperturbations, cellular, structural, components, dominant, subtype, throughout, world, reasons, we, have, previously, mentioned, due, overabundance, collagentranscribing, genes, we, wanted, explore, whether, potentialgenetic, link, exists, literature, search, identified, study, correlating, ehlersdanlos, syndrome, eds, disease, caused, bycollagen, gene, perturbations, development, gc29ehlersdanlos, syndrome, also, presents, with, gastrointestinalinvolvement, such, as, increased, rates, heartburn, which, arisk, factor, developing, esophageal, cancer3031, based, on, thelocation, these, gastric, tumors, within, stomach, that, inthe, proximal, stomach, near, esophagus, connectionbetween, gastric, esophageal, cancers, it, quite, possiblethere, may, be, much, stronger, correlation, between, eds, anddiffuse, gc, than, previously, thoughtwe, have, found, gc, overall, does, not, share, many, molecularsimilarities, with, welldifferentiated, subtype, gc, withinthe, scope, our, analysis, we, have, found, only, similaritycldn1, expression, claudin, , gene, involved, coding, forthe, protein, involved, epithelial, barrier, functions, part, ofthe, claudin, family, within, gc, cldn1, has, found, be, differentially, expressed, gc, has, been, found, be, upregulatedin, small, patient, population, being, linked, poor, survival, outcomes, indicative, an, oncogenic, function32, other, groupshave, found, claudin1, has, tumor, suppressive, activities, canreverse, epithelialtomesenchymal, transition, gc, cellsand, found, be, downregulated, intestinal, type, gc, aof, , patients, cohort3334, it, clear, that, work, needs, be, donein, order, elucidate, role, cldn1, plays, within, intestinaltype, gastric, tumors, as, it, has, differing, functions, based, on, 0ctechnology, cancer, research, , treatmenttable, , top, significantly, upregulated, genes, based, on, molecular, subtype, gastric, cancer, well, differentiated, poorly, differentiatedmixed, subtype, based, on, oncomine, databaseafold, change, diffusevs, normal, averagep, valuekegg, pathway, analysisgastric, cancersubtypegene, namethy1timp1bgncol1a2sulf1col6a3olfml2brab31thbs2col1a1ttyh3thy1cadube2ccldn1prc1dazap1atp11adcaf13mthfd1lcol6a3fbn1rcc2ahcytgif1fn1myo9bvcanlummcm4pi3kakt, focal, adhesion, ecm, receptor, proteoglycanspi3kakt, focal, adhesion, ecm, receptorimmune, component161e12124e11, hif, signaling238e11223e10139e9, metabolism585e9404e8361e9, membrane, trafficking118e8165e7232e23, transporter346e21202e8phagosome, pi3kakt, focal, adhesion, ecmreceptor, interactionpi3kakt, focal, adhesion, ecm, receptor, proteoglycansimmune, componentphenylpropanoid, biosynthesis, metabolic, pathways, biosynthesis, ofsecondary, metabolitesmrna, surveillance262e20, ubiquitinmediated, proteolysis650e15, cell, adhesion, tight, junction134e14, tubulin, binding, protein680e8768e19, metabolism, translocase971e8893e9109e7191e7161e9213e6733e9943e9ribosome, biogenesisone, carbon, metabolismpi3kakt, signaling, focal, adhesion, ecmreceptor, interactiontgfb, signalingcysteine, methionine, metabolismtgfb, signalingpi3kakt, signaling, focal, adhesion, ecmreceptor, interactionregulation, actin, cytoskeleton, proteoglycans, pathways, cancer224e6, membrane, trafficking260e6380e6833e6cell, adhesion, molecules, camsproteoglycans, cancerdna, replication, cell, cyclediffusediffusediffusediffusediffusediffusediffusediffusediffusediffuseintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalmixedmixedmixedmixedmixedmixedmixedmixedmixedmixedabbreviations, ecm, extracellular, matrix, kegg, kyoto, encyclopedia, genes, genomes, tgfb, transforming, growth, factor, betaap, values, were, calculated, via, oncomine, software, kegg, pathway, analysis, used, analyze, gene, functionliterature, many, processes, underlying, intestinal, gcinvolve, alterations, metabolism, cellular, crosstalktable, , it, not, surprising, that, intestinal, diffuse, gcsare, distinctly, different, but, we, did, find, similarity, with, thy1expression, both, having, similar, fold, changes, although, thisgene, has, not, been, investigated, gc, it, overexpressed, inthe, pancreatic, cancer, microenvironment35, further, investigation, may, be, needed, as, gene, may, have, importance, gcdevelopmentwe, finally, investigated, mixed, subtype, gc, subtypethat, commonly, overlooked, within, literature, table, interestingly, mixed, gc, has, some, similarities, diffusesubtype, including, pi3kakt, signaling, collagen, transcribinggene, upregulation, cellular, anizational, componentsinterestingly, we, have, found, genes, perturbed, within, thissubtype, are, involved, driving, number, genetic, diseasessuch, as, marfan, syndrome, fbn1, hypermethioninemiaahcy, research, has, shown, marfan, syndrome, due, aberrant, tgfb, signaling, can, induce, gc, development, murinemodel36, hypermethioninemia, which, can, go, undetected, foryears, found, induce, aggressive, cancers, by, protectingtumors, from, 5flurouracil, 5fuinduced, death, chemotherapy, commonly, used, treat, gc3738, it, likely, diffusesubtype, not, only, subtype, with, strong, genetic, link, butthe, mixed, subtype, may, have, stronger, genetic, component, thanpreviously, thought, we, hypothesize, some, genetic, diversity, within, gc, masked, when, analyzed, as, whole, whichfurther, supports, notion, disease, being, highlyheterogeneousgenetic, analysis, downregulated, gc, genesthere, are, about, twice, as, many, published, studies, looking, atupregulated, gc, genes, compared, downregulated, , vs, most, common, downregulated, gc, genes, are, influenced, part, by, aberrant, dna, methylation3940, other, thanthis, much, less, studied, pertaining, highly, significant, downregulated, genes, gc, using, oncomine, database, we, have, 0csexton, et, altable, , top, significantly, downregulated, genes, according, oncomine, database, gastric, canceragene, namelifrcwh43rdh12mfsd4mettl7aatp4bslc2a12ghrlmaladh7fold, change, diffusevs, normal, averagep, valuekegg, pathway, analysis, , , , , , , , , , 251e6cytokinecytokine, receptor, interaction, signaling, pluripotency, stem, cells279e9136e8220e5227e5165e10365e10617e8119e9947e8jakstat, signalingretinol, metabolism, metabolic, pathwaysoxidative, phosphorylation, metabolic, pathways, gastric, acid, secretiontransportercamp, signaling, neuroactive, ligandreceptor, interaction, growth, hormonesynthesis, secretion, actionglycolysisgluconeogenesis, fatty, acid, degradation, tyrosine, metabolism, retinolmetabolism, chemical, carcinogenesisabbreviation, kegg, kyoto, encyclopedia, genes, genomesap, values, were, calculated, via, oncomine, software, kegg, pathway, analysis, used, analyze, gene, functionfound, most, significant, downregulated, genes, were, lifrrdh12, msfd4, atp4b, ghrl, adh7, all, these, arepoorly, represented, within, literature, table, , we, haveinvestigated, survival, outcomes, select, genes, from, table, that, have, not, been, investigated, gastric, cancer, best, ofour, knowledge, these, genes, include, mettl7a, malslc2a12, cwh43, figure, 1a, we, found, trend, towardimproved, survival, with, upregulated, cwh43, downregulated, metll7awe, have, included, protein, interaction, networks, genes, we, have, obtained, using, string, databasefigure, 1be, slc2a12, interacts, with, akt1, commonly, studied, gene, interest, within, gc, known, contribute, chemoresistance41, although, many, interacting, proteins, are, not, aswell, studied, as, akt1, various, genes, such, as, mtus1, pgap3aldoa, pmp22, have, been, shown, within, literature, toonly, influence, gc, but, pancreatic, cancer, as, well4246, it, clearthat, further, investigation, into, these, understudied, specific, geneticinteraction, networks, are, needed, we, then, wanted, look, intowhether, any, these, genetic, aberrations, or, their, interactor, proteins, were, targetable, do, we, utilized, dgidb, mettl7a, methyltransferase, that, located, primarily, lipiddroplets, silenced, via, dna, methylation, thyroid, cancer47, there, variety, drug, interactions, within, networkof, mettl7a, including, cda, gemcitabine, cytaribine, deoxycytidine, lta4, h, kelatophan, ubenimex, variety, preliminary, drug, compounds, b2, m, pembrolizumab, qpctpramipexole, aldoa, variety, preliminary, compoundsand, hp, estradiol, pyridoxine, pembrolizumab, has, been, fdaapproved, treatment, advanced, staged, gc, with, positivepdl1, expression, b2m, acquired, mutations, were, found, conferresistance, pembrolizumab, other, malignancies48, but, little, isknown, gc, downregulation, these, genes, may, partiallyexplain, why, there, some, efficacy, issues, with, pembrolizumabor, other, chemotherapies, mal, encodes, membrane, proteinwithin, endoplasmic, reticulum, er, tcells, involvedin, myelin, biogenesis49, drug, interactions, within, networkinclude, acta1, kabiramide, c, latrunculin, ab, aplyronine, anda, variety, preclinical, compounds, limk1, dabrafenibpmp22, progesterone, mag, gsk249320, cwh43, isinvolved, cell, wall, biogenesis, involved, lipid, remodeling50, drugs, that, interact, with, protein, network, include, upp2fluorouracil, brivudine, understanding, genetic, landscape, ofgc, gene, interaction, networks, how, those, genes, respond, totherapies, may, explain, partially, why, disease, highly, resistant, conventional, chemotherapies, however, more, work, isneeded, understand, possible, underlying, resistance, mechanisms, within, subsets, gc, that, would, bring, forward, idealpopulations, that, benefit, from, conventional, commonly, usedtherapiesincreasing, interest, has, been, placed, around, small, rnasincluding, mirnas, involvement, within, gc, development5152we, wanted, investigate, interaction, networks, betweenthese, uncharacterized, genes, interest, bold, mirnasusing, mirwalk, database, we, found, mirna, interactwith, our, genes, interest, figure, 1fi, many, mirnasare, uncharacterized, gc, but, we, did, find, that, mirna612mir612, mettl7a, interacting, mirna, induces, pax8, atumorsuppressor, represses, foxm1, inhibit, angiogenesis, metastasis, gc53, our, labs, work, part, involves, studying, role, nuclear, export, mirna, expression, uncovering, ways, which, tumor, suppressive, mirnas, canbe, upregulated, within, nucleus, by, manipulating, nuclearexport, nuclear, export, via, xpo1, has, limited, role, exportingmirna, from, nucleus, cytosol, rather, than, its, nuclearexport, family, member, xpo5, which, exports, majority, ofcellular, mirnas54, xpo1, overexpression, found, be, atherapeutic, target, gc, we, have, found, blocking, protein, with, small, fda, approved, molecule, selinexor, xpovio, influences, expression, subset, tumorassociatedmirnas55, furthermore, we, have, found, via, small, rnasequencing, that, after, xpo1, inhibition, with, selinexor, as, well, 0ctechnology, cancer, research, , treatmentfigure, , gastric, cancer, highly, heterogeneous, disease, survival, curves, taken, from, human, protein, atlas, cwh43, mettl7aslc2a12, mal, bd, protein, interaction, networks, cwh43, mettl7a, slc2a12, mal, taken, from, string, database, ehmirna, interaction, networks, found, from, top, interactions, with, cwh43, mettl7a, slc2a12, mal, mirdb, as, second, generation, inhibitor, kpt8602, mir7977cwh43, interacting, mirna, significantly, upregulated, foldchange, , p, ¼, 392e23, fold, change, , p, ¼, 546e, early, stage, diffuse, gastric, cell, line, snu1, suggestiveof, tumor, suppressive, role, mirna, connectionbetween, nuclear, export, cancerspecific, mirnas, gc, has, 0csexton, et, altable, , top, significantly, downregulated, genes, based, on, molecular, subtype, gastric, cancer, well, differentiated, poorly, differentiatedmixed, subtype, based, on, oncomine, databaseagenenamemt1gmt1fgcnt2slc9a1ppfibp2dbtmt1mpxmp2mt1hgsta2malpga3sidt2adrb2brp44, lsstgcnt2ckmt2rab27astk32bfgapxmp2nrxn1gsta2pkibpou2af1slc22a23aqp4mlxcxcl14fold, change, diffuse, vsnormal, averagep, value, kegg, pathway, analysisgastric, cancersubtype, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 143e4, mineral, absorption213e10, mineral, absorption597e7, glycosphingolipid, biosynthesis, metabolism762e7, transporter150e9654e4, valine, leucine, isoleucine, degradation, propionate, metabolism, metabolicpathwayperoxisome903e7172e9113e6, mineral, absorption231e9, glutathione, metabolism, drug, metabolism, platinum, drug, resistancepathways, cancer, chemical, carcinogenesis881e11, ribosome, biogenesis454e12, protein, digestion, absorption199e10, 103e12, camp, signaling, neuroactive, ligandreceptor, interaction188e12, mitochondrial, biogenesis422e8camp, signaling, neuroactive, ligandreceptor, interaction, gastric, acidsecretion, growth, hormone, synthesis, secretion, action206e12, glycosphingolipid, biosynthesis, metabolic, pathways537e8, arginine, proline, metabolism, metabolic, pathways258e12, membrane, trafficking156e9, metabolism318e10, membrane, trafficking175e8190e7, cell, adhesion, molecules, cams155e6, glutathione, metabolism, drug, metabolism, platinum, drug, resistanceperoxisomepathways, cancer, chemical, carcinogenesis184e6890e7111e5, anic, acid, transporters384e6, bile, secretion, vasopressinregulated, water, absorption139e5139e5, cytokinecytokine, receptor, interaction, viral, protein, interaction, chemokineinsulin, resistance, nonalcoholic, fatty, liver, disease, naflddiffusediffusediffusediffusediffusediffusediffusediffusediffusediffuseintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalintestinalmixedmixedmixedmixedmixedmixedmixedmixedmixedmixedabbreviation, kegg, kyoto, encyclopedia, genes, genomesap, values, were, calculated, via, oncomine, software, kegg, pathway, analysis, used, analyze, gene, functionsignaling, pathwaynot, been, investigated, depth, we, are, working, toward, not, onlycharacterizing, novel, interaction, but, also, using, information, uncover, novel, genes, pertinent, gc, growth, anddevelopmentgenetic, analysis, downregulated, gc, genes, usinglauren, type, classified, gcswe, stratified, data, sets, based, on, respective, lauren, distinguished, subtype, as, we, did, previously, have, highlightedthe, vast, heterogenetic, molecular, landscape, within, diffuseintestinal, mixed, table, , gc, subtypes, all, subtypes, areexpectedly, distinct, from, one, another, within, our, molecular, analysis, diffuse, intestinal, type, gcs, seem, have, moreprominent, downregulation, metabolism, related, genes, suchas, gsta2, dbt, gsta2, involved, with, chemoresistancedue, action, glutathione, metabolism, an, antioxidant, andthis, observation, suggests, that, subtype, may, be, more, sensitiveto, platinum, drugs56, overall, downregulation, metabolicpathways, may, also, point, an, increase, warburg, effectthis, alternative, metabolic, pathway, has, been, suggested, contribute, phenotypically, high, rates, invasion, aggressivegcs57, we, also, observed, downregulation, adrb2, theintestinal, type, gc, table, , zhang, et, al, described, adrb2signaling, as, essential, gc, likely, related, stressinduced, tumor, induction58, they, suggest, treating, with, antagonists, ardb2, likely, will, provide, survival, benefit, may, beimportant, note, be, beneficial, nonintestinal, like, gcsbecause, there, clear, trend, significant, downregulation, ofthis, gene, , , fold, differencewe, next, assessed, molecular, aberrations, downregulated, genes, mixed, subtype, gc, table, , interestingly, 0ctechnology, cancer, research, , treatmentwe, found, various, genes, that, are, significantly, downregulatedwith, no, pathway, analysis, no, real, evidence, mechanismat, protein, level, table, , pkib, function, has, not, beenexplored, within, literature, regard, gc, but, has, beenshown, promote, proliferation, through, pi3kakt, pathwayin, breast, cancer59, pou2af1, another, gene, that, has, not, beencharacterized, within, gc, literature, but, has, been, found, bea, highrisk, gene, gastrointestinal, stromal, tumors, type, ofsoft, tissue, sarcoma, rheumatoid, arthritis6061, again, themixed, subtype, molecularly, different, from, intestinal, anddiffuse, gastric, subtypes, based, on, genetic, pathway, analysiswith, notably, less, involvement, metabolism, related, genesalthough, expected, due, its, difference, subtypingthe, mixed, gastric, subtype, has, much, smaller, representationwithin, literature, than, intestinal, diffuse, types, itis, clear, that, further, investigation, needed, better, understanding, diverse, nature, downregulated, genes, allaspects, gc, needed, as, first, step, identify, new, therapeutic, options, that, will, benefit, patients, with, gcgastric, cancer, exhibits, high, molecular, differencesbetween, genderswithin, united, states, men, women, older, than, , are, athigher, risk, developing, gc, while, male, population, ishigher, risk, welldifferentiated, gc, development, than, thefemale, population, mainly, due, protective, effect, estrogen, against, developing, h, pylori, induced, gastric, carcinogenesis62, females, have, higher, incidence, poorly, differentiatedgcs, compared, their, male, counterparts, reasons, largelyunknown, various, environmental, factors, play, role, diseasedevelopment, as, whole, including, obesity, smoking, drinkingand, poor, diet6366, retrospective, study, by, kim, et, al, hasshown, that, women, not, only, have, higher, incidence, diffusetype, gc, but, have, worse, overall, prognosis, as, well, as, geneticdifferences, compared, men, including, erb, expression67, suggesting, hormonal, component, may, also, be, contributing, factor, subset, disease, due, evident, genderdisparities, gc, we, investigated, underlying, moleculardifferences, between, male, female, patients, by, preforminggeo2r, analysis, on, gse118916, data, set, our, results, showstriking, differences, differentially, expressed, genes, betweenmales, femalesoverall, both, male, female, patients, with, gc, showed, anabundance, upregulated, genes, figure, 2a, after, stratifyingbased, on, gender, female, patients, with, gc, have, higherabundance, upregulated, genes, oncogenic, like, genes, genes, greater, than, 5fold, upregulation, compared, downregulated, genes, figure, 2b, while, male, patients, with, gc, have, agreater, abundance, downregulated, genes, tumor, suppressorlike, genes, figure, 2b, trend, can, also, be, seen, from, just, thetop, differentially, expressed, genes, provided, tables, current, treatment, options, gc, are, somewhat, limited, achieving, longterm, survival, benefit, we, wanted, use, ourcohorts, identify, whether, there, are, differences, actionabletargets, between, gendersfemale, patients, with, gc, are, vastly, underrepresentedwithin, clinical, studieswe, found, no, direct, druggable, targets, according, dgidbdatabase, with, top, differentially, expressed, genes, therefore, we, looked, further, into, individual, proteinproteininteraction, networks, using, string, database, figure, 2cfbroadening, scope, our, search, allowed, us, find, manypotential, druggable, targets, table, , we, narrowed, scopeof, our, search, inhibitorsantagonist, type, compounds, due, tothe, substantial, genes, found, be, upregulated, many, thedruggable, targets, such, as, estimated, glomerular, filtration, rateegfr, tyrosine, kinase, inhibitors, tkis, are, currently, beingexplored, variety, malignancies, including, gc, erlotinibwas, investigated, phase, ii, clinical, trial, combination, withoxaliplatinleucovorin5fu, metastatic, gc68, lapatinib, atki, responsible, inhibiting, her2neu, egfr, wastested, phase, iii, clinical, trial, tytan, trial, asianpatients, with, gc69, there, no, statistically, significant, difference, overall, survival, paclitaxel, plus, lapatinib, overpaclitaxel, alone70, we, looked, further, into, patient, demographics, tytan, trial, noticed, large, underrepresentation, female, patients, within, all, arms, study, total, female, patients, another, example, trial, withbortezomib, which, interacts, with, adam17, pathway, andhas, been, tried, unsuccessfully, phase, ii, clinical, trials, combination, with, paclitaxel, carboplatin, metastatic, patientswith, gc71, as, with, lapatinib, trial, one, had, an, overrepresentation, male, patients, , compared, femalepatients, , common, occurrence, within, many, thegc, clinical, trials, combination, new, therapies, with, paclitaxel, or, some, type, taxol, we, have, found, female, cohortto, have, an, abundance, druggable, targets, interact, with, paclitaxel, including, epb41l4b, capn9, table, , but, largelythis, demographic, underrepresented, within, clinical, trial, studies, it, clear, that, based, on, molecular, profile, femalepatients, with, gc, issue, demands, further, investigationmale, patients, with, gc, may, benefit, from, hormoneinhibiting, therapiesas, we, have, previously, mentioned, male, cohort, has, anopposite, molecular, profile, compared, female, cohort, withwhen, screening, actionable, drug, targets, we, limited, thescope, our, analysis, agonists, due, substantial, geneticdownregulation, already, occurring, naturally, notion, thatmale, patients, with, gc, have, an, abundance, tumor, suppressorlike, genes, doing, so, we, have, found, direct, druggable, targetssuch, as, sstr1, gpt, table, , gpt, gene, that, encodesthe, alanine, aminotransaminase, , protein, catalyzes, thereversible, transamination, between, alanine, 2oxoglutaratewithin, tricarboxylic, acid, tca, cycle, generate, pyruvatea, tca, intermediate, glutamate72, glucagon, tacrolimus, interact, with, gpt, but, stimulation, gene, wouldlikely, enhance, glucose, metabolism, through, tca, cyclelikely, being, nonbeneficial, as, treatment, option, furthermore, 0csexton, et, alfigure, , male, female, patients, with, gastric, cancer, have, different, molecular, signatures, density, plots, , differentially, expressedgenes, gse118916, data, set, all, gastric, cancer, cases, within, cohort, b, male, female, cohort, density, plots, , differentiallyexpressed, genes, gse118916, data, set, cg, string, database, interaction, networks, protein, networks, from, genes, found, bedifferentially, expressed, female, gastric, cancer, cases, within, cohort, btd, capns9, epb41l4b, adam17, tomil1tacrolimus, can, influence, development, lymphomas73although, targeting, gpt, would, not, be, beneficial, targetingsstr1, may, have, more, benefit, hypermethylation, sstr1was, found, contribute, pathogenesis, gc, by, actingin, tumor, suppressive, manner, hypermethylation, wasfound, be, caused, by, epsteinbarr, virus, infection74, positive, 0ctechnology, cancer, research, , treatmenttable, , genes, found, be, significantly, differentially, expressed, within, female, cohort, from, geo, database, gse118916afold, change, diffuse, vsgene, namenormal, averagep, value, drugfbx13dmrta1btdpfdn2gramd1ccapn9pbldepb41l4badam17, , 109e9, 201e8, testosterone, tretinoin, ly294002201e8, biotin, hydrocortisone, aspartic, acid, celiponase, alfa319e9, 533e8, 620e8, emricasan, paclitaxel, rizatriptan, celecoxib, idronoxil956e8, 961e8, paclitaxel, vindesine, colchicine, docetaxel, cabzitaxel, erbulin, mesylate, ixabepilonelexibulin, tamoxifen, ornithine144e7, cetuximab, nimotuzumab, tesevatinib, infliximab, etanercept, adalimumab, golimumabhydrocortisone, everolimus, methotrexate, mercaptopurine, bortezomib, prednisolonedexamethasone, ribociclib, nitrogacestat, dacomitinib, lapatinib, erlotinib, poziotinibibrutinib, pelitinibtom1l1155e7, erlotinib, afatinib, gefitinib, cetuximab, lapatinib, panitumumab, rociletinib, icotiniblacomi]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,13,14,15,17,18,19,20,21,22,23,24,25,26,28,29,30,33,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,52,53,54,55,57,58,59,61,62,63,64,65,66,68,70,71,72,73,74,76,77,78,80,81,83,84,86,87,89,90,92,94,95,96,97,98,99,100,101,104,105,108,109,110,111,112,113,114,115,117,119,120,121,122,124,126,128,130,131,132,135,136,137,139,142,143,144,145,146,147,149,150,154,156,158,162,164,166,167,168,169,170,171,173,175,177,178,181,182,187,188,189,190,191,192,194,197,198,201,204,205,207,209,210,212,215,216,217,219,220,221,225,226,227,228,230,231,232,235,237,240,241,242,243,244,245,246,248,250,252,253,256,258,262,264,268,269,270,271,278,279,284,285,287,289,290,293,295,296,297,298,301,305,306,308,309,310,313,317,319,320,325,326,327,328,329,331,335,338,339,343,345,347,348,350,352,357,359,363,364,365,366,368,370,372,373,374,376,378,386,387,388,389,390,393,396,398,404,405,408,410,411,412,414,415,419,421,424,426,432,433,434,437,438,446,456,460,461,462,463,464,468,471,472,474,479,484,491,492,494,497,499,500,503,504,511,512,520,530,532,542,548,549,551,552,555,559,562,569,576,578,580,581,587,591,593,597,598,609,610,611,614,619,620,628,629,630,631,635,638,639,642,647,652,654,657,661,666,668,672,673,679,680,683,685,691,692,693,701,703,704,706,710,711,714,715,716,717,720,726,727,729,731,733,736,752,753,760,763,764,765,766,769,780,781,785,789,795,797,804,808,809,810,818,820,841,853,859,860,870,874,877,879,886,887,888,890,893,907,911,923,925,928,932,935,937,938,940,942,947,950,954,955,964,967,969,973,975,984,986,996,1008,1011,1022,1027,1028,1030,1035,1042,1046,1051,1053,1056,1057,1059,1060,1061,1063,1073,1080,1081,1082,1084,1087,1092,1093,1096,1097,1099,1125,1133,1135,1140,1146,1149,1150,1154,1167,1168,1172,1174,1176,1179,1181,1186,1190,1203,1205,1210,1212,1213,1215,1219,1220,1229,1238,1240,1245,1247,1249,1251,1256,1264,1266,1271,1278,1282,1300,1308,1325,1331,1341,1345,1348,1352,1353,1360,1368,1377,1390,1405,1407,1412,1423,1426,1428,1435,1437,1438,1439,1442,1450,1453,1456,1459,1461,1464,1474,1492,1495,1500,1504,1506,1509,1519,1520,1543,1557,1564,1576,1578,1580,1595,1620,1635,1643,1658,1668,1670,1672,1676,1681,1684,1687,1689,1702,1706,1709,1719,1752,1759,1782,1788,1813,1819,1834,1837,1848,1850,1853,1862,1884,1885,1886,1894,1907,1918,1922,1946,1948,1968,1986,1990,2025,2026,2051,2054,2055,2056,2068,2069,2076,2092,2115,2131,2133,2135,2156,2177,2184,2193,2195,2197,2221,2228,2256,2270,2278,2282,2283,2291,2303,2308,2311,2316,2328,2336,2345,2361,2364,2401,2412,2422,2430,2447,2459,2461,2471,2489,2501,2512,2519,2526,2531,2534,2536,2554,2567,2583,2587,2599,2610,2616,2619,2641,2660,2677,2691,2694,2705,2754,2755,2767,2769,2770,2786,2797,2825,2828,2859,2896,2907,2912,2927,2959,2978,2982,2991,3003,3028,3030,3034,3044,3069,3086,3093,3118,3144,3153,3190,3211,3217,3230,3237,3251,3276,3297,3300,3304,3307,3311,3316,3374,3381,3383,3387,3431,3437,3439,3455,3485,3531,3555,3561,3585,3612,3619,3632,3651,3655,3675,3743,3756,3778,3797,3816,3827,3882,3895,3918,3952,3954,3956,3972,3978,3983,4038,4063,4090,4104,4106,4122,4126,4132,4201,4240,4242,4265,4283,4295,4300,4306,4361,4400,4402,4410,4535,4558,4615,4656,4726,4772,4813,4816,4926,4935,4937,4970,4972,5010,5033,5039,5063,5169,5241,5254,5298,5327,5345,5373,5404,5412,5414,5460,5464,5472,5498,5511,5515,5668,5710,5720,5728,5730,5764,5773,5778,5818,5886,5912,5962,5975,6036,6040,6042,6084,6146,6170,6225,6269,6401,6454,6469,6511,6540,6560,6577,6676,6753,6754,6839,6853,6887,7020,7065,7237,7283,7298,7299,7336,7424,7450,7458,7466,7469,7510,7559,7649,7667,7677,7768,7774,7877,7972,8011,8277,8371,8447,8453,8467,8515,8550,8554,8570,8601,8764,8775,8886,8895,9015,9029,9120,9299,9598,9605,9706,9721,9817,9825,9853,9868,9905,9906,10096,10101,10159,10203,10266,10359,11173,11185,11204,11253,11258,11310,11337,11350,11389,11460,11521,11724,11837,11908,11988,12060,12088,12100,12142,12380,12401,12474,12559,12575,12592,12655,12821,12866,12934,13082,13161,13285,13307,13346,13481,13504,13597,13724,13747,13854,13866,13942,14160,14420,14526,14569,14838,14948,14982,15353,15457,15749,15827,15916,15925,16411,16415,16449,16983,17015,17084,17548,17683,17727,17779,17804,18046,18153,18189,18298,18315,18511,18784,18844,19037,19077,19104,19115,19229,19261,19343,19560,19595,19615,19675,19714,19787,19794,19837,19939,20116,20137,20181,20337,20338,20426,20862,21352,21749,22140,22275,22351,22373,22526,22950,23048,23194,23542,23562,23736,24068,24234,24393,24784,24817,24968,25052,25249,25256,25304,25650,25882,25893,26069,26193,26551,27283,27530,27592,27653,27833,27968,28242,28573,28841,29684,29992,29997,30029,30169,30240,30395,30518,30773,31012,31017,31155,31332,31551,32069,32197,32330,32350,32426,32433,32950,34291,34775,35212,35281,35927,36162,36632,36645,37222,37865,38175,38345,38717,38764,38957,39098,39105,39337,39707,40271,40432,40479,40767,40797,40970,41282,41486,41854,41986,43802,44193,45099,45577,46604,47637,47643,47944,48148,48494,48898,49659,49977,50456,50697,51071,51398,51493,53032,53394,53585,54355,54742,55569,57365,58073,58412,58566,58600,58653,58991,59243,59474,59531,59619,59621,60098,60325,61120,61417,61581,61619,61957,62703,62807,63720,63876,64205,64271,64470,65516,66590,67578,68182,68672,69217,69581,70307,71203,71249,71432,71500,72123,72426,72892,73005,74064,74847,75795,81635,82321,82519,82709,82759,83150,83151,83341,83727,84016,84222,84348,84710,84794,85414,85501,85737,86523,86625,87468,87981,88412,88680,88999,89694,90057,90656,90886,91028,91214,91533,91568,91997,92109,92329,92787,92921,93170,93831,93908,94435,94555,94611,94936,95177,95834,96196,96263,96956,97177,97383,97928,98520,98911,98931,99103,99272,99383,99539,99573,99669,99689,99765,100182,100301,100323,100597,101200,101363,101923,102141,102177,102498,102616,102948,104065,104625,104636,104912,104949,105047,105334,105711,105830,105871,105933,106751,107431,108633,108901,109099,109391,109409,110109,110242,110397,110523,110715,110817,110924,111207,112925,113203,113387,113692,113817,114151,114227,114306,114685,114854,114861,115060,115091,115104,115403,115409,116192,116416,116509,117011,117069,117165,117403,117534,117961,118003,118138,118446,118490,118542,119076,119280,119342,119634,119764,119808,119812,119933,119936,120059,120891,121537,121539,121642,122553,122834,123336,123807,125095,126218,126255,126265,126717,126834,127287,127926,128687,128731,128774,128920,128993,129277,129301,129475,129971,130211,130847,130942,131138,131616,132549,132749,132942,133059,133915,134108,134715,134864,134914,134939,135132,135140,135444,135621,136289,136452,136615,136658,136905,137231,137301,137629,137679,138375,138882,139150,139230,139475,139503,140849,142119,142736,142875,143215,143462,143783,144215,144712,145465,145643,145672,145792,146670,146757,146864,147182,147704,147718,147841,148105,148626,148767,149683,149943,150065,151298,151329,151393,151399,152289,152407,152790,154126,154387,154503,155007,155014,155319,155724,155977,156316,156423,156832,157125,157307,157532,158167,158398,158900,159214,159219,159348,159637,159655,160779,160968,161945,162244,162792,162983,163212,163247,163650,163841,163885,163941,163971,164052,164519,164550,164991,165484,166386,166765,166850,166855,166894,167138,167185,167439,167932,168604,168922,168933,169244,169576,169681,169687,169754,169936,169958,170008,170416,170460,171004,171032,171948,172054,172270,173574,173604,173917,173933,173946,174049,174084,174230,174589,174650,174882,174945,175823,175940,176281,176448,176904,176951,177080,177220,177237,177314,177459,178358,178844,179268,179513,179673,181070,181643,181960,182973,182998,183529,184895,185014,185454,185633,186182,186400,186934,187216,187277,187744,187786,188057,188199,188489,188877,188926,189083,189090,189154,189933,189954,190136,190295,190412,190589,190623,190633,190798,190876,190900,190976,191296,191866,192940,193229,193479,193812,194355,194369,194458,194917,194996,195173,195210,195221,195359,196528,196548,196848,196857,197133,197914,198726,198884,199164,199249,199335,199494,199602,199775,200023,200053,200637,200870,201442,201535,201830,202164,202187,202870,203023,203109,203241,203677,203765,204074,204507,204722,204723,204787,205058,205491,205630,205739,206603,206672,206843,206960,206972,207106,207731,208815,208884,208935,209208,209252,209682],[104.0,41.0,8.0,11.0,23.0,40.0,22.0,16.0,11.0,15.0,17.0,20.0,9.0,5.0,22.0,3.0,7.0,34.0,3.0,10.0,35.0,7.0,16.0,8.0,7.0,7.0,3.0,16.0,7.0,12.0,10.0,3.0,5.0,20.0,2.0,56.0,12.0,9.0,4.0,5.0,13.0,2.0,9.0,1.0,11.0,6.0,15.0,13.0,6.0,7.0,1.0,1.0,2.0,9.0,11.0,1.0,1.0,2.0,1.0,2.0,11.0,3.0,1.0,8.0,3.0,33.0,11.0,2.0,3.0,3.0,6.0,3.0,2.0,6.0,2.0,2.0,2.0,1.0,3.0,6.0,12.0,4.0,5.0,1.0,2.0,2.0,8.0,5.0,2.0,2.0,1.0,11.0,3.0,5.0,6.0,8.0,2.0,10.0,1.0,1.0,2.0,3.0,1.0,3.0,7.0,10.0,2.0,1.0,2.0,1.0,2.0,3.0,1.0,2.0,2.0,1.0,4.0,1.0,1.0,5.0,2.0,3.0,1.0,5.0,4.0,1.0,1.0,9.0,2.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,8.0,4.0,10.0,2.0,1.0,13.0,1.0,7.0,1.0,7.0,2.0,3.0,2.0,8.0,7.0,2.0,1.0,7.0,2.0,4.0,1.0,2.0,37.0,2.0,4.0,1.0,1.0,2.0,5.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,6.0,1.0,1.0,5.0,6.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,7.0,3.0,5.0,1.0,9.0,2.0,2.0,1.0,2.0,5.0,2.0,5.0,1.0,1.0,10.0,1.0,1.0,3.0,4.0,2.0,8.0,5.0,4.0,1.0,1.0,3.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,3.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,9.0,1.0,2.0,2.0,1.0,3.0,5.0,2.0,1.0,1.0,1.0,3.0,4.0,1.0,2.0,6.0,6.0,1.0,2.0,14.0,3.0,1.0,3.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,6.0,3.0,1.0,6.0,2.0,1.0,1.0,2.0,1.0,13.0,1.0,2.0,2.0,6.0,14.0,3.0,1.0,26.0,1.0,1.0,3.0,2.0,1.0,4.0,3.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,10.0,14.0,2.0,3.0,6.0,11.0,1.0,1.0,3.0,1.0,5.0,2.0,3.0,1.0,9.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,17.0,1.0,1.0,2.0,2.0,9.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,6.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,4.0,1.0,2.0,1.0,3.0,2.0,1.0,10.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,4.0,1.0,1.0,1.0,7.0,6.0,1.0,1.0,1.0,1.0,1.0,5.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,2.0,1.0,2.0,5.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,5.0,1.0,2.0,1.0,3.0,3.0,3.0,1.0,1.0,3.0,7.0,3.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,6.0,6.0,5.0,1.0,1.0,8.0,1.0,1.0,1.0,67.0,1.0,1.0,3.0,2.0,1.0,2.0,1.0,7.0,1.0,2.0,3.0,1.0,2.0,1.0,3.0,1.0,8.0,1.0,1.0,2.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,9.0,1.0,2.0,5.0,2.0,1.0,1.0,9.0,1.0,1.0,1.0,1.0,1.0,19.0,3.0,1.0,1.0,1.0,2.0,4.0,1.0,4.0,1.0,3.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,3.0,1.0,4.0,2.0,2.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,4.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,9.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,6.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,6.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,3.0,4.0,1.0,1.0,1.0,1.0,3.0,1.0,5.0,4.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,10.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,4.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,4.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,5.0,2.0,1.0,6.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,5.0,1.0,5.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n",
      "|[, scars, burns, , healingvolume, , , , , reuse, guidelinessagepubcomjournalspermissions, the, authors, , journalssagepubcomhomesbhkeloids, are, pathological, scars, that, grow, over, time, and, extend, beyond, the, initial, site, of, injury, after, impaired, wound, , healing, , these, , scars, , frequently, , recur, , and, , rarely, , regress, , they, , are, , aesthetically, , disfiguring, , can, cause, pain, itching, discomfort, as, well, as, psychological, stress, often, affecting, quality, of, life, many, treatment, modalities, including, surgical, and, nonsurgical, have, been, explored, and, have, been, reported, to, be, beneficial, however, none, have, been, absolutely, satisfactory, or, optimal, for, the, treatment, of, all, keloid, subtypes, to, date, this, , poses, , a, , major, , challenge, , to, , clinicians, , often, , a, , combinational, , therapeutic, , approach, , appears, , to, , offer, the, best, results, with, higher, patient, satisfaction, compared, to, monotherapy, the, aetiopathogenesis, of, keloids, is, , not, , fully, , elucidated, , however, , with, , recent, , advances, , in, , molecular, , biology, , and, , genetics, , insight, , is, , being, gained, on, the, complex, process, of, scar, formation, and, hence, new, therapeutic, and, management, options, for, keloids, , in, , this, , paper, , we, , explore, , the, , literature, , and, , summarise, , the, , general, , concepts, , surrounding, , keloid, development, , and, , review, , both, , current, , corticosteroids, , surgical, , excision, , siliconebased, , products, , pressure, therapy, , radiotherapy, , cryotherapy, , laser, , therapy, , imiquimod, , and, , 5fluorouracil, , and, , emerging, , stem, , cell, therapy, mitomycin, c, verapamil, interferons, bleomycin, botulinum, toxin, type, a, and, angiotensinconverting, enzyme, inhibitors, treatments, increased, knowledge, and, understanding, in, this, area, may, potentially, lead, to, the, discovery, and, development, of, novel, therapeutic, options, that, are, more, efficacious, for, all, keloid, typeskeywordskeloids, scar, recurrence, wound, healing, treatment, managementlay, summarykeloids, are, problematic, scars, that, are, difficult, to, treat, and, manage, the, aetiopathogenesis, of, keloids, is, not, clear, however, recent, advances, in, molecular, biology, and, genetics, are, beginning, to, shed, light, on, the, underlying, mechanisms, implicated, in, keloid, scar, formation, which, will, hopefully, lead, to, the, development, of, treatment, options, for, all, keloid, types, this, review, summarises, current, and, emerging, therapiesintroductionwound, healing, is, an, intricate, and, complex, series, of, , processes, , comprising, , overlapping, , phases, , of, inflammation, granulation, tissue, formation, and, tissue, remodelling, and, results, in, tissue, structure, integrity, and, damage, being, restored1, abnormal, wound, healing, can, give, rise, to, keloids, which, are, benign, dermal, fibroproliferative, nodular, lesions, that, , tend, , to, , recur, , after, , excision, , keloid, , scars, , faculty, of, medical, sciences, the, university, of, the, west, indies, cave, hill, campus, bridgetown, barbados, west, indies, pine, medical, centre, 3rd, avenue, belleville, st, michael, barbados, west, indiescorresponding, authornkemcho, ojeh, faculty, of, medical, sciences, the, university, of, the, west, indies, cave, hill, campus, po, box, , st, michael, bridgetown, bb, , barbados, west, indies, email, nkemchoojehcavehilluwieducreative, commons, non, commercial, cc, bync, this, , is, distributed, under, the, terms, of, the, creative, commons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permits, noncommercial, use, reproduction, and, distribution, of, the, work, without, further, permission, provided, the, original, work, is, attributed, as, specified, on, the, sage, and, , , , access, pages, ussagepubcomenusnam, accessatsage, 0c, scars, burns, , healinginfluence, , in, , keloid, , aetiology9, , although, , no, , one, specific, gene, has, been, associated, with, the, development, of, keloids, a, number, of, genes, and, gene, loci, have, been, identified610, genomewide, association, studies, and, admixture, mapping, studies, have, identified, singlenucleotide, polymorphisms, across, certain, loci, genetically, linked, to, keloid, development, including, , the, , nedd4, , gene, , which, , encodes, , e3, ubiquitin, , ligase, , enzyme, , and, , the, , myosin, , genes, my01e, and, myo7a10, studies, have, also, reported, the, involvement, of, several, human, leucocyte, antigen, hla, alleles, p53, bcl2, and, fas, genes1014, furthermore, , rare, , genetic, , disorders, , have, , been, reported, , to, , present, , with, , spontaneous, , keloids, including, dubowitz, syndrome, bethlem, myopathy, rubinsteintaybi, , syndrome, , noonan, , syndrome, geominne, , syndrome, , and, , others1017, , these, , lines, of, evidence, suggest, that, genetic, factors, play, a, role, on, keloid, predispositionpathophysiology, of, keloidskeloid, , pathology, , is, , complex, , involving, , both, genetic, and, environmental, factors, keloids, form, as, a, result, of, abnormal, wound, healing, and, excessive, dermal, fibrosis, development, of, keloids, has, been, linked, to, overproliferation, and, reduced, apoptosis, of, dermal, fibroblasts, overproduction, of, collagen, fibres, and, other, extracellular, matrix, ecm, components, as, well, as, abnormal, ecm, production, and, remodelling1, , various, , cytokines, , growth, , factors, and, proteolytic, enzymes, have, been, implicated, in, the, , formation, , of, , keloids, , including, , transforming, growth, factor, tgf, epidermal, growth, factor, egf, vascular, endothelial, growth, factor, vegf, plateletderived, growth, factor, pdgf, connective, tissue, , growth, , factor, , ctgf, , tumour, , necrosis, factorî±, , tnfî±, insulinlike, , growth, , factor1, , igf1, fibroblast, growth, factor, fgf, interleukin6, , il6, , and, , matrix, , metalloproteinases, mmps31418, , furthermore, , signalling, , pathways, such, as, tolllike, receptor, signalling, smad, signalling, and, fibronectin, have, been, reported, to, be, associated, with, keloid, development1819histopathology, of, keloidshistologically, keloids, comprise, an, abundance, of, unordered, , dermal, , collagen, , and, , vasculature, , with, high, , inflammatorycell, , infiltrate, , and, , overactive, mesenchymal, , cells1415, , in, , addition, , to, , collagen, elastin, , fibronectin, , and, , proteoglycans, , are, , deposited, in, excess, amounts, in, keloid, scars9, collagen, creates, , frequent, , crosslinks, , in, , ordinary, , wounds, whereas, collagen, is, irregularly, anised, in, keloids, forming, nodules, in, the, dermis20, during, normal, figure, , , earlobe, keloids, as, a, consequence, of, ear, piercingarise, from, skin, trauma, or, inflammation, and, may, develop, , years, , after, , the, , initial, , insult, , and, , rarely, regress2, the, scar, tissue, extends, beyond, the, original, wound, site, and, can, be, disfiguring, and, cause, psychosocial, , issues, , impairing, , quality, , of, , life3, , in, addition, , patients, , may, , present, , with, , symptoms, such, as, burning, pain, pruritus, movement, limitation, and, hyperaesthesia2aetiologythe, , aetiology, , of, , keloids, , is, , still, , poorly, , understood, the, most, common, regions, of, the, skin, for, keloids, include, upper, arms, skin, overlying, joints, chest, shoulders, and, headneck, regions, particularly, , the, , ear, , lobes, , figure, , , , the, , anatomical, location, of, a, keloid, appears, to, alter, its, morphological, characteristics, some, keloids, can, develop, spontaneously, , however, , most, , occur, , years, , after, local, trauma, and, other, events, including, inflammation, surgery, burns, elective, cosmesis, foreign, body, reactions, acne, insect, bites, vaccinations, or, mechanical, force45epidemiology, and, keloid, geneticsthe, incidence, of, keloids, is, highest, among, darkerpigmented, , persons, , of, , african, , asian, , and, hispanic, , descent, , and, , is, , estimated, , to, , be, , in, , the, range, , of, , , , males, , and, , females, , have, , an, equal, risk, of, developing, keloids6, although, incidence, , is, , slightly, , increased, , in, , females, , likely, attributable, to, them, having, more, cosmetic, procedures, , like, , ear, , piercing7, , persons, , aged, , , years, , are, , also, , at, , a, , higher, , risk, , of, , developing, keloids, , additional, , risk, , factors, , include, , having, blood, , type, , a, , hyperige, , and, , hormonal, , peaks, during, pregnancy, or, puberty8familial, , keloid, , case, , studies, , and, , twin, , studies, support, , the, , notion, , that, , genetic, , factors, , have, , an, 0cojeh, , for, the, treatment, of, keloids2627, intralesional, tac, injections, have, been, shown, to, reduce, scar, volume, and, height, improve, scar, pliability, and, diminish, associated, scar, pain, and, itching8, as, well, as, prevent, recurrence3, , corticosteroids, , have, , antiinflammatory, , and, , antimitotic, , properties1, , several, , other, mechanisms, , have, , been, , reported, , by, , which, , corticosteroids, reduce, keloid, scar, including, inhibition, of, , fibroblast, , growth, , attenuation, , of, , procollagen, and, , glycosaminoglycan, , synthesis, , reduction, , of, endothelial, , budding, , and, , enhancement, , of, , collagen, , and, , fibroblast, , degeneration2829, , corticos, teroids, , inhibit, , tgf1, , expression, , and, , induce, apoptosis, in, fibroblasts, inhibit, vegf, and, alphaglobulins, which, are, involved, in, the, wound, healing, , process28, , vegf, , which, , promotes, angiogenesis, was, reported, to, be, highly, expressed, in, , keloid, , fibroblasts, , compared, , to, , controls, , but, exogenous, , addition, , of, , the, , glucocorticoid, , dexamethasone, , suppressed, , its, , expression, , in, , vitro32, furthermore, vegf, expression, was, overexpressed, in, , keloid, , tissue, , which, , later, , reduced, , following, intralesional, tac, injections, in, vivo33tac, , is, , typically, , administered, , at, , intervals, , of, , , weeks, , until, , pruritic, , and, , painassociated, symptoms, , diminish, , and, , the, , scar, , flattens34, , the, dose, , of, , tac, , is, , in, , the, , range, , of, , , , mgml, depending, , on, , the, , size, , and, , anatomical, , location, of, the, lesion, and, the, age, of, the, patient34, tac, is, used, either, alone, as, a, monotherapy, or, in, combination, , with, , other, , treatment, , modalities13, , the, response, , rates, , to, , corticosteroid, , injections, , vary, clinically, , with, , regression, , rates, , in, , the, , range, , of, , , reported, , after, , one, , year, , and, , recurrence, , rates, , in, , the, , range, , of, , , , reported, after, , five, , years3, , combined, , therapy, , comprising, surgical, excision, followed, by, tac, treatment, also, varied, , with, , reported, , recurrence, , rates, , in, , the, range, , of, , , , previous, , clinical, , studies, where, tac, was, used, alone, reported, efficacy, and, good, , clinical, , outcome, , with, , this, , treatment, , including, reduced, keloid, height, length, width, related, pruritus, and, erythema, and, improved, pliability3637, , a, , recent, , randomised, , parallelgroup, study, , that, , compared, , the, , role, , of, , intralesional, tac, , fractional, , co2, , laser, , or, , intralesional, , verapamil, , in, , the, , treatment, , of, , keloid, , in, , , , patients, showed, reduction, in, scar, height, vascularity, and, pliability, in, all, three, groups, using, the, vancouver, scar, scale, score, however, pigmentation, was, not, completely, resolved, with, any, of, the, treatments, the, , response, , was, , fastest, , with, , tac, , followed, , by, verapamil, and, laser, and, this, was, statistically, significant38, however, intralesional, tac, in, combination, with, other, treatment, modalities, such, as, 5fluorouracil, , 5fu, , pulsed, , dye, , laser, , pdl, surgery, , interferon, , ifnî±2b, , verapamil, , and, figure, , , current, and, emerging, treatment, strategieswound, healing, the, early, wound, immature, collagen, type, iii, can, be, modified, into, mature, collagen, type, i, in, keloid, tissue, it, mostly, comprises, disanised, collagen, types, i, and, iii, made, up, of, palestaining, , hypocellular, , collagen, , clusters, , lacking, nodules, or, surplus, myofibroblasts21, furthermore, recent, research, has, provided, four, distinct, findings, only, present, in, keloid, specimens, , presence, of, keloidal, , hyalinised, , collagen, , , , presence, , of, , a, tonguelike, , advancing, , edge, , underneath, , normalappearing, , epidermis, , and, , papillary, , dermis, , , , a, horizontal, cellular, fibrous, band, in, the, upper, reticular, dermis, and, , a, prominent, fascialike, band22treatment, of, keloidscurrently, various, forms, of, treatment, for, keloids, exist, however, no, single, treatment, has, proven, to, be, , the, , most, , effective, , this, , review, , will, , explore, and, , discuss, , current, , and, , emerging, , treatment, modalities, , figure, , , , some, , of, , the, , ongoing, , or, completed, clinical, trials, of, keloid, therapy, registered, on, clinicaltrialsgov, and, accessed, on, , , , may, , , , are, , summarised, , in, , table, , , studies, with, the, status, terminated, suspended, or, withdrawn, were, excludedcurrent, treatmentscorticosteroidsseveral, corticosteroids, can, be, used, for, the, treatment, of, scars, including, triamcinolone, acetonide, tac, , hydrocortisone, , acetate, , dexamethasone, and, methyl, prednisolone24, however, since, , tac, has, been, the, most, widely, used, corticosteroid, 0c, scars, burns, , healingtcnvi, esahptcnlebacilppa, ton, , vogslairtlacinilcesahpyduts, noitnevretnisnoitidnoc, , , , yamnodessecca, vogslairtacinlil, , cnoypareht, doek, fo, slairt, lliacinilc, , elbateltit, ydutsreifitneditcnlebacilppa, ton, , ybdewoll, iednotecaenoonicmairt, llanoiseartnliilsdoek, fo, tnemtaerteht, n, iof, resal, oc, lanoitcarfidoekli, sdorets, lanoiseartnl, , ii, svyparehtdoretsdetsissa, resal, , lanoitcarftcnlebacilppa, tontcnlebacilppa, tontcnvi, esahp, trs, ypareht, noitadar, liaicifrepus, ienmativ, enocilis, enositrocordyh, yparehtyhcarbetaresod, ihgh, tnavudahtij, , wnoisicxe, lacigrus, cihportrepyh, idoeklidoeklidoekl, trs, yparehtnoitadari, , l, laicifrepus, fonoitauaveevitcepsortera, , ilsdoek, fo, tnemtaert, rof, yparehtyhcarbetaresodhghi, , , , isracsdoekdnal, , dnaytili, , , llbareoteht, gnitauaveydutsevitarapmocdezimodnara, , , tcnlebacilppa, ton, , llamsaphcir, teetap, suogootuallidoekl, , llllamsaphcir, teetap, suogootuayb, racsdoek, fo, tnemtaertli, , tcb®tiknegerhti, , wdenatboitcbtiknegerhti, , wdenatboi, l, ieg, tcartxenono, ro, draugracs, noitolamredem, xirtacicracscihportrepyh, ildna, sdoek, fo, tnemtaerteht, rof, separehti, , l, acipotowt, foycaciffe, , sracscihportrepyhtcni, esahp, muiclac, fonoitcenj, i, laruomutartniidoeklrefsnartortceeybdewol, , llof, edirohcltcniii, esahp, , , dnaenoonicmairt, llanoiseartnliidoekl, ienodnefrip, l, ilsdoek, fo, tnemtaerteht, rof, noitaroportceemuiclacl, , , acipotdnaenoonicmairtl, , lanoiseartnl, i, foycaciffeienodnefrip, lacipotnoitcenji, ufidoekllygooisyhpohtapdna, tnemtaert, , gnirracsdoekli, , iioalsdal, sracsdoek, fo, tnemtaert, rofltcnii, esahp, i, esahp, inks, gnviltneavuqeiil, dereyalib, fargilpasresalidoekl, , iil, tenragmunmuamuirttymumydoenideslupgno, l, dna, oc, lanoitcarfidoekl, fo, tnemtaertn, , ii, sresal, tenragmunmuamuirttymumydoenli, , , , fonoitneverpdna, tnemtaerteht, rof, farg, ilpa, , foyduts, toli, paisdoekl, ilsdoekdesicxe, foecnerrucer, , , , deslupgnoldnaedixodnobraci, , , l, anoitcarfgnisuydutsa, , deunitnoc, cihportrepyhtcnlebacilppa, tonyparehtoyrc, lanoiseartnli, xirtacic, idoekl, , eht, rof, eciveddesab, sagnogranahti, , , , wyparehtoyrc, lanoiseartnli, , sracscihportrepyhdnadoek, fo, tnemtaertli, tcniii, esahpxirtacic, fonoitacil, ppa, lacipot, sracs, cihportrepyhcihportrepyhidoekl, ilsracs, sdoekdna, sracscihportrepyh, , fo, tnemtaerteht, n, i, ixrtacci, , sracscihportrepyhdnadoek, fo, tnemtaertli, tcnlebacilppa, tonyparehtoyrc, lanoiseartnli, xirtacic, idoekl, rof, yparehtoyrc, lanoiseartnl, , , i, foesueht, fonoitauaveevitcepsorpl, 0cojeh, , tcnvi, esahpresal, , , ptkmneht, foycaciffe, idoekl, cihportrepyheahcun, siliadoekl, xirtacic, xirtacic, racs, lacigrus, racs, reifitnedi, vogslairtlacinilcesahpyduts, noitnevretnisnoitidnocdeunitnoc, , elbateltit, ydutstcnlebacilppa, tonresal, , eyddeslup, cihportrepyh, idoekl, , , , deslupmnagnisu, tnemtaert, racsnohtdweslup, fo, tceffei, , , tcnlebacilppa, ton, thgil, , avuderutcafunamnamreg, , idoeklsracs, amredorelcssnoitidnoc, rali, , imsdnaamredorelcs, fo, tnemtaert, rof, thglavui, resaleyd, ecivedgnitti, me, gnisorbif, rehtosnoitidnoctcnlebacilppa, ton, ecivederusserptcnvi, esahpl, egenocilis, lacipot, cihportrepyh, idoeklilerusserp, sdoek, rae, fo, tnemtaerteht, n, i, , ecivederusserpidoekl, fo, tnemtaerteht, no, , l, egenocili, isgnyrdfles, tnerapsnart, fo, tceffesracssracs, l, ianmodbacihportrepyhtcnlebacilppa, tonypareht, noitadariidoekl, yrtsigernoitadardoeklii, tcniii, esahpnosahtemateb, fonoitacil, ppa, lacipot, sracs, cihportrepyhsretehtac, suonev, lartnec, retfa, sracstcni, esahpii, esahptcn, i, esahpii, esahp, dna, sll, , dicacidisuf, dnaetareavl, isdoeklidocitrococuglnoitadarri, ibvu, amredorelcs, idoekl, inks, fo, tnemtaerteht, n, i, ypareht, thgl, bvuil, b, teovartlui, leraunnaamounargl, sracs, siliadoekl, enca, desilacolxirtam, l, amredderetlahti, w, snoitidnoc, lecfvs, suogootua, fo, snoitcenji, axal, situc, racs, inkscsdaxirtacic, idoekl, , ideviredesopda, suogootuahtil, , , waxal, situcdna, sracs, foypareht, sll, ecmets, lamyhcnesemtcnlebacilppa, ton, gnitti, , meavuderutcafunamnamreg, , amredorelcs, idoeklsnoitidnoc, ralimetsys, thgil, lamounarg, sracs, enca, leraunna, , imsdnaamredorelcs, rof, thglavui, ilteovartlu, vu, fvs, sll, ecnoitcarf, raucsavl, lamorts, fvs, etahpsohp, lynatit, muissatop, ptk, sll, ecmets, l, amyhcnesemdeviredesopdai, hserf, fo, tnemtaerteht, rof, resalptkmn, , , l, evona, foyduts, to, lip, csda, licaruoroulf, ufsracs, lacigrus, 0c, scars, burns, , healinga, variety, of, methods, can, be, used, for, the, surgical, removal, of, keloids, depending, on, the, size, of, the, , keloid, , anatomical, , location, , skin, , type, , and, age, of, patient52, these, include, linear, closure, and, flap, , coverage, , excision, , with, , grafting, , wplasty, and, , zplasty53, , to, , reduce, , risk, , of, , keloid, , recurrence, , the, , surgeon, , performing, , the, , excision, should, establish, tensionfree, wound, closure, as, a, general, , rule, , closure, , of, , the, , wound, , should, , be, accomplished, with, minimal, tension, and, sutures, leaving, everted, wound, borders, zplasties, threelayered, , sutures, , subcutaneousfascial, , tensile, reduction, , sutures, , or, , local, , ï¬ap, , surgery, , can, , be, employed, , on, , a, , casebycase, , basis5455, , the, , final, outcome, of, the, scar, is, often, positively, correlated, with, , the, , experience, , of, , the, , operating, , surgeon, and, , technique, , utilised, , as, , well, , as, , the, , patients, active, participation, in, their, wound, care52siliconebased, productssince, , the, , 1980s, , siliconebased, , products, , have, been, used, in, the, treatment, of, keloids, and, hypertrophic, , scars, , with, , silicone, , gel, , or, , silicone, , gel, sheeting, , considered, , as, , firstline, , therapy, , for, minor, keloids, and, hypertrophic, scars2635, there, are, , various, , other, , forms, , of, , silicone, , including, creams, sprays, gel, cushion, and, liquid24, the, precise, mechanism, of, action, of, silicone, products, is, not, fully, understood, but, it, is, proposed, that, they, enhance, hydration, and, create, an, occlusive, environment53, which, influences, fibroblast, regulation, and, , decreases, , collagen, , synthesis56, , silicone, , gel, sheeting, , has, , been, , shown, , to, , have, , minimal, , side, effects, , including, , local, , irritation, , which, , can, , be, resolved, , quickly24, , studies, , have, , shown, , that, , the, beneficial, , effects, , of, , silicone, , gel, , sheets, , include, pain, reduction, tenderness, and, pruritus, and, flattening, the, keloid57, the, silicone, gel, sheeting, is, recommended, to, be, worn, from, two, weeks, after, primary, , wound, , treatment, , for, , , , h, , for, , , months58studies, have, demonstrated, an, improvement, of, up, to, , in, keloid, scars, after, using, silicone, gel, , sheeting35, , and, , a, , decrease, , in, , the, , incidence, rates, , of, , keloids, , and, , hypertrophic, , scars, , after, , surgery59, , in, , addition, , controlled, , studies, , have, reported, the, clinical, effectiveness, of, silicone, gel, and, silicone, gel, sheeting, in, the, prevention, and, treatment, of, keloids3558, however, a, recent, metaanalysis, , review60, , and, , cochrane, , review61, , found, that, even, though, studies, published, data, in, support, of, the, efficacy, of, silicone, gel, sheeting, in, the, treatment, , and, , prevention, , of, , keloid, , and, , hypertrophic, , scarring, , they, , provided, , weak, , evidence, and, , were, , of, , poor, , quality60, , therefore, , given, figure, , , auricular, keloid, surgical, excision, used, as, monotherapy, auricular, keloid, before, a, and, after, b, surgical, excisonsurgery, all, yielded, significant, improvements, compared, to, treatment, with, tac, monotherapy339intralesional, , steroid, , injections, , can, , cause, , several, , adverse, , side, , effects, , such, , as, , telangiectasis, atrophy, steroid, acne, pigmentary, changes, necrosis, ulcerations, and, systemic, side, effects3, there, is, also, , significant, , pain, , associated, , with, , intradermal, corticosteroid, injections, that, can, be, reduced, when, local, anaesthetic, lidocaine, is, administered, to, control, the, pain44, furthermore, the, side, effects, have, been, reported, to, diminish, when, intralesional, tac, is, used, in, combination, with, 5fu45surgical, excisionsurgical, excision, is, a, traditional, method, of, removing, keloids, figure, , however, excision, creates, a, new, wound, and, can, result, in, a, similar, or, larger, keloid47, , therefore, , surgical, , excision, , is, , not, , recommended, as, a, monotherapy, as, it, results, in, high, recurrence, , rates, , in, , the, , range, , of, , , for, better, postoperative, surgical, outcomes, surgical, excision, is, often, combined, with, other, forms, of, treatment, , including, , radiotherapy, , intralesional, corticosteroid, , injections, , ifn, , injection, , bleomycin, cryotherapy, pressure, therapy, and, silicone, gel, or, sheeting82649, successful, use, of, dermal, substitutes, and, epidermal, skin, grafting, with, keloid, excision, has, also, been, reported50, a, recent, case, series, study, , in, , which, , , , patients, , with, , anterior, , chest, wall, keloids, were, given, a, treatment, protocol, consisting, , of, , complete, , excision, , zplasty, , postoperative, adjuvant, radiotherapy, and, postsurgical, wound, selfmanagement, , reported, , excellent, , outcomes, with, a, recurrence, rate, of, only, , the, use, of, steroid, tape, and, injections, helped, to, resolve, the, recurrence, of, keloids51, 0cojeh, , the, , lack, , of, , substantial, , evidence, , welldesigned, clinical, trials, and, studies, are, required, to, gain, a, better, understanding, of, the, effectiveness, of, siliconebased, products, in, preventing, and, treating, keloidspressure, therapypressure, therapy, has, been, used, to, treat, and, manage, keloids, and, hypertrophic, scars, for, decades3563, it, has, been, routinely, employed, as, firstline, treatment, , in, , the, , treatment, , of, , hypertrophic, , scarring, resulting, , from, , burns64, , the, , underlying, , mechanisms, of, action, of, compression, techniques, remain, unclear, however, several, hypotheses, exist, some, of, which, include, increased, pressure, to, the, scar, surface, , reduces, , perfusion, , and, , decreased, , oxygen, , to, the, location, of, injury, reduces, collagen, synthesis, it, is, , also, , thought, , that, , pressure, , increases, , apoptosis, reduces, , scar, , hydration, , stabilising, , mast, , cells, , and, decreases, angiogenesis165, the, application, of, pressure, can, be, achieved, using, a, variety, of, materials, such, as, adhesive, plaster, moulds, pressure, earrings, and, , customfitted, , splints16, , which, , have, , improved, scar, cosmesis, and, rates, of, keloid, recurrence66, a, continuous, , pressure, , of, , , , mmhg, , preferably, at, the, lower, range, soon, after, wound, reepithelialisation, for, , h, per, day, for, , , months, is, recommended166869, the, efficacy, of, pressure, therapy, depends, mainly, on, the, anatomical, location, of, the, scar, with, trunk, and, limb, areas, being, more, appropriate, , sites, , for, , pressure, , therapy, , in, , addition, , a, pressure, garment, is, predominantly, used, for, auricular, , keloids, , where, , pressure, , clips, , are, , commonly, utilised, , after, , surgery6670, , as, , an, , adjuvant, , therapy, this, form, of, pressure, garment, has, also, been, successfully, , used, , to, , prevent, , the, , recurrence, , of, keloids6667, in, contrast, a, metaanalysis, review, that, analysed, , the, , effectiveness, , of, , pressure, , garment, therapy, , for, , the, , prevention, , of, , abnormal, , scarring, after, , burn, , injury, , was, , unable, , to, , demonstrate, , any, beneficial, effects, of, pressure, garment, therapy, on, prevention, , or, , treatment, , of, , abnormal, , scarring59, notwithstanding, success, rates, of, pressure, therapy, are, contingent, upon, patient, compliance69, which, can, sometimes, be, low, due, to, discomfort, overall, pressure, therapy, is, tolerated, better, and, is, devoid, of, the, pain, often, associated, with, intralesional, therapies, and, hence, can, be, considered, as, a, good, adjuvant, therapy, for, keloid, scarsradiotherapyin, , the, treatment, of, keloids, using, superficial, xray, irradiation, was, first, described71, since, then, it, has, been, used, less, frequently, as, a, monotherapy, and, more, widely, as, an, effective, adjunct, treatment, after, surgical, excision72, with, success, rates, in, the, range, , of, , , , and, , recurrence, , rates, , of, about, , radioactive, skin, patches, have, also, been, used, in, combination, with, other, treatment, modalities, , for, , keloids7879, , radiotherapy, , is, , most, commonly, used, , h, after, surgical, excision7480, and, acts, by, suppressing, angiogenesis, and, inhibiting, ï¬broblast, activity1, decreased, fibroblast, proliferation, , induced, , cell, , senescence, , and, , apoptosis, leading, to, reduction, in, collagen, production, and, suppression, , of, , keloid, , development, , have, , also, been, reported81different, , radiotherapy, , modalities, , have, been, , used, , after, , surgical, , excision, , including, electron, , beam, , radiotherapy, , brachytherapy, superï¬cial, and, orthovoltage, radiotherapy, with, varying, , degrees, , of, , success84, , mankowski, , et, a0, al, conducted, , a, , literature, , review, , of, , , , studies, , to, compare, , the, , clinical, , outcome, , of, , different, forms, of, radiation, treatment, used, for, the, management, of, keloids77, the, metaanalysis, demonstrated, , that, , radiation, , used, , as, , monotherapy, yielded, higher, rates, of, recurrence, , compared, , to, , combinational, , therapy, , with, , postsurgery, excision, , comparison, between, the, different, , radiationbased, , treatments, , revealed, that, the, lowest, rate, of, recurrence, was, observed, with, , brachytherapy, , , , followed, , jointly, , by, xray, , , , and, , electron, , beam, , , , the, authors, , also, , reported, , that, , the, , rate, , of, , recurrence, was, dependent, on, anatomical, site, of, the, keloid, , with, , chest, , keloids, , having, , the, , highest, recurrence, rate73the, , adverse, , effects, , of, , radiotherapy, , often, linked, , with, , dose, , of, , radiation, , used, , can, , be, grouped, into, acute, skin, reactions, and, late, complications, acute, reactions, arise, as, early, as, seven, days, after, keloid, treatment, and, include, oedema, necrosis, , ulceration, , desquamation, , erythema, and, , pigmentary, , changes, , with, , the, , latter, , two, being, , the, , most, , common, , late, , complications, which, include, changes, in, pigment, atrophy, telangiectasis, , and, , alopecia, , may, , present, , several, weeks, after, radiotherapy, emollient, and, steroid, ointment, used, after, radiotherapy, can, help, alleviate, the, side, effects19, a, recommended, radiation, dose, , , gy, over, several, sessions, can, also, minimise, , adverse, , effects1980, , radiotherapy, , carries, , a, risk, of, malignancy8586, therefore, caution, should, be, used, in, radiationvulnerable, sites, such, as, the, head, , neck, , thyroid, , and, , breast, , and, , in, , patients, aged, , , years2, protecting, fragile, ans, and, selecting, , the, , most, , appropriate, , sitedependent, dose, protocol, can, help, minimise, further, complications, of, radiotherapy87, 0c, scars, burns, , healingcryotherapycryotherapy, is, a, lowtemperature, treatment, that, causes, , vascular, , damage, , resulting, in, , tissue, , necrosis88, it, has, been, used, to, treat, keloids, as, a, monotherapy, or, in, combination, with, other, treatment, , methods, , such, , as, , intralesional, , steroid, , injections89, , various, , delivery, , methods, , used, , for, cryotherapy, include, spray, and, contact, probes, or, the, intralesionalneedle, , cryoprobe, , method, compared, to, contact, and, spray, methods, intralesionalneedle, , cryoprobe, , was, , found, , to, , be, , the, most, effective, method, in, treating, keloid, scars90, positive, outcomes, were, observed, in, a, number, of, studies, , that, , used, , liquid, , nitrogen, , and, , cryotherapy, to, treat, keloids, with, success, rates, in, the, range, of, external, , cryotherapy, , has, , been, , associated, with, several, side, effects, including, hypopigmentation, , blistering, , pain, , delayed, , healing, , and, , infection9093, moreover, larger, keloids, have, been, shown, to, need, multiple, cryotherapy, sessions9093, to, , minimise, , side, , effects, , intralesional, , cryotherapy, was, introduced, and, there, are, now, a, number, of, , nitrogenbased, , cryodevices, , that, , have, , been, described, for, the, treatment, of, keloid, scars, with, two, , commercially, , available, , a, , liquid, , nitrogenbased, device88, and, an, argon, gasbased, device94, the, , intralesional, , cryotherapy, , was, , designed, , to, overcome, the, hypopigmentation, seen, mostly, in, darkskinned, individuals, with, external, cryotherapy, it, works, by, destroying, the, core, of, the, keloid, sparing, the, surface, epithelial, cells, including, melanocytes9596, , as, , a, , result, , it, , enhances, , volume, decrease, , while, , minimising, , the, , risk, , of, , hypopigmentation, and, other, surface, reactions90, a, recent, comprehensive, , review, , based, , on, , the, , preferred, reporting, items, for, systematic, reviews, and, metaanalysis, was, performed, to, investigate, the, efficacy, of, , intralesional, , cryotherapy, , on, , keloid, , scars90, the, review, of, eight, studies, that, met, the, inclusion, criteria, , revealed, , that, , average, , scar, , volume, decreased, , in, , the, , range, , of, , , , but, , complete, eradication, of, the, scar, on, average, was, lacking, recurrence, of, keloid, scars, was, in, the, range, of, , , , the, , authors, , also, , reported, , that, patients, , complaints, , of, , pain, , and, , pruritus, , was, considerably, , reduced, , however, , hypopigmentation, was, seen, mostly, in, fitzpatrick, , skin, type, patients, after, treatment90laser, therapylaser, , therapy, , for, , keloid, , treatment, , was, , introduced, in, the, 1980s97, since, then, different, systems, have, been, used, for, the, treatment, of, keloid, and, hypertrophic, scars4898, these, lasers, target, skin, chromophores, like, haemoglobin, and, melanin, based, on, the, principle, of, selective, photothermolysis99, , lasers, , can, , be, , classified, , as, ablative, , and, , nonablative, , the, , most, , common, ablative, , lasers, , include, , the, , 2940nm, , erbiumdoped, , yttrium, , aluminium, , garnet, , eryag, laser, and, the, 10600nm, carbon, dioxide, co2, laser, these, emit, a, laser, beam, that, is, absorbed, by, , water, , in, , the, , skin, , leading, , to, , local, , tissue, destruction, , and, , reduction, , of, , lesion, , volume3, common, , examples, , of, , nonablative, lasers, include, 585nm, or, 595nm, pdls, 1064nm, neodymiumdopedyttriumaluminiumgarnet, ndyag, neodymiumdopedvanadate, , ndvan, , laser, , and, , , , nm, qswitched, , ndyag, , laser, , with, , low, , fluence100, these, lasers, induce, thermal, injury, to, the, scars, microvasculature, , leading, , to, , thrombosis, , and, ischaemia, , which, , result, , in, , collagen, , denaturation, and, collagen, fibre, realignment101532nm, laser, laser, , therapy, , requires, , several, , treatments, , at, intervals, of, , weeks, depending, on, scar, type, and, type, , of, , laser, , used98104, , with, , possible, , side, , effects, including, itching, pigmentary, changes, blister, formation, , and, , postoperative, , purpura98, , the, , use, , of, the, , nonfractional, , vascular, , , , nm, , pdl, , in, the, , treatment, , of, , keloid, , and, , hypertrophic, , scars, has, been, welldocumented105, and, has, response, rates, in, the, range, of, , pdl, monotherapy, has, been, shown, to, be, effective108110, as, well, as, co2, laser, monotherapy38111112, in, a, clinical, study, where, , patients, with, moderate, to, severe, keloids, were, , treated, , with, , highenergy, , pulsed, , co2, , laser, the, , treatment, , was, , efficacious, , and, , welltolerated, with, minimal, side, effects112, in, other, studies, where, co2, laser, ablation, was, compared, with, other, forms, of, treatment, co2, laser, was, as, efficient, as, the, other, forms38111, it, must, be, noted, however, that, these, studies, are, small, and, randomised, controlled, studies, are, lacking98laser, therapy, such, as, pdl, co2, and, ndyag, have, , been, , associated, , with, , a, , high, , rate, , of, , recurrence, at, , months111113, however, optimal, results, , can, , be, , achieved, , with, , combination, , treatment, , especially, , with, , intralesional, , tac, , injections116, , kumar, , and, , coworkers, , conducted, , a, cohort, , study, , on, , , , patients, , with, , keloids, , previously, treated, with, an, ndyag, laser, and, reported, complete, scar, resolution, and, flattening, in, seven, patients, , only, , when, , intralesional, , tac, , was, , used, after, , laser, , therapy41, , moreover, , combined, , therapy, , with, , pdl, , and, , tac119, , and, , pdl, , tac, , and, 5fu36, , were, , shown, , to, , produce, , better, , clinical, results, in, a, recent, study, that, evaluated, and, compared, , the, , efficacy, , of, , combination, , therapy, , of, 0cojeh, , scars, statistically, fractional, co2, laser, and, intralesional, tac, injection, or, tac, injection, alone, in, keloid, and, hypertrophic, significant, improvements, were, reported, in, overall, scar, quality, , with, , the, , combined, , treatment, , options, , comto, , tac, , monotherapy120, , moreover, pared, combined, , co2, , laser, , and, , ifnî±2b, , injections, given, to, patients, with, auricular, keloids, resulted, in, no, recurrence, in, , of, patients, three, years, after, treatment121, laser, therapy, can, also, be, combined, , with, , other, , laser, , treatment, , topical, , corticosteroids, , and, , cyanoacrylate, , glue98, , and, , have, shown, , promising, , results, , however, , larger, , controlled, clinical, studies, are, needed, to, further, evaluate, their, efficacy, and, safetyrecently, , lasers, , are, , also, , being, , explored, , as, tools, for, assisted, drug, delivery, kraeva, et, a0al, proposed, an, alternative, technique, of, corticosteroid, administration, , of, , laserassisted, , drug, , delivery, , of, topical, tac, this, was, shown, to, be, effective, when, used, , on, , a, , keloid, , on, , the, , posterior, , scalp, , of, , a, patient, after, each, co2, laser, session122, more, efficient, , intraepidermal, , drug, , delivery, , options, , are, also, being, investigated, singhal, et, a0al, developed, taccontaining, , polymeric, , microps, , that, were, prepared, using, a, cryomilling, technique, for, freezing, fracture, after, ablation, with, a, fractional, eryag, laser, these, microps, can, be, deposited, in, cutaneous, micropores, and, provide, highdose, intraepidermal, , reservoir, , systems, , with, minimal, transdermal, permeation, leading, to, sustained, and, targeted, local, drug, delivery123it, must, be, noted, that, one, of, the, biggest, limitations, in, studies, available, at, present, is, the, lack, of, , histological, , definition, , between, , keloid, , and, hypertrophic, scars, so, conclusions, are, not, , valid, on, efficacyimiquimod, , creamimiquimod, , cream, is, approved, for, the, treatment, , of, , basal, , cell, , carcinoma, , actinic, , keratoses, and, genital, warts21, as, an, immuneresponse, modifier, it, stimulates, the, production, of, proinflammatory, , cytokines, , such, , as, , tnfî±, , interleukins, , and, ifns, by, activated, tcells124, thereby, changing, the, expression, , of, , genes, , associated, , with, , apoptosis125, and, reducing, collagen, production16, studies, have, reported, , conflicting, , findings, , regarding, , efficacy, of, , imiquimod, , , , cream, , postoperatively, , following, keloid, excision, likely, due, to, keloid, location, many, studie]                                                                                                                                                                                                                                                                                                                            |[, scars, burns, , healingvolume, , , , , reuse, guidelinessagepubcomjournalspermissions, authors, , journalssagepubcomhomesbhkeloids, pathological, scars, grow, time, extend, beyond, initial, site, injury, impaired, wound, , healing, , , scars, , frequently, , recur, , , rarely, , regress, , , , aesthetically, , disfiguring, , cause, pain, itching, discomfort, well, psychological, stress, often, affecting, quality, life, many, treatment, modalities, including, surgical, nonsurgical, explored, reported, beneficial, however, none, absolutely, satisfactory, optimal, treatment, keloid, subtypes, date, , poses, , , major, , challenge, , , clinicians, , often, , , combinational, , therapeutic, , approach, , appears, , , offer, best, results, higher, patient, satisfaction, compared, monotherapy, aetiopathogenesis, keloids, , , fully, , elucidated, , however, , , recent, , advances, , , molecular, , biology, , , genetics, , insight, , , gained, complex, process, scar, formation, hence, new, therapeutic, management, options, keloids, , , , paper, , , explore, , , literature, , , summarise, , , general, , concepts, , surrounding, , keloid, development, , , review, , , current, , corticosteroids, , surgical, , excision, , siliconebased, , products, , pressure, therapy, , radiotherapy, , cryotherapy, , laser, , therapy, , imiquimod, , , 5fluorouracil, , , emerging, , stem, , cell, therapy, mitomycin, c, verapamil, interferons, bleomycin, botulinum, toxin, type, angiotensinconverting, enzyme, inhibitors, treatments, increased, knowledge, understanding, area, may, potentially, lead, discovery, development, novel, therapeutic, options, efficacious, keloid, typeskeywordskeloids, scar, recurrence, wound, healing, treatment, managementlay, summarykeloids, problematic, scars, difficult, treat, manage, aetiopathogenesis, keloids, clear, however, recent, advances, molecular, biology, genetics, beginning, shed, light, underlying, mechanisms, implicated, keloid, scar, formation, hopefully, lead, development, treatment, options, keloid, types, review, summarises, current, emerging, therapiesintroductionwound, healing, intricate, complex, series, , processes, , comprising, , overlapping, , phases, , inflammation, granulation, tissue, formation, tissue, remodelling, results, tissue, structure, integrity, damage, restored1, abnormal, wound, healing, give, rise, keloids, benign, dermal, fibroproliferative, nodular, lesions, , tend, , , recur, , , excision, , keloid, , scars, , faculty, medical, sciences, university, west, indies, cave, hill, campus, bridgetown, barbados, west, indies, pine, medical, centre, 3rd, avenue, belleville, st, michael, barbados, west, indiescorresponding, authornkemcho, ojeh, faculty, medical, sciences, university, west, indies, cave, hill, campus, po, box, , st, michael, bridgetown, bb, , barbados, west, indies, email, nkemchoojehcavehilluwieducreative, commons, non, commercial, cc, bync, , distributed, terms, creative, commons, attributionnoncommercial, , license, creativecommonslicensesbync40, permits, noncommercial, use, reproduction, distribution, work, without, permission, provided, original, work, attributed, specified, sage, , , , access, pages, ussagepubcomenusnam, accessatsage, 0c, scars, burns, , healinginfluence, , , keloid, , aetiology9, , although, , , one, specific, gene, associated, development, keloids, number, genes, gene, loci, identified610, genomewide, association, studies, admixture, mapping, studies, identified, singlenucleotide, polymorphisms, across, certain, loci, genetically, linked, keloid, development, including, , , nedd4, , gene, , , encodes, , e3, ubiquitin, , ligase, , enzyme, , , , myosin, , genes, my01e, myo7a10, studies, also, reported, involvement, several, human, leucocyte, antigen, hla, alleles, p53, bcl2, fas, genes1014, furthermore, , rare, , genetic, , disorders, , , reported, , , present, , , spontaneous, , keloids, including, dubowitz, syndrome, bethlem, myopathy, rubinsteintaybi, , syndrome, , noonan, , syndrome, geominne, , syndrome, , , others1017, , , lines, evidence, suggest, genetic, factors, play, role, keloid, predispositionpathophysiology, keloidskeloid, , pathology, , , complex, , involving, , genetic, environmental, factors, keloids, form, result, abnormal, wound, healing, excessive, dermal, fibrosis, development, keloids, linked, overproliferation, reduced, apoptosis, dermal, fibroblasts, overproduction, collagen, fibres, extracellular, matrix, ecm, components, well, abnormal, ecm, production, remodelling1, , various, , cytokines, , growth, , factors, proteolytic, enzymes, implicated, , formation, , , keloids, , including, , transforming, growth, factor, tgf, epidermal, growth, factor, egf, vascular, endothelial, growth, factor, vegf, plateletderived, growth, factor, pdgf, connective, tissue, , growth, , factor, , ctgf, , tumour, , necrosis, factorî±, , tnfî±, insulinlike, , growth, , factor1, , igf1, fibroblast, growth, factor, fgf, interleukin6, , il6, , , matrix, , metalloproteinases, mmps31418, , furthermore, , signalling, , pathways, tolllike, receptor, signalling, smad, signalling, fibronectin, reported, associated, keloid, development1819histopathology, keloidshistologically, keloids, comprise, abundance, unordered, , dermal, , collagen, , , vasculature, , high, , inflammatorycell, , infiltrate, , , overactive, mesenchymal, , cells1415, , , addition, , , collagen, elastin, , fibronectin, , , proteoglycans, , , deposited, excess, amounts, keloid, scars9, collagen, creates, , frequent, , crosslinks, , , ordinary, , wounds, whereas, collagen, irregularly, anised, keloids, forming, nodules, dermis20, normal, figure, , , earlobe, keloids, consequence, ear, piercingarise, skin, trauma, inflammation, may, develop, , years, , , , initial, , insult, , , rarely, regress2, scar, tissue, extends, beyond, original, wound, site, disfiguring, cause, psychosocial, , issues, , impairing, , quality, , , life3, , addition, , patients, , may, , present, , , symptoms, burning, pain, pruritus, movement, limitation, hyperaesthesia2aetiologythe, , aetiology, , , keloids, , , still, , poorly, , understood, common, regions, skin, keloids, include, upper, arms, skin, overlying, joints, chest, shoulders, headneck, regions, particularly, , , ear, , lobes, , figure, , , , , anatomical, location, keloid, appears, alter, morphological, characteristics, keloids, develop, spontaneously, , however, , , occur, , years, , local, trauma, events, including, inflammation, surgery, burns, elective, cosmesis, foreign, body, reactions, acne, insect, bites, vaccinations, mechanical, force45epidemiology, keloid, geneticsthe, incidence, keloids, highest, among, darkerpigmented, , persons, , , african, , asian, , hispanic, , descent, , , , estimated, , , , , range, , , , , males, , , females, , , equal, risk, developing, keloids6, although, incidence, , , slightly, , increased, , , females, , likely, attributable, cosmetic, procedures, , like, , ear, , piercing7, , persons, , aged, , , years, , , also, , , , higher, , risk, , , developing, keloids, , additional, , risk, , factors, , include, , blood, , type, , , hyperige, , , hormonal, , peaks, pregnancy, puberty8familial, , keloid, , case, , studies, , , twin, , studies, support, , , notion, , , genetic, , factors, , , 0cojeh, , treatment, keloids2627, intralesional, tac, injections, shown, reduce, scar, volume, height, improve, scar, pliability, diminish, associated, scar, pain, itching8, well, prevent, recurrence3, , corticosteroids, , , antiinflammatory, , , antimitotic, , properties1, , several, , mechanisms, , , , reported, , , , corticosteroids, reduce, keloid, scar, including, inhibition, , fibroblast, , growth, , attenuation, , , procollagen, , glycosaminoglycan, , synthesis, , reduction, , endothelial, , budding, , , enhancement, , , collagen, , , fibroblast, , degeneration2829, , corticos, teroids, , inhibit, , tgf1, , expression, , , induce, apoptosis, fibroblasts, inhibit, vegf, alphaglobulins, involved, wound, healing, , process28, , vegf, , , promotes, angiogenesis, reported, highly, expressed, , keloid, , fibroblasts, , compared, , , controls, , exogenous, , addition, , , , glucocorticoid, , dexamethasone, , suppressed, , , expression, , , vitro32, furthermore, vegf, expression, overexpressed, , keloid, , tissue, , , later, , reduced, , following, intralesional, tac, injections, vivo33tac, , , typically, , administered, , , intervals, , , , weeks, , , pruritic, , , painassociated, symptoms, , diminish, , , , scar, , flattens34, , dose, , , tac, , , , , range, , , , , mgml, depending, , , , size, , , anatomical, , location, lesion, age, patient34, tac, used, either, alone, monotherapy, combination, , , , treatment, , modalities13, , response, , rates, , , corticosteroid, , injections, , vary, clinically, , , regression, , rates, , , , range, , , , reported, , , one, , year, , , recurrence, , rates, , , , range, , , , , reported, , five, , years3, , combined, , therapy, , comprising, surgical, excision, followed, tac, treatment, also, varied, , , reported, , recurrence, , rates, , , range, , , , , previous, , clinical, , studies, tac, used, alone, reported, efficacy, good, , clinical, , outcome, , , , treatment, , including, reduced, keloid, height, length, width, related, pruritus, erythema, improved, pliability3637, , , recent, , randomised, , parallelgroup, study, , , compared, , , role, , , intralesional, tac, , fractional, , co2, , laser, , , intralesional, , verapamil, , , , treatment, , , keloid, , , , , patients, showed, reduction, scar, height, vascularity, pliability, three, groups, using, vancouver, scar, scale, score, however, pigmentation, completely, resolved, treatments, , response, , , fastest, , , tac, , followed, , verapamil, laser, statistically, significant38, however, intralesional, tac, combination, treatment, modalities, 5fluorouracil, , 5fu, , pulsed, , dye, , laser, , pdl, surgery, , interferon, , ifnî±2b, , verapamil, , figure, , , current, emerging, treatment, strategieswound, healing, early, wound, immature, collagen, type, iii, modified, mature, collagen, type, keloid, tissue, mostly, comprises, disanised, collagen, types, iii, made, palestaining, , hypocellular, , collagen, , clusters, , lacking, nodules, surplus, myofibroblasts21, furthermore, recent, research, provided, four, distinct, findings, present, keloid, specimens, , presence, keloidal, , hyalinised, , collagen, , , , presence, , , tonguelike, , advancing, , edge, , underneath, , normalappearing, , epidermis, , , papillary, , dermis, , , , horizontal, cellular, fibrous, band, upper, reticular, dermis, , prominent, fascialike, band22treatment, keloidscurrently, various, forms, treatment, keloids, exist, however, single, treatment, proven, , , , effective, , , review, , , explore, , discuss, , current, , , emerging, , treatment, modalities, , figure, , , , , , , ongoing, , completed, clinical, trials, keloid, therapy, registered, clinicaltrialsgov, accessed, , , , may, , , , , summarised, , , table, , , studies, status, terminated, suspended, withdrawn, excludedcurrent, treatmentscorticosteroidsseveral, corticosteroids, used, treatment, scars, including, triamcinolone, acetonide, tac, , hydrocortisone, , acetate, , dexamethasone, methyl, prednisolone24, however, since, , tac, widely, used, corticosteroid, 0c, scars, burns, , healingtcnvi, esahptcnlebacilppa, ton, , vogslairtlacinilcesahpyduts, noitnevretnisnoitidnoc, , , , yamnodessecca, vogslairtacinlil, , cnoypareht, doek, fo, slairt, lliacinilc, , elbateltit, ydutsreifitneditcnlebacilppa, ton, , ybdewoll, iednotecaenoonicmairt, llanoiseartnliilsdoek, fo, tnemtaerteht, n, iof, resal, oc, lanoitcarfidoekli, sdorets, lanoiseartnl, , ii, svyparehtdoretsdetsissa, resal, , lanoitcarftcnlebacilppa, tontcnlebacilppa, tontcnvi, esahp, trs, ypareht, noitadar, liaicifrepus, ienmativ, enocilis, enositrocordyh, yparehtyhcarbetaresod, ihgh, tnavudahtij, , wnoisicxe, lacigrus, cihportrepyh, idoeklidoeklidoekl, trs, yparehtnoitadari, , l, laicifrepus, fonoitauaveevitcepsortera, , ilsdoek, fo, tnemtaert, rof, yparehtyhcarbetaresodhghi, , , , isracsdoekdnal, , dnaytili, , , llbareoteht, gnitauaveydutsevitarapmocdezimodnara, , , tcnlebacilppa, ton, , llamsaphcir, teetap, suogootuallidoekl, , llllamsaphcir, teetap, suogootuayb, racsdoek, fo, tnemtaertli, , tcb®tiknegerhti, , wdenatboitcbtiknegerhti, , wdenatboi, l, ieg, tcartxenono, ro, draugracs, noitolamredem, xirtacicracscihportrepyh, ildna, sdoek, fo, tnemtaerteht, rof, separehti, , l, acipotowt, foycaciffe, , sracscihportrepyhtcni, esahp, muiclac, fonoitcenj, laruomutartniidoeklrefsnartortceeybdewol, , llof, edirohcltcniii, esahp, , , dnaenoonicmairt, llanoiseartnliidoekl, ienodnefrip, l, ilsdoek, fo, tnemtaerteht, rof, noitaroportceemuiclacl, , , acipotdnaenoonicmairtl, , lanoiseartnl, foycaciffeienodnefrip, lacipotnoitcenji, ufidoekllygooisyhpohtapdna, tnemtaert, , gnirracsdoekli, , iioalsdal, sracsdoek, fo, tnemtaert, rofltcnii, esahp, esahp, inks, gnviltneavuqeiil, dereyalib, fargilpasresalidoekl, , iil, tenragmunmuamuirttymumydoenideslupgno, l, dna, oc, lanoitcarfidoekl, fo, tnemtaertn, , ii, sresal, tenragmunmuamuirttymumydoenli, , , , fonoitneverpdna, tnemtaerteht, rof, farg, ilpa, , foyduts, toli, paisdoekl, ilsdoekdesicxe, foecnerrucer, , , , deslupgnoldnaedixodnobraci, , , l, anoitcarfgnisuydutsa, , deunitnoc, cihportrepyhtcnlebacilppa, tonyparehtoyrc, lanoiseartnli, xirtacic, idoekl, , eht, rof, eciveddesab, sagnogranahti, , , , wyparehtoyrc, lanoiseartnli, , sracscihportrepyhdnadoek, fo, tnemtaertli, tcniii, esahpxirtacic, fonoitacil, ppa, lacipot, sracs, cihportrepyhcihportrepyhidoekl, ilsracs, sdoekdna, sracscihportrepyh, , fo, tnemtaerteht, n, ixrtacci, , sracscihportrepyhdnadoek, fo, tnemtaertli, tcnlebacilppa, tonyparehtoyrc, lanoiseartnli, xirtacic, idoekl, rof, yparehtoyrc, lanoiseartnl, , , foesueht, fonoitauaveevitcepsorpl, 0cojeh, , tcnvi, esahpresal, , , ptkmneht, foycaciffe, idoekl, cihportrepyheahcun, siliadoekl, xirtacic, xirtacic, racs, lacigrus, racs, reifitnedi, vogslairtlacinilcesahpyduts, noitnevretnisnoitidnocdeunitnoc, , elbateltit, ydutstcnlebacilppa, tonresal, , eyddeslup, cihportrepyh, idoekl, , , , deslupmnagnisu, tnemtaert, racsnohtdweslup, fo, tceffei, , , tcnlebacilppa, ton, thgil, , avuderutcafunamnamreg, , idoeklsracs, amredorelcssnoitidnoc, rali, , imsdnaamredorelcs, fo, tnemtaert, rof, thglavui, resaleyd, ecivedgnitti, gnisorbif, rehtosnoitidnoctcnlebacilppa, ton, ecivederusserptcnvi, esahpl, egenocilis, lacipot, cihportrepyh, idoeklilerusserp, sdoek, rae, fo, tnemtaerteht, n, , ecivederusserpidoekl, fo, tnemtaerteht, , l, egenocili, isgnyrdfles, tnerapsnart, fo, tceffesracssracs, l, ianmodbacihportrepyhtcnlebacilppa, tonypareht, noitadariidoekl, yrtsigernoitadardoeklii, tcniii, esahpnosahtemateb, fonoitacil, ppa, lacipot, sracs, cihportrepyhsretehtac, suonev, lartnec, retfa, sracstcni, esahpii, esahptcn, esahpii, esahp, dna, sll, , dicacidisuf, dnaetareavl, isdoeklidocitrococuglnoitadarri, ibvu, amredorelcs, idoekl, inks, fo, tnemtaerteht, n, ypareht, thgl, bvuil, b, teovartlui, leraunnaamounargl, sracs, siliadoekl, enca, desilacolxirtam, l, amredderetlahti, w, snoitidnoc, lecfvs, suogootua, fo, snoitcenji, axal, situc, racs, inkscsdaxirtacic, idoekl, , ideviredesopda, suogootuahtil, , , waxal, situcdna, sracs, foypareht, sll, ecmets, lamyhcnesemtcnlebacilppa, ton, gnitti, , meavuderutcafunamnamreg, , amredorelcs, idoeklsnoitidnoc, ralimetsys, thgil, lamounarg, sracs, enca, leraunna, , imsdnaamredorelcs, rof, thglavui, ilteovartlu, vu, fvs, sll, ecnoitcarf, raucsavl, lamorts, fvs, etahpsohp, lynatit, muissatop, ptk, sll, ecmets, l, amyhcnesemdeviredesopdai, hserf, fo, tnemtaerteht, rof, resalptkmn, , , l, evona, foyduts, lip, csda, licaruoroulf, ufsracs, lacigrus, 0c, scars, burns, , healinga, variety, methods, used, surgical, removal, keloids, depending, size, , keloid, , anatomical, , location, , skin, , type, , age, patient52, include, linear, closure, flap, , coverage, , excision, , , grafting, , wplasty, , zplasty53, , , reduce, , risk, , , keloid, , recurrence, , , surgeon, , performing, , , excision, establish, tensionfree, wound, closure, general, , rule, , closure, , , , wound, , , accomplished, minimal, tension, sutures, leaving, everted, wound, borders, zplasties, threelayered, , sutures, , subcutaneousfascial, , tensile, reduction, , sutures, , , local, , ï¬ap, , surgery, , , employed, , , , casebycase, , basis5455, , , final, outcome, scar, often, positively, correlated, , , experience, , , , operating, , surgeon, , technique, , utilised, , , well, , , , patients, active, participation, wound, care52siliconebased, productssince, , , 1980s, , siliconebased, , products, , used, treatment, keloids, hypertrophic, , scars, , , silicone, , gel, , , silicone, , gel, sheeting, , considered, , , firstline, , therapy, , minor, keloids, hypertrophic, scars2635, , various, , , forms, , , silicone, , including, creams, sprays, gel, cushion, liquid24, precise, mechanism, action, silicone, products, fully, understood, proposed, enhance, hydration, create, occlusive, environment53, influences, fibroblast, regulation, , decreases, , collagen, , synthesis56, , silicone, , gel, sheeting, , , , shown, , , , minimal, , side, effects, , including, , local, , irritation, , , , resolved, , quickly24, , studies, , , shown, , , beneficial, , effects, , , silicone, , gel, , sheets, , include, pain, reduction, tenderness, pruritus, flattening, keloid57, silicone, gel, sheeting, recommended, worn, two, weeks, primary, , wound, , treatment, , , , , h, , , , months58studies, demonstrated, improvement, , keloid, scars, using, silicone, gel, , sheeting35, , , , decrease, , , , incidence, rates, , , keloids, , , hypertrophic, , scars, , , surgery59, , , addition, , controlled, , studies, , reported, clinical, effectiveness, silicone, gel, silicone, gel, sheeting, prevention, treatment, keloids3558, however, recent, metaanalysis, , review60, , , cochrane, , review61, , found, even, though, studies, published, data, support, efficacy, silicone, gel, sheeting, treatment, , , prevention, , , keloid, , , hypertrophic, , scarring, , , provided, , weak, , evidence, , , , poor, , quality60, , therefore, , given, figure, , , auricular, keloid, surgical, excision, used, monotherapy, auricular, keloid, b, surgical, excisonsurgery, yielded, significant, improvements, compared, treatment, tac, monotherapy339intralesional, , steroid, , injections, , , cause, , several, , adverse, , side, , effects, , , , telangiectasis, atrophy, steroid, acne, pigmentary, changes, necrosis, ulcerations, systemic, side, effects3, also, , significant, , pain, , associated, , , intradermal, corticosteroid, injections, reduced, local, anaesthetic, lidocaine, administered, control, pain44, furthermore, side, effects, reported, diminish, intralesional, tac, used, combination, 5fu45surgical, excisionsurgical, excision, traditional, method, removing, keloids, figure, , however, excision, creates, new, wound, result, similar, larger, keloid47, , therefore, , surgical, , excision, , , , recommended, monotherapy, results, high, recurrence, , rates, , , , range, , , , better, postoperative, surgical, outcomes, surgical, excision, often, combined, forms, treatment, , including, , radiotherapy, , intralesional, corticosteroid, , injections, , ifn, , injection, , bleomycin, cryotherapy, pressure, therapy, silicone, gel, sheeting82649, successful, use, dermal, substitutes, epidermal, skin, grafting, keloid, excision, also, reported50, recent, case, series, study, , , , , , patients, , , anterior, , chest, wall, keloids, given, treatment, protocol, consisting, , , complete, , excision, , zplasty, , postoperative, adjuvant, radiotherapy, postsurgical, wound, selfmanagement, , reported, , excellent, , outcomes, recurrence, rate, , use, steroid, tape, injections, helped, resolve, recurrence, keloids51, 0cojeh, , , lack, , , substantial, , evidence, , welldesigned, clinical, trials, studies, required, gain, better, understanding, effectiveness, siliconebased, products, preventing, treating, keloidspressure, therapypressure, therapy, used, treat, manage, keloids, hypertrophic, scars, decades3563, routinely, employed, firstline, treatment, , , , treatment, , , hypertrophic, , scarring, resulting, , , burns64, , , underlying, , mechanisms, action, compression, techniques, remain, unclear, however, several, hypotheses, exist, include, increased, pressure, scar, surface, , reduces, , perfusion, , , decreased, , oxygen, , location, injury, reduces, collagen, synthesis, , also, , thought, , , pressure, , increases, , apoptosis, reduces, , scar, , hydration, , stabilising, , mast, , cells, , decreases, angiogenesis165, application, pressure, achieved, using, variety, materials, adhesive, plaster, moulds, pressure, earrings, , customfitted, , splints16, , , , improved, scar, cosmesis, rates, keloid, recurrence66, continuous, , pressure, , , , , mmhg, , preferably, lower, range, soon, wound, reepithelialisation, , h, per, day, , , months, recommended166869, efficacy, pressure, therapy, depends, mainly, anatomical, location, scar, trunk, limb, areas, appropriate, , sites, , , pressure, , therapy, , , addition, , pressure, garment, predominantly, used, auricular, , keloids, , , pressure, , clips, , , commonly, utilised, , , surgery6670, , , , adjuvant, , therapy, form, pressure, garment, also, successfully, , used, , , prevent, , , recurrence, , keloids6667, contrast, metaanalysis, review, analysed, , , effectiveness, , , pressure, , garment, therapy, , , , prevention, , , abnormal, , scarring, , burn, , injury, , , unable, , , demonstrate, , beneficial, effects, pressure, garment, therapy, prevention, , , treatment, , , abnormal, , scarring59, notwithstanding, success, rates, pressure, therapy, contingent, upon, patient, compliance69, sometimes, low, due, discomfort, overall, pressure, therapy, tolerated, better, devoid, pain, often, associated, intralesional, therapies, hence, considered, good, adjuvant, therapy, keloid, scarsradiotherapyin, , treatment, keloids, using, superficial, xray, irradiation, first, described71, since, used, less, frequently, monotherapy, widely, effective, adjunct, treatment, surgical, excision72, success, rates, range, , , , , , recurrence, , rates, , , radioactive, skin, patches, also, used, combination, treatment, modalities, , , keloids7879, , radiotherapy, , , commonly, used, , h, surgical, excision7480, acts, suppressing, angiogenesis, inhibiting, ï¬broblast, activity1, decreased, fibroblast, proliferation, , induced, , cell, , senescence, , , apoptosis, leading, reduction, collagen, production, suppression, , , keloid, , development, , , also, reported81different, , radiotherapy, , modalities, , , used, , , surgical, , excision, , including, electron, , beam, , radiotherapy, , brachytherapy, superï¬cial, orthovoltage, radiotherapy, varying, , degrees, , , success84, , mankowski, , et, a0, al, conducted, , , literature, , review, , , , , studies, , compare, , , clinical, , outcome, , , different, forms, radiation, treatment, used, management, keloids77, metaanalysis, demonstrated, , , radiation, , used, , , monotherapy, yielded, higher, rates, recurrence, , compared, , , combinational, , therapy, , , postsurgery, excision, , comparison, different, , radiationbased, , treatments, , revealed, lowest, rate, recurrence, observed, , brachytherapy, , , , followed, , jointly, , xray, , , , , electron, , beam, , , , authors, , also, , reported, , , , rate, , , recurrence, dependent, anatomical, site, keloid, , , chest, , keloids, , , , highest, recurrence, rate73the, , adverse, , effects, , , radiotherapy, , often, linked, , , dose, , , radiation, , used, , , grouped, acute, skin, reactions, late, complications, acute, reactions, arise, early, seven, days, keloid, treatment, include, oedema, necrosis, , ulceration, , desquamation, , erythema, , pigmentary, , changes, , , , latter, , two, , , , common, , late, , complications, include, changes, pigment, atrophy, telangiectasis, , , alopecia, , may, , present, , several, weeks, radiotherapy, emollient, steroid, ointment, used, radiotherapy, help, alleviate, side, effects19, recommended, radiation, dose, , , gy, several, sessions, also, minimise, , adverse, , effects1980, , radiotherapy, , carries, , risk, malignancy8586, therefore, caution, used, radiationvulnerable, sites, head, , neck, , thyroid, , , breast, , , , patients, aged, , , years2, protecting, fragile, ans, selecting, , , , appropriate, , sitedependent, dose, protocol, help, minimise, complications, radiotherapy87, 0c, scars, burns, , healingcryotherapycryotherapy, lowtemperature, treatment, causes, , vascular, , damage, , resulting, , tissue, , necrosis88, used, treat, keloids, monotherapy, combination, treatment, , methods, , , , intralesional, , steroid, , injections89, , various, , delivery, , methods, , used, , cryotherapy, include, spray, contact, probes, intralesionalneedle, , cryoprobe, , method, compared, contact, spray, methods, intralesionalneedle, , cryoprobe, , , found, , , , effective, method, treating, keloid, scars90, positive, outcomes, observed, number, studies, , , used, , liquid, , nitrogen, , , cryotherapy, treat, keloids, success, rates, range, external, , cryotherapy, , , , associated, several, side, effects, including, hypopigmentation, , blistering, , pain, , delayed, , healing, , , infection9093, moreover, larger, keloids, shown, need, multiple, cryotherapy, sessions9093, , minimise, , side, , effects, , intralesional, , cryotherapy, introduced, number, , nitrogenbased, , cryodevices, , , , described, treatment, keloid, scars, two, , commercially, , available, , , liquid, , nitrogenbased, device88, argon, gasbased, device94, , intralesional, , cryotherapy, , , designed, , overcome, hypopigmentation, seen, mostly, darkskinned, individuals, external, cryotherapy, works, destroying, core, keloid, sparing, surface, epithelial, cells, including, melanocytes9596, , , , result, , , enhances, , volume, decrease, , , minimising, , , risk, , , hypopigmentation, surface, reactions90, recent, comprehensive, , review, , based, , , , preferred, reporting, items, systematic, reviews, metaanalysis, performed, investigate, efficacy, , intralesional, , cryotherapy, , , keloid, , scars90, review, eight, studies, met, inclusion, criteria, , revealed, , , average, , scar, , volume, decreased, , , , range, , , , , , complete, eradication, scar, average, lacking, recurrence, keloid, scars, range, , , , , authors, , also, , reported, , patients, , complaints, , , pain, , , pruritus, , considerably, , reduced, , however, , hypopigmentation, seen, mostly, fitzpatrick, , skin, type, patients, treatment90laser, therapylaser, , therapy, , , keloid, , treatment, , , introduced, 1980s97, since, different, systems, used, treatment, keloid, hypertrophic, scars4898, lasers, target, skin, chromophores, like, haemoglobin, melanin, based, principle, selective, photothermolysis99, , lasers, , , , classified, , ablative, , , nonablative, , , , common, ablative, , lasers, , include, , , 2940nm, , erbiumdoped, , yttrium, , aluminium, , garnet, , eryag, laser, 10600nm, carbon, dioxide, co2, laser, emit, laser, beam, absorbed, , water, , , , skin, , leading, , , local, , tissue, destruction, , , reduction, , , lesion, , volume3, common, , examples, , , nonablative, lasers, include, 585nm, 595nm, pdls, 1064nm, neodymiumdopedyttriumaluminiumgarnet, ndyag, neodymiumdopedvanadate, , ndvan, , laser, , , , , nm, qswitched, , ndyag, , laser, , , low, , fluence100, lasers, induce, thermal, injury, scars, microvasculature, , leading, , , thrombosis, , ischaemia, , , result, , , collagen, , denaturation, collagen, fibre, realignment101532nm, laser, laser, , therapy, , requires, , several, , treatments, , intervals, , weeks, depending, scar, type, type, , , laser, , used98104, , , possible, , side, , effects, including, itching, pigmentary, changes, blister, formation, , , postoperative, , purpura98, , , use, , , nonfractional, , vascular, , , , nm, , pdl, , , treatment, , , keloid, , , hypertrophic, , scars, welldocumented105, response, rates, range, , pdl, monotherapy, shown, effective108110, well, co2, laser, monotherapy38111112, clinical, study, , patients, moderate, severe, keloids, , treated, , , highenergy, , pulsed, , co2, , laser, , treatment, , , efficacious, , , welltolerated, minimal, side, effects112, studies, co2, laser, ablation, compared, forms, treatment, co2, laser, efficient, forms38111, must, noted, however, studies, small, randomised, controlled, studies, lacking98laser, therapy, pdl, co2, ndyag, , , associated, , , , high, , rate, , , recurrence, , months111113, however, optimal, results, , , , achieved, , , combination, , treatment, , especially, , , intralesional, , tac, , injections116, , kumar, , , coworkers, , conducted, , cohort, , study, , , , , patients, , , keloids, , previously, treated, ndyag, laser, reported, complete, scar, resolution, flattening, seven, patients, , , , intralesional, , tac, , , used, , laser, , therapy41, , moreover, , combined, , therapy, , , pdl, , , tac119, , , pdl, , tac, , 5fu36, , , shown, , , produce, , better, , clinical, results, recent, study, evaluated, compared, , , efficacy, , , combination, , therapy, , 0cojeh, , scars, statistically, fractional, co2, laser, intralesional, tac, injection, tac, injection, alone, keloid, hypertrophic, significant, improvements, reported, overall, scar, quality, , , , combined, , treatment, , options, , comto, , tac, , monotherapy120, , moreover, pared, combined, , co2, , laser, , , ifnî±2b, , injections, given, patients, auricular, keloids, resulted, recurrence, , patients, three, years, treatment121, laser, therapy, also, combined, , , , laser, , treatment, , topical, , corticosteroids, , , cyanoacrylate, , glue98, , , shown, , promising, , results, , however, , larger, , controlled, clinical, studies, needed, evaluate, efficacy, safetyrecently, , lasers, , , also, , , explored, , tools, assisted, drug, delivery, kraeva, et, a0al, proposed, alternative, technique, corticosteroid, administration, , , laserassisted, , drug, , delivery, , topical, tac, shown, effective, used, , , , keloid, , , , posterior, , scalp, , , patient, co2, laser, session122, efficient, , intraepidermal, , drug, , delivery, , options, , also, investigated, singhal, et, a0al, developed, taccontaining, , polymeric, , microps, , prepared, using, cryomilling, technique, freezing, fracture, ablation, fractional, eryag, laser, microps, deposited, cutaneous, micropores, provide, highdose, intraepidermal, , reservoir, , systems, , minimal, transdermal, permeation, leading, sustained, targeted, local, drug, delivery123it, must, noted, one, biggest, limitations, studies, available, present, lack, , histological, , definition, , , keloid, , hypertrophic, scars, conclusions, , valid, efficacyimiquimod, , creamimiquimod, , cream, approved, treatment, , , basal, , cell, , carcinoma, , actinic, , keratoses, genital, warts21, immuneresponse, modifier, stimulates, production, proinflammatory, , cytokines, , , , tnfî±, , interleukins, , ifns, activated, tcells124, thereby, changing, expression, , , genes, , associated, , , apoptosis125, reducing, collagen, production16, studies, reported, , conflicting, , findings, , regarding, , efficacy, , imiquimod, , , , cream, , postoperatively, , following, keloid, excision, likely, due, keloid, location, many, studie]|[, scars, burns, , healingvolume, , , , , reuse, guidelinessagepubcomjournalspermissions, authors, , journalssagepubcomhomesbhkeloids, are, pathological, scars, that, grow, over, time, extend, beyond, initial, site, injury, after, impaired, wound, , healing, , these, , scars, , frequently, , recur, , , rarely, , regress, , they, , are, , aesthetically, , disfiguring, , can, cause, pain, itching, discomfort, as, well, as, psychological, stress, often, affecting, quality, life, many, treatment, modalities, including, surgical, nonsurgical, have, been, explored, have, been, reported, be, beneficial, however, none, have, been, absolutely, satisfactory, or, optimal, treatment, all, keloid, subtypes, date, , poses, , , major, , challenge, , , clinicians, , often, , , combinational, , therapeutic, , approach, , appears, , , offer, best, results, with, higher, patient, satisfaction, compared, monotherapy, aetiopathogenesis, keloids, , not, , fully, , elucidated, , however, , with, , recent, , advances, , , molecular, , biology, , , genetics, , insight, , , being, gained, on, complex, process, scar, formation, hence, new, therapeutic, management, options, keloids, , , , paper, , we, , explore, , , literature, , , summarise, , , general, , concepts, , surrounding, , keloid, development, , , review, , both, , current, , corticosteroids, , surgical, , excision, , siliconebased, , products, , pressure, therapy, , radiotherapy, , cryotherapy, , laser, , therapy, , imiquimod, , , 5fluorouracil, , , emerging, , stem, , cell, therapy, mitomycin, c, verapamil, interferons, bleomycin, botulinum, toxin, type, angiotensinconverting, enzyme, inhibitors, treatments, increased, knowledge, understanding, area, may, potentially, lead, discovery, development, novel, therapeutic, options, that, are, more, efficacious, all, keloid, typeskeywordskeloids, scar, recurrence, wound, healing, treatment, managementlay, summarykeloids, are, problematic, scars, that, are, difficult, treat, manage, aetiopathogenesis, keloids, not, clear, however, recent, advances, molecular, biology, genetics, are, beginning, shed, light, on, underlying, mechanisms, implicated, keloid, scar, formation, which, will, hopefully, lead, development, treatment, options, all, keloid, types, review, summarises, current, emerging, therapiesintroductionwound, healing, an, intricate, complex, series, , processes, , comprising, , overlapping, , phases, , inflammation, granulation, tissue, formation, tissue, remodelling, results, tissue, structure, integrity, damage, being, restored1, abnormal, wound, healing, can, give, rise, keloids, which, are, benign, dermal, fibroproliferative, nodular, lesions, that, , tend, , , recur, , after, , excision, , keloid, , scars, , faculty, medical, sciences, university, west, indies, cave, hill, campus, bridgetown, barbados, west, indies, pine, medical, centre, 3rd, avenue, belleville, st, michael, barbados, west, indiescorresponding, authornkemcho, ojeh, faculty, medical, sciences, university, west, indies, cave, hill, campus, po, box, , st, michael, bridgetown, bb, , barbados, west, indies, email, nkemchoojehcavehilluwieducreative, commons, non, commercial, cc, bync, , distributed, under, terms, creative, commons, attributionnoncommercial, , license, creativecommonslicensesbync40, which, permits, noncommercial, use, reproduction, distribution, work, without, further, permission, provided, original, work, attributed, as, specified, on, sage, , , , access, pages, ussagepubcomenusnam, accessatsage, 0c, scars, burns, , healinginfluence, , , keloid, , aetiology9, , although, , no, , one, specific, gene, has, been, associated, with, development, keloids, number, genes, gene, loci, have, been, identified610, genomewide, association, studies, admixture, mapping, studies, have, identified, singlenucleotide, polymorphisms, across, certain, loci, genetically, linked, keloid, development, including, , , nedd4, , gene, , which, , encodes, , e3, ubiquitin, , ligase, , enzyme, , , , myosin, , genes, my01e, myo7a10, studies, have, also, reported, involvement, several, human, leucocyte, antigen, hla, alleles, p53, bcl2, fas, genes1014, furthermore, , rare, , genetic, , disorders, , have, , been, reported, , , present, , with, , spontaneous, , keloids, including, dubowitz, syndrome, bethlem, myopathy, rubinsteintaybi, , syndrome, , noonan, , syndrome, geominne, , syndrome, , , others1017, , these, , lines, evidence, suggest, that, genetic, factors, play, role, on, keloid, predispositionpathophysiology, keloidskeloid, , pathology, , , complex, , involving, , both, genetic, environmental, factors, keloids, form, as, result, abnormal, wound, healing, excessive, dermal, fibrosis, development, keloids, has, been, linked, overproliferation, reduced, apoptosis, dermal, fibroblasts, overproduction, collagen, fibres, other, extracellular, matrix, ecm, components, as, well, as, abnormal, ecm, production, remodelling1, , various, , cytokines, , growth, , factors, proteolytic, enzymes, have, been, implicated, , formation, , , keloids, , including, , transforming, growth, factor, tgf, epidermal, growth, factor, egf, vascular, endothelial, growth, factor, vegf, plateletderived, growth, factor, pdgf, connective, tissue, , growth, , factor, , ctgf, , tumour, , necrosis, factorî±, , tnfî±, insulinlike, , growth, , factor1, , igf1, fibroblast, growth, factor, fgf, interleukin6, , il6, , , matrix, , metalloproteinases, mmps31418, , furthermore, , signalling, , pathways, such, as, tolllike, receptor, signalling, smad, signalling, fibronectin, have, been, reported, be, associated, with, keloid, development1819histopathology, keloidshistologically, keloids, comprise, an, abundance, unordered, , dermal, , collagen, , , vasculature, , with, high, , inflammatorycell, , infiltrate, , , overactive, mesenchymal, , cells1415, , , addition, , , collagen, elastin, , fibronectin, , , proteoglycans, , are, , deposited, excess, amounts, keloid, scars9, collagen, creates, , frequent, , crosslinks, , , ordinary, , wounds, whereas, collagen, irregularly, anised, keloids, forming, nodules, dermis20, during, normal, figure, , , earlobe, keloids, as, consequence, ear, piercingarise, from, skin, trauma, or, inflammation, may, develop, , years, , after, , , initial, , insult, , , rarely, regress2, scar, tissue, extends, beyond, original, wound, site, can, be, disfiguring, cause, psychosocial, , issues, , impairing, , quality, , , life3, , addition, , patients, , may, , present, , with, , symptoms, such, as, burning, pain, pruritus, movement, limitation, hyperaesthesia2aetiologythe, , aetiology, , , keloids, , , still, , poorly, , understood, most, common, regions, skin, keloids, include, upper, arms, skin, overlying, joints, chest, shoulders, headneck, regions, particularly, , , ear, , lobes, , figure, , , , , anatomical, location, keloid, appears, alter, its, morphological, characteristics, some, keloids, can, develop, spontaneously, , however, , most, , occur, , years, , after, local, trauma, other, events, including, inflammation, surgery, burns, elective, cosmesis, foreign, body, reactions, acne, insect, bites, vaccinations, or, mechanical, force45epidemiology, keloid, geneticsthe, incidence, keloids, highest, among, darkerpigmented, , persons, , , african, , asian, , hispanic, , descent, , , , estimated, , , be, , , range, , , , , males, , , females, , have, , an, equal, risk, developing, keloids6, although, incidence, , , slightly, , increased, , , females, , likely, attributable, them, having, more, cosmetic, procedures, , like, , ear, , piercing7, , persons, , aged, , , years, , are, , also, , at, , , higher, , risk, , , developing, keloids, , additional, , risk, , factors, , include, , having, blood, , type, , , hyperige, , , hormonal, , peaks, during, pregnancy, or, puberty8familial, , keloid, , case, , studies, , , twin, , studies, support, , , notion, , that, , genetic, , factors, , have, , an, 0cojeh, , treatment, keloids2627, intralesional, tac, injections, have, been, shown, reduce, scar, volume, height, improve, scar, pliability, diminish, associated, scar, pain, itching8, as, well, as, prevent, recurrence3, , corticosteroids, , have, , antiinflammatory, , , antimitotic, , properties1, , several, , other, mechanisms, , have, , been, , reported, , by, , which, , corticosteroids, reduce, keloid, scar, including, inhibition, , fibroblast, , growth, , attenuation, , , procollagen, , glycosaminoglycan, , synthesis, , reduction, , endothelial, , budding, , , enhancement, , , collagen, , , fibroblast, , degeneration2829, , corticos, teroids, , inhibit, , tgf1, , expression, , , induce, apoptosis, fibroblasts, inhibit, vegf, alphaglobulins, which, are, involved, wound, healing, , process28, , vegf, , which, , promotes, angiogenesis, reported, be, highly, expressed, , keloid, , fibroblasts, , compared, , , controls, , but, exogenous, , addition, , , , glucocorticoid, , dexamethasone, , suppressed, , its, , expression, , , vitro32, furthermore, vegf, expression, overexpressed, , keloid, , tissue, , which, , later, , reduced, , following, intralesional, tac, injections, vivo33tac, , , typically, , administered, , at, , intervals, , , , weeks, , until, , pruritic, , , painassociated, symptoms, , diminish, , , , scar, , flattens34, , dose, , , tac, , , , , range, , , , , mgml, depending, , on, , , size, , , anatomical, , location, lesion, age, patient34, tac, used, either, alone, as, monotherapy, or, combination, , with, , other, , treatment, , modalities13, , response, , rates, , , corticosteroid, , injections, , vary, clinically, , with, , regression, , rates, , , , range, , , , reported, , after, , one, , year, , , recurrence, , rates, , , , range, , , , , reported, after, , five, , years3, , combined, , therapy, , comprising, surgical, excision, followed, by, tac, treatment, also, varied, , with, , reported, , recurrence, , rates, , , range, , , , , previous, , clinical, , studies, where, tac, used, alone, reported, efficacy, good, , clinical, , outcome, , with, , , treatment, , including, reduced, keloid, height, length, width, related, pruritus, erythema, improved, pliability3637, , , recent, , randomised, , parallelgroup, study, , that, , compared, , , role, , , intralesional, tac, , fractional, , co2, , laser, , or, , intralesional, , verapamil, , , , treatment, , , keloid, , , , , patients, showed, reduction, scar, height, vascularity, pliability, all, three, groups, using, vancouver, scar, scale, score, however, pigmentation, not, completely, resolved, with, any, treatments, , response, , , fastest, , with, , tac, , followed, , by, verapamil, laser, statistically, significant38, however, intralesional, tac, combination, with, other, treatment, modalities, such, as, 5fluorouracil, , 5fu, , pulsed, , dye, , laser, , pdl, surgery, , interferon, , ifnî±2b, , verapamil, , figure, , , current, emerging, treatment, strategieswound, healing, early, wound, immature, collagen, type, iii, can, be, modified, into, mature, collagen, type, i, keloid, tissue, it, mostly, comprises, disanised, collagen, types, i, iii, made, up, palestaining, , hypocellular, , collagen, , clusters, , lacking, nodules, or, surplus, myofibroblasts21, furthermore, recent, research, has, provided, four, distinct, findings, only, present, keloid, specimens, , presence, keloidal, , hyalinised, , collagen, , , , presence, , , tonguelike, , advancing, , edge, , underneath, , normalappearing, , epidermis, , , papillary, , dermis, , , , horizontal, cellular, fibrous, band, upper, reticular, dermis, , prominent, fascialike, band22treatment, keloidscurrently, various, forms, treatment, keloids, exist, however, no, single, treatment, has, proven, be, , , most, , effective, , , review, , will, , explore, , discuss, , current, , , emerging, , treatment, modalities, , figure, , , , some, , , , ongoing, , or, completed, clinical, trials, keloid, therapy, registered, on, clinicaltrialsgov, accessed, on, , , , may, , , , are, , summarised, , , table, , , studies, with, status, terminated, suspended, or, withdrawn, were, excludedcurrent, treatmentscorticosteroidsseveral, corticosteroids, can, be, used, treatment, scars, including, triamcinolone, acetonide, tac, , hydrocortisone, , acetate, , dexamethasone, methyl, prednisolone24, however, since, , tac, has, been, most, widely, used, corticosteroid, 0c, scars, burns, , healingtcnvi, esahptcnlebacilppa, ton, , vogslairtlacinilcesahpyduts, noitnevretnisnoitidnoc, , , , yamnodessecca, vogslairtacinlil, , cnoypareht, doek, fo, slairt, lliacinilc, , elbateltit, ydutsreifitneditcnlebacilppa, ton, , ybdewoll, iednotecaenoonicmairt, llanoiseartnliilsdoek, fo, tnemtaerteht, n, iof, resal, oc, lanoitcarfidoekli, sdorets, lanoiseartnl, , ii, svyparehtdoretsdetsissa, resal, , lanoitcarftcnlebacilppa, tontcnlebacilppa, tontcnvi, esahp, trs, ypareht, noitadar, liaicifrepus, ienmativ, enocilis, enositrocordyh, yparehtyhcarbetaresod, ihgh, tnavudahtij, , wnoisicxe, lacigrus, cihportrepyh, idoeklidoeklidoekl, trs, yparehtnoitadari, , l, laicifrepus, fonoitauaveevitcepsortera, , ilsdoek, fo, tnemtaert, rof, yparehtyhcarbetaresodhghi, , , , isracsdoekdnal, , dnaytili, , , llbareoteht, gnitauaveydutsevitarapmocdezimodnara, , , tcnlebacilppa, ton, , llamsaphcir, teetap, suogootuallidoekl, , llllamsaphcir, teetap, suogootuayb, racsdoek, fo, tnemtaertli, , tcb®tiknegerhti, , wdenatboitcbtiknegerhti, , wdenatboi, l, ieg, tcartxenono, ro, draugracs, noitolamredem, xirtacicracscihportrepyh, ildna, sdoek, fo, tnemtaerteht, rof, separehti, , l, acipotowt, foycaciffe, , sracscihportrepyhtcni, esahp, muiclac, fonoitcenj, i, laruomutartniidoeklrefsnartortceeybdewol, , llof, edirohcltcniii, esahp, , , dnaenoonicmairt, llanoiseartnliidoekl, ienodnefrip, l, ilsdoek, fo, tnemtaerteht, rof, noitaroportceemuiclacl, , , acipotdnaenoonicmairtl, , lanoiseartnl, i, foycaciffeienodnefrip, lacipotnoitcenji, ufidoekllygooisyhpohtapdna, tnemtaert, , gnirracsdoekli, , iioalsdal, sracsdoek, fo, tnemtaert, rofltcnii, esahp, i, esahp, inks, gnviltneavuqeiil, dereyalib, fargilpasresalidoekl, , iil, tenragmunmuamuirttymumydoenideslupgno, l, dna, oc, lanoitcarfidoekl, fo, tnemtaertn, , ii, sresal, tenragmunmuamuirttymumydoenli, , , , fonoitneverpdna, tnemtaerteht, rof, farg, ilpa, , foyduts, toli, paisdoekl, ilsdoekdesicxe, foecnerrucer, , , , deslupgnoldnaedixodnobraci, , , l, anoitcarfgnisuydutsa, , deunitnoc, cihportrepyhtcnlebacilppa, tonyparehtoyrc, lanoiseartnli, xirtacic, idoekl, , eht, rof, eciveddesab, sagnogranahti, , , , wyparehtoyrc, lanoiseartnli, , sracscihportrepyhdnadoek, fo, tnemtaertli, tcniii, esahpxirtacic, fonoitacil, ppa, lacipot, sracs, cihportrepyhcihportrepyhidoekl, ilsracs, sdoekdna, sracscihportrepyh, , fo, tnemtaerteht, n, i, ixrtacci, , sracscihportrepyhdnadoek, fo, tnemtaertli, tcnlebacilppa, tonyparehtoyrc, lanoiseartnli, xirtacic, idoekl, rof, yparehtoyrc, lanoiseartnl, , , i, foesueht, fonoitauaveevitcepsorpl, 0cojeh, , tcnvi, esahpresal, , , ptkmneht, foycaciffe, idoekl, cihportrepyheahcun, siliadoekl, xirtacic, xirtacic, racs, lacigrus, racs, reifitnedi, vogslairtlacinilcesahpyduts, noitnevretnisnoitidnocdeunitnoc, , elbateltit, ydutstcnlebacilppa, tonresal, , eyddeslup, cihportrepyh, idoekl, , , , deslupmnagnisu, tnemtaert, racsnohtdweslup, fo, tceffei, , , tcnlebacilppa, ton, thgil, , avuderutcafunamnamreg, , idoeklsracs, amredorelcssnoitidnoc, rali, , imsdnaamredorelcs, fo, tnemtaert, rof, thglavui, resaleyd, ecivedgnitti, me, gnisorbif, rehtosnoitidnoctcnlebacilppa, ton, ecivederusserptcnvi, esahpl, egenocilis, lacipot, cihportrepyh, idoeklilerusserp, sdoek, rae, fo, tnemtaerteht, n, i, , ecivederusserpidoekl, fo, tnemtaerteht, no, , l, egenocili, isgnyrdfles, tnerapsnart, fo, tceffesracssracs, l, ianmodbacihportrepyhtcnlebacilppa, tonypareht, noitadariidoekl, yrtsigernoitadardoeklii, tcniii, esahpnosahtemateb, fonoitacil, ppa, lacipot, sracs, cihportrepyhsretehtac, suonev, lartnec, retfa, sracstcni, esahpii, esahptcn, i, esahpii, esahp, dna, sll, , dicacidisuf, dnaetareavl, isdoeklidocitrococuglnoitadarri, ibvu, amredorelcs, idoekl, inks, fo, tnemtaerteht, n, i, ypareht, thgl, bvuil, b, teovartlui, leraunnaamounargl, sracs, siliadoekl, enca, desilacolxirtam, l, amredderetlahti, w, snoitidnoc, lecfvs, suogootua, fo, snoitcenji, axal, situc, racs, inkscsdaxirtacic, idoekl, , ideviredesopda, suogootuahtil, , , waxal, situcdna, sracs, foypareht, sll, ecmets, lamyhcnesemtcnlebacilppa, ton, gnitti, , meavuderutcafunamnamreg, , amredorelcs, idoeklsnoitidnoc, ralimetsys, thgil, lamounarg, sracs, enca, leraunna, , imsdnaamredorelcs, rof, thglavui, ilteovartlu, vu, fvs, sll, ecnoitcarf, raucsavl, lamorts, fvs, etahpsohp, lynatit, muissatop, ptk, sll, ecmets, l, amyhcnesemdeviredesopdai, hserf, fo, tnemtaerteht, rof, resalptkmn, , , l, evona, foyduts, lip, csda, licaruoroulf, ufsracs, lacigrus, 0c, scars, burns, , healinga, variety, methods, can, be, used, surgical, removal, keloids, depending, on, size, , keloid, , anatomical, , location, , skin, , type, , age, patient52, these, include, linear, closure, flap, , coverage, , excision, , with, , grafting, , wplasty, , zplasty53, , , reduce, , risk, , , keloid, , recurrence, , , surgeon, , performing, , , excision, should, establish, tensionfree, wound, closure, as, general, , rule, , closure, , , , wound, , should, , be, accomplished, with, minimal, tension, sutures, leaving, everted, wound, borders, zplasties, threelayered, , sutures, , subcutaneousfascial, , tensile, reduction, , sutures, , or, , local, , ï¬ap, , surgery, , can, , be, employed, , on, , , casebycase, , basis5455, , , final, outcome, scar, often, positively, correlated, with, , , experience, , , , operating, , surgeon, , technique, , utilised, , as, , well, , as, , , patients, active, participation, their, wound, care52siliconebased, productssince, , , 1980s, , siliconebased, , products, , have, been, used, treatment, keloids, hypertrophic, , scars, , with, , silicone, , gel, , or, , silicone, , gel, sheeting, , considered, , as, , firstline, , therapy, , minor, keloids, hypertrophic, scars2635, there, are, , various, , other, , forms, , , silicone, , including, creams, sprays, gel, cushion, liquid24, precise, mechanism, action, silicone, products, not, fully, understood, but, it, proposed, that, they, enhance, hydration, create, an, occlusive, environment53, which, influences, fibroblast, regulation, , decreases, , collagen, , synthesis56, , silicone, , gel, sheeting, , has, , been, , shown, , , have, , minimal, , side, effects, , including, , local, , irritation, , which, , can, , be, resolved, , quickly24, , studies, , have, , shown, , that, , beneficial, , effects, , , silicone, , gel, , sheets, , include, pain, reduction, tenderness, pruritus, flattening, keloid57, silicone, gel, sheeting, recommended, be, worn, from, two, weeks, after, primary, , wound, , treatment, , , , , h, , , , months58studies, have, demonstrated, an, improvement, up, , keloid, scars, after, using, silicone, gel, , sheeting35, , , , decrease, , , , incidence, rates, , , keloids, , , hypertrophic, , scars, , after, , surgery59, , , addition, , controlled, , studies, , have, reported, clinical, effectiveness, silicone, gel, silicone, gel, sheeting, prevention, treatment, keloids3558, however, recent, metaanalysis, , review60, , , cochrane, , review61, , found, that, even, though, studies, published, data, support, efficacy, silicone, gel, sheeting, treatment, , , prevention, , , keloid, , , hypertrophic, , scarring, , they, , provided, , weak, , evidence, , were, , , poor, , quality60, , therefore, , given, figure, , , auricular, keloid, surgical, excision, used, as, monotherapy, auricular, keloid, before, after, b, surgical, excisonsurgery, all, yielded, significant, improvements, compared, treatment, with, tac, monotherapy339intralesional, , steroid, , injections, , can, , cause, , several, , adverse, , side, , effects, , such, , as, , telangiectasis, atrophy, steroid, acne, pigmentary, changes, necrosis, ulcerations, systemic, side, effects3, there, also, , significant, , pain, , associated, , with, , intradermal, corticosteroid, injections, that, can, be, reduced, when, local, anaesthetic, lidocaine, administered, control, pain44, furthermore, side, effects, have, been, reported, diminish, when, intralesional, tac, used, combination, with, 5fu45surgical, excisionsurgical, excision, traditional, method, removing, keloids, figure, , however, excision, creates, new, wound, can, result, similar, or, larger, keloid47, , therefore, , surgical, , excision, , , not, , recommended, as, monotherapy, as, it, results, high, recurrence, , rates, , , , range, , , , better, postoperative, surgical, outcomes, surgical, excision, often, combined, with, other, forms, treatment, , including, , radiotherapy, , intralesional, corticosteroid, , injections, , ifn, , injection, , bleomycin, cryotherapy, pressure, therapy, silicone, gel, or, sheeting82649, successful, use, dermal, substitutes, epidermal, skin, grafting, with, keloid, excision, has, also, been, reported50, recent, case, series, study, , , which, , , , patients, , with, , anterior, , chest, wall, keloids, were, given, treatment, protocol, consisting, , , complete, , excision, , zplasty, , postoperative, adjuvant, radiotherapy, postsurgical, wound, selfmanagement, , reported, , excellent, , outcomes, with, recurrence, rate, only, , use, steroid, tape, injections, helped, resolve, recurrence, keloids51, 0cojeh, , , lack, , , substantial, , evidence, , welldesigned, clinical, trials, studies, are, required, gain, better, understanding, effectiveness, siliconebased, products, preventing, treating, keloidspressure, therapypressure, therapy, has, been, used, treat, manage, keloids, hypertrophic, scars, decades3563, it, has, been, routinely, employed, as, firstline, treatment, , , , treatment, , , hypertrophic, , scarring, resulting, , from, , burns64, , , underlying, , mechanisms, action, compression, techniques, remain, unclear, however, several, hypotheses, exist, some, which, include, increased, pressure, scar, surface, , reduces, , perfusion, , , decreased, , oxygen, , location, injury, reduces, collagen, synthesis, it, , also, , thought, , that, , pressure, , increases, , apoptosis, reduces, , scar, , hydration, , stabilising, , mast, , cells, , decreases, angiogenesis165, application, pressure, can, be, achieved, using, variety, materials, such, as, adhesive, plaster, moulds, pressure, earrings, , customfitted, , splints16, , which, , have, , improved, scar, cosmesis, rates, keloid, recurrence66, continuous, , pressure, , , , , mmhg, , preferably, at, lower, range, soon, after, wound, reepithelialisation, , h, per, day, , , months, recommended166869, efficacy, pressure, therapy, depends, mainly, on, anatomical, location, scar, with, trunk, limb, areas, being, more, appropriate, , sites, , , pressure, , therapy, , , addition, , pressure, garment, predominantly, used, auricular, , keloids, , where, , pressure, , clips, , are, , commonly, utilised, , after, , surgery6670, , as, , an, , adjuvant, , therapy, form, pressure, garment, has, also, been, successfully, , used, , , prevent, , , recurrence, , keloids6667, contrast, metaanalysis, review, that, analysed, , , effectiveness, , , pressure, , garment, therapy, , , , prevention, , , abnormal, , scarring, after, , burn, , injury, , , unable, , , demonstrate, , any, beneficial, effects, pressure, garment, therapy, on, prevention, , or, , treatment, , , abnormal, , scarring59, notwithstanding, success, rates, pressure, therapy, are, contingent, upon, patient, compliance69, which, can, sometimes, be, low, due, discomfort, overall, pressure, therapy, tolerated, better, devoid, pain, often, associated, with, intralesional, therapies, hence, can, be, considered, as, good, adjuvant, therapy, keloid, scarsradiotherapyin, , treatment, keloids, using, superficial, xray, irradiation, first, described71, since, then, it, has, been, used, less, frequently, as, monotherapy, more, widely, as, an, effective, adjunct, treatment, after, surgical, excision72, with, success, rates, range, , , , , , recurrence, , rates, , about, , radioactive, skin, patches, have, also, been, used, combination, with, other, treatment, modalities, , , keloids7879, , radiotherapy, , , most, commonly, used, , h, after, surgical, excision7480, acts, by, suppressing, angiogenesis, inhibiting, ï¬broblast, activity1, decreased, fibroblast, proliferation, , induced, , cell, , senescence, , , apoptosis, leading, reduction, collagen, production, suppression, , , keloid, , development, , have, , also, been, reported81different, , radiotherapy, , modalities, , have, been, , used, , after, , surgical, , excision, , including, electron, , beam, , radiotherapy, , brachytherapy, superï¬cial, orthovoltage, radiotherapy, with, varying, , degrees, , , success84, , mankowski, , et, a0, al, conducted, , , literature, , review, , , , , studies, , compare, , , clinical, , outcome, , , different, forms, radiation, treatment, used, management, keloids77, metaanalysis, demonstrated, , that, , radiation, , used, , as, , monotherapy, yielded, higher, rates, recurrence, , compared, , , combinational, , therapy, , with, , postsurgery, excision, , comparison, between, different, , radiationbased, , treatments, , revealed, that, lowest, rate, recurrence, observed, with, , brachytherapy, , , , followed, , jointly, , by, xray, , , , , electron, , beam, , , , authors, , also, , reported, , that, , , rate, , , recurrence, dependent, on, anatomical, site, keloid, , with, , chest, , keloids, , having, , , highest, recurrence, rate73the, , adverse, , effects, , , radiotherapy, , often, linked, , with, , dose, , , radiation, , used, , can, , be, grouped, into, acute, skin, reactions, late, complications, acute, reactions, arise, as, early, as, seven, days, after, keloid, treatment, include, oedema, necrosis, , ulceration, , desquamation, , erythema, , pigmentary, , changes, , with, , , latter, , two, being, , , most, , common, , late, , complications, which, include, changes, pigment, atrophy, telangiectasis, , , alopecia, , may, , present, , several, weeks, after, radiotherapy, emollient, steroid, ointment, used, after, radiotherapy, can, help, alleviate, side, effects19, recommended, radiation, dose, , , gy, over, several, sessions, can, also, minimise, , adverse, , effects1980, , radiotherapy, , carries, , risk, malignancy8586, therefore, caution, should, be, used, radiationvulnerable, sites, such, as, head, , neck, , thyroid, , , breast, , , , patients, aged, , , years2, protecting, fragile, ans, selecting, , , most, , appropriate, , sitedependent, dose, protocol, can, help, minimise, further, complications, radiotherapy87, 0c, scars, burns, , healingcryotherapycryotherapy, lowtemperature, treatment, that, causes, , vascular, , damage, , resulting, , tissue, , necrosis88, it, has, been, used, treat, keloids, as, monotherapy, or, combination, with, other, treatment, , methods, , such, , as, , intralesional, , steroid, , injections89, , various, , delivery, , methods, , used, , cryotherapy, include, spray, contact, probes, or, intralesionalneedle, , cryoprobe, , method, compared, contact, spray, methods, intralesionalneedle, , cryoprobe, , , found, , , be, , most, effective, method, treating, keloid, scars90, positive, outcomes, were, observed, number, studies, , that, , used, , liquid, , nitrogen, , , cryotherapy, treat, keloids, with, success, rates, range, external, , cryotherapy, , has, , been, , associated, with, several, side, effects, including, hypopigmentation, , blistering, , pain, , delayed, , healing, , , infection9093, moreover, larger, keloids, have, been, shown, need, multiple, cryotherapy, sessions9093, , minimise, , side, , effects, , intralesional, , cryotherapy, introduced, there, are, now, number, , nitrogenbased, , cryodevices, , that, , have, , been, described, treatment, keloid, scars, with, two, , commercially, , available, , , liquid, , nitrogenbased, device88, an, argon, gasbased, device94, , intralesional, , cryotherapy, , , designed, , overcome, hypopigmentation, seen, mostly, darkskinned, individuals, with, external, cryotherapy, it, works, by, destroying, core, keloid, sparing, surface, epithelial, cells, including, melanocytes9596, , as, , , result, , it, , enhances, , volume, decrease, , while, , minimising, , , risk, , , hypopigmentation, other, surface, reactions90, recent, comprehensive, , review, , based, , on, , , preferred, reporting, items, systematic, reviews, metaanalysis, performed, investigate, efficacy, , intralesional, , cryotherapy, , on, , keloid, , scars90, review, eight, studies, that, met, inclusion, criteria, , revealed, , that, , average, , scar, , volume, decreased, , , , range, , , , , but, , complete, eradication, scar, on, average, lacking, recurrence, keloid, scars, range, , , , , authors, , also, , reported, , that, patients, , complaints, , , pain, , , pruritus, , considerably, , reduced, , however, , hypopigmentation, seen, mostly, fitzpatrick, , skin, type, patients, after, treatment90laser, therapylaser, , therapy, , , keloid, , treatment, , , introduced, 1980s97, since, then, different, systems, have, been, used, treatment, keloid, hypertrophic, scars4898, these, lasers, target, skin, chromophores, like, haemoglobin, melanin, based, on, principle, selective, photothermolysis99, , lasers, , can, , be, , classified, , as, ablative, , , nonablative, , , most, , common, ablative, , lasers, , include, , , 2940nm, , erbiumdoped, , yttrium, , aluminium, , garnet, , eryag, laser, 10600nm, carbon, dioxide, co2, laser, these, emit, laser, beam, that, absorbed, by, , water, , , , skin, , leading, , , local, , tissue, destruction, , , reduction, , , lesion, , volume3, common, , examples, , , nonablative, lasers, include, 585nm, or, 595nm, pdls, 1064nm, neodymiumdopedyttriumaluminiumgarnet, ndyag, neodymiumdopedvanadate, , ndvan, , laser, , , , , nm, qswitched, , ndyag, , laser, , with, , low, , fluence100, these, lasers, induce, thermal, injury, scars, microvasculature, , leading, , , thrombosis, , ischaemia, , which, , result, , , collagen, , denaturation, collagen, fibre, realignment101532nm, laser, laser, , therapy, , requires, , several, , treatments, , at, intervals, , weeks, depending, on, scar, type, type, , , laser, , used98104, , with, , possible, , side, , effects, including, itching, pigmentary, changes, blister, formation, , , postoperative, , purpura98, , , use, , , nonfractional, , vascular, , , , nm, , pdl, , , treatment, , , keloid, , , hypertrophic, , scars, has, been, welldocumented105, has, response, rates, range, , pdl, monotherapy, has, been, shown, be, effective108110, as, well, as, co2, laser, monotherapy38111112, clinical, study, where, , patients, with, moderate, severe, keloids, were, , treated, , with, , highenergy, , pulsed, , co2, , laser, , treatment, , , efficacious, , , welltolerated, with, minimal, side, effects112, other, studies, where, co2, laser, ablation, compared, with, other, forms, treatment, co2, laser, as, efficient, as, other, forms38111, it, must, be, noted, however, that, these, studies, are, small, randomised, controlled, studies, are, lacking98laser, therapy, such, as, pdl, co2, ndyag, have, , been, , associated, , with, , , high, , rate, , , recurrence, at, , months111113, however, optimal, results, , can, , be, , achieved, , with, , combination, , treatment, , especially, , with, , intralesional, , tac, , injections116, , kumar, , , coworkers, , conducted, , cohort, , study, , on, , , , patients, , with, , keloids, , previously, treated, with, an, ndyag, laser, reported, complete, scar, resolution, flattening, seven, patients, , only, , when, , intralesional, , tac, , , used, after, , laser, , therapy41, , moreover, , combined, , therapy, , with, , pdl, , , tac119, , , pdl, , tac, , 5fu36, , were, , shown, , , produce, , better, , clinical, results, recent, study, that, evaluated, compared, , , efficacy, , , combination, , therapy, , 0cojeh, , scars, statistically, fractional, co2, laser, intralesional, tac, injection, or, tac, injection, alone, keloid, hypertrophic, significant, improvements, were, reported, overall, scar, quality, , with, , , combined, , treatment, , options, , comto, , tac, , monotherapy120, , moreover, pared, combined, , co2, , laser, , , ifnî±2b, , injections, given, patients, with, auricular, keloids, resulted, no, recurrence, , patients, three, years, after, treatment121, laser, therapy, can, also, be, combined, , with, , other, , laser, , treatment, , topical, , corticosteroids, , , cyanoacrylate, , glue98, , , have, shown, , promising, , results, , however, , larger, , controlled, clinical, studies, are, needed, further, evaluate, their, efficacy, safetyrecently, , lasers, , are, , also, , being, , explored, , as, tools, assisted, drug, delivery, kraeva, et, a0al, proposed, an, alternative, technique, corticosteroid, administration, , , laserassisted, , drug, , delivery, , topical, tac, shown, be, effective, when, used, , on, , , keloid, , on, , , posterior, , scalp, , , patient, after, each, co2, laser, session122, more, efficient, , intraepidermal, , drug, , delivery, , options, , are, also, being, investigated, singhal, et, a0al, developed, taccontaining, , polymeric, , microps, , that, were, prepared, using, cryomilling, technique, freezing, fracture, after, ablation, with, fractional, eryag, laser, these, microps, can, be, deposited, cutaneous, micropores, provide, highdose, intraepidermal, , reservoir, , systems, , with, minimal, transdermal, permeation, leading, sustained, targeted, local, drug, delivery123it, must, be, noted, that, one, biggest, limitations, studies, available, at, present, lack, , histological, , definition, , between, , keloid, , hypertrophic, scars, so, conclusions, are, not, , valid, on, efficacyimiquimod, , creamimiquimod, , cream, approved, treatment, , , basal, , cell, , carcinoma, , actinic, , keratoses, genital, warts21, as, an, immuneresponse, modifier, it, stimulates, production, proinflammatory, , cytokines, , such, , as, , tnfî±, , interleukins, , ifns, by, activated, tcells124, thereby, changing, expression, , , genes, , associated, , with, , apoptosis125, reducing, collagen, production16, studies, have, reported, , conflicting, , findings, , regarding, , efficacy, , imiquimod, , , , cream, , postoperatively, , following, keloid, excision, likely, due, keloid, location, many, studie]|(224581,[0,1,2,3,4,5,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,26,28,33,35,36,37,38,39,40,41,42,43,44,45,47,49,50,52,53,54,57,58,59,61,62,66,67,68,70,72,74,76,77,78,80,81,82,83,84,85,86,87,88,90,91,92,93,94,95,96,97,98,99,100,101,104,105,108,109,110,113,114,115,117,119,120,123,124,128,129,130,132,134,136,137,139,140,141,143,144,147,148,149,151,154,155,156,158,160,161,162,165,166,167,168,169,170,171,172,173,174,175,176,177,180,184,185,187,188,189,190,191,192,196,197,201,203,205,207,208,211,215,216,220,221,223,225,226,230,234,236,240,241,244,245,249,253,254,255,258,260,261,262,263,264,268,269,270,272,274,275,276,277,278,279,281,283,284,286,287,288,295,299,301,305,307,308,309,310,313,315,317,321,323,325,328,330,338,340,343,348,349,352,355,358,359,361,363,366,367,368,370,372,374,377,378,380,383,386,389,390,393,396,397,400,404,408,409,412,413,415,421,426,427,428,431,436,437,440,446,447,448,455,460,464,465,469,470,473,475,482,486,489,490,498,499,501,503,513,517,520,521,523,528,529,531,532,534,538,540,547,549,555,559,561,564,569,572,573,574,576,577,581,589,591,596,604,609,617,618,619,623,625,629,631,636,638,643,644,646,647,648,650,652,655,657,659,661,662,669,670,672,674,677,678,682,685,687,688,691,692,704,707,709,710,718,721,726,731,733,737,739,741,743,746,749,752,754,759,760,761,762,763,766,768,769,770,772,775,780,795,798,799,807,810,816,818,823,824,836,840,847,848,853,860,862,872,873,875,877,878,885,886,887,892,899,901,905,907,909,911,916,935,938,942,943,949,954,966,968,978,981,982,983,988,992,998,1023,1026,1031,1035,1039,1054,1058,1059,1061,1074,1084,1085,1094,1103,1105,1106,1107,1114,1120,1125,1126,1129,1135,1140,1154,1160,1174,1177,1180,1184,1186,1189,1195,1203,1204,1205,1208,1220,1222,1224,1227,1233,1237,1239,1241,1249,1256,1262,1267,1269,1276,1282,1283,1284,1288,1298,1299,1304,1308,1312,1316,1317,1322,1330,1345,1348,1353,1356,1362,1367,1368,1372,1390,1395,1404,1406,1409,1412,1426,1435,1440,1446,1454,1455,1457,1461,1464,1470,1487,1488,1492,1496,1497,1503,1509,1512,1537,1554,1567,1571,1574,1592,1596,1597,1613,1617,1648,1666,1671,1674,1682,1687,1694,1695,1708,1715,1728,1738,1743,1749,1756,1759,1771,1778,1779,1789,1791,1792,1814,1837,1840,1859,1872,1920,1929,1971,2003,2021,2025,2030,2035,2044,2045,2046,2061,2067,2079,2086,2100,2108,2117,2118,2123,2125,2132,2135,2139,2151,2154,2158,2164,2166,2177,2180,2189,2197,2199,2216,2217,2221,2228,2236,2271,2273,2276,2283,2285,2287,2288,2341,2349,2364,2370,2371,2376,2383,2419,2422,2459,2467,2472,2475,2511,2513,2514,2551,2567,2569,2570,2599,2604,2606,2638,2671,2682,2687,2690,2705,2720,2726,2730,2731,2738,2759,2761,2788,2822,2823,2828,2850,2853,2868,2873,2874,2875,2890,2906,2941,2981,3008,3019,3040,3056,3103,3111,3113,3114,3137,3140,3151,3171,3189,3199,3203,3210,3211,3221,3230,3240,3246,3252,3288,3297,3312,3314,3315,3321,3333,3339,3346,3357,3386,3393,3394,3412,3423,3428,3441,3444,3467,3471,3477,3492,3494,3501,3592,3593,3651,3689,3712,3714,3739,3759,3768,3813,3816,3827,3861,3879,3919,3935,3974,3983,4006,4024,4050,4051,4091,4094,4132,4156,4174,4191,4234,4239,4306,4331,4339,4343,4375,4403,4427,4457,4506,4514,4546,4570,4575,4581,4633,4645,4704,4709,4711,4714,4778,4781,4823,4869,4887,4938,4958,4986,5043,5057,5060,5071,5182,5207,5276,5293,5303,5324,5374,5380,5382,5461,5469,5478,5545,5563,5600,5650,5685,5692,5708,5761,5816,5818,5828,5920,5969,6014,6021,6040,6088,6091,6170,6244,6283,6285,6295,6326,6330,6352,6387,6411,6418,6429,6456,6463,6468,6553,6557,6623,6669,6671,6702,6784,6846,6848,6901,6912,6920,6930,6960,6982,6984,6991,7086,7099,7121,7291,7297,7310,7321,7331,7465,7469,7487,7511,7530,7618,7624,7650,7746,7763,7766,7819,7845,7891,8018,8134,8150,8175,8242,8305,8453,8465,8469,8476,8493,8635,8740,8758,8781,8816,8817,8850,8866,9033,9074,9181,9200,9217,9257,9269,9317,9407,9502,9504,9547,9758,9788,9802,9805,9891,9943,10045,10163,10191,10219,10266,10306,10321,10364,10405,10425,10542,10629,10677,10992,11129,11203,11219,11350,11478,11516,11614,11947,11988,12052,12054,12066,12086,12146,12178,12211,12233,12359,12369,12468,12496,12497,12559,12624,12633,12643,12658,12686,12694,12769,13104,13217,13218,13494,13645,13678,13692,13756,13799,13897,13971,14000,14012,14106,14277,14547,14580,14617,14778,14979,15027,15049,15114,15172,15233,15383,15399,15407,15425,15512,15568,15672,15676,15787,16024,16061,16212,16369,16823,17194,17582,17655,17656,17698,17737,18247,18725,19015,19085,19159,19325,19343,19476,19539,19714,20066,20434,20521,20525,20573,20664,20883,21100,21395,21413,21711,21951,22458,22565,22720,22941,22965,22995,23342,23945,24326,24343,24389,24566,24651,24660,24704,24778,24789,25121,25434,25982,26319,26750,27437,27528,27842,28261,28561,28840,29055,29329,29352,29652,30139,30299,30395,30491,30560,30859,30865,30929,31013,31101,31161,31231,31245,31256,31334,31511,31589,31672,32919,33184,33204,33911,34503,34984,35126,35245,35275,35289,35755,35960,35964,36126,36824,37209,37213,37453,37612,37813,38125,38774,38821,41038,41084,41219,41325,41353,41617,41857,42198,42729,44884,46661,46848,48740,49087,50127,50438,50492,51196,52009,52192,52754,53879,54868,55799,56130,56255,56423,56959,57125,57252,57328,57453,57529,57723,58936,59745,60114,61341,61372,61386,61868,62279,63011,63048,63350,63597,63633,63804,65705,66274,66637,67242,68831,69015,69570,69613,69823,69962,70024,70185,70206,70259,70632,71447,71572,71666,71987,72044,72198,73343,74300,74917,80396,81030,81598,81741,81749,81818,82317,82327,82408,82687,82695,83084,83126,83526,83614,83709,85152,85832,86404,86567,86769,87428,87452,87614,87878,87893,88396,88509,89129,89720,89853,90621,91000,91125,91187,91205,91756,91834,92388,92580,93153,93238,93388,93492,93938,94257,94316,94326,94333,95352,95672,96721,97175,97958,98460,98845,99916,100122,100864,102210,102365,102982,103527,103843,103948,104570,104767,105395,105844,106214,106743,106961,107015,107132,107273,107322,107611,108294,108762,109129,109226,109544,109571,109712,109734,110184,110470,110675,110948,111360,111422,111553,111565,111633,111892,112540,112980,113312,113373,113405,113767,113841,114452,114655,114752,114864,115796,116183,116542,116815,116897,117019,117348,117541,117776,118623,119066,119204,119223,119822,119893,119950,120875,120949,121141,121357,122660,122785,122938,123266,123636,123684,123793,124415,125134,125350,125839,126004,126721,127108,127331,127465,127603,127826,128004,128182,128586,129622,129763,129818,130151,130263,130639,131529,131685,131697,132476,132519,132959,133527,133572,133994,134078,134097,134336,134562,134759,135256,135665,135766,135796,136079,136140,136766,136842,137185,137419,137522,137525,137609,137759,137774,137996,138404,139179,139356,139406,139681,139773,139930,140691,140747,141569,141645,142063,142469,142494,142883,142982,144199,144223,144290,144378,144424,144587,144752,145199,145380,145671,145725,145923,146066,146777,147204,147534,147753,147931,148608,148659,149274,149490,149593,150107,150312,150623,151743,151880,152304,153478,153714,154193,154478,154647,155672,155954,156042,156092,156412,156565,156587,156720,157216,157252,157280,157391,157842,157914,157973,158200,158277,158294,158438,159079,159849,159962,160673,161044,161135,161202,161464,161563,161914,162001,162052,162208,162589,163036,163181,163486,164060,164066,164226,164457,164651,165324,165363,165383,165715,166580,166738,167659,167715,169281,169430,169455,169680,169801,171113,171289,171691,171770,171775,171924,171946,172009,172360,172444,172457,172725,172974,173381,173725,174015,174258,174916,174984,175023,175986,176979,177162,177366,178074,178961,179443,179539,179571,179644,179651,179755,180171,180539,180750,180976,181284,181429,181906,182016,182200,182226,183145,183975,184210,185666,185853,186358,186388,186520,186783,186812,187040,187267,187405,187903,190676,190697,190751,191001,191167,191448,191704,191988,193629,193744,194023,194301,194307,194363,194682,194993,195706,195915,195922,196088,196244,197062,197338,197603,198034,198230,198317,199070,199287,199404,200056,200072,200415,200705,200894,201764,201895,202050,202291,202786,203449,203605,203627,203668,203702,203966,203970,204877,205041,205436,205591,206532,206647,206707,206784,207016,207109,207504,207848,207962,207974,208023,208772,209374,209663,209666,210743,210792,210879,210890],[1460.0,59.0,8.0,8.0,27.0,43.0,2.0,10.0,18.0,21.0,3.0,22.0,3.0,4.0,28.0,22.0,6.0,12.0,1.0,5.0,1.0,30.0,16.0,6.0,5.0,2.0,15.0,26.0,8.0,42.0,5.0,16.0,24.0,3.0,31.0,11.0,4.0,23.0,20.0,6.0,9.0,3.0,3.0,5.0,14.0,1.0,2.0,3.0,8.0,3.0,4.0,8.0,6.0,5.0,9.0,1.0,2.0,1.0,1.0,2.0,3.0,1.0,6.0,1.0,3.0,3.0,18.0,3.0,1.0,2.0,1.0,9.0,15.0,2.0,3.0,3.0,4.0,2.0,3.0,8.0,3.0,1.0,2.0,2.0,2.0,3.0,3.0,9.0,15.0,3.0,1.0,9.0,1.0,9.0,3.0,3.0,2.0,1.0,2.0,1.0,2.0,1.0,4.0,2.0,4.0,3.0,5.0,1.0,1.0,3.0,2.0,7.0,23.0,4.0,1.0,3.0,1.0,1.0,6.0,2.0,1.0,5.0,2.0,3.0,2.0,1.0,1.0,2.0,11.0,10.0,1.0,1.0,1.0,8.0,1.0,2.0,1.0,5.0,2.0,3.0,1.0,2.0,1.0,2.0,4.0,1.0,2.0,2.0,2.0,5.0,3.0,2.0,1.0,1.0,1.0,2.0,2.0,8.0,2.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,7.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,2.0,5.0,4.0,1.0,1.0,4.0,4.0,1.0,1.0,2.0,3.0,4.0,2.0,1.0,2.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,7.0,2.0,2.0,1.0,12.0,3.0,3.0,1.0,4.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,8.0,12.0,4.0,3.0,5.0,1.0,1.0,5.0,1.0,3.0,2.0,4.0,1.0,1.0,2.0,13.0,1.0,2.0,3.0,3.0,4.0,1.0,1.0,1.0,1.0,3.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,3.0,1.0,2.0,4.0,1.0,1.0,3.0,4.0,1.0,1.0,6.0,3.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,4.0,16.0,1.0,2.0,1.0,6.0,1.0,3.0,7.0,3.0,1.0,1.0,2.0,10.0,2.0,2.0,6.0,4.0,4.0,3.0,4.0,3.0,4.0,1.0,10.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,3.0,1.0,3.0,1.0,8.0,1.0,6.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,11.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,6.0,2.0,1.0,3.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,3.0,2.0,1.0,3.0,3.0,2.0,1.0,3.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,4.0,2.0,2.0,2.0,2.0,1.0,1.0,2.0,1.0,3.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,9.0,2.0,1.0,16.0,4.0,1.0,2.0,1.0,3.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,15.0,2.0,1.0,2.0,3.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,3.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,4.0,1.0,4.0,1.0,1.0,1.0,4.0,3.0,3.0,2.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,2.0,6.0,1.0,8.0,1.0,1.0,2.0,5.0,2.0,1.0,2.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,2.0,2.0,1.0,1.0,2.0,3.0,2.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,11.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,10.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,2.0,17.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,24.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,15.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,19.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,47.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,20.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,34.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,9.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,21.0,1.0,1.0,2.0,1.0,1.0,1.0,10.0,19.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,4.0,6.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,15.0,1.0,1.0,1.0,1.0,12.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,6.0,1.0,10.0,5.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,6.0,1.0,1.0,9.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,2.0,2.0,5.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,4.0,1.0,3.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,2.0,1.0,4.0,4.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,3.0,3.0,1.0,1.0,3.0,1.0,2.0,3.0,1.0,3.0,3.0,1.0,3.0,2.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,3.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,2.0,2.0,2.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n",
      "|[, in, , a, novel, coronavirus, sarscov2, was, found, to, cause, a, highly, contagious, disease, characterized, by, pneumonia, the, disease, covid19, quickly, spread, around, the, globe, escalating, to, a, global, pandemic, in, this, review, we, discuss, the, virological, immunological, and, imaging, approaches, harnessed, for, covid19, diagnosis, and, research, covid19, shares, many, clinical, characteristics, with, other, respiratory, illnessesaccurate, and, early, detection, of, the, infection, is, pivotal, to, controlling, the, outbreak, as, this, enables, case, identification, isolation, and, contact, tracing, we, summarize, the, available, literature, on, current, laboratory, and, pointofcare, diagnostics, highlight, their, strengths, and, limitations, and, describe, the, emerging, diagnostic, approaches, on, the, horizonwe, also, discuss, the, various, research, techniques, that, are, being, used, to, evaluate, host, immunity, in, laboratoryconfirmed, patients, additionally, pathological, imaging, of, tissue, samples, from, affected, patients, has, a, critical, role, in, guiding, investigations, on, this, disease, conventional, techniques, such, as, immunohistochemistry, and, immunofluorescence, have, been, frequently, used, to, characterize, the, immune, microenvironment, in, covid19, we, also, outline, the, emerging, imaging, techniques, such, as, the, rnascope, which, might, also, aid, in, our, understanding, of, the, significance, of, covid19specific, biomarkers, such, as, the, angiotensinconverting, enzyme, , ace2, cellular, receptoroverall, , great, , progress, , has, , been, , made, , in, , covid19, , research, , in, , a, , short, , period, , extensive, , global, , collation, , of, , our, current, knowledge, of, sarscov2, will, provide, insights, into, novel, treatment, modalities, such, as, monoclonal, antibodies, and, support, the, development, of, a, sarscov2, vaccinekeywordscovid19, immunology, pathology, diagnostics, specific, t, cellsintroductionin, december, , a, novel, respiratory, disease, named, coronavirus, disease, , covid19, was, detected, by, physicians, in, wuhan, china, the, disease, was, found, to, be, caused, by, , the, , severe, , acute, , respiratory, , syndrome, , sarscov2, rna, , virus12, , within, , a, , matter, , of, , weeks, , covid19, , had, spread, rapidly, and, escalated, to, a, global, pandemic, at, the, time, , of, , writing, , june, , , , , million, , cases, , had, , been, reported, and, , patients, had, succumbed, to, the, disease, , worldwide3, , indeed, , patients, , with, , covid19, , are, , at, high, , risk, , of, , developing, , a, , severe, , and, , critical, , disease4, therefore, rapid, and, accurate, diagnostic, tests, are, urgently, needed, , to, , effectively, , isolate, , identify, , and, , treat, , infected, individuals, and, to, contain, the, spread, of, the, virus, failure, to, do, so, will, inevitably, lead, to, spikes, in, cases, and, the, resultant, overcrowding, , and, , collapse, , of, , healthcare, , services5, moreover, research, into, this, novel, virus, is, also, critical, to, understand, , its, , pathogenesis, , and, , its, , interaction, , with, , the, human, , immune, , system, , insights, , from, , such, , research, , will, guide, the, design, of, public, health, policies, and, protocols, to, 1lee, kong, chian, school, of, medicine, nanyang, technological, university, singapore, singapore2yong, loo, lin, school, of, medicine, national, university, of, singapore, singapore, singapore3institute, of, molecular, cell, biology, imcb, agency, of, science, technology, and, research, astar, singapore, singapore4department, of, anatomical, pathology, singapore, general, hospital, singapore, singaporethese, authors, contributed, equallyreceived, june, , , and, in, revised, form, july, , , accepted, for, publication, july, , corresponding, authorjoe, poh, sheng, yeong, institute, of, molecular, cell, biology, imcb, agency, of, science, technology, and, research, astar, , college, road, academia, level, , diagnostics, tower, singapore, , singapore, email, yeongpsimcbastaredusg, 0c, slas, technology, , identify, susceptible, individuals, and, diagnostic, prognostic, and, treatment, approaches, for, patientscurrent, , diagnostic, , approaches, , predominantly, , involve, established, virological, procedures, such, as, nucleic, acid, hybridization, techniques, reversetranscriptase, pcr, [rtpcr], and, recombinase, , polymerase, , amplification, , rpa, , as, , well, , as, immunologic, , approaches, like, , antibody, , assays, , each, approach, , boasts, , unique, , strengths, , and, , weaknesses, , for, instance, while, rtpcr, demonstrates, high, sensitivity, and, specificity, , its, , capabilities, , have, , been, , severely, , limited, , for, practical, reasons, during, this, current, pandemic, due, to, global, shortages, of, skilled, personnel, reagents, and, equipment, and, a, processing, time, of, up, to, , days, by, contrast, immunologic, tests, such, as, antibody, assays, are, rapid, and, require, minimal, equipment, , but, , they, , have, , limited, , utility, , in, , the, , context, , of, acute, diagnosis, of, sarscov2, infections, this, is, because, it, can, take, several, days, to, weeks, following, symptom, onset, for, a, patient, to, mount, a, detectable, antibody, response6immunological, tools, in, research, include, enzymelinked, immunosorbent, , assays, , elisas, , flow, , cytometry, , and, mass, cytometry, cytof, imaging, techniques, for, pathological, analyses, include, conventional, approaches, such, as, hematoxylineosin, he, staining, immunohistochemical, ihc, , staining, , or, , transmission, , electron, , microscopy, tem, and, rnascope, each, of, these, methods, is, used, to, examine, the, pathophysiology, underlying, covid19, from, a, different, perspective, each, with, their, own, advantages, and, disadvantages, , for, , example, , it, , has, , been, , established, , that, the, entry, of, sarscov2, intro, cells, depends, on, the, binding, of, viral, proteins, with, the, human, receptor, angiotensinconverting, , enzyme, , , , ace2, , receptors7, , additionally, evidence, , shows, , that, , the, , type, , ii, , transmembrane, , protease, tmprss2, is, also, essential, for, viral, entry, by, priming, the, viral, spike, protein, for, binding, to, ace28, therefore, considerable, , research, , efforts, , employing, , different, , techniques, have, , been, , directed, , at, , mapping, , the, , distribution, , of, ace2, and, , tmprss2, , in, , tissues, , and, , their, , relationship, , to, , the, observed, manifestations, of, disease, together, the, combination, of, these, approaches, has, advanced, our, understanding, of, covid19in, , this, , review, , we, , discuss, , the, , current, , approaches, , in, covid19, diagnosis, and, research, with, a, focus, on, findings, from, , virological, , and, , pathological, , imaging, , methods, , we, also, , discuss, , immunological, , methods, , which, , are, , increasingly, , recognized, , as, , an, , integral, , component, , of, , the, , disease, processdiagnosticsthe, most, common, symptoms, of, covid19, at, initial, presentation, , are, , nonspecific, , and, , include, , a, , high, , fever, , a, , new, and, , persistent, , cough, , and, , fatigue910, , due, , to, , similarities, between, the, clinical, characteristics, of, covid19, and, many, other, respiratory, illnesses, the, accurate, and, early, detection, of, infection, is, pivotal, for, outbreak, control, any, delays, in, diagnosis, are, increasingly, measured, in, lives, lostaccording, to, the, world, health, anization, who, the, immediate, goal, for, research, into, covid19, diagnostics, is, the, , development, , of, , rna, , assays, , antibody, , and, , antigen, assays, , and, , pointofcare, , detection11, , the, , intermediateterm, priority, would, be, their, integration, into, multiplex, diagnostic, , platforms, , while, , the, , longterm, , goal, , would, , be, , the, investigation, of, prognostic, markersin, this, section, we, summarize, the, current, and, emerging, diagnostic, , tools, , for, , sarscov2, , through, , the, , lens, , of, immunologylabbased, testsrtpcr, , molecular, , testing, , the, , detection, , of, , viral, , nucleic, acids, by, rtpcr, is, the, primary, method, used, to, confirm, a, suspected, , case, , of, , covid19, , rtpcr, , and, , other, , nucleic, acid, hybridization, techniques, are, an, integral, part, of, virology, and, are, applied, in, a, broad, range, of, settings, including, screening, , diagnosis, , informing, , medical, , and, , therapeutic, decisions, and, assessing, cure, rates, from, therapy12, chinese, officials, released, the, genomic, sequence, of, sarscov2, to, public, databases, early, in, the, course, of, the, outbreak13, and, the, who, has, since, published, seven, protocols, for, rtpcrbased, diagnostics, because, of, the, high, sensitivity, and, specificity, of, rtpcr, it, is, regarded, as, the, gold, standard, for, virus, detection14, there, are, two, essential, steps, in, the, process, , viral, rna, extraction, and, , pcr, amplification, and, , probebased, , detection, , multiple, , largescale, , highthroughput, , instruments, , are, , available, , for, , automating, , both, steps, such, as, the, roche, cobas, , system, which, has, an, advertised, throughput, of, , tests, per, , hours15however, rtpcrbased, testing, is, costly, and, timeconsuming, requiring, up, to, , days, using, centralized, laboratory, equipment, and, skilled, personnel, furthermore, global, supply, , chain, , challenges, , have, , led, , to, , significant, , shortages, , of, essential, reagents, lastly, falsenegative, results, due, to, low, sample, , volumes, , variable, , sampling, , techniques, , and, , sampling, , locations, , sample, , degradation, , during, , transportation, andor, improper, nucleic, acid, extraction, are, a, concern16, in, , addition, , the, , differences, , in, , detectable, , viral, , material, , in, different, sampling, locations, eg, nasopharyngeal, vs, bronchoalveolar, lavage, fluid, [balf], vs, rectal, samples, might, also, , explain, , the, , falsepositive, , rtpcr, , results, , on, , repeat, testing, , in, , recovered, , covid19, , patients, , indeed, , one, postmortem, case, study, revealed, residual, virus, in, lung, tissue, despite, , consecutive, , negative, , results, , on, , pcr, , testing, , from, nasopharyngeal, , swabs19, , separately, , winichakoon, , et, , al, outlined, a, case, of, repeatedly, negative, nasopharyngeal, and, oropharyngeal, , swabs, , in, , a, , clinically, , deteriorating, , patient, where, only, a, balf, pcr, test, returned, positive20given, the, high, expression, of, ace2, on, alveolar, epithelial, cells, and, negative, expression, on, nasal, oral, and, nasopharynx, , 0ctan, et, al, cells21, , it, , would, , be, , prudent, , to, , perform, , bronchoalveolar, lavage, , on, , patients, , to, , rule, , out, , falsenegative, , results, , from, swabs, of, upper, respiratory, tract, samples20labbased, , immunological, , assays, , in, , contrast, , to, , rtpcr, techniques, , that, , detect, , viral, , nucleic, , acids, , serological, , and, immunological, , assays, , aim, , to, , detect, , antibodies, , against, sarscov2, or, antigenic, proteins, in, infected, individuals, neutralization, assays, are, considered, the, gold, standard, for, assessing, , neutralizing, , protective, , antibodies22, , however, these, , assays, , require, , specialized, , biosafety, , level, , , , bsl3, facilities, , and, , still, , take, , several, , days, , to, , complete, another, type, of, labbased, antibody, assay, is, the, traditional, elisa, which, , detects, , all, , binding, , antibodies, , the, , four, , principal, types, of, elisa, are, direct, indirect, competitive, and, sandwich, , elisa, , the, , indirect, , elisa, , is, , the, , most, , common, method, , for, , determining, , antibody, , concentrations, , elisas, have, , good, , concordance, , with, , neutralization, , assays, , for, , the, detection, of, antibody, responses, in, sarscov223, unfortunately, , both, , methods, , require, , skilled, , operators, , and, , are, limited, by, low, throughput, due, to, the, absence, of, fully, automated, systemsserological, , diagnostics, , offer, , several, , advantages, , re, quirements, , for, , specimen, , quality, , are, , comparatively, , less, stringent, , than, , for, , nucleic, , acid, , tests, , as, , the, , antibodies, , are, uniformly, , distributed, , in, , the, , serum24, , consequently, , sampling, , location, , concerns, , do, , not, , apply, , here, , furthermore, good, correlation, between, igg, elisas, performed, on, both, conventional, serum, samples, and, plasma, samples, have, been, reported25, of, which, the, latter, may, be, conveniently, obtained, from, residual, blood, submitted, for, other, routine, laboratory, testsone, pitfall, of, antibody, assays, is, their, limited, utility, early, in, the, course, of, any, infection, sparse, data, are, available, with, regard, to, the, antibody, responses, produced, by, patients, with, covid19, it, seems, that, sarscov2, igm, is, detectable, at, a, , median, , of, , , , days, , after, , symptom, , onset, , while, , igg, , is, detectable, , after, , , , days26, , with, , the, , seroconversion, , rate, approaching, , , , by, , day, , , , an, , italian, , research, , group, noted, , that, , the, , performance, , of, , a, , commercial, , vivadiag, covid19, igmigg, test, was, very, poor, with, a, sensitivity, of, only, , and, a, negative, predictive, value, of, , in, a, cohort, of, suspected, covid19, patients, in, the, emergency, room, setting27, as, such, we, believe, that, for, now, rtpcr, testing, , is, , likely, , more, , appropriate, , for, , diagnosing, , acute, covid19notably, , a, , longitudinal, , study, , examining, , the, , iggigm, profiles, , of, , , , patients, , found, , that, , seroconversion, , for, , igg, and, igm, occurred, in, no, specific, chronological, order, with, a, median, , of, , , , days, , after, , symptom, , onset28, , all, , patients, achieved, , seroconversion, , by, , day, , , , consequently, , the, detection, of, both, igg, and, igm, simultaneously, rather, than, one, antibody, alone, would, be, idealanother, , concern, , surrounding, , serologic, , diagnostics, , is, the, production, of, falsepositive, results, from, crossreactivity, due, to, the, high, prevalence, of, the, four, endemic, human, coronaviruses, , in, , the, , human, , population, , in, , sarscov2, the, spike, s, protein, which, includes, two, regions, s1, and, s2, , and, , the, , nucleocapsid, , n, , protein, , np, , are, , the, , major, immunogens29, and, therefore, most, diagnostics, rely, on, the, detection, , of, , antibodies, , specific, , for, , these, , antigens, , one, work, , suggests, , that, , of, , the, , possible, , targets, , the, , s1, , subunit, antigen, is, more, specific, than, either, the, whole, s, antigen, or, the, n, antigen, for, detecting, sarscov2, antibodies, with, no, crossreactivity, to, other, coronaviruses, except, for, sarscov23, , given, , that, , only, , , , sarscov, , infections, , were, recorded, worldwide30, the, risk, of, false, positives, from, this, crossreactivity, , is, , miniscule, , however, , np, , elisas, , are, more, sensitive, than, s1, in, detecting, antibodies, in, those, with, a, mild, infection23, importantly, as, in, sarscov, most, of, the, neutralizing, antibodies, are, directed, against, the, s, protein31, , of, , which, , s1, , contains, , a, , receptorbinding, , domain, rbd, responsible, for, making, contact, with, ace2, to, facilitate, , viral, , entry7, , thus, , theoretically, , only, , diagnostics, , that, detect, s1specific, antibodies, are, suitable, to, infer, immunity, to, , covid19, , this, , fact, , is, , corroborated, , by, , evidence, , that, antis, rbd, but, not, antinp, igg, levels, correlated, with, neutralizing, antibody, titers, in, sera, from, a, cohort, of, , recovered, patients32, the, number, of, commercial, antibody, assays, is, , growing, , detecting, , either, , antinp, , antibodies, , antis1s, antibodies, , or, , both, , there, , is, , also, , large, , variation, , in, , their, claimed, sensitivities, and, specificities33, based, on, the, available, evidence, an, ideal, serological, assay, would, be, a, combined, test, that, simultaneously, detects, both, antibodies, to, np, and, s1, antigens, assessment, of, antinp, antibodies, has, good, sensitivity, and, would, be, best, suited, for, supporting, the, diagnosis, , of, , infection, , while, , the, , additional, , antis1, , antibody, assay, would, allow, for, the, determination, of, immunityrapid, testspointofcare, rtpcr, tests, , a, small, number, of, commercial, pointofcare, tests, utilizing, rtpcr, have, been, developed, these, typically, involve, the, same, methodology, as, conventional, rtpcr, but, implemented, with, automated, and, portable, , benchtopsized, , instruments, , that, , can, , be, , operated, closer, , to, , patient, , care, , settings, , than, , a, , centralized, , laboratory, , a, , prominent, , example, , is, , cepheids, , xpert, , xpress, sarscov2, run, on, the, gene, xpert, platform, this, apparatus, can, provide, a, result, within, , min, others, include, the, mesabiotech, accula, test, and, microsensdx, rapiprep, covid19, despite, displaying, good, sensitivity, and, specificity, , these, , instruments, , are, , generally, , limited, , by, , a, , very, low, , throughput, , of, , only, , one, , to, , four, , tests, , per, , run, , per, machine34, and, as, such, are, only, suited, to, small, laboratories, or, clinics, 0c, slas, technology, , figure, , , loopmediated, isothermal, amplification, lamp, a, lamp, begins, when, the, forward, inner, primer, fip, binds, to, the, a2c, region, while, the, forward, primer, a1, binds, to, a1c, which, displaces, the, fip, complementary, strand, b, the, backward, inner, primer, bip, binds, b2c, while, the, backward, primer, b3, binds, b3c, and, displaces, the, bip, complementary, strand, c, a, complementary, sequence, that, initiates, loop, formation, is, produced, d, loop, structures, are, formed, that, allow, for, lamp, with, the, use, of, loop, primersfigure, , , crispr, technique, viral, rna, is, converted, to, dsdna, using, rtrpa, recombinase, polymerase, amplification, a, the, cas12a, nuclease, enzyme, is, activated, upon, complex, binding, to, the, target, sequence, resulting, in, cleavage, of, the, target, sequence, and, the, fluorescent, rna, reporter, b, t7, transcription, converts, dna, to, complementary, rna, cas13, nuclease, enzyme, activity, is, activated, upon, complex, binding, to, the, target, sequence, resulting, in, a, similar, cleavage, of, the, target, sequence, and, the, fluorescent, rna, reporterimmunological, assaysrapid, , antibody, , assays, , compared, , with, , labbased, , antibody, assays, rapid, assays, such, as, lateral, flow, immunoassays, lfias, fig, , and, chemiluminescent, immunoassays, clias, fig, , offer, the, benefits, of, rapid, diagnostic, testing, at, a, low, cost, these, assays, do, not, require, specialized, equipment, or, expertise35, and, are, thus, excellent, candidates, for, , pointofcare, , testing, , or, , deployment, , on, , a, , large, , scale, this, an, area, of, intense, interest, with, governments, worldwide, , aiming, , to, , order, , millions, , of, , tests, , to, , inform, , policy, makers, about, attack, rates, in, their, populations36, lfias, are, predominantly, , singleuse, , kits, , designed, , for, , pointofcare, use, while, clias, are, fully, automated, analyzers, that, permit, very, high, testing, throughputunfortunately, , these, , tests, , do, , not, , quantify, , the, , antibody, titers, , and, , the, , performance, , of, , lfias, , has, , been, , called, , into, question, one, evaluation, of, nine, commercial, lfias, reported, a, sensitivity, ranging, from, only, , to, , versus, rtpcr, and, , , , to, , , , versus, , elisa37, , meanwhile, , the, , performance, of, clias, is, superior, with, good, sensitivity, and, specificity, levels, similar, to, those, of, elisa38, otherwise, these, tests, , share, , the, , same, , advantages, , and, , drawbacks, , as, , the, , 0ctan, et, al, table, , , summary, of, diagnostic, approaches, for, covid19categorytype, of, testtypical, test, result, timecharacteristicsexamplesvirologicmolecular, rtpcrdaysgold, standard, high, sensitivity, who, rtpcr, protocolstests, , pointofcare, rtpcr, minlamp, crispr, himmunologic, testslfia, for, antibodies, minantigensand, specificity, high, throughput, but, lab, basedrapid, good, sensitivity, and, specificity, pointofcare, , testing, but, low, throughputrapid, good, sensitivity, and, specificity, pointofcare, , testing, but, low, throughputrapid, pointofcare, testing, but, not, quantitative, poor, sensitivitycepheid, xpert, xpress, sarscov2sherlock, biosciences, sherlockvivadiag, covid19, igmigg, rapid, testcorisbio, covid19, ag, respistripepitope, diagnostics, kt1033, edi, novel, coronavirus, covid19, elisa, kitroche, elecsys, antisarscov2, , , traditional, elisa, hgood, sensitivity, and, specificity, but, lab, based, not, automatedclia, minrapid, good, sensitivity, and, specificity, high, throughput, , but, lab, basedneutralization, assaydaysgold, standard, high, sensitivity, not, commercially, and, specificity, able, to, quantify, neutralizing, antibodies, but, requires, bsl3, lab, facilityavailablelabbased, antibody, assays, discussed, above, the, characteristics, and, unique, advantages, and, disadvantages, of, these, different, methodologies, are, outlined, in, table, antigen, assays, , an, alternative, approach, to, immunological, assays, is, to, directly, detect, sarscov2, viral, antigens, several, , commercial, , pointofcare, , antigen, , tests, , are, , available, but, their, performance, remains, to, be, evaluated, these, tests, may, be, suitable, for, making, an, early, diagnosis, and, are, deployable, as, pointofcare, assays, however, they, face, the, same, , sampling, , limitations, , as, , rtpcr, , and, , are, , hypothetically, hampered, by, limited, sensitivity, due, to, the, omission, of, , an, , amplification, , process, , unlike, , nucleic, , acid, , testing, for, , example, , one, , multicenter, , study, , evaluating, , the, , corisbio, covid19, ag, respistrip, a, lateral, flow, assay, for, the, sarscov2, np, reported, a, test, sensitivity, of, only, rapid, , nonpcr, , molecular, , testing, , nucleic, , acid, , testing, using, nonpcr, methods, is, an, emerging, approach, for, rapid, diagnostics, , and, , several, , assays, , have, , received, , food, , and, drug, administration, fda, emergency, use, authorization, which, , facilitates, , the, , distribution, , of, , unapproved, , medical, products, or, the, offlabel, use, of, approved, medical, products, , when, , certain, , criteria, , are, , met, , these, , methods, , share, high, sensitivity, and, specificity, on, par, with, rtpcr, but, with, , the, , principal, , advantages, , of, , more, , rapid, , testing, , at, , a, lower, cost40lamp, fig, , is, one, such, novel, isothermal, nucleic, acid, amplification, method, that, does, not, require, a, thermal, cycler, one, example, is, the, id, now, covid19, test, from, abbott, diagnostics, which, can, deliver, results, in, just, , min43, and, uses, , a, , lightweight, , portable, , instrument, , allowing, , onsite, testing, of, swab, samples, however, it, has, a, limited, throughput, of, only, one, sample, per, runthe, crispr, enzymes, cas12, and, cas13, have, also, been, adapted, , for, , rapid, , nucleic, , acid, , sensing, , , , fig, , , , the, detectr, , assay, , by, , mammoth, , biosciences45, , as, , well, , as, the, , sherlock, , assay, , by, , sherlock, , biosciences46, , potentially, offers, sensitivity, and, specificity, comparable, to, those, of, rtpcr, but, can, be, completed, in, , h, however, these, approaches, are, still, in, the, early, stages, of, commercialization, and, current, applications, are, available, only, as, test, kits, to, be, run, in, labs, while, pointofcare, versions, exist, as, proofofconcept, demonstrations47, nonetheless, their, inherent, characteristics, hold, great, potential, for, diagnosis, in, the, futureprognostication, of, diseaseprofiling, , of, , genetic, , susceptibility, , work, , is, , in, , progress, , to, ascertain, the, possible, genetic, basis, for, the, apparent, variations, in, covid19, susceptibility, and, disease, severity, cao, et, al, compared, expression, quantitative, trait, loci, eqtl, for, ace2, in, different, populations, finding, significantly, greater, eqtl, variants, associated, with, higher, ace2, expression, in, , 0c, slas, technology, , figure, , , lateral, flow, immunoassay, lfia, a, serum, sample, deposited, on, the, sample, pad, b, antisarscov2, antibodies, in, the, sample, will, bind, to, the, target, antigen, with, a, labeled, tag, c, immobilized, antihuman, igm, antibodies, will, capture, the, sarscov2, antibodyantigen, complex, d, control, antibodies, are, captured, by, immobilized, antibodies, in, the, control, lineserum, prognostic, markers, , another, application, of, immunological, methods, would, be, to, measure, markers, that, enable, prognostication, , in, , covid19, , higher, , titers, , of, , antibodies, against, , sarscov2, , have, , been, , associated, , with, , more, severe, , disease2350, , similar, , to, , previous, , studies, , in, , middle, east, , respiratory, , syndrome, , merscov51, , elisa, , has, been, used, to, provide, a, quantitative, measurement, of, serum, and, , plasma, , igm, , and, , igg, , antibodies, , by, , monitoring, , the, kinetics, of, igm, and, igg, antibodies, specific, to, the, n, and, s, proteins, on, sarscov2, it, was, found, that, intensive, care, unit, icu, patients, had, a, significantly, lower, level, of, sigg, within, , , , weeks, , of, , symptom, , onset, , but, , a, , higher, , level, , of, nigg, antibodies, compared, with, nonicu, patients52, this, finding, highlights, the, possible, utility, of, sigg, and, nigg, as, a, prognostic, tool, for, covid19, patientsthe, ddimer, level, which, consists, of, crosslinked, fibrin, degradation, products, that, reflect, ongoing, blood, clot, formation, , and, , breakdown, , activity, , in, , the, , body, , is, , another, , proposed, , prognostic, , marker, , modern, , commercial, , assays, , for, ddimers, are, based, on, monoclonal, antibodies, employing, either, elisa, or, microlatex, agglutination, assays53, reports, have, emerged, that, elevated, ddimer, levels, suggestive, of, a, hypercoagulable, state, are, associated, with, drastically, worse, outcomes, a, chinese, group, reported, that, ddimer, levels, of, ¥, , µgml, , on, , admission, , were, , associated, , with, , a, , , times, , increased, , mortality, , relative, , to, , ddimer, , levels, , of, , , µgml, in, a, cohort, of, , covid19, patients54, this, finding, of, ddimer, levels, as, a, negative, prognostic, marker, was, also, noted, in, other, studies, conducted, in, china455, and, the, netherlands56similarly, , interleukin, , il6, , a, , key, , component, , of, , the, cytokine, release, syndrome, is, another, marker, measured, by, elisa, , and, , has, , been, , described, , to, , independently, , predict, adverse, outcomes, in, covid195758, tumor, necrosis, factor, alpha, , tnfî±, , another, , important, , proinflammatory, , cytokine, , has, , also, , been, , found, , to, , be, , strongly, , correlated, , with, figure, , , chemiluminescence, enzyme, immunoassay, clia, sarscov2, antigens, will, capture, igm, and, igg, antibodies, from, the, sample, serum, secondary, antibodies, that, are, conjugated, with, horseradish, peroxidase, hrp, bind, to, the, captured, primary, igm, and, igg, antibodies, and, react, with, a, chemiluminescent, substrate, to, generate, a, strong, chemiluminescent, signal, that, is, measured, in, terms, of, relative, light, units, rlueast, , asian, , populations, , but, , reported, , no, , direct, , evidence, supporting, , the, , existence, , of, , s, , proteinbindingresistant, ace2, mutants48, out, of, , identified, protein, altering, variants, separately, stawiski, et, al, analyzed, ace2, polymorphisms, , within, , a, , much, , larger, , population, , dataset, , spanning, more, than, , population, groups, across, the, world, and, performed, structural, predictions, to, identify, variants, that, might, confer, protection, or, rather, increase, susceptibility, to, sarscov2, s, protein, binding49, out, of, a, total, of, , identified, proteinaltering, ace2, variants, , variants, were, predicted, to, increase, susceptibility, while, , variants, were, speculated, to, , confer, , protection, , however, , the, , degree, , of, , changes, , in, receptorvirus, binding, interactions, for, each, structural, variant, was, not, quantified, these, findings, represent, significant, developments, in, our, understanding, of, population, risk, profiles, for, covid19, and, future, coronavirus, infections, 0ctan, et, al, endan, , damage, , and, , mortality, , even, , after, , adjusting, , for, disease, severity, scores59, gao, et, al, examined, both, il6, and, ddimer, levels, they, proposed, a, panel, comprising, tandem, testing, of, these, two, markers, which, produced, a, sensitivity, of, , , , and, , specificity, , of, , , , in, , early, , prediction, , of, severe, covid1958, elevated, troponin, levels, a, marker, of, myocardial, , injury, , measured, , with, , elisa, , immunoassays, also, strongly, predict, progression, to, death, in, patients, with, severe, illness60, these, results, suggest, that, multiplex, cytokine, and, serum, marker, profiling, will, be, a, powerful, tool, in, stratifying, , patients, , that, , may, , guide, , clinical, , decisions, , and, resource, allocationsummary, , in, sum, rapid, progress, has, been, made, in, diagnostics, for, covid19, yet, the, race, against, time, continues, for, researchers, and, biotechnology, firms, to, develop, rapid, costeffective, , and, , reliable, , test, , kits, , that, , can, , be, , deployed, on, a, large, scale, at, the, time, of, writing, labbased, rtpcr, testing, , has, , been, , the, , dominant, , diagnostic, , approach, , but, alternative, molecular, approaches, like, isothermal, amplification, and, crispr, which, have, clear, advantages, are, on, the, horizon, immunological, tests, such, as, clia, and, lfia, will, become, increasingly, important, because, of, the, urgent, need, for, , pointofcare, , diagnostics, , for, , mass, , testing, , of, , infected, asymptomatic, individuals, and, their, close, contacts, and, will, be, , valuable, , in, , complementing, , molecular, , approaches, , for, confirming, , infection, , furthermore, , immunological, , assays, will, , be, , in, , great, , demand, , by, , policy, , makers, , worldwide, , for, the, , assessment, , of, , immunity, , to, , covid19, , however, , the, performance, of, these, serological, tests, varies, significantly, particularly, , their, , degree, , of, , sensitivity, , and, , specificity, , we, believe, that, caution, must, be, taken, in, the, interpretation, of, these, tests, detailed, evaluation, of, the, reliability, of, serological, tests, will, be, a, key, area, for, future, research, lastly, given, the, , importance, , of, , techniques, , like, , elisa, , in, , prognosticating, covid19, immunological, methods, will, undoubtedly, occupy, a, crucial, role, in, achieving, all, levels, of, the, whos, short, medium, and, longterm, diagnostic, goalscovid19, research, toolsimmunological, approachescovid19, , infection, , has, , a, , poor, , prognosis, , in, , individuals, with, , comorbidities, , and, , abnormal, , immune, , functions, although, , research, , surrounding, , covid19, , is, , still, , in, , its, infancy, several, studies, have, revealed, lymphopenia, and, the, cytokine, , storm, , as, , underlying, , mechanisms, , correlating, , to, disease, progression, here, we, discuss, the, various, immunological, techniques, involved, in, assessing, host, immunity, in, covid19, patientselisa, , as, , discussed, , elisa, , has, , also, , been, , used, , to, , detect, the, , inflammatory, , cytokines, , implicated, , in, , the, , cytokine, storm, seen, in, patients, with, severe, respiratory, failure, due, to, covid19, , one, , study, , found, , that, , the, , immune, , dysregulation, in, patients, with, severe, respiratory, failure, was, due, to, a, significantly, , increased, , production, , of, , il6, , and, , defective, lymphoid, function, because, of, an, il6mediated, decrease, in, hladr, , expression, , on, , cd14, , monocytes, , interestingly, interferongamma, , ifnî³, , levels, , were, , below, , the, , detection, level, in, these, patients, suggesting, that, t, helper, th, , cells, are, , unlikely, , to, , be, , major, , players, , in, , the, , overinflammatory, response, , of, , severe, , patients61, , a, , similar, , observation, , was, made, in, a, separate, study, whereby, inflammatory, cytokines, that, mediate, major, immune, responses, such, as, tnfî±, and, il1î², , were, , not, , significantly, , elevated, , in, , icu, , patients62, these, findings, demonstrate, that, the, immunophenotype, of, patients, with, covid19, can, vary, depending, on, presently, unclear, host, immune, factors, and, the, severity, of, their, condition, this, , relationship, , between, , disease, , severity, , and, , cytokine, storm, has, also, been, highlighted, in, other, studies, that, found, , a, , significantly, , elevated, , plasma, , concentration, , of, granulocyte, , colonystimulating, , factor, , gcsf, , ip10, ccl2, and, ccl3, in, icu, patients, compared, with, nonicu, patients63elisa, is, also, being, used, as, a, companion, diagnostic, tool, for, therapeutic, purposes, in, a, study, that, explored, the, use, of, convalescent, plasma, therapy, from, donors, as, a, form, of, treatment, in, severe, covid19, elisa, was, used, to, assess, the, neutralizing, activity, of, the, rbdspecific, igm, and, igg, antibodies, found, in, the, donor, convalescent, plasma64, after, the, transfusion, was, complete, elisa, was, also, used, to, detect, igg, , igm, , and, , neutralizing, , antibody, , titers, , in, , the, , sera, , of, patients, to, assess, the, response, to, treatment65enzymelinked, immunosorbent, spot, , enzymelinked, immunosorbent, spot, elispot, is, a, sensitive, immunoassay, that, quantitatively, measures, cytokinesecreting, cells, at, the, singlecell, level, providing, insight, into, immunerelated, cellular, activities66, hence, it, is, a, promising, tool, for, characterizing, specific, tcell, , immunity, , in, , covid19, , patients, , by, , ifnî³, elispot, , analysis, , it, , was, , revealed, , that, , convalescent, covid19, , patients, , had, , significantly, , increased, , levels, , of, ifnî³secreting, t, cells, when, compared, with, healthy, donors, a, , significant, , correlation, , between, , neutralizing, , antibody, titers, and, npspecific, t, cells, was, identified, in, these, patients, suggesting, , that, , a, , combination, , of, , humoral, , and, , cellular, immunity, , is, , integral, , to, , clearing, , sarscov2, , interestingly, , it, , was, , noted, , that, , in, , convalescent, , patients, , , , weeks, ifnî³secreting, , tcell, , numbers, , had, postdischarge, decreased, suggesting, that, they, may, not, be, maintained, for, a, prolonged, period, of, time, even, in, recovered, patients67elispot, is, also, serving, a, vital, role, in, vaccine, development, through, the, detection, of, potential, tcell, epitopes, in, , the, , s, , protein, , rbd, , of, , sarscov268, , one, , study, , was, able, , to, , harness, , elispot, , assays, , to, , identify, , three, , tcell, epitopes, that, induced, a, strong, adaptive, immune, response, , 0c, slas, technology, , postimmunization, demonstrating, the, promise, of, elispot, assays, , in, , the, , area, , of, , vaccine, , development32, , recently, elispot, has, also, been, applied, to, assess, the, immunogenicity, of, newly, developed, vaccines, one, such, study, successfully, , utilized, , an, , ifnî³, , elispot, , assay, , to, , evaluate, tcell, responses, to, a, new, sarscov2, vaccine, in, murine, splenocytes, and, rhesus, macaque, peripheral, blood, mononuclear, cells, pbmcs, the, promising, findings, from, this, animal, study, informed, the, start, of, a, phase, i, clinical, trial, with, , the, , same, , vaccine, , highlighting, , the, , usefulness, , of, elispot, in, assessing, immune, responses, to, new, vaccines, and, promoting, vaccine, development69flow, cytometry, , unlike, elisa, and, elispot, flow, cytometry, determines, the, number, of, cytokinesecreting, cells, and, has, the, capacity, to, immunophenotype, based, on, surface, and, intracellular, markers70, in, relation, to, the, current, pandemic, this, technique, enables, the, detection, sorting, and, analysis, of, multiple, subpopulations, of, immune, cells, specific, to, covid, using, flow, cytometry, researchers, detected, a, cytotoxic, immune, , environment, , in, , patient, , blood, , samples, , despite, , a, reduction, in, the, overall, lymphocyte, population71, as, part, of, the, sarscov2, antiviral, response, peripheral, lymphocytes, , retain, , the, , capacity, , to, , activate, , and, , differentiate, , into, subpopulations, , such, , as, , antibodysecreting, , cells, , cd3cd19cd27hicd38hi, follicular, t, cells, cd4cxcr5icospd1, , cd4, th, , cells, , cd38hladrcd4, , cytotoxic, t, tc, cells, cd38hladrcd8, and, regulatory, t, , treg, , cells, , cd3cd4cd25cd127, , these, , tc, cells, harbor, large, amounts, of, cytotoxic, granules, while, cd4, th, , cells, , skewed, , toward, , a, , proinflammatory, th1, , and, , th17, phenotype727375, the, overall, hyperinflammation, and, cytotoxic, environment, supports, the, notion, that, a, cytokine, storm, could, be, liable, for, the, multisystemic, insults, in, patients, with, severe, covid19elicitation, of, antiviral, tcell, responses, specific, to, sarscov2, is, of, utmost, importance, to, establishing, viral, control, many, studies, have, demonstrated, robust, antiviral, responses, however, there, is, no, known, set, of, markers, reported, to, identify, , sarscov2specific, , t, , cells, , collectively, , most, groups, , have, , characterized, , sarscov2specific, , t, , cells, based, on, hladr, cd38, cd69, cd25, cd44, and, ki67, expression, t]|[, , novel, coronavirus, sarscov2, found, cause, highly, contagious, disease, characterized, pneumonia, disease, covid19, quickly, spread, around, globe, escalating, global, pandemic, review, discuss, virological, immunological, imaging, approaches, harnessed, covid19, diagnosis, research, covid19, shares, many, clinical, characteristics, respiratory, illnessesaccurate, early, detection, infection, pivotal, controlling, outbreak, enables, case, identification, isolation, contact, tracing, summarize, available, literature, current, laboratory, pointofcare, diagnostics, highlight, strengths, limitations, describe, emerging, diagnostic, approaches, horizonwe, also, discuss, various, research, techniques, used, evaluate, host, immunity, laboratoryconfirmed, patients, additionally, pathological, imaging, tissue, samples, affected, patients, critical, role, guiding, investigations, disease, conventional, techniques, immunohistochemistry, immunofluorescence, frequently, used, characterize, immune, microenvironment, covid19, also, outline, emerging, imaging, techniques, rnascope, might, also, aid, understanding, significance, covid19specific, biomarkers, angiotensinconverting, enzyme, , ace2, cellular, receptoroverall, , great, , progress, , , , made, , , covid19, , research, , , , short, , period, , extensive, , global, , collation, , , current, knowledge, sarscov2, provide, insights, novel, treatment, modalities, monoclonal, antibodies, support, development, sarscov2, vaccinekeywordscovid19, immunology, pathology, diagnostics, specific, cellsintroductionin, december, , novel, respiratory, disease, named, coronavirus, disease, , covid19, detected, physicians, wuhan, china, disease, found, caused, , , severe, , acute, , respiratory, , syndrome, , sarscov2, rna, , virus12, , within, , , matter, , , weeks, , covid19, , spread, rapidly, escalated, global, pandemic, time, , , writing, , june, , , , , million, , cases, , , reported, , patients, succumbed, disease, , worldwide3, , indeed, , patients, , , covid19, , , high, , risk, , , developing, , , severe, , , critical, , disease4, therefore, rapid, accurate, diagnostic, tests, urgently, needed, , , effectively, , isolate, , identify, , , treat, , infected, individuals, contain, spread, virus, failure, inevitably, lead, spikes, cases, resultant, overcrowding, , , collapse, , , healthcare, , services5, moreover, research, novel, virus, also, critical, understand, , , pathogenesis, , , , interaction, , , human, , immune, , system, , insights, , , , research, , guide, design, public, health, policies, protocols, 1lee, kong, chian, school, medicine, nanyang, technological, university, singapore, singapore2yong, loo, lin, school, medicine, national, university, singapore, singapore, singapore3institute, molecular, cell, biology, imcb, agency, science, technology, research, astar, singapore, singapore4department, anatomical, pathology, singapore, general, hospital, singapore, singaporethese, authors, contributed, equallyreceived, june, , , revised, form, july, , , accepted, publication, july, , corresponding, authorjoe, poh, sheng, yeong, institute, molecular, cell, biology, imcb, agency, science, technology, research, astar, , college, road, academia, level, , diagnostics, tower, singapore, , singapore, email, yeongpsimcbastaredusg, 0c, slas, technology, , identify, susceptible, individuals, diagnostic, prognostic, treatment, approaches, patientscurrent, , diagnostic, , approaches, , predominantly, , involve, established, virological, procedures, nucleic, acid, hybridization, techniques, reversetranscriptase, pcr, [rtpcr], recombinase, , polymerase, , amplification, , rpa, , , well, , immunologic, , approaches, like, , antibody, , assays, , approach, , boasts, , unique, , strengths, , , weaknesses, , instance, rtpcr, demonstrates, high, sensitivity, specificity, , , capabilities, , , , severely, , limited, , practical, reasons, current, pandemic, due, global, shortages, skilled, personnel, reagents, equipment, processing, time, , days, contrast, immunologic, tests, antibody, assays, rapid, require, minimal, equipment, , , , , limited, , utility, , , , context, , acute, diagnosis, sarscov2, infections, take, several, days, weeks, following, symptom, onset, patient, mount, detectable, antibody, response6immunological, tools, research, include, enzymelinked, immunosorbent, , assays, , elisas, , flow, , cytometry, , mass, cytometry, cytof, imaging, techniques, pathological, analyses, include, conventional, approaches, hematoxylineosin, staining, immunohistochemical, ihc, , staining, , , transmission, , electron, , microscopy, tem, rnascope, methods, used, examine, pathophysiology, underlying, covid19, different, perspective, advantages, disadvantages, , , example, , , , , established, , entry, sarscov2, intro, cells, depends, binding, viral, proteins, human, receptor, angiotensinconverting, , enzyme, , , , ace2, , receptors7, , additionally, evidence, , shows, , , , type, , ii, , transmembrane, , protease, tmprss2, also, essential, viral, entry, priming, viral, spike, protein, binding, ace28, therefore, considerable, , research, , efforts, , employing, , different, , techniques, , , directed, , , mapping, , , distribution, , ace2, , tmprss2, , , tissues, , , , relationship, , , observed, manifestations, disease, together, combination, approaches, advanced, understanding, covid19in, , , review, , , discuss, , , current, , approaches, , covid19, diagnosis, research, focus, findings, , virological, , , pathological, , imaging, , methods, , also, , discuss, , immunological, , methods, , , , increasingly, , recognized, , , , integral, , component, , , , disease, processdiagnosticsthe, common, symptoms, covid19, initial, presentation, , , nonspecific, , , include, , , high, , fever, , , new, , persistent, , cough, , , fatigue910, , due, , , similarities, clinical, characteristics, covid19, many, respiratory, illnesses, accurate, early, detection, infection, pivotal, outbreak, control, delays, diagnosis, increasingly, measured, lives, lostaccording, world, health, anization, immediate, goal, research, covid19, diagnostics, , development, , , rna, , assays, , antibody, , , antigen, assays, , , pointofcare, , detection11, , , intermediateterm, priority, integration, multiplex, diagnostic, , platforms, , , , longterm, , goal, , , , investigation, prognostic, markersin, section, summarize, current, emerging, diagnostic, , tools, , , sarscov2, , , , lens, , immunologylabbased, testsrtpcr, , molecular, , testing, , , detection, , , viral, , nucleic, acids, rtpcr, primary, method, used, confirm, suspected, , case, , , covid19, , rtpcr, , , , nucleic, acid, hybridization, techniques, integral, part, virology, applied, broad, range, settings, including, screening, , diagnosis, , informing, , medical, , , therapeutic, decisions, assessing, cure, rates, therapy12, chinese, officials, released, genomic, sequence, sarscov2, public, databases, early, course, outbreak13, since, published, seven, protocols, rtpcrbased, diagnostics, high, sensitivity, specificity, rtpcr, regarded, gold, standard, virus, detection14, two, essential, steps, process, , viral, rna, extraction, , pcr, amplification, , probebased, , detection, , multiple, , largescale, , highthroughput, , instruments, , , available, , , automating, , steps, roche, cobas, , system, advertised, throughput, , tests, per, , hours15however, rtpcrbased, testing, costly, timeconsuming, requiring, , days, using, centralized, laboratory, equipment, skilled, personnel, furthermore, global, supply, , chain, , challenges, , , led, , , significant, , shortages, , essential, reagents, lastly, falsenegative, results, due, low, sample, , volumes, , variable, , sampling, , techniques, , , sampling, , locations, , sample, , degradation, , , transportation, andor, improper, nucleic, acid, extraction, concern16, , addition, , , differences, , , detectable, , viral, , material, , different, sampling, locations, eg, nasopharyngeal, vs, bronchoalveolar, lavage, fluid, [balf], vs, rectal, samples, might, also, , explain, , , falsepositive, , rtpcr, , results, , , repeat, testing, , , recovered, , covid19, , patients, , indeed, , one, postmortem, case, study, revealed, residual, virus, lung, tissue, despite, , consecutive, , negative, , results, , , pcr, , testing, , nasopharyngeal, , swabs19, , separately, , winichakoon, , et, , al, outlined, case, repeatedly, negative, nasopharyngeal, oropharyngeal, , swabs, , , , clinically, , deteriorating, , patient, balf, pcr, test, returned, positive20given, high, expression, ace2, alveolar, epithelial, cells, negative, expression, nasal, oral, nasopharynx, , 0ctan, et, al, cells21, , , , , prudent, , , perform, , bronchoalveolar, lavage, , , patients, , , rule, , , falsenegative, , results, , swabs, upper, respiratory, tract, samples20labbased, , immunological, , assays, , , contrast, , , rtpcr, techniques, , , detect, , viral, , nucleic, , acids, , serological, , immunological, , assays, , aim, , , detect, , antibodies, , sarscov2, antigenic, proteins, infected, individuals, neutralization, assays, considered, gold, standard, assessing, , neutralizing, , protective, , antibodies22, , however, , assays, , require, , specialized, , biosafety, , level, , , , bsl3, facilities, , , still, , take, , several, , days, , , complete, another, type, labbased, antibody, assay, traditional, elisa, , detects, , , binding, , antibodies, , , four, , principal, types, elisa, direct, indirect, competitive, sandwich, , elisa, , , indirect, , elisa, , , , , common, method, , , determining, , antibody, , concentrations, , elisas, , good, , concordance, , , neutralization, , assays, , , detection, antibody, responses, sarscov223, unfortunately, , , methods, , require, , skilled, , operators, , , limited, low, throughput, due, absence, fully, automated, systemsserological, , diagnostics, , offer, , several, , advantages, , re, quirements, , , specimen, , quality, , , comparatively, , less, stringent, , , , nucleic, , acid, , tests, , , , antibodies, , uniformly, , distributed, , , , serum24, , consequently, , sampling, , location, , concerns, , , , apply, , , furthermore, good, correlation, igg, elisas, performed, conventional, serum, samples, plasma, samples, reported25, latter, may, conveniently, obtained, residual, blood, submitted, routine, laboratory, testsone, pitfall, antibody, assays, limited, utility, early, course, infection, sparse, data, available, regard, antibody, responses, produced, patients, covid19, seems, sarscov2, igm, detectable, , median, , , , , days, , , symptom, , onset, , , igg, , detectable, , , , , days26, , , , seroconversion, , rate, approaching, , , , , day, , , , , italian, , research, , group, noted, , , , performance, , , , commercial, , vivadiag, covid19, igmigg, test, poor, sensitivity, , negative, predictive, value, , cohort, suspected, covid19, patients, emergency, room, setting27, believe, rtpcr, testing, , , likely, , , appropriate, , , diagnosing, , acute, covid19notably, , , longitudinal, , study, , examining, , , iggigm, profiles, , , , , patients, , found, , , seroconversion, , , igg, igm, occurred, specific, chronological, order, median, , , , , days, , , symptom, , onset28, , , patients, achieved, , seroconversion, , , day, , , , consequently, , detection, igg, igm, simultaneously, rather, one, antibody, alone, idealanother, , concern, , surrounding, , serologic, , diagnostics, , production, falsepositive, results, crossreactivity, due, high, prevalence, four, endemic, human, coronaviruses, , , , human, , population, , , sarscov2, spike, protein, includes, two, regions, s1, s2, , , , nucleocapsid, , n, , protein, , np, , , , major, immunogens29, therefore, diagnostics, rely, detection, , , antibodies, , specific, , , , antigens, , one, work, , suggests, , , , , possible, , targets, , , s1, , subunit, antigen, specific, either, whole, antigen, n, antigen, detecting, sarscov2, antibodies, crossreactivity, coronaviruses, except, sarscov23, , given, , , , , , sarscov, , infections, , recorded, worldwide30, risk, false, positives, crossreactivity, , , miniscule, , however, , np, , elisas, , sensitive, s1, detecting, antibodies, mild, infection23, importantly, sarscov, neutralizing, antibodies, directed, protein31, , , , s1, , contains, , , receptorbinding, , domain, rbd, responsible, making, contact, ace2, facilitate, , viral, , entry7, , thus, , theoretically, , , diagnostics, , detect, s1specific, antibodies, suitable, infer, immunity, , covid19, , , fact, , , corroborated, , , evidence, , antis, rbd, antinp, igg, levels, correlated, neutralizing, antibody, titers, sera, cohort, , recovered, patients32, number, commercial, antibody, assays, , growing, , detecting, , either, , antinp, , antibodies, , antis1s, antibodies, , , , , , also, , large, , variation, , , claimed, sensitivities, specificities33, based, available, evidence, ideal, serological, assay, combined, test, simultaneously, detects, antibodies, np, s1, antigens, assessment, antinp, antibodies, good, sensitivity, best, suited, supporting, diagnosis, , , infection, , , , additional, , antis1, , antibody, assay, allow, determination, immunityrapid, testspointofcare, rtpcr, tests, , small, number, commercial, pointofcare, tests, utilizing, rtpcr, developed, typically, involve, methodology, conventional, rtpcr, implemented, automated, portable, , benchtopsized, , instruments, , , , , operated, closer, , , patient, , care, , settings, , , , centralized, , laboratory, , , prominent, , example, , , cepheids, , xpert, , xpress, sarscov2, run, gene, xpert, platform, apparatus, provide, result, within, , min, others, include, mesabiotech, accula, test, microsensdx, rapiprep, covid19, despite, displaying, good, sensitivity, specificity, , , instruments, , , generally, , limited, , , , low, , throughput, , , , one, , , four, , tests, , per, , run, , per, machine34, suited, small, laboratories, clinics, 0c, slas, technology, , figure, , , loopmediated, isothermal, amplification, lamp, lamp, begins, forward, inner, primer, fip, binds, a2c, region, forward, primer, a1, binds, a1c, displaces, fip, complementary, strand, b, backward, inner, primer, bip, binds, b2c, backward, primer, b3, binds, b3c, displaces, bip, complementary, strand, c, complementary, sequence, initiates, loop, formation, produced, d, loop, structures, formed, allow, lamp, use, loop, primersfigure, , , crispr, technique, viral, rna, converted, dsdna, using, rtrpa, recombinase, polymerase, amplification, cas12a, nuclease, enzyme, activated, upon, complex, binding, target, sequence, resulting, cleavage, target, sequence, fluorescent, rna, reporter, b, t7, transcription, converts, dna, complementary, rna, cas13, nuclease, enzyme, activity, activated, upon, complex, binding, target, sequence, resulting, similar, cleavage, target, sequence, fluorescent, rna, reporterimmunological, assaysrapid, , antibody, , assays, , compared, , , labbased, , antibody, assays, rapid, assays, lateral, flow, immunoassays, lfias, fig, , chemiluminescent, immunoassays, clias, fig, , offer, benefits, rapid, diagnostic, testing, low, cost, assays, require, specialized, equipment, expertise35, thus, excellent, candidates, , pointofcare, , testing, , , deployment, , , , large, , scale, area, intense, interest, governments, worldwide, , aiming, , , order, , millions, , , tests, , , inform, , policy, makers, attack, rates, populations36, lfias, predominantly, , singleuse, , kits, , designed, , , pointofcare, use, clias, fully, automated, analyzers, permit, high, testing, throughputunfortunately, , , tests, , , , quantify, , , antibody, titers, , , , performance, , , lfias, , , , called, , question, one, evaluation, nine, commercial, lfias, reported, sensitivity, ranging, , , versus, rtpcr, , , , , , , versus, , elisa37, , meanwhile, , , performance, clias, superior, good, sensitivity, specificity, levels, similar, elisa38, otherwise, tests, , share, , , , advantages, , , drawbacks, , , , 0ctan, et, al, table, , , summary, diagnostic, approaches, covid19categorytype, testtypical, test, result, timecharacteristicsexamplesvirologicmolecular, rtpcrdaysgold, standard, high, sensitivity, rtpcr, protocolstests, , pointofcare, rtpcr, minlamp, crispr, himmunologic, testslfia, antibodies, minantigensand, specificity, high, throughput, lab, basedrapid, good, sensitivity, specificity, pointofcare, , testing, low, throughputrapid, good, sensitivity, specificity, pointofcare, , testing, low, throughputrapid, pointofcare, testing, quantitative, poor, sensitivitycepheid, xpert, xpress, sarscov2sherlock, biosciences, sherlockvivadiag, covid19, igmigg, rapid, testcorisbio, covid19, ag, respistripepitope, diagnostics, kt1033, edi, novel, coronavirus, covid19, elisa, kitroche, elecsys, antisarscov2, , , traditional, elisa, hgood, sensitivity, specificity, lab, based, automatedclia, minrapid, good, sensitivity, specificity, high, throughput, , lab, basedneutralization, assaydaysgold, standard, high, sensitivity, commercially, specificity, able, quantify, neutralizing, antibodies, requires, bsl3, lab, facilityavailablelabbased, antibody, assays, discussed, characteristics, unique, advantages, disadvantages, different, methodologies, outlined, table, antigen, assays, , alternative, approach, immunological, assays, directly, detect, sarscov2, viral, antigens, several, , commercial, , pointofcare, , antigen, , tests, , , available, performance, remains, evaluated, tests, may, suitable, making, early, diagnosis, deployable, pointofcare, assays, however, face, , sampling, , limitations, , , rtpcr, , , , hypothetically, hampered, limited, sensitivity, due, omission, , , amplification, , process, , unlike, , nucleic, , acid, , testing, , example, , one, , multicenter, , study, , evaluating, , , corisbio, covid19, ag, respistrip, lateral, flow, assay, sarscov2, np, reported, test, sensitivity, rapid, , nonpcr, , molecular, , testing, , nucleic, , acid, , testing, using, nonpcr, methods, emerging, approach, rapid, diagnostics, , , several, , assays, , , received, , food, , drug, administration, fda, emergency, use, authorization, , facilitates, , , distribution, , , unapproved, , medical, products, offlabel, use, approved, medical, products, , , certain, , criteria, , , met, , , methods, , share, high, sensitivity, specificity, par, rtpcr, , , principal, , advantages, , , , rapid, , testing, , , lower, cost40lamp, fig, , one, novel, isothermal, nucleic, acid, amplification, method, require, thermal, cycler, one, example, id, covid19, test, abbott, diagnostics, deliver, results, , min43, uses, , , lightweight, , portable, , instrument, , allowing, , onsite, testing, swab, samples, however, limited, throughput, one, sample, per, runthe, crispr, enzymes, cas12, cas13, also, adapted, , , rapid, , nucleic, , acid, , sensing, , , , fig, , , , detectr, , assay, , , mammoth, , biosciences45, , , well, , , sherlock, , assay, , , sherlock, , biosciences46, , potentially, offers, sensitivity, specificity, comparable, rtpcr, completed, , h, however, approaches, still, early, stages, commercialization, current, applications, available, test, kits, run, labs, pointofcare, versions, exist, proofofconcept, demonstrations47, nonetheless, inherent, characteristics, hold, great, potential, diagnosis, futureprognostication, diseaseprofiling, , , genetic, , susceptibility, , work, , , , progress, , ascertain, possible, genetic, basis, apparent, variations, covid19, susceptibility, disease, severity, cao, et, al, compared, expression, quantitative, trait, loci, eqtl, ace2, different, populations, finding, significantly, greater, eqtl, variants, associated, higher, ace2, expression, , 0c, slas, technology, , figure, , , lateral, flow, immunoassay, lfia, serum, sample, deposited, sample, pad, b, antisarscov2, antibodies, sample, bind, target, antigen, labeled, tag, c, immobilized, antihuman, igm, antibodies, capture, sarscov2, antibodyantigen, complex, d, control, antibodies, captured, immobilized, antibodies, control, lineserum, prognostic, markers, , another, application, immunological, methods, measure, markers, enable, prognostication, , , covid19, , higher, , titers, , , antibodies, , sarscov2, , , , associated, , , severe, , disease2350, , similar, , , previous, , studies, , , middle, east, , respiratory, , syndrome, , merscov51, , elisa, , used, provide, quantitative, measurement, serum, , plasma, , igm, , , igg, , antibodies, , , monitoring, , kinetics, igm, igg, antibodies, specific, n, proteins, sarscov2, found, intensive, care, unit, icu, patients, significantly, lower, level, sigg, within, , , , weeks, , , symptom, , onset, , , , higher, , level, , nigg, antibodies, compared, nonicu, patients52, finding, highlights, possible, utility, sigg, nigg, prognostic, tool, covid19, patientsthe, ddimer, level, consists, crosslinked, fibrin, degradation, products, reflect, ongoing, blood, clot, formation, , , breakdown, , activity, , , , body, , , another, , proposed, , prognostic, , marker, , modern, , commercial, , assays, , ddimers, based, monoclonal, antibodies, employing, either, elisa, microlatex, agglutination, assays53, reports, emerged, elevated, ddimer, levels, suggestive, hypercoagulable, state, associated, drastically, worse, outcomes, chinese, group, reported, ddimer, levels, ¥, , µgml, , , admission, , , associated, , , , , times, , increased, , mortality, , relative, , , ddimer, , levels, , , , µgml, cohort, , covid19, patients54, finding, ddimer, levels, negative, prognostic, marker, also, noted, studies, conducted, china455, netherlands56similarly, , interleukin, , il6, , , key, , component, , , cytokine, release, syndrome, another, marker, measured, elisa, , , , , described, , , independently, , predict, adverse, outcomes, covid195758, tumor, necrosis, factor, alpha, , tnfî±, , another, , important, , proinflammatory, , cytokine, , , also, , , found, , , , strongly, , correlated, , figure, , , chemiluminescence, enzyme, immunoassay, clia, sarscov2, antigens, capture, igm, igg, antibodies, sample, serum, secondary, antibodies, conjugated, horseradish, peroxidase, hrp, bind, captured, primary, igm, igg, antibodies, react, chemiluminescent, substrate, generate, strong, chemiluminescent, signal, measured, terms, relative, light, units, rlueast, , asian, , populations, , , reported, , , direct, , evidence, supporting, , , existence, , , , proteinbindingresistant, ace2, mutants48, , identified, protein, altering, variants, separately, stawiski, et, al, analyzed, ace2, polymorphisms, , within, , , much, , larger, , population, , dataset, , spanning, , population, groups, across, world, performed, structural, predictions, identify, variants, might, confer, protection, rather, increase, susceptibility, sarscov2, protein, binding49, total, , identified, proteinaltering, ace2, variants, , variants, predicted, increase, susceptibility, , variants, speculated, , confer, , protection, , however, , , degree, , , changes, , receptorvirus, binding, interactions, structural, variant, quantified, findings, represent, significant, developments, understanding, population, risk, profiles, covid19, future, coronavirus, infections, 0ctan, et, al, endan, , damage, , , mortality, , even, , , adjusting, , disease, severity, scores59, gao, et, al, examined, il6, ddimer, levels, proposed, panel, comprising, tandem, testing, two, markers, produced, sensitivity, , , , , specificity, , , , , , early, , prediction, , severe, covid1958, elevated, troponin, levels, marker, myocardial, , injury, , measured, , , elisa, , immunoassays, also, strongly, predict, progression, death, patients, severe, illness60, results, suggest, multiplex, cytokine, serum, marker, profiling, powerful, tool, stratifying, , patients, , , may, , guide, , clinical, , decisions, , resource, allocationsummary, , sum, rapid, progress, made, diagnostics, covid19, yet, race, time, continues, researchers, biotechnology, firms, develop, rapid, costeffective, , , reliable, , test, , kits, , , , , deployed, large, scale, time, writing, labbased, rtpcr, testing, , , , , dominant, , diagnostic, , approach, , alternative, molecular, approaches, like, isothermal, amplification, crispr, clear, advantages, horizon, immunological, tests, clia, lfia, become, increasingly, important, urgent, need, , pointofcare, , diagnostics, , , mass, , testing, , , infected, asymptomatic, individuals, close, contacts, , valuable, , , complementing, , molecular, , approaches, , confirming, , infection, , furthermore, , immunological, , assays, , , , great, , demand, , , policy, , makers, , worldwide, , , assessment, , , immunity, , , covid19, , however, , performance, serological, tests, varies, significantly, particularly, , , degree, , , sensitivity, , , specificity, , believe, caution, must, taken, interpretation, tests, detailed, evaluation, reliability, serological, tests, key, area, future, research, lastly, given, , importance, , , techniques, , like, , elisa, , , prognosticating, covid19, immunological, methods, undoubtedly, occupy, crucial, role, achieving, levels, whos, short, medium, longterm, diagnostic, goalscovid19, research, toolsimmunological, approachescovid19, , infection, , , , poor, , prognosis, , , individuals, , comorbidities, , , abnormal, , immune, , functions, although, , research, , surrounding, , covid19, , , still, , , infancy, several, studies, revealed, lymphopenia, cytokine, , storm, , , underlying, , mechanisms, , correlating, , disease, progression, discuss, various, immunological, techniques, involved, assessing, host, immunity, covid19, patientselisa, , , discussed, , elisa, , , also, , , used, , , detect, , inflammatory, , cytokines, , implicated, , , , cytokine, storm, seen, patients, severe, respiratory, failure, due, covid19, , one, , study, , found, , , , immune, , dysregulation, patients, severe, respiratory, failure, due, significantly, , increased, , production, , , il6, , , defective, lymphoid, function, il6mediated, decrease, hladr, , expression, , , cd14, , monocytes, , interestingly, interferongamma, , ifnî³, , levels, , , , , detection, level, patients, suggesting, helper, th, , cells, , unlikely, , , , major, , players, , , , overinflammatory, response, , , severe, , patients61, , , similar, , observation, , made, separate, study, whereby, inflammatory, cytokines, mediate, major, immune, responses, tnfî±, il1î², , , , significantly, , elevated, , , icu, , patients62, findings, demonstrate, immunophenotype, patients, covid19, vary, depending, presently, unclear, host, immune, factors, severity, condition, , relationship, , , disease, , severity, , , cytokine, storm, also, highlighted, studies, found, , , significantly, , elevated, , plasma, , concentration, , granulocyte, , colonystimulating, , factor, , gcsf, , ip10, ccl2, ccl3, icu, patients, compared, nonicu, patients63elisa, also, used, companion, diagnostic, tool, therapeutic, purposes, study, explored, use, convalescent, plasma, therapy, donors, form, treatment, severe, covid19, elisa, used, assess, neutralizing, activity, rbdspecific, igm, igg, antibodies, found, donor, convalescent, plasma64, transfusion, complete, elisa, also, used, detect, igg, , igm, , , neutralizing, , antibody, , titers, , , , sera, , patients, assess, response, treatment65enzymelinked, immunosorbent, spot, , enzymelinked, immunosorbent, spot, elispot, sensitive, immunoassay, quantitatively, measures, cytokinesecreting, cells, singlecell, level, providing, insight, immunerelated, cellular, activities66, hence, promising, tool, characterizing, specific, tcell, , immunity, , , covid19, , patients, , , ifnî³, elispot, , analysis, , , , revealed, , , convalescent, covid19, , patients, , , significantly, , increased, , levels, , ifnî³secreting, cells, compared, healthy, donors, , significant, , correlation, , , neutralizing, , antibody, titers, npspecific, cells, identified, patients, suggesting, , , , combination, , , humoral, , , cellular, immunity, , , integral, , , clearing, , sarscov2, , interestingly, , , , noted, , , , convalescent, , patients, , , , weeks, ifnî³secreting, , tcell, , numbers, , postdischarge, decreased, suggesting, may, maintained, prolonged, period, time, even, recovered, patients67elispot, also, serving, vital, role, vaccine, development, detection, potential, tcell, epitopes, , , , protein, , rbd, , , sarscov268, , one, , study, , able, , , harness, , elispot, , assays, , , identify, , three, , tcell, epitopes, induced, strong, adaptive, immune, response, , 0c, slas, technology, , postimmunization, demonstrating, promise, elispot, assays, , , , area, , , vaccine, , development32, , recently, elispot, also, applied, assess, immunogenicity, newly, developed, vaccines, one, study, successfully, , utilized, , , ifnî³, , elispot, , assay, , , evaluate, tcell, responses, new, sarscov2, vaccine, murine, splenocytes, rhesus, macaque, peripheral, blood, mononuclear, cells, pbmcs, promising, findings, animal, study, informed, start, phase, clinical, trial, , , , vaccine, , highlighting, , , usefulness, , elispot, assessing, immune, responses, new, vaccines, promoting, vaccine, development69flow, cytometry, , unlike, elisa, elispot, flow, cytometry, determines, number, cytokinesecreting, cells, capacity, immunophenotype, based, surface, intracellular, markers70, relation, current, pandemic, technique, enables, detection, sorting, analysis, multiple, subpopulations, immune, cells, specific, covid, using, flow, cytometry, researchers, detected, cytotoxic, immune, , environment, , , patient, , blood, , samples, , despite, , reduction, overall, lymphocyte, population71, part, sarscov2, antiviral, response, peripheral, lymphocytes, , retain, , , capacity, , , activate, , , differentiate, , subpopulations, , , , antibodysecreting, , cells, , cd3cd19cd27hicd38hi, follicular, cells, cd4cxcr5icospd1, , cd4, th, , cells, , cd38hladrcd4, , cytotoxic, tc, cells, cd38hladrcd8, regulatory, , treg, , cells, , cd3cd4cd25cd127, , , tc, cells, harbor, large, amounts, cytotoxic, granules, cd4, th, , cells, , skewed, , toward, , , proinflammatory, th1, , , th17, phenotype727375, overall, hyperinflammation, cytotoxic, environment, supports, notion, cytokine, storm, liable, multisystemic, insults, patients, severe, covid19elicitation, antiviral, tcell, responses, specific, sarscov2, utmost, importance, establishing, viral, control, many, studies, demonstrated, robust, antiviral, responses, however, known, set, markers, reported, identify, , sarscov2specific, , , cells, , collectively, , groups, , , characterized, , sarscov2specific, , , cells, based, hladr, cd38, cd69, cd25, cd44, ki67, expression]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |[, , novel, coronavirus, sarscov2, found, cause, highly, contagious, disease, characterized, by, pneumonia, disease, covid19, quickly, spread, around, globe, escalating, global, pandemic, review, we, discuss, virological, immunological, imaging, approaches, harnessed, covid19, diagnosis, research, covid19, shares, many, clinical, characteristics, with, other, respiratory, illnessesaccurate, early, detection, infection, pivotal, controlling, outbreak, as, enables, case, identification, isolation, contact, tracing, we, summarize, available, literature, on, current, laboratory, pointofcare, diagnostics, highlight, their, strengths, limitations, describe, emerging, diagnostic, approaches, on, horizonwe, also, discuss, various, research, techniques, that, are, being, used, evaluate, host, immunity, laboratoryconfirmed, patients, additionally, pathological, imaging, tissue, samples, from, affected, patients, has, critical, role, guiding, investigations, on, disease, conventional, techniques, such, as, immunohistochemistry, immunofluorescence, have, been, frequently, used, characterize, immune, microenvironment, covid19, we, also, outline, emerging, imaging, techniques, such, as, rnascope, which, might, also, aid, our, understanding, significance, covid19specific, biomarkers, such, as, angiotensinconverting, enzyme, , ace2, cellular, receptoroverall, , great, , progress, , has, , been, , made, , , covid19, , research, , , , short, , period, , extensive, , global, , collation, , , our, current, knowledge, sarscov2, will, provide, insights, into, novel, treatment, modalities, such, as, monoclonal, antibodies, support, development, sarscov2, vaccinekeywordscovid19, immunology, pathology, diagnostics, specific, t, cellsintroductionin, december, , novel, respiratory, disease, named, coronavirus, disease, , covid19, detected, by, physicians, wuhan, china, disease, found, be, caused, by, , , severe, , acute, , respiratory, , syndrome, , sarscov2, rna, , virus12, , within, , , matter, , , weeks, , covid19, , had, spread, rapidly, escalated, global, pandemic, at, time, , , writing, , june, , , , , million, , cases, , had, , been, reported, , patients, had, succumbed, disease, , worldwide3, , indeed, , patients, , with, , covid19, , are, , at, high, , risk, , , developing, , , severe, , , critical, , disease4, therefore, rapid, accurate, diagnostic, tests, are, urgently, needed, , , effectively, , isolate, , identify, , , treat, , infected, individuals, contain, spread, virus, failure, do, so, will, inevitably, lead, spikes, cases, resultant, overcrowding, , , collapse, , , healthcare, , services5, moreover, research, into, novel, virus, also, critical, understand, , its, , pathogenesis, , , its, , interaction, , with, , human, , immune, , system, , insights, , from, , such, , research, , will, guide, design, public, health, policies, protocols, 1lee, kong, chian, school, medicine, nanyang, technological, university, singapore, singapore2yong, loo, lin, school, medicine, national, university, singapore, singapore, singapore3institute, molecular, cell, biology, imcb, agency, science, technology, research, astar, singapore, singapore4department, anatomical, pathology, singapore, general, hospital, singapore, singaporethese, authors, contributed, equallyreceived, june, , , revised, form, july, , , accepted, publication, july, , corresponding, authorjoe, poh, sheng, yeong, institute, molecular, cell, biology, imcb, agency, science, technology, research, astar, , college, road, academia, level, , diagnostics, tower, singapore, , singapore, email, yeongpsimcbastaredusg, 0c, slas, technology, , identify, susceptible, individuals, diagnostic, prognostic, treatment, approaches, patientscurrent, , diagnostic, , approaches, , predominantly, , involve, established, virological, procedures, such, as, nucleic, acid, hybridization, techniques, reversetranscriptase, pcr, [rtpcr], recombinase, , polymerase, , amplification, , rpa, , as, , well, , as, immunologic, , approaches, like, , antibody, , assays, , each, approach, , boasts, , unique, , strengths, , , weaknesses, , instance, while, rtpcr, demonstrates, high, sensitivity, specificity, , its, , capabilities, , have, , been, , severely, , limited, , practical, reasons, during, current, pandemic, due, global, shortages, skilled, personnel, reagents, equipment, processing, time, up, , days, by, contrast, immunologic, tests, such, as, antibody, assays, are, rapid, require, minimal, equipment, , but, , they, , have, , limited, , utility, , , , context, , acute, diagnosis, sarscov2, infections, because, it, can, take, several, days, weeks, following, symptom, onset, patient, mount, detectable, antibody, response6immunological, tools, research, include, enzymelinked, immunosorbent, , assays, , elisas, , flow, , cytometry, , mass, cytometry, cytof, imaging, techniques, pathological, analyses, include, conventional, approaches, such, as, hematoxylineosin, he, staining, immunohistochemical, ihc, , staining, , or, , transmission, , electron, , microscopy, tem, rnascope, each, these, methods, used, examine, pathophysiology, underlying, covid19, from, different, perspective, each, with, their, own, advantages, disadvantages, , , example, , it, , has, , been, , established, , that, entry, sarscov2, intro, cells, depends, on, binding, viral, proteins, with, human, receptor, angiotensinconverting, , enzyme, , , , ace2, , receptors7, , additionally, evidence, , shows, , that, , , type, , ii, , transmembrane, , protease, tmprss2, also, essential, viral, entry, by, priming, viral, spike, protein, binding, ace28, therefore, considerable, , research, , efforts, , employing, , different, , techniques, have, , been, , directed, , at, , mapping, , , distribution, , ace2, , tmprss2, , , tissues, , , their, , relationship, , , observed, manifestations, disease, together, combination, these, approaches, has, advanced, our, understanding, covid19in, , , review, , we, , discuss, , , current, , approaches, , covid19, diagnosis, research, with, focus, on, findings, from, , virological, , , pathological, , imaging, , methods, , we, also, , discuss, , immunological, , methods, , which, , are, , increasingly, , recognized, , as, , an, , integral, , component, , , , disease, processdiagnosticsthe, most, common, symptoms, covid19, at, initial, presentation, , are, , nonspecific, , , include, , , high, , fever, , , new, , persistent, , cough, , , fatigue910, , due, , , similarities, between, clinical, characteristics, covid19, many, other, respiratory, illnesses, accurate, early, detection, infection, pivotal, outbreak, control, any, delays, diagnosis, are, increasingly, measured, lives, lostaccording, world, health, anization, who, immediate, goal, research, into, covid19, diagnostics, , development, , , rna, , assays, , antibody, , , antigen, assays, , , pointofcare, , detection11, , , intermediateterm, priority, would, be, their, integration, into, multiplex, diagnostic, , platforms, , while, , , longterm, , goal, , would, , be, , investigation, prognostic, markersin, section, we, summarize, current, emerging, diagnostic, , tools, , , sarscov2, , through, , , lens, , immunologylabbased, testsrtpcr, , molecular, , testing, , , detection, , , viral, , nucleic, acids, by, rtpcr, primary, method, used, confirm, suspected, , case, , , covid19, , rtpcr, , , other, , nucleic, acid, hybridization, techniques, are, an, integral, part, virology, are, applied, broad, range, settings, including, screening, , diagnosis, , informing, , medical, , , therapeutic, decisions, assessing, cure, rates, from, therapy12, chinese, officials, released, genomic, sequence, sarscov2, public, databases, early, course, outbreak13, who, has, since, published, seven, protocols, rtpcrbased, diagnostics, because, high, sensitivity, specificity, rtpcr, it, regarded, as, gold, standard, virus, detection14, there, are, two, essential, steps, process, , viral, rna, extraction, , pcr, amplification, , probebased, , detection, , multiple, , largescale, , highthroughput, , instruments, , are, , available, , , automating, , both, steps, such, as, roche, cobas, , system, which, has, an, advertised, throughput, , tests, per, , hours15however, rtpcrbased, testing, costly, timeconsuming, requiring, up, , days, using, centralized, laboratory, equipment, skilled, personnel, furthermore, global, supply, , chain, , challenges, , have, , led, , , significant, , shortages, , essential, reagents, lastly, falsenegative, results, due, low, sample, , volumes, , variable, , sampling, , techniques, , , sampling, , locations, , sample, , degradation, , during, , transportation, andor, improper, nucleic, acid, extraction, are, concern16, , addition, , , differences, , , detectable, , viral, , material, , different, sampling, locations, eg, nasopharyngeal, vs, bronchoalveolar, lavage, fluid, [balf], vs, rectal, samples, might, also, , explain, , , falsepositive, , rtpcr, , results, , on, , repeat, testing, , , recovered, , covid19, , patients, , indeed, , one, postmortem, case, study, revealed, residual, virus, lung, tissue, despite, , consecutive, , negative, , results, , on, , pcr, , testing, , from, nasopharyngeal, , swabs19, , separately, , winichakoon, , et, , al, outlined, case, repeatedly, negative, nasopharyngeal, oropharyngeal, , swabs, , , , clinically, , deteriorating, , patient, where, only, balf, pcr, test, returned, positive20given, high, expression, ace2, on, alveolar, epithelial, cells, negative, expression, on, nasal, oral, nasopharynx, , 0ctan, et, al, cells21, , it, , would, , be, , prudent, , , perform, , bronchoalveolar, lavage, , on, , patients, , , rule, , out, , falsenegative, , results, , from, swabs, upper, respiratory, tract, samples20labbased, , immunological, , assays, , , contrast, , , rtpcr, techniques, , that, , detect, , viral, , nucleic, , acids, , serological, , immunological, , assays, , aim, , , detect, , antibodies, , against, sarscov2, or, antigenic, proteins, infected, individuals, neutralization, assays, are, considered, gold, standard, assessing, , neutralizing, , protective, , antibodies22, , however, these, , assays, , require, , specialized, , biosafety, , level, , , , bsl3, facilities, , , still, , take, , several, , days, , , complete, another, type, labbased, antibody, assay, traditional, elisa, which, , detects, , all, , binding, , antibodies, , , four, , principal, types, elisa, are, direct, indirect, competitive, sandwich, , elisa, , , indirect, , elisa, , , , most, , common, method, , , determining, , antibody, , concentrations, , elisas, have, , good, , concordance, , with, , neutralization, , assays, , , detection, antibody, responses, sarscov223, unfortunately, , both, , methods, , require, , skilled, , operators, , , are, limited, by, low, throughput, due, absence, fully, automated, systemsserological, , diagnostics, , offer, , several, , advantages, , re, quirements, , , specimen, , quality, , are, , comparatively, , less, stringent, , than, , , nucleic, , acid, , tests, , as, , , antibodies, , are, uniformly, , distributed, , , , serum24, , consequently, , sampling, , location, , concerns, , do, , not, , apply, , here, , furthermore, good, correlation, between, igg, elisas, performed, on, both, conventional, serum, samples, plasma, samples, have, been, reported25, which, latter, may, be, conveniently, obtained, from, residual, blood, submitted, other, routine, laboratory, testsone, pitfall, antibody, assays, their, limited, utility, early, course, any, infection, sparse, data, are, available, with, regard, antibody, responses, produced, by, patients, with, covid19, it, seems, that, sarscov2, igm, detectable, at, , median, , , , , days, , after, , symptom, , onset, , while, , igg, , detectable, , after, , , , days26, , with, , , seroconversion, , rate, approaching, , , , by, , day, , , , an, , italian, , research, , group, noted, , that, , , performance, , , , commercial, , vivadiag, covid19, igmigg, test, very, poor, with, sensitivity, only, , negative, predictive, value, , cohort, suspected, covid19, patients, emergency, room, setting27, as, such, we, believe, that, now, rtpcr, testing, , , likely, , more, , appropriate, , , diagnosing, , acute, covid19notably, , , longitudinal, , study, , examining, , , iggigm, profiles, , , , , patients, , found, , that, , seroconversion, , , igg, igm, occurred, no, specific, chronological, order, with, median, , , , , days, , after, , symptom, , onset28, , all, , patients, achieved, , seroconversion, , by, , day, , , , consequently, , detection, both, igg, igm, simultaneously, rather, than, one, antibody, alone, would, be, idealanother, , concern, , surrounding, , serologic, , diagnostics, , production, falsepositive, results, from, crossreactivity, due, high, prevalence, four, endemic, human, coronaviruses, , , , human, , population, , , sarscov2, spike, s, protein, which, includes, two, regions, s1, s2, , , , nucleocapsid, , n, , protein, , np, , are, , , major, immunogens29, therefore, most, diagnostics, rely, on, detection, , , antibodies, , specific, , , these, , antigens, , one, work, , suggests, , that, , , , possible, , targets, , , s1, , subunit, antigen, more, specific, than, either, whole, s, antigen, or, n, antigen, detecting, sarscov2, antibodies, with, no, crossreactivity, other, coronaviruses, except, sarscov23, , given, , that, , only, , , , sarscov, , infections, , were, recorded, worldwide30, risk, false, positives, from, crossreactivity, , , miniscule, , however, , np, , elisas, , are, more, sensitive, than, s1, detecting, antibodies, those, with, mild, infection23, importantly, as, sarscov, most, neutralizing, antibodies, are, directed, against, s, protein31, , , which, , s1, , contains, , , receptorbinding, , domain, rbd, responsible, making, contact, with, ace2, facilitate, , viral, , entry7, , thus, , theoretically, , only, , diagnostics, , that, detect, s1specific, antibodies, are, suitable, infer, immunity, , covid19, , , fact, , , corroborated, , by, , evidence, , that, antis, rbd, but, not, antinp, igg, levels, correlated, with, neutralizing, antibody, titers, sera, from, cohort, , recovered, patients32, number, commercial, antibody, assays, , growing, , detecting, , either, , antinp, , antibodies, , antis1s, antibodies, , or, , both, , there, , , also, , large, , variation, , , their, claimed, sensitivities, specificities33, based, on, available, evidence, an, ideal, serological, assay, would, be, combined, test, that, simultaneously, detects, both, antibodies, np, s1, antigens, assessment, antinp, antibodies, has, good, sensitivity, would, be, best, suited, supporting, diagnosis, , , infection, , while, , , additional, , antis1, , antibody, assay, would, allow, determination, immunityrapid, testspointofcare, rtpcr, tests, , small, number, commercial, pointofcare, tests, utilizing, rtpcr, have, been, developed, these, typically, involve, same, methodology, as, conventional, rtpcr, but, implemented, with, automated, portable, , benchtopsized, , instruments, , that, , can, , be, , operated, closer, , , patient, , care, , settings, , than, , , centralized, , laboratory, , , prominent, , example, , , cepheids, , xpert, , xpress, sarscov2, run, on, gene, xpert, platform, apparatus, can, provide, result, within, , min, others, include, mesabiotech, accula, test, microsensdx, rapiprep, covid19, despite, displaying, good, sensitivity, specificity, , these, , instruments, , are, , generally, , limited, , by, , , very, low, , throughput, , , only, , one, , , four, , tests, , per, , run, , per, machine34, as, such, are, only, suited, small, laboratories, or, clinics, 0c, slas, technology, , figure, , , loopmediated, isothermal, amplification, lamp, lamp, begins, when, forward, inner, primer, fip, binds, a2c, region, while, forward, primer, a1, binds, a1c, which, displaces, fip, complementary, strand, b, backward, inner, primer, bip, binds, b2c, while, backward, primer, b3, binds, b3c, displaces, bip, complementary, strand, c, complementary, sequence, that, initiates, loop, formation, produced, d, loop, structures, are, formed, that, allow, lamp, with, use, loop, primersfigure, , , crispr, technique, viral, rna, converted, dsdna, using, rtrpa, recombinase, polymerase, amplification, cas12a, nuclease, enzyme, activated, upon, complex, binding, target, sequence, resulting, cleavage, target, sequence, fluorescent, rna, reporter, b, t7, transcription, converts, dna, complementary, rna, cas13, nuclease, enzyme, activity, activated, upon, complex, binding, target, sequence, resulting, similar, cleavage, target, sequence, fluorescent, rna, reporterimmunological, assaysrapid, , antibody, , assays, , compared, , with, , labbased, , antibody, assays, rapid, assays, such, as, lateral, flow, immunoassays, lfias, fig, , chemiluminescent, immunoassays, clias, fig, , offer, benefits, rapid, diagnostic, testing, at, low, cost, these, assays, do, not, require, specialized, equipment, or, expertise35, are, thus, excellent, candidates, , pointofcare, , testing, , or, , deployment, , on, , , large, , scale, an, area, intense, interest, with, governments, worldwide, , aiming, , , order, , millions, , , tests, , , inform, , policy, makers, about, attack, rates, their, populations36, lfias, are, predominantly, , singleuse, , kits, , designed, , , pointofcare, use, while, clias, are, fully, automated, analyzers, that, permit, very, high, testing, throughputunfortunately, , these, , tests, , do, , not, , quantify, , , antibody, titers, , , , performance, , , lfias, , has, , been, , called, , into, question, one, evaluation, nine, commercial, lfias, reported, sensitivity, ranging, from, only, , , versus, rtpcr, , , , , , , versus, , elisa37, , meanwhile, , , performance, clias, superior, with, good, sensitivity, specificity, levels, similar, those, elisa38, otherwise, these, tests, , share, , , same, , advantages, , , drawbacks, , as, , , 0ctan, et, al, table, , , summary, diagnostic, approaches, covid19categorytype, testtypical, test, result, timecharacteristicsexamplesvirologicmolecular, rtpcrdaysgold, standard, high, sensitivity, who, rtpcr, protocolstests, , pointofcare, rtpcr, minlamp, crispr, himmunologic, testslfia, antibodies, minantigensand, specificity, high, throughput, but, lab, basedrapid, good, sensitivity, specificity, pointofcare, , testing, but, low, throughputrapid, good, sensitivity, specificity, pointofcare, , testing, but, low, throughputrapid, pointofcare, testing, but, not, quantitative, poor, sensitivitycepheid, xpert, xpress, sarscov2sherlock, biosciences, sherlockvivadiag, covid19, igmigg, rapid, testcorisbio, covid19, ag, respistripepitope, diagnostics, kt1033, edi, novel, coronavirus, covid19, elisa, kitroche, elecsys, antisarscov2, , , traditional, elisa, hgood, sensitivity, specificity, but, lab, based, not, automatedclia, minrapid, good, sensitivity, specificity, high, throughput, , but, lab, basedneutralization, assaydaysgold, standard, high, sensitivity, not, commercially, specificity, able, quantify, neutralizing, antibodies, but, requires, bsl3, lab, facilityavailablelabbased, antibody, assays, discussed, above, characteristics, unique, advantages, disadvantages, these, different, methodologies, are, outlined, table, antigen, assays, , an, alternative, approach, immunological, assays, directly, detect, sarscov2, viral, antigens, several, , commercial, , pointofcare, , antigen, , tests, , are, , available, but, their, performance, remains, be, evaluated, these, tests, may, be, suitable, making, an, early, diagnosis, are, deployable, as, pointofcare, assays, however, they, face, same, , sampling, , limitations, , as, , rtpcr, , , are, , hypothetically, hampered, by, limited, sensitivity, due, omission, , an, , amplification, , process, , unlike, , nucleic, , acid, , testing, , example, , one, , multicenter, , study, , evaluating, , , corisbio, covid19, ag, respistrip, lateral, flow, assay, sarscov2, np, reported, test, sensitivity, only, rapid, , nonpcr, , molecular, , testing, , nucleic, , acid, , testing, using, nonpcr, methods, an, emerging, approach, rapid, diagnostics, , , several, , assays, , have, , received, , food, , drug, administration, fda, emergency, use, authorization, which, , facilitates, , , distribution, , , unapproved, , medical, products, or, offlabel, use, approved, medical, products, , when, , certain, , criteria, , are, , met, , these, , methods, , share, high, sensitivity, specificity, on, par, with, rtpcr, but, with, , , principal, , advantages, , , more, , rapid, , testing, , at, , lower, cost40lamp, fig, , one, such, novel, isothermal, nucleic, acid, amplification, method, that, does, not, require, thermal, cycler, one, example, id, now, covid19, test, from, abbott, diagnostics, which, can, deliver, results, just, , min43, uses, , , lightweight, , portable, , instrument, , allowing, , onsite, testing, swab, samples, however, it, has, limited, throughput, only, one, sample, per, runthe, crispr, enzymes, cas12, cas13, have, also, been, adapted, , , rapid, , nucleic, , acid, , sensing, , , , fig, , , , detectr, , assay, , by, , mammoth, , biosciences45, , as, , well, , as, , sherlock, , assay, , by, , sherlock, , biosciences46, , potentially, offers, sensitivity, specificity, comparable, those, rtpcr, but, can, be, completed, , h, however, these, approaches, are, still, early, stages, commercialization, current, applications, are, available, only, as, test, kits, be, run, labs, while, pointofcare, versions, exist, as, proofofconcept, demonstrations47, nonetheless, their, inherent, characteristics, hold, great, potential, diagnosis, futureprognostication, diseaseprofiling, , , genetic, , susceptibility, , work, , , , progress, , ascertain, possible, genetic, basis, apparent, variations, covid19, susceptibility, disease, severity, cao, et, al, compared, expression, quantitative, trait, loci, eqtl, ace2, different, populations, finding, significantly, greater, eqtl, variants, associated, with, higher, ace2, expression, , 0c, slas, technology, , figure, , , lateral, flow, immunoassay, lfia, serum, sample, deposited, on, sample, pad, b, antisarscov2, antibodies, sample, will, bind, target, antigen, with, labeled, tag, c, immobilized, antihuman, igm, antibodies, will, capture, sarscov2, antibodyantigen, complex, d, control, antibodies, are, captured, by, immobilized, antibodies, control, lineserum, prognostic, markers, , another, application, immunological, methods, would, be, measure, markers, that, enable, prognostication, , , covid19, , higher, , titers, , , antibodies, against, , sarscov2, , have, , been, , associated, , with, , more, severe, , disease2350, , similar, , , previous, , studies, , , middle, east, , respiratory, , syndrome, , merscov51, , elisa, , has, been, used, provide, quantitative, measurement, serum, , plasma, , igm, , , igg, , antibodies, , by, , monitoring, , kinetics, igm, igg, antibodies, specific, n, s, proteins, on, sarscov2, it, found, that, intensive, care, unit, icu, patients, had, significantly, lower, level, sigg, within, , , , weeks, , , symptom, , onset, , but, , , higher, , level, , nigg, antibodies, compared, with, nonicu, patients52, finding, highlights, possible, utility, sigg, nigg, as, prognostic, tool, covid19, patientsthe, ddimer, level, which, consists, crosslinked, fibrin, degradation, products, that, reflect, ongoing, blood, clot, formation, , , breakdown, , activity, , , , body, , , another, , proposed, , prognostic, , marker, , modern, , commercial, , assays, , ddimers, are, based, on, monoclonal, antibodies, employing, either, elisa, or, microlatex, agglutination, assays53, reports, have, emerged, that, elevated, ddimer, levels, suggestive, hypercoagulable, state, are, associated, with, drastically, worse, outcomes, chinese, group, reported, that, ddimer, levels, ¥, , µgml, , on, , admission, , were, , associated, , with, , , , times, , increased, , mortality, , relative, , , ddimer, , levels, , , , µgml, cohort, , covid19, patients54, finding, ddimer, levels, as, negative, prognostic, marker, also, noted, other, studies, conducted, china455, netherlands56similarly, , interleukin, , il6, , , key, , component, , , cytokine, release, syndrome, another, marker, measured, by, elisa, , , has, , been, , described, , , independently, , predict, adverse, outcomes, covid195758, tumor, necrosis, factor, alpha, , tnfî±, , another, , important, , proinflammatory, , cytokine, , has, , also, , been, , found, , , be, , strongly, , correlated, , with, figure, , , chemiluminescence, enzyme, immunoassay, clia, sarscov2, antigens, will, capture, igm, igg, antibodies, from, sample, serum, secondary, antibodies, that, are, conjugated, with, horseradish, peroxidase, hrp, bind, captured, primary, igm, igg, antibodies, react, with, chemiluminescent, substrate, generate, strong, chemiluminescent, signal, that, measured, terms, relative, light, units, rlueast, , asian, , populations, , but, , reported, , no, , direct, , evidence, supporting, , , existence, , , s, , proteinbindingresistant, ace2, mutants48, out, , identified, protein, altering, variants, separately, stawiski, et, al, analyzed, ace2, polymorphisms, , within, , , much, , larger, , population, , dataset, , spanning, more, than, , population, groups, across, world, performed, structural, predictions, identify, variants, that, might, confer, protection, or, rather, increase, susceptibility, sarscov2, s, protein, binding49, out, total, , identified, proteinaltering, ace2, variants, , variants, were, predicted, increase, susceptibility, while, , variants, were, speculated, , confer, , protection, , however, , , degree, , , changes, , receptorvirus, binding, interactions, each, structural, variant, not, quantified, these, findings, represent, significant, developments, our, understanding, population, risk, profiles, covid19, future, coronavirus, infections, 0ctan, et, al, endan, , damage, , , mortality, , even, , after, , adjusting, , disease, severity, scores59, gao, et, al, examined, both, il6, ddimer, levels, they, proposed, panel, comprising, tandem, testing, these, two, markers, which, produced, sensitivity, , , , , specificity, , , , , , early, , prediction, , severe, covid1958, elevated, troponin, levels, marker, myocardial, , injury, , measured, , with, , elisa, , immunoassays, also, strongly, predict, progression, death, patients, with, severe, illness60, these, results, suggest, that, multiplex, cytokine, serum, marker, profiling, will, be, powerful, tool, stratifying, , patients, , that, , may, , guide, , clinical, , decisions, , resource, allocationsummary, , sum, rapid, progress, has, been, made, diagnostics, covid19, yet, race, against, time, continues, researchers, biotechnology, firms, develop, rapid, costeffective, , , reliable, , test, , kits, , that, , can, , be, , deployed, on, large, scale, at, time, writing, labbased, rtpcr, testing, , has, , been, , , dominant, , diagnostic, , approach, , but, alternative, molecular, approaches, like, isothermal, amplification, crispr, which, have, clear, advantages, are, on, horizon, immunological, tests, such, as, clia, lfia, will, become, increasingly, important, because, urgent, need, , pointofcare, , diagnostics, , , mass, , testing, , , infected, asymptomatic, individuals, their, close, contacts, will, be, , valuable, , , complementing, , molecular, , approaches, , confirming, , infection, , furthermore, , immunological, , assays, will, , be, , , great, , demand, , by, , policy, , makers, , worldwide, , , assessment, , , immunity, , , covid19, , however, , performance, these, serological, tests, varies, significantly, particularly, , their, , degree, , , sensitivity, , , specificity, , we, believe, that, caution, must, be, taken, interpretation, these, tests, detailed, evaluation, reliability, serological, tests, will, be, key, area, future, research, lastly, given, , importance, , , techniques, , like, , elisa, , , prognosticating, covid19, immunological, methods, will, undoubtedly, occupy, crucial, role, achieving, all, levels, whos, short, medium, longterm, diagnostic, goalscovid19, research, toolsimmunological, approachescovid19, , infection, , has, , , poor, , prognosis, , , individuals, with, , comorbidities, , , abnormal, , immune, , functions, although, , research, , surrounding, , covid19, , , still, , , its, infancy, several, studies, have, revealed, lymphopenia, cytokine, , storm, , as, , underlying, , mechanisms, , correlating, , disease, progression, here, we, discuss, various, immunological, techniques, involved, assessing, host, immunity, covid19, patientselisa, , as, , discussed, , elisa, , has, , also, , been, , used, , , detect, , inflammatory, , cytokines, , implicated, , , , cytokine, storm, seen, patients, with, severe, respiratory, failure, due, covid19, , one, , study, , found, , that, , , immune, , dysregulation, patients, with, severe, respiratory, failure, due, significantly, , increased, , production, , , il6, , , defective, lymphoid, function, because, an, il6mediated, decrease, hladr, , expression, , on, , cd14, , monocytes, , interestingly, interferongamma, , ifnî³, , levels, , were, , below, , , detection, level, these, patients, suggesting, that, t, helper, th, , cells, are, , unlikely, , , be, , major, , players, , , , overinflammatory, response, , , severe, , patients61, , , similar, , observation, , made, separate, study, whereby, inflammatory, cytokines, that, mediate, major, immune, responses, such, as, tnfî±, il1î², , were, , not, , significantly, , elevated, , , icu, , patients62, these, findings, demonstrate, that, immunophenotype, patients, with, covid19, can, vary, depending, on, presently, unclear, host, immune, factors, severity, their, condition, , relationship, , between, , disease, , severity, , , cytokine, storm, has, also, been, highlighted, other, studies, that, found, , , significantly, , elevated, , plasma, , concentration, , granulocyte, , colonystimulating, , factor, , gcsf, , ip10, ccl2, ccl3, icu, patients, compared, with, nonicu, patients63elisa, also, being, used, as, companion, diagnostic, tool, therapeutic, purposes, study, that, explored, use, convalescent, plasma, therapy, from, donors, as, form, treatment, severe, covid19, elisa, used, assess, neutralizing, activity, rbdspecific, igm, igg, antibodies, found, donor, convalescent, plasma64, after, transfusion, complete, elisa, also, used, detect, igg, , igm, , , neutralizing, , antibody, , titers, , , , sera, , patients, assess, response, treatment65enzymelinked, immunosorbent, spot, , enzymelinked, immunosorbent, spot, elispot, sensitive, immunoassay, that, quantitatively, measures, cytokinesecreting, cells, at, singlecell, level, providing, insight, into, immunerelated, cellular, activities66, hence, it, promising, tool, characterizing, specific, tcell, , immunity, , , covid19, , patients, , by, , ifnî³, elispot, , analysis, , it, , , revealed, , that, , convalescent, covid19, , patients, , had, , significantly, , increased, , levels, , ifnî³secreting, t, cells, when, compared, with, healthy, donors, , significant, , correlation, , between, , neutralizing, , antibody, titers, npspecific, t, cells, identified, these, patients, suggesting, , that, , , combination, , , humoral, , , cellular, immunity, , , integral, , , clearing, , sarscov2, , interestingly, , it, , , noted, , that, , , convalescent, , patients, , , , weeks, ifnî³secreting, , tcell, , numbers, , had, postdischarge, decreased, suggesting, that, they, may, not, be, maintained, prolonged, period, time, even, recovered, patients67elispot, also, serving, vital, role, vaccine, development, through, detection, potential, tcell, epitopes, , , s, , protein, , rbd, , , sarscov268, , one, , study, , able, , , harness, , elispot, , assays, , , identify, , three, , tcell, epitopes, that, induced, strong, adaptive, immune, response, , 0c, slas, technology, , postimmunization, demonstrating, promise, elispot, assays, , , , area, , , vaccine, , development32, , recently, elispot, has, also, been, applied, assess, immunogenicity, newly, developed, vaccines, one, such, study, successfully, , utilized, , an, , ifnî³, , elispot, , assay, , , evaluate, tcell, responses, new, sarscov2, vaccine, murine, splenocytes, rhesus, macaque, peripheral, blood, mononuclear, cells, pbmcs, promising, findings, from, animal, study, informed, start, phase, i, clinical, trial, with, , , same, , vaccine, , highlighting, , , usefulness, , elispot, assessing, immune, responses, new, vaccines, promoting, vaccine, development69flow, cytometry, , unlike, elisa, elispot, flow, cytometry, determines, number, cytokinesecreting, cells, has, capacity, immunophenotype, based, on, surface, intracellular, markers70, relation, current, pandemic, technique, enables, detection, sorting, analysis, multiple, subpopulations, immune, cells, specific, covid, using, flow, cytometry, researchers, detected, cytotoxic, immune, , environment, , , patient, , blood, , samples, , despite, , reduction, overall, lymphocyte, population71, as, part, sarscov2, antiviral, response, peripheral, lymphocytes, , retain, , , capacity, , , activate, , , differentiate, , into, subpopulations, , such, , as, , antibodysecreting, , cells, , cd3cd19cd27hicd38hi, follicular, t, cells, cd4cxcr5icospd1, , cd4, th, , cells, , cd38hladrcd4, , cytotoxic, t, tc, cells, cd38hladrcd8, regulatory, t, , treg, , cells, , cd3cd4cd25cd127, , these, , tc, cells, harbor, large, amounts, cytotoxic, granules, while, cd4, th, , cells, , skewed, , toward, , , proinflammatory, th1, , , th17, phenotype727375, overall, hyperinflammation, cytotoxic, environment, supports, notion, that, cytokine, storm, could, be, liable, multisystemic, insults, patients, with, severe, covid19elicitation, antiviral, tcell, responses, specific, sarscov2, utmost, importance, establishing, viral, control, many, studies, have, demonstrated, robust, antiviral, responses, however, there, no, known, set, markers, reported, identify, , sarscov2specific, , t, , cells, , collectively, , most, groups, , have, , characterized, , sarscov2specific, , t, , cells, based, on, hladr, cd38, cd69, cd25, cd44, ki67, expression, t]                                                                                                                                                                                                                                                                                                                               |(224581,[0,1,2,3,4,5,7,8,9,10,11,12,13,14,15,17,18,19,20,21,22,23,24,25,26,27,28,30,31,33,35,36,37,38,39,40,42,43,44,45,46,47,48,49,50,51,52,53,54,55,57,58,59,60,61,62,63,65,66,67,68,69,70,72,73,74,75,76,77,78,81,82,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,103,105,107,108,109,110,111,112,113,114,115,118,119,120,123,124,126,127,130,131,134,136,137,138,143,144,146,147,148,149,152,154,155,156,157,158,159,160,164,167,168,171,173,174,176,177,181,182,183,184,186,187,189,191,193,194,196,197,198,203,205,206,207,210,213,214,216,217,220,221,224,225,226,227,229,230,232,234,235,236,238,239,241,242,244,245,246,248,249,254,255,256,257,262,263,264,265,266,268,269,270,273,274,275,276,277,279,280,281,284,287,288,290,292,293,295,298,301,303,305,307,308,309,310,313,314,320,322,323,325,327,329,330,331,332,335,336,337,338,340,345,348,351,352,353,355,356,357,358,359,360,361,362,363,366,367,368,370,372,373,375,377,378,379,381,383,385,386,387,388,390,391,392,393,396,398,401,404,408,409,411,412,413,414,415,421,424,427,430,436,437,439,441,446,447,454,463,464,465,466,468,470,473,474,478,479,480,482,483,484,486,489,493,497,498,499,501,506,507,509,512,513,515,519,520,521,523,525,527,532,537,538,541,542,543,546,547,550,551,555,558,568,569,570,571,574,576,577,585,592,594,596,597,599,606,607,609,610,612,615,617,618,619,625,626,629,636,637,638,639,645,648,650,652,658,660,661,662,667,669,677,679,680,683,688,691,692,693,702,713,714,715,716,717,719,721,725,730,732,733,735,736,737,740,741,742,743,745,755,759,762,763,765,769,772,773,775,776,778,783,785,789,792,796,799,802,807,808,811,812,816,818,823,832,840,841,842,844,847,848,850,853,854,863,866,869,873,877,879,880,881,887,889,892,893,895,902,905,908,910,912,916,935,937,943,944,948,965,967,972,979,982,983,993,996,1001,1011,1018,1020,1021,1024,1027,1029,1034,1036,1038,1047,1051,1054,1055,1059,1061,1066,1069,1070,1079,1083,1084,1093,1094,1100,1101,1105,1110,1113,1119,1120,1122,1129,1133,1141,1146,1150,1151,1152,1163,1164,1166,1167,1168,1176,1191,1201,1202,1203,1204,1208,1212,1214,1215,1216,1219,1221,1225,1229,1233,1234,1244,1251,1257,1261,1262,1264,1266,1269,1274,1286,1298,1299,1300,1304,1318,1330,1335,1345,1347,1348,1350,1355,1356,1362,1363,1364,1368,1394,1395,1399,1400,1404,1409,1415,1416,1421,1435,1438,1441,1450,1454,1457,1459,1474,1477,1479,1481,1491,1493,1497,1504,1506,1507,1510,1513,1527,1532,1542,1549,1553,1554,1564,1567,1568,1570,1572,1573,1574,1583,1591,1597,1613,1614,1627,1636,1637,1643,1654,1663,1667,1672,1674,1676,1677,1683,1684,1704,1705,1706,1716,1721,1728,1731,1733,1741,1745,1754,1756,1757,1761,1765,1772,1777,1781,1813,1815,1818,1825,1835,1838,1845,1849,1850,1853,1863,1869,1873,1874,1878,1897,1899,1905,1907,1924,1928,1930,1953,1954,1956,1973,1978,1983,1986,1997,2002,2003,2010,2011,2015,2018,2030,2033,2036,2044,2055,2063,2079,2086,2090,2102,2115,2134,2139,2142,2143,2148,2149,2154,2156,2158,2159,2164,2167,2168,2171,2173,2182,2212,2224,2236,2241,2243,2248,2250,2255,2266,2268,2273,2278,2285,2292,2294,2295,2300,2305,2309,2323,2324,2347,2348,2349,2351,2354,2359,2379,2390,2407,2419,2424,2443,2456,2466,2471,2476,2485,2510,2514,2515,2520,2524,2529,2532,2540,2546,2551,2556,2557,2563,2564,2566,2572,2582,2596,2597,2605,2623,2635,2642,2643,2652,2653,2654,2655,2660,2679,2689,2692,2694,2702,2738,2750,2755,2756,2759,2788,2819,2841,2842,2862,2864,2865,2868,2869,2872,2876,2879,2885,2912,2913,2917,2936,2942,2949,2954,2959,2981,2989,2994,2997,2998,3001,3007,3014,3028,3034,3036,3056,3060,3086,3093,3094,3110,3111,3116,3117,3126,3129,3132,3151,3152,3179,3201,3208,3210,3211,3214,3217,3219,3225,3232,3243,3264,3274,3277,3300,3314,3333,3340,3343,3348,3359,3382,3403,3409,3413,3418,3423,3426,3429,3431,3432,3453,3470,3477,3485,3486,3494,3496,3519,3530,3540,3564,3586,3588,3592,3601,3602,3616,3633,3655,3699,3727,3728,3735,3771,3786,3837,3850,3860,3875,3888,3937,3980,4003,4030,4057,4079,4084,4090,4148,4154,4156,4159,4170,4183,4192,4205,4214,4218,4223,4224,4235,4239,4277,4303,4313,4321,4325,4352,4355,4357,4420,4432,4441,4452,4482,4485,4499,4522,4529,4546,4550,4558,4612,4623,4661,4681,4736,4780,4795,4800,4807,4827,4830,4836,4908,4932,4958,4960,4964,4975,5030,5059,5087,5093,5111,5127,5139,5162,5174,5182,5186,5188,5237,5244,5326,5341,5345,5368,5382,5455,5473,5492,5504,5545,5559,5568,5575,5614,5686,5716,5719,5742,5750,5754,5768,5868,5908,5938,5949,5987,6031,6040,6044,6069,6085,6123,6149,6176,6245,6248,6269,6282,6317,6321,6343,6402,6426,6437,6444,6458,6470,6501,6559,6625,6642,6710,6713,6731,6761,6791,6796,6801,6871,6919,6958,6967,6975,6977,6988,7000,7028,7106,7143,7176,7218,7230,7233,7283,7378,7387,7410,7527,7546,7624,7656,7672,7692,7698,7704,7705,7714,7722,7752,7758,7820,7828,7834,7850,7853,7941,7944,8049,8230,8286,8372,8374,8453,8536,8564,8583,8593,8628,8670,8737,8747,8772,8792,8802,8808,8824,8877,8897,8946,9104,9116,9134,9199,9228,9281,9364,9397,9436,9511,9825,9836,9854,9872,9908,9980,10117,10192,10198,10229,10251,10262,10387,10451,10484,10543,10562,10577,10657,10709,10782,10791,10850,10870,10910,10930,10967,11149,11339,11368,11505,11579,11656,11671,11683,11713,11771,11901,11903,11907,11917,11959,11971,11972,12083,12153,12175,12188,12289,12358,12543,12569,12604,12650,12666,12700,12750,13022,13170,13216,13321,13675,13724,13772,13849,13851,13891,13941,13989,14142,14198,14339,14826,15026,15086,15103,15195,15208,15210,15332,15432,15560,15569,15626,15667,15805,15852,15901,15928,16079,16123,16737,16825,17041,17345,17464,17489,17662,18060,18102,18343,18525,18949,19185,19377,19937,20053,20111,20290,20327,20660,21098,21120,21385,21545,21620,21657,22183,22366,22390,22701,22967,23196,23377,23527,23556,24225,24547,24580,24779,25040,25532,25755,25766,25894,25951,26528,26643,26958,27497,27629,28028,28271,28342,28420,28659,28809,28902,29300,29313,29506,29604,29635,29868,30088,30260,30336,30408,30858,31016,31025,31266,31531,31552,31626,31649,31712,32017,32182,33143,33570,33593,33968,34080,34346,35076,35781,36222,36811,37636,37753,38083,38520,38665,38885,39304,39484,40809,40924,40929,41074,41610,41732,41799,42044,45062,45619,45855,45868,45925,45949,46274,46463,46722,46756,46811,46913,46984,47272,47282,47330,47499,47540,47733,47801,48192,48239,48332,48491,48670,48978,48994,49107,49152,49473,49541,49881,50300,50308,51114,51216,51442,51665,51927,51932,52010,52266,52320,52364,52419,52469,52510,52664,52895,53040,53158,53316,53682,53731,54013,54025,54234,54359,54450,54470,54687,54698,54880,54958,55421,55529,55787,55801,55893,55947,56236,56690,56713,56905,57024,57286,57289,57517,57570,57613,57829,57877,58016,58144,58301,58565,58655,58676,58869,58955,59049,59163,59403,59452,59606,59857,59987,60009,60215,60334,60438,60734,60828,60900,61009,61083,61344,61864,62216,62560,62718,62815,62901,63298,63566,63577,63761,63854,64133,64167,64332,64444,64486,64685,64890,64937,65154,65159,65290,65434,65438,65742,65775,65969,65988,66447,66457,66674,66675,66934,66969,67039,67049,67131,67208,67323,67464,67750,68068,68258,68564,68576,68608,68692,68829,68915,69191,69194,69445,69620,69651,69862,70074,70386,70691,71008,71176,71563,71595,71644,71647,71801,71820,71890,71985,72148,72395,73096,73105,73198,73300,73448,73468,73632,73964,73985,73988,74142,74652,74661,74743,74760,74796,74811],[1353.0,42.0,6.0,20.0,43.0,36.0,18.0,24.0,10.0,26.0,16.0,41.0,2.0,6.0,24.0,9.0,12.0,9.0,9.0,1.0,16.0,13.0,11.0,1.0,4.0,4.0,4.0,2.0,1.0,18.0,9.0,22.0,3.0,3.0,19.0,5.0,19.0,10.0,4.0,7.0,6.0,5.0,13.0,7.0,4.0,2.0,7.0,1.0,4.0,6.0,7.0,2.0,3.0,11.0,12.0,5.0,4.0,7.0,1.0,3.0,4.0,10.0,3.0,6.0,6.0,17.0,2.0,4.0,8.0,2.0,12.0,3.0,3.0,4.0,5.0,12.0,6.0,7.0,3.0,4.0,7.0,2.0,5.0,8.0,7.0,3.0,16.0,5.0,3.0,3.0,3.0,4.0,6.0,15.0,4.0,12.0,2.0,7.0,5.0,10.0,3.0,1.0,1.0,3.0,5.0,2.0,2.0,1.0,4.0,2.0,2.0,7.0,1.0,10.0,1.0,2.0,1.0,3.0,1.0,1.0,40.0,2.0,3.0,1.0,9.0,3.0,2.0,1.0,3.0,10.0,2.0,2.0,4.0,6.0,2.0,1.0,2.0,3.0,7.0,1.0,1.0,3.0,2.0,8.0,8.0,1.0,1.0,6.0,3.0,4.0,2.0,7.0,5.0,1.0,2.0,2.0,2.0,1.0,1.0,6.0,2.0,3.0,1.0,4.0,2.0,1.0,2.0,6.0,2.0,2.0,5.0,2.0,3.0,1.0,6.0,4.0,6.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,2.0,7.0,8.0,2.0,2.0,2.0,4.0,3.0,1.0,3.0,2.0,6.0,1.0,1.0,3.0,8.0,8.0,5.0,6.0,1.0,2.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,2.0,4.0,4.0,2.0,2.0,1.0,1.0,3.0,1.0,1.0,3.0,3.0,4.0,2.0,4.0,1.0,6.0,4.0,4.0,23.0,1.0,3.0,1.0,2.0,7.0,2.0,3.0,1.0,3.0,3.0,3.0,1.0,7.0,1.0,1.0,5.0,1.0,2.0,19.0,1.0,2.0,1.0,1.0,4.0,1.0,3.0,1.0,19.0,3.0,2.0,4.0,2.0,1.0,1.0,3.0,10.0,2.0,1.0,7.0,2.0,1.0,1.0,2.0,1.0,10.0,1.0,2.0,1.0,1.0,2.0,4.0,2.0,1.0,1.0,8.0,5.0,1.0,4.0,11.0,1.0,1.0,11.0,1.0,1.0,4.0,1.0,2.0,1.0,8.0,1.0,1.0,3.0,2.0,7.0,2.0,2.0,4.0,4.0,2.0,1.0,1.0,2.0,1.0,2.0,3.0,2.0,1.0,1.0,27.0,5.0,2.0,3.0,1.0,5.0,3.0,1.0,2.0,3.0,4.0,1.0,1.0,1.0,2.0,1.0,10.0,1.0,2.0,3.0,6.0,2.0,6.0,4.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,25.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,2.0,2.0,4.0,2.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,5.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,2.0,2.0,1.0,2.0,4.0,3.0,6.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,19.0,2.0,1.0,4.0,5.0,3.0,6.0,1.0,4.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,7.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,8.0,2.0,1.0,1.0,2.0,2.0,16.0,1.0,2.0,1.0,7.0,1.0,6.0,6.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,14.0,1.0,3.0,2.0,5.0,5.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,4.0,1.0,3.0,1.0,3.0,1.0,2.0,2.0,3.0,1.0,1.0,5.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,4.0,2.0,1.0,1.0,12.0,2.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,4.0,2.0,1.0,2.0,1.0,1.0,4.0,7.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,3.0,3.0,2.0,1.0,1.0,1.0,11.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,3.0,11.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,4.0,5.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,3.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,2.0,3.0,2.0,1.0,1.0,3.0,6.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,16.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,11.0,1.0,1.0,2.0,5.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,2.0,2.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,10.0,1.0,1.0,1.0,2.0,2.0,2.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,5.0,14.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,3.0,1.0,1.0,1.0,2.0,1.0,10.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,14.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,10.0,1.0,1.0,6.0,2.0,2.0,6.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,3.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,2.0,2.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,8.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,2.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,8.0,1.0,2.0,1.0,2.0,6.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,13.0,1.0,2.0,1.0,1.0,1.0,6.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,2.0,1.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,4.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,4.0,3.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,3.0,3.0,1.0,1.0,2.0,3.0,1.0,3.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n",
      "|[, cabozantinib, is, an, oral, multikinase, inhibitor, whose, targets, include, vascular, endothelial, growth, factor, receptors, met, and, the, tam, family, of, kinases, tyro3, axl, mer, cabozantinib, is, approved, for, patients, with, advanced, hepatocellular, carcinoma, who, have, been, previously, treated, with, sorafenib, based, on, improved, overall, survival, and, progressionfree, survival, relative, to, placebo, in, the, phase, iii, celestial, study, during, celestial, the, most, common, adverse, events, aes, experienced, by, patients, receiving, cabozantinib, included, palmarplantar, erythrodysesthesia, fatigue, gastrointestinalrelated, events, and, hypertension, these, aes, can, significantly, impact, treatment, tolerability, and, patient, quality, of, life, however, aes, can, be, effectively, managed, with, supportive, care, and, dose, modifications, during, celestial, more, than, half, of, the, patients, receiving, cabozantinib, required, a, dose, reduction, while, the, rate, of, treatment, discontinuation, due, to, aes, was, low, here, we, review, the, safety, profile, of, cabozantinib, and, provide, guidance, on, the, prevention, and, management, of, the, more, common, aes, based, on, current, evidence, from, the, literature, as, well, as, our, clinical, experience, we, consider, the, specific, challenges, faced, by, clinicians, in, treating, this, patient, population, and, discuss, factors, that, may, affect, exposure, and, tolerability, to, cabozantinib, , introductionthere, has, been, a, marked, increase, in, liver, cancer, deaths, in, recent, years, in, , there, were, a0, new, cases, of, liver, cancer, worldwide, and, liver, cancer, accounted, for, almost, , deaths, making, it, the, sixth, most, prevalent, cancer, worldwide, [], the, most, common, primary, malignancy, of, the, liver, is, hepatocellular, carcinoma, hcc, [], the, frequency, burden, and, etiology, of, hcc, vary, across, geographic, regions, and, populations, but, are, linked, to, prevalence, of, predisposing, chronic, hepatic, conditions, such, as, electronic, supplementary, material, , the, online, version, of, this, , , s1152, , , contains, supplementary, material, which, is, available, to, authorized, userskey, points, cabozantinib, represents, a, treatment, option, for, patients, with, advanced, hepatocellular, carcinoma, who, progress, after, sorafenibadverse, events, associated, with, cabozantinib, may, be, effectively, managed, with, supportive, care, and, dose, modifications, thereby, allowing, patients, to, continue, treatment, at, the, appropriate, dose, with, minimum, interruptionstudies, of, cabozantinib, in, the, firstline, setting, are, ongoing, by, understanding, the, safety, profile, of, this, drug, clinicians, will, be, able, to, balance, efficacy, with, tolerability, for, each, patient, , , gabriel, schwartz, , , gabrielschwartzucsfedu, , gastrointestinal, medical, oncology, clinic, university, of, a0california, san, francisco, , fourth, st, fourth, floor, san, a0francisco, ca, a0, usaindiana, university, health, simon, cancer, center, indianapolis, in, usa, , , department, of, a0medicine, university, of, a0california, san, francisco, san, a0francisco, ca, usairccs, istituto, clinico, humanitas, rozzano, milan, italy, viral, hepatitis, and, nonalcoholic, fatty, liver, disease, nafld, or, nonalcoholic, steatohepatitis, nash, which, generally, develop, in, the, setting, of, cirrhosis, [, ], in, recent, years, the, incidence, of, nonviral, hcc, has, increased, while, the, proportion, of, hcc, cases, related, to, viral, hepatitis, has, declined, [, ], additional, risk, factors, for, hcc, include, alcohol, consumption, smoking, obesity, and, diabetes, [], as, the, epidemiology, of, these, conditions, has, evolved, so, too, has, the, etiology, of, hcc, []vol0123456789, 0c, g, a0schwartz, et, alfor, patients, with, advanced, hcc, the, vascular, endothelial, growth, factor, receptor, vegfrtargeting, tyrosine, kinase, inhibitor, tki, sorafenib, has, been, a, standard, of, care, [], however, the, treatment, landscape, has, been, transformed, in, recent, years, with, the, introduction, of, newer, tkis, immunotherapies, and, monoclonal, antibody, therapies, [], this, provides, clinicians, and, patients, with, a, variety, of, treatment, options, based, on, mechanism, of, action, and, safety, profilecabozantinib, , is, , a, , multikinase, , inhibitor, , that, , targets, vegfr, , met, the, tam, family, of, kinases, tyro3, axl, mer, ret, ros1, kit, trkb, flt3, and, tie2, [, ], several, of, which, are, implicated, in, tumor, growth, angiogenesis, and, immune, regulation, [], vegfr, met, and, axl, have, been, implicated, in, the, pathogenesis, of, hcc, [], a, capsule, formulation, of, cabozantinib, was, first, approved, in, , for, treatment, of, progressive, metastatic, medullary, thyroid, carcinoma, mtc, [], the, tablet, formulation, not, bioequivalent, or, interchangeable, with, the, capsule, [], was, subsequently, approved, for, patients, with, advanced, renal, cell, carcinoma, rcc, [, ], and, more, recently, for, patients, with, advanced, hcc, who, have, received, prior, sorafenib, [, ], the, approval, in, hcc, was, based, on, outcomes, from, the, pivotal, phase, iii, celestial, trial, which, showed, significantly, improved, overall, survival, os, and, progressionfree, survival, pfs, with, cabozantinib, relative, to, placebo, in, patients, who, received, prior, sorafenib, [], the, safety, profile, of, cabozantinib, was, manageable, nearly, all, patients, receiving, cabozantinib, experienced, an, adverse, event, ae, but, these, were, effectively, managed, with, dose, modification, and, supportive, care, measuresclinicians, treating, patients, with, advanced, hcc, can, face, significant, challenges, as, many, patients, present, with, cirrhosis, and, comorbidities, that, can, impact, treatment, tolerability, adequate, assessment, of, liver, function, and, management, of, comorbidities, are, therefore, essential, before, and, during, hcc, treatment, [], here, we, provide, guidance, on, the, management, of, aes, associated, with, cabozantinib, in, patients, with, advanced, hcc, we, briefly, review, outcomes, from, celestial, and, focus, on, managing, some, of, the, more, common, aes, experienced, by, patients, based, on, current, evidence, from, the, literature, as, well, as, our, own, clinical, experience, , , cabozantinib, in, a0hepatocellular, carcinoma, celestialin, the, phase, iii, celestial, study, patients, with, advanced, hcc, were, randomized, , to, treatment, with, cabozantinib, a0mg, daily, or, placebo, [], patients, were, required, to, have, had, prior, treatment, with, sorafenib, and, could, have, received, up, to, two, prior, systemic, regimens, for, hcc, eastern, cooperative, oncology, group, ecog, performance, status, ps, of, , or, , and, childpugh, class, a, liver, function, see, electronic, supplementary, table, a0, for, definition, were, also, required, at, the, second, planned, interim, analysis, , patients, had, been, randomized, the, study, met, its, primary, endpoint, with, significantly, improved, os, with, cabozantinib, relative, to, placebo, median, os, was, , versus, , months, hazard, ratio, , , confidence, interval, [ci], , p, a0, a0, cabozantinib, also, improved, pfs, with, a, median, of, , versus, , months, hazard, ratio, , , ci, , p, a0, a0, as, well, the, objective, response, rate, per, response, evaluation, criteria, in, solid, tumors, recist, v11, , vs, a0, p, a0, a0, , , safety, and, a0tolerabilityallcause, ae, rates, were, generally, higher, in, the, cabozantinib, arm, than, in, the, placebo, arm, some, of, the, more, common, aes, experienced, by, patients, in, the, cabozantinib, a0, versus, placebo, arms, included, diarrhea, , vs, , decreased, appetite, , vs, , palmarplantar, erythrodysesthesia, ppe, , vs, , fatigue, , vs, , nausea, , vs, , hypertension, , vs, , vomiting, , vs, , asthenia, , vs, , and, increased, aspartate, aminotransferase, ast, , vs, , fig, a0, the, most, common, grade, , aes, in, the, cabozantinib, versus, placebo, arms, were, ppe, , vs, , hypertension, , vs, , increased, ast, , vs, , fatigue, , vs, , and, diarrhea, , vs, , overall, the, safety, profile, of, cabozantinib, was, consistent, with, those, from, the, phase, iii, studies, in, rcc, and, mtc, with, gastrointestinal, gi, events, ppe, fatigue, and, hypertension, being, the, most, common, aes, experienced, by, patients, across, studies, [, , ]in, addition, to, supportive, care, measures, protocolspecified, dose, modification, including, dose, interruption, and, reduction, was, utilized, to, manage, aes, [], eightyfour, percent, of, patients, in, the, cabozantinib, arm, had, an, ae, that, led, to, dose, interruption, and, , had, a, dose, interruption, due, to, a, grade, , ae, [], sixtytwo, percent, of, patients, had, at, least, one, dose, reduction, due, to, an, ae, [], and, , dose, reduced, due, to, a, grade, , ae, [], thirtythree, percent, of, patients, had, a, second, dose, reduction, [], median, time, to, first, and, second, dose, reduction, in, the, cabozantinib, arm, was, a0days, and, a0days, respectively, ppe, was, the, event, that, most, commonly, led, to, dose, interruption, , and, dose, reduction, , followed, by, diarrhea, , and, , and, fatigue, , and, , [], although, most, patients, receiving, cabozantinib, required, a, dose, interruption, the, rate, of, discontinuation, due, to, treatmentrelated, aes, was, relatively, low, , in, the, cabozantinib, arm, vs, , in, the, placebo, arm, indicating, that, the, majority, of, aes, were, adequately, managed, with, dose, modification, and, supportive, care, in, the, cabozantinib, group, aes, that, led, to, treatment, discontinuation, in, ¥, a0, of, patients, were, ppe, fatigue, decreased, appetite, diarrhea, and, nausea, in, a, subgroup, analysis, of, patients, 0cae, any, grade, [grade, , grade, ]fatigue, , [, ]hypertension, , [, ]increased, ast, , [, ]increased, alt, , [, ]asthenia, , [, ]nausea, , [, ]vomiting, , [, ]decrease, appetite, , [, ]weight, loss, , [, ]diarrhea, , [, ]constipation, , [, ]abdominal, pain, , [, ]ppe, , [, ]fig, , , , incidence, , rates, , for, , select, , aes, , experienced, , by, , patients, , with, hcc, receiving, cabozantinib, during, the, celestial, trial, [], aes, are, , color, , coded, , by, , system, , blue, , gastrointestinal, , purple, , skin, , and, subcutaneous, tissue, green, constitutional, orange, hepatic, disorders, red, , cardiovascularhematological, , disorders, , ae, , adverse, , event, , alt, alanine, aminotransferase, ast, aspartate, aminotransferase, hcc, hepatocellular, carcinoma, ppe, palmarplantar, erythrodysesthesiawho, received, sorafenib, as, the, only, prior, treatment, for, hcc, duration, of, prior, sorafenib, did, not, appear, to, impact, the, types, or, rates, of, grade, , aes, []generally, the, more, common, aes, emerged, in, the, first, , weeks, of, treatment, fig, a0, however, clinicians, should, be, aware, of, infrequent, or, serious, events, that, can, occur, in, the, later, phases, of, treatment, hemorrhagic, events, of, grade, , or, higher, were, reported, in, , of, patients, in, the, cabozantinib, arm, including, five, patients, , with, a, grade, , event, bleeding, complications, are, associated, with, antiangiogenic, therapies, and, may, arise, as, a, result, of, reduced, vascular, integrity, [], median, time, to, onset, of, hemorrhagic, events, was, a0weeks, in, celestial, other, grade, , or, higher, rare, but, serious, aes, in, patients, receiving, cabozantinib, included, fistulas, , of, patients, gi, perforations, , and, arterial, , and, venous, or, mixed, thrombotic, events, , [], median, time, to, first, occurrence, was, approximately, a0weeks, for, gi, perforations, , weeks, for, venous, and, arterial, thromboembolisms, and, , weeks, for, fistulas, [], two, patients, in, the, cabozantinib, arm, , had, developed, childpugh, c, ie, decompensated, cirrhosis, by, the, week, , assessment, []reversible, posterior, leukoencephalopathy, syndrome, rpls, a, syndrome, of, subcortical, vasogenic, edema, diagnosed, by, magnetic, resonance, imaging, has, been, reported, with, cabozantinib, and, other, tkis, [, ], although, there, were, no, rpls, events, during, celestial, [], clinicians, should, be, aware, of, the, symptoms, which, include, headaches, seizures, confusion, changes, to, vision, or, altered, mental, function, [, ], osteonecrosis, of, the, jaw, onj, whereby, necrotic, jaw, bone, becomes, exposed, is, another, rare, but, serious, ae, associated, with, tkis, including, cabozantinib, [], although, again, there, were, no, onj, events, reported, during, this, study, [], the, use, of, antiresorptive, drugs, in, patients, with, bone, metastases, is, also, associated, with, development, of, onj, []a, post, hoc, analysis, estimated, the, incremental, qualityadjusted, lifeyears, accrued, with, cabozantinib, compared, with, placebo, using, the, fivedimension, fivelevel, euroqol, questionnaire, [], cabozantinib, treatment, was, associated, with, an, initial, decline, in, mean, total, qualityadjusted, lifeyears, during, the, first, , a0months, relative, to, placebo, followed, by, longterm, improvement, that, was, significantly, greater, than, that, observed, with, placebo, p, a0, a0management, of, cabozantinibassociated, adverse, events, in, patients, with, hepatocellular, carcinoma, 0c, fig, , , , rates, , and, timing, of, select, aes, in, patients, with, hcc, receiving, cabozantinib, during, the, celestial, trial, the, size, of, the, circle, is, proportional, to, the, ae, rate, aes, are, color, coded, by, system, blue, gastrointestinal, purple, skin, and, subcutaneous, tissue, green, constitutional, orange, hepatic, disorders, red, cardiovascularhematological, disorders, black, generalother, ae, adverse, event, ate, arterial, thrombotic, event, gi, gastrointestinal, gr, grade, hcc, hepatocellular, carcinoma, ppe, palmarplantar, erythrodysesthesia, vte, venous, thrombotic, eventmedian, time, to, first, dosereduction, to, , mg, weeksg, a0schwartz, et, almedian, time, to, seconddose, reduction, to, , mg, weeksfistulas, hemorrhage, gr, , ates, vte, wound, complication, gi, perforations, hepatic, encephalopathy, diarrhea, ppe, hypertension, median, time, to, first, occurrence, weeks, , , factors, affecting, tolerability, of, a0cabozantinib, , , comorbiditieshcc, emerges, primarily, in, older, adults, [], in, addition, to, the, underlying, hcc, etiology, older, adults, with, hcc, are, likely, to, have, additional, comorbidities, such, as, cardiovascular, or, pulmonary, disease, [], and, it, is, not, uncommon, for, patients, with, hcc, to, have, multiple, comorbidities, [], liver, cirrhosis, with, compromised, liver, function, and, decreased, hepatic, reserve, is, a, major, risk, factor, for, hcc, development, other, hccrelated, comorbidities, include, hepatitis, b, virushepatitis, c, virus, infection, alcoholic, liver, disease, nash, and, diabetes, [], in, addition, metabolic, syndrome, characterized, by, hyperlipidemia, and, hypertension, is, linked, to, development, of, nafld, which, may, progress, to, nash, cirrhosis, and, finally, hcc, [], for, patients, with, hcc, assessment, of, liver, function, is, a, key, step, in, treatment, decisionmaking, [], patients, with, moderate, or, severe, hepatic, impairment, are, predominantly, excluded, from, clinical, trials, in, hcc, therefore, treatment, of, these, patients, is, complicated, by, a, lack, of, prospective, clinical, data, as, well, as, competing, comorbidities, []although, the, number, of, patients, with, hcc, and, prior, an, transplant, is, limited, these, patients, are, generally, excluded, from, clinical, trials, and, treatment, is, complicated, by, the, need, for, immunosuppression, tkis, may, be, used, to, treat, posttransplant, hcc, recurrence, although, supporting, data, are, limited, the, use, of, tkis, in, these, patients, is, complex, so, treatment, decisions, should, involve, collaboration, between, the, oncology, and, transplant, medicine, care, teams, the, use, of, sorafenib, in, patients, receiving, mammalian, target, of, rapamycin, inhibitorbased, immunosuppression, has, been, associated, with, an, increased, risk, of, fatal, bleeding, [, ], immunotherapies, are, associated, with, an, increased, risk, of, an, rejection, in, posttransplant, patients, [], , , cabozantinib, clearance, and, a0exposuretkis, are, associated, with, high, interpatient, variability, in, clearance, and, exposure, which, may, affect, both, efficacy, and, tolerability, this, variability, may, be, due, to, a, variety, of, factors, including, genetic, background, drugdrug, interactions, drugfood, interactions, and, renal, or, hepatic, impairment, [], as, evidenced, by, exposureresponse, modeling, patients, with, low, clearance, of, cabozantinib, may, have, higher, exposure, and, an, increased, risk, of, developing, certain, aes, [, ], awareness, of, these, nuances, may, help, clinicians, to, mitigate, their, effects, thereby, balancing, efficacy, with, tolerability, , , hepatic, and, a0renal, impairmentaccording, to, pharmacokinetic, analyses, of, patients, with, hcc, and, other, tumor, types, mild, hepatic, impairment, is, predicted, to, have, a, minimal, effect, on, cabozantinib, exposure, [], therefore, adjustment, of, the, recommended, 60mg, starting, dose, is, not, necessary, for, patients, with, childpugh, a, 0cliver, function, [, ], data, on, the, pharmacokinetics, of, cabozantinib, in, patients, with, moderate, childpugh, b, or, severe, childpugh, c, hepatic, impairment, are, limited, [], as, per, the, us, food, and, drug, administration, fda, prescribing, information, the, starting, dose, of, cabozantinib, should, be, reduced, to, , mg, in, patients, with, moderate, hepatic, impairment, while, cabozantinib, is, not, recommended, for, patients, with, severe, hepatic, impairment, [], note, that, the, european, summary, of, product, characteristics, smpc, does, not, recommend, dose, adjustments, for, moderate, hepatic, impairment, owing, to, limited, data, [], for, patients, with, hcc, increased, exposure, due, to, hepatic, impairment, should, be, considered, if, intolerable, aes, develop, and, dose, modification, undertaken, as, recommended, fig, a0, [, ], cabozantinib, should, be, used, with, caution, in, patients, with, mild, or, moderate, renal, impairment, owing, to, the, potential, for, increased, exposure, although, no, dose, adjustments, are, necessary, cabozantinib, is, not, recommended, for, use, in, patients, with, severe, renal, impairment, owing, to, lack, of, data, on, safety, and, efficacy, in, this, population, [, , ], , , drugdrug, and, a0drugfood, interactionsgiven, the, range, of, comorbidities, that, may, exist, in, patients, with, advanced, hcc, it, is, important, to, review, all, concomitant, medications, for, potential, interactions, prior, to, initiation, of, treatment, with, cabozantinib, certain, medications, and, foods, have, been, shown, to, modulate, the, pharmacokinetics, of, cabozantinib, which, may, in, turn, impact, exposure, levels, efficacy, and, risk, of, aes, cabozantinib, is, metabolized, in, the, liver, primarily, by, the, enzyme, cytochrome, p450, 3a4, cyp3a4, [], therefore, cyp3a4, inhibitors, or, inducers, may, impact, exposure, examples, of, cyp3a4, inducersinhibitors, are, shown, in, electronic, supplementary, table, a0, strong, cyp3a4, inhibitorsinducers, should, be, avoided, in, patients, receiving, cabozantinib, if, concomitant, administration, of, a, strong, cyp3a4, inhibitor, is, necessary, then, the, cabozantinib, recommended, dose, at, initiation, , mg, except, for¢, patients, with, moderate, hepatic, impairment, or, coadministration, of, a, strong, cyp3a4, inhibitor, initiate, cabozantinib, at, , mg, ¢, patients, with, coadministration, of, a, strong, cyp3a4, inducer, initiate, cabozantinib, at, , mg, safety, assessmentno, aesgrade, grade, , ae, or, onjsupportive, caresee, tables, dosemodificationimprovementtolerableelbarelotnilitnu, esod, dlohgrade, ¤continue, at, tolerated, dosereduce, dose, by, , mg, and, restart, , , , mg, , , mg, , , , mg, , , mg, , , , , mg, , , mg, , , , , mg, , , mg, or, discontinueimmediate, discontinuation¢, severe, hemorrhage¢, development, of, gi, perforation, or, unmanageable, fistula¢, serious, thromboembolic, event, eg, myocardial, infarction, cerebral, infarction¢, hypertensive, crisis, or, severe, hypertension, despite, optimal, medical, management¢, nephrotic, syndrome¢, reversible, posterior, leukoencephalopathy, syndromefig, , , , cabozantinib, dosing, algorithm, [, ], ae, adverse, event, cyp3a4, cytochrome, p450, 3a4, gi, gastrointestinal, onj, osteonecrosis, of, the, jawmanagement, of, cabozantinibassociated, adverse, events, in, patients, with, hepatocellular, carcinoma, 0c, g, a0schwartz, et, aldose, should, be, reduced, by, a0mg, for, example, from, , to, a0mg, [], conversely, the, cabozantinib, dose, should, be, increased, by, a0mg, if, strong, cyp3a4, inducers, need, to, be, coadministered, [, ]cabozantinib, should, not, be, taken, with, any, food, as, this, may, affect, absorption, [], the, label, recommends, that, cabozantinib, be, taken, at, least, , h, before, or, at, least, , h, after, eating, [], grapefruit, and, grapefruit, juice, are, strong, cyp3a4, inhibitors, and, should, be, avoided, [, ]cabozantinib, may, be, used, with, caution, in, patients, who, are, receiving, concurrent, antiarrhythmics, or, other, qtprolonging, agents, [], this, is, based, on, a, study, of, patients, with, mtc, who, received, a, daily, 140mg, capsule, dose, of, cabozantinib, recommended, for, this, indication, in, which, the, mean, deltadelta, qt, interval, was, increased, by, approximately, , a0ms, with, upper, , cis, not, exceeding, , ms, [], such, an, increase, is, within, the, range, considered, to, be, acceptable, for, oncology, drugs, in, this, setting, [], no, patient, in, the, aforementioned, study, or, in, celestial, had, a, confirmed, qtcf, qt, corrected, using, fridericias, method, a0, ms, [], which, is, considered, clinically, significant, [], for, patients, receiving, cabozantinib, monitoring, with, periodic, electrocardiogram, and, electrolyte, measurements, may, be, advisable, particularly, in, patients, with, risk, factors, such, as, cardiac, disease, or, a, prior, history, of, qt, prolongation, [], concomitant, use, of, proton, pump, inhibitors, ppis, such, as, esomeprazole, does, not, affect, cabozantinib, exposure, levels, [], however, ppis, may, cause, hypomagnesemia, which, is, linked, to, an, increased, risk, of, qt, prolongation, [], therefore, coadministration, of, ppis, and, cabozantinib, should, be, undertaken, with, caution, following, an, individualized, assessment, of, the, patients, baseline, magnesium, levels, and, concomitant, medications, that, may, also, influence, qt, , , pretreatment, assessmentsgiven, the, heterogeneity, of, the, hcc, patient, population, and, the, complexity, associated, with, comorbidities, and, concomitant, medications, all, patients, should, undergo, a, comprehensive, assessment, of, medical, history, prior, to, initiation, of, treatment, with, cabozantinib, ideally, the, multidisciplinary, care, team, should, include, an, oncology, pharmacist, [], a, brown, bag, medication, review, should, be, carried, out, prior, to, treatment, initiation, [], whereby, the, patient, brings, in, all, current, medications, including, overthecounter, medicines, vitamins, herbal, remedies, etc, therapeutic, duplications, should, be, eliminated, for, example, concomitant, ppis, and, histamine, h2, antagonists, h2, blockers, switching, and, deprescribing, should, be, considered, where, possible, to, minimize, the, risk, of, drugdrug, interactions, , , adverse, event, managementthe, ae, profile, of, cabozantinib, is, generally, similar, to, that, of, other, vegfrtargeting, tkis, with, girelated, aes, fatigue, ppe, and, hypertension, being, the, most, common, aes, [], other, aes, that, occur, less, frequently, can, also, have, a, significant, impact, on, quality, of, life, qol, and, treatment, adherence, such, as, mucosal, inflammation, [], hepatobiliary, aes, such, as, elevated, ast, alanine, aminotransferase, alt, and, bilirubin, are, particularly, relevant, in, the, context, of, advanced, hcc, and, need, to, be, carefully, monitoredprophylactic, and, supportive, care, measures, for, the, more, common, cabozantinibassociated, aes, grade, , or, tolerable, grade, , are, outlined, in, tables, a0, , , , and, discussed, in, the, upcoming, sections, symptom, gradings, are, summarized, in, electronic, supplementary, table, a0, dose, interruption, is, recommended, for, management, of, intolerable, grade, , aes, not, resolved, with, supportive, care, measures, or, for, any, grade, , aes, fig, a0, [, ], cabozantinib, may, be, reinitiated, at, a, reduced, dose, once, the, event, resolves, to, grade, ¤, a0, , , palmarplantar, erythrodysesthesiappe, is, one, of, the, more, common, events, associated, with, anticancer, therapies, including, vegfrtargeting, multikinase, inhibitors, [], ppe, is, characterized, by, pain, redness, tingling, and, swelling, of, hands, and, feet, [], presentation, may, vary, according, to, the, etiologic, agent, ppe, induced, by, tkis, is, typically, localized, to, pressurebearing, areas, in, contrast, to, that, caused, by, chemotherapy, which, has, a, more, diffuse, pattern, it, has, been, hypothesized, that, inhibition, of, multiple, angiogenic, pathways, by, tkis, may, compromise, repair, of, capillary, microtrauma, in, areas, exposed, to, mechanical, stress, such, as, the, hands, and, feet, [, ], although, not, lifethreatening, ppe, can, rapidly, progress, to, a, debilitating, condition, negatively, impacting, qol, [, ]prophylaxis, and, prompt, management, of, emerging, symptoms, may, help, to, minimize, the, impact, of, ppe, on, qol, and, adherence, table, a0, prophylactic, measures, predominantly, involve, skin, care, practices, to, remove, hyperkeratotic, areas, and, to, minimize, friction, and, damage, prior, to, the, start, of, treatment, [, ], recommendations, include, use, of, thick, cotton, gloves, and, socks, padded, insoles, in, shoes, and, avoidance, of, heat, or, friction, on, the, hands, and, feet, [, ], patients, with, potentially, predisposing, comorbidities, such, as, peripheral, neuropathy, [, ], as, well, as, patients, with, persistent, symptoms, may, benefit, from, involvement, of, a, podiatrist, andor, dermatologist, within, their, multidisciplinary, care, team, [], treatment, strategies, involve, moisturization, prevention, of, infection, and, analgesia, [, , ], monitoring, is, crucial, so, that, emerging, symptoms, can, be, proactively, managed, patients, should, be, assessed, at, baseline, 0ctable, , , , adverse, event, management, strategiespalmarplantar, erythrodysesthesia, ppe, ppeprophylaxisprovide, education, on, prophylactic, skin, care, before, starting, treatment, []advise, manicure, and, pedicure, before, and, during, treatment, to, remove, hyperkeratotic, areas, [, ]protect, sensitive, areas, recommend, sunscreen, with, spf, protection, ¥, a0, thick, cotton, gloves, and, socks, padded, insoles, and, wellfitting, shoes, avoid, heat, sources, and, use, cooling, aids, and, avoid, activities, that, may, cause, force, or, rubbing, on, the, hands, and, feet, eg, heavy, lifting, dish, washing, [, , ], delegate, such, tasks, to, caregiversadvise, on, optimal, hand, cleaning, avoid, fragrancedfoaming, soaps, and, hand, sanitizers, containing, alcohol, ensure, hands, are, dried, thoroughly, after, cleaning, []prophylactically, administer, keratolytic, cream, eg, , urea, [, ]monitor, regularly, in, order, to, proactively, manage, skin, toxicities, evaluate, at, baseline, monitor, up, to, weekly, for, the, first, , months, and, monthly, thereafter, [, ]supportive, carecontinue, prophylactic, measures, []maintain, moisture, of, skin, using, emollients, [, , ]consider, topical, treatment, with, salicylic, acid, urea, , cream, either, alone, or, with, tazarotene, cream, or, , fluorouracil, cream, andor, clobetasol, , cream, topical, analgesics, may, be, added, for, pain, control, [, , ]topical, cortisone, and, clobetasol, , may, also, be, used, consider, oral, analgesics, eg, nsaids, pregabalin, cautious, use, of, opioids, [, , ]consult, with, a, dermatologist, to, drain, blisters, and, remove, hyperkeratotic, areas, []to, prevent, infection, of, cracked, skin, soak, in, equal, parts, vinegar, and, water, for, , min, per, day, [], a0antibiotics, should, be, prescribed, only, if, there, is, evidence, of, infection, [], a0there, is, limited, evidence, for, the, use, of, pyridoxine, vitamin, b6, []nsaid, nonsteroidal, antiinflammatory, drug, spf, sun, protection, factortable, , , , adverse, event, management, strategiesfatigue, fatigueprophylaxisprovide, patient, education, about, fatigue, management, tools, and, available, support, []establish, baseline, fatigue, levels, with, a, fatigue, scale, and, remeasure, regularly, during, patient, visits, []ensure, adequate, fluid, and, nutritional, intake, []advise, behavioral, modifications, balancing, rest, with, physical, activity, recommendations, include, relaxation, massage, yoga, aerobic, or, resistance, exercise, programs, and, energy, conservation, strategies, []assess, thyroid, function, prior, to, treatment, and, monitor, during, treatment, [, ]supportive, carerule, out, alternative, causes, of, fatigue, eg, anemia, endocrine, disorders, such, as, hypothyroidism, pain, dehydration, hypercalcemia, or, depressionanxiety, [, ]advise, patient, to, increase, activity, consider, referral, to, a, physical, therapist, []consider, referral, to, nutritional, counselor, for, nutritional, therapy, []incorporate, psychosocial, measures, including, cognitive, therapy, social, support, biofeedback, and, sleep, therapy, []incorporate, management, with, psychostimulants, eg, methylphenidate, [, ], or, corticosteroids, eg, methylprednisolone, []owing, to, effects, on, cyp3a45, substrates, including, cabozantinib, longterm, use, of, modafinil, should, be, avoided, []cyp3a4, cytochrome, p450, 3a4, cyp2c19, cytochrome, p450, 2c19management, of, cabozantinibassociated, adverse, events, in, patients, with, hepatocellular, carcinoma, 0c, g, a0schwartz, et, altable, , , , adverse, event, management, strategiesgastrointestinal, gastrointestinaldiarrheaprophylaxisinstruct, patients, to, monitor, food, and, fluid, intake, [], a0recommended, water, intake, per, day, from, all, beverages, and, food, [], , l, , oz, for, women, , l, , oz, for, men, a0advise, patients, to, keep, a, stool, diary, and, to, promptly, report, diarrhea, to, their, healthcare, provider, [, ]advise, patients, to, avoid, foods, that, may, cause, gi, events, such, as, lactosecontaining, foods, caffeine, highfat, or, highfiber, food, eg, nuts, seeds, legumes, and, raw, fruit, and, vegetables, [, ]implement, dehydration, prevention, management, through, oral, rehydration, with, electrolytes, []supportive, careadminister, loperamide, at, the, first, sign, of, diarrhea, [, , ], a0, mg, orally, followed, by, , mg, every, , h, until, , h, after, last, bowel, movement, maximum, of, , mg, in, , h, a0for, chronic, diarrhea, , mg, twice, daily, titrated, as, needed, a0alternatives, to, loperamide, include, diphenoxylate, and, tincture, of, opium, []implement, supportive, dietary, modifications, continuous, oral, hydration, correction, of, fluid, and, electrolytes, small, frequent, meals, avoid, lactosecontaining, food, and, drink, [, ], a0the, brat, bananas, rice, applesauce, toast, diet, may, help, to, alleviate, mild, diarrhea, []if, there, are, signs, of, severe, dehydration, administer, iv, fluid, replacement, isotonic, saline, or, balanced, salt, solution, []rule, out, nontreatmentrelated, causes, eg, infectious, diarrhea, []decreased, appetiteprophylaxisadvise, patients, to, monitor, their, appetite, and, weight, []encourage, patients, to, consume, highprotein, calorierich, food, fruit, and, vegetables, nutritional, supplements, that, they, may, snack, on, throughout, the, day, [, ]advise, patients, to, preprepare, and, freeze, nutritional, preferred, food, []supportive, caretreat, underlying, nausea, []consider, involving, a, dietitian, who, may, recommend, scheduled, eating, times, []recommend, a, highcalorie, diet, []provide, dietary, education, alongside, dietary, modifications, andor, nutritionalvitamin, supplements, []use, a, pharmacologic, agent, to, stimulate, appetite, such, as, a, cb1, receptor, agonist, dronabinol, [, ], systemic, corticosteroid, methylprednisolone, [, ], progestin, megestrol, acetate, [, ], or, mirtazapine, [, ]nauseavomitingprophylaxisassess, risk, factors, for, nauseavomiting, prior, to, treatment, []metoclopramide, may, be, administered, prophylactically, []advise, patients, to, avoid, foods, that, are, overly, sweet, greasy, fried, or, spicy, []supportive, careantiemetic, agents, such, as, dopamine, receptor, antagonists, eg, metoclopramide, prochlorperazine, or, 5ht3, receptor, agonists, eg, ondansetron, are, recommended, for, management, of, nausea, or, vomiting, [, ], a0certain, nk1, receptor, agonists, eg, aprepitant, and, netupitant, and, dexamethasone, are, inducers, inhibitors, andor, substrates, of, cyp3a4, and, thus, could, alter, cabozantinib, exposure, [, ], however, the, potential, for, ondansetron, to, prolong, the, qt, interval, must, also, be, considered, [], there, is, moderate, evidence, for, olanzapine, an, antipsychotic, drug, that, blocks, multiple, neurotransmitters, as, an, antiemetic, in, this, setting, [], 0ctable, , , , continuedmucosal, inflammationstomatitisprophylaxisa, comprehensive, dental, examination, should, be, conducted, prior, to, treatment, to, identify, potential, complications, []mitigation, of, potential, risk, factors, [, ], a0modification, of, illfitting, dentures, a0appropriate, care, for, preexisting, dental, problems, such, as, caries, ulcers, etcregular, oral, assessments, should, be, conducted, throughout, treatment, [, ]educate, patients, on, good, oral, hygiene, and, oral, care, protocols, including, written, instructions, [], a0the, oral, cavity, should, be, washed, using, salinecontaining, mouthwash, up, to, four, times, daily, and, dentures, should, be, regularly, cleaned, []painful, stimuli, eg, smoking, alcohol, hot, fooddrink, sharp, or, spicy, food, should, be, avoided, [, ]supportive, caretreat, pain, with, doxepin, , mouthwash, or, viscous, lidocaine, , [, ]lactobacillus, lozenges, may, be, used, to, reduce, inflammation, []obtain, bacterialviral, culture, if, oral, infection, is, suspected, and, treat, infection, as, clinically, indicated, []5ht3, 5hydroxytryptamine, cb1, cannabinoid, cyp3a4, cytochrome, p450, 3a4, gi, gastrointestinal, iv, intravenous, nk, neurokinintable, , , , adverse, event, management, strategieshypertension, hypertensionprophylaxismonitor, bp, before, initiation, of, cabozantinib, using, a, minimum, of, two, standardized, bp, measurements, alongside, patient, history, physical, assessment, directed, laboratory, evaluation, and, an, instrument, test, to, determine, cardiovascular, risk, factors, [, ]educate, patients, on, bp, selfmonitoring, and, advise, they, keep, a, bp, log, []bp, should, be, well, controlled, prior, to, initiating, cabozantinib, ensure, patients, who, have, already, been, prescribed, antihypertensive, therapy, are, adherent, and, that, therapy, has, been, titrated, to, effective, doses, [, ]check, for, potential, drugdrug, interactions, of, existing, antihypertensive, agents, with, cabozantinib, supplementary, table, a0consider, effects, of, concomitant, medications, on, bp, eg, antiinflammatory, drugs, can, increase, bp, opiates, can, lower, bp, []monitor, bp, during, cabozantinib, treatment, weekly, during, first, cycle, every, ¥, a0, weeks, thereafter, []supportive, careadd, antihypertensive, medications, or, increase, dose, of, existing, medication, as, indicated, [, ]patients, with, portal, hypertension, should, be, treated, with, nonselective, betablockers, []the, antihypertensive, agent, should, be, carefully, considered, owing, to, potential, inhibition, of, cyp3a4, [, ], supplementary, table, a0, a0thiazides, angiotensinconverting, enzyme, inhibitors, and, angiotensin, receptor, blockers, may, be, used, to, treat, hypertension, and, are, not, known, cyp3a4, substrates, [, ], a0thiazide, diuretics, should, be, prescribed, with, caution, owing, to, the, associated, risk, of, diarrhea, [], a0diltiazem, and, verapamil, are, moderate, inhibitors, of, cyp3a4, [], a0amlodipine, felodipine, lercanidipine, nisoldipine, and, nifedipine, are, not, considered, to, be, cyp3a4, inhibitors, []bp, blood, pressure, cyp3a4, cytochrome, p450, 3a4and, monitored, at, least, weekly, for, the, first, , months, of, treatment, and, monthly, thereafter, [, ], close, monitoring, in, the, early, stages, of, treatment, need, not, involve, weekly, visitsphone, calls, from, a, clinician, nurse, or, pharmacist, may, facilitate, monitoring, in, between, scheduled, appointments, [], patients, should, be, encouraged, to, report, early, signs, of, ppe, to, their, healthcare, provider, [], it, may, also, be, reassuring, for, patients, to, know, that, early, reporting, and, management, of, aes]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |[, cabozantinib, oral, multikinase, inhibitor, whose, targets, include, vascular, endothelial, growth, factor, receptors, met, tam, family, kinases, tyro3, axl, mer, cabozantinib, approved, patients, advanced, hepatocellular, carcinoma, previously, treated, sorafenib, based, improved, overall, survival, progressionfree, survival, relative, placebo, phase, iii, celestial, study, celestial, common, adverse, events, aes, experienced, patients, receiving, cabozantinib, included, palmarplantar, erythrodysesthesia, fatigue, gastrointestinalrelated, events, hypertension, aes, significantly, impact, treatment, tolerability, patient, quality, life, however, aes, effectively, managed, supportive, care, dose, modifications, celestial, half, patients, receiving, cabozantinib, required, dose, reduction, rate, treatment, discontinuation, due, aes, low, review, safety, profile, cabozantinib, provide, guidance, prevention, management, common, aes, based, current, evidence, literature, well, clinical, experience, consider, specific, challenges, faced, clinicians, treating, patient, population, discuss, factors, may, affect, exposure, tolerability, cabozantinib, , introductionthere, marked, increase, liver, cancer, deaths, recent, years, , a0, new, cases, liver, cancer, worldwide, liver, cancer, accounted, almost, , deaths, making, sixth, prevalent, cancer, worldwide, [], common, primary, malignancy, liver, hepatocellular, carcinoma, hcc, [], frequency, burden, etiology, hcc, vary, across, geographic, regions, populations, linked, prevalence, predisposing, chronic, hepatic, conditions, electronic, supplementary, material, , online, version, , , s1152, , , contains, supplementary, material, available, authorized, userskey, points, cabozantinib, represents, treatment, option, patients, advanced, hepatocellular, carcinoma, progress, sorafenibadverse, events, associated, cabozantinib, may, effectively, managed, supportive, care, dose, modifications, thereby, allowing, patients, continue, treatment, appropriate, dose, minimum, interruptionstudies, cabozantinib, firstline, setting, ongoing, understanding, safety, profile, drug, clinicians, able, balance, efficacy, tolerability, patient, , , gabriel, schwartz, , , gabrielschwartzucsfedu, , gastrointestinal, medical, oncology, clinic, university, a0california, san, francisco, , fourth, st, fourth, floor, san, a0francisco, ca, a0, usaindiana, university, health, simon, cancer, center, indianapolis, usa, , , department, a0medicine, university, a0california, san, francisco, san, a0francisco, ca, usairccs, istituto, clinico, humanitas, rozzano, milan, italy, viral, hepatitis, nonalcoholic, fatty, liver, disease, nafld, nonalcoholic, steatohepatitis, nash, generally, develop, setting, cirrhosis, [, ], recent, years, incidence, nonviral, hcc, increased, proportion, hcc, cases, related, viral, hepatitis, declined, [, ], additional, risk, factors, hcc, include, alcohol, consumption, smoking, obesity, diabetes, [], epidemiology, conditions, evolved, etiology, hcc, []vol0123456789, 0c, g, a0schwartz, et, alfor, patients, advanced, hcc, vascular, endothelial, growth, factor, receptor, vegfrtargeting, tyrosine, kinase, inhibitor, tki, sorafenib, standard, care, [], however, treatment, landscape, transformed, recent, years, introduction, newer, tkis, immunotherapies, monoclonal, antibody, therapies, [], provides, clinicians, patients, variety, treatment, options, based, mechanism, action, safety, profilecabozantinib, , , , multikinase, , inhibitor, , , targets, vegfr, , met, tam, family, kinases, tyro3, axl, mer, ret, ros1, kit, trkb, flt3, tie2, [, ], several, implicated, tumor, growth, angiogenesis, immune, regulation, [], vegfr, met, axl, implicated, pathogenesis, hcc, [], capsule, formulation, cabozantinib, first, approved, , treatment, progressive, metastatic, medullary, thyroid, carcinoma, mtc, [], tablet, formulation, bioequivalent, interchangeable, capsule, [], subsequently, approved, patients, advanced, renal, cell, carcinoma, rcc, [, ], recently, patients, advanced, hcc, received, prior, sorafenib, [, ], approval, hcc, based, outcomes, pivotal, phase, iii, celestial, trial, showed, significantly, improved, overall, survival, os, progressionfree, survival, pfs, cabozantinib, relative, placebo, patients, received, prior, sorafenib, [], safety, profile, cabozantinib, manageable, nearly, patients, receiving, cabozantinib, experienced, adverse, event, ae, effectively, managed, dose, modification, supportive, care, measuresclinicians, treating, patients, advanced, hcc, face, significant, challenges, many, patients, present, cirrhosis, comorbidities, impact, treatment, tolerability, adequate, assessment, liver, function, management, comorbidities, therefore, essential, hcc, treatment, [], provide, guidance, management, aes, associated, cabozantinib, patients, advanced, hcc, briefly, review, outcomes, celestial, focus, managing, common, aes, experienced, patients, based, current, evidence, literature, well, clinical, experience, , , cabozantinib, a0hepatocellular, carcinoma, celestialin, phase, iii, celestial, study, patients, advanced, hcc, randomized, , treatment, cabozantinib, a0mg, daily, placebo, [], patients, required, prior, treatment, sorafenib, received, two, prior, systemic, regimens, hcc, eastern, cooperative, oncology, group, ecog, performance, status, ps, , , childpugh, class, liver, function, see, electronic, supplementary, table, a0, definition, also, required, second, planned, interim, analysis, , patients, randomized, study, met, primary, endpoint, significantly, improved, os, cabozantinib, relative, placebo, median, os, , versus, , months, hazard, ratio, , , confidence, interval, [ci], , p, a0, a0, cabozantinib, also, improved, pfs, median, , versus, , months, hazard, ratio, , , ci, , p, a0, a0, well, objective, response, rate, per, response, evaluation, criteria, solid, tumors, recist, v11, , vs, a0, p, a0, a0, , , safety, a0tolerabilityallcause, ae, rates, generally, higher, cabozantinib, arm, placebo, arm, common, aes, experienced, patients, cabozantinib, a0, versus, placebo, arms, included, diarrhea, , vs, , decreased, appetite, , vs, , palmarplantar, erythrodysesthesia, ppe, , vs, , fatigue, , vs, , nausea, , vs, , hypertension, , vs, , vomiting, , vs, , asthenia, , vs, , increased, aspartate, aminotransferase, ast, , vs, , fig, a0, common, grade, , aes, cabozantinib, versus, placebo, arms, ppe, , vs, , hypertension, , vs, , increased, ast, , vs, , fatigue, , vs, , diarrhea, , vs, , overall, safety, profile, cabozantinib, consistent, phase, iii, studies, rcc, mtc, gastrointestinal, gi, events, ppe, fatigue, hypertension, common, aes, experienced, patients, across, studies, [, , ]in, addition, supportive, care, measures, protocolspecified, dose, modification, including, dose, interruption, reduction, utilized, manage, aes, [], eightyfour, percent, patients, cabozantinib, arm, ae, led, dose, interruption, , dose, interruption, due, grade, , ae, [], sixtytwo, percent, patients, least, one, dose, reduction, due, ae, [], , dose, reduced, due, grade, , ae, [], thirtythree, percent, patients, second, dose, reduction, [], median, time, first, second, dose, reduction, cabozantinib, arm, a0days, a0days, respectively, ppe, event, commonly, led, dose, interruption, , dose, reduction, , followed, diarrhea, , , fatigue, , , [], although, patients, receiving, cabozantinib, required, dose, interruption, rate, discontinuation, due, treatmentrelated, aes, relatively, low, , cabozantinib, arm, vs, , placebo, arm, indicating, majority, aes, adequately, managed, dose, modification, supportive, care, cabozantinib, group, aes, led, treatment, discontinuation, ¥, a0, patients, ppe, fatigue, decreased, appetite, diarrhea, nausea, subgroup, analysis, patients, 0cae, grade, [grade, , grade, ]fatigue, , [, ]hypertension, , [, ]increased, ast, , [, ]increased, alt, , [, ]asthenia, , [, ]nausea, , [, ]vomiting, , [, ]decrease, appetite, , [, ]weight, loss, , [, ]diarrhea, , [, ]constipation, , [, ]abdominal, pain, , [, ]ppe, , [, ]fig, , , , incidence, , rates, , , select, , aes, , experienced, , , patients, , hcc, receiving, cabozantinib, celestial, trial, [], aes, , color, , coded, , , system, , blue, , gastrointestinal, , purple, , skin, , subcutaneous, tissue, green, constitutional, orange, hepatic, disorders, red, , cardiovascularhematological, , disorders, , ae, , adverse, , event, , alt, alanine, aminotransferase, ast, aspartate, aminotransferase, hcc, hepatocellular, carcinoma, ppe, palmarplantar, erythrodysesthesiawho, received, sorafenib, prior, treatment, hcc, duration, prior, sorafenib, appear, impact, types, rates, grade, , aes, []generally, common, aes, emerged, first, , weeks, treatment, fig, a0, however, clinicians, aware, infrequent, serious, events, occur, later, phases, treatment, hemorrhagic, events, grade, , higher, reported, , patients, cabozantinib, arm, including, five, patients, , grade, , event, bleeding, complications, associated, antiangiogenic, therapies, may, arise, result, reduced, vascular, integrity, [], median, time, onset, hemorrhagic, events, a0weeks, celestial, grade, , higher, rare, serious, aes, patients, receiving, cabozantinib, included, fistulas, , patients, gi, perforations, , arterial, , venous, mixed, thrombotic, events, , [], median, time, first, occurrence, approximately, a0weeks, gi, perforations, , weeks, venous, arterial, thromboembolisms, , weeks, fistulas, [], two, patients, cabozantinib, arm, , developed, childpugh, c, ie, decompensated, cirrhosis, week, , assessment, []reversible, posterior, leukoencephalopathy, syndrome, rpls, syndrome, subcortical, vasogenic, edema, diagnosed, magnetic, resonance, imaging, reported, cabozantinib, tkis, [, ], although, rpls, events, celestial, [], clinicians, aware, symptoms, include, headaches, seizures, confusion, changes, vision, altered, mental, function, [, ], osteonecrosis, jaw, onj, whereby, necrotic, jaw, bone, becomes, exposed, another, rare, serious, ae, associated, tkis, including, cabozantinib, [], although, onj, events, reported, study, [], use, antiresorptive, drugs, patients, bone, metastases, also, associated, development, onj, []a, post, hoc, analysis, estimated, incremental, qualityadjusted, lifeyears, accrued, cabozantinib, compared, placebo, using, fivedimension, fivelevel, euroqol, questionnaire, [], cabozantinib, treatment, associated, initial, decline, mean, total, qualityadjusted, lifeyears, first, , a0months, relative, placebo, followed, longterm, improvement, significantly, greater, observed, placebo, p, a0, a0management, cabozantinibassociated, adverse, events, patients, hepatocellular, carcinoma, 0c, fig, , , , rates, , timing, select, aes, patients, hcc, receiving, cabozantinib, celestial, trial, size, circle, proportional, ae, rate, aes, color, coded, system, blue, gastrointestinal, purple, skin, subcutaneous, tissue, green, constitutional, orange, hepatic, disorders, red, cardiovascularhematological, disorders, black, generalother, ae, adverse, event, ate, arterial, thrombotic, event, gi, gastrointestinal, gr, grade, hcc, hepatocellular, carcinoma, ppe, palmarplantar, erythrodysesthesia, vte, venous, thrombotic, eventmedian, time, first, dosereduction, , mg, weeksg, a0schwartz, et, almedian, time, seconddose, reduction, , mg, weeksfistulas, hemorrhage, gr, , ates, vte, wound, complication, gi, perforations, hepatic, encephalopathy, diarrhea, ppe, hypertension, median, time, first, occurrence, weeks, , , factors, affecting, tolerability, a0cabozantinib, , , comorbiditieshcc, emerges, primarily, older, adults, [], addition, underlying, hcc, etiology, older, adults, hcc, likely, additional, comorbidities, cardiovascular, pulmonary, disease, [], uncommon, patients, hcc, multiple, comorbidities, [], liver, cirrhosis, compromised, liver, function, decreased, hepatic, reserve, major, risk, factor, hcc, development, hccrelated, comorbidities, include, hepatitis, b, virushepatitis, c, virus, infection, alcoholic, liver, disease, nash, diabetes, [], addition, metabolic, syndrome, characterized, hyperlipidemia, hypertension, linked, development, nafld, may, progress, nash, cirrhosis, finally, hcc, [], patients, hcc, assessment, liver, function, key, step, treatment, decisionmaking, [], patients, moderate, severe, hepatic, impairment, predominantly, excluded, clinical, trials, hcc, therefore, treatment, patients, complicated, lack, prospective, clinical, data, well, competing, comorbidities, []although, number, patients, hcc, prior, transplant, limited, patients, generally, excluded, clinical, trials, treatment, complicated, need, immunosuppression, tkis, may, used, treat, posttransplant, hcc, recurrence, although, supporting, data, limited, use, tkis, patients, complex, treatment, decisions, involve, collaboration, oncology, transplant, medicine, care, teams, use, sorafenib, patients, receiving, mammalian, target, rapamycin, inhibitorbased, immunosuppression, associated, increased, risk, fatal, bleeding, [, ], immunotherapies, associated, increased, risk, rejection, posttransplant, patients, [], , , cabozantinib, clearance, a0exposuretkis, associated, high, interpatient, variability, clearance, exposure, may, affect, efficacy, tolerability, variability, may, due, variety, factors, including, genetic, background, drugdrug, interactions, drugfood, interactions, renal, hepatic, impairment, [], evidenced, exposureresponse, modeling, patients, low, clearance, cabozantinib, may, higher, exposure, increased, risk, developing, certain, aes, [, ], awareness, nuances, may, help, clinicians, mitigate, effects, thereby, balancing, efficacy, tolerability, , , hepatic, a0renal, impairmentaccording, pharmacokinetic, analyses, patients, hcc, tumor, types, mild, hepatic, impairment, predicted, minimal, effect, cabozantinib, exposure, [], therefore, adjustment, recommended, 60mg, starting, dose, necessary, patients, childpugh, 0cliver, function, [, ], data, pharmacokinetics, cabozantinib, patients, moderate, childpugh, b, severe, childpugh, c, hepatic, impairment, limited, [], per, us, food, drug, administration, fda, prescribing, information, starting, dose, cabozantinib, reduced, , mg, patients, moderate, hepatic, impairment, cabozantinib, recommended, patients, severe, hepatic, impairment, [], note, european, summary, product, characteristics, smpc, recommend, dose, adjustments, moderate, hepatic, impairment, owing, limited, data, [], patients, hcc, increased, exposure, due, hepatic, impairment, considered, intolerable, aes, develop, dose, modification, undertaken, recommended, fig, a0, [, ], cabozantinib, used, caution, patients, mild, moderate, renal, impairment, owing, potential, increased, exposure, although, dose, adjustments, necessary, cabozantinib, recommended, use, patients, severe, renal, impairment, owing, lack, data, safety, efficacy, population, [, , ], , , drugdrug, a0drugfood, interactionsgiven, range, comorbidities, may, exist, patients, advanced, hcc, important, review, concomitant, medications, potential, interactions, prior, initiation, treatment, cabozantinib, certain, medications, foods, shown, modulate, pharmacokinetics, cabozantinib, may, turn, impact, exposure, levels, efficacy, risk, aes, cabozantinib, metabolized, liver, primarily, enzyme, cytochrome, p450, 3a4, cyp3a4, [], therefore, cyp3a4, inhibitors, inducers, may, impact, exposure, examples, cyp3a4, inducersinhibitors, shown, electronic, supplementary, table, a0, strong, cyp3a4, inhibitorsinducers, avoided, patients, receiving, cabozantinib, concomitant, administration, strong, cyp3a4, inhibitor, necessary, cabozantinib, recommended, dose, initiation, , mg, except, for¢, patients, moderate, hepatic, impairment, coadministration, strong, cyp3a4, inhibitor, initiate, cabozantinib, , mg, ¢, patients, coadministration, strong, cyp3a4, inducer, initiate, cabozantinib, , mg, safety, assessmentno, aesgrade, grade, , ae, onjsupportive, caresee, tables, dosemodificationimprovementtolerableelbarelotnilitnu, esod, dlohgrade, ¤continue, tolerated, dosereduce, dose, , mg, restart, , , , mg, , , mg, , , , mg, , , mg, , , , , mg, , , mg, , , , , mg, , , mg, discontinueimmediate, discontinuation¢, severe, hemorrhage¢, development, gi, perforation, unmanageable, fistula¢, serious, thromboembolic, event, eg, myocardial, infarction, cerebral, infarction¢, hypertensive, crisis, severe, hypertension, despite, optimal, medical, management¢, nephrotic, syndrome¢, reversible, posterior, leukoencephalopathy, syndromefig, , , , cabozantinib, dosing, algorithm, [, ], ae, adverse, event, cyp3a4, cytochrome, p450, 3a4, gi, gastrointestinal, onj, osteonecrosis, jawmanagement, cabozantinibassociated, adverse, events, patients, hepatocellular, carcinoma, 0c, g, a0schwartz, et, aldose, reduced, a0mg, example, , a0mg, [], conversely, cabozantinib, dose, increased, a0mg, strong, cyp3a4, inducers, need, coadministered, [, ]cabozantinib, taken, food, may, affect, absorption, [], label, recommends, cabozantinib, taken, least, , h, least, , h, eating, [], grapefruit, grapefruit, juice, strong, cyp3a4, inhibitors, avoided, [, ]cabozantinib, may, used, caution, patients, receiving, concurrent, antiarrhythmics, qtprolonging, agents, [], based, study, patients, mtc, received, daily, 140mg, capsule, dose, cabozantinib, recommended, indication, mean, deltadelta, qt, interval, increased, approximately, , a0ms, upper, , cis, exceeding, , ms, [], increase, within, range, considered, acceptable, oncology, drugs, setting, [], patient, aforementioned, study, celestial, confirmed, qtcf, qt, corrected, using, fridericias, method, a0, ms, [], considered, clinically, significant, [], patients, receiving, cabozantinib, monitoring, periodic, electrocardiogram, electrolyte, measurements, may, advisable, particularly, patients, risk, factors, cardiac, disease, prior, history, qt, prolongation, [], concomitant, use, proton, pump, inhibitors, ppis, esomeprazole, affect, cabozantinib, exposure, levels, [], however, ppis, may, cause, hypomagnesemia, linked, increased, risk, qt, prolongation, [], therefore, coadministration, ppis, cabozantinib, undertaken, caution, following, individualized, assessment, patients, baseline, magnesium, levels, concomitant, medications, may, also, influence, qt, , , pretreatment, assessmentsgiven, heterogeneity, hcc, patient, population, complexity, associated, comorbidities, concomitant, medications, patients, undergo, comprehensive, assessment, medical, history, prior, initiation, treatment, cabozantinib, ideally, multidisciplinary, care, team, include, oncology, pharmacist, [], brown, bag, medication, review, carried, prior, treatment, initiation, [], whereby, patient, brings, current, medications, including, overthecounter, medicines, vitamins, herbal, remedies, etc, therapeutic, duplications, eliminated, example, concomitant, ppis, histamine, h2, antagonists, h2, blockers, switching, deprescribing, considered, possible, minimize, risk, drugdrug, interactions, , , adverse, event, managementthe, ae, profile, cabozantinib, generally, similar, vegfrtargeting, tkis, girelated, aes, fatigue, ppe, hypertension, common, aes, [], aes, occur, less, frequently, also, significant, impact, quality, life, qol, treatment, adherence, mucosal, inflammation, [], hepatobiliary, aes, elevated, ast, alanine, aminotransferase, alt, bilirubin, particularly, relevant, context, advanced, hcc, need, carefully, monitoredprophylactic, supportive, care, measures, common, cabozantinibassociated, aes, grade, , tolerable, grade, , outlined, tables, a0, , , , discussed, upcoming, sections, symptom, gradings, summarized, electronic, supplementary, table, a0, dose, interruption, recommended, management, intolerable, grade, , aes, resolved, supportive, care, measures, grade, , aes, fig, a0, [, ], cabozantinib, may, reinitiated, reduced, dose, event, resolves, grade, ¤, a0, , , palmarplantar, erythrodysesthesiappe, one, common, events, associated, anticancer, therapies, including, vegfrtargeting, multikinase, inhibitors, [], ppe, characterized, pain, redness, tingling, swelling, hands, feet, [], presentation, may, vary, according, etiologic, agent, ppe, induced, tkis, typically, localized, pressurebearing, areas, contrast, caused, chemotherapy, diffuse, pattern, hypothesized, inhibition, multiple, angiogenic, pathways, tkis, may, compromise, repair, capillary, microtrauma, areas, exposed, mechanical, stress, hands, feet, [, ], although, lifethreatening, ppe, rapidly, progress, debilitating, condition, negatively, impacting, qol, [, ]prophylaxis, prompt, management, emerging, symptoms, may, help, minimize, impact, ppe, qol, adherence, table, a0, prophylactic, measures, predominantly, involve, skin, care, practices, remove, hyperkeratotic, areas, minimize, friction, damage, prior, start, treatment, [, ], recommendations, include, use, thick, cotton, gloves, socks, padded, insoles, shoes, avoidance, heat, friction, hands, feet, [, ], patients, potentially, predisposing, comorbidities, peripheral, neuropathy, [, ], well, patients, persistent, symptoms, may, benefit, involvement, podiatrist, andor, dermatologist, within, multidisciplinary, care, team, [], treatment, strategies, involve, moisturization, prevention, infection, analgesia, [, , ], monitoring, crucial, emerging, symptoms, proactively, managed, patients, assessed, baseline, 0ctable, , , , adverse, event, management, strategiespalmarplantar, erythrodysesthesia, ppe, ppeprophylaxisprovide, education, prophylactic, skin, care, starting, treatment, []advise, manicure, pedicure, treatment, remove, hyperkeratotic, areas, [, ]protect, sensitive, areas, recommend, sunscreen, spf, protection, ¥, a0, thick, cotton, gloves, socks, padded, insoles, wellfitting, shoes, avoid, heat, sources, use, cooling, aids, avoid, activities, may, cause, force, rubbing, hands, feet, eg, heavy, lifting, dish, washing, [, , ], delegate, tasks, caregiversadvise, optimal, hand, cleaning, avoid, fragrancedfoaming, soaps, hand, sanitizers, containing, alcohol, ensure, hands, dried, thoroughly, cleaning, []prophylactically, administer, keratolytic, cream, eg, , urea, [, ]monitor, regularly, order, proactively, manage, skin, toxicities, evaluate, baseline, monitor, weekly, first, , months, monthly, thereafter, [, ]supportive, carecontinue, prophylactic, measures, []maintain, moisture, skin, using, emollients, [, , ]consider, topical, treatment, salicylic, acid, urea, , cream, either, alone, tazarotene, cream, , fluorouracil, cream, andor, clobetasol, , cream, topical, analgesics, may, added, pain, control, [, , ]topical, cortisone, clobetasol, , may, also, used, consider, oral, analgesics, eg, nsaids, pregabalin, cautious, use, opioids, [, , ]consult, dermatologist, drain, blisters, remove, hyperkeratotic, areas, []to, prevent, infection, cracked, skin, soak, equal, parts, vinegar, water, , min, per, day, [], a0antibiotics, prescribed, evidence, infection, [], a0there, limited, evidence, use, pyridoxine, vitamin, b6, []nsaid, nonsteroidal, antiinflammatory, drug, spf, sun, protection, factortable, , , , adverse, event, management, strategiesfatigue, fatigueprophylaxisprovide, patient, education, fatigue, management, tools, available, support, []establish, baseline, fatigue, levels, fatigue, scale, remeasure, regularly, patient, visits, []ensure, adequate, fluid, nutritional, intake, []advise, behavioral, modifications, balancing, rest, physical, activity, recommendations, include, relaxation, massage, yoga, aerobic, resistance, exercise, programs, energy, conservation, strategies, []assess, thyroid, function, prior, treatment, monitor, treatment, [, ]supportive, carerule, alternative, causes, fatigue, eg, anemia, endocrine, disorders, hypothyroidism, pain, dehydration, hypercalcemia, depressionanxiety, [, ]advise, patient, increase, activity, consider, referral, physical, therapist, []consider, referral, nutritional, counselor, nutritional, therapy, []incorporate, psychosocial, measures, including, cognitive, therapy, social, support, biofeedback, sleep, therapy, []incorporate, management, psychostimulants, eg, methylphenidate, [, ], corticosteroids, eg, methylprednisolone, []owing, effects, cyp3a45, substrates, including, cabozantinib, longterm, use, modafinil, avoided, []cyp3a4, cytochrome, p450, 3a4, cyp2c19, cytochrome, p450, 2c19management, cabozantinibassociated, adverse, events, patients, hepatocellular, carcinoma, 0c, g, a0schwartz, et, altable, , , , adverse, event, management, strategiesgastrointestinal, gastrointestinaldiarrheaprophylaxisinstruct, patients, monitor, food, fluid, intake, [], a0recommended, water, intake, per, day, beverages, food, [], , l, , oz, women, , l, , oz, men, a0advise, patients, keep, stool, diary, promptly, report, diarrhea, healthcare, provider, [, ]advise, patients, avoid, foods, may, cause, gi, events, lactosecontaining, foods, caffeine, highfat, highfiber, food, eg, nuts, seeds, legumes, raw, fruit, vegetables, [, ]implement, dehydration, prevention, management, oral, rehydration, electrolytes, []supportive, careadminister, loperamide, first, sign, diarrhea, [, , ], a0, mg, orally, followed, , mg, every, , h, , h, last, bowel, movement, maximum, , mg, , h, a0for, chronic, diarrhea, , mg, twice, daily, titrated, needed, a0alternatives, loperamide, include, diphenoxylate, tincture, opium, []implement, supportive, dietary, modifications, continuous, oral, hydration, correction, fluid, electrolytes, small, frequent, meals, avoid, lactosecontaining, food, drink, [, ], a0the, brat, bananas, rice, applesauce, toast, diet, may, help, alleviate, mild, diarrhea, []if, signs, severe, dehydration, administer, iv, fluid, replacement, isotonic, saline, balanced, salt, solution, []rule, nontreatmentrelated, causes, eg, infectious, diarrhea, []decreased, appetiteprophylaxisadvise, patients, monitor, appetite, weight, []encourage, patients, consume, highprotein, calorierich, food, fruit, vegetables, nutritional, supplements, may, snack, throughout, day, [, ]advise, patients, preprepare, freeze, nutritional, preferred, food, []supportive, caretreat, underlying, nausea, []consider, involving, dietitian, may, recommend, scheduled, eating, times, []recommend, highcalorie, diet, []provide, dietary, education, alongside, dietary, modifications, andor, nutritionalvitamin, supplements, []use, pharmacologic, agent, stimulate, appetite, cb1, receptor, agonist, dronabinol, [, ], systemic, corticosteroid, methylprednisolone, [, ], progestin, megestrol, acetate, [, ], mirtazapine, [, ]nauseavomitingprophylaxisassess, risk, factors, nauseavomiting, prior, treatment, []metoclopramide, may, administered, prophylactically, []advise, patients, avoid, foods, overly, sweet, greasy, fried, spicy, []supportive, careantiemetic, agents, dopamine, receptor, antagonists, eg, metoclopramide, prochlorperazine, 5ht3, receptor, agonists, eg, ondansetron, recommended, management, nausea, vomiting, [, ], a0certain, nk1, receptor, agonists, eg, aprepitant, netupitant, dexamethasone, inducers, inhibitors, andor, substrates, cyp3a4, thus, alter, cabozantinib, exposure, [, ], however, potential, ondansetron, prolong, qt, interval, must, also, considered, [], moderate, evidence, olanzapine, antipsychotic, drug, blocks, multiple, neurotransmitters, antiemetic, setting, [], 0ctable, , , , continuedmucosal, inflammationstomatitisprophylaxisa, comprehensive, dental, examination, conducted, prior, treatment, identify, potential, complications, []mitigation, potential, risk, factors, [, ], a0modification, illfitting, dentures, a0appropriate, care, preexisting, dental, problems, caries, ulcers, etcregular, oral, assessments, conducted, throughout, treatment, [, ]educate, patients, good, oral, hygiene, oral, care, protocols, including, written, instructions, [], a0the, oral, cavity, washed, using, salinecontaining, mouthwash, four, times, daily, dentures, regularly, cleaned, []painful, stimuli, eg, smoking, alcohol, hot, fooddrink, sharp, spicy, food, avoided, [, ]supportive, caretreat, pain, doxepin, , mouthwash, viscous, lidocaine, , [, ]lactobacillus, lozenges, may, used, reduce, inflammation, []obtain, bacterialviral, culture, oral, infection, suspected, treat, infection, clinically, indicated, []5ht3, 5hydroxytryptamine, cb1, cannabinoid, cyp3a4, cytochrome, p450, 3a4, gi, gastrointestinal, iv, intravenous, nk, neurokinintable, , , , adverse, event, management, strategieshypertension, hypertensionprophylaxismonitor, bp, initiation, cabozantinib, using, minimum, two, standardized, bp, measurements, alongside, patient, history, physical, assessment, directed, laboratory, evaluation, instrument, test, determine, cardiovascular, risk, factors, [, ]educate, patients, bp, selfmonitoring, advise, keep, bp, log, []bp, well, controlled, prior, initiating, cabozantinib, ensure, patients, already, prescribed, antihypertensive, therapy, adherent, therapy, titrated, effective, doses, [, ]check, potential, drugdrug, interactions, existing, antihypertensive, agents, cabozantinib, supplementary, table, a0consider, effects, concomitant, medications, bp, eg, antiinflammatory, drugs, increase, bp, opiates, lower, bp, []monitor, bp, cabozantinib, treatment, weekly, first, cycle, every, ¥, a0, weeks, thereafter, []supportive, careadd, antihypertensive, medications, increase, dose, existing, medication, indicated, [, ]patients, portal, hypertension, treated, nonselective, betablockers, []the, antihypertensive, agent, carefully, considered, owing, potential, inhibition, cyp3a4, [, ], supplementary, table, a0, a0thiazides, angiotensinconverting, enzyme, inhibitors, angiotensin, receptor, blockers, may, used, treat, hypertension, known, cyp3a4, substrates, [, ], a0thiazide, diuretics, prescribed, caution, owing, associated, risk, diarrhea, [], a0diltiazem, verapamil, moderate, inhibitors, cyp3a4, [], a0amlodipine, felodipine, lercanidipine, nisoldipine, nifedipine, considered, cyp3a4, inhibitors, []bp, blood, pressure, cyp3a4, cytochrome, p450, 3a4and, monitored, least, weekly, first, , months, treatment, monthly, thereafter, [, ], close, monitoring, early, stages, treatment, need, involve, weekly, visitsphone, calls, clinician, nurse, pharmacist, may, facilitate, monitoring, scheduled, appointments, [], patients, encouraged, report, early, signs, ppe, healthcare, provider, [], may, also, reassuring, patients, know, early, reporting, management, aes]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |[, cabozantinib, an, oral, multikinase, inhibitor, whose, targets, include, vascular, endothelial, growth, factor, receptors, met, tam, family, kinases, tyro3, axl, mer, cabozantinib, approved, patients, with, advanced, hepatocellular, carcinoma, who, have, been, previously, treated, with, sorafenib, based, on, improved, overall, survival, progressionfree, survival, relative, placebo, phase, iii, celestial, study, during, celestial, most, common, adverse, events, aes, experienced, by, patients, receiving, cabozantinib, included, palmarplantar, erythrodysesthesia, fatigue, gastrointestinalrelated, events, hypertension, these, aes, can, significantly, impact, treatment, tolerability, patient, quality, life, however, aes, can, be, effectively, managed, with, supportive, care, dose, modifications, during, celestial, more, than, half, patients, receiving, cabozantinib, required, dose, reduction, while, rate, treatment, discontinuation, due, aes, low, here, we, review, safety, profile, cabozantinib, provide, guidance, on, prevention, management, more, common, aes, based, on, current, evidence, from, literature, as, well, as, our, clinical, experience, we, consider, specific, challenges, faced, by, clinicians, treating, patient, population, discuss, factors, that, may, affect, exposure, tolerability, cabozantinib, , introductionthere, has, been, marked, increase, liver, cancer, deaths, recent, years, , there, were, a0, new, cases, liver, cancer, worldwide, liver, cancer, accounted, almost, , deaths, making, it, sixth, most, prevalent, cancer, worldwide, [], most, common, primary, malignancy, liver, hepatocellular, carcinoma, hcc, [], frequency, burden, etiology, hcc, vary, across, geographic, regions, populations, but, are, linked, prevalence, predisposing, chronic, hepatic, conditions, such, as, electronic, supplementary, material, , online, version, , , s1152, , , contains, supplementary, material, which, available, authorized, userskey, points, cabozantinib, represents, treatment, option, patients, with, advanced, hepatocellular, carcinoma, who, progress, after, sorafenibadverse, events, associated, with, cabozantinib, may, be, effectively, managed, with, supportive, care, dose, modifications, thereby, allowing, patients, continue, treatment, at, appropriate, dose, with, minimum, interruptionstudies, cabozantinib, firstline, setting, are, ongoing, by, understanding, safety, profile, drug, clinicians, will, be, able, balance, efficacy, with, tolerability, each, patient, , , gabriel, schwartz, , , gabrielschwartzucsfedu, , gastrointestinal, medical, oncology, clinic, university, a0california, san, francisco, , fourth, st, fourth, floor, san, a0francisco, ca, a0, usaindiana, university, health, simon, cancer, center, indianapolis, usa, , , department, a0medicine, university, a0california, san, francisco, san, a0francisco, ca, usairccs, istituto, clinico, humanitas, rozzano, milan, italy, viral, hepatitis, nonalcoholic, fatty, liver, disease, nafld, or, nonalcoholic, steatohepatitis, nash, which, generally, develop, setting, cirrhosis, [, ], recent, years, incidence, nonviral, hcc, has, increased, while, proportion, hcc, cases, related, viral, hepatitis, has, declined, [, ], additional, risk, factors, hcc, include, alcohol, consumption, smoking, obesity, diabetes, [], as, epidemiology, these, conditions, has, evolved, so, too, has, etiology, hcc, []vol0123456789, 0c, g, a0schwartz, et, alfor, patients, with, advanced, hcc, vascular, endothelial, growth, factor, receptor, vegfrtargeting, tyrosine, kinase, inhibitor, tki, sorafenib, has, been, standard, care, [], however, treatment, landscape, has, been, transformed, recent, years, with, introduction, newer, tkis, immunotherapies, monoclonal, antibody, therapies, [], provides, clinicians, patients, with, variety, treatment, options, based, on, mechanism, action, safety, profilecabozantinib, , , , multikinase, , inhibitor, , that, , targets, vegfr, , met, tam, family, kinases, tyro3, axl, mer, ret, ros1, kit, trkb, flt3, tie2, [, ], several, which, are, implicated, tumor, growth, angiogenesis, immune, regulation, [], vegfr, met, axl, have, been, implicated, pathogenesis, hcc, [], capsule, formulation, cabozantinib, first, approved, , treatment, progressive, metastatic, medullary, thyroid, carcinoma, mtc, [], tablet, formulation, not, bioequivalent, or, interchangeable, with, capsule, [], subsequently, approved, patients, with, advanced, renal, cell, carcinoma, rcc, [, ], more, recently, patients, with, advanced, hcc, who, have, received, prior, sorafenib, [, ], approval, hcc, based, on, outcomes, from, pivotal, phase, iii, celestial, trial, which, showed, significantly, improved, overall, survival, os, progressionfree, survival, pfs, with, cabozantinib, relative, placebo, patients, who, received, prior, sorafenib, [], safety, profile, cabozantinib, manageable, nearly, all, patients, receiving, cabozantinib, experienced, an, adverse, event, ae, but, these, were, effectively, managed, with, dose, modification, supportive, care, measuresclinicians, treating, patients, with, advanced, hcc, can, face, significant, challenges, as, many, patients, present, with, cirrhosis, comorbidities, that, can, impact, treatment, tolerability, adequate, assessment, liver, function, management, comorbidities, are, therefore, essential, before, during, hcc, treatment, [], here, we, provide, guidance, on, management, aes, associated, with, cabozantinib, patients, with, advanced, hcc, we, briefly, review, outcomes, from, celestial, focus, on, managing, some, more, common, aes, experienced, by, patients, based, on, current, evidence, from, literature, as, well, as, our, own, clinical, experience, , , cabozantinib, a0hepatocellular, carcinoma, celestialin, phase, iii, celestial, study, patients, with, advanced, hcc, were, randomized, , treatment, with, cabozantinib, a0mg, daily, or, placebo, [], patients, were, required, have, had, prior, treatment, with, sorafenib, could, have, received, up, two, prior, systemic, regimens, hcc, eastern, cooperative, oncology, group, ecog, performance, status, ps, , or, , childpugh, class, liver, function, see, electronic, supplementary, table, a0, definition, were, also, required, at, second, planned, interim, analysis, , patients, had, been, randomized, study, met, its, primary, endpoint, with, significantly, improved, os, with, cabozantinib, relative, placebo, median, os, , versus, , months, hazard, ratio, , , confidence, interval, [ci], , p, a0, a0, cabozantinib, also, improved, pfs, with, median, , versus, , months, hazard, ratio, , , ci, , p, a0, a0, as, well, objective, response, rate, per, response, evaluation, criteria, solid, tumors, recist, v11, , vs, a0, p, a0, a0, , , safety, a0tolerabilityallcause, ae, rates, were, generally, higher, cabozantinib, arm, than, placebo, arm, some, more, common, aes, experienced, by, patients, cabozantinib, a0, versus, placebo, arms, included, diarrhea, , vs, , decreased, appetite, , vs, , palmarplantar, erythrodysesthesia, ppe, , vs, , fatigue, , vs, , nausea, , vs, , hypertension, , vs, , vomiting, , vs, , asthenia, , vs, , increased, aspartate, aminotransferase, ast, , vs, , fig, a0, most, common, grade, , aes, cabozantinib, versus, placebo, arms, were, ppe, , vs, , hypertension, , vs, , increased, ast, , vs, , fatigue, , vs, , diarrhea, , vs, , overall, safety, profile, cabozantinib, consistent, with, those, from, phase, iii, studies, rcc, mtc, with, gastrointestinal, gi, events, ppe, fatigue, hypertension, being, most, common, aes, experienced, by, patients, across, studies, [, , ]in, addition, supportive, care, measures, protocolspecified, dose, modification, including, dose, interruption, reduction, utilized, manage, aes, [], eightyfour, percent, patients, cabozantinib, arm, had, an, ae, that, led, dose, interruption, , had, dose, interruption, due, grade, , ae, [], sixtytwo, percent, patients, had, at, least, one, dose, reduction, due, an, ae, [], , dose, reduced, due, grade, , ae, [], thirtythree, percent, patients, had, second, dose, reduction, [], median, time, first, second, dose, reduction, cabozantinib, arm, a0days, a0days, respectively, ppe, event, that, most, commonly, led, dose, interruption, , dose, reduction, , followed, by, diarrhea, , , fatigue, , , [], although, most, patients, receiving, cabozantinib, required, dose, interruption, rate, discontinuation, due, treatmentrelated, aes, relatively, low, , cabozantinib, arm, vs, , placebo, arm, indicating, that, majority, aes, were, adequately, managed, with, dose, modification, supportive, care, cabozantinib, group, aes, that, led, treatment, discontinuation, ¥, a0, patients, were, ppe, fatigue, decreased, appetite, diarrhea, nausea, subgroup, analysis, patients, 0cae, any, grade, [grade, , grade, ]fatigue, , [, ]hypertension, , [, ]increased, ast, , [, ]increased, alt, , [, ]asthenia, , [, ]nausea, , [, ]vomiting, , [, ]decrease, appetite, , [, ]weight, loss, , [, ]diarrhea, , [, ]constipation, , [, ]abdominal, pain, , [, ]ppe, , [, ]fig, , , , incidence, , rates, , , select, , aes, , experienced, , by, , patients, , with, hcc, receiving, cabozantinib, during, celestial, trial, [], aes, are, , color, , coded, , by, , system, , blue, , gastrointestinal, , purple, , skin, , subcutaneous, tissue, green, constitutional, orange, hepatic, disorders, red, , cardiovascularhematological, , disorders, , ae, , adverse, , event, , alt, alanine, aminotransferase, ast, aspartate, aminotransferase, hcc, hepatocellular, carcinoma, ppe, palmarplantar, erythrodysesthesiawho, received, sorafenib, as, only, prior, treatment, hcc, duration, prior, sorafenib, did, not, appear, impact, types, or, rates, grade, , aes, []generally, more, common, aes, emerged, first, , weeks, treatment, fig, a0, however, clinicians, should, be, aware, infrequent, or, serious, events, that, can, occur, later, phases, treatment, hemorrhagic, events, grade, , or, higher, were, reported, , patients, cabozantinib, arm, including, five, patients, , with, grade, , event, bleeding, complications, are, associated, with, antiangiogenic, therapies, may, arise, as, result, reduced, vascular, integrity, [], median, time, onset, hemorrhagic, events, a0weeks, celestial, other, grade, , or, higher, rare, but, serious, aes, patients, receiving, cabozantinib, included, fistulas, , patients, gi, perforations, , arterial, , venous, or, mixed, thrombotic, events, , [], median, time, first, occurrence, approximately, a0weeks, gi, perforations, , weeks, venous, arterial, thromboembolisms, , weeks, fistulas, [], two, patients, cabozantinib, arm, , had, developed, childpugh, c, ie, decompensated, cirrhosis, by, week, , assessment, []reversible, posterior, leukoencephalopathy, syndrome, rpls, syndrome, subcortical, vasogenic, edema, diagnosed, by, magnetic, resonance, imaging, has, been, reported, with, cabozantinib, other, tkis, [, ], although, there, were, no, rpls, events, during, celestial, [], clinicians, should, be, aware, symptoms, which, include, headaches, seizures, confusion, changes, vision, or, altered, mental, function, [, ], osteonecrosis, jaw, onj, whereby, necrotic, jaw, bone, becomes, exposed, another, rare, but, serious, ae, associated, with, tkis, including, cabozantinib, [], although, again, there, were, no, onj, events, reported, during, study, [], use, antiresorptive, drugs, patients, with, bone, metastases, also, associated, with, development, onj, []a, post, hoc, analysis, estimated, incremental, qualityadjusted, lifeyears, accrued, with, cabozantinib, compared, with, placebo, using, fivedimension, fivelevel, euroqol, questionnaire, [], cabozantinib, treatment, associated, with, an, initial, decline, mean, total, qualityadjusted, lifeyears, during, first, , a0months, relative, placebo, followed, by, longterm, improvement, that, significantly, greater, than, that, observed, with, placebo, p, a0, a0management, cabozantinibassociated, adverse, events, patients, with, hepatocellular, carcinoma, 0c, fig, , , , rates, , timing, select, aes, patients, with, hcc, receiving, cabozantinib, during, celestial, trial, size, circle, proportional, ae, rate, aes, are, color, coded, by, system, blue, gastrointestinal, purple, skin, subcutaneous, tissue, green, constitutional, orange, hepatic, disorders, red, cardiovascularhematological, disorders, black, generalother, ae, adverse, event, ate, arterial, thrombotic, event, gi, gastrointestinal, gr, grade, hcc, hepatocellular, carcinoma, ppe, palmarplantar, erythrodysesthesia, vte, venous, thrombotic, eventmedian, time, first, dosereduction, , mg, weeksg, a0schwartz, et, almedian, time, seconddose, reduction, , mg, weeksfistulas, hemorrhage, gr, , ates, vte, wound, complication, gi, perforations, hepatic, encephalopathy, diarrhea, ppe, hypertension, median, time, first, occurrence, weeks, , , factors, affecting, tolerability, a0cabozantinib, , , comorbiditieshcc, emerges, primarily, older, adults, [], addition, underlying, hcc, etiology, older, adults, with, hcc, are, likely, have, additional, comorbidities, such, as, cardiovascular, or, pulmonary, disease, [], it, not, uncommon, patients, with, hcc, have, multiple, comorbidities, [], liver, cirrhosis, with, compromised, liver, function, decreased, hepatic, reserve, major, risk, factor, hcc, development, other, hccrelated, comorbidities, include, hepatitis, b, virushepatitis, c, virus, infection, alcoholic, liver, disease, nash, diabetes, [], addition, metabolic, syndrome, characterized, by, hyperlipidemia, hypertension, linked, development, nafld, which, may, progress, nash, cirrhosis, finally, hcc, [], patients, with, hcc, assessment, liver, function, key, step, treatment, decisionmaking, [], patients, with, moderate, or, severe, hepatic, impairment, are, predominantly, excluded, from, clinical, trials, hcc, therefore, treatment, these, patients, complicated, by, lack, prospective, clinical, data, as, well, as, competing, comorbidities, []although, number, patients, with, hcc, prior, an, transplant, limited, these, patients, are, generally, excluded, from, clinical, trials, treatment, complicated, by, need, immunosuppression, tkis, may, be, used, treat, posttransplant, hcc, recurrence, although, supporting, data, are, limited, use, tkis, these, patients, complex, so, treatment, decisions, should, involve, collaboration, between, oncology, transplant, medicine, care, teams, use, sorafenib, patients, receiving, mammalian, target, rapamycin, inhibitorbased, immunosuppression, has, been, associated, with, an, increased, risk, fatal, bleeding, [, ], immunotherapies, are, associated, with, an, increased, risk, an, rejection, posttransplant, patients, [], , , cabozantinib, clearance, a0exposuretkis, are, associated, with, high, interpatient, variability, clearance, exposure, which, may, affect, both, efficacy, tolerability, variability, may, be, due, variety, factors, including, genetic, background, drugdrug, interactions, drugfood, interactions, renal, or, hepatic, impairment, [], as, evidenced, by, exposureresponse, modeling, patients, with, low, clearance, cabozantinib, may, have, higher, exposure, an, increased, risk, developing, certain, aes, [, ], awareness, these, nuances, may, help, clinicians, mitigate, their, effects, thereby, balancing, efficacy, with, tolerability, , , hepatic, a0renal, impairmentaccording, pharmacokinetic, analyses, patients, with, hcc, other, tumor, types, mild, hepatic, impairment, predicted, have, minimal, effect, on, cabozantinib, exposure, [], therefore, adjustment, recommended, 60mg, starting, dose, not, necessary, patients, with, childpugh, 0cliver, function, [, ], data, on, pharmacokinetics, cabozantinib, patients, with, moderate, childpugh, b, or, severe, childpugh, c, hepatic, impairment, are, limited, [], as, per, us, food, drug, administration, fda, prescribing, information, starting, dose, cabozantinib, should, be, reduced, , mg, patients, with, moderate, hepatic, impairment, while, cabozantinib, not, recommended, patients, with, severe, hepatic, impairment, [], note, that, european, summary, product, characteristics, smpc, does, not, recommend, dose, adjustments, moderate, hepatic, impairment, owing, limited, data, [], patients, with, hcc, increased, exposure, due, hepatic, impairment, should, be, considered, if, intolerable, aes, develop, dose, modification, undertaken, as, recommended, fig, a0, [, ], cabozantinib, should, be, used, with, caution, patients, with, mild, or, moderate, renal, impairment, owing, potential, increased, exposure, although, no, dose, adjustments, are, necessary, cabozantinib, not, recommended, use, patients, with, severe, renal, impairment, owing, lack, data, on, safety, efficacy, population, [, , ], , , drugdrug, a0drugfood, interactionsgiven, range, comorbidities, that, may, exist, patients, with, advanced, hcc, it, important, review, all, concomitant, medications, potential, interactions, prior, initiation, treatment, with, cabozantinib, certain, medications, foods, have, been, shown, modulate, pharmacokinetics, cabozantinib, which, may, turn, impact, exposure, levels, efficacy, risk, aes, cabozantinib, metabolized, liver, primarily, by, enzyme, cytochrome, p450, 3a4, cyp3a4, [], therefore, cyp3a4, inhibitors, or, inducers, may, impact, exposure, examples, cyp3a4, inducersinhibitors, are, shown, electronic, supplementary, table, a0, strong, cyp3a4, inhibitorsinducers, should, be, avoided, patients, receiving, cabozantinib, if, concomitant, administration, strong, cyp3a4, inhibitor, necessary, then, cabozantinib, recommended, dose, at, initiation, , mg, except, for¢, patients, with, moderate, hepatic, impairment, or, coadministration, strong, cyp3a4, inhibitor, initiate, cabozantinib, at, , mg, ¢, patients, with, coadministration, strong, cyp3a4, inducer, initiate, cabozantinib, at, , mg, safety, assessmentno, aesgrade, grade, , ae, or, onjsupportive, caresee, tables, dosemodificationimprovementtolerableelbarelotnilitnu, esod, dlohgrade, ¤continue, at, tolerated, dosereduce, dose, by, , mg, restart, , , , mg, , , mg, , , , mg, , , mg, , , , , mg, , , mg, , , , , mg, , , mg, or, discontinueimmediate, discontinuation¢, severe, hemorrhage¢, development, gi, perforation, or, unmanageable, fistula¢, serious, thromboembolic, event, eg, myocardial, infarction, cerebral, infarction¢, hypertensive, crisis, or, severe, hypertension, despite, optimal, medical, management¢, nephrotic, syndrome¢, reversible, posterior, leukoencephalopathy, syndromefig, , , , cabozantinib, dosing, algorithm, [, ], ae, adverse, event, cyp3a4, cytochrome, p450, 3a4, gi, gastrointestinal, onj, osteonecrosis, jawmanagement, cabozantinibassociated, adverse, events, patients, with, hepatocellular, carcinoma, 0c, g, a0schwartz, et, aldose, should, be, reduced, by, a0mg, example, from, , a0mg, [], conversely, cabozantinib, dose, should, be, increased, by, a0mg, if, strong, cyp3a4, inducers, need, be, coadministered, [, ]cabozantinib, should, not, be, taken, with, any, food, as, may, affect, absorption, [], label, recommends, that, cabozantinib, be, taken, at, least, , h, before, or, at, least, , h, after, eating, [], grapefruit, grapefruit, juice, are, strong, cyp3a4, inhibitors, should, be, avoided, [, ]cabozantinib, may, be, used, with, caution, patients, who, are, receiving, concurrent, antiarrhythmics, or, other, qtprolonging, agents, [], based, on, study, patients, with, mtc, who, received, daily, 140mg, capsule, dose, cabozantinib, recommended, indication, which, mean, deltadelta, qt, interval, increased, by, approximately, , a0ms, with, upper, , cis, not, exceeding, , ms, [], such, an, increase, within, range, considered, be, acceptable, oncology, drugs, setting, [], no, patient, aforementioned, study, or, celestial, had, confirmed, qtcf, qt, corrected, using, fridericias, method, a0, ms, [], which, considered, clinically, significant, [], patients, receiving, cabozantinib, monitoring, with, periodic, electrocardiogram, electrolyte, measurements, may, be, advisable, particularly, patients, with, risk, factors, such, as, cardiac, disease, or, prior, history, qt, prolongation, [], concomitant, use, proton, pump, inhibitors, ppis, such, as, esomeprazole, does, not, affect, cabozantinib, exposure, levels, [], however, ppis, may, cause, hypomagnesemia, which, linked, an, increased, risk, qt, prolongation, [], therefore, coadministration, ppis, cabozantinib, should, be, undertaken, with, caution, following, an, individualized, assessment, patients, baseline, magnesium, levels, concomitant, medications, that, may, also, influence, qt, , , pretreatment, assessmentsgiven, heterogeneity, hcc, patient, population, complexity, associated, with, comorbidities, concomitant, medications, all, patients, should, undergo, comprehensive, assessment, medical, history, prior, initiation, treatment, with, cabozantinib, ideally, multidisciplinary, care, team, should, include, an, oncology, pharmacist, [], brown, bag, medication, review, should, be, carried, out, prior, treatment, initiation, [], whereby, patient, brings, all, current, medications, including, overthecounter, medicines, vitamins, herbal, remedies, etc, therapeutic, duplications, should, be, eliminated, example, concomitant, ppis, histamine, h2, antagonists, h2, blockers, switching, deprescribing, should, be, considered, where, possible, minimize, risk, drugdrug, interactions, , , adverse, event, managementthe, ae, profile, cabozantinib, generally, similar, that, other, vegfrtargeting, tkis, with, girelated, aes, fatigue, ppe, hypertension, being, most, common, aes, [], other, aes, that, occur, less, frequently, can, also, have, significant, impact, on, quality, life, qol, treatment, adherence, such, as, mucosal, inflammation, [], hepatobiliary, aes, such, as, elevated, ast, alanine, aminotransferase, alt, bilirubin, are, particularly, relevant, context, advanced, hcc, need, be, carefully, monitoredprophylactic, supportive, care, measures, more, common, cabozantinibassociated, aes, grade, , or, tolerable, grade, , are, outlined, tables, a0, , , , discussed, upcoming, sections, symptom, gradings, are, summarized, electronic, supplementary, table, a0, dose, interruption, recommended, management, intolerable, grade, , aes, not, resolved, with, supportive, care, measures, or, any, grade, , aes, fig, a0, [, ], cabozantinib, may, be, reinitiated, at, reduced, dose, once, event, resolves, grade, ¤, a0, , , palmarplantar, erythrodysesthesiappe, one, more, common, events, associated, with, anticancer, therapies, including, vegfrtargeting, multikinase, inhibitors, [], ppe, characterized, by, pain, redness, tingling, swelling, hands, feet, [], presentation, may, vary, according, etiologic, agent, ppe, induced, by, tkis, typically, localized, pressurebearing, areas, contrast, that, caused, by, chemotherapy, which, has, more, diffuse, pattern, it, has, been, hypothesized, that, inhibition, multiple, angiogenic, pathways, by, tkis, may, compromise, repair, capillary, microtrauma, areas, exposed, mechanical, stress, such, as, hands, feet, [, ], although, not, lifethreatening, ppe, can, rapidly, progress, debilitating, condition, negatively, impacting, qol, [, ]prophylaxis, prompt, management, emerging, symptoms, may, help, minimize, impact, ppe, on, qol, adherence, table, a0, prophylactic, measures, predominantly, involve, skin, care, practices, remove, hyperkeratotic, areas, minimize, friction, damage, prior, start, treatment, [, ], recommendations, include, use, thick, cotton, gloves, socks, padded, insoles, shoes, avoidance, heat, or, friction, on, hands, feet, [, ], patients, with, potentially, predisposing, comorbidities, such, as, peripheral, neuropathy, [, ], as, well, as, patients, with, persistent, symptoms, may, benefit, from, involvement, podiatrist, andor, dermatologist, within, their, multidisciplinary, care, team, [], treatment, strategies, involve, moisturization, prevention, infection, analgesia, [, , ], monitoring, crucial, so, that, emerging, symptoms, can, be, proactively, managed, patients, should, be, assessed, at, baseline, 0ctable, , , , adverse, event, management, strategiespalmarplantar, erythrodysesthesia, ppe, ppeprophylaxisprovide, education, on, prophylactic, skin, care, before, starting, treatment, []advise, manicure, pedicure, before, during, treatment, remove, hyperkeratotic, areas, [, ]protect, sensitive, areas, recommend, sunscreen, with, spf, protection, ¥, a0, thick, cotton, gloves, socks, padded, insoles, wellfitting, shoes, avoid, heat, sources, use, cooling, aids, avoid, activities, that, may, cause, force, or, rubbing, on, hands, feet, eg, heavy, lifting, dish, washing, [, , ], delegate, such, tasks, caregiversadvise, on, optimal, hand, cleaning, avoid, fragrancedfoaming, soaps, hand, sanitizers, containing, alcohol, ensure, hands, are, dried, thoroughly, after, cleaning, []prophylactically, administer, keratolytic, cream, eg, , urea, [, ]monitor, regularly, order, proactively, manage, skin, toxicities, evaluate, at, baseline, monitor, up, weekly, first, , months, monthly, thereafter, [, ]supportive, carecontinue, prophylactic, measures, []maintain, moisture, skin, using, emollients, [, , ]consider, topical, treatment, with, salicylic, acid, urea, , cream, either, alone, or, with, tazarotene, cream, or, , fluorouracil, cream, andor, clobetasol, , cream, topical, analgesics, may, be, added, pain, control, [, , ]topical, cortisone, clobetasol, , may, also, be, used, consider, oral, analgesics, eg, nsaids, pregabalin, cautious, use, opioids, [, , ]consult, with, dermatologist, drain, blisters, remove, hyperkeratotic, areas, []to, prevent, infection, cracked, skin, soak, equal, parts, vinegar, water, , min, per, day, [], a0antibiotics, should, be, prescribed, only, if, there, evidence, infection, [], a0there, limited, evidence, use, pyridoxine, vitamin, b6, []nsaid, nonsteroidal, antiinflammatory, drug, spf, sun, protection, factortable, , , , adverse, event, management, strategiesfatigue, fatigueprophylaxisprovide, patient, education, about, fatigue, management, tools, available, support, []establish, baseline, fatigue, levels, with, fatigue, scale, remeasure, regularly, during, patient, visits, []ensure, adequate, fluid, nutritional, intake, []advise, behavioral, modifications, balancing, rest, with, physical, activity, recommendations, include, relaxation, massage, yoga, aerobic, or, resistance, exercise, programs, energy, conservation, strategies, []assess, thyroid, function, prior, treatment, monitor, during, treatment, [, ]supportive, carerule, out, alternative, causes, fatigue, eg, anemia, endocrine, disorders, such, as, hypothyroidism, pain, dehydration, hypercalcemia, or, depressionanxiety, [, ]advise, patient, increase, activity, consider, referral, physical, therapist, []consider, referral, nutritional, counselor, nutritional, therapy, []incorporate, psychosocial, measures, including, cognitive, therapy, social, support, biofeedback, sleep, therapy, []incorporate, management, with, psychostimulants, eg, methylphenidate, [, ], or, corticosteroids, eg, methylprednisolone, []owing, effects, on, cyp3a45, substrates, including, cabozantinib, longterm, use, modafinil, should, be, avoided, []cyp3a4, cytochrome, p450, 3a4, cyp2c19, cytochrome, p450, 2c19management, cabozantinibassociated, adverse, events, patients, with, hepatocellular, carcinoma, 0c, g, a0schwartz, et, altable, , , , adverse, event, management, strategiesgastrointestinal, gastrointestinaldiarrheaprophylaxisinstruct, patients, monitor, food, fluid, intake, [], a0recommended, water, intake, per, day, from, all, beverages, food, [], , l, , oz, women, , l, , oz, men, a0advise, patients, keep, stool, diary, promptly, report, diarrhea, their, healthcare, provider, [, ]advise, patients, avoid, foods, that, may, cause, gi, events, such, as, lactosecontaining, foods, caffeine, highfat, or, highfiber, food, eg, nuts, seeds, legumes, raw, fruit, vegetables, [, ]implement, dehydration, prevention, management, through, oral, rehydration, with, electrolytes, []supportive, careadminister, loperamide, at, first, sign, diarrhea, [, , ], a0, mg, orally, followed, by, , mg, every, , h, until, , h, after, last, bowel, movement, maximum, , mg, , h, a0for, chronic, diarrhea, , mg, twice, daily, titrated, as, needed, a0alternatives, loperamide, include, diphenoxylate, tincture, opium, []implement, supportive, dietary, modifications, continuous, oral, hydration, correction, fluid, electrolytes, small, frequent, meals, avoid, lactosecontaining, food, drink, [, ], a0the, brat, bananas, rice, applesauce, toast, diet, may, help, alleviate, mild, diarrhea, []if, there, are, signs, severe, dehydration, administer, iv, fluid, replacement, isotonic, saline, or, balanced, salt, solution, []rule, out, nontreatmentrelated, causes, eg, infectious, diarrhea, []decreased, appetiteprophylaxisadvise, patients, monitor, their, appetite, weight, []encourage, patients, consume, highprotein, calorierich, food, fruit, vegetables, nutritional, supplements, that, they, may, snack, on, throughout, day, [, ]advise, patients, preprepare, freeze, nutritional, preferred, food, []supportive, caretreat, underlying, nausea, []consider, involving, dietitian, who, may, recommend, scheduled, eating, times, []recommend, highcalorie, diet, []provide, dietary, education, alongside, dietary, modifications, andor, nutritionalvitamin, supplements, []use, pharmacologic, agent, stimulate, appetite, such, as, cb1, receptor, agonist, dronabinol, [, ], systemic, corticosteroid, methylprednisolone, [, ], progestin, megestrol, acetate, [, ], or, mirtazapine, [, ]nauseavomitingprophylaxisassess, risk, factors, nauseavomiting, prior, treatment, []metoclopramide, may, be, administered, prophylactically, []advise, patients, avoid, foods, that, are, overly, sweet, greasy, fried, or, spicy, []supportive, careantiemetic, agents, such, as, dopamine, receptor, antagonists, eg, metoclopramide, prochlorperazine, or, 5ht3, receptor, agonists, eg, ondansetron, are, recommended, management, nausea, or, vomiting, [, ], a0certain, nk1, receptor, agonists, eg, aprepitant, netupitant, dexamethasone, are, inducers, inhibitors, andor, substrates, cyp3a4, thus, could, alter, cabozantinib, exposure, [, ], however, potential, ondansetron, prolong, qt, interval, must, also, be, considered, [], there, moderate, evidence, olanzapine, an, antipsychotic, drug, that, blocks, multiple, neurotransmitters, as, an, antiemetic, setting, [], 0ctable, , , , continuedmucosal, inflammationstomatitisprophylaxisa, comprehensive, dental, examination, should, be, conducted, prior, treatment, identify, potential, complications, []mitigation, potential, risk, factors, [, ], a0modification, illfitting, dentures, a0appropriate, care, preexisting, dental, problems, such, as, caries, ulcers, etcregular, oral, assessments, should, be, conducted, throughout, treatment, [, ]educate, patients, on, good, oral, hygiene, oral, care, protocols, including, written, instructions, [], a0the, oral, cavity, should, be, washed, using, salinecontaining, mouthwash, up, four, times, daily, dentures, should, be, regularly, cleaned, []painful, stimuli, eg, smoking, alcohol, hot, fooddrink, sharp, or, spicy, food, should, be, avoided, [, ]supportive, caretreat, pain, with, doxepin, , mouthwash, or, viscous, lidocaine, , [, ]lactobacillus, lozenges, may, be, used, reduce, inflammation, []obtain, bacterialviral, culture, if, oral, infection, suspected, treat, infection, as, clinically, indicated, []5ht3, 5hydroxytryptamine, cb1, cannabinoid, cyp3a4, cytochrome, p450, 3a4, gi, gastrointestinal, iv, intravenous, nk, neurokinintable, , , , adverse, event, management, strategieshypertension, hypertensionprophylaxismonitor, bp, before, initiation, cabozantinib, using, minimum, two, standardized, bp, measurements, alongside, patient, history, physical, assessment, directed, laboratory, evaluation, an, instrument, test, determine, cardiovascular, risk, factors, [, ]educate, patients, on, bp, selfmonitoring, advise, they, keep, bp, log, []bp, should, be, well, controlled, prior, initiating, cabozantinib, ensure, patients, who, have, already, been, prescribed, antihypertensive, therapy, are, adherent, that, therapy, has, been, titrated, effective, doses, [, ]check, potential, drugdrug, interactions, existing, antihypertensive, agents, with, cabozantinib, supplementary, table, a0consider, effects, concomitant, medications, on, bp, eg, antiinflammatory, drugs, can, increase, bp, opiates, can, lower, bp, []monitor, bp, during, cabozantinib, treatment, weekly, during, first, cycle, every, ¥, a0, weeks, thereafter, []supportive, careadd, antihypertensive, medications, or, increase, dose, existing, medication, as, indicated, [, ]patients, with, portal, hypertension, should, be, treated, with, nonselective, betablockers, []the, antihypertensive, agent, should, be, carefully, considered, owing, potential, inhibition, cyp3a4, [, ], supplementary, table, a0, a0thiazides, angiotensinconverting, enzyme, inhibitors, angiotensin, receptor, blockers, may, be, used, treat, hypertension, are, not, known, cyp3a4, substrates, [, ], a0thiazide, diuretics, should, be, prescribed, with, caution, owing, associated, risk, diarrhea, [], a0diltiazem, verapamil, are, moderate, inhibitors, cyp3a4, [], a0amlodipine, felodipine, lercanidipine, nisoldipine, nifedipine, are, not, considered, be, cyp3a4, inhibitors, []bp, blood, pressure, cyp3a4, cytochrome, p450, 3a4and, monitored, at, least, weekly, first, , months, treatment, monthly, thereafter, [, ], close, monitoring, early, stages, treatment, need, not, involve, weekly, visitsphone, calls, from, clinician, nurse, or, pharmacist, may, facilitate, monitoring, between, scheduled, appointments, [], patients, should, be, encouraged, report, early, signs, ppe, their, healthcare, provider, [], it, may, also, be, reassuring, patients, know, that, early, reporting, management, aes]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,13,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,32,33,35,36,37,38,39,40,42,43,44,45,47,48,50,51,52,54,55,57,58,59,60,61,62,63,66,68,70,71,72,73,74,78,79,80,81,82,85,87,88,89,90,91,92,94,95,97,98,99,101,103,104,105,106,109,110,111,113,114,115,117,118,119,120,123,124,126,129,130,131,134,137,138,139,141,142,143,144,145,146,149,150,153,155,157,158,159,160,161,164,166,167,168,169,171,172,173,174,176,180,181,188,190,191,194,195,196,198,200,201,202,203,204,205,207,209,214,216,218,221,223,224,225,226,227,229,230,231,232,235,236,241,244,249,254,258,260,263,264,265,267,268,270,273,274,275,276,278,279,280,281,283,284,285,286,289,290,294,295,296,299,300,301,303,305,306,307,309,313,315,316,317,320,323,325,326,327,328,330,331,334,335,336,345,352,354,357,359,360,366,367,368,370,372,374,375,376,377,378,379,380,388,396,399,400,402,405,408,412,414,417,422,427,428,429,430,433,436,437,438,439,440,447,456,458,459,461,464,468,469,470,471,474,477,478,482,483,484,486,488,494,496,498,503,508,509,510,513,517,519,520,528,532,534,539,543,546,547,549,550,551,552,554,555,557,562,564,565,567,570,572,574,575,581,588,595,596,608,609,610,618,619,623,630,636,638,644,645,647,648,653,658,659,662,669,670,675,680,681,688,691,692,694,698,699,704,708,711,714,716,723,724,726,729,732,737,751,752,753,754,755,758,765,768,771,773,776,787,789,798,800,803,807,812,818,819,822,823,825,830,836,837,838,840,841,849,852,855,863,865,868,873,877,883,885,892,895,905,906,907,912,915,917,918,919,925,932,936,937,940,942,943,946,947,956,960,962,964,965,967,968,970,971,976,979,988,992,1012,1013,1027,1030,1035,1036,1039,1042,1044,1045,1047,1048,1051,1053,1054,1057,1058,1059,1061,1062,1067,1069,1072,1075,1076,1077,1079,1084,1086,1089,1091,1094,1095,1103,1107,1111,1113,1120,1124,1126,1129,1131,1133,1142,1153,1154,1157,1158,1159,1160,1164,1167,1172,1180,1186,1192,1194,1195,1198,1201,1203,1208,1212,1220,1221,1231,1233,1237,1239,1247,1252,1263,1264,1267,1271,1274,1278,1282,1283,1296,1308,1309,1315,1317,1327,1328,1336,1348,1362,1367,1369,1377,1381,1384,1390,1393,1395,1399,1405,1406,1424,1425,1432,1435,1476,1487,1496,1500,1501,1509,1510,1512,1526,1532,1542,1545,1547,1550,1552,1565,1568,1598,1602,1603,1606,1608,1615,1621,1631,1636,1642,1647,1651,1660,1666,1668,1670,1673,1679,1681,1695,1697,1704,1718,1744,1745,1746,1754,1757,1795,1834,1840,1841,1853,1884,1910,1924,1926,1941,1956,1958,2001,2002,2003,2012,2013,2022,2025,2038,2040,2055,2060,2061,2079,2080,2082,2087,2089,2092,2100,2120,2135,2150,2183,2189,2190,2202,2203,2208,2209,2210,2213,2223,2227,2231,2245,2247,2253,2256,2285,2311,2328,2339,2348,2373,2374,2386,2398,2406,2415,2419,2424,2430,2450,2453,2457,2467,2471,2485,2488,2493,2497,2514,2535,2540,2543,2557,2563,2564,2570,2594,2609,2613,2624,2625,2642,2648,2664,2665,2674,2678,2682,2693,2695,2711,2715,2717,2726,2741,2743,2795,2797,2799,2806,2807,2821,2826,2830,2831,2839,2849,2850,2860,2868,2876,2879,2897,2901,2911,2913,2953,2956,2961,2981,2994,2998,3003,3019,3029,3048,3084,3085,3103,3112,3122,3151,3167,3197,3201,3211,3217,3237,3242,3248,3253,3267,3294,3298,3314,3327,3334,3339,3342,3393,3409,3419,3432,3435,3441,3451,3470,3477,3507,3514,3543,3572,3581,3606,3610,3614,3619,3647,3653,3661,3684,3708,3715,3722,3743,3753,3810,3816,3844,3857,3873,3878,3888,3899,3913,3947,3970,3991,4006,4076,4098,4121,4129,4131,4138,4169,4177,4185,4194,4202,4206,4234,4243,4259,4287,4297,4305,4306,4308,4321,4336,4343,4346,4353,4366,4380,4384,4392,4424,4462,4481,4497,4529,4610,4617,4628,4670,4690,4754,4795,4798,4833,4855,4947,4969,4972,4999,5028,5039,5060,5062,5097,5103,5134,5147,5203,5209,5211,5257,5278,5290,5300,5319,5362,5375,5379,5385,5393,5400,5410,5412,5426,5470,5483,5527,5538,5545,5548,5560,5562,5593,5661,5670,5709,5744,5767,5790,5801,5828,5831,5836,5862,5869,5872,5923,5938,5941,5953,5981,5992,6004,6024,6071,6114,6196,6198,6239,6283,6302,6340,6353,6387,6436,6448,6450,6563,6650,6666,6669,6702,6707,6726,6771,6800,6923,6924,6960,6964,6982,7097,7099,7126,7170,7230,7234,7286,7291,7367,7392,7464,7624,7626,7641,7768,7839,7843,7847,7898,7967,8012,8056,8062,8085,8097,8119,8128,8153,8195,8218,8232,8251,8331,8367,8463,8516,8533,8554,8592,8612,8646,8714,8837,8859,8866,8868,8918,8976,9024,9169,9187,9194,9214,9427,9470,9485,9490,9575,9623,9706,9753,9775,9788,9802,9820,9828,9830,9912,9948,9986,9999,10086,10121,10175,10293,10403,10411,10424,10529,10585,10644,10682,10692,10695,10701,10706,10781,10841,10861,10878,10918,10977,11041,11088,11097,11105,11307,11425,11503,11571,11666,11876,12072,12224,12283,12309,12342,12396,12575,12736,12956,13016,13113,13130,13153,13223,13295,13400,13405,13602,13634,13666,13950,14548,14609,14641,14708,14749,14825,14835,14867,14883,14902,14995,15049,15142,15485,15697,15831,16003,16444,16583,16588,16634,17094,17155,17232,17304,17344,17523,17650,18318,18662,18823,18847,18902,19487,19931,19933,20160,20381,20454,20615,20924,21167,22017,22210,22450,22849,23193,23197,23209,23569,23611,23624,23786,24008,24818,25001,25291,25412,25878,25944,26100,26120,26202,26463,26496,26776,26924,27069,27306,27478,27733,27801,27825,28134,28181,28355,28579,28843,28850,28943,29021,29305,29443,29526,29706,29896,30055,30169,30703,30705,30896,30962,31140,31492,31653,32767,32837,32979,33132,33289,33346,33354,33623,34463,34803,34811,34859,34998,35473,37116,37166,38317,38465,38744,39067,39199,39239,39581,40006,40194,40406,40526,40996,41005,41243,41646,41713,41889,43818,44062,46085,46929,47143,48036,48467,48616,49734,50196,50733,50859,51044,51684,53563,54424,56906,56985,57073,58067,58220,58654,58712,59420,61588,62255,62294,62636,63320,64033,64804,64816,64942,65562,66081,66352,66907,67700,68858,70118,71079,72933,73107,73537,73856,76066,80657,81653,81714,82413,82813,83814,84605,84866,85305,85869,86589,86788,87172,89034,90717,91265,91362,92442,92886,93448,93696,94790,94815,95411,95446,96128,96417,97876,98005,98393,98732,99437,99540,100318,101621,103239,103389,103521,104494,104771,105426,106016,106864,107350,107794,108081,108377,108456,109114,109578,109759,109892,109923,110213,110287,111234,111816,111964,112207,112413,112892,112997,113237,114317,114357,114513,114639,115065,115200,115460,115773,115985,116353,116666,116875,117946,118316,118690,119004,119208,119222,119811,120458,120751,121098,121255,121309,121391,123107,123289,123849,124293,126095,127065,127411,127747,127895,128380,129217,130397,131000,131634,132184,133230,133581,133740,134339,134573,134936,135480,135608,136516,136758,138448,138959,139005,139793,141501,141844,144124,144502,144635,145710,146015,146239,147081,147202,147972,148302,148774,149394,150524,151377,151402,151685,151929,153515,154958,155811,157090,159929,160437,160780,161042,161718,162218,162279,163012,163124,164016,164287,164971,165361,165712,166593,167610,167805,167888,168360,168387,168805,168963,170580,172811,173270,173655,174390,176433,176485,176850,177075,177811,178681,178715,178955,179973,180340,180809,181059,181434,182642,183209,183281,183617,184144,184303,184811,184866,184932,185263,185873,186421,186850,187414,187586,187990,188340,188660,189081,189504,190779,190844,190879,191930,193147,193521,194104,195131,196006,196104,196806,196914,199413,199593,200919,205022,205480,206288,206701,206964,207142,208190,208324,208559,209573,209714,210004,210279,210622,210645],[237.0,95.0,12.0,27.0,26.0,34.0,5.0,79.0,44.0,23.0,11.0,30.0,1.0,48.0,10.0,14.0,17.0,4.0,6.0,5.0,12.0,12.0,15.0,2.0,5.0,5.0,2.0,4.0,3.0,65.0,8.0,6.0,7.0,37.0,5.0,12.0,4.0,12.0,5.0,4.0,10.0,2.0,4.0,5.0,2.0,4.0,34.0,3.0,7.0,3.0,2.0,4.0,2.0,1.0,2.0,5.0,12.0,13.0,4.0,9.0,8.0,15.0,6.0,66.0,1.0,5.0,3.0,1.0,1.0,3.0,4.0,11.0,1.0,1.0,8.0,5.0,3.0,4.0,10.0,1.0,2.0,2.0,10.0,32.0,1.0,1.0,2.0,6.0,2.0,6.0,3.0,2.0,9.0,4.0,6.0,2.0,1.0,3.0,2.0,1.0,13.0,1.0,1.0,11.0,26.0,3.0,4.0,3.0,1.0,1.0,8.0,1.0,3.0,3.0,1.0,4.0,7.0,5.0,3.0,8.0,11.0,3.0,3.0,1.0,6.0,2.0,2.0,3.0,2.0,2.0,16.0,2.0,1.0,7.0,7.0,2.0,3.0,1.0,2.0,2.0,1.0,1.0,12.0,3.0,1.0,1.0,1.0,3.0,5.0,2.0,1.0,2.0,5.0,1.0,2.0,15.0,6.0,1.0,1.0,5.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,4.0,11.0,1.0,1.0,1.0,4.0,6.0,1.0,1.0,2.0,1.0,1.0,6.0,7.0,5.0,1.0,1.0,4.0,1.0,1.0,3.0,4.0,1.0,5.0,3.0,1.0,2.0,6.0,1.0,2.0,2.0,1.0,1.0,10.0,2.0,3.0,3.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,4.0,5.0,7.0,10.0,3.0,4.0,2.0,1.0,1.0,3.0,1.0,3.0,1.0,5.0,2.0,1.0,1.0,30.0,1.0,2.0,1.0,29.0,2.0,1.0,1.0,4.0,5.0,1.0,16.0,1.0,1.0,2.0,1.0,1.0,7.0,3.0,5.0,1.0,3.0,3.0,1.0,3.0,2.0,1.0,4.0,1.0,15.0,4.0,1.0,2.0,2.0,3.0,2.0,5.0,1.0,3.0,4.0,1.0,7.0,1.0,2.0,1.0,4.0,1.0,5.0,4.0,6.0,1.0,2.0,1.0,1.0,4.0,1.0,2.0,1.0,8.0,9.0,1.0,3.0,2.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,14.0,7.0,34.0,5.0,1.0,1.0,1.0,3.0,8.0,2.0,2.0,2.0,1.0,2.0,13.0,3.0,7.0,2.0,2.0,2.0,1.0,1.0,2.0,1.0,2.0,5.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,4.0,16.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,9.0,1.0,1.0,1.0,1.0,14.0,1.0,2.0,5.0,2.0,1.0,2.0,1.0,4.0,2.0,2.0,4.0,1.0,2.0,1.0,8.0,1.0,1.0,1.0,6.0,8.0,1.0,1.0,2.0,8.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,3.0,1.0,2.0,1.0,1.0,3.0,2.0,7.0,3.0,1.0,1.0,1.0,2.0,8.0,1.0,1.0,3.0,1.0,2.0,2.0,1.0,4.0,1.0,5.0,3.0,1.0,1.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,19.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,3.0,3.0,1.0,1.0,1.0,2.0,4.0,2.0,1.0,2.0,1.0,1.0,1.0,6.0,1.0,2.0,1.0,4.0,1.0,2.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,8.0,2.0,1.0,1.0,1.0,1.0,10.0,1.0,1.0,2.0,1.0,11.0,1.0,1.0,3.0,2.0,3.0,3.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,5.0,2.0,15.0,2.0,8.0,2.0,1.0,1.0,1.0,14.0,1.0,2.0,1.0,2.0,5.0,9.0,3.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,32.0,3.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,11.0,2.0,1.0,1.0,1.0,4.0,9.0,2.0,1.0,3.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,2.0,11.0,2.0,6.0,1.0,3.0,1.0,1.0,2.0,8.0,1.0,2.0,2.0,2.0,3.0,3.0,2.0,1.0,1.0,11.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,13.0,1.0,1.0,2.0,1.0,1.0,2.0,3.0,4.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,5.0,4.0,1.0,2.0,11.0,1.0,2.0,4.0,2.0,1.0,2.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,6.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,67.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,2.0,5.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,1.0,7.0,1.0,1.0,1.0,5.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,6.0,1.0,1.0,2.0,3.0,1.0,2.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,5.0,2.0,2.0,2.0,3.0,1.0,2.0,1.0,1.0,2.0,1.0,8.0,2.0,6.0,1.0,1.0,17.0,5.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,2.0,1.0,2.0,5.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,4.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,15.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,6.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,4.0,7.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,5.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,5.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,3.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,11.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,4.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,2.0,1.0,4.0,1.0,2.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,2.0,1.0,3.0,3.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n",
      "|[\", despite, several, efforts, the, development, of, an, effective, vaccine, for, covid19, may, take, a, much, longer, timetraditionalnatural, medicine, already, experienced, by, humans, could, be, an, earlier, solution, considering, the, researchteams, experience, in, using, nanoclays, as, highaffinity, material, for, cancer, metastasis, melanoma, treatment, andbone, regeneration, we, propose, to, use, these, nanoclays, for, the, preventiontreatment, of, covid19, owing, to, highaffinity, nanoclays, would, capture, the, viruses, before, the, latter, get, engaged, with, human, hace2, in, this, studymolecularlevel, simulations, and, modeling, of, the, interaction, of, coronavirus, spike, and, hace2, proteins, wereperformed, with, and, without, nanoclays, the, results, showed, a, very, high, level, of, affinitycohesiveness, among, sarscov2, spike, and, nanoclays, as, compared, to, the, one, between, the, former, and, hace2, we, premise, that, these, nanoclays, since, already, being, used, as, drug, carriers, could, also, be, injected, as, claysalone, medicine, recommendationshave, also, been, provided, for, future, in, vitro, and, in, vivo, studiesbackgroundthe, sudden, emergence, and, rapid, spread, of, novel, coronavirus, sarscov2, have, significantly, affected, thehealth, and, lives, of, human, beings, in, addition, to, criticallyaffecting, the, world, economy, sarscov2, spike, s, bindswith, high, affinity, to, human, angiotensinconverting, enzyme, , hace2, and, uses, it, as, an, entry, receptor, to, invade, target, cells, fig, 1a, b, [], the, virussurface, spikeprotein, mediates, coronavirus, entry, into, host, cellssarscov2, spike, protein, contains, a, receptorbindingdomain, rbd, that, recognizes, explicitly, as, its, receptorhace2, [, ], the, surface, of, hace2, contains, two, virusbinding, hotspots, that, are, criticalfor, sarscov2, sbinding, several, naturally, selected, mutations, in, sarscov2, rbd, surround, these, hotspots, and, regulate, theinfectivity, pathogenesis, and, crossspecies, and, humantohuman, transmissions, of, sarscov2, [, , ]at, present, there, are, no, clinically, approved, vaccinesor, drugs, that, specifically, target, sarscov2, followingthe, real, protocol, of, developing, a, vaccine, it, may, takemuch, longer, time, to, come, up, with, an, effective, vaccine, correspondence, habibrehmankfupmedusa3engineering, , research, international, eri, riyadh, saudi, arabiafull, list, of, author, information, is, available, at, the, end, of, the, there, is, a, lot, of, interest, in, the, development, of, therapeutic, antibodies, against, sarscov2, despite, many, efthese, antibodies, have, not, yet, beenforts, howeverdiscovered, [], exceptin, a, few, trials, [], one, trialshowed, the, potent, neutralization, of, sarscov2, bybinding, to, the, rbd, of, its, s, glycoprotein, [], in, this, trial[], antibody, cocktails, a, mixture, of, different, antibodiesis, recommended, due, to, the, increased, neutralization, effect, it, has, on, sarscov2, however, use, of, antibodiesin, the, past, from, convalescent, patients, of, sarscov, totreat, sarscov, infection, has, shown, adverse, reactionsin, the, patients, such, as, antibodydependent, enhancement, ade, causing, increased, viral, infectivity, and, otherharmful, immune, responses, [], moreover, based, on, theexperience, with, the, vaccine, development, efforts, forsarscov, and, mers, chances, of, the, materialization, ofthe, efforts, being, made, for, sarscov2, seems, quitethin, therefore, naturaltraditional, medicines, that, have, ahistory, of, safe, consumptioningestion, by, humans, couldbe, considered, as, one, of, the, treatment, options, for, sarscov2, being, a, natural, material, and, a, history, of, humanuseconsumption, we, suggest, highly, charged, nanoclays, to, be, used, as, coronavirus, blockers, and, inhibitorsof, the, spikemediated, entry, into, the, human, cells, the, authors, , , , access, this, , is, licensed, under, a, creative, commons, attribution, , international, licensewhich, permits, use, sharing, adaptation, distribution, and, reproduction, in, any, medium, or, format, as, long, as, you, giveappropriate, credit, to, the, original, authors, and, the, source, provide, a, link, to, the, creative, commons, licence, and, indicate, ifchanges, were, made, the, images, or, other, third, party, material, in, this, , are, included, in, the, 's, creative, commonslicence, unless, indicated, otherwise, in, a, credit, line, to, the, material, if, material, is, not, included, in, the, 's, creative, commonslicence, and, your, intended, use, is, not, permitted, by, statutory, regulation, or, exceeds, the, permitted, use, you, will, need, to, obtainpermission, directly, from, the, copyright, holder, to, view, a, copy, of, this, licence, visit, httpcreativecommonslicensesby40, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, fig, , schematics, of, the, sarscov2, attack, on, human, hace2, and, the, subsequent, immune, system, response, a, b, rbd, binding, hace2, withoutan, interference, c, rbd, complexed, with, the, antibody, at, receptor, attachment, site, hence, competing, with, hace2, d, rbd, complexed, with, rbd, at, asite, other, than, where, receptor, attaches, resulting, in, the, alteration, of, rbd, structure, and, interruption, of, lock, and, key, binding, of, rbd, to, hace2nanoclays, nanosized, natural, materials, originatingfrom, minerals, of, the, sedimentary, rocks, have, got, avery, high, affinity, to, bacteria, and, viruses, [], due, toisomorphous, substitution, in, their, molecular, structurethese, nanoclays, exhibit, charge, deficiency, on, theirsurfaces, this, charge, deficiency, on, their, surfaces, isneutralized, by, the, water, molecules, and, the, dissolvedcations, fig, , the, charged, structure, and, large, surface, area, of, clay, nanops, give, them, an, affinityfor, charged, entities, as, found, on, bacterial, surfacesand, bacterial, toxins, their, distinct, biomedical, properties, include, high, absorption, the, ability, to, engulf, microbes, and, no, toxicity, each, of, the, electrically, activeclay, minerals, has, its, distinct, morphology, characteristics, and, interaction, behavior, the, most, studied, biomedical, application, of, nanoclays, includes, serving, ascarriers, and, complexes, for, anticancer, drugs, such, as5fluorouracil, and, trastuzumab, [], they, havetherefore, been, a, potential, alternate, medicine, for, several, diseases, [], clay, nanops, due, to, theiradhesive, nature, have, also, been, used, as, carriers, forsustainedrelease, medicine, [, ], nanoclays, havealso, successfully, been, used, to, adsorb, and, treat, bovinerotavirus, and, bovine, coronavirus, [], researchers[], intercalated, methotrexate, mtx, an, anticanceragentinto, the, anionic, clay, to, create, a, nanohybriddrug, they, used, the, coprecipitation, and, subsequenthydrothermal, methodology, to, prepare, this, chemicallystructurally, and, morphologically, welldefined, twodimensional, drugclay, nanohybrid, the, researchers[], discovered, that, due, to, the, biocompatibility, andhigh, loading, capacity, bentonite, nanoclay, could, beused, for, the, preparation, of, the, drugdelivery, vehiclesthey, prepared, doxorubicinbentonitein, thisto, form, ananoclay, complex, doxbent, complexsustainedreleaseintradrugdeliverystudysystem, for, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, fig, , a, sem, image, and, b, the, corresponding, molecular, structure, of, namontmorillonite, showing, the, configuration, isomorphous, substitutioncharge, deficiency, and, interlayer, cations, from, []tumoral, chemotherapy, of, melanoma, as, montmorillonite, clay, is, recently, being, studied, to, be, used, as, anadditive, and, drug, carrier, materialthese, nanoclaycomposites, appeal, their, use, in, various, dosing, formmainly, for, controlled, release, of, the, drug, [], the, researchers, [], also, discovered, that, nanoclays, can, beused, into, recent, dual, functional, drug, delivery, systemsddss, to, have, efficiency, in, the, drug, delivery, and, soreduce, the, toxicity, of, doxorubicin, dox, that, is, being, used, for, thyroid, cancer, treatment, using, a, libraryof, , singlesingle, type, photo, cleavable, amphiphilicjanus, dendrimers, researchers, [], developed, a, selfassembling, lightresponsive, dendrimersomes, vesicleplatform, similar, to, the, nanoclays, surface, modifiedbioactive, virusmimicking, anic, nanovesicles, fromglycodendrimersomes, have, structural, modificationsthat, contribute, to, manifest, sarscov2, and, hostpathogenic, molecular, interactions, that, help, the, virusto, escape, from, the, human, immune, system, []through, considerable, previous, research, we, developedbasic, characterization, and, behavior, modeling, ofthecharged, clay, minerals, [], and, their, applications, in, thecontrol, of, cancer, metastasis, [], in, vitro, and, in, vivo, studies, on, melanoma, treatment, [], and, the, calcium, depositionbone, regeneration, studies, [], in, a, previous, study, bythe, authors, [], it, was, demonstrated, that, clay, nanops, had, got, a, high, affinity, to, the, charged, surfaces, thehigh, attraction, affinity, of, the, nanoclays, and, the, increasednonspecific, adhesion, attraction, of, the, cancer, cells, makenanoclays, favorable, candidates, to, control, cancer, metastasis, in, that, study, we, demonstrated, the, possible, use, of, twocharged, clay, minerals, to, control, the, metastasis, of, thecancer, cells, namontmorillonite, swy3, and, palygorskitepfll, further, to, the, findings, of, the, authors, previous, research, [], on, the, use, of, these, nanoclays, for, the, control, ofcancer, metastasis, we, also, through, in, vitro, and, in, vivostudies, established, that, these, nanoclays, have, inhibitory, effects, on, melanoma, cancer, cells, mainly, on, cell, proliferationand, viability, [], in, these, previous, studies, in, addition, tolaboratory, experiments, molecularlevel, simulations, werealso, performed, on, the, nanoclay, and, cells, interactionsthese, simulations, provided, the, assessment, of, the, relativelevel, of, cohesivenessaffinity, in, the, interactions, with, andwithout, clay, nanopsperceptionthroughthisestablishingbased, on, all, the, above, experience, of, the, authors, onthe, highaffinity, potential, of, nanoclays, we, propose, thatthe, nanoclays, could, be, mimicked, as, antibodies, and, canthus, attract, and, engulf, coronaviruses, before, they, get, engaged, with, human, hace2, this, paper, is, a, first, steptowardsamolecularlevelsimulation, and, modeling, approachbased, on, the, results, of, the, molecularlevel, simulationsan, outline, of, the, recommendations, for, the, next, phasesof, in, vitro, and, in, vivo, research, is, also, provided, as, thesenanoclays, are, also, successfully, being, used, as, medicinecarriers, we, also, premise, that, they, can, also, be, injectedingested, as, claysalone, medicine, and, thus, we, haveproposed, a, tentative, nanoclays, administration, methodology, for, this, purposematerialsmoleculesselection, and, formulation, of, sarscov2, and, hace2molecules, of, sarscov2, spike, s, and, hace2, were, acquired, from, the, protein, data, bank, website, rcsb, [], 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, the, molecular, models, of, sarscov2, spike, s, andhace2, formulated, in, materials, studio, software, [], arerespectively, shown, in, fig, 3a, b, before, being, subject, tothe, simulations, these, molecules, were, charged, using, thecharge, equilibration, method, qeq, of, the, softwareselection, and, formulation, of, nanoclay, crystallitenamontmorillonite, one, of, the, most, active, members, ofthe, smectite, group, of, clay, minerals, was, selected, for, thestudy, namontmorillonite, is, a, layered, phyllosilicate, claysmectite, fig, , in, the, colloidal, form, the, space, between, neighboring, layers, can, contain, free, sodium, calcium, or, magnesium, cations, that, are, electrostaticallyattracted, to, external, negatively, charged, surfaces, [], inits, dry, powdered, state, namontmorillonite, exists, asequidimensionalflakessheets, with, dimensions, of, approximately, , ã, , ã, , microns, fig, 2a, thesenegative, charges, on, their, interlayer, surfaces, are, balancedby, the, cations, as, colloids, the, interlayer, cations, get, dissociated, from, the, clay, ps, and, associate, themselveswith, the, other, negatively, charged, surfaces, these, ps, also, have, positively, charged, edges, due, to, the, presence, of, the, broken, bonds, at, their, ends, morphology, andfurther, characteristics, of, these, nanoclays, are, providedin, table, , while, formulation, of, their, crystallites, in, materials, studio, software, are, explained, belowin, the, software, namontmorillonite, crystallites, wereformulated, based, on, fundamental, properties, such, ascec, exchangeable, cations, and, interlayer, charges, table, the, size, of, the, molecularcrystallite, size, was, selectedbased, on, the, results, of, the, p, size, analysis, usingthe, dynamic, light, scattering, dls, technique, [], thefinal, form, of, clay, crystallite, created, in, the, software, istheseshown, in, fig, 3c, afterthe, preparation, ofcrystallites, in, the, design, mode, of, the, software, using, theinherent, properties, these, were, charged, using, the, chargeequilibration, method, qeq, of, the, softwaremethodsmolecularlevel, simulationsthis, part, of, the, study, consisted, of, the, simulation, andassessment, of, the, interactions, of, the, sarscov2, spikes, with, clay, crystallites, and, with, hace2, although, thesemodels, may, not, be, the, complete, replication, of, the, actual, in, vitro, conditions, these, have, been, incorporatedwith, all, the, essentialinteractions, and, are, quite, wellsuited, for, the, intended, relative, and, comparative, studyin, the, software, the, sorption, and, simulations, of, theformulated, configurations, of, sarscov2, s, namontmorillonite, crystallites, and, hace2, were, carriedout, using, monte, carlo, mc, and, molecular, mechanicsmm, techniques, the, enhancement, of, affinity, in, all, thesimulated, configurations, was, assessed, in, terms, of, thecalculated, cohesive, energy, density, cedced, beingconsidered, as, a, measurement, of, the, cohesiveness, of, themolecular, system, due, to, the, largesized, computationsinvolved, in, the, simulationsthese, calculations, werecarried, out, using, the, highperformance, computing, facilities, hpc, at, kfupm, ksa, the, overall, methodologyand, the, choice, of, particular, methods, and, the, simulationparameters, were, based, on, authors, previous, research[], while, it, is, detailed, in, the, subsequent, sectionsarscov2, spike, s, interactions, with, hace2, and, claycrystallitesto, simulate, the, interaction, of, sarscov2, s, with, claycrystallites, various, numbers, of, the, crystallites, of, namontmorillonite, clay, were, sorbed, on, sarscov2, smodel, for, these, sorption, simulations, the, metropolisfig, , molecularlevel, models, of, a, sarscov2, spike, b, hace2, and, c, namontmorillonite, crystallite, formulated, in, materials, studio, software, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, lnoitauccoflnoitcaretninoitcaretninoitcaretnininoisrepsidretawnoisrepsidygrenelatotygrenewdvygrenebalraopcilihpordyhacanretawytiniffasî³laitnetopvmpzatezreyalretniegrahclardehartetlardehatcolebaegnahcxeegrahcegrahcsnoitacqemgcececafrusnaeragmslarenmirehtoliacmehclaumrofacilisoisgmlaacanecruosytnuocasuywkoorc][ywsyacletinolliromtnomanfonoitaziretcarahcliacmehcdnalacisyhpfoyrammuselbat, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, monte, carlo, method, was, selected, in, the, sorption, module, of, the, software, in, each, sorption, step, clay, crystallitesoccupy, spaces, around, the, spike, s, model, to, lower, theoverall, energy, of, the, complex, the, required, number, ofcrystallites, were, sorbed, in, a, maximum, of, , stepsand, then, the, energy, of, the, system, was, minimized, usingthe, forcite, module, of, the, software, based, on, the, mdprinciples, the, similar, sorption, process, was, repeated, forthe, interaction, modeling, of, the, sarscov2, spike, molecule, with, hace2, in, this, process, hace2, moleculeswere, sorbed, around, the, rbd, of, the, spike, s, of, sarscov2, after, the, completion, of, the, sorption, process, theenergy, of, the, formulation, was, minimized, using, mdbased, module, of, the, softwarethe, forcite, module, ofthe, software, incorporatingnpt, constant, number, of, ps, pressure, andtemperature, ensemble, was, used, for, md, simulationswith, a, modified, universal, force, field, [], the, simulations, were, run, for, , to, , ps, with, an, interval, of, 05fs, ortill, a, constant, volume, is, obtained, a, berendsen, thermostat, with, a, decay, constant, of, , ps, was, used, to, controlthe, temperature, during, the, simulation, during, the, mdsimulations, the, assumed, temperature, was, kept, constantat, , k, , °c, with, an, atmospheric, pressure, , kpaa, berendsen, barostat, with, a, decay, constant, of, , pswas, used, to, control, the, pressure, of, the, system, theberendsen, methodology, was, considered, as, the, most, appropriate, for, the, single, crystallites, after, several, trials, involving, other, thermostats, and, barostats, available, in, thesoftware, in, the, monte, carlo, method, the, parametersfor, the, ratios, of, exchange, conformer, rotate, translateand, regrow, were, selected, as, , , , , and, respectively, with, the, corresponding, probabilities, as, , , , and, , amplitudes, adapted, for, rotationand, translation, were, °, and, , , respectivelycohesive, energy, density, ced, measurementin, this, study, the, assessment, of, the, affinitybindinglevelin, the, sarscov2clay, crystallites, and, sarscov2hace2, complexes, was, measured, through, thechanges, in, the, ced, after, the, sorption, of, clay, crystallites, and, the, subsequent, performance, of, moleculardynamics, of, each, of, the, configurations, the, ced, wasdetermined, using, the, cohesive, energy, density, optionof, the, forcite, module, of, the, software, the, authorshave, experienced, that, the, ced, concept, consisting, ofthe, total, van, der, waals, and, electrostatic, ceds, canquite, closely, explain, the, various, molecularlevel, processes, and, interactions, and, simulate, the, extent, of, affinitybinding, created, among, the, simulated, complexes[], quantitatively, ced, is, defined, as, the, amountof, energy, needed, for, the, transition, of, , mol, of, material, from, the, liquid, to, the, gaseous, phase, it, is, also, ameasureofaffinityattractivenessthe, mutualofmolecules, and, is, expressed, both, as, electrostatic, andvan, der, waalsan, nptensembleaveraged, overforcesin, the, forcite, module, van, der, waals, energies, wereevaluated, using, atombased, cutoffsin, this, methodnonbond, interactions, are, simply, calculated, to, a, cutoffdistance, and, interactions, beyond, this, distance, are, ignored, to, avoid, the, discontinuities, caused, by, direct, cutoffs, most, simulations, use, a, switching, function, to, turnoff, nonbond, interactions, over, a, range, of, distancessmoothly, an, effective, potential, is, created, by, multiplyingthe, actual, potential, by, the, smoothing, function, thechoice, of, the, function, in, the, intermediate, range, is, crucial, and, should, be, continuously, differentiable, in, this, region, so, that, forces, can, be, calculated, in, this, study, acubic, spline, smoothing, function, was, used, with, a, splinewidth, of, , , and, a, cutoff, distance, of, , results, and, discussionsthe, final, configuration, of, the, sarscov2, shace2complex, is, shown, in, fig, 4a, while, the, complexes, between, sarscov2, spike, and, different, numbers, of, claynamontmorillonite, crystallites, are, respectively, shownin, fig, 4b, c, for, comparison, purposes, total, ceds, ofvarious, proportionsnumbers, of, the, clay, crystallites, onthe, sarscov2, spike, and, the, interaction, of, the, laterwith, hace2, are, plotted, in, fig, based, on, our, experience, we, have, hypothesized, thatnanoclays, due, to, their, high, adhesive, properties, couldalso, act, as, sarscov2, inhibitors, they, can, do, it, bystrongly, associating, with, the, spike, s, present, on, sarscov2, the, results, obtained, from, the, molecularlevelsimulations, of, the, interactions, indicate, that, due, to, veryhigh, ced, between, sarscov2, and, the, nanoclays, ascompared, to, the, former, and, hace2, fig, , they, couldinhibit, sarscov2, from, getting, engaged, with, hace2moreover, it, could, also, be, concluded, from, fig, , thatthe, extent, of, inhibition, due, to, nanoclays, is, increased, inquantity, dosagedependent, waynanoclay, interactions, with, sarscov2, spike, sauthors, in, their, earlier, research, have, demonstrated, therole, of, nanoclays, in, promoting, adhesion, among, thecancer, cells, and, their, microenvironment, and, hence, controlling, metastasis, [], adhesion, measurements, of, , mix, of, namontmorillonite, and, palygorskite, showedan, increase, in, adhesion, by, , among, cancer, cells, andthe, extracellular, matrix, proteins, fig, 6a, a, corresponding, sem, of, the, nanoclays, binding, the, raji, cells, and, thefibronectin, proteins, is, shown, in, fig, 6b, sample, imagingwas, performed, in, sem, mode, in, an, fei, esemfeg, xl, atthe, miller, school, of, medicine, university, ofmiami, florida, authors, also, discovered, in, their, previousresearch, that, electrostatic, van, der, waals, and, zp, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, fig, , molecularlevel, simulation, results, in, materials, studio, software, a, sarscov2, s, and, hace2, ced, , , jcm3, b, sarscov2, s, modelinteracting, with, twelve, crystallites, of, namontmorillonite, ced, , , jcm3, and, c, sarscov2, s, model, interacting, with, twentyfour, crystallites, ofnamontmorillonite, ced, , , jcm3obtained, using, sorption, technique, implemented, in, the, softwareattractions, seem, to, be, dominating, in, the, adhesion, processes, [], we, conclude, that, the, same, mechanismswould, have, also, facilitated, the, binding, of, the, adhesivesurfaces, of, the, nanoclays, to, the, spike, of, sarscov2fig, , zp, is, a, measure, of, the, dispersion, or, flocculationtendency, in, the, colloidal, form, including, the, interactions, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, fig, , variation, of, cohesive, energy, density, ced, for, sarscov2, shace2, and, the, complexes, of, the, former, with, different, numbers, ofnamontmorillonite, crystalliteswith, the, other, constituents, present, in, the, suspensionmedium, as, a, general, rule, a, zeta, potential, greater, than, mv, either, positive, or, negative, indicates, dispersiontendency, while, a, zeta, potential, of, less, than, , mv, generally, results, in, agglomeration, higher, dispersion, tendencies, zp, of, the, clay, nanops, used, in, the, study, , to, , , mv, lead, to, higher, dispersion, tendency, andhence, in, the, generation, of, higher, surface, area, amplifyingthe, interactions, with, the, sarscov2, spike, althoughbased, on, their, zp, namontmorillonite, nanopshave, hydrophilic, nature, they, in, the, presence, of, saltsalso, promote, secondary, adhesion, mechanisms, betweenhydrophobic, and, hydrophilic, surfaces, [], it, should, alsobe, noted, that, these, clay, nanops, have, high, dispersion, tendency, due, to, their, hydrophilic, nature, and, relatively, higher, repulsive, acidbase, ab, interactions, table, high, dispersion, in, turn, results, in, the, generation, ofhigh, surface, area, for, increasing, the, attractive, interactions, higher, surface, areas, promote, larger, attractionsdue, to, the, van, der, waal, attractions, and, the, electrostaticforces, among, oppositely, charged, surfaces, besides, although, of, relatively, lesser, degree, positively, chargededges, of, namontmorillonite, ps, also, get, electrically, attracted, to, the, spike, sthe, results, of, the, molecularlevel, simulations, for, theinteraction, of, sarscov2, spike, s, with, the, clay, crystallites, fig, , also, confirm, the, above, interaction, behaviors, it, has, been, observed, that, the, sorption, of, the, claynanops, results, in, the, formation, of, closely, interacting, strong, van, der, waals, attraction, fields, these, van, derwaals, attraction, fields, create, higher, ced, of, the, claysarscov2, configuration, substantial, increase, in, totalced, after, the, addition, of, clay, crystallites, fig, , is, alsoa, testimony, of, a, very, high, affinity, of, sarscov2, withthese, ps, as, compared, to, the, affinity, of, the, formerwith, hace2systemagglutinationnanoclays, as, pseudoantibodiesbased, on, all, the, current, and, past, research, by, the, authors, establishing, the, highaffinity, potential, of, nanoclays, we, premise, that, nanoclays, could, be, mimicked, asantibodies, and, can, thus, attract, and, engulf, coronavirusesbefore, they, get, engaged, with, human, hace2, antibodiesare, glycoproteins, synthesized, by, plasma, cells, as, part, ofthe, adaptive, immune, response, to, assist, in, the, clearanceof, infection, from, the, body, antibodies, aid, in, infectionclearance, in, multiple, ways, such, as, opsonization, of, pathogens, to, facilitate, phagocytosis, activation, of, the, complementandneutralization, of, viruses, and, toxins, when, bound, to, theviral, surface, proteins, antibodies, prevent, the, entry, of, theviruses, into, the, cell, by, preventing, the, attachment, of, viruses, to, their, target, receptor, on, the, cell, antibody, binding, can, occur, at, different, sites, on, the, surface, proteinleading, to, various, mechanisms, that, cause, the, same, effect, in, the, case, of, sarscov2, two, viral, neutralizationmechanisms, by, antibodies, have, been, observed, [, ]and, shown, in, fig, 1c, d, one, of, the, mechanisms, involvesdirect, binding, of, antibodies, to, the, attachment, site, of, thesarscov2rbd, resulting, in, the, antibody, competingwith, the, target, receptor, hace2, another, mechanism, involves, the, binding, of, antibodies, to, the, other, sites, onrbd, without, any, competition, with, the, target, receptorthe, latter, is, shown, to, be, involved, in, neutralization, byof, microbes, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, fig, , a, summary, of, adhesion, force, measurements, among, rajirajifn, assembly, using, afm, before, and, after, treatment, with, various, proportionsof, namontmorillonite, and, palygorskite, clay, nanops, [], error, bars, represent, the, variations, in, the, trials, b, sem, image, of, the, binding, of, rajicells, and, fibronectin, proteins, produced, by, nanoclaysthe, most, potent, monoclonal, antibody, mab, discoveredin, the, study, [, ], analogous, to, the, antibodies, interaction, with, sarscov2, rbd, inhibiting, the, latter, toengage, with, hace2, a, similar, molecularlevel, model, isprepared, for, nanoclays, resulting, in, a, similar, inhibitionof, the, coronaviruses, and, shown, in, fig, , owing, to, theirvery, high, affinity, nanoclays, would, get, attracted, tospikes, of, sarscov2, and, thus, restrict, engagement, ofrbds, of, these, spikes, with, hace2proposed, nanoclay, administration, methodologyclay, use, as, drug, carriers, has, been, tested, multiple, timesyielding, promising, results, of, little, to, no, cytotoxicity, tocells, of, the, human, body, kaolinite, clay, mineral, wastested, for, use, in, a, potential, drug, delivery, system, andwas, shown, to, have, high, biocompatibility, and, very, lowas[]negligiblecytotoxicity, [], poly, dllactidecoglycolidemontmorillonite, nanop, cytotoxicity, in, vitro, was, alsodemonstratedpalygorskitepolyethyleneiminefluorescein, isothiocyanate, nanocomposites, also, exhibited, almost, no, cytotoxicity, in, vitro[], authors, have, also, experienced, injecting, nanoclayssubcutaneously, for, the, treatment, of, melanoma, duringin, vivo, studies, [], based, on, the, use, of, clay, as, a, cancerdrug, carrier, and, in, other, sustainedrelease, medicine[], we, propose, that, nanoclays, may, be, injected, asclayalone, medicine, subject, to, the, verification, in, vivoand, clinical, trialsalthough, nanoclays, are, nonbiodegradable, a, comprehensive, understanding, of, the, design, of, the, similar, inanic, nanops, with, their, metabolic, performancein, the, body, carried, out, in, the, study, [], could, also, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, fig, , three, possible, mechanisms, of, interactions, of, montmorillonite, nanoclay, with, the, sarscov2, spike, s, , electrostatic, attraction, amongpositively, charged, nanop, edges, and, naca, ions, with, negatively, charged, virus, surfaces, , van, der, waals, attractions, , zpelectrostatic, interactionscategorize, these, nanoclays, as, human, body, clearable, inanic, agentsconclusions, and, recommendationsbased, on, all, the, current, and, past, research, by, the, authors, establishing, the, highaffinity, potential, of, nanoclays, these, could, be, mimicked, as, antibodies, and, canthus, attract, and, engulf, coronaviruses, before, they, get, engaged, with, human, hace2the, results, of, the, molecularlevel, simulations, for, theinteraction, of, sarscov2, spike, s, with, the, clay, crystallites, result, in, the, formation, of, closely, interacting, strongvan, der, waals, attraction, fields, these, van, der, waals, attraction, fields, create, higher, ced, of, the, claysarscov, configuration, substantial, increase, in, total, ced, afterfig, , interaction, mechanism, of, nanoclay, ps, with, sarscov2, spike, s, inhibiting, the, interaction, of, the, later, with, hace2, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , of, addition, of, clay, crystallites, is, also, a, testimony, of, a, veryhigh, affinity, of, sarscov2, with, these, ps, as, compared, to, the, affinity, of, the, former, with, hace2we, propose, to, continue, the, research, by, carrying, outin, vitro, interaction, studies, between, sarscov2, anddifferent, percentage, of, nanoclays, based, on, theoptimum, dose, of, nanoclay, developed, in, the, in, vitrophase, we, suggest, to, carry, out, in, vivo, studies, on, the, animals, the, animal, study, should, be, carried, out, both, withand, without, nanoclay, to, finalize, the, nanoclay, dose, andshould, lay, the, foundation, for, the, clinical, trialsacknowledgementsthe, authors, highly, acknowledge, kfupm, for, providing, highperformancecomputing, research, facilitiesauthors, contributionsall, the, authors, equally, participated, at, all, the, research, levels, the, authorsread, and, approved, the, final, manuscriptfundingno, fundingavailability, of, data, and, materialsall, data, generated, or, analyzed, during, this, study, are, included, in, thispublished, ethics, approval, and, consent, to, participatenot, applicableconsent, for, publicationnot, applicablecompeting, intereststhe, authors, declare, that, they, have, no, competing, interestsauthor, details1civil, , environmental, engineering, department, king, fahd, university, ofpetroleum, , minerals, kfupm, dhahran, saudi, arabia, 2royal, college, ofsurgeons, in, ireland, rcsi, bahrain, campus, busaiteen, bahrain, 3engineering, research, international, eri, riyadh, saudi, arabiareceived, , july, , accepted, , august, referencesewen, callaway, and, nik, spencer, the, race, for, coronavirus, vaccines, agraphical, guide, eight, ways, in, which, scientists, hope, to, provide, immunityto, sarscov2, news, feature, nature, vol, , , april, li, f, li, w, h, farzan, m, , harrison, s, c, structure, of, sars, coronavirusspike, receptorbinding, domain, complexed, with, receptor, science, , , httpsdoi101126science1116480, li, wh, , , angiotensinconverting, enzyme, , is, a, functional, receptorfor, the, sars, coronavirus, nature, , httpsdoi101038nature02145li, f, , structural, analysis, of, major, species, barriers, between, humansand, palm, civets, for, severe, acute, respiratory, syndrome, coronavirusinfections, j, virol, , httpsdoi101128jvi0044208, wu, kl, peng, gq, wilken, m, geraghty, rj, li, f, , mechanisms, of, hostreceptor, adaptation, by, severe, acute, respiratory, syndrome, coronavirus, jbiol, chem, , httpsdoi101074jbcm111325803, wang, c, li, w, drabek, d, okba, nma, van, haperen, r, osterhaus, adme, , a, human, monoclonal, antibody, blocking, sarscov2, infection, natcommun, jiang, s, hillyer, c, du, l, , neutralizing, antibodies, against, sarscov2and, other, human, coronaviruses, trends, immunol, pinto, d, park, yj, beltramello, m, walls, ac, tortorici, ma, bianchi, s, , crossneutralization, of, sarscov2, by, a, human, monoclonal, sarscov, antibody, nature, da, rocha, dias, s, salmonson, t, van, zwietenboot, b, jonsson, b, marchetti, sschellens, jh, pignatti, f, , the, european, medicines, agency, review, ofvemurafenib, zelboraf®, for, the, treatment, of, adult, patients, with, braf, v600mutationpositive, unresectable, or, metastatic, melanoma, summary, of, thescientific, assessment, of, the, committee, for, medicinal, products, for, humanuse, eur, j, cancer, sahel, n, abduljauwad, and, habiburrehman, ahmed, enhancing, cancer, celladhesion, with, clay, nanops, for, countering, metastasis, nature, scientificreports, , april, , httpsdoi101038s4159801942498y, zhang, y, long, m, huang, p, yang, h, chang, s, hu, y, mao, l, intercalated, 2d, nanoclay, for, emerging, drug, delivery, in, cancer, therapynano, res, , chianelli, r, r, , das, s, , us, patent, no, , washington, dc, us, patent, and, trademark, office, han, s, liu, f, wu, j, zhang, y, xie, y, wu, t, y, , targeting, of, fluorescentpalygorskite, polyethyleneimine, nanocomposite, to, cancer, cells, appl, claysci, sun, b, ranganathan, b, feng, ss, , multifunctional, poly, d, llactidecoglycolide, montmorillonite, plgammt, nanops, decorated, bytrastuzumab, for, targeted, chemotherapy, of, breast, cancer, biomaterialslin, fh, lee, yh, jian, ch, wong, jm, shieh, mj, wang, cy, , a, study, ofpurified, montmorillonite, intercalated, with, 5fluorouracil, as, drug, carrierbiomaterials, , bothiraja, c, thorat, uh, pawar, ap, shaikh, ks, , chitosan, coated, layeredclay, montmorillonite, nanocomposites, modulate, oral, delivery, of, paclitaxel, incolonic, cancer, mater, technol, 29sup3b120b126kevadiya, bd, thumbar, rp, rajput, mm, rajkumar, s, brambhatt, h, joshi, gvbajaj, hc, , montmorillonitepolyîµcaprolactone, composites, asversatile, layered, material, reservoirs, for, anticancer, drug, and, controlledrelease, property, eur, j, pharm, sci, , guo, my, wang, af, muhammad, f, qi, wx, ren, h, guo, yj, zhu, gs, halloysite, nanotubes, a, multifunctional, nanovehicle, for, anticancer, drugdelivery, chin, j, chem, , martã­nez, c, d, cationic, clays, upon, cancer, therapy, virtual, multidisciplinaryconference, quaesti, , konta, j, , clay, and, man, clay, raw, materials, in, the, service, of, man, applclay, sci, , murray, hh, , traditional, and, new, applications, for, kaolin, smectite, andpalygorskite, a, general, overview, appl, clay, sci, , volzone, c, , retention, of, pollutant, gases, comparison, between, clayminerals, and, their, modified, products, appl, clay, sci, , dong, y, feng, ss, , poly, dllactidecoglycolidemontmorillonitenanops, for, oral, delivery, of, anticancer, drugs, biomaterials, , clarka, kj, sarrb, ab, grantb, pg, phillipsb, td, woodea, gn, , in, vitrostudies, on, the, use, of, clay, clay, minerals, and, charcoal, to, adsorb, bovinerotavirus, and, bovine, coronavirus, vet, microbiol, , choi, g, huiyan, p, alothman, z, vinu, a, yun, c, choy, j, anionic, clay, asthe, drug, delivery, vehicle, tumor, targeting, function, of, layered, doublehydroxidemethotrexate, nanohybrid, in, c33a, orthotopic, cervical, cancermodel, international, journal, of, nanomedicine, doi, httpsdoi102147ijns95611, , , hosseini, f, hosseini, f, jafari, s, m, and, taheri, a, bentonite, nanoclaybaseddrugdelivery, systems, for, treating, melanoma, clay, minerals, doi, httpsdoi101180clm201842018, inamuddin, asiri, a, m, and, mohammad, ali, applications, of, nanocompositematerials, in, drug, delivery, doi, httpsdoi101016c20160050751, avolume, in, woodhead, publishing, series, in, biomaterials, , zhang, y, long, m, huang, p, yang, h, chang, s, hu, y, tang, a, and, maol, emerging, integrated, nanoclayfacilitated, drug, delivery, system, forpapillary, thyroid, cancer, therapy, doi, 101038srep33335, sci, rep, , li, s, xia, b, javed, b, hasley, w, d, melendezdavila, a, liu, m, kerzner, magarwal, s, xiao, q, torre, p, bermudez, j, g, rahimi, k, kostina, n, ymã¶ller, m, rodriguezemmenegger, c, klein, m, percec, v, and, good, m, cdirect, visualization, of, vesicle, disassembly, and, reassembly, usingphotocleavable, dendrimers, elucidates, cargo, release, mechanisms, acs, 0cabduljauwad, , nanoscale, resear]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |[\", despite, several, efforts, development, effective, vaccine, covid19, may, take, much, longer, timetraditionalnatural, medicine, already, experienced, humans, earlier, solution, considering, researchteams, experience, using, nanoclays, highaffinity, material, cancer, metastasis, melanoma, treatment, andbone, regeneration, propose, use, nanoclays, preventiontreatment, covid19, owing, highaffinity, nanoclays, capture, viruses, latter, get, engaged, human, hace2, studymolecularlevel, simulations, modeling, interaction, coronavirus, spike, hace2, proteins, wereperformed, without, nanoclays, results, showed, high, level, affinitycohesiveness, among, sarscov2, spike, nanoclays, compared, one, former, hace2, premise, nanoclays, since, already, used, drug, carriers, also, injected, claysalone, medicine, recommendationshave, also, provided, future, vitro, vivo, studiesbackgroundthe, sudden, emergence, rapid, spread, novel, coronavirus, sarscov2, significantly, affected, thehealth, lives, human, beings, addition, criticallyaffecting, world, economy, sarscov2, spike, bindswith, high, affinity, human, angiotensinconverting, enzyme, , hace2, uses, entry, receptor, invade, target, cells, fig, 1a, b, [], virussurface, spikeprotein, mediates, coronavirus, entry, host, cellssarscov2, spike, protein, contains, receptorbindingdomain, rbd, recognizes, explicitly, receptorhace2, [, ], surface, hace2, contains, two, virusbinding, hotspots, criticalfor, sarscov2, sbinding, several, naturally, selected, mutations, sarscov2, rbd, surround, hotspots, regulate, theinfectivity, pathogenesis, crossspecies, humantohuman, transmissions, sarscov2, [, , ]at, present, clinically, approved, vaccinesor, drugs, specifically, target, sarscov2, followingthe, real, protocol, developing, vaccine, may, takemuch, longer, time, come, effective, vaccine, correspondence, habibrehmankfupmedusa3engineering, , research, international, eri, riyadh, saudi, arabiafull, list, author, information, available, end, lot, interest, development, therapeutic, antibodies, sarscov2, despite, many, efthese, antibodies, yet, beenforts, howeverdiscovered, [], exceptin, trials, [], one, trialshowed, potent, neutralization, sarscov2, bybinding, rbd, glycoprotein, [], trial[], antibody, cocktails, mixture, different, antibodiesis, recommended, due, increased, neutralization, effect, sarscov2, however, use, antibodiesin, past, convalescent, patients, sarscov, totreat, sarscov, infection, shown, adverse, reactionsin, patients, antibodydependent, enhancement, ade, causing, increased, viral, infectivity, otherharmful, immune, responses, [], moreover, based, theexperience, vaccine, development, efforts, forsarscov, mers, chances, materialization, ofthe, efforts, made, sarscov2, seems, quitethin, therefore, naturaltraditional, medicines, ahistory, safe, consumptioningestion, humans, couldbe, considered, one, treatment, options, sarscov2, natural, material, history, humanuseconsumption, suggest, highly, charged, nanoclays, used, coronavirus, blockers, inhibitorsof, spikemediated, entry, human, cells, authors, , , , access, , licensed, creative, commons, attribution, , international, licensewhich, permits, use, sharing, adaptation, distribution, reproduction, medium, format, long, giveappropriate, credit, original, authors, source, provide, link, creative, commons, licence, indicate, ifchanges, made, images, third, party, material, , included, 's, creative, commonslicence, unless, indicated, otherwise, credit, line, material, material, included, 's, creative, commonslicence, intended, use, permitted, statutory, regulation, exceeds, permitted, use, need, obtainpermission, directly, copyright, holder, view, copy, licence, visit, httpcreativecommonslicensesby40, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , schematics, sarscov2, attack, human, hace2, subsequent, immune, system, response, b, rbd, binding, hace2, withoutan, interference, c, rbd, complexed, antibody, receptor, attachment, site, hence, competing, hace2, d, rbd, complexed, rbd, asite, receptor, attaches, resulting, alteration, rbd, structure, interruption, lock, key, binding, rbd, hace2nanoclays, nanosized, natural, materials, originatingfrom, minerals, sedimentary, rocks, got, avery, high, affinity, bacteria, viruses, [], due, toisomorphous, substitution, molecular, structurethese, nanoclays, exhibit, charge, deficiency, theirsurfaces, charge, deficiency, surfaces, isneutralized, water, molecules, dissolvedcations, fig, , charged, structure, large, surface, area, clay, nanops, give, affinityfor, charged, entities, found, bacterial, surfacesand, bacterial, toxins, distinct, biomedical, properties, include, high, absorption, ability, engulf, microbes, toxicity, electrically, activeclay, minerals, distinct, morphology, characteristics, interaction, behavior, studied, biomedical, application, nanoclays, includes, serving, ascarriers, complexes, anticancer, drugs, as5fluorouracil, trastuzumab, [], havetherefore, potential, alternate, medicine, several, diseases, [], clay, nanops, due, theiradhesive, nature, also, used, carriers, forsustainedrelease, medicine, [, ], nanoclays, havealso, successfully, used, adsorb, treat, bovinerotavirus, bovine, coronavirus, [], researchers[], intercalated, methotrexate, mtx, anticanceragentinto, anionic, clay, create, nanohybriddrug, used, coprecipitation, subsequenthydrothermal, methodology, prepare, chemicallystructurally, morphologically, welldefined, twodimensional, drugclay, nanohybrid, researchers[], discovered, due, biocompatibility, andhigh, loading, capacity, bentonite, nanoclay, beused, preparation, drugdelivery, vehiclesthey, prepared, doxorubicinbentonitein, thisto, form, ananoclay, complex, doxbent, complexsustainedreleaseintradrugdeliverystudysystem, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , sem, image, b, corresponding, molecular, structure, namontmorillonite, showing, configuration, isomorphous, substitutioncharge, deficiency, interlayer, cations, []tumoral, chemotherapy, melanoma, montmorillonite, clay, recently, studied, used, anadditive, drug, carrier, materialthese, nanoclaycomposites, appeal, use, various, dosing, formmainly, controlled, release, drug, [], researchers, [], also, discovered, nanoclays, beused, recent, dual, functional, drug, delivery, systemsddss, efficiency, drug, delivery, soreduce, toxicity, doxorubicin, dox, used, thyroid, cancer, treatment, using, libraryof, , singlesingle, type, photo, cleavable, amphiphilicjanus, dendrimers, researchers, [], developed, selfassembling, lightresponsive, dendrimersomes, vesicleplatform, similar, nanoclays, surface, modifiedbioactive, virusmimicking, anic, nanovesicles, fromglycodendrimersomes, structural, modificationsthat, contribute, manifest, sarscov2, hostpathogenic, molecular, interactions, help, virusto, escape, human, immune, system, []through, considerable, previous, research, developedbasic, characterization, behavior, modeling, ofthecharged, clay, minerals, [], applications, thecontrol, cancer, metastasis, [], vitro, vivo, studies, melanoma, treatment, [], calcium, depositionbone, regeneration, studies, [], previous, study, bythe, authors, [], demonstrated, clay, nanops, got, high, affinity, charged, surfaces, thehigh, attraction, affinity, nanoclays, increasednonspecific, adhesion, attraction, cancer, cells, makenanoclays, favorable, candidates, control, cancer, metastasis, study, demonstrated, possible, use, twocharged, clay, minerals, control, metastasis, thecancer, cells, namontmorillonite, swy3, palygorskitepfll, findings, authors, previous, research, [], use, nanoclays, control, ofcancer, metastasis, also, vitro, vivostudies, established, nanoclays, inhibitory, effects, melanoma, cancer, cells, mainly, cell, proliferationand, viability, [], previous, studies, addition, tolaboratory, experiments, molecularlevel, simulations, werealso, performed, nanoclay, cells, interactionsthese, simulations, provided, assessment, relativelevel, cohesivenessaffinity, interactions, andwithout, clay, nanopsperceptionthroughthisestablishingbased, experience, authors, onthe, highaffinity, potential, nanoclays, propose, thatthe, nanoclays, mimicked, antibodies, canthus, attract, engulf, coronaviruses, get, engaged, human, hace2, paper, first, steptowardsamolecularlevelsimulation, modeling, approachbased, results, molecularlevel, simulationsan, outline, recommendations, next, phasesof, vitro, vivo, research, also, provided, thesenanoclays, also, successfully, used, medicinecarriers, also, premise, also, injectedingested, claysalone, medicine, thus, haveproposed, tentative, nanoclays, administration, methodology, purposematerialsmoleculesselection, formulation, sarscov2, hace2molecules, sarscov2, spike, hace2, acquired, protein, data, bank, website, rcsb, [], 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , molecular, models, sarscov2, spike, andhace2, formulated, materials, studio, software, [], arerespectively, shown, fig, 3a, b, subject, tothe, simulations, molecules, charged, using, thecharge, equilibration, method, qeq, softwareselection, formulation, nanoclay, crystallitenamontmorillonite, one, active, members, ofthe, smectite, group, clay, minerals, selected, thestudy, namontmorillonite, layered, phyllosilicate, claysmectite, fig, , colloidal, form, space, neighboring, layers, contain, free, sodium, calcium, magnesium, cations, electrostaticallyattracted, external, negatively, charged, surfaces, [], inits, dry, powdered, state, namontmorillonite, exists, asequidimensionalflakessheets, dimensions, approximately, , ã, , ã, , microns, fig, 2a, thesenegative, charges, interlayer, surfaces, balancedby, cations, colloids, interlayer, cations, get, dissociated, clay, ps, associate, themselveswith, negatively, charged, surfaces, ps, also, positively, charged, edges, due, presence, broken, bonds, ends, morphology, andfurther, characteristics, nanoclays, providedin, table, , formulation, crystallites, materials, studio, software, explained, belowin, software, namontmorillonite, crystallites, wereformulated, based, fundamental, properties, ascec, exchangeable, cations, interlayer, charges, table, size, molecularcrystallite, size, selectedbased, results, p, size, analysis, usingthe, dynamic, light, scattering, dls, technique, [], thefinal, form, clay, crystallite, created, software, istheseshown, fig, 3c, afterthe, preparation, ofcrystallites, design, mode, software, using, theinherent, properties, charged, using, chargeequilibration, method, qeq, softwaremethodsmolecularlevel, simulationsthis, part, study, consisted, simulation, andassessment, interactions, sarscov2, spikes, clay, crystallites, hace2, although, thesemodels, may, complete, replication, actual, vitro, conditions, incorporatedwith, essentialinteractions, quite, wellsuited, intended, relative, comparative, studyin, software, sorption, simulations, theformulated, configurations, sarscov2, namontmorillonite, crystallites, hace2, carriedout, using, monte, carlo, mc, molecular, mechanicsmm, techniques, enhancement, affinity, thesimulated, configurations, assessed, terms, thecalculated, cohesive, energy, density, cedced, beingconsidered, measurement, cohesiveness, themolecular, system, due, largesized, computationsinvolved, simulationsthese, calculations, werecarried, using, highperformance, computing, facilities, hpc, kfupm, ksa, overall, methodologyand, choice, particular, methods, simulationparameters, based, authors, previous, research[], detailed, subsequent, sectionsarscov2, spike, interactions, hace2, claycrystallitesto, simulate, interaction, sarscov2, claycrystallites, various, numbers, crystallites, namontmorillonite, clay, sorbed, sarscov2, smodel, sorption, simulations, metropolisfig, , molecularlevel, models, sarscov2, spike, b, hace2, c, namontmorillonite, crystallite, formulated, materials, studio, software, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , lnoitauccoflnoitcaretninoitcaretninoitcaretnininoisrepsidretawnoisrepsidygrenelatotygrenewdvygrenebalraopcilihpordyhacanretawytiniffasî³laitnetopvmpzatezreyalretniegrahclardehartetlardehatcolebaegnahcxeegrahcegrahcsnoitacqemgcececafrusnaeragmslarenmirehtoliacmehclaumrofacilisoisgmlaacanecruosytnuocasuywkoorc][ywsyacletinolliromtnomanfonoitaziretcarahcliacmehcdnalacisyhpfoyrammuselbat, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , monte, carlo, method, selected, sorption, module, software, sorption, step, clay, crystallitesoccupy, spaces, around, spike, model, lower, theoverall, energy, complex, required, number, ofcrystallites, sorbed, maximum, , stepsand, energy, system, minimized, usingthe, forcite, module, software, based, mdprinciples, similar, sorption, process, repeated, forthe, interaction, modeling, sarscov2, spike, molecule, hace2, process, hace2, moleculeswere, sorbed, around, rbd, spike, sarscov2, completion, sorption, process, theenergy, formulation, minimized, using, mdbased, module, softwarethe, forcite, module, ofthe, software, incorporatingnpt, constant, number, ps, pressure, andtemperature, ensemble, used, md, simulationswith, modified, universal, force, field, [], simulations, run, , , ps, interval, 05fs, ortill, constant, volume, obtained, berendsen, thermostat, decay, constant, , ps, used, controlthe, temperature, simulation, mdsimulations, assumed, temperature, kept, constantat, , k, , °c, atmospheric, pressure, , kpaa, berendsen, barostat, decay, constant, , pswas, used, control, pressure, system, theberendsen, methodology, considered, appropriate, single, crystallites, several, trials, involving, thermostats, barostats, available, thesoftware, monte, carlo, method, parametersfor, ratios, exchange, conformer, rotate, translateand, regrow, selected, , , , , respectively, corresponding, probabilities, , , , , amplitudes, adapted, rotationand, translation, °, , , respectivelycohesive, energy, density, ced, measurementin, study, assessment, affinitybindinglevelin, sarscov2clay, crystallites, sarscov2hace2, complexes, measured, thechanges, ced, sorption, clay, crystallites, subsequent, performance, moleculardynamics, configurations, ced, wasdetermined, using, cohesive, energy, density, optionof, forcite, module, software, authorshave, experienced, ced, concept, consisting, ofthe, total, van, der, waals, electrostatic, ceds, canquite, closely, explain, various, molecularlevel, processes, interactions, simulate, extent, affinitybinding, created, among, simulated, complexes[], quantitatively, ced, defined, amountof, energy, needed, transition, , mol, material, liquid, gaseous, phase, also, ameasureofaffinityattractivenessthe, mutualofmolecules, expressed, electrostatic, andvan, der, waalsan, nptensembleaveraged, overforcesin, forcite, module, van, der, waals, energies, wereevaluated, using, atombased, cutoffsin, methodnonbond, interactions, simply, calculated, cutoffdistance, interactions, beyond, distance, ignored, avoid, discontinuities, caused, direct, cutoffs, simulations, use, switching, function, turnoff, nonbond, interactions, range, distancessmoothly, effective, potential, created, multiplyingthe, actual, potential, smoothing, function, thechoice, function, intermediate, range, crucial, continuously, differentiable, region, forces, calculated, study, acubic, spline, smoothing, function, used, splinewidth, , , cutoff, distance, , results, discussionsthe, final, configuration, sarscov2, shace2complex, shown, fig, 4a, complexes, sarscov2, spike, different, numbers, claynamontmorillonite, crystallites, respectively, shownin, fig, 4b, c, comparison, purposes, total, ceds, ofvarious, proportionsnumbers, clay, crystallites, onthe, sarscov2, spike, interaction, laterwith, hace2, plotted, fig, based, experience, hypothesized, thatnanoclays, due, high, adhesive, properties, couldalso, act, sarscov2, inhibitors, bystrongly, associating, spike, present, sarscov2, results, obtained, molecularlevelsimulations, interactions, indicate, due, veryhigh, ced, sarscov2, nanoclays, ascompared, former, hace2, fig, , couldinhibit, sarscov2, getting, engaged, hace2moreover, also, concluded, fig, , thatthe, extent, inhibition, due, nanoclays, increased, inquantity, dosagedependent, waynanoclay, interactions, sarscov2, spike, sauthors, earlier, research, demonstrated, therole, nanoclays, promoting, adhesion, among, thecancer, cells, microenvironment, hence, controlling, metastasis, [], adhesion, measurements, , mix, namontmorillonite, palygorskite, showedan, increase, adhesion, , among, cancer, cells, andthe, extracellular, matrix, proteins, fig, 6a, corresponding, sem, nanoclays, binding, raji, cells, thefibronectin, proteins, shown, fig, 6b, sample, imagingwas, performed, sem, mode, fei, esemfeg, xl, atthe, miller, school, medicine, university, ofmiami, florida, authors, also, discovered, previousresearch, electrostatic, van, der, waals, zp, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , molecularlevel, simulation, results, materials, studio, software, sarscov2, hace2, ced, , , jcm3, b, sarscov2, modelinteracting, twelve, crystallites, namontmorillonite, ced, , , jcm3, c, sarscov2, model, interacting, twentyfour, crystallites, ofnamontmorillonite, ced, , , jcm3obtained, using, sorption, technique, implemented, softwareattractions, seem, dominating, adhesion, processes, [], conclude, mechanismswould, also, facilitated, binding, adhesivesurfaces, nanoclays, spike, sarscov2fig, , zp, measure, dispersion, flocculationtendency, colloidal, form, including, interactions, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , variation, cohesive, energy, density, ced, sarscov2, shace2, complexes, former, different, numbers, ofnamontmorillonite, crystalliteswith, constituents, present, suspensionmedium, general, rule, zeta, potential, greater, mv, either, positive, negative, indicates, dispersiontendency, zeta, potential, less, , mv, generally, results, agglomeration, higher, dispersion, tendencies, zp, clay, nanops, used, study, , , , mv, lead, higher, dispersion, tendency, andhence, generation, higher, surface, area, amplifyingthe, interactions, sarscov2, spike, althoughbased, zp, namontmorillonite, nanopshave, hydrophilic, nature, presence, saltsalso, promote, secondary, adhesion, mechanisms, betweenhydrophobic, hydrophilic, surfaces, [], alsobe, noted, clay, nanops, high, dispersion, tendency, due, hydrophilic, nature, relatively, higher, repulsive, acidbase, ab, interactions, table, high, dispersion, turn, results, generation, ofhigh, surface, area, increasing, attractive, interactions, higher, surface, areas, promote, larger, attractionsdue, van, der, waal, attractions, electrostaticforces, among, oppositely, charged, surfaces, besides, although, relatively, lesser, degree, positively, chargededges, namontmorillonite, ps, also, get, electrically, attracted, spike, sthe, results, molecularlevel, simulations, theinteraction, sarscov2, spike, clay, crystallites, fig, , also, confirm, interaction, behaviors, observed, sorption, claynanops, results, formation, closely, interacting, strong, van, der, waals, attraction, fields, van, derwaals, attraction, fields, create, higher, ced, claysarscov2, configuration, substantial, increase, totalced, addition, clay, crystallites, fig, , alsoa, testimony, high, affinity, sarscov2, withthese, ps, compared, affinity, formerwith, hace2systemagglutinationnanoclays, pseudoantibodiesbased, current, past, research, authors, establishing, highaffinity, potential, nanoclays, premise, nanoclays, mimicked, asantibodies, thus, attract, engulf, coronavirusesbefore, get, engaged, human, hace2, antibodiesare, glycoproteins, synthesized, plasma, cells, part, ofthe, adaptive, immune, response, assist, clearanceof, infection, body, antibodies, aid, infectionclearance, multiple, ways, opsonization, pathogens, facilitate, phagocytosis, activation, complementandneutralization, viruses, toxins, bound, theviral, surface, proteins, antibodies, prevent, entry, theviruses, cell, preventing, attachment, viruses, target, receptor, cell, antibody, binding, occur, different, sites, surface, proteinleading, various, mechanisms, cause, effect, case, sarscov2, two, viral, neutralizationmechanisms, antibodies, observed, [, ]and, shown, fig, 1c, d, one, mechanisms, involvesdirect, binding, antibodies, attachment, site, thesarscov2rbd, resulting, antibody, competingwith, target, receptor, hace2, another, mechanism, involves, binding, antibodies, sites, onrbd, without, competition, target, receptorthe, latter, shown, involved, neutralization, byof, microbes, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , summary, adhesion, force, measurements, among, rajirajifn, assembly, using, afm, treatment, various, proportionsof, namontmorillonite, palygorskite, clay, nanops, [], error, bars, represent, variations, trials, b, sem, image, binding, rajicells, fibronectin, proteins, produced, nanoclaysthe, potent, monoclonal, antibody, mab, discoveredin, study, [, ], analogous, antibodies, interaction, sarscov2, rbd, inhibiting, latter, toengage, hace2, similar, molecularlevel, model, isprepared, nanoclays, resulting, similar, inhibitionof, coronaviruses, shown, fig, , owing, theirvery, high, affinity, nanoclays, get, attracted, tospikes, sarscov2, thus, restrict, engagement, ofrbds, spikes, hace2proposed, nanoclay, administration, methodologyclay, use, drug, carriers, tested, multiple, timesyielding, promising, results, little, cytotoxicity, tocells, human, body, kaolinite, clay, mineral, wastested, use, potential, drug, delivery, system, andwas, shown, high, biocompatibility, lowas[]negligiblecytotoxicity, [], poly, dllactidecoglycolidemontmorillonite, nanop, cytotoxicity, vitro, alsodemonstratedpalygorskitepolyethyleneiminefluorescein, isothiocyanate, nanocomposites, also, exhibited, almost, cytotoxicity, vitro[], authors, also, experienced, injecting, nanoclayssubcutaneously, treatment, melanoma, duringin, vivo, studies, [], based, use, clay, cancerdrug, carrier, sustainedrelease, medicine[], propose, nanoclays, may, injected, asclayalone, medicine, subject, verification, vivoand, clinical, trialsalthough, nanoclays, nonbiodegradable, comprehensive, understanding, design, similar, inanic, nanops, metabolic, performancein, body, carried, study, [], also, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , three, possible, mechanisms, interactions, montmorillonite, nanoclay, sarscov2, spike, , electrostatic, attraction, amongpositively, charged, nanop, edges, naca, ions, negatively, charged, virus, surfaces, , van, der, waals, attractions, , zpelectrostatic, interactionscategorize, nanoclays, human, body, clearable, inanic, agentsconclusions, recommendationsbased, current, past, research, authors, establishing, highaffinity, potential, nanoclays, mimicked, antibodies, canthus, attract, engulf, coronaviruses, get, engaged, human, hace2the, results, molecularlevel, simulations, theinteraction, sarscov2, spike, clay, crystallites, result, formation, closely, interacting, strongvan, der, waals, attraction, fields, van, der, waals, attraction, fields, create, higher, ced, claysarscov, configuration, substantial, increase, total, ced, afterfig, , interaction, mechanism, nanoclay, ps, sarscov2, spike, inhibiting, interaction, later, hace2, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , addition, clay, crystallites, also, testimony, veryhigh, affinity, sarscov2, ps, compared, affinity, former, hace2we, propose, continue, research, carrying, outin, vitro, interaction, studies, sarscov2, anddifferent, percentage, nanoclays, based, theoptimum, dose, nanoclay, developed, vitrophase, suggest, carry, vivo, studies, animals, animal, study, carried, withand, without, nanoclay, finalize, nanoclay, dose, andshould, lay, foundation, clinical, trialsacknowledgementsthe, authors, highly, acknowledge, kfupm, providing, highperformancecomputing, research, facilitiesauthors, contributionsall, authors, equally, participated, research, levels, authorsread, approved, final, manuscriptfundingno, fundingavailability, data, materialsall, data, generated, analyzed, study, included, thispublished, ethics, approval, consent, participatenot, applicableconsent, publicationnot, applicablecompeting, intereststhe, authors, declare, competing, interestsauthor, details1civil, , environmental, engineering, department, king, fahd, university, ofpetroleum, , minerals, kfupm, dhahran, saudi, arabia, 2royal, college, ofsurgeons, ireland, rcsi, bahrain, campus, busaiteen, bahrain, 3engineering, research, international, eri, riyadh, saudi, arabiareceived, , july, , accepted, , august, referencesewen, callaway, nik, spencer, race, coronavirus, vaccines, agraphical, guide, eight, ways, scientists, hope, provide, immunityto, sarscov2, news, feature, nature, vol, , , april, li, f, li, w, h, farzan, m, , harrison, c, structure, sars, coronavirusspike, receptorbinding, domain, complexed, receptor, science, , , httpsdoi101126science1116480, li, wh, , , angiotensinconverting, enzyme, , functional, receptorfor, sars, coronavirus, nature, , httpsdoi101038nature02145li, f, , structural, analysis, major, species, barriers, humansand, palm, civets, severe, acute, respiratory, syndrome, coronavirusinfections, j, virol, , httpsdoi101128jvi0044208, wu, kl, peng, gq, wilken, m, geraghty, rj, li, f, , mechanisms, hostreceptor, adaptation, severe, acute, respiratory, syndrome, coronavirus, jbiol, chem, , httpsdoi101074jbcm111325803, wang, c, li, w, drabek, d, okba, nma, van, haperen, r, osterhaus, adme, , human, monoclonal, antibody, blocking, sarscov2, infection, natcommun, jiang, hillyer, c, du, l, , neutralizing, antibodies, sarscov2and, human, coronaviruses, trends, immunol, pinto, d, park, yj, beltramello, m, walls, ac, tortorici, ma, bianchi, , crossneutralization, sarscov2, human, monoclonal, sarscov, antibody, nature, da, rocha, dias, salmonson, van, zwietenboot, b, jonsson, b, marchetti, sschellens, jh, pignatti, f, , european, medicines, agency, review, ofvemurafenib, zelboraf®, treatment, adult, patients, braf, v600mutationpositive, unresectable, metastatic, melanoma, summary, thescientific, assessment, committee, medicinal, products, humanuse, eur, j, cancer, sahel, n, abduljauwad, habiburrehman, ahmed, enhancing, cancer, celladhesion, clay, nanops, countering, metastasis, nature, scientificreports, , april, , httpsdoi101038s4159801942498y, zhang, y, long, m, huang, p, yang, h, chang, hu, y, mao, l, intercalated, 2d, nanoclay, emerging, drug, delivery, cancer, therapynano, res, , chianelli, r, r, , das, , us, patent, , washington, dc, us, patent, trademark, office, han, liu, f, wu, j, zhang, y, xie, y, wu, y, , targeting, fluorescentpalygorskite, polyethyleneimine, nanocomposite, cancer, cells, appl, claysci, sun, b, ranganathan, b, feng, ss, , multifunctional, poly, d, llactidecoglycolide, montmorillonite, plgammt, nanops, decorated, bytrastuzumab, targeted, chemotherapy, breast, cancer, biomaterialslin, fh, lee, yh, jian, ch, wong, jm, shieh, mj, wang, cy, , study, ofpurified, montmorillonite, intercalated, 5fluorouracil, drug, carrierbiomaterials, , bothiraja, c, thorat, uh, pawar, ap, shaikh, ks, , chitosan, coated, layeredclay, montmorillonite, nanocomposites, modulate, oral, delivery, paclitaxel, incolonic, cancer, mater, technol, 29sup3b120b126kevadiya, bd, thumbar, rp, rajput, mm, rajkumar, brambhatt, h, joshi, gvbajaj, hc, , montmorillonitepolyîµcaprolactone, composites, asversatile, layered, material, reservoirs, anticancer, drug, controlledrelease, property, eur, j, pharm, sci, , guo, wang, af, muhammad, f, qi, wx, ren, h, guo, yj, zhu, gs, halloysite, nanotubes, multifunctional, nanovehicle, anticancer, drugdelivery, chin, j, chem, , martã­nez, c, d, cationic, clays, upon, cancer, therapy, virtual, multidisciplinaryconference, quaesti, , konta, j, , clay, man, clay, raw, materials, service, man, applclay, sci, , murray, hh, , traditional, new, applications, kaolin, smectite, andpalygorskite, general, overview, appl, clay, sci, , volzone, c, , retention, pollutant, gases, comparison, clayminerals, modified, products, appl, clay, sci, , dong, y, feng, ss, , poly, dllactidecoglycolidemontmorillonitenanops, oral, delivery, anticancer, drugs, biomaterials, , clarka, kj, sarrb, ab, grantb, pg, phillipsb, td, woodea, gn, , vitrostudies, use, clay, clay, minerals, charcoal, adsorb, bovinerotavirus, bovine, coronavirus, vet, microbiol, , choi, g, huiyan, p, alothman, z, vinu, yun, c, choy, j, anionic, clay, asthe, drug, delivery, vehicle, tumor, targeting, function, layered, doublehydroxidemethotrexate, nanohybrid, c33a, orthotopic, cervical, cancermodel, international, journal, nanomedicine, doi, httpsdoi102147ijns95611, , , hosseini, f, hosseini, f, jafari, m, taheri, bentonite, nanoclaybaseddrugdelivery, systems, treating, melanoma, clay, minerals, doi, httpsdoi101180clm201842018, inamuddin, asiri, m, mohammad, ali, applications, nanocompositematerials, drug, delivery, doi, httpsdoi101016c20160050751, avolume, woodhead, publishing, series, biomaterials, , zhang, y, long, m, huang, p, yang, h, chang, hu, y, tang, maol, emerging, integrated, nanoclayfacilitated, drug, delivery, system, forpapillary, thyroid, cancer, therapy, doi, 101038srep33335, sci, rep, , li, xia, b, javed, b, hasley, w, d, melendezdavila, liu, m, kerzner, magarwal, xiao, q, torre, p, bermudez, j, g, rahimi, k, kostina, n, ymã¶ller, m, rodriguezemmenegger, c, klein, m, percec, v, good, m, cdirect, visualization, vesicle, disassembly, reassembly, usingphotocleavable, dendrimers, elucidates, cargo, release, mechanisms, acs, 0cabduljauwad, , nanoscale, resear]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |[\", despite, several, efforts, development, an, effective, vaccine, covid19, may, take, much, longer, timetraditionalnatural, medicine, already, experienced, by, humans, could, be, an, earlier, solution, considering, researchteams, experience, using, nanoclays, as, highaffinity, material, cancer, metastasis, melanoma, treatment, andbone, regeneration, we, propose, use, these, nanoclays, preventiontreatment, covid19, owing, highaffinity, nanoclays, would, capture, viruses, before, latter, get, engaged, with, human, hace2, studymolecularlevel, simulations, modeling, interaction, coronavirus, spike, hace2, proteins, wereperformed, with, without, nanoclays, results, showed, very, high, level, affinitycohesiveness, among, sarscov2, spike, nanoclays, as, compared, one, between, former, hace2, we, premise, that, these, nanoclays, since, already, being, used, as, drug, carriers, could, also, be, injected, as, claysalone, medicine, recommendationshave, also, been, provided, future, vitro, vivo, studiesbackgroundthe, sudden, emergence, rapid, spread, novel, coronavirus, sarscov2, have, significantly, affected, thehealth, lives, human, beings, addition, criticallyaffecting, world, economy, sarscov2, spike, s, bindswith, high, affinity, human, angiotensinconverting, enzyme, , hace2, uses, it, as, an, entry, receptor, invade, target, cells, fig, 1a, b, [], virussurface, spikeprotein, mediates, coronavirus, entry, into, host, cellssarscov2, spike, protein, contains, receptorbindingdomain, rbd, that, recognizes, explicitly, as, its, receptorhace2, [, ], surface, hace2, contains, two, virusbinding, hotspots, that, are, criticalfor, sarscov2, sbinding, several, naturally, selected, mutations, sarscov2, rbd, surround, these, hotspots, regulate, theinfectivity, pathogenesis, crossspecies, humantohuman, transmissions, sarscov2, [, , ]at, present, there, are, no, clinically, approved, vaccinesor, drugs, that, specifically, target, sarscov2, followingthe, real, protocol, developing, vaccine, it, may, takemuch, longer, time, come, up, with, an, effective, vaccine, correspondence, habibrehmankfupmedusa3engineering, , research, international, eri, riyadh, saudi, arabiafull, list, author, information, available, at, end, there, lot, interest, development, therapeutic, antibodies, against, sarscov2, despite, many, efthese, antibodies, have, not, yet, beenforts, howeverdiscovered, [], exceptin, few, trials, [], one, trialshowed, potent, neutralization, sarscov2, bybinding, rbd, its, s, glycoprotein, [], trial[], antibody, cocktails, mixture, different, antibodiesis, recommended, due, increased, neutralization, effect, it, has, on, sarscov2, however, use, antibodiesin, past, from, convalescent, patients, sarscov, totreat, sarscov, infection, has, shown, adverse, reactionsin, patients, such, as, antibodydependent, enhancement, ade, causing, increased, viral, infectivity, otherharmful, immune, responses, [], moreover, based, on, theexperience, with, vaccine, development, efforts, forsarscov, mers, chances, materialization, ofthe, efforts, being, made, sarscov2, seems, quitethin, therefore, naturaltraditional, medicines, that, have, ahistory, safe, consumptioningestion, by, humans, couldbe, considered, as, one, treatment, options, sarscov2, being, natural, material, history, humanuseconsumption, we, suggest, highly, charged, nanoclays, be, used, as, coronavirus, blockers, inhibitorsof, spikemediated, entry, into, human, cells, authors, , , , access, , licensed, under, creative, commons, attribution, , international, licensewhich, permits, use, sharing, adaptation, distribution, reproduction, any, medium, or, format, as, long, as, you, giveappropriate, credit, original, authors, source, provide, link, creative, commons, licence, indicate, ifchanges, were, made, images, or, other, third, party, material, , are, included, 's, creative, commonslicence, unless, indicated, otherwise, credit, line, material, if, material, not, included, 's, creative, commonslicence, your, intended, use, not, permitted, by, statutory, regulation, or, exceeds, permitted, use, you, will, need, obtainpermission, directly, from, copyright, holder, view, copy, licence, visit, httpcreativecommonslicensesby40, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , schematics, sarscov2, attack, on, human, hace2, subsequent, immune, system, response, b, rbd, binding, hace2, withoutan, interference, c, rbd, complexed, with, antibody, at, receptor, attachment, site, hence, competing, with, hace2, d, rbd, complexed, with, rbd, at, asite, other, than, where, receptor, attaches, resulting, alteration, rbd, structure, interruption, lock, key, binding, rbd, hace2nanoclays, nanosized, natural, materials, originatingfrom, minerals, sedimentary, rocks, have, got, avery, high, affinity, bacteria, viruses, [], due, toisomorphous, substitution, their, molecular, structurethese, nanoclays, exhibit, charge, deficiency, on, theirsurfaces, charge, deficiency, on, their, surfaces, isneutralized, by, water, molecules, dissolvedcations, fig, , charged, structure, large, surface, area, clay, nanops, give, them, an, affinityfor, charged, entities, as, found, on, bacterial, surfacesand, bacterial, toxins, their, distinct, biomedical, properties, include, high, absorption, ability, engulf, microbes, no, toxicity, each, electrically, activeclay, minerals, has, its, distinct, morphology, characteristics, interaction, behavior, most, studied, biomedical, application, nanoclays, includes, serving, ascarriers, complexes, anticancer, drugs, such, as5fluorouracil, trastuzumab, [], they, havetherefore, been, potential, alternate, medicine, several, diseases, [], clay, nanops, due, theiradhesive, nature, have, also, been, used, as, carriers, forsustainedrelease, medicine, [, ], nanoclays, havealso, successfully, been, used, adsorb, treat, bovinerotavirus, bovine, coronavirus, [], researchers[], intercalated, methotrexate, mtx, an, anticanceragentinto, anionic, clay, create, nanohybriddrug, they, used, coprecipitation, subsequenthydrothermal, methodology, prepare, chemicallystructurally, morphologically, welldefined, twodimensional, drugclay, nanohybrid, researchers[], discovered, that, due, biocompatibility, andhigh, loading, capacity, bentonite, nanoclay, could, beused, preparation, drugdelivery, vehiclesthey, prepared, doxorubicinbentonitein, thisto, form, ananoclay, complex, doxbent, complexsustainedreleaseintradrugdeliverystudysystem, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , sem, image, b, corresponding, molecular, structure, namontmorillonite, showing, configuration, isomorphous, substitutioncharge, deficiency, interlayer, cations, from, []tumoral, chemotherapy, melanoma, as, montmorillonite, clay, recently, being, studied, be, used, as, anadditive, drug, carrier, materialthese, nanoclaycomposites, appeal, their, use, various, dosing, formmainly, controlled, release, drug, [], researchers, [], also, discovered, that, nanoclays, can, beused, into, recent, dual, functional, drug, delivery, systemsddss, have, efficiency, drug, delivery, soreduce, toxicity, doxorubicin, dox, that, being, used, thyroid, cancer, treatment, using, libraryof, , singlesingle, type, photo, cleavable, amphiphilicjanus, dendrimers, researchers, [], developed, selfassembling, lightresponsive, dendrimersomes, vesicleplatform, similar, nanoclays, surface, modifiedbioactive, virusmimicking, anic, nanovesicles, fromglycodendrimersomes, have, structural, modificationsthat, contribute, manifest, sarscov2, hostpathogenic, molecular, interactions, that, help, virusto, escape, from, human, immune, system, []through, considerable, previous, research, we, developedbasic, characterization, behavior, modeling, ofthecharged, clay, minerals, [], their, applications, thecontrol, cancer, metastasis, [], vitro, vivo, studies, on, melanoma, treatment, [], calcium, depositionbone, regeneration, studies, [], previous, study, bythe, authors, [], it, demonstrated, that, clay, nanops, had, got, high, affinity, charged, surfaces, thehigh, attraction, affinity, nanoclays, increasednonspecific, adhesion, attraction, cancer, cells, makenanoclays, favorable, candidates, control, cancer, metastasis, that, study, we, demonstrated, possible, use, twocharged, clay, minerals, control, metastasis, thecancer, cells, namontmorillonite, swy3, palygorskitepfll, further, findings, authors, previous, research, [], on, use, these, nanoclays, control, ofcancer, metastasis, we, also, through, vitro, vivostudies, established, that, these, nanoclays, have, inhibitory, effects, on, melanoma, cancer, cells, mainly, on, cell, proliferationand, viability, [], these, previous, studies, addition, tolaboratory, experiments, molecularlevel, simulations, werealso, performed, on, nanoclay, cells, interactionsthese, simulations, provided, assessment, relativelevel, cohesivenessaffinity, interactions, with, andwithout, clay, nanopsperceptionthroughthisestablishingbased, on, all, above, experience, authors, onthe, highaffinity, potential, nanoclays, we, propose, thatthe, nanoclays, could, be, mimicked, as, antibodies, canthus, attract, engulf, coronaviruses, before, they, get, engaged, with, human, hace2, paper, first, steptowardsamolecularlevelsimulation, modeling, approachbased, on, results, molecularlevel, simulationsan, outline, recommendations, next, phasesof, vitro, vivo, research, also, provided, as, thesenanoclays, are, also, successfully, being, used, as, medicinecarriers, we, also, premise, that, they, can, also, be, injectedingested, as, claysalone, medicine, thus, we, haveproposed, tentative, nanoclays, administration, methodology, purposematerialsmoleculesselection, formulation, sarscov2, hace2molecules, sarscov2, spike, s, hace2, were, acquired, from, protein, data, bank, website, rcsb, [], 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , molecular, models, sarscov2, spike, s, andhace2, formulated, materials, studio, software, [], arerespectively, shown, fig, 3a, b, before, being, subject, tothe, simulations, these, molecules, were, charged, using, thecharge, equilibration, method, qeq, softwareselection, formulation, nanoclay, crystallitenamontmorillonite, one, most, active, members, ofthe, smectite, group, clay, minerals, selected, thestudy, namontmorillonite, layered, phyllosilicate, claysmectite, fig, , colloidal, form, space, between, neighboring, layers, can, contain, free, sodium, calcium, or, magnesium, cations, that, are, electrostaticallyattracted, external, negatively, charged, surfaces, [], inits, dry, powdered, state, namontmorillonite, exists, asequidimensionalflakessheets, with, dimensions, approximately, , ã, , ã, , microns, fig, 2a, thesenegative, charges, on, their, interlayer, surfaces, are, balancedby, cations, as, colloids, interlayer, cations, get, dissociated, from, clay, ps, associate, themselveswith, other, negatively, charged, surfaces, these, ps, also, have, positively, charged, edges, due, presence, broken, bonds, at, their, ends, morphology, andfurther, characteristics, these, nanoclays, are, providedin, table, , while, formulation, their, crystallites, materials, studio, software, are, explained, belowin, software, namontmorillonite, crystallites, wereformulated, based, on, fundamental, properties, such, ascec, exchangeable, cations, interlayer, charges, table, size, molecularcrystallite, size, selectedbased, on, results, p, size, analysis, usingthe, dynamic, light, scattering, dls, technique, [], thefinal, form, clay, crystallite, created, software, istheseshown, fig, 3c, afterthe, preparation, ofcrystallites, design, mode, software, using, theinherent, properties, these, were, charged, using, chargeequilibration, method, qeq, softwaremethodsmolecularlevel, simulationsthis, part, study, consisted, simulation, andassessment, interactions, sarscov2, spikes, with, clay, crystallites, with, hace2, although, thesemodels, may, not, be, complete, replication, actual, vitro, conditions, these, have, been, incorporatedwith, all, essentialinteractions, are, quite, wellsuited, intended, relative, comparative, studyin, software, sorption, simulations, theformulated, configurations, sarscov2, s, namontmorillonite, crystallites, hace2, were, carriedout, using, monte, carlo, mc, molecular, mechanicsmm, techniques, enhancement, affinity, all, thesimulated, configurations, assessed, terms, thecalculated, cohesive, energy, density, cedced, beingconsidered, as, measurement, cohesiveness, themolecular, system, due, largesized, computationsinvolved, simulationsthese, calculations, werecarried, out, using, highperformance, computing, facilities, hpc, at, kfupm, ksa, overall, methodologyand, choice, particular, methods, simulationparameters, were, based, on, authors, previous, research[], while, it, detailed, subsequent, sectionsarscov2, spike, s, interactions, with, hace2, claycrystallitesto, simulate, interaction, sarscov2, s, with, claycrystallites, various, numbers, crystallites, namontmorillonite, clay, were, sorbed, on, sarscov2, smodel, these, sorption, simulations, metropolisfig, , molecularlevel, models, sarscov2, spike, b, hace2, c, namontmorillonite, crystallite, formulated, materials, studio, software, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , lnoitauccoflnoitcaretninoitcaretninoitcaretnininoisrepsidretawnoisrepsidygrenelatotygrenewdvygrenebalraopcilihpordyhacanretawytiniffasî³laitnetopvmpzatezreyalretniegrahclardehartetlardehatcolebaegnahcxeegrahcegrahcsnoitacqemgcececafrusnaeragmslarenmirehtoliacmehclaumrofacilisoisgmlaacanecruosytnuocasuywkoorc][ywsyacletinolliromtnomanfonoitaziretcarahcliacmehcdnalacisyhpfoyrammuselbat, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , monte, carlo, method, selected, sorption, module, software, each, sorption, step, clay, crystallitesoccupy, spaces, around, spike, s, model, lower, theoverall, energy, complex, required, number, ofcrystallites, were, sorbed, maximum, , stepsand, then, energy, system, minimized, usingthe, forcite, module, software, based, on, mdprinciples, similar, sorption, process, repeated, forthe, interaction, modeling, sarscov2, spike, molecule, with, hace2, process, hace2, moleculeswere, sorbed, around, rbd, spike, s, sarscov2, after, completion, sorption, process, theenergy, formulation, minimized, using, mdbased, module, softwarethe, forcite, module, ofthe, software, incorporatingnpt, constant, number, ps, pressure, andtemperature, ensemble, used, md, simulationswith, modified, universal, force, field, [], simulations, were, run, , , ps, with, an, interval, 05fs, ortill, constant, volume, obtained, berendsen, thermostat, with, decay, constant, , ps, used, controlthe, temperature, during, simulation, during, mdsimulations, assumed, temperature, kept, constantat, , k, , °c, with, an, atmospheric, pressure, , kpaa, berendsen, barostat, with, decay, constant, , pswas, used, control, pressure, system, theberendsen, methodology, considered, as, most, appropriate, single, crystallites, after, several, trials, involving, other, thermostats, barostats, available, thesoftware, monte, carlo, method, parametersfor, ratios, exchange, conformer, rotate, translateand, regrow, were, selected, as, , , , , respectively, with, corresponding, probabilities, as, , , , , amplitudes, adapted, rotationand, translation, were, °, , , respectivelycohesive, energy, density, ced, measurementin, study, assessment, affinitybindinglevelin, sarscov2clay, crystallites, sarscov2hace2, complexes, measured, through, thechanges, ced, after, sorption, clay, crystallites, subsequent, performance, moleculardynamics, each, configurations, ced, wasdetermined, using, cohesive, energy, density, optionof, forcite, module, software, authorshave, experienced, that, ced, concept, consisting, ofthe, total, van, der, waals, electrostatic, ceds, canquite, closely, explain, various, molecularlevel, processes, interactions, simulate, extent, affinitybinding, created, among, simulated, complexes[], quantitatively, ced, defined, as, amountof, energy, needed, transition, , mol, material, from, liquid, gaseous, phase, it, also, ameasureofaffinityattractivenessthe, mutualofmolecules, expressed, both, as, electrostatic, andvan, der, waalsan, nptensembleaveraged, overforcesin, forcite, module, van, der, waals, energies, wereevaluated, using, atombased, cutoffsin, methodnonbond, interactions, are, simply, calculated, cutoffdistance, interactions, beyond, distance, are, ignored, avoid, discontinuities, caused, by, direct, cutoffs, most, simulations, use, switching, function, turnoff, nonbond, interactions, over, range, distancessmoothly, an, effective, potential, created, by, multiplyingthe, actual, potential, by, smoothing, function, thechoice, function, intermediate, range, crucial, should, be, continuously, differentiable, region, so, that, forces, can, be, calculated, study, acubic, spline, smoothing, function, used, with, splinewidth, , , cutoff, distance, , results, discussionsthe, final, configuration, sarscov2, shace2complex, shown, fig, 4a, while, complexes, between, sarscov2, spike, different, numbers, claynamontmorillonite, crystallites, are, respectively, shownin, fig, 4b, c, comparison, purposes, total, ceds, ofvarious, proportionsnumbers, clay, crystallites, onthe, sarscov2, spike, interaction, laterwith, hace2, are, plotted, fig, based, on, our, experience, we, have, hypothesized, thatnanoclays, due, their, high, adhesive, properties, couldalso, act, as, sarscov2, inhibitors, they, can, do, it, bystrongly, associating, with, spike, s, present, on, sarscov2, results, obtained, from, molecularlevelsimulations, interactions, indicate, that, due, veryhigh, ced, between, sarscov2, nanoclays, ascompared, former, hace2, fig, , they, couldinhibit, sarscov2, from, getting, engaged, with, hace2moreover, it, could, also, be, concluded, from, fig, , thatthe, extent, inhibition, due, nanoclays, increased, inquantity, dosagedependent, waynanoclay, interactions, with, sarscov2, spike, sauthors, their, earlier, research, have, demonstrated, therole, nanoclays, promoting, adhesion, among, thecancer, cells, their, microenvironment, hence, controlling, metastasis, [], adhesion, measurements, , mix, namontmorillonite, palygorskite, showedan, increase, adhesion, by, , among, cancer, cells, andthe, extracellular, matrix, proteins, fig, 6a, corresponding, sem, nanoclays, binding, raji, cells, thefibronectin, proteins, shown, fig, 6b, sample, imagingwas, performed, sem, mode, an, fei, esemfeg, xl, atthe, miller, school, medicine, university, ofmiami, florida, authors, also, discovered, their, previousresearch, that, electrostatic, van, der, waals, zp, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , molecularlevel, simulation, results, materials, studio, software, sarscov2, s, hace2, ced, , , jcm3, b, sarscov2, s, modelinteracting, with, twelve, crystallites, namontmorillonite, ced, , , jcm3, c, sarscov2, s, model, interacting, with, twentyfour, crystallites, ofnamontmorillonite, ced, , , jcm3obtained, using, sorption, technique, implemented, softwareattractions, seem, be, dominating, adhesion, processes, [], we, conclude, that, same, mechanismswould, have, also, facilitated, binding, adhesivesurfaces, nanoclays, spike, sarscov2fig, , zp, measure, dispersion, or, flocculationtendency, colloidal, form, including, interactions, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , variation, cohesive, energy, density, ced, sarscov2, shace2, complexes, former, with, different, numbers, ofnamontmorillonite, crystalliteswith, other, constituents, present, suspensionmedium, as, general, rule, zeta, potential, greater, than, mv, either, positive, or, negative, indicates, dispersiontendency, while, zeta, potential, less, than, , mv, generally, results, agglomeration, higher, dispersion, tendencies, zp, clay, nanops, used, study, , , , mv, lead, higher, dispersion, tendency, andhence, generation, higher, surface, area, amplifyingthe, interactions, with, sarscov2, spike, althoughbased, on, their, zp, namontmorillonite, nanopshave, hydrophilic, nature, they, presence, saltsalso, promote, secondary, adhesion, mechanisms, betweenhydrophobic, hydrophilic, surfaces, [], it, should, alsobe, noted, that, these, clay, nanops, have, high, dispersion, tendency, due, their, hydrophilic, nature, relatively, higher, repulsive, acidbase, ab, interactions, table, high, dispersion, turn, results, generation, ofhigh, surface, area, increasing, attractive, interactions, higher, surface, areas, promote, larger, attractionsdue, van, der, waal, attractions, electrostaticforces, among, oppositely, charged, surfaces, besides, although, relatively, lesser, degree, positively, chargededges, namontmorillonite, ps, also, get, electrically, attracted, spike, sthe, results, molecularlevel, simulations, theinteraction, sarscov2, spike, s, with, clay, crystallites, fig, , also, confirm, above, interaction, behaviors, it, has, been, observed, that, sorption, claynanops, results, formation, closely, interacting, strong, van, der, waals, attraction, fields, these, van, derwaals, attraction, fields, create, higher, ced, claysarscov2, configuration, substantial, increase, totalced, after, addition, clay, crystallites, fig, , alsoa, testimony, very, high, affinity, sarscov2, withthese, ps, as, compared, affinity, formerwith, hace2systemagglutinationnanoclays, as, pseudoantibodiesbased, on, all, current, past, research, by, authors, establishing, highaffinity, potential, nanoclays, we, premise, that, nanoclays, could, be, mimicked, asantibodies, can, thus, attract, engulf, coronavirusesbefore, they, get, engaged, with, human, hace2, antibodiesare, glycoproteins, synthesized, by, plasma, cells, as, part, ofthe, adaptive, immune, response, assist, clearanceof, infection, from, body, antibodies, aid, infectionclearance, multiple, ways, such, as, opsonization, pathogens, facilitate, phagocytosis, activation, complementandneutralization, viruses, toxins, when, bound, theviral, surface, proteins, antibodies, prevent, entry, theviruses, into, cell, by, preventing, attachment, viruses, their, target, receptor, on, cell, antibody, binding, can, occur, at, different, sites, on, surface, proteinleading, various, mechanisms, that, cause, same, effect, case, sarscov2, two, viral, neutralizationmechanisms, by, antibodies, have, been, observed, [, ]and, shown, fig, 1c, d, one, mechanisms, involvesdirect, binding, antibodies, attachment, site, thesarscov2rbd, resulting, antibody, competingwith, target, receptor, hace2, another, mechanism, involves, binding, antibodies, other, sites, onrbd, without, any, competition, with, target, receptorthe, latter, shown, be, involved, neutralization, byof, microbes, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , summary, adhesion, force, measurements, among, rajirajifn, assembly, using, afm, before, after, treatment, with, various, proportionsof, namontmorillonite, palygorskite, clay, nanops, [], error, bars, represent, variations, trials, b, sem, image, binding, rajicells, fibronectin, proteins, produced, by, nanoclaysthe, most, potent, monoclonal, antibody, mab, discoveredin, study, [, ], analogous, antibodies, interaction, with, sarscov2, rbd, inhibiting, latter, toengage, with, hace2, similar, molecularlevel, model, isprepared, nanoclays, resulting, similar, inhibitionof, coronaviruses, shown, fig, , owing, theirvery, high, affinity, nanoclays, would, get, attracted, tospikes, sarscov2, thus, restrict, engagement, ofrbds, these, spikes, with, hace2proposed, nanoclay, administration, methodologyclay, use, as, drug, carriers, has, been, tested, multiple, timesyielding, promising, results, little, no, cytotoxicity, tocells, human, body, kaolinite, clay, mineral, wastested, use, potential, drug, delivery, system, andwas, shown, have, high, biocompatibility, very, lowas[]negligiblecytotoxicity, [], poly, dllactidecoglycolidemontmorillonite, nanop, cytotoxicity, vitro, alsodemonstratedpalygorskitepolyethyleneiminefluorescein, isothiocyanate, nanocomposites, also, exhibited, almost, no, cytotoxicity, vitro[], authors, have, also, experienced, injecting, nanoclayssubcutaneously, treatment, melanoma, duringin, vivo, studies, [], based, on, use, clay, as, cancerdrug, carrier, other, sustainedrelease, medicine[], we, propose, that, nanoclays, may, be, injected, asclayalone, medicine, subject, verification, vivoand, clinical, trialsalthough, nanoclays, are, nonbiodegradable, comprehensive, understanding, design, similar, inanic, nanops, with, their, metabolic, performancein, body, carried, out, study, [], could, also, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , fig, , three, possible, mechanisms, interactions, montmorillonite, nanoclay, with, sarscov2, spike, s, , electrostatic, attraction, amongpositively, charged, nanop, edges, naca, ions, with, negatively, charged, virus, surfaces, , van, der, waals, attractions, , zpelectrostatic, interactionscategorize, these, nanoclays, as, human, body, clearable, inanic, agentsconclusions, recommendationsbased, on, all, current, past, research, by, authors, establishing, highaffinity, potential, nanoclays, these, could, be, mimicked, as, antibodies, canthus, attract, engulf, coronaviruses, before, they, get, engaged, with, human, hace2the, results, molecularlevel, simulations, theinteraction, sarscov2, spike, s, with, clay, crystallites, result, formation, closely, interacting, strongvan, der, waals, attraction, fields, these, van, der, waals, attraction, fields, create, higher, ced, claysarscov, configuration, substantial, increase, total, ced, afterfig, , interaction, mechanism, nanoclay, ps, with, sarscov2, spike, s, inhibiting, interaction, later, with, hace2, 0cabduljauwad, , nanoscale, research, letters, , , , , , , , , , , , page, , addition, clay, crystallites, also, testimony, veryhigh, affinity, sarscov2, with, these, ps, as, compared, affinity, former, with, hace2we, propose, continue, research, by, carrying, outin, vitro, interaction, studies, between, sarscov2, anddifferent, percentage, nanoclays, based, on, theoptimum, dose, nanoclay, developed, vitrophase, we, suggest, carry, out, vivo, studies, on, animals, animal, study, should, be, carried, out, both, withand, without, nanoclay, finalize, nanoclay, dose, andshould, lay, foundation, clinical, trialsacknowledgementsthe, authors, highly, acknowledge, kfupm, providing, highperformancecomputing, research, facilitiesauthors, contributionsall, authors, equally, participated, at, all, research, levels, authorsread, approved, final, manuscriptfundingno, fundingavailability, data, materialsall, data, generated, or, analyzed, during, study, are, included, thispublished, ethics, approval, consent, participatenot, applicableconsent, publicationnot, applicablecompeting, intereststhe, authors, declare, that, they, have, no, competing, interestsauthor, details1civil, , environmental, engineering, department, king, fahd, university, ofpetroleum, , minerals, kfupm, dhahran, saudi, arabia, 2royal, college, ofsurgeons, ireland, rcsi, bahrain, campus, busaiteen, bahrain, 3engineering, research, international, eri, riyadh, saudi, arabiareceived, , july, , accepted, , august, referencesewen, callaway, nik, spencer, race, coronavirus, vaccines, agraphical, guide, eight, ways, which, scientists, hope, provide, immunityto, sarscov2, news, feature, nature, vol, , , april, li, f, li, w, h, farzan, m, , harrison, s, c, structure, sars, coronavirusspike, receptorbinding, domain, complexed, with, receptor, science, , , httpsdoi101126science1116480, li, wh, , , angiotensinconverting, enzyme, , functional, receptorfor, sars, coronavirus, nature, , httpsdoi101038nature02145li, f, , structural, analysis, major, species, barriers, between, humansand, palm, civets, severe, acute, respiratory, syndrome, coronavirusinfections, j, virol, , httpsdoi101128jvi0044208, wu, kl, peng, gq, wilken, m, geraghty, rj, li, f, , mechanisms, hostreceptor, adaptation, by, severe, acute, respiratory, syndrome, coronavirus, jbiol, chem, , httpsdoi101074jbcm111325803, wang, c, li, w, drabek, d, okba, nma, van, haperen, r, osterhaus, adme, , human, monoclonal, antibody, blocking, sarscov2, infection, natcommun, jiang, s, hillyer, c, du, l, , neutralizing, antibodies, against, sarscov2and, other, human, coronaviruses, trends, immunol, pinto, d, park, yj, beltramello, m, walls, ac, tortorici, ma, bianchi, s, , crossneutralization, sarscov2, by, human, monoclonal, sarscov, antibody, nature, da, rocha, dias, s, salmonson, t, van, zwietenboot, b, jonsson, b, marchetti, sschellens, jh, pignatti, f, , european, medicines, agency, review, ofvemurafenib, zelboraf®, treatment, adult, patients, with, braf, v600mutationpositive, unresectable, or, metastatic, melanoma, summary, thescientific, assessment, committee, medicinal, products, humanuse, eur, j, cancer, sahel, n, abduljauwad, habiburrehman, ahmed, enhancing, cancer, celladhesion, with, clay, nanops, countering, metastasis, nature, scientificreports, , april, , httpsdoi101038s4159801942498y, zhang, y, long, m, huang, p, yang, h, chang, s, hu, y, mao, l, intercalated, 2d, nanoclay, emerging, drug, delivery, cancer, therapynano, res, , chianelli, r, r, , das, s, , us, patent, no, , washington, dc, us, patent, trademark, office, han, s, liu, f, wu, j, zhang, y, xie, y, wu, t, y, , targeting, fluorescentpalygorskite, polyethyleneimine, nanocomposite, cancer, cells, appl, claysci, sun, b, ranganathan, b, feng, ss, , multifunctional, poly, d, llactidecoglycolide, montmorillonite, plgammt, nanops, decorated, bytrastuzumab, targeted, chemotherapy, breast, cancer, biomaterialslin, fh, lee, yh, jian, ch, wong, jm, shieh, mj, wang, cy, , study, ofpurified, montmorillonite, intercalated, with, 5fluorouracil, as, drug, carrierbiomaterials, , bothiraja, c, thorat, uh, pawar, ap, shaikh, ks, , chitosan, coated, layeredclay, montmorillonite, nanocomposites, modulate, oral, delivery, paclitaxel, incolonic, cancer, mater, technol, 29sup3b120b126kevadiya, bd, thumbar, rp, rajput, mm, rajkumar, s, brambhatt, h, joshi, gvbajaj, hc, , montmorillonitepolyîµcaprolactone, composites, asversatile, layered, material, reservoirs, anticancer, drug, controlledrelease, property, eur, j, pharm, sci, , guo, my, wang, af, muhammad, f, qi, wx, ren, h, guo, yj, zhu, gs, halloysite, nanotubes, multifunctional, nanovehicle, anticancer, drugdelivery, chin, j, chem, , martã­nez, c, d, cationic, clays, upon, cancer, therapy, virtual, multidisciplinaryconference, quaesti, , konta, j, , clay, man, clay, raw, materials, service, man, applclay, sci, , murray, hh, , traditional, new, applications, kaolin, smectite, andpalygorskite, general, overview, appl, clay, sci, , volzone, c, , retention, pollutant, gases, comparison, between, clayminerals, their, modified, products, appl, clay, sci, , dong, y, feng, ss, , poly, dllactidecoglycolidemontmorillonitenanops, oral, delivery, anticancer, drugs, biomaterials, , clarka, kj, sarrb, ab, grantb, pg, phillipsb, td, woodea, gn, , vitrostudies, on, use, clay, clay, minerals, charcoal, adsorb, bovinerotavirus, bovine, coronavirus, vet, microbiol, , choi, g, huiyan, p, alothman, z, vinu, yun, c, choy, j, anionic, clay, asthe, drug, delivery, vehicle, tumor, targeting, function, layered, doublehydroxidemethotrexate, nanohybrid, c33a, orthotopic, cervical, cancermodel, international, journal, nanomedicine, doi, httpsdoi102147ijns95611, , , hosseini, f, hosseini, f, jafari, s, m, taheri, bentonite, nanoclaybaseddrugdelivery, systems, treating, melanoma, clay, minerals, doi, httpsdoi101180clm201842018, inamuddin, asiri, m, mohammad, ali, applications, nanocompositematerials, drug, delivery, doi, httpsdoi101016c20160050751, avolume, woodhead, publishing, series, biomaterials, , zhang, y, long, m, huang, p, yang, h, chang, s, hu, y, tang, maol, emerging, integrated, nanoclayfacilitated, drug, delivery, system, forpapillary, thyroid, cancer, therapy, doi, 101038srep33335, sci, rep, , li, s, xia, b, javed, b, hasley, w, d, melendezdavila, liu, m, kerzner, magarwal, s, xiao, q, torre, p, bermudez, j, g, rahimi, k, kostina, n, ymã¶ller, m, rodriguezemmenegger, c, klein, m, percec, v, good, m, cdirect, visualization, vesicle, disassembly, reassembly, usingphotocleavable, dendrimers, elucidates, cargo, release, mechanisms, acs, 0cabduljauwad, , nanoscale, resear]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |(224581,[0,1,2,3,4,5,6,7,8,9,10,11,12,13,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,32,33,34,35,36,37,38,39,40,42,43,44,45,46,47,49,50,51,54,55,57,58,59,60,61,62,63,64,65,66,67,69,73,74,75,76,77,78,79,80,81,82,83,85,86,87,89,90,91,92,93,94,95,96,99,101,104,106,108,109,110,112,113,115,116,118,119,120,122,123,125,129,130,131,132,134,137,138,142,144,145,146,147,148,151,152,153,156,158,159,160,163,166,167,169,170,173,175,178,179,180,182,188,189,191,192,194,196,197,199,200,202,205,207,215,216,217,218,220,221,222,223,224,225,230,231,232,235,236,240,241,243,244,245,246,248,249,250,253,255,260,262,265,266,269,270,274,275,280,281,285,288,292,294,295,299,301,303,305,306,308,311,312,313,315,317,321,322,324,325,332,333,336,337,340,343,345,346,348,350,353,355,358,359,360,361,366,367,374,377,379,380,381,383,387,389,394,397,398,400,408,409,410,413,416,418,419,421,423,424,425,426,427,428,431,435,436,437,439,441,442,445,447,448,450,452,453,457,463,464,466,471,474,475,476,477,484,486,490,492,494,497,498,499,505,507,517,518,519,524,529,532,542,543,547,548,549,550,551,555,558,559,560,562,563,571,576,579,582,584,590,594,596,600,605,608,609,617,619,622,623,627,629,633,636,637,638,639,640,646,647,650,654,660,661,667,668,669,686,687,692,697,700,701,703,707,716,718,725,729,731,732,736,742,743,747,749,756,762,765,772,774,775,778,782,785,789,791,792,793,794,797,805,806,807,808,809,811,814,820,824,825,831,832,834,835,838,841,842,848,856,857,859,873,876,881,882,884,886,890,893,896,898,901,911,914,916,920,929,932,933,938,948,954,958,982,986,991,992,994,996,997,999,1001,1007,1011,1012,1022,1034,1036,1037,1039,1041,1046,1047,1051,1059,1061,1067,1071,1075,1076,1081,1083,1084,1086,1094,1099,1104,1122,1125,1132,1134,1135,1136,1137,1140,1143,1145,1157,1160,1164,1176,1180,1189,1192,1195,1198,1202,1206,1209,1214,1231,1232,1234,1241,1242,1245,1248,1259,1261,1266,1267,1268,1273,1274,1276,1279,1286,1297,1298,1304,1305,1311,1317,1321,1323,1330,1335,1339,1348,1350,1352,1353,1363,1380,1387,1393,1402,1409,1417,1422,1426,1428,1435,1437,1454,1456,1457,1458,1459,1462,1470,1477,1487,1497,1509,1512,1514,1521,1527,1543,1549,1553,1554,1573,1582,1585,1597,1600,1610,1614,1615,1617,1620,1633,1637,1638,1640,1651,1655,1660,1666,1670,1686,1693,1695,1700,1711,1720,1741,1744,1749,1750,1757,1758,1769,1770,1773,1779,1781,1806,1814,1820,1834,1835,1851,1853,1854,1857,1860,1874,1897,1915,1917,1923,1930,1934,1940,1974,1977,1981,1992,2007,2019,2025,2047,2049,2075,2082,2084,2101,2111,2115,2133,2135,2143,2145,2149,2154,2156,2159,2179,2183,2197,2198,2213,2222,2228,2262,2266,2268,2285,2296,2297,2304,2333,2356,2362,2365,2400,2412,2420,2429,2448,2455,2459,2474,2475,2489,2508,2509,2510,2512,2524,2536,2540,2544,2554,2572,2586,2587,2589,2590,2600,2622,2640,2643,2646,2658,2690,2695,2708,2716,2746,2758,2777,2825,2837,2845,2853,2871,2878,2886,2889,2891,2896,2908,2912,2931,2932,2936,2968,2973,2976,2979,2999,3021,3042,3048,3072,3076,3084,3087,3090,3092,3095,3116,3132,3161,3181,3228,3248,3251,3252,3257,3258,3273,3280,3288,3318,3331,3335,3351,3374,3397,3405,3410,3423,3426,3439,3442,3448,3460,3480,3486,3518,3530,3544,3545,3601,3626,3647,3664,3694,3702,3706,3721,3745,3840,3844,3855,3862,3869,3876,3877,3898,3909,4018,4032,4069,4086,4088,4103,4106,4112,4153,4188,4193,4231,4242,4246,4277,4283,4294,4326,4359,4369,4462,4482,4580,4594,4609,4611,4612,4615,4627,4635,4675,4787,4850,4858,4900,4908,4937,4962,4963,4967,4988,5001,5018,5030,5031,5046,5064,5076,5144,5217,5233,5295,5300,5344,5382,5416,5474,5490,5505,5543,5545,5553,5564,5594,5595,5606,5618,5647,5653,5661,5725,5737,5748,5886,5889,5897,5916,5926,5966,5993,6028,6036,6059,6075,6149,6173,6216,6243,6362,6402,6408,6422,6424,6458,6504,6547,6589,6602,6642,6671,6681,6738,6761,6762,6779,6780,6827,6838,6867,6876,6919,6923,6933,7007,7025,7043,7085,7097,7154,7185,7234,7239,7248,7285,7346,7347,7408,7411,7419,7521,7567,7588,7601,7676,7682,7695,7737,7739,7746,7870,7872,7910,7924,7927,7938,8003,8033,8117,8167,8178,8189,8254,8334,8383,8419,8576,8618,8635,8681,8711,8724,8868,8900,8921,8943,8946,8961,9005,9039,9117,9158,9206,9228,9274,9275,9401,9472,9535,9695,9800,9836,9844,9888,10047,10081,10112,10144,10171,10198,10361,10420,10512,10590,10622,10674,10719,10755,10784,10809,10818,10826,10919,11023,11031,11082,11166,11200,11276,11339,11377,11428,11432,11597,11722,11739,11756,11825,11836,11878,11908,11920,12000,12031,12112,12279,12471,12496,12735,12768,12782,12807,12817,12952,12956,13000,13080,13139,13178,13269,13326,13553,13610,13611,13619,13720,13725,13869,14044,14195,14245,14326,14403,14502,14540,14656,14938,15019,15031,15122,15193,15373,15439,15447,15464,15626,15674,15690,15754,15767,15930,15970,15981,16076,16116,16121,16209,16253,16404,16520,16568,16611,17070,17202,17301,17512,17641,17780,17921,17938,18349,18377,18431,18516,19003,19235,19255,19257,19409,19442,19975,20278,20327,20576,21087,21144,21201,21725,21769,21780,22333,22492,22568,22627,22779,22994,23014,23039,23071,23193,23232,23511,23678,23798,24168,24309,24339,24464,25102,25349,25445,25670,25682,25985,26010,26078,26188,26268,26720,27354,27608,27695,27718,28411,28498,28686,28946,29179,29409,29547,29689,29742,29752,30160,30511,30815,31029,31462,31740,32129,32365,32506,32920,33388,33471,33776,33846,33888,33935,34022,34170,34481,34511,34932,34962,35260,35418,35580,35747,35854,36051,36144,36371,36374,36698,36780,37728,38114,38131,38221,38825,38944,38976,39284,39454,39474,40084,40294,40597,40968,41222,41391,41414,42782,44237,45202,45274,45462,45692,46770,47068,47209,47584,47882,48413,48433,49330,49876,49942,50481,50854,50923,51058,51740,51774,52517,52732,53305,53493,53679,53693,54486,54575,54819,55167,55248,55449,56439,56476,56731,57163,57344,57542,57555,58465,58843,59291,59450,59657,59853,60346,60697,60968,62501,62533,62591,63461,63939,64383,64861,66240,66779,67185,68381,68672,69514,69977,70070,70230,70440,70958,71234,71408,71602,71691,71991,72672,72745,73249,73580,73641,74225,74718,81081,81134,81198,82299,82393,83207,83276,83735,83778,83950,84277,84439,84689,84966,85067,85442,85690,86170,86697,86771,86877,86910,86979,87245,87335,87619,87933,88128,89529,89816,89917,89975,90056,90440,90619,90745,90827,92425,92684,93070,93472,93774,93978,93999,94013,94082,94286,94484,94695,94907,95749,95785,96024,96117,96330,96359,96469,96603,96789,96805,97113,97118,97630,98318,98837,99359,99536,99715,99886,99898,100333,100796,101002,101739,102145,102462,103496,103949,104420,104489,104503,104722,104818,104824,105598,105660,106106,106180,106448,106694,106885,107215,108565,109071,109115,109216,110035,110373,111818,112738,113024,113412,113538,113567,113572,113601,113622,113698,114448,114538,115318,115681,115778,115939,115940,116077,116415,116429,117316,117542,117908,117944,118441,118817,119631,120040,120375,120948,121251,121952,122622,122687,123150,123971,124643,124863,125436,125814,126326,126947,127495,127693,128042,128170,129042,129526,130174,130188,130208,130501,130503,130610,130948,131218,131340,131586,131622,131732,131947,132198,132406,132541,132711,132810,132862,133079,133436,133594,133688,134827,134944,134948,135018,135153,136308,136334,136350,136551,137018,137564,137674,137737,138333,138986,139403,139985,140253,140318,140745,140817,141265,141268,141304,141461,141910,142215,142249,142291,142433,142786,142866,143259,143420,143470,143568,143810,144037,144709,145074,145110,145175,145221,145302,145402,145670,146736,146746,148327,148450,148635,148981,149142,149305,149423,149700,149779,150320,150437,150611,150646,150743,150844,150876,151198,151302,151627,152502,152768,152944,154061,154188,155032,156101,156581,156705,157004,157150,158103,158296,158418,158602,159365,159416,159647,159933,160547,160653,160671,160766,160926,161502,162268,162367,162404,162567,162687,162910,163298,163492,163494,163750,164454,164470,164482,165063,165955,165996,166337,166763,167081,167183,167203,167220,167258,167305,167354,167359,167388,168413,168478,168823,169261,170259,170656,170994,171379,171746,171978,172863,173361,173366,173561,175118,175227,175350,175905,177005,177070,177535,177636,177821,178374,178521,178625,178869,179299,179696,179942,180342,180477,181002,181066,181449,181798,182331,182947,182985,183254,184254,184642,184750,184821,185584,185810,186303,186449,186718,186940,187046,187305,187383,187418,187757,187802,188082,188104,189718,190037,190101,190222,190289,191171,191908,192453,192525,192890,193175,193324,193412,193720,193787,194809,194922,194951,195068,195086,195212,195782,195870,196163,196796,198520,199393,199441,200002,200133,200216,200626,200810,200900,201034,201210,201687,202001,202404,202926,203027,203060,204499,204636,204754,204756,204860,205076,205232,205360,206195,206354,206637,207320,207475,208170,208465,208474,208902,209067,209152,209218,209249,209868,210218,210303,210562,210665,210737,210740],[235.0,48.0,11.0,17.0,25.0,38.0,15.0,10.0,3.0,8.0,30.0,11.0,15.0,3.0,16.0,12.0,7.0,10.0,14.0,11.0,3.0,18.0,1.0,4.0,1.0,12.0,23.0,7.0,5.0,2.0,27.0,20.0,8.0,13.0,19.0,7.0,6.0,5.0,5.0,8.0,10.0,6.0,7.0,2.0,6.0,12.0,2.0,1.0,4.0,3.0,8.0,12.0,13.0,1.0,5.0,3.0,1.0,11.0,29.0,5.0,2.0,2.0,1.0,4.0,7.0,14.0,1.0,3.0,5.0,1.0,17.0,2.0,1.0,3.0,4.0,11.0,1.0,3.0,4.0,2.0,2.0,5.0,1.0,4.0,13.0,2.0,8.0,3.0,21.0,3.0,1.0,1.0,7.0,2.0,10.0,8.0,1.0,7.0,3.0,1.0,3.0,1.0,2.0,2.0,1.0,3.0,2.0,4.0,3.0,2.0,2.0,3.0,1.0,11.0,6.0,2.0,2.0,1.0,3.0,9.0,2.0,8.0,1.0,4.0,1.0,1.0,10.0,4.0,7.0,8.0,2.0,5.0,2.0,1.0,10.0,1.0,5.0,4.0,5.0,2.0,1.0,2.0,1.0,5.0,1.0,2.0,1.0,1.0,3.0,2.0,1.0,3.0,7.0,1.0,6.0,1.0,7.0,3.0,1.0,2.0,1.0,1.0,4.0,1.0,8.0,2.0,2.0,1.0,3.0,5.0,3.0,1.0,3.0,1.0,1.0,1.0,2.0,4.0,3.0,2.0,2.0,1.0,1.0,4.0,13.0,5.0,5.0,7.0,2.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,50.0,1.0,3.0,2.0,1.0,2.0,2.0,2.0,1.0,2.0,7.0,3.0,1.0,2.0,2.0,1.0,6.0,2.0,1.0,2.0,1.0,2.0,2.0,4.0,7.0,5.0,3.0,6.0,3.0,10.0,1.0,3.0,1.0,2.0,2.0,4.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,4.0,2.0,2.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,11.0,1.0,1.0,12.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,7.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,2.0,3.0,1.0,1.0,3.0,4.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,9.0,3.0,1.0,1.0,2.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,1.0,15.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,2.0,1.0,5.0,1.0,4.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,4.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,7.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,7.0,1.0,1.0,1.0,3.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,4.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,10.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,9.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,9.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,6.0,4.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,2.0,2.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,3.0,4.0,2.0,1.0,1.0,1.0,2.0,9.0,3.0,2.0,4.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,4.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,10.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,2.0,7.0,1.0,2.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,22.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,9.0,1.0,1.0,1.0,10.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,12.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,10.0,1.0,1.0,1.0,34.0,8.0,1.0,1.0,1.0,1.0,1.0,23.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,32.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,3.0,3.0,1.0,1.0,1.0,2.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,2.0,11.0,1.0,1.0,1.0,2.0,4.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,11.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,16.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,7.0,1.0,13.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,13.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,11.0,1.0,3.0,1.0,1.0,4.0,10.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,8.0,1.0,1.0,1.0,1.0,1.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,7.0,3.0,5.0,1.0,1.0,2.0,1.0,3.0,3.0,2.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n",
      "|[, purpose, of, review, recognize, which, are, the, elements, that, predict, why, a, person, is, aging, faster, or, slower, and, which, interventionwe, can, arrange, to, slow, down, the, process, which, permits, to, prevent, or, delay, the, progression, of, multimorbidity, and, disabilityrecent, findings, aging, is, a, complex, process, that, leads, to, changes, in, all, the, systems, of, the, body, and, all, the, functions, of, theperson, however, aging, develops, at, different, rates, in, different, people, and, chronological, age, is, not, always, consistent, withbiological, agesummary, gerontologists, are, focused, not, only, on, finding, the, best, theory, able, to, explain, aging, but, also, on, identifying, one, or, moremarkers, which, are, able, to, describe, aging, processes, these, biomarkers, are, necessary, to, better, define, the, agingrelated, pathologies, manage, multimorbidity, and, improve, the, quality, of, life, the, aim, of, this, paper, is, to, review, the, most, recent, evidence, onaging, biomarkers, and, the, clusters, related, to, them, for, personalization, of, treatmentskeywords, biomarker, of, aging, , frailty, syndrome, , aging, phenotype, , quality, of, life, , multimorbidity, , life, expectancy, , socialneedsintroductionmost, people, dont, grow, up, most, people, age, they, findparking, spaces, honour, their, credit, cards, get, married, havechildren, and, call, that, maturity, what, that, is, is, agingmaya, angelou, one, of, the, biggest, megatrends, impactingthe, world, today, is, population, aging, aging, is, a, topic, thathas, captivated, both, scientists, and, philosophers, throughouthistory, but, aging, as, a, population, scenario, emerged, on, athis, , is, part, of, the, topical, collection, on, geriatric, oncology, beatrice, di, capuabeatricedicapuagmailcom, uoc, di, radioterapia, oncologica, dipartimento, diagnostica, perimmagini, radioterapia, oncologica, e, ematologia, fondazionepoliclinico, universitario, a, gemelli, irccs, rome, italy, dipartimento, di, scienze, dellinvecchiamento, neurologicheortopediche, e, della, testacollo, fondazione, policlinico, universitarioa, gemelli, irccs, rome, italy, moffitt, cancer, center, tampa, fl, usaworldwide, scale, for, the, first, time, in, the, last, century, thus, itis, hard, to, really, identify, a, definition, of, aging, it, is, a, decrease, infitness, with, chronological, age, it, is, a, developmental, phasebeyond, the, normal, life, trajectory, and, it, is, a, time, of, the, increased, risk, of, physical, and, psychological, disabilities, testingthe, limits, of, resilienceaging, occurs, at, a, different, rate, in, varying, geographic, regions, of, the, worldeurope, is, currently, the, oldest, region, with, , of, thetotal, population, aged, , and, older, however, the, asia, andlatin, america, older, population, is, growing, fast, with, asiasolder, population, almost, tripling, in, size, from, , million, in, to, , million, in, , []all, these, data, do, not, consider, aging, as, an, epiphenomenonbut, an, individual, data, of, the, global, population, just, a, chronological, number, aging, is, intrinsically, a, complex, scenariocharacterized, by, changes, that, take, place, at, different, levels, ofbiological, systems, biological, age, is, of, course, influenced, bychronological, age, but, chronological, age, is, by, itself, not, representative, of, biological, age, biological, age, is, determined, byphysiological, reserve, and, functional, status, assessing, biological, age, is, essential, to, predict, life, expectancy, and, resilience, to, 0c, , , , page, , of, curr, oncol, rep, , , , , , , , , , , , stressors, [], if, any, definition, of, aging, may, appear, incompleteand, insufficient, much, more, difficult, and, complex, is, to, findthe, marker, or, biomarker, that, can, identify, itmany, theories, currently, trying, to, explain, aging, processesand, many, biomarkers, are, identified, to, measure, aging, and, itsevolutionary, stages, theories, and, biomarkers, are, not, studiedto, extend, life, span, but, to, guide, therapeutic, choices, and, optimize, patient, management, and, personalization, of, carethe, purpose, of, this, paper, is, not, purely, to, list, which, biomarkers, are, able, to, identify, the, various, stages, of, aging, ratherexplain, how, an, epiphenomenon, natural, and, physiological, isso, complex, [], how, many, factors, are, protagonists, in, its, development, and, how, many, actors, and, characters, play, in, maximizing, its, individual, features, taking, into, account, social, andmorbidity, biomarker, these, factors, such, as, frailty, loss, ofautonomy, essential, needs, and, comorbidities, influence, theaging, process, and, are, able, to, justify, why, the, biological, ageof, a, person, living, in, a, country, does, not, correspond, to, the, ageof, another, person, living, in, a, country, with, better, sociosanitaryconditionsclinical, and, biological, aging, phenotypesthe, aging, phenotype, can, be, described, as, a, complex, mosaicresulting, from, the, interaction, of, a, variety, of, environmentalstochastic, and, geneticepigenetic, eventsstimuli, impinginglifelong, on, our, body, [, ]there, is, no, clear, evidence, which, molecular, cellular, orphysiological, changes, are, the, most, important, drivers, of, theaging, process, andor, how, they, influence, one, another, [], in, itsbroadest, sense, aging, merely, refers, to, the, changes, that, occurduring, an, anisms, life, span, though, the, rate, at, which, thesetake, place, varies, widely, [], despite, its, enormous, complexityinvolving, combinations, of, these, variables, a, small, number, ofbasic, molecular, mechanisms, underpin, the, aging, process, including, a, set, of, evolutionary, highly, conserved, basic, biological, mechanisms, responsible, for, body, maintenance, and, repairone, of, the, key, mechanisms, is, inflammation, a, typical, featureof, the, aging, process, is, the, development, of, a, chronic, lowgrade, inflammatory, status, named, inflammaging, [8cid129], whichemerged, as, critical, in, the, pathogenesis, of, major, agerelatedchronic, diseases, such, as, atherosclerosis, type, , diabetes, and, neuro, degeneration, inflammaging, plays, a, pivotal, role, in, themost, important, geriatric, conditions, such, as, sarc, ia, [9cid129cid129]osteoporosis, [], frailty, and, disability, thus, contributing, tomortality, [], interestingly, a, variety, of, tissues, adipose, tissue, muscle, ans, brain, liver, systems, immune, systemand, ecosystems, gut, microbiota, of, the, body, indicated, assubsystems, can, contribute, to, the, onset, and, progressionof, such, a, systemic, inflammatory, state, [], by, increasing, theproduction, of, several, proinflammatory, mediators, or, loweringthat, of, the, antiinflammatory, ones, [8cid129]to, differentiate, the, innocuous, changes, from, those, leadingto, increased, risk, of, disease, disability, or, death, biogerontologists, tend, to, use, a, more, precise, termsenescencewhen, describing, aging, [], senescence, is, thereforethe, progressive, deterioration, of, bodily, functions, over, time, andnormal, human, aging, has, been, associated, with, a, loss, of, complexity, in, a, wide, range, of, physiological, processes, and, anatomic, structures, [], including, blood, pressure, [], strideintervals, [], respiratory, cycles, [], and, vision, [], amongothers, such, as, postural, dynamics, [], ultimately, leading, todecreased, fertility, and, increased, risk, or, mortality, []systemic, consequences, of, aging, are, widespread, but, theycan, be, clustered, into, four, domains, fig, , changing, in, body, compositionthe, balance, between, energy, availability, and, energydemandsignaling, networks, that, maintain, homeostasis, neurodegenerationthese, changes, develop, in, parallel, and, affect, each, otherthrough, many, feedforward, and, feedback, loopthe, phenotype, that, results, from, the, aging, process, is, characterized, by, increased, susceptibility, to, disease, high, risk, ofmultiple, coexisting, diseases, impaired, response, to, stress, theemergence, of, geriatric, syndromes, altered, response, to, treatment, high, risk, of, disability, and, loss, of, personal, autonomywith, all, its, psychological, and, social, consequences, on, theother, hand, all, these, factors, influence, aging, itself, in, a, dynamic, and, parallel, way, so, that, they, can, be, considered, as, not, onlya, consequence, of, aging, but, also, an, integral, part, of, the, agingprocesstheories, of, aginghuman, aging, is, currently, defined, as, a, dynamic, process, involving, the, continual, adaptation, of, the, body, to, lifelong, exposure, tointernal, and, external, damaging, as, conceptualized, in, the, remodelling, theory, of, aging, [21cid129cid129], theories, of, aging, are, generallyclassified, as, either, program, or, damage, theories, programmedaging, theories, suggest, that, there, is, a, deliberate, deterioration, withage, because, a, limited, life, span, results, in, evolutionary, benefits[], this, plan, could, be, a, result, of, aging, genes, the, firstdescribed, mutation, to, yield, a, significant, extension, in, the, life, spanof, caenorhabditis, elegans, was, in, the, agei, gene, which, wasshown, to, result, in, a, , increase, in, mean, life, span, and, a, increase, in, maximum, life, span, of, this, anism, []evolutionary, biologists, may, argue, that, aging, occurs, due, to, theabsence, of, natural, selection, at, the, postreproductive, stage, of, life[], although, such, aging, theories, are, subjectively, appealing, asthey, convey, a, cure, for, aging, the, accumulation, of, damage, is, aspontaneous, entropydriven, process, [], among, the, damage, 0ccurr, oncol, rep, , , , , , , , , , , , fig, , systemic, consequences, ofagingpage, , of, , , , , theories, a, prevailing, idea, is, that, of, oxidative, damage, reactiveoxygen, species, ros, are, generated, during, metabolism, throughseveral, interrelated, reactions, the, supposition, that, aging, may, becaused, by, ros, has, been, further, substantiated, by, studies, involving, transgenic, animals, for, genes, encoding, antioxidants, the, lifespan, of, drosophila, melanogaster, has, been, extended, by, overexpression, of, both, superoxide, dismutase, sod, and, catalase, bothantioxidant, enzymes, [], since, mitochondria, are, the, major, producer, of, ros, in, mammalian, cells, mitochondrial, dnamtdna, is, therefore, particularly, susceptible, to, oxidative, damage, [], mitochondrial, maintenance, is, therefore, essential, topreserve, cellular, homeostasis, and, impaired, mitochondrial, maintenance, has, been, described, as, a, shared, hallmark, of, numeroushuman, pathologies, and, aging, [], mitochondrial, dna, varieswith, age, and, it, is, commonly, considered, that, dna, hypomethylation, is, a, typical, aspect, of, the, aging, process, [], ros, are, activeintermediates, of, dna, methylation, as, well, as, histone, modification, these, reactive, oxygen, species, may, play, a, role, in, epigeneticprocesses, physiological, phenotypic, variations, caused, by, external, or, environmental, factors, that, switch, genes, onoff, throughreactions, of, nucleophilic, substitution, at, the, dna, levelconsequently, it, has, been, suggested, that, better, preservation, ofdna, methylation, levels, slower, cell, metabolism, and, improvedcontrol, in, signal, transmission, through, epigenetic, mechanismscould, be, key, processes, involved, in, human, longevity, oxidativedamage, to, proteins, is, irreversible, and, irreparable, [], and, mustbe, degraded, by, the, proteasome, the, proteasome, is, the, mostimportant, proteolytic, machinery, in, eukaryotic, cells, largely, responsible, for, the, removal, of, oxidized, proteins, and, the, preventionof, its, aggregation, [], however, it, has, been, shown, that, theactivity, of, proteasome, is, impaired, during, aging, leading, to, theaccumulation, of, oxidizing, proteins, aggresome, and, lipofuscinsocalled, the, age, pigment, similarly, to, oxidative, damage, nitrosamine, damagethat, caused, by, reactive, nitrogen, speciesrns, such, as, nitric, oxidehas, been, suggested, to, also, contribute, to, agerelated, diseases, namely, hepatic, steatosis, and, apoptosis, [], as, well, as, functional, and, structural, changes, in, the, cardiovascular, system, [, ], sleep, homeostasis, [], psychological, disorders, [], and, dementia, []most, supporters, of, the, genomic, instability, theory, of, agingrefer, to, telomere, shortening, [], and, mutation, in, dna, mitochondrial, telomeres, are, the, repeated, dna, sequences, at, theends, of, linear, chromosomes, which, are, unable, to, be, fullyreplicated, by, dna, polymerasesmutations, in, mtdna, cause, a, wide, range, of, human, mitochondrial, diseases, and, have, been, implicated, in, agerelateddiseases, and, agingbiomarker, featuresfinding, the, biomarker, of, aging, is, one, of, the, most, importantgoals, of, medicine, the, national, institutes, of, healthbiomarkers, definitions, working, group, defined, a, biomarkeras, a, characteristic, that, is, objectively, measured, and, evaluatedas, an, indicator, of, normal, biological, processes, pathogenicprocesses, or, pharmacologic, responses, to, a, therapeutic, intervention, []the, american, federation, for, aging, research, afar, recommends, the, following, criteria, for, biomarkers, of, aging, [39cid129]it, must, predict, a, persons, physiological, cognitive, andphysical, function, in, an, agerelated, way, independentlyof, chronological, age, 0c, , , , page, , of, curr, oncol, rep, , , , , , , , , , , , it, must, be, testable, and, not, harmful, to, test, subjects, forexample, a, blood, test, or, an, imaging, technique, it, mustalso, be, technically, simple, to, perform, and, it, must, be, accurate, and, reproducibly, without, the, need, for, specializedequipment, or, techniquesit, should, work, in, laboratory, animals, as, well, as, humanssince, preliminary, testing, is, always, done, in, nonhumansubjectsferrucci, et, al, reviewed, the, biomarkers, proposed, as, elements, of, a, theory, based, on, the, balance, between, resiliencemechanisms, and, accumulated, damages, where, biomarkersact, in, reducing, resilience, mechanisms, or, increasing, damages[40cid129], tables, , and, the, pathways, eligible, to, become, biomarkers, are, thefollowinggenomic, instability, endogenous, and, exogenous, agents, continuously, challenge, the, integrity, of, dna, when, dna, repairmechanisms, cannot, manage, the, repeated, damage, the, result, isan, accumulation, of, dna, somatic, mutations, this, phenomenon, causes, dysregulation, of, gene, expression, and, the, production, of, altered, proteins, that, lead, to, cellular, damage, somaticmutation, accumulation, has, been, observed, in, skeletal, musclecells, neurons, and, lymphocytes, b, related, to, aging, []nevertheless, quantification, of, dna, repair, capacity, in, humanshas, yet, to, be, finalized, []telomere, attrition, telomeres, are, the, dna, sequences, that, areplaced, at, the, end, of, the, dna, chain, and, protect, thetable, , biological, changesunderlying, aginggenomic, instabilitytelomere, attritionepigenetic, alterationscid129, dna, methylationcid129, histone, modificationcid129, noncoding, rnaloss, of, proteostasismitochondrial, dysfunctioncellular, senescencederegulated, nutrientsensingsteam, cell, exhaustionaltered, intercellular, communicationchromosome, ends, from, damage, during, each, replicationtelomeres, are, reproduced, but, not, completely, so, with, agingthey, become, shorter, and, contribute, to, cellular, senescence[], to, date, different, techniques, are, available, to, detecttelomere, length, in, circulating, cells, however, no, techniqueshave, been, validated, for, evaluating, aging, because, of, the, heterogeneity, between, different, cells, between, individuals, andhigh, measurement, errors, that, make, these, techniques, not, yetvalid, in, clinical, practice, []epigenetic, alterations, epigenetics, refers, to, those, mechanismsexternal, to, dna, that, modulate, gene, expression, in, cells, theregulation, of, gene, expression, determines, the, phenotypic, characteristics, of, the, different, cells, and, tissues, the, main, mechanismsare, dna, methylation, histone, modification, and, noncodingrna, while, dna, methylation, is, easily, measured, in, circulatingcells, and, seems, to, be, correlated, to, aging, [, ], measuringhistone, modification, or, noncoding, rna, is, difficult, and, expensive, recent, evidence, correlates, dna, methylation, with, agingand, agerelated, chronic, diseases, in, humans, [, ]individuals, with, higher, levels, of, dna, methylation, have, a, higherrisk, of, developing, several, agerelated, diseases, and, prematuremortality, for, all, causes, and, cardiovascular, diseases, [], as, wellas, physical, and, cognitive, functions, [, ]loss, of, proteostasis, the, repair, of, damaged, structures, or, theirelimination, is, fundamental, to, maintain, cell, integrity, and, function, [], studies, suggest, that, proteostasis, becomes, defectivewith, aging, and, contributes, to, immunosenescence, [], and, thatautophagy, appears, to, be, more, functional, in, longlived, peopleaccumulation, of, dna, somatic, mutationsdysregulation, of, gene, expressionaltered, proteins, productiontelomere, shortening, contribute, tocellular, senescencealtered, gene, expressionrelated, to, agerelated, chronic, diseasesaccumulation, of, damaged, structuresaltered, energy, productionincreased, ros, productionapoptosisprogrammed, cell, deathactivation, of, pathways, leading, to, apoptosisproduction, of, saspincrease, of, life, span, in, dietary, restrictiondecline, of, regenerative, potentialinflammagingdysfunction, of, endocrine, neuronaland, immune, systems, 0ccurr, oncol, rep, , , , , , , , , , , , page, , of, , , , , table, , measurable, biomarkers, classified, by, respective, hallmarkspathways, measuredmeasurable, biomarkershallmarkgenomic, instabilitytelomere, shorteningcellular, senescencecid129, dna, repair, mechanismscid129, dna, modificationscid129, telomere, lengthcid129, markers, of, dna, damage, responsecid129, telomerase, activitycid129, senescent, markers, in, blood, and, tissueepigenetic, changes, or, epigenetic, clockcid129, dna, methylationcid129, histone, acetylationcid129, noncoding, rnamitochondrialdecreased, autophagy, proteostasiscid129, mitochondrial, volumenumbershapecid129, mito, respirationcid129, markers, of, biogenesiscid129, mtdna, copy, number, and, haplotypescid129, autophagy, markerscid129, chaperon, proteinsstem, cell, exhaustionderegulated, nutrientsensingaltered, intercellular, communicationcid129, proliferative, capacity, in, vitrocid129, resistance, to, stresscid129, growth, hormone, gh, axiscid129, metabolism, alterationscid129, measures, of, inflammationcid129, yh2ax, immunohistochemistrycid129leukocyte, telomere, lengthcid129mir31hgcid129, p16ink4acid129, senescenceassociated, secretoryphenotype, sasp, proteinscid129, measures, of, dna, methylationcid129, sirt1, sirt2, sirt3, sirt6, sirt7cid129, dosage, of, circulating, micrornas, mir34amir21, mir1263p, mir151a3pmir181a5p, mir1248cid129, p31, mri, spectroscopycid129, growth, differentiating, factor, , gdf15cid129, nadcid129, target, of, rapamycin, torcid129, protein, carbamylationcid129, advanced, glycation, end, productscid129, insulinlike, growth, factor, igf1cid129, hgba1ccid129, il6cid129, tnfî±cid129, crp, creactive, proteincid129, tnfrii, tumor, necrosis, factorî±, rii[], measuring, the, loss, of, proteostasis, mechanism, could, be, agood, biomarker, but, to, date, there, are, no, valid, techniques, forthis, purposemitochondrial, dysfunction, the, main, role, of, mitochondria, isto, guarantee, energy, for, the, cell, through, the, production, ofatp, they, are, also, involved, in, signaling, by, the, productionof, ros, and, in, apoptosisprogrammed, cell, deathmitochondrial, dysfunction, is, a, good, biomarker, of, aging, andis, associated, with, disability, in, older, persons, through, the, reduction, of, muscle, strength, [65cid129]many, techniques, are, measuring, oxidative, phosphorylationand, ros, generation, that, have, been, associated, with, chronicdisease, [, ], nevertheless, the, relation, with, aging, is, notcompletely, validatedcellular, senescence, genomic, instability, telomere, shorteningand, other, endogenous, and, exogenous, mechanisms, can, inducethe, cell, to, activate, specific, pathways, that, lead, to, apoptosis[], this, process, is, called, cellular, senescence, and, is, characterized, by, structural, and, functional, changes, in, the, cell, []senescent, cells, produce, proinflammatory, cytokines, andchemokines, growth, factors, and, matrix, proteases, called, senescenceassociated, secretory, phenotype, sasp, [, ]which, may, induce, some, agerelated, diseases, [], thedetection, of, sasp, has, been, proposed, as, a, biomarker, of, aging[]deregulated, nutrientsensing, genetic, mutations, in, growthhormone, and, the, insulinlike, growth, factor, have, been, linkedto, longevity, [], moreover, dietary, restriction, showed, to, increase, life, span, in, primates, [, ], for, these, reasons, thispathway, has, been, proposed, as, biomarkers, of, agingsteam, cell, exhaustion, the, decline, in, the, regenerative, potential, is, one, of, the, elements, at, the, base, of, aging, [], despitepharmacological, interventions, being, explored, to, counteractthis, phenomenon, [], evidences, are, still, poor, 0c, , , , page, , of, curr, oncol, rep, , , , , , , , , , , , altered, intercellular, communication, with, aging, we, also, observe, changes, in, intercellular, communication, as, inflammatory, reaction, increases, the, other, communication, ways, becomedysfunctional, endocrine, neuronal, immune, system, []as, we, discussed, earlier, inflammation, can, be, inappropriately, increased, in, aging, and, this, has, been, related, to, agerelated, disease, [, ]indeed, the, pathways, described, as, potential, biomarkers, ofaging, are, strongly, related, to, inflammation, for, this, reasonmeasuring, circulating, levels, of, cytokines, is, considered, anew, field, of, research, [, 84cid129, ]aging, and, life, expectancyaging, and, life, expectancy, are, closely, related, in, a, broadsense, determining, an, individuals, life, expectancy, is, also, away, of, schematizing, his, or, her, aging, process, life, expectancyis, a, statistical, measure, of, the, average, time, an, anism, isexpected, to, live, based, on, the, year, of, its, birth, leb, itscurrent, age, and, demographic, factors, including, gender, []in, the, last, decades, life, expectancy, has, increased, in, high, income, country, the, rise, in, human, life, expectancy, has, involveddeclines, in, intrinsic, and, extrinsic, mortality, processes, associated, respectively, with, senescence, and, environmental, challenges, []in, association, to, this, increased, longevity, there, are, diseasescalled, agerelated, that, increase, quadratically, with, age, andcause, a, progressive, loss, of, physical, mental, and, cognitiveintegrities, leading, to, impaired, function, and, increased, vulnerability, to, morbidity, mortality, [], and, disability, in, additionto, increasing, care, needs, and, agerelated, burden, measuredthrough, the, sum, of, disabilityadjusted, life, years, dalys, ofthese, diseases, among, these, adults, fig, , ninetytwo, of, the, of, the, global, burden, of, disease, causes, were, identified, asagerelated, diseases, in, particular, cardiovascular, diseaseneoplasm, and, chronic, respiratory, disorders, are, those, withhigher, agerelated, disease, burden, []determinants, of, frailty, syndrome, as, agingbiomarkerfrailty, can, be, defined, as, a, state, of, increased, vulnerabilityto, stressors, or, a, loss, of, capacity, to, resolve, homeostasisperturbation, frailty, condition, is, closely, related, to, aging[88cid129cid129], and, the, frailty, indexes, can, consequently, be, considered, biomarkers, of, aging, themselves, in, frail, individuals, it, is, possible, to, find, both, changing, in, body, composition, and, balance, between, energy, availability, and, energydemand, moreover, in, the, definition, of, frailty, it, is, welldescribed, how, signaling, networks, maintain, homeostasisand, association, with, neurodegeneration, these, fouraspects, all, refer, to, the, hallmarks, of, aging, frailty, is, associated, with, adverse, clinical, outcomes, including, falls, institutionalization, and, death, [88cid129cid129]two, principal, models, emerged, in, the, last, decades, that, areable, to, conceptualize, and, consequently, measure, frailty, in, everyday, clinical, practice, and, research, the, frailty, phenotypemodel, and, the, cumulative, deficits, modelthe, frailty, phenotype, was, first, described, by, fried, and, colleagues, in, , analyzing, data, from, the, cardiovascularhealth, study, chs, involving, , men, and, women, aged, years, and, older, in, this, study, it, was, investigated, whichcharacteristics, of, the, population, were, predictive, of, falls, disability, hospitalization, and, death, their, operational, definitionof, frailty, included, a, cluster, of, at, least, three, of, the, followingvariables, unintentional, weight, loss, selfreported, exhaustionlow, energy, expenditure, slow, gait, speed, and, weak, gripstrength, this, model, does, not, take, into, consideration, cognitive, impairment, as, a, cause, of, increased, vulnerability, as, thiscould, contribute, to, functional, decline, and, adverse, events, inolder, people, [, ]the, cumulative, deficits, model, was, developed, byrockwood, and, colleagues, as, part, of, the, prospectivecanadian, study, of, health, and, aging, csha, involvinga, cohort, of, , older, adults, [], the, authors, identified, , parameters, including, diseases, disabilities, signssymptoms, and, laboratory, values, which, were, defined, asdeficits, the, sum, of, the, deficits, in, a, single, individualallowed, for, the, calculation, of, a, frailty, index, ie, thenumber, of, deficits, divided, by, , frailty, in, this, modelis, not, considered, as, a, cluster, of, symptoms, but, is, conceptualized, as, a, gradable, syndrome, with, a, higher, number, ofdeficits, implying, an, increased, vulnerability, state, the, twomodels, of, frailty, show, significant, overlap, although, theycapture, slightly, different, sides, of, the, same, problem, it, isimportant, to, notice, that, physical, frailty, is, frequently, associated, with, multimorbidity, [, 93cid129, ]it, has, been, observed, that, the, frailty, phenotype, construct, is, intrinsically, related, to, mobility, issues, indeedin, older, adults, physical, performance, measures, are, a, robust, and, consistent, predictor, for, disability, hospitalization, institutionalization, and, death, both, in, the, researchand, in, the, clinical, setting, lower, physical, performance, isfrequently, associated, with, loss, of, skeletal, muscle, massand, quality, causing, reduced, strength, and, functional, impairment, [95cid129cid129], this, process, has, been, called, sarc, iaeven, though, sarc, ia, has, been, long, associated, withaging, it, has, to, be, acknowledged, that, it, can, develop, muchearlier, in, life, [], different, definitions, exist, for, this, condition, for, the, operational, definition, of, sarc, ia, both, inthe, clinic, and, for, research, purposes, that, prioritize, theassessment, of, muscle, strength, over, muscle, mass, to, identity, sarc, ic, patients, strength, is, more, closely, related, tosurvival, and, functional, decline, compared, with, muscle, 0ccurr, oncol, rep, , , , , , , , , , , , page, , of, , , , , cardiovascular, diseasesatrial, ï¬brillaæon, and, ï¬uæ©er, endocardiæs, hypertensive, heart, disease, intracerebralhaemorrhage, ischaemic, heart, disease, ischaemic, stroke, myocardiæs, nonrheumaæc, valve, disease, other, cardiomyopathy, other, cardiovascular, and, circulatory, diseases, peripheralartery, diseaseneoplasmsleukaemia, lymphoma, mulæple, myeloma, myelodysplasæc, syndroms, and, other, hematopoieæc, neoplasms, brain, and, nervous, system, cancer, breastcancer, prostate, cancer, larynx, cancer, lip, and, oral, cavity, cancer, oesophagealcancer, stomach, cancer, colon, and, rectum, cancer, liver, cancer, gallbladder, and, biliary, tract, cancer, pancreaæc, cancer, kidney, cancer, bladder, cancer, melanoma, and, nonmelanoma, skin, cancer, ovarian, cancer, uterine, cancer, thyroid, cancer, tracheal, bronchus, and, lung, cancer, mesothelioma, othermalignant, neoplasms, other, benign, and, insitu, neoplasmsgastrointestinal, endocrine, and, kidney, diseaseschronic, kidney, disease, type, , diabetes, mellitus, cirrhosis, due, to, nonalcoholicsteatohepaææs, pancreaææs, paralyæc, ileus, and, intesænal, obstrucæon, pepæculcer, disease, vascular, intesænal, disorders, diarrhoeal, diseasesskin, and, subcutaneous, diseasescelluliæs, decubitus, ulcer, fungal, skin, diseases, pyoderma, other, skin, and, subcutaneousdiseasesfig, , agerelated, diseases, adapted, from, chang, et, al, []mass, [95cid129cid129], according, to, ewgsop, criteria, sarc, iais, defined, by, the, presence, of, low, muscle, strength, criterion, , and, either, or, low, muscle, quantity, or, quality, criterion, , or, low, physical, performance, criterion, , [95cid129cid129]the, physical, performance, parameters, used, in, the, identification, of, frailty, syndrome, both, integrated, eg, sppb, andalone, walking, speed, handgrip, strength, can, be, used, as, agingperformance, biomarkersdetermination, of, medical, and, social, needswhy, consider, medical, and, social, needs, aging, biomarkersin, , robert, j, havighurst, said, in, considering, theneeds, of, older, people, it, is, well, first, to, remember, that, olderpeople, have, the, needs, that, are, common, to, all, people, andsecond, that, they, have, special, needs, due, to, the, fact, that, theyare, old, people, this, sentence, describes, everything, there, is, toknow, about, the, need, for, the, elderly, and, answers, the, questionbeforein, every, society, and, age, there, is, what, is, meant, by, normality, an, elderly, person, in, this, scenario, needs, what, is, needed, tomaintain, this, level, of, normalcy, activity, of, daily, living, andinstrumental, activity, of, daily, living, adl, and, iadl, aloneremodelled, according, to, the, context, and, gender, can, identifythe, minimum, necessary, conducting, needs, assessment, various, areas, must, be, considered, including, physical, health, mental, health, emotional, care, social, cultural, economic, nutritional, service, security, legal, and, educationalchronic, respiratory, diseasesasbestosis, chronic, obstrucæve, pulmonary, disease, coal, worker, pneumoconiosis, intersææallung, disease, and, pulmonary, sarcoidosis, other, pneumoconiosis, silicosis, lower, respiratoryinfecæonsneurological, disordersalzheimers, disease, and, other, demenæas, motor, neuron, disease, parkinsonsdisease, encephaliæs, pneumococcal, meningiæsage, related, diseasesense, an, diseaseshearing, loss, vision, loss, ex, agerelated, macular, degeneraæon, cataract, glaucoma, other, sense, an, diseases, refracæon, disorders, trachomainjuriesdrowning, environmental, heat, and, cold, exposure, falls, foreign, body, in, other, body, part, other, transport, injuries, other, unintenæonal, injuriesother, diseasescongenital, musculoskeletal, and, limb, anomalies, digesæve, congenital, anomalies, endocrine, metabolic, blood, and, immune, disorders, other, haemoglobinopathies, and, haemolyæcanaemiasmany, tools, are, used, to, evaluate, peoples, needs, the, majority, of, these, tools, are, focused, on, physical, performance, ableto, maintain, autonomy, few, studies, focus, on, social, needs, andthe, costs, of, care, in, the, west, world, , of, patients, accountfor, , of, total, health, care, expenditures, this, , is, represented, by, older, people, individuals, with, multiple, chronic, conditions, many, medications, frequent, hospitalizations, and, limitations, on, their, ability, to, perform, basic, daily, functions, due, tophysical, mental, or, psychosocial, challenge, []since, the, health, care, and, social, needs, of, older, adults, differfrom, that, of, other, adults, it, is, necessary, to, identify, the, needs, ofthe, elderly, to, make, proper, plans, that, will, promote, their, healthcurrently, most, of, the, conducted, studies, had, mainly, focused, on, the, elderly, physical, health, needs, and, had, neglectedto, take, into, account, other, needs, such, as, social, and, health, careneeds, furthermore, in, addition, to, quantitative, studies, discovering, the, older, adults, perceptions, of, their, own, health, needsis, also, necessaryconclusionthere, is, a, large, interest, of, researchers, in, biomarkers, of, agingand, despite, some, of, them, seem, to, be, very, promising, biological, biomarkers, are, still, far, from, a, clinical, application, to, datethere, is, no, technique, that, meets, the, mentioned, criteria, of, theideal, biomarker, [40cid129], moreover, we, know, that, the, biologicalpathways, are, the, final, agents, of, aging, but, on, one, side, theycan, be, influenced, by, social, economic, and, environmental, factors, and, on, the, other, side, they, express, in, various, disease, and, 0c, , , , page, , of, curr, oncol, rep, , , , , , , , , , , , disabilities, of, the, person, physical, and, cognitive, impairmentsagerelated, disease, systems, functions, sensory, functions, etcfig, to, date, more, than, a, single, biomarker, to, assess, agingwe, should, consider, a, cluster, of, biomarkers, that, comprisethe, various, elements, that, we, analyzed, social, and, educational, aspects, economic, factors, country, of, origin, presence, of, agerelated, disease, presence, of, dependence, indaily, activities, physical, capability, cognitive, functionlung, and, cardiovascular, function, and, presence, of, sensorydysfunctions, in, table, , we, propose, several, clinical, andlaboratory, biomarkers, that, can, be, used, in, clinical, practiceand, researchthe, geriatric, assessment, ga, can, currently, be, considered, a, system, capable, of, monitoring, multiple, biomarkersclinical, and, laboratory, of, aging, and, at, the, same, timeable, to, relate, them, to, each, other, through, the, ga, it, ispossible, to, make, a, prediction, of, the, risk, of, toxicity, of, atreatment, of, life, expectancy, of, social, needs, and, of, compliance, with, the, treatments, ga, is, composed, indeed, byseveral, evaluations, made, through, standardized, toolswhich, examine, various, aspects, of, the, person, a, multidimensional, assessmentalthough, it, seems, difficult, to, imagine, a, geriatric, assessment, as, a, biomarker, currently, for, its, characteristicsand, for, the, high, predictivity, it, has, it, can, be, consideredthe, gold, standard, in, the, management, of, the, older, individual, and, instrumenttoward, which, other, biomarkersshould, be, evaluatedthe, purpose, of, this, paper, was, to, evaluate, the, multipleaspects, that, distinguish, the, aging, process, aging, must, nofig, , mechanisms, connectingdifferent, clusters, of, biomarkerslonger, be, described, as, a, simple, demographic, event, butas, a, complex, mosaic, in, which, several, tesserae, relate, toeach, other, some, in, a, very, evident, way, others, often, in, amore, subdued, but, all, fundamental, way, each, aging, theory, has, attempted, to, justify, this, process, effectively, however, there, is, no, single, biomarker, to, date, that, has, beenfound, able, to, identify, the, stage, of, this, process, at, thesame, time, clinical, clusters, have, been, added, to, purelybiological, markers, and, social, ones, should, certainly, beconsidered, it, therefore, becomes, important, not, to, consider, biomarkers, only, as, life, span, but, to, try, to, overcomethis, link, and, focus, on, the, set, of, factors, that, influencingeach, other, are, able, to, guide, aging, in, good, health, andgood, quality, of, life, towards, a, lived, aging, as, a, slowdecline, at, the, time, we, are, writing, this, paper, covid, infection, is, reaping, victims, especially, in, italy, thehighest, mortality, is, observed, among, the, older, adultsbut, surprisingly, it, seems, to, maintain, similar, values, between, the, youngest, and, oldest, old, over, , yearscurrently, no, plausible, justification, is, provided, for, thesedata, in, frailty, the, number, of, comorbidities, the, reducedfunctional, reserve, was, the, most, used, reasons, indirectlythis, infection, is, highlighting, the, need, to, use, parametersthat, can, more, easily, identify, the, aging, process, regardlessof, chronological, agethe, studies, analyzed, in, the, literature, show, that, if, on, theone, hand, there, are, physiological, biomarkers, able, ofhighlighting, some, features, of, aging, other, functionalmarkers, performance, social, and, economic, status, somepathologies, and, the, presence, of, addiction, are, able, ofspeed, it, up, or, slow, it]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |[, purpose, review, recognize, elements, predict, person, aging, faster, slower, interventionwe, arrange, slow, process, permits, prevent, delay, progression, multimorbidity, disabilityrecent, findings, aging, complex, process, leads, changes, systems, body, functions, theperson, however, aging, develops, different, rates, different, people, chronological, age, always, consistent, withbiological, agesummary, gerontologists, focused, finding, best, theory, able, explain, aging, also, identifying, one, moremarkers, able, describe, aging, processes, biomarkers, necessary, better, define, agingrelated, pathologies, manage, multimorbidity, improve, quality, life, aim, paper, review, recent, evidence, onaging, biomarkers, clusters, related, personalization, treatmentskeywords, biomarker, aging, , frailty, syndrome, , aging, phenotype, , quality, life, , multimorbidity, , life, expectancy, , socialneedsintroductionmost, people, dont, grow, people, age, findparking, spaces, honour, credit, cards, get, married, havechildren, call, maturity, agingmaya, angelou, one, biggest, megatrends, impactingthe, world, today, population, aging, aging, topic, thathas, captivated, scientists, philosophers, throughouthistory, aging, population, scenario, emerged, athis, , part, topical, collection, geriatric, oncology, beatrice, di, capuabeatricedicapuagmailcom, uoc, di, radioterapia, oncologica, dipartimento, diagnostica, perimmagini, radioterapia, oncologica, e, ematologia, fondazionepoliclinico, universitario, a, gemelli, irccs, rome, italy, dipartimento, di, scienze, dellinvecchiamento, neurologicheortopediche, e, della, testacollo, fondazione, policlinico, universitarioa, gemelli, irccs, rome, italy, moffitt, cancer, center, tampa, fl, usaworldwide, scale, first, time, last, century, thus, itis, hard, really, identify, definition, aging, decrease, infitness, chronological, age, developmental, phasebeyond, normal, life, trajectory, time, increased, risk, physical, psychological, disabilities, testingthe, limits, resilienceaging, occurs, different, rate, varying, geographic, regions, worldeurope, currently, oldest, region, , thetotal, population, aged, , older, however, asia, andlatin, america, older, population, growing, fast, asiasolder, population, almost, tripling, size, , million, , million, , []all, data, consider, aging, epiphenomenonbut, individual, data, global, population, chronological, number, aging, intrinsically, complex, scenariocharacterized, changes, take, place, different, levels, ofbiological, systems, biological, age, course, influenced, bychronological, age, chronological, age, representative, biological, age, biological, age, determined, byphysiological, reserve, functional, status, assessing, biological, age, essential, predict, life, expectancy, resilience, 0c, , , , page, , curr, oncol, rep, , , , , , , , , , , , stressors, [], definition, aging, may, appear, incompleteand, insufficient, much, difficult, complex, findthe, marker, biomarker, identify, itmany, theories, currently, trying, explain, aging, processesand, many, biomarkers, identified, measure, aging, itsevolutionary, stages, theories, biomarkers, studiedto, extend, life, span, guide, therapeutic, choices, optimize, patient, management, personalization, carethe, purpose, paper, purely, list, biomarkers, able, identify, various, stages, aging, ratherexplain, epiphenomenon, natural, physiological, isso, complex, [], many, factors, protagonists, development, many, actors, characters, play, maximizing, individual, features, taking, account, social, andmorbidity, biomarker, factors, frailty, loss, ofautonomy, essential, needs, comorbidities, influence, theaging, process, able, justify, biological, ageof, person, living, country, correspond, ageof, another, person, living, country, better, sociosanitaryconditionsclinical, biological, aging, phenotypesthe, aging, phenotype, described, complex, mosaicresulting, interaction, variety, environmentalstochastic, geneticepigenetic, eventsstimuli, impinginglifelong, body, [, ]there, clear, evidence, molecular, cellular, orphysiological, changes, important, drivers, theaging, process, andor, influence, one, another, [], itsbroadest, sense, aging, merely, refers, changes, occurduring, anisms, life, span, though, rate, thesetake, place, varies, widely, [], despite, enormous, complexityinvolving, combinations, variables, small, number, ofbasic, molecular, mechanisms, underpin, aging, process, including, set, evolutionary, highly, conserved, basic, biological, mechanisms, responsible, body, maintenance, repairone, key, mechanisms, inflammation, typical, featureof, aging, process, development, chronic, lowgrade, inflammatory, status, named, inflammaging, [8cid129], whichemerged, critical, pathogenesis, major, agerelatedchronic, diseases, atherosclerosis, type, , diabetes, neuro, degeneration, inflammaging, plays, pivotal, role, themost, important, geriatric, conditions, sarc, ia, [9cid129cid129]osteoporosis, [], frailty, disability, thus, contributing, tomortality, [], interestingly, variety, tissues, adipose, tissue, muscle, ans, brain, liver, systems, immune, systemand, ecosystems, gut, microbiota, body, indicated, assubsystems, contribute, onset, progressionof, systemic, inflammatory, state, [], increasing, theproduction, several, proinflammatory, mediators, loweringthat, antiinflammatory, ones, [8cid129]to, differentiate, innocuous, changes, leadingto, increased, risk, disease, disability, death, biogerontologists, tend, use, precise, termsenescencewhen, describing, aging, [], senescence, thereforethe, progressive, deterioration, bodily, functions, time, andnormal, human, aging, associated, loss, complexity, wide, range, physiological, processes, anatomic, structures, [], including, blood, pressure, [], strideintervals, [], respiratory, cycles, [], vision, [], amongothers, postural, dynamics, [], ultimately, leading, todecreased, fertility, increased, risk, mortality, []systemic, consequences, aging, widespread, theycan, clustered, four, domains, fig, , changing, body, compositionthe, balance, energy, availability, energydemandsignaling, networks, maintain, homeostasis, neurodegenerationthese, changes, develop, parallel, affect, otherthrough, many, feedforward, feedback, loopthe, phenotype, results, aging, process, characterized, increased, susceptibility, disease, high, risk, ofmultiple, coexisting, diseases, impaired, response, stress, theemergence, geriatric, syndromes, altered, response, treatment, high, risk, disability, loss, personal, autonomywith, psychological, social, consequences, theother, hand, factors, influence, aging, dynamic, parallel, way, considered, onlya, consequence, aging, also, integral, part, agingprocesstheories, aginghuman, aging, currently, defined, dynamic, process, involving, continual, adaptation, body, lifelong, exposure, tointernal, external, damaging, conceptualized, remodelling, theory, aging, [21cid129cid129], theories, aging, generallyclassified, either, program, damage, theories, programmedaging, theories, suggest, deliberate, deterioration, withage, limited, life, span, results, evolutionary, benefits[], plan, result, aging, genes, firstdescribed, mutation, yield, significant, extension, life, spanof, caenorhabditis, elegans, agei, gene, wasshown, result, , increase, mean, life, span, increase, maximum, life, span, anism, []evolutionary, biologists, may, argue, aging, occurs, due, theabsence, natural, selection, postreproductive, stage, life[], although, aging, theories, subjectively, appealing, asthey, convey, cure, aging, accumulation, damage, aspontaneous, entropydriven, process, [], among, damage, 0ccurr, oncol, rep, , , , , , , , , , , , fig, , systemic, consequences, ofagingpage, , , , , , theories, prevailing, idea, oxidative, damage, reactiveoxygen, species, ros, generated, metabolism, throughseveral, interrelated, reactions, supposition, aging, may, becaused, ros, substantiated, studies, involving, transgenic, animals, genes, encoding, antioxidants, lifespan, drosophila, melanogaster, extended, overexpression, superoxide, dismutase, sod, catalase, bothantioxidant, enzymes, [], since, mitochondria, major, producer, ros, mammalian, cells, mitochondrial, dnamtdna, therefore, particularly, susceptible, oxidative, damage, [], mitochondrial, maintenance, therefore, essential, topreserve, cellular, homeostasis, impaired, mitochondrial, maintenance, described, shared, hallmark, numeroushuman, pathologies, aging, [], mitochondrial, dna, varieswith, age, commonly, considered, dna, hypomethylation, typical, aspect, aging, process, [], ros, activeintermediates, dna, methylation, well, histone, modification, reactive, oxygen, species, may, play, role, epigeneticprocesses, physiological, phenotypic, variations, caused, external, environmental, factors, switch, genes, onoff, throughreactions, nucleophilic, substitution, dna, levelconsequently, suggested, better, preservation, ofdna, methylation, levels, slower, cell, metabolism, improvedcontrol, signal, transmission, epigenetic, mechanismscould, key, processes, involved, human, longevity, oxidativedamage, proteins, irreversible, irreparable, [], mustbe, degraded, proteasome, proteasome, mostimportant, proteolytic, machinery, eukaryotic, cells, largely, responsible, removal, oxidized, proteins, preventionof, aggregation, [], however, shown, theactivity, proteasome, impaired, aging, leading, theaccumulation, oxidizing, proteins, aggresome, lipofuscinsocalled, age, pigment, similarly, oxidative, damage, nitrosamine, damagethat, caused, reactive, nitrogen, speciesrns, nitric, oxidehas, suggested, also, contribute, agerelated, diseases, namely, hepatic, steatosis, apoptosis, [], well, functional, structural, changes, cardiovascular, system, [, ], sleep, homeostasis, [], psychological, disorders, [], dementia, []most, supporters, genomic, instability, theory, agingrefer, telomere, shortening, [], mutation, dna, mitochondrial, telomeres, repeated, dna, sequences, theends, linear, chromosomes, unable, fullyreplicated, dna, polymerasesmutations, mtdna, cause, wide, range, human, mitochondrial, diseases, implicated, agerelateddiseases, agingbiomarker, featuresfinding, biomarker, aging, one, importantgoals, medicine, national, institutes, healthbiomarkers, definitions, working, group, defined, biomarkeras, a, characteristic, objectively, measured, evaluatedas, indicator, normal, biological, processes, pathogenicprocesses, pharmacologic, responses, therapeutic, intervention, []the, american, federation, aging, research, afar, recommends, following, criteria, biomarkers, aging, [39cid129]it, must, predict, persons, physiological, cognitive, andphysical, function, agerelated, way, independentlyof, chronological, age, 0c, , , , page, , curr, oncol, rep, , , , , , , , , , , , must, testable, harmful, test, subjects, forexample, blood, test, imaging, technique, mustalso, technically, simple, perform, must, accurate, reproducibly, without, need, specializedequipment, techniquesit, work, laboratory, animals, well, humanssince, preliminary, testing, always, done, nonhumansubjectsferrucci, et, al, reviewed, biomarkers, proposed, elements, theory, based, balance, resiliencemechanisms, accumulated, damages, biomarkersact, reducing, resilience, mechanisms, increasing, damages[40cid129], tables, , pathways, eligible, become, biomarkers, thefollowinggenomic, instability, endogenous, exogenous, agents, continuously, challenge, integrity, dna, dna, repairmechanisms, manage, repeated, damage, result, isan, accumulation, dna, somatic, mutations, phenomenon, causes, dysregulation, gene, expression, production, altered, proteins, lead, cellular, damage, somaticmutation, accumulation, observed, skeletal, musclecells, neurons, lymphocytes, b, related, aging, []nevertheless, quantification, dna, repair, capacity, humanshas, yet, finalized, []telomere, attrition, telomeres, dna, sequences, areplaced, end, dna, chain, protect, thetable, , biological, changesunderlying, aginggenomic, instabilitytelomere, attritionepigenetic, alterationscid129, dna, methylationcid129, histone, modificationcid129, noncoding, rnaloss, proteostasismitochondrial, dysfunctioncellular, senescencederegulated, nutrientsensingsteam, cell, exhaustionaltered, intercellular, communicationchromosome, ends, damage, replicationtelomeres, reproduced, completely, agingthey, become, shorter, contribute, cellular, senescence[], date, different, techniques, available, detecttelomere, length, circulating, cells, however, techniqueshave, validated, evaluating, aging, heterogeneity, different, cells, individuals, andhigh, measurement, errors, make, techniques, yetvalid, clinical, practice, []epigenetic, alterations, epigenetics, refers, mechanismsexternal, dna, modulate, gene, expression, cells, theregulation, gene, expression, determines, phenotypic, characteristics, different, cells, tissues, main, mechanismsare, dna, methylation, histone, modification, noncodingrna, dna, methylation, easily, measured, circulatingcells, seems, correlated, aging, [, ], measuringhistone, modification, noncoding, rna, difficult, expensive, recent, evidence, correlates, dna, methylation, agingand, agerelated, chronic, diseases, humans, [, ]individuals, higher, levels, dna, methylation, higherrisk, developing, several, agerelated, diseases, prematuremortality, causes, cardiovascular, diseases, [], wellas, physical, cognitive, functions, [, ]loss, proteostasis, repair, damaged, structures, theirelimination, fundamental, maintain, cell, integrity, function, [], studies, suggest, proteostasis, becomes, defectivewith, aging, contributes, immunosenescence, [], thatautophagy, appears, functional, longlived, peopleaccumulation, dna, somatic, mutationsdysregulation, gene, expressionaltered, proteins, productiontelomere, shortening, contribute, tocellular, senescencealtered, gene, expressionrelated, agerelated, chronic, diseasesaccumulation, damaged, structuresaltered, energy, productionincreased, ros, productionapoptosisprogrammed, cell, deathactivation, pathways, leading, apoptosisproduction, saspincrease, life, span, dietary, restrictiondecline, regenerative, potentialinflammagingdysfunction, endocrine, neuronaland, immune, systems, 0ccurr, oncol, rep, , , , , , , , , , , , page, , , , , , table, , measurable, biomarkers, classified, respective, hallmarkspathways, measuredmeasurable, biomarkershallmarkgenomic, instabilitytelomere, shorteningcellular, senescencecid129, dna, repair, mechanismscid129, dna, modificationscid129, telomere, lengthcid129, markers, dna, damage, responsecid129, telomerase, activitycid129, senescent, markers, blood, tissueepigenetic, changes, epigenetic, clockcid129, dna, methylationcid129, histone, acetylationcid129, noncoding, rnamitochondrialdecreased, autophagy, proteostasiscid129, mitochondrial, volumenumbershapecid129, mito, respirationcid129, markers, biogenesiscid129, mtdna, copy, number, haplotypescid129, autophagy, markerscid129, chaperon, proteinsstem, cell, exhaustionderegulated, nutrientsensingaltered, intercellular, communicationcid129, proliferative, capacity, vitrocid129, resistance, stresscid129, growth, hormone, gh, axiscid129, metabolism, alterationscid129, measures, inflammationcid129, yh2ax, immunohistochemistrycid129leukocyte, telomere, lengthcid129mir31hgcid129, p16ink4acid129, senescenceassociated, secretoryphenotype, sasp, proteinscid129, measures, dna, methylationcid129, sirt1, sirt2, sirt3, sirt6, sirt7cid129, dosage, circulating, micrornas, mir34amir21, mir1263p, mir151a3pmir181a5p, mir1248cid129, p31, mri, spectroscopycid129, growth, differentiating, factor, , gdf15cid129, nadcid129, target, rapamycin, torcid129, protein, carbamylationcid129, advanced, glycation, end, productscid129, insulinlike, growth, factor, igf1cid129, hgba1ccid129, il6cid129, tnfî±cid129, crp, creactive, proteincid129, tnfrii, tumor, necrosis, factorî±, rii[], measuring, loss, proteostasis, mechanism, agood, biomarker, date, valid, techniques, forthis, purposemitochondrial, dysfunction, main, role, mitochondria, isto, guarantee, energy, cell, production, ofatp, also, involved, signaling, productionof, ros, apoptosisprogrammed, cell, deathmitochondrial, dysfunction, good, biomarker, aging, andis, associated, disability, older, persons, reduction, muscle, strength, [65cid129]many, techniques, measuring, oxidative, phosphorylationand, ros, generation, associated, chronicdisease, [, ], nevertheless, relation, aging, notcompletely, validatedcellular, senescence, genomic, instability, telomere, shorteningand, endogenous, exogenous, mechanisms, inducethe, cell, activate, specific, pathways, lead, apoptosis[], process, called, cellular, senescence, characterized, structural, functional, changes, cell, []senescent, cells, produce, proinflammatory, cytokines, andchemokines, growth, factors, matrix, proteases, called, senescenceassociated, secretory, phenotype, sasp, [, ]which, may, induce, agerelated, diseases, [], thedetection, sasp, proposed, biomarker, aging[]deregulated, nutrientsensing, genetic, mutations, growthhormone, insulinlike, growth, factor, linkedto, longevity, [], moreover, dietary, restriction, showed, increase, life, span, primates, [, ], reasons, thispathway, proposed, biomarkers, agingsteam, cell, exhaustion, decline, regenerative, potential, one, elements, base, aging, [], despitepharmacological, interventions, explored, counteractthis, phenomenon, [], evidences, still, poor, 0c, , , , page, , curr, oncol, rep, , , , , , , , , , , , altered, intercellular, communication, aging, also, observe, changes, intercellular, communication, inflammatory, reaction, increases, communication, ways, becomedysfunctional, endocrine, neuronal, immune, system, []as, discussed, earlier, inflammation, inappropriately, increased, aging, related, agerelated, disease, [, ]indeed, pathways, described, potential, biomarkers, ofaging, strongly, related, inflammation, reasonmeasuring, circulating, levels, cytokines, considered, anew, field, research, [, 84cid129, ]aging, life, expectancyaging, life, expectancy, closely, related, broadsense, determining, individuals, life, expectancy, also, away, schematizing, aging, process, life, expectancyis, statistical, measure, average, time, anism, isexpected, live, based, year, birth, leb, itscurrent, age, demographic, factors, including, gender, []in, last, decades, life, expectancy, increased, high, income, country, rise, human, life, expectancy, involveddeclines, intrinsic, extrinsic, mortality, processes, associated, respectively, senescence, environmental, challenges, []in, association, increased, longevity, diseasescalled, agerelated, increase, quadratically, age, andcause, progressive, loss, physical, mental, cognitiveintegrities, leading, impaired, function, increased, vulnerability, morbidity, mortality, [], disability, additionto, increasing, care, needs, agerelated, burden, measuredthrough, sum, disabilityadjusted, life, years, dalys, ofthese, diseases, among, adults, fig, , ninetytwo, global, burden, disease, causes, identified, asagerelated, diseases, particular, cardiovascular, diseaseneoplasm, chronic, respiratory, disorders, withhigher, agerelated, disease, burden, []determinants, frailty, syndrome, agingbiomarkerfrailty, defined, state, increased, vulnerabilityto, stressors, loss, capacity, resolve, homeostasisperturbation, frailty, condition, closely, related, aging[88cid129cid129], frailty, indexes, consequently, considered, biomarkers, aging, frail, individuals, possible, find, changing, body, composition, balance, energy, availability, energydemand, moreover, definition, frailty, welldescribed, signaling, networks, maintain, homeostasisand, association, neurodegeneration, fouraspects, refer, hallmarks, aging, frailty, associated, adverse, clinical, outcomes, including, falls, institutionalization, death, [88cid129cid129]two, principal, models, emerged, last, decades, areable, conceptualize, consequently, measure, frailty, everyday, clinical, practice, research, frailty, phenotypemodel, cumulative, deficits, modelthe, frailty, phenotype, first, described, fried, colleagues, , analyzing, data, cardiovascularhealth, study, chs, involving, , men, women, aged, years, older, study, investigated, whichcharacteristics, population, predictive, falls, disability, hospitalization, death, operational, definitionof, frailty, included, cluster, least, three, followingvariables, unintentional, weight, loss, selfreported, exhaustionlow, energy, expenditure, slow, gait, speed, weak, gripstrength, model, take, consideration, cognitive, impairment, cause, increased, vulnerability, thiscould, contribute, functional, decline, adverse, events, inolder, people, [, ]the, cumulative, deficits, model, developed, byrockwood, colleagues, part, prospectivecanadian, study, health, aging, csha, involvinga, cohort, , older, adults, [], authors, identified, , parameters, including, diseases, disabilities, signssymptoms, laboratory, values, defined, asdeficits, sum, deficits, single, individualallowed, calculation, frailty, index, ie, thenumber, deficits, divided, , frailty, modelis, considered, cluster, symptoms, conceptualized, gradable, syndrome, higher, number, ofdeficits, implying, increased, vulnerability, state, twomodels, frailty, show, significant, overlap, although, theycapture, slightly, different, sides, problem, isimportant, notice, physical, frailty, frequently, associated, multimorbidity, [, 93cid129, ]it, observed, frailty, phenotype, construct, intrinsically, related, mobility, issues, indeedin, older, adults, physical, performance, measures, robust, consistent, predictor, disability, hospitalization, institutionalization, death, researchand, clinical, setting, lower, physical, performance, isfrequently, associated, loss, skeletal, muscle, massand, quality, causing, reduced, strength, functional, impairment, [95cid129cid129], process, called, sarc, iaeven, though, sarc, ia, long, associated, withaging, acknowledged, develop, muchearlier, life, [], different, definitions, exist, condition, operational, definition, sarc, ia, inthe, clinic, research, purposes, prioritize, theassessment, muscle, strength, muscle, mass, identity, sarc, ic, patients, strength, closely, related, tosurvival, functional, decline, compared, muscle, 0ccurr, oncol, rep, , , , , , , , , , , , page, , , , , , cardiovascular, diseasesatrial, ï¬brillaæon, ï¬uæ©er, endocardiæs, hypertensive, heart, disease, intracerebralhaemorrhage, ischaemic, heart, disease, ischaemic, stroke, myocardiæs, nonrheumaæc, valve, disease, cardiomyopathy, cardiovascular, circulatory, diseases, peripheralartery, diseaseneoplasmsleukaemia, lymphoma, mulæple, myeloma, myelodysplasæc, syndroms, hematopoieæc, neoplasms, brain, nervous, system, cancer, breastcancer, prostate, cancer, larynx, cancer, lip, oral, cavity, cancer, oesophagealcancer, stomach, cancer, colon, rectum, cancer, liver, cancer, gallbladder, biliary, tract, cancer, pancreaæc, cancer, kidney, cancer, bladder, cancer, melanoma, nonmelanoma, skin, cancer, ovarian, cancer, uterine, cancer, thyroid, cancer, tracheal, bronchus, lung, cancer, mesothelioma, othermalignant, neoplasms, benign, insitu, neoplasmsgastrointestinal, endocrine, kidney, diseaseschronic, kidney, disease, type, , diabetes, mellitus, cirrhosis, due, nonalcoholicsteatohepaææs, pancreaææs, paralyæc, ileus, intesænal, obstrucæon, pepæculcer, disease, vascular, intesænal, disorders, diarrhoeal, diseasesskin, subcutaneous, diseasescelluliæs, decubitus, ulcer, fungal, skin, diseases, pyoderma, skin, subcutaneousdiseasesfig, , agerelated, diseases, adapted, chang, et, al, []mass, [95cid129cid129], according, ewgsop, criteria, sarc, iais, defined, presence, low, muscle, strength, criterion, , either, low, muscle, quantity, quality, criterion, , low, physical, performance, criterion, , [95cid129cid129]the, physical, performance, parameters, used, identification, frailty, syndrome, integrated, eg, sppb, andalone, walking, speed, handgrip, strength, used, agingperformance, biomarkersdetermination, medical, social, needswhy, consider, medical, social, needs, aging, biomarkersin, , robert, j, havighurst, said, in, considering, theneeds, older, people, well, first, remember, olderpeople, needs, common, people, andsecond, special, needs, due, fact, theyare, old, people, sentence, describes, everything, toknow, need, elderly, answers, questionbeforein, every, society, age, meant, normality, elderly, person, scenario, needs, needed, tomaintain, level, normalcy, activity, daily, living, andinstrumental, activity, daily, living, adl, iadl, aloneremodelled, according, context, gender, identifythe, minimum, necessary, conducting, needs, assessment, various, areas, must, considered, including, physical, health, mental, health, emotional, care, social, cultural, economic, nutritional, service, security, legal, educationalchronic, respiratory, diseasesasbestosis, chronic, obstrucæve, pulmonary, disease, coal, worker, pneumoconiosis, intersææallung, disease, pulmonary, sarcoidosis, pneumoconiosis, silicosis, lower, respiratoryinfecæonsneurological, disordersalzheimers, disease, demenæas, motor, neuron, disease, parkinsonsdisease, encephaliæs, pneumococcal, meningiæsage, related, diseasesense, diseaseshearing, loss, vision, loss, ex, agerelated, macular, degeneraæon, cataract, glaucoma, sense, diseases, refracæon, disorders, trachomainjuriesdrowning, environmental, heat, cold, exposure, falls, foreign, body, body, part, transport, injuries, unintenæonal, injuriesother, diseasescongenital, musculoskeletal, limb, anomalies, digesæve, congenital, anomalies, endocrine, metabolic, blood, immune, disorders, haemoglobinopathies, haemolyæcanaemiasmany, tools, used, evaluate, peoples, needs, majority, tools, focused, physical, performance, ableto, maintain, autonomy, studies, focus, social, needs, andthe, costs, care, west, world, , patients, accountfor, , total, health, care, expenditures, , represented, older, people, individuals, multiple, chronic, conditions, many, medications, frequent, hospitalizations, limitations, ability, perform, basic, daily, functions, due, tophysical, mental, psychosocial, challenge, []since, health, care, social, needs, older, adults, differfrom, adults, necessary, identify, needs, ofthe, elderly, make, proper, plans, promote, healthcurrently, conducted, studies, mainly, focused, elderly, physical, health, needs, neglectedto, take, account, needs, social, health, careneeds, furthermore, addition, quantitative, studies, discovering, older, adults, perceptions, health, needsis, also, necessaryconclusionthere, large, interest, researchers, biomarkers, agingand, despite, seem, promising, biological, biomarkers, still, far, clinical, application, datethere, technique, meets, mentioned, criteria, theideal, biomarker, [40cid129], moreover, know, biologicalpathways, final, agents, aging, one, side, theycan, influenced, social, economic, environmental, factors, side, express, various, disease, 0c, , , , page, , curr, oncol, rep, , , , , , , , , , , , disabilities, person, physical, cognitive, impairmentsagerelated, disease, systems, functions, sensory, functions, etcfig, date, single, biomarker, assess, agingwe, consider, cluster, biomarkers, comprisethe, various, elements, analyzed, social, educational, aspects, economic, factors, country, origin, presence, agerelated, disease, presence, dependence, indaily, activities, physical, capability, cognitive, functionlung, cardiovascular, function, presence, sensorydysfunctions, table, , propose, several, clinical, andlaboratory, biomarkers, used, clinical, practiceand, researchthe, geriatric, assessment, ga, currently, considered, system, capable, monitoring, multiple, biomarkersclinical, laboratory, aging, timeable, relate, ga, ispossible, make, prediction, risk, toxicity, atreatment, life, expectancy, social, needs, compliance, treatments, ga, composed, indeed, byseveral, evaluations, made, standardized, toolswhich, examine, various, aspects, person, multidimensional, assessmentalthough, seems, difficult, imagine, geriatric, assessment, biomarker, currently, characteristicsand, high, predictivity, consideredthe, gold, standard, management, older, individual, instrumenttoward, biomarkersshould, evaluatedthe, purpose, paper, evaluate, multipleaspects, distinguish, aging, process, aging, must, nofig, , mechanisms, connectingdifferent, clusters, biomarkerslonger, described, simple, demographic, event, butas, complex, mosaic, several, tesserae, relate, toeach, evident, way, others, often, amore, subdued, fundamental, way, aging, theory, attempted, justify, process, effectively, however, single, biomarker, date, beenfound, able, identify, stage, process, thesame, time, clinical, clusters, added, purelybiological, markers, social, ones, certainly, beconsidered, therefore, becomes, important, consider, biomarkers, life, span, try, overcomethis, link, focus, set, factors, influencingeach, able, guide, aging, good, health, andgood, quality, life, towards, lived, aging, slowdecline, time, writing, paper, covid, infection, reaping, victims, especially, italy, thehighest, mortality, observed, among, older, adultsbut, surprisingly, seems, maintain, similar, values, youngest, oldest, old, , yearscurrently, plausible, justification, provided, thesedata, frailty, number, comorbidities, reducedfunctional, reserve, used, reasons, indirectlythis, infection, highlighting, need, use, parametersthat, easily, identify, aging, process, regardlessof, chronological, agethe, studies, analyzed, literature, show, theone, hand, physiological, biomarkers, able, ofhighlighting, features, aging, functionalmarkers, performance, social, economic, status, somepathologies, presence, addiction, able, ofspeed, slow]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |[, purpose, review, recognize, which, are, elements, that, predict, why, person, aging, faster, or, slower, which, interventionwe, can, arrange, slow, down, process, which, permits, prevent, or, delay, progression, multimorbidity, disabilityrecent, findings, aging, complex, process, that, leads, changes, all, systems, body, all, functions, theperson, however, aging, develops, at, different, rates, different, people, chronological, age, not, always, consistent, withbiological, agesummary, gerontologists, are, focused, not, only, on, finding, best, theory, able, explain, aging, but, also, on, identifying, one, or, moremarkers, which, are, able, describe, aging, processes, these, biomarkers, are, necessary, better, define, agingrelated, pathologies, manage, multimorbidity, improve, quality, life, aim, paper, review, most, recent, evidence, onaging, biomarkers, clusters, related, them, personalization, treatmentskeywords, biomarker, aging, , frailty, syndrome, , aging, phenotype, , quality, life, , multimorbidity, , life, expectancy, , socialneedsintroductionmost, people, dont, grow, up, most, people, age, they, findparking, spaces, honour, their, credit, cards, get, married, havechildren, call, that, maturity, what, that, agingmaya, angelou, one, biggest, megatrends, impactingthe, world, today, population, aging, aging, topic, thathas, captivated, both, scientists, philosophers, throughouthistory, but, aging, as, population, scenario, emerged, on, athis, , part, topical, collection, on, geriatric, oncology, beatrice, di, capuabeatricedicapuagmailcom, uoc, di, radioterapia, oncologica, dipartimento, diagnostica, perimmagini, radioterapia, oncologica, e, ematologia, fondazionepoliclinico, universitario, a, gemelli, irccs, rome, italy, dipartimento, di, scienze, dellinvecchiamento, neurologicheortopediche, e, della, testacollo, fondazione, policlinico, universitarioa, gemelli, irccs, rome, italy, moffitt, cancer, center, tampa, fl, usaworldwide, scale, first, time, last, century, thus, itis, hard, really, identify, definition, aging, it, decrease, infitness, with, chronological, age, it, developmental, phasebeyond, normal, life, trajectory, it, time, increased, risk, physical, psychological, disabilities, testingthe, limits, resilienceaging, occurs, at, different, rate, varying, geographic, regions, worldeurope, currently, oldest, region, with, , thetotal, population, aged, , older, however, asia, andlatin, america, older, population, growing, fast, with, asiasolder, population, almost, tripling, size, from, , million, , million, , []all, these, data, do, not, consider, aging, as, an, epiphenomenonbut, an, individual, data, global, population, just, chronological, number, aging, intrinsically, complex, scenariocharacterized, by, changes, that, take, place, at, different, levels, ofbiological, systems, biological, age, course, influenced, bychronological, age, but, chronological, age, by, itself, not, representative, biological, age, biological, age, determined, byphysiological, reserve, functional, status, assessing, biological, age, essential, predict, life, expectancy, resilience, 0c, , , , page, , curr, oncol, rep, , , , , , , , , , , , stressors, [], if, any, definition, aging, may, appear, incompleteand, insufficient, much, more, difficult, complex, findthe, marker, or, biomarker, that, can, identify, itmany, theories, currently, trying, explain, aging, processesand, many, biomarkers, are, identified, measure, aging, itsevolutionary, stages, theories, biomarkers, are, not, studiedto, extend, life, span, but, guide, therapeutic, choices, optimize, patient, management, personalization, carethe, purpose, paper, not, purely, list, which, biomarkers, are, able, identify, various, stages, aging, ratherexplain, how, an, epiphenomenon, natural, physiological, isso, complex, [], how, many, factors, are, protagonists, its, development, how, many, actors, characters, play, maximizing, its, individual, features, taking, into, account, social, andmorbidity, biomarker, these, factors, such, as, frailty, loss, ofautonomy, essential, needs, comorbidities, influence, theaging, process, are, able, justify, why, biological, ageof, person, living, country, does, not, correspond, ageof, another, person, living, country, with, better, sociosanitaryconditionsclinical, biological, aging, phenotypesthe, aging, phenotype, can, be, described, as, complex, mosaicresulting, from, interaction, variety, environmentalstochastic, geneticepigenetic, eventsstimuli, impinginglifelong, on, our, body, [, ]there, no, clear, evidence, which, molecular, cellular, orphysiological, changes, are, most, important, drivers, theaging, process, andor, how, they, influence, one, another, [], itsbroadest, sense, aging, merely, refers, changes, that, occurduring, an, anisms, life, span, though, rate, at, which, thesetake, place, varies, widely, [], despite, its, enormous, complexityinvolving, combinations, these, variables, small, number, ofbasic, molecular, mechanisms, underpin, aging, process, including, set, evolutionary, highly, conserved, basic, biological, mechanisms, responsible, body, maintenance, repairone, key, mechanisms, inflammation, typical, featureof, aging, process, development, chronic, lowgrade, inflammatory, status, named, inflammaging, [8cid129], whichemerged, as, critical, pathogenesis, major, agerelatedchronic, diseases, such, as, atherosclerosis, type, , diabetes, neuro, degeneration, inflammaging, plays, pivotal, role, themost, important, geriatric, conditions, such, as, sarc, ia, [9cid129cid129]osteoporosis, [], frailty, disability, thus, contributing, tomortality, [], interestingly, variety, tissues, adipose, tissue, muscle, ans, brain, liver, systems, immune, systemand, ecosystems, gut, microbiota, body, indicated, assubsystems, can, contribute, onset, progressionof, such, systemic, inflammatory, state, [], by, increasing, theproduction, several, proinflammatory, mediators, or, loweringthat, antiinflammatory, ones, [8cid129]to, differentiate, innocuous, changes, from, those, leadingto, increased, risk, disease, disability, or, death, biogerontologists, tend, use, more, precise, termsenescencewhen, describing, aging, [], senescence, thereforethe, progressive, deterioration, bodily, functions, over, time, andnormal, human, aging, has, been, associated, with, loss, complexity, wide, range, physiological, processes, anatomic, structures, [], including, blood, pressure, [], strideintervals, [], respiratory, cycles, [], vision, [], amongothers, such, as, postural, dynamics, [], ultimately, leading, todecreased, fertility, increased, risk, or, mortality, []systemic, consequences, aging, are, widespread, but, theycan, be, clustered, into, four, domains, fig, , changing, body, compositionthe, balance, between, energy, availability, energydemandsignaling, networks, that, maintain, homeostasis, neurodegenerationthese, changes, develop, parallel, affect, each, otherthrough, many, feedforward, feedback, loopthe, phenotype, that, results, from, aging, process, characterized, by, increased, susceptibility, disease, high, risk, ofmultiple, coexisting, diseases, impaired, response, stress, theemergence, geriatric, syndromes, altered, response, treatment, high, risk, disability, loss, personal, autonomywith, all, its, psychological, social, consequences, on, theother, hand, all, these, factors, influence, aging, itself, dynamic, parallel, way, so, that, they, can, be, considered, as, not, onlya, consequence, aging, but, also, an, integral, part, agingprocesstheories, aginghuman, aging, currently, defined, as, dynamic, process, involving, continual, adaptation, body, lifelong, exposure, tointernal, external, damaging, as, conceptualized, remodelling, theory, aging, [21cid129cid129], theories, aging, are, generallyclassified, as, either, program, or, damage, theories, programmedaging, theories, suggest, that, there, deliberate, deterioration, withage, because, limited, life, span, results, evolutionary, benefits[], plan, could, be, result, aging, genes, firstdescribed, mutation, yield, significant, extension, life, spanof, caenorhabditis, elegans, agei, gene, which, wasshown, result, , increase, mean, life, span, increase, maximum, life, span, anism, []evolutionary, biologists, may, argue, that, aging, occurs, due, theabsence, natural, selection, at, postreproductive, stage, life[], although, such, aging, theories, are, subjectively, appealing, asthey, convey, cure, aging, accumulation, damage, aspontaneous, entropydriven, process, [], among, damage, 0ccurr, oncol, rep, , , , , , , , , , , , fig, , systemic, consequences, ofagingpage, , , , , , theories, prevailing, idea, that, oxidative, damage, reactiveoxygen, species, ros, are, generated, during, metabolism, throughseveral, interrelated, reactions, supposition, that, aging, may, becaused, by, ros, has, been, further, substantiated, by, studies, involving, transgenic, animals, genes, encoding, antioxidants, lifespan, drosophila, melanogaster, has, been, extended, by, overexpression, both, superoxide, dismutase, sod, catalase, bothantioxidant, enzymes, [], since, mitochondria, are, major, producer, ros, mammalian, cells, mitochondrial, dnamtdna, therefore, particularly, susceptible, oxidative, damage, [], mitochondrial, maintenance, therefore, essential, topreserve, cellular, homeostasis, impaired, mitochondrial, maintenance, has, been, described, as, shared, hallmark, numeroushuman, pathologies, aging, [], mitochondrial, dna, varieswith, age, it, commonly, considered, that, dna, hypomethylation, typical, aspect, aging, process, [], ros, are, activeintermediates, dna, methylation, as, well, as, histone, modification, these, reactive, oxygen, species, may, play, role, epigeneticprocesses, physiological, phenotypic, variations, caused, by, external, or, environmental, factors, that, switch, genes, onoff, throughreactions, nucleophilic, substitution, at, dna, levelconsequently, it, has, been, suggested, that, better, preservation, ofdna, methylation, levels, slower, cell, metabolism, improvedcontrol, signal, transmission, through, epigenetic, mechanismscould, be, key, processes, involved, human, longevity, oxidativedamage, proteins, irreversible, irreparable, [], mustbe, degraded, by, proteasome, proteasome, mostimportant, proteolytic, machinery, eukaryotic, cells, largely, responsible, removal, oxidized, proteins, preventionof, its, aggregation, [], however, it, has, been, shown, that, theactivity, proteasome, impaired, during, aging, leading, theaccumulation, oxidizing, proteins, aggresome, lipofuscinsocalled, age, pigment, similarly, oxidative, damage, nitrosamine, damagethat, caused, by, reactive, nitrogen, speciesrns, such, as, nitric, oxidehas, been, suggested, also, contribute, agerelated, diseases, namely, hepatic, steatosis, apoptosis, [], as, well, as, functional, structural, changes, cardiovascular, system, [, ], sleep, homeostasis, [], psychological, disorders, [], dementia, []most, supporters, genomic, instability, theory, agingrefer, telomere, shortening, [], mutation, dna, mitochondrial, telomeres, are, repeated, dna, sequences, at, theends, linear, chromosomes, which, are, unable, be, fullyreplicated, by, dna, polymerasesmutations, mtdna, cause, wide, range, human, mitochondrial, diseases, have, been, implicated, agerelateddiseases, agingbiomarker, featuresfinding, biomarker, aging, one, most, importantgoals, medicine, national, institutes, healthbiomarkers, definitions, working, group, defined, biomarkeras, a, characteristic, that, objectively, measured, evaluatedas, an, indicator, normal, biological, processes, pathogenicprocesses, or, pharmacologic, responses, therapeutic, intervention, []the, american, federation, aging, research, afar, recommends, following, criteria, biomarkers, aging, [39cid129]it, must, predict, persons, physiological, cognitive, andphysical, function, an, agerelated, way, independentlyof, chronological, age, 0c, , , , page, , curr, oncol, rep, , , , , , , , , , , , it, must, be, testable, not, harmful, test, subjects, forexample, blood, test, or, an, imaging, technique, it, mustalso, be, technically, simple, perform, it, must, be, accurate, reproducibly, without, need, specializedequipment, or, techniquesit, should, work, laboratory, animals, as, well, as, humanssince, preliminary, testing, always, done, nonhumansubjectsferrucci, et, al, reviewed, biomarkers, proposed, as, elements, theory, based, on, balance, between, resiliencemechanisms, accumulated, damages, where, biomarkersact, reducing, resilience, mechanisms, or, increasing, damages[40cid129], tables, , pathways, eligible, become, biomarkers, are, thefollowinggenomic, instability, endogenous, exogenous, agents, continuously, challenge, integrity, dna, when, dna, repairmechanisms, cannot, manage, repeated, damage, result, isan, accumulation, dna, somatic, mutations, phenomenon, causes, dysregulation, gene, expression, production, altered, proteins, that, lead, cellular, damage, somaticmutation, accumulation, has, been, observed, skeletal, musclecells, neurons, lymphocytes, b, related, aging, []nevertheless, quantification, dna, repair, capacity, humanshas, yet, be, finalized, []telomere, attrition, telomeres, are, dna, sequences, that, areplaced, at, end, dna, chain, protect, thetable, , biological, changesunderlying, aginggenomic, instabilitytelomere, attritionepigenetic, alterationscid129, dna, methylationcid129, histone, modificationcid129, noncoding, rnaloss, proteostasismitochondrial, dysfunctioncellular, senescencederegulated, nutrientsensingsteam, cell, exhaustionaltered, intercellular, communicationchromosome, ends, from, damage, during, each, replicationtelomeres, are, reproduced, but, not, completely, so, with, agingthey, become, shorter, contribute, cellular, senescence[], date, different, techniques, are, available, detecttelomere, length, circulating, cells, however, no, techniqueshave, been, validated, evaluating, aging, because, heterogeneity, between, different, cells, between, individuals, andhigh, measurement, errors, that, make, these, techniques, not, yetvalid, clinical, practice, []epigenetic, alterations, epigenetics, refers, those, mechanismsexternal, dna, that, modulate, gene, expression, cells, theregulation, gene, expression, determines, phenotypic, characteristics, different, cells, tissues, main, mechanismsare, dna, methylation, histone, modification, noncodingrna, while, dna, methylation, easily, measured, circulatingcells, seems, be, correlated, aging, [, ], measuringhistone, modification, or, noncoding, rna, difficult, expensive, recent, evidence, correlates, dna, methylation, with, agingand, agerelated, chronic, diseases, humans, [, ]individuals, with, higher, levels, dna, methylation, have, higherrisk, developing, several, agerelated, diseases, prematuremortality, all, causes, cardiovascular, diseases, [], as, wellas, physical, cognitive, functions, [, ]loss, proteostasis, repair, damaged, structures, or, theirelimination, fundamental, maintain, cell, integrity, function, [], studies, suggest, that, proteostasis, becomes, defectivewith, aging, contributes, immunosenescence, [], thatautophagy, appears, be, more, functional, longlived, peopleaccumulation, dna, somatic, mutationsdysregulation, gene, expressionaltered, proteins, productiontelomere, shortening, contribute, tocellular, senescencealtered, gene, expressionrelated, agerelated, chronic, diseasesaccumulation, damaged, structuresaltered, energy, productionincreased, ros, productionapoptosisprogrammed, cell, deathactivation, pathways, leading, apoptosisproduction, saspincrease, life, span, dietary, restrictiondecline, regenerative, potentialinflammagingdysfunction, endocrine, neuronaland, immune, systems, 0ccurr, oncol, rep, , , , , , , , , , , , page, , , , , , table, , measurable, biomarkers, classified, by, respective, hallmarkspathways, measuredmeasurable, biomarkershallmarkgenomic, instabilitytelomere, shorteningcellular, senescencecid129, dna, repair, mechanismscid129, dna, modificationscid129, telomere, lengthcid129, markers, dna, damage, responsecid129, telomerase, activitycid129, senescent, markers, blood, tissueepigenetic, changes, or, epigenetic, clockcid129, dna, methylationcid129, histone, acetylationcid129, noncoding, rnamitochondrialdecreased, autophagy, proteostasiscid129, mitochondrial, volumenumbershapecid129, mito, respirationcid129, markers, biogenesiscid129, mtdna, copy, number, haplotypescid129, autophagy, markerscid129, chaperon, proteinsstem, cell, exhaustionderegulated, nutrientsensingaltered, intercellular, communicationcid129, proliferative, capacity, vitrocid129, resistance, stresscid129, growth, hormone, gh, axiscid129, metabolism, alterationscid129, measures, inflammationcid129, yh2ax, immunohistochemistrycid129leukocyte, telomere, lengthcid129mir31hgcid129, p16ink4acid129, senescenceassociated, secretoryphenotype, sasp, proteinscid129, measures, dna, methylationcid129, sirt1, sirt2, sirt3, sirt6, sirt7cid129, dosage, circulating, micrornas, mir34amir21, mir1263p, mir151a3pmir181a5p, mir1248cid129, p31, mri, spectroscopycid129, growth, differentiating, factor, , gdf15cid129, nadcid129, target, rapamycin, torcid129, protein, carbamylationcid129, advanced, glycation, end, productscid129, insulinlike, growth, factor, igf1cid129, hgba1ccid129, il6cid129, tnfî±cid129, crp, creactive, proteincid129, tnfrii, tumor, necrosis, factorî±, rii[], measuring, loss, proteostasis, mechanism, could, be, agood, biomarker, but, date, there, are, no, valid, techniques, forthis, purposemitochondrial, dysfunction, main, role, mitochondria, isto, guarantee, energy, cell, through, production, ofatp, they, are, also, involved, signaling, by, productionof, ros, apoptosisprogrammed, cell, deathmitochondrial, dysfunction, good, biomarker, aging, andis, associated, with, disability, older, persons, through, reduction, muscle, strength, [65cid129]many, techniques, are, measuring, oxidative, phosphorylationand, ros, generation, that, have, been, associated, with, chronicdisease, [, ], nevertheless, relation, with, aging, notcompletely, validatedcellular, senescence, genomic, instability, telomere, shorteningand, other, endogenous, exogenous, mechanisms, can, inducethe, cell, activate, specific, pathways, that, lead, apoptosis[], process, called, cellular, senescence, characterized, by, structural, functional, changes, cell, []senescent, cells, produce, proinflammatory, cytokines, andchemokines, growth, factors, matrix, proteases, called, senescenceassociated, secretory, phenotype, sasp, [, ]which, may, induce, some, agerelated, diseases, [], thedetection, sasp, has, been, proposed, as, biomarker, aging[]deregulated, nutrientsensing, genetic, mutations, growthhormone, insulinlike, growth, factor, have, been, linkedto, longevity, [], moreover, dietary, restriction, showed, increase, life, span, primates, [, ], these, reasons, thispathway, has, been, proposed, as, biomarkers, agingsteam, cell, exhaustion, decline, regenerative, potential, one, elements, at, base, aging, [], despitepharmacological, interventions, being, explored, counteractthis, phenomenon, [], evidences, are, still, poor, 0c, , , , page, , curr, oncol, rep, , , , , , , , , , , , altered, intercellular, communication, with, aging, we, also, observe, changes, intercellular, communication, as, inflammatory, reaction, increases, other, communication, ways, becomedysfunctional, endocrine, neuronal, immune, system, []as, we, discussed, earlier, inflammation, can, be, inappropriately, increased, aging, has, been, related, agerelated, disease, [, ]indeed, pathways, described, as, potential, biomarkers, ofaging, are, strongly, related, inflammation, reasonmeasuring, circulating, levels, cytokines, considered, anew, field, research, [, 84cid129, ]aging, life, expectancyaging, life, expectancy, are, closely, related, broadsense, determining, an, individuals, life, expectancy, also, away, schematizing, his, or, her, aging, process, life, expectancyis, statistical, measure, average, time, an, anism, isexpected, live, based, on, year, its, birth, leb, itscurrent, age, demographic, factors, including, gender, []in, last, decades, life, expectancy, has, increased, high, income, country, rise, human, life, expectancy, has, involveddeclines, intrinsic, extrinsic, mortality, processes, associated, respectively, with, senescence, environmental, challenges, []in, association, increased, longevity, there, are, diseasescalled, agerelated, that, increase, quadratically, with, age, andcause, progressive, loss, physical, mental, cognitiveintegrities, leading, impaired, function, increased, vulnerability, morbidity, mortality, [], disability, additionto, increasing, care, needs, agerelated, burden, measuredthrough, sum, disabilityadjusted, life, years, dalys, ofthese, diseases, among, these, adults, fig, , ninetytwo, global, burden, disease, causes, were, identified, asagerelated, diseases, particular, cardiovascular, diseaseneoplasm, chronic, respiratory, disorders, are, those, withhigher, agerelated, disease, burden, []determinants, frailty, syndrome, as, agingbiomarkerfrailty, can, be, defined, as, state, increased, vulnerabilityto, stressors, or, loss, capacity, resolve, homeostasisperturbation, frailty, condition, closely, related, aging[88cid129cid129], frailty, indexes, can, consequently, be, considered, biomarkers, aging, themselves, frail, individuals, it, possible, find, both, changing, body, composition, balance, between, energy, availability, energydemand, moreover, definition, frailty, it, welldescribed, how, signaling, networks, maintain, homeostasisand, association, with, neurodegeneration, these, fouraspects, all, refer, hallmarks, aging, frailty, associated, with, adverse, clinical, outcomes, including, falls, institutionalization, death, [88cid129cid129]two, principal, models, emerged, last, decades, that, areable, conceptualize, consequently, measure, frailty, everyday, clinical, practice, research, frailty, phenotypemodel, cumulative, deficits, modelthe, frailty, phenotype, first, described, by, fried, colleagues, , analyzing, data, from, cardiovascularhealth, study, chs, involving, , men, women, aged, years, older, study, it, investigated, whichcharacteristics, population, were, predictive, falls, disability, hospitalization, death, their, operational, definitionof, frailty, included, cluster, at, least, three, followingvariables, unintentional, weight, loss, selfreported, exhaustionlow, energy, expenditure, slow, gait, speed, weak, gripstrength, model, does, not, take, into, consideration, cognitive, impairment, as, cause, increased, vulnerability, as, thiscould, contribute, functional, decline, adverse, events, inolder, people, [, ]the, cumulative, deficits, model, developed, byrockwood, colleagues, as, part, prospectivecanadian, study, health, aging, csha, involvinga, cohort, , older, adults, [], authors, identified, , parameters, including, diseases, disabilities, signssymptoms, laboratory, values, which, were, defined, asdeficits, sum, deficits, single, individualallowed, calculation, frailty, index, ie, thenumber, deficits, divided, by, , frailty, modelis, not, considered, as, cluster, symptoms, but, conceptualized, as, gradable, syndrome, with, higher, number, ofdeficits, implying, an, increased, vulnerability, state, twomodels, frailty, show, significant, overlap, although, theycapture, slightly, different, sides, same, problem, it, isimportant, notice, that, physical, frailty, frequently, associated, with, multimorbidity, [, 93cid129, ]it, has, been, observed, that, frailty, phenotype, construct, intrinsically, related, mobility, issues, indeedin, older, adults, physical, performance, measures, are, robust, consistent, predictor, disability, hospitalization, institutionalization, death, both, researchand, clinical, setting, lower, physical, performance, isfrequently, associated, with, loss, skeletal, muscle, massand, quality, causing, reduced, strength, functional, impairment, [95cid129cid129], process, has, been, called, sarc, iaeven, though, sarc, ia, has, been, long, associated, withaging, it, has, be, acknowledged, that, it, can, develop, muchearlier, life, [], different, definitions, exist, condition, operational, definition, sarc, ia, both, inthe, clinic, research, purposes, that, prioritize, theassessment, muscle, strength, over, muscle, mass, identity, sarc, ic, patients, strength, more, closely, related, tosurvival, functional, decline, compared, with, muscle, 0ccurr, oncol, rep, , , , , , , , , , , , page, , , , , , cardiovascular, diseasesatrial, ï¬brillaæon, ï¬uæ©er, endocardiæs, hypertensive, heart, disease, intracerebralhaemorrhage, ischaemic, heart, disease, ischaemic, stroke, myocardiæs, nonrheumaæc, valve, disease, other, cardiomyopathy, other, cardiovascular, circulatory, diseases, peripheralartery, diseaseneoplasmsleukaemia, lymphoma, mulæple, myeloma, myelodysplasæc, syndroms, other, hematopoieæc, neoplasms, brain, nervous, system, cancer, breastcancer, prostate, cancer, larynx, cancer, lip, oral, cavity, cancer, oesophagealcancer, stomach, cancer, colon, rectum, cancer, liver, cancer, gallbladder, biliary, tract, cancer, pancreaæc, cancer, kidney, cancer, bladder, cancer, melanoma, nonmelanoma, skin, cancer, ovarian, cancer, uterine, cancer, thyroid, cancer, tracheal, bronchus, lung, cancer, mesothelioma, othermalignant, neoplasms, other, benign, insitu, neoplasmsgastrointestinal, endocrine, kidney, diseaseschronic, kidney, disease, type, , diabetes, mellitus, cirrhosis, due, nonalcoholicsteatohepaææs, pancreaææs, paralyæc, ileus, intesænal, obstrucæon, pepæculcer, disease, vascular, intesænal, disorders, diarrhoeal, diseasesskin, subcutaneous, diseasescelluliæs, decubitus, ulcer, fungal, skin, diseases, pyoderma, other, skin, subcutaneousdiseasesfig, , agerelated, diseases, adapted, from, chang, et, al, []mass, [95cid129cid129], according, ewgsop, criteria, sarc, iais, defined, by, presence, low, muscle, strength, criterion, , either, or, low, muscle, quantity, or, quality, criterion, , or, low, physical, performance, criterion, , [95cid129cid129]the, physical, performance, parameters, used, identification, frailty, syndrome, both, integrated, eg, sppb, andalone, walking, speed, handgrip, strength, can, be, used, as, agingperformance, biomarkersdetermination, medical, social, needswhy, consider, medical, social, needs, aging, biomarkersin, , robert, j, havighurst, said, in, considering, theneeds, older, people, it, well, first, remember, that, olderpeople, have, needs, that, are, common, all, people, andsecond, that, they, have, special, needs, due, fact, that, theyare, old, people, sentence, describes, everything, there, toknow, about, need, elderly, answers, questionbeforein, every, society, age, there, what, meant, by, normality, an, elderly, person, scenario, needs, what, needed, tomaintain, level, normalcy, activity, daily, living, andinstrumental, activity, daily, living, adl, iadl, aloneremodelled, according, context, gender, can, identifythe, minimum, necessary, conducting, needs, assessment, various, areas, must, be, considered, including, physical, health, mental, health, emotional, care, social, cultural, economic, nutritional, service, security, legal, educationalchronic, respiratory, diseasesasbestosis, chronic, obstrucæve, pulmonary, disease, coal, worker, pneumoconiosis, intersææallung, disease, pulmonary, sarcoidosis, other, pneumoconiosis, silicosis, lower, respiratoryinfecæonsneurological, disordersalzheimers, disease, other, demenæas, motor, neuron, disease, parkinsonsdisease, encephaliæs, pneumococcal, meningiæsage, related, diseasesense, an, diseaseshearing, loss, vision, loss, ex, agerelated, macular, degeneraæon, cataract, glaucoma, other, sense, an, diseases, refracæon, disorders, trachomainjuriesdrowning, environmental, heat, cold, exposure, falls, foreign, body, other, body, part, other, transport, injuries, other, unintenæonal, injuriesother, diseasescongenital, musculoskeletal, limb, anomalies, digesæve, congenital, anomalies, endocrine, metabolic, blood, immune, disorders, other, haemoglobinopathies, haemolyæcanaemiasmany, tools, are, used, evaluate, peoples, needs, majority, these, tools, are, focused, on, physical, performance, ableto, maintain, autonomy, few, studies, focus, on, social, needs, andthe, costs, care, west, world, , patients, accountfor, , total, health, care, expenditures, , represented, by, older, people, individuals, with, multiple, chronic, conditions, many, medications, frequent, hospitalizations, limitations, on, their, ability, perform, basic, daily, functions, due, tophysical, mental, or, psychosocial, challenge, []since, health, care, social, needs, older, adults, differfrom, that, other, adults, it, necessary, identify, needs, ofthe, elderly, make, proper, plans, that, will, promote, their, healthcurrently, most, conducted, studies, had, mainly, focused, on, elderly, physical, health, needs, had, neglectedto, take, into, account, other, needs, such, as, social, health, careneeds, furthermore, addition, quantitative, studies, discovering, older, adults, perceptions, their, own, health, needsis, also, necessaryconclusionthere, large, interest, researchers, biomarkers, agingand, despite, some, them, seem, be, very, promising, biological, biomarkers, are, still, far, from, clinical, application, datethere, no, technique, that, meets, mentioned, criteria, theideal, biomarker, [40cid129], moreover, we, know, that, biologicalpathways, are, final, agents, aging, but, on, one, side, theycan, be, influenced, by, social, economic, environmental, factors, on, other, side, they, express, various, disease, 0c, , , , page, , curr, oncol, rep, , , , , , , , , , , , disabilities, person, physical, cognitive, impairmentsagerelated, disease, systems, functions, sensory, functions, etcfig, date, more, than, single, biomarker, assess, agingwe, should, consider, cluster, biomarkers, that, comprisethe, various, elements, that, we, analyzed, social, educational, aspects, economic, factors, country, origin, presence, agerelated, disease, presence, dependence, indaily, activities, physical, capability, cognitive, functionlung, cardiovascular, function, presence, sensorydysfunctions, table, , we, propose, several, clinical, andlaboratory, biomarkers, that, can, be, used, clinical, practiceand, researchthe, geriatric, assessment, ga, can, currently, be, considered, system, capable, monitoring, multiple, biomarkersclinical, laboratory, aging, at, same, timeable, relate, them, each, other, through, ga, it, ispossible, make, prediction, risk, toxicity, atreatment, life, expectancy, social, needs, compliance, with, treatments, ga, composed, indeed, byseveral, evaluations, made, through, standardized, toolswhich, examine, various, aspects, person, multidimensional, assessmentalthough, it, seems, difficult, imagine, geriatric, assessment, as, biomarker, currently, its, characteristicsand, high, predictivity, it, has, it, can, be, consideredthe, gold, standard, management, older, individual, instrumenttoward, which, other, biomarkersshould, be, evaluatedthe, purpose, paper, evaluate, multipleaspects, that, distinguish, aging, process, aging, must, nofig, , mechanisms, connectingdifferent, clusters, biomarkerslonger, be, described, as, simple, demographic, event, butas, complex, mosaic, which, several, tesserae, relate, toeach, other, some, very, evident, way, others, often, amore, subdued, but, all, fundamental, way, each, aging, theory, has, attempted, justify, process, effectively, however, there, no, single, biomarker, date, that, has, beenfound, able, identify, stage, process, at, thesame, time, clinical, clusters, have, been, added, purelybiological, markers, social, ones, should, certainly, beconsidered, it, therefore, becomes, important, not, consider, biomarkers, only, as, life, span, but, try, overcomethis, link, focus, on, set, factors, that, influencingeach, other, are, able, guide, aging, good, health, andgood, quality, life, towards, lived, aging, as, slowdecline, at, time, we, are, writing, paper, covid, infection, reaping, victims, especially, italy, thehighest, mortality, observed, among, older, adultsbut, surprisingly, it, seems, maintain, similar, values, between, youngest, oldest, old, over, , yearscurrently, no, plausible, justification, provided, thesedata, frailty, number, comorbidities, reducedfunctional, reserve, most, used, reasons, indirectlythis, infection, highlighting, need, use, parametersthat, can, more, easily, identify, aging, process, regardlessof, chronological, agethe, studies, analyzed, literature, show, that, if, on, theone, hand, there, are, physiological, biomarkers, able, ofhighlighting, some, features, aging, other, functionalmarkers, performance, social, economic, status, somepathologies, presence, addiction, are, able, ofspeed, it, up, or, slow, it]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |(224581,[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,27,28,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,57,59,60,61,62,63,68,70,72,73,74,76,78,79,80,81,85,86,87,90,92,94,95,96,97,98,99,100,101,103,104,105,106,108,109,110,112,113,114,115,116,117,118,119,120,123,124,125,126,127,128,130,131,132,133,134,135,136,137,138,140,142,143,146,147,148,149,151,155,156,157,158,159,161,166,167,168,171,173,174,177,182,185,187,188,189,190,191,194,195,196,197,198,200,201,202,203,204,206,207,209,211,212,213,214,216,217,218,221,224,225,226,229,232,235,236,237,242,243,244,249,253,258,260,262,264,265,268,270,274,278,279,280,281,283,284,287,291,294,296,301,302,305,307,308,311,312,313,316,318,320,322,325,330,335,337,340,343,347,351,352,355,357,358,361,363,367,368,373,374,375,376,377,378,380,382,384,386,390,391,393,395,396,397,398,399,401,403,412,413,414,415,417,421,423,424,426,427,428,429,432,433,439,445,447,448,450,458,463,464,466,468,469,470,477,479,482,486,488,489,492,498,499,507,508,515,519,520,523,524,528,532,534,536,537,538,543,547,550,551,555,556,557,563,566,569,572,574,580,583,586,591,594,595,596,604,606,615,619,627,629,631,634,636,638,639,641,642,643,644,649,654,658,659,661,673,677,681,682,684,685,688,692,697,701,706,707,711,713,715,716,718,719,720,723,727,728,729,731,735,737,739,741,750,762,763,764,766,767,770,773,781,783,785,793,796,805,808,810,812,818,820,839,840,845,846,850,851,852,854,855,873,875,876,878,879,882,883,885,887,895,899,901,903,905,911,913,914,915,917,925,929,937,938,942,951,954,955,956,961,967,968,976,982,984,988,994,996,997,1004,1007,1013,1021,1026,1030,1033,1039,1042,1045,1047,1048,1049,1051,1053,1054,1061,1067,1068,1069,1070,1071,1077,1079,1081,1084,1085,1086,1087,1092,1100,1106,1110,1113,1114,1117,1120,1121,1122,1129,1146,1150,1151,1153,1159,1175,1176,1184,1186,1187,1195,1202,1211,1212,1213,1241,1247,1262,1264,1266,1284,1290,1301,1314,1315,1325,1332,1336,1341,1345,1353,1355,1359,1360,1368,1382,1384,1387,1390,1395,1409,1411,1424,1437,1444,1445,1453,1455,1457,1461,1478,1480,1481,1485,1491,1493,1500,1501,1504,1505,1532,1538,1540,1546,1549,1551,1554,1557,1565,1568,1572,1573,1574,1578,1584,1592,1596,1600,1615,1621,1626,1637,1643,1646,1654,1663,1665,1666,1669,1671,1674,1685,1686,1689,1695,1704,1705,1709,1720,1721,1741,1743,1745,1751,1752,1758,1777,1787,1806,1815,1838,1839,1863,1865,1873,1874,1878,1896,1898,1902,1920,1931,1932,1940,1942,1950,1954,1957,1961,1966,1967,1976,1994,2001,2003,2006,2012,2024,2036,2046,2056,2061,2068,2077,2079,2087,2092,2093,2096,2100,2103,2106,2115,2117,2132,2153,2156,2159,2163,2175,2178,2199,2211,2212,2216,2227,2242,2244,2261,2262,2263,2264,2267,2272,2273,2281,2296,2305,2316,2318,2340,2354,2361,2377,2378,2381,2398,2431,2433,2446,2450,2453,2461,2471,2476,2506,2513,2514,2527,2537,2538,2541,2557,2561,2587,2588,2598,2638,2640,2648,2652,2663,2664,2668,2671,2674,2676,2690,2713,2719,2722,2741,2749,2760,2761,2797,2819,2831,2832,2839,2850,2854,2856,2864,2870,2876,2879,2883,2904,2940,2954,2955,2957,2959,2961,2963,2967,3001,3023,3036,3052,3060,3076,3084,3093,3101,3102,3114,3116,3122,3125,3144,3156,3180,3190,3199,3205,3211,3214,3227,3230,3244,3249,3250,3261,3281,3312,3315,3321,3331,3336,3337,3342,3343,3358,3371,3387,3393,3416,3432,3440,3443,3450,3474,3478,3496,3506,3511,3531,3543,3559,3598,3621,3632,3639,3669,3681,3694,3706,3714,3722,3737,3759,3768,3773,3779,3850,3862,3928,3955,3958,3984,3997,4003,4010,4014,4033,4055,4087,4102,4110,4111,4180,4194,4195,4226,4241,4272,4283,4284,4299,4314,4321,4348,4375,4376,4394,4402,4403,4408,4420,4468,4473,4482,4527,4532,4556,4612,4615,4617,4633,4649,4652,4699,4706,4745,4752,4772,4780,4833,4849,4874,4882,4893,4916,4957,4959,4974,5009,5023,5080,5104,5144,5181,5207,5226,5239,5252,5267,5269,5277,5290,5314,5346,5428,5481,5499,5514,5563,5599,5670,5708,5732,5746,5750,5764,5766,5780,5800,5825,5828,5872,5889,5899,5903,5909,5936,5977,6027,6037,6041,6060,6095,6244,6254,6297,6307,6312,6316,6345,6356,6381,6389,6412,6466,6535,6576,6581,6823,6832,6833,6908,6982,7026,7032,7054,7058,7112,7134,7166,7176,7190,7252,7263,7310,7362,7491,7527,7535,7577,7586,7596,7618,7713,7732,7772,7777,7905,7927,7972,7976,8012,8043,8175,8212,8281,8282,8298,8325,8342,8350,8383,8393,8419,8468,8528,8607,8698,8781,8794,8820,8866,8931,8958,9033,9176,9188,9201,9222,9226,9328,9467,9479,9502,9512,9586,9676,9707,9759,9862,9870,9909,9921,9937,9947,9957,9984,10148,10172,10217,10439,10520,10558,10605,10627,10669,10684,10718,10911,10992,11021,11032,11097,11242,11292,11355,11462,11467,11518,11529,11653,11715,11717,11808,11835,11972,12017,12064,12086,12140,12148,12184,12197,12236,12406,12558,12623,12643,12644,12761,12892,13062,13120,13176,13223,13297,13400,13437,13619,13678,13706,13733,13801,13810,13815,13858,13928,14014,14063,14139,14187,14263,14350,14404,14437,14440,14492,14510,14559,14589,14663,14825,14934,14988,15151,15213,15279,15341,15362,15380,15821,15983,16049,16237,16338,16441,16696,16698,16769,16788,16903,17147,17424,17455,17882,17975,18072,18114,18273,18286,18307,18474,18772,18853,19064,19290,19298,19498,19548,19582,19594,19607,19689,19755,19842,19903,20028,20109,20130,20351,20504,20826,20997,21023,21402,21464,21494,21564,21719,21799,21809,21938,22024,22291,22306,22364,22432,22527,22611,23025,23033,23090,23127,23267,23277,23303,23607,23731,23828,23841,24382,24383,24513,24690,24899,25033,25071,25103,25291,25551,25602,25651,25680,25853,25925,26454,26901,27591,27969,27972,28149,28183,28196,28304,28376,28466,28469,29308,29341,29660,30009,30450,30467,30809,30852,31022,31814,31830,32393,32522,32558,32618,33278,33611,33680,33837,33989,34427,34875,35000,35098,35116,35118,35263,35398,35613,36076,37204,37344,37963,38275,38322,38770,38809,38891,38926,39182,39214,39305,39379,39385,39547,40013,40204,40487,40698,40851,41068,41172,41383,41629,41764,43060,45244,45281,45677,46533,46745,46882,47125,48152,48406,48872,49551,49589,49841,50291,50523,50792,51065,52931,53676,54350,55649,55796,56141,56151,56729,57264,57460,57681,58086,58286,58320,58647,58965,59303,59376,60269,60448,60570,60824,61605,62445,62949,63412,63997,64673,65101,66259,67078,67657,68773,69055,69456,69465,69698,71461,71857,72236,72458,72477,72624,73799,74023,74342,80742,80946,81107,81245,81265,81542,81622,81794,81858,82143,82361,83265,83290,83487,83978,84157,84177,84570,84582,84750,85400,85447,85790,86337,86413,86532,86871,86973,87007,87436,88029,88159,88206,88969,89081,89148,89365,89653,89854,90256,91160,91522,91570,91809,91861,92063,92374,93133,93220,93409,93481,94509,94586,94746,95161,95457,95473,95917,96315,96724,96870,96996,97315,97576,97853,97865,98303,98543,98560,98645,99070,99185,99883,99964,100196,100704,100854,100977,101053,101249,101931,102117,102330,102632,102635,103135,103331,104158,104204,104373,104802,104984,105081,105503,106398,106504,106944,108210,108386,108889,108944,109088,109412,109568,109829,110036,110214,110394,110682,110877,110964,111239,111554,111769,112523,112893,113019,113197,113733,113830,113995,114110,114287,114772,114870,115048,115260,115725,117220,117307,117838,118325,118640,118648,119103,119263,119302,120116,120644,120647,120845,121225,121236,121512,121721,121877,122054,122521,123006,123363,123799,124039,124235,124672,125115,125326,126561,126746,127382,127683,127788,127959,127992,128007,128386,128490,129198,129271,129533,130171,130304,131386,131470,132211,132327,132494,132888,132896,133255,133418,133506,133694,133939,134278,134434,134472,134650,134974,135347,135481,135892,136314,136458,136870,137120,137442,138167,138239,138255,138323,138589,138929,139679,140129,140728,140774,140836,140968,141068,141644,141840,141994,142154,142481,142611,143116,143191,143261,143357,143415,143712,143754,144771,145116,145459,146042,146123,146506,146673,147382,147970,148388,148697,148982,148993,149036,149216,150083,150306,150353,150432,150812,151040,151078,151192,151549,151778,151962,152306,153214,153966,154042,154341,154925,155801,156175,156614,156643,156788,157359,157374,158361,159323,159974,160892,160912,161256,162437,162496,162829,162982,163061,163097,163098,163299,163956,164441,164617,164792,165022,165234,165329,166055,166106,166223,166351,166845,167516,167817,167840,169008,169152,169159,169177,169495,170083,171116,171135,171294,171328,171353,171529,171747,172593,173189,173734,173985,174211,174782,175047,175167,175506,175510,176160,176313,176460,176542,176782,177654,177665,177961,178208,178265,179670,180768,181136,181575,181784,182240,182715,183283,183361,183523,183751,184134,184267,184342,184637,184678,185671,186397,186465,187381,187384,187412,187413,188097,188551,188669,188880,188972,189024,189048,189317,189853,190350,190508,191382,191762,191808,192062,192134,192137,192276,192990,193400,193792,193794,193879,193942,194733,195796,195842,195982,196190,197097,197153,197297,198260,198492,199159,199202,199867,200130,200392,200400,200971,201082,201717,202000,202325,202529,202853,202911,202960,202982,203061,203180,203269,203562,203694,203969,205149,205186,205278,205584,205731,205740,206276,206578,206591,206939,207165,207861,208189,208259,208272,208398,208479,209504,209561,209882,209924,210002,210063,210624,210689],[146.0,22.0,3.0,20.0,47.0,39.0,17.0,7.0,2.0,23.0,16.0,8.0,40.0,10.0,3.0,26.0,1.0,13.0,14.0,6.0,3.0,3.0,7.0,12.0,14.0,1.0,3.0,6.0,1.0,34.0,7.0,1.0,5.0,11.0,1.0,8.0,19.0,2.0,19.0,25.0,6.0,16.0,1.0,6.0,17.0,2.0,8.0,1.0,2.0,6.0,5.0,1.0,22.0,1.0,4.0,6.0,1.0,1.0,8.0,6.0,6.0,2.0,8.0,4.0,2.0,12.0,1.0,5.0,4.0,9.0,4.0,11.0,6.0,6.0,5.0,4.0,2.0,12.0,2.0,3.0,5.0,2.0,1.0,1.0,4.0,4.0,7.0,1.0,1.0,2.0,2.0,7.0,6.0,5.0,2.0,6.0,2.0,6.0,1.0,2.0,9.0,2.0,2.0,2.0,5.0,1.0,2.0,3.0,2.0,2.0,3.0,4.0,15.0,1.0,2.0,1.0,1.0,1.0,9.0,3.0,2.0,1.0,2.0,2.0,2.0,2.0,3.0,1.0,3.0,4.0,6.0,3.0,25.0,5.0,2.0,3.0,1.0,2.0,9.0,4.0,4.0,1.0,1.0,2.0,3.0,1.0,4.0,1.0,4.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,3.0,1.0,2.0,2.0,1.0,4.0,3.0,1.0,5.0,1.0,4.0,2.0,2.0,4.0,2.0,4.0,2.0,1.0,4.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,3.0,1.0,2.0,7.0,1.0,10.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,5.0,5.0,1.0,15.0,5.0,2.0,1.0,7.0,2.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,2.0,3.0,3.0,1.0,17.0,1.0,5.0,6.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,4.0,10.0,1.0,9.0,1.0,1.0,2.0,6.0,1.0,1.0,1.0,3.0,1.0,6.0,2.0,1.0,2.0,1.0,2.0,3.0,7.0,13.0,4.0,3.0,3.0,6.0,1.0,1.0,2.0,6.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,3.0,3.0,2.0,5.0,24.0,2.0,1.0,1.0,3.0,1.0,6.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,3.0,1.0,7.0,1.0,1.0,10.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,2.0,4.0,2.0,2.0,3.0,1.0,3.0,2.0,1.0,3.0,3.0,2.0,1.0,3.0,2.0,4.0,2.0,2.0,10.0,2.0,2.0,3.0,6.0,3.0,1.0,1.0,1.0,2.0,1.0,18.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,3.0,2.0,1.0,5.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,3.0,3.0,2.0,1.0,5.0,1.0,1.0,5.0,7.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,4.0,3.0,2.0,3.0,1.0,1.0,5.0,1.0,3.0,1.0,11.0,1.0,3.0,1.0,2.0,12.0,1.0,1.0,1.0,3.0,2.0,6.0,1.0,1.0,3.0,4.0,1.0,5.0,2.0,3.0,3.0,1.0,2.0,8.0,5.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,2.0,1.0,5.0,1.0,1.0,3.0,2.0,2.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,7.0,2.0,7.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,3.0,5.0,1.0,1.0,13.0,1.0,1.0,4.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,8.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,3.0,1.0,1.0,5.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,14.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,2.0,4.0,7.0,2.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,4.0,4.0,1.0,3.0,1.0,2.0,2.0,1.0,3.0,1.0,1.0,3.0,2.0,2.0,1.0,4.0,1.0,5.0,1.0,5.0,1.0,3.0,3.0,1.0,1.0,2.0,2.0,2.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,4.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,3.0,4.0,63.0,1.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,3.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,4.0,2.0,6.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,2.0,3.0,1.0,3.0,3.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,4.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,6.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,7.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,13.0,1.0,1.0,1.0,2.0,1.0,18.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,8.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,6.0,2.0,6.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n",
      "|[neurologic, manifestations, of, systemic, disease, d, lapides, section, editorneurologic, manifestationsof, systemic, disease, sleepdisorderseric, m, davis, md1chintan, ramani, mbbs1mark, quigg, md, msc2address1division, of, pulmonary, and, critical, care, department, of, medicine, university, ofvirginia, charlottesville, va, usaemail, emd9bvirginiaedu2department, of, neurology, university, of, virginia, charlottesville, va, usa, springer, sciencebusiness, media, llc, part, of, springer, nature, this, , is, part, of, the, topical, collection, on, neurologic, manifestations, of, systemic, diseasekeywords, sleep, disorders, i, sleep, manifestations, of, systemic, diseases, i, sleep, impacts, on, health, i, sleep, apnea, iinsomniaabstractpurpose, of, review, sleep, is, intimately, involved, in, overall, health, and, wellbeing, we, provide, acomprehensive, report, on, the, interplay, between, systemic, diseases, and, sleep, to, optimizethe, outcomes, of, systemic, disordersrecent, findings, spanning, the, categories, of, endocrinologic, disorders, metabolictoxicdisturbances, renal, cardiovascular, pulmonary, gastrointestinal, infectious, diseases, autoimmune, disorders, malignancy, and, critical, illness, the, review, highlights, the, prevalentcoexisting, pathology, of, sleep, across, the, spectrum, of, systemic, disorders, although, it, is, rarethat, treating, a, sleep, symptom, can, cure, disease, attention, to, sleep, may, improve, quality, oflife, and, may, mitigate, or, improve, the, underlying, disorder, recent, controversies, inassessing, the, cardiovascular, relationship, with, sleep, have, called, into, question, some, ofthe, benefits, of, treating, comorbid, sleep, disorders, thereby, highlighting, the, need, for, anongoing, rigorous, investigation, into, how, sleep, interplays, with, systemic, diseasessummary, systemic, diseases, often, have, sleep, manifestations, and, this, report, will, help, theclinician, identify, key, risk, factors, linking, sleep, disorders, to, systemic, diseases, so, as, tooptimize, the, overall, care, of, the, patient, 0c, , , , page, , of, introductioncurr, treat, options, neurol, , , , , , , , , , , , , all, earths, species, maintain, a, solar, 24h, cycle, of, rest, andactivity, and, disrupting, the, cycle, affects, adaptation, andhomeostasis, sleeps, quotidian, normalness, meansthat, analogous, to, fish, not, knowing, about, water, until, itis, dry, sleep, is, not, commonly, thought, about, until, it, isdisruptedfor, example, about, , of, the, adult, populationcomplain, of, transient, insomnia, and, about, , experience, chronic, insomnia, that, disrupts, daytime, function[], patients, with, chronic, insomnia, experience, less, workproductivity, more, absenteeism, more, accidents, andmore, hospitalizations, leading, to, direct, treatment, costsof, approximately, 60b, annually, [], considering, thepotential, widespread, reach, of, comorbid, sleep, disordersevaluating, sleep, in, the, neurological, patient, is, importantthis, review, will, introduce, the, accepted, anizationof, sleep, disorders, review, important, features, in, historytaking, and, evaluation, and, survey, the, systemic, diseasesthat, have, important, comorbidities, with, particular, sleepdisordersgeneral, considerationsclassification, of, sleep, disordersan, abridged, listing, of, sleep, disorders, from, the, american, academy, of, sleepmedicine, table, , provides, an, overview, of, the, current, classification, []insomnia, is, a, chronic, dissatisfaction, with, sleep, duration, and, quality, that, isassociated, with, daytime, dysfunction, although, pharmacologic, treatment, isoften, pursued, for, chronic, insomnia, management, outcomes, are, often, betteraddressing, underlying, factors, with, the, early, use, of, cognitivebehavioral, therapyfor, insomnia, cbti, []sleeprelated, breathing, disorders, involve, dysfunction, of, the, respiratory, systemduring, sleep, usually, resulting, in, daytime, hypersomnia, obstructive, sleepapnea, osa, central, sleep, apnea, csa, and, respiratory, effort, related, arousalsare, classified, under, this, category, treatment, options, including, continuouspositive, airway, pressure, cpap, positional, therapy, mandibular, advancementdevices, healthy, weight, loss, and, even, a, novel, cranial, nerve, stimulator, whichprotrudes, the, tongue, forward, during, sleep, [4cid129cid129]central, hypersomnias, are, defined, as, a, primary, dysregulation, of, sleep, resultingfrom, dysfunction, of, the, central, nervous, system, that, causes, daytimehypersomnia, often, treatment, addresses, the, underlying, cause, and, may, includeuse, of, strategic, napping, and, wakepromoting, medicationscircadian, disorders, consist, of, various, lesions, or, external, disruptions, of, thecircadian, timing, system, that, desynchronize, the, brains, clock, from, the, externalsolar, lightdark, cycle, resulting, in, hypersomnia, or, insomnia, in, a, clockdependent, fashion, treatment, of, circadian, rhythm, disorders, involves, adjustinglife, around, the, patients, desired, sleep, time, or, augmenting, factors, that, entrainthe, bodys, clockparasomnias, represent, disorders, of, faulty, inhibition, of, waking, behaviors, thatarise, inappropriately, during, sleep, and, are, divided, into, those, that, occur, duringnonrem, sleep, rem, sleep, or, state, transitions, rem, sleep, behavior, disorder, is, aparasomnia, characterized, by, loss, of, muscle, atonia, during, rem, sleep, thatusually, occurs, in, patients, with, neurodegenerative, disorders, it, is, often, treatedeffectively, addressing, other, sleep, disturbances, and, treating, with, clonazepam, ormelatonin, [], 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , of, , , , , , table, , abridged, classification, of, the, aasm, sleep, disordersinsomniachronic, insomnia, disordershortterm, insomnia, disorderexcessive, time, in, bedshort, sleepersleeprelated, breathing, disordersobstructive, sleep, apneacentral, sleep, apneasleeprelated, hypoventilation, disorderssleeprelated, hypoxemia, disorderscentral, disorders, of, hypersomnolencenarcolepsy, types, , and, idiopathic, hypersomniakleinelevin, syndromehypersomnia, due, to, medical, disorder, medication, substance, psychiatric, disorderinsufficient, sleep, syndromecircadian, rhythm, sleepwake, disordersdelayedadvancedirregularnon, , hshift, workjet, lagparasomniasnrem, relatedarousal, disordersconfusional, arousalssleepwalkingsleep, terrorssleeprelated, eating, disorderrem, relatedrem, sleep, behavior, disorderrecurrent, isolated, sleep, paralysisnightmare, disorderotherexploding, head, syndromesleeprelated, hallucinationsenuresissleep, talkingsleeprelated, movement, disorders, 0ccurr, treat, options, neurol, , , , , , , , , , , , , , , , , page, , of, table, , continuedrestless, legs, syndromeperiodic, limb, movement, disorderleg, crampsbruxismrhythmic, movement, disorderbenign, sleep, myoclonus, of, infancypropriospinal, myoclonus, at, sleep, onsetnormal, variantssleep, historysleeprelated, movement, disorders, consist, of, fragmentary, often, repetitive, bodymovements, that, can, disrupt, sleep, or, sometimes, worse, disturb, the, sleep, of, bedpartners, periodic, limb, movement, disorder, plmd, and, restless, legs, syndromerls, both, fall, under, this, category, and, are, treated, with, repletion, of, iron, storesand, consideration, of, dopaminergic, agonists, []a, sleep, history, helps, a, patient, disclose, sleep, findings, and, helps, the, physiciananize, it, into, categories, of, hypersomnia, sleep, habits, and, scheduling, sleepcharacteristics, environmental, issues, and, sleep, interrupters, table, the, epworth, sleepiness, scale, quantifies, the, degree, of, hypersomnia, []most, adults, require, , h, of, daily, sleep, [], and, prefer, it, anized, into, eithera, monophasic, nocturnal, schedule, or, in, a, biphasic, pattern, augmented, with, anafternoon, siesta, the, sleep, pattern, characterizes, the, presence, and, severity, ofsleeponset, insomnia, sleep, maintenance, insomnia, or, terminal, insomnia, insomnia, distributed, within, the, last, half, of, the, sleep, period, catchup, sleep, aphenomenon, of, prolonged, sleep, on, a, free, day, is, a, classic, sign, of, sleepdeprivation, habitual, earlyphase, advances, morning, larks, latephase, delays, night, owls, or, a, chaotic, irregular, schedule, can, be, a, sign, of, circadiandisorders, one, also, must, inquire, about, common, sleep, disruptors, including, legmovements, snoring, witnessed, apneas, and, environmental, factorsdiagnostic, testing, modalitiessleep, diarypolysomnographythe, sleep, diary, often, available, through, standardized, forms, or, evenwebsites, or, smartphone, apps, consists, of, , weeks, of, selfreported, sleeptimesthe, overnight, polysomnography, psg, is, the, goldstandard, measurementof, sleep, architecture, respiratory, disorders, such, as, osa, and, parasomniasin, the, case, of, osa, the, unattended, home, sleep, study, has, had, an, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , of, , , , , , table, , a, categorical, sleep, historyhypersomniaepworth, sleepiness, scale, , considering, the, last, , weeks, how, likely, would, you, fall, asleep, while, doing, each, task, not, at, all, points, slight, , moderate, , severe, , normal, ¤, , pointssitting, and, readingwatching, tvsitting, inactive, in, public, lecture, church, ¦car, passenger, for, an, hourlying, down, to, rest, in, the, afternoonsitting, conversationsitting, quietly, alone, after, lunchdriving, stopped, in, trafficschedulesleep, timeworkday, bedtime, and, out, of, bedtimeweekday, bedtime, and, out, of, bedtimewhat, is, your, estimated, sleep, latency, if, , , min, what, are, you, doing, in, bed, before, you, fall, asleephow, often, do, you, awaken, at, night, and, whydo, you, need, an, alarm, clock, to, awaken, in, the, morninghow, many, days, of, the, week, do, you, nap, and, for, how, longenvironmentdo, you, have, a, bedroomdo, you, have, a, bedpartner, tv, mobile, phone, or, other, electronicswhat, are, you, doing, right, before, bedtimehow, much, caffeine, coffeeteasoda, popenergy, drinks, and, alcohol, do, you, consume, and, when, is, the, latest, intakeinterruptersdo, you, have, leg, pain, or, restlessnessdo, you, have, chronic, pain, that, prevents, or, interrupts, sleepdo, you, have, daytime, hallucinations, or, dreams, severe, or, lucid, nightmares, sleep, paralysis, or, cataplexydo, you, snore, or, have, witnessed, apneasmultiple, sleep, latency, testincreasing, role, as, a, diagnostic, testing, alternative, to, the, traditional, inlabpsg, concerns, of, other, sleep, disorders, or, those, that, may, be, presentcomorbidly, with, probable, osa, require, inlab, psg, that, can, measure, sleeparchitecture, and, sleepassociated, movementsthe, multiple, sleep, latency, test, mslt, consists, of, a, series, of, , daytime, napsfrom, which, sleep, onset, is, calculated, the, test, in, combination, with, psgperformed, the, night, before, is, the, gold, standard, in, measuringhypersomnia, especially, in, the, evaluation, of, narcolepsy, 0c, , , , page, , of, actigraphypersonal, devicescurr, treat, options, neurol, , , , , , , , , , , , , wrist, actigraphy, provides, measurements, of, longterm, patterns, of, rest, andactivity, as, proxies, for, sleep, and, wakefulness, such, patterns, can, help, tocorroborate, histories, of, sleep, duration, and, timingpopular, smartphones, and, other, ambulatory, devices, with, physiologicalmonitoring, capabilities, may, transform, the, evaluation, of, sleep, however, arecent, comparison, of, different, brands, of, activity, trackers, found, that, sleepwake, measurements, varied, widely, in, comparison, with, sleep, diaries, orstandard, psg, [], the, overall, conclusion, is, that, at, the, beginning, of, wearable, devices, are, not, ready, for, reliable, quantification, of, sleep, acrossindividuals, although, serial, recordings, confined, to, a, single, individual, mayhold, some, value, these, measurements, have, yet, to, be, validatedsleep, comorbidities, with, systemic, diseasesendocrine, disordersthyroid, diseaseconsidering, the, various, sleep, disorders, and, diagnostic, tools, afforded, by, a, goodsleep, history, and, sleep, testing, understanding, the, relationship, between, sleepdisorders, and, systemic, diseases, has, farreaching, implications, in, optimizing, thecare, of, the, patient, the, following, sections, will, address, sleep, manifestations, ofvarious, neurological, disorders, arising, from, systemic, disease, based, on, an, systemalmost, half, of, the, patients, with, hypothyroidism, report, at, least, one, sleep, complaint, such, as, restless, sleep, choking, hypersomnia, or, fatigue, [], osa, is, presentin, approximately, , [], a, unique, mechanism, of, airway, restriction, in, hypothyroidism, is, myxedematous, mucoprotein, deposition, in, the, airways, soft, tissuesand, dilator, muscles, even, though, myxedema, can, be, absent, [], larger, goiters, canalso, cause, osa, by, external, compression, of, the, airway, []on, the, other, side, of, the, thyroid, spectrum, hyperthyroidism, is, most, closelyassociated, with, insomnia, occurring, in, , of, patients, [], arousaldisordersspecifically, sleep, walkingalso, occur, especially, in, the, setting, ofthyrotoxicosis, [], proposed, to, arise, from, frequent, arousals, and, impairmentof, attaining, slowwave, sleep, as, the, direct, result, of, thyroid, hormonebeyond, the, treatment, of, the, specific, sleep, disorder, sleep, problems, usuallyremit, following, appropriate, treatment, of, the, underlying, thyroid, disorder, []type, , diabetes, mellitussleep, disorders, affect, high, proportions, of, those, with, type, , diabetes, mellitusdm, surveys, of, patients, with, dm, compared, with, those, of, controls, show, a, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , of, , , , , , nearly, 2fold, propensity, for, insomnia, fourfold, higher, use, of, sedativehypnoticsand, a, 10fold, higher, rate, of, hypersomnolence, [], osa, is, highly, prevalent, indm, and, many, are, undiagnosed, [], contributors, to, a, multifactorial, series, ofsleep, disruptors, include, periodic, limb, movements, and, restless, legs, syndromerls, diabetic, neuropathy, and, fluctuations, in, blood, glucose, []dm, presents, an, excellent, model, by, which, to, demonstrate, the, reciprocaleffects, of, sleep, disruption, on, the, primary, disease, first, sleep, disturbances, affectthe, regulation, of, the, neuroendocrine, control, of, appetite, sleep, deprivationpromotes, overeating, through, hyperactivity, of, orexin, system, [], and, activatesthe, hypothalamicpituitaryadrenal, system, to, increase, cortisol, secretionresulting, in, impaired, glucose, tolerance, [, ], these, multiple, mechanismssupport, clinical, observations, that, untreated, osa, may, be, reason, for, the, ineffective, treatment, of, dm, and, that, accordingly, treatment, with, cpap, leads, toimprovements, in, glycemic, control, in, some, patients, []sex, hormones, and, gender, affect, the, distribution, and, susceptibility, to, a, varietyof, sleep, disorders, men, on, the, basis, of, relative, airway, collapsibility, haveapproximately, a, twofold, increased, risk, of, osa, compared, with, women, , in, males, and, , in, females, [], a, potential, side, effect, in, thetreatment, of, hypoandrogenism, is, the, facilitation, of, osa, given, the, impacttestosterone, has, on, upper, airway, collapsibility, []testosterone, levels, may, affect, the, propensity, for, chronic, insomnia, menwith, hypoandrogenism, demonstrate, reduced, sleep, efficiency, increased, nighttime, awakenings, and, reduced, deep, sleep, compared, with, the, normaltestosteronelevel, controls, although, it, is, not, clear, whether, these, features, improve, with, testosterone, therapy, [], women, experience, higher, rates, of, chronicinsomnia, risk, ratio, of, , for, women, versus, men, which, becomes, even, morepronounced, in, the, elderly, [], despite, sleeping, longer, overall, sleep, quality, isoften, lower, in, women, than, men, []the, distribution, of, sleep, disorders, in, women, varies, with, reproductivelifespan, younger, women, are, more, susceptible, to, restless, legs, syndromerls, mainly, on, the, basis, of, mensesassociated, irondeficiency, during, pregnancy, women, are, at, significantly, increased, risk, for, the, development, of, rlswith, an, overall, prevalence, exceeding, , of, all, pregnant, patients, [], treatment, of, rls, in, pregnancy, involves, iron, supplementation, with, a, goal, ferritinlevel, , , mcgl, often, oral, iron, repletion, is, adequate, although, there, arereports, of, intravenous, iron, therapy, in, severe, cases, of, pregnancyrelated, rlsand, irondeficiency, [], pregnancy, is, also, associated, with, an, increased, prevalence, of, osa, up, to, , of, pregnant, patients, during, the, third, trimester, whichis, associated, with, increased, risks, of, complications, including, gestational, hypertension, gestational, dm, and, preeclampsia, []although, not, a, particular, systemic, neurological, disease, pharmacological, effectson, sleep, form, an, important, aspect, of, neurological, sleep, medicine, since, manymedications, that, are, used, by, neurologists, may, affect, sleep, table, , showscommon, medications, that, provoke, insomnia, hypersomnolence, respiratorysuppression, parasomnias, and, rlsperiodic, limb, movement, disordersex, hormonesmedications, 0c, , , , page, , of, curr, treat, options, neurol, , , , , , , , , , , , , table, , medication, classes, and, specific, examples, that, can, cause, sleep, disturbancesinsomniacentral, nervous, system, stimulants, methylphenidate, amphetamines, modafinilcaffeineantidepressantsselective, serotonergic, reuptake, inhibitors, fluoxetine, sertralineselective, norepinephrine, reuptake, inhibitors, venlafaxine, duloxetinesecondary, tricyclic, antidepressants, desipramine, nortriptylinecardiovascularbeta2, agonists, albuterolvasopressors, epinephrine, dopaminecorticosteroidssympathetic, amines, phenterminehypersomniabenzodiazepines, alprazolam, diazepamnonbenzodiazepine, receptor, agonists, zolpidem, eszopicloneopioidsh1, antihistamines, diphenhydramineantiepileptic, agents, phenytoin, levetiracetamantidepressantsselective, serotonergic, reuptake, inhibitors, paroxetine, sertralinetertiary, tricyclic, antidepressants, amitriptylinetypical, and, atypical, antipsychotics, haloperidol, olanzapinedopaminergic, agonists, ropinirole, carbidopalevodopaanticholinergic, medicationscentrally, acting, î±, , agonists, clonidine, dexmedetomidinerespiratory, suppressionopioids, oxycodone, morphinebenzodiazepines, diazepam, clonazepamalcoholphenobarbitalparasomniasantidepressants, clomipramine, fluoxetine, citalopramnonbenzodiazepine, receptor, agonists, zolpidemcaffeinealcohol, withdrawalrestless, legs, syndrome, and, periodic, limb, movementsselective, serotonergic, reuptake, inhibitors, fluoxetine, mirtazapineantipsychotics, haloperidol, risperidonetricyclic, antidepressants, amitriptyline, clomipramine, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , of, , , , , , renal, diseaseinfectious, diseasessleep, disturbances, are, highly, prevalent, in, patients, with, chronic, kidney, diseaseckd, spanning, the, broad, spectrum, of, sleep, disorders, including, hypersomniainsomnia, sleeprelated, breathing, and, rlsthe, prevalence, of, osa, in, ckd, ranges, from, , to, , rates, that, are, notexplained, solely, by, overlapping, comorbidities, common, to, both, osa, and, ckd[], the, cooccurrence, of, both, ckd, and, osa, is, associated, with, increasedcardiovascular, events, and, allcause, mortality, [], usually, osa, develops, inpatients, with, ckd, independent, of, underlying, renal, dysfunction, but, someevidence, shows, that, ckd, can, cause, or, exacerbate, osa, and, central, sleep, apneaproposed, mechanisms, for, this, causal, relationship, include, uremic, neuropathyaltered, chemosensitivity, and, hypervolemia, [], accordingly, renal, replacement, therapy, and, fluid, removal, [], may, improve, obstructive, or, central, sleepapnea, conversely, treatment, of, sleep, apnea, with, pap, may, improve, renalfunction, in, those, with, borderline, renal, impairment, []rls, is, a, common, and, debilitating, symptom, in, patients, with, ckd, occurringin, up, to, , of, patients, on, hemodialysis, compared, with, that, in, approximately, of, the, general, population, [], although, rls, symptoms, generally, follow, acircadian, rhythmicity, with, increased, symptoms, occurring, at, night, rls, symptoms, can, occur, during, the, long, periods, of, daytime, inactivity, during, hemodialysis, [], treatment, is, primarily, focused, on, ensuring, adequate, iron, stores, thenconsidering, medical, therapy, as, per, routine, care, of, rlssleep, disorders, and, infectious, diseases, have, few, specific, associations, in, general, acute, infection, is, associated, with, mild, encephalopathy, that, masquerades, ashypersomnolence, and, fatigue, proinflammatory, cytokines, are, implicated, inthe, development, of, these, constitutional, symptoms, some, infections, howeverdirectly, affect, regulatory, centers, of, the, sleepwake, systemencephalitis, lethargica, is, a, historical, pandemic, cause, of, hypersomnolence, ofrenewed, interest, since, this, review, is, being, written, in, the, middle, of, the, covid, pandemic, also, known, as, von, economos, encephalitis, it, occurred, inassociation, with, the, spanish, flu, pandemic, of, , [], an, estimated, , millionwere, affected, worldwide, the, most, common, subtype, the, somnolentophthalmoplegic, form, developed, after, flulike, symptoms, of, fever, and, malaiseand, consisted, of, subsequent, ophthalmoplegia, accompanied, by, long, periods, ofhypersomnia, despite, the, appearance, of, deep, sleep, patients, could, be, easilyawoken, and, sometimes, maintained, memories, of, activities, that, had, transpiredaround, them, while, asleep, this, state, of, acute, akinetic, psuedosomnulencecould, be, followed, by, the, development, of, chronic, postencephaliticparkinsonismthe, pandemic, associated, with, the, severe, acute, respiratory, syndrome, coronavirus, , sarscov2, ie, covid19, occurring, during, the, writing, of, thisreview, features, evolving, literature, the, first, reports, centered, on, respiratorysymptoms, although, the, involvement, of, the, nervous, system, now, appearsprevalent, [], sleep, disorders, have, yet, to, be, specifically, reported, howeverthe, psychological, responses, to, social, distancing, change, in, schedules, and, otherfeatures, of, an, active, pandemic, have, caused, a, wave, of, anxiety, and, depressionwhich, in, turn, have, been, associated, with, poor, sleep, quality, for, example, a, 0c, , , , page, , of, curr, treat, options, neurol, , , , , , , , , , , , , survey, of, , chinese, health, care, workers, showed, prevalences, of, depressionat, , anxiety, at, , and, insomnia, at, , []postinfectious, or, postvaccination, narcolepsy, is, rare, but, is, important, in, developing, overall, hypotheses, in, the, etiology, of, idiopathic, narcolepsy, in, , certainvaccinations, in, europe, for, the, h1n1, pandemic, caused, narcolepsy, at, a, risk, of, in, pediatric, patients, [], fortunately, the, risk, of, postvaccinationnarcolepsy, appeared, confined, to, specific, vaccine, formulations, the, incidenthowever, has, led, to, ongoing, research, in, the, immunological, etiology, ofnarcolepsyafrican, trypanosomiasis, or, sleeping, sickness, remains, important, in, the, developing, world, it, is, a, parasitic, infection, spread, by, the, tsetse, fly, that, is, endemic, insubsaharan, africa, the, first, symptoms, include, fever, headaches, and, lymphadenopathy, once, the, parasite, enters, the, central, nervous, system, disorderedfragmented, sleep, ensues, often, with, inversion, of, the, circadian, sleepwake, cyclethe, world, health, anization, outlines, treatment, with, a, regimen, of, antiparasitic, medications, once, symptoms, have, started, []nonalcoholic, fatty, liver, disease, nafld, consists, of, idiopathic, hepatic, steatosiswith, a, prevalence, of, , to, , of, the, general, population, with, increasedfrequency, in, individuals, with, obesity, or, dm, [], given, these, coassociationsosa, is, common, untreated, osa, may, exacerbate, liver, injury, because, of, oxidative, stress, and, systemic, inflammation, [], and, is, a, risk, in, conversion, fromnafld, to, liver, fibrosis, [], trials, with, cpap, have, shown, inconsistent, resultsin, markers, of, liver, injury, following, treatment, of, osa, []the, symptoms, of, gastroesophageal, reflux, disease, gerd, worsen, during, sleepparticularly, if, sleep, occurs, soon, after, a, meal, [], the, lower, esophageal, sphincter, that, normally, prevents, reflux, may, be, compromised, by, the, increase, inthoracic, pressure, in, the, setting, of, the, upper, airway, obstruction, [], patientswith, symptoms, of, gerd, should, be, screened, for, osa, and, conversely, interruption, of, sleep, in, absence, of, osa, may, improve, with, treatment, with, a, protonpump, inhibitor, ppi, [], or, by, simply, elevating, the, head, of, the, bedinflammatory, bowel, disease, ibd, has, bilateral, interactions, with, sleep, []given, the, relationship, between, sleep, deprivationfragmentation, on, cytokineregulation, and, immune, dysfunction, it, is, hypothesized, that, poor, sleep, qualityworsens, overall, symptoms, of, ibd, [, ], additionally, the, proinflammatorystate, disrupts, the, circadian, rhythm, [], subjective, and, objective, measurementsof, sleep, quality, and, timing, should, be, considered, in, patients, with, ibd, particularly, in, those, who, have, frequent, inflammatory, flares, despite, otherwise, adequate, management, an, algorithmic, approach, to, sleep, assessment, in, ibd, patients, has, been, proposed, by, canakis, et, al, []systemic, lupus, erythematosus, and, rheumatoid, arthritis, serve, as, the, prototypical, diseases, of, this, group, of, disorders, with, a, prevalence, of, sleep, disturbancesof, greater, than, , [], the, mechanisms, of, sleep, disturbances, as, well, as, thereciprocal, relationship, in, the, contribution, of, poor, sleep, to, worse, autoimmunestatus, are, thought, to, be, similar, to, those, described, above, with, ibd, [, ], thespecific, sleep, disorders, prevalent, in, this, group, are, osa, and, periodic, limbgastrointestinal, systemautoimmune, disorders, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , of, , , , , , pulmonarymovement, disorder, plmd, both, with, greater, than, , prevalence, [, ]as, seen, above, hypersomnolence, and, activitylimiting, fatigue, arise, from, specificsleep, disorders, pain, and, medication, side, effects, well, as, the, primary, effects, ofthe, primary, proinflammatory, status, [, ], often, treating, the, underlyingautoimmune, disorder, improves, associated, fatigue, however, if, sleepiness, persists, then, evaluating, for, a, comorbid, sleep, disorder, such, as, obstructive, sleepapnea, is, indicatedone, syndrome, with, possible, autoimmune, origins, is, chronic, fatigue, syndromesleep, disturbances, insomnia, and, unrefreshing, sleep, are, common, symptoms, yetpatients, rarely, report, relief, despite, appropriate, identification, and, treatment, ofcomorbid, sleep, disorders, [], cognitivebehavioral, therapy, cbt, and, gradedexercise, therapy, are, commonly, pursued, treatment, approaches, []obstructive, lung, diseases, most, commonly, asthma, chronic, obstructive, pulmonary, disease, copd, and, less, common, disorders, such, as, cystic, fibrosiscf, or, bronchiolitis, obliterans, may, affect, nocturnal, ventilation, osa, andcopd, often, overlap, given, shared, body, habitus, and, other, mutual, risk, factorsestimates, of, comorbid, osa, and, copd, range, from, , to, , [], patients, withsevere, copd, treated, with, nocturnal, noninvasive, ventilation, nippv, a, moreadvanced, form, of, positive, airway, pressure, experience, an, absolute, risk, reduction, of, , of, the, risk, of, hospital, readmission, or, death, at, , months, compared, with, those, treated, with, standard, care, and, without, nippv, [64cid129]insomnia, is, another, common, complaint, among, patients, with, copd, circadian, bronchial, constriction, may, cause, nocturnal, wheezing, dyspnea, or, othersymptoms, of, asthma, prompting, the, patient, to, awaken, [], in, addition, thehyperadrenergic, response, to, beta, , agonist, inhalers, used, in, treatment, for, acutedyspnea, impairs, sleep, onset, see, table, the, growing, success, in, treatments, for, cf, patients, means, that, sleep, disordersarising, from, their, intrinsic, obstructive, lung, disease, are, now, coming, to, theattention, of, caregivers, many, factors, contribute, to, sleep, disruption, includingchronic, cough, frequent, infections, abdominal, discomfort, reflux, frequentstools, medication, side, effects, and, psychological, disease, [], in, addition, tosleep, disruption, patients, with, cf, are, susceptible, to, hypoventilation, thatworsens, with, disease, progression, use, of, nippv, in, highrisk, patients, withhypercapnia, has, been, shown, to, improve, physiologic, parameters, and, at, timescan, positively, impact, symptoms, particularly, in, patients, who, have, severedisease, while, awaiting, lung, transplant, []restrictive, lung, diseases, defined, by, a, reduced, total, lung, capacity, includethose, with, parenchymal, damage, such, as, idiopathic, fibrosis, hypersensitivitypneumonitis, or, other, interstitial, pneumonias, alternatively, lung, parenchymais, normal, in, restrictive, diseases, such, as, obesity, hypoventilation, syndromehemidiaphragm, paresis, or, neuromuscular, disorders, muscular, dystrophiesamyotrophic, lateral, sclerosis, restrictive, lung, disease, patients, as, seen, abovewith, obstructive, disease, patients, are, susceptible, to, nocturnal, hypoventilationsubsequent, co2, retention, and, compensatory, sleep, fragmentation, use, ofnippv, in, patients, with, severe, restrictive, lung, disease, spanning, obesityhypoventilation, syndrome, to, muscular, dystrophies, and, als, has, had, positiveimpacts, on, survival, and, quality, of, life, [, ], 0c, , , , page, , of, cardiaccurr, treat, options, neurol, , , , , , , , , , , , , over, , of, patients, with, congestive, heart, failure, chf, have, comorbid, osamainly, on, the, basis, of, mutual, risk, factors, of, dm, hypertension, obesity, andolder, age, [, ], in, addition, insomnia, in, those, with, chf, may, arise, from, avariety, of, factors, including, diuretic, medications, and, subsequent, nocturiapositional, heart, failure, symptoms, increased, adrenergic, status, or, psychosocialfactors, [], treatments, addressing, comorbid, osa, and, insomnia, improve, sleepquality, but, demonstrate, mixed, results, in, terms, of, longterm, cardiovascularoutcomes, [, ]patients, with, acute, myocardial, infarction, ami, experience, both, acute, andchronic, sleep, disorders, due, to, the, circadian, variability, of, adrenergic, hormonesand, cardiac, and, systemic, vasculature, [], the, timings, of, ami, sudden, cardiacdeath, and, arrhythmia, occur, with, increased, frequency, at, night, [], cardiacischemia, may, present, a, series, of, nocturnal, symptoms, including, paroxysmaldyspnea, chest, pain, agitation, or, insomnia, surviving, patients, are, at, risk, forchronic, sleep, disorders, such, as, insomnia, and, sleepdisordered, breathing, withor, without, the, cooccurrence, of, anxiety, or, depression, []retrospective, longitudinal, data, demonstrate, that, those, with, osa, and, whoare, adherent, with, cpap, experience, improved, cardiovascular, morbidity, andmortality, over, nonadherent, patients, [], however, these, findings, have, notbeen, clearly, supported, by, prospective, randomized, trials, the, sleep, apneacardiovascular, endpoints, trial, save, trial, has, called, into, question, the, causallink, between, the, treatment, of, osa, and, cardiovascular, outcomes, with, a, meanfollowup, of, , years, those, randomized, to, pap, experienced, no, significantimprovements, in, study, endpoints, of, death, from, cardiovascular, causes, amistroke, and, hospitalization, for, unstable, angina, chf, or, transient, ischemicattack, compared, with, controls, [78cid129cid129], because, of, possible, insufficient, cpapuse, and, because, of, the, lack, of, main, indications, for, cpap, treatment, such, assevere, sleepiness, interpretation, of, the, findings, of, this, large, trial, remainscontroversial, in, practice, these, authors, often, pursue, cpap, treatment, for, patients, with, osa, and, cardiovascular, risk, factors, even, in, the, absence, of, sleepiness, at, least, for, a, trial, period, to, assess, adherence, to, treatment, and, to, determineif, there, are, subjective, and, objective, improvements, to, sleep, qualitywith, a, prevalence, range, of, , osa, is, common, in, patients, with, atrialfibrillation, and, other, arrhythmias, [], accordingly, the, sleep, heart, healthstudy, showed, a, two, to, fivefold, higher, risk, of, arrhythmia, in, patients, with, severeosa, compared, with, that, in, controls, [], retrospective, series, show, that, inpatients, with, atrial, fibrillation, and, untreated, osa, the, risk, of, atrial, fibrillationrecurrence, following, cardioversion, is, , compared, with, , in, patients, whoare, adherent, to, cpap, [], however, a, prospective, randomized, control, trialcalled, retrospective, findings, into, question, [], similar, in, design, to, the, savetrial, patients, with, atrial, fibrillation, were, randomized, to, cpap, versus, usualtherapy, from, a, cohort, in, which, sleepiness, was, specifically, excluded, this, smalltrial, , total, assessed, the, primary, outcome, of, time, to, arrhythmia, recurrenceboth, arms, had, recurrence, rates, of, , although, the, trial, showed, that, cpapitself, provides, no, specific, benefit, to, those, with, atrial, fibrillation, the, outcomesfor, treatment, of, those, with, both, disorders, remain, unclearalthough, the, above, studies, centered, on, associations, between, cardiac, diseaseand, osa, patients, with, chf, ami, and, atrial, fibrillation, experience, high, rates, of, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , of, , , , , , cancercritical, illnesscentral, sleep, apnea, csa, as, well, exceeding, , in, patients, with, mild, symptomatic, chf, as, an, example, [], cheynestokes, respiration, a, cyclical, form, ofcsa, results, when, circulatory, impairment, perturbs, the, normal, responsivenessin, respiratory, control, resulting, in, alterations, in, the, loop, gain, in, modulatingchanges, in, carbon, dioxide, and, oxygen, levels, in, the, bloodstream, [], analogous, to, overly, aggressive, adjustments, to, a, thermostat, in, response, to, changingtemperature, the, presence, of, csa, has, been, considered, a, marker, of, increasedmortality, in, patients, with, chf, although, aims, to, resolve, the, treatment, of, csawith, cpap, or, more, advanced, modalities, have, not, clearly, demonstrated, animprovement, in, cardiovascular, outcomes, []estimates, of, the, prevalence, of, sleep, disturbances, across, cancer, patients, range, widelyfrom, , to, , [, ], insomnia, is, the, most, common, disorder, with, prevalencelevels, ranging, from, , to, , [, ], patients, with, cancer, who, undergo, psghave, shorter, total, sleep, times, longer, times, in, bed, low, sleep, efficiency, andproportionately, less, deep, sleep, than, controls, [], insomnia, in, patients, with, canceris, driven, by, a, multitude, of, factors, including, preexisting, socioeconomic, andpsychiatric, disorders, fatigue, age, rls, pain, and, medication, effects, [, ]treatment, follows, that, for, the, general, population, although, sedativehypnoticsare, most, commonly, prescribed, no, evidence, exists, for, specific, pharmacologicinterventions, for, sleep, disturbances, in, this, population, [], cognitivebehavioraltherapy, is, currently, the, recommended, firstline, treatment, for, chronic, insomnia[], because, the, rarity, of, trained, psychologists, makes, finding, a, provider, difficult, insome, circumstances, the, electronic, delivery, of, cognitivebehavioral, therapy, hasbeen, sought, as, an, alternative, to, facetoface, therapy, [, ]the, bilateral, interactions, between, sleep, and, critical, illness, form, a, rapidlychanging, area, of, investigation, which, is, made, particularly, challenging, giventhe, difficulties, in, measuring, sleep, in, critically, ill, patients, [, ], lack, ofsleepor, its, encephalopathic, analogmay, affect, outcomes, in, critical, illnessesfor, example, a, lack, of, scorable, rem, sleep, correlates, with, longer, ventilatorweaning, time, compared, with, controls, with, intact, rem, [], failure, rates, onnoninvasive, ventilation, are, impacted, by, sleep, continuity, [], delirium, acommon, neurobehavioral, syndrome, seen, in, upwards, of, , of, patients, inthe, icu, [, ], is, associated, with, significantly, worse, outcomes, i]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |[neurologic, manifestations, systemic, disease, d, lapides, section, editorneurologic, manifestationsof, systemic, disease, sleepdisorderseric, m, davis, md1chintan, ramani, mbbs1mark, quigg, md, msc2address1division, pulmonary, critical, care, department, medicine, university, ofvirginia, charlottesville, va, usaemail, emd9bvirginiaedu2department, neurology, university, virginia, charlottesville, va, usa, springer, sciencebusiness, media, llc, part, springer, nature, , part, topical, collection, neurologic, manifestations, systemic, diseasekeywords, sleep, disorders, sleep, manifestations, systemic, diseases, sleep, impacts, health, sleep, apnea, iinsomniaabstractpurpose, review, sleep, intimately, involved, overall, health, wellbeing, provide, acomprehensive, report, interplay, systemic, diseases, sleep, optimizethe, outcomes, systemic, disordersrecent, findings, spanning, categories, endocrinologic, disorders, metabolictoxicdisturbances, renal, cardiovascular, pulmonary, gastrointestinal, infectious, diseases, autoimmune, disorders, malignancy, critical, illness, review, highlights, prevalentcoexisting, pathology, sleep, across, spectrum, systemic, disorders, although, rarethat, treating, sleep, symptom, cure, disease, attention, sleep, may, improve, quality, oflife, may, mitigate, improve, underlying, disorder, recent, controversies, inassessing, cardiovascular, relationship, sleep, called, question, ofthe, benefits, treating, comorbid, sleep, disorders, thereby, highlighting, need, anongoing, rigorous, investigation, sleep, interplays, systemic, diseasessummary, systemic, diseases, often, sleep, manifestations, report, help, theclinician, identify, key, risk, factors, linking, sleep, disorders, systemic, diseases, tooptimize, overall, care, patient, 0c, , , , page, , introductioncurr, treat, options, neurol, , , , , , , , , , , , , earths, species, maintain, solar, 24h, cycle, rest, andactivity, disrupting, cycle, affects, adaptation, andhomeostasis, sleeps, quotidian, normalness, meansthat, analogous, fish, knowing, water, itis, dry, sleep, commonly, thought, isdisruptedfor, example, , adult, populationcomplain, transient, insomnia, , experience, chronic, insomnia, disrupts, daytime, function[], patients, chronic, insomnia, experience, less, workproductivity, absenteeism, accidents, andmore, hospitalizations, leading, direct, treatment, costsof, approximately, 60b, annually, [], considering, thepotential, widespread, reach, comorbid, sleep, disordersevaluating, sleep, neurological, patient, importantthis, review, introduce, accepted, anizationof, sleep, disorders, review, important, features, historytaking, evaluation, survey, systemic, diseasesthat, important, comorbidities, particular, sleepdisordersgeneral, considerationsclassification, sleep, disordersan, abridged, listing, sleep, disorders, american, academy, sleepmedicine, table, , provides, overview, current, classification, []insomnia, chronic, dissatisfaction, sleep, duration, quality, isassociated, daytime, dysfunction, although, pharmacologic, treatment, isoften, pursued, chronic, insomnia, management, outcomes, often, betteraddressing, underlying, factors, early, use, cognitivebehavioral, therapyfor, insomnia, cbti, []sleeprelated, breathing, disorders, involve, dysfunction, respiratory, systemduring, sleep, usually, resulting, daytime, hypersomnia, obstructive, sleepapnea, osa, central, sleep, apnea, csa, respiratory, effort, related, arousalsare, classified, category, treatment, options, including, continuouspositive, airway, pressure, cpap, positional, therapy, mandibular, advancementdevices, healthy, weight, loss, even, novel, cranial, nerve, stimulator, whichprotrudes, tongue, forward, sleep, [4cid129cid129]central, hypersomnias, defined, primary, dysregulation, sleep, resultingfrom, dysfunction, central, nervous, system, causes, daytimehypersomnia, often, treatment, addresses, underlying, cause, may, includeuse, strategic, napping, wakepromoting, medicationscircadian, disorders, consist, various, lesions, external, disruptions, thecircadian, timing, system, desynchronize, brains, clock, externalsolar, lightdark, cycle, resulting, hypersomnia, insomnia, clockdependent, fashion, treatment, circadian, rhythm, disorders, involves, adjustinglife, around, patients, desired, sleep, time, augmenting, factors, entrainthe, bodys, clockparasomnias, represent, disorders, faulty, inhibition, waking, behaviors, thatarise, inappropriately, sleep, divided, occur, duringnonrem, sleep, rem, sleep, state, transitions, rem, sleep, behavior, disorder, aparasomnia, characterized, loss, muscle, atonia, rem, sleep, thatusually, occurs, patients, neurodegenerative, disorders, often, treatedeffectively, addressing, sleep, disturbances, treating, clonazepam, ormelatonin, [], 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , table, , abridged, classification, aasm, sleep, disordersinsomniachronic, insomnia, disordershortterm, insomnia, disorderexcessive, time, bedshort, sleepersleeprelated, breathing, disordersobstructive, sleep, apneacentral, sleep, apneasleeprelated, hypoventilation, disorderssleeprelated, hypoxemia, disorderscentral, disorders, hypersomnolencenarcolepsy, types, , idiopathic, hypersomniakleinelevin, syndromehypersomnia, due, medical, disorder, medication, substance, psychiatric, disorderinsufficient, sleep, syndromecircadian, rhythm, sleepwake, disordersdelayedadvancedirregularnon, , hshift, workjet, lagparasomniasnrem, relatedarousal, disordersconfusional, arousalssleepwalkingsleep, terrorssleeprelated, eating, disorderrem, relatedrem, sleep, behavior, disorderrecurrent, isolated, sleep, paralysisnightmare, disorderotherexploding, head, syndromesleeprelated, hallucinationsenuresissleep, talkingsleeprelated, movement, disorders, 0ccurr, treat, options, neurol, , , , , , , , , , , , , , , , , page, , table, , continuedrestless, legs, syndromeperiodic, limb, movement, disorderleg, crampsbruxismrhythmic, movement, disorderbenign, sleep, myoclonus, infancypropriospinal, myoclonus, sleep, onsetnormal, variantssleep, historysleeprelated, movement, disorders, consist, fragmentary, often, repetitive, bodymovements, disrupt, sleep, sometimes, worse, disturb, sleep, bedpartners, periodic, limb, movement, disorder, plmd, restless, legs, syndromerls, fall, category, treated, repletion, iron, storesand, consideration, dopaminergic, agonists, []a, sleep, history, helps, patient, disclose, sleep, findings, helps, physiciananize, categories, hypersomnia, sleep, habits, scheduling, sleepcharacteristics, environmental, issues, sleep, interrupters, table, epworth, sleepiness, scale, quantifies, degree, hypersomnia, []most, adults, require, , h, daily, sleep, [], prefer, anized, eithera, monophasic, nocturnal, schedule, biphasic, pattern, augmented, anafternoon, siesta, sleep, pattern, characterizes, presence, severity, ofsleeponset, insomnia, sleep, maintenance, insomnia, terminal, insomnia, insomnia, distributed, within, last, half, sleep, period, catchup, sleep, aphenomenon, prolonged, sleep, free, day, classic, sign, sleepdeprivation, habitual, earlyphase, advances, morning, larks, latephase, delays, night, owls, chaotic, irregular, schedule, sign, circadiandisorders, one, also, must, inquire, common, sleep, disruptors, including, legmovements, snoring, witnessed, apneas, environmental, factorsdiagnostic, testing, modalitiessleep, diarypolysomnographythe, sleep, diary, often, available, standardized, forms, evenwebsites, smartphone, apps, consists, , weeks, selfreported, sleeptimesthe, overnight, polysomnography, psg, goldstandard, measurementof, sleep, architecture, respiratory, disorders, osa, parasomniasin, case, osa, unattended, home, sleep, study, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , table, , categorical, sleep, historyhypersomniaepworth, sleepiness, scale, , considering, last, , weeks, likely, fall, asleep, task, points, slight, , moderate, , severe, , normal, ¤, , pointssitting, readingwatching, tvsitting, inactive, public, lecture, church, ¦car, passenger, hourlying, rest, afternoonsitting, conversationsitting, quietly, alone, lunchdriving, stopped, trafficschedulesleep, timeworkday, bedtime, bedtimeweekday, bedtime, bedtimewhat, estimated, sleep, latency, , , min, bed, fall, asleephow, often, awaken, night, whydo, need, alarm, clock, awaken, morninghow, many, days, week, nap, longenvironmentdo, bedroomdo, bedpartner, tv, mobile, phone, electronicswhat, right, bedtimehow, much, caffeine, coffeeteasoda, popenergy, drinks, alcohol, consume, latest, intakeinterruptersdo, leg, pain, restlessnessdo, chronic, pain, prevents, interrupts, sleepdo, daytime, hallucinations, dreams, severe, lucid, nightmares, sleep, paralysis, cataplexydo, snore, witnessed, apneasmultiple, sleep, latency, testincreasing, role, diagnostic, testing, alternative, traditional, inlabpsg, concerns, sleep, disorders, may, presentcomorbidly, probable, osa, require, inlab, psg, measure, sleeparchitecture, sleepassociated, movementsthe, multiple, sleep, latency, test, mslt, consists, series, , daytime, napsfrom, sleep, onset, calculated, test, combination, psgperformed, night, gold, standard, measuringhypersomnia, especially, evaluation, narcolepsy, 0c, , , , page, , actigraphypersonal, devicescurr, treat, options, neurol, , , , , , , , , , , , , wrist, actigraphy, provides, measurements, longterm, patterns, rest, andactivity, proxies, sleep, wakefulness, patterns, help, tocorroborate, histories, sleep, duration, timingpopular, smartphones, ambulatory, devices, physiologicalmonitoring, capabilities, may, transform, evaluation, sleep, however, arecent, comparison, different, brands, activity, trackers, found, sleepwake, measurements, varied, widely, comparison, sleep, diaries, orstandard, psg, [], overall, conclusion, beginning, wearable, devices, ready, reliable, quantification, sleep, acrossindividuals, although, serial, recordings, confined, single, individual, mayhold, value, measurements, yet, validatedsleep, comorbidities, systemic, diseasesendocrine, disordersthyroid, diseaseconsidering, various, sleep, disorders, diagnostic, tools, afforded, goodsleep, history, sleep, testing, understanding, relationship, sleepdisorders, systemic, diseases, farreaching, implications, optimizing, thecare, patient, following, sections, address, sleep, manifestations, ofvarious, neurological, disorders, arising, systemic, disease, based, systemalmost, half, patients, hypothyroidism, report, least, one, sleep, complaint, restless, sleep, choking, hypersomnia, fatigue, [], osa, presentin, approximately, , [], unique, mechanism, airway, restriction, hypothyroidism, myxedematous, mucoprotein, deposition, airways, soft, tissuesand, dilator, muscles, even, though, myxedema, absent, [], larger, goiters, canalso, cause, osa, external, compression, airway, []on, side, thyroid, spectrum, hyperthyroidism, closelyassociated, insomnia, occurring, , patients, [], arousaldisordersspecifically, sleep, walkingalso, occur, especially, setting, ofthyrotoxicosis, [], proposed, arise, frequent, arousals, impairmentof, attaining, slowwave, sleep, direct, result, thyroid, hormonebeyond, treatment, specific, sleep, disorder, sleep, problems, usuallyremit, following, appropriate, treatment, underlying, thyroid, disorder, []type, , diabetes, mellitussleep, disorders, affect, high, proportions, type, , diabetes, mellitusdm, surveys, patients, dm, compared, controls, show, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , nearly, 2fold, propensity, insomnia, fourfold, higher, use, sedativehypnoticsand, 10fold, higher, rate, hypersomnolence, [], osa, highly, prevalent, indm, many, undiagnosed, [], contributors, multifactorial, series, ofsleep, disruptors, include, periodic, limb, movements, restless, legs, syndromerls, diabetic, neuropathy, fluctuations, blood, glucose, []dm, presents, excellent, model, demonstrate, reciprocaleffects, sleep, disruption, primary, disease, first, sleep, disturbances, affectthe, regulation, neuroendocrine, control, appetite, sleep, deprivationpromotes, overeating, hyperactivity, orexin, system, [], activatesthe, hypothalamicpituitaryadrenal, system, increase, cortisol, secretionresulting, impaired, glucose, tolerance, [, ], multiple, mechanismssupport, clinical, observations, untreated, osa, may, reason, ineffective, treatment, dm, accordingly, treatment, cpap, leads, toimprovements, glycemic, control, patients, []sex, hormones, gender, affect, distribution, susceptibility, varietyof, sleep, disorders, men, basis, relative, airway, collapsibility, haveapproximately, twofold, increased, risk, osa, compared, women, , males, , females, [], potential, side, effect, thetreatment, hypoandrogenism, facilitation, osa, given, impacttestosterone, upper, airway, collapsibility, []testosterone, levels, may, affect, propensity, chronic, insomnia, menwith, hypoandrogenism, demonstrate, reduced, sleep, efficiency, increased, nighttime, awakenings, reduced, deep, sleep, compared, normaltestosteronelevel, controls, although, clear, whether, features, improve, testosterone, therapy, [], women, experience, higher, rates, chronicinsomnia, risk, ratio, , women, versus, men, becomes, even, morepronounced, elderly, [], despite, sleeping, longer, overall, sleep, quality, isoften, lower, women, men, []the, distribution, sleep, disorders, women, varies, reproductivelifespan, younger, women, susceptible, restless, legs, syndromerls, mainly, basis, mensesassociated, irondeficiency, pregnancy, women, significantly, increased, risk, development, rlswith, overall, prevalence, exceeding, , pregnant, patients, [], treatment, rls, pregnancy, involves, iron, supplementation, goal, ferritinlevel, , , mcgl, often, oral, iron, repletion, adequate, although, arereports, intravenous, iron, therapy, severe, cases, pregnancyrelated, rlsand, irondeficiency, [], pregnancy, also, associated, increased, prevalence, osa, , pregnant, patients, third, trimester, whichis, associated, increased, risks, complications, including, gestational, hypertension, gestational, dm, preeclampsia, []although, particular, systemic, neurological, disease, pharmacological, effectson, sleep, form, important, aspect, neurological, sleep, medicine, since, manymedications, used, neurologists, may, affect, sleep, table, , showscommon, medications, provoke, insomnia, hypersomnolence, respiratorysuppression, parasomnias, rlsperiodic, limb, movement, disordersex, hormonesmedications, 0c, , , , page, , curr, treat, options, neurol, , , , , , , , , , , , , table, , medication, classes, specific, examples, cause, sleep, disturbancesinsomniacentral, nervous, system, stimulants, methylphenidate, amphetamines, modafinilcaffeineantidepressantsselective, serotonergic, reuptake, inhibitors, fluoxetine, sertralineselective, norepinephrine, reuptake, inhibitors, venlafaxine, duloxetinesecondary, tricyclic, antidepressants, desipramine, nortriptylinecardiovascularbeta2, agonists, albuterolvasopressors, epinephrine, dopaminecorticosteroidssympathetic, amines, phenterminehypersomniabenzodiazepines, alprazolam, diazepamnonbenzodiazepine, receptor, agonists, zolpidem, eszopicloneopioidsh1, antihistamines, diphenhydramineantiepileptic, agents, phenytoin, levetiracetamantidepressantsselective, serotonergic, reuptake, inhibitors, paroxetine, sertralinetertiary, tricyclic, antidepressants, amitriptylinetypical, atypical, antipsychotics, haloperidol, olanzapinedopaminergic, agonists, ropinirole, carbidopalevodopaanticholinergic, medicationscentrally, acting, î±, , agonists, clonidine, dexmedetomidinerespiratory, suppressionopioids, oxycodone, morphinebenzodiazepines, diazepam, clonazepamalcoholphenobarbitalparasomniasantidepressants, clomipramine, fluoxetine, citalopramnonbenzodiazepine, receptor, agonists, zolpidemcaffeinealcohol, withdrawalrestless, legs, syndrome, periodic, limb, movementsselective, serotonergic, reuptake, inhibitors, fluoxetine, mirtazapineantipsychotics, haloperidol, risperidonetricyclic, antidepressants, amitriptyline, clomipramine, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , renal, diseaseinfectious, diseasessleep, disturbances, highly, prevalent, patients, chronic, kidney, diseaseckd, spanning, broad, spectrum, sleep, disorders, including, hypersomniainsomnia, sleeprelated, breathing, rlsthe, prevalence, osa, ckd, ranges, , , rates, notexplained, solely, overlapping, comorbidities, common, osa, ckd[], cooccurrence, ckd, osa, associated, increasedcardiovascular, events, allcause, mortality, [], usually, osa, develops, inpatients, ckd, independent, underlying, renal, dysfunction, someevidence, shows, ckd, cause, exacerbate, osa, central, sleep, apneaproposed, mechanisms, causal, relationship, include, uremic, neuropathyaltered, chemosensitivity, hypervolemia, [], accordingly, renal, replacement, therapy, fluid, removal, [], may, improve, obstructive, central, sleepapnea, conversely, treatment, sleep, apnea, pap, may, improve, renalfunction, borderline, renal, impairment, []rls, common, debilitating, symptom, patients, ckd, occurringin, , patients, hemodialysis, compared, approximately, general, population, [], although, rls, symptoms, generally, follow, acircadian, rhythmicity, increased, symptoms, occurring, night, rls, symptoms, occur, long, periods, daytime, inactivity, hemodialysis, [], treatment, primarily, focused, ensuring, adequate, iron, stores, thenconsidering, medical, therapy, per, routine, care, rlssleep, disorders, infectious, diseases, specific, associations, general, acute, infection, associated, mild, encephalopathy, masquerades, ashypersomnolence, fatigue, proinflammatory, cytokines, implicated, inthe, development, constitutional, symptoms, infections, howeverdirectly, affect, regulatory, centers, sleepwake, systemencephalitis, lethargica, historical, pandemic, cause, hypersomnolence, ofrenewed, interest, since, review, written, middle, covid, pandemic, also, known, von, economos, encephalitis, occurred, inassociation, spanish, flu, pandemic, , [], estimated, , millionwere, affected, worldwide, common, subtype, somnolentophthalmoplegic, form, developed, flulike, symptoms, fever, malaiseand, consisted, subsequent, ophthalmoplegia, accompanied, long, periods, ofhypersomnia, despite, appearance, deep, sleep, patients, easilyawoken, sometimes, maintained, memories, activities, transpiredaround, asleep, state, acute, akinetic, psuedosomnulencecould, followed, development, chronic, postencephaliticparkinsonismthe, pandemic, associated, severe, acute, respiratory, syndrome, coronavirus, , sarscov2, ie, covid19, occurring, writing, thisreview, features, evolving, literature, first, reports, centered, respiratorysymptoms, although, involvement, nervous, system, appearsprevalent, [], sleep, disorders, yet, specifically, reported, howeverthe, psychological, responses, social, distancing, change, schedules, otherfeatures, active, pandemic, caused, wave, anxiety, depressionwhich, turn, associated, poor, sleep, quality, example, 0c, , , , page, , curr, treat, options, neurol, , , , , , , , , , , , , survey, , chinese, health, care, workers, showed, prevalences, depressionat, , anxiety, , insomnia, , []postinfectious, postvaccination, narcolepsy, rare, important, developing, overall, hypotheses, etiology, idiopathic, narcolepsy, , certainvaccinations, europe, h1n1, pandemic, caused, narcolepsy, risk, pediatric, patients, [], fortunately, risk, postvaccinationnarcolepsy, appeared, confined, specific, vaccine, formulations, incidenthowever, led, ongoing, research, immunological, etiology, ofnarcolepsyafrican, trypanosomiasis, sleeping, sickness, remains, important, developing, world, parasitic, infection, spread, tsetse, fly, endemic, insubsaharan, africa, first, symptoms, include, fever, headaches, lymphadenopathy, parasite, enters, central, nervous, system, disorderedfragmented, sleep, ensues, often, inversion, circadian, sleepwake, cyclethe, world, health, anization, outlines, treatment, regimen, antiparasitic, medications, symptoms, started, []nonalcoholic, fatty, liver, disease, nafld, consists, idiopathic, hepatic, steatosiswith, prevalence, , , general, population, increasedfrequency, individuals, obesity, dm, [], given, coassociationsosa, common, untreated, osa, may, exacerbate, liver, injury, oxidative, stress, systemic, inflammation, [], risk, conversion, fromnafld, liver, fibrosis, [], trials, cpap, shown, inconsistent, resultsin, markers, liver, injury, following, treatment, osa, []the, symptoms, gastroesophageal, reflux, disease, gerd, worsen, sleepparticularly, sleep, occurs, soon, meal, [], lower, esophageal, sphincter, normally, prevents, reflux, may, compromised, increase, inthoracic, pressure, setting, upper, airway, obstruction, [], patientswith, symptoms, gerd, screened, osa, conversely, interruption, sleep, absence, osa, may, improve, treatment, protonpump, inhibitor, ppi, [], simply, elevating, head, bedinflammatory, bowel, disease, ibd, bilateral, interactions, sleep, []given, relationship, sleep, deprivationfragmentation, cytokineregulation, immune, dysfunction, hypothesized, poor, sleep, qualityworsens, overall, symptoms, ibd, [, ], additionally, proinflammatorystate, disrupts, circadian, rhythm, [], subjective, objective, measurementsof, sleep, quality, timing, considered, patients, ibd, particularly, frequent, inflammatory, flares, despite, otherwise, adequate, management, algorithmic, approach, sleep, assessment, ibd, patients, proposed, canakis, et, al, []systemic, lupus, erythematosus, rheumatoid, arthritis, serve, prototypical, diseases, group, disorders, prevalence, sleep, disturbancesof, greater, , [], mechanisms, sleep, disturbances, well, thereciprocal, relationship, contribution, poor, sleep, worse, autoimmunestatus, thought, similar, described, ibd, [, ], thespecific, sleep, disorders, prevalent, group, osa, periodic, limbgastrointestinal, systemautoimmune, disorders, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , pulmonarymovement, disorder, plmd, greater, , prevalence, [, ]as, seen, hypersomnolence, activitylimiting, fatigue, arise, specificsleep, disorders, pain, medication, side, effects, well, primary, effects, ofthe, primary, proinflammatory, status, [, ], often, treating, underlyingautoimmune, disorder, improves, associated, fatigue, however, sleepiness, persists, evaluating, comorbid, sleep, disorder, obstructive, sleepapnea, indicatedone, syndrome, possible, autoimmune, origins, chronic, fatigue, syndromesleep, disturbances, insomnia, unrefreshing, sleep, common, symptoms, yetpatients, rarely, report, relief, despite, appropriate, identification, treatment, ofcomorbid, sleep, disorders, [], cognitivebehavioral, therapy, cbt, gradedexercise, therapy, commonly, pursued, treatment, approaches, []obstructive, lung, diseases, commonly, asthma, chronic, obstructive, pulmonary, disease, copd, less, common, disorders, cystic, fibrosiscf, bronchiolitis, obliterans, may, affect, nocturnal, ventilation, osa, andcopd, often, overlap, given, shared, body, habitus, mutual, risk, factorsestimates, comorbid, osa, copd, range, , , [], patients, withsevere, copd, treated, nocturnal, noninvasive, ventilation, nippv, moreadvanced, form, positive, airway, pressure, experience, absolute, risk, reduction, , risk, hospital, readmission, death, , months, compared, treated, standard, care, without, nippv, [64cid129]insomnia, another, common, complaint, among, patients, copd, circadian, bronchial, constriction, may, cause, nocturnal, wheezing, dyspnea, othersymptoms, asthma, prompting, patient, awaken, [], addition, thehyperadrenergic, response, beta, , agonist, inhalers, used, treatment, acutedyspnea, impairs, sleep, onset, see, table, growing, success, treatments, cf, patients, means, sleep, disordersarising, intrinsic, obstructive, lung, disease, coming, theattention, caregivers, many, factors, contribute, sleep, disruption, includingchronic, cough, frequent, infections, abdominal, discomfort, reflux, frequentstools, medication, side, effects, psychological, disease, [], addition, tosleep, disruption, patients, cf, susceptible, hypoventilation, thatworsens, disease, progression, use, nippv, highrisk, patients, withhypercapnia, shown, improve, physiologic, parameters, timescan, positively, impact, symptoms, particularly, patients, severedisease, awaiting, lung, transplant, []restrictive, lung, diseases, defined, reduced, total, lung, capacity, includethose, parenchymal, damage, idiopathic, fibrosis, hypersensitivitypneumonitis, interstitial, pneumonias, alternatively, lung, parenchymais, normal, restrictive, diseases, obesity, hypoventilation, syndromehemidiaphragm, paresis, neuromuscular, disorders, muscular, dystrophiesamyotrophic, lateral, sclerosis, restrictive, lung, disease, patients, seen, abovewith, obstructive, disease, patients, susceptible, nocturnal, hypoventilationsubsequent, co2, retention, compensatory, sleep, fragmentation, use, ofnippv, patients, severe, restrictive, lung, disease, spanning, obesityhypoventilation, syndrome, muscular, dystrophies, als, positiveimpacts, survival, quality, life, [, ], 0c, , , , page, , cardiaccurr, treat, options, neurol, , , , , , , , , , , , , , patients, congestive, heart, failure, chf, comorbid, osamainly, basis, mutual, risk, factors, dm, hypertension, obesity, andolder, age, [, ], addition, insomnia, chf, may, arise, avariety, factors, including, diuretic, medications, subsequent, nocturiapositional, heart, failure, symptoms, increased, adrenergic, status, psychosocialfactors, [], treatments, addressing, comorbid, osa, insomnia, improve, sleepquality, demonstrate, mixed, results, terms, longterm, cardiovascularoutcomes, [, ]patients, acute, myocardial, infarction, ami, experience, acute, andchronic, sleep, disorders, due, circadian, variability, adrenergic, hormonesand, cardiac, systemic, vasculature, [], timings, ami, sudden, cardiacdeath, arrhythmia, occur, increased, frequency, night, [], cardiacischemia, may, present, series, nocturnal, symptoms, including, paroxysmaldyspnea, chest, pain, agitation, insomnia, surviving, patients, risk, forchronic, sleep, disorders, insomnia, sleepdisordered, breathing, withor, without, cooccurrence, anxiety, depression, []retrospective, longitudinal, data, demonstrate, osa, whoare, adherent, cpap, experience, improved, cardiovascular, morbidity, andmortality, nonadherent, patients, [], however, findings, notbeen, clearly, supported, prospective, randomized, trials, sleep, apneacardiovascular, endpoints, trial, save, trial, called, question, causallink, treatment, osa, cardiovascular, outcomes, meanfollowup, , years, randomized, pap, experienced, significantimprovements, study, endpoints, death, cardiovascular, causes, amistroke, hospitalization, unstable, angina, chf, transient, ischemicattack, compared, controls, [78cid129cid129], possible, insufficient, cpapuse, lack, main, indications, cpap, treatment, assevere, sleepiness, interpretation, findings, large, trial, remainscontroversial, practice, authors, often, pursue, cpap, treatment, patients, osa, cardiovascular, risk, factors, even, absence, sleepiness, least, trial, period, assess, adherence, treatment, determineif, subjective, objective, improvements, sleep, qualitywith, prevalence, range, , osa, common, patients, atrialfibrillation, arrhythmias, [], accordingly, sleep, heart, healthstudy, showed, two, fivefold, higher, risk, arrhythmia, patients, severeosa, compared, controls, [], retrospective, series, show, inpatients, atrial, fibrillation, untreated, osa, risk, atrial, fibrillationrecurrence, following, cardioversion, , compared, , patients, whoare, adherent, cpap, [], however, prospective, randomized, control, trialcalled, retrospective, findings, question, [], similar, design, savetrial, patients, atrial, fibrillation, randomized, cpap, versus, usualtherapy, cohort, sleepiness, specifically, excluded, smalltrial, , total, assessed, primary, outcome, time, arrhythmia, recurrenceboth, arms, recurrence, rates, , although, trial, showed, cpapitself, provides, specific, benefit, atrial, fibrillation, outcomesfor, treatment, disorders, remain, unclearalthough, studies, centered, associations, cardiac, diseaseand, osa, patients, chf, ami, atrial, fibrillation, experience, high, rates, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , cancercritical, illnesscentral, sleep, apnea, csa, well, exceeding, , patients, mild, symptomatic, chf, example, [], cheynestokes, respiration, cyclical, form, ofcsa, results, circulatory, impairment, perturbs, normal, responsivenessin, respiratory, control, resulting, alterations, the, loop, gain, modulatingchanges, carbon, dioxide, oxygen, levels, bloodstream, [], analogous, overly, aggressive, adjustments, thermostat, response, changingtemperature, presence, csa, considered, marker, increasedmortality, patients, chf, although, aims, resolve, treatment, csawith, cpap, advanced, modalities, clearly, demonstrated, animprovement, cardiovascular, outcomes, []estimates, prevalence, sleep, disturbances, across, cancer, patients, range, widelyfrom, , , [, ], insomnia, common, disorder, prevalencelevels, ranging, , , [, ], patients, cancer, undergo, psghave, shorter, total, sleep, times, longer, times, bed, low, sleep, efficiency, andproportionately, less, deep, sleep, controls, [], insomnia, patients, canceris, driven, multitude, factors, including, preexisting, socioeconomic, andpsychiatric, disorders, fatigue, age, rls, pain, medication, effects, [, ]treatment, follows, general, population, although, sedativehypnoticsare, commonly, prescribed, evidence, exists, specific, pharmacologicinterventions, sleep, disturbances, population, [], cognitivebehavioraltherapy, currently, recommended, firstline, treatment, chronic, insomnia[], rarity, trained, psychologists, makes, finding, provider, difficult, insome, circumstances, electronic, delivery, cognitivebehavioral, therapy, hasbeen, sought, alternative, facetoface, therapy, [, ]the, bilateral, interactions, sleep, critical, illness, form, rapidlychanging, area, investigation, made, particularly, challenging, giventhe, difficulties, measuring, sleep, critically, ill, patients, [, ], lack, ofsleepor, encephalopathic, analogmay, affect, outcomes, critical, illnessesfor, example, lack, scorable, rem, sleep, correlates, longer, ventilatorweaning, time, compared, controls, intact, rem, [], failure, rates, onnoninvasive, ventilation, impacted, sleep, continuity, [], delirium, acommon, neurobehavioral, syndrome, seen, upwards, , patients, inthe, icu, [, ], associated, significantly, worse, outcomes]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |[neurologic, manifestations, systemic, disease, d, lapides, section, editorneurologic, manifestationsof, systemic, disease, sleepdisorderseric, m, davis, md1chintan, ramani, mbbs1mark, quigg, md, msc2address1division, pulmonary, critical, care, department, medicine, university, ofvirginia, charlottesville, va, usaemail, emd9bvirginiaedu2department, neurology, university, virginia, charlottesville, va, usa, springer, sciencebusiness, media, llc, part, springer, nature, , part, topical, collection, on, neurologic, manifestations, systemic, diseasekeywords, sleep, disorders, i, sleep, manifestations, systemic, diseases, i, sleep, impacts, on, health, i, sleep, apnea, iinsomniaabstractpurpose, review, sleep, intimately, involved, overall, health, wellbeing, we, provide, acomprehensive, report, on, interplay, between, systemic, diseases, sleep, optimizethe, outcomes, systemic, disordersrecent, findings, spanning, categories, endocrinologic, disorders, metabolictoxicdisturbances, renal, cardiovascular, pulmonary, gastrointestinal, infectious, diseases, autoimmune, disorders, malignancy, critical, illness, review, highlights, prevalentcoexisting, pathology, sleep, across, spectrum, systemic, disorders, although, it, rarethat, treating, sleep, symptom, can, cure, disease, attention, sleep, may, improve, quality, oflife, may, mitigate, or, improve, underlying, disorder, recent, controversies, inassessing, cardiovascular, relationship, with, sleep, have, called, into, question, some, ofthe, benefits, treating, comorbid, sleep, disorders, thereby, highlighting, need, anongoing, rigorous, investigation, into, how, sleep, interplays, with, systemic, diseasessummary, systemic, diseases, often, have, sleep, manifestations, report, will, help, theclinician, identify, key, risk, factors, linking, sleep, disorders, systemic, diseases, so, as, tooptimize, overall, care, patient, 0c, , , , page, , introductioncurr, treat, options, neurol, , , , , , , , , , , , , all, earths, species, maintain, solar, 24h, cycle, rest, andactivity, disrupting, cycle, affects, adaptation, andhomeostasis, sleeps, quotidian, normalness, meansthat, analogous, fish, not, knowing, about, water, until, itis, dry, sleep, not, commonly, thought, about, until, it, isdisruptedfor, example, about, , adult, populationcomplain, transient, insomnia, about, , experience, chronic, insomnia, that, disrupts, daytime, function[], patients, with, chronic, insomnia, experience, less, workproductivity, more, absenteeism, more, accidents, andmore, hospitalizations, leading, direct, treatment, costsof, approximately, 60b, annually, [], considering, thepotential, widespread, reach, comorbid, sleep, disordersevaluating, sleep, neurological, patient, importantthis, review, will, introduce, accepted, anizationof, sleep, disorders, review, important, features, historytaking, evaluation, survey, systemic, diseasesthat, have, important, comorbidities, with, particular, sleepdisordersgeneral, considerationsclassification, sleep, disordersan, abridged, listing, sleep, disorders, from, american, academy, sleepmedicine, table, , provides, an, overview, current, classification, []insomnia, chronic, dissatisfaction, with, sleep, duration, quality, that, isassociated, with, daytime, dysfunction, although, pharmacologic, treatment, isoften, pursued, chronic, insomnia, management, outcomes, are, often, betteraddressing, underlying, factors, with, early, use, cognitivebehavioral, therapyfor, insomnia, cbti, []sleeprelated, breathing, disorders, involve, dysfunction, respiratory, systemduring, sleep, usually, resulting, daytime, hypersomnia, obstructive, sleepapnea, osa, central, sleep, apnea, csa, respiratory, effort, related, arousalsare, classified, under, category, treatment, options, including, continuouspositive, airway, pressure, cpap, positional, therapy, mandibular, advancementdevices, healthy, weight, loss, even, novel, cranial, nerve, stimulator, whichprotrudes, tongue, forward, during, sleep, [4cid129cid129]central, hypersomnias, are, defined, as, primary, dysregulation, sleep, resultingfrom, dysfunction, central, nervous, system, that, causes, daytimehypersomnia, often, treatment, addresses, underlying, cause, may, includeuse, strategic, napping, wakepromoting, medicationscircadian, disorders, consist, various, lesions, or, external, disruptions, thecircadian, timing, system, that, desynchronize, brains, clock, from, externalsolar, lightdark, cycle, resulting, hypersomnia, or, insomnia, clockdependent, fashion, treatment, circadian, rhythm, disorders, involves, adjustinglife, around, patients, desired, sleep, time, or, augmenting, factors, that, entrainthe, bodys, clockparasomnias, represent, disorders, faulty, inhibition, waking, behaviors, thatarise, inappropriately, during, sleep, are, divided, into, those, that, occur, duringnonrem, sleep, rem, sleep, or, state, transitions, rem, sleep, behavior, disorder, aparasomnia, characterized, by, loss, muscle, atonia, during, rem, sleep, thatusually, occurs, patients, with, neurodegenerative, disorders, it, often, treatedeffectively, addressing, other, sleep, disturbances, treating, with, clonazepam, ormelatonin, [], 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , table, , abridged, classification, aasm, sleep, disordersinsomniachronic, insomnia, disordershortterm, insomnia, disorderexcessive, time, bedshort, sleepersleeprelated, breathing, disordersobstructive, sleep, apneacentral, sleep, apneasleeprelated, hypoventilation, disorderssleeprelated, hypoxemia, disorderscentral, disorders, hypersomnolencenarcolepsy, types, , idiopathic, hypersomniakleinelevin, syndromehypersomnia, due, medical, disorder, medication, substance, psychiatric, disorderinsufficient, sleep, syndromecircadian, rhythm, sleepwake, disordersdelayedadvancedirregularnon, , hshift, workjet, lagparasomniasnrem, relatedarousal, disordersconfusional, arousalssleepwalkingsleep, terrorssleeprelated, eating, disorderrem, relatedrem, sleep, behavior, disorderrecurrent, isolated, sleep, paralysisnightmare, disorderotherexploding, head, syndromesleeprelated, hallucinationsenuresissleep, talkingsleeprelated, movement, disorders, 0ccurr, treat, options, neurol, , , , , , , , , , , , , , , , , page, , table, , continuedrestless, legs, syndromeperiodic, limb, movement, disorderleg, crampsbruxismrhythmic, movement, disorderbenign, sleep, myoclonus, infancypropriospinal, myoclonus, at, sleep, onsetnormal, variantssleep, historysleeprelated, movement, disorders, consist, fragmentary, often, repetitive, bodymovements, that, can, disrupt, sleep, or, sometimes, worse, disturb, sleep, bedpartners, periodic, limb, movement, disorder, plmd, restless, legs, syndromerls, both, fall, under, category, are, treated, with, repletion, iron, storesand, consideration, dopaminergic, agonists, []a, sleep, history, helps, patient, disclose, sleep, findings, helps, physiciananize, it, into, categories, hypersomnia, sleep, habits, scheduling, sleepcharacteristics, environmental, issues, sleep, interrupters, table, epworth, sleepiness, scale, quantifies, degree, hypersomnia, []most, adults, require, , h, daily, sleep, [], prefer, it, anized, into, eithera, monophasic, nocturnal, schedule, or, biphasic, pattern, augmented, with, anafternoon, siesta, sleep, pattern, characterizes, presence, severity, ofsleeponset, insomnia, sleep, maintenance, insomnia, or, terminal, insomnia, insomnia, distributed, within, last, half, sleep, period, catchup, sleep, aphenomenon, prolonged, sleep, on, free, day, classic, sign, sleepdeprivation, habitual, earlyphase, advances, morning, larks, latephase, delays, night, owls, or, chaotic, irregular, schedule, can, be, sign, circadiandisorders, one, also, must, inquire, about, common, sleep, disruptors, including, legmovements, snoring, witnessed, apneas, environmental, factorsdiagnostic, testing, modalitiessleep, diarypolysomnographythe, sleep, diary, often, available, through, standardized, forms, or, evenwebsites, or, smartphone, apps, consists, , weeks, selfreported, sleeptimesthe, overnight, polysomnography, psg, goldstandard, measurementof, sleep, architecture, respiratory, disorders, such, as, osa, parasomniasin, case, osa, unattended, home, sleep, study, has, had, an, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , table, , categorical, sleep, historyhypersomniaepworth, sleepiness, scale, , considering, last, , weeks, how, likely, would, you, fall, asleep, while, doing, each, task, not, at, all, points, slight, , moderate, , severe, , normal, ¤, , pointssitting, readingwatching, tvsitting, inactive, public, lecture, church, ¦car, passenger, an, hourlying, down, rest, afternoonsitting, conversationsitting, quietly, alone, after, lunchdriving, stopped, trafficschedulesleep, timeworkday, bedtime, out, bedtimeweekday, bedtime, out, bedtimewhat, your, estimated, sleep, latency, if, , , min, what, are, you, doing, bed, before, you, fall, asleephow, often, do, you, awaken, at, night, whydo, you, need, an, alarm, clock, awaken, morninghow, many, days, week, do, you, nap, how, longenvironmentdo, you, have, bedroomdo, you, have, bedpartner, tv, mobile, phone, or, other, electronicswhat, are, you, doing, right, before, bedtimehow, much, caffeine, coffeeteasoda, popenergy, drinks, alcohol, do, you, consume, when, latest, intakeinterruptersdo, you, have, leg, pain, or, restlessnessdo, you, have, chronic, pain, that, prevents, or, interrupts, sleepdo, you, have, daytime, hallucinations, or, dreams, severe, or, lucid, nightmares, sleep, paralysis, or, cataplexydo, you, snore, or, have, witnessed, apneasmultiple, sleep, latency, testincreasing, role, as, diagnostic, testing, alternative, traditional, inlabpsg, concerns, other, sleep, disorders, or, those, that, may, be, presentcomorbidly, with, probable, osa, require, inlab, psg, that, can, measure, sleeparchitecture, sleepassociated, movementsthe, multiple, sleep, latency, test, mslt, consists, series, , daytime, napsfrom, which, sleep, onset, calculated, test, combination, with, psgperformed, night, before, gold, standard, measuringhypersomnia, especially, evaluation, narcolepsy, 0c, , , , page, , actigraphypersonal, devicescurr, treat, options, neurol, , , , , , , , , , , , , wrist, actigraphy, provides, measurements, longterm, patterns, rest, andactivity, as, proxies, sleep, wakefulness, such, patterns, can, help, tocorroborate, histories, sleep, duration, timingpopular, smartphones, other, ambulatory, devices, with, physiologicalmonitoring, capabilities, may, transform, evaluation, sleep, however, arecent, comparison, different, brands, activity, trackers, found, that, sleepwake, measurements, varied, widely, comparison, with, sleep, diaries, orstandard, psg, [], overall, conclusion, that, at, beginning, wearable, devices, are, not, ready, reliable, quantification, sleep, acrossindividuals, although, serial, recordings, confined, single, individual, mayhold, some, value, these, measurements, have, yet, be, validatedsleep, comorbidities, with, systemic, diseasesendocrine, disordersthyroid, diseaseconsidering, various, sleep, disorders, diagnostic, tools, afforded, by, goodsleep, history, sleep, testing, understanding, relationship, between, sleepdisorders, systemic, diseases, has, farreaching, implications, optimizing, thecare, patient, following, sections, will, address, sleep, manifestations, ofvarious, neurological, disorders, arising, from, systemic, disease, based, on, an, systemalmost, half, patients, with, hypothyroidism, report, at, least, one, sleep, complaint, such, as, restless, sleep, choking, hypersomnia, or, fatigue, [], osa, presentin, approximately, , [], unique, mechanism, airway, restriction, hypothyroidism, myxedematous, mucoprotein, deposition, airways, soft, tissuesand, dilator, muscles, even, though, myxedema, can, be, absent, [], larger, goiters, canalso, cause, osa, by, external, compression, airway, []on, other, side, thyroid, spectrum, hyperthyroidism, most, closelyassociated, with, insomnia, occurring, , patients, [], arousaldisordersspecifically, sleep, walkingalso, occur, especially, setting, ofthyrotoxicosis, [], proposed, arise, from, frequent, arousals, impairmentof, attaining, slowwave, sleep, as, direct, result, thyroid, hormonebeyond, treatment, specific, sleep, disorder, sleep, problems, usuallyremit, following, appropriate, treatment, underlying, thyroid, disorder, []type, , diabetes, mellitussleep, disorders, affect, high, proportions, those, with, type, , diabetes, mellitusdm, surveys, patients, with, dm, compared, with, those, controls, show, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , nearly, 2fold, propensity, insomnia, fourfold, higher, use, sedativehypnoticsand, 10fold, higher, rate, hypersomnolence, [], osa, highly, prevalent, indm, many, are, undiagnosed, [], contributors, multifactorial, series, ofsleep, disruptors, include, periodic, limb, movements, restless, legs, syndromerls, diabetic, neuropathy, fluctuations, blood, glucose, []dm, presents, an, excellent, model, by, which, demonstrate, reciprocaleffects, sleep, disruption, on, primary, disease, first, sleep, disturbances, affectthe, regulation, neuroendocrine, control, appetite, sleep, deprivationpromotes, overeating, through, hyperactivity, orexin, system, [], activatesthe, hypothalamicpituitaryadrenal, system, increase, cortisol, secretionresulting, impaired, glucose, tolerance, [, ], these, multiple, mechanismssupport, clinical, observations, that, untreated, osa, may, be, reason, ineffective, treatment, dm, that, accordingly, treatment, with, cpap, leads, toimprovements, glycemic, control, some, patients, []sex, hormones, gender, affect, distribution, susceptibility, varietyof, sleep, disorders, men, on, basis, relative, airway, collapsibility, haveapproximately, twofold, increased, risk, osa, compared, with, women, , males, , females, [], potential, side, effect, thetreatment, hypoandrogenism, facilitation, osa, given, impacttestosterone, has, on, upper, airway, collapsibility, []testosterone, levels, may, affect, propensity, chronic, insomnia, menwith, hypoandrogenism, demonstrate, reduced, sleep, efficiency, increased, nighttime, awakenings, reduced, deep, sleep, compared, with, normaltestosteronelevel, controls, although, it, not, clear, whether, these, features, improve, with, testosterone, therapy, [], women, experience, higher, rates, chronicinsomnia, risk, ratio, , women, versus, men, which, becomes, even, morepronounced, elderly, [], despite, sleeping, longer, overall, sleep, quality, isoften, lower, women, than, men, []the, distribution, sleep, disorders, women, varies, with, reproductivelifespan, younger, women, are, more, susceptible, restless, legs, syndromerls, mainly, on, basis, mensesassociated, irondeficiency, during, pregnancy, women, are, at, significantly, increased, risk, development, rlswith, an, overall, prevalence, exceeding, , all, pregnant, patients, [], treatment, rls, pregnancy, involves, iron, supplementation, with, goal, ferritinlevel, , , mcgl, often, oral, iron, repletion, adequate, although, there, arereports, intravenous, iron, therapy, severe, cases, pregnancyrelated, rlsand, irondeficiency, [], pregnancy, also, associated, with, an, increased, prevalence, osa, up, , pregnant, patients, during, third, trimester, whichis, associated, with, increased, risks, complications, including, gestational, hypertension, gestational, dm, preeclampsia, []although, not, particular, systemic, neurological, disease, pharmacological, effectson, sleep, form, an, important, aspect, neurological, sleep, medicine, since, manymedications, that, are, used, by, neurologists, may, affect, sleep, table, , showscommon, medications, that, provoke, insomnia, hypersomnolence, respiratorysuppression, parasomnias, rlsperiodic, limb, movement, disordersex, hormonesmedications, 0c, , , , page, , curr, treat, options, neurol, , , , , , , , , , , , , table, , medication, classes, specific, examples, that, can, cause, sleep, disturbancesinsomniacentral, nervous, system, stimulants, methylphenidate, amphetamines, modafinilcaffeineantidepressantsselective, serotonergic, reuptake, inhibitors, fluoxetine, sertralineselective, norepinephrine, reuptake, inhibitors, venlafaxine, duloxetinesecondary, tricyclic, antidepressants, desipramine, nortriptylinecardiovascularbeta2, agonists, albuterolvasopressors, epinephrine, dopaminecorticosteroidssympathetic, amines, phenterminehypersomniabenzodiazepines, alprazolam, diazepamnonbenzodiazepine, receptor, agonists, zolpidem, eszopicloneopioidsh1, antihistamines, diphenhydramineantiepileptic, agents, phenytoin, levetiracetamantidepressantsselective, serotonergic, reuptake, inhibitors, paroxetine, sertralinetertiary, tricyclic, antidepressants, amitriptylinetypical, atypical, antipsychotics, haloperidol, olanzapinedopaminergic, agonists, ropinirole, carbidopalevodopaanticholinergic, medicationscentrally, acting, î±, , agonists, clonidine, dexmedetomidinerespiratory, suppressionopioids, oxycodone, morphinebenzodiazepines, diazepam, clonazepamalcoholphenobarbitalparasomniasantidepressants, clomipramine, fluoxetine, citalopramnonbenzodiazepine, receptor, agonists, zolpidemcaffeinealcohol, withdrawalrestless, legs, syndrome, periodic, limb, movementsselective, serotonergic, reuptake, inhibitors, fluoxetine, mirtazapineantipsychotics, haloperidol, risperidonetricyclic, antidepressants, amitriptyline, clomipramine, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , renal, diseaseinfectious, diseasessleep, disturbances, are, highly, prevalent, patients, with, chronic, kidney, diseaseckd, spanning, broad, spectrum, sleep, disorders, including, hypersomniainsomnia, sleeprelated, breathing, rlsthe, prevalence, osa, ckd, ranges, from, , , rates, that, are, notexplained, solely, by, overlapping, comorbidities, common, both, osa, ckd[], cooccurrence, both, ckd, osa, associated, with, increasedcardiovascular, events, allcause, mortality, [], usually, osa, develops, inpatients, with, ckd, independent, underlying, renal, dysfunction, but, someevidence, shows, that, ckd, can, cause, or, exacerbate, osa, central, sleep, apneaproposed, mechanisms, causal, relationship, include, uremic, neuropathyaltered, chemosensitivity, hypervolemia, [], accordingly, renal, replacement, therapy, fluid, removal, [], may, improve, obstructive, or, central, sleepapnea, conversely, treatment, sleep, apnea, with, pap, may, improve, renalfunction, those, with, borderline, renal, impairment, []rls, common, debilitating, symptom, patients, with, ckd, occurringin, up, , patients, on, hemodialysis, compared, with, that, approximately, general, population, [], although, rls, symptoms, generally, follow, acircadian, rhythmicity, with, increased, symptoms, occurring, at, night, rls, symptoms, can, occur, during, long, periods, daytime, inactivity, during, hemodialysis, [], treatment, primarily, focused, on, ensuring, adequate, iron, stores, thenconsidering, medical, therapy, as, per, routine, care, rlssleep, disorders, infectious, diseases, have, few, specific, associations, general, acute, infection, associated, with, mild, encephalopathy, that, masquerades, ashypersomnolence, fatigue, proinflammatory, cytokines, are, implicated, inthe, development, these, constitutional, symptoms, some, infections, howeverdirectly, affect, regulatory, centers, sleepwake, systemencephalitis, lethargica, historical, pandemic, cause, hypersomnolence, ofrenewed, interest, since, review, being, written, middle, covid, pandemic, also, known, as, von, economos, encephalitis, it, occurred, inassociation, with, spanish, flu, pandemic, , [], an, estimated, , millionwere, affected, worldwide, most, common, subtype, somnolentophthalmoplegic, form, developed, after, flulike, symptoms, fever, malaiseand, consisted, subsequent, ophthalmoplegia, accompanied, by, long, periods, ofhypersomnia, despite, appearance, deep, sleep, patients, could, be, easilyawoken, sometimes, maintained, memories, activities, that, had, transpiredaround, them, while, asleep, state, acute, akinetic, psuedosomnulencecould, be, followed, by, development, chronic, postencephaliticparkinsonismthe, pandemic, associated, with, severe, acute, respiratory, syndrome, coronavirus, , sarscov2, ie, covid19, occurring, during, writing, thisreview, features, evolving, literature, first, reports, centered, on, respiratorysymptoms, although, involvement, nervous, system, now, appearsprevalent, [], sleep, disorders, have, yet, be, specifically, reported, howeverthe, psychological, responses, social, distancing, change, schedules, otherfeatures, an, active, pandemic, have, caused, wave, anxiety, depressionwhich, turn, have, been, associated, with, poor, sleep, quality, example, 0c, , , , page, , curr, treat, options, neurol, , , , , , , , , , , , , survey, , chinese, health, care, workers, showed, prevalences, depressionat, , anxiety, at, , insomnia, at, , []postinfectious, or, postvaccination, narcolepsy, rare, but, important, developing, overall, hypotheses, etiology, idiopathic, narcolepsy, , certainvaccinations, europe, h1n1, pandemic, caused, narcolepsy, at, risk, pediatric, patients, [], fortunately, risk, postvaccinationnarcolepsy, appeared, confined, specific, vaccine, formulations, incidenthowever, has, led, ongoing, research, immunological, etiology, ofnarcolepsyafrican, trypanosomiasis, or, sleeping, sickness, remains, important, developing, world, it, parasitic, infection, spread, by, tsetse, fly, that, endemic, insubsaharan, africa, first, symptoms, include, fever, headaches, lymphadenopathy, once, parasite, enters, central, nervous, system, disorderedfragmented, sleep, ensues, often, with, inversion, circadian, sleepwake, cyclethe, world, health, anization, outlines, treatment, with, regimen, antiparasitic, medications, once, symptoms, have, started, []nonalcoholic, fatty, liver, disease, nafld, consists, idiopathic, hepatic, steatosiswith, prevalence, , , general, population, with, increasedfrequency, individuals, with, obesity, or, dm, [], given, these, coassociationsosa, common, untreated, osa, may, exacerbate, liver, injury, because, oxidative, stress, systemic, inflammation, [], risk, conversion, fromnafld, liver, fibrosis, [], trials, with, cpap, have, shown, inconsistent, resultsin, markers, liver, injury, following, treatment, osa, []the, symptoms, gastroesophageal, reflux, disease, gerd, worsen, during, sleepparticularly, if, sleep, occurs, soon, after, meal, [], lower, esophageal, sphincter, that, normally, prevents, reflux, may, be, compromised, by, increase, inthoracic, pressure, setting, upper, airway, obstruction, [], patientswith, symptoms, gerd, should, be, screened, osa, conversely, interruption, sleep, absence, osa, may, improve, with, treatment, with, protonpump, inhibitor, ppi, [], or, by, simply, elevating, head, bedinflammatory, bowel, disease, ibd, has, bilateral, interactions, with, sleep, []given, relationship, between, sleep, deprivationfragmentation, on, cytokineregulation, immune, dysfunction, it, hypothesized, that, poor, sleep, qualityworsens, overall, symptoms, ibd, [, ], additionally, proinflammatorystate, disrupts, circadian, rhythm, [], subjective, objective, measurementsof, sleep, quality, timing, should, be, considered, patients, with, ibd, particularly, those, who, have, frequent, inflammatory, flares, despite, otherwise, adequate, management, an, algorithmic, approach, sleep, assessment, ibd, patients, has, been, proposed, by, canakis, et, al, []systemic, lupus, erythematosus, rheumatoid, arthritis, serve, as, prototypical, diseases, group, disorders, with, prevalence, sleep, disturbancesof, greater, than, , [], mechanisms, sleep, disturbances, as, well, as, thereciprocal, relationship, contribution, poor, sleep, worse, autoimmunestatus, are, thought, be, similar, those, described, above, with, ibd, [, ], thespecific, sleep, disorders, prevalent, group, are, osa, periodic, limbgastrointestinal, systemautoimmune, disorders, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , pulmonarymovement, disorder, plmd, both, with, greater, than, , prevalence, [, ]as, seen, above, hypersomnolence, activitylimiting, fatigue, arise, from, specificsleep, disorders, pain, medication, side, effects, well, as, primary, effects, ofthe, primary, proinflammatory, status, [, ], often, treating, underlyingautoimmune, disorder, improves, associated, fatigue, however, if, sleepiness, persists, then, evaluating, comorbid, sleep, disorder, such, as, obstructive, sleepapnea, indicatedone, syndrome, with, possible, autoimmune, origins, chronic, fatigue, syndromesleep, disturbances, insomnia, unrefreshing, sleep, are, common, symptoms, yetpatients, rarely, report, relief, despite, appropriate, identification, treatment, ofcomorbid, sleep, disorders, [], cognitivebehavioral, therapy, cbt, gradedexercise, therapy, are, commonly, pursued, treatment, approaches, []obstructive, lung, diseases, most, commonly, asthma, chronic, obstructive, pulmonary, disease, copd, less, common, disorders, such, as, cystic, fibrosiscf, or, bronchiolitis, obliterans, may, affect, nocturnal, ventilation, osa, andcopd, often, overlap, given, shared, body, habitus, other, mutual, risk, factorsestimates, comorbid, osa, copd, range, from, , , [], patients, withsevere, copd, treated, with, nocturnal, noninvasive, ventilation, nippv, moreadvanced, form, positive, airway, pressure, experience, an, absolute, risk, reduction, , risk, hospital, readmission, or, death, at, , months, compared, with, those, treated, with, standard, care, without, nippv, [64cid129]insomnia, another, common, complaint, among, patients, with, copd, circadian, bronchial, constriction, may, cause, nocturnal, wheezing, dyspnea, or, othersymptoms, asthma, prompting, patient, awaken, [], addition, thehyperadrenergic, response, beta, , agonist, inhalers, used, treatment, acutedyspnea, impairs, sleep, onset, see, table, growing, success, treatments, cf, patients, means, that, sleep, disordersarising, from, their, intrinsic, obstructive, lung, disease, are, now, coming, theattention, caregivers, many, factors, contribute, sleep, disruption, includingchronic, cough, frequent, infections, abdominal, discomfort, reflux, frequentstools, medication, side, effects, psychological, disease, [], addition, tosleep, disruption, patients, with, cf, are, susceptible, hypoventilation, thatworsens, with, disease, progression, use, nippv, highrisk, patients, withhypercapnia, has, been, shown, improve, physiologic, parameters, at, timescan, positively, impact, symptoms, particularly, patients, who, have, severedisease, while, awaiting, lung, transplant, []restrictive, lung, diseases, defined, by, reduced, total, lung, capacity, includethose, with, parenchymal, damage, such, as, idiopathic, fibrosis, hypersensitivitypneumonitis, or, other, interstitial, pneumonias, alternatively, lung, parenchymais, normal, restrictive, diseases, such, as, obesity, hypoventilation, syndromehemidiaphragm, paresis, or, neuromuscular, disorders, muscular, dystrophiesamyotrophic, lateral, sclerosis, restrictive, lung, disease, patients, as, seen, abovewith, obstructive, disease, patients, are, susceptible, nocturnal, hypoventilationsubsequent, co2, retention, compensatory, sleep, fragmentation, use, ofnippv, patients, with, severe, restrictive, lung, disease, spanning, obesityhypoventilation, syndrome, muscular, dystrophies, als, has, had, positiveimpacts, on, survival, quality, life, [, ], 0c, , , , page, , cardiaccurr, treat, options, neurol, , , , , , , , , , , , , over, , patients, with, congestive, heart, failure, chf, have, comorbid, osamainly, on, basis, mutual, risk, factors, dm, hypertension, obesity, andolder, age, [, ], addition, insomnia, those, with, chf, may, arise, from, avariety, factors, including, diuretic, medications, subsequent, nocturiapositional, heart, failure, symptoms, increased, adrenergic, status, or, psychosocialfactors, [], treatments, addressing, comorbid, osa, insomnia, improve, sleepquality, but, demonstrate, mixed, results, terms, longterm, cardiovascularoutcomes, [, ]patients, with, acute, myocardial, infarction, ami, experience, both, acute, andchronic, sleep, disorders, due, circadian, variability, adrenergic, hormonesand, cardiac, systemic, vasculature, [], timings, ami, sudden, cardiacdeath, arrhythmia, occur, with, increased, frequency, at, night, [], cardiacischemia, may, present, series, nocturnal, symptoms, including, paroxysmaldyspnea, chest, pain, agitation, or, insomnia, surviving, patients, are, at, risk, forchronic, sleep, disorders, such, as, insomnia, sleepdisordered, breathing, withor, without, cooccurrence, anxiety, or, depression, []retrospective, longitudinal, data, demonstrate, that, those, with, osa, whoare, adherent, with, cpap, experience, improved, cardiovascular, morbidity, andmortality, over, nonadherent, patients, [], however, these, findings, have, notbeen, clearly, supported, by, prospective, randomized, trials, sleep, apneacardiovascular, endpoints, trial, save, trial, has, called, into, question, causallink, between, treatment, osa, cardiovascular, outcomes, with, meanfollowup, , years, those, randomized, pap, experienced, no, significantimprovements, study, endpoints, death, from, cardiovascular, causes, amistroke, hospitalization, unstable, angina, chf, or, transient, ischemicattack, compared, with, controls, [78cid129cid129], because, possible, insufficient, cpapuse, because, lack, main, indications, cpap, treatment, such, assevere, sleepiness, interpretation, findings, large, trial, remainscontroversial, practice, these, authors, often, pursue, cpap, treatment, patients, with, osa, cardiovascular, risk, factors, even, absence, sleepiness, at, least, trial, period, assess, adherence, treatment, determineif, there, are, subjective, objective, improvements, sleep, qualitywith, prevalence, range, , osa, common, patients, with, atrialfibrillation, other, arrhythmias, [], accordingly, sleep, heart, healthstudy, showed, two, fivefold, higher, risk, arrhythmia, patients, with, severeosa, compared, with, that, controls, [], retrospective, series, show, that, inpatients, with, atrial, fibrillation, untreated, osa, risk, atrial, fibrillationrecurrence, following, cardioversion, , compared, with, , patients, whoare, adherent, cpap, [], however, prospective, randomized, control, trialcalled, retrospective, findings, into, question, [], similar, design, savetrial, patients, with, atrial, fibrillation, were, randomized, cpap, versus, usualtherapy, from, cohort, which, sleepiness, specifically, excluded, smalltrial, , total, assessed, primary, outcome, time, arrhythmia, recurrenceboth, arms, had, recurrence, rates, , although, trial, showed, that, cpapitself, provides, no, specific, benefit, those, with, atrial, fibrillation, outcomesfor, treatment, those, with, both, disorders, remain, unclearalthough, above, studies, centered, on, associations, between, cardiac, diseaseand, osa, patients, with, chf, ami, atrial, fibrillation, experience, high, rates, 0ccurr, treat, options, neurol, , , , , , , , , , , , , page, , , , , , , cancercritical, illnesscentral, sleep, apnea, csa, as, well, exceeding, , patients, with, mild, symptomatic, chf, as, an, example, [], cheynestokes, respiration, cyclical, form, ofcsa, results, when, circulatory, impairment, perturbs, normal, responsivenessin, respiratory, control, resulting, alterations, the, loop, gain, modulatingchanges, carbon, dioxide, oxygen, levels, bloodstream, [], analogous, overly, aggressive, adjustments, thermostat, response, changingtemperature, presence, csa, has, been, considered, marker, increasedmortality, patients, with, chf, although, aims, resolve, treatment, csawith, cpap, or, more, advanced, modalities, have, not, clearly, demonstrated, animprovement, cardiovascular, outcomes, []estimates, prevalence, sleep, disturbances, across, cancer, patients, range, widelyfrom, , , [, ], insomnia, most, common, disorder, with, prevalencelevels, ranging, from, , , [, ], patients, with, cancer, who, undergo, psghave, shorter, total, sleep, times, longer, times, bed, low, sleep, efficiency, andproportionately, less, deep, sleep, than, controls, [], insomnia, patients, with, canceris, driven, by, multitude, factors, including, preexisting, socioeconomic, andpsychiatric, disorders, fatigue, age, rls, pain, medication, effects, [, ]treatment, follows, that, general, population, although, sedativehypnoticsare, most, commonly, prescribed, no, evidence, exists, specific, pharmacologicinterventions, sleep, disturbances, population, [], cognitivebehavioraltherapy, currently, recommended, firstline, treatment, chronic, insomnia[], because, rarity, trained, psychologists, makes, finding, provider, difficult, insome, circumstances, electronic, delivery, cognitivebehavioral, therapy, hasbeen, sought, as, an, alternative, facetoface, therapy, [, ]the, bilateral, interactions, between, sleep, critical, illness, form, rapidlychanging, area, investigation, which, made, particularly, challenging, giventhe, difficulties, measuring, sleep, critically, ill, patients, [, ], lack, ofsleepor, its, encephalopathic, analogmay, affect, outcomes, critical, illnessesfor, example, lack, scorable, rem, sleep, correlates, with, longer, ventilatorweaning, time, compared, with, controls, with, intact, rem, [], failure, rates, onnoninvasive, ventilation, are, impacted, by, sleep, continuity, [], delirium, acommon, neurobehavioral, syndrome, seen, upwards, , patients, inthe, icu, [, ], associated, with, significantly, worse, outcomes, i]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,15,16,17,18,19,20,21,22,23,24,28,31,32,33,35,36,37,38,39,40,42,43,44,45,47,48,49,50,51,52,54,55,57,60,61,62,64,66,68,70,71,72,73,74,75,77,78,79,80,81,82,85,86,87,88,89,90,91,92,94,95,96,98,99,100,103,104,105,106,108,109,110,111,113,115,116,118,119,120,123,125,126,128,129,130,131,134,136,138,140,143,144,145,146,147,148,149,151,152,155,157,158,159,160,161,164,166,167,169,170,171,172,174,176,184,186,188,189,190,191,192,196,198,201,203,204,205,210,213,214,218,220,221,223,224,226,227,229,230,232,234,235,236,242,245,249,253,262,263,264,268,269,270,278,280,281,283,286,287,294,296,299,301,305,307,308,309,312,313,315,317,320,323,327,334,335,336,338,340,343,348,351,352,353,357,359,360,361,365,366,368,370,371,374,377,380,384,385,386,388,393,396,397,398,401,402,408,409,410,412,413,417,421,423,427,428,429,430,431,436,438,439,440,447,448,455,461,462,463,464,466,468,469,470,471,473,480,486,488,492,494,496,497,499,505,507,508,509,512,513,515,519,524,525,527,528,534,537,546,549,550,551,555,557,558,564,566,567,568,572,573,574,576,577,585,589,590,595,596,598,608,609,610,617,619,625,629,635,637,638,641,642,643,645,646,647,648,649,650,652,659,662,670,673,677,682,683,688,691,692,696,697,698,702,707,711,713,715,716,717,723,725,726,731,733,735,736,739,740,741,742,743,750,752,759,764,765,767,770,774,783,785,789,797,798,807,808,811,815,818,822,825,832,834,836,840,845,848,851,856,864,868,877,882,883,885,887,892,899,912,915,919,927,935,940,947,953,955,961,964,965,968,971,972,974,976,984,988,992,996,1007,1026,1033,1034,1038,1039,1042,1044,1045,1047,1048,1049,1054,1059,1060,1066,1071,1077,1081,1084,1087,1092,1100,1101,1102,1103,1106,1107,1114,1120,1122,1131,1132,1133,1140,1142,1151,1160,1164,1166,1167,1172,1176,1186,1189,1194,1202,1203,1222,1237,1244,1254,1257,1264,1266,1267,1278,1296,1297,1304,1308,1309,1310,1315,1328,1335,1336,1340,1345,1347,1348,1353,1356,1359,1371,1372,1377,1388,1400,1406,1422,1424,1425,1439,1459,1461,1462,1470,1474,1476,1480,1497,1509,1512,1515,1527,1532,1537,1542,1545,1572,1584,1591,1594,1598,1614,1621,1627,1637,1639,1647,1655,1660,1665,1679,1682,1685,1687,1697,1704,1710,1720,1721,1743,1744,1756,1771,1782,1802,1813,1827,1841,1849,1850,1857,1861,1886,1890,1898,1900,1902,1903,1904,1914,1918,1920,1957,1961,1973,2000,2003,2011,2015,2016,2025,2036,2038,2040,2052,2079,2088,2096,2100,2117,2121,2132,2135,2142,2160,2167,2168,2183,2191,2200,2202,2206,2211,2223,2238,2240,2248,2263,2270,2271,2273,2278,2290,2298,2323,2325,2328,2337,2343,2351,2369,2371,2395,2397,2398,2407,2424,2437,2441,2449,2462,2472,2477,2501,2514,2533,2543,2551,2563,2566,2567,2579,2581,2588,2593,2594,2595,2609,2628,2648,2664,2675,2690,2695,2705,2711,2713,2717,2728,2735,2743,2749,2752,2754,2758,2767,2784,2785,2813,2819,2830,2839,2849,2854,2861,2864,2872,2890,2896,2898,2907,2913,2919,2942,2972,2982,3001,3021,3036,3050,3055,3060,3061,3062,3072,3094,3121,3130,3140,3151,3156,3158,3176,3202,3205,3210,3223,3230,3242,3243,3265,3305,3319,3323,3343,3345,3400,3419,3438,3444,3447,3451,3454,3469,3470,3473,3500,3513,3524,3577,3585,3591,3610,3618,3619,3639,3651,3655,3684,3692,3730,3731,3743,3765,3768,3777,3779,3781,3801,3808,3814,3816,3861,3877,3879,3917,3937,3995,4005,4011,4052,4102,4137,4157,4165,4170,4183,4189,4202,4223,4234,4242,4260,4305,4306,4314,4340,4346,4353,4393,4399,4420,4439,4440,4466,4476,4483,4503,4521,4558,4566,4572,4576,4581,4603,4632,4649,4677,4678,4689,4709,4772,4780,4798,4863,4877,4906,5014,5020,5023,5060,5092,5097,5132,5211,5222,5255,5290,5328,5331,5354,5386,5393,5429,5465,5490,5587,5589,5592,5638,5739,5746,5773,5829,5852,5873,5942,5980,6130,6147,6169,6220,6283,6302,6354,6359,6366,6372,6395,6399,6446,6450,6461,6482,6518,6538,6544,6559,6576,6579,6658,6660,6682,6816,6840,6849,6871,6930,6934,6944,6948,6964,6966,6970,6976,6983,7097,7120,7176,7286,7316,7321,7361,7439,7473,7485,7487,7512,7555,7568,7577,7617,7640,7667,7705,7773,7805,7862,7875,7960,7972,7974,8007,8065,8093,8119,8141,8153,8175,8193,8235,8313,8324,8363,8399,8443,8538,8544,8709,8756,8781,8817,8848,8850,8866,8906,9005,9024,9060,9140,9149,9208,9253,9364,9422,9454,9483,9504,9565,9656,9849,9890,9985,10033,10067,10073,10102,10175,10187,10223,10227,10396,10424,10439,10452,10611,10623,10692,10755,10861,10884,10916,10935,11009,11080,11097,11204,11314,11358,11376,11445,11454,11627,11662,11688,11821,11833,11876,12078,12139,12202,12223,12239,12331,12417,12485,12595,12659,12714,12733,12761,12847,12994,13092,13135,13295,13313,13340,13404,13525,13580,13681,13860,13883,13903,13950,13964,13979,13982,14070,14191,14561,14637,14644,14684,14731,14760,14884,14887,14934,14960,14961,14977,15116,15268,15293,15403,15474,15565,15582,15591,15634,15658,15690,15846,15896,15912,15965,16089,16117,16157,16209,16348,16634,16803,16961,16989,17081,17094,17399,17506,17568,17857,18098,18404,18477,18511,19092,19137,19434,19483,19529,19806,19903,20019,20062,20265,20335,20357,20382,21226,21458,21587,21635,21729,21891,21910,22009,22262,22272,22446,22557,22643,22644,22850,23021,23066,23098,23427,23607,23613,23786,23899,24023,24422,24508,24525,24664,24716,25098,25267,25360,25412,25672,25756,25842,25847,25877,25881,25944,25959,25997,26243,26398,26474,26497,26544,26607,26767,26815,26924,27036,27283,27488,27724,28251,28280,28597,28650,29129,29385,29402,29743,29831,29858,29875,30044,30138,30146,30383,30483,30546,30773,31136,31140,31324,32073,32275,32441,32485,32592,32644,32748,33273,33412,33958,34093,34119,34136,34230,34234,35005,35243,35323,35478,35484,37246,37624,37788,38010,38079,38137,38214,38483,38605,39047,39186,39541,39619,39967,40224,40242,40799,40879,41121,41582,41713,41806,41956,42048,45412,45574,46978,47060,47144,47966,48611,48837,49384,49389,49443,49862,49912,49968,50058,50066,50668,51075,51222,51504,52013,52551,52941,53273,54203,54866,54912,55296,55503,55570,55633,56008,56928,57264,57619,57838,58076,58950,59008,59479,59981,60788,61702,61892,62802,63265,65081,65562,65899,67285,68138,68219,68381,68927,69020,71251,71309,71409,71607,72407,72592,73236,73450,73882,73903,74137,80656,80849,80921,81325,81533,82388,83415,83670,84569,84645,85273,85797,86085,86194,86688,87122,87141,87195,87355,87404,87477,87612,88012,88046,88100,88232,88380,88611,89256,89803,90489,90685,90826,90882,91700,91979,92002,92059,92275,92966,93015,93072,93296,93940,94482,94522,95059,95480,95562,95772,96567,96814,97042,98624,98775,99305,99484,99784,99805,100617,100663,100880,101378,101386,101431,101933,101991,102142,102700,103090,103329,103532,104816,104927,104935,104943,104999,105029,105155,105230,105576,106141,106548,107336,107752,108170,108318,108371,108666,109101,109234,109394,109403,109550,109703,109939,110012,110057,110417,110497,110819,110946,111039,111578,111656,111670,111963,112132,112482,112877,113109,113284,113655,113947,114000,114066,114116,114153,114740,115094,115473,115553,115671,115850,115970,116058,116109,116248,116729,117017,117073,117554,117761,117769,118041,118187,118460,118733,119081,119443,119656,120692,120730,121043,121205,123067,123099,123302,123306,123357,123842,124448,124731,124977,125549,126176,126551,126842,126931,127078,127267,127360,128177,128333,129158,129163,129473,129631,129891,130123,130149,130315,130821,132699,132784,132785,132890,133052,133283,133713,133769,133999,134187,134956,135482,135899,135991,136088,136517,137062,137069,137078,138054,138181,138544,138576,138662,138704,138818,139085,139169,139260,139852,140028,140053,140101,140261,140761,140860,140948,141334,141374,141437,141737,141806,141970,142404,142501,142623,142630,143059,143181,143480,143853,143860,143979,144351,144450,144757,145730,146009,146364,147064,147313,147955,148371,148896,149210,149516,149736,150041,150318,150521,150577,150917,151021,151112,151359,151637,152471,152503,152849,152931,153897,154403,154467,154982,155135,155292,155366,155530,155749,156059,156275,156366,156965,157131,157190,157558,158329,158400,159407,159456,159542,159715,160033,160244,161018,161070,161122,161614,161673,162389,162937,163542,163675,163721,164017,164431,164473,164559,164618,164647,164659,165211,165244,165445,165672,165810,165817,166034,166148,166176,166336,166617,166881,167678,168309,168408,168991,169131,169189,169211,169505,169559,169609,169880,170430,170468,170562,170882,171115,171150,171228,171239,171290,171694,172424,173011,173203,173786,173796,173884,175034,175090,175753,176204,176503,176619,177189,177270,177299,177562,178399,178461,179857,179880,180264,180683,180740,181220,182180,182671,182776,182931,183319,183450,184071,186243,186642,186780,186853,187150,187320,188170,188348,188539,188876,189149,190182,190210,190695,191620,191821,191885,192538,193044,193457,193518,193707,193976,193987,194081,194278,194538,194717,194919,195059,195475,195477,196000,196343,196352,196751,196818,196844,197049,197061,197558,197586,198122,198170,198197,198288,198700,199187,199220,199410,199411,199525,200166,200749,202190,203009,203425,203430,203729,203742,204378,204443,204829,205247,205496,205774,205918,206525,206853,206897,207170,207312,207448,207777,207937,208405,209128,209201,209325,209623,210210,210310,210344,210364,210613,210770],[267.0,89.0,1.0,16.0,31.0,22.0,2.0,40.0,36.0,16.0,12.0,24.0,12.0,5.0,15.0,15.0,1.0,2.0,1.0,21.0,5.0,7.0,6.0,8.0,50.0,3.0,2.0,7.0,25.0,3.0,10.0,3.0,4.0,9.0,3.0,9.0,1.0,16.0,2.0,1.0,2.0,1.0,17.0,4.0,8.0,2.0,2.0,9.0,1.0,1.0,8.0,15.0,1.0,4.0,4.0,9.0,1.0,1.0,8.0,14.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,8.0,4.0,6.0,5.0,4.0,7.0,3.0,4.0,1.0,1.0,2.0,5.0,10.0,1.0,1.0,3.0,1.0,1.0,2.0,12.0,1.0,7.0,4.0,4.0,1.0,4.0,3.0,4.0,2.0,2.0,9.0,1.0,1.0,2.0,1.0,2.0,1.0,3.0,2.0,1.0,8.0,1.0,1.0,2.0,2.0,3.0,1.0,9.0,1.0,3.0,3.0,3.0,1.0,2.0,3.0,3.0,1.0,5.0,4.0,1.0,3.0,1.0,1.0,2.0,1.0,3.0,13.0,4.0,1.0,4.0,7.0,1.0,1.0,5.0,3.0,1.0,1.0,1.0,7.0,4.0,1.0,5.0,2.0,2.0,1.0,2.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,10.0,6.0,2.0,5.0,2.0,2.0,2.0,3.0,1.0,1.0,1.0,7.0,3.0,2.0,10.0,6.0,2.0,1.0,11.0,3.0,1.0,1.0,4.0,1.0,5.0,1.0,2.0,2.0,1.0,5.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,3.0,2.0,3.0,1.0,1.0,1.0,3.0,6.0,2.0,1.0,1.0,1.0,3.0,5.0,1.0,5.0,1.0,3.0,2.0,2.0,1.0,1.0,11.0,1.0,2.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,2.0,2.0,5.0,1.0,1.0,14.0,1.0,1.0,2.0,6.0,2.0,2.0,1.0,1.0,1.0,2.0,14.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,5.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,4.0,2.0,2.0,6.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,3.0,4.0,4.0,1.0,2.0,2.0,2.0,1.0,5.0,3.0,1.0,8.0,2.0,1.0,2.0,2.0,1.0,5.0,4.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,4.0,1.0,2.0,1.0,129.0,3.0,1.0,1.0,1.0,1.0,2.0,12.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,2.0,1.0,2.0,1.0,3.0,2.0,2.0,1.0,1.0,2.0,3.0,1.0,5.0,1.0,5.0,3.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,2.0,2.0,2.0,8.0,7.0,4.0,2.0,3.0,1.0,3.0,5.0,1.0,1.0,2.0,1.0,17.0,1.0,1.0,1.0,1.0,1.0,37.0,2.0,2.0,1.0,4.0,1.0,1.0,2.0,3.0,1.0,1.0,2.0,4.0,7.0,1.0,5.0,1.0,2.0,3.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,3.0,1.0,3.0,1.0,2.0,2.0,2.0,4.0,2.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,3.0,1.0,2.0,2.0,1.0,6.0,3.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,12.0,2.0,4.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,4.0,2.0,1.0,1.0,3.0,2.0,3.0,1.0,1.0,3.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,3.0,2.0,7.0,1.0,13.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,3.0,1.0,5.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,5.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,10.0,6.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,30.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,4.0,1.0,3.0,1.0,5.0,2.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,6.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,9.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,7.0,12.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,24.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,6.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,3.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,2.0,4.0,1.0,1.0,3.0,3.0,3.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,6.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,5.0,1.0,5.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,4.0,2.0,3.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n",
      "|[endocrinesypostoperative, vocal, fold, dysfunction, in, covid19, era, are, we, still, intime, for, a, recoveryelena, bonati, , elena, giovanna, bignami2, , paolo, del, rio1received, , may, , , accepted, , july, , springer, sciencebusiness, media, llc, part, of, springer, nature, to, the, editorthe, novel, , coronavirus, covid19, is, a, highly, contagious, zoonosis, produced, by, sarscov2, which, arose, inchina, and, spread, all, over, the, world, transmitting, from, manto, man, through, respiratory, secretions, in, march, , itwas, deï¬ned, by, the, world, health, anization, who, as, apandemic, to, underline, its, spread, and, severityhealthcare, professionals, are, one, of, the, categories, most, atrisk, of, contracting, the, infection, in, particular, when, theiractivity, involves, the, direct, management, of, the, patientsairways, among, these, categories, we, can, count, anesthetistshead, and, neck, surgeons, otolaryngologists, maxillofacialsurgeons, ophthalmologists, and, dentists, for, these, reasonsthe, latest, evidencebased, recommendations, for, otolaryngology, and, head, and, neck, surgery, practice, suggest, thathealthcare, facilities, should, prioritize, urgent, and, emergencyvisits, and, procedures, until, this, condition, stabilizes, ceasingelective, care, []nevertheless, oncological, surgical, activity, althoughslowed, down, did, not, stop, in, most, hub, hospitals, regardingthyroid, cancer, thyroid, surgery, is, complex, and, the, rate, ofnerve, damage, is, still, considerable, immediate, postoperativevocal, fold, rate, is, , in, our, case, study, and, decrease, to, after, , months, postoperative, dysphonia, can, becaused, by, several, factors, other, than, nerve, damage, such, astracheal, intubation, or, scarring, in, the, thyroid, lodge, it, istherefore, important, to, identify, the, cause, of, vocal, corddysfunction, and, treat, it, correctly, at, the, right, time, if, anunilateral, vocal, fold, paresisparalysis, is, diagnosedthetreatment, consist, in, improving, the, speech, while, in, case, of, elena, bonatiebonati86gmailcom, general, surgery, unit, department, of, medicine, and, surgeryparma, university, hospital, parma, italy, unit, of, anesthesiology, department, of, medicine, and, surgeryparma, university, hospital, parma, italybilateral, vocal, fold, paresisparalysis, respiratory, obstructionalso, needs, to, be, urgently, treated, fortunately, we, havebroughtthe, incidence, of, this, last, and, most, dangerouscomplication, to, , at, our, clinic, since, the, introduction, in, of, the, routine, use, of, intraoperative, neuromonitoringduring, thyroidectomythe, latest, guidelines, published, by, the, americanin, march, association, of, endocrine, surgeonsrecommend, laryngeal, examination, in, patients, with, knownor, suspected, new, recurrent, laryngeal, nerve, dysfunctionafter, thyroidectomy, for, additional, evaluation, and, possibletreatment, with, a, speech, pathologist, according, to, theamerican, academy, of, otolaryngologyhead, and, necksurgery, they, assert, that, early, referral, , weeks, postsurgery, to, a, laryngologistin, combination, with, earlyintervention, results, in, superior, voice, outcomes, since, theideal, time, for, vocal, fold, augmentation, is, , months, afterthyroidectomy, []a, metaanalysis, about, therapy, for, vocal, fold, paresisparalysis, after, thyroidectomy, concluded, that, the, timingof, therapy, for, unilateral, vocal, fold, paralysis, after, thyroidectomy, has, a, significant, impact, on, the, effect, sizebeing, significantly, greater, if, therapy, is, performed, within, months, this, may, be, explained, by, progressive, atrofolds, and, disappearance, of, nervephy, offunction, so, that, vocalfold, movements, cannot, berecovered, []the, vocalpatients, who, underwent, thyroid, surgery, from, february, and, who, had, experienced, a, vocal, fold, disfunctionvfd, were, unable, to, undergo, a, laryngoscopy, nor, muchless, a, speech, therapy, according, to, health, measuresnecessary, to, contain, the, spread, of, the, virus, this, unfortunately, causes, a, progressively, reduced, possibility, ofrecovery, increasing, the, speciï¬c, morbidity, related, to, surgery, for, thyroid, cancer, in, this, period, the, only, indicationthat, we, can, give, to, patients, is, the, rest, of, the, voice, to, avoidthe, establishment, of, compensation, mechanisms, worseningthe, clinical, picture, waiting, to, be, able, to, resume, the, correcttreatment, 0ctherapeutic, diagnostic, pathways, in, the, covid19, erahave, become, difï¬cult, and, dangerous, logarithms, that, mustconsider, the, need, for, patient, care, and, the, possibility, oftreatments, delay, in, safety, but, also, the, risk, of, contagion, ofthe, patientsleast, protection, ofhealthcare, personnel, the, hospital, setup, has, been, significantly, changed, and, much, of, the, economic, structuraland, human, health, resources, have, been, dedicated, to, themanagement, of, the, covid, pandemicthemselves, and, notin, parallel, with, the, covid19, emergency, we, areexperiencing, another, health, emergencythe, one, thatinvolves, the, management, of, noncovid19, patients, evenin, the, second, phase, of, the, pandemic, only, urgent, healthservices, are, provided, a, reanizing, effort, within, theindividual, healthcare, companies, is, required, to, guaranteetreatment, even, for, noncovid19, patientsmoreoverthe, covid19, pandemic, highlighted, the, limits, andweaknesses, of, our, health, system, and, now, that, the, correctprotocols, for, the, protection, of, healthcare, personnel, havebeen, described, allthe, all, healthcare, companies, shouldequip, their, staff, with, the, appropriate, materials, such, as, n95masks, hair, cover, protective, coverall, gown, gloves, faceshields, goggles, and, shoe, covers, in, the, face, of, higherexpenses, this, would, allow, the, resumption, of, activitiesminimizing, the, risk, of, an, increase, in, the, rate, of, infectionroutine, health, practices, must, be, reconsidered, preferring, less, invasive, techniques, in, order, toscreen, patients, who, need, secondlevel, examination, evenif, not, used, yet, in, our, hospital, transcutaneous, laryngealultrasonography, is, a, valid, noninvasive, and, painlessalternative, method, in, the, assessment, of, vocal, cords, it, hasbeen, demonstrated, in, a, recent, prospective, multicentricstudy, that, it, has, concordance, with, laryngoscopy, in, themajority, of, cases, and, so, it, can, be, a, valid, alternative, asï¬rstline, exam, for, vocalfold, examination, pre, andpostoperativelyendocrinefinally, the, growing, use, of, virtual, platforms, for, the, needof, social, distancing, could, encourage, their, application, evenin, healthcare, services, that, can, be, performed, by, teleconference, such, as, speech, therapywe, can, assess, that, covid19, pandemic, is, causingdirect, morbidity, and, mortality, and, even, a, related, one, dueto, missed, or, delayed, treatment, of, multiple, noncovid19diseases, the, delivery, of, the, health, service, should, beimproved, and, the, health, system, itself, must, be, modernizedto, adapt, to, new, needscompliance, with, ethical, standardsconï¬ict, of, interest, the, authors, declare, that, they, have, no, conï¬ict, ofinterestpublishers, note, springer, nature, remains, neutral, with, regard, tojurisdictional, claims, in, published, maps, and, institutional, afï¬liationsreferences, lp, kowalski, a, sanabria, ja, ridge, wt, ng, r, de, breea, rinaldo, rp, takes, a, a, mkitie, al, carvalho, cr, bradford, v, paleri, dm, hartl, v, vander, poorten, ij, nixon, c, piazzapd, lacy, jp, rodrigo, o, guntinaslichius, wm, mendenhalla, dcruz, awm, lee, a, ferlito, covid19, pandemic, effectsand, evidencebased, recommendations, for, otolaryngology, and, headand, neck, surgery, practice, head, neck, , 101002hed26164, kn, patel, l, yip, cc, lubitz, eg, grubbs, bs, miller, w, shenp, angelos, h, chen, gm, doherty, tj, fahey, 3rd, e, kebebewva, livolsi, nd, perrier, ja, sipos, ja, sosa, d, stewardrp, tufano, cr, mchenry, se, carty, the, american, associationof, endocrine, surgeons, guidelines, for, the, deï¬nitive, surgical, management, of, thyroid, disease, in, adults, ann, surg, , e21e93, , x, chen, p, wan, y, yu, m, li, y, xu, p, huang, z, huang, typesand, timing, of, therapy, for, vocal, fold, paresisparalysis, after, thyroidectomy, a, systematic, review, and, metaanalysis, j, voice, , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |[endocrinesypostoperative, vocal, fold, dysfunction, covid19, era, still, intime, recoveryelena, bonati, , elena, giovanna, bignami2, , paolo, del, rio1received, , may, , , accepted, , july, , springer, sciencebusiness, media, llc, part, springer, nature, editorthe, novel, , coronavirus, covid19, highly, contagious, zoonosis, produced, sarscov2, arose, inchina, spread, world, transmitting, manto, man, respiratory, secretions, march, , itwas, deï¬ned, world, health, anization, apandemic, underline, spread, severityhealthcare, professionals, one, categories, atrisk, contracting, infection, particular, theiractivity, involves, direct, management, patientsairways, among, categories, count, anesthetistshead, neck, surgeons, otolaryngologists, maxillofacialsurgeons, ophthalmologists, dentists, reasonsthe, latest, evidencebased, recommendations, otolaryngology, head, neck, surgery, practice, suggest, thathealthcare, facilities, prioritize, urgent, emergencyvisits, procedures, condition, stabilizes, ceasingelective, care, []nevertheless, oncological, surgical, activity, althoughslowed, stop, hub, hospitals, regardingthyroid, cancer, thyroid, surgery, complex, rate, ofnerve, damage, still, considerable, immediate, postoperativevocal, fold, rate, , case, study, decrease, to, , months, postoperative, dysphonia, becaused, several, factors, nerve, damage, astracheal, intubation, scarring, thyroid, lodge, istherefore, important, identify, cause, vocal, corddysfunction, treat, correctly, right, time, anunilateral, vocal, fold, paresisparalysis, diagnosedthetreatment, consist, improving, speech, case, elena, bonatiebonati86gmailcom, general, surgery, unit, department, medicine, surgeryparma, university, hospital, parma, italy, unit, anesthesiology, department, medicine, surgeryparma, university, hospital, parma, italybilateral, vocal, fold, paresisparalysis, respiratory, obstructionalso, needs, urgently, treated, fortunately, havebroughtthe, incidence, last, dangerouscomplication, , clinic, since, introduction, routine, use, intraoperative, neuromonitoringduring, thyroidectomythe, latest, guidelines, published, americanin, march, association, endocrine, surgeonsrecommend, laryngeal, examination, patients, knownor, suspected, new, recurrent, laryngeal, nerve, dysfunctionafter, thyroidectomy, additional, evaluation, possibletreatment, speech, pathologist, according, theamerican, academy, otolaryngologyhead, necksurgery, assert, early, referral, , weeks, postsurgery, laryngologistin, combination, earlyintervention, results, superior, voice, outcomes, since, theideal, time, vocal, fold, augmentation, , months, afterthyroidectomy, []a, metaanalysis, therapy, vocal, fold, paresisparalysis, thyroidectomy, concluded, timingof, therapy, unilateral, vocal, fold, paralysis, thyroidectomy, significant, impact, effect, sizebeing, significantly, greater, therapy, performed, within, months, may, explained, progressive, atrofolds, disappearance, nervephy, offunction, vocalfold, movements, berecovered, []the, vocalpatients, underwent, thyroid, surgery, february, experienced, vocal, fold, disfunctionvfd, unable, undergo, laryngoscopy, muchless, speech, therapy, according, health, measuresnecessary, contain, spread, virus, unfortunately, causes, progressively, reduced, possibility, ofrecovery, increasing, speciï¬c, morbidity, related, surgery, thyroid, cancer, period, indicationthat, give, patients, rest, voice, avoidthe, establishment, compensation, mechanisms, worseningthe, clinical, picture, waiting, able, resume, correcttreatment, 0ctherapeutic, diagnostic, pathways, covid19, erahave, become, difï¬cult, dangerous, logarithms, mustconsider, need, patient, care, possibility, oftreatments, delay, safety, also, risk, contagion, ofthe, patientsleast, protection, ofhealthcare, personnel, hospital, setup, significantly, changed, much, economic, structuraland, human, health, resources, dedicated, themanagement, covid, pandemicthemselves, notin, parallel, covid19, emergency, areexperiencing, another, health, emergencythe, one, thatinvolves, management, noncovid19, patients, evenin, second, phase, pandemic, urgent, healthservices, provided, reanizing, effort, within, theindividual, healthcare, companies, required, guaranteetreatment, even, noncovid19, patientsmoreoverthe, covid19, pandemic, highlighted, limits, andweaknesses, health, system, correctprotocols, protection, healthcare, personnel, havebeen, described, allthe, healthcare, companies, shouldequip, staff, appropriate, materials, n95masks, hair, cover, protective, coverall, gown, gloves, faceshields, goggles, shoe, covers, face, higherexpenses, allow, resumption, activitiesminimizing, risk, increase, rate, infectionroutine, health, practices, must, reconsidered, preferring, less, invasive, techniques, order, toscreen, patients, need, secondlevel, examination, evenif, used, yet, hospital, transcutaneous, laryngealultrasonography, valid, noninvasive, painlessalternative, method, assessment, vocal, cords, hasbeen, demonstrated, recent, prospective, multicentricstudy, concordance, laryngoscopy, themajority, cases, valid, alternative, asï¬rstline, exam, vocalfold, examination, pre, andpostoperativelyendocrinefinally, growing, use, virtual, platforms, needof, social, distancing, encourage, application, evenin, healthcare, services, performed, teleconference, speech, therapywe, assess, covid19, pandemic, causingdirect, morbidity, mortality, even, related, one, dueto, missed, delayed, treatment, multiple, noncovid19diseases, delivery, health, service, beimproved, health, system, must, modernizedto, adapt, new, needscompliance, ethical, standardsconï¬ict, interest, authors, declare, conï¬ict, ofinterestpublishers, note, springer, nature, remains, neutral, regard, tojurisdictional, claims, published, maps, institutional, afï¬liationsreferences, lp, kowalski, sanabria, ja, ridge, wt, ng, r, de, breea, rinaldo, rp, takes, mkitie, al, carvalho, cr, bradford, v, paleri, dm, hartl, v, vander, poorten, ij, nixon, c, piazzapd, lacy, jp, rodrigo, o, guntinaslichius, wm, mendenhalla, dcruz, awm, lee, ferlito, covid19, pandemic, effectsand, evidencebased, recommendations, otolaryngology, headand, neck, surgery, practice, head, neck, , 101002hed26164, kn, patel, l, yip, cc, lubitz, eg, grubbs, bs, miller, w, shenp, angelos, h, chen, gm, doherty, tj, fahey, 3rd, e, kebebewva, livolsi, nd, perrier, ja, sipos, ja, sosa, d, stewardrp, tufano, cr, mchenry, se, carty, american, associationof, endocrine, surgeons, guidelines, deï¬nitive, surgical, management, thyroid, disease, adults, ann, surg, , e21e93, , x, chen, p, wan, y, yu, m, li, y, xu, p, huang, z, huang, typesand, timing, therapy, vocal, fold, paresisparalysis, thyroidectomy, systematic, review, metaanalysis, j, voice, , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |[endocrinesypostoperative, vocal, fold, dysfunction, covid19, era, are, we, still, intime, recoveryelena, bonati, , elena, giovanna, bignami2, , paolo, del, rio1received, , may, , , accepted, , july, , springer, sciencebusiness, media, llc, part, springer, nature, editorthe, novel, , coronavirus, covid19, highly, contagious, zoonosis, produced, by, sarscov2, which, arose, inchina, spread, all, over, world, transmitting, from, manto, man, through, respiratory, secretions, march, , itwas, deï¬ned, by, world, health, anization, who, as, apandemic, underline, its, spread, severityhealthcare, professionals, are, one, categories, most, atrisk, contracting, infection, particular, when, theiractivity, involves, direct, management, patientsairways, among, these, categories, we, can, count, anesthetistshead, neck, surgeons, otolaryngologists, maxillofacialsurgeons, ophthalmologists, dentists, these, reasonsthe, latest, evidencebased, recommendations, otolaryngology, head, neck, surgery, practice, suggest, thathealthcare, facilities, should, prioritize, urgent, emergencyvisits, procedures, until, condition, stabilizes, ceasingelective, care, []nevertheless, oncological, surgical, activity, althoughslowed, down, did, not, stop, most, hub, hospitals, regardingthyroid, cancer, thyroid, surgery, complex, rate, ofnerve, damage, still, considerable, immediate, postoperativevocal, fold, rate, , our, case, study, decrease, to, after, , months, postoperative, dysphonia, can, becaused, by, several, factors, other, than, nerve, damage, such, astracheal, intubation, or, scarring, thyroid, lodge, it, istherefore, important, identify, cause, vocal, corddysfunction, treat, it, correctly, at, right, time, if, anunilateral, vocal, fold, paresisparalysis, diagnosedthetreatment, consist, improving, speech, while, case, elena, bonatiebonati86gmailcom, general, surgery, unit, department, medicine, surgeryparma, university, hospital, parma, italy, unit, anesthesiology, department, medicine, surgeryparma, university, hospital, parma, italybilateral, vocal, fold, paresisparalysis, respiratory, obstructionalso, needs, be, urgently, treated, fortunately, we, havebroughtthe, incidence, last, most, dangerouscomplication, , at, our, clinic, since, introduction, routine, use, intraoperative, neuromonitoringduring, thyroidectomythe, latest, guidelines, published, by, americanin, march, association, endocrine, surgeonsrecommend, laryngeal, examination, patients, with, knownor, suspected, new, recurrent, laryngeal, nerve, dysfunctionafter, thyroidectomy, additional, evaluation, possibletreatment, with, speech, pathologist, according, theamerican, academy, otolaryngologyhead, necksurgery, they, assert, that, early, referral, , weeks, postsurgery, laryngologistin, combination, with, earlyintervention, results, superior, voice, outcomes, since, theideal, time, vocal, fold, augmentation, , months, afterthyroidectomy, []a, metaanalysis, about, therapy, vocal, fold, paresisparalysis, after, thyroidectomy, concluded, that, timingof, therapy, unilateral, vocal, fold, paralysis, after, thyroidectomy, has, significant, impact, on, effect, sizebeing, significantly, greater, if, therapy, performed, within, months, may, be, explained, by, progressive, atrofolds, disappearance, nervephy, offunction, so, that, vocalfold, movements, cannot, berecovered, []the, vocalpatients, who, underwent, thyroid, surgery, from, february, who, had, experienced, vocal, fold, disfunctionvfd, were, unable, undergo, laryngoscopy, nor, muchless, speech, therapy, according, health, measuresnecessary, contain, spread, virus, unfortunately, causes, progressively, reduced, possibility, ofrecovery, increasing, speciï¬c, morbidity, related, surgery, thyroid, cancer, period, only, indicationthat, we, can, give, patients, rest, voice, avoidthe, establishment, compensation, mechanisms, worseningthe, clinical, picture, waiting, be, able, resume, correcttreatment, 0ctherapeutic, diagnostic, pathways, covid19, erahave, become, difï¬cult, dangerous, logarithms, that, mustconsider, need, patient, care, possibility, oftreatments, delay, safety, but, also, risk, contagion, ofthe, patientsleast, protection, ofhealthcare, personnel, hospital, setup, has, been, significantly, changed, much, economic, structuraland, human, health, resources, have, been, dedicated, themanagement, covid, pandemicthemselves, notin, parallel, with, covid19, emergency, we, areexperiencing, another, health, emergencythe, one, thatinvolves, management, noncovid19, patients, evenin, second, phase, pandemic, only, urgent, healthservices, are, provided, reanizing, effort, within, theindividual, healthcare, companies, required, guaranteetreatment, even, noncovid19, patientsmoreoverthe, covid19, pandemic, highlighted, limits, andweaknesses, our, health, system, now, that, correctprotocols, protection, healthcare, personnel, havebeen, described, allthe, all, healthcare, companies, shouldequip, their, staff, with, appropriate, materials, such, as, n95masks, hair, cover, protective, coverall, gown, gloves, faceshields, goggles, shoe, covers, face, higherexpenses, would, allow, resumption, activitiesminimizing, risk, an, increase, rate, infectionroutine, health, practices, must, be, reconsidered, preferring, less, invasive, techniques, order, toscreen, patients, who, need, secondlevel, examination, evenif, not, used, yet, our, hospital, transcutaneous, laryngealultrasonography, valid, noninvasive, painlessalternative, method, assessment, vocal, cords, it, hasbeen, demonstrated, recent, prospective, multicentricstudy, that, it, has, concordance, with, laryngoscopy, themajority, cases, so, it, can, be, valid, alternative, asï¬rstline, exam, vocalfold, examination, pre, andpostoperativelyendocrinefinally, growing, use, virtual, platforms, needof, social, distancing, could, encourage, their, application, evenin, healthcare, services, that, can, be, performed, by, teleconference, such, as, speech, therapywe, can, assess, that, covid19, pandemic, causingdirect, morbidity, mortality, even, related, one, dueto, missed, or, delayed, treatment, multiple, noncovid19diseases, delivery, health, service, should, beimproved, health, system, itself, must, be, modernizedto, adapt, new, needscompliance, with, ethical, standardsconï¬ict, interest, authors, declare, that, they, have, no, conï¬ict, ofinterestpublishers, note, springer, nature, remains, neutral, with, regard, tojurisdictional, claims, published, maps, institutional, afï¬liationsreferences, lp, kowalski, sanabria, ja, ridge, wt, ng, r, de, breea, rinaldo, rp, takes, mkitie, al, carvalho, cr, bradford, v, paleri, dm, hartl, v, vander, poorten, ij, nixon, c, piazzapd, lacy, jp, rodrigo, o, guntinaslichius, wm, mendenhalla, dcruz, awm, lee, ferlito, covid19, pandemic, effectsand, evidencebased, recommendations, otolaryngology, headand, neck, surgery, practice, head, neck, , 101002hed26164, kn, patel, l, yip, cc, lubitz, eg, grubbs, bs, miller, w, shenp, angelos, h, chen, gm, doherty, tj, fahey, 3rd, e, kebebewva, livolsi, nd, perrier, ja, sipos, ja, sosa, d, stewardrp, tufano, cr, mchenry, se, carty, american, associationof, endocrine, surgeons, guidelines, deï¬nitive, surgical, management, thyroid, disease, adults, ann, surg, , e21e93, , x, chen, p, wan, y, yu, m, li, y, xu, p, huang, z, huang, typesand, timing, therapy, vocal, fold, paresisparalysis, after, thyroidectomy, systematic, review, metaanalysis, j, voice, , 0c']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |(224581,[0,1,2,3,4,5,6,8,9,10,11,12,15,16,17,18,19,20,22,23,24,29,33,34,35,36,37,38,39,40,42,43,44,45,48,49,50,54,55,57,58,61,63,64,66,70,73,74,75,76,81,89,93,94,97,98,99,103,105,109,111,114,118,122,123,126,131,133,136,143,144,145,147,148,149,151,152,160,163,164,165,167,172,173,180,185,186,188,190,209,214,218,220,224,227,229,232,235,241,244,245,247,249,258,270,275,276,280,283,286,289,310,338,343,345,348,349,353,367,368,370,374,380,386,394,396,401,408,421,426,460,463,464,466,468,471,475,480,484,486,492,496,497,499,503,504,513,517,519,538,546,551,552,560,568,569,572,601,617,620,629,633,652,661,683,688,692,696,701,714,735,736,742,746,761,765,767,773,785,788,797,807,832,849,885,924,982,984,1023,1045,1050,1071,1079,1083,1095,1103,1108,1113,1131,1176,1177,1183,1201,1203,1214,1217,1222,1232,1242,1244,1266,1276,1277,1299,1302,1315,1336,1343,1348,1411,1436,1450,1451,1457,1458,1470,1491,1501,1564,1614,1635,1637,1645,1660,1665,1668,1685,1689,1731,1749,1756,1850,1880,1891,1903,1928,1951,1957,1988,1991,1999,2003,2058,2078,2082,2087,2102,2110,2113,2142,2245,2284,2369,2395,2450,2453,2485,2487,2510,2541,2546,2548,2564,2590,2593,2630,2634,2640,2711,2728,2819,2839,2849,2896,2916,2968,2982,2988,3001,3083,3154,3220,3249,3256,3300,3422,3428,3484,3524,3530,3545,3717,3721,3888,3931,3984,4045,4121,4173,4184,4235,4248,4284,4354,4355,4403,4447,4576,4623,4633,4670,4678,4702,4738,4882,4948,5027,5188,5200,5211,5217,5219,5266,5289,5295,5328,5368,5419,5719,5912,5929,5937,6048,6236,6402,6446,6453,6468,6583,6640,7035,7117,7283,7338,7371,7386,7421,7640,7888,7897,8271,8587,8612,8648,8653,9213,9310,9450,9698,9983,10017,10069,10100,10175,10292,10320,10385,11075,11892,12121,12139,12497,12579,13008,13135,13289,13527,13860,14108,14283,14380,14644,15336,15733,15739,16123,16616,17077,17180,17220,17934,18116,18247,18255,18514,18648,19160,19929,21229,21308,21925,22233,22263,22311,22748,22911,24615,24899,25411,25572,27508,29257,29878,30350,30875,31909,33894,34093,34562,34698,35722,36213,36574,37217,37492,37533,39409,40204,40680,41221,41483,41487,49551,49624,50273,50664,51020,51532,52748,53202,53476,53602,53669,54438,54646,54997,55042,56578,57367,60944,61803,64111,66635,71350,72054,72300,73751,73943,74048,81232,85639,86989,89443,91171,94193,95236,95564,101602,102113,103997,104186,104277,104926,106642,106916,107166,107301,107653,109283,111326,111719,115208,115326,115476,117748,118317,118870,121763,121841,122817,123142,124505,125514,127781,131481,132183,132775,136559,137130,137324,137556,140054,140098,140482,141371,143313,144253,144385,146156,148868,150891,151062,152255,153444,154282,154318,155162,155424,155808,156180,158027,158406,158839,158876,159535,160301,161424,163088,167095,168186,168751,169062,169871,170139,174614,175077,175819,175876,178094,179353,179493,182093,182901,182959,183478,184651,185915,186208,186568,188002,188220,188275,193336,193614,194001,195746,197331,197356,198594,199210,199414,199471,199934,201410,203137,204212,205306,207428,207453,208498,209039,209596,209734,210116],[15.0,8.0,1.0,6.0,9.0,3.0,2.0,4.0,2.0,1.0,2.0,3.0,7.0,3.0,2.0,1.0,5.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,3.0,4.0,2.0,5.0,1.0,6.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,2.0,2.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,8.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,7.0,5.0,2.0,4.0,6.0,1.0,1.0,2.0,1.0,1.0,4.0,5.0,2.0,2.0,1.0,2.0,1.0,2.0,2.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,9.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,10.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n",
      "|[neck, tissues, a, a0systematic, reviewjerome, a0r, a0lechien1234, stphane, a0hans13, a0·, maria, a0r, a0barillari18, a0·, giovanni, a0cammaroto19, a0·, graldine, a0descamps12, a0·, julien, a0hsieh110, a0·, luigi, a0vaira111, a0·, giacomo, a0de, a0riu111, a0·, leigh, a0sowerby112, a0·, isabelle, a0gengler113, a0·, justin, a0michel15, a0·, sven, a0saussez124, a0·, thomas, a0radulesco15, a0·, christian, a0calvohenriquez16, a0·, carlos, a0m, a0chiesaestomba17, a0·, received, , july, , , accepted, , august, , , springer, sciencebusiness, media, llc, part, of, springer, nature, abstractto, review, the, data, regarding, the, expression, of, angiotensin, converting, enzyme2, ace2, and, transmembrane, protease, serine2, tmprss2, in, head, and, neck, tissue, scopus, cochrane, library, medrxiv, google, scholar, and, pubmedmedline, were, searched, by, four, independent, investigators, for, studies, investigating, ace2, or, tmprss2, expressions, in, head, and, neck, tissues, the, following, outcomes, were, considered, sample, origin, animal, versus, human, detection, method, anatomical, location, and, cell, types, prisma, checklist, and, modified, population, intervention, comparison, outcome, timing, and, setting, picots, framework, were, used, to, perform, the, review, of, the, , identified, studies, , met, our, inclusion, criteria, thirteen, studies, were, conducted, during, the, severe, acute, respiratory, syndrome, a0coronavirus2, sarscov2, pandemic, ace2, and, tmprss2, were, expressed, in, oral, pharyngeal, sinusonasal, human, mucosa, the, following, cell, types, expressed, ace2, basal, apical, goblet, minor, salivary, and, endothelial, cells, tmprss2, was, found, in, goblet, and, apical, respiratory, cells, ace2, and, tmprss2, were, found, in, the, olfactory, region, especially, in, sustentacular, nonneural, and, neural, stem, cells, animal, studies, suggested, that, ace2, expression, may, vary, regarding, age, there, was, an, important, heterogeneity, between, studies, in, the, methods, used, to, detect, ace2, and, tmprss2, leading, to, a, potential, identification, bias, the, sarscov2, receptors, ace2, and, tmprss2, are, both, expressed, in, many, head, and, neck, tissues, enabling, the, viral, entry, into, the, host, anismkeywords, , ace2, a0·, tmprss2, a0·, sarscov2, a0·, covid, a0·, coronavirus, a0·, head, neckintroductionthe, renin, angiotensin, aldosterone, system, is, one, of, the, most, important, systems, regulating, the, homeostasis, of, cardiovascular, and, pulmonary, function, this, involves, many, molecules, including, angiotensin, converting, enzyme2, ace2, [], ace2, is, also, known, to, be, the, functional, receptor, of, some, coronavirus, species, as, initially, discovered, in, , during, the, severe, acute, respiratory, syndrome, coronavirus, sarscov, epidemic, [], the, current, pandemic, of, coronavirus, disease, jerome, r, lechien, and, thomas, radulesco, have, contributed, equally, to, the, paper, and, are, joint, as, cofirst, authorsjustin, michel, and, sven, saussez, equally, contributed, to, the, paper, and, are, cosenior, authorsjeromelechienumonsacbe, , , jerome, r, lechien, , extended, author, information, available, on, the, last, page, of, the, , covid19, has, brought, to, light, the, importance, of, ace2, regarding, development, of, infection, viral, spread, and, the, development, of, the, clinical, covid19, [], at, the, same, time, another, sarscov2, receptor, has, been, identified, the, transmembrane, protease, serine2, tmprss2, []ace2, and, tmprss2, tissue, expressions, are, particularly, important, to, identify, viral, entry, pathways, and, to, better, understand, the, anrelated, clinical, presentation, of, the, disease, [, ], further, evaluation, of, ace2, and, tmprss2, expression, in, ear, nose, and, throat, mucosa, is, warranted, to, shed, light, on, the, pathophysiology, of, disease, in, the, head, and, neck, []the, aim, of, this, systematic, review, is, to, summarize, the, current, data, about, the, expression, of, ace2, and, tmprss2, in, head, , neck, tissuevol01234567891, 0c, methodsthe, review, was, conducted, regarding, the, preferred, reporting, items, for, a, systematic, review, and, metaanalysis, prisma, checklist, [], a, modified, population, intervention, comparison, outcome, timing, and, setting, picots, framework, , was, , used, , to, , structure, , the, , review, , process, [], for, this, review, the, picots, structure, was, kept, but, adapted, to, experimentalbasic, research, studies, on, human, and, animal, tissuesstudiesanimal, and, human, experimental, published, studies, in, englishlanguage, peerreviewed, journals, were, considered, preprint, studies, were, also, considered, in, light, of, the, current, pandemic, and, the, significant, wealth, of, knowledge, derived, over, the, last, few, months, all, studies, where, investigators, assessed, ace2, or, tmprss2, expressions, in, head, , neck, tissues, through, immunochemistry, ihc, in, a0situ, hybridization, western, blot, rna, sequencing, rnaseq, or, reverse, transcription, polymerase, chain, reaction, rtpcr, were, evaluatedparticipants, and, a0inclusion, criteriathe, papers, had, to, include, either, human, or, animal, subjects, the, authors, extracted, substantial, information, about, the, sample, characteristics, including, species, involved, and, ace2, and, tmprss2, identification, methodoutcomesthe, primary, outcome, studied, was, tissue, expression, of, ace2, and, tmprss2, the, anatomical, location, the, types, of, cells, that, expressed, both, receptors, were, recorded, particular, attention, was, paid, to, the, method, used, to, detect, ace2tmprss2, in, tissues, additional, useful, information, such, as, viral, impact, on, the, functioning, of, the, tissuecell, that, expressed, the, receptor, or, interindividual, differences, were, also, collectedintervention, and, a0comparisonbecause, the, aim, of, the, study, was, to, investigate, the, tissue, ace2, and, tmprss2, expression, we, did, not, consider, potential, intervention, on, patient, or, animal, modelshead, and, neck, pathologytiming, and, a0settingwe, included, the, studies, where, the, receptor, analysis, was, made, on, normal, subjects, andor, infected, patientssearch, strategythe, pubmedmedline, google, scholar, medrxiv, scopus, and, cochrane, search, was, conducted, by, , independent, authors, jrl, tr, cch, gd, cmce, to, identify, papers, published, between, january, , and, april, , the, authors, screened, publications, with, database, s, and, available, full, texts, referring, to, the, condition, the, following, keywords, were, used, for, the, search, strategy, ace2², tmprss2², covid19², covid, sars, coronav, coronavirus, salivary, gland, receptor, head, neck, nasal, ear, nose, throat, ent, tissue, and, cell, the, authors, investigated, papers, for, number, of, samplesindividuals, study, type, , design, inclusion, criteria, and, ace2tmprss2, detection, outcomesresultsthe, electronic, search, identified, , papers, of, which, , met, our, inclusion, criteria, table, a0, [], a, total, of, , studies, investigated, the, expression, of, ace2, and, tmprss2, in, human, head, and, neck, tissues, while, five, papers, focused, on, mouse, and, two, on, monkey, samples, respectively, table, a0, one, study, focused, on, ace2, genetic, analysis, without, reporting, sitespecific, anatomical, expression, [], the, flow, chart, of, the, study, process, is, available, in, fig, a0, five, studies, were, preprint, [, , ]tissue, expression, in, a0humanace2, expressionace2, was, assessed, in, , studies, [], the, expression, of, ace2, was, found, in, all, mucosa, of, the, respiratory, upper, tract, including, trachea, [, , , , ], sinus, and, nasal, cavities, [, , ], among, the, respiratory, mucosa, ace2, was, expressed, in, several, types, of, cells, including, epithelial, goblet, and, endothelial, cells, [, , ], one, study, reported, that, ace2, was, expressed, on, ciliated, epithelial, cells, and, not, on, nonciliated, goblet, cells, [], butowt, et, a0al, compared, the, intensity, of, expression, of, ace2, in, the, upper, and, lower, respiratory, tract, [], they, found, that, nasal, epithelial, cells, had, lower, levels, of, ace2, expression, compared, with, epithelial, cells, of, the, lower, respiratory, tract, [], among, the, nasal, region, two, studies, investigated, the, ace2, expression, in, the, , 0chead, and, neck, pathology, table, , , , studies, reporting, ace2, or, tmprss2, head, and, neck, expressionauthorsdesignvaarala, mixed, [], studyhamming, humansamples, methodshuman, tmprss2mousehuman, ace2rnaseqace2, , tmprss2, expressionsalivary, glandstmprss2, humanoral, nasal, nasopharyngeal, epithelium, , endotheliumace2, human, all, mucosa, [], studyihchumanjia, [], studyhuman, ace2tracheal, epithelium, , endotheliumihc, , biotinylation, ace2, humanliuexperimenal, monkey, ace2, [], studyihcnaso, oro, hypopharyngeal, , tracheal, epitheliumace2, monkeyvirion, in, salivabilinska, animal, [], studybrannmixed, [], studybutowtmixed, [], studymouse, ace2, , tmprss2, olfactory, epitheliumrnaseq, rtpcrace2, sustentacular, cellsin, situ, hybridization, tmprss2, sustentacular, cellswb, , ihcmouse, ace2, , tmprss2, olfactory, epitheliumhuman, rnaseqace2, , tmprss2, mouse, nonneuronal, cellsace2, , tmprss2, human, glial, and, neuronal, stem, cellsmouse, ace2, , tmprss2, olfactory, epitheliumhuman, rnaseqace2, mouse, , human, non, neuronal, cellscaohumanhuman, ace2, gene, [], studygenetic, analyzischenhuman, [], studyhikmethuman, [], studyhuman, ace2rnaseqhuman, ace2ihcleehumanhuman, ace2tmprss2, mouse, , human, neuronal, , nonneuronal, cellsrespiratory, epitheliumace2, , tmprss2, human, lower, airway, , nasalno, localization, providedsalivary, glandsace2, humannasopharyngeal, epitheliumace2, human, no, expression, in, nasopharynxtracheal, nasal, , sinusal, epitheliumfindings, tmprss2, is, expressed, in, human, salivary, gland, tissues, ace2, was, found, in, endothelial, arteries, , veins, and, epithelial, cells, of, nasal, rhinopharyngeal, and, oral, mucosa, precisely, the, epithelium, expression, concerned, the, basal, layer, cells, ace2, was, more, expressed, on, the, apical, than, the, basolateral, surface, of, polarized, airway, epithelia, ace2, is, expressed, in, salivary, gland, ducts, of, the, pharyngeal, glands, ace2, was, expressed, in, epithelial, cells, lamina, propria, respiratory, tract, virus, was, found, in, saliva, of, infected, monkeys, ace2, , tmprss2, are, expressed, in, sustentacular, cells, of, the, olfactory, epithelium, but, notmuch, less, in, most, olfactory, receptor, neurons, expression, of, the, entry, proteins, increases, in, animals, of, old, age, in, human, ace2, , tmprss2, were, not, identified, in, purified, olfactory, neurons, ace2, was, identified, in, glial, cells, , olfactory, stem, cells, nasal, epithelial, cells, have, lower, levels, of, ace2, , tmprss2, compared, with, epithelial, cells, of, the, lower, respiratory, tract, ace2, has, nonneuronal, expression, in, olfactory, epithelium, the, expression, of, ace2, , tmprss2, mouse, were, increased, in, elderly, mouse, unique, expression, quantitative, trait, loci, variants, were, found, for, ace2, the, genotypes, of, ace2, gene, polymorphism, may, be, characterized, by, higher, expression, levels, of, ace2, in, east, asian, population, there, would, be, different, susceptibility, or, response, to, sarscov2, in, different, populations, ace2, is, expressed, in, human, granular, cells, of, salivary, glands, there, was, no, ace2, expression, in, nasopharyngeal, cells, ace2, is, expressed, in, ciliated, epithelial, cells, cilia, anelle, 0c, table, , , , continuedauthorsdesign, [], studyhumanlihikmethuman, [], study, [], studysungnak, human, [], studysamples, methodsihcace2, , tmprss2, expressionace2, humanhuman, ace2human, ace2ihcrnaseqthyroidnasopharyngeal, epitheliumace2, human, no, expression, in, nasopharynxace2, humanhuman, ace2, , tmprss2, airway, , nasal, epitheliumrnaseqace2, humantmprss2, human, subset, of, ace2, cellsxuhumanhuman, ace2, , tmprss2, oral, epithelium, [], studyrnaseqhumanxu, [], studywuhuman, [], studyhuman, ace2rnaseqhuman, ace2rnaseqace2, humanace2, humanoral, t, cells, b, cells, , fibroblastsace2, humanminor, salivary, glandsace2, humannasal, , oral, epitheliumhead, and, neck, pathologyfindings2there, was, no, ace2, expression, in, the, nonciliated, goblet, cells, ace2, expression, is, influenced, by, patient, demographics, clinical, characteristics, comorbidities, or, medication, use, the, use, of, ace, inhibitor, drugs, did, not, increase, ace2, protein, expression, ace2, is, expressed, by, thyroid, cells, there, was, no, ace2, expression, in, nasopharyngeal, cells, ace2, was, expressed, in, airway, epithelial, cells, ace2, is, more, expressed, in, nasal, epithelial, cells, compared, with, other, respiratory, cells, goblet, , ciliated, cells, tmprss2, is, only, expressed, in, a, subset, of, ace2, , cells, ace2, is, expressed, in, the, oral, cavity, epithelial, cells, ace2, expression, was, higher, in, tongue, than, buccal, and, gingival, tissues, ace2, is, expressed, in, minor, salivary, glands, ace, is, expressed, in, nasal, epithelial, cells, the, was, a, higher, virus, concentration, in, the, nasalswab, comparing, with, throatswab, which, is, attributed, to, ace2expression, in, nasal, epithelial, cells, ace2, , tmprss2, are, coexpressed, in, nasal, goblet, secretory, cellsmixedziegler, [], studyace2, angiotensin, converting, enzyme2, ihc, immunohistochemistry, rtpcr, reverse, transcription, polymerase, chain, reaction, sarscov2, severe, acute, respiratory, syndrome, a0coronavirus2, tmprss2, transmembrane, protease, serine2, wb, western, blottinghuman, ace2, , tmprss2, sinusal, , nasal, goblet, epithelial, cellsmonkey, rnaseqace2, , tmprss2, humanmucosa, of, the, olfactory, region, including, olfactory, bulb, [, ], the, ace2, receptor, was, identified, in, sustentacularnonneuronal, cells, of, the, olfactory, tissues, moreover, ace2, was, found, in, a, low, proportion, of, neuronal, stem, cells, in, the, olfactory, bulb, [, ], the, expression, of, ace2, in, olfactory, neurons, nonstem, cells, remains, uncertain, because, butowt, et, a0al, and, brann, et, a0al, observed, that, ace2, has, only, nonneuronal, expression, pattern, in, olfactory, epithelium, [, ]five, studies, investigated, ace2, expression, in, oral, and, pharyngeal, regions, including, oral, and, hypo, oro, and, nasopharyngeal, spaces, [, , ], the, study, that, explored, ace2, expression, in, human, nasopharynx, [], did, not, exhibit, significant, ace2, immunostaining, in, nasopharyngeal, cells, [], ace2, receptor, was, identified, in, oral, endothelial, [], epithelial, [, , ], and, salivary, [], cells, xu, et, a0al, found, that, ace2, was, also, expressed, in, t, and, b, cells, as, well, as, fibroblasts, of, the, oral, cavity, [], moreover, ace2, was, expressed, in, major, salivary, gland, tissues, [], and, thyroid, tissue, [], in, many, publications, authors, reported, the, type, of, cells, goblet, versus, epithelial, versus, stem, cells, that, expressed, ace2, or, tmprss2, table, a0, interestingly, xu, et, a0al, almost, as, much, ace2, expression, in, the, thyroid, as, in, the, lungs, []the, genetic, analysis, of, cao, et, a0al, reported, that, there, are, , unique, expression, quantitative, trait, loci, variants, in, the, east, asian, population, supporting, a, gene, polymorphism, and, tissuerelated, differences, between, individuals, [], 0chead, and, neck, pathology, fig, , , , flow, chart, ace2, angiotensin, converting, enzyme2, tmprss2, transmembrane, protease, serine2tmprss2, expressiontmprss2, expression, was, investigated, in, , studies, [, , , , ], similarly, to, ace2, tmprss2, was, identified, in, nasal, [, , ], and, respiratory, mucosa, cells, [], including, both, epithelial, and, goblet, cells, with, higher, expression, in, lower, airway, compared, with, upper, airway, [], moreover, tmprss2, receptor, was, identified, in, sustentacular, and, neuronal, olfactory, cells, [, ], but, not, in, olfactory, neurons, [], tmprss2, was, also, identified, in, salivary, major, gland, tissue, []ace2, , tmprss2, tissue, expression, in, a0mouse, and, a0monkeysix, studies, used, animal, models, to, assess, ace2, or, tmprss2, expressions, in, head, and, neck, tissues, [, , ], the, mouse, studies, of, butowt, et, a0al, and, bilinska, et, a0al, revealed, that, elderly, mice, had, higher, expression, of, both, ace2, and, tmprss2, in, nasal, mucosa, compared, with, younger, mice, [, ], in, olfactory, tissue, ace2, was, identified, in, sustentacularnonneuronal, and, neural, stem, cells, of, mice, [], liu, et, a0al, analyzed, ace2, expression, in, monkeys, [], , 0c, head, and, neck, pathologytable, , , , summary, of, cell, expression, of, ace2, and, tmprss2authorsbilinska, []brann, []samplesmousehuman, , mousetissueolfactoryolfactorybutowt, []human, , mousenasalolfactorychen, []hamming, []hikmet, []jia, []lee, []li, []liu, []sungnak, []vaarala, []xu, []xu, []wu, []ziegler, []humanhumanhumanhumanhumanhumanmonkeyhumanmajor, salivary, glandoral, nasal, nasopharyngealnasopharyngealtracheal, nasal, sinusalthyroidpharyngealtrachealtracheal, , nasalhuman, , mousehumanmajor, salivary, glandoralhumanhumanhuman, mouse, monkeyminor, salivary, glandnasaloralnasal, , sinusalcell, typessustentatorialsustentatorialneuronalstem, neuronalepithelialsustentatorialneuronalgranularbasal, layerendothelialepithelialapical, epithelialendothelialapical, epithelialgobletunspecifiedminor, salivary, ductalbasal, layergobletapical, epithelialunspecifiedapical, epithelialfibroblastt, and, bcellsunspecifiedunspecifiedbasal, layergobletace2natmprss2nananananananananananananananananaace2, angiotensin, converting, enzyme2, na, not, available, tmprss2, transmembrane, protease, serine2reporting, a, higher, ace2, expression, in, tracheal, naso, oro, and, hypopharyngeal, tissues, as, well, as, in, the, salivary, ducts, of, the, pharyngeal, gland, and, consequently, in, saliva, in, this, study, the, cell, expression, was, mainly, localized, in, the, lamina, propria, in, the, same, vein, vaarala, et, a0al, reported, tmprss2, expression, in, mouse, salivary, tissues, []cell, detection, methodsthe, following, methods, have, been, used, for, detecting, ace2, and, tmprss2, in, cells, of, human, and, animal, tissue, rnaseq, n, , , ihc, n, , , rtpcr, n, , , in, a0situ, hybridization, ish, n, , , and, wb, n, , , different, detection, approaches, were, used, in, , studies, [, ], one, study, reported, specific, genetic, analysis, [], there, were, significant, differences, between, studies, regarding, methods, used, while, ziegler, et, a0al, and, sungnak, et, a0al, detected, ace2, by, rnaseq, in, goblet, cells, lee, et, a0al, did, not, find, any, immunohistochemical, labeling, [, , ], however, the, results, reported, in, sustentacular, cells, agree, in, the, same, direction, whatever, the, technique, used, whether, by, rnaseq, or, by, ish, and, immunocytochemistry, [], the, discrepancies, are, rather, observed, between, studies, having, performed, immunohistochemistry, indeed, using, two, different, antibodies, hikmet, did, not, find, ace2, expression, in, nasopharynx, epithelium, whereas, others, demonstrated, the, staining, of, the, apical, surface, of, epithelia, and, ciliated, epithelial, cells, [, , ], interestingly, all, the, studies, which, carried, out, rnaseq, found, an, expression, of, ace2, or, tmprss2, at, the, epithelial, level, which, implies, that, the, technique, used, could, generate, biases, between, the, studies, [, , ], 0chead, and, neck, pathology, discussionthe, presentation, of, covid19, infection, may, be, in, several, clinical, forms, ranging, from, anosmia, in, isolation, to, severe, multiple, an, failure, and, death, the, mechanisms, underlying, the, covid19, polymorphism, are, still, unknown, to, infect, tissues, sarscov2, needs, to, entry, into, the, cells, which, is, allowed, through, ace2, and, tmprss2, receptors, [], the, identification, of, virus, receptor, expression, in, the, tissues, makes, particularly, sense, to, better, understand, the, clinical, expression, of, the, disease, this, systematic, review, sheds, light, on, many, pointsfirst, ace2, and, tmprss2, receptors, are, expressed, in, epithelial, and, nonepithelial, cells, throughout, the, head, and, neck, the, head, and, neck, expression, may, support, the, otolaryngological, clinical, picture, of, the, disease, which, was, recently, found, in, european, and, north, american, covid, patients, [, , , ], by, entering, the, body, via, the, epithelial, cells, of, the, upper, aerodigestive, tract, mucosa, the, sarscov2, virus, leads, to, an, inflammatory, reaction, and, the, development, of, otolaryngological, symptoms, nasal, entrance, of, the, virus, through, high, ace2, expression, was, supported, in, the, study, of, wu, et, a0al, who, found, a, higher, virus, concentration, in, nasal, swabs, compared, with, throat, swabs, []the, olfactory, cleft, is, a, nasal, region, that, has, drawn, the, attention, of, many, researchers, over, the, past, few, weeks, indeed, recent, data, supported, that, more, than, , of, covid19, patients, developed, subjective, olfactory, dysfunction, especially, when, patients, suffered, from, mildtomoderate, forms, of, the, disease, [, , , ], because, ace2, and, tmprss2, are, both, expressed, in, the, nasal, mucosa, of, the, olfactory, cleft, entrance, into, the, olfactory, bulb, seems, plausible, once, in, the, bulb, according, to, some, human, studies, [, ], the, virus, could, infect, cells, that, express, ace2, or, tmprss2, namely, glial, and, neuronal, stem, cells, fig, a0integrating, the, molecular, clinical, and, radiological, characteristics, of, sarscov2, olfactory, loss, may, shed, light, about, its, pathophysiological, process, taking, into, account, that, the, loss, is, often, temporary, sarscov2, may, primarily, infect, the, sustentacular, cells, supporting, the, olfactory, sensory, neurons, this, infection, may, cause, rapid, disruption, of, the, olfactory, epithelium, structure, and, function, with, a, possible, inflammatory, response, inducing, sudden, onset, smell, loss, this, inflammation, is, observed, in, a, minority, of, patient, with, congested, olfactory, cleft, who, underwent, ct, scan, [, , , ]ace2, and, tmprss2, are, also, found, in, horizontal, basal, olfactory, stem, cells, located, in, the, basal, layer, they, are, less, exposed, to, the, external, environment, thus, less, likely, to, be, infected, in, first, line, the, loss, would, have, been, more, fig, , , , epithelium, of, olfactory, cleft, the, figure, summarizes, the, olfactory, cleft, epithelium, 0c, head, and, neck, pathologyprogressive, however, once, infected, they, might, slow, down, recovery, time, because, horizontal, basal, cells, give, rise, to, many, cell, type, in, the, olfactory, epithelium, they, may, also, contribute, to, virus, spread, to, the, olfactory, bulb, vascular, pericytes, magnetic, resonance, imaging, mri, studies, of, the, olfactory, bulb, [, ], in, which, ace2, are, only, expressed, in, vascular, pericytes, but, not, in, neurons, may, show, inflammatory, signs, suggesting, that, the, infection, process, can, extend, more, centrally, and, promote, inflammatory, response, [], inflammatory, causes, are, often, quickly, reversible, for, example, after, a, oneweek, trial, of, high, dose, of, corticosteroids, or, simply, days, after, the, resolution, of, the, viral, infection, suggesting, that, the, olfactory, neurons, and, bulbs, are, still, somewhat, intact, this, seems, to, be, the, case, for, a, majority, of, patients, in, contrast, with, more, sustained, destruction, of, neuronal, olfactory, structures, the, recovery, time, is, much, longer, and, may, take, , a0years, given, the, slow, neuroregeneration, process, [, ]in, this, systematic, review, we, found, that, three, studies, reported, high, ace2, expression, in, major, or, minor, salivary, gland, human, tissues, [, , ], these, data, corroborate, the, literature, findings, that, reported, a, salivary, pattern, of, sarscov2, and, related, parotitis, [, ], moreover, the, virus, spread, into, the, salivary, gland, tissues, allows, us, a, better, understanding, the, mechanisms, underlying, salivary, transmission, interestingly, in, , liu, et, a0al, observed, that, monkeys, infected, by, sarscov, had, a, salivary, viral, spread, which, was, associated, with, a, salivary, virion, excretion, [], these, data, support, the, need, to, conduct, future, studies, investigating, the, presence, of, sarscov2, in, the, saliva, of, infected, human, and, to, corroborate, the, saliva, findings, with, the, ace2, salivary, gland, expressionthe, head, and, neck, expression, of, ace2, and, tmprss2, and, the, related, otolaryngological, symptom, pattern, seems, obvious, but, could, vary, across, individuals, and, populations, in, support, of, this, lee, et, a0al, observed, that, ace2, expression, is, influenced, by, patient, demographics, clinical, characteristics, comorbidities, and, medication, [], as, reported, in, the, genetic, analysis, of, cao, et, a0al, there, would, be, different, susceptibilities, or, responses, to, sarscov2, in, different, populations, [], the, polymorphism, of, ace2, and, tmprss2, expression, could, explain, the, clinical, differences, between, individuals, indeed, many, physicians, reported, in, clinical, and, epidemiological, studies, different, clinical, presentation, of, the, disease, [, ], which, could, be, associated, with, virus, mutations, [, , ], the, virus, mutations, and, the, related, impact, on, receptor, binding, and, infectivity, is, another, point, that, has, to, be, considered, in, future, studies, otherwise, according, to, the, bgee, database, https, bgee, expression, of, ace2, and, tmprss2, evaluated, in, murine, models, may, increase, with, age, these, findings, have, to, be, confirmed, in, humans, but, could, explain, more, severe, clinical, pictures, in, the, elderlythe, present, study, has, several, limitations, first, the, heterogeneity, between, studies, about, the, detection, method, may, lead, to, detection, bias, as, some, approaches, are, more, sensitive, than, others, some, studies, interrogate, gene, expression, at, mrna, level, and, others, at, protein, levels, both, types, of, analysis, having, their, advantages, and, limitations, compared, to, transcriptomic, analyzes, immunohistochemistry, brings, additional, important, spatial, information, in, tissue, samples, but, recently, sorokin, et, a0al, demonstrated, high, and, statistically, significant, correlations, between, the, rna, sequencing, and, immunohistochemical, measurements, [], interestingly, they, highlighted, the, complementarity, of, both, techniques, for, measuring, cancer, biomarkers, in, ffpe, samples, however, differences, observed, across, ihc, studies, suggest, the, involvement, of, many, parameters, the, antibody, specificity, is, a, big, challenge, to, ensure, reproducibility, of, antibodybased, studies, and, given, the, high, homology, between, ace1, and, ace2, cautions, must, be, taken, regarding, antibody, selection, besides, a, report, from, the, international, working, group, for, antibody, validation, iwgav, proposed, five, scientific, approaches, to, validate, antibody, specificity, [], then, such, strategies, must, be, considered, in, future, investigations, to, confirm, the, published, observations, in, addition, it, seems, essential, to, enlarge, and, diversify, patient, cohorts, and, to, combine, transcriptomic, and, proteomic, strategies, as, well, as, colocalize, different, markers, of, sarscov2, such, as, ace2, and, tmprss2, to, provide, an, accurate, representation, of, ace2, expression, through, all, head, and, neck, areas, of, the, whole, populationsecond, the, majority, of, studies, that, were, conducted, during, the, sarscov2, pandemic, did, not, consider, many, demographic, and, clinical, factors, such, as, the, age, of, patients, from, who, the, tissues, were, extracted, or, the, use, of, ace, inhibitor, medications, among, others, third, some, otolaryngological, regions, remain, uninvestigated, such, as, the, vocal, folds, the, investigation, of, these, remaining, regions, may, shed, further, light, on, some, recently, reported, unusual, clinical, phenomena, such, as, severe, dysphonia, []conclusionace2, and, tmprss2, are, both, expressed, in, head, and, neck, tissues, which, may, explain, the, otolaryngological, clinical, pattern, of, the, disease, and, the, entry, of, sarscov2, into, the, host, anism, future, studies, considering, demographical, and, clinical, characteristics, of, patients, from, who, the, tissues, are, extracted, are, needed, to, better, understand, the, cell, entry, mechanisms, of, sarscov2author, contributions, , jr, tr, ss, jm, design, acquisition, of, data, data, analysis, , interpretation, drafting, final, approval, and, accountability, , 0chead, and, neck, pathology, for, the, work, final, approval, of, the, version, to, be, published, agreement, to, be, accountable, for, all, aspects, of, the, work, in, ensuring, that, questions, related, to, the, accuracy, or, integrity, of, any, part, of, the, work, are, appropriately, investigated, and, resolved, cch, cmce, mrb, ig, design, data, analysis, , interpretation, revising, the, manuscript, for, important, intellectual, content, final, approval, of, the, version, to, be, published, final, approval, and, accountability, for, the, work, final, approval, of, the, version, to, be, published, agreement, to, be, accountable, for, all, aspects, of, the, work, in, ensuring, that, questions, related, to, the, accuracy, or, integrity, of, any, part, of, the, work, are, appropriately, investigated, and, resolved, ls, sh, gc, gd, jh, lv, gr, design, acquisition, of, data, data, analysis, , interpretation, drafting, some, parts, of, the, manuscript, final, approval, of, the, version, to, be, published, final, approval, and, accountability, for, the, work, final, approval, of, the, version, to, be, published, agreement, to, be, accountable, for, all, aspects, of, the, work, in, ensuring, that, questions, related, to, the, accuracy, or, integrity, of, any, part, of, the, work, are, appropriately, investigated, and, resolvedcompliance, with, ethical, standards, conflict, of, interest, , the, authors, declare, that, they, have, no, conflict, of, interestreferences, , , , crackower, ma, sarao, r, oudit, gy, et, a0al, angiotensinconverting, enzyme, , is, an, essential, regulator, of, heart, function, nature, , , , , li, w, moore, mj, vasilieva, n, sui, j, wong, sk, berne, ma, somasundaran, , m, , sullivan, , jl, , luzuriaga, , k, , greenough, tc, , choe, , h, , farzan, , m, , angiotensinconverting, , enzyme, , , is, , a, , functional, , receptor, , for, , the, , sars, , coronavirus, , nature, , , , , wang, z, xu, x, scrnaseq, profiling, of, human, testes, reveals, the, presence, of, the, ace2, receptor, a, target, for, sarscov2, infection, in, spermatogonia, leydig, and, sertoli, cells, cells, , https, doi103390cells, , , , , , shang, j, wan, y, luo, c, ye, g, geng, q, auerbach, a, li, f, cell, entry, mechanisms, of, sarscov2, proc, natl, acad, sci, usa, , https, doi101073pnas20031, , , , , , vaira, la, hopkins, c, salzano, g, et, a0al, olfactory, and, gustatory, function, impairment, in, covid19, patients, an, italian, objective, multicenterstudy, head, neck, https, doi101002hed26269, , , , , lechien, jr, chiesaestomba, cm, place, s, van, laethem, y, cabaraux, p, mat, q, huet, k, plzak, j, horoi, m, hans, s, barillari, mr, cammaroto, g, fakhry, n, martiny, d, ayad, t, jouffe, l, hopkins, c, saussez, s, covid19, task, force, of, yoifos, clinical, and, epidemiological, characteristics, of, , european, patients, with, mildtomoderate, coronavirus, disease, , j, intern, med, , https, doi101111joim13089, , , , , lechien, jr, chiesaestomba, cm, de, siati, dr, et, a0al, olfactory, and, gustatory, dysfunctions, as, a, clinical, presentation, of, mildtomoderate, forms, of, the, coronavirus, disease, covid19, a, multicenter, european, study, eur, arch, otorhinolaryngol, , https, doi101007s0040, , , , , , mcinnes, mdf, moher, d, thombs, bd, et, a0al, preferred, reporting, items, for, a, systematic, review, and, metaanalysis, of, diagnostic, test, accuracy, studies, the, prismadta, statement, jama, , https, doi101001jama201719163, , , , , thompson, m, tiwari, a, fu, r, moe, e, buckley, di, a, framework, to, facilitate, the, use, of, systematic, reviews, and, metaanalyses, in, the, design, of, primary, research, studies, rockville, agency, for, healthcare, research, and, quality, us, , , , vaarala, mh, porvari, ks, kellokumpu, s, kyll¶nen, ap, vihko, pt, expression, of, transmembrane, serine, protease, tmprss2, in, mouse, and, human, tissues, j, pathol, , https, doi10100210969896200099999999, , , hamming, i, timens, w, bulthuis, ml, lely, at, navis, g, van, goor, h, tissue, distribution, of, ace2, protein, the, functional, receptor, for, sars, coronavirus, a, first, step, in, understanding, sars, pathogenesis, j, pathol, , https, doi101002path1570, , , jia, hp, look, dc, shi, l, et, a0al, ace2, receptor, expression, and, , severe, , acute, , respiratory, , syndrome, , coronavirus, , infection, , depend, , on, , differentiation, , of, , human, , airway, , epithelia, j, , virol, , , , https, doi101128jvi792314614, , , , , liu, l, wei, q, alvarez, x, et, a0al, epithelial, cells, lining, salivary, gland, ducts, are, early, target, cells, of, severe, acute, respiratory, syndrome, coronavirus, infection, in, the, upper, respiratory, tracts, of, rhesus, macaques, j, virol, , https, doi101128jvi02292, , , , bilinska, k, jakubowska, p, von, bartheld, cs, butowt, r, expression, of, the, sarscov2, entry, proteins, ace2, and, tmprss2, in, cells, of, the, olfactory, epithelium, identification, of, cell, types, and, trends, with, age, acs, chem, neurosci, , https, doi101021acsch, emneu, ro0c002, , , , brann, dh, tsukahara, t, weinreb, c, et, a0al, nonneuronal, expression, of, sarscov2, entry, genes, in, the, olfactory, system, suggests, mechanisms, underlying, covid19associated, anosmia, preprint, https, doi1011012020032500908, , , , butowt, r, bilinska, k, sarscov2, olfaction, brain, infection, and, the, urgent, need, for, clinical, samples, allowing, earlier, virus, detection, acs, chem, neurosci, , https, doi101021acsch, emneu, ro0c001, , , , cao, y, li, l, feng, z, wan, s, huang, p, sun, x, wen, f, huang, x, ning, g, wang, w, comparative, genetic, analysis, of, the, novel, coronavirus, 2019ncovsarscov2, receptor, ace2, in, different, populations, cell, discov, , https, doi101038s4142, , , , chen, r, wang, k, yu, j, et, a0al, the, spatial, and, celltype, distribution, of, sarscov2, receptor, ace2, in, human, and, mouse, brain, preprint, https, doi1011012020040703065, , , , hikmet, f, mar, l, uhln, m, lindskog, c, the, protein, expression, profile, of, ace2, in, human, tissues, biorxiv, , https, doi1011012020033101604, , , , lee, it, nakayama, t, wu, ct, et, a0al, robust, ace2, protein, expression, localizes, to, the, motile, cilia, of, the, respiratory, tract, epithelia, and, is, not, increased, by, ace, inhibitors, or, angiotensin, receptor, blockers, preprint, https, doi1011012020050820092, , , , li, my, li, l, zhang, y, wang, xs, expression, of, the, sarscov2, cell, receptor, gene, ace2, in, a, wide, variety, of, human, tissues, infect, dis, poverty, , https, doi101186s4024, , x, , , sungnak, w, huang, n, bcavin, c, et, a0al, sarscov2, entry, factors, are, highly, expressed, in, nasal, epithelial, cells, together, with, innate, immune, genes, nat, med, , https, doi101038s4159, , , , xu, h, zhong, l, deng, j, peng, j, dan, h, zeng, x, li, t, chen, q, high, expression, of, ace2, receptor, of, 2019ncov, on, the, epithelial, cells, of, oral, mucosa, int, j, oral, sci, , https, doi101038s4136, 80200074x, , , xu, j, li, y, gan, f, du, y, yao, y, salivary, glands, potential, reservoirs, for, covid19, asymptomatic, infection, j, dent, res, , https, doi10117700220, , , , , , wu, c, zheng, s, chen, y, zheng, m, singlecell, rna, expression, profiling, of, ace2, the, putative, receptor, of, wuhan, 2019ncov, in, the, nasal, tissue, https, doi1011012020021120022, , 0c, head, and, neck, pathology, , , ziegler, cgk, allon, sj, nyquist, sk, et, a0al, sarscov2, receptor, ace2, is, an, interferonstimulated, gene, in, human, airway, epithelial, cells, and, is, detected, in, specific, cell, subsets, across, tissues, cell, 2020s0092, https, doi101016jcell202004035, , , kaye, r, chang, cwd, kazahaya, k, brereton, j, denneny, jc, iii, covid19, anosmia, reporting, tool, initial, findings, otolaryngol, head, neck, surg, , https, doi10117701945, , , , , , lechien, jr, chiesaestomba, cm, hans, s, barillari, mr, jouffe, l, saussez, s, loss, of, smell, and, taste, in, , european, patients, with, mild, to, moderate, covid19, ann, intern, med, , https, doi107326m202428, , , vaira, la, salzano, g, deiana, g, de, riu, g, anosmia, and, ageusia, common, findings, in, covid19, patients, laryngoscope, , https, doi101002lary28692, , , , spinato, g, fabbris, c, polesel, j, cazzador, d, borsetto, d]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |[neck, tissues, a0systematic, reviewjerome, a0r, a0lechien1234, stphane, a0hans13, a0·, maria, a0r, a0barillari18, a0·, giovanni, a0cammaroto19, a0·, graldine, a0descamps12, a0·, julien, a0hsieh110, a0·, luigi, a0vaira111, a0·, giacomo, a0de, a0riu111, a0·, leigh, a0sowerby112, a0·, isabelle, a0gengler113, a0·, justin, a0michel15, a0·, sven, a0saussez124, a0·, thomas, a0radulesco15, a0·, christian, a0calvohenriquez16, a0·, carlos, a0m, a0chiesaestomba17, a0·, received, , july, , , accepted, , august, , , springer, sciencebusiness, media, llc, part, springer, nature, abstractto, review, data, regarding, expression, angiotensin, converting, enzyme2, ace2, transmembrane, protease, serine2, tmprss2, head, neck, tissue, scopus, cochrane, library, medrxiv, google, scholar, pubmedmedline, searched, four, independent, investigators, studies, investigating, ace2, tmprss2, expressions, head, neck, tissues, following, outcomes, considered, sample, origin, animal, versus, human, detection, method, anatomical, location, cell, types, prisma, checklist, modified, population, intervention, comparison, outcome, timing, setting, picots, framework, used, perform, review, , identified, studies, , met, inclusion, criteria, thirteen, studies, conducted, severe, acute, respiratory, syndrome, a0coronavirus2, sarscov2, pandemic, ace2, tmprss2, expressed, oral, pharyngeal, sinusonasal, human, mucosa, following, cell, types, expressed, ace2, basal, apical, goblet, minor, salivary, endothelial, cells, tmprss2, found, goblet, apical, respiratory, cells, ace2, tmprss2, found, olfactory, region, especially, sustentacular, nonneural, neural, stem, cells, animal, studies, suggested, ace2, expression, may, vary, regarding, age, important, heterogeneity, studies, methods, used, detect, ace2, tmprss2, leading, potential, identification, bias, sarscov2, receptors, ace2, tmprss2, expressed, many, head, neck, tissues, enabling, viral, entry, host, anismkeywords, , ace2, a0·, tmprss2, a0·, sarscov2, a0·, covid, a0·, coronavirus, a0·, head, neckintroductionthe, renin, angiotensin, aldosterone, system, one, important, systems, regulating, homeostasis, cardiovascular, pulmonary, function, involves, many, molecules, including, angiotensin, converting, enzyme2, ace2, [], ace2, also, known, functional, receptor, coronavirus, species, initially, discovered, , severe, acute, respiratory, syndrome, coronavirus, sarscov, epidemic, [], current, pandemic, coronavirus, disease, jerome, r, lechien, thomas, radulesco, contributed, equally, paper, joint, cofirst, authorsjustin, michel, sven, saussez, equally, contributed, paper, cosenior, authorsjeromelechienumonsacbe, , , jerome, r, lechien, , extended, author, information, available, last, page, , covid19, brought, light, importance, ace2, regarding, development, infection, viral, spread, development, clinical, covid19, [], time, another, sarscov2, receptor, identified, transmembrane, protease, serine2, tmprss2, []ace2, tmprss2, tissue, expressions, particularly, important, identify, viral, entry, pathways, better, understand, anrelated, clinical, presentation, disease, [, ], evaluation, ace2, tmprss2, expression, ear, nose, throat, mucosa, warranted, shed, light, pathophysiology, disease, head, neck, []the, aim, systematic, review, summarize, current, data, expression, ace2, tmprss2, head, , neck, tissuevol01234567891, 0c, methodsthe, review, conducted, regarding, preferred, reporting, items, systematic, review, metaanalysis, prisma, checklist, [], modified, population, intervention, comparison, outcome, timing, setting, picots, framework, , , used, , , structure, , , review, , process, [], review, picots, structure, kept, adapted, experimentalbasic, research, studies, human, animal, tissuesstudiesanimal, human, experimental, published, studies, englishlanguage, peerreviewed, journals, considered, preprint, studies, also, considered, light, current, pandemic, significant, wealth, knowledge, derived, last, months, studies, investigators, assessed, ace2, tmprss2, expressions, head, , neck, tissues, immunochemistry, ihc, a0situ, hybridization, western, blot, rna, sequencing, rnaseq, reverse, transcription, polymerase, chain, reaction, rtpcr, evaluatedparticipants, a0inclusion, criteriathe, papers, include, either, human, animal, subjects, authors, extracted, substantial, information, sample, characteristics, including, species, involved, ace2, tmprss2, identification, methodoutcomesthe, primary, outcome, studied, tissue, expression, ace2, tmprss2, anatomical, location, types, cells, expressed, receptors, recorded, particular, attention, paid, method, used, detect, ace2tmprss2, tissues, additional, useful, information, viral, impact, functioning, tissuecell, expressed, receptor, interindividual, differences, also, collectedintervention, a0comparisonbecause, aim, study, investigate, tissue, ace2, tmprss2, expression, consider, potential, intervention, patient, animal, modelshead, neck, pathologytiming, a0settingwe, included, studies, receptor, analysis, made, normal, subjects, andor, infected, patientssearch, strategythe, pubmedmedline, google, scholar, medrxiv, scopus, cochrane, search, conducted, , independent, authors, jrl, tr, cch, gd, cmce, identify, papers, published, january, , april, , authors, screened, publications, database, available, full, texts, referring, condition, following, keywords, used, search, strategy, ace2², tmprss2², covid19², covid, sars, coronav, coronavirus, salivary, gland, receptor, head, neck, nasal, ear, nose, throat, ent, tissue, cell, authors, investigated, papers, number, samplesindividuals, study, type, , design, inclusion, criteria, ace2tmprss2, detection, outcomesresultsthe, electronic, search, identified, , papers, , met, inclusion, criteria, table, a0, [], total, , studies, investigated, expression, ace2, tmprss2, human, head, neck, tissues, five, papers, focused, mouse, two, monkey, samples, respectively, table, a0, one, study, focused, ace2, genetic, analysis, without, reporting, sitespecific, anatomical, expression, [], flow, chart, study, process, available, fig, a0, five, studies, preprint, [, , ]tissue, expression, a0humanace2, expressionace2, assessed, , studies, [], expression, ace2, found, mucosa, respiratory, upper, tract, including, trachea, [, , , , ], sinus, nasal, cavities, [, , ], among, respiratory, mucosa, ace2, expressed, several, types, cells, including, epithelial, goblet, endothelial, cells, [, , ], one, study, reported, ace2, expressed, ciliated, epithelial, cells, nonciliated, goblet, cells, [], butowt, et, a0al, compared, intensity, expression, ace2, upper, lower, respiratory, tract, [], found, nasal, epithelial, cells, lower, levels, ace2, expression, compared, epithelial, cells, lower, respiratory, tract, [], among, nasal, region, two, studies, investigated, ace2, expression, , 0chead, neck, pathology, table, , , , studies, reporting, ace2, tmprss2, head, neck, expressionauthorsdesignvaarala, mixed, [], studyhamming, humansamples, methodshuman, tmprss2mousehuman, ace2rnaseqace2, , tmprss2, expressionsalivary, glandstmprss2, humanoral, nasal, nasopharyngeal, epithelium, , endotheliumace2, human, mucosa, [], studyihchumanjia, [], studyhuman, ace2tracheal, epithelium, , endotheliumihc, , biotinylation, ace2, humanliuexperimenal, monkey, ace2, [], studyihcnaso, oro, hypopharyngeal, , tracheal, epitheliumace2, monkeyvirion, salivabilinska, animal, [], studybrannmixed, [], studybutowtmixed, [], studymouse, ace2, , tmprss2, olfactory, epitheliumrnaseq, rtpcrace2, sustentacular, cellsin, situ, hybridization, tmprss2, sustentacular, cellswb, , ihcmouse, ace2, , tmprss2, olfactory, epitheliumhuman, rnaseqace2, , tmprss2, mouse, nonneuronal, cellsace2, , tmprss2, human, glial, neuronal, stem, cellsmouse, ace2, , tmprss2, olfactory, epitheliumhuman, rnaseqace2, mouse, , human, non, neuronal, cellscaohumanhuman, ace2, gene, [], studygenetic, analyzischenhuman, [], studyhikmethuman, [], studyhuman, ace2rnaseqhuman, ace2ihcleehumanhuman, ace2tmprss2, mouse, , human, neuronal, , nonneuronal, cellsrespiratory, epitheliumace2, , tmprss2, human, lower, airway, , nasalno, localization, providedsalivary, glandsace2, humannasopharyngeal, epitheliumace2, human, expression, nasopharynxtracheal, nasal, , sinusal, epitheliumfindings, tmprss2, expressed, human, salivary, gland, tissues, ace2, found, endothelial, arteries, , veins, epithelial, cells, nasal, rhinopharyngeal, oral, mucosa, precisely, epithelium, expression, concerned, basal, layer, cells, ace2, expressed, apical, basolateral, surface, polarized, airway, epithelia, ace2, expressed, salivary, gland, ducts, pharyngeal, glands, ace2, expressed, epithelial, cells, lamina, propria, respiratory, tract, virus, found, saliva, infected, monkeys, ace2, , tmprss2, expressed, sustentacular, cells, olfactory, epithelium, notmuch, less, olfactory, receptor, neurons, expression, entry, proteins, increases, animals, old, age, human, ace2, , tmprss2, identified, purified, olfactory, neurons, ace2, identified, glial, cells, , olfactory, stem, cells, nasal, epithelial, cells, lower, levels, ace2, , tmprss2, compared, epithelial, cells, lower, respiratory, tract, ace2, nonneuronal, expression, olfactory, epithelium, expression, ace2, , tmprss2, mouse, increased, elderly, mouse, unique, expression, quantitative, trait, loci, variants, found, ace2, genotypes, ace2, gene, polymorphism, may, characterized, higher, expression, levels, ace2, east, asian, population, different, susceptibility, response, sarscov2, different, populations, ace2, expressed, human, granular, cells, salivary, glands, ace2, expression, nasopharyngeal, cells, ace2, expressed, ciliated, epithelial, cells, cilia, anelle, 0c, table, , , , continuedauthorsdesign, [], studyhumanlihikmethuman, [], study, [], studysungnak, human, [], studysamples, methodsihcace2, , tmprss2, expressionace2, humanhuman, ace2human, ace2ihcrnaseqthyroidnasopharyngeal, epitheliumace2, human, expression, nasopharynxace2, humanhuman, ace2, , tmprss2, airway, , nasal, epitheliumrnaseqace2, humantmprss2, human, subset, ace2, cellsxuhumanhuman, ace2, , tmprss2, oral, epithelium, [], studyrnaseqhumanxu, [], studywuhuman, [], studyhuman, ace2rnaseqhuman, ace2rnaseqace2, humanace2, humanoral, cells, b, cells, , fibroblastsace2, humanminor, salivary, glandsace2, humannasal, , oral, epitheliumhead, neck, pathologyfindings2there, ace2, expression, nonciliated, goblet, cells, ace2, expression, influenced, patient, demographics, clinical, characteristics, comorbidities, medication, use, use, ace, inhibitor, drugs, increase, ace2, protein, expression, ace2, expressed, thyroid, cells, ace2, expression, nasopharyngeal, cells, ace2, expressed, airway, epithelial, cells, ace2, expressed, nasal, epithelial, cells, compared, respiratory, cells, goblet, , ciliated, cells, tmprss2, expressed, subset, ace2, , cells, ace2, expressed, oral, cavity, epithelial, cells, ace2, expression, higher, tongue, buccal, gingival, tissues, ace2, expressed, minor, salivary, glands, ace, expressed, nasal, epithelial, cells, higher, virus, concentration, nasalswab, comparing, throatswab, attributed, ace2expression, nasal, epithelial, cells, ace2, , tmprss2, coexpressed, nasal, goblet, secretory, cellsmixedziegler, [], studyace2, angiotensin, converting, enzyme2, ihc, immunohistochemistry, rtpcr, reverse, transcription, polymerase, chain, reaction, sarscov2, severe, acute, respiratory, syndrome, a0coronavirus2, tmprss2, transmembrane, protease, serine2, wb, western, blottinghuman, ace2, , tmprss2, sinusal, , nasal, goblet, epithelial, cellsmonkey, rnaseqace2, , tmprss2, humanmucosa, olfactory, region, including, olfactory, bulb, [, ], ace2, receptor, identified, sustentacularnonneuronal, cells, olfactory, tissues, moreover, ace2, found, low, proportion, neuronal, stem, cells, olfactory, bulb, [, ], expression, ace2, olfactory, neurons, nonstem, cells, remains, uncertain, butowt, et, a0al, brann, et, a0al, observed, ace2, nonneuronal, expression, pattern, olfactory, epithelium, [, ]five, studies, investigated, ace2, expression, oral, pharyngeal, regions, including, oral, hypo, oro, nasopharyngeal, spaces, [, , ], study, explored, ace2, expression, human, nasopharynx, [], exhibit, significant, ace2, immunostaining, nasopharyngeal, cells, [], ace2, receptor, identified, oral, endothelial, [], epithelial, [, , ], salivary, [], cells, xu, et, a0al, found, ace2, also, expressed, b, cells, well, fibroblasts, oral, cavity, [], moreover, ace2, expressed, major, salivary, gland, tissues, [], thyroid, tissue, [], many, publications, authors, reported, type, cells, goblet, versus, epithelial, versus, stem, cells, expressed, ace2, tmprss2, table, a0, interestingly, xu, et, a0al, almost, much, ace2, expression, thyroid, lungs, []the, genetic, analysis, cao, et, a0al, reported, , unique, expression, quantitative, trait, loci, variants, east, asian, population, supporting, gene, polymorphism, tissuerelated, differences, individuals, [], 0chead, neck, pathology, fig, , , , flow, chart, ace2, angiotensin, converting, enzyme2, tmprss2, transmembrane, protease, serine2tmprss2, expressiontmprss2, expression, investigated, , studies, [, , , , ], similarly, ace2, tmprss2, identified, nasal, [, , ], respiratory, mucosa, cells, [], including, epithelial, goblet, cells, higher, expression, lower, airway, compared, upper, airway, [], moreover, tmprss2, receptor, identified, sustentacular, neuronal, olfactory, cells, [, ], olfactory, neurons, [], tmprss2, also, identified, salivary, major, gland, tissue, []ace2, , tmprss2, tissue, expression, a0mouse, a0monkeysix, studies, used, animal, models, assess, ace2, tmprss2, expressions, head, neck, tissues, [, , ], mouse, studies, butowt, et, a0al, bilinska, et, a0al, revealed, elderly, mice, higher, expression, ace2, tmprss2, nasal, mucosa, compared, younger, mice, [, ], olfactory, tissue, ace2, identified, sustentacularnonneuronal, neural, stem, cells, mice, [], liu, et, a0al, analyzed, ace2, expression, monkeys, [], , 0c, head, neck, pathologytable, , , , summary, cell, expression, ace2, tmprss2authorsbilinska, []brann, []samplesmousehuman, , mousetissueolfactoryolfactorybutowt, []human, , mousenasalolfactorychen, []hamming, []hikmet, []jia, []lee, []li, []liu, []sungnak, []vaarala, []xu, []xu, []wu, []ziegler, []humanhumanhumanhumanhumanhumanmonkeyhumanmajor, salivary, glandoral, nasal, nasopharyngealnasopharyngealtracheal, nasal, sinusalthyroidpharyngealtrachealtracheal, , nasalhuman, , mousehumanmajor, salivary, glandoralhumanhumanhuman, mouse, monkeyminor, salivary, glandnasaloralnasal, , sinusalcell, typessustentatorialsustentatorialneuronalstem, neuronalepithelialsustentatorialneuronalgranularbasal, layerendothelialepithelialapical, epithelialendothelialapical, epithelialgobletunspecifiedminor, salivary, ductalbasal, layergobletapical, epithelialunspecifiedapical, epithelialfibroblastt, bcellsunspecifiedunspecifiedbasal, layergobletace2natmprss2nananananananananananananananananaace2, angiotensin, converting, enzyme2, na, available, tmprss2, transmembrane, protease, serine2reporting, higher, ace2, expression, tracheal, naso, oro, hypopharyngeal, tissues, well, salivary, ducts, pharyngeal, gland, consequently, saliva, study, cell, expression, mainly, localized, lamina, propria, vein, vaarala, et, a0al, reported, tmprss2, expression, mouse, salivary, tissues, []cell, detection, methodsthe, following, methods, used, detecting, ace2, tmprss2, cells, human, animal, tissue, rnaseq, n, , , ihc, n, , , rtpcr, n, , , a0situ, hybridization, ish, n, , , wb, n, , , different, detection, approaches, used, , studies, [, ], one, study, reported, specific, genetic, analysis, [], significant, differences, studies, regarding, methods, used, ziegler, et, a0al, sungnak, et, a0al, detected, ace2, rnaseq, goblet, cells, lee, et, a0al, find, immunohistochemical, labeling, [, , ], however, results, reported, sustentacular, cells, agree, direction, whatever, technique, used, whether, rnaseq, ish, immunocytochemistry, [], discrepancies, rather, observed, studies, performed, immunohistochemistry, indeed, using, two, different, antibodies, hikmet, find, ace2, expression, nasopharynx, epithelium, whereas, others, demonstrated, staining, apical, surface, epithelia, ciliated, epithelial, cells, [, , ], interestingly, studies, carried, rnaseq, found, expression, ace2, tmprss2, epithelial, level, implies, technique, used, generate, biases, studies, [, , ], 0chead, neck, pathology, discussionthe, presentation, covid19, infection, may, several, clinical, forms, ranging, anosmia, isolation, severe, multiple, failure, death, mechanisms, underlying, covid19, polymorphism, still, unknown, infect, tissues, sarscov2, needs, entry, cells, allowed, ace2, tmprss2, receptors, [], identification, virus, receptor, expression, tissues, makes, particularly, sense, better, understand, clinical, expression, disease, systematic, review, sheds, light, many, pointsfirst, ace2, tmprss2, receptors, expressed, epithelial, nonepithelial, cells, throughout, head, neck, head, neck, expression, may, support, otolaryngological, clinical, picture, disease, recently, found, european, north, american, covid, patients, [, , , ], entering, body, via, epithelial, cells, upper, aerodigestive, tract, mucosa, sarscov2, virus, leads, inflammatory, reaction, development, otolaryngological, symptoms, nasal, entrance, virus, high, ace2, expression, supported, study, wu, et, a0al, found, higher, virus, concentration, nasal, swabs, compared, throat, swabs, []the, olfactory, cleft, nasal, region, drawn, attention, many, researchers, past, weeks, indeed, recent, data, supported, , covid19, patients, developed, subjective, olfactory, dysfunction, especially, patients, suffered, mildtomoderate, forms, disease, [, , , ], ace2, tmprss2, expressed, nasal, mucosa, olfactory, cleft, entrance, olfactory, bulb, seems, plausible, bulb, according, human, studies, [, ], virus, infect, cells, express, ace2, tmprss2, namely, glial, neuronal, stem, cells, fig, a0integrating, molecular, clinical, radiological, characteristics, sarscov2, olfactory, loss, may, shed, light, pathophysiological, process, taking, account, loss, often, temporary, sarscov2, may, primarily, infect, sustentacular, cells, supporting, olfactory, sensory, neurons, infection, may, cause, rapid, disruption, olfactory, epithelium, structure, function, possible, inflammatory, response, inducing, sudden, onset, smell, loss, inflammation, observed, minority, patient, congested, olfactory, cleft, underwent, ct, scan, [, , , ]ace2, tmprss2, also, found, horizontal, basal, olfactory, stem, cells, located, basal, layer, less, exposed, external, environment, thus, less, likely, infected, first, line, loss, fig, , , , epithelium, olfactory, cleft, figure, summarizes, olfactory, cleft, epithelium, 0c, head, neck, pathologyprogressive, however, infected, might, slow, recovery, time, horizontal, basal, cells, give, rise, many, cell, type, olfactory, epithelium, may, also, contribute, virus, spread, olfactory, bulb, vascular, pericytes, magnetic, resonance, imaging, mri, studies, olfactory, bulb, [, ], ace2, expressed, vascular, pericytes, neurons, may, show, inflammatory, signs, suggesting, infection, process, extend, centrally, promote, inflammatory, response, [], inflammatory, causes, often, quickly, reversible, example, oneweek, trial, high, dose, corticosteroids, simply, days, resolution, viral, infection, suggesting, olfactory, neurons, bulbs, still, somewhat, intact, seems, case, majority, patients, contrast, sustained, destruction, neuronal, olfactory, structures, recovery, time, much, longer, may, take, , a0years, given, slow, neuroregeneration, process, [, ]in, systematic, review, found, three, studies, reported, high, ace2, expression, major, minor, salivary, gland, human, tissues, [, , ], data, corroborate, literature, findings, reported, salivary, pattern, sarscov2, related, parotitis, [, ], moreover, virus, spread, salivary, gland, tissues, allows, us, better, understanding, mechanisms, underlying, salivary, transmission, interestingly, , liu, et, a0al, observed, monkeys, infected, sarscov, salivary, viral, spread, associated, salivary, virion, excretion, [], data, support, need, conduct, future, studies, investigating, presence, sarscov2, saliva, infected, human, corroborate, saliva, findings, ace2, salivary, gland, expressionthe, head, neck, expression, ace2, tmprss2, related, otolaryngological, symptom, pattern, seems, obvious, vary, across, individuals, populations, support, lee, et, a0al, observed, ace2, expression, influenced, patient, demographics, clinical, characteristics, comorbidities, medication, [], reported, genetic, analysis, cao, et, a0al, different, susceptibilities, responses, sarscov2, different, populations, [], polymorphism, ace2, tmprss2, expression, explain, clinical, differences, individuals, indeed, many, physicians, reported, clinical, epidemiological, studies, different, clinical, presentation, disease, [, ], associated, virus, mutations, [, , ], virus, mutations, related, impact, receptor, binding, infectivity, another, point, considered, future, studies, otherwise, according, bgee, database, https, bgee, expression, ace2, tmprss2, evaluated, murine, models, may, increase, age, findings, confirmed, humans, explain, severe, clinical, pictures, elderlythe, present, study, several, limitations, first, heterogeneity, studies, detection, method, may, lead, detection, bias, approaches, sensitive, others, studies, interrogate, gene, expression, mrna, level, others, protein, levels, types, analysis, advantages, limitations, compared, transcriptomic, analyzes, immunohistochemistry, brings, additional, important, spatial, information, tissue, samples, recently, sorokin, et, a0al, demonstrated, high, statistically, significant, correlations, rna, sequencing, immunohistochemical, measurements, [], interestingly, highlighted, complementarity, techniques, measuring, cancer, biomarkers, ffpe, samples, however, differences, observed, across, ihc, studies, suggest, involvement, many, parameters, antibody, specificity, big, challenge, ensure, reproducibility, antibodybased, studies, given, high, homology, ace1, ace2, cautions, must, taken, regarding, antibody, selection, besides, report, international, working, group, antibody, validation, iwgav, proposed, five, scientific, approaches, validate, antibody, specificity, [], strategies, must, considered, future, investigations, confirm, published, observations, addition, seems, essential, enlarge, diversify, patient, cohorts, combine, transcriptomic, proteomic, strategies, well, colocalize, different, markers, sarscov2, ace2, tmprss2, provide, accurate, representation, ace2, expression, head, neck, areas, whole, populationsecond, majority, studies, conducted, sarscov2, pandemic, consider, many, demographic, clinical, factors, age, patients, tissues, extracted, use, ace, inhibitor, medications, among, others, third, otolaryngological, regions, remain, uninvestigated, vocal, folds, investigation, remaining, regions, may, shed, light, recently, reported, unusual, clinical, phenomena, severe, dysphonia, []conclusionace2, tmprss2, expressed, head, neck, tissues, may, explain, otolaryngological, clinical, pattern, disease, entry, sarscov2, host, anism, future, studies, considering, demographical, clinical, characteristics, patients, tissues, extracted, needed, better, understand, cell, entry, mechanisms, sarscov2author, contributions, , jr, tr, ss, jm, design, acquisition, data, data, analysis, , interpretation, drafting, final, approval, accountability, , 0chead, neck, pathology, work, final, approval, version, published, agreement, accountable, aspects, work, ensuring, questions, related, accuracy, integrity, part, work, appropriately, investigated, resolved, cch, cmce, mrb, ig, design, data, analysis, , interpretation, revising, manuscript, important, intellectual, content, final, approval, version, published, final, approval, accountability, work, final, approval, version, published, agreement, accountable, aspects, work, ensuring, questions, related, accuracy, integrity, part, work, appropriately, investigated, resolved, ls, sh, gc, gd, jh, lv, gr, design, acquisition, data, data, analysis, , interpretation, drafting, parts, manuscript, final, approval, version, published, final, approval, accountability, work, final, approval, version, published, agreement, accountable, aspects, work, ensuring, questions, related, accuracy, integrity, part, work, appropriately, investigated, resolvedcompliance, ethical, standards, conflict, interest, , authors, declare, conflict, interestreferences, , , , crackower, ma, sarao, r, oudit, gy, et, a0al, angiotensinconverting, enzyme, , essential, regulator, heart, function, nature, , , , , li, w, moore, mj, vasilieva, n, sui, j, wong, sk, berne, ma, somasundaran, , m, , sullivan, , jl, , luzuriaga, , k, , greenough, tc, , choe, , h, , farzan, , m, , angiotensinconverting, , enzyme, , , , , functional, , receptor, , , , sars, , coronavirus, , nature, , , , , wang, z, xu, x, scrnaseq, profiling, human, testes, reveals, presence, ace2, receptor, target, sarscov2, infection, spermatogonia, leydig, sertoli, cells, cells, , https, doi103390cells, , , , , , shang, j, wan, y, luo, c, ye, g, geng, q, auerbach, li, f, cell, entry, mechanisms, sarscov2, proc, natl, acad, sci, usa, , https, doi101073pnas20031, , , , , , vaira, la, hopkins, c, salzano, g, et, a0al, olfactory, gustatory, function, impairment, covid19, patients, italian, objective, multicenterstudy, head, neck, https, doi101002hed26269, , , , , lechien, jr, chiesaestomba, cm, place, van, laethem, y, cabaraux, p, mat, q, huet, k, plzak, j, horoi, m, hans, barillari, mr, cammaroto, g, fakhry, n, martiny, d, ayad, jouffe, l, hopkins, c, saussez, covid19, task, force, yoifos, clinical, epidemiological, characteristics, , european, patients, mildtomoderate, coronavirus, disease, , j, intern, med, , https, doi101111joim13089, , , , , lechien, jr, chiesaestomba, cm, de, siati, dr, et, a0al, olfactory, gustatory, dysfunctions, clinical, presentation, mildtomoderate, forms, coronavirus, disease, covid19, multicenter, european, study, eur, arch, otorhinolaryngol, , https, doi101007s0040, , , , , , mcinnes, mdf, moher, d, thombs, bd, et, a0al, preferred, reporting, items, systematic, review, metaanalysis, diagnostic, test, accuracy, studies, prismadta, statement, jama, , https, doi101001jama201719163, , , , , thompson, m, tiwari, fu, r, moe, e, buckley, di, framework, facilitate, use, systematic, reviews, metaanalyses, design, primary, research, studies, rockville, agency, healthcare, research, quality, us, , , , vaarala, mh, porvari, ks, kellokumpu, kyll¶nen, ap, vihko, pt, expression, transmembrane, serine, protease, tmprss2, mouse, human, tissues, j, pathol, , https, doi10100210969896200099999999, , , hamming, timens, w, bulthuis, ml, lely, navis, g, van, goor, h, tissue, distribution, ace2, protein, functional, receptor, sars, coronavirus, first, step, understanding, sars, pathogenesis, j, pathol, , https, doi101002path1570, , , jia, hp, look, dc, shi, l, et, a0al, ace2, receptor, expression, , severe, , acute, , respiratory, , syndrome, , coronavirus, , infection, , depend, , , differentiation, , , human, , airway, , epithelia, j, , virol, , , , https, doi101128jvi792314614, , , , , liu, l, wei, q, alvarez, x, et, a0al, epithelial, cells, lining, salivary, gland, ducts, early, target, cells, severe, acute, respiratory, syndrome, coronavirus, infection, upper, respiratory, tracts, rhesus, macaques, j, virol, , https, doi101128jvi02292, , , , bilinska, k, jakubowska, p, von, bartheld, cs, butowt, r, expression, sarscov2, entry, proteins, ace2, tmprss2, cells, olfactory, epithelium, identification, cell, types, trends, age, acs, chem, neurosci, , https, doi101021acsch, emneu, ro0c002, , , , brann, dh, tsukahara, weinreb, c, et, a0al, nonneuronal, expression, sarscov2, entry, genes, olfactory, system, suggests, mechanisms, underlying, covid19associated, anosmia, preprint, https, doi1011012020032500908, , , , butowt, r, bilinska, k, sarscov2, olfaction, brain, infection, urgent, need, clinical, samples, allowing, earlier, virus, detection, acs, chem, neurosci, , https, doi101021acsch, emneu, ro0c001, , , , cao, y, li, l, feng, z, wan, huang, p, sun, x, wen, f, huang, x, ning, g, wang, w, comparative, genetic, analysis, novel, coronavirus, 2019ncovsarscov2, receptor, ace2, different, populations, cell, discov, , https, doi101038s4142, , , , chen, r, wang, k, yu, j, et, a0al, spatial, celltype, distribution, sarscov2, receptor, ace2, human, mouse, brain, preprint, https, doi1011012020040703065, , , , hikmet, f, mar, l, uhln, m, lindskog, c, protein, expression, profile, ace2, human, tissues, biorxiv, , https, doi1011012020033101604, , , , lee, nakayama, wu, ct, et, a0al, robust, ace2, protein, expression, localizes, motile, cilia, respiratory, tract, epithelia, increased, ace, inhibitors, angiotensin, receptor, blockers, preprint, https, doi1011012020050820092, , , , li, li, l, zhang, y, wang, xs, expression, sarscov2, cell, receptor, gene, ace2, wide, variety, human, tissues, infect, dis, poverty, , https, doi101186s4024, , x, , , sungnak, w, huang, n, bcavin, c, et, a0al, sarscov2, entry, factors, highly, expressed, nasal, epithelial, cells, together, innate, immune, genes, nat, med, , https, doi101038s4159, , , , xu, h, zhong, l, deng, j, peng, j, dan, h, zeng, x, li, chen, q, high, expression, ace2, receptor, 2019ncov, epithelial, cells, oral, mucosa, int, j, oral, sci, , https, doi101038s4136, 80200074x, , , xu, j, li, y, gan, f, du, y, yao, y, salivary, glands, potential, reservoirs, covid19, asymptomatic, infection, j, dent, res, , https, doi10117700220, , , , , , wu, c, zheng, chen, y, zheng, m, singlecell, rna, expression, profiling, ace2, putative, receptor, wuhan, 2019ncov, nasal, tissue, https, doi1011012020021120022, , 0c, head, neck, pathology, , , ziegler, cgk, allon, sj, nyquist, sk, et, a0al, sarscov2, receptor, ace2, interferonstimulated, gene, human, airway, epithelial, cells, detected, specific, cell, subsets, across, tissues, cell, 2020s0092, https, doi101016jcell202004035, , , kaye, r, chang, cwd, kazahaya, k, brereton, j, denneny, jc, iii, covid19, anosmia, reporting, tool, initial, findings, otolaryngol, head, neck, surg, , https, doi10117701945, , , , , , lechien, jr, chiesaestomba, cm, hans, barillari, mr, jouffe, l, saussez, loss, smell, taste, , european, patients, mild, moderate, covid19, ann, intern, med, , https, doi107326m202428, , , vaira, la, salzano, g, deiana, g, de, riu, g, anosmia, ageusia, common, findings, covid19, patients, laryngoscope, , https, doi101002lary28692, , , , spinato, g, fabbris, c, polesel, j, cazzador, d, borsetto, d]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |[neck, tissues, a0systematic, reviewjerome, a0r, a0lechien1234, stphane, a0hans13, a0·, maria, a0r, a0barillari18, a0·, giovanni, a0cammaroto19, a0·, graldine, a0descamps12, a0·, julien, a0hsieh110, a0·, luigi, a0vaira111, a0·, giacomo, a0de, a0riu111, a0·, leigh, a0sowerby112, a0·, isabelle, a0gengler113, a0·, justin, a0michel15, a0·, sven, a0saussez124, a0·, thomas, a0radulesco15, a0·, christian, a0calvohenriquez16, a0·, carlos, a0m, a0chiesaestomba17, a0·, received, , july, , , accepted, , august, , , springer, sciencebusiness, media, llc, part, springer, nature, abstractto, review, data, regarding, expression, angiotensin, converting, enzyme2, ace2, transmembrane, protease, serine2, tmprss2, head, neck, tissue, scopus, cochrane, library, medrxiv, google, scholar, pubmedmedline, were, searched, by, four, independent, investigators, studies, investigating, ace2, or, tmprss2, expressions, head, neck, tissues, following, outcomes, were, considered, sample, origin, animal, versus, human, detection, method, anatomical, location, cell, types, prisma, checklist, modified, population, intervention, comparison, outcome, timing, setting, picots, framework, were, used, perform, review, , identified, studies, , met, our, inclusion, criteria, thirteen, studies, were, conducted, during, severe, acute, respiratory, syndrome, a0coronavirus2, sarscov2, pandemic, ace2, tmprss2, were, expressed, oral, pharyngeal, sinusonasal, human, mucosa, following, cell, types, expressed, ace2, basal, apical, goblet, minor, salivary, endothelial, cells, tmprss2, found, goblet, apical, respiratory, cells, ace2, tmprss2, were, found, olfactory, region, especially, sustentacular, nonneural, neural, stem, cells, animal, studies, suggested, that, ace2, expression, may, vary, regarding, age, there, an, important, heterogeneity, between, studies, methods, used, detect, ace2, tmprss2, leading, potential, identification, bias, sarscov2, receptors, ace2, tmprss2, are, both, expressed, many, head, neck, tissues, enabling, viral, entry, into, host, anismkeywords, , ace2, a0·, tmprss2, a0·, sarscov2, a0·, covid, a0·, coronavirus, a0·, head, neckintroductionthe, renin, angiotensin, aldosterone, system, one, most, important, systems, regulating, homeostasis, cardiovascular, pulmonary, function, involves, many, molecules, including, angiotensin, converting, enzyme2, ace2, [], ace2, also, known, be, functional, receptor, some, coronavirus, species, as, initially, discovered, , during, severe, acute, respiratory, syndrome, coronavirus, sarscov, epidemic, [], current, pandemic, coronavirus, disease, jerome, r, lechien, thomas, radulesco, have, contributed, equally, paper, are, joint, as, cofirst, authorsjustin, michel, sven, saussez, equally, contributed, paper, are, cosenior, authorsjeromelechienumonsacbe, , , jerome, r, lechien, , extended, author, information, available, on, last, page, , covid19, has, brought, light, importance, ace2, regarding, development, infection, viral, spread, development, clinical, covid19, [], at, same, time, another, sarscov2, receptor, has, been, identified, transmembrane, protease, serine2, tmprss2, []ace2, tmprss2, tissue, expressions, are, particularly, important, identify, viral, entry, pathways, better, understand, anrelated, clinical, presentation, disease, [, ], further, evaluation, ace2, tmprss2, expression, ear, nose, throat, mucosa, warranted, shed, light, on, pathophysiology, disease, head, neck, []the, aim, systematic, review, summarize, current, data, about, expression, ace2, tmprss2, head, , neck, tissuevol01234567891, 0c, methodsthe, review, conducted, regarding, preferred, reporting, items, systematic, review, metaanalysis, prisma, checklist, [], modified, population, intervention, comparison, outcome, timing, setting, picots, framework, , , used, , , structure, , , review, , process, [], review, picots, structure, kept, but, adapted, experimentalbasic, research, studies, on, human, animal, tissuesstudiesanimal, human, experimental, published, studies, englishlanguage, peerreviewed, journals, were, considered, preprint, studies, were, also, considered, light, current, pandemic, significant, wealth, knowledge, derived, over, last, few, months, all, studies, where, investigators, assessed, ace2, or, tmprss2, expressions, head, , neck, tissues, through, immunochemistry, ihc, a0situ, hybridization, western, blot, rna, sequencing, rnaseq, or, reverse, transcription, polymerase, chain, reaction, rtpcr, were, evaluatedparticipants, a0inclusion, criteriathe, papers, had, include, either, human, or, animal, subjects, authors, extracted, substantial, information, about, sample, characteristics, including, species, involved, ace2, tmprss2, identification, methodoutcomesthe, primary, outcome, studied, tissue, expression, ace2, tmprss2, anatomical, location, types, cells, that, expressed, both, receptors, were, recorded, particular, attention, paid, method, used, detect, ace2tmprss2, tissues, additional, useful, information, such, as, viral, impact, on, functioning, tissuecell, that, expressed, receptor, or, interindividual, differences, were, also, collectedintervention, a0comparisonbecause, aim, study, investigate, tissue, ace2, tmprss2, expression, we, did, not, consider, potential, intervention, on, patient, or, animal, modelshead, neck, pathologytiming, a0settingwe, included, studies, where, receptor, analysis, made, on, normal, subjects, andor, infected, patientssearch, strategythe, pubmedmedline, google, scholar, medrxiv, scopus, cochrane, search, conducted, by, , independent, authors, jrl, tr, cch, gd, cmce, identify, papers, published, between, january, , april, , authors, screened, publications, with, database, s, available, full, texts, referring, condition, following, keywords, were, used, search, strategy, ace2², tmprss2², covid19², covid, sars, coronav, coronavirus, salivary, gland, receptor, head, neck, nasal, ear, nose, throat, ent, tissue, cell, authors, investigated, papers, number, samplesindividuals, study, type, , design, inclusion, criteria, ace2tmprss2, detection, outcomesresultsthe, electronic, search, identified, , papers, which, , met, our, inclusion, criteria, table, a0, [], total, , studies, investigated, expression, ace2, tmprss2, human, head, neck, tissues, while, five, papers, focused, on, mouse, two, on, monkey, samples, respectively, table, a0, one, study, focused, on, ace2, genetic, analysis, without, reporting, sitespecific, anatomical, expression, [], flow, chart, study, process, available, fig, a0, five, studies, were, preprint, [, , ]tissue, expression, a0humanace2, expressionace2, assessed, , studies, [], expression, ace2, found, all, mucosa, respiratory, upper, tract, including, trachea, [, , , , ], sinus, nasal, cavities, [, , ], among, respiratory, mucosa, ace2, expressed, several, types, cells, including, epithelial, goblet, endothelial, cells, [, , ], one, study, reported, that, ace2, expressed, on, ciliated, epithelial, cells, not, on, nonciliated, goblet, cells, [], butowt, et, a0al, compared, intensity, expression, ace2, upper, lower, respiratory, tract, [], they, found, that, nasal, epithelial, cells, had, lower, levels, ace2, expression, compared, with, epithelial, cells, lower, respiratory, tract, [], among, nasal, region, two, studies, investigated, ace2, expression, , 0chead, neck, pathology, table, , , , studies, reporting, ace2, or, tmprss2, head, neck, expressionauthorsdesignvaarala, mixed, [], studyhamming, humansamples, methodshuman, tmprss2mousehuman, ace2rnaseqace2, , tmprss2, expressionsalivary, glandstmprss2, humanoral, nasal, nasopharyngeal, epithelium, , endotheliumace2, human, all, mucosa, [], studyihchumanjia, [], studyhuman, ace2tracheal, epithelium, , endotheliumihc, , biotinylation, ace2, humanliuexperimenal, monkey, ace2, [], studyihcnaso, oro, hypopharyngeal, , tracheal, epitheliumace2, monkeyvirion, salivabilinska, animal, [], studybrannmixed, [], studybutowtmixed, [], studymouse, ace2, , tmprss2, olfactory, epitheliumrnaseq, rtpcrace2, sustentacular, cellsin, situ, hybridization, tmprss2, sustentacular, cellswb, , ihcmouse, ace2, , tmprss2, olfactory, epitheliumhuman, rnaseqace2, , tmprss2, mouse, nonneuronal, cellsace2, , tmprss2, human, glial, neuronal, stem, cellsmouse, ace2, , tmprss2, olfactory, epitheliumhuman, rnaseqace2, mouse, , human, non, neuronal, cellscaohumanhuman, ace2, gene, [], studygenetic, analyzischenhuman, [], studyhikmethuman, [], studyhuman, ace2rnaseqhuman, ace2ihcleehumanhuman, ace2tmprss2, mouse, , human, neuronal, , nonneuronal, cellsrespiratory, epitheliumace2, , tmprss2, human, lower, airway, , nasalno, localization, providedsalivary, glandsace2, humannasopharyngeal, epitheliumace2, human, no, expression, nasopharynxtracheal, nasal, , sinusal, epitheliumfindings, tmprss2, expressed, human, salivary, gland, tissues, ace2, found, endothelial, arteries, , veins, epithelial, cells, nasal, rhinopharyngeal, oral, mucosa, precisely, epithelium, expression, concerned, basal, layer, cells, ace2, more, expressed, on, apical, than, basolateral, surface, polarized, airway, epithelia, ace2, expressed, salivary, gland, ducts, pharyngeal, glands, ace2, expressed, epithelial, cells, lamina, propria, respiratory, tract, virus, found, saliva, infected, monkeys, ace2, , tmprss2, are, expressed, sustentacular, cells, olfactory, epithelium, but, notmuch, less, most, olfactory, receptor, neurons, expression, entry, proteins, increases, animals, old, age, human, ace2, , tmprss2, were, not, identified, purified, olfactory, neurons, ace2, identified, glial, cells, , olfactory, stem, cells, nasal, epithelial, cells, have, lower, levels, ace2, , tmprss2, compared, with, epithelial, cells, lower, respiratory, tract, ace2, has, nonneuronal, expression, olfactory, epithelium, expression, ace2, , tmprss2, mouse, were, increased, elderly, mouse, unique, expression, quantitative, trait, loci, variants, were, found, ace2, genotypes, ace2, gene, polymorphism, may, be, characterized, by, higher, expression, levels, ace2, east, asian, population, there, would, be, different, susceptibility, or, response, sarscov2, different, populations, ace2, expressed, human, granular, cells, salivary, glands, there, no, ace2, expression, nasopharyngeal, cells, ace2, expressed, ciliated, epithelial, cells, cilia, anelle, 0c, table, , , , continuedauthorsdesign, [], studyhumanlihikmethuman, [], study, [], studysungnak, human, [], studysamples, methodsihcace2, , tmprss2, expressionace2, humanhuman, ace2human, ace2ihcrnaseqthyroidnasopharyngeal, epitheliumace2, human, no, expression, nasopharynxace2, humanhuman, ace2, , tmprss2, airway, , nasal, epitheliumrnaseqace2, humantmprss2, human, subset, ace2, cellsxuhumanhuman, ace2, , tmprss2, oral, epithelium, [], studyrnaseqhumanxu, [], studywuhuman, [], studyhuman, ace2rnaseqhuman, ace2rnaseqace2, humanace2, humanoral, t, cells, b, cells, , fibroblastsace2, humanminor, salivary, glandsace2, humannasal, , oral, epitheliumhead, neck, pathologyfindings2there, no, ace2, expression, nonciliated, goblet, cells, ace2, expression, influenced, by, patient, demographics, clinical, characteristics, comorbidities, or, medication, use, use, ace, inhibitor, drugs, did, not, increase, ace2, protein, expression, ace2, expressed, by, thyroid, cells, there, no, ace2, expression, nasopharyngeal, cells, ace2, expressed, airway, epithelial, cells, ace2, more, expressed, nasal, epithelial, cells, compared, with, other, respiratory, cells, goblet, , ciliated, cells, tmprss2, only, expressed, subset, ace2, , cells, ace2, expressed, oral, cavity, epithelial, cells, ace2, expression, higher, tongue, than, buccal, gingival, tissues, ace2, expressed, minor, salivary, glands, ace, expressed, nasal, epithelial, cells, higher, virus, concentration, nasalswab, comparing, with, throatswab, which, attributed, ace2expression, nasal, epithelial, cells, ace2, , tmprss2, are, coexpressed, nasal, goblet, secretory, cellsmixedziegler, [], studyace2, angiotensin, converting, enzyme2, ihc, immunohistochemistry, rtpcr, reverse, transcription, polymerase, chain, reaction, sarscov2, severe, acute, respiratory, syndrome, a0coronavirus2, tmprss2, transmembrane, protease, serine2, wb, western, blottinghuman, ace2, , tmprss2, sinusal, , nasal, goblet, epithelial, cellsmonkey, rnaseqace2, , tmprss2, humanmucosa, olfactory, region, including, olfactory, bulb, [, ], ace2, receptor, identified, sustentacularnonneuronal, cells, olfactory, tissues, moreover, ace2, found, low, proportion, neuronal, stem, cells, olfactory, bulb, [, ], expression, ace2, olfactory, neurons, nonstem, cells, remains, uncertain, because, butowt, et, a0al, brann, et, a0al, observed, that, ace2, has, only, nonneuronal, expression, pattern, olfactory, epithelium, [, ]five, studies, investigated, ace2, expression, oral, pharyngeal, regions, including, oral, hypo, oro, nasopharyngeal, spaces, [, , ], study, that, explored, ace2, expression, human, nasopharynx, [], did, not, exhibit, significant, ace2, immunostaining, nasopharyngeal, cells, [], ace2, receptor, identified, oral, endothelial, [], epithelial, [, , ], salivary, [], cells, xu, et, a0al, found, that, ace2, also, expressed, t, b, cells, as, well, as, fibroblasts, oral, cavity, [], moreover, ace2, expressed, major, salivary, gland, tissues, [], thyroid, tissue, [], many, publications, authors, reported, type, cells, goblet, versus, epithelial, versus, stem, cells, that, expressed, ace2, or, tmprss2, table, a0, interestingly, xu, et, a0al, almost, as, much, ace2, expression, thyroid, as, lungs, []the, genetic, analysis, cao, et, a0al, reported, that, there, are, , unique, expression, quantitative, trait, loci, variants, east, asian, population, supporting, gene, polymorphism, tissuerelated, differences, between, individuals, [], 0chead, neck, pathology, fig, , , , flow, chart, ace2, angiotensin, converting, enzyme2, tmprss2, transmembrane, protease, serine2tmprss2, expressiontmprss2, expression, investigated, , studies, [, , , , ], similarly, ace2, tmprss2, identified, nasal, [, , ], respiratory, mucosa, cells, [], including, both, epithelial, goblet, cells, with, higher, expression, lower, airway, compared, with, upper, airway, [], moreover, tmprss2, receptor, identified, sustentacular, neuronal, olfactory, cells, [, ], but, not, olfactory, neurons, [], tmprss2, also, identified, salivary, major, gland, tissue, []ace2, , tmprss2, tissue, expression, a0mouse, a0monkeysix, studies, used, animal, models, assess, ace2, or, tmprss2, expressions, head, neck, tissues, [, , ], mouse, studies, butowt, et, a0al, bilinska, et, a0al, revealed, that, elderly, mice, had, higher, expression, both, ace2, tmprss2, nasal, mucosa, compared, with, younger, mice, [, ], olfactory, tissue, ace2, identified, sustentacularnonneuronal, neural, stem, cells, mice, [], liu, et, a0al, analyzed, ace2, expression, monkeys, [], , 0c, head, neck, pathologytable, , , , summary, cell, expression, ace2, tmprss2authorsbilinska, []brann, []samplesmousehuman, , mousetissueolfactoryolfactorybutowt, []human, , mousenasalolfactorychen, []hamming, []hikmet, []jia, []lee, []li, []liu, []sungnak, []vaarala, []xu, []xu, []wu, []ziegler, []humanhumanhumanhumanhumanhumanmonkeyhumanmajor, salivary, glandoral, nasal, nasopharyngealnasopharyngealtracheal, nasal, sinusalthyroidpharyngealtrachealtracheal, , nasalhuman, , mousehumanmajor, salivary, glandoralhumanhumanhuman, mouse, monkeyminor, salivary, glandnasaloralnasal, , sinusalcell, typessustentatorialsustentatorialneuronalstem, neuronalepithelialsustentatorialneuronalgranularbasal, layerendothelialepithelialapical, epithelialendothelialapical, epithelialgobletunspecifiedminor, salivary, ductalbasal, layergobletapical, epithelialunspecifiedapical, epithelialfibroblastt, bcellsunspecifiedunspecifiedbasal, layergobletace2natmprss2nananananananananananananananananaace2, angiotensin, converting, enzyme2, na, not, available, tmprss2, transmembrane, protease, serine2reporting, higher, ace2, expression, tracheal, naso, oro, hypopharyngeal, tissues, as, well, as, salivary, ducts, pharyngeal, gland, consequently, saliva, study, cell, expression, mainly, localized, lamina, propria, same, vein, vaarala, et, a0al, reported, tmprss2, expression, mouse, salivary, tissues, []cell, detection, methodsthe, following, methods, have, been, used, detecting, ace2, tmprss2, cells, human, animal, tissue, rnaseq, n, , , ihc, n, , , rtpcr, n, , , a0situ, hybridization, ish, n, , , wb, n, , , different, detection, approaches, were, used, , studies, [, ], one, study, reported, specific, genetic, analysis, [], there, were, significant, differences, between, studies, regarding, methods, used, while, ziegler, et, a0al, sungnak, et, a0al, detected, ace2, by, rnaseq, goblet, cells, lee, et, a0al, did, not, find, any, immunohistochemical, labeling, [, , ], however, results, reported, sustentacular, cells, agree, same, direction, whatever, technique, used, whether, by, rnaseq, or, by, ish, immunocytochemistry, [], discrepancies, are, rather, observed, between, studies, having, performed, immunohistochemistry, indeed, using, two, different, antibodies, hikmet, did, not, find, ace2, expression, nasopharynx, epithelium, whereas, others, demonstrated, staining, apical, surface, epithelia, ciliated, epithelial, cells, [, , ], interestingly, all, studies, which, carried, out, rnaseq, found, an, expression, ace2, or, tmprss2, at, epithelial, level, which, implies, that, technique, used, could, generate, biases, between, studies, [, , ], 0chead, neck, pathology, discussionthe, presentation, covid19, infection, may, be, several, clinical, forms, ranging, from, anosmia, isolation, severe, multiple, an, failure, death, mechanisms, underlying, covid19, polymorphism, are, still, unknown, infect, tissues, sarscov2, needs, entry, into, cells, which, allowed, through, ace2, tmprss2, receptors, [], identification, virus, receptor, expression, tissues, makes, particularly, sense, better, understand, clinical, expression, disease, systematic, review, sheds, light, on, many, pointsfirst, ace2, tmprss2, receptors, are, expressed, epithelial, nonepithelial, cells, throughout, head, neck, head, neck, expression, may, support, otolaryngological, clinical, picture, disease, which, recently, found, european, north, american, covid, patients, [, , , ], by, entering, body, via, epithelial, cells, upper, aerodigestive, tract, mucosa, sarscov2, virus, leads, an, inflammatory, reaction, development, otolaryngological, symptoms, nasal, entrance, virus, through, high, ace2, expression, supported, study, wu, et, a0al, who, found, higher, virus, concentration, nasal, swabs, compared, with, throat, swabs, []the, olfactory, cleft, nasal, region, that, has, drawn, attention, many, researchers, over, past, few, weeks, indeed, recent, data, supported, that, more, than, , covid19, patients, developed, subjective, olfactory, dysfunction, especially, when, patients, suffered, from, mildtomoderate, forms, disease, [, , , ], because, ace2, tmprss2, are, both, expressed, nasal, mucosa, olfactory, cleft, entrance, into, olfactory, bulb, seems, plausible, once, bulb, according, some, human, studies, [, ], virus, could, infect, cells, that, express, ace2, or, tmprss2, namely, glial, neuronal, stem, cells, fig, a0integrating, molecular, clinical, radiological, characteristics, sarscov2, olfactory, loss, may, shed, light, about, its, pathophysiological, process, taking, into, account, that, loss, often, temporary, sarscov2, may, primarily, infect, sustentacular, cells, supporting, olfactory, sensory, neurons, infection, may, cause, rapid, disruption, olfactory, epithelium, structure, function, with, possible, inflammatory, response, inducing, sudden, onset, smell, loss, inflammation, observed, minority, patient, with, congested, olfactory, cleft, who, underwent, ct, scan, [, , , ]ace2, tmprss2, are, also, found, horizontal, basal, olfactory, stem, cells, located, basal, layer, they, are, less, exposed, external, environment, thus, less, likely, be, infected, first, line, loss, would, have, been, more, fig, , , , epithelium, olfactory, cleft, figure, summarizes, olfactory, cleft, epithelium, 0c, head, neck, pathologyprogressive, however, once, infected, they, might, slow, down, recovery, time, because, horizontal, basal, cells, give, rise, many, cell, type, olfactory, epithelium, they, may, also, contribute, virus, spread, olfactory, bulb, vascular, pericytes, magnetic, resonance, imaging, mri, studies, olfactory, bulb, [, ], which, ace2, are, only, expressed, vascular, pericytes, but, not, neurons, may, show, inflammatory, signs, suggesting, that, infection, process, can, extend, more, centrally, promote, inflammatory, response, [], inflammatory, causes, are, often, quickly, reversible, example, after, oneweek, trial, high, dose, corticosteroids, or, simply, days, after, resolution, viral, infection, suggesting, that, olfactory, neurons, bulbs, are, still, somewhat, intact, seems, be, case, majority, patients, contrast, with, more, sustained, destruction, neuronal, olfactory, structures, recovery, time, much, longer, may, take, , a0years, given, slow, neuroregeneration, process, [, ]in, systematic, review, we, found, that, three, studies, reported, high, ace2, expression, major, or, minor, salivary, gland, human, tissues, [, , ], these, data, corroborate, literature, findings, that, reported, salivary, pattern, sarscov2, related, parotitis, [, ], moreover, virus, spread, into, salivary, gland, tissues, allows, us, better, understanding, mechanisms, underlying, salivary, transmission, interestingly, , liu, et, a0al, observed, that, monkeys, infected, by, sarscov, had, salivary, viral, spread, which, associated, with, salivary, virion, excretion, [], these, data, support, need, conduct, future, studies, investigating, presence, sarscov2, saliva, infected, human, corroborate, saliva, findings, with, ace2, salivary, gland, expressionthe, head, neck, expression, ace2, tmprss2, related, otolaryngological, symptom, pattern, seems, obvious, but, could, vary, across, individuals, populations, support, lee, et, a0al, observed, that, ace2, expression, influenced, by, patient, demographics, clinical, characteristics, comorbidities, medication, [], as, reported, genetic, analysis, cao, et, a0al, there, would, be, different, susceptibilities, or, responses, sarscov2, different, populations, [], polymorphism, ace2, tmprss2, expression, could, explain, clinical, differences, between, individuals, indeed, many, physicians, reported, clinical, epidemiological, studies, different, clinical, presentation, disease, [, ], which, could, be, associated, with, virus, mutations, [, , ], virus, mutations, related, impact, on, receptor, binding, infectivity, another, point, that, has, be, considered, future, studies, otherwise, according, bgee, database, https, bgee, expression, ace2, tmprss2, evaluated, murine, models, may, increase, with, age, these, findings, have, be, confirmed, humans, but, could, explain, more, severe, clinical, pictures, elderlythe, present, study, has, several, limitations, first, heterogeneity, between, studies, about, detection, method, may, lead, detection, bias, as, some, approaches, are, more, sensitive, than, others, some, studies, interrogate, gene, expression, at, mrna, level, others, at, protein, levels, both, types, analysis, having, their, advantages, limitations, compared, transcriptomic, analyzes, immunohistochemistry, brings, additional, important, spatial, information, tissue, samples, but, recently, sorokin, et, a0al, demonstrated, high, statistically, significant, correlations, between, rna, sequencing, immunohistochemical, measurements, [], interestingly, they, highlighted, complementarity, both, techniques, measuring, cancer, biomarkers, ffpe, samples, however, differences, observed, across, ihc, studies, suggest, involvement, many, parameters, antibody, specificity, big, challenge, ensure, reproducibility, antibodybased, studies, given, high, homology, between, ace1, ace2, cautions, must, be, taken, regarding, antibody, selection, besides, report, from, international, working, group, antibody, validation, iwgav, proposed, five, scientific, approaches, validate, antibody, specificity, [], then, such, strategies, must, be, considered, future, investigations, confirm, published, observations, addition, it, seems, essential, enlarge, diversify, patient, cohorts, combine, transcriptomic, proteomic, strategies, as, well, as, colocalize, different, markers, sarscov2, such, as, ace2, tmprss2, provide, an, accurate, representation, ace2, expression, through, all, head, neck, areas, whole, populationsecond, majority, studies, that, were, conducted, during, sarscov2, pandemic, did, not, consider, many, demographic, clinical, factors, such, as, age, patients, from, who, tissues, were, extracted, or, use, ace, inhibitor, medications, among, others, third, some, otolaryngological, regions, remain, uninvestigated, such, as, vocal, folds, investigation, these, remaining, regions, may, shed, further, light, on, some, recently, reported, unusual, clinical, phenomena, such, as, severe, dysphonia, []conclusionace2, tmprss2, are, both, expressed, head, neck, tissues, which, may, explain, otolaryngological, clinical, pattern, disease, entry, sarscov2, into, host, anism, future, studies, considering, demographical, clinical, characteristics, patients, from, who, tissues, are, extracted, are, needed, better, understand, cell, entry, mechanisms, sarscov2author, contributions, , jr, tr, ss, jm, design, acquisition, data, data, analysis, , interpretation, drafting, final, approval, accountability, , 0chead, neck, pathology, work, final, approval, version, be, published, agreement, be, accountable, all, aspects, work, ensuring, that, questions, related, accuracy, or, integrity, any, part, work, are, appropriately, investigated, resolved, cch, cmce, mrb, ig, design, data, analysis, , interpretation, revising, manuscript, important, intellectual, content, final, approval, version, be, published, final, approval, accountability, work, final, approval, version, be, published, agreement, be, accountable, all, aspects, work, ensuring, that, questions, related, accuracy, or, integrity, any, part, work, are, appropriately, investigated, resolved, ls, sh, gc, gd, jh, lv, gr, design, acquisition, data, data, analysis, , interpretation, drafting, some, parts, manuscript, final, approval, version, be, published, final, approval, accountability, work, final, approval, version, be, published, agreement, be, accountable, all, aspects, work, ensuring, that, questions, related, accuracy, or, integrity, any, part, work, are, appropriately, investigated, resolvedcompliance, with, ethical, standards, conflict, interest, , authors, declare, that, they, have, no, conflict, interestreferences, , , , crackower, ma, sarao, r, oudit, gy, et, a0al, angiotensinconverting, enzyme, , an, essential, regulator, heart, function, nature, , , , , li, w, moore, mj, vasilieva, n, sui, j, wong, sk, berne, ma, somasundaran, , m, , sullivan, , jl, , luzuriaga, , k, , greenough, tc, , choe, , h, , farzan, , m, , angiotensinconverting, , enzyme, , , , , functional, , receptor, , , , sars, , coronavirus, , nature, , , , , wang, z, xu, x, scrnaseq, profiling, human, testes, reveals, presence, ace2, receptor, target, sarscov2, infection, spermatogonia, leydig, sertoli, cells, cells, , https, doi103390cells, , , , , , shang, j, wan, y, luo, c, ye, g, geng, q, auerbach, li, f, cell, entry, mechanisms, sarscov2, proc, natl, acad, sci, usa, , https, doi101073pnas20031, , , , , , vaira, la, hopkins, c, salzano, g, et, a0al, olfactory, gustatory, function, impairment, covid19, patients, an, italian, objective, multicenterstudy, head, neck, https, doi101002hed26269, , , , , lechien, jr, chiesaestomba, cm, place, s, van, laethem, y, cabaraux, p, mat, q, huet, k, plzak, j, horoi, m, hans, s, barillari, mr, cammaroto, g, fakhry, n, martiny, d, ayad, t, jouffe, l, hopkins, c, saussez, s, covid19, task, force, yoifos, clinical, epidemiological, characteristics, , european, patients, with, mildtomoderate, coronavirus, disease, , j, intern, med, , https, doi101111joim13089, , , , , lechien, jr, chiesaestomba, cm, de, siati, dr, et, a0al, olfactory, gustatory, dysfunctions, as, clinical, presentation, mildtomoderate, forms, coronavirus, disease, covid19, multicenter, european, study, eur, arch, otorhinolaryngol, , https, doi101007s0040, , , , , , mcinnes, mdf, moher, d, thombs, bd, et, a0al, preferred, reporting, items, systematic, review, metaanalysis, diagnostic, test, accuracy, studies, prismadta, statement, jama, , https, doi101001jama201719163, , , , , thompson, m, tiwari, fu, r, moe, e, buckley, di, framework, facilitate, use, systematic, reviews, metaanalyses, design, primary, research, studies, rockville, agency, healthcare, research, quality, us, , , , vaarala, mh, porvari, ks, kellokumpu, s, kyll¶nen, ap, vihko, pt, expression, transmembrane, serine, protease, tmprss2, mouse, human, tissues, j, pathol, , https, doi10100210969896200099999999, , , hamming, i, timens, w, bulthuis, ml, lely, at, navis, g, van, goor, h, tissue, distribution, ace2, protein, functional, receptor, sars, coronavirus, first, step, understanding, sars, pathogenesis, j, pathol, , https, doi101002path1570, , , jia, hp, look, dc, shi, l, et, a0al, ace2, receptor, expression, , severe, , acute, , respiratory, , syndrome, , coronavirus, , infection, , depend, , on, , differentiation, , , human, , airway, , epithelia, j, , virol, , , , https, doi101128jvi792314614, , , , , liu, l, wei, q, alvarez, x, et, a0al, epithelial, cells, lining, salivary, gland, ducts, are, early, target, cells, severe, acute, respiratory, syndrome, coronavirus, infection, upper, respiratory, tracts, rhesus, macaques, j, virol, , https, doi101128jvi02292, , , , bilinska, k, jakubowska, p, von, bartheld, cs, butowt, r, expression, sarscov2, entry, proteins, ace2, tmprss2, cells, olfactory, epithelium, identification, cell, types, trends, with, age, acs, chem, neurosci, , https, doi101021acsch, emneu, ro0c002, , , , brann, dh, tsukahara, t, weinreb, c, et, a0al, nonneuronal, expression, sarscov2, entry, genes, olfactory, system, suggests, mechanisms, underlying, covid19associated, anosmia, preprint, https, doi1011012020032500908, , , , butowt, r, bilinska, k, sarscov2, olfaction, brain, infection, urgent, need, clinical, samples, allowing, earlier, virus, detection, acs, chem, neurosci, , https, doi101021acsch, emneu, ro0c001, , , , cao, y, li, l, feng, z, wan, s, huang, p, sun, x, wen, f, huang, x, ning, g, wang, w, comparative, genetic, analysis, novel, coronavirus, 2019ncovsarscov2, receptor, ace2, different, populations, cell, discov, , https, doi101038s4142, , , , chen, r, wang, k, yu, j, et, a0al, spatial, celltype, distribution, sarscov2, receptor, ace2, human, mouse, brain, preprint, https, doi1011012020040703065, , , , hikmet, f, mar, l, uhln, m, lindskog, c, protein, expression, profile, ace2, human, tissues, biorxiv, , https, doi1011012020033101604, , , , lee, it, nakayama, t, wu, ct, et, a0al, robust, ace2, protein, expression, localizes, motile, cilia, respiratory, tract, epithelia, not, increased, by, ace, inhibitors, or, angiotensin, receptor, blockers, preprint, https, doi1011012020050820092, , , , li, my, li, l, zhang, y, wang, xs, expression, sarscov2, cell, receptor, gene, ace2, wide, variety, human, tissues, infect, dis, poverty, , https, doi101186s4024, , x, , , sungnak, w, huang, n, bcavin, c, et, a0al, sarscov2, entry, factors, are, highly, expressed, nasal, epithelial, cells, together, with, innate, immune, genes, nat, med, , https, doi101038s4159, , , , xu, h, zhong, l, deng, j, peng, j, dan, h, zeng, x, li, t, chen, q, high, expression, ace2, receptor, 2019ncov, on, epithelial, cells, oral, mucosa, int, j, oral, sci, , https, doi101038s4136, 80200074x, , , xu, j, li, y, gan, f, du, y, yao, y, salivary, glands, potential, reservoirs, covid19, asymptomatic, infection, j, dent, res, , https, doi10117700220, , , , , , wu, c, zheng, s, chen, y, zheng, m, singlecell, rna, expression, profiling, ace2, putative, receptor, wuhan, 2019ncov, nasal, tissue, https, doi1011012020021120022, , 0c, head, neck, pathology, , , ziegler, cgk, allon, sj, nyquist, sk, et, a0al, sarscov2, receptor, ace2, an, interferonstimulated, gene, human, airway, epithelial, cells, detected, specific, cell, subsets, across, tissues, cell, 2020s0092, https, doi101016jcell202004035, , , kaye, r, chang, cwd, kazahaya, k, brereton, j, denneny, jc, iii, covid19, anosmia, reporting, tool, initial, findings, otolaryngol, head, neck, surg, , https, doi10117701945, , , , , , lechien, jr, chiesaestomba, cm, hans, s, barillari, mr, jouffe, l, saussez, s, loss, smell, taste, , european, patients, with, mild, moderate, covid19, ann, intern, med, , https, doi107326m202428, , , vaira, la, salzano, g, deiana, g, de, riu, g, anosmia, ageusia, common, findings, covid19, patients, laryngoscope, , https, doi101002lary28692, , , , spinato, g, fabbris, c, polesel, j, cazzador, d, borsetto, d]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |(224581,[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,26,27,28,29,30,32,33,34,35,36,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,57,58,59,60,61,62,63,64,65,66,67,68,69,72,73,74,75,76,77,78,79,81,82,84,86,87,88,90,92,93,94,95,96,97,98,99,101,102,105,106,107,108,109,112,114,115,116,118,119,120,122,123,124,127,128,130,131,132,133,134,137,138,140,141,142,146,147,148,149,151,152,153,156,157,158,159,163,164,166,167,169,171,173,174,176,179,180,182,184,187,188,189,190,194,196,197,199,201,202,206,207,208,209,214,215,216,217,219,220,221,223,224,226,230,231,234,235,236,239,242,243,244,245,246,247,249,250,252,253,258,262,264,265,266,268,269,270,274,275,276,277,280,281,286,288,289,294,307,309,310,311,313,314,320,322,327,329,330,334,336,340,342,343,348,350,351,353,355,356,358,359,361,362,365,366,368,369,370,371,374,375,378,379,388,394,396,397,400,404,408,409,411,413,415,417,419,420,421,425,431,432,436,438,450,451,452,453,456,463,464,465,466,468,470,472,474,475,480,482,483,484,486,494,496,497,498,499,500,504,507,509,513,515,516,520,532,537,541,542,545,546,547,549,550,551,555,558,562,566,567,569,577,579,583,589,590,591,592,594,595,596,597,599,601,602,603,609,610,618,631,633,637,638,641,648,653,654,655,657,659,661,667,672,677,682,683,684,691,697,704,712,718,719,724,731,732,735,738,739,742,745,747,754,758,759,761,762,770,772,777,779,786,797,801,802,806,809,810,812,814,817,818,823,824,832,836,838,839,843,846,851,853,857,860,864,877,881,882,885,887,890,892,901,905,918,924,925,929,932,934,941,942,943,944,957,964,967,975,978,984,985,990,993,1001,1012,1021,1023,1024,1027,1036,1045,1048,1049,1050,1051,1054,1059,1061,1064,1066,1071,1073,1081,1093,1094,1100,1110,1111,1113,1119,1120,1121,1136,1139,1141,1150,1151,1157,1161,1166,1168,1176,1177,1187,1191,1195,1196,1201,1205,1208,1210,1214,1217,1220,1221,1222,1232,1238,1241,1242,1244,1247,1248,1262,1264,1266,1278,1293,1298,1300,1308,1318,1320,1350,1355,1359,1374,1381,1385,1387,1390,1400,1405,1431,1440,1451,1453,1457,1458,1462,1467,1468,1474,1496,1499,1504,1506,1510,1532,1537,1542,1549,1552,1554,1561,1562,1569,1570,1585,1590,1591,1595,1598,1610,1613,1614,1615,1621,1636,1638,1639,1643,1647,1665,1667,1670,1672,1674,1682,1683,1684,1685,1689,1700,1704,1705,1714,1720,1733,1736,1744,1749,1752,1761,1777,1779,1781,1802,1803,1838,1843,1851,1852,1860,1863,1865,1866,1869,1872,1874,1880,1883,1893,1898,1900,1907,1908,1913,1915,1917,1921,1932,1942,1951,1954,1956,1962,1967,2003,2020,2050,2053,2054,2060,2068,2089,2108,2121,2124,2125,2145,2152,2156,2159,2185,2227,2236,2240,2254,2262,2264,2266,2268,2281,2292,2304,2312,2316,2328,2351,2354,2361,2364,2368,2383,2389,2392,2398,2399,2420,2424,2430,2459,2464,2492,2493,2497,2520,2532,2536,2537,2540,2543,2544,2585,2593,2601,2615,2631,2635,2638,2641,2648,2655,2679,2690,2692,2717,2718,2720,2726,2727,2736,2760,2762,2788,2791,2794,2817,2829,2837,2839,2854,2896,2921,2932,2949,2954,2957,2997,2998,3000,3001,3017,3066,3076,3086,3098,3099,3120,3131,3157,3165,3172,3197,3199,3203,3215,3221,3225,3258,3277,3290,3300,3317,3364,3383,3393,3429,3442,3450,3454,3456,3477,3527,3531,3537,3540,3548,3567,3578,3591,3593,3613,3621,3640,3650,3670,3707,3732,3735,3737,3745,3765,3769,3771,3831,3838,3863,3875,3894,3985,4051,4064,4103,4104,4133,4152,4194,4235,4246,4250,4267,4288,4343,4359,4369,4380,4398,4427,4473,4498,4510,4566,4576,4589,4594,4612,4663,4675,4680,4786,4835,4883,4895,4923,4958,4961,4995,5015,5030,5186,5211,5231,5241,5300,5341,5366,5374,5401,5425,5457,5470,5519,5545,5549,5553,5708,5724,5756,5790,5864,5868,5881,5929,5950,5980,5987,6044,6048,6132,6239,6271,6288,6318,6330,6332,6336,6354,6359,6389,6390,6407,6544,6553,6582,6595,6701,6806,6812,6938,6946,6960,6975,7042,7055,7058,7156,7232,7242,7243,7297,7299,7315,7318,7347,7371,7378,7398,7440,7446,7450,7461,7470,7488,7535,7640,7652,7786,7806,7915,7964,7976,8028,8036,8084,8120,8124,8186,8212,8215,8263,8308,8379,8419,8507,8853,8855,8868,9005,9015,9095,9096,9127,9196,9224,9241,9335,9405,9505,9526,9644,9684,9755,9789,10060,10065,10072,10075,10085,10115,10203,10224,10627,10695,10719,10755,10797,11049,11274,11825,11887,12026,12043,12125,12248,12408,12445,12748,12951,13005,13006,13111,13179,13454,13470,13491,13598,13686,13759,13997,14217,14894,15152,15165,15210,15541,15612,15937,16054,16242,16254,16306,16420,16516,16544,16662,16780,16908,17034,17148,17725,17932,18005,18062,18289,18407,18457,18607,18630,18638,19160,19162,19571,19652,19999,20168,20195,20258,20408,20579,20597,20624,20775,21063,21120,21217,22222,22438,23448,23499,23829,23957,24423,24427,24447,24666,25128,25310,25544,25714,26166,26247,26353,26765,27411,27563,28276,28563,28598,28926,28964,29184,29376,29499,29636,29724,30415,30428,30500,30794,31047,31366,31546,31680,31745,31868,32049,32185,32294,33568,33578,33637,33961,34051,34093,34109,34249,35032,35798,36208,36780,37072,37401,37569,38928,38931,39004,39261,39371,39592,39644,39763,39776,39780,40143,40655,40782,41533,41574,42252,43002,43406,44039,44901,45462,45557,45718,45964,46371,47226,47276,47491,47749,48151,48550,49251,50432,51552,51653,52056,52093,52546,53177,53473,54281,55686,56149,56425,57563,57822,57991,57998,58368,58388,63191,63846,64060,64626,65251,66065,66093,66463,67790,69418,70936,71550,71689,72278,72840,73703,74144,74350,74641,80968,81151,82332,82814,82884,83631,84550,84936,86724,87331,87363,87414,88006,88062,88127,88525,88640,88745,89004,89187,89364,89555,90232,92237,92342,92638,92826,93234,93590,93648,94248,95994,97104,97519,97541,98357,98550,99628,100358,100669,101254,101912,102647,102822,103234,103462,103784,105811,105959,106052,106093,106767,106884,107445,107878,108270,108279,108375,108825,109209,109238,109456,109790,109887,110843,111121,112351,112585,113503,113937,114133,114417,114419,114462,116194,117486,118722,119270,119311,120210,120391,120747,120856,122113,122264,122302,122844,122872,124008,124397,124519,124828,125242,125370,125802,126028,127935,128091,128640,129757,130410,130981,131341,131463,132099,132474,132831,133635,133667,136281,136515,136851,136856,136932,137627,138058,139671,139751,139787,139824,140793,141518,141808,141809,141835,142454,142699,143815,145803,145922,146078,146723,146942,147135,147536,148026,148417,149185,149272,150182,152772,152839,152878,154635,154878,155301,156324,156872,158604,158641,158766,158829,158936,159574,159830,160827,161274,161686,161971,162443,163246,163623,163690,164272,164345,164754,165665,166463,166571,167738,167994,168403,168423,168450,169099,169651,170075,171133,171623,172225,172437,172779,173712,174116,174406,174691,175204,175451,177437,177944,178720,179170,179489,179525,180150,181597,181687,181695,181708,181762,182125,182640,183381,183882,184331,184372,184417,184796,185150,185672,185765,186020,186377,187636,188999,189654,189951,190649,191497,191558,192183,193146,193431,194286,194958,195753,195776,196018,196313,197101,197323,197629,198220,198808,198883,201217,201917,202237,202834,203058,204039,205214,205352,206102,206268,206711,206845,207403,207598,210242],[285.0,21.0,20.0,12.0,28.0,18.0,1.0,66.0,10.0,22.0,17.0,5.0,25.0,12.0,64.0,20.0,13.0,5.0,8.0,2.0,12.0,10.0,6.0,10.0,12.0,1.0,4.0,10.0,3.0,10.0,47.0,7.0,16.0,11.0,4.0,8.0,7.0,2.0,2.0,3.0,2.0,6.0,1.0,5.0,38.0,10.0,1.0,19.0,1.0,29.0,6.0,14.0,4.0,1.0,8.0,2.0,4.0,4.0,8.0,2.0,6.0,9.0,4.0,8.0,2.0,6.0,8.0,4.0,6.0,4.0,30.0,14.0,5.0,29.0,1.0,3.0,1.0,9.0,6.0,11.0,2.0,8.0,1.0,2.0,3.0,6.0,4.0,7.0,4.0,1.0,3.0,5.0,23.0,4.0,3.0,1.0,2.0,3.0,7.0,1.0,6.0,7.0,7.0,8.0,3.0,12.0,24.0,1.0,3.0,4.0,2.0,1.0,3.0,6.0,1.0,5.0,4.0,1.0,1.0,1.0,6.0,2.0,3.0,12.0,9.0,1.0,1.0,3.0,3.0,8.0,4.0,3.0,2.0,1.0,3.0,6.0,1.0,2.0,4.0,8.0,2.0,1.0,11.0,3.0,3.0,6.0,4.0,1.0,1.0,6.0,7.0,1.0,3.0,2.0,29.0,2.0,5.0,29.0,4.0,1.0,1.0,2.0,4.0,1.0,2.0,4.0,21.0,4.0,1.0,2.0,7.0,2.0,1.0,2.0,3.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,10.0,6.0,3.0,2.0,1.0,10.0,5.0,1.0,3.0,6.0,4.0,1.0,6.0,8.0,2.0,9.0,1.0,4.0,3.0,1.0,5.0,1.0,1.0,1.0,5.0,11.0,2.0,1.0,4.0,3.0,25.0,4.0,1.0,5.0,3.0,1.0,2.0,1.0,1.0,4.0,3.0,1.0,2.0,1.0,1.0,5.0,4.0,1.0,7.0,1.0,2.0,1.0,26.0,3.0,5.0,7.0,1.0,9.0,1.0,1.0,2.0,5.0,1.0,2.0,1.0,8.0,2.0,3.0,2.0,1.0,1.0,1.0,4.0,2.0,1.0,16.0,2.0,1.0,1.0,6.0,4.0,1.0,4.0,1.0,12.0,1.0,2.0,2.0,3.0,2.0,1.0,2.0,3.0,1.0,3.0,1.0,1.0,3.0,3.0,1.0,5.0,2.0,1.0,2.0,1.0,3.0,1.0,11.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,3.0,2.0,3.0,1.0,8.0,116.0,4.0,5.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,3.0,4.0,2.0,5.0,5.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,8.0,8.0,3.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,8.0,1.0,5.0,1.0,3.0,1.0,1.0,2.0,11.0,2.0,2.0,3.0,1.0,5.0,26.0,1.0,2.0,2.0,1.0,1.0,3.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,3.0,1.0,1.0,8.0,3.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,3.0,4.0,2.0,1.0,1.0,1.0,5.0,1.0,3.0,4.0,1.0,2.0,1.0,2.0,4.0,1.0,2.0,1.0,2.0,1.0,4.0,2.0,1.0,6.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,6.0,1.0,1.0,1.0,2.0,1.0,1.0,5.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,7.0,2.0,1.0,1.0,2.0,1.0,3.0,1.0,4.0,4.0,1.0,4.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,4.0,4.0,20.0,3.0,1.0,2.0,3.0,4.0,2.0,2.0,2.0,1.0,2.0,1.0,2.0,6.0,1.0,1.0,6.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,5.0,1.0,4.0,2.0,4.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,2.0,1.0,3.0,2.0,3.0,2.0,1.0,2.0,4.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,63.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,3.0,1.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,9.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,27.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,5.0,8.0,1.0,1.0,2.0,4.0,3.0,4.0,2.0,2.0,2.0,1.0,13.0,1.0,1.0,2.0,10.0,1.0,6.0,1.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,11.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,38.0,1.0,1.0,1.0,1.0,1.0,23.0,3.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,24.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,7.0,1.0,2.0,7.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,19.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,2.0,1.0,4.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,11.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,5.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,3.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,5.0,1.0,4.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,5.0,1.0,5.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,5.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,3.0,3.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n",
      "|[molecular, medicine, the, role, of, selenium, metabolism, andselenoproteins, in, cartilage, homeostasisand, arthropathiesdonghyun, kang, , jeeyeon, lee, , cuiyan, wu3, xiong, guo3, byeong, jae, lee24, jangsoo, chun5, andjinhong, kim, abstractas, an, essential, nutrient, and, trace, element, selenium, is, required, for, living, anisms, and, its, beneï¬cial, roles, in, humanhealth, have, been, well, recognized, the, role, of, selenium, is, mainly, played, through, selenoproteins, synthesized, by, theselenium, metabolic, system, selenoproteins, have, a, wide, range, of, cellular, functions, including, regulation, of, seleniumtransport, thyroid, hormones, immunity, and, redox, homeostasis, selenium, deï¬ciency, contributes, to, various, diseasessuch, as, cardiovascular, disease, cancer, liver, disease, and, arthropathykashinbeck, disease, kbd, and, osteoarthritisoa, a, skeletal, developmental, disorder, kbd, has, been, reported, in, lowselenium, areas, of, china, north, korea, and, thesiberian, region, of, russia, and, can, be, alleviated, by, selenium, supplementation, oa, the, most, common, form, of, arthritisis, a, degenerative, disease, caused, by, an, imbalance, in, matrix, metabolism, and, is, characterized, by, cartilage, destructionoxidative, stress, serves, as, a, major, cause, of, the, initiation, of, oa, pathogenesis, selenium, deï¬ciency, and, dysregulation, ofselenoproteins, are, associated, with, impairments, to, redox, homeostasis, in, cartilage, we, review, the, recently, exploredroles, of, selenium, metabolism, and, selenoproteins, in, cartilage, with, an, emphasis, on, two, arthropathies, kbd, and, oamoreover, we, discuss, the, potential, of, therapeutic, strategies, targeting, the, biological, functions, of, selenium, andselenoproteins, for, oa, treatmentintroductionselenium, se, is, an, essential, trace, element, in, humans12selenium, is, generally, taken, up, from, the, diet, through, foodor, other, forms, of, external, supplementation, dietaryselenium, is, obtained, in, the, form, of, selenomethioninesemet, selenocysteine, sec, selenite, and, selenate, signiï¬cant, health, beneï¬ts, have, been, attributed, to, seleniummetabolic, systems, that, play, major, physiological, roles, inthyroid, hormone, metabolism, immunity, and, antioxidantdefense23, selenium, is, required, for, the, production, ofthyroid, hormonemetabolizing, enzymes, and, seleniumcorrespondence, jinhong, kim, jinhkimsnuackr1center, for, rna, research, institute, for, basic, science, seoul, , south, korea2department, of, biological, sciences, college, of, natural, sciences, seoul, nationaluniversity, seoul, , south, koreafull, list, of, author, information, is, available, at, the, end, of, the, these, authors, contributed, equally, donghyun, kang, jeeyeon, leesupplementation, is, thought, to, improve, the, function, ofthyrocytes, and, immune, cells4, selenium, supplementationdemonstrated, immunostimulant, effects, such, as, enhancedproliferation, of, activated, t, cells, activation, of, naturalkiller, cells, and, tumor, cytotoxicity, mediated, by, cytotoxiclymphocytes56, in, contrast, selenium, deï¬ciency, is, associated, with, the, occurrence, virulence, and, disease, progression, of, viral, infections7selenium, inadequacy, can, lead, to, various, types, ofdiseases, most, notably, cardiovascular, disease8, cancer13, hepatopathy1617, and, arthropathy, cardiovascular, diseases, are, associated, with, systemic, seleniumlevel, with, a, higher, risk, at, , or, , î¼gl, seleniumconcentration, in, the, blood10, a, type, of, endemic, cardiomyopathy, keshan, disease, is, linked, to, selenium, deï¬ciency811, keshan, disease, occurs, in, lowselenium, areasin, chinasodium, seleniteand, is, prevented, by, the, authors, , , access, this, , is, licensed, under, a, creative, commons, attribution, , international, license, which, permits, use, sharing, adaptation, distribution, and, reproductionin, any, medium, or, format, as, long, as, you, give, appropriate, credit, to, the, original, authors, and, the, source, provide, a, link, to, the, creative, commons, license, and, indicate, ifchanges, were, made, the, images, or, other, third, party, material, in, this, , are, included, in, the, s, creative, commons, license, unless, indicated, otherwise, in, a, credit, line, to, the, material, ifmaterial, is, not, included, in, the, s, creative, commons, license, and, your, intended, use, is, not, permitted, by, statutory, regulation, or, exceeds, the, permitted, use, you, will, need, to, obtainpermission, directly, from, the, copyright, holder, to, view, a, copy, of, this, license, visit, httpcreativecommonslicensesby40ofï¬cial, journal, of, the, korean, society, for, biochemistry, and, molecular, biology, 0ckang, , experimental, , molecular, medicinepage, , of, studiesepidemiologicalsupplementation12, lowselenium, status, is, correlatedwith, a, significantly, increased, risk, of, cancer, incidenceand, mortality13haveprovided, evidence, on, the, cancerpreventing, effects, ofselenium18, selenium, deï¬ciency, is, also, characterizedby, elevated, levels, of, oxidative, stress, markers, in, the, liver21which, significantly, contribute, to, liver, injury17, the, oxidative, stress, caused, by, selenium, deï¬ciency, further, plays, adetrimental, role, in, joint, development, selenium, deï¬ciency, is, the, main, cause, of, endemic, kashinbeck, diseasekbd, which, is, mainly, reported, in, lowselenium, areas, ofchina, north, korea, and, the, siberian, region, of, russiamoreover, there, is, a, growing, body, of, evidence, suggestingthat, the, pathogenesis, of, osteoarthritis, oa, the, mostcommon, form, of, arthritis, may, be, associated, with, selenium, deï¬ciency, by, resulting, in, oxidative, stress22however, it, is, noteworthy, that, excessive, selenium, intakecan, also, cause, selenosis2930, which, accompanies, adversesymptoms, including, fatigue, diarrhea, nausea, increasedheart, rate, necrosis, in, liver, and, kidney, and, neurologicaldamage, chroniccompromisesimmune, and, reproductive, systems, in, humanseventuallyselenosisoa, is, characterized, by, progressive, loss, of, cartilageextracellular, matrix, ecm, and, pathological, changes, inother, joint, tissues, such, as, subchondral, bone, sclerosisosteophyte, formation, and, synovial, ammation31, cartilage, destruction, is, considered, a, hallmark, of, oa, and, is, aresult, of, increased, production, of, catabolic, effectors32and, reduced, matrix, biosynthesis, by, chondrocytes36, oa, isassociated, with, multiple, etiologies, involving, systemicfactors, such, as, age37, as, well, as, local, factors, such, asmechanical, stress38, driven, by, weightbearing, and, jointinstability, both, oacausing, factors, have, been, found, tocause, oxidative, stress, in, chondrocytes, oxidative, stressresults, from, the, abnormal, production, of, reactive, oxygenspecies, ros, and, the, loss, of, cellular, antioxidant, capacitymany, preclinical, and, clinical, studies, have, indicated, theaccumulation, of, oxidative, burden, in, chondrocytesundergoing, osteoarthritic, changes3940, emerging, evidence, suggests, that, oxidative, stress, is, mechanisticallylinked, to, the, initiation, of, osteoarthritic, changes, inchondrocytes, through, the, acquisition, of, senescent, phenotypes36, therefore, restoring, redox, homeostasis, canserve, as, a, rational, therapeutic, strategy, to, alleviate, oaprogression, here, we, review, the, role, of, selenium, metabolism, in, cartilage, and, bone, and, the, signiï¬cance, ofmaintaining, its, homeostasis, in, the, context, of, joint, diseases, such, as, kbd, and, oaoverview, of, the, selenium, metabolic, systemthe, selenium, metabolic, system, and, the, biosynthesis, ofselenoproteinsselenium, metabolism, is, a, systemic, process, that, includesandtransformationtransportationabsorptiontheofï¬cial, journal, of, the, korean, society, for, biochemistry, and, molecular, biologyexcretion, of, selenium, fig, , selenium, is, obtained, inanic, formssemet, and, secand, inanic, formsselenite, and, selenatefrom, diet, selenium, is, taken, up, bythe, liver, that, synthesizes, and, exports, selenop, whicheventually, circulates, through, the, bloodstream, selenopwith, multiple, sec, residues41, transports, selenium, to, othertissues, and, ans42, and, the, transported, selenium, isconverted, to, selenophosphate, by, intracellular, seleniummetabolic, pathways, selenium, is, excreted, through, exhalation, and, urine, in, the, form, of, smallmolecule, metabolites, formed, by, sequential, methylation4344selenium, plays, biological, roles, predominantly, in, theform, of, selenoproteins, synthesized, by, the, seleniummetabolic, system, ingested, inanic, selenium, is, ï¬rstreduced, to, hydrogen, selenide, h2se, via, glutathionegsh, and, thioredoxin, txn, systems, selenide, is, furtherconverted, to, sec, amino, acids, for, incorporation, intospeciï¬c, sites, of, selenoproteins, such, as, the, catalytic, sites, ofa, selenoenzyme, mechanistically, selenophosphate, synthetase, , sephs2, catalyzes, the, production, of, selenophosphate, through, the, reduction, of, hydrogen, selenidethe, subsequent, reaction, with, phosphoseryltrna, psertrna[ser]sec, yields, sectrna[ser]sec, sec, amino, acids, areincorporated, into, polypeptidethrough, themachinery, utilizing, the, uga, codon, selenocysteineinsertion, sequence, binding, protein, , sbp2, binds, toselenocysteine, insertion, sequence, secis, element, whichis, located, in, the, ²untranslated, region, ²utr, of, selenoprotein, mrna, and, mediates, the, transfer, of, sectrna[ser]sec, to, the, asite, of, ribosome, which, recognizesthe, uga, codon, as, the, sec, integration, codon, collectivelythe, selenoprotein, translation, machinery, consists, of, seciselement, sbp2, secspeciï¬c, eukaryotic, elongation, factoreefsec, and, aminoacylated, sectrna[ser]sec, therebyenabling, uga, to, be, recognized, as, a, sec, codon, and, utilized, for, translation, into, the, growing, polypeptidechainsselenoproteinssome, ofselenoprotein, is, deï¬ned, as, a, protein, containing, secamino, acid, residue, the, biological, functions, of, seleniumare, mostly, exerted, through, selenoprotein, domains, thatcontain, sec, residues, twentyï¬ve, selenoprotein, geneshave, been, identiï¬ed, in, the, human, genome45, in, mice, atotal, of, , selenoproteins, have, been, characterized46, andtargeted, deletion, ofthese, selenoproteinsdemonstrated, their, essential, roles, in, developmental, processes, and, in, disease, pathogenesis, selenoproteins, can, beclassiï¬ed, into, subfamilies, based, on, their, cellular, functionssuch, as, those, implicated, in, antioxidation, gpx1, gpx2gpx3, gpx4, redox, regulation, txnrd1, txnrd2txnrd3, msrb1, selenoh, selenom, selenowthyroid, hormone, metabolism, dio1, dio2, dio3, selenium, transport, and, storage, selenop, selenophosphatesynthesis, sephs2, calcium, metabolism, selenok, 0ckang, , experimental, , molecular, medicinepage, , of, fig, , selenium, metabolic, system, in, mammals, selenium, is, absorbed, from, the, diet, undergoes, several, conversion, steps, and, is, incorporated, intopolypeptide, chains, completing, selenoprotein, synthesis, dietary, sources, of, selenium, uptake, exist, in, inanic, form, such, as, selenate, and, selenite, andanic, form, such, as, sec, and, semet, inanic, forms, are, reduced, by, txnrdtrx, or, grxgsh, systems, and, anic, forms, are, cleaved, by, sclyforming, selenide, selenophosphate, is, synthesized, from, selenide, by, sephs2, and, the, subsequent, reaction, with, psertrna[ser]sec, mediated, by, sepsecsyields, sectrna[ser]sec, sectrna[ser]sec, is, transferred, to, the, asite, of, ribosome, mediated, by, sbp2, which, binds, to, secis, located, in, the, ²utr, of, aselenoprotein, mrna, finally, the, uga, codon, is, recognized, as, the, sec, integration, codon, abbreviations, semet, selenomethionine, secselenocysteine, grx, glutathione, reductase, trx, thioredoxin, txnrd, thioredoxin, reductase, gsh, glutathione, mgl, methionine, gammalyase, sclyselenocysteine, lyase, sephs2, selenophosphate, synthetase, , sars, seryltrna, synthetase, pstk, phosphoserylseptrna, kinase, sepsecs, septrnasectrna, synthase, eefsec, secspeciï¬c, eukaryotic, elongation, factor, sbp2, secis, binding, protein, selenot, myogenesis, selenon, protein, foldingselenof, selenoi, selenos, and, protein, ampylation, selenoo4748, the, functions, of, other, selenoproteins, such, as, gpx6, and, selenov, still, remain, unclearglutathione, peroxidases, gpxs, such, as, gpx1, cytosolicgpx, gpx2, gastrointestinal, gpx, and, gpx4, phospholipid, hydroperoxide, gpx, catalyze, the, decompositionof, a, great, variety, of, peroxides, thus, protecting, cellsagainst, oxidative, damage4950, thioredoxin, reductasestxnrds, employ, nadph, as, an, electron, donor, to, revertoxidized, txn, to, a, reduced, dithiol, the, oxidation, status, ofwhich, is, critically, implicated, in, regulating, various, cellbehaviors, including, proliferation, and, apoptosis51, thephysiological, signiï¬cance, of, txnrds, is, further, supported, by, the, embryonic, lethality, of, txnrd1, or, txnrd2knockout, mice5253, deiodinases, dios, regulate, thyroidhormone, metabolism, by, catalyzing, the, conversion, ofthyroid, hormones, from, precursor, thyroxine, t4, to, biologically, active, triiodothyronine, t3, or, inactive, reverset3, rt354, the, expression, levels, of, several, selenoproteinsofï¬cial, journal, of, the, korean, society, for, biochemistry, and, molecular, biologyare, uenced, by, the, extent, of, selenium, uptake, forexample, seleniumdeï¬cient, animals, and, human, cell, linesexhibit, reduced, transcription, of, selenoproteins, such, asgpx1, dios, selenoi, and, selenow55, a, subset, ofselenoproteins, such, as, gpx1, and, selenow, is, moresensitive, to, selenium, supplementation, or, deï¬ciency, thehierarchy, of, selenoprotein, expression, is, more, apparentwhen, the, intracellular, level, of, selenium, is, limited1seleniumresponsive, genesgenesareseleniumcontainingseleniumresponsivethe, genes, whoseexpression, patterns, are, uenced, by, supplementationwith, selenium, orcompoundstreatment, of, a, cancer, cell, line, with, methylseleninic, acidin, , genes58, theseinduced, expression, changesresponsive, genes, were, closely, associated, with, annotationsrelated, to, cell, cycle, regulation, androgenresponsive, genesand, phase, ii, detoxiï¬cation, pathway, selenium, supplementation, of, macrophages, diminished, the, expression, oflipopolysaccharide, lpsinduced, proammatory, genes, 0ckang, , experimental, , molecular, medicinepage, , of, such, as, cyclooxygenase2, cox2, and, tumor, necrosisfactorî±, tnfî±59, suggesting, that, selenium, has, antiammatory, effects, on, the, immune, system, the, ctddatabase, httpctdbase, reports, the, effect, of, environmental, chemicals, including, selenium, on, gene, expression, proï¬les, in, various, human, tissuesthe, role, of, selenium, and, selenoproteins, incartilage, development, and, kbdselenium, levels, and, its, role, in, joint, tissuesjoints, are, composed, of, various, types, of, connective, tissues, including, cartilage, bone, synovium, meniscus, andligament, among, these, tissues, cartilage, is, the, maincomponent, that, absorbs, mechanical, stress, cushioningbones, from, impacting, each, other, during, various, weightbearing, activities, in, the, human, knee, joint, the, seleniumconcentration, in, cartilage, is, approximately, , î¼gkg, dryweight, whereas, the, selenium, concentrations, in, ligamentand, meniscus, are, , and, , î¼gkg, dry, weight, respectively6061, the, requirement, of, adequate, physiologicalselenium, levels, for, maintaining, cartilage, homeostasis, hasbeen, recognized, selenium, deï¬ciency, retards, the, growthand, development, of, cartilage, and, bone62, growthretardation, was, observed, in, rats, after, two, generations, ofselenium, deï¬ciency62, mice, fed, a, diet, deï¬cient, in, selenium, resulted, in, ï¬brocartilage, formation, at, the, articularsurface, ultimately, showing, degeneration, of, articularcartilage63, selenium, deï¬ciency, induced, the, expression, ofthe, chondrocyte, hypertrophy, marker, gene, type, x, collagencolx, in, articular, cartilage64, the, expression, of, parathyroid, hormonerelated, protein, pthrp, which, controlschondrocyte, maturation, during, endochondral, ossiï¬cation, was, enhanced, in, both, articular, cartilage, andhypertrophic, growth, plate, following, selenium, deï¬ciencythese, changes, were, in, line, with, the, phenotypic, changesobserved, in, the, cartilage, of, kbd, patients64, however, itshould, be, noted, that, growth, retardation, caused, by, selenium, deï¬ciency, may, also, be, associated, with, the, deregulation, of, bone, metabolism65, in, a, study, by, cao, et, alselenium, deï¬ciency, severely, compromised, bone, microarchitecture, as, a, result, of, increased, bone, resorption66abnormalities, in, selenium, metabolism, and, skeletaldevelopment, diseasesselenium, deï¬ciency, is, regarded, as, one, of, the, initiatingfactors, of, kbd, which, is, an, endemic, osteoarthropathycaused, by, the, premature, closure, of, epiphyseal, plate, andthe, impaired, skeletal, development, skeletal, deformities, inhands, ï¬ngers, knees, and, elbows, and, in, severe, casesdwarï¬sm, and, movement, disorders, are, the, symptoms, ofkbd22, the, kbd, area, roughly, coincides, with, lowselenium, areas, including, a, geological, belt, extendingfrom, northeast, to, southwest, china, north, korea, andeastern, siberia22, a, metaanalysis, showed, that, seleniumofï¬cial, journal, of, the, korean, society, for, biochemistry, and, molecular, biologylevels, in, the, water, soil, cereal, and, corn, in, kbd, endemicregions, were, lower, than, they, were, in, nonendemicregions, supporting, the, fact, that, the, level, of, selenium, intissue, is, predominantly, affected, by, dietary, intake23, in, linewith, this, ï¬nding, selenium, levels, in, the, whole, bloodserum, hair, and, urine, of, kbd, patients, were, markedlylower, than, those, of, healthy, controls24selenoprotein, gene, polymorphisms, are, associated, withincreased, susceptibility, to, kbd, there, were, significantdifferences, in, the, allelic, frequency, of, gpx1, pro198leurs1050450, between, the, kbd, and, control, group67, inaddition, the, mrna, level, of, gpx1, and, enzyme, activity, oftotal, gpx, in, blood, were, lower, in, the, kbd, group, thanthey, were, in, the, control, group67, haplotypes, of, tccttc, and, ttt, of, rs1050450, rs3811699, and, rs1800668in, gpx1, gene, also, had, a, significant, link, to, kbd68, asinglenucleotide, polymorphism, snp, in, the, promoterregion, of, selenos, rs28665122, 105g, , a, was, relatedto, the, increased, risk, of, kbd, and, upregulation, of, pi3kaktsignaling, in, patients, with, kbd69, in, this, study, tertbutylhydroperoxide, tbhptreatmentinduced, chondrocyteapoptosis, was, mitigated, by, selenium, supplementation, viasodium, selenitetreatment, which, suppressed, thepi3kakt, pathway, the, minor, aallele, of, selenofrs5859, was, associated, with, a, significantly, higher, incidenceof, kbd70the, animals, fed, a, seleniumdeï¬cient, diet, recapitulatedsome, of, the, pathological, manifestations, of, kbd, stronglysupporting, the, notion, that, selenium, deï¬ciency, is, criticallyassociated, with, the, development, of, this, endemic, arthropathy, selenium, deï¬ciency, impaired, bone, and, cartilagegrowth, with, the, exhibition, of, premature, chondrocytehypertrophy, as, evidenced, by, an, increased, expression, ofcolx, compatible, with, the, phenotypes, in, kbd, cartilage64the, lowselenium, condition, in, combination, with, threemycotoxins, deoxynivalenol, don, nivalenol, niv, and, t, yielded, procatabolic, changes, and, hypertrophic, phenotype, of, chondrocytes, as, evidenced, by, the, loss, of, aggrecanand, type, ii, collagen, colii, and, the, increase, in, colx, andmatrix, metalloproteinases, mmps, expressionrespectively71, in, contrast, selenium, supplementation, partiallyalleviated, these, mycotoxininduced, damages, in, chondrocytes71, in, rats, dietary, selenium, deï¬ciency, over, twogenerations, caused, the, onset, of, physiological, seleniuminsufï¬ciency72, in, this, condition, pathological, changes, inthe, epiphyseal, plate, were, observed, with, the, decreasedexpression, of, colii, and, gpx1, in, the, chondrocytes, suggesting, a, possible, association, of, reduced, chondrocyte, anabolism, and, antioxidant, capacity, with, the, epiphyseal, platelesions, observed, in, kbd72, the, relevance, ofimpairedselenium, metabolism, to, the, onset, of, kbd, was, furthervalidated, using, a, mouse, genetic, deletion, model, targeteddeletion, of, sectrna[ser]sec, trsp, gene, in, osteochondroprogenitor, cells, from, embryonic, stage, caused, the, 0ckang, , experimental, , molecular, medicinepage, , of, depletion, of, selenoproteins, in, skeletal, systems, causinggrowth, retardation, abnormalities, in, the, epiphyseal, growthplate, delayed, endochondral, ossiï¬cationand, chondronecrosis, which, recapitulated, the, major, pathologicalfeatures, of, kbd73as, a, prophylactic, treatment, selenium, supplementationswere, given, to, children, living, in, a, kbd, area, the, supplemented, group, showed, elevated, physiological, seleniumlevels, in, their, hair, samples, and, exhibited, a, substantiallylower, prevalence, of, kbd74, a, metaanalysis, including, ï¬verandomized, controlled, trials, rcts, and, ten, prospectivenonrcts, statistically, demonstrated, the, beneï¬ts, of, selenium, supplementation, in, preventing, kbd, in, children75selenium, metabolism, and, oaphysiological, signiï¬cance, of, oxidative, stress, inchondrocytesoa, is, the, most, common, form, of, arthritis, and, is, primarilycharacterized, by, the, loss, of, cartilagespeciï¬c, ecm, and, otherpathological, changes, in, joints, including, subchondral, bonesclerosis, osteophyte, formation, and, synovial, ammation31articular, cartilage, is, composed, of, abundant, proteoglycans, inwhich, sulfated, glycosaminoglycan, chains, such, as, chondroitinsulfates, are, bound, to, a, core, protein, such, as, aggrecan, loss, ofcartilage, matrix, during, oa, progression, is, a, combined, resultof, increased, catabolic, process, in, cartilage, and, reduced, anabolic, activity, of, chondrocytes, the, molecularlevel, understanding, of, oa, pathogenesis, has, led, to, the, identiï¬cation, ofmajor, catabolic, enzymes, adamts576, mmp377, andmmp1378, which, mediate, the, degradation, of, cartilagematrix, proammatory, cytokines, drive, the, expression, ofthese, catabolic, factors, in, chondrocytes, through, the, activationof, transcription, factors, such, as, hif2î±32, and, nfîºb79abnormalities, in, various, metabolic, pathways, such, as, glucose80, or, amino, acid, metabolic, system81, in, chondrocyteshave, been, implicated, in, activating, catabolic, cascades, inosteoarthritic, cartilage82, moreover, increased, cellular, uptakeof, zn2, through, the, upregulation, of, zinc, transporter, zip8activates, metalregulatory, transcription, factor1, mtf1which, in, turn, induces, the, expression, of, matrixdegradingenzymes, in, chondrocytes3383, regulation, of, catabolism, bythefurthershowed, the, association, of, metabolic, abnormalities, with, thecatabolic, process, of, oa34cholesterolch25hcyp7b1rorî±axismeanwhile, the, upstream, regulatory, mechanism, eliciting, an, imbalance, in, oa, matrix, homeostasis, needs, furtherinvestigation, oacausing, factorssuch, as, age, andmechanical, stress, lead, to, excessive, oxidative, stress, inchondrocytes3738, consistently, clinical, and, preclinicaloa, studies, indicated, a, cumulative, oxidative, burden, inosteoarthritic, chondrocytes3940, emerging, evidence, suggests, that, oxidative, stress, plays, a, significant, role, in, oadevelopment, and, the, disease, progression, can, be, mitigatedby, counteracting, oxidative, stress3684in, generalofï¬cial, journal, of, the, korean, society, for, biochemistry, and, molecular, biologyoxidative, stress, results, from, the, abnormal, production, ofros, and, the, loss, of, cellular, antioxidant, capacity, synovialï¬uid, from, patients, with, latestage, oa, who, were, undergoing, knee, joint, replacement, had, a, lower, level, of, oxidoreductases, than, that, from, healthy, controls87, in, partthe, increase, in, oxidative, stress, is, attributable, to, mitochondrial, dysfunction, in, oa, chondrocytes8889, oachondrocytes, displayed, reduced, mitochondrial, dnacontent, mitochondrial, dysfunction, and, diminishedexpression, of, nrf2, which, regulates, the, transcription, ofoxidoreductase, genes89, similarly, chondrocytes, fromaged, individuals, exhibited, increased, ros, burden, andmitochondrial, and, genomic, dna, damage90, therefore, the, proper, maintenance, of, redox, homeostasis, canpotentially, serve, as, a, rational, therapeutic, strategy, toprotect, against, oa, progressionpotential, roles, of, selenium, metabolism, in, oathe, protective, effect, of, selenium, in, oa, has, beenexplored, in, a, large, number, of, epidemiological, and, geneticstudies, table, , the, concentration, of, selenium, in, serumwas, significantly, lower, in, oa, patients, than, that, of, normalcontrols25, similarly, the, results, from, a, populationbasedcohort, study, demonstrated, the, linkage, between, lowselenium, levels, in, toenails, with, oaassociated, pain, anddisease, severity2627, several, studies, have, indicated, thatcartilage, matrix, homeostasis, is, impaired, in, seleniumdeï¬ciency, lowselenium, status, diminished, coliiexpression, level, regulated, by, sox9, which, is, known, as, amaster, regulator, required, for, maintaining, cartilage, matrixin, fact, sox9, was, destabilized, by, thehomeostasisdownregulation, ofseleniumresponsive, prmt5, thatsustains, sox9, stability, via, methylation93, in, anotherstudy, rats, fed, a, seleniumdeï¬cient, diet, exhibited, lowsulfotransferase, activity, which, resulted, in, diminishedforcontents, ofmechanicalcartilagematrix28, in, contrast, selenium, supplementation, ameliorated, the, spontaneous, degeneration, of, articular, cartilagein, str1, n, mice, by, increasing, the, expression, of, gpxs94in, cultured, chondrocytes, pretreatment, with, semetmarkedly, inhibited, nitric, oxide, no, and, prostaglandine2, pge2, production, in, response, to, proammatorycytokine, il1î²95, expression, of, sbp2, a, factor, recognizingsecis, element, had, a, positive, correlation, with, gpx1, andgpx4, expression, and, antioxidant, capacity, in, chondrocytes96, oxidation, resistance, mediated, by, sbp2, wasdiminished, in, response, to, il1î², treatment, in, vitro, and, indamaged, regions, of, cartilage, in, oa, patients96, downregulation, of, selenoprotein, mrnas, including, gpx397gpx1, and, gpx49698, and, selenop99, was, observed, inhuman, and, mouse, oa, chondrocytessulfated, glycosaminoglycan, essentialstressabsorbingpropertyofgenetic, factors, such, as, snps, in, selenoproteins, wereidentiï¬ed, to, be, risk, factors, for, oa, development, a, gag, 0ckang, , experimental, , molecular, medicinepage, , of, table, , list, of, selenoproteins, associated, with, the, pathogenesis, of, arthropathies, kbd, and, oagenegpx1gpx3gpx4dio2dio3selenofselenopselenosfunctionexpression, in, oasnpantioxidantreduction, of, hydrogen, peroxide, and, anic, peroxidesdownregulatedplasma, antioxidantdetoxiï¬cation, of, lipid, hydroperoxidesmetabolism, of, lipidsactivation, of, hormonesdeiodination, of, t4, to, t3inactivation, of, hormonesconversion, of, t4, to, rt3protein, foldingstorage, and, transport, of, seantioxidant, propertiesprotein, foldingerassociated, protein, degradationdownregulateddownregulatedupregulateddownregulatedrs1050450, kbdrs3811699, kbdrs1800668, kbdrs225014, oars12885300, oars945006, oars5859, kbdrs28665122, kbdrefhaplotype, in, selenos, gene, was, significantly, associatedwith, increased, levels, ofammatory, factors, in, oapatient, plasma100, snps, in, dio2, which, converts, precursor, thyroid, hormone, t4, to, its, active, form, t3, were, alsorelated, to, genetic, susceptibility, to, oa, developmentlevels, of, dio2, mrna, and, protein, were, markedly, upregulated, in, oa, cartilage101, a, common, dio2, haplotypecomposed, of, the, minor, callele, of, snp, rs225014, and, thecommon, callele, of, snp, rs12885300, was, significantlyassociated, with, advanced, hip, oa, as, indicated, by, a, higherodds, ratio101, locus, rs225014, which, confers, risk, tooa, was, associated, with, the, differential, methylation, ofcpg, located, in, the, upstream, region, of, dio2, gene, andwas, correlated, with, upregulated, dio2, expression, inoa104, meanwhile, dio3, depletes, the, resources, that, canbe, utilized, for, the, production, of, active, thyroid, moleculesby, catalyzing, the, conversion, of, t4, and, t3, into, inactivemetabolites, the, minor, gallele, of, the, dio3, variantrs945006, was, associated, with, a, protective, effect, againstoa, development105however, a, few, aspects, regarding, the, relationshipbetween, selenium, and, oa, remain, controversial, firstseveral, studies, indicate, that, there, are, no, differences, inselenium, levels, between, oa, and, normal, tissues, theselenium, concentrations, in, synovial, ï¬uid, and, plasma, of, oa, patients, were, not, significantly, different, from, thoseof, , healthy, controls106, similarly, no, significant, difference, in, selenium, concentration, was, noted, between, sixdogs, with, posttraumatic, oa, and, six, control, dogs107second, the, beneï¬cial, effect, of, selenium, supplementationin, alleviating, oa, symptoms, has, been, debated, the, resultsfrom, a, controlled, doubleblind, trial, of, , patientsofï¬cial, journal, of, the, korean, society, for, biochemistry, and, molecular, biologyrevealed, that, the, supplementation, of, a, formulation, containing, selenium, with, vitamins, a, c, and, e, seace, didnot, have, any, remarkable, curative, effect, compared, to, aplacebo108, in, a, study, with, an, independent, cohort, theprevalence, of, radiographic, knee, oa, was, not, significantlyassociated, with, dietary, selenium, intake109nonethelessit, is, apparent, that, selenium, deï¬ciencydysregulation, of, selenoproteins, and, genetic, variations, inselenoprotein, genes, serve, as, potential, risk, factors, for, oathe, vital, role, of, selenium, metabolism, in, maintainingcartilage, homeostasis, is, expected, considering, its, criticalinvolvementin, regulating, cellular, processes, such, aschondrogenic, differentiation, of, progenitor, cells, maintenance, of, redox, homeostasis, and, dna, damage, repair, inchondrocytes, which, are, covered, in, the, next, sectionintracellular, roles, of, selenium, metabolism, andselenoproteins, in, cartilagechondrogenic, differentiation, programs, of, progenitor, cellsselenium, exerts, various, beneï¬cial, effects, to, promoteproliferation, and, differentiation, of, chondrogenic, progenitorcells110111, selenium, supplementation, stimulated, the, proliferation, of, atdc5, chondrogenic, cells, even, under, serumdeprivation, by, inducing, cyclin, d1, expression110, deï¬ciencyof, selenoo, interfered, with, the, chondrogenic, differentiation, of, atdc5, cells, by, suppressing, the, expression, ofchondrogenic, genes, sox9, colii, and, aggrecan, anddecreasing, the, activity, of, alkaline, phosphatase112, knockdown, of, gpx1, reduced, the, chondrogenic, differentiation, ofatdc5, cells, by, modulating, intracellular, gshoxidizedgsh, gssg, ratio113, selenop, was, differentially, upregulatedduring, the, chondrogenic, differentiation, of, micromass, 0ckang, , experimental, , molecular, medicinepage, , of, culture, of, mesenchymal, cells, isolated, from, mouse, limbbuds114, in, line, with, the, effects, of, selenium, metabolism, andselenoproteins, in, chondrogenic, progenitor, cells, observedin, vitro, deï¬cient, uptake, of, selenium, severely, affectedchondrogenic, differentiation, of, mesenchymal, lineage, cellsin, mice64andosteochondroprogenitorspeciï¬c, deletion, of, trsp, genesignificantly, impaired, chondrogenic, programs, causingabnormalities, in, bone, and, cartilage, development, in, mice73endochondralossiï¬cationthusantioxidant, defense, and, redox, homeostasisfunction, ofattributed, to, thethe, protective, effects, of, selenium, on, cartilage, are, primarilyantioxidantdefense115, the, metabolism, and, survival, of, chondrogenic, progenitors, and, chondrocytes, are, greatly, compromised, by, ros, including, free, radicals, peroxides, andsuperoxide, anions118, recent, studies, strongly, supportthe, notion, that, mitochondrial, dysfunction, and, oxidativestress, are, the, main, drivers, of, oa, pathogenesis37although, ros, play, essential, roles, in, the, maintenance, ofbasal, cellular, activities, such, as, chondrocyte, proliferationand, matrix, remodeling, in, cartilage, excessive, oxidativestress, causes, detrimental, events, such, as, cellular, senescence36121, dedifferentiation122, and, apoptosis123, roscause, oxidative, damage, to, various, cellular, componentsand, disrupt, the, balance, between, ecm, catabolism, andanabolism119, ros, suppress, mitochondrial, oxidativephosphorylation, and, atp, production, which, are, essentially, required, to, sustain, cartilage, matrix, synthesis124, inaddition, ros, induce, matrix, degeneration, through, theupregulation, of, matrixdegrading, enzyme, expressionwhile, this, effecttreatment123125, the, detrimental, effects, of, ros, on, cartilagehomeostasis, can, be, effectively, alleviated, by, augmentingcellular, antioxidant, activity, under, stress, conditions, andseveral, attempts, have, been, made, to, treat, oa, by, targetingthe, regulators, involved, in, oxidative, stress, production, incartilage84is, abolished, by, antioxidantthe, protective, role, of, selenium, metabolism, is, thoughtto, be, exerted, through, the, neutralization, of, ros, viaantioxidant, activities, of, selenoproteins, including, gpxsand, txnrds, bone, marrow, stromal, cells, cultured, inmedium, supplemented, with, low, selenite, concentrationexhibited, ros, accumulation, along, with, the, reducedexpression, of, gpxs, txnrds, and, other, seleniumindependentinmicronuclei, generation, which, is, an, indication, of, chromosome, damage126, both, gpx1, expression, and, activitywere, substantially, lower, in, mice, fed, a, seleniumdeï¬cientdiet, than, those, in, mice, fed, a, normal, dietleading, todecreased, trabecular, number, reduced, femoral, trabecularvolumetotal, bone, volume, ratio, and, trabecular, separation66, the, rats, exposed, to, a, seleniumdeï¬cient, diet, witht2, toxin, showed, increased, lipid, peroxidation, level, andoxidoreductaseenzymesresultingofï¬cial, journal, of, the, korean, society, for, biochemistry, and, molecular, biologydecreased, antioxidant, gpx, activity, in, their, serum, andcartilage127, a, seleniumdeï¬cient, dietinduced, theexpression, of, mir1385p, which, in, turn, suppressed, theexpression, of, selenom, that, has, antioxidant, functionand, caused, mitochondrial, dysfunction, and, apoptosis, ofchondrocytes128, lead, pbinduced, oxidative, stress, andtoxicity, reduced, the, expression, of, selenoprotein, mrnasand, the, effect, was, mitigated, by, selenium, supplementation129, in, summary, the, antioxidant, properties, of, selenoproteins, showed, therapeutic, potential, by, counteractingthe, accumulation, of, damage, induced, by, oxidative, stress, incartilagedna, damage, repairit, is, well, known, that, dna, damage, pathways, play, substantial, roles, in, the, progression, of, arthropathies119, theexpression, of, genes, related, to, dna, damage, was, changedin, the, cartilage, of, kbd, patients130131, chronic, dnadamage, induces, the, initiation, of, apoptosis, or, cellularsenescence, in, chondrocytes36132133, selenium, has, apotential, to, reduce, dna, damage, and, increase, dnarepair, capacity134, in, part, the, beneï¬cial, effect, of, seleniumon, genomic, stability, is, associated, with, the, antioxidationeffect, of, selenoproteins, such, as, gpxs, and, txnrdswhich, remove, ros, before, they, cause, dna, damage134cancer, cells, supplemented, with, selenium, , nm, sodiumselenite, or, , î¼m, semet, showed, elevated, levels, of, gpx1and, txnrd1, enzyme, activity, effectively, protectingagainst, dna, strand, breaks, induced, by, ultraviolet, a, orh2o2induced, oxidative, stress135, semet, reduced, theextent, of, dna, damage, and, enhanced, dna, repair, capacity, by, inducing, repair, complex, formation, in, dnadamaged, cells, through, u]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |[molecular, medicine, role, selenium, metabolism, andselenoproteins, cartilage, homeostasisand, arthropathiesdonghyun, kang, , jeeyeon, lee, , cuiyan, wu3, xiong, guo3, byeong, jae, lee24, jangsoo, chun5, andjinhong, kim, abstractas, essential, nutrient, trace, element, selenium, required, living, anisms, beneï¬cial, roles, humanhealth, well, recognized, role, selenium, mainly, played, selenoproteins, synthesized, theselenium, metabolic, system, selenoproteins, wide, range, cellular, functions, including, regulation, seleniumtransport, thyroid, hormones, immunity, redox, homeostasis, selenium, deï¬ciency, contributes, various, diseasessuch, cardiovascular, disease, cancer, liver, disease, arthropathykashinbeck, disease, kbd, osteoarthritisoa, skeletal, developmental, disorder, kbd, reported, lowselenium, areas, china, north, korea, thesiberian, region, russia, alleviated, selenium, supplementation, oa, common, form, arthritisis, degenerative, disease, caused, imbalance, matrix, metabolism, characterized, cartilage, destructionoxidative, stress, serves, major, cause, initiation, oa, pathogenesis, selenium, deï¬ciency, dysregulation, ofselenoproteins, associated, impairments, redox, homeostasis, cartilage, review, recently, exploredroles, selenium, metabolism, selenoproteins, cartilage, emphasis, two, arthropathies, kbd, oamoreover, discuss, potential, therapeutic, strategies, targeting, biological, functions, selenium, andselenoproteins, oa, treatmentintroductionselenium, se, essential, trace, element, humans12selenium, generally, taken, diet, foodor, forms, external, supplementation, dietaryselenium, obtained, form, selenomethioninesemet, selenocysteine, sec, selenite, selenate, signiï¬cant, health, beneï¬ts, attributed, seleniummetabolic, systems, play, major, physiological, roles, inthyroid, hormone, metabolism, immunity, antioxidantdefense23, selenium, required, production, ofthyroid, hormonemetabolizing, enzymes, seleniumcorrespondence, jinhong, kim, jinhkimsnuackr1center, rna, research, institute, basic, science, seoul, , south, korea2department, biological, sciences, college, natural, sciences, seoul, nationaluniversity, seoul, , south, koreafull, list, author, information, available, end, authors, contributed, equally, donghyun, kang, jeeyeon, leesupplementation, thought, improve, function, ofthyrocytes, immune, cells4, selenium, supplementationdemonstrated, immunostimulant, effects, enhancedproliferation, activated, cells, activation, naturalkiller, cells, tumor, cytotoxicity, mediated, cytotoxiclymphocytes56, contrast, selenium, deï¬ciency, associated, occurrence, virulence, disease, progression, viral, infections7selenium, inadequacy, lead, various, types, ofdiseases, notably, cardiovascular, disease8, cancer13, hepatopathy1617, arthropathy, cardiovascular, diseases, associated, systemic, seleniumlevel, higher, risk, , , î¼gl, seleniumconcentration, blood10, type, endemic, cardiomyopathy, keshan, disease, linked, selenium, deï¬ciency811, keshan, disease, occurs, lowselenium, areasin, chinasodium, seleniteand, prevented, authors, , , access, , licensed, creative, commons, attribution, , international, license, permits, use, sharing, adaptation, distribution, reproductionin, medium, format, long, give, appropriate, credit, original, authors, source, provide, link, creative, commons, license, indicate, ifchanges, made, images, third, party, material, , included, s, creative, commons, license, unless, indicated, otherwise, credit, line, material, ifmaterial, included, s, creative, commons, license, intended, use, permitted, statutory, regulation, exceeds, permitted, use, need, obtainpermission, directly, copyright, holder, view, copy, license, visit, httpcreativecommonslicensesby40ofï¬cial, journal, korean, society, biochemistry, molecular, biology, 0ckang, , experimental, , molecular, medicinepage, , studiesepidemiologicalsupplementation12, lowselenium, status, correlatedwith, significantly, increased, risk, cancer, incidenceand, mortality13haveprovided, evidence, cancerpreventing, effects, ofselenium18, selenium, deï¬ciency, also, characterizedby, elevated, levels, oxidative, stress, markers, liver21which, significantly, contribute, liver, injury17, oxidative, stress, caused, selenium, deï¬ciency, plays, adetrimental, role, joint, development, selenium, deï¬ciency, main, cause, endemic, kashinbeck, diseasekbd, mainly, reported, lowselenium, areas, ofchina, north, korea, siberian, region, russiamoreover, growing, body, evidence, suggestingthat, pathogenesis, osteoarthritis, oa, mostcommon, form, arthritis, may, associated, selenium, deï¬ciency, resulting, oxidative, stress22however, noteworthy, excessive, selenium, intakecan, also, cause, selenosis2930, accompanies, adversesymptoms, including, fatigue, diarrhea, nausea, increasedheart, rate, necrosis, liver, kidney, neurologicaldamage, chroniccompromisesimmune, reproductive, systems, humanseventuallyselenosisoa, characterized, progressive, loss, cartilageextracellular, matrix, ecm, pathological, changes, inother, joint, tissues, subchondral, bone, sclerosisosteophyte, formation, synovial, ammation31, cartilage, destruction, considered, hallmark, oa, aresult, increased, production, catabolic, effectors32and, reduced, matrix, biosynthesis, chondrocytes36, oa, isassociated, multiple, etiologies, involving, systemicfactors, age37, well, local, factors, asmechanical, stress38, driven, weightbearing, jointinstability, oacausing, factors, found, tocause, oxidative, stress, chondrocytes, oxidative, stressresults, abnormal, production, reactive, oxygenspecies, ros, loss, cellular, antioxidant, capacitymany, preclinical, clinical, studies, indicated, theaccumulation, oxidative, burden, chondrocytesundergoing, osteoarthritic, changes3940, emerging, evidence, suggests, oxidative, stress, mechanisticallylinked, initiation, osteoarthritic, changes, inchondrocytes, acquisition, senescent, phenotypes36, therefore, restoring, redox, homeostasis, canserve, rational, therapeutic, strategy, alleviate, oaprogression, review, role, selenium, metabolism, cartilage, bone, signiï¬cance, ofmaintaining, homeostasis, context, joint, diseases, kbd, oaoverview, selenium, metabolic, systemthe, selenium, metabolic, system, biosynthesis, ofselenoproteinsselenium, metabolism, systemic, process, includesandtransformationtransportationabsorptiontheofï¬cial, journal, korean, society, biochemistry, molecular, biologyexcretion, selenium, fig, , selenium, obtained, inanic, formssemet, secand, inanic, formsselenite, selenatefrom, diet, selenium, taken, bythe, liver, synthesizes, exports, selenop, whicheventually, circulates, bloodstream, selenopwith, multiple, sec, residues41, transports, selenium, othertissues, ans42, transported, selenium, isconverted, selenophosphate, intracellular, seleniummetabolic, pathways, selenium, excreted, exhalation, urine, form, smallmolecule, metabolites, formed, sequential, methylation4344selenium, plays, biological, roles, predominantly, theform, selenoproteins, synthesized, seleniummetabolic, system, ingested, inanic, selenium, ï¬rstreduced, hydrogen, selenide, h2se, via, glutathionegsh, thioredoxin, txn, systems, selenide, furtherconverted, sec, amino, acids, incorporation, intospeciï¬c, sites, selenoproteins, catalytic, sites, ofa, selenoenzyme, mechanistically, selenophosphate, synthetase, , sephs2, catalyzes, production, selenophosphate, reduction, hydrogen, selenidethe, subsequent, reaction, phosphoseryltrna, psertrna[ser]sec, yields, sectrna[ser]sec, sec, amino, acids, areincorporated, polypeptidethrough, themachinery, utilizing, uga, codon, selenocysteineinsertion, sequence, binding, protein, , sbp2, binds, toselenocysteine, insertion, sequence, secis, element, whichis, located, ²untranslated, region, ²utr, selenoprotein, mrna, mediates, transfer, sectrna[ser]sec, asite, ribosome, recognizesthe, uga, codon, sec, integration, codon, collectivelythe, selenoprotein, translation, machinery, consists, seciselement, sbp2, secspeciï¬c, eukaryotic, elongation, factoreefsec, aminoacylated, sectrna[ser]sec, therebyenabling, uga, recognized, sec, codon, utilized, translation, growing, polypeptidechainsselenoproteinssome, ofselenoprotein, deï¬ned, protein, containing, secamino, acid, residue, biological, functions, seleniumare, mostly, exerted, selenoprotein, domains, thatcontain, sec, residues, twentyï¬ve, selenoprotein, geneshave, identiï¬ed, human, genome45, mice, atotal, , selenoproteins, characterized46, andtargeted, deletion, ofthese, selenoproteinsdemonstrated, essential, roles, developmental, processes, disease, pathogenesis, selenoproteins, beclassiï¬ed, subfamilies, based, cellular, functionssuch, implicated, antioxidation, gpx1, gpx2gpx3, gpx4, redox, regulation, txnrd1, txnrd2txnrd3, msrb1, selenoh, selenom, selenowthyroid, hormone, metabolism, dio1, dio2, dio3, selenium, transport, storage, selenop, selenophosphatesynthesis, sephs2, calcium, metabolism, selenok, 0ckang, , experimental, , molecular, medicinepage, , fig, , selenium, metabolic, system, mammals, selenium, absorbed, diet, undergoes, several, conversion, steps, incorporated, intopolypeptide, chains, completing, selenoprotein, synthesis, dietary, sources, selenium, uptake, exist, inanic, form, selenate, selenite, andanic, form, sec, semet, inanic, forms, reduced, txnrdtrx, grxgsh, systems, anic, forms, cleaved, sclyforming, selenide, selenophosphate, synthesized, selenide, sephs2, subsequent, reaction, psertrna[ser]sec, mediated, sepsecsyields, sectrna[ser]sec, sectrna[ser]sec, transferred, asite, ribosome, mediated, sbp2, binds, secis, located, ²utr, aselenoprotein, mrna, finally, uga, codon, recognized, sec, integration, codon, abbreviations, semet, selenomethionine, secselenocysteine, grx, glutathione, reductase, trx, thioredoxin, txnrd, thioredoxin, reductase, gsh, glutathione, mgl, methionine, gammalyase, sclyselenocysteine, lyase, sephs2, selenophosphate, synthetase, , sars, seryltrna, synthetase, pstk, phosphoserylseptrna, kinase, sepsecs, septrnasectrna, synthase, eefsec, secspeciï¬c, eukaryotic, elongation, factor, sbp2, secis, binding, protein, selenot, myogenesis, selenon, protein, foldingselenof, selenoi, selenos, protein, ampylation, selenoo4748, functions, selenoproteins, gpx6, selenov, still, remain, unclearglutathione, peroxidases, gpxs, gpx1, cytosolicgpx, gpx2, gastrointestinal, gpx, gpx4, phospholipid, hydroperoxide, gpx, catalyze, decompositionof, great, variety, peroxides, thus, protecting, cellsagainst, oxidative, damage4950, thioredoxin, reductasestxnrds, employ, nadph, electron, donor, revertoxidized, txn, reduced, dithiol, oxidation, status, ofwhich, critically, implicated, regulating, various, cellbehaviors, including, proliferation, apoptosis51, thephysiological, signiï¬cance, txnrds, supported, embryonic, lethality, txnrd1, txnrd2knockout, mice5253, deiodinases, dios, regulate, thyroidhormone, metabolism, catalyzing, conversion, ofthyroid, hormones, precursor, thyroxine, t4, biologically, active, triiodothyronine, t3, inactive, reverset3, rt354, expression, levels, several, selenoproteinsofï¬cial, journal, korean, society, biochemistry, molecular, biologyare, uenced, extent, selenium, uptake, forexample, seleniumdeï¬cient, animals, human, cell, linesexhibit, reduced, transcription, selenoproteins, asgpx1, dios, selenoi, selenow55, subset, ofselenoproteins, gpx1, selenow, moresensitive, selenium, supplementation, deï¬ciency, thehierarchy, selenoprotein, expression, apparentwhen, intracellular, level, selenium, limited1seleniumresponsive, genesgenesareseleniumcontainingseleniumresponsivethe, genes, whoseexpression, patterns, uenced, supplementationwith, selenium, orcompoundstreatment, cancer, cell, line, methylseleninic, acidin, , genes58, theseinduced, expression, changesresponsive, genes, closely, associated, annotationsrelated, cell, cycle, regulation, androgenresponsive, genesand, phase, ii, detoxiï¬cation, pathway, selenium, supplementation, macrophages, diminished, expression, oflipopolysaccharide, lpsinduced, proammatory, genes, 0ckang, , experimental, , molecular, medicinepage, , cyclooxygenase2, cox2, tumor, necrosisfactorî±, tnfî±59, suggesting, selenium, antiammatory, effects, immune, system, ctddatabase, httpctdbase, reports, effect, environmental, chemicals, including, selenium, gene, expression, proï¬les, various, human, tissuesthe, role, selenium, selenoproteins, incartilage, development, kbdselenium, levels, role, joint, tissuesjoints, composed, various, types, connective, tissues, including, cartilage, bone, synovium, meniscus, andligament, among, tissues, cartilage, maincomponent, absorbs, mechanical, stress, cushioningbones, impacting, various, weightbearing, activities, human, knee, joint, seleniumconcentration, cartilage, approximately, , î¼gkg, dryweight, whereas, selenium, concentrations, ligamentand, meniscus, , , î¼gkg, dry, weight, respectively6061, requirement, adequate, physiologicalselenium, levels, maintaining, cartilage, homeostasis, hasbeen, recognized, selenium, deï¬ciency, retards, growthand, development, cartilage, bone62, growthretardation, observed, rats, two, generations, ofselenium, deï¬ciency62, mice, fed, diet, deï¬cient, selenium, resulted, ï¬brocartilage, formation, articularsurface, ultimately, showing, degeneration, articularcartilage63, selenium, deï¬ciency, induced, expression, ofthe, chondrocyte, hypertrophy, marker, gene, type, x, collagencolx, articular, cartilage64, expression, parathyroid, hormonerelated, protein, pthrp, controlschondrocyte, maturation, endochondral, ossiï¬cation, enhanced, articular, cartilage, andhypertrophic, growth, plate, following, selenium, deï¬ciencythese, changes, line, phenotypic, changesobserved, cartilage, kbd, patients64, however, itshould, noted, growth, retardation, caused, selenium, deï¬ciency, may, also, associated, deregulation, bone, metabolism65, study, cao, et, alselenium, deï¬ciency, severely, compromised, bone, microarchitecture, result, increased, bone, resorption66abnormalities, selenium, metabolism, skeletaldevelopment, diseasesselenium, deï¬ciency, regarded, one, initiatingfactors, kbd, endemic, osteoarthropathycaused, premature, closure, epiphyseal, plate, andthe, impaired, skeletal, development, skeletal, deformities, inhands, ï¬ngers, knees, elbows, severe, casesdwarï¬sm, movement, disorders, symptoms, ofkbd22, kbd, area, roughly, coincides, lowselenium, areas, including, geological, belt, extendingfrom, northeast, southwest, china, north, korea, andeastern, siberia22, metaanalysis, showed, seleniumofï¬cial, journal, korean, society, biochemistry, molecular, biologylevels, water, soil, cereal, corn, kbd, endemicregions, lower, nonendemicregions, supporting, fact, level, selenium, intissue, predominantly, affected, dietary, intake23, linewith, ï¬nding, selenium, levels, whole, bloodserum, hair, urine, kbd, patients, markedlylower, healthy, controls24selenoprotein, gene, polymorphisms, associated, withincreased, susceptibility, kbd, significantdifferences, allelic, frequency, gpx1, pro198leurs1050450, kbd, control, group67, inaddition, mrna, level, gpx1, enzyme, activity, oftotal, gpx, blood, lower, kbd, group, thanthey, control, group67, haplotypes, tccttc, ttt, rs1050450, rs3811699, rs1800668in, gpx1, gene, also, significant, link, kbd68, asinglenucleotide, polymorphism, snp, promoterregion, selenos, rs28665122, 105g, , relatedto, increased, risk, kbd, upregulation, pi3kaktsignaling, patients, kbd69, study, tertbutylhydroperoxide, tbhptreatmentinduced, chondrocyteapoptosis, mitigated, selenium, supplementation, viasodium, selenitetreatment, suppressed, thepi3kakt, pathway, minor, aallele, selenofrs5859, associated, significantly, higher, incidenceof, kbd70the, animals, fed, seleniumdeï¬cient, diet, recapitulatedsome, pathological, manifestations, kbd, stronglysupporting, notion, selenium, deï¬ciency, criticallyassociated, development, endemic, arthropathy, selenium, deï¬ciency, impaired, bone, cartilagegrowth, exhibition, premature, chondrocytehypertrophy, evidenced, increased, expression, ofcolx, compatible, phenotypes, kbd, cartilage64the, lowselenium, condition, combination, threemycotoxins, deoxynivalenol, nivalenol, niv, yielded, procatabolic, changes, hypertrophic, phenotype, chondrocytes, evidenced, loss, aggrecanand, type, ii, collagen, colii, increase, colx, andmatrix, metalloproteinases, mmps, expressionrespectively71, contrast, selenium, supplementation, partiallyalleviated, mycotoxininduced, damages, chondrocytes71, rats, dietary, selenium, deï¬ciency, twogenerations, caused, onset, physiological, seleniuminsufï¬ciency72, condition, pathological, changes, inthe, epiphyseal, plate, observed, decreasedexpression, colii, gpx1, chondrocytes, suggesting, possible, association, reduced, chondrocyte, anabolism, antioxidant, capacity, epiphyseal, platelesions, observed, kbd72, relevance, ofimpairedselenium, metabolism, onset, kbd, furthervalidated, using, mouse, genetic, deletion, model, targeteddeletion, sectrna[ser]sec, trsp, gene, osteochondroprogenitor, cells, embryonic, stage, caused, 0ckang, , experimental, , molecular, medicinepage, , depletion, selenoproteins, skeletal, systems, causinggrowth, retardation, abnormalities, epiphyseal, growthplate, delayed, endochondral, ossiï¬cationand, chondronecrosis, recapitulated, major, pathologicalfeatures, kbd73as, prophylactic, treatment, selenium, supplementationswere, given, children, living, kbd, area, supplemented, group, showed, elevated, physiological, seleniumlevels, hair, samples, exhibited, substantiallylower, prevalence, kbd74, metaanalysis, including, ï¬verandomized, controlled, trials, rcts, ten, prospectivenonrcts, statistically, demonstrated, beneï¬ts, selenium, supplementation, preventing, kbd, children75selenium, metabolism, oaphysiological, signiï¬cance, oxidative, stress, inchondrocytesoa, common, form, arthritis, primarilycharacterized, loss, cartilagespeciï¬c, ecm, otherpathological, changes, joints, including, subchondral, bonesclerosis, osteophyte, formation, synovial, ammation31articular, cartilage, composed, abundant, proteoglycans, inwhich, sulfated, glycosaminoglycan, chains, chondroitinsulfates, bound, core, protein, aggrecan, loss, ofcartilage, matrix, oa, progression, combined, resultof, increased, catabolic, process, cartilage, reduced, anabolic, activity, chondrocytes, molecularlevel, understanding, oa, pathogenesis, led, identiï¬cation, ofmajor, catabolic, enzymes, adamts576, mmp377, andmmp1378, mediate, degradation, cartilagematrix, proammatory, cytokines, drive, expression, ofthese, catabolic, factors, chondrocytes, activationof, transcription, factors, hif2î±32, nfîºb79abnormalities, various, metabolic, pathways, glucose80, amino, acid, metabolic, system81, chondrocyteshave, implicated, activating, catabolic, cascades, inosteoarthritic, cartilage82, moreover, increased, cellular, uptakeof, zn2, upregulation, zinc, transporter, zip8activates, metalregulatory, transcription, factor1, mtf1which, turn, induces, expression, matrixdegradingenzymes, chondrocytes3383, regulation, catabolism, bythefurthershowed, association, metabolic, abnormalities, thecatabolic, process, oa34cholesterolch25hcyp7b1rorî±axismeanwhile, upstream, regulatory, mechanism, eliciting, imbalance, oa, matrix, homeostasis, needs, furtherinvestigation, oacausing, factorssuch, age, andmechanical, stress, lead, excessive, oxidative, stress, inchondrocytes3738, consistently, clinical, preclinicaloa, studies, indicated, cumulative, oxidative, burden, inosteoarthritic, chondrocytes3940, emerging, evidence, suggests, oxidative, stress, plays, significant, role, oadevelopment, disease, progression, mitigatedby, counteracting, oxidative, stress3684in, generalofï¬cial, journal, korean, society, biochemistry, molecular, biologyoxidative, stress, results, abnormal, production, ofros, loss, cellular, antioxidant, capacity, synovialï¬uid, patients, latestage, oa, undergoing, knee, joint, replacement, lower, level, oxidoreductases, healthy, controls87, partthe, increase, oxidative, stress, attributable, mitochondrial, dysfunction, oa, chondrocytes8889, oachondrocytes, displayed, reduced, mitochondrial, dnacontent, mitochondrial, dysfunction, diminishedexpression, nrf2, regulates, transcription, ofoxidoreductase, genes89, similarly, chondrocytes, fromaged, individuals, exhibited, increased, ros, burden, andmitochondrial, genomic, dna, damage90, therefore, proper, maintenance, redox, homeostasis, canpotentially, serve, rational, therapeutic, strategy, toprotect, oa, progressionpotential, roles, selenium, metabolism, oathe, protective, effect, selenium, oa, beenexplored, large, number, epidemiological, geneticstudies, table, , concentration, selenium, serumwas, significantly, lower, oa, patients, normalcontrols25, similarly, results, populationbasedcohort, study, demonstrated, linkage, lowselenium, levels, toenails, oaassociated, pain, anddisease, severity2627, several, studies, indicated, thatcartilage, matrix, homeostasis, impaired, seleniumdeï¬ciency, lowselenium, status, diminished, coliiexpression, level, regulated, sox9, known, amaster, regulator, required, maintaining, cartilage, matrixin, fact, sox9, destabilized, thehomeostasisdownregulation, ofseleniumresponsive, prmt5, thatsustains, sox9, stability, via, methylation93, anotherstudy, rats, fed, seleniumdeï¬cient, diet, exhibited, lowsulfotransferase, activity, resulted, diminishedforcontents, ofmechanicalcartilagematrix28, contrast, selenium, supplementation, ameliorated, spontaneous, degeneration, articular, cartilagein, str1, n, mice, increasing, expression, gpxs94in, cultured, chondrocytes, pretreatment, semetmarkedly, inhibited, nitric, oxide, prostaglandine2, pge2, production, response, proammatorycytokine, il1î²95, expression, sbp2, factor, recognizingsecis, element, positive, correlation, gpx1, andgpx4, expression, antioxidant, capacity, chondrocytes96, oxidation, resistance, mediated, sbp2, wasdiminished, response, il1î², treatment, vitro, indamaged, regions, cartilage, oa, patients96, downregulation, selenoprotein, mrnas, including, gpx397gpx1, gpx49698, selenop99, observed, inhuman, mouse, oa, chondrocytessulfated, glycosaminoglycan, essentialstressabsorbingpropertyofgenetic, factors, snps, selenoproteins, wereidentiï¬ed, risk, factors, oa, development, gag, 0ckang, , experimental, , molecular, medicinepage, , table, , list, selenoproteins, associated, pathogenesis, arthropathies, kbd, oagenegpx1gpx3gpx4dio2dio3selenofselenopselenosfunctionexpression, oasnpantioxidantreduction, hydrogen, peroxide, anic, peroxidesdownregulatedplasma, antioxidantdetoxiï¬cation, lipid, hydroperoxidesmetabolism, lipidsactivation, hormonesdeiodination, t4, t3inactivation, hormonesconversion, t4, rt3protein, foldingstorage, transport, seantioxidant, propertiesprotein, foldingerassociated, protein, degradationdownregulateddownregulatedupregulateddownregulatedrs1050450, kbdrs3811699, kbdrs1800668, kbdrs225014, oars12885300, oars945006, oars5859, kbdrs28665122, kbdrefhaplotype, selenos, gene, significantly, associatedwith, increased, levels, ofammatory, factors, oapatient, plasma100, snps, dio2, converts, precursor, thyroid, hormone, t4, active, form, t3, alsorelated, genetic, susceptibility, oa, developmentlevels, dio2, mrna, protein, markedly, upregulated, oa, cartilage101, common, dio2, haplotypecomposed, minor, callele, snp, rs225014, thecommon, callele, snp, rs12885300, significantlyassociated, advanced, hip, oa, indicated, higherodds, ratio101, locus, rs225014, confers, risk, tooa, associated, differential, methylation, ofcpg, located, upstream, region, dio2, gene, andwas, correlated, upregulated, dio2, expression, inoa104, meanwhile, dio3, depletes, resources, canbe, utilized, production, active, thyroid, moleculesby, catalyzing, conversion, t4, t3, inactivemetabolites, minor, gallele, dio3, variantrs945006, associated, protective, effect, againstoa, development105however, aspects, regarding, relationshipbetween, selenium, oa, remain, controversial, firstseveral, studies, indicate, differences, inselenium, levels, oa, normal, tissues, theselenium, concentrations, synovial, ï¬uid, plasma, oa, patients, significantly, different, thoseof, , healthy, controls106, similarly, significant, difference, selenium, concentration, noted, sixdogs, posttraumatic, oa, six, control, dogs107second, beneï¬cial, effect, selenium, supplementationin, alleviating, oa, symptoms, debated, resultsfrom, controlled, doubleblind, trial, , patientsofï¬cial, journal, korean, society, biochemistry, molecular, biologyrevealed, supplementation, formulation, containing, selenium, vitamins, c, e, seace, didnot, remarkable, curative, effect, compared, aplacebo108, study, independent, cohort, theprevalence, radiographic, knee, oa, significantlyassociated, dietary, selenium, intake109nonethelessit, apparent, selenium, deï¬ciencydysregulation, selenoproteins, genetic, variations, inselenoprotein, genes, serve, potential, risk, factors, oathe, vital, role, selenium, metabolism, maintainingcartilage, homeostasis, expected, considering, criticalinvolvementin, regulating, cellular, processes, aschondrogenic, differentiation, progenitor, cells, maintenance, redox, homeostasis, dna, damage, repair, inchondrocytes, covered, next, sectionintracellular, roles, selenium, metabolism, andselenoproteins, cartilagechondrogenic, differentiation, programs, progenitor, cellsselenium, exerts, various, beneï¬cial, effects, promoteproliferation, differentiation, chondrogenic, progenitorcells110111, selenium, supplementation, stimulated, proliferation, atdc5, chondrogenic, cells, even, serumdeprivation, inducing, cyclin, d1, expression110, deï¬ciencyof, selenoo, interfered, chondrogenic, differentiation, atdc5, cells, suppressing, expression, ofchondrogenic, genes, sox9, colii, aggrecan, anddecreasing, activity, alkaline, phosphatase112, knockdown, gpx1, reduced, chondrogenic, differentiation, ofatdc5, cells, modulating, intracellular, gshoxidizedgsh, gssg, ratio113, selenop, differentially, upregulatedduring, chondrogenic, differentiation, micromass, 0ckang, , experimental, , molecular, medicinepage, , culture, mesenchymal, cells, isolated, mouse, limbbuds114, line, effects, selenium, metabolism, andselenoproteins, chondrogenic, progenitor, cells, observedin, vitro, deï¬cient, uptake, selenium, severely, affectedchondrogenic, differentiation, mesenchymal, lineage, cellsin, mice64andosteochondroprogenitorspeciï¬c, deletion, trsp, genesignificantly, impaired, chondrogenic, programs, causingabnormalities, bone, cartilage, development, mice73endochondralossiï¬cationthusantioxidant, defense, redox, homeostasisfunction, ofattributed, thethe, protective, effects, selenium, cartilage, primarilyantioxidantdefense115, metabolism, survival, chondrogenic, progenitors, chondrocytes, greatly, compromised, ros, including, free, radicals, peroxides, andsuperoxide, anions118, recent, studies, strongly, supportthe, notion, mitochondrial, dysfunction, oxidativestress, main, drivers, oa, pathogenesis37although, ros, play, essential, roles, maintenance, ofbasal, cellular, activities, chondrocyte, proliferationand, matrix, remodeling, cartilage, excessive, oxidativestress, causes, detrimental, events, cellular, senescence36121, dedifferentiation122, apoptosis123, roscause, oxidative, damage, various, cellular, componentsand, disrupt, balance, ecm, catabolism, andanabolism119, ros, suppress, mitochondrial, oxidativephosphorylation, atp, production, essentially, required, sustain, cartilage, matrix, synthesis124, inaddition, ros, induce, matrix, degeneration, theupregulation, matrixdegrading, enzyme, expressionwhile, effecttreatment123125, detrimental, effects, ros, cartilagehomeostasis, effectively, alleviated, augmentingcellular, antioxidant, activity, stress, conditions, andseveral, attempts, made, treat, oa, targetingthe, regulators, involved, oxidative, stress, production, incartilage84is, abolished, antioxidantthe, protective, role, selenium, metabolism, thoughtto, exerted, neutralization, ros, viaantioxidant, activities, selenoproteins, including, gpxsand, txnrds, bone, marrow, stromal, cells, cultured, inmedium, supplemented, low, selenite, concentrationexhibited, ros, accumulation, along, reducedexpression, gpxs, txnrds, seleniumindependentinmicronuclei, generation, indication, chromosome, damage126, gpx1, expression, activitywere, substantially, lower, mice, fed, seleniumdeï¬cientdiet, mice, fed, normal, dietleading, todecreased, trabecular, number, reduced, femoral, trabecularvolumetotal, bone, volume, ratio, trabecular, separation66, rats, exposed, seleniumdeï¬cient, diet, witht2, toxin, showed, increased, lipid, peroxidation, level, andoxidoreductaseenzymesresultingofï¬cial, journal, korean, society, biochemistry, molecular, biologydecreased, antioxidant, gpx, activity, serum, andcartilage127, seleniumdeï¬cient, dietinduced, theexpression, mir1385p, turn, suppressed, theexpression, selenom, antioxidant, functionand, caused, mitochondrial, dysfunction, apoptosis, ofchondrocytes128, lead, pbinduced, oxidative, stress, andtoxicity, reduced, expression, selenoprotein, mrnasand, effect, mitigated, selenium, supplementation129, summary, antioxidant, properties, selenoproteins, showed, therapeutic, potential, counteractingthe, accumulation, damage, induced, oxidative, stress, incartilagedna, damage, repairit, well, known, dna, damage, pathways, play, substantial, roles, progression, arthropathies119, theexpression, genes, related, dna, damage, changedin, cartilage, kbd, patients130131, chronic, dnadamage, induces, initiation, apoptosis, cellularsenescence, chondrocytes36132133, selenium, apotential, reduce, dna, damage, increase, dnarepair, capacity134, part, beneï¬cial, effect, seleniumon, genomic, stability, associated, antioxidationeffect, selenoproteins, gpxs, txnrdswhich, remove, ros, cause, dna, damage134cancer, cells, supplemented, selenium, , nm, sodiumselenite, , î¼m, semet, showed, elevated, levels, gpx1and, txnrd1, enzyme, activity, effectively, protectingagainst, dna, strand, breaks, induced, ultraviolet, orh2o2induced, oxidative, stress135, semet, reduced, theextent, dna, damage, enhanced, dna, repair, capacity, inducing, repair, complex, formation, dnadamaged, cells, u]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |[molecular, medicine, role, selenium, metabolism, andselenoproteins, cartilage, homeostasisand, arthropathiesdonghyun, kang, , jeeyeon, lee, , cuiyan, wu3, xiong, guo3, byeong, jae, lee24, jangsoo, chun5, andjinhong, kim, abstractas, an, essential, nutrient, trace, element, selenium, required, living, anisms, its, beneï¬cial, roles, humanhealth, have, been, well, recognized, role, selenium, mainly, played, through, selenoproteins, synthesized, by, theselenium, metabolic, system, selenoproteins, have, wide, range, cellular, functions, including, regulation, seleniumtransport, thyroid, hormones, immunity, redox, homeostasis, selenium, deï¬ciency, contributes, various, diseasessuch, as, cardiovascular, disease, cancer, liver, disease, arthropathykashinbeck, disease, kbd, osteoarthritisoa, skeletal, developmental, disorder, kbd, has, been, reported, lowselenium, areas, china, north, korea, thesiberian, region, russia, can, be, alleviated, by, selenium, supplementation, oa, most, common, form, arthritisis, degenerative, disease, caused, by, an, imbalance, matrix, metabolism, characterized, by, cartilage, destructionoxidative, stress, serves, as, major, cause, initiation, oa, pathogenesis, selenium, deï¬ciency, dysregulation, ofselenoproteins, are, associated, with, impairments, redox, homeostasis, cartilage, we, review, recently, exploredroles, selenium, metabolism, selenoproteins, cartilage, with, an, emphasis, on, two, arthropathies, kbd, oamoreover, we, discuss, potential, therapeutic, strategies, targeting, biological, functions, selenium, andselenoproteins, oa, treatmentintroductionselenium, se, an, essential, trace, element, humans12selenium, generally, taken, up, from, diet, through, foodor, other, forms, external, supplementation, dietaryselenium, obtained, form, selenomethioninesemet, selenocysteine, sec, selenite, selenate, signiï¬cant, health, beneï¬ts, have, been, attributed, seleniummetabolic, systems, that, play, major, physiological, roles, inthyroid, hormone, metabolism, immunity, antioxidantdefense23, selenium, required, production, ofthyroid, hormonemetabolizing, enzymes, seleniumcorrespondence, jinhong, kim, jinhkimsnuackr1center, rna, research, institute, basic, science, seoul, , south, korea2department, biological, sciences, college, natural, sciences, seoul, nationaluniversity, seoul, , south, koreafull, list, author, information, available, at, end, these, authors, contributed, equally, donghyun, kang, jeeyeon, leesupplementation, thought, improve, function, ofthyrocytes, immune, cells4, selenium, supplementationdemonstrated, immunostimulant, effects, such, as, enhancedproliferation, activated, t, cells, activation, naturalkiller, cells, tumor, cytotoxicity, mediated, by, cytotoxiclymphocytes56, contrast, selenium, deï¬ciency, associated, with, occurrence, virulence, disease, progression, viral, infections7selenium, inadequacy, can, lead, various, types, ofdiseases, most, notably, cardiovascular, disease8, cancer13, hepatopathy1617, arthropathy, cardiovascular, diseases, are, associated, with, systemic, seleniumlevel, with, higher, risk, at, , or, , î¼gl, seleniumconcentration, blood10, type, endemic, cardiomyopathy, keshan, disease, linked, selenium, deï¬ciency811, keshan, disease, occurs, lowselenium, areasin, chinasodium, seleniteand, prevented, by, authors, , , access, , licensed, under, creative, commons, attribution, , international, license, which, permits, use, sharing, adaptation, distribution, reproductionin, any, medium, or, format, as, long, as, you, give, appropriate, credit, original, authors, source, provide, link, creative, commons, license, indicate, ifchanges, were, made, images, or, other, third, party, material, , are, included, s, creative, commons, license, unless, indicated, otherwise, credit, line, material, ifmaterial, not, included, s, creative, commons, license, your, intended, use, not, permitted, by, statutory, regulation, or, exceeds, permitted, use, you, will, need, obtainpermission, directly, from, copyright, holder, view, copy, license, visit, httpcreativecommonslicensesby40ofï¬cial, journal, korean, society, biochemistry, molecular, biology, 0ckang, , experimental, , molecular, medicinepage, , studiesepidemiologicalsupplementation12, lowselenium, status, correlatedwith, significantly, increased, risk, cancer, incidenceand, mortality13haveprovided, evidence, on, cancerpreventing, effects, ofselenium18, selenium, deï¬ciency, also, characterizedby, elevated, levels, oxidative, stress, markers, liver21which, significantly, contribute, liver, injury17, oxidative, stress, caused, by, selenium, deï¬ciency, further, plays, adetrimental, role, joint, development, selenium, deï¬ciency, main, cause, endemic, kashinbeck, diseasekbd, which, mainly, reported, lowselenium, areas, ofchina, north, korea, siberian, region, russiamoreover, there, growing, body, evidence, suggestingthat, pathogenesis, osteoarthritis, oa, mostcommon, form, arthritis, may, be, associated, with, selenium, deï¬ciency, by, resulting, oxidative, stress22however, it, noteworthy, that, excessive, selenium, intakecan, also, cause, selenosis2930, which, accompanies, adversesymptoms, including, fatigue, diarrhea, nausea, increasedheart, rate, necrosis, liver, kidney, neurologicaldamage, chroniccompromisesimmune, reproductive, systems, humanseventuallyselenosisoa, characterized, by, progressive, loss, cartilageextracellular, matrix, ecm, pathological, changes, inother, joint, tissues, such, as, subchondral, bone, sclerosisosteophyte, formation, synovial, ammation31, cartilage, destruction, considered, hallmark, oa, aresult, increased, production, catabolic, effectors32and, reduced, matrix, biosynthesis, by, chondrocytes36, oa, isassociated, with, multiple, etiologies, involving, systemicfactors, such, as, age37, as, well, as, local, factors, such, asmechanical, stress38, driven, by, weightbearing, jointinstability, both, oacausing, factors, have, been, found, tocause, oxidative, stress, chondrocytes, oxidative, stressresults, from, abnormal, production, reactive, oxygenspecies, ros, loss, cellular, antioxidant, capacitymany, preclinical, clinical, studies, have, indicated, theaccumulation, oxidative, burden, chondrocytesundergoing, osteoarthritic, changes3940, emerging, evidence, suggests, that, oxidative, stress, mechanisticallylinked, initiation, osteoarthritic, changes, inchondrocytes, through, acquisition, senescent, phenotypes36, therefore, restoring, redox, homeostasis, canserve, as, rational, therapeutic, strategy, alleviate, oaprogression, here, we, review, role, selenium, metabolism, cartilage, bone, signiï¬cance, ofmaintaining, its, homeostasis, context, joint, diseases, such, as, kbd, oaoverview, selenium, metabolic, systemthe, selenium, metabolic, system, biosynthesis, ofselenoproteinsselenium, metabolism, systemic, process, that, includesandtransformationtransportationabsorptiontheofï¬cial, journal, korean, society, biochemistry, molecular, biologyexcretion, selenium, fig, , selenium, obtained, inanic, formssemet, secand, inanic, formsselenite, selenatefrom, diet, selenium, taken, up, bythe, liver, that, synthesizes, exports, selenop, whicheventually, circulates, through, bloodstream, selenopwith, multiple, sec, residues41, transports, selenium, othertissues, ans42, transported, selenium, isconverted, selenophosphate, by, intracellular, seleniummetabolic, pathways, selenium, excreted, through, exhalation, urine, form, smallmolecule, metabolites, formed, by, sequential, methylation4344selenium, plays, biological, roles, predominantly, theform, selenoproteins, synthesized, by, seleniummetabolic, system, ingested, inanic, selenium, ï¬rstreduced, hydrogen, selenide, h2se, via, glutathionegsh, thioredoxin, txn, systems, selenide, furtherconverted, sec, amino, acids, incorporation, intospeciï¬c, sites, selenoproteins, such, as, catalytic, sites, ofa, selenoenzyme, mechanistically, selenophosphate, synthetase, , sephs2, catalyzes, production, selenophosphate, through, reduction, hydrogen, selenidethe, subsequent, reaction, with, phosphoseryltrna, psertrna[ser]sec, yields, sectrna[ser]sec, sec, amino, acids, areincorporated, into, polypeptidethrough, themachinery, utilizing, uga, codon, selenocysteineinsertion, sequence, binding, protein, , sbp2, binds, toselenocysteine, insertion, sequence, secis, element, whichis, located, ²untranslated, region, ²utr, selenoprotein, mrna, mediates, transfer, sectrna[ser]sec, asite, ribosome, which, recognizesthe, uga, codon, as, sec, integration, codon, collectivelythe, selenoprotein, translation, machinery, consists, seciselement, sbp2, secspeciï¬c, eukaryotic, elongation, factoreefsec, aminoacylated, sectrna[ser]sec, therebyenabling, uga, be, recognized, as, sec, codon, utilized, translation, into, growing, polypeptidechainsselenoproteinssome, ofselenoprotein, deï¬ned, as, protein, containing, secamino, acid, residue, biological, functions, seleniumare, mostly, exerted, through, selenoprotein, domains, thatcontain, sec, residues, twentyï¬ve, selenoprotein, geneshave, been, identiï¬ed, human, genome45, mice, atotal, , selenoproteins, have, been, characterized46, andtargeted, deletion, ofthese, selenoproteinsdemonstrated, their, essential, roles, developmental, processes, disease, pathogenesis, selenoproteins, can, beclassiï¬ed, into, subfamilies, based, on, their, cellular, functionssuch, as, those, implicated, antioxidation, gpx1, gpx2gpx3, gpx4, redox, regulation, txnrd1, txnrd2txnrd3, msrb1, selenoh, selenom, selenowthyroid, hormone, metabolism, dio1, dio2, dio3, selenium, transport, storage, selenop, selenophosphatesynthesis, sephs2, calcium, metabolism, selenok, 0ckang, , experimental, , molecular, medicinepage, , fig, , selenium, metabolic, system, mammals, selenium, absorbed, from, diet, undergoes, several, conversion, steps, incorporated, intopolypeptide, chains, completing, selenoprotein, synthesis, dietary, sources, selenium, uptake, exist, inanic, form, such, as, selenate, selenite, andanic, form, such, as, sec, semet, inanic, forms, are, reduced, by, txnrdtrx, or, grxgsh, systems, anic, forms, are, cleaved, by, sclyforming, selenide, selenophosphate, synthesized, from, selenide, by, sephs2, subsequent, reaction, with, psertrna[ser]sec, mediated, by, sepsecsyields, sectrna[ser]sec, sectrna[ser]sec, transferred, asite, ribosome, mediated, by, sbp2, which, binds, secis, located, ²utr, aselenoprotein, mrna, finally, uga, codon, recognized, as, sec, integration, codon, abbreviations, semet, selenomethionine, secselenocysteine, grx, glutathione, reductase, trx, thioredoxin, txnrd, thioredoxin, reductase, gsh, glutathione, mgl, methionine, gammalyase, sclyselenocysteine, lyase, sephs2, selenophosphate, synthetase, , sars, seryltrna, synthetase, pstk, phosphoserylseptrna, kinase, sepsecs, septrnasectrna, synthase, eefsec, secspeciï¬c, eukaryotic, elongation, factor, sbp2, secis, binding, protein, selenot, myogenesis, selenon, protein, foldingselenof, selenoi, selenos, protein, ampylation, selenoo4748, functions, other, selenoproteins, such, as, gpx6, selenov, still, remain, unclearglutathione, peroxidases, gpxs, such, as, gpx1, cytosolicgpx, gpx2, gastrointestinal, gpx, gpx4, phospholipid, hydroperoxide, gpx, catalyze, decompositionof, great, variety, peroxides, thus, protecting, cellsagainst, oxidative, damage4950, thioredoxin, reductasestxnrds, employ, nadph, as, an, electron, donor, revertoxidized, txn, reduced, dithiol, oxidation, status, ofwhich, critically, implicated, regulating, various, cellbehaviors, including, proliferation, apoptosis51, thephysiological, signiï¬cance, txnrds, further, supported, by, embryonic, lethality, txnrd1, or, txnrd2knockout, mice5253, deiodinases, dios, regulate, thyroidhormone, metabolism, by, catalyzing, conversion, ofthyroid, hormones, from, precursor, thyroxine, t4, biologically, active, triiodothyronine, t3, or, inactive, reverset3, rt354, expression, levels, several, selenoproteinsofï¬cial, journal, korean, society, biochemistry, molecular, biologyare, uenced, by, extent, selenium, uptake, forexample, seleniumdeï¬cient, animals, human, cell, linesexhibit, reduced, transcription, selenoproteins, such, asgpx1, dios, selenoi, selenow55, subset, ofselenoproteins, such, as, gpx1, selenow, moresensitive, selenium, supplementation, or, deï¬ciency, thehierarchy, selenoprotein, expression, more, apparentwhen, intracellular, level, selenium, limited1seleniumresponsive, genesgenesareseleniumcontainingseleniumresponsivethe, genes, whoseexpression, patterns, are, uenced, by, supplementationwith, selenium, orcompoundstreatment, cancer, cell, line, with, methylseleninic, acidin, , genes58, theseinduced, expression, changesresponsive, genes, were, closely, associated, with, annotationsrelated, cell, cycle, regulation, androgenresponsive, genesand, phase, ii, detoxiï¬cation, pathway, selenium, supplementation, macrophages, diminished, expression, oflipopolysaccharide, lpsinduced, proammatory, genes, 0ckang, , experimental, , molecular, medicinepage, , such, as, cyclooxygenase2, cox2, tumor, necrosisfactorî±, tnfî±59, suggesting, that, selenium, has, antiammatory, effects, on, immune, system, ctddatabase, httpctdbase, reports, effect, environmental, chemicals, including, selenium, on, gene, expression, proï¬les, various, human, tissuesthe, role, selenium, selenoproteins, incartilage, development, kbdselenium, levels, its, role, joint, tissuesjoints, are, composed, various, types, connective, tissues, including, cartilage, bone, synovium, meniscus, andligament, among, these, tissues, cartilage, maincomponent, that, absorbs, mechanical, stress, cushioningbones, from, impacting, each, other, during, various, weightbearing, activities, human, knee, joint, seleniumconcentration, cartilage, approximately, , î¼gkg, dryweight, whereas, selenium, concentrations, ligamentand, meniscus, are, , , î¼gkg, dry, weight, respectively6061, requirement, adequate, physiologicalselenium, levels, maintaining, cartilage, homeostasis, hasbeen, recognized, selenium, deï¬ciency, retards, growthand, development, cartilage, bone62, growthretardation, observed, rats, after, two, generations, ofselenium, deï¬ciency62, mice, fed, diet, deï¬cient, selenium, resulted, ï¬brocartilage, formation, at, articularsurface, ultimately, showing, degeneration, articularcartilage63, selenium, deï¬ciency, induced, expression, ofthe, chondrocyte, hypertrophy, marker, gene, type, x, collagencolx, articular, cartilage64, expression, parathyroid, hormonerelated, protein, pthrp, which, controlschondrocyte, maturation, during, endochondral, ossiï¬cation, enhanced, both, articular, cartilage, andhypertrophic, growth, plate, following, selenium, deï¬ciencythese, changes, were, line, with, phenotypic, changesobserved, cartilage, kbd, patients64, however, itshould, be, noted, that, growth, retardation, caused, by, selenium, deï¬ciency, may, also, be, associated, with, deregulation, bone, metabolism65, study, by, cao, et, alselenium, deï¬ciency, severely, compromised, bone, microarchitecture, as, result, increased, bone, resorption66abnormalities, selenium, metabolism, skeletaldevelopment, diseasesselenium, deï¬ciency, regarded, as, one, initiatingfactors, kbd, which, an, endemic, osteoarthropathycaused, by, premature, closure, epiphyseal, plate, andthe, impaired, skeletal, development, skeletal, deformities, inhands, ï¬ngers, knees, elbows, severe, casesdwarï¬sm, movement, disorders, are, symptoms, ofkbd22, kbd, area, roughly, coincides, with, lowselenium, areas, including, geological, belt, extendingfrom, northeast, southwest, china, north, korea, andeastern, siberia22, metaanalysis, showed, that, seleniumofï¬cial, journal, korean, society, biochemistry, molecular, biologylevels, water, soil, cereal, corn, kbd, endemicregions, were, lower, than, they, were, nonendemicregions, supporting, fact, that, level, selenium, intissue, predominantly, affected, by, dietary, intake23, linewith, ï¬nding, selenium, levels, whole, bloodserum, hair, urine, kbd, patients, were, markedlylower, than, those, healthy, controls24selenoprotein, gene, polymorphisms, are, associated, withincreased, susceptibility, kbd, there, were, significantdifferences, allelic, frequency, gpx1, pro198leurs1050450, between, kbd, control, group67, inaddition, mrna, level, gpx1, enzyme, activity, oftotal, gpx, blood, were, lower, kbd, group, thanthey, were, control, group67, haplotypes, tccttc, ttt, rs1050450, rs3811699, rs1800668in, gpx1, gene, also, had, significant, link, kbd68, asinglenucleotide, polymorphism, snp, promoterregion, selenos, rs28665122, 105g, , relatedto, increased, risk, kbd, upregulation, pi3kaktsignaling, patients, with, kbd69, study, tertbutylhydroperoxide, tbhptreatmentinduced, chondrocyteapoptosis, mitigated, by, selenium, supplementation, viasodium, selenitetreatment, which, suppressed, thepi3kakt, pathway, minor, aallele, selenofrs5859, associated, with, significantly, higher, incidenceof, kbd70the, animals, fed, seleniumdeï¬cient, diet, recapitulatedsome, pathological, manifestations, kbd, stronglysupporting, notion, that, selenium, deï¬ciency, criticallyassociated, with, development, endemic, arthropathy, selenium, deï¬ciency, impaired, bone, cartilagegrowth, with, exhibition, premature, chondrocytehypertrophy, as, evidenced, by, an, increased, expression, ofcolx, compatible, with, phenotypes, kbd, cartilage64the, lowselenium, condition, combination, with, threemycotoxins, deoxynivalenol, don, nivalenol, niv, t, yielded, procatabolic, changes, hypertrophic, phenotype, chondrocytes, as, evidenced, by, loss, aggrecanand, type, ii, collagen, colii, increase, colx, andmatrix, metalloproteinases, mmps, expressionrespectively71, contrast, selenium, supplementation, partiallyalleviated, these, mycotoxininduced, damages, chondrocytes71, rats, dietary, selenium, deï¬ciency, over, twogenerations, caused, onset, physiological, seleniuminsufï¬ciency72, condition, pathological, changes, inthe, epiphyseal, plate, were, observed, with, decreasedexpression, colii, gpx1, chondrocytes, suggesting, possible, association, reduced, chondrocyte, anabolism, antioxidant, capacity, with, epiphyseal, platelesions, observed, kbd72, relevance, ofimpairedselenium, metabolism, onset, kbd, furthervalidated, using, mouse, genetic, deletion, model, targeteddeletion, sectrna[ser]sec, trsp, gene, osteochondroprogenitor, cells, from, embryonic, stage, caused, 0ckang, , experimental, , molecular, medicinepage, , depletion, selenoproteins, skeletal, systems, causinggrowth, retardation, abnormalities, epiphyseal, growthplate, delayed, endochondral, ossiï¬cationand, chondronecrosis, which, recapitulated, major, pathologicalfeatures, kbd73as, prophylactic, treatment, selenium, supplementationswere, given, children, living, kbd, area, supplemented, group, showed, elevated, physiological, seleniumlevels, their, hair, samples, exhibited, substantiallylower, prevalence, kbd74, metaanalysis, including, ï¬verandomized, controlled, trials, rcts, ten, prospectivenonrcts, statistically, demonstrated, beneï¬ts, selenium, supplementation, preventing, kbd, children75selenium, metabolism, oaphysiological, signiï¬cance, oxidative, stress, inchondrocytesoa, most, common, form, arthritis, primarilycharacterized, by, loss, cartilagespeciï¬c, ecm, otherpathological, changes, joints, including, subchondral, bonesclerosis, osteophyte, formation, synovial, ammation31articular, cartilage, composed, abundant, proteoglycans, inwhich, sulfated, glycosaminoglycan, chains, such, as, chondroitinsulfates, are, bound, core, protein, such, as, aggrecan, loss, ofcartilage, matrix, during, oa, progression, combined, resultof, increased, catabolic, process, cartilage, reduced, anabolic, activity, chondrocytes, molecularlevel, understanding, oa, pathogenesis, has, led, identiï¬cation, ofmajor, catabolic, enzymes, adamts576, mmp377, andmmp1378, which, mediate, degradation, cartilagematrix, proammatory, cytokines, drive, expression, ofthese, catabolic, factors, chondrocytes, through, activationof, transcription, factors, such, as, hif2î±32, nfîºb79abnormalities, various, metabolic, pathways, such, as, glucose80, or, amino, acid, metabolic, system81, chondrocyteshave, been, implicated, activating, catabolic, cascades, inosteoarthritic, cartilage82, moreover, increased, cellular, uptakeof, zn2, through, upregulation, zinc, transporter, zip8activates, metalregulatory, transcription, factor1, mtf1which, turn, induces, expression, matrixdegradingenzymes, chondrocytes3383, regulation, catabolism, bythefurthershowed, association, metabolic, abnormalities, with, thecatabolic, process, oa34cholesterolch25hcyp7b1rorî±axismeanwhile, upstream, regulatory, mechanism, eliciting, an, imbalance, oa, matrix, homeostasis, needs, furtherinvestigation, oacausing, factorssuch, as, age, andmechanical, stress, lead, excessive, oxidative, stress, inchondrocytes3738, consistently, clinical, preclinicaloa, studies, indicated, cumulative, oxidative, burden, inosteoarthritic, chondrocytes3940, emerging, evidence, suggests, that, oxidative, stress, plays, significant, role, oadevelopment, disease, progression, can, be, mitigatedby, counteracting, oxidative, stress3684in, generalofï¬cial, journal, korean, society, biochemistry, molecular, biologyoxidative, stress, results, from, abnormal, production, ofros, loss, cellular, antioxidant, capacity, synovialï¬uid, from, patients, with, latestage, oa, who, were, undergoing, knee, joint, replacement, had, lower, level, oxidoreductases, than, that, from, healthy, controls87, partthe, increase, oxidative, stress, attributable, mitochondrial, dysfunction, oa, chondrocytes8889, oachondrocytes, displayed, reduced, mitochondrial, dnacontent, mitochondrial, dysfunction, diminishedexpression, nrf2, which, regulates, transcription, ofoxidoreductase, genes89, similarly, chondrocytes, fromaged, individuals, exhibited, increased, ros, burden, andmitochondrial, genomic, dna, damage90, therefore, proper, maintenance, redox, homeostasis, canpotentially, serve, as, rational, therapeutic, strategy, toprotect, against, oa, progressionpotential, roles, selenium, metabolism, oathe, protective, effect, selenium, oa, has, beenexplored, large, number, epidemiological, geneticstudies, table, , concentration, selenium, serumwas, significantly, lower, oa, patients, than, that, normalcontrols25, similarly, results, from, populationbasedcohort, study, demonstrated, linkage, between, lowselenium, levels, toenails, with, oaassociated, pain, anddisease, severity2627, several, studies, have, indicated, thatcartilage, matrix, homeostasis, impaired, seleniumdeï¬ciency, lowselenium, status, diminished, coliiexpression, level, regulated, by, sox9, which, known, as, amaster, regulator, required, maintaining, cartilage, matrixin, fact, sox9, destabilized, by, thehomeostasisdownregulation, ofseleniumresponsive, prmt5, thatsustains, sox9, stability, via, methylation93, anotherstudy, rats, fed, seleniumdeï¬cient, diet, exhibited, lowsulfotransferase, activity, which, resulted, diminishedforcontents, ofmechanicalcartilagematrix28, contrast, selenium, supplementation, ameliorated, spontaneous, degeneration, articular, cartilagein, str1, n, mice, by, increasing, expression, gpxs94in, cultured, chondrocytes, pretreatment, with, semetmarkedly, inhibited, nitric, oxide, no, prostaglandine2, pge2, production, response, proammatorycytokine, il1î²95, expression, sbp2, factor, recognizingsecis, element, had, positive, correlation, with, gpx1, andgpx4, expression, antioxidant, capacity, chondrocytes96, oxidation, resistance, mediated, by, sbp2, wasdiminished, response, il1î², treatment, vitro, indamaged, regions, cartilage, oa, patients96, downregulation, selenoprotein, mrnas, including, gpx397gpx1, gpx49698, selenop99, observed, inhuman, mouse, oa, chondrocytessulfated, glycosaminoglycan, essentialstressabsorbingpropertyofgenetic, factors, such, as, snps, selenoproteins, wereidentiï¬ed, be, risk, factors, oa, development, gag, 0ckang, , experimental, , molecular, medicinepage, , table, , list, selenoproteins, associated, with, pathogenesis, arthropathies, kbd, oagenegpx1gpx3gpx4dio2dio3selenofselenopselenosfunctionexpression, oasnpantioxidantreduction, hydrogen, peroxide, anic, peroxidesdownregulatedplasma, antioxidantdetoxiï¬cation, lipid, hydroperoxidesmetabolism, lipidsactivation, hormonesdeiodination, t4, t3inactivation, hormonesconversion, t4, rt3protein, foldingstorage, transport, seantioxidant, propertiesprotein, foldingerassociated, protein, degradationdownregulateddownregulatedupregulateddownregulatedrs1050450, kbdrs3811699, kbdrs1800668, kbdrs225014, oars12885300, oars945006, oars5859, kbdrs28665122, kbdrefhaplotype, selenos, gene, significantly, associatedwith, increased, levels, ofammatory, factors, oapatient, plasma100, snps, dio2, which, converts, precursor, thyroid, hormone, t4, its, active, form, t3, were, alsorelated, genetic, susceptibility, oa, developmentlevels, dio2, mrna, protein, were, markedly, upregulated, oa, cartilage101, common, dio2, haplotypecomposed, minor, callele, snp, rs225014, thecommon, callele, snp, rs12885300, significantlyassociated, with, advanced, hip, oa, as, indicated, by, higherodds, ratio101, locus, rs225014, which, confers, risk, tooa, associated, with, differential, methylation, ofcpg, located, upstream, region, dio2, gene, andwas, correlated, with, upregulated, dio2, expression, inoa104, meanwhile, dio3, depletes, resources, that, canbe, utilized, production, active, thyroid, moleculesby, catalyzing, conversion, t4, t3, into, inactivemetabolites, minor, gallele, dio3, variantrs945006, associated, with, protective, effect, againstoa, development105however, few, aspects, regarding, relationshipbetween, selenium, oa, remain, controversial, firstseveral, studies, indicate, that, there, are, no, differences, inselenium, levels, between, oa, normal, tissues, theselenium, concentrations, synovial, ï¬uid, plasma, oa, patients, were, not, significantly, different, from, thoseof, , healthy, controls106, similarly, no, significant, difference, selenium, concentration, noted, between, sixdogs, with, posttraumatic, oa, six, control, dogs107second, beneï¬cial, effect, selenium, supplementationin, alleviating, oa, symptoms, has, been, debated, resultsfrom, controlled, doubleblind, trial, , patientsofï¬cial, journal, korean, society, biochemistry, molecular, biologyrevealed, that, supplementation, formulation, containing, selenium, with, vitamins, c, e, seace, didnot, have, any, remarkable, curative, effect, compared, aplacebo108, study, with, an, independent, cohort, theprevalence, radiographic, knee, oa, not, significantlyassociated, with, dietary, selenium, intake109nonethelessit, apparent, that, selenium, deï¬ciencydysregulation, selenoproteins, genetic, variations, inselenoprotein, genes, serve, as, potential, risk, factors, oathe, vital, role, selenium, metabolism, maintainingcartilage, homeostasis, expected, considering, its, criticalinvolvementin, regulating, cellular, processes, such, aschondrogenic, differentiation, progenitor, cells, maintenance, redox, homeostasis, dna, damage, repair, inchondrocytes, which, are, covered, next, sectionintracellular, roles, selenium, metabolism, andselenoproteins, cartilagechondrogenic, differentiation, programs, progenitor, cellsselenium, exerts, various, beneï¬cial, effects, promoteproliferation, differentiation, chondrogenic, progenitorcells110111, selenium, supplementation, stimulated, proliferation, atdc5, chondrogenic, cells, even, under, serumdeprivation, by, inducing, cyclin, d1, expression110, deï¬ciencyof, selenoo, interfered, with, chondrogenic, differentiation, atdc5, cells, by, suppressing, expression, ofchondrogenic, genes, sox9, colii, aggrecan, anddecreasing, activity, alkaline, phosphatase112, knockdown, gpx1, reduced, chondrogenic, differentiation, ofatdc5, cells, by, modulating, intracellular, gshoxidizedgsh, gssg, ratio113, selenop, differentially, upregulatedduring, chondrogenic, differentiation, micromass, 0ckang, , experimental, , molecular, medicinepage, , culture, mesenchymal, cells, isolated, from, mouse, limbbuds114, line, with, effects, selenium, metabolism, andselenoproteins, chondrogenic, progenitor, cells, observedin, vitro, deï¬cient, uptake, selenium, severely, affectedchondrogenic, differentiation, mesenchymal, lineage, cellsin, mice64andosteochondroprogenitorspeciï¬c, deletion, trsp, genesignificantly, impaired, chondrogenic, programs, causingabnormalities, bone, cartilage, development, mice73endochondralossiï¬cationthusantioxidant, defense, redox, homeostasisfunction, ofattributed, thethe, protective, effects, selenium, on, cartilage, are, primarilyantioxidantdefense115, metabolism, survival, chondrogenic, progenitors, chondrocytes, are, greatly, compromised, by, ros, including, free, radicals, peroxides, andsuperoxide, anions118, recent, studies, strongly, supportthe, notion, that, mitochondrial, dysfunction, oxidativestress, are, main, drivers, oa, pathogenesis37although, ros, play, essential, roles, maintenance, ofbasal, cellular, activities, such, as, chondrocyte, proliferationand, matrix, remodeling, cartilage, excessive, oxidativestress, causes, detrimental, events, such, as, cellular, senescence36121, dedifferentiation122, apoptosis123, roscause, oxidative, damage, various, cellular, componentsand, disrupt, balance, between, ecm, catabolism, andanabolism119, ros, suppress, mitochondrial, oxidativephosphorylation, atp, production, which, are, essentially, required, sustain, cartilage, matrix, synthesis124, inaddition, ros, induce, matrix, degeneration, through, theupregulation, matrixdegrading, enzyme, expressionwhile, effecttreatment123125, detrimental, effects, ros, on, cartilagehomeostasis, can, be, effectively, alleviated, by, augmentingcellular, antioxidant, activity, under, stress, conditions, andseveral, attempts, have, been, made, treat, oa, by, targetingthe, regulators, involved, oxidative, stress, production, incartilage84is, abolished, by, antioxidantthe, protective, role, selenium, metabolism, thoughtto, be, exerted, through, neutralization, ros, viaantioxidant, activities, selenoproteins, including, gpxsand, txnrds, bone, marrow, stromal, cells, cultured, inmedium, supplemented, with, low, selenite, concentrationexhibited, ros, accumulation, along, with, reducedexpression, gpxs, txnrds, other, seleniumindependentinmicronuclei, generation, which, an, indication, chromosome, damage126, both, gpx1, expression, activitywere, substantially, lower, mice, fed, seleniumdeï¬cientdiet, than, those, mice, fed, normal, dietleading, todecreased, trabecular, number, reduced, femoral, trabecularvolumetotal, bone, volume, ratio, trabecular, separation66, rats, exposed, seleniumdeï¬cient, diet, witht2, toxin, showed, increased, lipid, peroxidation, level, andoxidoreductaseenzymesresultingofï¬cial, journal, korean, society, biochemistry, molecular, biologydecreased, antioxidant, gpx, activity, their, serum, andcartilage127, seleniumdeï¬cient, dietinduced, theexpression, mir1385p, which, turn, suppressed, theexpression, selenom, that, has, antioxidant, functionand, caused, mitochondrial, dysfunction, apoptosis, ofchondrocytes128, lead, pbinduced, oxidative, stress, andtoxicity, reduced, expression, selenoprotein, mrnasand, effect, mitigated, by, selenium, supplementation129, summary, antioxidant, properties, selenoproteins, showed, therapeutic, potential, by, counteractingthe, accumulation, damage, induced, by, oxidative, stress, incartilagedna, damage, repairit, well, known, that, dna, damage, pathways, play, substantial, roles, progression, arthropathies119, theexpression, genes, related, dna, damage, changedin, cartilage, kbd, patients130131, chronic, dnadamage, induces, initiation, apoptosis, or, cellularsenescence, chondrocytes36132133, selenium, has, apotential, reduce, dna, damage, increase, dnarepair, capacity134, part, beneï¬cial, effect, seleniumon, genomic, stability, associated, with, antioxidationeffect, selenoproteins, such, as, gpxs, txnrdswhich, remove, ros, before, they, cause, dna, damage134cancer, cells, supplemented, with, selenium, , nm, sodiumselenite, or, , î¼m, semet, showed, elevated, levels, gpx1and, txnrd1, enzyme, activity, effectively, protectingagainst, dna, strand, breaks, induced, by, ultraviolet, orh2o2induced, oxidative, stress135, semet, reduced, theextent, dna, damage, enhanced, dna, repair, capacity, by, inducing, repair, complex, formation, dnadamaged, cells, through, u]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |(224581,[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,17,18,19,20,22,23,24,25,26,27,28,33,36,37,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,57,58,60,61,62,67,68,69,70,71,72,73,74,76,77,78,80,81,82,85,86,88,89,90,91,92,94,95,96,97,99,100,101,102,103,107,108,109,110,112,113,115,117,119,120,121,125,126,127,128,129,130,131,132,133,134,137,138,140,142,143,145,148,149,151,158,159,162,164,168,170,171,173,174,175,177,185,188,189,190,192,194,197,198,200,203,204,206,211,212,213,216,219,220,221,222,224,225,226,231,232,235,236,238,240,244,246,247,248,249,250,252,257,258,262,264,265,269,270,278,281,283,284,287,290,298,299,303,308,309,312,315,321,325,327,329,332,338,342,343,345,346,352,355,357,358,361,362,363,366,367,371,372,374,377,378,383,385,387,388,389,398,402,403,405,413,416,423,427,428,429,433,434,436,441,445,446,447,453,457,459,461,463,464,467,469,470,472,474,476,477,479,486,489,490,491,492,493,505,508,515,517,521,523,525,534,541,547,555,558,559,565,569,570,574,577,580,590,594,595,597,600,603,605,607,613,621,627,640,643,646,647,649,650,652,655,657,660,668,670,673,674,677,685,688,693,700,701,703,706,715,716,721,727,729,731,732,740,741,743,750,751,753,760,762,766,768,774,781,792,793,795,799,806,807,813,816,819,820,821,823,825,826,831,834,839,848,850,855,859,862,863,864,866,874,882,885,888,891,896,901,905,910,911,912,914,917,920,922,926,929,938,940,941,944,954,958,961,963,965,966,967,968,971,974,978,988,997,1000,1007,1013,1017,1027,1028,1031,1034,1036,1041,1042,1043,1048,1051,1056,1059,1063,1073,1081,1093,1094,1096,1102,1111,1113,1117,1121,1122,1130,1132,1134,1137,1138,1151,1154,1161,1164,1168,1177,1179,1190,1195,1200,1206,1209,1211,1213,1215,1218,1232,1258,1259,1264,1271,1273,1290,1301,1311,1316,1317,1325,1334,1339,1342,1344,1348,1353,1363,1368,1376,1381,1390,1402,1404,1417,1437,1450,1454,1468,1479,1481,1485,1486,1493,1509,1513,1526,1529,1537,1539,1562,1566,1567,1574,1575,1584,1600,1623,1626,1642,1666,1682,1685,1689,1693,1704,1720,1724,1741,1745,1749,1758,1770,1773,1791,1864,1883,1886,1894,1909,1911,1932,1933,1956,1958,1966,1967,1971,1999,2006,2053,2054,2055,2069,2075,2084,2093,2112,2118,2130,2132,2134,2145,2161,2168,2172,2178,2183,2207,2211,2222,2234,2237,2239,2244,2250,2275,2285,2294,2307,2309,2314,2316,2318,2352,2364,2381,2392,2408,2426,2434,2437,2440,2450,2459,2487,2507,2509,2514,2547,2557,2566,2579,2582,2599,2608,2609,2628,2653,2680,2682,2690,2702,2705,2707,2710,2718,2735,2743,2776,2781,2793,2795,2799,2804,2811,2819,2831,2840,2853,2865,2868,2877,2884,2898,2906,2922,2927,2932,2956,2965,2972,2982,3012,3013,3022,3052,3211,3215,3221,3228,3240,3251,3254,3273,3276,3314,3332,3337,3343,3368,3378,3428,3438,3466,3494,3509,3540,3580,3630,3643,3690,3693,3704,3717,3733,3750,3786,3790,3825,3833,3873,3877,3920,3968,3971,3996,4023,4031,4061,4070,4091,4132,4200,4202,4218,4234,4240,4268,4280,4300,4325,4388,4422,4434,4441,4492,4513,4519,4531,4539,4639,4704,4762,4768,4802,4859,4890,4893,4899,4913,4916,4933,4936,4959,4969,4978,5057,5116,5128,5202,5204,5210,5229,5238,5374,5381,5396,5483,5510,5521,5531,5559,5572,5589,5610,5709,5717,5728,5756,5809,5835,5845,5859,5909,5939,5952,5971,6037,6040,6049,6109,6133,6192,6222,6225,6270,6295,6340,6369,6421,6447,6461,6557,6573,6577,6594,6597,6617,6669,6755,6797,6803,6871,6879,6912,6923,7077,7104,7142,7150,7190,7255,7313,7458,7512,7526,7551,7693,7833,7897,7924,8046,8057,8071,8107,8110,8119,8134,8161,8185,8242,8303,8350,8374,8468,8476,8625,8656,8819,8871,8873,8894,8923,8965,9001,9074,9188,9193,9208,9228,9236,9254,9284,9289,9300,9317,9393,9448,9467,9532,9572,9774,9889,9949,10016,10049,10124,10191,10266,10282,10324,10473,10533,10552,10702,10733,10773,10781,10796,10809,11015,11071,11100,11167,11246,11315,11388,11454,11537,11673,11687,11704,11744,11763,11986,12083,12148,12245,12292,12388,12466,12514,12537,12560,12606,12611,12751,12883,12906,12918,13066,13088,13170,13275,13316,13401,13526,13583,13952,13973,14091,14162,14312,14529,14860,14878,14936,15110,15115,15237,15373,15419,15429,15544,15570,15727,15913,15924,15970,16171,16202,16276,16400,16476,16788,16836,16925,17139,17358,17647,17709,17851,18239,18302,18419,18621,18859,18863,18964,19028,19112,19188,19392,19449,19538,19905,19978,20175,20211,20269,20664,20765,21286,21370,22203,22353,22471,22713,22868,22890,22960,23124,23160,23790,23846,23908,24431,24534,24695,24709,24917,24931,25087,25205,25305,25417,25519,25710,26281,26350,26577,27810,28114,28428,28573,28686,28756,28994,29115,29501,29615,30245,30422,30450,30480,30520,30657,30758,30785,30932,30974,31001,31035,31106,31234,31538,31542,31731,32324,32396,32481,32551,32558,32939,33912,34331,34440,34546,34593,34973,35317,35525,35704,35867,35939,36485,37055,37281,38051,38088,38115,38737,38926,39065,39434,39512,39708,39973,40236,40449,40488,40523,40549,40603,40732,41208,41797,41838,42141,42232,43802,45417,46264,46483,46650,47303,47703,48107,48615,48843,48974,49200,49990,50419,50428,50453,50546,50604,51366,51611,51793,51816,52360,52650,52696,53408,54704,55271,55574,55665,55770,57060,57678,57949,58061,58477,58653,58870,60761,60861,60901,60951,61602,61716,62513,62605,62607,62648,62733,62980,63120,63376,64291,66348,66433,67569,68342,68353,68384,68833,69391,70093,70957,72884,72969,73033,73181,73822,74174,74567,74615,74640,81117,81639,81706,81825,82003,82904,83003,83009,83128,83156,83576,83750,84116,84300,85114,85191,85282,85336,86012,86224,86453,86762,86963,87054,87393,87837,87862,87973,88000,88058,88577,88688,88795,89082,89177,89822,91124,91460,91482,91908,91982,92047,92187,92589,93152,93165,93452,93586,95441,95734,95878,95886,96105,96115,96262,96299,96537,96620,96840,96958,96975,97004,97420,97493,97755,98277,99215,99759,100427,100514,100714,100746,100775,100883,100947,100948,101088,101368,101687,101893,102019,102720,102770,103065,103098,103281,103753,103886,104146,104388,104966,105008,105072,105094,105147,105479,105658,105826,106070,106310,106650,106893,107179,107226,107492,107555,107836,108139,108383,108408,108794,108843,109202,109597,109655,109707,109966,110277,110421,110490,111019,111070,111768,111862,111869,112768,112810,112862,112933,113398,114042,114440,114560,114653,114789,114915,115840,116390,116508,116573,117266,118444,118658,118906,119149,119928,119976,120025,120823,120902,121082,121174,121563,121666,121829,122428,122519,122587,122750,122879,122898,123007,123075,123209,123704,123788,124685,124779,124896,124899,125214,125272,125595,125613,125892,126278,126565,126667,127533,127553,127622,127633,127657,127767,127772,128367,128570,128974,129063,129093,130003,130259,130339,130537,130819,131130,131690,132036,132210,132315,132490,132611,133016,133894,134114,134147,134657,134942,135215,135466,135831,135903,136207,136408,136486,136712,136729,136895,138203,138321,138395,138497,138587,139329,139381,139627,139727,140700,141151,141242,141346,141559,141659,142290,142473,142977,142995,143688,144108,144256,144388,145188,145726,145858,146206,146514,146628,146927,147029,147352,147635,147657,148112,148179,148280,148383,148546,149268,149528,149879,150174,150305,150820,151023,151603,152158,152244,152259,152477,152936,153346,153456,153847,154162,154241,154263,154765,154954,155037,155067,155142,155149,155675,155783,156532,157052,157149,157390,157552,157657,157724,157869,158433,158897,159913,159919,160100,160776,160893,160944,161506,161716,161997,162091,162447,162722,162946,163039,163131,163752,163787,163864,164036,164581,164638,165010,165636,165680,166130,166141,166204,166236,166432,166486,166654,166990,167218,167563,167825,168126,168247,168300,168540,168588,169071,169255,169271,169534,169690,170106,170323,170537,170650,170919,170966,171250,172397,172467,172858,173334,173545,173572,173812,174074,174127,174605,174952,175057,175148,175233,175467,175643,176140,176315,176630,177142,177388,178335,178462,178496,178679,178701,179795,180330,181015,181049,181212,181252,182184,183038,183504,183820,184313,184543,184829,184967,185120,185167,185213,185259,185539,185556,185788,185794,185880,186102,186790,186843,186960,187129,187264,187416,187635,187787,188430,188556,188991,189064,189107,189398,189598,189640,189691,189846,189892,190122,190771,190783,190986,191128,191764,191785,191904,191932,192129,192153,192617,192658,192758,193359,193394,193488,193876,193974,194621,194934,195391,195953,196604,196679,196986,197207,198017,198168,198273,198400,198450,198611,199131,199326,199543,199872,199906,199924,199963,200762,200868,201004,201084,201195,201228,201395,201517,201838,202617,203110,203529,203632,203696,204027,205092,205506,205580,205607,205848,206101,206508,206881,206998,207334,207473,207572,207687,207728,207829,207996,208314,208593,209036,209456,209489,209610,209662,210036,210041,210057,210110,210163,210270,210334,210468],[46.0,42.0,14.0,49.0,21.0,41.0,3.0,12.0,5.0,11.0,7.0,14.0,17.0,3.0,17.0,9.0,3.0,10.0,3.0,4.0,9.0,19.0,4.0,2.0,1.0,2.0,5.0,4.0,3.0,2.0,7.0,1.0,6.0,9.0,1.0,3.0,5.0,9.0,5.0,9.0,2.0,2.0,2.0,1.0,7.0,2.0,5.0,5.0,1.0,9.0,1.0,1.0,1.0,12.0,2.0,6.0,1.0,1.0,3.0,22.0,4.0,1.0,2.0,5.0,4.0,2.0,1.0,1.0,2.0,6.0,10.0,3.0,3.0,3.0,1.0,4.0,3.0,3.0,9.0,2.0,5.0,7.0,1.0,1.0,5.0,1.0,6.0,1.0,3.0,2.0,11.0,2.0,2.0,1.0,1.0,4.0,2.0,7.0,2.0,12.0,2.0,1.0,3.0,4.0,2.0,1.0,2.0,1.0,7.0,3.0,8.0,1.0,7.0,3.0,2.0,1.0,2.0,3.0,3.0,2.0,1.0,4.0,9.0,2.0,3.0,3.0,1.0,1.0,1.0,14.0,3.0,5.0,1.0,4.0,1.0,2.0,1.0,4.0,2.0,2.0,2.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,3.0,5.0,1.0,4.0,3.0,2.0,1.0,2.0,2.0,4.0,4.0,2.0,3.0,1.0,3.0,1.0,1.0,2.0,3.0,1.0,11.0,6.0,1.0,2.0,1.0,1.0,2.0,9.0,2.0,2.0,5.0,1.0,4.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,4.0,1.0,1.0,3.0,2.0,4.0,9.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,10.0,1.0,1.0,1.0,1.0,1.0,2.0,7.0,1.0,7.0,1.0,4.0,4.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,1.0,4.0,1.0,9.0,3.0,16.0,2.0,3.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,18.0,1.0,4.0,6.0,2.0,1.0,6.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,7.0,7.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,3.0,1.0,1.0,5.0,3.0,1.0,1.0,1.0,1.0,7.0,2.0,1.0,3.0,1.0,8.0,1.0,1.0,2.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,2.0,2.0,1.0,1.0,4.0,1.0,2.0,3.0,2.0,1.0,1.0,2.0,1.0,9.0,1.0,19.0,1.0,1.0,2.0,4.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,3.0,5.0,1.0,1.0,2.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,3.0,4.0,1.0,2.0,1.0,1.0,4.0,2.0,1.0,2.0,1.0,2.0,2.0,8.0,2.0,3.0,2.0,1.0,1.0,10.0,6.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,4.0,2.0,1.0,3.0,2.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,3.0,3.0,1.0,1.0,3.0,4.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,10.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,3.0,2.0,2.0,1.0,1.0,3.0,1.0,3.0,1.0,2.0,4.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,6.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,3.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,10.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,4.0,1.0,1.0,3.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,75.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,2.0,1.0,1.0,7.0,2.0,2.0,3.0,1.0,5.0,1.0,1.0,7.0,3.0,3.0,2.0,1.0,1.0,1.0,4.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,2.0,1.0,2.0,1.0,2.0,16.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,22.0,1.0,1.0,9.0,2.0,1.0,4.0,2.0,1.0,1.0,1.0,28.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,8.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,20.0,1.0,3.0,1.0,1.0,1.0,1.0,10.0,3.0,1.0,1.0,1.0,1.0,1.0,17.0,4.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,3.0,1.0,5.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,8.0,1.0,1.0,8.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,6.0,6.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,5.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,4.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,2.0,1.0,2.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n",
      "|[increasing, relevancy, of, geospatial, technologies, such, as, geographic, information, system, gis, inthe, public, health, domain, particularly, for, the, infectious, disease, surveillance, and, modelling, strategies, traditionally, thedisease, mapping, tasks, have, faced, many, challenges, authors, rarely, documented, the, evidence, that, were, used, to, createmap, , before, evolution, of, gis, many, errors, aroused, in, mapping, tasks, which, were, expanded, extremely, at, global, scalesand, , there, were, no, ï¬delity, assessment, of, maps, which, resulted, in, inaccurate, precision, this, study, on, infectious, diseasesgeosurveillance, is, divided, into, four, broad, sections, with, emphasis, on, handling, geographical, and, temporal, issues, to, help, inpublic, health, decisionmaking, and, planning, policies, , geospatial, mapping, of, diseases, using, its, spatial, and, temporalinformation, to, understand, their, behaviour, across, geography, , the, citizens, involvement, as, volunteers, in, giving, healthand, disease, data, to, assess, the, critical, situation, for, diseases, spread, and, prevention, in, neighbourhood, effect, , scientiï¬canalysis, of, healthrelated, behaviour, using, mathematical, epidemiological, and, geostatistical, approaches, with, , capacitybuilding, program, to, illustrate, each, theme, recent, case, studies, are, cited, and, case, studies, are, performed, on, covid19, todemonstrate, selected, modelskeywords, geospatial, technology, 01, citizen, science, 01, public, health, 01, covid19, 01, mathematical, epidemiologyintroductionthe, public, health, sectors, increasing, demand, for, mappinganalytics, and, visualization, had, started, a, date, back, in, thelast, , years, which, has, resulted, in, a, growing, informationage, technology, for, communicable, disease, surveillance, andepidemiology, baker, , , bos, and, blobel, friede, , , friede, , khan, , , reeder, , yu, and, edberg, , this, continuous, publichealth, burden, with, advances, in, information, technology, sameer, saransameeriirsgovinpriyanka, singhpriyankaiirsgovinvishal, kumarvishalkumariirsgovinprakash, chauhanprakashiirsgovinindian, institute, of, remote, sensing, indian, space, researchanisation, , kalidas, road, dehradun, , indiacombined, with, spatial, data, led, to, the, development, ofvarious, tools, and, systems, that, provides, visualization, ofdisease, data, in, space, and, time, dredger, , , kothari, , robertson, and, nelson, , schriml, et, althe, ï¬rst, integral, deï¬nition, of, public, health, was, given, bywinslow, , as, science, and, art, of, preventing, diseaseprolonging, life, and, promoting, health, through, the, anized, efforts, and, informed, choices, of, society, anizations, public, and, private, communities, and, individualsthe, american, public, health, association, apha, mentioned, public, health, as, a, practice, of, preventing, the, spreadof, disease, and, an, aim, of, promoting, good, health, from, smallcommunities, to, across, the, world, turnock, , advances, in, information, technology, and, spatial, features, resultedin, geospatialtechnology, which, is, acute, for, mappingsurveillance, predicting, outbreaks, detecting, clustering, andanalysing, spread, patterns, of, infectious, diseases, with, epidemic, or, pandemic, potential, in, communities, and, acrossterritories, avruskin, , , carpenter, , castronovo, , , dominkovics, , , gao, , 0c, heymann, and, brilliant, , hills, , klompas, , , reis, , , geospatial, technology, has, provided, visualization, and, analytical, tools, topublic, health, professionals, and, decision, makers, to, executediseases, control, programs, in, affected, andor, suspectedregions, and, make, analysis, and, predictions, possible, thatwas, once, technologically, out, of, reachgeospatial, technology, includes, geographical, information, systems, gis, global, positioning, systems, gps, andsatellitebased, technologies, such, as, remote, sensing, rsgis, is, known, for, geographic, data, capture, input, updatemanipulation, transformation, analysis, query, modellingand, visualization, of, all, forms, of, geographically, referencedinformation, through, the, set, of, computer, programs, bonhamcarter, , gps, provides, positioning, navigationand, timing, pnt, services, by, capturing, data, from, satellitesand, providing, it, to, users, eldredge, , , and, rs, isan, earth, observation, instrumentthat, delivers, regionalinformation, on, climatic, factors, and, landscape, featurestherefore, gps, and, rs, provide, regional, and, spatialinformation, while, gis, provides, geospatial, data, integrationas, well, as, accurate, geospatial, analysis, in, realtime, mannerzhen, , geospatial, technology, and, infectiousdisease, surveillanceinfectious, diseases, mostly, adapts, antimicrobial, andmobility, features, later, formed, in, a, shape, of, pandemic, andor, epidemic, chen, , , cheng, , , lee, andnishiura, , which, forced, public, health, authorities, tounderstand, not, only, the, diseases, virulence, but, also, itsdemographic, and, environmentalfactors, that, helps, inmaking, spread, patterns, though, space, and, time, domaincroner, , for, example, the, global, spread, of, highlypathogenic, avian, uenza, hpai, h5n1, in, , withno, effective, vaccines, led, to, concern, among, public, healthdecision, makers, in, spite, of, many, international, programsrappole, and, huba´lek, , the, reason, behind, theirconcern, was, they, were, lacking, of, disease, surveillance, toolin, its, initial, stage, which, caused, inaccessibility, to, populations, atrisk, and, faced, difï¬culties, in, implementingimmunization, strategies, at, a, global, scale, kitler, , stoto, , , however, the, impact, of, environmentaland, demographic, factors, also, plays, a, major, role, as, this, caninform, about, the, interaction, between, hosts, and, pathogensand, patterns, of, spread, in, space, and, timethe, gis, provides, dynamic, maps, to, understand, geographical, distribution, of, diseases, for, analysis, on, frequencyof, cases, disease, mapping, spatial, cluster, of, diseases, disease, association, with, environmentalfactors, networkanalysis, etc, with, such, a, visualization, and, analyticaljournal, of, the, indian, society, of, remote, sensingforservice, frameworkcapabilities, gis, technology, is, holding, a, widespreadgrowth, in, public, health, ahmad, , 2011a, b, booman, , hanaï¬bojd, , , kolivras, , martin, , nykiforuk, and, flaman, , abdul, rasam, , zhang, , , zhen, , , theseamless, integration, of, gis, with, realtime, infectious, diseaserelated, diverse, datasets, through, webbased, mappingto, the, development, of, geospatial, dashboardleadsgeospatialinfectious, diseasesurveillance, dent, , gao, , , yun, , theinfectious, diseaserelated, data, mightinclude, diseasesurveillance, data, activeconï¬rmed, cases, and, health, system, data, hospital, visits, emergency, services, availabilitynursedoctor, availabilityicubed, availability, many, source, geospatialstandards, of, , , geospatialconsortium, ogc, are, used, as, a, web, map, servicewms, web, coverage, service, wcs, web, processingservice, wps, web, feature, service, wfs, etc, bulatovic´, , , gao, , , to, visualize, accesspublish, and, manipulate, geospatial, resources, also, manyother, popular, industrial, geospatial, standards, are, developedby, esri, google, yahoo, and, mapinfo, granell, , to, fetch, locationbased, data, and, provide, infectiousdisease, surveillance, dashboard, to, monitor, and, control, thegeographically, spread, of, disease, zhang, , , thegeocoded, really, simple, syndication, georss, taggedxml, ï¬les, from, georss, services, can, also, be, used, toprovide, geocoded, infectious, disease, news, from, socialmedia, platform, tolentino, , , kasshout, andalhinnawi, 2013a, b, kodong, , historical, contextthe, mapping, of, infectious, diseases, using, geospatial, andinformation, technology, to, beneï¬t, public, health, is, not, a, newway, of, tracking, the, diseases, ahmad, , , cui, , hirsch, , hornsby, , matthew, , may, , mujica, , nicholson, and, mather, noble, , , perl, and, moalem, , williams, , the, historical, disease, mapping, has, faced, manychallenges, authors, rarely, documented, the, evidencethat, were, used, to, create, map, , after, mapping, had, beenimplemented, before, the, beginning, of, geographical, information, systems, many, errors, arouse, which, were, expandedextremely, at, global, scales, and, , there, were, no, ï¬delityassessment, of, maps, which, resulted, in, inaccurate, precisionbut, nowadays, wide, range, of, geospatial, applications, areavailable, in, public, health, community, with, a, possibilities, ofvisualization, analysis, detection, of, clusters, formed, andcalculate, diseaserelated, metrics, such, as, incidence, andprevalence, rate, beck, , , clarke, , , hay, jacquez, , kleinschmidt, , , lawson, and, 0cjournal, of, the, indian, society, of, remote, sensingleimich, , moore, and, carpenter, , robinson, wilkinson, , the, earliest, mapping, for, visualisation, ofthe, linkbetween, disease, and, place, was, done, in, , on, plagueepidemic, in, italy, dent, , during, cholera, outbreak, in, the, study, of, physician, john, snow, had, made, a, novelcontribution, in, history, of, public, health, and, epidemiologyby, using, cartography, applications, and, geographic, visualization, in, ï¬ghting, cholera, after, , years, the, maps, wereidentiï¬ed, as, a, communication, tool, in, understanding, andtracking, of, infectious, diseases, such, as, the, , uenzapandemic, yellow, fever, and, cholera, since, then, revolutionof, webbased, tools, started, in, applied, health, geographyboulos, , the, trend, of, infectious, disease, mappingcould, be, seen, from, , review, of, the, health, gis, literature, which, demonstrated, that, , research, papers, out, of, were, focused, on, infectious, disease, mapping, lyseen, covid19the, ongoing, pandemic, outbreak, targeting, humans, respiratory, system, was, recently, discovered, in, december, by, the, name, of, coronavirus, disease, , covid19, worldhealth, anization, from, a, cluster, of, patients, with, acuterespiratory, distress, syndrome, in, wuhan, hubei, provincechina, huang, , , lu, , 2020a, b, and, spreadglobally, by, march, , this, pathogenic, disease, is, structurally, related, to, the, coronavirus, cov, which, belongs, tofamily, coronaviridae, and, the, order, nidovirales, thisfamily, is, classiï¬ed, into, four, generaalphacoronavirusbetacoronavirus, gammacoronavirus, and, deltacoronavirus, on, the, basis, of, their, phylogenetic, and, genomicanalysis, the, species, of, alphacoronavirus, and, betacoronavirus, infect, mammals, causes, respiratory, illness, inhumans, and, gastroenteritis, in, animals, while, species, ofgammacoronaviruses, and, deltacoronaviruses, infect, birdsbut, some, of, them, can, also, infect, mammals, woo, et, alfrom, betacoronavirus, the, two, virusgenussevere, acute, respiratory, syndrome, sarscovor, middle, east, respiratory, syndrome, merscovhadearlier, demonstrated, that, coronaviruses, can, cause, signiï¬cant, public, threat, ge, , , the, covid19, is, categorizedby, world, healthanization, who, on, the, basis, of, genomic, sequencinganalysis, ofrespiratory, tract, samples, which, isobtained, from, total, of, nine, patients, huang, , , lu, 2020a, b, covid19, has, started, behaving, like, theonceinacentury, pandemic, by, affecting, healthy, adults, aswell, as, elderly, people, with, some, health, issues, and, byinfecting, others, at, an, exponential, rate, of, increase, thansars, or, mersinto, betacoronavirusspecieslowergeospatial, technologyduring, occurrence, of, diseases, geospatial, technologies, andservices, could, help, in, representing, the, spatiotemporalinformation, and, in, analysing, the, dynamic, spread, of, diseases, as, mentioned, by, boulos, , geospatial, technologies, and, services, which, performs, in, real, time, mannerare, tremendously, relevantto, create, a, spatial, healthinformation, infrastructure, in, this, section, a, review, onmany, geospatial, technologies, with, enabled, it, services, iscarried, out, to, understand, and, analyse, the, spread, and, outbreak, of, disease, with, a, case, study, on, covid19, pandemiccitizen, scienceissues, and, concernsthe, expansion, of, citizen, science, from, biodiversity, andecological, domain, haklay, , millerrushing, , to, public, health, community, across, spatial, extentsmade, an, urgent, need, to, study, its, different, forms, crowl, , the, indepth, report, of, eu, describes, taxonomyof, citizen, science, in, three, levels, european, commission, described, in, roy, , wiggins, andcrowston, , and, haklay, , roy, , categorized, citizen, science, by, participants, number, and, oftheir, spread, local, and, mass, and, thoroughnesstime, and, resource, investment, or, king, , described, for, the, people, with, the, people, or, by, the, people, about, citizen, science, activities, wiggins, andcrownston, , classiï¬ed, citizen, science, projects, inconservation, managing, natural, resources, action, addressing, localinvestigation, answering, scientiï¬c, questions, and, education, providingknowledge, to, citizens, haklay, , classiï¬ed, citizenscience, into, four, levels, based, on, participants, engagement, level, , is, crowdsourcing, in, which, citizens, withless, or, no, knowledge, on, activity, perform, as, sensors, tocomplete, computing, tasks, , level, , is, distributed, intelligence, where, citizens, are, being, trained, with, skills, forinterpretation, of, collected, data, , level, , is, participatoryscience, in, which, citizens, decide, about, research, questionsand, types, of, data, to, be, collected, and, , level, , is, extremewhere, citizens, are, fully, involved, in, deï¬ning, researchstrategies, data, collection, data, interpretation, and, performing, scientiï¬c, analysis, apparentlythe, concept, ofcitizen, science, is, rare, in, public, health, domain, but, some, ofits, contribution, seen, in, some, studies, which, not, only, helpsin, predicting, disease, risks, but, also, in, combating, theinfectious, diseases, curtisrobles, , , palmer, , smolinski, , , wilson, , another, approach, similar, to, citizen, science, is, popularepidemiology, in, which, experts, and, laypersons, jointly, 0ccollect, environmental, data, responsible, for, particular, healthconsequences, brown, , or, street, science, as, a, process, in, which, general, public, communities, actively, engagedin, deï¬ning, problems, framing, of, research, questions, anddecisionmaking, activities, about, research, design, corburncrowdsourcevgi, mobile, appsdespite, technological, and, computational, developments, ingeoweb, many, web, technologies, such, as, jquery, andajax, mapping, apis, like, google, and, gps, devicesresulted, in, a, new, revolution, of, neogeography, turner, where, mapping, is, done, by, crowd, and, can, bereached, by, anyone, from, general, public, members, groupsuch, revolution, brought, a, trend, of, volunteered, geographicinformation, vgi, which, is, ï¬rst, coined, and, explained, bygoodchild, 2007a, according, to, goodchild, 2007b, vgihighlighted, the, human, capabilities, in, collecting, geospatialinformation, by, using, ï¬ve, senses, and, then, integrating, withexternal, sensors, of, mobile, devices, like, gps, accelerometer, camera, digital, compass, and, microphone, gives, valuable, datasets, which, can, neither, be, retrieved, from, satelliteimagery, nor, collected, with, any, gps, receivers, anothersuccessful, term, in, geospatial, mapping, using, mobile, technology, is, crowdsourcing, heipke, , hudsonsmith, , which, was, coined, by, howe, thatinvolves, the, collection, of, geospatial, information, or, mapping, of, any, particular, activity, by, an, undeï¬ned, crowd, ornetwork, of, people, both, terms, vgi, and, crowdsourcingslightly, differ, but, they, are, usually, recognized, as, a, synonyms, or, even, as, a, combined, term, crowdsourcing, geographic, information, sui, , , over, the, lastdecade, vgioriented, , source, mobileareepicollect, aanensen, , , for, ecology, and, epidemiology, noisetube, maisonneuve, , , httpnoisetubenet, and, noise, battle, garciamartä±´, , for, noise, monitoring, skywatch, windoo, httpwindoochfor, weather, monitoring, mappiness, httpwwwmappinessukfor, behavioural, analysis, mackerron, andmourato, appsthe, , source, mechanism, for, data, collection, usingandroid, devices, can, be, performed, by, , , data, kitodk, suite107, https, datakit, which, is, composed, of, odk, collect, and, odk, aggregate, odk, collecthttps, datakitusecollect, provides, a, customizable, framework, for, geospatial, data, collection, and, odkaggregate, is, a, web, application, that, runs, on, apachetomcat, server, httptomcatapache, to, store, collecteddata, through, a, synchronization, with, a, databaseforexample, postgresql, brunette, , , as, suchsuites, performance, can, be, seen, in, various, activities, likeagricultural, monitoring, krosing, and, roybal, journal, of, the, indian, society, of, remote, sensingmonitoring, of, deforestation, and, school, attendance, documentation, of, war, crimes, and, health, programs, anokwa, digital, contact, tracingnowadays, covid19, has, become, the, greatest, threat, forpublic, health, in, last, , years, and, due, to, such, pandemicvarious, levels, of, lockdown, are, issued, across, the, world, tobreak, its, chain, of, infection, transmission, however, this, isthe, ï¬rst, approach, to, invade, the, contagion, but, once, itwould, be, lifted, this, pandemic, would, start, in, a, new, wayand, might, reach, its, highest, peak, by, infecting, more, andmore, population, ferguson, , , thereforetocombat, with, such, a, global, pandemic, threat, anotherapproach, is, discovered, by, a, group, of, researchers, known, asdigital, contact, tracingsmartphonebased, contact, tracing, is, known, as, a, digitalcontact, tracing, which, presents, a, sustainable, solution, tolimit, the, transmission, of, infectious, disease, by, tracing, theirpotential, transmission, routes, in, a, population, howeversuch, an, app, presents, signiï¬cant, concerns, regarding, privacy, the, digital, contact, tracing, works, on, the, principle, ofcrowdsource, data, by, measuring, the, proximity, to, aninfectious, person, in, previous, diseases, risk, surveillancethe, contact, tracing, apps, were, used, to, pool, location, timestamped, data, to, determine, the, exposures, to, risk, of, infectionssacks, , , such, data, are, highly, personal, and, leadmany, privacy, concerns, smith, , , but, they, werenot, always, accurate, to, infer, the, exposure, risks, due, to, noisydata, farrahi, , , therefore, various, smartphoneapps, are, developed, in, covid19, pandemic, in, which, someapps, use, location, for, proximity, and, some, of, them, are, notusing, location, services, of, mobile, device, subject, to, theprivacypreserving, naturecovid19, contact, tracingin, order, to, illuminate, the, epidemiology, of, covid19, andto, characterize, its, severity, lipsitch, , , there, is, anurgent, need, of, digital, platform, that, captures, realtimeaccurate, information, on, covid19, patients, diseasesdiagnosis, treatment, and, clinical, reports, and, whom, theyget, interacted, at, which, place, to, detect, clusters, and, generatealerts, such, information, may, help, in, understanding, riskfactors, of, infection, and, in, predicting, the, next, generation, ofinfectious, persons, fitzgerald, , addressing, thisunprecedented, challenge, many, mobile, apps, have, beendeveloped, and, are, being, used, at, large, scale, and, some, ofthem, are, as, follows, 0cjournal, of, the, indian, society, of, remote, sensing¢, covid, symptom, study, covid, symptom, trackerthis, mobile, app, is, developed, in, collaboration, of, zoeglobal, ltd, a, digital, health, care, company, and, a, groupof, academic, scientists, from, massachusetts, generalhospital, and, kings, college, london, which, waslaunched, in, uk, on, march, , , and, becameavailable, after, , days, in, usa, this, app, enquires, aboutage, location, and, other, diseases, risks, and, also, a, selfreporting, function, is, enabled, which, is, associated, withcovid19, infection, and, exposure, drew, , this, app, retrieve, updates, on, healthcare, workersexperiences, who, are, on, covid19, duty, their, stressand, anxiety, and, use, of, personal, protective, equipmentppe, kits, are, being, surveyed, through, this, app, toobserve, intensity, of, health, care, workers, drew, et, alappimplemented¢, aarogya, setuthis, mobile, app, is, launched, on, april, , by, government, of, india, to, aware, general, publicon, covid19, symptoms, government, advisory, measures, online, consultation, facility, and, dynamics, ofdisease, thiscrowdsourcingapproach, by, which, general, public, members, enter, theirdetails, for, selfassessment, and, this, assessment, is, thenused, to, trace, the, infectious, contacts, or, agents, as, adigital, contact, tracing, concept, this, app, uses, locationservices, to, geolocate, the, users, and, bluetooth, tomaintain, the, log, of, contacts, when, one, userdevicecomes, in, contact, with, another, userdevice, and, as, suchdigital, contact, tracing, activity, helps, in, identifying, thecluster, of, diseases, and, communities, which, are, at, risk, ofinfection, the, aarogya, setu, app, was, downloadedby, , , million, users, within, , days, of, its, launchupadhyay, , and, by, using, apps, crowdsourcedata, the, indian, government, detected, approx, positive, casesinformed, , probable, users, ofbeing, at, risk, and, identiï¬ed, , potential, clusters, thetimes, of, indianumerous, digital, contact, tracing, apps, are, in, use, indifferent, parts, of, worldtrackcovid, yasaka, , tracetogether, bay, , , wetrace, de, carli, , and, google, and, apples, recently, announcedjoint, initiative, li, and, guo, covid19, data, visualization, and, exploratorydata, analysiswith, early, experiences, of, epidemics, such, as, sarscov, boulos, , and, the, , merscovgikonyo, , , and, other, seasonal, ï¬us, online, realtime, or, nearrealtime, mapping, of, diseases, occurrencesusing, geospatial, technologies, and, web, applications, havealways, been, used, as, a, pivotal, webbased, tools, in, trackinghealth, threats, and, combating, infectious, diseases, thissection, described, a, range, of, mapping, dashboards, based, ongeospatialtechnologies, for, tracking, and, unfolding, thecoronavirus, disease, around, the, world, some, of, the, globaland, national, geospatial, initiatives, with, an, aim, to, supplyinformation, faster, than, diseases, are, as, summarized, intable, infectious, diseases, modellingthe, intention, of, infectious, diseases, surveillance, is, to, detectepidemics, in, their, early, stages, so, that, the, countermeasurescould, be, taken, for, preventing, its, wide, spread, suchsurveillance, tasks, require, many, epidemiological, and, statistical, methods, with, geospatial, features, in, investigatingepidemics, preferably, from, localized, areas, the, reason, forpreferring, the, local, areas, for, investigation, is, because, epidemics, generally, emerged, in, small, areas, and, then, spreadwidely, if, they, are, not, controlled, however, some, methodsrequire, rigorous, conventions, in, their, underlying, modelsand, are, too, problematical, to, be, applied, on, small, areasthereforefordetecting, diseases, prevalence, with, case, studies, on, smalldatasets, which, would, be, more, useful, for, public, healthactivitiessection, discussessimple, methodsthisclusteringclustering, deals, with, the, study, of, spatialtemporal, patternsof, the, spread, of, communicable, diseases, and, identiï¬cationof, other, diseaserelated, aspects, allied, with, heterogeneousgeographical, distribution, which, might, be, helpful, in, elucidating, the, diseases, spread, mechanism, such, study, andanalysis, on, spacetime, patterns, is, a, kind, of, diseasesurveillance, which, involves, detecting, the, outbreak, clustersof, active, cases, monitoring, of, localisation, and, isolation, ofinfectious, agents, and, relative, risks, assessment, of, affectedsites, at, early, stage, clements, , , cromley, kulldorff, , this, study, on, geographical, clustering, ofinfectious, diseases, with, temporal, features, helps, in, makingstrategies, that, dynamically, update, on, emergence, source, ofdisease, outbreak, to, help, epidemiologists, and, decisionmakers, for, identiï¬cation, of, spread, and, risk, zones, thusclustering, helps, to, enable, timely, prevention, and, containment, measures, and, timely, resource, allocation, to, mitigatethe, diffusion, of, diseasesbased, on, spacetime, surveillance, of, diseases, spacetime, scan, statistic, kulldorff, , is, one, of, the, clusterdetection, tools, which, is, widely, used, in, geographicalsurveillance, of, diseases, during, epidemic, andor, pandemicthe, spacetime, scan, statistic, comes, with, two, versionsprospective, and, retrospective, desjardins, , 0ctable, , summary, table, for, geospatial, dashboards, for, covid19project, namedatasetsscopepurposejournal, of, the, indian, society, of, remote, sensingwho, coronavirus, disease, covid19whos, ofï¬cial, datadashboard, dong, , httpscovid19whointglobal, visualization, of, ofï¬cial, daily, counts, ofconï¬rmed, cases, and, deaths, related, tocovid19, with, time, stamps, using, esriarcgis, online, serviceexploratory, data, analysis, using, 3d, graphto, perform, countrywise, analysis, usingpopulation, conï¬rmed, cases, cumulativecases, deaths, and, cumulative, deathsprovides, daily, aggregate, case, and, deathcount, in, csvjohns, hopkins, university, covid19aggregated, data, from, who, europeanglobal, dashboard, for, visualizing, realtimedashboard, dong, , , httpscoronavirusjhuedumaphtmlcentre, for, disease, prevention, andcontrol, ecdc, worldometers, bnonews, us, cdc, 1point3arces, covidtracking, project, and, dxymapping, of, covid19, with, graphs, onconï¬rmed, and, daily, casescritical, trend, analysis, on, new, cases, perday, mortality, and, fatality, analysis, inpopulation, timeline, of, outbreak, etcisros, bhuvan, covid19, geospatialsolution, httpsbhuvanapp3nrscgovincoronacorona_dashboarddashboarddashboardphptypecitizencovid19, data, source, mohfwindiatime, series, visualization, of, activerecovered, and, deceased, cases, frommarch, , to, till, dategraphical, analysis, on, spread, trend, ofcovid19, daywise, and, statewisecovid19india, httpswwwcm, health, m, handles, press, trust, ofindiavisualization, of, cumulative, and, dailycovid19indiaindia, state, press, bulletins, pbi, and, anireportsnumbers, of, conï¬rmed, active, recovereddeceased, and, tested, statewise, casesthrough, maps, and, graphsprovides, daily, covid19, cases, in, stateand, district, and, cases, reassigned, to, statesthrough, apimapmyindia, covid19, httpsmapscovid19, data, source, mohfwindiaprovides, api, on, corona, dashboards, tomapmyindiacomcoronadistricts_containment_zonecontainment_zone_gradienthunger, relief, centres, source, mygovhunger, , night, shelter, source, mygovndmavisualize, cases, at, district, and, state, levelhotspots, treatment, centres, testing, labsquarantine, centres, containment, zoneslockdown, issues, hunger, relief, hunterand, night, sheltersmonthly, climate, explorer, for, covid19httpscdsclimatecopernicuseuappsc3sappc3smonthlyclimatecovid19explorermonthly, covid19, cases, source, jhuglobal, visualization, of, covid19, fatalities, withcsseatmospheric, compositionpm10, and, no2source, cams, eac4meteorological, datahumidity, , hpaand, surface, air, temperature, on, hourly, andmonthly, average, rate, source, era5reanalysisclimatic, and, atmospheric, variations, onmonthly, basisexploratory, analysis, on, correlation, ofpollutants, and, speciï¬c, humidity, withcovid19, deathsexperimental, covid19, and, globalcovid19, cases, source, jhu, csseglobal, visualize, earthquake, as, a, cause, of, increaseseismic, risk, map, httpsmaps, quakemapcovid1920200520v3grm234900global, earthquake, risk, map, source, gemglobal, earthquake, modelin, covid19, cases, due, to, peoplesdisplacement, from, damaged, buildingsowusu, , , and, difference, between, both, is, thatprospective, neglects, historical, clusters, which, may, havepreviously, occurred, before, the, most, current, time, period, ofanalysis, with, no, health, threat, kulldorff, , thereforethe, prospective, version, of, spacetime, scan, statistic, iscommonly, used, to, detect, statistically, signiï¬cant, active, orevolving, clusters, of, diseases, for, the, present, time, periodand, when, more, data, become, available, the, tool, can, be, rerun, to, detect, new, evolving, clusters, with, update, on, relativerisks, for, each, affected, sites, previously, the, prospectivespacetime, scan, statistic, was, used, in, thyroid, cancerkulldorff, , shigellosis, jones, , , measlesyin, , , syndromic, surveillance, yih, , and, many, other, diseases, however, cluster, analysis, of, 0cjournal, of, the, indian, society, of, remote, sensingdiseases, can, be, performed, through, several, packages, andlibraries, in, r, go´mezrubio, , , and, pythonsoftware, yeng, , the, contribution, of, cluster, detections, and, analysis, incovid19, pandemic, is, becoming, useful, nowadays, as, itdetects, active, and, emerging, clusters, of, covid19, andnotify, epidemiologist, decision, makers, and, public, healthcare, ofï¬cials, which, can, help, in, eradicating, infections, fromaffected, sites, and, improving, interventions, quarantine, andisolation, measures, the, signiï¬cant, applications, of, clustering, with, respect, to, infectious, diseases, modelling, aredemonstrated, across, the, world, zarikas, , , forexample, india, bhosale, and, shinde, , usa, desjardins, , , hohl, , , brazil, martines, , italy, cereda, , , china, ji, , , liu, 2020a, b, qiu, , , zhang, , , singapore, bhosale, and, shinde, , pung, , , southkorea, shim, , , french, alps, danis, , germany, pfefferle, , , sergipe, andrade, , etcoutlier, analysisthe, outlier, is, deï¬ned, by, hawkins, , as, an, observationwhich, deviates, so, much, from, the, other, observations, as, toarouse, suspicions, thatit, was, generated, by, a, differentmechanism, in, other, words, when, data, generation, processstarts, behaving, abnormal, and, reï¬ects, the, abnormalities, orerrors, in, data, such, abnormalities, are, known, as, outliersbansal, , , however, the, outliers, generally, holdadvantageous, information, about, the, systems, unusual, characteristics, and, entities, which, impact, the, data, generationprocess, some, of, the, useful, applications, of, outliers, in, diseases, are, cleynen, , , dai, and, bikdash, krishnan, , , lo, , , prensner, , washington, , wu, and, krishnan, , clusteringalgorithms, are, optimized, to, ï¬nd, clusters, rather, than, outliersand, the, accuracy, of, outlier, detection, depends, on, how, goodthe, clustering, algorithm, captures, the, structure, of, clustersmaximum, entropy, modelling, maxent, approachin, context, of, disease, systems, disease, transmission, risksdepend, on, distribution, of, pathogens, species, in, space, andtime, in, some, complex, environmental, conditions, townsend, and, as, such, treatments, are, focused, mainly, on, spatialdimensions, therefore, diseases, transmission, risks, are, purelyhandled, through, geographical, phenomena, such, geographical, link, with, diseases, leads, to, the, challenge, of, spatialmapping, of, disease, transmission, which, overcame, throughthe, branches, of, biodiversity, scienceecology, and, biogeography, such, approach, of, ecological, and, biogeographical, modelling, can, be, seen, from, various, studies, on, diseasetransmission, risks, mapping, for, example, arboleda, , deka, and, morshed, , ferreira, , holt, , , mweya, , , nakazawa, , reeves, , , samy, , , qian, , zhao, , , zhu, , following, recent, studies, on, geographical, mapping, ofpathogens, causing, disease, transmission, machine, learningbased, maximum, entropy, method, maxent, elith, , phillips, , is, applied, on, spatial, records, ofcovid19, with, a, set, of, , bioclimatic, environmentalvariables, from, worldclim, poggio, , , ramä±´rezvillegas, and, bueno, cabrera, to, analyse, theirfavourable, environmental, conditions, as, shown, in, fig, and, table, , required, in, maintaining, its, population, themaxent, principle, is, to, estimate, the, target, probability, distribution, by, applying, the, maximum, entropy, to, distributionwhich, is, most, spread, or, closest, this, study, is, carried, out, inr, software, ihaka, and, gentleman, , and, a, geographical, dataset, consists, of, latitude, and, longitude, of, thoseregions, which, were, affected, till, march, figure, , depicts, the, habitat, suitability, map, of, virus, withprobability, range, in, colour, scale, to, visualize, the, highsuitability, light, and, dark, green, colour, medium, suitabilityyellow, and, dark, brownlow, suitability, light, browncolour, and, unsuitable, grey, colour, table, , lists, thefavourable, bioclimatic, variables, and, their, contribution, inpercent, in, maintaining, the, suitability, of, virussusceptibleinfectiousrecovered, sir, modelepidemiology, deals, with, the, study, of, pattern, and, occurrence, of, diseases, in, space, and, time, associated, with, otherfactors, such, as, environment, demography, and, the, translation, of, epidemiology, into, mathematical, equations, todescribe, the, spread, of, infectious, diseases, is, known, asmathematical, epidemiology, allen, , , rayner, andbender, , the, mathematical, epidemiology, model, isimplemented, to, understand, the, transmission, dynamics, ofcommunicable, diseases, by, categorizing, population, intosusceptible, infectious, and, recovered, compartments, theï¬rst, basic, model, known, as, susceptibleinfectiousrecovered, sir, model, was, proposed, by, kermack, andmckendrick, , to, describe, the, transmission, of, epidemic, diseases, from, individual, to, individual, the, sirmodel, is, a, set, of, nonlinear, ordinary, differential, equationswhich, is, mathematically, deï¬ned, as, follows¼, l, n, ã¾, sã°ã, 00, bsi¼, bsi, 00, ci, 00, li¼, ci, 00, lrdsdtdidtdrdtã°1ãã°2ãã°3ã, 0cjournal, of, the, indian, society, of, remote, sensingfig, , predicted, suitability, of, betacoronavirus, using, data, till, march, table, , responsible, bioclimatic, variables, in, suitability, modellingheres, is, the, class, of, susceptible, individuals, who, are, not, yetcontracted, to, diseasei, is, the, class, of, infectious, people, who, are, now, infectedwith, disease, and, become, infectious, to, infect, others¢, r, is, class, of, recovered, individuals, who, have, recoverednow, and, are, removed, from, class, s¢, n, is, a, total, population, size, n, , s, , i, , r, and, t, istime, in, days, or, weeks¢, b, is, the, contact, rate, of, infected, person, with, suspected¢¢¢bioclimatic, variablespercent, contributionmean, temperature, of, coldest, quarterprecipitation, of, wettest, monthmean, diurnal, rangeisothermalityannual, mean, temperaturemax, temperature, of, warmest, monthprecipitation, of, coldest, quarterprecipitation, of, wettest, quarterannual, precipitationprecipitation, of, driest, quartermean, temperature, of, driest, quartermean, temperature, of, wettest, quarterprecipitation, seasonalitytemperature, seasonalityprecipitation, of, warmest, quartermean, temperature, of, warmest, quartertemperature, annual, rangeprecipitation, of, driest, monthmin, temperature, of, coldest, monthperson, per, dayc, is, the, infectious, period, and, average, infectious, periodis, 1c¢, l, is, the, per, capita, death, rate, which, is, adjusted, by, birthrate, lnthere, are, many, other, compartment, models, derived, fromthe, basic, epidemic, model, sir, with, more, compartmentsand, transitions, susceptibleexposedinfectiousrecovered, seir, li, and, muldowney, , , susceptibleinfectiousexposedrecovereddeadseirdpiccolomiini, and, zama, , , susceptibleinfectiousexposedrecoveredsusceptible, seirs, liu, and, zhang, susceptibleinfectiousquarantinerecoveredsiqr, erdem]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |[increasing, relevancy, geospatial, technologies, geographic, information, system, gis, inthe, public, health, domain, particularly, infectious, disease, surveillance, modelling, strategies, traditionally, thedisease, mapping, tasks, faced, many, challenges, authors, rarely, documented, evidence, used, createmap, , evolution, gis, many, errors, aroused, mapping, tasks, expanded, extremely, global, scalesand, , ï¬delity, assessment, maps, resulted, inaccurate, precision, study, infectious, diseasesgeosurveillance, divided, four, broad, sections, emphasis, handling, geographical, temporal, issues, help, inpublic, health, decisionmaking, planning, policies, , geospatial, mapping, diseases, using, spatial, temporalinformation, understand, behaviour, across, geography, , citizens, involvement, volunteers, giving, healthand, disease, data, assess, critical, situation, diseases, spread, prevention, neighbourhood, effect, , scientiï¬canalysis, healthrelated, behaviour, using, mathematical, epidemiological, geostatistical, approaches, , capacitybuilding, program, illustrate, theme, recent, case, studies, cited, case, studies, performed, covid19, todemonstrate, selected, modelskeywords, geospatial, technology, 01, citizen, science, 01, public, health, 01, covid19, 01, mathematical, epidemiologyintroductionthe, public, health, sectors, increasing, demand, mappinganalytics, visualization, started, date, back, thelast, , years, resulted, growing, informationage, technology, communicable, disease, surveillance, andepidemiology, baker, , , bos, blobel, friede, , , friede, , khan, , , reeder, , yu, edberg, , continuous, publichealth, burden, advances, information, technology, sameer, saransameeriirsgovinpriyanka, singhpriyankaiirsgovinvishal, kumarvishalkumariirsgovinprakash, chauhanprakashiirsgovinindian, institute, remote, sensing, indian, space, researchanisation, , kalidas, road, dehradun, , indiacombined, spatial, data, led, development, ofvarious, tools, systems, provides, visualization, ofdisease, data, space, time, dredger, , , kothari, , robertson, nelson, , schriml, et, althe, ï¬rst, integral, deï¬nition, public, health, given, bywinslow, , science, art, preventing, diseaseprolonging, life, promoting, health, anized, efforts, informed, choices, society, anizations, public, private, communities, individualsthe, american, public, health, association, apha, mentioned, public, health, practice, preventing, spreadof, disease, aim, promoting, good, health, smallcommunities, across, world, turnock, , advances, information, technology, spatial, features, resultedin, geospatialtechnology, acute, mappingsurveillance, predicting, outbreaks, detecting, clustering, andanalysing, spread, patterns, infectious, diseases, epidemic, pandemic, potential, communities, acrossterritories, avruskin, , , carpenter, , castronovo, , , dominkovics, , , gao, , 0c, heymann, brilliant, , hills, , klompas, , , reis, , , geospatial, technology, provided, visualization, analytical, tools, topublic, health, professionals, decision, makers, executediseases, control, programs, affected, andor, suspectedregions, make, analysis, predictions, possible, thatwas, technologically, reachgeospatial, technology, includes, geographical, information, systems, gis, global, positioning, systems, gps, andsatellitebased, technologies, remote, sensing, rsgis, known, geographic, data, capture, input, updatemanipulation, transformation, analysis, query, modellingand, visualization, forms, geographically, referencedinformation, set, computer, programs, bonhamcarter, , gps, provides, positioning, navigationand, timing, pnt, services, capturing, data, satellitesand, providing, users, eldredge, , , rs, isan, earth, observation, instrumentthat, delivers, regionalinformation, climatic, factors, landscape, featurestherefore, gps, rs, provide, regional, spatialinformation, gis, provides, geospatial, data, integrationas, well, accurate, geospatial, analysis, realtime, mannerzhen, , geospatial, technology, infectiousdisease, surveillanceinfectious, diseases, mostly, adapts, antimicrobial, andmobility, features, later, formed, shape, pandemic, andor, epidemic, chen, , , cheng, , , lee, andnishiura, , forced, public, health, authorities, tounderstand, diseases, virulence, also, itsdemographic, environmentalfactors, helps, inmaking, spread, patterns, though, space, time, domaincroner, , example, global, spread, highlypathogenic, avian, uenza, hpai, h5n1, , withno, effective, vaccines, led, concern, among, public, healthdecision, makers, spite, many, international, programsrappole, huba´lek, , reason, behind, theirconcern, lacking, disease, surveillance, toolin, initial, stage, caused, inaccessibility, populations, atrisk, faced, difï¬culties, implementingimmunization, strategies, global, scale, kitler, , stoto, , , however, impact, environmentaland, demographic, factors, also, plays, major, role, caninform, interaction, hosts, pathogensand, patterns, spread, space, timethe, gis, provides, dynamic, maps, understand, geographical, distribution, diseases, analysis, frequencyof, cases, disease, mapping, spatial, cluster, diseases, disease, association, environmentalfactors, networkanalysis, etc, visualization, analyticaljournal, indian, society, remote, sensingforservice, frameworkcapabilities, gis, technology, holding, widespreadgrowth, public, health, ahmad, , 2011a, b, booman, , hanaï¬bojd, , , kolivras, , martin, , nykiforuk, flaman, , abdul, rasam, , zhang, , , zhen, , , theseamless, integration, gis, realtime, infectious, diseaserelated, diverse, datasets, webbased, mappingto, development, geospatial, dashboardleadsgeospatialinfectious, diseasesurveillance, dent, , gao, , , yun, , theinfectious, diseaserelated, data, mightinclude, diseasesurveillance, data, activeconï¬rmed, cases, health, system, data, hospital, visits, emergency, services, availabilitynursedoctor, availabilityicubed, availability, many, source, geospatialstandards, , , geospatialconsortium, ogc, used, web, map, servicewms, web, coverage, service, wcs, web, processingservice, wps, web, feature, service, wfs, etc, bulatovic´, , , gao, , , visualize, accesspublish, manipulate, geospatial, resources, also, manyother, popular, industrial, geospatial, standards, developedby, esri, google, yahoo, mapinfo, granell, , fetch, locationbased, data, provide, infectiousdisease, surveillance, dashboard, monitor, control, thegeographically, spread, disease, zhang, , , thegeocoded, really, simple, syndication, georss, taggedxml, ï¬les, georss, services, also, used, toprovide, geocoded, infectious, disease, news, socialmedia, platform, tolentino, , , kasshout, andalhinnawi, 2013a, b, kodong, , historical, contextthe, mapping, infectious, diseases, using, geospatial, andinformation, technology, beneï¬t, public, health, newway, tracking, diseases, ahmad, , , cui, , hirsch, , hornsby, , matthew, , may, , mujica, , nicholson, mather, noble, , , perl, moalem, , williams, , historical, disease, mapping, faced, manychallenges, authors, rarely, documented, evidencethat, used, create, map, , mapping, beenimplemented, beginning, geographical, information, systems, many, errors, arouse, expandedextremely, global, scales, , ï¬delityassessment, maps, resulted, inaccurate, precisionbut, nowadays, wide, range, geospatial, applications, areavailable, public, health, community, possibilities, ofvisualization, analysis, detection, clusters, formed, andcalculate, diseaserelated, metrics, incidence, andprevalence, rate, beck, , , clarke, , , hay, jacquez, , kleinschmidt, , , lawson, 0cjournal, indian, society, remote, sensingleimich, , moore, carpenter, , robinson, wilkinson, , earliest, mapping, visualisation, ofthe, linkbetween, disease, place, done, , plagueepidemic, italy, dent, , cholera, outbreak, study, physician, john, snow, made, novelcontribution, history, public, health, epidemiologyby, using, cartography, applications, geographic, visualization, ï¬ghting, cholera, , years, maps, wereidentiï¬ed, communication, tool, understanding, andtracking, infectious, diseases, , uenzapandemic, yellow, fever, cholera, since, revolutionof, webbased, tools, started, applied, health, geographyboulos, , trend, infectious, disease, mappingcould, seen, , review, health, gis, literature, demonstrated, , research, papers, focused, infectious, disease, mapping, lyseen, covid19the, ongoing, pandemic, outbreak, targeting, humans, respiratory, system, recently, discovered, december, name, coronavirus, disease, , covid19, worldhealth, anization, cluster, patients, acuterespiratory, distress, syndrome, wuhan, hubei, provincechina, huang, , , lu, , 2020a, b, spreadglobally, march, , pathogenic, disease, structurally, related, coronavirus, cov, belongs, tofamily, coronaviridae, order, nidovirales, thisfamily, classiï¬ed, four, generaalphacoronavirusbetacoronavirus, gammacoronavirus, deltacoronavirus, basis, phylogenetic, genomicanalysis, species, alphacoronavirus, betacoronavirus, infect, mammals, causes, respiratory, illness, inhumans, gastroenteritis, animals, species, ofgammacoronaviruses, deltacoronaviruses, infect, birdsbut, also, infect, mammals, woo, et, alfrom, betacoronavirus, two, virusgenussevere, acute, respiratory, syndrome, sarscovor, middle, east, respiratory, syndrome, merscovhadearlier, demonstrated, coronaviruses, cause, signiï¬cant, public, threat, ge, , , covid19, categorizedby, world, healthanization, basis, genomic, sequencinganalysis, ofrespiratory, tract, samples, isobtained, total, nine, patients, huang, , , lu, 2020a, b, covid19, started, behaving, like, theonceinacentury, pandemic, affecting, healthy, adults, aswell, elderly, people, health, issues, byinfecting, others, exponential, rate, increase, thansars, mersinto, betacoronavirusspecieslowergeospatial, technologyduring, occurrence, diseases, geospatial, technologies, andservices, help, representing, spatiotemporalinformation, analysing, dynamic, spread, diseases, mentioned, boulos, , geospatial, technologies, services, performs, real, time, mannerare, tremendously, relevantto, create, spatial, healthinformation, infrastructure, section, review, onmany, geospatial, technologies, enabled, services, iscarried, understand, analyse, spread, outbreak, disease, case, study, covid19, pandemiccitizen, scienceissues, concernsthe, expansion, citizen, science, biodiversity, andecological, domain, haklay, , millerrushing, , public, health, community, across, spatial, extentsmade, urgent, need, study, different, forms, crowl, , indepth, report, eu, describes, taxonomyof, citizen, science, three, levels, european, commission, described, roy, , wiggins, andcrowston, , haklay, , roy, , categorized, citizen, science, participants, number, oftheir, spread, local, mass, thoroughnesstime, resource, investment, king, , described, for, people, people, people, citizen, science, activities, wiggins, andcrownston, , classiï¬ed, citizen, science, projects, inconservation, managing, natural, resources, action, addressing, localinvestigation, answering, scientiï¬c, questions, education, providingknowledge, citizens, haklay, , classiï¬ed, citizenscience, four, levels, based, participants, engagement, level, , crowdsourcing, citizens, withless, knowledge, activity, perform, sensors, tocomplete, computing, tasks, , level, , distributed, intelligence, citizens, trained, skills, forinterpretation, collected, data, , level, , participatoryscience, citizens, decide, research, questionsand, types, data, collected, , level, , extremewhere, citizens, fully, involved, deï¬ning, researchstrategies, data, collection, data, interpretation, performing, scientiï¬c, analysis, apparentlythe, concept, ofcitizen, science, rare, public, health, domain, ofits, contribution, seen, studies, helpsin, predicting, disease, risks, also, combating, theinfectious, diseases, curtisrobles, , , palmer, , smolinski, , , wilson, , another, approach, similar, citizen, science, popularepidemiology, experts, laypersons, jointly, 0ccollect, environmental, data, responsible, particular, healthconsequences, brown, , street, science, process, general, public, communities, actively, engagedin, deï¬ning, problems, framing, research, questions, anddecisionmaking, activities, research, design, corburncrowdsourcevgi, mobile, appsdespite, technological, computational, developments, ingeoweb, many, web, technologies, jquery, andajax, mapping, apis, like, google, gps, devicesresulted, new, revolution, neogeography, turner, mapping, done, crowd, bereached, anyone, general, public, members, groupsuch, revolution, brought, trend, volunteered, geographicinformation, vgi, ï¬rst, coined, explained, bygoodchild, 2007a, according, goodchild, 2007b, vgihighlighted, human, capabilities, collecting, geospatialinformation, using, ï¬ve, senses, integrating, withexternal, sensors, mobile, devices, like, gps, accelerometer, camera, digital, compass, microphone, gives, valuable, datasets, neither, retrieved, satelliteimagery, collected, gps, receivers, anothersuccessful, term, geospatial, mapping, using, mobile, technology, crowdsourcing, heipke, , hudsonsmith, , coined, howe, thatinvolves, collection, geospatial, information, mapping, particular, activity, undeï¬ned, crowd, ornetwork, people, terms, vgi, crowdsourcingslightly, differ, usually, recognized, synonyms, even, combined, term, crowdsourcing, geographic, information, sui, , , lastdecade, vgioriented, , source, mobileareepicollect, aanensen, , , ecology, epidemiology, noisetube, maisonneuve, , , httpnoisetubenet, noise, battle, garciamartä±´, , noise, monitoring, skywatch, windoo, httpwindoochfor, weather, monitoring, mappiness, httpwwwmappinessukfor, behavioural, analysis, mackerron, andmourato, appsthe, , source, mechanism, data, collection, usingandroid, devices, performed, , , data, kitodk, suite107, https, datakit, composed, odk, collect, odk, aggregate, odk, collecthttps, datakitusecollect, provides, customizable, framework, geospatial, data, collection, odkaggregate, web, application, runs, apachetomcat, server, httptomcatapache, store, collecteddata, synchronization, databaseforexample, postgresql, brunette, , , suchsuites, performance, seen, various, activities, likeagricultural, monitoring, krosing, roybal, journal, indian, society, remote, sensingmonitoring, deforestation, school, attendance, documentation, war, crimes, health, programs, anokwa, digital, contact, tracingnowadays, covid19, become, greatest, threat, forpublic, health, last, , years, due, pandemicvarious, levels, lockdown, issued, across, world, tobreak, chain, infection, transmission, however, isthe, ï¬rst, approach, invade, contagion, itwould, lifted, pandemic, start, new, wayand, might, reach, highest, peak, infecting, andmore, population, ferguson, , , thereforetocombat, global, pandemic, threat, anotherapproach, discovered, group, researchers, known, asdigital, contact, tracingsmartphonebased, contact, tracing, known, digitalcontact, tracing, presents, sustainable, solution, tolimit, transmission, infectious, disease, tracing, theirpotential, transmission, routes, population, howeversuch, app, presents, signiï¬cant, concerns, regarding, privacy, digital, contact, tracing, works, principle, ofcrowdsource, data, measuring, proximity, aninfectious, person, previous, diseases, risk, surveillancethe, contact, tracing, apps, used, pool, location, timestamped, data, determine, exposures, risk, infectionssacks, , , data, highly, personal, leadmany, privacy, concerns, smith, , , werenot, always, accurate, infer, exposure, risks, due, noisydata, farrahi, , , therefore, various, smartphoneapps, developed, covid19, pandemic, someapps, use, location, proximity, notusing, location, services, mobile, device, subject, theprivacypreserving, naturecovid19, contact, tracingin, order, illuminate, epidemiology, covid19, andto, characterize, severity, lipsitch, , , anurgent, need, digital, platform, captures, realtimeaccurate, information, covid19, patients, diseasesdiagnosis, treatment, clinical, reports, theyget, interacted, place, detect, clusters, generatealerts, information, may, help, understanding, riskfactors, infection, predicting, next, generation, ofinfectious, persons, fitzgerald, , addressing, thisunprecedented, challenge, many, mobile, apps, beendeveloped, used, large, scale, ofthem, follows, 0cjournal, indian, society, remote, sensing¢, covid, symptom, study, covid, symptom, trackerthis, mobile, app, developed, collaboration, zoeglobal, ltd, digital, health, care, company, groupof, academic, scientists, massachusetts, generalhospital, kings, college, london, waslaunched, uk, march, , , becameavailable, , days, usa, app, enquires, aboutage, location, diseases, risks, also, selfreporting, function, enabled, associated, withcovid19, infection, exposure, drew, , app, retrieve, updates, healthcare, workersexperiences, covid19, duty, stressand, anxiety, use, personal, protective, equipmentppe, kits, surveyed, app, toobserve, intensity, health, care, workers, drew, et, alappimplemented¢, aarogya, setuthis, mobile, app, launched, april, , government, india, aware, general, publicon, covid19, symptoms, government, advisory, measures, online, consultation, facility, dynamics, ofdisease, thiscrowdsourcingapproach, general, public, members, enter, theirdetails, selfassessment, assessment, thenused, trace, infectious, contacts, agents, adigital, contact, tracing, concept, app, uses, locationservices, geolocate, users, bluetooth, tomaintain, log, contacts, one, userdevicecomes, contact, another, userdevice, suchdigital, contact, tracing, activity, helps, identifying, thecluster, diseases, communities, risk, ofinfection, aarogya, setu, app, downloadedby, , , million, users, within, , days, launchupadhyay, , using, apps, crowdsourcedata, indian, government, detected, approx, positive, casesinformed, , probable, users, ofbeing, risk, identiï¬ed, , potential, clusters, thetimes, indianumerous, digital, contact, tracing, apps, use, indifferent, parts, worldtrackcovid, yasaka, , tracetogether, bay, , , wetrace, de, carli, , google, apples, recently, announcedjoint, initiative, li, guo, covid19, data, visualization, exploratorydata, analysiswith, early, experiences, epidemics, sarscov, boulos, , , merscovgikonyo, , , seasonal, ï¬us, online, realtime, nearrealtime, mapping, diseases, occurrencesusing, geospatial, technologies, web, applications, havealways, used, pivotal, webbased, tools, trackinghealth, threats, combating, infectious, diseases, thissection, described, range, mapping, dashboards, based, ongeospatialtechnologies, tracking, unfolding, thecoronavirus, disease, around, world, globaland, national, geospatial, initiatives, aim, supplyinformation, faster, diseases, summarized, intable, infectious, diseases, modellingthe, intention, infectious, diseases, surveillance, detectepidemics, early, stages, countermeasurescould, taken, preventing, wide, spread, suchsurveillance, tasks, require, many, epidemiological, statistical, methods, geospatial, features, investigatingepidemics, preferably, localized, areas, reason, forpreferring, local, areas, investigation, epidemics, generally, emerged, small, areas, spreadwidely, controlled, however, methodsrequire, rigorous, conventions, underlying, modelsand, problematical, applied, small, areasthereforefordetecting, diseases, prevalence, case, studies, smalldatasets, useful, public, healthactivitiessection, discussessimple, methodsthisclusteringclustering, deals, study, spatialtemporal, patternsof, spread, communicable, diseases, identiï¬cationof, diseaserelated, aspects, allied, heterogeneousgeographical, distribution, might, helpful, elucidating, diseases, spread, mechanism, study, andanalysis, spacetime, patterns, kind, diseasesurveillance, involves, detecting, outbreak, clustersof, active, cases, monitoring, localisation, isolation, ofinfectious, agents, relative, risks, assessment, affectedsites, early, stage, clements, , , cromley, kulldorff, , study, geographical, clustering, ofinfectious, diseases, temporal, features, helps, makingstrategies, dynamically, update, emergence, source, ofdisease, outbreak, help, epidemiologists, decisionmakers, identiï¬cation, spread, risk, zones, thusclustering, helps, enable, timely, prevention, containment, measures, timely, resource, allocation, mitigatethe, diffusion, diseasesbased, spacetime, surveillance, diseases, spacetime, scan, statistic, kulldorff, , one, clusterdetection, tools, widely, used, geographicalsurveillance, diseases, epidemic, andor, pandemicthe, spacetime, scan, statistic, comes, two, versionsprospective, retrospective, desjardins, , 0ctable, , summary, table, geospatial, dashboards, covid19project, namedatasetsscopepurposejournal, indian, society, remote, sensingwho, coronavirus, disease, covid19whos, ofï¬cial, datadashboard, dong, , httpscovid19whointglobal, visualization, ofï¬cial, daily, counts, ofconï¬rmed, cases, deaths, related, tocovid19, time, stamps, using, esriarcgis, online, serviceexploratory, data, analysis, using, 3d, graphto, perform, countrywise, analysis, usingpopulation, conï¬rmed, cases, cumulativecases, deaths, cumulative, deathsprovides, daily, aggregate, case, deathcount, csvjohns, hopkins, university, covid19aggregated, data, europeanglobal, dashboard, visualizing, realtimedashboard, dong, , , httpscoronavirusjhuedumaphtmlcentre, disease, prevention, andcontrol, ecdc, worldometers, bnonews, us, cdc, 1point3arces, covidtracking, project, dxymapping, covid19, graphs, onconï¬rmed, daily, casescritical, trend, analysis, new, cases, perday, mortality, fatality, analysis, inpopulation, timeline, outbreak, etcisros, bhuvan, covid19, geospatialsolution, httpsbhuvanapp3nrscgovincoronacorona_dashboarddashboarddashboardphptypecitizencovid19, data, source, mohfwindiatime, series, visualization, activerecovered, deceased, cases, frommarch, , till, dategraphical, analysis, spread, trend, ofcovid19, daywise, statewisecovid19india, httpswwwcm, health, m, handles, press, trust, ofindiavisualization, cumulative, dailycovid19indiaindia, state, press, bulletins, pbi, anireportsnumbers, conï¬rmed, active, recovereddeceased, tested, statewise, casesthrough, maps, graphsprovides, daily, covid19, cases, stateand, district, cases, reassigned, statesthrough, apimapmyindia, covid19, httpsmapscovid19, data, source, mohfwindiaprovides, api, corona, dashboards, tomapmyindiacomcoronadistricts_containment_zonecontainment_zone_gradienthunger, relief, centres, source, mygovhunger, , night, shelter, source, mygovndmavisualize, cases, district, state, levelhotspots, treatment, centres, testing, labsquarantine, centres, containment, zoneslockdown, issues, hunger, relief, hunterand, night, sheltersmonthly, climate, explorer, covid19httpscdsclimatecopernicuseuappsc3sappc3smonthlyclimatecovid19explorermonthly, covid19, cases, source, jhuglobal, visualization, covid19, fatalities, withcsseatmospheric, compositionpm10, no2source, cams, eac4meteorological, datahumidity, , hpaand, surface, air, temperature, hourly, andmonthly, average, rate, source, era5reanalysisclimatic, atmospheric, variations, onmonthly, basisexploratory, analysis, correlation, ofpollutants, speciï¬c, humidity, withcovid19, deathsexperimental, covid19, globalcovid19, cases, source, jhu, csseglobal, visualize, earthquake, cause, increaseseismic, risk, map, httpsmaps, quakemapcovid1920200520v3grm234900global, earthquake, risk, map, source, gemglobal, earthquake, modelin, covid19, cases, due, peoplesdisplacement, damaged, buildingsowusu, , , difference, thatprospective, neglects, historical, clusters, may, havepreviously, occurred, current, time, period, ofanalysis, health, threat, kulldorff, , thereforethe, prospective, version, spacetime, scan, statistic, iscommonly, used, detect, statistically, signiï¬cant, active, orevolving, clusters, diseases, present, time, periodand, data, become, available, tool, rerun, detect, new, evolving, clusters, update, relativerisks, affected, sites, previously, prospectivespacetime, scan, statistic, used, thyroid, cancerkulldorff, , shigellosis, jones, , , measlesyin, , , syndromic, surveillance, yih, , many, diseases, however, cluster, analysis, 0cjournal, indian, society, remote, sensingdiseases, performed, several, packages, andlibraries, r, go´mezrubio, , , pythonsoftware, yeng, , contribution, cluster, detections, analysis, incovid19, pandemic, becoming, useful, nowadays, itdetects, active, emerging, clusters, covid19, andnotify, epidemiologist, decision, makers, public, healthcare, ofï¬cials, help, eradicating, infections, fromaffected, sites, improving, interventions, quarantine, andisolation, measures, signiï¬cant, applications, clustering, respect, infectious, diseases, modelling, aredemonstrated, across, world, zarikas, , , forexample, india, bhosale, shinde, , usa, desjardins, , , hohl, , , brazil, martines, , italy, cereda, , , china, ji, , , liu, 2020a, b, qiu, , , zhang, , , singapore, bhosale, shinde, , pung, , , southkorea, shim, , , french, alps, danis, , germany, pfefferle, , , sergipe, andrade, , etcoutlier, analysisthe, outlier, deï¬ned, hawkins, , an, observationwhich, deviates, much, observations, toarouse, suspicions, thatit, generated, differentmechanism, words, data, generation, processstarts, behaving, abnormal, reï¬ects, abnormalities, orerrors, data, abnormalities, known, outliersbansal, , , however, outliers, generally, holdadvantageous, information, systems, unusual, characteristics, entities, impact, data, generationprocess, useful, applications, outliers, diseases, cleynen, , , dai, bikdash, krishnan, , , lo, , , prensner, , washington, , wu, krishnan, , clusteringalgorithms, optimized, ï¬nd, clusters, rather, outliersand, accuracy, outlier, detection, depends, goodthe, clustering, algorithm, captures, structure, clustersmaximum, entropy, modelling, maxent, approachin, context, disease, systems, disease, transmission, risksdepend, distribution, pathogens, species, space, andtime, complex, environmental, conditions, townsend, treatments, focused, mainly, spatialdimensions, therefore, diseases, transmission, risks, purelyhandled, geographical, phenomena, geographical, link, diseases, leads, challenge, spatialmapping, disease, transmission, overcame, throughthe, branches, biodiversity, scienceecology, biogeography, approach, ecological, biogeographical, modelling, seen, various, studies, diseasetransmission, risks, mapping, example, arboleda, , deka, morshed, , ferreira, , holt, , , mweya, , , nakazawa, , reeves, , , samy, , , qian, , zhao, , , zhu, , following, recent, studies, geographical, mapping, ofpathogens, causing, disease, transmission, machine, learningbased, maximum, entropy, method, maxent, elith, , phillips, , applied, spatial, records, ofcovid19, set, , bioclimatic, environmentalvariables, worldclim, poggio, , , ramä±´rezvillegas, bueno, cabrera, analyse, theirfavourable, environmental, conditions, shown, fig, table, , required, maintaining, population, themaxent, principle, estimate, target, probability, distribution, applying, maximum, entropy, distributionwhich, spread, closest, study, carried, inr, software, ihaka, gentleman, , geographical, dataset, consists, latitude, longitude, thoseregions, affected, till, march, figure, , depicts, habitat, suitability, map, virus, withprobability, range, colour, scale, visualize, highsuitability, light, dark, green, colour, medium, suitabilityyellow, dark, brownlow, suitability, light, browncolour, unsuitable, grey, colour, table, , lists, thefavourable, bioclimatic, variables, contribution, inpercent, maintaining, suitability, virussusceptibleinfectiousrecovered, sir, modelepidemiology, deals, study, pattern, occurrence, diseases, space, time, associated, otherfactors, environment, demography, translation, epidemiology, mathematical, equations, todescribe, spread, infectious, diseases, known, asmathematical, epidemiology, allen, , , rayner, andbender, , mathematical, epidemiology, model, isimplemented, understand, transmission, dynamics, ofcommunicable, diseases, categorizing, population, intosusceptible, infectious, recovered, compartments, theï¬rst, basic, model, known, susceptibleinfectiousrecovered, sir, model, proposed, kermack, andmckendrick, , describe, transmission, epidemic, diseases, individual, individual, sirmodel, set, nonlinear, ordinary, differential, equationswhich, mathematically, deï¬ned, follows¼, l, n, ã¾, sã°ã, 00, bsi¼, bsi, 00, ci, 00, li¼, ci, 00, lrdsdtdidtdrdtã°1ãã°2ãã°3ã, 0cjournal, indian, society, remote, sensingfig, , predicted, suitability, betacoronavirus, using, data, till, march, table, , responsible, bioclimatic, variables, suitability, modellingheres, class, susceptible, individuals, yetcontracted, diseasei, class, infectious, people, infectedwith, disease, become, infectious, infect, others¢, r, class, recovered, individuals, recoverednow, removed, class, s¢, n, total, population, size, n, , , , r, istime, days, weeks¢, b, contact, rate, infected, person, suspected¢¢¢bioclimatic, variablespercent, contributionmean, temperature, coldest, quarterprecipitation, wettest, monthmean, diurnal, rangeisothermalityannual, mean, temperaturemax, temperature, warmest, monthprecipitation, coldest, quarterprecipitation, wettest, quarterannual, precipitationprecipitation, driest, quartermean, temperature, driest, quartermean, temperature, wettest, quarterprecipitation, seasonalitytemperature, seasonalityprecipitation, warmest, quartermean, temperature, warmest, quartertemperature, annual, rangeprecipitation, driest, monthmin, temperature, coldest, monthperson, per, dayc, infectious, period, average, infectious, periodis, 1c¢, l, per, capita, death, rate, adjusted, birthrate, lnthere, many, compartment, models, derived, fromthe, basic, epidemic, model, sir, compartmentsand, transitions, susceptibleexposedinfectiousrecovered, seir, li, muldowney, , , susceptibleinfectiousexposedrecovereddeadseirdpiccolomiini, zama, , , susceptibleinfectiousexposedrecoveredsusceptible, seirs, liu, zhang, susceptibleinfectiousquarantinerecoveredsiqr, erdem]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |[increasing, relevancy, geospatial, technologies, such, as, geographic, information, system, gis, inthe, public, health, domain, particularly, infectious, disease, surveillance, modelling, strategies, traditionally, thedisease, mapping, tasks, have, faced, many, challenges, authors, rarely, documented, evidence, that, were, used, createmap, , before, evolution, gis, many, errors, aroused, mapping, tasks, which, were, expanded, extremely, at, global, scalesand, , there, were, no, ï¬delity, assessment, maps, which, resulted, inaccurate, precision, study, on, infectious, diseasesgeosurveillance, divided, into, four, broad, sections, with, emphasis, on, handling, geographical, temporal, issues, help, inpublic, health, decisionmaking, planning, policies, , geospatial, mapping, diseases, using, its, spatial, temporalinformation, understand, their, behaviour, across, geography, , citizens, involvement, as, volunteers, giving, healthand, disease, data, assess, critical, situation, diseases, spread, prevention, neighbourhood, effect, , scientiï¬canalysis, healthrelated, behaviour, using, mathematical, epidemiological, geostatistical, approaches, with, , capacitybuilding, program, illustrate, each, theme, recent, case, studies, are, cited, case, studies, are, performed, on, covid19, todemonstrate, selected, modelskeywords, geospatial, technology, 01, citizen, science, 01, public, health, 01, covid19, 01, mathematical, epidemiologyintroductionthe, public, health, sectors, increasing, demand, mappinganalytics, visualization, had, started, date, back, thelast, , years, which, has, resulted, growing, informationage, technology, communicable, disease, surveillance, andepidemiology, baker, , , bos, blobel, friede, , , friede, , khan, , , reeder, , yu, edberg, , continuous, publichealth, burden, with, advances, information, technology, sameer, saransameeriirsgovinpriyanka, singhpriyankaiirsgovinvishal, kumarvishalkumariirsgovinprakash, chauhanprakashiirsgovinindian, institute, remote, sensing, indian, space, researchanisation, , kalidas, road, dehradun, , indiacombined, with, spatial, data, led, development, ofvarious, tools, systems, that, provides, visualization, ofdisease, data, space, time, dredger, , , kothari, , robertson, nelson, , schriml, et, althe, ï¬rst, integral, deï¬nition, public, health, given, bywinslow, , as, science, art, preventing, diseaseprolonging, life, promoting, health, through, anized, efforts, informed, choices, society, anizations, public, private, communities, individualsthe, american, public, health, association, apha, mentioned, public, health, as, practice, preventing, spreadof, disease, an, aim, promoting, good, health, from, smallcommunities, across, world, turnock, , advances, information, technology, spatial, features, resultedin, geospatialtechnology, which, acute, mappingsurveillance, predicting, outbreaks, detecting, clustering, andanalysing, spread, patterns, infectious, diseases, with, epidemic, or, pandemic, potential, communities, acrossterritories, avruskin, , , carpenter, , castronovo, , , dominkovics, , , gao, , 0c, heymann, brilliant, , hills, , klompas, , , reis, , , geospatial, technology, has, provided, visualization, analytical, tools, topublic, health, professionals, decision, makers, executediseases, control, programs, affected, andor, suspectedregions, make, analysis, predictions, possible, thatwas, once, technologically, out, reachgeospatial, technology, includes, geographical, information, systems, gis, global, positioning, systems, gps, andsatellitebased, technologies, such, as, remote, sensing, rsgis, known, geographic, data, capture, input, updatemanipulation, transformation, analysis, query, modellingand, visualization, all, forms, geographically, referencedinformation, through, set, computer, programs, bonhamcarter, , gps, provides, positioning, navigationand, timing, pnt, services, by, capturing, data, from, satellitesand, providing, it, users, eldredge, , , rs, isan, earth, observation, instrumentthat, delivers, regionalinformation, on, climatic, factors, landscape, featurestherefore, gps, rs, provide, regional, spatialinformation, while, gis, provides, geospatial, data, integrationas, well, as, accurate, geospatial, analysis, realtime, mannerzhen, , geospatial, technology, infectiousdisease, surveillanceinfectious, diseases, mostly, adapts, antimicrobial, andmobility, features, later, formed, shape, pandemic, andor, epidemic, chen, , , cheng, , , lee, andnishiura, , which, forced, public, health, authorities, tounderstand, not, only, diseases, virulence, but, also, itsdemographic, environmentalfactors, that, helps, inmaking, spread, patterns, though, space, time, domaincroner, , example, global, spread, highlypathogenic, avian, uenza, hpai, h5n1, , withno, effective, vaccines, led, concern, among, public, healthdecision, makers, spite, many, international, programsrappole, huba´lek, , reason, behind, theirconcern, they, were, lacking, disease, surveillance, toolin, its, initial, stage, which, caused, inaccessibility, populations, atrisk, faced, difï¬culties, implementingimmunization, strategies, at, global, scale, kitler, , stoto, , , however, impact, environmentaland, demographic, factors, also, plays, major, role, as, caninform, about, interaction, between, hosts, pathogensand, patterns, spread, space, timethe, gis, provides, dynamic, maps, understand, geographical, distribution, diseases, analysis, on, frequencyof, cases, disease, mapping, spatial, cluster, diseases, disease, association, with, environmentalfactors, networkanalysis, etc, with, such, visualization, analyticaljournal, indian, society, remote, sensingforservice, frameworkcapabilities, gis, technology, holding, widespreadgrowth, public, health, ahmad, , 2011a, b, booman, , hanaï¬bojd, , , kolivras, , martin, , nykiforuk, flaman, , abdul, rasam, , zhang, , , zhen, , , theseamless, integration, gis, with, realtime, infectious, diseaserelated, diverse, datasets, through, webbased, mappingto, development, geospatial, dashboardleadsgeospatialinfectious, diseasesurveillance, dent, , gao, , , yun, , theinfectious, diseaserelated, data, mightinclude, diseasesurveillance, data, activeconï¬rmed, cases, health, system, data, hospital, visits, emergency, services, availabilitynursedoctor, availabilityicubed, availability, many, source, geospatialstandards, , , geospatialconsortium, ogc, are, used, as, web, map, servicewms, web, coverage, service, wcs, web, processingservice, wps, web, feature, service, wfs, etc, bulatovic´, , , gao, , , visualize, accesspublish, manipulate, geospatial, resources, also, manyother, popular, industrial, geospatial, standards, are, developedby, esri, google, yahoo, mapinfo, granell, , fetch, locationbased, data, provide, infectiousdisease, surveillance, dashboard, monitor, control, thegeographically, spread, disease, zhang, , , thegeocoded, really, simple, syndication, georss, taggedxml, ï¬les, from, georss, services, can, also, be, used, toprovide, geocoded, infectious, disease, news, from, socialmedia, platform, tolentino, , , kasshout, andalhinnawi, 2013a, b, kodong, , historical, contextthe, mapping, infectious, diseases, using, geospatial, andinformation, technology, beneï¬t, public, health, not, newway, tracking, diseases, ahmad, , , cui, , hirsch, , hornsby, , matthew, , may, , mujica, , nicholson, mather, noble, , , perl, moalem, , williams, , historical, disease, mapping, has, faced, manychallenges, authors, rarely, documented, evidencethat, were, used, create, map, , after, mapping, had, beenimplemented, before, beginning, geographical, information, systems, many, errors, arouse, which, were, expandedextremely, at, global, scales, , there, were, no, ï¬delityassessment, maps, which, resulted, inaccurate, precisionbut, nowadays, wide, range, geospatial, applications, areavailable, public, health, community, with, possibilities, ofvisualization, analysis, detection, clusters, formed, andcalculate, diseaserelated, metrics, such, as, incidence, andprevalence, rate, beck, , , clarke, , , hay, jacquez, , kleinschmidt, , , lawson, 0cjournal, indian, society, remote, sensingleimich, , moore, carpenter, , robinson, wilkinson, , earliest, mapping, visualisation, ofthe, linkbetween, disease, place, done, , on, plagueepidemic, italy, dent, , during, cholera, outbreak, study, physician, john, snow, had, made, novelcontribution, history, public, health, epidemiologyby, using, cartography, applications, geographic, visualization, ï¬ghting, cholera, after, , years, maps, wereidentiï¬ed, as, communication, tool, understanding, andtracking, infectious, diseases, such, as, , uenzapandemic, yellow, fever, cholera, since, then, revolutionof, webbased, tools, started, applied, health, geographyboulos, , trend, infectious, disease, mappingcould, be, seen, from, , review, health, gis, literature, which, demonstrated, that, , research, papers, out, were, focused, on, infectious, disease, mapping, lyseen, covid19the, ongoing, pandemic, outbreak, targeting, humans, respiratory, system, recently, discovered, december, by, name, coronavirus, disease, , covid19, worldhealth, anization, from, cluster, patients, with, acuterespiratory, distress, syndrome, wuhan, hubei, provincechina, huang, , , lu, , 2020a, b, spreadglobally, by, march, , pathogenic, disease, structurally, related, coronavirus, cov, which, belongs, tofamily, coronaviridae, order, nidovirales, thisfamily, classiï¬ed, into, four, generaalphacoronavirusbetacoronavirus, gammacoronavirus, deltacoronavirus, on, basis, their, phylogenetic, genomicanalysis, species, alphacoronavirus, betacoronavirus, infect, mammals, causes, respiratory, illness, inhumans, gastroenteritis, animals, while, species, ofgammacoronaviruses, deltacoronaviruses, infect, birdsbut, some, them, can, also, infect, mammals, woo, et, alfrom, betacoronavirus, two, virusgenussevere, acute, respiratory, syndrome, sarscovor, middle, east, respiratory, syndrome, merscovhadearlier, demonstrated, that, coronaviruses, can, cause, signiï¬cant, public, threat, ge, , , covid19, categorizedby, world, healthanization, who, on, basis, genomic, sequencinganalysis, ofrespiratory, tract, samples, which, isobtained, from, total, nine, patients, huang, , , lu, 2020a, b, covid19, has, started, behaving, like, theonceinacentury, pandemic, by, affecting, healthy, adults, aswell, as, elderly, people, with, some, health, issues, byinfecting, others, at, an, exponential, rate, increase, thansars, or, mersinto, betacoronavirusspecieslowergeospatial, technologyduring, occurrence, diseases, geospatial, technologies, andservices, could, help, representing, spatiotemporalinformation, analysing, dynamic, spread, diseases, as, mentioned, by, boulos, , geospatial, technologies, services, which, performs, real, time, mannerare, tremendously, relevantto, create, spatial, healthinformation, infrastructure, section, review, onmany, geospatial, technologies, with, enabled, it, services, iscarried, out, understand, analyse, spread, outbreak, disease, with, case, study, on, covid19, pandemiccitizen, scienceissues, concernsthe, expansion, citizen, science, from, biodiversity, andecological, domain, haklay, , millerrushing, , public, health, community, across, spatial, extentsmade, an, urgent, need, study, its, different, forms, crowl, , indepth, report, eu, describes, taxonomyof, citizen, science, three, levels, european, commission, described, roy, , wiggins, andcrowston, , haklay, , roy, , categorized, citizen, science, by, participants, number, oftheir, spread, local, mass, thoroughnesstime, resource, investment, or, king, , described, for, people, with, people, or, by, people, about, citizen, science, activities, wiggins, andcrownston, , classiï¬ed, citizen, science, projects, inconservation, managing, natural, resources, action, addressing, localinvestigation, answering, scientiï¬c, questions, education, providingknowledge, citizens, haklay, , classiï¬ed, citizenscience, into, four, levels, based, on, participants, engagement, level, , crowdsourcing, which, citizens, withless, or, no, knowledge, on, activity, perform, as, sensors, tocomplete, computing, tasks, , level, , distributed, intelligence, where, citizens, are, being, trained, with, skills, forinterpretation, collected, data, , level, , participatoryscience, which, citizens, decide, about, research, questionsand, types, data, be, collected, , level, , extremewhere, citizens, are, fully, involved, deï¬ning, researchstrategies, data, collection, data, interpretation, performing, scientiï¬c, analysis, apparentlythe, concept, ofcitizen, science, rare, public, health, domain, but, some, ofits, contribution, seen, some, studies, which, not, only, helpsin, predicting, disease, risks, but, also, combating, theinfectious, diseases, curtisrobles, , , palmer, , smolinski, , , wilson, , another, approach, similar, citizen, science, popularepidemiology, which, experts, laypersons, jointly, 0ccollect, environmental, data, responsible, particular, healthconsequences, brown, , or, street, science, as, process, which, general, public, communities, actively, engagedin, deï¬ning, problems, framing, research, questions, anddecisionmaking, activities, about, research, design, corburncrowdsourcevgi, mobile, appsdespite, technological, computational, developments, ingeoweb, many, web, technologies, such, as, jquery, andajax, mapping, apis, like, google, gps, devicesresulted, new, revolution, neogeography, turner, where, mapping, done, by, crowd, can, bereached, by, anyone, from, general, public, members, groupsuch, revolution, brought, trend, volunteered, geographicinformation, vgi, which, ï¬rst, coined, explained, bygoodchild, 2007a, according, goodchild, 2007b, vgihighlighted, human, capabilities, collecting, geospatialinformation, by, using, ï¬ve, senses, then, integrating, withexternal, sensors, mobile, devices, like, gps, accelerometer, camera, digital, compass, microphone, gives, valuable, datasets, which, can, neither, be, retrieved, from, satelliteimagery, nor, collected, with, any, gps, receivers, anothersuccessful, term, geospatial, mapping, using, mobile, technology, crowdsourcing, heipke, , hudsonsmith, , which, coined, by, howe, thatinvolves, collection, geospatial, information, or, mapping, any, particular, activity, by, an, undeï¬ned, crowd, ornetwork, people, both, terms, vgi, crowdsourcingslightly, differ, but, they, are, usually, recognized, as, synonyms, or, even, as, combined, term, crowdsourcing, geographic, information, sui, , , over, lastdecade, vgioriented, , source, mobileareepicollect, aanensen, , , ecology, epidemiology, noisetube, maisonneuve, , , httpnoisetubenet, noise, battle, garciamartä±´, , noise, monitoring, skywatch, windoo, httpwindoochfor, weather, monitoring, mappiness, httpwwwmappinessukfor, behavioural, analysis, mackerron, andmourato, appsthe, , source, mechanism, data, collection, usingandroid, devices, can, be, performed, by, , , data, kitodk, suite107, https, datakit, which, composed, odk, collect, odk, aggregate, odk, collecthttps, datakitusecollect, provides, customizable, framework, geospatial, data, collection, odkaggregate, web, application, that, runs, on, apachetomcat, server, httptomcatapache, store, collecteddata, through, synchronization, with, databaseforexample, postgresql, brunette, , , as, suchsuites, performance, can, be, seen, various, activities, likeagricultural, monitoring, krosing, roybal, journal, indian, society, remote, sensingmonitoring, deforestation, school, attendance, documentation, war, crimes, health, programs, anokwa, digital, contact, tracingnowadays, covid19, has, become, greatest, threat, forpublic, health, last, , years, due, such, pandemicvarious, levels, lockdown, are, issued, across, world, tobreak, its, chain, infection, transmission, however, isthe, ï¬rst, approach, invade, contagion, but, once, itwould, be, lifted, pandemic, would, start, new, wayand, might, reach, its, highest, peak, by, infecting, more, andmore, population, ferguson, , , thereforetocombat, with, such, global, pandemic, threat, anotherapproach, discovered, by, group, researchers, known, asdigital, contact, tracingsmartphonebased, contact, tracing, known, as, digitalcontact, tracing, which, presents, sustainable, solution, tolimit, transmission, infectious, disease, by, tracing, theirpotential, transmission, routes, population, howeversuch, an, app, presents, signiï¬cant, concerns, regarding, privacy, digital, contact, tracing, works, on, principle, ofcrowdsource, data, by, measuring, proximity, aninfectious, person, previous, diseases, risk, surveillancethe, contact, tracing, apps, were, used, pool, location, timestamped, data, determine, exposures, risk, infectionssacks, , , such, data, are, highly, personal, leadmany, privacy, concerns, smith, , , but, they, werenot, always, accurate, infer, exposure, risks, due, noisydata, farrahi, , , therefore, various, smartphoneapps, are, developed, covid19, pandemic, which, someapps, use, location, proximity, some, them, are, notusing, location, services, mobile, device, subject, theprivacypreserving, naturecovid19, contact, tracingin, order, illuminate, epidemiology, covid19, andto, characterize, its, severity, lipsitch, , , there, anurgent, need, digital, platform, that, captures, realtimeaccurate, information, on, covid19, patients, diseasesdiagnosis, treatment, clinical, reports, whom, theyget, interacted, at, which, place, detect, clusters, generatealerts, such, information, may, help, understanding, riskfactors, infection, predicting, next, generation, ofinfectious, persons, fitzgerald, , addressing, thisunprecedented, challenge, many, mobile, apps, have, beendeveloped, are, being, used, at, large, scale, some, ofthem, are, as, follows, 0cjournal, indian, society, remote, sensing¢, covid, symptom, study, covid, symptom, trackerthis, mobile, app, developed, collaboration, zoeglobal, ltd, digital, health, care, company, groupof, academic, scientists, from, massachusetts, generalhospital, kings, college, london, which, waslaunched, uk, on, march, , , becameavailable, after, , days, usa, app, enquires, aboutage, location, other, diseases, risks, also, selfreporting, function, enabled, which, associated, withcovid19, infection, exposure, drew, , app, retrieve, updates, on, healthcare, workersexperiences, who, are, on, covid19, duty, their, stressand, anxiety, use, personal, protective, equipmentppe, kits, are, being, surveyed, through, app, toobserve, intensity, health, care, workers, drew, et, alappimplemented¢, aarogya, setuthis, mobile, app, launched, on, april, , by, government, india, aware, general, publicon, covid19, symptoms, government, advisory, measures, online, consultation, facility, dynamics, ofdisease, thiscrowdsourcingapproach, by, which, general, public, members, enter, theirdetails, selfassessment, assessment, thenused, trace, infectious, contacts, or, agents, as, adigital, contact, tracing, concept, app, uses, locationservices, geolocate, users, bluetooth, tomaintain, log, contacts, when, one, userdevicecomes, contact, with, another, userdevice, as, suchdigital, contact, tracing, activity, helps, identifying, thecluster, diseases, communities, which, are, at, risk, ofinfection, aarogya, setu, app, downloadedby, , , million, users, within, , days, its, launchupadhyay, , by, using, apps, crowdsourcedata, indian, government, detected, approx, positive, casesinformed, , probable, users, ofbeing, at, risk, identiï¬ed, , potential, clusters, thetimes, indianumerous, digital, contact, tracing, apps, are, use, indifferent, parts, worldtrackcovid, yasaka, , tracetogether, bay, , , wetrace, de, carli, , google, apples, recently, announcedjoint, initiative, li, guo, covid19, data, visualization, exploratorydata, analysiswith, early, experiences, epidemics, such, as, sarscov, boulos, , , merscovgikonyo, , , other, seasonal, ï¬us, online, realtime, or, nearrealtime, mapping, diseases, occurrencesusing, geospatial, technologies, web, applications, havealways, been, used, as, pivotal, webbased, tools, trackinghealth, threats, combating, infectious, diseases, thissection, described, range, mapping, dashboards, based, ongeospatialtechnologies, tracking, unfolding, thecoronavirus, disease, around, world, some, globaland, national, geospatial, initiatives, with, an, aim, supplyinformation, faster, than, diseases, are, as, summarized, intable, infectious, diseases, modellingthe, intention, infectious, diseases, surveillance, detectepidemics, their, early, stages, so, that, countermeasurescould, be, taken, preventing, its, wide, spread, suchsurveillance, tasks, require, many, epidemiological, statistical, methods, with, geospatial, features, investigatingepidemics, preferably, from, localized, areas, reason, forpreferring, local, areas, investigation, because, epidemics, generally, emerged, small, areas, then, spreadwidely, if, they, are, not, controlled, however, some, methodsrequire, rigorous, conventions, their, underlying, modelsand, are, too, problematical, be, applied, on, small, areasthereforefordetecting, diseases, prevalence, with, case, studies, on, smalldatasets, which, would, be, more, useful, public, healthactivitiessection, discussessimple, methodsthisclusteringclustering, deals, with, study, spatialtemporal, patternsof, spread, communicable, diseases, identiï¬cationof, other, diseaserelated, aspects, allied, with, heterogeneousgeographical, distribution, which, might, be, helpful, elucidating, diseases, spread, mechanism, such, study, andanalysis, on, spacetime, patterns, kind, diseasesurveillance, which, involves, detecting, outbreak, clustersof, active, cases, monitoring, localisation, isolation, ofinfectious, agents, relative, risks, assessment, affectedsites, at, early, stage, clements, , , cromley, kulldorff, , study, on, geographical, clustering, ofinfectious, diseases, with, temporal, features, helps, makingstrategies, that, dynamically, update, on, emergence, source, ofdisease, outbreak, help, epidemiologists, decisionmakers, identiï¬cation, spread, risk, zones, thusclustering, helps, enable, timely, prevention, containment, measures, timely, resource, allocation, mitigatethe, diffusion, diseasesbased, on, spacetime, surveillance, diseases, spacetime, scan, statistic, kulldorff, , one, clusterdetection, tools, which, widely, used, geographicalsurveillance, diseases, during, epidemic, andor, pandemicthe, spacetime, scan, statistic, comes, with, two, versionsprospective, retrospective, desjardins, , 0ctable, , summary, table, geospatial, dashboards, covid19project, namedatasetsscopepurposejournal, indian, society, remote, sensingwho, coronavirus, disease, covid19whos, ofï¬cial, datadashboard, dong, , httpscovid19whointglobal, visualization, ofï¬cial, daily, counts, ofconï¬rmed, cases, deaths, related, tocovid19, with, time, stamps, using, esriarcgis, online, serviceexploratory, data, analysis, using, 3d, graphto, perform, countrywise, analysis, usingpopulation, conï¬rmed, cases, cumulativecases, deaths, cumulative, deathsprovides, daily, aggregate, case, deathcount, csvjohns, hopkins, university, covid19aggregated, data, from, who, europeanglobal, dashboard, visualizing, realtimedashboard, dong, , , httpscoronavirusjhuedumaphtmlcentre, disease, prevention, andcontrol, ecdc, worldometers, bnonews, us, cdc, 1point3arces, covidtracking, project, dxymapping, covid19, with, graphs, onconï¬rmed, daily, casescritical, trend, analysis, on, new, cases, perday, mortality, fatality, analysis, inpopulation, timeline, outbreak, etcisros, bhuvan, covid19, geospatialsolution, httpsbhuvanapp3nrscgovincoronacorona_dashboarddashboarddashboardphptypecitizencovid19, data, source, mohfwindiatime, series, visualization, activerecovered, deceased, cases, frommarch, , till, dategraphical, analysis, on, spread, trend, ofcovid19, daywise, statewisecovid19india, httpswwwcm, health, m, handles, press, trust, ofindiavisualization, cumulative, dailycovid19indiaindia, state, press, bulletins, pbi, anireportsnumbers, conï¬rmed, active, recovereddeceased, tested, statewise, casesthrough, maps, graphsprovides, daily, covid19, cases, stateand, district, cases, reassigned, statesthrough, apimapmyindia, covid19, httpsmapscovid19, data, source, mohfwindiaprovides, api, on, corona, dashboards, tomapmyindiacomcoronadistricts_containment_zonecontainment_zone_gradienthunger, relief, centres, source, mygovhunger, , night, shelter, source, mygovndmavisualize, cases, at, district, state, levelhotspots, treatment, centres, testing, labsquarantine, centres, containment, zoneslockdown, issues, hunger, relief, hunterand, night, sheltersmonthly, climate, explorer, covid19httpscdsclimatecopernicuseuappsc3sappc3smonthlyclimatecovid19explorermonthly, covid19, cases, source, jhuglobal, visualization, covid19, fatalities, withcsseatmospheric, compositionpm10, no2source, cams, eac4meteorological, datahumidity, , hpaand, surface, air, temperature, on, hourly, andmonthly, average, rate, source, era5reanalysisclimatic, atmospheric, variations, onmonthly, basisexploratory, analysis, on, correlation, ofpollutants, speciï¬c, humidity, withcovid19, deathsexperimental, covid19, globalcovid19, cases, source, jhu, csseglobal, visualize, earthquake, as, cause, increaseseismic, risk, map, httpsmaps, quakemapcovid1920200520v3grm234900global, earthquake, risk, map, source, gemglobal, earthquake, modelin, covid19, cases, due, peoplesdisplacement, from, damaged, buildingsowusu, , , difference, between, both, thatprospective, neglects, historical, clusters, which, may, havepreviously, occurred, before, most, current, time, period, ofanalysis, with, no, health, threat, kulldorff, , thereforethe, prospective, version, spacetime, scan, statistic, iscommonly, used, detect, statistically, signiï¬cant, active, orevolving, clusters, diseases, present, time, periodand, when, more, data, become, available, tool, can, be, rerun, detect, new, evolving, clusters, with, update, on, relativerisks, each, affected, sites, previously, prospectivespacetime, scan, statistic, used, thyroid, cancerkulldorff, , shigellosis, jones, , , measlesyin, , , syndromic, surveillance, yih, , many, other, diseases, however, cluster, analysis, 0cjournal, indian, society, remote, sensingdiseases, can, be, performed, through, several, packages, andlibraries, r, go´mezrubio, , , pythonsoftware, yeng, , contribution, cluster, detections, analysis, incovid19, pandemic, becoming, useful, nowadays, as, itdetects, active, emerging, clusters, covid19, andnotify, epidemiologist, decision, makers, public, healthcare, ofï¬cials, which, can, help, eradicating, infections, fromaffected, sites, improving, interventions, quarantine, andisolation, measures, signiï¬cant, applications, clustering, with, respect, infectious, diseases, modelling, aredemonstrated, across, world, zarikas, , , forexample, india, bhosale, shinde, , usa, desjardins, , , hohl, , , brazil, martines, , italy, cereda, , , china, ji, , , liu, 2020a, b, qiu, , , zhang, , , singapore, bhosale, shinde, , pung, , , southkorea, shim, , , french, alps, danis, , germany, pfefferle, , , sergipe, andrade, , etcoutlier, analysisthe, outlier, deï¬ned, by, hawkins, , as, an, observationwhich, deviates, so, much, from, other, observations, as, toarouse, suspicions, thatit, generated, by, differentmechanism, other, words, when, data, generation, processstarts, behaving, abnormal, reï¬ects, abnormalities, orerrors, data, such, abnormalities, are, known, as, outliersbansal, , , however, outliers, generally, holdadvantageous, information, about, systems, unusual, characteristics, entities, which, impact, data, generationprocess, some, useful, applications, outliers, diseases, are, cleynen, , , dai, bikdash, krishnan, , , lo, , , prensner, , washington, , wu, krishnan, , clusteringalgorithms, are, optimized, ï¬nd, clusters, rather, than, outliersand, accuracy, outlier, detection, depends, on, how, goodthe, clustering, algorithm, captures, structure, clustersmaximum, entropy, modelling, maxent, approachin, context, disease, systems, disease, transmission, risksdepend, on, distribution, pathogens, species, space, andtime, some, complex, environmental, conditions, townsend, as, such, treatments, are, focused, mainly, on, spatialdimensions, therefore, diseases, transmission, risks, are, purelyhandled, through, geographical, phenomena, such, geographical, link, with, diseases, leads, challenge, spatialmapping, disease, transmission, which, overcame, throughthe, branches, biodiversity, scienceecology, biogeography, such, approach, ecological, biogeographical, modelling, can, be, seen, from, various, studies, on, diseasetransmission, risks, mapping, example, arboleda, , deka, morshed, , ferreira, , holt, , , mweya, , , nakazawa, , reeves, , , samy, , , qian, , zhao, , , zhu, , following, recent, studies, on, geographical, mapping, ofpathogens, causing, disease, transmission, machine, learningbased, maximum, entropy, method, maxent, elith, , phillips, , applied, on, spatial, records, ofcovid19, with, set, , bioclimatic, environmentalvariables, from, worldclim, poggio, , , ramä±´rezvillegas, bueno, cabrera, analyse, theirfavourable, environmental, conditions, as, shown, fig, table, , required, maintaining, its, population, themaxent, principle, estimate, target, probability, distribution, by, applying, maximum, entropy, distributionwhich, most, spread, or, closest, study, carried, out, inr, software, ihaka, gentleman, , geographical, dataset, consists, latitude, longitude, thoseregions, which, were, affected, till, march, figure, , depicts, habitat, suitability, map, virus, withprobability, range, colour, scale, visualize, highsuitability, light, dark, green, colour, medium, suitabilityyellow, dark, brownlow, suitability, light, browncolour, unsuitable, grey, colour, table, , lists, thefavourable, bioclimatic, variables, their, contribution, inpercent, maintaining, suitability, virussusceptibleinfectiousrecovered, sir, modelepidemiology, deals, with, study, pattern, occurrence, diseases, space, time, associated, with, otherfactors, such, as, environment, demography, translation, epidemiology, into, mathematical, equations, todescribe, spread, infectious, diseases, known, asmathematical, epidemiology, allen, , , rayner, andbender, , mathematical, epidemiology, model, isimplemented, understand, transmission, dynamics, ofcommunicable, diseases, by, categorizing, population, intosusceptible, infectious, recovered, compartments, theï¬rst, basic, model, known, as, susceptibleinfectiousrecovered, sir, model, proposed, by, kermack, andmckendrick, , describe, transmission, epidemic, diseases, from, individual, individual, sirmodel, set, nonlinear, ordinary, differential, equationswhich, mathematically, deï¬ned, as, follows¼, l, n, ã¾, sã°ã, 00, bsi¼, bsi, 00, ci, 00, li¼, ci, 00, lrdsdtdidtdrdtã°1ãã°2ãã°3ã, 0cjournal, indian, society, remote, sensingfig, , predicted, suitability, betacoronavirus, using, data, till, march, table, , responsible, bioclimatic, variables, suitability, modellingheres, class, susceptible, individuals, who, are, not, yetcontracted, diseasei, class, infectious, people, who, are, now, infectedwith, disease, become, infectious, infect, others¢, r, class, recovered, individuals, who, have, recoverednow, are, removed, from, class, s¢, n, total, population, size, n, , s, , i, , r, t, istime, days, or, weeks¢, b, contact, rate, infected, person, with, suspected¢¢¢bioclimatic, variablespercent, contributionmean, temperature, coldest, quarterprecipitation, wettest, monthmean, diurnal, rangeisothermalityannual, mean, temperaturemax, temperature, warmest, monthprecipitation, coldest, quarterprecipitation, wettest, quarterannual, precipitationprecipitation, driest, quartermean, temperature, driest, quartermean, temperature, wettest, quarterprecipitation, seasonalitytemperature, seasonalityprecipitation, warmest, quartermean, temperature, warmest, quartertemperature, annual, rangeprecipitation, driest, monthmin, temperature, coldest, monthperson, per, dayc, infectious, period, average, infectious, periodis, 1c¢, l, per, capita, death, rate, which, adjusted, by, birthrate, lnthere, are, many, other, compartment, models, derived, fromthe, basic, epidemic, model, sir, with, more, compartmentsand, transitions, susceptibleexposedinfectiousrecovered, seir, li, muldowney, , , susceptibleinfectiousexposedrecovereddeadseirdpiccolomiini, zama, , , susceptibleinfectiousexposedrecoveredsusceptible, seirs, liu, zhang, susceptibleinfectiousquarantinerecoveredsiqr, erdem]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |(224581,[0,1,2,3,4,5,8,9,10,11,12,15,16,17,18,20,21,22,23,24,26,27,28,30,33,35,37,38,39,40,42,43,44,45,47,48,50,51,52,54,55,57,59,60,61,64,65,67,68,69,70,72,73,74,76,78,81,82,84,85,86,91,92,93,94,95,96,98,99,100,101,103,104,107,108,109,111,112,113,114,115,118,122,123,125,126,131,134,143,144,145,146,147,148,149,151,152,156,158,159,161,164,167,169,171,173,180,184,185,186,188,190,191,192,194,195,201,207,209,212,216,218,220,221,223,224,225,226,227,229,231,234,235,239,241,242,244,245,255,257,260,262,263,267,269,270,274,275,279,280,288,298,299,301,308,309,311,312,313,316,318,320,328,330,332,334,336,343,351,352,356,358,359,360,361,366,367,368,370,373,374,377,381,384,385,386,388,391,394,398,401,409,411,419,424,426,428,434,435,453,464,466,470,473,476,477,481,484,486,490,492,496,497,498,499,503,504,506,510,512,517,519,521,525,528,543,547,548,551,555,567,568,576,577,579,596,600,601,604,608,610,617,619,623,629,634,637,638,642,646,648,652,657,660,668,673,674,677,686,690,692,693,697,699,701,703,707,713,714,716,724,727,731,732,733,735,742,764,767,769,772,776,777,781,783,785,796,802,805,812,818,820,824,840,844,845,850,853,855,873,877,878,885,887,895,898,899,901,908,909,912,913,914,929,932,934,935,943,964,965,966,970,972,976,978,982,984,990,992,996,1011,1012,1017,1027,1029,1033,1034,1036,1042,1044,1045,1049,1054,1059,1060,1062,1069,1071,1076,1077,1086,1091,1101,1102,1110,1111,1114,1118,1120,1131,1136,1140,1144,1145,1146,1157,1158,1164,1166,1191,1194,1195,1201,1221,1232,1236,1242,1244,1257,1261,1265,1266,1271,1282,1283,1298,1306,1307,1308,1315,1317,1318,1344,1347,1353,1355,1359,1361,1363,1367,1369,1371,1374,1400,1404,1406,1429,1436,1437,1444,1448,1450,1459,1474,1483,1485,1487,1491,1499,1504,1521,1540,1549,1550,1552,1553,1568,1594,1598,1613,1614,1627,1629,1643,1667,1672,1676,1682,1684,1705,1709,1740,1741,1743,1745,1751,1753,1756,1760,1777,1808,1809,1815,1817,1835,1836,1849,1850,1851,1854,1868,1869,1880,1891,1895,1897,1898,1900,1913,1917,1931,1932,1950,1954,1966,1971,1975,1977,1978,1982,1988,1991,2004,2043,2046,2068,2075,2076,2079,2080,2087,2106,2110,2131,2139,2147,2149,2157,2158,2167,2168,2176,2178,2182,2193,2202,2223,2242,2250,2285,2295,2312,2316,2323,2344,2346,2365,2372,2378,2397,2409,2415,2424,2461,2467,2476,2477,2487,2493,2499,2520,2524,2533,2546,2552,2581,2586,2587,2590,2621,2624,2626,2629,2638,2640,2642,2653,2689,2707,2736,2740,2750,2760,2766,2811,2819,2825,2840,2853,2854,2864,2866,2883,2890,2896,2907,2912,2921,2922,2936,2942,2945,2955,2976,3001,3002,3017,3026,3042,3107,3111,3129,3130,3149,3151,3158,3166,3167,3215,3225,3230,3233,3234,3236,3261,3270,3288,3306,3311,3326,3327,3329,3333,3347,3359,3364,3382,3386,3399,3410,3422,3432,3467,3468,3513,3516,3529,3553,3616,3633,3660,3669,3688,3694,3717,3728,3753,3757,3772,3777,3786,3797,3804,3820,3855,3856,3857,3875,3879,3927,3938,3982,4009,4053,4067,4073,4094,4099,4183,4235,4241,4248,4256,4258,4277,4309,4321,4332,4340,4352,4375,4394,4399,4415,4480,4487,4489,4530,4535,4614,4616,4677,4680,4682,4688,4690,4691,4692,4709,4822,4834,4858,4870,4881,4938,4952,4960,4969,5039,5074,5092,5110,5140,5180,5211,5271,5286,5305,5327,5407,5429,5436,5437,5458,5493,5495,5504,5523,5529,5578,5588,5600,5605,5616,5617,5637,5663,5698,5716,5731,5744,5750,5772,5852,5864,5905,5909,5971,5990,6020,6065,6070,6080,6096,6121,6163,6180,6184,6232,6267,6291,6296,6408,6420,6490,6499,6511,6515,6556,6559,6566,6598,6639,6643,6658,6681,6701,6731,6745,6771,6831,6867,6873,6881,6898,6922,6925,6939,7000,7055,7068,7071,7113,7242,7263,7385,7417,7478,7504,7507,7586,7589,7629,7641,7680,7687,7752,7834,7875,7881,7961,7962,8012,8039,8051,8052,8076,8146,8161,8179,8180,8226,8260,8308,8363,8365,8383,8435,8463,8537,8617,8637,8702,8706,8719,8730,8769,8793,8877,8903,8916,8973,9043,9142,9191,9201,9206,9291,9376,9392,9422,9437,9454,9481,9505,9525,9533,9535,9553,9583,9595,9604,9618,9681,9734,9826,9864,9913,10001,10141,10153,10162,10192,10211,10229,10248,10251,10274,10479,10525,10583,10607,10622,10635,10677,10728,10760,10826,10884,10938,10996,11051,11187,11202,11224,11341,11344,11462,11547,11771,11833,12072,12120,12240,12279,12304,12310,12359,12431,12539,12542,12590,12639,12744,12754,12822,12847,12905,12906,12922,12959,13002,13005,13033,13083,13278,13302,13311,13348,13351,13417,13459,13518,13583,13651,13738,13847,13867,13921,13956,14018,14049,14088,14140,14246,14247,14263,14287,14402,14417,14498,14500,14703,14858,15105,15176,15206,15255,15269,15345,15424,15457,15588,15643,15735,15746,15757,15819,15838,15947,15992,16160,16209,16234,16251,16261,16544,16616,16622,16749,16769,16775,16807,16950,16999,17033,17106,17286,17453,17488,17504,17528,17656,17798,17895,17991,18000,18026,18051,18105,18218,18235,18499,18598,18642,18744,19188,19198,19248,19394,19462,19689,19713,19804,19957,20120,20238,20259,20263,20338,20528,20579,20654,20908,20970,21059,21138,21145,21267,21331,21787,21790,22163,22182,22620,22750,22926,22993,22996,23199,23661,23839,24175,24304,24699,24810,25253,25309,25431,25611,25846,25871,26047,26070,26200,26285,26840,27458,27544,27668,27907,28194,28259,28574,28914,29248,29624,29980,30165,30247,30331,30452,30557,30800,30804,31190,31308,31337,31980,32035,32486,33500,33519,33668,33718,33724,33916,33987,34151,34338,34348,34562,35131,35312,35720,35749,35788,36540,37283,37295,37388,37476,37739,37784,38149,38431,38599,39168,39246,39401,39458,39794,39865,39886,40057,40193,40819,40990,41332,41372,41512,41594,41607,41608,41705,41729,41741,41894,41944,42032,42136,42498,43208,45389,45450,45688,46021,46586,46730,46872,47556,47880,48369,49289,49506,49802,50377,50600,50994,51648,51667,52227,54077,54150,54401,54646,56183,56305,56622,56665,57158,57183,57361,58109,58785,58805,59234,60116,60819,61628,61701,62841,64160,64967,65292,65531,66959,67007,67354,67953,68084,68807,68974,69883,70332,70663,72145,72590,73620,74263,74552,74658,74838,77189,78242,78992,80904,81709,81766,81915,82449,82484,82602,82614,82688,82706,83289,83816,84590,84686,84720,84898,85004,85160,86037,86064,86349,86648,86731,86761,86981,87187,87336,87462,87483,87710,87812,87941,88078,88145,88245,88326,88622,88656,88763,89054,89209,89291,89345,89410,89921,90046,90157,90218,90288,90592,90637,90784,90954,91605,91641,91786,91992,92570,92620,93139,93187,93257,93557,93794,94608,95224,95284,95354,95443,95530,95662,95740,95775,96012,96174,96744,97185,97325,97795,97968,98246,98745,99532,99750,100543,100586,100587,100841,101224,101394,101506,101509,101812,101839,101967,102077,102484,102513,102560,102601,102619,102747,102778,102783,103148,103157,103241,103460,103787,104152,104762,105112,105236,105295,105519,105588,105702,105784,106479,106655,106701,107041,107151,107316,107365,107404,107573,107575,107720,108525,108823,108969,109630,110067,110174,110253,110327,110352,110542,110794,110836,111192,111460,111835,112004,112260,112435,112488,112909,113313,113348,113625,113694,113837,113969,113970,113977,114045,114329,114666,114679,114766,115253,115572,116004,116122,116152,116162,116256,116345,116374,116501,116950,116965,117178,117204,117539,117643,118051,118329,118362,118853,118860,119500,119622,119643,119689,119726,119786,120249,120250,121086,121779,122137,122723,122741,122788,122809,122964,122965,123201,123213,123295,123589,124224,124282,124440,124471,124557,124694,125271,125607,125687,125747,125772,126962,127004,127094,127272,127431,127967,128025,128463,128656,128695,128762,128768,128928,129826,129894,129945,130021,130031,130329,130416,130595,130596,130685,131202,131393,131413,131645,132375,132390,132442,132709,132901,133258,133323,133386,133678,133930,134049,134243,134775,134793,134842,134938,135329,135352,135464,135671,135803,135856,136214,136333,136735,136903,137248,137381,138073,138129,138881,139363,139665,140096,140288,140311,140411,140736,141061,141413,142538,142682,142859,143305,143589,143629,143679,144180,144222,144586,144715,145495,145504,145770,146133,146317,146409,146435,146551,146744,147105,147164,147573,147762,147825,148286,148341,148441,148529,148565,149563,149884,149952,150331,150497,150758,150822,151544,151777,152147,152182,152192,152295,152491,152835,153162,153835,153888,153916,154014,154105,154247,154340,154431,154630,154736,154842,154956,155078,155307,155369,155557,155588,155775,155909,156002,156087,156113,156235,156350,156405,156869,157356,157395,157676,157814,158037,158440,158451,158504,158607,158914,158939,158954,158969,159023,159143,159638,160066,160299,160371,160449,160508,160694,160792,160848,160899,161200,161258,161400,161567,162028,162047,162616,162848,162963,162986,163227,163244,163501,163530,163902,164224,164512,164655,164677,165091,165394,165423,165562,165566,165752,165815,166274,166298,166608,166648,166823,166893,167115,167244,167304,167920,167927,167947,168044,168364,168404,168520,168756,169038,169377,169394,169615,169776,169792,170225,170591,170594,170700,170851,170906,171350,171692,171698,171859,171871,171941,172531,172632,172657,173088,173434,173716,174651,174981,175011,175014,175520,176168,176760,176845,177143,177154,177188,177206,177647,177749,178098,178143,178377,178428,178538,178651,178801,178916,178993,179232,179553,179694,180299,181149,181246,181349,181519,181745,182011,182496,182722,182752,182767,182926,183036,183258,183428,183460,183468,183483,183602,183926,184002,184082,184165,184204,184316,184488,184688,184893,185010,185126,185241,185250,185511,185519,185800,185926,185976,186029,186225,186250,186603,187093,187145,187568,187996,188080,188193,188318,188645,189049,189308,189471,189478,190476,190637,190712,190956,190974,191002,191072,191512,191544,191934,192304,192505,192642,193168,193276,193426,193485,193602,194224,194448,194683,195183,195286,195317,195507,195574,195743,195775,195794,195840,196404,196470,196534,196781,197189,197681,197826,197869,198005,198256,198264,198955,199241,199372,199678,199682,199922,200603,200696,200996,201166,201204,201239,201452,201671,201743,202446,202699,202845,203208,203334,203613,203733,203922,204033,204104,204170,204191,204354,204742,204759,205271,205536,205626,205643,205747,206204,206301,207053,207275,207497,207521,207533,207609,208184,208273,208497,208726,209337,209488,209626,209652,209851,210084,210179,210546],[289.0,37.0,10.0,26.0,9.0,36.0,3.0,12.0,37.0,19.0,29.0,14.0,2.0,10.0,6.0,10.0,30.0,3.0,38.0,5.0,10.0,1.0,2.0,15.0,7.0,10.0,2.0,1.0,5.0,3.0,1.0,2.0,4.0,11.0,6.0,26.0,1.0,1.0,3.0,3.0,2.0,7.0,6.0,3.0,2.0,1.0,1.0,3.0,2.0,1.0,7.0,4.0,3.0,17.0,1.0,4.0,6.0,2.0,1.0,2.0,1.0,2.0,2.0,3.0,2.0,5.0,4.0,6.0,3.0,1.0,1.0,3.0,1.0,1.0,4.0,9.0,13.0,4.0,2.0,2.0,3.0,1.0,3.0,7.0,4.0,27.0,7.0,2.0,5.0,1.0,1.0,2.0,3.0,2.0,2.0,1.0,22.0,1.0,2.0,2.0,3.0,6.0,2.0,3.0,1.0,4.0,2.0,1.0,2.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,10.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,3.0,2.0,1.0,1.0,2.0,9.0,3.0,1.0,1.0,4.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,2.0,4.0,2.0,1.0,1.0,2.0,3.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,34.0,10.0,2.0,1.0,5.0,1.0,3.0,1.0,2.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,5.0,3.0,3.0,2.0,3.0,3.0,4.0,1.0,3.0,6.0,1.0,2.0,1.0,1.0,2.0,2.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,4.0,1.0,3.0,1.0,2.0,3.0,1.0,2.0,2.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,21.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,2.0,12.0,1.0,2.0,1.0,2.0,4.0,3.0,1.0,1.0,2.0,1.0,3.0,2.0,4.0,5.0,1.0,1.0,8.0,1.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,3.0,3.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,8.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,5.0,6.0,3.0,1.0,3.0,1.0,1.0,1.0,3.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,6.0,10.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,3.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,3.0,2.0,1.0,2.0,2.0,1.0,1.0,4.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,2.0,1.0,2.0,5.0,3.0,2.0,1.0,1.0,1.0,2.0,8.0,2.0,2.0,2.0,1.0,2.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,4.0,1.0,1.0,1.0,5.0,1.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,3.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,4.0,1.0,2.0,4.0,16.0,1.0,3.0,2.0,1.0,4.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,5.0,4.0,1.0,1.0,1.0,1.0,7.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,4.0,9.0,2.0,1.0,2.0,6.0,1.0,1.0,1.0,6.0,1.0,1.0,8.0,1.0,1.0,2.0,5.0,1.0,2.0,1.0,5.0,1.0,11.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,21.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,7.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,2.0,6.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,6.0,1.0,2.0,1.0,17.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,3.0,1.0,1.0,2.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,4.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,7.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,4.0,10.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,7.0,4.0,1.0,1.0,1.0,1.0,3.0,2.0,1.0,1.0,1.0,2.0,1.0,9.0,4.0,1.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,4.0,3.0,5.0,2.0,1.0,2.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,9.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,8.0,2.0,9.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,3.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,5.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,22.0,6.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,2.0,1.0,1.0,2.0,8.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,8.0,1.0,1.0,1.0,2.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,2.0,1.0,1.0,1.0,1.0,3.0,2.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,7.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,3.0,3.0,2.0,1.0,1.0,1.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,3.0,3.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])|\n",
      "|[generate, a, map, of, the, copy, number, variations, cnv, segregating, in, a, population, of, murcianogranadina, goats, the, most, important, dairy, breed, in, spain, and, to, ascertain, the, main, biological, functions, of, the, genes, that, map, to, copy, number, variable, regionsresults, , using, a, dataset, that, comprised, , murcianogranadina, goats, genotyped, with, the, goat, snp50, beadchip, we, were, able, to, detect, , and, , autosomal, cnv, with, the, penncnv, and, quantisnp, software, respectively, by, applying, the, ensemblecnv, algorithm, these, cnv, were, assembled, into, , cnv, regions, cnvr, of, which, , , of, the, total, cnvr, count, were, consistently, called, by, penncnv, and, quantisnp, and, used, in, subsequent, analyses, in, this, set, of, , cnvr, we, identified, , gain, , loss, and, , gainloss, events, the, total, length, of, all, the, cnvr, , mb, represented, , of, the, goat, autosomal, genome, , mb, whereas, their, size, ranged, from, , kb, to, , mb, with, an, average, size, of, , kb, functional, annotation, of, the, genes, that, overlapped, with, the, cnvr, revealed, an, enrichment, of, pathways, related, with, olfactory, transduction, foldenrichment, , , qvalue, , , , , abc, transporters, foldenrichment, , , qvalue, , , , , and, bile, secretion, foldenrichment, , , qvalue, , , , conclusions, , a, previous, study, reported, that, the, average, number, of, cnvr, per, goat, breed, was, , , , cnvr50, breeds, which, is, much, smaller, than, the, number, we, found, here, , cnvr, we, attribute, this, difference, to, the, fact, that, the, previous, study, included, multiple, caprine, breeds, that, were, represented, by, small, to, moderate, numbers, of, individuals, given, the, low, frequencies, of, cnv, in, our, study, the, average, frequency, of, cnv, is, , such, a, design, would, probably, underestimate, the, levels, of, the, diversity, of, cnv, at, the, withinbreed, level, we, also, observed, that, functions, related, with, sensory, perception, metabolism, and, embryo, development, are, overrepresented, in, the, set, of, genes, that, overlapped, with, cnv, and, that, these, loci, often, belong, to, large, multigene, families, with, tens, hundreds, or, thousands, of, paralogous, members, a, feature, that, could, favor, the, occurrence, of, duplications, or, deletions, by, nonallelic, homologous, recombinationcorrespondence, , marcelamillsuabcat, centre, for, research, in, agricultural, genomics, crag, csicirtauabub, universitat, aut²noma, de, barcelona, , bellaterra, spainfull, list, of, author, information, is, available, at, the, end, of, the, backgroundcopy, , number, , variations, , cnv, , encompass, , genomic, deletions, or, duplications, with, sizes, ranging, from, , base, pairs, bp, to, several, megabases, mb, and, which, display, polymorphisms, in, terms, of, copy, number, among, individuals, of, a, particular, species, [], in, livestock, a, broad, array, , of, , phenotypes, , related, , with, , among, , others, , morphology, [, ], pigmentation, [], sexual, development, , the, authors, , this, , is, licensed, under, a, creative, commons, attribution, , international, license, which, permits, use, sharing, adaptation, distribution, and, reproduction, in, any, medium, or, format, as, long, as, you, give, appropriate, credit, to, the, original, authors, and, the, source, provide, a, link, to, the, creative, commons, licence, and, indicate, if, changes, were, made, the, images, or, other, third, party, material, in, this, , are, included, in, the, s, creative, commons, licence, unless, indicated, otherwise, in, a, credit, line, to, the, material, if, material, is, not, included, in, the, s, creative, commons, licence, and, your, intended, use, is, not, permitted, by, statutory, regulation, or, exceeds, the, permitted, use, you, will, need, to, obtain, permission, directly, from, the, copyright, holder, to, view, a, copy, of, this, licence, visit, httpcreat, iveco, mmons, licen, sesby40, the, creative, commons, public, domain, dedication, waiver, httpcreat, iveco, mmons, publi, cdoma, inzero10, applies, to, the, data, made, available, in, this, , unless, otherwise, stated, in, a, credit, line, to, the, data, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , of, [], , and, , susceptibility, , to, , disease, , [], , is, , caused, , by, , the, segregation, of, cnv, genome, scans, to, detect, structural, variations, , in, , cattle, , have, , revealed, , that, , cnv, , regions, cnvr, are, often, enriched, in, genes, that, are, involved, in, immunity, [], metabolism, [, ], embryo, development, [, ], and, sensory, perception, [, ], there, is, evidence, that, the, , dnds, ratios, of, genes, that, map, to, taurine, cnv, are, generally, higher, than, those, of, genes, that, do, not, overlap, with, cnv, which, indicates, that, cnv, genes, probably, evolve, under, reduced, selective, constraint, [], the, analysis, of, gene, networks, has, also, shown, that, genes, that, , colocalize, , with, , duplications, , tend, , to, , have, , fewer, interactions, with, other, genes, than, loci, that, do, not, overlap, , with, , cnv, , reinforcing, , the, , idea, , that, , genes, , mapping, to, duplicated, regions, have, fewer, essential, housekeeping, functions, , than, , noncnv, , genes, , and, , also, , have, , reduced, pleiotropy, []although, structural, chromosomal, variations, can, have, strong, , effects, , on, , gene, , expression, , and, , phenotypic, , variability, , technical, , limitations, , and, , the, , moderate, , quality, of, genome, assemblies, have, hampered, cnv, mapping, in, livestock, , [], , until, , recently, , this, , has, , been, , particularly, true, for, goats, in, , fontanesi, et, a0al, [], published, the, first, , caprine, , cnv, , map, , by, , identifying, , with, , the, , bovine, a0k, acgh, array, , cnvr, including, , and, , copy, loss, and, gain, variants, respectively, later, on, resequencing, , the, , genome, , of, , individuals, , from, , several, , caprine, breeds, , made, , it, , possible, , to, , identify, , cnv, , that, , overlap, with, , pigmentation, genes, and, to, detect, an, association, between, increased, asip, copy, number, and, light, pigmentation, , [], , the, , first, , worldwide, , survey, , of, , copy, , number, , variation, , in, , goats, , was, , performed, , within, , the, , goat, adaptmap, project, httpwwwgoata, daptm, ap, and, involved, the, genomewide, genotyping, of, , goats, from, , breeds, [], this, study, resulted, in, the, identification, of, , cnvr, among, which, several, overlapped, with, genes, that, , are, , functionally, , related, , with, , local, , adaptation, , such, as, coat, color, muscle, development, metabolic, processes, and, embryonic, development, [], moreover, the, patterns, of, the, diversity, of, cnv, differed, according, to, geographic, origin, , which, , indicates, , that, , they, , have, , been, , influenced, by, population, history, [], in, another, study, on, , individuals, from, , east, african, goat, breeds, nandolo, et, a0al, [], detected, , cnvr, more, recently, henkel, et, a0al, [], demonstrated, the, existence, of, complex, patterns, of, structural, variation, in, the, regions, containing, the, caprine, asip, and, kit, genes, with, potential, causal, effects, on, pigmentation, in, spite, of, these, efforts, the, description, of, structural, chromosomal, , variation, , in, , goats, , is, , still, , lagging, , behind, that, of, other, domestic, species, most, of, the, cnv, surveys, in, goats, have, analyzed, large, populations, that, represent, a, mixture, of, different, breeds, each, with, a, limited, number, of, individuals, [, ], thus, making, it, difficult, to, assess, the, magnitude, of, the, cnv, diversity, at, the, withinbreed, level, our, goal, was, to, fill, this, gap, by, analyzing, a, population, of, , individuals, from, a, single, spanish, breed, murcianogranadina, , and, , to, , investigate, , the, , functional, , roles, , of, genes, that, map, to, cnvr, and, compare, these, results, with, data, obtained, in, composite, goat, populationsmethodsgenomic, dna, extraction, and, a0highthroughput, genotypingblood, , samples, , from, , , , murcianogranadina, , female, goats, , from, , , , farms, , that, , are, , connected, , through, , the, use, , of, , artificial, , insemination, , were, , collected, , in, , edta, k3, , coated, , vacuum, , tubes, , and, , stored, , at, , , a0, °c, , before, processing, , genomic, , dna, , was, , isolated, , by, , a, , modified, saltingout, procedure, [], four, volumes, of, red, cell, lysis, , solution, , trishcl, , a0, mmoll, , ph, , , , edta, a0mmoll, tween, , , were, added, to, a0ml, of, whole, blood, and, this, mixture, was, centrifuged, at, g, pelleted, cells, were, resuspended, in, a0ml, lysis, buffer, trishcl, , a0, mmoll, , ph, , , , edta, , a0, mmoll, , sds, , , nacl, , a0, mmoll, , plus, , , , µl, , proteinase, , k, , a0, mgml, the, resulting, mixture, was, incubated, at, a0°c, for, , h, followed, by, centrifugation, at, g, in, the, presence, of, a0ml, of, ammonium, acetate, a0moll, the, supernatant, , a0ml, was, mixed, with, a0ml, of, isopropanol, , which, was, subsequently, centrifuged, at, g, for, a0min, the, , supernatant, , was, , removed, , and, , the, , dna, , pellet, , was, washed, , with, , a0, ml, , of, , ethanol, , , , after, , centrifuging, at, g, for, a0min, the, dna, precipitate, was, dried, at, room, temperature, and, resuspended, in, a0ml, of, te, buffer, a0mmoll, tris, ph, , , a0mmoll, edta, ph, , highthroughput, , genotyping, , of, , the, , , , murcianogranadina, dna, samples, was, carried, out, with, the, goat, snp50, , beadchip, , [], , according, , to, , the, , manufacturers, instructions, , illumina, , signal, , intensity, , ratios, , ie, , log, , r, ratio, or, lrr, the, total, probe, intensity, of, a, snp, referred, to, a, canonical, set, of, normal, controls, [], and, b, allele, frequencies, or, baf, relative, quantity, of, one, allele, compared, , to, , the, , other, , one, , [], , were, , exported, , for, , each, single, nucleotide, polymorphism, snp, with, the, genomestudio, , software, , , , illumina, , https, emeaillum, inacom, then, snp, coordinates, were, converted, to, the, latest, version, of, the, goat, reference, genome, ars1, [], after, filtering, , out, , unmapped, , and, , nonautosomal, , snps, , and, those, with, a, call, rate, lower, than, , a, set, of, , snps, remained, for, cnv, mappingcopy, number, variant, calling, with, a0penncnv, and, a0quantisnpbased, , on, , their, , excellent, , performance, , in, , comparative, , studies, , we, , selected, , two, , software, , packages, , penncnv, v105, [], and, quantisnp, v2, [], to, call, cnv, in, the, murcianogranadina, population, [, ], the, penncnv, software, [], detects, cnv, by, applying, the, default, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , of, parameters, of, the, hiddenmarkov, model, population, frequencies, of, b, alleles, were, compiled, based, on, the, baf, of, each, snp, in, the, population, we, used, the, gcmodelfile, option, , to, , adjust, , genomic, , waves, , [], , the, , number, , of, goat, chromosomes, was, set, with, the, lastchr, , instruction, the, quantisnp, analysis, [], assumes, an, objective, bayes, hiddenmarkov, model, to, improve, the, accuracy, of, segmental, , aneuploidy, , identification, , and, , mapping, , this, cnv, calling, software, was, run, under, default, parameters, by, modifying, the, chr, , option, the, cnv, that, were, supported, , by, , less, , than, , three, , snps, , were, , removed, , from, the, filtered, set, used, heredefinition, and, a0functional, annotation, of, a0copy, number, variant, regionswe, used, the, ensemblecnv, algorithm, beta, version, [], to, , assemble, , cnvr, , all, , cnv, , called, , by, , penncnv, , andor, , quantisnp, , were, , combined, , to, , generate, , a, , set, , of, , initial, , cnvr, , by, , using, , the, , heuristic, , algorithm, , threshold, of, , minimum, , overlap, , , , described, , in, , [], , subsequently, cnvr, boundaries, were, refined, by, considering, the, local, correlation, structure, of, the, lrr, values, of, the, snps, , mapping, , to, , cnvr, , [], , then, , we, , reassigned, , the, cnv, , calls, , that, , were, , initially, , obtained, , with, , penncnv, and, quantisnp, to, each, refined, cnvr, so, that, the, final, set, , of, , cnvr, , comprised, , only, , those, , that, , were, , simultaneously, , detected, , by, , both, , callers, , the, , resulting, , cnvr, were, matched, to, gene, features, that, are, annotated, in, the, national, , center, , for, , biotechnology, , information, , ncbi, https, wwwncbinlmnihgov, , by, , using, , bedtools, v2250, , [], , in, , addition, , we, , performed, , gene, , ontology, go, enrichment, and, pathway, analyses, using, the, david, bioinformatics, , resources, , , , [, , ], , based, , on, , human, and, , goat, , background, , gene, , sets, , the, , statistical, , significance, was, set, to, a, qvalue, ¤, confirmation, of, a0copy, number, variant, regions, by, a0quantitative, realtime, pcrin, , order, , to, , evaluate, , the, , rate, , of, , false, , positives, , in, , our, experiment, , we, , conducted, , quantitative, , realtime, , pcr, qpcr, , experiments, , to, , obtain, , an, , independent, , estimate, , of, , the, , copy, , number, , of, , four, , putative, , cnvr, cnvr_371_chr5, , cnvr_506_chr6, , cnvr_160_chr2, and, cnvr_1229_chr21, primers, were, designed, with, the, primer, express, software, applied, biosystems, to, amplify, specific, , regions, , of, , the, , adamts20, , bst1, , nckap5, and, , tnfaip2, , genes, , see, , additional, , file, a0, , , table, a0, s1, as, , reference, , genes, , we, , used, , the, , melanocortin, , , , receptor, , mc1r, , and, , glucagon, , gcg, , , genes, , see, , additional, file, a0, table, a0s1, loci, [, ], quantitative, pcr, reactions, contained, a0ng, genomic, dna, , µl, , , sybrselect, master, mix, applied, biosystems, a0pmol, of, each, forward, , and, , reverse, , primer, , and, , ultrapure, , water, , to, , a, maximum, final, volume, of, , µl, each, sample, was, analyzed, in, triplicate, in, order, to, obtain, averaged, copy, number, estimates, reactions, were, loaded, onto, 384well, plates, and, run, in, a, quantstudio, a0k, flex, realtime, pcr, system, instrument, applied, biosystems, the, specificity, of, the, , pcr, , reactions, , was, , evaluated, , with, , a, , melting, , curve, analysis, procedure, and, the, efficiency, , was, assessed, with, standard, curves, thus, relative, copy, number, , was, , inferred, , with, , the, , qbase, , software, , biogazelle, ghent, belgium, by, using, the, , îîct, approach, [], copy, number, values, were, calibrated, by, taking, as, a, reference, four, samples, which, according, to, goat, snp50, beadchip, data, had, two, copies, of, the, investigated, genomic, lociresultsdetection, of, a0copy, number, variation, in, a0murcianogranadina, goatsthe, initial, calling, with, penncnv, and, quantisnp, yielded, , , and, , , , autosomal, , cnv, , respectively, , by, , using, the, , ensemblecnv, , tool, , [], , we, , assigned, , these, , cnv, into, , cnvr, with, refined, boundaries, of, which, , , , of, , the, , total, , cnvr, , count, , were, , detected, , simultaneously, , by, , penncnv, , and, , quantisnp, , the, , resulting, cnvr, included, , copy, gain, , copy, loss, and, , copy, gainloss, , variants, , fig, a0, , , and, , table, a0, , , and, , see, , additional, , file, a0, , , table, a0, s2, , the, , total, , length, , of, , the, , cnvr, covered, a0mb, , of, the, goat, autosomal, genome, a0mb, whereas, their, individual, size, ranged, from, a0kb, to, a0mb, with, an, average, of, a0kb, fig, a02a, and, table, a0, , , moreover, , we, , found, , that, , , , of, , the, , cnvr, showed, , minimum, , allele, , frequencies, , lower, , than, , , with, an, average, frequency, of, , fig, a02b, in, addition, , cnvr, with, frequencies, higher, than, , were, distributed, over, seven, caprine, chromosomes, with, a, frequency, of, , cnvr_1229_chr21, was, the, cnvr, with, the, highest, frequency, in, the, whole, dataset, see, additional, file, a0, table, a0s2, by, using, the, bedtools, v2250, program, [], , of, the, cnvr, that, we, detected, overlapped, with, , unique, cnvr, published, by, liu, et, a0al, [], fig, a0, and, see, additional, file, a0, table, a0s2, the, cnvr, that, were, detected, in, both, studies, are, referred, to, as, shared, cnvr, whereas, those, that, were, identified, in, our, study, only, are, referred, to, as, nonshared, cnvr, fig, a0, six, of, the, ten, shared, cnvr, with, frequencies, higher, than, , show, positional, concordance, with, six, cnvr, detected, by, liu, et, a0al, [], see, additional, file, a0, table, a0s2functional, annotation, of, a0the, a0genes, that, a0are, located, in, a0copy, number, variable, regionswithin, the, cnvr, defined, in, our, study, we, detected, , proteincoding, , genes, , according, , to, , the, , goat, , reference, genome, , annotation, , ars1, , [], , from, , the, , ncbi, , database, see, additional, file, a0, table, a0s2, and, additional, file, a0, , 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , of, fig, , , genomic, distribution, of, , cnvr, detected, with, the, penncnv, and, quantisnp, software, on, the, , caprine, autosomes, squares, triangles, and, circles, represent, copy, number, gain, loss, and, gainloss, events, respectively, red, and, black, colors, represent, shared, and, nonshared, cnvr, respectively, shared, cnvr, are, those, detected, both, in, our, study, and, in, liu, et, al, [], while, nonshared, cnvr, are, those, identified, only, in, our, studytable, a0s3, in, a, survey, of, the, diversity, of, cnv, in, goats, with, , a, , worldwide, , distribution, , liu, , et, a0, al, , [], , detected, , copy, number, variable, genes, of, which, , were, also, identified, in, our, study, and, are, referred, to, as, shared, copy, number, variable, genes, see, additional, file, a0, table, a0s3, among, , the, , shared, , copy, , number, , variable, , genes, , the, asip, , and, , adamts20, , genes, , are, , particularly, , relevant, they, , are, , involved, , in, , pigmentation, , [, , , , , , , , ], and, colocalize, with, selection, signals, detected, in, a, worldwide, , sample, , of, , goats, , [], , in, , addition, , we, , found, , that, about, , , of, the, annotated, genes, that, colocalize, with, cnvr, are, olfactory, receptors, or, olfactory, receptorlike, genes, see, additional, file, a0, table, a0s3, consistently, the, , most, , significantly, , enriched, , pathway, , was, , olfactory, transduction, , qvalue, , , , , , table, a0, , , followed, by, abc, transporter, qvalue, , , , , table, a0, a, significant, pathway, related, with, immunity, ie, fc, epsilon, ri, signaling, qvalue, , , was, also, identified, based, on, a, , human, , background, , gene, , set, , table, a0, , , several, , overrepresented, go, terms, were, related, with, embryonic, skeletal, , system, , morphogenesis, , qvalue, , , , , , and, gprotein, coupled, purinergic, nucleotide, receptor, activity, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , of, table, , , main, , features, , of, a0, copy, , number, , variation, , regions, cnvr, detected, in, a0, murcianogranadina, goatssummary, statisticstotalgainlossgainlosstotal, length, mbtotal, number, of, cnvrnumber, of, cnvr, , , kbnumber, of, cnvr, , kbnumber, of, cnvr, , kbnumber, of, cnvr, , kbnumber, of, cnvr, , kb, mbnumber, of, cnvr, ¥, , mbaverage, number, of, snps, per, cnvrminimum, size, of, cnvr, kbmaximum, size, of, cnvr, kbaverage, cnvr, size, kbstandard, deviation, of, cnvr, size, kb, , , , qvalue, , , , , , table, a0, , , interestingly, , the, , copy, number, , variable, , genes, , were, , also, , enriched, , in, , pathways, with, , metabolic, , significance, , such, , as, , prolactin, , signaling, and, insulin, signaling, as, well, as, go, terms, related, with, feeding, behavior, but, none, of, these, pathways, reached, the, significance, , threshold, , qvalue, ¤, , , after, , correction, for, multiple, testing, see, additional, file, a0, table, a0s4, several, of, the, pathways, outlined, in, additional, file, a0, table, a0s4, play, important, roles, in, immunity, eg, chemokine, signaling, b, cell, receptor, signaling, and, t, cell, receptor, signaling, cancer, eg, endometrial, cancer, proteoglycans, in, cancer, , thyroid, , cancer, , as, , well, , as, , in, , oncogenic, , signaling, , eg, , ras, , and, , erbb, , signaling, , see, , additional, , file, a0, , table, a0s4, but, most, of, them, are, not, significant, after, correction, for, multiple, testingfig, , , histograms, displaying, the, distribution, of, cnvr, according, to, their, size, a, and, frequency, b, cnvr, that, were, longer, than, , kb, were, included, in, the, kb, bin, whereas, those, with, frequencies, above, , were, grouped, in, the, , bin, the, histograms, were, drawn, by, using, the, ggplot2, package, httpggplo, t2tidyv, erse, implemented, in, r, https, wwwrproje, ct, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , of, table, , , functional, enrichment, of, a0genes, colocalizing, with, a0cnvr, detected, in, a0, murcianogranadina, goatsbackground, gene, setcategory, idtermnumber, of, a0genesfold, enrichment, p, valueqvaluegoatgoatgoathumanhumanhumanhumanhumanhumanhumankeggkeggkeggkegggobpgobpgobpgoccgomfgomfolfactory, transductionabc, transportersbile, secretionfc, epsilon, ri, signaling, pathwaychx04740chx02010chx04976hsa04664go0009952, anteriorposterior, pattern, specificationgo0048704, embryonic, skeletal, system, morphogenesisgo0035589, gprotein, coupled, purinergic, nucleotide, receptor, signaling, pathwaygo0016020, membranego0003677, dna, bindinggo0045028, gprotein, coupled, purinergic, nucleotide, receptor, activity126e, 161e333e, 427e446e, 570e140e, 176e936e, 161e713e, 122e418e, 716e145e, 198e110e, 160e424e, 622ekegg, kyoto, encyclopedia, of, genes, and, genomes, pathway, gomf, gene, ontology, go, term, related, with, molecular, function, gobp, go, term, related, with, biological, process, gocc, go, term, related, with, cellular, componentvalidation, of, a0four, copy, number, variants, by, a0realtime, quantitative, polymerase, chain, reactionin, order, to, confirm, our, results, we, selected, four, cnvr, ie, , cnvr_371_chr5, , cnvr_506_chr6, , cnvr_160_chr2, , and, , cnvr_1229_chr21, , that, , colocalized, , with, the, , adamts20, , bst1, , nckap5, , and, , tnfaip2, , genes, respectively, , the, , primers, , used, , to, , amplify, , these, , cnvr, are, , listed, , in, , additional, , file, a0, , , table, a0, s1, , as, , shown, , in, fig, a0, , , the, , estimated, , copy, , numbers, , obtained, , by, , qpcr, analysis, of, murcianogranadina, goat, samples, were, , to, , , , copies, , relative, , to, , the, , calibrator, , adamts20, , to, , copies, bst1, , to, , copies, nckap5, and, , to, , copies, tnfaip2, according, to, dhaene, et, a0, al, , [], , copy, , number, , estimates, , between, , , , and, , most, likely, correspond, to, a, normal, copy, number, of, , whereas, any, number, below, or, above, these, thresholds, could, represent, a, deletion, or, a, duplication, respectively, thus, , based, , on, , these, , values, , evidence, , of, , copy, , number, variation, , was, , inferred, , for, , three, , of, , the, , four, , genes, , analyzed, by, qpcrfig, , , relative, quantification, of, four, copy, number, variation, regions, by, realtime, quantitative, polymerase, chain, reaction, analysis, a, cnvr_371_chr5, adamts20, b, cnvr_506_chr6, bst1, c, cnvr_160_chr2, nckap5, d, cnvr_1229_chr21, tnfaip2, the, x, and, y, axes, represent, sample, id, and, relative, quantification, of, cnvr, mean, ±, standard, error, with, each, sample, analyzed, in, triplicate, respectively, as, calibrator, we, used, the, average, of, four, samples, estimated, to, have, two, copies, diploid, status, based, on, the, goat, snp50, beadchip, analysis, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , of, discussionin, this, work, our, aim, was, to, characterize, copy, number, variation, , in, , murcianogranadina, , goats, , a, , native, , spanish, breed, used, for, milk, production, by, genotyping, , murcianogranadina, , goats, , with, , a, , snp, , array, , we, , were, able, , to, , identify, , , , cnvr, , covering, , , , of, , the, , goat, genome, , whereas, , liu, , et, a0, al, , [], , identified, , cnvr, , that, covered, , , of, the, goat, genome, the, latter, higher, percentage, reported, by, liu, et, a0al, [], can, be, explained, by, the, fact, that, they, analyzed, , breeds, with, different, geographical, , origins, , ie, , a, , composite, , population, , that, , is, probably, much, more, diverse, than, that, used, in, our, work, besides, , the, , pipeline, , that, , we, , used, , to, , identify, , cnvr, is, more, stringent, than, that, employed, by, liu, et, a0al, [], removing, cnvr, that, were, not, consistently, detected, by, penncnv, and, quantisnp, in, the, literature, estimates, of, , to, , for, cnvr, coverage, in, the, human, genome, are, reported, [], our, results, and, those, obtained, by, liu, et, a0al, [], are, consistent, with, these, valuesindeed, , when, , liu, , et, a0, al, , [], , calculated, , the, , cnvr, length, , for, , each, , breed, , normalized, , by, , the, , goat, , genome, size, their, results, agreed, well, with, our, estimate, of, , for, , instance, , this, , parameter, , reached, , values, , of, , , in, , goats, , from, , southeastern, , africa, , and, , , , in, , goats, from, , northwestern, , africa, , and, , eastern, , mediterranean, whereas, it, was, lowest, , for, individuals, from, west, asia, , [], , the, , number, , of, , cnv, , detected, , at, , the, , withinbreed, , level, , by, , liu, , et, a0, al, , [], , was, , on, , average, , , , cnv, per, breed, and, ranged, from, , to, , whereas, the, average, number, of, cnvr, was, only, , , per, breed, [], since, the, number, of, detected, cnvr, is, proportional, to, population, size, for, most, of, the, breeds, investigated, in, [], the, level, of, withinbreed, cnv, variation, is, probably, underestimated, in, summary, one, important, conclusion, from, our, study, is, that, the, magnitude, of, cnv, diversity, at, the, withinbreed, , level, , is, , likely, , to, , be, , much, , larger, , than, , that, previously, , reported, , in, , studies, , that, , analyzed, , multiple, populations, , each, , represented, , by, , a, , small, , or, , moderate, number, of, individualsmost, of, the, cnvr, that, we, report, here, ranged, in, size, from, , to, a0kb, with, a, mean, size, of, a0kb, similarly, the, average, cnvr, size, reported, by, liu, et, a0al, [], was, a0kb, both, estimates, are, quite, large, and, reflect, that, mediumdensity, snp, arrays, are, not, well, suited, to, detect, small, cnvr, in, spite, of, their, high, abundance, in, cattle, the, , average, , sizes, , of, , cnvr, , detected, , with, , the, , illumina, bovinehd, genotyping, beadchip, a0k, snps, [], illumina, wholegenome, sequencing, and, pacbio, sequencing, [], , were, , , , , , and, , a0, kb, , respectively, , another, consistent, feature, of, cnvr, is, that, in, general, their, frequencies, are, low, or, very, low, in, our, study, approximately, , , of, , the, , cnvr, , had, , frequencies, , lower, , than, , , , and, the, average, frequency, was, , liu, et, a0al, [], reported, lower, , cnvr, , frequencies, , ranging, , from, , , , alpine, and, , northern, , european, , goats, , to, , , , northwestern, african, goats, this, decreased, average, cnvr, frequency, is, , not, , very, , significant, , and, , probably, , reflects, , differences, in, , sampling, , size, , and, , the, , use, , of, , composite, , populations, with, , multiple, , breeds, , each, , one, , with, , its, , specific, , cnvr, frequenciesthe, cnvr, detected, in, our, study, covered, , proteincoding, , genes, , pathway, , analyses, , reflected, , a, , substantial, enrichment, , of, , genes, , that, , are, , involved, , in, , olfactory, , perception, , which, , is, , consistent, , with, , previous, , reports, , in, cattle, [, ], in, this, regard, there, is, an, important, difference, between, our, results, and, those, by, liu, et, a0al, [], whereas, in, the, study, of, liu, et, a0al, [], the, term, sensory, perception, was, underrepresented, among, the, cnv, genes, fold, enrichment, , , in, our, work, the, terms, olfactory, transduction, , fold, , enrichment, , , , and, , gprotein, coupled, , purinergic, , nucleotide, , receptor, , activity, , fold, enrichment, , , , were, , overrepresented, , and, , many, cnv, , genes, , were, , olfactory, , receptors, , the, , two, , terms, mentioned, , before, , are, , closely, , related, , because, , a, , broad, array, of, purinergic, receptors, are, differentially, expressed, in, , the, , olfactory, , receptor, , neurons, , that, , modulate, , odor, responsiveness, , [], , moreover, , purinergic, , nucleotides, are, , important, , neuromodulators, , of, , peripheral, , auditory, and, visual, sensory, systems, [], in, cattle, keel, et, a0al, [], reported, that, sensory, perception, of, smell, and, gprotein, , coupled, , receptor, , signaling, , pathway, , were, , significantly, overrepresented, in, the, proteincoding, genes, that, overlapped, , with, , cnvr, , similarly, , upadhyay, , et, a0, al, , [], showed, that, sensory, perceptions, of, smell, and, chemical, , stimuli, , are, , enriched, , in, , their, , set, , of, , cnv, , genes, , a, potential, , explanation, , for, , the, , underrepresentation, , of, the, sensory, perception, functional, category, among, the, genes, overlapping, cnv, reported, by, liu, et, a0al, [], could, be, that, in, goats, these, genes, are, not, well, annotated, yet, so, the, majority, of, them, are, identified, with, a, loc, prefix, and, a, number, and, as, a, consequence, of, this, they, are, not, , correctly, , detected, , by, , panther, , [], , thus, , biasing, the, , results, , obtained, , in, , the, , gene, , ontology, , enrichment, analysisloci, , belonging, , to, , large, , multigene, , families, , might, , be, more, , prone, , to, , colocalize, , with, , cnv, , because, , paralogous, , genes, , can, , act, , as, , templates, , in, , nonallelic, , homologous, , recombination, , events, , which, , promote, , increases, or, , reductions, , in, , copy, , number, , [], , it, , should, , be, , noted, that, olfactory, receptor, genes, constitute, the, largest, gene, superfamily, , and, , in, , humans, , more, , than, , , , genes, , and, pseudogenes, , have, , been, , identified, , [], , in, , cattle, , , olfactory, receptor, genes, and, pseudogenes, are, distributed, in, , , , clusters, , across, , , , bovine, , chromosomes, , [], , and, similar, numbers, have, been, reported, for, pigs, [], moreover, , purifying, , selection, , against, , cnv, , is, , probably, , less, , 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , of, intense, in, regions, that, contain, olfactoryreceptor, genes, than, in, genomic, regions, that, contain, genes, with, essential, functions, [], interestingly, copy, number, changes, in, the, olfactory, receptor, genes, of, wild, and, domestic, mammals, might, have, consequences, on, food, foraging, as, well, as, on, mate, and, predator, recognition, [, ]in, the, set, of, genes, that, colocalize, with, cnvr, we, also, detected, , an, , enrichment, , of, , loci, , related, , with, , the, , multigene, , family, , of, , atp, , binding, , cassette, , abc, , transporters, , a, , result, , that, , agrees, , well, , with, , previous, , findings, , in, humans, , [], , and, , cattle, , [, , ], , in, , mammals, , abc, transporters, fulfill, the, mission, of, carrying, a, broad, array, of, endogenous, substrates, such, as, amino, acids, peptides, sugars, anions, and, hydrophobic, compounds, and, metabolites, , across, , lipid, , membranes, , at, , least, , , , abc, , genes, that, belong, to, eight, subfamilies, have, been, identified, in, the, human, genome, [], copy, number, variation, in, the, human, abcc4, and, abcc6, genes, is, associated, with, susceptibility, , to, , esophageal, , squamous, , cell, , carcinoma, , [], and, to, the, rare, autosomal, recessive, disease, pseudoxanthoma, elasticum, [], respectively, moreover, largescale, deletions, of, the, human, abca1, gene, are, a, causative, factor, , for, , hypoalphalipoproteinemia, , [], , a, , disease, , that, , is, characterized, by, the, complete, absence, of, the, apolipoprotein, ai, and, extremely, low, levels, of, plasma, highdensity, lipoprotein, , hdl, , cholesterol, , we, , also, , found, , a, , highly, significant, enrichment, of, pathways, related, with, embryo, development, , anteriorposterior, , pattern, , specification, embryonic, skeletal, system, morphogenesis, as, previously, reported, [], these, pathways, are, featured, by, genes, that, belong, to, the, hox, multigene, family, of, transcription, factors, possibly, reflecting, the, genomic, instability, of, certain, homeobox, gene, clusters, as, evidenced, by, the, existence, of, many, syntenyparalogy, breakpoints, and, assembly, gaps, as, outlined, in, comparative, studies, []although, , not, , significant, , after, , correction, , for, , multiple, testing, , we, , detected, , an, , enrichment, , of, , pathways, , with, metabolic, , significance, , such, , as, , prolactin, , and, , insulin, signaling, which, could, have, an, impact, on, milk, production, , and, , growth, , [], , interestingly, , the, , comparison, of, our, work, with, that, of, liu, et, a0al, [], revealed, , proteincoding, genes, that, colocalize, with, the, set, of, shared, cnvr, one, of, the, most, relevant, shared, genes, encodes, asip, a, protein, that, increases, the, ratio, of, pheomelanin, to, , eumelanin, , by, , binding, , to, , the, , melanocortin, , , , receptor, , and, , delivering, , an, , antagonist, , signal, , that, , blocks, , the, downstream, expression, of, eumelanogenic, enzymes, [], mutations, in, the, asip, gene, play, critical, roles, in, animal, pigmentation, [], for, instance, the, causal, factor, of, the, white, color, typical, of, many, sheep, breeds, is, the, ubiquitous, expression, of, a, duplicated, copy, of, the, asip, coding, sequence, , which, , is, , regulated, , by, , a, , duplicated, , promoter, corresponding, , to, , the, , itchy, , e3, , ubiquitin, , protein, , ligase, gene, , [, , ], , although, , some, , studies, , proposed, , that, , the, asip, cnv, might, be, associated, with, different, pigmentation, patterns, in, goats, [, , ], no, functional, assay, has, verified, an, association, of, asip, copy, number, with, asip, mrna, , levels, , another, , interesting, , shared, , copy, , number, variable, gene, is, adamts20, which, was, also, identified, in, two, previous, cnv, surveys, [, ], this, gene, encodes, a, metalloproteinase, with, an, important, role, in, melanoblast, survival, by, mediating, kit, signaling, [], and, in, palatogenesis, [], bertolini, et, a0al, [], performed, a, selection, scan, in, white, vs, colored, black, and, red, goats, and, detected, a, selective, sweep, in, the, adamts20, gene, in, the, light, of, these, , results, , the, , potential, , involvement, , of, , a, , structural, variation, , in, , adamts20, , in, , goat, , pigmentation, , should, be, explored, further, moreover, it, is, worthwhile, to, mention, that, several, cnvr, genes, have, functions, related, with, production, , and, , reproduction, , traits, , for, , instance, , the, nckap5, gene, which, colocalizes, with, cnvr_160_chr2, frequency, , , is, associated, with, milk, fat, percentage, in, , cattle, , [], , taking, , the, , above, , evidence, , into, , account, the, implication, of, structural, chromosomal, variations, in, the, , genetic, , determinism, , of, , traits, , of, , economic, , interest, with, a, complex, inheritance, deserves, further, exploration, by, designing, tools, that, allow, inferring, cnvr, genotypes, with, high, confidenceconclusionswith, , the, , penncnv, , and, , quantisnp, , software, , we, detected, , , , cnvr, , in, , the, , genome, , of, , the, , murcianogranadina, , breed, , in, , a, a0, previous, , study, , [], , that, , used, , a, less, , stringent, , pipeline, , only, , penncnv, , was, , used, , and, included, , multiple, , populations, , with, , small, , to, , moderate, , sample, , sizes, , the, , average, , number, , of, , cnvr, , events, per, breed, was, , , one, conclusion, of, our, study, is, that, cnv, surveys, which, are, based, on, a, broad, array, of, breeds, represented, , by, , only, , a, , few, , individuals, , underestimate, the, true, levels, of, the, cnv, diversity, at, the, withinbreed, level, the, main, reason, for, this, outcome, is, that, since, the, majority, of, cnv, have, very, low, frequencies, they, cannot, be, detected, efficiently, when, sample, size, is, small, and, in, consequence, , much, , of, , the, , existing, , variation, , is, , missed, we, have, also, found, that, genes, that, overlap, with, cnv, are, functionally, related, with, olfactory, transduction, embryo, development, , abc, , transporters, , and, , gprotein, , coupled, purinergic, , nucleotide, , receptor, , activity, , most, , of, , these, genes, , belong, , to, , large, , multigene, , families, , encompassing, tens, , hundreds, , or, , thousands, , of, , paralogous, , genes, , that, could, act, as, substrates, in, nonallelic, homologous, recombination, , events, , which, , is, , one, , of, , the, , main, , mechanisms, generating, , duplications, , and, , deletions, , in, , humans, , and, other, , species, , finally, , we, , detected, , cnv, , that, , colocalize, with, the, asip, and, adamts20, pigmentation, genes, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , of, which, according, to, previous, studies, have, been, subjected, to, positive, selection, for, coat, color, in, goatssupplementary, informationsupplementary, information, accompanies, this, paper, at, https, doi101186s1271, , , additional, file, a0, table, a0s1, list, of, primers, used, in, the, realtime, quanti]                                                                                                                     |[generate, map, copy, number, variations, cnv, segregating, population, murcianogranadina, goats, important, dairy, breed, spain, ascertain, main, biological, functions, genes, map, copy, number, variable, regionsresults, , using, dataset, comprised, , murcianogranadina, goats, genotyped, goat, snp50, beadchip, able, detect, , , autosomal, cnv, penncnv, quantisnp, software, respectively, applying, ensemblecnv, algorithm, cnv, assembled, , cnv, regions, cnvr, , , total, cnvr, count, consistently, called, penncnv, quantisnp, used, subsequent, analyses, set, , cnvr, identified, , gain, , loss, , gainloss, events, total, length, cnvr, , mb, represented, , goat, autosomal, genome, , mb, whereas, size, ranged, , kb, , mb, average, size, , kb, functional, annotation, genes, overlapped, cnvr, revealed, enrichment, pathways, related, olfactory, transduction, foldenrichment, , , qvalue, , , , , abc, transporters, foldenrichment, , , qvalue, , , , , bile, secretion, foldenrichment, , , qvalue, , , , conclusions, , previous, study, reported, average, number, cnvr, per, goat, breed, , , , cnvr50, breeds, much, smaller, number, found, , cnvr, attribute, difference, fact, previous, study, included, multiple, caprine, breeds, represented, small, moderate, numbers, individuals, given, low, frequencies, cnv, study, average, frequency, cnv, , design, probably, underestimate, levels, diversity, cnv, withinbreed, level, also, observed, functions, related, sensory, perception, metabolism, embryo, development, overrepresented, set, genes, overlapped, cnv, loci, often, belong, large, multigene, families, tens, hundreds, thousands, paralogous, members, feature, favor, occurrence, duplications, deletions, nonallelic, homologous, recombinationcorrespondence, , marcelamillsuabcat, centre, research, agricultural, genomics, crag, csicirtauabub, universitat, aut²noma, de, barcelona, , bellaterra, spainfull, list, author, information, available, end, backgroundcopy, , number, , variations, , cnv, , encompass, , genomic, deletions, duplications, sizes, ranging, , base, pairs, bp, several, megabases, mb, display, polymorphisms, terms, copy, number, among, individuals, particular, species, [], livestock, broad, array, , , phenotypes, , related, , , among, , others, , morphology, [, ], pigmentation, [], sexual, development, , authors, , , licensed, creative, commons, attribution, , international, license, permits, use, sharing, adaptation, distribution, reproduction, medium, format, long, give, appropriate, credit, original, authors, source, provide, link, creative, commons, licence, indicate, changes, made, images, third, party, material, , included, s, creative, commons, licence, unless, indicated, otherwise, credit, line, material, material, included, s, creative, commons, licence, intended, use, permitted, statutory, regulation, exceeds, permitted, use, need, obtain, permission, directly, copyright, holder, view, copy, licence, visit, httpcreat, iveco, mmons, licen, sesby40, creative, commons, public, domain, dedication, waiver, httpcreat, iveco, mmons, publi, cdoma, inzero10, applies, data, made, available, , unless, otherwise, stated, credit, line, data, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , [], , , susceptibility, , , disease, , [], , , caused, , , segregation, cnv, genome, scans, detect, structural, variations, , , cattle, , , revealed, , , cnv, , regions, cnvr, often, enriched, genes, involved, immunity, [], metabolism, [, ], embryo, development, [, ], sensory, perception, [, ], evidence, , dnds, ratios, genes, map, taurine, cnv, generally, higher, genes, overlap, cnv, indicates, cnv, genes, probably, evolve, reduced, selective, constraint, [], analysis, gene, networks, also, shown, genes, , colocalize, , , duplications, , tend, , , , fewer, interactions, genes, loci, overlap, , , cnv, , reinforcing, , , idea, , , genes, , mapping, duplicated, regions, fewer, essential, housekeeping, functions, , , noncnv, , genes, , , also, , , reduced, pleiotropy, []although, structural, chromosomal, variations, strong, , effects, , , gene, , expression, , , phenotypic, , variability, , technical, , limitations, , , , moderate, , quality, genome, assemblies, hampered, cnv, mapping, livestock, , [], , , recently, , , , , particularly, true, goats, , fontanesi, et, a0al, [], published, first, , caprine, , cnv, , map, , , identifying, , , , bovine, a0k, acgh, array, , cnvr, including, , , copy, loss, gain, variants, respectively, later, resequencing, , , genome, , , individuals, , , several, , caprine, breeds, , made, , , possible, , , identify, , cnv, , , overlap, , pigmentation, genes, detect, association, increased, asip, copy, number, light, pigmentation, , [], , , first, , worldwide, , survey, , , copy, , number, , variation, , , goats, , , performed, , within, , , goat, adaptmap, project, httpwwwgoata, daptm, ap, involved, genomewide, genotyping, , goats, , breeds, [], study, resulted, identification, , cnvr, among, several, overlapped, genes, , , functionally, , related, , , local, , adaptation, , coat, color, muscle, development, metabolic, processes, embryonic, development, [], moreover, patterns, diversity, cnv, differed, according, geographic, origin, , , indicates, , , , , , influenced, population, history, [], another, study, , individuals, , east, african, goat, breeds, nandolo, et, a0al, [], detected, , cnvr, recently, henkel, et, a0al, [], demonstrated, existence, complex, patterns, structural, variation, regions, containing, caprine, asip, kit, genes, potential, causal, effects, pigmentation, spite, efforts, description, structural, chromosomal, , variation, , , goats, , , still, , lagging, , behind, domestic, species, cnv, surveys, goats, analyzed, large, populations, represent, mixture, different, breeds, limited, number, individuals, [, ], thus, making, difficult, assess, magnitude, cnv, diversity, withinbreed, level, goal, fill, gap, analyzing, population, , individuals, single, spanish, breed, murcianogranadina, , , , investigate, , , functional, , roles, , genes, map, cnvr, compare, results, data, obtained, composite, goat, populationsmethodsgenomic, dna, extraction, a0highthroughput, genotypingblood, , samples, , , , , murcianogranadina, , female, goats, , , , , farms, , , , connected, , , use, , , artificial, , insemination, , , collected, , , edta, k3, , coated, , vacuum, , tubes, , , stored, , , , a0, °c, , processing, , genomic, , dna, , , isolated, , , , modified, saltingout, procedure, [], four, volumes, red, cell, lysis, , solution, , trishcl, , a0, mmoll, , ph, , , , edta, a0mmoll, tween, , , added, a0ml, whole, blood, mixture, centrifuged, g, pelleted, cells, resuspended, a0ml, lysis, buffer, trishcl, , a0, mmoll, , ph, , , , edta, , a0, mmoll, , sds, , , nacl, , a0, mmoll, , plus, , , , µl, , proteinase, , k, , a0, mgml, resulting, mixture, incubated, a0°c, , h, followed, centrifugation, g, presence, a0ml, ammonium, acetate, a0moll, supernatant, , a0ml, mixed, a0ml, isopropanol, , subsequently, centrifuged, g, a0min, , supernatant, , , removed, , , , dna, , pellet, , washed, , , a0, ml, , , ethanol, , , , , centrifuging, g, a0min, dna, precipitate, dried, room, temperature, resuspended, a0ml, te, buffer, a0mmoll, tris, ph, , , a0mmoll, edta, ph, , highthroughput, , genotyping, , , , , , murcianogranadina, dna, samples, carried, goat, snp50, , beadchip, , [], , according, , , , manufacturers, instructions, , illumina, , signal, , intensity, , ratios, , ie, , log, , r, ratio, lrr, total, probe, intensity, snp, referred, canonical, set, normal, controls, [], b, allele, frequencies, baf, relative, quantity, one, allele, compared, , , , , one, , [], , , exported, , , single, nucleotide, polymorphism, snp, genomestudio, , software, , , , illumina, , https, emeaillum, inacom, snp, coordinates, converted, latest, version, goat, reference, genome, ars1, [], filtering, , , unmapped, , , nonautosomal, , snps, , call, rate, lower, , set, , snps, remained, cnv, mappingcopy, number, variant, calling, a0penncnv, a0quantisnpbased, , , , excellent, , performance, , , comparative, , studies, , , selected, , two, , software, , packages, , penncnv, v105, [], quantisnp, v2, [], call, cnv, murcianogranadina, population, [, ], penncnv, software, [], detects, cnv, applying, default, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , parameters, hiddenmarkov, model, population, frequencies, b, alleles, compiled, based, baf, snp, population, used, gcmodelfile, option, , , adjust, , genomic, , waves, , [], , , number, , goat, chromosomes, set, lastchr, , instruction, quantisnp, analysis, [], assumes, objective, bayes, hiddenmarkov, model, improve, accuracy, segmental, , aneuploidy, , identification, , , mapping, , cnv, calling, software, run, default, parameters, modifying, chr, , option, cnv, supported, , , less, , , three, , snps, , , removed, , filtered, set, used, heredefinition, a0functional, annotation, a0copy, number, variant, regionswe, used, ensemblecnv, algorithm, beta, version, [], , assemble, , cnvr, , , cnv, , called, , , penncnv, , andor, , quantisnp, , , combined, , , generate, , , set, , , initial, , cnvr, , , using, , , heuristic, , algorithm, , threshold, , minimum, , overlap, , , , described, , , [], , subsequently, cnvr, boundaries, refined, considering, local, correlation, structure, lrr, values, snps, , mapping, , , cnvr, , [], , , , reassigned, , cnv, , calls, , , , initially, , obtained, , , penncnv, quantisnp, refined, cnvr, final, set, , , cnvr, , comprised, , , , , , simultaneously, , detected, , , , callers, , , resulting, , cnvr, matched, gene, features, annotated, national, , center, , , biotechnology, , information, , ncbi, https, wwwncbinlmnihgov, , , using, , bedtools, v2250, , [], , , addition, , , performed, , gene, , ontology, go, enrichment, pathway, analyses, using, david, bioinformatics, , resources, , , , [, , ], , based, , , human, , goat, , background, , gene, , sets, , , statistical, , significance, set, qvalue, ¤, confirmation, a0copy, number, variant, regions, a0quantitative, realtime, pcrin, , order, , , evaluate, , , rate, , , false, , positives, , , experiment, , , conducted, , quantitative, , realtime, , pcr, qpcr, , experiments, , , obtain, , , independent, , estimate, , , , copy, , number, , , four, , putative, , cnvr, cnvr_371_chr5, , cnvr_506_chr6, , cnvr_160_chr2, cnvr_1229_chr21, primers, designed, primer, express, software, applied, biosystems, amplify, specific, , regions, , , , adamts20, , bst1, , nckap5, , tnfaip2, , genes, , see, , additional, , file, a0, , , table, a0, s1, , reference, , genes, , , used, , , melanocortin, , , , receptor, , mc1r, , , glucagon, , gcg, , , genes, , see, , additional, file, a0, table, a0s1, loci, [, ], quantitative, pcr, reactions, contained, a0ng, genomic, dna, , µl, , , sybrselect, master, mix, applied, biosystems, a0pmol, forward, , , reverse, , primer, , , ultrapure, , water, , , maximum, final, volume, , µl, sample, analyzed, triplicate, order, obtain, averaged, copy, number, estimates, reactions, loaded, onto, 384well, plates, run, quantstudio, a0k, flex, realtime, pcr, system, instrument, applied, biosystems, specificity, , pcr, , reactions, , , evaluated, , , , melting, , curve, analysis, procedure, efficiency, , assessed, standard, curves, thus, relative, copy, number, , , inferred, , , , qbase, , software, , biogazelle, ghent, belgium, using, , îîct, approach, [], copy, number, values, calibrated, taking, reference, four, samples, according, goat, snp50, beadchip, data, two, copies, investigated, genomic, lociresultsdetection, a0copy, number, variation, a0murcianogranadina, goatsthe, initial, calling, penncnv, quantisnp, yielded, , , , , , autosomal, , cnv, , respectively, , , using, , ensemblecnv, , tool, , [], , , assigned, , , cnv, , cnvr, refined, boundaries, , , , , , total, , cnvr, , count, , , detected, , simultaneously, , , penncnv, , , quantisnp, , , resulting, cnvr, included, , copy, gain, , copy, loss, , copy, gainloss, , variants, , fig, a0, , , , table, a0, , , , see, , additional, , file, a0, , , table, a0, s2, , , total, , length, , , , cnvr, covered, a0mb, , goat, autosomal, genome, a0mb, whereas, individual, size, ranged, a0kb, a0mb, average, a0kb, fig, a02a, table, a0, , , moreover, , , found, , , , , , , cnvr, showed, , minimum, , allele, , frequencies, , lower, , , , average, frequency, , fig, a02b, addition, , cnvr, frequencies, higher, , distributed, seven, caprine, chromosomes, frequency, , cnvr_1229_chr21, cnvr, highest, frequency, whole, dataset, see, additional, file, a0, table, a0s2, using, bedtools, v2250, program, [], , cnvr, detected, overlapped, , unique, cnvr, published, liu, et, a0al, [], fig, a0, see, additional, file, a0, table, a0s2, cnvr, detected, studies, referred, shared, cnvr, whereas, identified, study, referred, nonshared, cnvr, fig, a0, six, ten, shared, cnvr, frequencies, higher, , show, positional, concordance, six, cnvr, detected, liu, et, a0al, [], see, additional, file, a0, table, a0s2functional, annotation, a0the, a0genes, a0are, located, a0copy, number, variable, regionswithin, cnvr, defined, study, detected, , proteincoding, , genes, , according, , , , goat, , reference, genome, , annotation, , ars1, , [], , , , ncbi, , database, see, additional, file, a0, table, a0s2, additional, file, a0, , 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , fig, , , genomic, distribution, , cnvr, detected, penncnv, quantisnp, software, , caprine, autosomes, squares, triangles, circles, represent, copy, number, gain, loss, gainloss, events, respectively, red, black, colors, represent, shared, nonshared, cnvr, respectively, shared, cnvr, detected, study, liu, et, al, [], nonshared, cnvr, identified, studytable, a0s3, survey, diversity, cnv, goats, , , worldwide, , distribution, , liu, , et, a0, al, , [], , detected, , copy, number, variable, genes, , also, identified, study, referred, shared, copy, number, variable, genes, see, additional, file, a0, table, a0s3, among, , , shared, , copy, , number, , variable, , genes, , asip, , , adamts20, , genes, , , particularly, , relevant, , , involved, , , pigmentation, , [, , , , , , , , ], colocalize, selection, signals, detected, worldwide, , sample, , , goats, , [], , , addition, , , found, , , , annotated, genes, colocalize, cnvr, olfactory, receptors, olfactory, receptorlike, genes, see, additional, file, a0, table, a0s3, consistently, , , significantly, , enriched, , pathway, , , olfactory, transduction, , qvalue, , , , , , table, a0, , , followed, abc, transporter, qvalue, , , , , table, a0, significant, pathway, related, immunity, ie, fc, epsilon, ri, signaling, qvalue, , , also, identified, based, , human, , background, , gene, , set, , table, a0, , , several, , overrepresented, go, terms, related, embryonic, skeletal, , system, , morphogenesis, , qvalue, , , , , , gprotein, coupled, purinergic, nucleotide, receptor, activity, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , table, , , main, , features, , a0, copy, , number, , variation, , regions, cnvr, detected, a0, murcianogranadina, goatssummary, statisticstotalgainlossgainlosstotal, length, mbtotal, number, cnvrnumber, cnvr, , , kbnumber, cnvr, , kbnumber, cnvr, , kbnumber, cnvr, , kbnumber, cnvr, , kb, mbnumber, cnvr, ¥, , mbaverage, number, snps, per, cnvrminimum, size, cnvr, kbmaximum, size, cnvr, kbaverage, cnvr, size, kbstandard, deviation, cnvr, size, kb, , , , qvalue, , , , , , table, a0, , , interestingly, , , copy, number, , variable, , genes, , , also, , enriched, , , pathways, , metabolic, , significance, , , , prolactin, , signaling, insulin, signaling, well, go, terms, related, feeding, behavior, none, pathways, reached, significance, , threshold, , qvalue, ¤, , , , correction, multiple, testing, see, additional, file, a0, table, a0s4, several, pathways, outlined, additional, file, a0, table, a0s4, play, important, roles, immunity, eg, chemokine, signaling, b, cell, receptor, signaling, cell, receptor, signaling, cancer, eg, endometrial, cancer, proteoglycans, cancer, , thyroid, , cancer, , , well, , , , oncogenic, , signaling, , eg, , ras, , , erbb, , signaling, , see, , additional, , file, a0, , table, a0s4, significant, correction, multiple, testingfig, , , histograms, displaying, distribution, cnvr, according, size, frequency, b, cnvr, longer, , kb, included, kb, bin, whereas, frequencies, , grouped, , bin, histograms, drawn, using, ggplot2, package, httpggplo, t2tidyv, erse, implemented, r, https, wwwrproje, ct, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , table, , , functional, enrichment, a0genes, colocalizing, a0cnvr, detected, a0, murcianogranadina, goatsbackground, gene, setcategory, idtermnumber, a0genesfold, enrichment, p, valueqvaluegoatgoatgoathumanhumanhumanhumanhumanhumanhumankeggkeggkeggkegggobpgobpgobpgoccgomfgomfolfactory, transductionabc, transportersbile, secretionfc, epsilon, ri, signaling, pathwaychx04740chx02010chx04976hsa04664go0009952, anteriorposterior, pattern, specificationgo0048704, embryonic, skeletal, system, morphogenesisgo0035589, gprotein, coupled, purinergic, nucleotide, receptor, signaling, pathwaygo0016020, membranego0003677, dna, bindinggo0045028, gprotein, coupled, purinergic, nucleotide, receptor, activity126e, 161e333e, 427e446e, 570e140e, 176e936e, 161e713e, 122e418e, 716e145e, 198e110e, 160e424e, 622ekegg, kyoto, encyclopedia, genes, genomes, pathway, gomf, gene, ontology, go, term, related, molecular, function, gobp, go, term, related, biological, process, gocc, go, term, related, cellular, componentvalidation, a0four, copy, number, variants, a0realtime, quantitative, polymerase, chain, reactionin, order, confirm, results, selected, four, cnvr, ie, , cnvr_371_chr5, , cnvr_506_chr6, , cnvr_160_chr2, , , cnvr_1229_chr21, , , colocalized, , , adamts20, , bst1, , nckap5, , , tnfaip2, , genes, respectively, , , primers, , used, , , amplify, , , cnvr, , listed, , , additional, , file, a0, , , table, a0, s1, , , shown, , fig, a0, , , , estimated, , copy, , numbers, , obtained, , , qpcr, analysis, murcianogranadina, goat, samples, , , , , copies, , relative, , , , calibrator, , adamts20, , , copies, bst1, , , copies, nckap5, , , copies, tnfaip2, according, dhaene, et, a0, al, , [], , copy, , number, , estimates, , , , , , likely, correspond, normal, copy, number, , whereas, number, thresholds, represent, deletion, duplication, respectively, thus, , based, , , , values, , evidence, , , copy, , number, variation, , , inferred, , , three, , , , four, , genes, , analyzed, qpcrfig, , , relative, quantification, four, copy, number, variation, regions, realtime, quantitative, polymerase, chain, reaction, analysis, cnvr_371_chr5, adamts20, b, cnvr_506_chr6, bst1, c, cnvr_160_chr2, nckap5, d, cnvr_1229_chr21, tnfaip2, x, y, axes, represent, sample, id, relative, quantification, cnvr, mean, ±, standard, error, sample, analyzed, triplicate, respectively, calibrator, used, average, four, samples, estimated, two, copies, diploid, status, based, goat, snp50, beadchip, analysis, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , discussionin, work, aim, characterize, copy, number, variation, , , murcianogranadina, , goats, , , native, , spanish, breed, used, milk, production, genotyping, , murcianogranadina, , goats, , , , snp, , array, , , able, , , identify, , , , cnvr, , covering, , , , , , goat, genome, , whereas, , liu, , et, a0, al, , [], , identified, , cnvr, , covered, , , goat, genome, latter, higher, percentage, reported, liu, et, a0al, [], explained, fact, analyzed, , breeds, different, geographical, , origins, , ie, , , composite, , population, , , probably, much, diverse, used, work, besides, , , pipeline, , , , used, , , identify, , cnvr, stringent, employed, liu, et, a0al, [], removing, cnvr, consistently, detected, penncnv, quantisnp, literature, estimates, , , cnvr, coverage, human, genome, reported, [], results, obtained, liu, et, a0al, [], consistent, valuesindeed, , , liu, , et, a0, al, , [], , calculated, , , cnvr, length, , , , breed, , normalized, , , , goat, , genome, size, results, agreed, well, estimate, , , instance, , , parameter, , reached, , values, , , , , goats, , , southeastern, , africa, , , , , , goats, , northwestern, , africa, , , eastern, , mediterranean, whereas, lowest, , individuals, west, asia, , [], , , number, , , cnv, , detected, , , , withinbreed, , level, , , liu, , et, a0, al, , [], , , , average, , , , cnv, per, breed, ranged, , , whereas, average, number, cnvr, , , per, breed, [], since, number, detected, cnvr, proportional, population, size, breeds, investigated, [], level, withinbreed, cnv, variation, probably, underestimated, summary, one, important, conclusion, study, magnitude, cnv, diversity, withinbreed, , level, , , likely, , , , much, , larger, , , previously, , reported, , , studies, , , analyzed, , multiple, populations, , , represented, , , , small, , , moderate, number, individualsmost, cnvr, report, ranged, size, , a0kb, mean, size, a0kb, similarly, average, cnvr, size, reported, liu, et, a0al, [], a0kb, estimates, quite, large, reflect, mediumdensity, snp, arrays, well, suited, detect, small, cnvr, spite, high, abundance, cattle, , average, , sizes, , , cnvr, , detected, , , , illumina, bovinehd, genotyping, beadchip, a0k, snps, [], illumina, wholegenome, sequencing, pacbio, sequencing, [], , , , , , , , a0, kb, , respectively, , another, consistent, feature, cnvr, general, frequencies, low, low, study, approximately, , , , , cnvr, , , frequencies, , lower, , , , , average, frequency, , liu, et, a0al, [], reported, lower, , cnvr, , frequencies, , ranging, , , , , alpine, , northern, , european, , goats, , , , , northwestern, african, goats, decreased, average, cnvr, frequency, , , , significant, , , probably, , reflects, , differences, , sampling, , size, , , , use, , , composite, , populations, , multiple, , breeds, , , one, , , , specific, , cnvr, frequenciesthe, cnvr, detected, study, covered, , proteincoding, , genes, , pathway, , analyses, , reflected, , , substantial, enrichment, , , genes, , , , involved, , , olfactory, , perception, , , , consistent, , , previous, , reports, , cattle, [, ], regard, important, difference, results, liu, et, a0al, [], whereas, study, liu, et, a0al, [], term, sensory, perception, underrepresented, among, cnv, genes, fold, enrichment, , , work, terms, olfactory, transduction, , fold, , enrichment, , , , , gprotein, coupled, , purinergic, , nucleotide, , receptor, , activity, , fold, enrichment, , , , , overrepresented, , , many, cnv, , genes, , , olfactory, , receptors, , , two, , terms, mentioned, , , , closely, , related, , , , broad, array, purinergic, receptors, differentially, expressed, , , olfactory, , receptor, , neurons, , , modulate, , odor, responsiveness, , [], , moreover, , purinergic, , nucleotides, , important, , neuromodulators, , , peripheral, , auditory, visual, sensory, systems, [], cattle, keel, et, a0al, [], reported, sensory, perception, smell, gprotein, , coupled, , receptor, , signaling, , pathway, , , significantly, overrepresented, proteincoding, genes, overlapped, , , cnvr, , similarly, , upadhyay, , et, a0, al, , [], showed, sensory, perceptions, smell, chemical, , stimuli, , , enriched, , , , set, , , cnv, , genes, , potential, , explanation, , , , underrepresentation, , sensory, perception, functional, category, among, genes, overlapping, cnv, reported, liu, et, a0al, [], goats, genes, well, annotated, yet, majority, identified, loc, prefix, number, consequence, , correctly, , detected, , , panther, , [], , thus, , biasing, , results, , obtained, , , , gene, , ontology, , enrichment, analysisloci, , belonging, , , large, , multigene, , families, , might, , , prone, , , colocalize, , , cnv, , , paralogous, , genes, , , act, , , templates, , , nonallelic, , homologous, , recombination, , events, , , promote, , increases, , reductions, , , copy, , number, , [], , , , , noted, olfactory, receptor, genes, constitute, largest, gene, superfamily, , , , humans, , , , , , genes, , pseudogenes, , , , identified, , [], , , cattle, , , olfactory, receptor, genes, pseudogenes, distributed, , , , clusters, , across, , , , bovine, , chromosomes, , [], , similar, numbers, reported, pigs, [], moreover, , purifying, , selection, , , cnv, , , probably, , less, , 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , intense, regions, contain, olfactoryreceptor, genes, genomic, regions, contain, genes, essential, functions, [], interestingly, copy, number, changes, olfactory, receptor, genes, wild, domestic, mammals, might, consequences, food, foraging, well, mate, predator, recognition, [, ]in, set, genes, colocalize, cnvr, also, detected, , , enrichment, , , loci, , related, , , , multigene, , family, , , atp, , binding, , cassette, , abc, , transporters, , , result, , , agrees, , well, , , previous, , findings, , humans, , [], , , cattle, , [, , ], , , mammals, , abc, transporters, fulfill, mission, carrying, broad, array, endogenous, substrates, amino, acids, peptides, sugars, anions, hydrophobic, compounds, metabolites, , across, , lipid, , membranes, , , least, , , , abc, , genes, belong, eight, subfamilies, identified, human, genome, [], copy, number, variation, human, abcc4, abcc6, genes, associated, susceptibility, , , esophageal, , squamous, , cell, , carcinoma, , [], rare, autosomal, recessive, disease, pseudoxanthoma, elasticum, [], respectively, moreover, largescale, deletions, human, abca1, gene, causative, factor, , , hypoalphalipoproteinemia, , [], , , disease, , , characterized, complete, absence, apolipoprotein, ai, extremely, low, levels, plasma, highdensity, lipoprotein, , hdl, , cholesterol, , , also, , found, , , highly, significant, enrichment, pathways, related, embryo, development, , anteriorposterior, , pattern, , specification, embryonic, skeletal, system, morphogenesis, previously, reported, [], pathways, featured, genes, belong, hox, multigene, family, transcription, factors, possibly, reflecting, genomic, instability, certain, homeobox, gene, clusters, evidenced, existence, many, syntenyparalogy, breakpoints, assembly, gaps, outlined, comparative, studies, []although, , , significant, , , correction, , , multiple, testing, , , detected, , , enrichment, , , pathways, , metabolic, , significance, , , , prolactin, , , insulin, signaling, impact, milk, production, , , growth, , [], , interestingly, , , comparison, work, liu, et, a0al, [], revealed, , proteincoding, genes, colocalize, set, shared, cnvr, one, relevant, shared, genes, encodes, asip, protein, increases, ratio, pheomelanin, , eumelanin, , , binding, , , , melanocortin, , , , receptor, , , delivering, , , antagonist, , signal, , , blocks, , downstream, expression, eumelanogenic, enzymes, [], mutations, asip, gene, play, critical, roles, animal, pigmentation, [], instance, causal, factor, white, color, typical, many, sheep, breeds, ubiquitous, expression, duplicated, copy, asip, coding, sequence, , , , regulated, , , , duplicated, , promoter, corresponding, , , , itchy, , e3, , ubiquitin, , protein, , ligase, gene, , [, , ], , although, , , studies, , proposed, , , asip, cnv, might, associated, different, pigmentation, patterns, goats, [, , ], functional, assay, verified, association, asip, copy, number, asip, mrna, , levels, , another, , interesting, , shared, , copy, , number, variable, gene, adamts20, also, identified, two, previous, cnv, surveys, [, ], gene, encodes, metalloproteinase, important, role, melanoblast, survival, mediating, kit, signaling, [], palatogenesis, [], bertolini, et, a0al, [], performed, selection, scan, white, vs, colored, black, red, goats, detected, selective, sweep, adamts20, gene, light, , results, , , potential, , involvement, , , , structural, variation, , , adamts20, , , goat, , pigmentation, , explored, moreover, worthwhile, mention, several, cnvr, genes, functions, related, production, , , reproduction, , traits, , , instance, , nckap5, gene, colocalizes, cnvr_160_chr2, frequency, , , associated, milk, fat, percentage, , cattle, , [], , taking, , , , evidence, , , account, implication, structural, chromosomal, variations, , genetic, , determinism, , , traits, , , economic, , interest, complex, inheritance, deserves, exploration, designing, tools, allow, inferring, cnvr, genotypes, high, confidenceconclusionswith, , , penncnv, , , quantisnp, , software, , detected, , , , cnvr, , , , genome, , , , murcianogranadina, , breed, , , a0, previous, , study, , [], , , used, , less, , stringent, , pipeline, , , penncnv, , , used, , included, , multiple, , populations, , , small, , , moderate, , sample, , sizes, , , average, , number, , , cnvr, , events, per, breed, , , one, conclusion, study, cnv, surveys, based, broad, array, breeds, represented, , , , , , individuals, , underestimate, true, levels, cnv, diversity, withinbreed, level, main, reason, outcome, since, majority, cnv, low, frequencies, detected, efficiently, sample, size, small, consequence, , much, , , , existing, , variation, , , missed, also, found, genes, overlap, cnv, functionally, related, olfactory, transduction, embryo, development, , abc, , transporters, , , gprotein, , coupled, purinergic, , nucleotide, , receptor, , activity, , , , genes, , belong, , , large, , multigene, , families, , encompassing, tens, , hundreds, , , thousands, , , paralogous, , genes, , act, substrates, nonallelic, homologous, recombination, , events, , , , one, , , , main, , mechanisms, generating, , duplications, , , deletions, , , humans, , , species, , finally, , , detected, , cnv, , , colocalize, asip, adamts20, pigmentation, genes, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , according, previous, studies, subjected, positive, selection, coat, color, goatssupplementary, informationsupplementary, information, accompanies, paper, https, doi101186s1271, , , additional, file, a0, table, a0s1, list, primers, used, realtime, quanti]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |[generate, map, copy, number, variations, cnv, segregating, population, murcianogranadina, goats, most, important, dairy, breed, spain, ascertain, main, biological, functions, genes, that, map, copy, number, variable, regionsresults, , using, dataset, that, comprised, , murcianogranadina, goats, genotyped, with, goat, snp50, beadchip, we, were, able, detect, , , autosomal, cnv, with, penncnv, quantisnp, software, respectively, by, applying, ensemblecnv, algorithm, these, cnv, were, assembled, into, , cnv, regions, cnvr, which, , , total, cnvr, count, were, consistently, called, by, penncnv, quantisnp, used, subsequent, analyses, set, , cnvr, we, identified, , gain, , loss, , gainloss, events, total, length, all, cnvr, , mb, represented, , goat, autosomal, genome, , mb, whereas, their, size, ranged, from, , kb, , mb, with, an, average, size, , kb, functional, annotation, genes, that, overlapped, with, cnvr, revealed, an, enrichment, pathways, related, with, olfactory, transduction, foldenrichment, , , qvalue, , , , , abc, transporters, foldenrichment, , , qvalue, , , , , bile, secretion, foldenrichment, , , qvalue, , , , conclusions, , previous, study, reported, that, average, number, cnvr, per, goat, breed, , , , cnvr50, breeds, which, much, smaller, than, number, we, found, here, , cnvr, we, attribute, difference, fact, that, previous, study, included, multiple, caprine, breeds, that, were, represented, by, small, moderate, numbers, individuals, given, low, frequencies, cnv, our, study, average, frequency, cnv, , such, design, would, probably, underestimate, levels, diversity, cnv, at, withinbreed, level, we, also, observed, that, functions, related, with, sensory, perception, metabolism, embryo, development, are, overrepresented, set, genes, that, overlapped, with, cnv, that, these, loci, often, belong, large, multigene, families, with, tens, hundreds, or, thousands, paralogous, members, feature, that, could, favor, occurrence, duplications, or, deletions, by, nonallelic, homologous, recombinationcorrespondence, , marcelamillsuabcat, centre, research, agricultural, genomics, crag, csicirtauabub, universitat, aut²noma, de, barcelona, , bellaterra, spainfull, list, author, information, available, at, end, backgroundcopy, , number, , variations, , cnv, , encompass, , genomic, deletions, or, duplications, with, sizes, ranging, from, , base, pairs, bp, several, megabases, mb, which, display, polymorphisms, terms, copy, number, among, individuals, particular, species, [], livestock, broad, array, , , phenotypes, , related, , with, , among, , others, , morphology, [, ], pigmentation, [], sexual, development, , authors, , , licensed, under, creative, commons, attribution, , international, license, which, permits, use, sharing, adaptation, distribution, reproduction, any, medium, or, format, as, long, as, you, give, appropriate, credit, original, authors, source, provide, link, creative, commons, licence, indicate, if, changes, were, made, images, or, other, third, party, material, , are, included, s, creative, commons, licence, unless, indicated, otherwise, credit, line, material, if, material, not, included, s, creative, commons, licence, your, intended, use, not, permitted, by, statutory, regulation, or, exceeds, permitted, use, you, will, need, obtain, permission, directly, from, copyright, holder, view, copy, licence, visit, httpcreat, iveco, mmons, licen, sesby40, creative, commons, public, domain, dedication, waiver, httpcreat, iveco, mmons, publi, cdoma, inzero10, applies, data, made, available, , unless, otherwise, stated, credit, line, data, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , [], , , susceptibility, , , disease, , [], , , caused, , by, , segregation, cnv, genome, scans, detect, structural, variations, , , cattle, , have, , revealed, , that, , cnv, , regions, cnvr, are, often, enriched, genes, that, are, involved, immunity, [], metabolism, [, ], embryo, development, [, ], sensory, perception, [, ], there, evidence, that, , dnds, ratios, genes, that, map, taurine, cnv, are, generally, higher, than, those, genes, that, do, not, overlap, with, cnv, which, indicates, that, cnv, genes, probably, evolve, under, reduced, selective, constraint, [], analysis, gene, networks, has, also, shown, that, genes, that, , colocalize, , with, , duplications, , tend, , , have, , fewer, interactions, with, other, genes, than, loci, that, do, not, overlap, , with, , cnv, , reinforcing, , , idea, , that, , genes, , mapping, duplicated, regions, have, fewer, essential, housekeeping, functions, , than, , noncnv, , genes, , , also, , have, , reduced, pleiotropy, []although, structural, chromosomal, variations, can, have, strong, , effects, , on, , gene, , expression, , , phenotypic, , variability, , technical, , limitations, , , , moderate, , quality, genome, assemblies, have, hampered, cnv, mapping, livestock, , [], , until, , recently, , , has, , been, , particularly, true, goats, , fontanesi, et, a0al, [], published, first, , caprine, , cnv, , map, , by, , identifying, , with, , , bovine, a0k, acgh, array, , cnvr, including, , , copy, loss, gain, variants, respectively, later, on, resequencing, , , genome, , , individuals, , from, , several, , caprine, breeds, , made, , it, , possible, , , identify, , cnv, , that, , overlap, with, , pigmentation, genes, detect, an, association, between, increased, asip, copy, number, light, pigmentation, , [], , , first, , worldwide, , survey, , , copy, , number, , variation, , , goats, , , performed, , within, , , goat, adaptmap, project, httpwwwgoata, daptm, ap, involved, genomewide, genotyping, , goats, from, , breeds, [], study, resulted, identification, , cnvr, among, which, several, overlapped, with, genes, that, , are, , functionally, , related, , with, , local, , adaptation, , such, as, coat, color, muscle, development, metabolic, processes, embryonic, development, [], moreover, patterns, diversity, cnv, differed, according, geographic, origin, , which, , indicates, , that, , they, , have, , been, , influenced, by, population, history, [], another, study, on, , individuals, from, , east, african, goat, breeds, nandolo, et, a0al, [], detected, , cnvr, more, recently, henkel, et, a0al, [], demonstrated, existence, complex, patterns, structural, variation, regions, containing, caprine, asip, kit, genes, with, potential, causal, effects, on, pigmentation, spite, these, efforts, description, structural, chromosomal, , variation, , , goats, , , still, , lagging, , behind, that, other, domestic, species, most, cnv, surveys, goats, have, analyzed, large, populations, that, represent, mixture, different, breeds, each, with, limited, number, individuals, [, ], thus, making, it, difficult, assess, magnitude, cnv, diversity, at, withinbreed, level, our, goal, fill, gap, by, analyzing, population, , individuals, from, single, spanish, breed, murcianogranadina, , , , investigate, , , functional, , roles, , genes, that, map, cnvr, compare, these, results, with, data, obtained, composite, goat, populationsmethodsgenomic, dna, extraction, a0highthroughput, genotypingblood, , samples, , from, , , , murcianogranadina, , female, goats, , from, , , , farms, , that, , are, , connected, , through, , use, , , artificial, , insemination, , were, , collected, , , edta, k3, , coated, , vacuum, , tubes, , , stored, , at, , , a0, °c, , before, processing, , genomic, , dna, , , isolated, , by, , , modified, saltingout, procedure, [], four, volumes, red, cell, lysis, , solution, , trishcl, , a0, mmoll, , ph, , , , edta, a0mmoll, tween, , , were, added, a0ml, whole, blood, mixture, centrifuged, at, g, pelleted, cells, were, resuspended, a0ml, lysis, buffer, trishcl, , a0, mmoll, , ph, , , , edta, , a0, mmoll, , sds, , , nacl, , a0, mmoll, , plus, , , , µl, , proteinase, , k, , a0, mgml, resulting, mixture, incubated, at, a0°c, , h, followed, by, centrifugation, at, g, presence, a0ml, ammonium, acetate, a0moll, supernatant, , a0ml, mixed, with, a0ml, isopropanol, , which, subsequently, centrifuged, at, g, a0min, , supernatant, , , removed, , , , dna, , pellet, , washed, , with, , a0, ml, , , ethanol, , , , after, , centrifuging, at, g, a0min, dna, precipitate, dried, at, room, temperature, resuspended, a0ml, te, buffer, a0mmoll, tris, ph, , , a0mmoll, edta, ph, , highthroughput, , genotyping, , , , , , murcianogranadina, dna, samples, carried, out, with, goat, snp50, , beadchip, , [], , according, , , , manufacturers, instructions, , illumina, , signal, , intensity, , ratios, , ie, , log, , r, ratio, or, lrr, total, probe, intensity, snp, referred, canonical, set, normal, controls, [], b, allele, frequencies, or, baf, relative, quantity, one, allele, compared, , , , other, , one, , [], , were, , exported, , , each, single, nucleotide, polymorphism, snp, with, genomestudio, , software, , , , illumina, , https, emeaillum, inacom, then, snp, coordinates, were, converted, latest, version, goat, reference, genome, ars1, [], after, filtering, , out, , unmapped, , , nonautosomal, , snps, , those, with, call, rate, lower, than, , set, , snps, remained, cnv, mappingcopy, number, variant, calling, with, a0penncnv, a0quantisnpbased, , on, , their, , excellent, , performance, , , comparative, , studies, , we, , selected, , two, , software, , packages, , penncnv, v105, [], quantisnp, v2, [], call, cnv, murcianogranadina, population, [, ], penncnv, software, [], detects, cnv, by, applying, default, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , parameters, hiddenmarkov, model, population, frequencies, b, alleles, were, compiled, based, on, baf, each, snp, population, we, used, gcmodelfile, option, , , adjust, , genomic, , waves, , [], , , number, , goat, chromosomes, set, with, lastchr, , instruction, quantisnp, analysis, [], assumes, an, objective, bayes, hiddenmarkov, model, improve, accuracy, segmental, , aneuploidy, , identification, , , mapping, , cnv, calling, software, run, under, default, parameters, by, modifying, chr, , option, cnv, that, were, supported, , by, , less, , than, , three, , snps, , were, , removed, , from, filtered, set, used, heredefinition, a0functional, annotation, a0copy, number, variant, regionswe, used, ensemblecnv, algorithm, beta, version, [], , assemble, , cnvr, , all, , cnv, , called, , by, , penncnv, , andor, , quantisnp, , were, , combined, , , generate, , , set, , , initial, , cnvr, , by, , using, , , heuristic, , algorithm, , threshold, , minimum, , overlap, , , , described, , , [], , subsequently, cnvr, boundaries, were, refined, by, considering, local, correlation, structure, lrr, values, snps, , mapping, , , cnvr, , [], , then, , we, , reassigned, , cnv, , calls, , that, , were, , initially, , obtained, , with, , penncnv, quantisnp, each, refined, cnvr, so, that, final, set, , , cnvr, , comprised, , only, , those, , that, , were, , simultaneously, , detected, , by, , both, , callers, , , resulting, , cnvr, were, matched, gene, features, that, are, annotated, national, , center, , , biotechnology, , information, , ncbi, https, wwwncbinlmnihgov, , by, , using, , bedtools, v2250, , [], , , addition, , we, , performed, , gene, , ontology, go, enrichment, pathway, analyses, using, david, bioinformatics, , resources, , , , [, , ], , based, , on, , human, , goat, , background, , gene, , sets, , , statistical, , significance, set, qvalue, ¤, confirmation, a0copy, number, variant, regions, by, a0quantitative, realtime, pcrin, , order, , , evaluate, , , rate, , , false, , positives, , , our, experiment, , we, , conducted, , quantitative, , realtime, , pcr, qpcr, , experiments, , , obtain, , an, , independent, , estimate, , , , copy, , number, , , four, , putative, , cnvr, cnvr_371_chr5, , cnvr_506_chr6, , cnvr_160_chr2, cnvr_1229_chr21, primers, were, designed, with, primer, express, software, applied, biosystems, amplify, specific, , regions, , , , adamts20, , bst1, , nckap5, , tnfaip2, , genes, , see, , additional, , file, a0, , , table, a0, s1, as, , reference, , genes, , we, , used, , , melanocortin, , , , receptor, , mc1r, , , glucagon, , gcg, , , genes, , see, , additional, file, a0, table, a0s1, loci, [, ], quantitative, pcr, reactions, contained, a0ng, genomic, dna, , µl, , , sybrselect, master, mix, applied, biosystems, a0pmol, each, forward, , , reverse, , primer, , , ultrapure, , water, , , maximum, final, volume, , µl, each, sample, analyzed, triplicate, order, obtain, averaged, copy, number, estimates, reactions, were, loaded, onto, 384well, plates, run, quantstudio, a0k, flex, realtime, pcr, system, instrument, applied, biosystems, specificity, , pcr, , reactions, , , evaluated, , with, , , melting, , curve, analysis, procedure, efficiency, , assessed, with, standard, curves, thus, relative, copy, number, , , inferred, , with, , , qbase, , software, , biogazelle, ghent, belgium, by, using, , îîct, approach, [], copy, number, values, were, calibrated, by, taking, as, reference, four, samples, which, according, goat, snp50, beadchip, data, had, two, copies, investigated, genomic, lociresultsdetection, a0copy, number, variation, a0murcianogranadina, goatsthe, initial, calling, with, penncnv, quantisnp, yielded, , , , , , autosomal, , cnv, , respectively, , by, , using, , ensemblecnv, , tool, , [], , we, , assigned, , these, , cnv, into, , cnvr, with, refined, boundaries, which, , , , , , total, , cnvr, , count, , were, , detected, , simultaneously, , by, , penncnv, , , quantisnp, , , resulting, cnvr, included, , copy, gain, , copy, loss, , copy, gainloss, , variants, , fig, a0, , , , table, a0, , , , see, , additional, , file, a0, , , table, a0, s2, , , total, , length, , , , cnvr, covered, a0mb, , goat, autosomal, genome, a0mb, whereas, their, individual, size, ranged, from, a0kb, a0mb, with, an, average, a0kb, fig, a02a, table, a0, , , moreover, , we, , found, , that, , , , , , cnvr, showed, , minimum, , allele, , frequencies, , lower, , than, , , with, an, average, frequency, , fig, a02b, addition, , cnvr, with, frequencies, higher, than, , were, distributed, over, seven, caprine, chromosomes, with, frequency, , cnvr_1229_chr21, cnvr, with, highest, frequency, whole, dataset, see, additional, file, a0, table, a0s2, by, using, bedtools, v2250, program, [], , cnvr, that, we, detected, overlapped, with, , unique, cnvr, published, by, liu, et, a0al, [], fig, a0, see, additional, file, a0, table, a0s2, cnvr, that, were, detected, both, studies, are, referred, as, shared, cnvr, whereas, those, that, were, identified, our, study, only, are, referred, as, nonshared, cnvr, fig, a0, six, ten, shared, cnvr, with, frequencies, higher, than, , show, positional, concordance, with, six, cnvr, detected, by, liu, et, a0al, [], see, additional, file, a0, table, a0s2functional, annotation, a0the, a0genes, that, a0are, located, a0copy, number, variable, regionswithin, cnvr, defined, our, study, we, detected, , proteincoding, , genes, , according, , , , goat, , reference, genome, , annotation, , ars1, , [], , from, , , ncbi, , database, see, additional, file, a0, table, a0s2, additional, file, a0, , 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , fig, , , genomic, distribution, , cnvr, detected, with, penncnv, quantisnp, software, on, , caprine, autosomes, squares, triangles, circles, represent, copy, number, gain, loss, gainloss, events, respectively, red, black, colors, represent, shared, nonshared, cnvr, respectively, shared, cnvr, are, those, detected, both, our, study, liu, et, al, [], while, nonshared, cnvr, are, those, identified, only, our, studytable, a0s3, survey, diversity, cnv, goats, with, , , worldwide, , distribution, , liu, , et, a0, al, , [], , detected, , copy, number, variable, genes, which, , were, also, identified, our, study, are, referred, as, shared, copy, number, variable, genes, see, additional, file, a0, table, a0s3, among, , , shared, , copy, , number, , variable, , genes, , asip, , , adamts20, , genes, , are, , particularly, , relevant, they, , are, , involved, , , pigmentation, , [, , , , , , , , ], colocalize, with, selection, signals, detected, worldwide, , sample, , , goats, , [], , , addition, , we, , found, , that, about, , , annotated, genes, that, colocalize, with, cnvr, are, olfactory, receptors, or, olfactory, receptorlike, genes, see, additional, file, a0, table, a0s3, consistently, , most, , significantly, , enriched, , pathway, , , olfactory, transduction, , qvalue, , , , , , table, a0, , , followed, by, abc, transporter, qvalue, , , , , table, a0, significant, pathway, related, with, immunity, ie, fc, epsilon, ri, signaling, qvalue, , , also, identified, based, on, , human, , background, , gene, , set, , table, a0, , , several, , overrepresented, go, terms, were, related, with, embryonic, skeletal, , system, , morphogenesis, , qvalue, , , , , , gprotein, coupled, purinergic, nucleotide, receptor, activity, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , table, , , main, , features, , a0, copy, , number, , variation, , regions, cnvr, detected, a0, murcianogranadina, goatssummary, statisticstotalgainlossgainlosstotal, length, mbtotal, number, cnvrnumber, cnvr, , , kbnumber, cnvr, , kbnumber, cnvr, , kbnumber, cnvr, , kbnumber, cnvr, , kb, mbnumber, cnvr, ¥, , mbaverage, number, snps, per, cnvrminimum, size, cnvr, kbmaximum, size, cnvr, kbaverage, cnvr, size, kbstandard, deviation, cnvr, size, kb, , , , qvalue, , , , , , table, a0, , , interestingly, , , copy, number, , variable, , genes, , were, , also, , enriched, , , pathways, with, , metabolic, , significance, , such, , as, , prolactin, , signaling, insulin, signaling, as, well, as, go, terms, related, with, feeding, behavior, but, none, these, pathways, reached, significance, , threshold, , qvalue, ¤, , , after, , correction, multiple, testing, see, additional, file, a0, table, a0s4, several, pathways, outlined, additional, file, a0, table, a0s4, play, important, roles, immunity, eg, chemokine, signaling, b, cell, receptor, signaling, t, cell, receptor, signaling, cancer, eg, endometrial, cancer, proteoglycans, cancer, , thyroid, , cancer, , as, , well, , as, , , oncogenic, , signaling, , eg, , ras, , , erbb, , signaling, , see, , additional, , file, a0, , table, a0s4, but, most, them, are, not, significant, after, correction, multiple, testingfig, , , histograms, displaying, distribution, cnvr, according, their, size, frequency, b, cnvr, that, were, longer, than, , kb, were, included, kb, bin, whereas, those, with, frequencies, above, , were, grouped, , bin, histograms, were, drawn, by, using, ggplot2, package, httpggplo, t2tidyv, erse, implemented, r, https, wwwrproje, ct, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , table, , , functional, enrichment, a0genes, colocalizing, with, a0cnvr, detected, a0, murcianogranadina, goatsbackground, gene, setcategory, idtermnumber, a0genesfold, enrichment, p, valueqvaluegoatgoatgoathumanhumanhumanhumanhumanhumanhumankeggkeggkeggkegggobpgobpgobpgoccgomfgomfolfactory, transductionabc, transportersbile, secretionfc, epsilon, ri, signaling, pathwaychx04740chx02010chx04976hsa04664go0009952, anteriorposterior, pattern, specificationgo0048704, embryonic, skeletal, system, morphogenesisgo0035589, gprotein, coupled, purinergic, nucleotide, receptor, signaling, pathwaygo0016020, membranego0003677, dna, bindinggo0045028, gprotein, coupled, purinergic, nucleotide, receptor, activity126e, 161e333e, 427e446e, 570e140e, 176e936e, 161e713e, 122e418e, 716e145e, 198e110e, 160e424e, 622ekegg, kyoto, encyclopedia, genes, genomes, pathway, gomf, gene, ontology, go, term, related, with, molecular, function, gobp, go, term, related, with, biological, process, gocc, go, term, related, with, cellular, componentvalidation, a0four, copy, number, variants, by, a0realtime, quantitative, polymerase, chain, reactionin, order, confirm, our, results, we, selected, four, cnvr, ie, , cnvr_371_chr5, , cnvr_506_chr6, , cnvr_160_chr2, , , cnvr_1229_chr21, , that, , colocalized, , with, , adamts20, , bst1, , nckap5, , , tnfaip2, , genes, respectively, , , primers, , used, , , amplify, , these, , cnvr, are, , listed, , , additional, , file, a0, , , table, a0, s1, , as, , shown, , fig, a0, , , , estimated, , copy, , numbers, , obtained, , by, , qpcr, analysis, murcianogranadina, goat, samples, were, , , , , copies, , relative, , , , calibrator, , adamts20, , , copies, bst1, , , copies, nckap5, , , copies, tnfaip2, according, dhaene, et, a0, al, , [], , copy, , number, , estimates, , between, , , , , most, likely, correspond, normal, copy, number, , whereas, any, number, below, or, above, these, thresholds, could, represent, deletion, or, duplication, respectively, thus, , based, , on, , these, , values, , evidence, , , copy, , number, variation, , , inferred, , , three, , , , four, , genes, , analyzed, by, qpcrfig, , , relative, quantification, four, copy, number, variation, regions, by, realtime, quantitative, polymerase, chain, reaction, analysis, cnvr_371_chr5, adamts20, b, cnvr_506_chr6, bst1, c, cnvr_160_chr2, nckap5, d, cnvr_1229_chr21, tnfaip2, x, y, axes, represent, sample, id, relative, quantification, cnvr, mean, ±, standard, error, with, each, sample, analyzed, triplicate, respectively, as, calibrator, we, used, average, four, samples, estimated, have, two, copies, diploid, status, based, on, goat, snp50, beadchip, analysis, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , discussionin, work, our, aim, characterize, copy, number, variation, , , murcianogranadina, , goats, , , native, , spanish, breed, used, milk, production, by, genotyping, , murcianogranadina, , goats, , with, , , snp, , array, , we, , were, able, , , identify, , , , cnvr, , covering, , , , , , goat, genome, , whereas, , liu, , et, a0, al, , [], , identified, , cnvr, , that, covered, , , goat, genome, latter, higher, percentage, reported, by, liu, et, a0al, [], can, be, explained, by, fact, that, they, analyzed, , breeds, with, different, geographical, , origins, , ie, , , composite, , population, , that, , probably, much, more, diverse, than, that, used, our, work, besides, , , pipeline, , that, , we, , used, , , identify, , cnvr, more, stringent, than, that, employed, by, liu, et, a0al, [], removing, cnvr, that, were, not, consistently, detected, by, penncnv, quantisnp, literature, estimates, , , cnvr, coverage, human, genome, are, reported, [], our, results, those, obtained, by, liu, et, a0al, [], are, consistent, with, these, valuesindeed, , when, , liu, , et, a0, al, , [], , calculated, , , cnvr, length, , , each, , breed, , normalized, , by, , , goat, , genome, size, their, results, agreed, well, with, our, estimate, , , instance, , , parameter, , reached, , values, , , , , goats, , from, , southeastern, , africa, , , , , , goats, from, , northwestern, , africa, , , eastern, , mediterranean, whereas, it, lowest, , individuals, from, west, asia, , [], , , number, , , cnv, , detected, , at, , , withinbreed, , level, , by, , liu, , et, a0, al, , [], , , on, , average, , , , cnv, per, breed, ranged, from, , , whereas, average, number, cnvr, only, , , per, breed, [], since, number, detected, cnvr, proportional, population, size, most, breeds, investigated, [], level, withinbreed, cnv, variation, probably, underestimated, summary, one, important, conclusion, from, our, study, that, magnitude, cnv, diversity, at, withinbreed, , level, , , likely, , , be, , much, , larger, , than, , that, previously, , reported, , , studies, , that, , analyzed, , multiple, populations, , each, , represented, , by, , , small, , or, , moderate, number, individualsmost, cnvr, that, we, report, here, ranged, size, from, , a0kb, with, mean, size, a0kb, similarly, average, cnvr, size, reported, by, liu, et, a0al, [], a0kb, both, estimates, are, quite, large, reflect, that, mediumdensity, snp, arrays, are, not, well, suited, detect, small, cnvr, spite, their, high, abundance, cattle, , average, , sizes, , , cnvr, , detected, , with, , , illumina, bovinehd, genotyping, beadchip, a0k, snps, [], illumina, wholegenome, sequencing, pacbio, sequencing, [], , were, , , , , , , a0, kb, , respectively, , another, consistent, feature, cnvr, that, general, their, frequencies, are, low, or, very, low, our, study, approximately, , , , , cnvr, , had, , frequencies, , lower, , than, , , , average, frequency, , liu, et, a0al, [], reported, lower, , cnvr, , frequencies, , ranging, , from, , , , alpine, , northern, , european, , goats, , , , , northwestern, african, goats, decreased, average, cnvr, frequency, , not, , very, , significant, , , probably, , reflects, , differences, , sampling, , size, , , , use, , , composite, , populations, with, , multiple, , breeds, , each, , one, , with, , its, , specific, , cnvr, frequenciesthe, cnvr, detected, our, study, covered, , proteincoding, , genes, , pathway, , analyses, , reflected, , , substantial, enrichment, , , genes, , that, , are, , involved, , , olfactory, , perception, , which, , , consistent, , with, , previous, , reports, , cattle, [, ], regard, there, an, important, difference, between, our, results, those, by, liu, et, a0al, [], whereas, study, liu, et, a0al, [], term, sensory, perception, underrepresented, among, cnv, genes, fold, enrichment, , , our, work, terms, olfactory, transduction, , fold, , enrichment, , , , , gprotein, coupled, , purinergic, , nucleotide, , receptor, , activity, , fold, enrichment, , , , were, , overrepresented, , , many, cnv, , genes, , were, , olfactory, , receptors, , , two, , terms, mentioned, , before, , are, , closely, , related, , because, , , broad, array, purinergic, receptors, are, differentially, expressed, , , olfactory, , receptor, , neurons, , that, , modulate, , odor, responsiveness, , [], , moreover, , purinergic, , nucleotides, are, , important, , neuromodulators, , , peripheral, , auditory, visual, sensory, systems, [], cattle, keel, et, a0al, [], reported, that, sensory, perception, smell, gprotein, , coupled, , receptor, , signaling, , pathway, , were, , significantly, overrepresented, proteincoding, genes, that, overlapped, , with, , cnvr, , similarly, , upadhyay, , et, a0, al, , [], showed, that, sensory, perceptions, smell, chemical, , stimuli, , are, , enriched, , , their, , set, , , cnv, , genes, , potential, , explanation, , , , underrepresentation, , sensory, perception, functional, category, among, genes, overlapping, cnv, reported, by, liu, et, a0al, [], could, be, that, goats, these, genes, are, not, well, annotated, yet, so, majority, them, are, identified, with, loc, prefix, number, as, consequence, they, are, not, , correctly, , detected, , by, , panther, , [], , thus, , biasing, , results, , obtained, , , , gene, , ontology, , enrichment, analysisloci, , belonging, , , large, , multigene, , families, , might, , be, more, , prone, , , colocalize, , with, , cnv, , because, , paralogous, , genes, , can, , act, , as, , templates, , , nonallelic, , homologous, , recombination, , events, , which, , promote, , increases, or, , reductions, , , copy, , number, , [], , it, , should, , be, , noted, that, olfactory, receptor, genes, constitute, largest, gene, superfamily, , , , humans, , more, , than, , , , genes, , pseudogenes, , have, , been, , identified, , [], , , cattle, , , olfactory, receptor, genes, pseudogenes, are, distributed, , , , clusters, , across, , , , bovine, , chromosomes, , [], , similar, numbers, have, been, reported, pigs, [], moreover, , purifying, , selection, , against, , cnv, , , probably, , less, , 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , intense, regions, that, contain, olfactoryreceptor, genes, than, genomic, regions, that, contain, genes, with, essential, functions, [], interestingly, copy, number, changes, olfactory, receptor, genes, wild, domestic, mammals, might, have, consequences, on, food, foraging, as, well, as, on, mate, predator, recognition, [, ]in, set, genes, that, colocalize, with, cnvr, we, also, detected, , an, , enrichment, , , loci, , related, , with, , , multigene, , family, , , atp, , binding, , cassette, , abc, , transporters, , , result, , that, , agrees, , well, , with, , previous, , findings, , humans, , [], , , cattle, , [, , ], , , mammals, , abc, transporters, fulfill, mission, carrying, broad, array, endogenous, substrates, such, as, amino, acids, peptides, sugars, anions, hydrophobic, compounds, metabolites, , across, , lipid, , membranes, , at, , least, , , , abc, , genes, that, belong, eight, subfamilies, have, been, identified, human, genome, [], copy, number, variation, human, abcc4, abcc6, genes, associated, with, susceptibility, , , esophageal, , squamous, , cell, , carcinoma, , [], rare, autosomal, recessive, disease, pseudoxanthoma, elasticum, [], respectively, moreover, largescale, deletions, human, abca1, gene, are, causative, factor, , , hypoalphalipoproteinemia, , [], , , disease, , that, , characterized, by, complete, absence, apolipoprotein, ai, extremely, low, levels, plasma, highdensity, lipoprotein, , hdl, , cholesterol, , we, , also, , found, , , highly, significant, enrichment, pathways, related, with, embryo, development, , anteriorposterior, , pattern, , specification, embryonic, skeletal, system, morphogenesis, as, previously, reported, [], these, pathways, are, featured, by, genes, that, belong, hox, multigene, family, transcription, factors, possibly, reflecting, genomic, instability, certain, homeobox, gene, clusters, as, evidenced, by, existence, many, syntenyparalogy, breakpoints, assembly, gaps, as, outlined, comparative, studies, []although, , not, , significant, , after, , correction, , , multiple, testing, , we, , detected, , an, , enrichment, , , pathways, , with, metabolic, , significance, , such, , as, , prolactin, , , insulin, signaling, which, could, have, an, impact, on, milk, production, , , growth, , [], , interestingly, , , comparison, our, work, with, that, liu, et, a0al, [], revealed, , proteincoding, genes, that, colocalize, with, set, shared, cnvr, one, most, relevant, shared, genes, encodes, asip, protein, that, increases, ratio, pheomelanin, , eumelanin, , by, , binding, , , , melanocortin, , , , receptor, , , delivering, , an, , antagonist, , signal, , that, , blocks, , downstream, expression, eumelanogenic, enzymes, [], mutations, asip, gene, play, critical, roles, animal, pigmentation, [], instance, causal, factor, white, color, typical, many, sheep, breeds, ubiquitous, expression, duplicated, copy, asip, coding, sequence, , which, , , regulated, , by, , , duplicated, , promoter, corresponding, , , , itchy, , e3, , ubiquitin, , protein, , ligase, gene, , [, , ], , although, , some, , studies, , proposed, , that, , asip, cnv, might, be, associated, with, different, pigmentation, patterns, goats, [, , ], no, functional, assay, has, verified, an, association, asip, copy, number, with, asip, mrna, , levels, , another, , interesting, , shared, , copy, , number, variable, gene, adamts20, which, also, identified, two, previous, cnv, surveys, [, ], gene, encodes, metalloproteinase, with, an, important, role, melanoblast, survival, by, mediating, kit, signaling, [], palatogenesis, [], bertolini, et, a0al, [], performed, selection, scan, white, vs, colored, black, red, goats, detected, selective, sweep, adamts20, gene, light, these, , results, , , potential, , involvement, , , , structural, variation, , , adamts20, , , goat, , pigmentation, , should, be, explored, further, moreover, it, worthwhile, mention, that, several, cnvr, genes, have, functions, related, with, production, , , reproduction, , traits, , , instance, , nckap5, gene, which, colocalizes, with, cnvr_160_chr2, frequency, , , associated, with, milk, fat, percentage, , cattle, , [], , taking, , , above, , evidence, , into, , account, implication, structural, chromosomal, variations, , genetic, , determinism, , , traits, , , economic, , interest, with, complex, inheritance, deserves, further, exploration, by, designing, tools, that, allow, inferring, cnvr, genotypes, with, high, confidenceconclusionswith, , , penncnv, , , quantisnp, , software, , we, detected, , , , cnvr, , , , genome, , , , murcianogranadina, , breed, , , a0, previous, , study, , [], , that, , used, , less, , stringent, , pipeline, , only, , penncnv, , , used, , included, , multiple, , populations, , with, , small, , , moderate, , sample, , sizes, , , average, , number, , , cnvr, , events, per, breed, , , one, conclusion, our, study, that, cnv, surveys, which, are, based, on, broad, array, breeds, represented, , by, , only, , , few, , individuals, , underestimate, true, levels, cnv, diversity, at, withinbreed, level, main, reason, outcome, that, since, majority, cnv, have, very, low, frequencies, they, cannot, be, detected, efficiently, when, sample, size, small, consequence, , much, , , , existing, , variation, , , missed, we, have, also, found, that, genes, that, overlap, with, cnv, are, functionally, related, with, olfactory, transduction, embryo, development, , abc, , transporters, , , gprotein, , coupled, purinergic, , nucleotide, , receptor, , activity, , most, , , these, genes, , belong, , , large, , multigene, , families, , encompassing, tens, , hundreds, , or, , thousands, , , paralogous, , genes, , that, could, act, as, substrates, nonallelic, homologous, recombination, , events, , which, , , one, , , , main, , mechanisms, generating, , duplications, , , deletions, , , humans, , other, , species, , finally, , we, , detected, , cnv, , that, , colocalize, with, asip, adamts20, pigmentation, genes, 0cguan, a0et, a0al, genet, sel, evol, , , , , , , , , , , , , page, , which, according, previous, studies, have, been, subjected, positive, selection, coat, color, goatssupplementary, informationsupplementary, information, accompanies, paper, at, https, doi101186s1271, , , additional, file, a0, table, a0s1, list, primers, used, realtime, quanti]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |(224581,[0,1,2,3,4,5,6,7,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,26,27,28,29,30,32,33,35,36,38,39,40,41,42,43,44,45,46,47,48,49,52,53,55,56,57,58,59,60,61,62,63,66,68,69,71,72,73,74,75,76,77,78,79,80,81,82,85,86,87,88,89,90,92,93,94,96,97,98,99,100,101,103,104,106,107,108,109,110,112,113,114,115,116,117,118,119,120,121,122,125,128,129,131,132,135,136,137,139,141,142,143,146,147,148,149,151,156,158,159,163,166,167,168,169,170,171,173,174,175,177,181,183,185,187,188,190,192,194,195,196,197,198,199,200,201,202,203,208,209,214,215,216,217,218,220,221,224,227,230,231,236,237,239,240,243,244,246,247,248,249,250,252,254,255,258,260,262,263,265,266,268,269,276,277,278,279,283,284,294,298,299,301,303,305,307,310,313,315,318,320,321,324,326,328,329,330,331,332,335,336,340,343,346,351,352,355,356,358,360,361,362,363,366,367,368,371,373,378,380,381,384,385,386,387,391,397,398,399,402,403,408,410,414,415,421,423,427,431,434,435,440,441,442,443,445,448,450,451,453,454,457,464,465,468,469,473,478,479,481,482,487,488,494,496,497,499,500,505,506,512,521,523,524,533,543,545,548,551,555,558,559,565,566,567,569,571,573,576,577,579,580,584,589,590,591,593,595,600,601,604,605,607,608,615,616,617,624,627,629,637,639,640,642,643,648,649,651,654,655,667,674,675,676,677,681,685,691,692,695,697,698,707,713,714,716,718,724,725,729,730,732,733,735,737,739,744,745,752,753,755,773,774,775,782,783,787,789,791,792,793,795,801,802,806,807,808,810,811,812,818,820,824,825,826,836,839,841,842,844,846,848,850,851,852,859,860,863,864,866,874,882,883,886,887,891,896,898,900,901,905,906,909,910,911,918,923,928,933,934,938,943,945,948,958,964,966,967,969,971,974,979,983,985,990,993,995,997,1007,1010,1012,1018,1021,1036,1037,1038,1041,1043,1055,1071,1073,1076,1079,1080,1086,1093,1096,1097,1100,1102,1103,1120,1121,1124,1132,1134,1137,1144,1145,1150,1151,1155,1157,1158,1163,1164,1167,1176,1184,1188,1191,1193,1200,1204,1206,1209,1218,1221,1241,1247,1249,1259,1262,1264,1266,1271,1273,1278,1298,1302,1308,1311,1312,1313,1339,1355,1360,1362,1374,1386,1387,1394,1399,1406,1411,1416,1419,1429,1432,1442,1443,1454,1462,1471,1475,1480,1481,1483,1487,1497,1502,1504,1506,1509,1516,1521,1528,1531,1534,1540,1560,1562,1564,1567,1574,1578,1582,1583,1589,1591,1600,1617,1623,1628,1629,1635,1637,1638,1643,1646,1647,1655,1674,1675,1678,1688,1706,1713,1719,1720,1724,1741,1746,1749,1764,1768,1769,1772,1779,1781,1784,1810,1818,1829,1830,1857,1861,1864,1865,1867,1888,1902,1905,1907,1909,1910,1913,1916,1919,1920,1922,1923,1929,1930,1931,1942,1985,1989,2001,2004,2029,2034,2036,2038,2045,2046,2079,2083,2088,2102,2111,2115,2123,2124,2129,2131,2155,2161,2166,2199,2203,2210,2241,2246,2264,2265,2270,2278,2281,2289,2291,2303,2314,2325,2334,2351,2373,2376,2385,2390,2394,2415,2422,2456,2459,2461,2465,2480,2484,2487,2507,2508,2510,2541,2551,2565,2581,2583,2590,2615,2617,2620,2623,2625,2626,2631,2632,2673,2687,2696,2713,2753,2754,2762,2764,2774,2781,2788,2807,2809,2812,2829,2830,2832,2835,2837,2852,2860,2870,2889,2909,2911,2912,2939,2940,2942,2950,2952,2989,3003,3022,3030,3052,3084,3109,3110,3111,3132,3139,3156,3168,3201,3208,3239,3255,3321,3325,3326,3336,3339,3389,3395,3420,3423,3444,3459,3467,3483,3501,3511,3515,3531,3551,3569,3618,3627,3631,3642,3652,3655,3658,3714,3719,3738,3739,3757,3778,3793,3819,3822,3875,3907,3935,3949,3970,3972,3974,3983,4012,4015,4023,4059,4074,4077,4079,4093,4103,4106,4130,4169,4175,4177,4200,4217,4231,4263,4270,4311,4326,4355,4357,4361,4393,4406,4423,4464,4473,4500,4515,4520,4532,4564,4597,4606,4624,4645,4660,4678,4684,4711,4726,4829,4830,4842,4868,4923,4959,4960,4968,5012,5022,5025,5051,5057,5142,5145,5199,5252,5253,5297,5321,5330,5346,5349,5380,5410,5442,5458,5483,5489,5501,5508,5541,5563,5599,5602,5603,5617,5678,5733,5790,5837,5882,5897,5908,5936,5971,6014,6053,6162,6199,6315,6317,6365,6414,6453,6485,6498,6518,6607,6625,6748,6758,6769,6845,6976,7035,7039,7101,7111,7143,7173,7189,7196,7221,7223,7230,7251,7284,7323,7332,7394,7429,7434,7444,7454,7474,7500,7529,7535,7574,7621,7718,7823,7828,7844,7858,7891,7941,7961,8009,8012,8026,8085,8103,8139,8172,8282,8287,8329,8415,8433,8441,8483,8494,8538,8542,8654,8764,8799,8812,8897,8899,8928,8947,9012,9079,9128,9175,9260,9403,9404,9411,9420,9481,9669,9795,9878,9979,10038,10266,10294,10394,10413,10927,10994,11110,11249,11260,11311,11313,11343,11405,11436,11443,11451,11491,11498,11504,11606,11650,11700,11734,11738,11939,12095,12267,12336,12425,12454,12694,12834,12992,13030,13100,13145,13221,13497,13504,13751,13866,13931,13950,14030,14248,14254,14418,14704,14867,15137,15155,15270,15366,15426,15429,15492,15528,15555,15560,15686,15904,15998,16079,16155,16254,16307,16389,16452,16577,16708,17210,17302,17531,17727,17760,18042,18208,18249,18542,19072,20004,20182,20219,20544,20566,20864,21135,21674,21705,21737,21831,21901,22232,22442,22637,22752,23710,23772,23906,24214,24290,24482,25455,25552,25716,25815,25853,25928,26211,26311,26370,26523,26725,27158,27617,27634,27678,28002,28250,28251,28327,28781,29280,29861,29909,30992,31604,31743,31938,32035,32277,32539,33708,33771,33799,34887,35161,35258,36123,36653,36901,37036,37117,37819,38675,38782,38881,39563,40108,40187,41728,42133,42195,46276,47252,49219,49676,50095,50352,53947,56199,56518,58063,58318,58645,60450,61282,61456,61926,64235,66339,67046,67872,68472,68670,68921,69612,69910,70710,70912,71528,73527,73834,74154,74456,79807,79825,82776,86113,86790,87365,87782,88755,89030,90087,91176,92235,92846,92909,93032,93291,93752,93859,94057,94216,94233,94391,95781,95964,96645,98066,98594,98813,98908,100532,100832,101201,101446,101760,101771,102707,104051,105391,106250,106299,108620,109004,109140,109383,109658,109784,111198,114044,114125,115602,116363,118805,119566,119836,120434,129859,130852,130969,131019,131856,132728,133613,136027,136256,137623,138461,139890,140308,143645,143912,145304,146274,146933,148271,148920,149164,149754,150896,151149,151617,154920,156795,158592,158726,159260,159517,160565,160585,160759,161029,161376,162794,163034,163344,163419,163430,164005,164142,164355,167133,168130,168648,169385,170553,171332,172141,172547,172999,173271,173996,174070,174225,174901,176311,178184,179339,179341,180898,182896,183614,184794,185095,185597,185753,185951,186384,186440,189940,193893,193932,197121,197542,197986,198386,198677,198725,199157,199645,199999,200801,201663,201722,202144,204270,205122,206372,208144,209779],[1620.0,91.0,39.0,54.0,82.0,25.0,4.0,1.0,15.0,16.0,19.0,36.0,4.0,3.0,8.0,3.0,15.0,14.0,27.0,15.0,4.0,18.0,20.0,11.0,8.0,7.0,3.0,1.0,6.0,75.0,10.0,13.0,14.0,2.0,3.0,5.0,53.0,6.0,5.0,1.0,3.0,2.0,6.0,3.0,7.0,23.0,18.0,16.0,1.0,5.0,1.0,5.0,4.0,7.0,1.0,20.0,1.0,3.0,1.0,1.0,5.0,2.0,5.0,1.0,6.0,5.0,22.0,15.0,2.0,8.0,5.0,10.0,3.0,2.0,10.0,2.0,1.0,4.0,3.0,8.0,3.0,5.0,2.0,5.0,1.0,45.0,2.0,2.0,12.0,5.0,1.0,1.0,1.0,6.0,6.0,6.0,2.0,8.0,1.0,5.0,1.0,4.0,5.0,2.0,2.0,2.0,2.0,1.0,2.0,13.0,7.0,1.0,1.0,46.0,6.0,2.0,5.0,2.0,2.0,1.0,6.0,2.0,7.0,3.0,1.0,2.0,1.0,2.0,2.0,3.0,7.0,5.0,5.0,5.0,7.0,1.0,1.0,2.0,10.0,1.0,15.0,1.0,1.0,2.0,3.0,1.0,9.0,1.0,1.0,1.0,9.0,1.0,24.0,7.0,6.0,1.0,2.0,6.0,2.0,1.0,2.0,4.0,1.0,14.0,3.0,4.0,4.0,25.0,5.0,1.0,6.0,2.0,1.0,5.0,7.0,2.0,1.0,1.0,7.0,7.0,15.0,4.0,5.0,4.0,6.0,2.0,4.0,15.0,3.0,1.0,5.0,2.0,2.0,5.0,1.0,2.0,1.0,3.0,1.0,1.0,2.0,3.0,1.0,1.0,8.0,1.0,7.0,2.0,2.0,1.0,7.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,3.0,6.0,3.0,1.0,5.0,3.0,1.0,1.0,1.0,2.0,1.0,1.0,13.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,2.0,1.0,3.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,15.0,3.0,2.0,5.0,1.0,1.0,4.0,1.0,1.0,1.0,3.0,5.0,1.0,1.0,5.0,1.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,1.0,1.0,3.0,1.0,8.0,1.0,2.0,9.0,3.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,16.0,2.0,4.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,13.0,2.0,1.0,1.0,2.0,12.0,1.0,1.0,1.0,2.0,1.0,3.0,2.0,1.0,1.0,2.0,4.0,1.0,1.0,9.0,1.0,2.0,2.0,2.0,8.0,3.0,2.0,2.0,2.0,1.0,3.0,11.0,2.0,1.0,3.0,1.0,2.0,2.0,3.0,3.0,4.0,2.0,2.0,1.0,1.0,2.0,13.0,3.0,2.0,1.0,1.0,3.0,1.0,1.0,2.0,2.0,3.0,1.0,2.0,1.0,33.0,1.0,1.0,4.0,1.0,1.0,2.0,2.0,5.0,1.0,1.0,1.0,1.0,1.0,3.0,4.0,1.0,1.0,12.0,2.0,4.0,3.0,7.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,10.0,2.0,1.0,3.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,2.0,4.0,3.0,1.0,2.0,1.0,2.0,1.0,8.0,1.0,1.0,1.0,1.0,2.0,1.0,8.0,2.0,2.0,1.0,1.0,2.0,4.0,1.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,2.0,6.0,1.0,2.0,1.0,1.0,2.0,3.0,1.0,2.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,3.0,2.0,2.0,1.0,3.0,1.0,1.0,3.0,1.0,4.0,2.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,4.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,3.0,5.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,4.0,3.0,7.0,1.0,1.0,1.0,1.0,6.0,3.0,2.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,4.0,2.0,5.0,2.0,2.0,1.0,2.0,4.0,1.0,1.0,1.0,6.0,2.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,2.0,1.0,1.0,2.0,2.0,4.0,2.0,1.0,1.0,2.0,1.0,2.0,6.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,3.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,1.0,3.0,3.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,11.0,1.0,1.0,1.0,10.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,2.0,8.0,1.0,2.0,3.0,1.0,3.0,4.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,2.0,19.0,3.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,4.0,4.0,6.0,1.0,2.0,4.0,1.0,3.0,1.0,2.0,1.0,4.0,1.0,3.0,5.0,1.0,1.0,1.0,2.0,3.0,1.0,2.0,2.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,78.0,1.0,1.0,1.0,1.0,48.0,1.0,3.0,2.0,2.0,2.0,2.0,2.0,6.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,4.0,1.0,1.0,2.0,1.0,1.0,1.0,4.0,1.0,4.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,4.0,1.0,4.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,5.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,5.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,2.0,6.0,2.0,1.0,6.0,1.0,2.0,3.0,1.0,1.0,2.0,1.0,1.0,2.0,1.0,1.0,7.0,1.0,2.0,5.0,1.0,1.0,19.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,3.0,2.0,1.0,1.0,2.0,1.0,5.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,1.0,4.0,4.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,2.0,1.0,3.0,1.0,1.0,2.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,2.0,3.0,2.0,3.0,2.0,1.0,8.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,2.0,4.0,2.0,3.0,2.0,9.0,1.0,2.0,1.0,7.0,1.0,2.0,12.0,1.0,1.0,1.0,9.0,2.0,2.0,11.0,1.0,11.0,1.0,4.0,1.0,1.0,8.0,1.0,10.0,1.0,4.0,7.0,10.0,2.0,1.0,1.0,1.0,1.0,9.0,7.0,1.0,1.0,1.0,5.0,1.0,1.0,4.0,1.0,1.0,1.0,2.0,8.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,6.0,1.0,1.0,1.0,1.0,1.0,4.0,1.0,1.0,2.0,5.0,1.0,1.0,1.0,1.0,2.0,5.0,1.0,1.0,2.0,2.0,1.0,2.0,1.0,5.0,1.0,2.0,1.0,1.0,4.0,4.0,3.0,2.0,1.0,4.0,4.0,3.0,1.0,4.0,4.0,1.0,4.0,1.0,1.0,2.0,4.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,1.0,1.0,1.0,1.0,3.0,3.0,3.0,3.0,1.0,2.0,3.0,3.0,1.0,2.0,1.0,1.0,1.0,2.0,1.0,1.0,1.0,2.0,2.0,1.0,1.0,1.0,1.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,2.0,1.0,2.0,1.0,2.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n",
      "+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n",
      "only showing top 20 rows\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# МІСЦЕ ДЛЯ КОДУ\n",
    "from pyspark.ml.feature import Tokenizer, StopWordsRemover, CountVectorizer\n",
    "from pyspark.ml import Pipeline\n",
    "\n",
    "# Токенізація тексту\n",
    "tokenizer = Tokenizer(inputCol=\"a\", outputCol=\"tokens\")\n",
    "\n",
    "# Створюємо власний список стоп-слів\n",
    "custom_stop_words = [\"the\", \"and\", \"is\", \"to\", \"of\", \"a\", \"in\", \"this\", \"was\", \"for\"]\n",
    "\n",
    "# Видалення стоп-слів за замовчуванням\n",
    "default_stop_words_remover = StopWordsRemover(inputCol=\"tokens\", outputCol=\"filtered_tokens_default\")\n",
    "\n",
    "# Видалення стоп-слів із використанням власного списку\n",
    "custom_stop_words_remover = StopWordsRemover(inputCol=\"tokens\", outputCol=\"filtered_tokens_custom\", stopWords=custom_stop_words)\n",
    "\n",
    "# Перетворення у векторну форму\n",
    "vectorizer = CountVectorizer(inputCol=\"filtered_tokens_custom\", outputCol=\"features\")\n",
    "\n",
    "# Об'єднання всіх етапів у pipeline\n",
    "pipeline = Pipeline(stages=[tokenizer, \n",
    "                            default_stop_words_remover, \n",
    "                            custom_stop_words_remover, \n",
    "                            vectorizer])\n",
    "\n",
    "# Тренуємо pipeline на даних\n",
    "model = pipeline.fit(tdf)\n",
    "\n",
    "# Застосовуємо pipeline до даних\n",
    "processed_data = model.transform(tdf)\n",
    "\n",
    "# Виводимо результати для перевірки\n",
    "processed_data.select(\"tokens\", \"filtered_tokens_default\", \"filtered_tokens_custom\", \"features\").show(truncate=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "6r8DcRU5CNh5"
   },
   "source": [
    "### Завдання №4\n",
    "* Застосуйте алгоритм кластеризації `КMeans` до перетвореної векторної форми тексту\n",
    "* визначить за правилом \"ліктя\" та оцінки оптимальну кількість кластерів\n",
    "* зробіть висновки"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "id": "unSSa9-hCOFk"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 13:52:09 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:09 WARN TaskSetManager: Stage 6 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:15 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:15 WARN TaskSetManager: Stage 9 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:20 WARN TaskSetManager: Stage 10 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:20 WARN TaskSetManager: Stage 11 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:21 WARN TaskSetManager: Stage 12 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:21 WARN TaskSetManager: Stage 13 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:22 WARN TaskSetManager: Stage 14 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:22 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:22 WARN TaskSetManager: Stage 15 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:22 WARN InstanceBuilder: Failed to load implementation from:dev.ludovic.netlib.blas.JNIBLAS\n",
      "24/12/07 13:52:22 WARN InstanceBuilder: Failed to load implementation from:dev.ludovic.netlib.blas.VectorBLAS\n",
      "24/12/07 13:52:23 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:23 WARN TaskSetManager: Stage 17 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:28 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:28 WARN TaskSetManager: Stage 19 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:28 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:28 WARN TaskSetManager: Stage 21 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:28 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:29 WARN TaskSetManager: Stage 23 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:29 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:29 WARN TaskSetManager: Stage 25 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:30 WARN DAGScheduler: Broadcasting large task binary with size 6.7 MiB\n",
      "24/12/07 13:52:30 WARN TaskSetManager: Stage 27 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:35 WARN DAGScheduler: Broadcasting large task binary with size 6.7 MiB\n",
      "24/12/07 13:52:35 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:35 WARN TaskSetManager: Stage 30 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:40 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:40 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:40 WARN TaskSetManager: Stage 33 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:46 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:46 WARN TaskSetManager: Stage 34 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:46 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:46 WARN TaskSetManager: Stage 35 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:47 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:47 WARN TaskSetManager: Stage 36 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:47 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:47 WARN TaskSetManager: Stage 37 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:48 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:48 WARN TaskSetManager: Stage 38 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:48 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:48 WARN TaskSetManager: Stage 39 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:49 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:49 WARN TaskSetManager: Stage 41 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:56 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:52:56 WARN TaskSetManager: Stage 43 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:52:57 WARN DAGScheduler: Broadcasting large task binary with size 8.4 MiB\n",
      "24/12/07 13:52:57 WARN TaskSetManager: Stage 45 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:03 WARN DAGScheduler: Broadcasting large task binary with size 8.4 MiB\n",
      "24/12/07 13:53:03 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:03 WARN TaskSetManager: Stage 48 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:08 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:08 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:08 WARN TaskSetManager: Stage 51 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:12 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:13 WARN TaskSetManager: Stage 52 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:13 WARN TaskSetManager: Stage 53 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:13 WARN TaskSetManager: Stage 54 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:14 WARN TaskSetManager: Stage 55 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:14 WARN TaskSetManager: Stage 56 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:14 WARN TaskSetManager: Stage 57 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:15 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:15 WARN TaskSetManager: Stage 59 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:20 WARN TaskSetManager: Stage 61 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:20 WARN TaskSetManager: Stage 63 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:20 WARN TaskSetManager: Stage 65 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:21 WARN TaskSetManager: Stage 67 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:21 WARN TaskSetManager: Stage 69 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:22 WARN DAGScheduler: Broadcasting large task binary with size 10.1 MiB\n",
      "24/12/07 13:53:22 WARN TaskSetManager: Stage 71 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:27 WARN DAGScheduler: Broadcasting large task binary with size 10.1 MiB\n",
      "24/12/07 13:53:27 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:27 WARN TaskSetManager: Stage 74 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:32 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:32 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:32 WARN TaskSetManager: Stage 77 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:36 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:36 WARN TaskSetManager: Stage 78 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:36 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:36 WARN TaskSetManager: Stage 79 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:37 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:37 WARN TaskSetManager: Stage 80 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:37 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:37 WARN TaskSetManager: Stage 81 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:38 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:38 WARN TaskSetManager: Stage 82 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:38 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:38 WARN TaskSetManager: Stage 83 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:39 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:39 WARN TaskSetManager: Stage 85 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:44 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:44 WARN TaskSetManager: Stage 87 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:44 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:44 WARN TaskSetManager: Stage 89 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:45 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:45 WARN TaskSetManager: Stage 91 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:45 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:45 WARN TaskSetManager: Stage 93 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:45 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:45 WARN TaskSetManager: Stage 95 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:46 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:46 WARN TaskSetManager: Stage 97 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:47 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:47 WARN TaskSetManager: Stage 99 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:47 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:47 WARN TaskSetManager: Stage 101 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:48 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:48 WARN TaskSetManager: Stage 103 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:48 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:48 WARN TaskSetManager: Stage 105 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:49 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:49 WARN TaskSetManager: Stage 107 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:49 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:49 WARN TaskSetManager: Stage 109 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:50 WARN DAGScheduler: Broadcasting large task binary with size 11.8 MiB\n",
      "24/12/07 13:53:50 WARN TaskSetManager: Stage 111 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:53:55 WARN DAGScheduler: Broadcasting large task binary with size 11.8 MiB\n",
      "24/12/07 13:53:55 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:53:55 WARN TaskSetManager: Stage 114 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:00 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:00 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:00 WARN TaskSetManager: Stage 117 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:04 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:04 WARN TaskSetManager: Stage 118 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:04 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:04 WARN TaskSetManager: Stage 119 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:05 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:05 WARN TaskSetManager: Stage 120 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:05 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:05 WARN TaskSetManager: Stage 121 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:06 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:06 WARN TaskSetManager: Stage 122 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:06 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:06 WARN TaskSetManager: Stage 123 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:07 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:07 WARN TaskSetManager: Stage 125 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:12 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:12 WARN TaskSetManager: Stage 127 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:12 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:12 WARN TaskSetManager: Stage 129 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:13 WARN TaskSetManager: Stage 131 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:13 WARN TaskSetManager: Stage 133 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:14 WARN TaskSetManager: Stage 135 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:14 WARN TaskSetManager: Stage 137 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:15 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:15 WARN TaskSetManager: Stage 139 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:15 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:15 WARN TaskSetManager: Stage 141 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:16 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:16 WARN TaskSetManager: Stage 143 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:16 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:16 WARN TaskSetManager: Stage 145 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:17 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:17 WARN TaskSetManager: Stage 147 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:18 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:18 WARN TaskSetManager: Stage 149 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:18 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:18 WARN TaskSetManager: Stage 151 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:19 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:19 WARN TaskSetManager: Stage 153 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:19 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:19 WARN TaskSetManager: Stage 155 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:20 WARN TaskSetManager: Stage 157 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:20 WARN TaskSetManager: Stage 159 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:21 WARN DAGScheduler: Broadcasting large task binary with size 13.5 MiB\n",
      "24/12/07 13:54:21 WARN TaskSetManager: Stage 161 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:26 WARN DAGScheduler: Broadcasting large task binary with size 13.5 MiB\n",
      "24/12/07 13:54:26 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:26 WARN TaskSetManager: Stage 164 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:31 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:31 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:31 WARN TaskSetManager: Stage 167 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:35 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:36 WARN TaskSetManager: Stage 168 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:36 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:36 WARN TaskSetManager: Stage 169 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:36 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:36 WARN TaskSetManager: Stage 170 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:37 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:37 WARN TaskSetManager: Stage 171 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:37 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:37 WARN TaskSetManager: Stage 172 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:37 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:37 WARN TaskSetManager: Stage 173 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:38 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:38 WARN TaskSetManager: Stage 175 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:44 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:44 WARN TaskSetManager: Stage 177 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:45 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:45 WARN TaskSetManager: Stage 179 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:45 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:46 WARN TaskSetManager: Stage 181 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:46 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:46 WARN TaskSetManager: Stage 183 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:47 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:47 WARN TaskSetManager: Stage 185 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:48 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:48 WARN TaskSetManager: Stage 187 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:49 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:49 WARN TaskSetManager: Stage 189 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:49 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:49 WARN TaskSetManager: Stage 191 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:50 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:50 WARN TaskSetManager: Stage 193 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:51 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:51 WARN TaskSetManager: Stage 195 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:52 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:52 WARN TaskSetManager: Stage 197 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:52 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:52 WARN TaskSetManager: Stage 199 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:53 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:53 WARN TaskSetManager: Stage 201 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:54 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:54 WARN TaskSetManager: Stage 203 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:55 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:55 WARN TaskSetManager: Stage 205 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:55 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:55 WARN TaskSetManager: Stage 207 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:56 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:54:56 WARN TaskSetManager: Stage 209 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:54:57 WARN DAGScheduler: Broadcasting large task binary with size 15.2 MiB\n",
      "24/12/07 13:54:57 WARN TaskSetManager: Stage 211 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:03 WARN DAGScheduler: Broadcasting large task binary with size 15.2 MiB\n",
      "24/12/07 13:55:03 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:03 WARN TaskSetManager: Stage 214 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:07 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:08 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:08 WARN TaskSetManager: Stage 217 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:12 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:12 WARN TaskSetManager: Stage 218 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:12 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:13 WARN TaskSetManager: Stage 219 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:13 WARN TaskSetManager: Stage 220 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:13 WARN TaskSetManager: Stage 221 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:14 WARN TaskSetManager: Stage 222 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:14 WARN TaskSetManager: Stage 223 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:15 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:15 WARN TaskSetManager: Stage 225 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:20 WARN TaskSetManager: Stage 227 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:20 WARN TaskSetManager: Stage 229 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:21 WARN TaskSetManager: Stage 231 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:21 WARN TaskSetManager: Stage 233 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:22 WARN DAGScheduler: Broadcasting large task binary with size 16.9 MiB\n",
      "24/12/07 13:55:22 WARN TaskSetManager: Stage 235 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:26 WARN DAGScheduler: Broadcasting large task binary with size 16.9 MiB\n",
      "24/12/07 13:55:27 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:27 WARN TaskSetManager: Stage 238 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:32 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:32 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:32 WARN TaskSetManager: Stage 241 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:36 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:36 WARN TaskSetManager: Stage 242 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:37 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:37 WARN TaskSetManager: Stage 243 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:37 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:37 WARN TaskSetManager: Stage 244 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:37 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:37 WARN TaskSetManager: Stage 245 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:38 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:38 WARN TaskSetManager: Stage 246 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:38 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:38 WARN TaskSetManager: Stage 247 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:39 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:39 WARN TaskSetManager: Stage 249 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:44 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:44 WARN TaskSetManager: Stage 251 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:45 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:45 WARN TaskSetManager: Stage 253 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:45 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:45 WARN TaskSetManager: Stage 255 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:46 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:46 WARN TaskSetManager: Stage 257 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:46 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:46 WARN TaskSetManager: Stage 259 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:47 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:47 WARN TaskSetManager: Stage 261 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:48 WARN DAGScheduler: Broadcasting large task binary with size 18.7 MiB\n",
      "24/12/07 13:55:48 WARN TaskSetManager: Stage 263 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:53 WARN DAGScheduler: Broadcasting large task binary with size 18.7 MiB\n",
      "24/12/07 13:55:53 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:53 WARN TaskSetManager: Stage 266 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:55:58 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:58 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:55:58 WARN TaskSetManager: Stage 269 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:02 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:02 WARN TaskSetManager: Stage 270 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:03 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:03 WARN TaskSetManager: Stage 271 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:03 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:03 WARN TaskSetManager: Stage 272 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:03 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:03 WARN TaskSetManager: Stage 273 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:04 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:04 WARN TaskSetManager: Stage 274 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:04 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:04 WARN TaskSetManager: Stage 275 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:05 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:05 WARN TaskSetManager: Stage 277 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:10 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:10 WARN TaskSetManager: Stage 279 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:10 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:10 WARN TaskSetManager: Stage 281 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:11 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:11 WARN TaskSetManager: Stage 283 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:12 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:12 WARN TaskSetManager: Stage 285 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:12 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:12 WARN TaskSetManager: Stage 287 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:13 WARN TaskSetManager: Stage 289 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:13 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:13 WARN TaskSetManager: Stage 291 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:14 WARN TaskSetManager: Stage 293 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:14 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:15 WARN TaskSetManager: Stage 295 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:15 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:15 WARN TaskSetManager: Stage 297 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:16 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:16 WARN TaskSetManager: Stage 299 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:16 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:16 WARN TaskSetManager: Stage 301 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:17 WARN DAGScheduler: Broadcasting large task binary with size 20.4 MiB\n",
      "24/12/07 13:56:17 WARN TaskSetManager: Stage 303 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:22 WARN DAGScheduler: Broadcasting large task binary with size 20.4 MiB\n",
      "                                                                                \r"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 13:56:23 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:23 WARN TaskSetManager: Stage 306 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:27 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:28 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:28 WARN TaskSetManager: Stage 309 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:32 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:32 WARN TaskSetManager: Stage 310 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:32 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:32 WARN TaskSetManager: Stage 311 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:33 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:33 WARN TaskSetManager: Stage 312 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:33 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:33 WARN TaskSetManager: Stage 313 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:34 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:34 WARN TaskSetManager: Stage 314 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:34 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:34 WARN TaskSetManager: Stage 315 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:35 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:35 WARN TaskSetManager: Stage 317 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:41 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:41 WARN TaskSetManager: Stage 319 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:42 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:42 WARN TaskSetManager: Stage 321 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:43 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:43 WARN TaskSetManager: Stage 323 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:44 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:44 WARN TaskSetManager: Stage 325 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:45 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:45 WARN TaskSetManager: Stage 327 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:46 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:46 WARN TaskSetManager: Stage 329 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:47 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:47 WARN TaskSetManager: Stage 331 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:48 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:48 WARN TaskSetManager: Stage 333 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:49 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:49 WARN TaskSetManager: Stage 335 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:50 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:50 WARN TaskSetManager: Stage 337 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:50 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:50 WARN TaskSetManager: Stage 339 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:51 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 13:56:51 WARN TaskSetManager: Stage 341 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:52 WARN DAGScheduler: Broadcasting large task binary with size 20.4 MiB\n",
      "24/12/07 13:56:52 WARN TaskSetManager: Stage 343 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:56:58 WARN DAGScheduler: Broadcasting large task binary with size 20.4 MiB\n",
      "24/12/07 13:56:59 WARN DAGScheduler: Broadcasting large task binary with size 20.4 MiB\n",
      "24/12/07 13:56:59 WARN TaskSetManager: Stage 346 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 13:57:04 WARN DAGScheduler: Broadcasting large task binary with size 20.4 MiB\n",
      "24/12/07 13:57:04 WARN TaskSetManager: Stage 348 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "[Stage 348:==========================================>              (6 + 2) / 8]\r"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Оптимальна кількість кластерів: 10\n",
      "Silhouette Score для кластеризації: 0.46879691462053225\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "                                                                                \r"
     ]
    }
   ],
   "source": [
    "# МІСЦЕ ДЛЯ КОДУ\n",
    "from pyspark.ml.clustering import KMeans\n",
    "from pyspark.ml.evaluation import ClusteringEvaluator\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Витягаємо векторизовані дані\n",
    "vector_data = processed_data.select(\"features\")\n",
    "\n",
    "# Функція для обчислення оцінки за правилом \"ліктя\"\n",
    "def calculate_elbow_curve(data, max_clusters=10):\n",
    "    wss = []  # Список для утримання сум квадратів відстаней (within-cluster sum of squares)\n",
    "    for k in range(2, max_clusters + 1):\n",
    "        kmeans = KMeans().setK(k).setSeed(1).setFeaturesCol(\"features\")\n",
    "        model = kmeans.fit(data)\n",
    "        wss.append(model.summary.trainingCost)\n",
    "    return wss\n",
    "\n",
    "# Обчислення оцінки за правилом \"ліктя\"\n",
    "max_clusters = 10\n",
    "wss = calculate_elbow_curve(vector_data, max_clusters=max_clusters)\n",
    "\n",
    "# Візуалізація правила \"ліктя\"\n",
    "plt.figure(figsize=(8, 6))\n",
    "plt.plot(range(2, max_clusters + 1), wss, marker='o', linestyle='--')\n",
    "plt.title('Elbow Method for Optimal K')\n",
    "plt.xlabel('Number of Clusters (K)')\n",
    "plt.ylabel('Within-Cluster Sum of Squares (WSS)')\n",
    "plt.grid()\n",
    "plt.show()\n",
    "\n",
    "# Вибір оптимальної кількості кластерів на основі \"ліктя\"\n",
    "optimal_k = wss.index(min(wss)) + 2\n",
    "\n",
    "# Кластеризація з оптимальною кількістю кластерів\n",
    "kmeans = KMeans().setK(optimal_k).setSeed(1).setFeaturesCol(\"features\")\n",
    "model = kmeans.fit(vector_data)\n",
    "\n",
    "# Прогнозування кластерів\n",
    "clustered_data = model.transform(vector_data)\n",
    "\n",
    "# Оцінка кластеризації\n",
    "evaluator = ClusteringEvaluator()\n",
    "silhouette_score = evaluator.evaluate(clustered_data)\n",
    "\n",
    "# Висновки\n",
    "print(f\"Оптимальна кількість кластерів: {optimal_k}\")\n",
    "print(f\"Silhouette Score для кластеризації: {silhouette_score}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Висновки\n",
    "\n",
    "За графіком можемо побачити, що реальна оптимальна кількість кластерів для даних становить 6 кластерів"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "RvZHlSLyCOeN"
   },
   "source": [
    "### Завдання №5\n",
    "* побудуйте модель для трьох кластерів\n",
    "* побудуйте `Confusion Matrix` для наявних класів та визначених кластерів\n",
    "* зробіть висновки про відповідность розподілу на кластери до існуючих класів\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "REiR7U_uCPXp"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "24/12/07 14:03:10 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:10 WARN TaskSetManager: Stage 370 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:15 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:15 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:15 WARN TaskSetManager: Stage 373 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:19 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:19 WARN TaskSetManager: Stage 374 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:20 WARN TaskSetManager: Stage 375 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:20 WARN TaskSetManager: Stage 376 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:20 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:20 WARN TaskSetManager: Stage 377 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:21 WARN TaskSetManager: Stage 378 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:21 WARN TaskSetManager: Stage 379 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:21 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:22 WARN TaskSetManager: Stage 381 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:26 WARN DAGScheduler: Broadcasting large task binary with size 3.2 MiB\n",
      "24/12/07 14:03:26 WARN TaskSetManager: Stage 383 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:27 WARN DAGScheduler: Broadcasting large task binary with size 8.4 MiB\n",
      "24/12/07 14:03:27 WARN TaskSetManager: Stage 385 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "24/12/07 14:03:31 WARN DAGScheduler: Broadcasting large task binary with size 8.4 MiB\n",
      "24/12/07 14:03:32 WARN DAGScheduler: Broadcasting large task binary with size 8.4 MiB\n",
      "24/12/07 14:03:32 WARN TaskSetManager: Stage 388 contains a task of very large size (20910 KiB). The maximum recommended task size is 1000 KiB.\n",
      "                                                                                \r"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Classification Report:\n",
      "              precision    recall  f1-score   support\n",
      "\n",
      "           0       0.35      0.79      0.48      2810\n",
      "           1       0.49      0.21      0.29      2580\n",
      "           2       0.00      0.00      0.00      2180\n",
      "\n",
      "    accuracy                           0.37      7570\n",
      "   macro avg       0.28      0.33      0.26      7570\n",
      "weighted avg       0.30      0.37      0.28      7570\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# МІСЦЕ ДЛЯ КОДУ\n",
    "from pyspark.sql.functions import col, when\n",
    "from sklearn.metrics import confusion_matrix, classification_report\n",
    "import pandas as pd\n",
    "import seaborn as sns\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Застосування моделі для трьох кластерів\n",
    "kmeans_3 = KMeans().setK(3).setSeed(1).setFeaturesCol(\"features\")\n",
    "model_3 = kmeans_3.fit(vector_data)\n",
    "clustered_data_3 = model_3.transform(processed_data)\n",
    "\n",
    "label_mapping = {\"Thyroid_Cancer\": 0, \"Colon_Cancer\": 1, \"Lung_Cancer\": 2}\n",
    "clustered_data_3 = clustered_data_3.withColumn(\"label\", when(col(\"0\") == \"Thyroid_Cancer\", 0)\n",
    "                                               .when(col(\"0\") == \"Colon_Cancer\", 1)\n",
    "                                               .when(col(\"0\") == \"Lung_Cancer\", 2))\n",
    "\n",
    "clustered_df = clustered_data_3.select(\"label\", \"prediction\").toPandas()\n",
    "\n",
    "conf_matrix = confusion_matrix(clustered_df[\"label\"], clustered_df[\"prediction\"])\n",
    "\n",
    "conf_df = pd.DataFrame(\n",
    "    conf_matrix,\n",
    "    index=[\"Thyroid_Cancer\", \"Colon_Cancer\", \"Lung_Cancer\"],\n",
    "    columns=[\"Cluster_0\", \"Cluster_1\", \"Cluster_2\"]\n",
    ")\n",
    "\n",
    "plt.figure(figsize=(8, 6))\n",
    "sns.heatmap(conf_df, annot=True, fmt=\"d\", cmap=\"Blues\", cbar=False)\n",
    "plt.title(\"Confusion Matrix: True Classes vs. Clusters\")\n",
    "plt.ylabel(\"True Classes\")\n",
    "plt.xlabel(\"Predicted Clusters\")\n",
    "plt.show()\n",
    "\n",
    "print(\"Classification Report:\")\n",
    "print(classification_report(clustered_df[\"label\"], clustered_df[\"prediction\"]))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Висновки:\n",
    "\n",
    "Результати класифікаційного звіту показують, що алгоритм кластеризації краще ідентифікує перший клас (0) із точністю 35% і повнотою 79%, тоді як другий клас (1) має помірну точність (49%) і низьку повноту (21%). Третій клас (2) не був ефективно кластеризований, із нульовими показниками точності, повноти та F1-оцінки. Загальна точність моделі становить 37%, а середні зважені значення для F1-оцінки та точності – 28%. Це свідчить про значну неоднорідність у розподілі кластерів і необхідність покращення моделі."
   ]
  }
 ],
 "metadata": {
  "colab": {
   "provenance": []
  },
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
